<?xml version="1.0" encoding="UTF-8" ?><xml><records><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>178</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">178</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Clinical implications</style></title><secondary-title><style face="normal" font="default" size="100%">Hypertension</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Hypertension (Dallas, Tex. : 1979)</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hypertension</style></full-title><abbr-1><style face="normal" font="default" size="100%">Hypertension (Dallas, Tex. : 1979)</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Hypertension</style></full-title><abbr-1><style face="normal" font="default" size="100%">Hypertension (Dallas, Tex. : 1979)</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">445</style></pages><volume><style face="normal" font="default" size="100%">64</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2014/08/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Autonomic Nervous System Diseases/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Baroreflex/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Small Vessel Diseases/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension/ complications</style></keyword><keyword><style face="normal" font="default" size="100%">KATP Channels/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle, Smooth, Vascular/ physiology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">PPAR gamma/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Tachycardia/ physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4563 (Electronic)&#xD;0194-911X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25122927</style></accession-num><notes><style face="normal" font="default" size="100%">Comment&#xD;United States&#xD;Hypertension. 2014 Sep;64(3):445. doi: 10.1161/HYPERTENSIONAHA.114.04247.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://hyper.ahajournals.org/content/hypertensionaha/64/3/445.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2202796314/-2014-Clinical implication.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/hypertensionaha.114.04247</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>118</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">118</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Abd-Elrahman, K. S.</style></author><author><style face="normal" font="default" size="100%">Walsh, M. P.</style></author><author><style face="normal" font="default" size="100%">Cole, W. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Smooth Muscle Research Group, Libin Cardiovascular Institute, Hotchkiss Brain Institute, and the Department of Physiology &amp; Pharmacology, Cumming School of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, AB T2N 4N1, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Abnormal Rho-associated kinase activity contributes to the dysfunctional myogenic response of cerebral arteries in type 2 diabetes</style></title><secondary-title><style face="normal" font="default" size="100%">Can J Physiol Pharmacol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Canadian journal of physiology and pharmacology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Can J Physiol Pharmacol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Canadian journal of physiology and pharmacology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Can J Physiol Pharmacol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Canadian journal of physiology and pharmacology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">177-84</style></pages><volume><style face="normal" font="default" size="100%">93</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2015/02/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Arteries/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Myogenin/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">rho-Associated Kinases/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1205-7541 (Electronic)&#xD;0008-4212 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25660561</style></accession-num><abstract><style face="normal" font="default" size="100%">The structural and functional integrity of the brain, and therefore, cognition, are critically dependent on the appropriate control of blood flow within the cerebral circulation. Inadequate flow leads to ischemia, whereas excessive flow causes small vessel rupture and (or) blood-brain-barrier disruption. Cerebral blood flow is controlled through the interplay of several physiological mechanisms that regulate the contractile state of vascular smooth muscle cells (VSMCs) within the walls of cerebral resistance arteries and arterioles. The myogenic response of cerebral VSMCs is a key mechanism that is responsible for maintaining constant blood flow during variations in systemic pressure, i.e., flow autoregulation. Inappropriate myogenic control of cerebral blood flow is associated with, and prognostic of, neurological deterioration and poor outcome in patients with several conditions, including type 2 diabetes. Here, we review recent advances in our understanding of the role of inappropriate Rho-associated kinase activity as a cause of impaired myogenic regulation of cerebral arterial diameter in type 2 diabetes.</style></abstract><notes><style face="normal" font="default" size="100%">Abd-Elrahman, Khaled S&#xD;Walsh, Michael P&#xD;Cole, William C&#xD;MOP-13505/Canadian Institutes of Health Research/Canada&#xD;MOP-97988/Canadian Institutes of Health Research/Canada&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Canada&#xD;Can J Physiol Pharmacol. 2015 Mar;93(3):177-84. doi: 10.1139/cjpp-2014-0437. Epub 2015 Jan 12.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1139/cjpp-2014-0437</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>375</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">375</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Abookasis, D.</style></author><author><style face="normal" font="default" size="100%">Zafrir, E.</style></author><author><style face="normal" font="default" size="100%">Nesher, E.</style></author><author><style face="normal" font="default" size="100%">Pinhasov, A.</style></author><author><style face="normal" font="default" size="100%">Sternklar, S.</style></author><author><style face="normal" font="default" size="100%">Mathews, M. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Ariel University Center of Samaria, Department of Electrical and Electronic Engineering, Ariel 44837, Israel.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Diffuse near-infrared reflectance spectroscopy during heatstroke in a mouse model: pilot study</style></title><secondary-title><style face="normal" font="default" size="100%">J Biomed Opt</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of biomedical optics</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Biomed Opt</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of biomedical optics</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Biomed Opt</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of biomedical optics</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">105009</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2012/10/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Absorption</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Anisotropy</style></keyword><keyword><style face="normal" font="default" size="100%">Body Temperature/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/blood supply/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Heat Stroke/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Spectroscopy, Near-Infrared/ methods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1560-2281 (Electronic)&#xD;1083-3668 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23085983</style></accession-num><abstract><style face="normal" font="default" size="100%">Heatstroke, a form of hyperthermia, is a life-threatening condition characterized by an elevated core body temperature that rises above 40 degrees C (104 degrees F) and central nervous system dysfunction that results in delirium, convulsions, or coma. Without emergency treatment, the victim lapses into a coma and death soon follows. The study presented was conducted with a diffuse reflectance spectroscopy (DRS) setup to assess the effects of brain dysfunction that occurred during heatstroke in mice model (n=6). It was hypothesized that DRS can be utilized in small animal studies to monitor change in internal brain tissue temperature during heatstroke injury since it induces a sequence of pathologic changes that change the tissue composition and structure. Heatstroke was induced by exposure of the mice body under general anesthesia, to a high ambient temperature. A type of DRS in which the brain tissue was illuminated through the intact scalp with a broadband light source and diffuse reflected spectra was employed, taking in the spectral region between 650 and 1000 nm and acquired at an angle of 90 deg at a position on the scalp approximately 12 mm from the illumination site. The temperature at the onset of the experiment was approximately 34 degrees C (rectal temperature) with increasing intervals of 1 degrees C until mouse death. The increase in temperature caused optical scattering signal changes consistent with a structural alteration of brain tissue, ultimately resulting in death. We have found that the peak absorbance intensity and its second derivative at specific wavelengths correlate well with temperature with an exponential dependence. Based on these findings, in order to estimate the influence of temperature on the internal brain tissue a reflectance-temperature index was established and was seen to correlate as well with measured temperature. Overall, results indicate variations in neural tissue properties during heatstroke and the feasibility to monitor and assess internal temperature variations using DRS. Although several approaches have described the rise in temperature and its impact on tissue, to the best of our knowledge no information is available describing the ability to monitor temperature during heatstroke with DRS. The motivation of this study was to successfully describe this ability.</style></abstract><notes><style face="normal" font="default" size="100%">Abookasis, David&#xD;Zafrir, Elad&#xD;Nesher, Elimelech&#xD;Pinhasov, Albert&#xD;Sternklar, Shmuel&#xD;Mathews, Marlon S&#xD;United States&#xD;J Biomed Opt. 2012 Oct;17(10):105009. doi: 10.1117/1.JBO.17.10.105009.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://biomedicaloptics.spiedigitallibrary.org/pdfaccess.ashx?url=/data/journals/biomedo/24226/jbo_17_10_105009.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3229358364/Abookasis-2012-Diffuse near-infrare.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1117/1.jbo.17.10.105009</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>416</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">416</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agostoni, E.</style></author><author><style face="normal" font="default" size="100%">Rigamonti, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology and Stroke Unit, Niguarda Ca Granda Hospital, Piazza Ospedale Maggiore 3, 20164 Milan, Italy. elioclemente.agostoni@ospedaleniguarda.it</style></auth-address><titles><title><style face="normal" font="default" size="100%">Migraine and small vessel diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Neurol Sci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurol Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurol Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">S51-4</style></pages><volume><style face="normal" font="default" size="100%">33 Suppl 1</style></volume><edition><style face="normal" font="default" size="100%">2012/06/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">CADASIL/epidemiology/genetics/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/epidemiology/genetics/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Small Vessel Diseases/ epidemiology/ genetics/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Microcirculation/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Migraine Disorders/ epidemiology/ genetics/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Diseases/epidemiology/genetics/physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1590-3478 (Electronic)&#xD;1590-1874 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22644171</style></accession-num><abstract><style face="normal" font="default" size="100%">It is remarkable that migraine is a prominent part of the phenotype of several genetic vasculopathies affecting small cerebral vessels, including cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, retinal vasculopathy with cerebral leukodystrophy and hereditary infantile hemiparesis, retinal arteriolar tortuosity and leucoencephalopathy. Moreover, several studies have reported an association between migraine and white matter lesions or clinically silent infarct-like abnormalities in the posterior circulation. In this review, we focus on genetic vasculopathies associated with migraine and speculate about the pathophysiological mechanism that can explain this comorbidity.</style></abstract><notes><style face="normal" font="default" size="100%">Agostoni, E&#xD;Rigamonti, A&#xD;Review&#xD;Italy&#xD;Neurol Sci. 2012 May;33 Suppl 1:S51-4. doi: 10.1007/s10072-012-1041-x.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/475/art%253A10.1007%252Fs10072-012-1041-x.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs10072-012-1041-x&amp;token2=exp=1484113006~acl=%2Fstatic%2Fpdf%2F475%2Fart%25253A10.1007%25252Fs10072-012-1041-x.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs10072-012-1041-x*~hmac=bee66d3e3d7864915196d7e48e95db65688bc8b86bff94ecbc8c1f741cee0df8</style></url></related-urls><pdf-urls><url>internal-pdf://0144242506/Agostoni-2012-Migraine and small v.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s10072-012-1041-x</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>457</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">457</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Akamatsu, Y.</style></author><author><style face="normal" font="default" size="100%">Shimizu, H.</style></author><author><style face="normal" font="default" size="100%">Saito, A.</style></author><author><style face="normal" font="default" size="100%">Fujimura, M.</style></author><author><style face="normal" font="default" size="100%">Tominaga, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan. redpine7219@hotmail.co.jp</style></auth-address><titles><title><style face="normal" font="default" size="100%">Consistent focal cerebral ischemia without posterior cerebral artery occlusion and its real-time monitoring in an intraluminal suture model in mice</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosurg</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neurosurgery</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosurg</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurosurgery</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosurg</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurosurgery</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">657-64</style></pages><volume><style face="normal" font="default" size="100%">116</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2011/12/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/classification/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Laser-Doppler Flowmetry</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Posterior Cerebral Artery/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Suture Techniques/instrumentation/ utilization</style></keyword><keyword><style face="normal" font="default" size="100%">Sutures/utilization</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1933-0693 (Electronic)&#xD;0022-3085 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22196098</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECT: In the intraluminal suture model of middle cerebral artery occlusion (MCAO) in the mouse, disturbance of blood flow from the internal carotid artery to the posterior cerebral artery (PCA) may affect the size of the infarction. In this study, PCA involvement in the model was investigated and modified for consistent MCAO without involving the PCA territory. METHODS: Thirty-seven C57Bl/6 mice were randomly divided into 4 groups according to the length of coating over the tip of the suture (1, 2, 3, or 4 mm) and subjected to transient MCAO for 2 hours. Real-time topographical cerebral blood flow was monitored over both hemispheres by laser speckle flowmetry. After 24 hours of reperfusion, the infarct territories and volumes were evaluated. RESULTS: The 1- and 2-mm coating groups showed all lesions in the MCA territory. In the 3- and 4-mm coating groups, 62.5% and 75% of mice, respectively, showed lesions in both the MCA and the PCA territories and other lesions in the MCA territory. Mice in the 1- and 2-mm coating groups had significantly smaller infarct volumes than the 3- and 4-mm groups. Laser speckle flowmetry was useful to distinguish whether the PCA territory would undergo infarction. CONCLUSIONS: Small changes in the coating length of the intraluminal suture may be critical, and 1-2 mm of coating appeared to be optimal to produce consistent MCAO without involving the PCA territory. Laser speckle flowmetry could predict the territory of infarction and improve the consistency of the infarct size.</style></abstract><notes><style face="normal" font="default" size="100%">Akamatsu, Yosuke&#xD;Shimizu, Hiroaki&#xD;Saito, Atsushi&#xD;Fujimura, Miki&#xD;Tominaga, Teiji&#xD;Comparative Study&#xD;United States&#xD;J Neurosurg. 2012 Mar;116(3):657-64. doi: 10.3171/2011.11.JNS111167. Epub 2011 Dec 23.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3171/2011.11.jns111167</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>169</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">169</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Albertsson, A. M.</style></author><author><style face="normal" font="default" size="100%">Bi, D.</style></author><author><style face="normal" font="default" size="100%">Duan, L.</style></author><author><style face="normal" font="default" size="100%">Zhang, X.</style></author><author><style face="normal" font="default" size="100%">Leavenworth, J. W.</style></author><author><style face="normal" font="default" size="100%">Qiao, L.</style></author><author><style face="normal" font="default" size="100%">Zhu, C.</style></author><author><style face="normal" font="default" size="100%">Cardell, S.</style></author><author><style face="normal" font="default" size="100%">Cantor, H.</style></author><author><style face="normal" font="default" size="100%">Hagberg, H.</style></author><author><style face="normal" font="default" size="100%">Mallard, C.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The immune response after hypoxia-ischemia in a mouse model of preterm brain injury</style></title><secondary-title><style face="normal" font="default" size="100%">J Neuroinflammation</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neuroinflammation</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neuroinflammation</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroinflammation</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neuroinflammation</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroinflammation</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">153</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><edition><style face="normal" font="default" size="100%">2014/09/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Animals, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fetal Hypoxia/ immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia-Ischemia, Brain/ immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunohistochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Reverse Transcriptase Polymerase Chain Reaction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 05</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1742-2094 (Electronic)&#xD;1742-2094 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25187205</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Preterm brain injury consists primarily of periventricular leukomalacia accompanied by elements of gray-matter injury, and these injuries are associated with cerebral palsy and cognitive impairments. Inflammation is believed to be an important contributing factor to these injuries. The aim of this study was to examine the immune response in a postnatal day (PND) 5 mouse model of preterm brain injury induced by hypoxia-ischemia (HI) that is characterized by focal white and gray-matter injury. METHODS: C57Bl/6 mice at PND 5 were subjected to unilateral HI induced by left carotid artery ligation and subsequent exposure to 10% O2 for 50 minutes, 70 minutes, or 80 minutes. At seven days post-HI, the white/gray-matter injury was examined. The immune responses in the brain after HI were examined at different time points after HI using RT-PCR and immunohistochemical staining. RESULTS: HI for 70 minutes in PND 5 mice induced local white-matter injury with focal cortical injury and hippocampal atrophy, features that are similar to those seen in preterm brain injury in human infants. HI for 50 minutes resulted in a small percentage of animals being injured, and HI for 80 minutes produced extensive infarction in multiple brain areas. Various immune responses, including changes in transcription factors and cytokines that are associated with a T-helper (Th)1/Th17-type response, an increased number of CD4+ T-cells, and elevated levels of triggering receptor expressed on myeloid cells 2 (TREM-2) and its adaptor protein DNAX activation protein of 12 kDa (DAP12) were observed using the HI 70 minute preterm brain injury model. CONCLUSIONS: We have established a reproducible model of HI in PND 5 mice that produces consistent local white/gray-matter brain damage that is relevant to preterm brain injury in human infants. This model provides a useful tool for studying preterm brain injury. Both innate and adaptive immune responses are observed after HI, and these show a strong pro-inflammatory Th1/Th17-type bias. Such findings provide a critical foundation for future studies on the mechanism of preterm brain injury and suggest that blocking the Th1/Th17-type immune response might provide neuroprotection after preterm brain injury.</style></abstract><notes><style face="normal" font="default" size="100%">Albertsson, Anna-Maj&#xD;Bi, Dan&#xD;Duan, Luqi&#xD;Zhang, Xiaoli&#xD;Leavenworth, Jianmei W&#xD;Qiao, Lili&#xD;Zhu, Changlian&#xD;Cardell, Susanna&#xD;Cantor, Harvey&#xD;Hagberg, Henrik&#xD;Mallard, Carina&#xD;Wang, Xiaoyang&#xD;WT094823 HH/Wellcome Trust/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Neuroinflammation. 2014 Sep 5;11:153. doi: 10.1186/s12974-014-0153-z.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/285/art%253A10.1186%252Fs12974-014-0153-z.pdf?originUrl=http%3A%2F%2Fjneuroinflammation.biomedcentral.com%2Farticle%2F10.1186%2Fs12974-014-0153-z&amp;token2=exp=1484112112~acl=%2Fstatic%2Fpdf%2F285%2Fart%25253A10.1186%25252Fs12974-014-0153-z.pdf*~hmac=c4c4e8e9b11d4566d8c72da6982e9ac8b89e71b9c3c5401fce0970c288279898</style></url></related-urls><pdf-urls><url>internal-pdf://1024796386/Albertsson-2014-The immune response.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4172879</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12974-014-0153-z</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>303</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">303</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ali, M. S.</style></author><author><style face="normal" font="default" size="100%">Starke, R. M.</style></author><author><style face="normal" font="default" size="100%">Jabbour, P. M.</style></author><author><style face="normal" font="default" size="100%">Tjoumakaris, S. I.</style></author><author><style face="normal" font="default" size="100%">Gonzalez, L. F.</style></author><author><style face="normal" font="default" size="100%">Rosenwasser, R. H.</style></author><author><style face="normal" font="default" size="100%">Owens, G. K.</style></author><author><style face="normal" font="default" size="100%">Koch, W. J.</style></author><author><style face="normal" font="default" size="100%">Greig, N. H.</style></author><author><style face="normal" font="default" size="100%">Dumont, A. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Joseph and Marie Field Cerebrovascular Research Laboratory, Division of Neurovascular &amp; Endovascular Surgery, Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">TNF-alpha induces phenotypic modulation in cerebral vascular smooth muscle cells: implications for cerebral aneurysm pathology</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1564-73</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2013/07/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/drug effects/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Arteries/drug effects/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Differentiation/drug effects/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Circle of Willis/drug effects/metabolism/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Epigenesis, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Markers/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Aneurysm/genetics/immunology/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Kruppel-Like Transcription Factors/genetics/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle, Smooth, Vascular/drug effects/metabolism/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Nuclear Proteins/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Promoter Regions, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Thalidomide/analogs &amp; derivatives/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Trans-Activators/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">Tumor Necrosis Factor-alpha/antagonists &amp; inhibitors/ pharmacology/physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23860374</style></accession-num><abstract><style face="normal" font="default" size="100%">Little is known about vascular smooth muscle cell (SMC) phenotypic modulation in the cerebral circulation or pathogenesis of intracranial aneurysms. Tumor necrosis factor-alpha (TNF-alpha) has been associated with aneurysms, but potential mechanisms are unclear. Cultured rat cerebral SMCs overexpressing myocardin induced expression of key SMC contractile genes (SM-alpha-actin, SM-22alpha, smooth muscle myosin heavy chain), while dominant-negative cells suppressed expression. Tumor necrosis factor-alpha treatment inhibited this contractile phenotype and induced pro-inflammatory/matrix-remodeling genes (monocyte chemoattractant protein-1, matrix metalloproteinase-3, matrix metalloproteinase-9, vascular cell adhesion molecule-1, interleukin-1 beta). Tumor necrosis factor-alpha increased expression of KLF4, a known regulator of SMC differentiation. Kruppel-like transcription factor 4 (KLF4) small interfering RNA abrogated TNF-alpha activation of inflammatory genes and suppression of contractile genes. These mechanisms were confirmed in vivo after exposure of rat carotid arteries to TNF-alpha and early on in a model of cerebral aneurysm formation. Treatment with the synthesized TNF-alpha inhibitor 3,6-dithiothalidomide reversed pathologic vessel wall alterations after induced hypertension and hemodynamic stress. Chromatin immunoprecipitation assays in vivo and in vitro demonstrated that TNF-alpha promotes epigenetic changes through KLF4-dependent alterations in promoter regions of myocardin, SMCs, and inflammatory genes. In conclusion, TNF-alpha induces phenotypic modulation of cerebral SMCs through myocardin and KLF4-regulated pathways. These results demonstrate a novel role for TNF-alpha in promoting a pro-inflammatory/matrix-remodeling phenotype, which has important implications for the mechanisms behind intracranial aneurysm formation.</style></abstract><notes><style face="normal" font="default" size="100%">Ali, Muhammad S&#xD;Starke, Robert M&#xD;Jabbour, Pascal M&#xD;Tjoumakaris, Stavropoula I&#xD;Gonzalez, L Fernando&#xD;Rosenwasser, Robert H&#xD;Owens, Gary K&#xD;Koch, Walter J&#xD;Greig, Nigel H&#xD;Dumont, Aaron S&#xD;R01 HL57353/HL/NHLBI NIH HHS/United States&#xD;Intramural NIH HHS/United States&#xD;R01 HL087867/HL/NHLBI NIH HHS/United States&#xD;K08 NS067072/NS/NINDS NIH HHS/United States&#xD;T32 HL007544/HL/NHLBI NIH HHS/United States&#xD;K08NS067072/NS/NINDS NIH HHS/United States&#xD;R01 HL057353/HL/NHLBI NIH HHS/United States&#xD;P01 HL07544/HL/NHLBI NIH HHS/United States&#xD;P01 HL091799/HL/NHLBI NIH HHS/United States&#xD;R01 HL098538/HL/NHLBI NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, N.I.H., Intramural&#xD;United States&#xD;J Cereb Blood Flow Metab. 2013 Oct;33(10):1564-73. doi: 10.1038/jcbfm.2013.109. Epub 2013 Jul 17.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3790924</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2013.109</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>224</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">224</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Amtul, Z.</style></author><author><style face="normal" font="default" size="100%">Whitehead, S. N.</style></author><author><style face="normal" font="default" size="100%">Keeley, R. J.</style></author><author><style face="normal" font="default" size="100%">Bechberger, J.</style></author><author><style face="normal" font="default" size="100%">Fisher, A. L.</style></author><author><style face="normal" font="default" size="100%">McDonald, R. J.</style></author><author><style face="normal" font="default" size="100%">Naus, C. C.</style></author><author><style face="normal" font="default" size="100%">Munoz, D. G.</style></author><author><style face="normal" font="default" size="100%">Cechetto, D. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">CIHR Group on Vascular Cognitive Impairment, Department of Anatomy and Cell Biology, Western University, London, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comorbid rat model of ischemia and beta-amyloid toxicity: striatal and cortical degeneration</style></title><secondary-title><style face="normal" font="default" size="100%">Brain Pathol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain pathology (Zurich, Switzerland)</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain Pathol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain pathology (Zurich, Switzerland)</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Brain Pathol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain pathology (Zurich, Switzerland)</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">24-32</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2014/04/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Amyloid beta-Peptides</style></keyword><keyword><style face="normal" font="default" size="100%">Amyloidosis/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Connexin 43/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Corpus Striatum/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelin-1</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Maze Learning/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Microglia/pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Degeneration/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Neurites/pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Protein-Tyrosine Kinases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Visual Perception/physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1750-3639 (Electronic)&#xD;1015-6305 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24725245</style></accession-num><abstract><style face="normal" font="default" size="100%">Levels of cerebral amyloid, presumably beta-amyloid (Abeta), toxicity and the incidence of cortical and subcortical ischemia increases with age. However, little is known about the severe pathological condition and dementia that occur as a result of the comorbid occurrence of this vascular risk factor and Abeta toxicity. Clinical studies have indicated that small ischemic lesions in the striatum are particularly important in generating dementia in combination with minor amyloid lesions. These cognitive deficits are highly likely to be caused by changes in the cortex. In this study, we examined the viability and morphological changes in microglial and neuronal cells, gap junction proteins (connexin43) and neuritic/axonal retraction (Fer Kinase) in the striatum and cerebral cortex using a comorbid rat model of striatal injections of endothelin-1 (ET1) and Abeta toxicity. The results demonstrated ventricular enlargement, striatal atrophy, substantial increases in beta-amyloid, ramified microglia and increases in neuritic retraction in the combined models of stroke and Abeta toxicity. Changes in connexin43 occurred equally in both groups of Abeta-treated rats, with and without focal ischemia. Although previous behavioral tests demonstrated impairment in memory and learning, the visual discrimination radial maze task did not show significant difference, suggesting the cognitive impairment in these models is not related to damage to the dorsolateral striatum. These results suggest an insight into the relationship between cortical/striatal atrophy, pathology and functional impairment.</style></abstract><notes><style face="normal" font="default" size="100%">Amtul, Zareen&#xD;Whitehead, Shawn N&#xD;Keeley, Robin J&#xD;Bechberger, John&#xD;Fisher, Alicia L&#xD;McDonald, Robert J&#xD;Naus, Christian C&#xD;Munoz, David G&#xD;Cechetto, David F&#xD;R1478A47/Canadian Institutes of Health Research/Canada&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Switzerland&#xD;Brain Pathol. 2015 Jan;25(1):24-32. doi: 10.1111/bpa.12149. Epub 2014 May 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/bpa.12149/asset/bpa12149.pdf?v=1&amp;t=ixshv1vy&amp;s=ba110761c59fb300b07c2b4680e7e9634fe0129b</style></url></related-urls><pdf-urls><url>internal-pdf://0158751063/Amtul-2015-Comorbid rat model o.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/bpa.12149</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>23</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">23</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">An, D.</style></author><author><style face="normal" font="default" size="100%">Park, J.</style></author><author><style face="normal" font="default" size="100%">Shin, J. I.</style></author><author><style face="normal" font="default" size="100%">Kim, H. J.</style></author><author><style face="normal" font="default" size="100%">Jung, D. I.</style></author><author><style face="normal" font="default" size="100%">Kang, J. H.</style></author><author><style face="normal" font="default" size="100%">Kim, G.</style></author><author><style face="normal" font="default" size="100%">Chang, D. W.</style></author><author><style face="normal" font="default" size="100%">Sur, J. H.</style></author><author><style face="normal" font="default" size="100%">Yang, M. P.</style></author><author><style face="normal" font="default" size="100%">Lee, C.</style></author><author><style face="normal" font="default" size="100%">Kang, B. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Molecular Imaging and Translational Research, Veterinary Medical Center, College of Veterinary Medicine, Chungbuk National University, Cheongju, South Korea.&#xD;Division of Convergence Biotechnology, Korea Basic Science Institute, Ochang, South Korea.&#xD;Department of Veterinary Pathology, Small Animal Tumor Diagnostic Center, College of Veterinary Medicine, Konkuk University, Seoul, South Korea.&#xD;Department of Biomedical Engineering, Kyung Hee University, Yongin, South Korea.&#xD;Research Institute of Life Sciences, Gyeongsang National University, Jinju, South Korea.&#xD;Veterinary Medical Center, College of Veterinary Medicine, Chungbuk National University, Cheongju, South Korea.&#xD;Laboratory of Molecular Imaging and Translational Research, Veterinary Medical Center, College of Veterinary Medicine, Chungbuk National University, Cheongju, South Korea. kangbt@chungbuk.ac.kr.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Temporal Evolution of MRI Characteristics in Dogs with Collagenase-Induced Intracerebral Hemorrhage</style></title><secondary-title><style face="normal" font="default" size="100%">Comp Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Comparative medicine</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Comp Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Comparative medicine</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Comp Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Comparative medicine</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">517-25</style></pages><volume><style face="normal" font="default" size="100%">65</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2015/12/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/chemically induced/diagnosis/surgery/ veterinary</style></keyword><keyword><style face="normal" font="default" size="100%">Collagenases/ toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Dog Diseases/chemically induced/ diagnosis/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Dogs</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1532-0820 (Print)&#xD;1532-0820 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26678369</style></accession-num><abstract><style face="normal" font="default" size="100%">Intracerebral hemorrhage (ICH) is one of the most lethal types of stroke. Neuroimaging techniques, particularly MRI, have improved the diagnostic accuracy of ICH. The MRI characteristics of the evolving stages of ICH in humans-but not those in dogs-have been described. In this study, we document the temporal MRI characteristics in a canine model of collagenase-induced ICH. Specifically, ICH was induced in 5 healthy beagles by injecting 500 U of bacterial collagenase from Clostridium histolyticum, which was delivered into the parietal lobe over 5 min by using a microinfusion pump. T1- and T2-weighted, fluid-attenuated inversion recovery, gradient-echo (GRE), and diffusion-weighted (DWI) imaging and measurement of the apparent diffusion coefficient (ADC) were performed serially at 6 different time points (before and 12 h, 3 d, 5 d, 10 d and 24 d after hemorrhage) by using a 3-T MR system. The temporal changes of T1 signal intensity (SI) corresponded well with the reported human data. The temporal changes of T2 and GRE sequences, with the exception of T2 and GRE hyperintensities at the early subacute stage, also matched. ADC measurements were high at the early subacute stage, and DWI-SI positively correlated with T2- and GRE-SI from the early subacute stage onward. In conclusion, MRI is an ideal method for characterizing the temporal evolution of parenchymal alterations after ICH in dogs. These data might be useful for differentiating clinical stages of ICH in dogs.</style></abstract><notes><style face="normal" font="default" size="100%">An, Daegi&#xD;Park, Junyong&#xD;Shin, Jong-Il&#xD;Kim, Hyung-Joong&#xD;Jung, Dong-In&#xD;Kang, Ji-Houn&#xD;Kim, Gonhyung&#xD;Chang, Dong-Woo&#xD;Sur, Jung-Hyang&#xD;Yang, Mhan-Pyo&#xD;Lee, Chulhyun&#xD;Kang, Byeong-Teck&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Comp Med. 2015 Dec;65(6):517-25.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4681246</style></custom2><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>218</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">218</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Andersson, E. R.</style></author><author><style face="normal" font="default" size="100%">Lendahl, U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Cell and Molecular Biology, Karolinska Institute, SE-171 77 Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Therapeutic modulation of Notch signalling--are we there yet?</style></title><secondary-title><style face="normal" font="default" size="100%">Nat Rev Drug Discov</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Nature reviews. Drug discovery</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nat Rev Drug Discov</style></full-title><abbr-1><style face="normal" font="default" size="100%">Nature reviews. Drug discovery</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Nat Rev Drug Discov</style></full-title><abbr-1><style face="normal" font="default" size="100%">Nature reviews. Drug discovery</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">357-78</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2014/05/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">CADASIL/drug therapy/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic/methods/trends</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Delivery Systems/methods/trends</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Leukemia/drug therapy/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/administration &amp; dosage/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Notch/antagonists &amp; inhibitors/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/drug effects/ physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1474-1784 (Electronic)&#xD;1474-1776 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24781550</style></accession-num><abstract><style face="normal" font="default" size="100%">The Notch signalling pathway is evolutionarily conserved and is crucial for the development and homeostasis of most tissues. Deregulated Notch signalling leads to various diseases, such as T cell leukaemia, Alagille syndrome and a stroke and dementia syndrome known as CADASIL, and so strategies to therapeutically modulate Notch signalling are of interest. Clinical trials of Notch pathway inhibitors in patients with solid tumours have been reported, and several approaches are under preclinical evaluation. In this Review, we focus on aspects of the pathway that are amenable to therapeutic intervention, diseases that could be targeted and the various Notch pathway modulation strategies that are currently being explored.</style></abstract><notes><style face="normal" font="default" size="100%">Andersson, Emma R&#xD;Lendahl, Urban&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;England&#xD;Nat Rev Drug Discov. 2014 May;13(5):357-78. doi: 10.1038/nrd4252.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.nature.com/nrd/journal/v13/n5/pdf/nrd4252.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2807055082/Andersson-2014-Therapeutic modulati.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/nrd4252</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>212</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">212</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Antman, E. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Cardiovascular Division, Brigham and Women&apos;s Hospital.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical research and the development of medical therapeutics</style></title><secondary-title><style face="normal" font="default" size="100%">Circ J</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Circulation journal : official journal of the Japanese Circulation Society</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Circ J</style></full-title><abbr-1><style face="normal" font="default" size="100%">Circulation journal : official journal of the Japanese Circulation Society</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Circ J</style></full-title><abbr-1><style face="normal" font="default" size="100%">Circulation journal : official journal of the Japanese Circulation Society</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1267-71</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2014/05/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Anticoagulants/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Biomedical Research/economics/ methods/ trends</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials, Phase III as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Induced Pluripotent Stem Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Stem Cell Transplantation/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">1347-4820 (Electronic)&#xD;1346-9843 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24837573</style></accession-num><abstract><style face="normal" font="default" size="100%">Clinical research plays a central role in the development of medical therapeutics, but the current system is estimated to take 10-15 years from initial discovery to regulatory approval, at a cost of approximately US$1 billion. Contrast the paths by which 2 anticoagulant options for atrial fibrillation were discovered and ultimately established as treatment options in clinical medicine. Warfarin was discovered by serendipity and compared with placebo in relatively small trials; this was associated with a low cost of development. The new oral anticoagulants were synthesized to provide highly specific, targeted inhibition of critical steps in the coagulation system. They were compared with warfarin for prevention of stroke and systemic embolic events in large, phase 3 trials; this resulted in very expensive development programs. Neither of these paths is desirable for future development of therapeutics. We need to focus on innovative approaches at the preclinical level (systems approach, greater use of inducible pluripotent stem cells, use of novel bioengineering platforms) and clinical trial level (adaptive design, greater use of new and emerging technology). Focusing on disruptive innovations for development of medical therapeutics has the potential to bring us closer to the goal of precision medicine where safer, more effective treatments are discovered in a more efficient system.</style></abstract><notes><style face="normal" font="default" size="100%">Antman, Elliott M&#xD;Review&#xD;Japan&#xD;Circ J. 2014;78(6):1267-71. Epub 2014 May 16.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>397</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">397</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Arrick, D. M.</style></author><author><style face="normal" font="default" size="100%">Sun, H.</style></author><author><style face="normal" font="default" size="100%">Mayhan, W. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Cellular Biology and Anatomy and the Center of Excellence in Cardiovascular Diseases and Sciences, Louisiana State University Health Science Center-Shreveport, Shreveport, LA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Influence of exercise training on ischemic brain injury in type 1 diabetic rats</style></title><secondary-title><style face="normal" font="default" size="100%">J Appl Physiol (1985)</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of applied physiology (Bethesda, Md. : 1985)</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Appl Physiol (1985)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of applied physiology (Bethesda, Md. : 1985)</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Appl Physiol (1985)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of applied physiology (Bethesda, Md. : 1985)</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1121-7</style></pages><volume><style face="normal" font="default" size="100%">113</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2012/08/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arterioles/metabolism/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/metabolism/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/ blood supply/metabolism/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 1/metabolism/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Cerebral Artery/metabolism/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide Synthase Type I/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide Synthase Type III/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Physical Conditioning, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/metabolism/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilation/physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1522-1601 (Electronic)&#xD;0161-7567 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22858624</style></accession-num><abstract><style face="normal" font="default" size="100%">While exercise training (ExT) appears to influence cerebrovascular function during type 1 diabetes (T1D), it is not clear whether this beneficial effect extends to protecting the brain from ischemia-induced brain injury. Thus our goal was to examine whether modest ExT could influence transient focal ischemia-induced brain injury along with nitric oxide synthase (NOS)-dependent dilation of cerebral (pial) arterioles during T1D. Sprague-Dawley rats were divided into four groups: nondiabetic sedentary, nondiabetic ExT, diabetic (streptozotocin; 50 mg/kg ip) sedentary, and diabetic ExT. In the first series of studies, we measured infarct volume in all groups of rats following right MCA occlusion for 2 h, followed by 24 h of reperfusion. In a second series of studies, a craniotomy was performed over the parietal cortex, and we measured responses of pial arterioles to an endothelial NOS (eNOS)-dependent, a neuronal NOS (nNOS)-dependent, and a NOS-independent agonist in all groups of rats. We found that sedentary diabetic rats had significantly larger total, cortical, and subcortical infarct volumes following ischemia-reperfusion than sedentary nondiabetic, nondiabetic ExT, and diabetic ExT rats. Infarct volumes were similar in sedentary nondiabetic, ExT nondiabetic, and ExT diabetic rats. In contrast, ExT did not alter infarct size in nondiabetic compared with sedentary nondiabetic rats. In addition, ExT diabetic rats had impaired eNOS- and nNOS-dependent, but not NOS-independent, vasodilation that was restored by ExT. Thus ExT of T1D rats lessened ischemic brain injury following middle cerebral artery occlusion and restored impaired eNOS- and nNOS-dependent vascular function. Since the incidence of ischemic stroke is increased during T1D, we suggest that our finding are significant in that modest ExT may be a viable preventative therapeutic approach to lessen ischemia-induced brain injury that may occur in T1D subjects.</style></abstract><notes><style face="normal" font="default" size="100%">Arrick, Denise M&#xD;Sun, Hong&#xD;Mayhan, William G&#xD;HL-090657/HL/NHLBI NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;United States&#xD;J Appl Physiol (1985). 2012 Oct;113(7):1121-7. doi: 10.1152/japplphysiol.00437.2012. Epub 2012 Aug 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://jap.physiology.org/content/jap/113/7/1121.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0077816739/Arrick-2012-Influence of exercis.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3774098</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1152/japplphysiol.00437.2012</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>417</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">417</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bae, O. N.</style></author><author><style face="normal" font="default" size="100%">Rajanikant, K.</style></author><author><style face="normal" font="default" size="100%">Min, J.</style></author><author><style face="normal" font="default" size="100%">Smith, J.</style></author><author><style face="normal" font="default" size="100%">Baek, S. H.</style></author><author><style face="normal" font="default" size="100%">Serfozo, K.</style></author><author><style face="normal" font="default" size="100%">Hejabian, S.</style></author><author><style face="normal" font="default" size="100%">Lee, K. Y.</style></author><author><style face="normal" font="default" size="100%">Kassab, M.</style></author><author><style face="normal" font="default" size="100%">Majid, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Cerebrovascular Diseases and Department of Neurology and Ophthalmology, Michigan State University, East Lansing, Michigan 48824, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Lymphocyte cell kinase activation mediates neuroprotection during ischemic preconditioning</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">7278-86</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">21</style></number><edition><style face="normal" font="default" size="100%">2012/05/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adaptor Proteins, Signal Transducing/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ enzymology/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Death/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/drug effects/ enzymology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Silencing/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose/deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Preconditioning/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">N-Methylaspartate/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/enzymology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Cell Culture</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Kinase C-epsilon/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/pharmacology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">May 23</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1529-2401 (Electronic)&#xD;0270-6474 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22623673</style></accession-num><abstract><style face="normal" font="default" size="100%">The molecular mechanisms underlying preconditioning (PC), a powerful endogenous neuroprotective phenomenon, remain to be fully elucidated. Once identified, these endogenous mechanisms could be manipulated for therapeutic gain. We investigated whether lymphocyte cell kinase (Lck), a member of the Src kinases family, mediates PC. We used both in vitro primary cortical neurons and in vivo mouse cerebral focal ischemia models of preconditioning, cellular injury, and neuroprotection. Genetically engineered mice deficient in Lck, gene silencing using siRNA, and pharmacological approaches were used. Cortical neurons preconditioned with sublethal exposure to NMDA or oxygen glucose deprivation (OGD) exhibited enhanced Lck kinase activity, and were resistant to injury on subsequent exposure to lethal levels of NMDA or OGD. Lck gene silencing using siRNA abolished tolerance against both stimuli. Lck-/- mice or neurons isolated from Lck-/- mice did not exhibit PC-induced tolerance. An Lck antagonist administered to wild-type mice significantly attenuated the neuroprotective effect of PC in the mouse focal ischemia model. Using pharmacological and gene silencing strategies, we also showed that PKCepsilon is an upstream regulator of Lck, and Fyn is a downstream target of Lck. We have discovered that Lck plays an essential role in PC in both cellular and animal models of stroke. Our data also show that the PKCepsilon-Lck-Fyn axis is a key mediator of PC. These findings provide new opportunities for stroke therapy development.</style></abstract><notes><style face="normal" font="default" size="100%">Bae, Ok-Nam&#xD;Rajanikant, Krishnamurthy&#xD;Min, Jiangyong&#xD;Smith, Jeremy&#xD;Baek, Seung-Hoon&#xD;Serfozo, Kelsey&#xD;Hejabian, Siamak&#xD;Lee, Ki Yong&#xD;Kassab, Mounzer&#xD;Majid, Arshad&#xD;R21 NS061067/NS/NINDS NIH HHS/United States&#xD;R21 NS064343/NS/NINDS NIH HHS/United States&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Neurosci. 2012 May 23;32(21):7278-86. doi: 10.1523/JNEUROSCI.6273-11.2012.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.jneurosci.org/content/jneuro/32/21/7278.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3751242967/Bae-2012-Lymphocyte cell kina.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3538119</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms379877</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1523/jneurosci.6273-11.2012</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>250</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">250</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bailey, E. L.</style></author><author><style face="normal" font="default" size="100%">McBride, M. W.</style></author><author><style face="normal" font="default" size="100%">Beattie, W.</style></author><author><style face="normal" font="default" size="100%">McClure, J. D.</style></author><author><style face="normal" font="default" size="100%">Graham, D.</style></author><author><style face="normal" font="default" size="100%">Dominiczak, A. F.</style></author><author><style face="normal" font="default" size="100%">Sudlow, C. L.</style></author><author><style face="normal" font="default" size="100%">Smith, C.</style></author><author><style face="normal" font="default" size="100%">Wardlaw, J. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Clinical Brain Sciences, University of Edinburgh, Western General Hospital, Edinburgh; Department of Bioengineering, Imperial College London, London.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Differential gene expression in multiple neurological, inflammatory and connective tissue pathways in a spontaneous model of human small vessel stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Neuropathol Appl Neurobiol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuropathology and applied neurobiology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuropathol Appl Neurobiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuropathology and applied neurobiology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuropathol Appl Neurobiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuropathology and applied neurobiology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">855-72</style></pages><volume><style face="normal" font="default" size="100%">40</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2014/01/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Small Vessel Diseases/ complications/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Connective Tissue/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Encephalitis/complications/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nervous System Diseases/complications/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Array Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred SHR</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1365-2990 (Electronic)&#xD;0305-1846 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24417612</style></accession-num><abstract><style face="normal" font="default" size="100%">AIMS: Cerebral small vessel disease (SVD) causes a fifth of all strokes plus diffuse brain damage leading to cognitive decline, physical disabilities and dementia. The aetiology and pathogenesis of SVD are unknown, but largely attributed to hypertension or microatheroma. METHODS: We used the spontaneously hypertensive stroke-prone rat (SHRSP), the closest spontaneous experimental model of human SVD, and age-matched control rats kept under identical, non-salt-loaded conditions, to perform a blinded analysis of mRNA microarray, qRT-PCR and pathway analysis in two brain regions (frontal and mid-coronal) commonly affected by SVD in the SHRSP at age five, 16 and 21 weeks. RESULTS: We found gene expression abnormalities, with fold changes ranging from 2.5 to 59 for the 10 most differentially expressed genes, related to endothelial tight junctions (reduced), nitric oxide bioavailability (reduced), myelination (impaired), glial and microglial activity (increased), matrix proteins (impaired), vascular reactivity (impaired) and albumin (reduced), consistent with protein expression defects in the same rats. All were present at age 5 weeks thus predating blood pressure elevation. &apos;Neurological&apos; and &apos;inflammatory&apos; pathways were more affected than &apos;vascular&apos; functional pathways. CONCLUSIONS: This set of defects, although individually modest, when acting in combination could explain the SHRSP&apos;s susceptibility to microvascular and brain injury, compared with control rats. Similar combined, individually modest, but multiple neurovascular unit defects, could explain susceptibility to spontaneous human SVD.</style></abstract><notes><style face="normal" font="default" size="100%">Bailey, Emma L&#xD;McBride, Martin W&#xD;Beattie, Wendy&#xD;McClure, John D&#xD;Graham, Delyth&#xD;Dominiczak, Anna F&#xD;Sudlow, Cathie L M&#xD;Smith, Colin&#xD;Wardlaw, Joanna M&#xD;CZB/4/517/Chief Scientist Office/United Kingdom&#xD;G1100616/Medical Research Council/United Kingdom&#xD;MR/L016400/1/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Neuropathol Appl Neurobiol. 2014 Dec;40(7):855-72. doi: 10.1111/nan.12116.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/nan.12116/asset/nan12116.pdf?v=1&amp;t=ixshvh2b&amp;s=a038caa1ebad4725c0ada0d7bf97d7eba6e775df</style></url></related-urls><pdf-urls><url>internal-pdf://2254676271/Bailey-2014-Differential gene ex.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4260148</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/nan.12116</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>492</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">492</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bailey, E. L.</style></author><author><style face="normal" font="default" size="100%">Wardlaw, J. M.</style></author><author><style face="normal" font="default" size="100%">Graham, D.</style></author><author><style face="normal" font="default" size="100%">Dominiczak, A. F.</style></author><author><style face="normal" font="default" size="100%">Sudlow, C. L.</style></author><author><style face="normal" font="default" size="100%">Smith, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Clinical Neurosciences Centre for Molecular Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cerebral small vessel endothelial structural changes predate hypertension in stroke-prone spontaneously hypertensive rats: a blinded, controlled immunohistochemical study of 5- to 21-week-old rats</style></title><secondary-title><style face="normal" font="default" size="100%">Neuropathol Appl Neurobiol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuropathology and applied neurobiology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuropathol Appl Neurobiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuropathology and applied neurobiology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuropathol Appl Neurobiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuropathology and applied neurobiology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">711-26</style></pages><volume><style face="normal" font="default" size="100%">37</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2011/03/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/blood supply/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Small Vessel Diseases/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelium, Vascular/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunohistochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred SHR</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred WKY</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Chloride, Dietary</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ pathology/physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1365-2990 (Electronic)&#xD;0305-1846 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">21392049</style></accession-num><abstract><style face="normal" font="default" size="100%">AIMS: The spontaneously hypertensive stroke-prone rat (SHRSP) is a potential animal model of human lacunar stroke, but there is little information on SHRSP small vessel pathology, especially in young rats. We investigated the structural changes that occur in cortical and subcortical vessels and adjacent tissue in SHRSP before, during and after the onset of hypertension. METHODS: We examined brains from SHRSP and Wistar Kyoto rats (WKY) at 5, 16 and 21 weeks of age. Structural changes in small arterioles and adjacent tissue were studied using antibodies to investigate different components of the neurovascular unit. We quantified staining in three standard regions, at two coronal levels. RESULTS: Immunostaining for claudin-5, a marker of endothelial tight junctions, was reduced in SHRSP at all ages compared to age-matched WKY controls. Smooth muscle actin, glial fibrillary acidic protein and ionized calcium-binding adaptor molecule 1 were increased in SHRSP vs. WKY by 16 weeks. Additionally, 21-week-old WKY and SHRSP rats fed a high-salt diet showed differences in claudin-5, glial fibrillary acidic protein and matrix metalloproteinase 9 staining compared to those fed a normal diet. CONCLUSION: Endothelial tight junction alterations of SHRSP rats from the earliest ages point towards increased susceptibility to blood-brain barrier dysfunction and stroke, which is exacerbated by salt loading. Salt loading may also damage the neurovascular unit in WKY controls.</style></abstract><notes><style face="normal" font="default" size="100%">Bailey, E L&#xD;Wardlaw, J M&#xD;Graham, D&#xD;Dominiczak, A F&#xD;Sudlow, C L M&#xD;Smith, C&#xD;CZB/4/517/Chief Scientist Office/United Kingdom&#xD;CH98001/British Heart Foundation/United Kingdom&#xD;RG/07/005/British Heart Foundation/United Kingdom&#xD;Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Neuropathol Appl Neurobiol. 2011 Dec;37(7):711-26. doi: 10.1111/j.1365-2990.2011.01170.x.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/j.1365-2990.2011.01170.x/asset/j.1365-2990.2011.01170.x.pdf?v=1&amp;t=ixshv8rm&amp;s=80a38c1aad8d9e02c908c01658aadf7cb22041d2</style></url></related-urls><pdf-urls><url>internal-pdf://1835238243/Bailey-2011-Cerebral small vesse.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1365-2990.2011.01170.x</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>146</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">146</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bal, S.</style></author><author><style face="normal" font="default" size="100%">Goyal, M.</style></author><author><style face="normal" font="default" size="100%">Smith, E.</style></author><author><style face="normal" font="default" size="100%">Demchuk, A. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Neurosciences and Radiology, Foothills Medical Centre, Calgary, Alberta, Canada.&#xD;Department of Clinical Neurosciences and Radiology, Foothills Medical Centre, Calgary, Alberta, Canada. Electronic address: ademchuk@ucalgary.ca.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Central nervous system imaging in diabetic cerebrovascular diseases and white matter hyperintensities</style></title><secondary-title><style face="normal" font="default" size="100%">Handb Clin Neurol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Handbook of clinical neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Handb Clin Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Handbook of clinical neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Handb Clin Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Handbook of clinical neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">291-315</style></pages><volume><style face="normal" font="default" size="100%">126</style></volume><edition><style face="normal" font="default" size="100%">2014/11/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Disorders/ diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus/ diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Diffusion Tensor Imaging/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Leukoencephalopathies/ diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Angiography/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroimaging/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Tomography, X-Ray Computed/methods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">0072-9752 (Print)&#xD;0072-9752 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25410230</style></accession-num><abstract><style face="normal" font="default" size="100%">Diabetes mellitus is an important vascular risk factor for cerebrovascular disease. This occurs through pathophysiologic changes to the microcirculation as arteriolosclerosis and to the macrocirculation as large artery atherosclerosis. Imaging techniques can provide detailed visualization of the cerebrovasculature using CT (computed tomography) angiography and MR (magnetic resonance) angiography. Newer techniques focused on advanced parenchymal imaging include CT perfusion, quantitative MRI, and diffusion tensor imaging; each identifies brain lesion burden due to diabetes mellitus. These imaging approaches have provided insights into the diabetes mellitus brain and cerebral circulation pathophysiology. Imaging has taught us that diabetics develop cerebral atrophy, silent infarcts, and white matter disease more rapidly than other patient populations. Longitudinal studies are needed to quantify the rate and extent of such structural brain and blood vessel changes and how they relate to cognitive decline. Diabetes prevention and treatment strategies will then be possible to slow the development of such changes.</style></abstract><notes><style face="normal" font="default" size="100%">Bal, Simerpreet&#xD;Goyal, Mayank&#xD;Smith, Eric&#xD;Demchuk, Andrew M&#xD;Review&#xD;Netherlands&#xD;Handb Clin Neurol. 2014;126:291-315. doi: 10.1016/B978-0-444-53480-4.00021-7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/B9780444534804000217/1-s2.0-B9780444534804000217-main.pdf?_tid=3960044e-d7bd-11e6-a9dd-00000aab0f01&amp;acdnat=1484112019_2aa9e7fa6bd0980ff50a2e930bc82333</style></url></related-urls><pdf-urls><url>internal-pdf://2832697535/Bal-2014-Central nervous syst.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/b978-0-444-53480-4.00021-7</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>269</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">269</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Banerjee, A.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Bodhankar, S.</style></author><author><style face="normal" font="default" size="100%">Vandenbark, A. A.</style></author><author><style face="normal" font="default" size="100%">Murphy, S. J.</style></author><author><style face="normal" font="default" size="100%">Offner, H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Phenotypic changes in immune cell subsets reflect increased infarct volume in male vs. female mice</style></title><secondary-title><style face="normal" font="default" size="100%">Transl Stroke Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Translational stroke research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Transl Stroke Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Translational stroke research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Transl Stroke Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Translational stroke research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">554-63</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2013/11/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, CD/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, CD44/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Differentiation, T-Lymphocyte/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">CD4-Positive T-Lymphocytes/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">CD8-Positive T-Lymphocytes/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/immunology/metabolism/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/immunology/metabolism/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Integrin alpha4beta1/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-10/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-2 Receptor beta Subunit/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lectins, C-Type/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/immunology/metabolism/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Sex Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Spleen/immunology/metabolism/ pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1868-601X (Electronic)&#xD;1868-4483 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24187596</style></accession-num><abstract><style face="normal" font="default" size="100%">Inflammatory responses in the brain after cerebral ischemia have been studied extensively in male mice, but not female mice, thus potentially giving a less-than-accurate view of gender associated pathological processes. In humans, cerebral infarcts are typically smaller in premenopausal females than in age-matched males. In the current study, we confirmed smaller infarcts in female vs. male mice after middle cerebral artery occlusion and 96 h of reperfusion. Moreover, we explored immunological alterations related to this difference and found that the percentage of CD4+ T lymphocytes was significantly higher in spleens in males than females, with increased expression of the activation markers, CD69 and CD44. In contrast, the percentage of CD8+ T lymphocytes was significantly higher in spleens of females than males, leading to the identification of a small but distinct population of IL-10-secreting CD8+CD122+ suppressor T cells that were also increased in females. Finally, we observed that males have a greater percentage of activated macrophages/microglia in the brain than females, as well as increased expression of the VLA-4 adhesion molecule in both brain and spleen. This new information suggesting gender-dependent immunological mechanisms in stroke implies that effective treatments for human stroke may also be gender specific.</style></abstract><notes><style face="normal" font="default" size="100%">Banerjee, Anirban&#xD;Wang, Jianming&#xD;Bodhankar, Sheetal&#xD;Vandenbark, Arthur A&#xD;Murphy, Stephanie J&#xD;Offner, Halina&#xD;R01 NS076013/NS/NINDS NIH HHS/United States&#xD;NS076013/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United States&#xD;Transl Stroke Res. 2013 Oct;4(5):554-63.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/131/art%253A10.1007%252Fs12975-013-0268-z.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12975-013-0268-z&amp;token2=exp=1484113039~acl=%2Fstatic%2Fpdf%2F131%2Fart%25253A10.1007%25252Fs12975-013-0268-z.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs12975-013-0268-z*~hmac=c207c68afddfe0730b860df385c77bae16494d4c39e7e4ae4ce3fd086c8bec63</style></url></related-urls><pdf-urls><url>internal-pdf://1475312518/Banerjee-2013-Phenotypic changes i.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3811047</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms498368</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12975-013-0268-z</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>423</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">423</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bao, Y.</style></author><author><style face="normal" font="default" size="100%">Qin, L.</style></author><author><style face="normal" font="default" size="100%">Kim, E.</style></author><author><style face="normal" font="default" size="100%">Bhosle, S.</style></author><author><style face="normal" font="default" size="100%">Guo, H.</style></author><author><style face="normal" font="default" size="100%">Febbraio, M.</style></author><author><style face="normal" font="default" size="100%">Haskew-Layton, R. E.</style></author><author><style face="normal" font="default" size="100%">Ratan, R.</style></author><author><style face="normal" font="default" size="100%">Cho, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Burke-Cornell Medical Research Institute, White Plains, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">CD36 is involved in astrocyte activation and astroglial scar formation</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1567-77</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2012/04/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, CD36/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/immunology/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Culture Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Line</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Proliferation</style></keyword><keyword><style face="normal" font="default" size="100%">Cicatrix/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Glial Fibrillary Acidic Protein</style></keyword><keyword><style face="normal" font="default" size="100%">Gliosis/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Attack, Transient/complications/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Tissue Proteins/biosynthesis/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroglia</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/etiology/metabolism/ pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22510603</style></accession-num><abstract><style face="normal" font="default" size="100%">Inflammation is an essential component for glial scar formation. However, the upstream mediator(s) that triggers the process has not been identified. Previously, we showed that the expression of CD36, an inflammatory mediator, occurs in a subset of astcotyes in the peri-infarct area where the glial scar forms. This study investigates a role for CD36 in astrocyte activation and glial scar formation in stroke. We observed that the expression of CD36 and glial fibrillary acidic protein (GFAP) coincided in control and injured astrocytes and in the brain. Furthermore, GFAP expression was attenuated in CD36 small interfering RNA transfected astrocytes or in the brain of CD36 knockout (KO) mice, suggesting its involvement in GFAP expression. Using an in-vitro model of wound healing, we found that CD36 deficiency attenuated the proliferation of astrocytes and delayed closure of the wound gap. Furthermore, stroke-induced GFAP expression and scar formation were significantly attenuated in the CD36 KO mice compared with wild type. These findings identify CD36 as a novel mediator for injury-induced astrogliosis and scar formation. Targeting CD36 may serve as a potential strategy to reduce glial scar formation in stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Bao, Yi&#xD;Qin, Luye&#xD;Kim, Eunhee&#xD;Bhosle, Sangram&#xD;Guo, Hengchang&#xD;Febbraio, Maria&#xD;Haskew-Layton, Renee E&#xD;Ratan, Rajiv&#xD;Cho, Sunghee&#xD;R01 HL082511/HL/NHLBI NIH HHS/United States&#xD;UL1 RR024996/RR/NCRR NIH HHS/United States&#xD;HL82511-04S1/HL/NHLBI NIH HHS/United States&#xD;UL1RR024996/RR/NCRR NIH HHS/United States&#xD;HL82511/HL/NHLBI NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Cereb Blood Flow Metab. 2012 Aug;32(8):1567-77. doi: 10.1038/jcbfm.2012.52. Epub 2012 Apr 18.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3421096</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2012.52</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>455</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">455</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Barinka, C.</style></author><author><style face="normal" font="default" size="100%">Rojas, C.</style></author><author><style face="normal" font="default" size="100%">Slusher, B.</style></author><author><style face="normal" font="default" size="100%">Pomper, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Biotechnology, Academy of Sciences of the Czech Republic, Videnska 1083, 14200 Praha 4, Czech Republic. cyril.barinka@img.cas.cz</style></auth-address><titles><title><style face="normal" font="default" size="100%">Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Med Chem</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Current medicinal chemistry</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Med Chem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current medicinal chemistry</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Curr Med Chem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current medicinal chemistry</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">856-70</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2012/01/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Glutamate Carboxypeptidase II/antagonists &amp; inhibitors/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nervous System Diseases/diagnosis/drug therapy/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Prostatic Neoplasms/diagnosis/drug therapy/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1875-533X (Electronic)&#xD;0929-8673 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22214450</style></accession-num><abstract><style face="normal" font="default" size="100%">Glutamate carboxypeptidase II (GCPII) is a membrane-bound binuclear zinc metallopeptidase with the highest expression levels found in the nervous and prostatic tissue. Throughout the nervous system, glia-bound GCPII is intimately involved in the neuron-neuron and neuron-glia signaling via the hydrolysis of N-acetylaspartylglutamate (NAAG), the most abundant mammalian peptidic neurotransmitter. The inhibition of the GCPII-controlled NAAG catabolism has been shown to attenuate neurotoxicity associated with enhanced glutamate transmission and GCPII-specific inhibitors demonstrate efficacy in multiple preclinical models including traumatic brain injury, stroke, neuropathic and inflammatory pain, amyotrophic lateral sclerosis, and schizophrenia. The second major area of pharmacological interventions targeting GCPII focuses on prostate carcinoma; GCPII expression levels are highly increased in androgen-independent and metastatic disease. Consequently, the enzyme serves as a potential target for imaging and therapy. This review offers a summary of GCPII structure, physiological functions in healthy tissues, and its association with various pathologies. The review also outlines the development of GCPII-specific small-molecule compounds and their use in preclinical and clinical settings.</style></abstract><notes><style face="normal" font="default" size="100%">Barinka, C&#xD;Rojas, C&#xD;Slusher, B&#xD;Pomper, M&#xD;R01 CA134675/CA/NCI NIH HHS/United States&#xD;CA 134675/CA/NCI NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Netherlands&#xD;Curr Med Chem. 2012;19(6):856-70.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3341092</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms371832</style></custom6><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>470</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">470</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Baron, M.</style></author><author><style face="normal" font="default" size="100%">Boulanger, C. M.</style></author><author><style face="normal" font="default" size="100%">Staels, B.</style></author><author><style face="normal" font="default" size="100%">Tailleux, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Universite Lille Nord de France, Lille, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cell-derived microparticles in atherosclerosis: biomarkers and targets for pharmacological modulation?</style></title><secondary-title><style face="normal" font="default" size="100%">J Cell Mol Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cellular and molecular medicine</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cell Mol Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cellular and molecular medicine</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cell Mol Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cellular and molecular medicine</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1365-76</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2011/11/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antioxidants/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Atherosclerosis/diagnosis/drug therapy/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular System/drug effects/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell-Derived Microparticles/drug effects/metabolism/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default" size="100%">Flow Cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypolipidemic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Infarction/drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Peroxisome Proliferator-Activated Receptors/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombosis/drug therapy/metabolism/pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1582-4934 (Electronic)&#xD;1582-1838 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22050954</style></accession-num><abstract><style face="normal" font="default" size="100%">Cardiovascular diseases remain an important cause of morbi-mortality. Atherosclerosis, which predisposes to cardiovascular disorders such as myocardial infarction and stroke, develops silently over several decades. Identification of circulating biomarkers to evaluate cardiovascular event risk and pathology prognosis is of particular importance. Microparticles (MPs) are small vesicles released from cells upon apoptosis or activation. Microparticles are present in blood of healthy individuals. Studies showing a modification of their concentrations in patients with cardiovascular risk factors and after cardiovascular events identify MPs as potential biomarkers of disease. Moreover, the pathophysiological properties of MPs may contribute to atherosclerosis development. In addition, pharmacological compounds, used in the treatment of cardiovascular disease, can reduce plasma MP concentrations. Nevertheless, numerous issues remain to be solved before MP measurement can be applied as routine biological tests to improve cardiovascular risk prediction. In particular, prospective studies to identify the predictive values of MPs in pathologies such as cardiovascular diseases are needed to demonstrate whether MPs are useful biomarkers for the early detection of the disease and its progression.</style></abstract><notes><style face="normal" font="default" size="100%">Baron, Morgane&#xD;Boulanger, Chantal M&#xD;Staels, Bart&#xD;Tailleux, Anne&#xD;Review&#xD;England&#xD;J Cell Mol Med. 2012 Jul;16(7):1365-76. doi: 10.1111/j.1582-4934.2011.01486.x.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/j.1582-4934.2011.01486.x/asset/jcmm1486.pdf?v=1&amp;t=ixshvls6&amp;s=5d38d121e684f8e5e33bd23b253af1869339b52c</style></url></related-urls><pdf-urls><url>internal-pdf://0295810254/Baron-2012-Cell-derived micropa.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3823207</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1582-4934.2011.01486.x</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>116</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">116</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Beard, D. J.</style></author><author><style face="normal" font="default" size="100%">McLeod, D. D.</style></author><author><style face="normal" font="default" size="100%">Logan, C. L.</style></author><author><style face="normal" font="default" size="100%">Murtha, L. A.</style></author><author><style face="normal" font="default" size="100%">Imtiaz, M. S.</style></author><author><style face="normal" font="default" size="100%">van Helden, D. F.</style></author><author><style face="normal" font="default" size="100%">Spratt, N. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, New South Wales, Australia.&#xD;1] School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, New South Wales, Australia [2] Computational Cardiology Laboratory, Victor Chang Cardiac Research Institute, Darlinghurst, New South Wales, Australia.&#xD;1] School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, New South Wales, Australia [2] Department of Neurology, John Hunter Hospital, Hunter New England Local Health District, New Lambton Heights, New South Wales, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Intracranial pressure elevation reduces flow through collateral vessels and the penetrating arterioles they supply. A possible explanation for &apos;collateral failure&apos; and infarct expansion after ischemic stroke</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">861-72</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2015/02/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arterioles/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Flow Velocity</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/complications/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hypertension/etiology/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/complications/pathology/ physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25669909</style></accession-num><abstract><style face="normal" font="default" size="100%">Recent human imaging studies indicate that reduced blood flow through pial collateral vessels (&apos;collateral failure&apos;) is associated with late infarct expansion despite stable arterial occlusion. The cause for &apos;collateral failure&apos; is unknown. We recently showed that intracranial pressure (ICP) rises dramatically but transiently 24 hours after even minor experimental stroke. We hypothesized that ICP elevation would reduce collateral blood flow. First, we investigated the regulation of flow through collateral vessels and the penetrating arterioles arising from them during stroke reperfusion. Wistar rats were subjected to intraluminal middle cerebral artery (MCA) occlusion (MCAo). Individual pial collateral and associated penetrating arteriole blood flow was quantified using fluorescent microspheres. Baseline bidirectional flow changed to MCA-directed flow and increased by &gt;450% immediately after MCAo. Collateral diameter changed minimally. Second, we determined the effect of ICP elevation on collateral and watershed penetrating arteriole flow. Intracranial pressure was artificially raised in stepwise increments during MCAo. The ICP increase was strongly correlated with collateral and penetrating arteriole flow reductions. Changes in collateral flow post-stroke appear to be primarily driven by the pressure drop across the collateral vessel, not vessel diameter. The ICP elevation reduces cerebral perfusion pressure and collateral flow, and is the possible explanation for &apos;collateral failure&apos; in stroke-in-progression.</style></abstract><notes><style face="normal" font="default" size="100%">Beard, Daniel J&#xD;McLeod, Damian D&#xD;Logan, Caitlin L&#xD;Murtha, Lucy A&#xD;Imtiaz, Mohammad S&#xD;van Helden, Dirk F&#xD;Spratt, Neil J&#xD;United States&#xD;J Cereb Blood Flow Metab. 2015 May;35(5):861-72. doi: 10.1038/jcbfm.2015.2. Epub 2015 Feb 11.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4420869</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2015.2</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>150</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">150</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Beaufort, N.</style></author><author><style face="normal" font="default" size="100%">Scharrer, E.</style></author><author><style face="normal" font="default" size="100%">Kremmer, E.</style></author><author><style face="normal" font="default" size="100%">Lux, V.</style></author><author><style face="normal" font="default" size="100%">Ehrmann, M.</style></author><author><style face="normal" font="default" size="100%">Huber, R.</style></author><author><style face="normal" font="default" size="100%">Houlden, H.</style></author><author><style face="normal" font="default" size="100%">Werring, D.</style></author><author><style face="normal" font="default" size="100%">Haffner, C.</style></author><author><style face="normal" font="default" size="100%">Dichgans, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute for Stroke and Dementia Research, Klinikum der Universitat Munchen, Ludwig Maximilians University, 81377 Munich, Germany;&#xD;Institute of Molecular Immunology, Helmholtz-Zentrum Munchen, 81377 Munich, Germany;&#xD;Centre for Medical Biotechnology, Faculty of Biology, University of Duisburg-Essen, 45141 Essen, Germany;&#xD;Centre for Medical Biotechnology, Faculty of Biology, University of Duisburg-Essen, 45141 Essen, Germany; Emeritus Group Structure Research, Max Planck Institute of Biochemistry, 82152 Martinsried, Germany; Center for Integrated Protein Science at the Department of Chemistry, Lehrstuhl fur Biochemie, Technische Unversitat Munchen, 85748 Garching, Germany; School of Biosciences, Cardiff University, Cardiff CF10 3US, Wales, United Kingdom; christof.haffner@med.uni-muenchen.de huber@biochem.mpg.de martin.dichgans@med.uni-muenchen.de.&#xD;Department of Molecular Neuroscience and Neurogenetics Laboratory, University College London (UCL) Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London WC1N 3BG, United Kingdom;&#xD;Stroke Research Group, Department of Brain Repair and Rehabilitation, UCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London WC1N 3BG, United Kingdom; and.&#xD;Institute for Stroke and Dementia Research, Klinikum der Universitat Munchen, Ludwig Maximilians University, 81377 Munich, Germany; christof.haffner@med.uni-muenchen.de huber@biochem.mpg.de martin.dichgans@med.uni-muenchen.de.&#xD;Institute for Stroke and Dementia Research, Klinikum der Universitat Munchen, Ludwig Maximilians University, 81377 Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), 80336 Munich, Germany christof.haffner@med.uni-muenchen.de huber@biochem.mpg.de martin.dichgans@med.uni-muenchen.de.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cerebral small vessel disease-related protease HtrA1 processes latent TGF-beta binding protein 1 and facilitates TGF-beta signaling</style></title><secondary-title><style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Proceedings of the National Academy of Sciences of the United States of America</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style></full-title><abbr-1><style face="normal" font="default" size="100%">Proceedings of the National Academy of Sciences of the United States of America</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style></full-title><abbr-1><style face="normal" font="default" size="100%">Proceedings of the National Academy of Sciences of the United States of America</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">16496-501</style></pages><volume><style face="normal" font="default" size="100%">111</style></volume><number><style face="normal" font="default" size="100%">46</style></number><edition><style face="normal" font="default" size="100%">2014/11/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Alopecia/ genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/ genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Connective Tissue Growth Factor/biosynthesis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Fibroblasts/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Fibronectins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">HEK293 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Latent TGF-beta Binding Proteins/genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Leukoencephalopathies/ genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation, Missense</style></keyword><keyword><style face="normal" font="default" size="100%">Point Mutation</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Binding</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Interaction Mapping</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Processing, Post-Translational</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/biosynthesis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Fusion Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Serine Endopeptidases/deficiency/genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Serpin E2/biosynthesis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">Spinal Diseases/ genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Transfection</style></keyword><keyword><style face="normal" font="default" size="100%">Transforming Growth Factor beta1/ physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 18</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1091-6490 (Electronic)&#xD;0027-8424 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25369932</style></accession-num><abstract><style face="normal" font="default" size="100%">High temperature requirement protein A1 (HtrA1) is a primarily secreted serine protease involved in a variety of cellular processes including transforming growth factor beta (TGF-beta) signaling. Loss of its activity causes cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL), an inherited form of cerebral small vessel disease leading to early-onset stroke and premature dementia. Dysregulated TGF-beta signaling is considered to promote CARASIL pathogenesis, but the underlying molecular mechanisms are incompletely understood. Here we present evidence from mouse brain tissue and embryonic fibroblasts as well as patient skin fibroblasts for a facilitating role of HtrA1 in TGF-beta pathway activation. We identify latent TGF-beta binding protein 1 (LTBP-1), an extracellular matrix protein and key regulator of TGF-beta bioavailability, as a novel HtrA1 target. Cleavage occurs at physiological protease concentrations, is prevented under HtrA1-deficient conditions as well as by CARASIL mutations and disrupts both LTBP-1 binding to fibronectin and its incorporation into the extracellular matrix. Hence, our data suggest an attenuation of TGF-beta signaling caused by a lack of HtrA1-mediated LTBP-1 processing as mechanism underlying CARASIL pathogenesis.</style></abstract><notes><style face="normal" font="default" size="100%">Beaufort, Nathalie&#xD;Scharrer, Eva&#xD;Kremmer, Elisabeth&#xD;Lux, Vanda&#xD;Ehrmann, Michael&#xD;Huber, Robert&#xD;Houlden, Henry&#xD;Werring, David&#xD;Haffner, Christof&#xD;Dichgans, Martin&#xD;G0802760/Medical Research Council/United Kingdom&#xD;MR/J004758/1/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16496-501. doi: 10.1073/pnas.1418087111. Epub 2014 Nov 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.pnas.org/content/111/46/16496.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3504127677/Beaufort-2014-Cerebral small vesse.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4246310</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1073/pnas.1418087111</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>182</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">182</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Beckmann,</style></author><author><style face="normal" font="default" size="100%">Oevermann,</style></author><author><style face="normal" font="default" size="100%">Golini,</style></author><author><style face="normal" font="default" size="100%">Steffen,</style></author><author><style face="normal" font="default" size="100%">Kircher,</style></author><author><style face="normal" font="default" size="100%">Carrera,</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Section of Neurology, Department of Small Animals, Vetsuisse Faculty, University of Zurich.&#xD;Division of Neurological Sciences, DCR-VPH, Vetsuisse Faculty, University of Berne.&#xD;Division of Diagnostic Imaging, Vetsuisse Faculty, University of Zurich.</style></auth-address><titles><title><style face="normal" font="default" size="100%">MRI findings in a case of canine tick born meningoencephalomyelitis</style></title><secondary-title><style face="normal" font="default" size="100%">Schweiz Arch Tierheilkd</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Schweizer Archiv fur Tierheilkunde</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Schweiz Arch Tierheilkd</style></full-title><abbr-1><style face="normal" font="default" size="100%">Schweizer Archiv fur Tierheilkunde</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Schweiz Arch Tierheilkd</style></full-title><abbr-1><style face="normal" font="default" size="100%">Schweizer Archiv fur Tierheilkunde</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">395-9</style></pages><volume><style face="normal" font="default" size="100%">156</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2014/08/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Dog Diseases/ diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Dogs</style></keyword><keyword><style face="normal" font="default" size="100%">Encephalitis, Tick-Borne/diagnosis/ veterinary</style></keyword><keyword><style face="normal" font="default" size="100%">Encephalomyelitis/diagnosis/ veterinary</style></keyword><keyword><style face="normal" font="default" size="100%">Fatal Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Meningoencephalitis/diagnosis/ veterinary</style></keyword><keyword><style face="normal" font="default" size="100%">Switzerland</style></keyword><keyword><style face="normal" font="default" size="100%">Schweiz und verursacht Meningoencephalomyelitis beim Hund. Wir beschreiben hier</style></keyword><keyword><style face="normal" font="default" size="100%">einen Fall von FSME beim Hund mit Tetraparese und Atemlahmung. Die</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetresonatztomographie zeigte intra-axiale bilateral symmetrische und</style></keyword><keyword><style face="normal" font="default" size="100%">hyperintense Lasionen in T2 gewichteten Sequenzen im Thalamus, den Basalkernen,</style></keyword><keyword><style face="normal" font="default" size="100%">der cerebralen weissen Substanz und dem Ventralhorn des Hals- Ruckenmarks. Diese</style></keyword><keyword><style face="normal" font="default" size="100%">Bildgebungsbefunde sind vergleichbar mit Bildgebungsbefunden von humanen FSME</style></keyword><keyword><style face="normal" font="default" size="100%">Fallen. Die Lasionen im MRI und im Diffusionsgewichteten MRI korrelieren mit</style></keyword><keyword><style face="normal" font="default" size="100%">Bereichen von vasogenem Odem in der Pathohistologie. In endemischen Gebieten</style></keyword><keyword><style face="normal" font="default" size="100%">sollte bei bilateral symmetrischen hyperintensen thalamischen Lasionen in T2</style></keyword><keyword><style face="normal" font="default" size="100%">gewichteten Sequenzen FSME als Differentialdiagnose in Betracht gezogen werden.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0036-7281 (Print)&#xD;0036-7281 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25082637</style></accession-num><abstract><style face="normal" font="default" size="100%">Tick borne encephalitis virus (TBE) is an endemic infectious agent in northeastern Switzerland causing mainly meningoencephalomyelitis in dogs. We report a canine case of tick born meningoencephalomyelitis resulting in flaccid tetraplegia and, subsequently, fatal respiratory failure. Magnetic resonance imaging (MRI) demonstrated intra-axial bilateral, symmetric, and hyperintense lesions in T2-weighted and Fluid Attenuated Inversion Recovery (FLAIR) sequences affecting thalamus, basal nuclei, cerebral white matter and ventral horns of the caudal cervical spine. These radiological findings overlap those described during flavivirus encephalitis affecting human beings. These lesions in MRI and diffusion weighted images correlated with areas of vasogenic edema detected histopathologically. In endemic regions, clinicians should be aware that bilateral, symmetrical hyperintense thalamic lesions in T2WI can be suggestive of flavivirus infection in dogs with encephalitis.</style></abstract><notes><style face="normal" font="default" size="100%">Beckmann&#xD;Oevermann&#xD;Golini&#xD;Steffen&#xD;Kircher&#xD;Carrera&#xD;Case Reports&#xD;Switzerland&#xD;Schweiz Arch Tierheilkd. 2014 Aug;156(8):395-9. doi: 10.1024/0036-7281/a000612.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1024/0036-7281/a000612</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>79</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">79</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Begum, G.</style></author><author><style face="normal" font="default" size="100%">Yuan, H.</style></author><author><style face="normal" font="default" size="100%">Kahle, K. T.</style></author><author><style face="normal" font="default" size="100%">Li, L.</style></author><author><style face="normal" font="default" size="100%">Wang, S.</style></author><author><style face="normal" font="default" size="100%">Shi, Y.</style></author><author><style face="normal" font="default" size="100%">Shmukler, B. E.</style></author><author><style face="normal" font="default" size="100%">Yang, S. S.</style></author><author><style face="normal" font="default" size="100%">Lin, S. H.</style></author><author><style face="normal" font="default" size="100%">Alper, S. L.</style></author><author><style face="normal" font="default" size="100%">Sun, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From the Department of Neurology, University of Pittsburgh, PA, (G.B., H.Y., L.L., S.W., Y.S., D.S.); Department of Neurosurgery, Boston Children&apos;s Hospital (K.T.K.), Manton Center for Orphan Diseases (K.T.K.), and Department of Medicine (B.E.S., S.L.A), Harvard Medical School, Boston, MA; Renal Division and Vascular Biology Center, Beth Israel Deaconess Medical Center, Boston, MA (B.E.S., S.L.A); Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan (S.-S.Y., S.-H.L.); and Veterans Affairs Pittsburgh Health Care System, Geriatric Research, Educational and Clinical Center, PA (D.S).&#xD;From the Department of Neurology, University of Pittsburgh, PA, (G.B., H.Y., L.L., S.W., Y.S., D.S.); Department of Neurosurgery, Boston Children&apos;s Hospital (K.T.K.), Manton Center for Orphan Diseases (K.T.K.), and Department of Medicine (B.E.S., S.L.A), Harvard Medical School, Boston, MA; Renal Division and Vascular Biology Center, Beth Israel Deaconess Medical Center, Boston, MA (B.E.S., S.L.A); Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan (S.-S.Y., S.-H.L.); and Veterans Affairs Pittsburgh Health Care System, Geriatric Research, Educational and Clinical Center, PA (D.S). sund@upmc.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inhibition of WNK3 Kinase Signaling Reduces Brain Damage and Accelerates Neurological Recovery After Stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1956-65</style></pages><volume><style face="normal" font="default" size="100%">46</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2015/06/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/ enzymology/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, 129 Strain</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Nervous System Diseases/ enzymology/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Protein-Serine-Threonine Kinases/ antagonists &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">inhibitors/ biosynthesis/deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery of Function/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ enzymology/pathology/physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26069258</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: WNK kinases, including WNK3, and the associated downstream Ste20/SPS1-related proline-alanine-rich protein kinase (SPAK) and oxidative stress responsive 1 (OSR1) kinases, comprise an important signaling cascade that regulates the cation-chloride cotransporters. Ischemia-induced stimulation of the bumetanide-sensitive Na(+)-K(+)-Cl(-) cotransporter (NKCC1) plays an important role in the pathophysiology of experimental stroke, but the mechanism of its regulation in this context is unknown. Here, we investigated the WNK3-SPAK/OSR1 pathway as a regulator of NKCC1 stimulation and their collective role in ischemic brain damage. METHOD: Wild-type WNK3 and WNK3 knockout mice were subjected to ischemic stroke via transient middle cerebral artery occlusion. Infarct volume, brain edema, blood brain barrier damage, white matter demyelination, and neurological deficits were assessed. Total and phosphorylated forms of WNK3 and SPAK/OSR1 were assayed by immunoblotting and immunostaining. In vitro ischemia studies in cultured neurons and immature oligodendrocytes were conducted using the oxygen-glucose deprivation/reoxygenation method. RESULTS: WNK3 knockout mice exhibited significantly decreased infarct volume and axonal demyelination, less cerebral edema, and accelerated neurobehavioral recovery compared with WNK3 wild-type mice subjected to middle cerebral artery occlusion. The neuroprotective phenotypes conferred by WNK3 knockout were associated with a decrease in stimulatory hyperphosphorylations of the SPAK/OSR1 catalytic T-loop and of NKCC1 stimulatory sites Thr(203)/Thr(207)/Thr(212), as well as with decreased cell surface expression of NKCC1. Genetic inhibition of WNK3 or small interfering RNA knockdown of SPAK/OSR1 increased the tolerance of cultured primary neurons and oligodendrocytes to in vitro ischemia. CONCLUSIONS: These data identify a novel role for the WNK3-SPAK/OSR1-NKCC1 signaling pathway in ischemic neuroglial injury and suggest the WNK3-SPAK/OSR1 kinase pathway as a therapeutic target for neuroprotection after ischemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Begum, Gulnaz&#xD;Yuan, Hui&#xD;Kahle, Kristopher T&#xD;Li, Liaoliao&#xD;Wang, Shaoxia&#xD;Shi, Yejie&#xD;Shmukler, Boris E&#xD;Yang, Sung-Sen&#xD;Lin, Shih-Hua&#xD;Alper, Seth L&#xD;Sun, Dandan&#xD;R01 NS038118/NS/NINDS NIH HHS/United States&#xD;T35 HL007765/HL/NHLBI NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Stroke. 2015 Jul;46(7):1956-65. doi: 10.1161/STROKEAHA.115.008939. Epub 2015 Jun 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/46/7/1956.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2397250424/Begum-2015-Inhibition of WNK3 K.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4643659</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms692023</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.115.008939</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>283</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">283</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Benke, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Pharmacology and Toxicology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland; Neuroscience Center Zurich, University of Zurich and ETH Zurich, 8057 Zurich, Switzerland. Electronic address: benke@pharma.uzh.ch.</style></auth-address><titles><title><style face="normal" font="default" size="100%">GABAB receptor trafficking and interacting proteins: targets for the development of highly specific therapeutic strategies to treat neurological disorders?</style></title><secondary-title><style face="normal" font="default" size="100%">Biochem Pharmacol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Biochemical pharmacology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Biochem Pharmacol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Biochemical pharmacology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Biochem Pharmacol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Biochemical pharmacology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1525-30</style></pages><volume><style face="normal" font="default" size="100%">86</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2013/10/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Binding Sites</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">GABA-B Receptor Agonists/adverse effects/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Nervous System Diseases/ drug therapy/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/administration &amp; dosage/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Binding</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Phosphatase 2/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Transport</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, GABA-B/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, N-Methyl-D-Aspartate/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 01</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1873-2968 (Electronic)&#xD;0006-2952 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24084431</style></accession-num><abstract><style face="normal" font="default" size="100%">GABAB receptors mediate slow inhibitory neurotransmission throughout the central nervous system thereby controlling the excitability of neurons. They have been implicated in numerous neurological disorders making them an attractive drug target. However, due to considerable side effects, the agonist baclofen is so far the only drug on the market targeting GABAB receptors, primarily for the treatment of spasticity. Because GABAB receptors are involved in a variety of brain functions it is rather unlikely to avoid unwanted effects with systemically administered drugs directly addressing ligand binding sites of the receptor. To minimize side effects, it would be desirable to target only those receptors involved in a given pathological state. This commentary discusses the idea that restoring impaired GABAB receptor function in diseased neurons by interfering with receptor-protein interactions may be an approach to specifically target only those receptors involved in the pathological state. Two recently discovered mechanisms that down-regulate the level of functional GABAB receptors most likely contribute to cerebral ischemia and neuropathic pain, respectively. In both mechanisms, small interfering peptides disrupting protein-protein interactions may offer a highly specific means to restore normal receptor function selectively at the site of malfunction. If restored functional GABAB receptor expression in these diseases has beneficial effects, this may serve as a starting point for the development of a highly specific therapeutic interventions. Such an approach is expected to minimize side effects because it promises to leave those GABAB receptors unaffected which are not involved in the dysfunction.</style></abstract><notes><style face="normal" font="default" size="100%">Benke, Dietmar&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;England&#xD;Biochem Pharmacol. 2013 Dec 1;86(11):1525-30. doi: 10.1016/j.bcp.2013.09.016. Epub 2013 Sep 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0006295213006217/1-s2.0-S0006295213006217-main.pdf?_tid=466390ca-d7bd-11e6-ae1a-00000aab0f26&amp;acdnat=1484112041_d4dd88caf6988423f929b453f41eef6e</style></url></related-urls><pdf-urls><url>internal-pdf://2398540100/Benke-2013-GABAB receptor traff.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.bcp.2013.09.016</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>373</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">373</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Benson, R. R.</style></author><author><style face="normal" font="default" size="100%">Gattu, R.</style></author><author><style face="normal" font="default" size="100%">Sewick, B.</style></author><author><style face="normal" font="default" size="100%">Kou, Z.</style></author><author><style face="normal" font="default" size="100%">Zakariah, N.</style></author><author><style face="normal" font="default" size="100%">Cavanaugh, J. M.</style></author><author><style face="normal" font="default" size="100%">Haacke, E. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Neurological Studies, Novi, MI, USA. drbenson@neurologicstudies.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">Detection of hemorrhagic and axonal pathology in mild traumatic brain injury using advanced MRI: implications for neurorehabilitation</style></title><secondary-title><style face="normal" font="default" size="100%">NeuroRehabilitation</style></secondary-title><alt-title><style face="normal" font="default" size="100%">NeuroRehabilitation</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">NeuroRehabilitation</style></full-title><abbr-1><style face="normal" font="default" size="100%">NeuroRehabilitation</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">NeuroRehabilitation</style></full-title><abbr-1><style face="normal" font="default" size="100%">NeuroRehabilitation</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">261-79</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2012/10/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Amyloid beta-Peptides/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Anisotropy</style></keyword><keyword><style face="normal" font="default" size="100%">Axons/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/metabolism/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/ complications/rehabilitation</style></keyword><keyword><style face="normal" font="default" size="100%">Diffuse Axonal Injury/diagnosis/metabolism/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Diffusion Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Glasgow Coma Scale</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Image Processing, Computer-Assisted</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hemorrhages/ diagnosis/ etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Fibers, Myelinated/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Statistics, Nonparametric</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1878-6448 (Electronic)&#xD;1053-8135 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23093454</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: There is a need to more accurately diagnose milder traumatic brain injuries with increasing awareness of the high prevalence in both military and civilian populations. Magnetic resonance imaging methods may be capable of detecting a number of the pathoanatomical and pathophysiological consequences of focal and diffuse traumatic brain injury. Susceptibility-weighted imaging (SWI) detects heme iron and reveals even small venous microhemorrhages occurring in diffuse vascular injury. Diffusion tensor imaging (DTI) reveals axonal injury by detecting alterations in water flow in and around injured axons. The overarching hypothesis of this paper is that newer, advanced MR imaging generates sensitive biomarkers of regional brain injury which allows for correlation with clinical signs and symptoms. METHODS: Studies involving subjects with a history of traumatic brain injury as well as healthy, non-trauma controls were used. Analysis involved comparison of TBI patients&apos; imaging results with healthy controls as well as correlation of imaging findings with clinical measures of injury severity. An additional animal study of Sprague-Dawley albino rats compared imaging results with histopathological findings after the animals were sacrificed and stained for b-APP. RESULTS: SWI revealed small foci of hemosiderin for some patients while aggregate lesion volume on SWI correlated with clinical injury severity indices. Similarly, DTI showed striking group differences for fractional anisotropy over the white matter globally, while tract and voxel-based regional results colocalized with SWI and FLAIR lesions in some cases and correlated with clinical deficits. For the rats, correlations were seen between imaging findings and staining of axonal injury. DISCUSSION: Animal data gave important tissue correlations with imaging results. SWI and DTI are commercially available sequences that can improve the diagnostic and prognostic ability of the trauma clinician. These biomarkers of regional brain injury which are present in imaging shortly after acute injury and persist indefinitely can inform clinicians and researchers about not only injury severity but also which neurobehavioral systems were injured. Analogous to stroke rehabilitation, having an understanding of the distribution of brain injury should ultimately allow for development of more effective rehabilitation strategies and more efficient clinical interventional trials.</style></abstract><notes><style face="normal" font="default" size="100%">Benson, Randall R&#xD;Gattu, Ramtilak&#xD;Sewick, Bradley&#xD;Kou, Zhifeng&#xD;Zakariah, Nisrine&#xD;Cavanaugh, John M&#xD;Haacke, E Mark&#xD;Netherlands&#xD;NeuroRehabilitation. 2012;31(3):261-79. doi: 10.3233/NRE-2012-0795.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://content.iospress.com/articles/neurorehabilitation/nre00795</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3233/nre-2012-0795</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>68</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">68</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Berezuk, C.</style></author><author><style face="normal" font="default" size="100%">Ramirez, J.</style></author><author><style face="normal" font="default" size="100%">Gao, F.</style></author><author><style face="normal" font="default" size="100%">Scott, C. J.</style></author><author><style face="normal" font="default" size="100%">Huroy, M.</style></author><author><style face="normal" font="default" size="100%">Swartz, R. H.</style></author><author><style face="normal" font="default" size="100%">Murray, B. J.</style></author><author><style face="normal" font="default" size="100%">Black, S. E.</style></author><author><style face="normal" font="default" size="100%">Boulos, M. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">LC Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute (SRI), University of Toronto, Canada.&#xD;Heart &amp; Stroke Foundation Canadian Partnership for Stroke Recovery, Sunnybrook Site, Toronto, Canada.&#xD;Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre (HSC), Toronto, Canada.&#xD;Institute of Medical Science, Faculty of Medicine, School of Graduate Studies University of Toronto, Toronto, Canada.&#xD;Department of Medicine (Neurology), University of Toronto and Sunnybrook HSC, Toronto, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Virchow-Robin Spaces: Correlations with Polysomnography-Derived Sleep Parameters</style></title><secondary-title><style face="normal" font="default" size="100%">Sleep</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Sleep</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Sleep</style></full-title><abbr-1><style face="normal" font="default" size="100%">Sleep</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Sleep</style></full-title><abbr-1><style face="normal" font="default" size="100%">Sleep</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">853-8</style></pages><volume><style face="normal" font="default" size="100%">38</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2015/07/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Basal Ganglia/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Imaging, Three-Dimensional</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Polysomnography</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Sleep/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 01</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1550-9109 (Electronic)&#xD;0161-8105 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26163465</style></accession-num><abstract><style face="normal" font="default" size="100%">STUDY OBJECTIVES: To test the hypothesis that enlarged Virchow-Robin space volumes (VRS) are associated with objective measures of poor quality sleep. DESIGN: Retrospective cross-sectional study. SETTING: Sunnybrook Health Sciences Centre. PATIENTS: Twenty-six patients being evaluated for cerebrovascular disease were assessed using polysomnography and high-resolution structural magnetic resonance imaging. MEASUREMENTS AND RESULTS: Regionalized VRS were quantified from three-dimensional high-resolution magnetic resonance imaging and correlated with measures of polysomnography-derived sleep parameters while controlling for age, stroke volume, body mass index, systolic blood pressure, and ventricular cerebrospinal fluid volume. Sleep efficiency was negatively correlated with total VRS (rho = -0.47, P = 0.03) and basal ganglia VRS (rho = -0.54, P = 0.01), whereas wake after sleep onset was positively correlated with basal ganglia VRS (rho = 0.52, P = 0.02). Furthermore, VRS in the basal ganglia were negatively correlated with duration of N3 (rho = -0.53, P = 0.01). CONCLUSIONS: These preliminary results suggest that sleep may play a role in perivascular clearance in ischemic brain disease, and invite future research into the potential relevance of Virchow-Robin spaces as an imaging biomarker for nocturnal metabolite clearance.</style></abstract><notes><style face="normal" font="default" size="100%">Berezuk, Courtney&#xD;Ramirez, Joel&#xD;Gao, Fuqiang&#xD;Scott, Christopher J M&#xD;Huroy, Menal&#xD;Swartz, Richard H&#xD;Murray, Brian J&#xD;Black, Sandra E&#xD;Boulos, Mark I&#xD;Canadian Institutes of Health Research/Canada&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Sleep. 2015 Jun 1;38(6):853-8. doi: 10.5665/sleep.4726.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4434551</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.5665/sleep.4726</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>413</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">413</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bersano, A.</style></author><author><style face="normal" font="default" size="100%">Debette, S.</style></author><author><style face="normal" font="default" size="100%">Zanier, E. R.</style></author><author><style face="normal" font="default" size="100%">Lanfranconi, S.</style></author><author><style face="normal" font="default" size="100%">De Simoni, M. G.</style></author><author><style face="normal" font="default" size="100%">Zuffardi, O.</style></author><author><style face="normal" font="default" size="100%">Micieli, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Emergency Neurology, IRCCS C. Mondino National Neurological Institute Foundation, Via Mondino 2, 27100 Pavia, Italy. anna.bersano@gmail.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">The genetics of small-vessel disease</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Med Chem</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Current medicinal chemistry</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Med Chem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current medicinal chemistry</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Curr Med Chem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current medicinal chemistry</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">4124-41</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">24</style></number><edition><style face="normal" font="default" size="100%">2012/06/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apolipoproteins E/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">CADASIL/genetics/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Amyloid Angiopathy/genetics/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Small Vessel Diseases/ genetics/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Collagen Type IV/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Exodeoxyribonucleases/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Fabry Disease/genetics/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphoproteins/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Notch3</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Notch/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">alpha-Galactosidase/genetics/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1875-533X (Electronic)&#xD;0929-8673 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22680632</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebral small-vessel disease (SVD) is a well-known cause of stroke, dementia and death, but its pathogenesis is not yet completely understood. The spectrum of neuroradiological manifestations associated with SVD is wide and may result from chronic and diffuse or acute and focal ischemia (leukoaraiosis and lacunar infarction) as well as from small-vessel rupture (cerebral microbleeds and intracerebral hemorrhage). Several lines of evidence from family and twin studies support the hypothesis that genetic factors may contribute to SVD pathogenesis. Identification of genetic susceptibility factors for SVD may improve our knowledge of SVD pathogenesis and help to identify new therapeutic targets to reduce the burden of SVD-related cognitive decline and stroke disability. A number of monogenic conditions presenting with clinical features of SVD have been described. Although monogenic disorders account for only a small proportion of SVD, study of these diseases may provide further insight into the pathogenesis of SVD. In most cases, however, SVD is thought to be a multifactorial disorder. Several genetic association studies, conducted using the candidate gene and, more recently, the genome-wide approach, have so far failed to demonstrate a convincing association between SVD and genetic variants. Methodological issues, particularly related to inaccurate or heterogeneous phenotyping and insufficient sample sizes, have been invoked as possible reasons for this. Large collaborative efforts and robust replication, as well as implementation of new genetic approaches, are necessary to identify genetic susceptibility factors for complex SVD.</style></abstract><notes><style face="normal" font="default" size="100%">Bersano, A&#xD;Debette, S&#xD;Zanier, E R&#xD;Lanfranconi, S&#xD;De Simoni, M G&#xD;Zuffardi, O&#xD;Micieli, G&#xD;Review&#xD;Netherlands&#xD;Curr Med Chem. 2012;19(24):4124-41.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>25</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">25</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Betteridge, D. J.</style></author><author><style face="normal" font="default" size="100%">Carmena, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Diabetes &amp;Endocrinology, University College Hospitals Trust, 3rd Floor Central, 250 Euston Road, London NW1 2PQ, UK.&#xD;Department of Medicine, University of Valencia, Avenida Blasco Ibanez, 17, 46010 Valencia, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The diabetogenic action of statins - mechanisms and clinical implications</style></title><secondary-title><style face="normal" font="default" size="100%">Nat Rev Endocrinol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Nature reviews. Endocrinology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nat Rev Endocrinol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Nature reviews. Endocrinology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Nat Rev Endocrinol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Nature reviews. Endocrinology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">99-110</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2015/12/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases/ drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2/ chemically induced/genetics/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Feeding Behavior</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hydroxymethylglutaryl CoA Reductases/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Hydroxymethylglutaryl-CoA Reductase Inhibitors/ adverse effects/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">In Vitro Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Insulin Resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Insulin-Secreting Cells/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Mendelian Randomization Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Reduction Behavior</style></keyword><keyword><style face="normal" font="default" size="100%">Secondary Prevention</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1759-5037 (Electronic)&#xD;1759-5029 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26668119</style></accession-num><abstract><style face="normal" font="default" size="100%">Treatment with statins has transformed primary and secondary prevention of cardiovascular disease (CVD), including thrombotic stroke. Evidence-based data demonstrate the benefits and safety of statin therapy and help to guide clinicians in the management of populations at high risk of CVD. Nevertheless, clinical trials, meta-analyses and observational studies highlight a 10-12% increase in new-onset diabetes mellitus (NODM) among patients receiving statins. The risk further increases with intensive therapy and among individuals with known risk factors for NODM. Mechanisms underpinning this effect are not yet fully understood; however, Mendelian randomization studies suggest that they are related to lowered activity of HMG-CoA reductase, the target of statin therapy. In vitro research indicates that statins potentially impair beta-cell function and decrease insulin sensitivity but how these findings relate to patients is unknown. In the clinic, statins should be prescribed on the basis of CVD risk and individual patient characteristics. In addition, diet and lifestyle interventions should be emphasized to help mitigate the risk of NODM. Individuals who develop NODM while taking statins do not exhibit increased microvascular disease, which is reassuring. In diabetes mellitus of long duration, the effect of statins on glycaemic control is small and unlikely to be clinically important.</style></abstract><notes><style face="normal" font="default" size="100%">Betteridge, D John&#xD;Carmena, Rafael&#xD;Review&#xD;England&#xD;Nat Rev Endocrinol. 2016 Feb;12(2):99-110. doi: 10.1038/nrendo.2015.194. Epub 2015 Dec 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.nature.com/nrendo/journal/v12/n2/pdf/nrendo.2015.194.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2921791458/Betteridge-2016-The diabetogenic act.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/nrendo.2015.194</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>213</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">213</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Beuing, O.</style></author><author><style face="normal" font="default" size="100%">Boese, A.</style></author><author><style face="normal" font="default" size="100%">Kyriakou, Y.</style></author><author><style face="normal" font="default" size="100%">Deuerling-Zengh, Y.</style></author><author><style face="normal" font="default" size="100%">Jollenbeck, B.</style></author><author><style face="normal" font="default" size="100%">Scherlach, C.</style></author><author><style face="normal" font="default" size="100%">Lenz, A.</style></author><author><style face="normal" font="default" size="100%">Serowy, S.</style></author><author><style face="normal" font="default" size="100%">Gugel, S.</style></author><author><style face="normal" font="default" size="100%">Rose, G.</style></author><author><style face="normal" font="default" size="100%">Skalej, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From the Institute of Neuroradiology (O.B., C.S., A.L., S.S., M.S.) oliver.beuing@med.ovgu.de.&#xD;Healthcare Telematics and Medical Engineering (A.B., S.G., G.R.), Otto von Guericke University, Magdeburg, Germany.&#xD;Siemens AG (Y.K., Y.D.-Z.), Healthcare Sector, Erlangen, Germany.&#xD;Department of Neurosurgery (B.J.).&#xD;From the Institute of Neuroradiology (O.B., C.S., A.L., S.S., M.S.).</style></auth-address><titles><title><style face="normal" font="default" size="100%">A novel technique for the measurement of CBF and CBV with robot-arm-mounted flat panel CT in a large-animal model</style></title><secondary-title><style face="normal" font="default" size="100%">AJNR Am J Neuroradiol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">AJNR. American journal of neuroradiology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">AJNR Am J Neuroradiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">AJNR. American journal of neuroradiology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">AJNR Am J Neuroradiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">AJNR. American journal of neuroradiology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1740-5</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2014/05/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Angiography/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Perfusion Imaging/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Robotics/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Sheep</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ diagnostic imaging</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1936-959X (Electronic)&#xD;0195-6108 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24831590</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: Endovascular therapy is an emerging treatment option in patients with acute ischemic stroke and especially in cases presenting late after symptom onset. Information about remaining viable tissue as measured with perfusion imaging is crucial for proper patient selection. The aim of this study was to investigate whether perfusion imaging with C-arm CT in the angiography suite is feasible and provides measurements comparable with ones made by CTP. MATERIALS AND METHODS: The MCA was occluded surgically in 6 sheep. Perfusion studies were performed before surgery, immediately after, and at 3 hours after MCA occlusion by using a robotic flat panel detector C-arm angiographic system. For comparison, conventional CTP was performed at the same time points. Two different protocols with the C-arm CT were tested. Images were analyzed by 2 readers with regard to the presence and size of perfusion abnormalities. RESULTS: With C-arm CT, perfusion abnormalities were detected with a high sensitivity and specificity when vessel occlusion was confirmed by criterion standard DSA. No difference was found between lesions sizes measured with the 2 C-arm CT protocols and CTP. Growth of the CBV lesions with time was captured with C-arm CT and CTP. CONCLUSIONS: In this small study, it was feasible to qualitatively measure CBV and CBF by using a flat panel detector angiographic system.</style></abstract><notes><style face="normal" font="default" size="100%">Beuing, O&#xD;Boese, A&#xD;Kyriakou, Y&#xD;Deuerling-Zengh, Y&#xD;Jollenbeck, B&#xD;Scherlach, C&#xD;Lenz, A&#xD;Serowy, S&#xD;Gugel, S&#xD;Rose, G&#xD;Skalej, M&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;AJNR Am J Neuroradiol. 2014 Sep;35(9):1740-5. doi: 10.3174/ajnr.A3973. Epub 2014 May 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.ajnr.org/content/35/9/1740.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0064494507/Beuing-2014-A novel technique fo.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3174/ajnr.A3973</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>290</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">290</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bhatt, A.</style></author><author><style face="normal" font="default" size="100%">Menon, A. A.</style></author><author><style face="normal" font="default" size="100%">Bhat, R.</style></author><author><style face="normal" font="default" size="100%">Ramamoorthi, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Kasturba Medical College, Manipal, Karnataka, India.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Myocarditis along with acute ischaemic cerebellar, pontine and lacunar infarction following viper bite</style></title><secondary-title><style face="normal" font="default" size="100%">BMJ Case Rep</style></secondary-title><alt-title><style face="normal" font="default" size="100%">BMJ case reports</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMJ Case Rep</style></full-title><abbr-1><style face="normal" font="default" size="100%">BMJ case reports</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">BMJ Case Rep</style></full-title><abbr-1><style face="normal" font="default" size="100%">BMJ case reports</style></abbr-1></alt-periodical><volume><style face="normal" font="default" size="100%">2013</style></volume><edition><style face="normal" font="default" size="100%">2013/09/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Infarction/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Stem Infarctions/ etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebellar Diseases/ etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Myocarditis/ etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Pons</style></keyword><keyword><style face="normal" font="default" size="100%">Snake Bites/ complications</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke, Lacunar/ etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Viper Venoms/ poisoning</style></keyword><keyword><style face="normal" font="default" size="100%">Viperidae</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 06</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1757-790X (Electronic)&#xD;1757-790X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24014571</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebrovascular complications are rare following viper bites. A 65-year-old man presented with loss of consciousness and developed haemiparesis following a viper bite. Coagulation parameters were severely deranged. MRI showed acute ischaemic infarction on the left side in the precentral and postcentral gyrus, hemipons and cerebellum. Troponin T was elevated and transient left bundle branch block was seen. The patient had a good outcome following treatment with Anti Snake Venom and supportive therapy. Possible mechanisms of infarction are discussed.</style></abstract><notes><style face="normal" font="default" size="100%">Bhatt, Alok&#xD;Menon, Aravind Ajakumar&#xD;Bhat, Rama&#xD;Ramamoorthi, Kusugodlu&#xD;Case Reports&#xD;England&#xD;BMJ Case Rep. 2013 Sep 6;2013. pii: bcr2013200336. doi: 10.1136/bcr-2013-200336.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://casereports.bmj.com/content/2013/bcr-2013-200336.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1783570743/Bhatt-2013-Myocarditis along wi.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3794210</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/bcr-2013-200336</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>246</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">246</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bitsikas, V.</style></author><author><style face="normal" font="default" size="100%">Riento, K.</style></author><author><style face="normal" font="default" size="100%">Howe, J. D.</style></author><author><style face="normal" font="default" size="100%">Barry, N. P.</style></author><author><style face="normal" font="default" size="100%">Nichols, B. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Molecular Biology, Medical Research Council, Cambridge, Cambridgeshire, United Kingdom.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The role of flotillins in regulating abeta production, investigated using flotillin 1-/-, flotillin 2-/- double knockout mice</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PloS one</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e85217</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2014/01/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Amyloid beta-Peptides/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Amyloid Angiopathy/genetics/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Embryo, Mammalian</style></keyword><keyword><style face="normal" font="default" size="100%">Fibroblasts/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Deletion</style></keyword><keyword><style face="normal" font="default" size="100%">Genes, Reporter</style></keyword><keyword><style face="normal" font="default" size="100%">Green Fluorescent Proteins/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Membrane Proteins/deficiency/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Cell Culture</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Transport</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203 (Electronic)&#xD;1932-6203 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24465508</style></accession-num><abstract><style face="normal" font="default" size="100%">Flotillin 1 and flotillin 2 associate in the plasma membrane to form microdomains that have roles in cell signaling, regulation of cell-cell contacts, membrane-cytoskeletal interactions, and endocytosis. They are thought to be involved in the trafficking and hence processing of the Amyloid Precursor Protein, APP. In this study we set out to obtain in vivo confirmation of a link between flotillins and cleavage of APP to release amyloidogenic Abeta peptide, and to generate tools that would allow us to ask whether flotillins are functionally redundant. We used a mouse model for Abeta-dependent cerebral amyloidosis, APPPS1 mice, combined with deletion of either flotillin 1 singly, or flotillin 1 and flotillin 2 together. There was a small but significant reduction in Abeta levels, and the abundance of congo-red stained plaques, in brains of 12 week old mice lacking flotillin 1. A similar reduction in Abeta levels was observed in the flotillin 1-/-, flotillin 2-/- double knockouts. We did not observe large effects on the clustering or endocytosis of APP in flotillin 1-/- mouse embryonic fibroblasts. We conclude that flotillins are likely to play some role in APP trafficking or processing, but the relevant cellular mechanisms require more investigation. The availability of flotillin 1-/-, flotillin 2-/- mice, which have no overt phenotypes, will facilitate research into flotillin function in vivo.</style></abstract><notes><style face="normal" font="default" size="100%">Bitsikas, Vassilis&#xD;Riento, Kirsi&#xD;Howe, Jonathan D&#xD;Barry, Nicholas P&#xD;Nichols, Benjamin J&#xD;MC_U105178778/Medical Research Council/United Kingdom&#xD;Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;PLoS One. 2014 Jan 21;9(1):e85217. doi: 10.1371/journal.pone.0085217. eCollection 2014.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0085217&amp;type=printable</style></url></related-urls><pdf-urls><url>internal-pdf://0247945902/Bitsikas-2014-The role of flotilli.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3897416</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0085217</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>225</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">225</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Blasi, F.</style></author><author><style face="normal" font="default" size="100%">Wei, Y.</style></author><author><style face="normal" font="default" size="100%">Balkaya, M.</style></author><author><style face="normal" font="default" size="100%">Tikka, S.</style></author><author><style face="normal" font="default" size="100%">Mandeville, J. B.</style></author><author><style face="normal" font="default" size="100%">Waeber, C.</style></author><author><style face="normal" font="default" size="100%">Ayata, C.</style></author><author><style face="normal" font="default" size="100%">Moskowitz, M. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From the Stroke and Neurovascular Research Laboratory, Department of Radiology (F.B., Y.W., M.B., C.A., M.A.M.), Stroke Service and Neuroscience Intensive Care Unit, Department of Neurology (C.A.), Department of Cell Biology (S.T.), and Department of Radiology, Martinos Center for Biomedical Imaging (J.B.M.), Massachusetts General Hospital, Harvard Medical School, Boston; and Department of Pharmacology, School of Pharmacy, University College Cork, Cork, Ireland (C.W.).</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recognition memory impairments after subcortical white matter stroke in mice</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1468-73</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2014/04/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Behavior, Animal/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/genetics/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Corpus Callosum/drug effects/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelin-1/administration &amp; dosage/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Leukoencephalopathies/genetics/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Memory Disorders/genetics/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Notch3</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Notch/ deficiency/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Recognition (Psychology)/ physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24723319</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: Small subcortical white matter infarcts are a common stroke subtype often associated with cognitive deficits. The lack of relevant models confined to white matter has limited the investigation of its pathophysiology. Here, we examine tissue and functional outcome after an ischemic lesion within corpus callosum in wild-type (WT) mice and in mice null for a gene, NOTCH3, linked to white matter ischemic injury in patients. METHODS: WT and NOTCH3 knockout mice were subjected to stereotactic microinjections of the potent vasoconstrictor endothelin-1 at the level of periventricular white matter to induce a focal ischemic lesion. Infarct location was confirmed by MRI, and brains were examined for lesion size and histology; behavioral deficits were assessed &lt;/=1 month in WT mice. RESULTS: Ischemic damage featured an early cerebral blood flow deficit, blood-brain barrier opening, and a lesion largely confined to white matter. At later stages, myelin and axonal degeneration and microglial/macrophage infiltration were found. WT mice displayed prolonged cognitive deficit when tested using a novel object recognition task. NOTCH3 mutants showed larger infarcts and greater cognitive deficit at 7 days post stroke. CONCLUSIONS: Taken together, these data show the usefulness of microinjections of endothelin-1 into periventricular white matter to study focal infarcts and cognitive deficit in WT mice. In short-term studies, stroke outcome was worse in NOTCH3 null mice, consistent with the notion that the lack of the NOTCH3 receptor affects white matter stroke susceptibility.</style></abstract><notes><style face="normal" font="default" size="100%">Blasi, Francesco&#xD;Wei, Ying&#xD;Balkaya, Mustafa&#xD;Tikka, Saara&#xD;Mandeville, Joseph B&#xD;Waeber, Christian&#xD;Ayata, Cenk&#xD;Moskowitz, Michael A&#xD;P30NS045776/NS/NINDS NIH HHS/United States&#xD;Comparative Study&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Stroke. 2014 May;45(5):1468-73. doi: 10.1161/STROKEAHA.114.005324. Epub 2014 Apr 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/45/5/1468.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://4077218547/Blasi-2014-Recognition memory i.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.114.005324</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>119</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">119</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Blasi, F.</style></author><author><style face="normal" font="default" size="100%">Whalen, M. J.</style></author><author><style face="normal" font="default" size="100%">Ayata, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Neurovascular Research Laboratory, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA.&#xD;1] Neuroscience Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA [2] Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA.&#xD;1] Neurovascular Research Laboratory, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA [2] Stroke Service and Neuroscience Intensive Care Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Lasting pure-motor deficits after focal posterior internal capsule white-matter infarcts in rats</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">977-84</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2015/02/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Axons/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelin-1/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Internal Capsule/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Motor Skills</style></keyword><keyword><style face="normal" font="default" size="100%">Myelin Sheath/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/complications/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">White Matter/ pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25649992</style></accession-num><abstract><style face="normal" font="default" size="100%">Small white-matter infarcts of the internal capsule are clinically prevalent but underrepresented among currently available animal models of ischemic stroke. In particular, the assessment of long-term outcome, a primary end point in clinical practice, has been challenging due to mild deficits and the rapid and often complete recovery in most experimental models. We, therefore, sought to develop a focal white-matter infarction model that can mimic the lasting neurologic deficits commonly observed in stroke patients. The potent vasoconstrictor endothelin-1 (n=24) or vehicle (n=9) was stereotactically injected into the internal capsule at one of three antero-posterior levels (1, 2, or 3 mm posterior to bregma) in male Sprague-Dawley rats. Endothelin-injected animals showed highly focal (~1 mm(3)) and reproducible ischemic infarcts, with severe axonal and myelin loss accompanied by cellular infiltration when examined 2 and 4 weeks after injection. Only those rats injected with endothelin-1 at the most posterior location developed robust and pure-motor deficits in adhesive removal, cylinder and foot-fault tests that persisted at 1 month, without detectable sensory impairments. In summary, we present an internal capsule stroke model optimized to produce lasting pure-motor deficits in rats that may be suitable to study neurologic recovery and rehabilitation after white-matter injury.</style></abstract><notes><style face="normal" font="default" size="100%">Blasi, Francesco&#xD;Whalen, Michael J&#xD;Ayata, Cenk&#xD;NS061505/NS/NINDS NIH HHS/United States&#xD;P50 NS051343/NS/NINDS NIH HHS/United States&#xD;R01 NS061505/NS/NINDS NIH HHS/United States&#xD;NS055104/NS/NINDS NIH HHS/United States&#xD;P01 NS055104/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Cereb Blood Flow Metab. 2015 Jun;35(6):977-84. doi: 10.1038/jcbfm.2015.7. Epub 2015 Feb 4.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4640262</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2015.7</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>314</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">314</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Boehm-Sturm, P.</style></author><author><style face="normal" font="default" size="100%">Farr, T. D.</style></author><author><style face="normal" font="default" size="100%">Adamczak, J.</style></author><author><style face="normal" font="default" size="100%">Jikeli, J. F.</style></author><author><style face="normal" font="default" size="100%">Mengler, L.</style></author><author><style face="normal" font="default" size="100%">Wiedermann, D.</style></author><author><style face="normal" font="default" size="100%">Kallur, T.</style></author><author><style face="normal" font="default" size="100%">Kiselev, V.</style></author><author><style face="normal" font="default" size="100%">Hoehn, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">In-Vivo-NMR Laboratory, Max Planck Institute for Neurological Research, Cologne, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Vascular changes after stroke in the rat: a longitudinal study using optimized magnetic resonance imaging</style></title><secondary-title><style face="normal" font="default" size="100%">Contrast Media Mol Imaging</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Contrast media &amp; molecular imaging</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Contrast Media Mol Imaging</style></full-title><abbr-1><style face="normal" font="default" size="100%">Contrast media &amp; molecular imaging</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Contrast Media Mol Imaging</style></full-title><abbr-1><style face="normal" font="default" size="100%">Contrast media &amp; molecular imaging</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">383-92</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2013/06/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Vessels/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Volume</style></keyword><keyword><style face="normal" font="default" size="100%">Contrast Media</style></keyword><keyword><style face="normal" font="default" size="100%">Corpus Striatum/blood supply/ diagnostic imaging/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Longitudinal Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Radiography</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ diagnostic imaging/pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep-Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1555-4317 (Electronic)&#xD;1555-4309 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23740808</style></accession-num><abstract><style face="normal" font="default" size="100%">During stroke, the reduction of blood flow leads to undersupply of oxygen and nutrients and, finally, to cell death, but also to upregulation of pro-angiogenic molecules and vascular remodeling. However, the temporal profile of vascular changes after stroke is still poorly understood. Here, we optimized steady-state contrast-enhanced magnetic resonance imaging (SSCE MRI) and followed the dynamic changes in vascular architecture for up to 4 weeks after transient middle cerebral artery occlusion (MCAO) in rats. Using MRI diffusion measurements and the changes of transversal relaxation rates DeltaR2 and DeltaR2* after injection of a superparamagnetic contrast agent, SSCE MRI provided several hemodynamic parameters: relative cerebral blood volume (rCBV), rCBV in small vessels, microvascular density, and relative vessel size. Six rats underwent SSCE MRI before MCAO and at 7, 14, 21 and 28 days after surgery. 5-Bromo-2&apos;deoxyuridine (BrdU) was injected between days 2 and 7 to label proliferating cells during this time. SSCE MRI depicted a decrease in microvessel density and an increase in vessel size in the ischemic striatum after stroke. A persistently decreased MRI vessel density was confirmed with histology at 28 days. BrdU + endothelial cells were found in regions close to the infarct indicating endothelial cell proliferation during the first week after MCAO; however, late-stage angiogenesis, as would be reflected by increased vessel density, was not detected. The optimized SSCE MRI protocol was used to follow spatio-temporal changes of important vessel characteristics, which may contribute to a better understanding of the role of angiogenesis at different stages after stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Boehm-Sturm, Philipp&#xD;Farr, Tracy D&#xD;Adamczak, Joanna&#xD;Jikeli, Jan F&#xD;Mengler, Luam&#xD;Wiedermann, Dirk&#xD;Kallur, Therese&#xD;Kiselev, Valerij&#xD;Hoehn, Mathias&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Contrast Media Mol Imaging. 2013 Sep-Oct;8(5):383-92. doi: 10.1002/cmmi.1534.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1002/cmmi.1534/asset/cmmi1534.pdf?v=1&amp;t=ixshwdn7&amp;s=c28c181104cd1736f0066be4506f141179e1df6e</style></url></related-urls><pdf-urls><url>internal-pdf://2800698792/Boehm-Sturm-2013-Vascular changes aft.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/cmmi.1534</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>399</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">399</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Braun, H.</style></author><author><style face="normal" font="default" size="100%">Bueche, C. Z.</style></author><author><style face="normal" font="default" size="100%">Garz, C.</style></author><author><style face="normal" font="default" size="100%">Oldag, A.</style></author><author><style face="normal" font="default" size="100%">Heinze, H. J.</style></author><author><style face="normal" font="default" size="100%">Goertler, M.</style></author><author><style face="normal" font="default" size="100%">Reymann, K. G.</style></author><author><style face="normal" font="default" size="100%">Schreiber, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Deutsches Zentrum fur Neurodegenerative Erkrankungen-DZNE Magdeburg, Germany. holger.braun@ifn-magdeburg.de</style></auth-address><titles><title><style face="normal" font="default" size="100%">Stases are associated with blood-brain barrier damage and a restricted activation of coagulation in SHRSP</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurol Sci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of the neurological sciences</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurol Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of the neurological sciences</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurol Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of the neurological sciences</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">71-6</style></pages><volume><style face="normal" font="default" size="100%">322</style></volume><number><style face="normal" font="default" size="100%">1-2</style></number><edition><style face="normal" font="default" size="100%">2012/07/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Coagulation/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/ pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Small Vessel Diseases/ complications</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Erythrocytes/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Hemostasis/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Leukoencephalopathies/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred SHR</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke, Lacunar/etiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">von Willebrand Factor/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1878-5883 (Electronic)&#xD;0022-510X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22831765</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebral small vessel disease (CSVD) is a chronically proceeding pathology of small brain vessels associated with white matter lesions, lacunar infarcts, brain atrophy and microbleeds. CSVD leads to slowly increasing cognitive and functional deficits but may also cause stroke-like symptoms, if vessels in critical brain areas are affected. Spontaneously hypertensive stroke-prone rats (SHRSP) exhibit several vascular risk factors, develop infarcts and hemorrhages and therefore represent a relevant model for the study of CSVD. Using this animal model, we recently demonstrated that intravasal accumulations of erythrocytes, we interpreted as stases, stand at the beginning of a pathological vascular cascade. After stases microbleeds occur, which are followed by reactive microthromboses. Bleeds and thromboses finally cause hemorrhagic infarcts. Immunohistochemical stainings show, that plasma proteins like IgG are deposited in the walls of vessels affected by stases. Further, we found small clots and thread-shaped aggregations of thrombocytes as well as thread-shaped structures of von Willebrand-Factor within stases. Thus, we conclude that blood-brain barrier damages occur in the neighborhood of stases and stases seem to be associated with a restricted activation of blood coagulation without formation of obstructive thromboses. Finally, we demonstrate that small vessel damage rarely appears in the cerebellum. Even animals with multiple cerebral infarcts may be free of any cerebellar vascular pathology.</style></abstract><notes><style face="normal" font="default" size="100%">Braun, Holger&#xD;Bueche, Celine Z&#xD;Garz, Cornelia&#xD;Oldag, Andreas&#xD;Heinze, Hans-Jochen&#xD;Goertler, Michael&#xD;Reymann, Klaus G&#xD;Schreiber, Stefanie&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;J Neurol Sci. 2012 Nov 15;322(1-2):71-6. doi: 10.1016/j.jns.2012.06.013. Epub 2012 Jul 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0022510X12003218/1-s2.0-S0022510X12003218-main.pdf?_tid=5b5341a6-d7bd-11e6-84f0-00000aab0f6c&amp;acdnat=1484112076_f66ee22b688dfcb1962e2ddd8302f517</style></url></related-urls><pdf-urls><url>internal-pdf://0072179691/Braun-2012-Stases are associate.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jns.2012.06.013</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>465</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">465</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brennecka, C. R.</style></author><author><style face="normal" font="default" size="100%">Preul, M. C.</style></author><author><style face="normal" font="default" size="100%">Bichard, W. D.</style></author><author><style face="normal" font="default" size="100%">Vernon, B. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Interventional Biomaterials, School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ, USA. Celeste.Riley@asu.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">In vivo experimental aneurysm embolization in a swine model with a liquid-to-solid gelling polymer system: initial biocompatibility and delivery strategy analysis</style></title><secondary-title><style face="normal" font="default" size="100%">World Neurosurg</style></secondary-title><alt-title><style face="normal" font="default" size="100%">World neurosurgery</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">World Neurosurg</style></full-title><abbr-1><style face="normal" font="default" size="100%">World neurosurgery</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">World Neurosurg</style></full-title><abbr-1><style face="normal" font="default" size="100%">World neurosurgery</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">469-80</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2011/11/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Biocompatible Materials/chemistry/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Artery Diseases/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Linking Reagents/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Delivery Systems/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Embolization, Therapeutic/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Gels</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Aneurysm/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Materials Testing</style></keyword><keyword><style face="normal" font="default" size="100%">Phase Transition</style></keyword><keyword><style face="normal" font="default" size="100%">Pilot Projects</style></keyword><keyword><style face="normal" font="default" size="100%">Polymers/chemistry/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Propylene Glycols/chemistry/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Swine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1878-8769 (Electronic)&#xD;1878-8750 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22120570</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: Current treatments for cerebral aneurysms are far from ideal. Platinum coils are prone to compaction, and currently used liquid embolics are delivered with angiotoxic agents. This work presents initial in vivo studies of a novel liquid-to-solid gelling polymer system (PPODA-QT), focusing on biocompatibility and effective delivery strategies. METHODS: PPODA-QT was used to embolize surgically created lateral wall carotid artery aneurysms in swine using three delivery strategies. Group 1 aneurysms were completely filled with PPODA-QT (n = 5), group 2 aneurysms were subcompletely (80%-90%) filled (n = 3), and group 3 aneurysms underwent three-dimensional coil placement followed by polymer embolization (n = 3). The study was designed such that three animals per treatment group survived to 1 month. RESULTS: The group 1 delivery strategy (100% filling) resulted in survival of 3/5 animals. This strategy led to aneurysm stretching, which resulted model failure in 2/5 animals. Group 2 aneurysms, although initially &lt;100% filled with the polymer, displayed robust neointimal tissue coverage and complete obliteration after 1 month. Group 3 aneurysms showed less prominent neointimal tissue coverage as well as two instances where excess polymer was found in the parent vessel. The PPODA-QT material showed good biocompatibility with vascular tissue in all animals at 1 month. CONCLUSIONS: This small-scale pilot study highlighted first-time in vivo use of PPODA-QT as an embolic agent for aneurysm treatment. Filling aneurysms to 80% to 90% capacity proved to be a safe and effective delivery strategy, and PPODA-QT showed excellent biocompatibility. This study indicates that future investigation of PPODA-QT for aneurysm embolization is warranted, as it may prove to be a viable alternative to current embolic materials.</style></abstract><notes><style face="normal" font="default" size="100%">Brennecka, Celeste R&#xD;Preul, Mark C&#xD;Bichard, William D&#xD;Vernon, Brent L&#xD;United States&#xD;World Neurosurg. 2012 Nov;78(5):469-80. doi: 10.1016/j.wneu.2011.10.029. Epub 2011 Nov 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S1878875011013039/1-s2.0-S1878875011013039-main.pdf?_tid=5fdfabc4-d7bd-11e6-ac53-00000aab0f27&amp;acdnat=1484112084_8cb65e833732ae62e10fd798b943dc55</style></url></related-urls><pdf-urls><url>internal-pdf://0330529280/Brennecka-2012-In vivo experimental.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.wneu.2011.10.029</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>365</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">365</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brima, T.</style></author><author><style face="normal" font="default" size="100%">Mikulecka, A.</style></author><author><style face="normal" font="default" size="100%">Otahal, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impacts of perinatal induced photothrombotic stroke on sensorimotor performance in adult rats</style></title><secondary-title><style face="normal" font="default" size="100%">Physiol Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Physiological research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Physiol Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Physiological research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Physiol Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Physiological research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">85-94</style></pages><volume><style face="normal" font="default" size="100%">62</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2012/11/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Behavior, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Thrombosis/ etiology/pathology/physiopathology/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Lasers</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Motor Activity</style></keyword><keyword><style face="normal" font="default" size="100%">Psychomotor Performance</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Rose Bengal</style></keyword><keyword><style face="normal" font="default" size="100%">Rotarod Performance Test</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ etiology/pathology/physiopathology/psychology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">1802-9973 (Electronic)&#xD;0862-8408 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23173682</style></accession-num><abstract><style face="normal" font="default" size="100%">Perinatal ischemic stroke is a leading cerebrovascular disorder occurring in infants around the time of birth associated with long term comorbidities including motor, cognitive and behavioral deficits. We sought to determine the impact of perinatal induced stroke on locomotion, behavior and motor function in rats. A photothrombotic model of ischemic stroke was used in rat at postnatal day 7. Presently, we induced two lesions of different extents, to assess the consequences of stroke on motor function, locomotion and possible correlations to morphological changes. Behavioral tests sensitive to sensorimotor changes were used; locomotion expressed as distance moved in the open field was monitored and histological changes were also assessed. Outcomes depicted two kinds of lesions of different shapes and sizes, relative to laser illumination. Motor performance of rats submitted to stroke was poor when compared to controls; a difference in motor performance was also noted between rats with small and large lesions. Correlations were observed between: motor performance and exposition time; volume ratio and exposition time; and in the rotarod between motor performance and volume ratio. Outcomes demonstrate that photothrombotic cerebral ischemic stroke induced in early postnatal period and tested in adulthood, indeed influenced functional performance governed by the affected brain regions.</style></abstract><notes><style face="normal" font="default" size="100%">Brima, T&#xD;Mikulecka, A&#xD;Otahal, J&#xD;Comparative Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Czech Republic&#xD;Physiol Res. 2013;62(1):85-94. Epub 2012 Nov 22.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>344</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">344</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brittain, J. F.</style></author><author><style face="normal" font="default" size="100%">McCabe, C.</style></author><author><style face="normal" font="default" size="100%">Khatun, H.</style></author><author><style face="normal" font="default" size="100%">Kaushal, N.</style></author><author><style face="normal" font="default" size="100%">Bridges, L. R.</style></author><author><style face="normal" font="default" size="100%">Holmes, W. M.</style></author><author><style face="normal" font="default" size="100%">Barrick, T. R.</style></author><author><style face="normal" font="default" size="100%">Graham, D.</style></author><author><style face="normal" font="default" size="100%">Dominiczak, A. F.</style></author><author><style face="normal" font="default" size="100%">Mhairi Macrae, I.</style></author><author><style face="normal" font="default" size="100%">Hainsworth, A. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Stroke and Dementia Research Centre, St Georges University of London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An MRI-histological study of white matter in stroke-free SHRSP</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">760-3</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2013/02/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/blood supply/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Arteries/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension/ complications</style></keyword><keyword><style face="normal" font="default" size="100%">Leukoencephalopathies/complications/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Myelin Basic Protein/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred SHR</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ complications</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23403376</style></accession-num><abstract><style face="normal" font="default" size="100%">Hypertension is associated with cerebral small vessel disease (SVD) and with diffuse white matter hyperintensities (WMH) on T2-weighted magnetic resonance imaging (MRI). We tested whether stroke-prone spontaneously hypertensive rats (SHRSP), a model of chronic hypertension, exhibit WMH. Male SHRSP (age 10 months) without stroke symptoms were compared with age-matched male WKY rats. Stroke-prone spontaneously hypertensive rats exhibited no WMH on MRI scans (T2, T2*, diffusion tensor imaging) and no neuropathological lesions. While leptomeningeal arteries exhibited fibrohyaline wall thickening, with decreased smooth muscle actin relative to WKY, deep penetrating arterioles within the caudate nuclei had no vasculopathy. We conclude that WMH are not an obligate feature of stroke-free SHRSP aged up to 10 months.</style></abstract><notes><style face="normal" font="default" size="100%">Brittain, John F&#xD;McCabe, Christopher&#xD;Khatun, Halima&#xD;Kaushal, Nitika&#xD;Bridges, Leslie R&#xD;Holmes, William M&#xD;Barrick, Thomas R&#xD;Graham, Delyth&#xD;Dominiczak, Anna F&#xD;Mhairi Macrae, I&#xD;Hainsworth, Atticus H&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Cereb Blood Flow Metab. 2013 May;33(5):760-3. doi: 10.1038/jcbfm.2013.14. Epub 2013 Feb 13.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3652693</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2013.14</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>14</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">14</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Burrows, F.</style></author><author><style face="normal" font="default" size="100%">Haley, M. J.</style></author><author><style face="normal" font="default" size="100%">Scott, E.</style></author><author><style face="normal" font="default" size="100%">Coutts, G.</style></author><author><style face="normal" font="default" size="100%">Lawrence, C. B.</style></author><author><style face="normal" font="default" size="100%">Allan, S. M.</style></author><author><style face="normal" font="default" size="100%">Schiessl, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Life Sciences, The University of Manchester, Stopford Building, Oxford Road, M13 9PT Manchester, UK.&#xD;Faculty of Life Sciences, The University of Manchester, Stopford Building, Oxford Road, M13 9PT Manchester, UK. Electronic address: i.schiessl@manchester.ac.uk.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Systemic inflammation affects reperfusion following transient cerebral ischaemia</style></title><secondary-title><style face="normal" font="default" size="100%">Exp Neurol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Experimental neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Exp Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Experimental neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Exp Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Experimental neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">252-60</style></pages><volume><style face="normal" font="default" size="100%">277</style></volume><edition><style face="normal" font="default" size="100%">2016/01/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Analysis of Variance</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, CD/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium-Binding Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Functional Laterality/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ complications/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-1/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Microfilament Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Oxyhemoglobins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion</style></keyword><keyword><style face="normal" font="default" size="100%">Spectrum Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Systemic Inflammatory Response Syndrome/ etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1090-2430 (Electronic)&#xD;0014-4886 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26795089</style></accession-num><abstract><style face="normal" font="default" size="100%">Reperfusion after stroke is critical for improved patient survival and recovery and can be achieved clinically through pharmacological (recombinant tissue plasminogen activator) or physical (endovascular intervention) means. Yet these approaches remain confined to a small percentage of stroke patients, often with incomplete reperfusion, and therefore there is an urgent need to learn more about the mechanisms underlying the no-reflow phenomenon that prevents restoration of adequate microvascular perfusion. Recent evidence suggests systemic inflammation as an important contributor to no-reflow and to further investigate this here we inject interleukin 1 (IL-1) i.p. 30 min prior to an ischaemic challenge using a remote filament to occlude the middle cerebral artery (MCA) in mice. Before, during and after the injection of IL-1 and occlusion we use two-dimensional optical imaging spectroscopy to record the spatial and temporal dynamics of oxyhaemoglobin concentration in the cortical areas supplied by the MCA. Our results reveal that systemic inflammation significantly reduces oxyhaemoglobin reperfusion as early as 3h after filament removal compared to vehicle injected animals. CD41 immunohistochemistry shows a significant increase of hyper-coagulated platelets within the microvessels in the stroked cortex of the IL-1 group compared to vehicle. We also observed an increase of pathophysiological biomarkers of ischaemic damage including elevated microglial activation co-localized with interleukin 1alpha (IL-1alpha), increased blood brain barrier breakdown as shown by IgG infiltration and increased pyknotic morphological changes of cresyl violet stained neurons. These data confirm systemic inflammation as an underlying cause of no-reflow in the post-ischaemic brain and that appropriate anti-inflammatory approaches could be beneficial in treating ischaemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Burrows, F&#xD;Haley, M J&#xD;Scott, E&#xD;Coutts, G&#xD;Lawrence, C B&#xD;Allan, S M&#xD;Schiessl, I&#xD;Biotechnology and Biological Sciences Research Council/United Kingdom&#xD;Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Exp Neurol. 2016 Mar;277:252-60. doi: 10.1016/j.expneurol.2016.01.013. Epub 2016 Jan 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0014488616300115/1-s2.0-S0014488616300115-main.pdf?_tid=7d5044e8-d7bd-11e6-a76c-00000aacb35e&amp;acdnat=1484112133_9840730c60d0abb32bbb43ac5e0721c0</style></url></related-urls><pdf-urls><url>internal-pdf://3906942400/Burrows-2016-Systemic inflammatio.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4767324</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.expneurol.2016.01.013</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>459</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">459</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cai, J.</style></author><author><style face="normal" font="default" size="100%">He, C.</style></author><author><style face="normal" font="default" size="100%">Yuan, F.</style></author><author><style face="normal" font="default" size="100%">Chen, L.</style></author><author><style face="normal" font="default" size="100%">Ling, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Shanghai Tenth People&apos;s Hospital, Tongji University School of Medicine, 301 Middle Yanchang Road, Shanghai, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A novel haemodynamic cerebral aneurysm model of rats with normal blood pressure</style></title><secondary-title><style face="normal" font="default" size="100%">J Clin Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Clin Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Clin Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">135-8</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2011/12/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Angiography/instrumentation/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Arteries/diagnostic imaging/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Hemodynamics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Aneurysm/ diagnosis/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1532-2653 (Electronic)&#xD;0967-5868 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22153799</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebral aneurysms of traditional animal models are usually too small to be imaged in vivo. A novel rat model induced by ligation of the unilateral common carotid artery and contralateral pterygopalatine and external carotid arteries was investigated. To evaluate the morphological changes of the cerebral arteries, synchrotron radiation angiography was utilised at 1 month, 2 months and 3 months after induction. Cerebral aneurysms and expansion of anterior cerebral arteries in these rats were identified when the animals were alive. This novel model is useful for cerebral aneurysm research.</style></abstract><notes><style face="normal" font="default" size="100%">Cai, Jun&#xD;He, Chuan&#xD;Yuan, Falei&#xD;Chen, Lujia&#xD;Ling, Feng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Validation Studies&#xD;Scotland&#xD;J Clin Neurosci. 2012 Jan;19(1):135-8. doi: 10.1016/j.jocn.2011.07.023. Epub 2011 Dec 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0967586811004875/1-s2.0-S0967586811004875-main.pdf?_tid=67cb0b08-d7bd-11e6-aca7-00000aacb35d&amp;acdnat=1484112097_2b758ab7fd3433814909c57b471e8521</style></url></related-urls><pdf-urls><url>internal-pdf://2081336406/Cai-2012-A novel haemodynamic.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jocn.2011.07.023</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>214</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">214</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cai, J.</style></author><author><style face="normal" font="default" size="100%">Hua, F.</style></author><author><style face="normal" font="default" size="100%">Yuan, L.</style></author><author><style face="normal" font="default" size="100%">Tang, W.</style></author><author><style face="normal" font="default" size="100%">Lu, J.</style></author><author><style face="normal" font="default" size="100%">Yu, S.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Hu, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Anesthesiology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.&#xD;Department of Urology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.&#xD;Department of Anesthesiology, The first Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Potential therapeutic effects of neurotrophins for acute and chronic neurological diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Biomed Res Int</style></secondary-title><alt-title><style face="normal" font="default" size="100%">BioMed research international</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Biomed Res Int</style></full-title><abbr-1><style face="normal" font="default" size="100%">BioMed research international</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Biomed Res Int</style></full-title><abbr-1><style face="normal" font="default" size="100%">BioMed research international</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">601084</style></pages><volume><style face="normal" font="default" size="100%">2014</style></volume><edition><style face="normal" font="default" size="100%">2014/05/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Acute Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Growth Factors/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Nervous System Diseases/ drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Neurodegenerative Diseases/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/pharmacology/therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">2314-6141 (Electronic)</style></isbn><accession-num><style face="normal" font="default" size="100%">24818146</style></accession-num><abstract><style face="normal" font="default" size="100%">The neurotrophins (NTs) nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), NT-3, and NT-4/5 are proteins that regulate cell proliferation, differentiation, and survival in both the developing and mature central nervous system (CNS) by binding to two receptor classes, Trk receptors and p75 NTR. Motivated by the broad growth- and survival-promoting effects of these proteins, numerous studies have attempted to use exogenous NTs to prevent the death of cells that are associated with neurological disease or promote the regeneration of severed axons caused by mechanical injury. Indeed, such neurotrophic effects have been repeatedly demonstrated in animal models of stroke, nerve injury, and neurodegenerative disease. However, limitations, including the short biological half-lives and poor blood-brain permeability of these proteins, prevent routine application from treating human disease. In this report, we reviewed evidence for the neuroprotective efficacy of NTs in animal models, highlighting outstanding technical challenges and discussing more recent attempts to harness the neuroprotective capacity of endogenous NTs using small molecule inducers and cell transplantation.</style></abstract><notes><style face="normal" font="default" size="100%">Cai, Junying&#xD;Hua, Fuzhou&#xD;Yuan, Linhui&#xD;Tang, Wei&#xD;Lu, Jun&#xD;Yu, Shuchun&#xD;Wang, Xifeng&#xD;Hu, Yanhui&#xD;Review&#xD;United States&#xD;Biomed Res Int. 2014;2014:601084. doi: 10.1155/2014/601084. Epub 2014 Apr 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://downloads.hindawi.com/journals/bmri/2014/601084.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1206425783/Cai-2014-Potential therapeuti.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4000962</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1155/2014/601084</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>92</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">92</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cai, Q.</style></author><author><style face="normal" font="default" size="100%">Chen, Z.</style></author><author><style face="normal" font="default" size="100%">Kong, D. K.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Xu, Z.</style></author><author><style face="normal" font="default" size="100%">Liu, B.</style></author><author><style face="normal" font="default" size="100%">Chen, Q.</style></author><author><style face="normal" font="default" size="100%">Zhou, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan City, Hubei Province, 430060, China; Department of Neurosurgery, Yale University, 333 Cedar Street, FMB 410, New Haven, CT 06520, USA.&#xD;Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan City, Hubei Province, 430060, China.&#xD;Department of Neurosurgery, Yale University, 333 Cedar Street, FMB 410, New Haven, CT 06520, USA.&#xD;Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan City, Hubei Province, 430060, China. Electronic address: chenqx666@sohu.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Novel microcatheter-based intracarotid delivery approach for MCAO/R mice</style></title><secondary-title><style face="normal" font="default" size="100%">Neurosci Lett</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuroscience letters</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurosci Lett</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience letters</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurosci Lett</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience letters</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">127-31</style></pages><volume><style face="normal" font="default" size="100%">597</style></volume><edition><style face="normal" font="default" size="100%">2015/04/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Artery, External/anatomy &amp; histology</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Artery, Internal/anatomy &amp; histology</style></keyword><keyword><style face="normal" font="default" size="100%">Catheters, Indwelling</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Neural Stem Cells/ transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-7972 (Electronic)&#xD;0304-3940 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25899778</style></accession-num><abstract><style face="normal" font="default" size="100%">The intra-arterial (IA) model by microcatheter administration was an effective way to deliver drugs or cells to the brain. All of these models were carried out introduced in rat rather than mice for the difficult and technically challenging due to their small caliber. In 2014, Alejandro Santillan first introduced this model in mice and we found that most of the operational steps were similar with the middle cerebral artery occlusion and reperfusion (MCAO/R) model. We attempted to combine these two techniques into a single model in mice and discovered that this technique was indeed possible. In our work, 12C57Bl/6J male mice were carried on middle cerebral artery occlusion for 60min and then the intra-arterial microcatheter was placed into the internal carotid artery (ICA) from the external carotid artery (ECA). GFP-Luc-Pro labeled mNSCs were infused through the microcatheter and then the blood flow perfusion was reestablished subsequently. The results showed that all 12 mice were carried on successfully the model of middle cerebral artery occlusion, and the placement of the microcatheter and the mNSCs perfusion were completed smoothly without exception. Which means that it is logical to combine the two models into one in order to facilitate studying of stroke. Meanwhile, during the dissection, we found the variation of occipital artery (OA) was noticeable and we classified first time this variation into four categories to attempt to protect the OA.</style></abstract><notes><style face="normal" font="default" size="100%">Cai, Qiang&#xD;Chen, Zhibiao&#xD;Kong, Derek Kai&#xD;Wang, Jun&#xD;Xu, Zhou&#xD;Liu, Baohui&#xD;Chen, Qianxue&#xD;Zhou, Jiangbing&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Ireland&#xD;Neurosci Lett. 2015 Jun 15;597:127-31. doi: 10.1016/j.neulet.2015.04.029. Epub 2015 Apr 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0304394015003183/1-s2.0-S0304394015003183-main.pdf?_tid=6ab674a6-d7bd-11e6-a58f-00000aab0f02&amp;acdnat=1484112102_30d08b3bedee550e1b18b3621edf57d0</style></url></related-urls><pdf-urls><url>internal-pdf://4240948161/Cai-2015-Novel microcatheter-.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neulet.2015.04.029</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>434</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">434</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cai, Q.</style></author><author><style face="normal" font="default" size="100%">Zakaria, H. M.</style></author><author><style face="normal" font="default" size="100%">Simone, A.</style></author><author><style face="normal" font="default" size="100%">Sheng, Z. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Synaptic Functions Section, Porter Neuroscience Research Center, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Room 2B-215, 35 Convent Drive, Bethesda, MD 20892-3706, USA. cai@biology.rutgers.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">Spatial parkin translocation and degradation of damaged mitochondria via mitophagy in live cortical neurons</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Biol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Current biology : CB</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Biol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current biology : CB</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Curr Biol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current biology : CB</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">545-52</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2012/02/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Autophagy</style></keyword><keyword><style face="normal" font="default" size="100%">Biological Transport, Active/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Carbonyl Cyanide m-Chlorophenyl Hydrazone/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/cytology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Knockdown Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Lysosomes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Membrane Potential, Mitochondrial</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Mitochondria/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Fusion Proteins/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Ubiquitin-Protein Ligases/antagonists &amp; inhibitors/genetics/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 20</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1879-0445 (Electronic)&#xD;0960-9822 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22342752</style></accession-num><abstract><style face="normal" font="default" size="100%">Mitochondria are essential for neuronal survival and function. Proper degradation of aged and damaged mitochondria through mitophagy is a key cellular pathway for mitochondrial quality control. Recent studies have indicated that PINK1/Parkin-mediated pathways ensure mitochondrial integrity and function. Translocation of Parkin to damaged mitochondria induces mitophagy in many nonneuronal cell types. However, evidence showing Parkin translocation in primary neurons is controversial, leaving unanswered questions as to how and where Parkin-mediated mitophagy occurs in neurons. Here, we report the unique process of dissipating mitochondrial Deltapsi(m)-induced and Parkin-mediated mitophagy in mature cortical neurons. Compared with nonneuronal cells, neuronal mitophagy is a much slower and compartmentally restricted process, coupled with reduced anterograde mitochondrial transport. Parkin-targeted mitochondria are accumulated in the somatodendritic regions where mature lysosomes are predominantly located. Time-lapse imaging shows dynamic formation and elimination of Parkin- and LC3-ring-like structures surrounding depolarized mitochondria through the autophagy-lysosomal pathway in the soma. Knocking down Parkin in neurons impairs the elimination of dysfunctional mitochondria. Thus, our study provides neuronal evidence for dynamic and spatial Parkin-mediated mitophagy, which will help us understand whether altered mitophagy contributes to pathogenesis of several major neurodegenerative diseases characterized by mitochondrial dysfunction and impaired transport.</style></abstract><notes><style face="normal" font="default" size="100%">Cai, Qian&#xD;Zakaria, Hesham Mostafa&#xD;Simone, Anthony&#xD;Sheng, Zu-Hang&#xD;R00 AG033658/AG/NIA NIH HHS/United States&#xD;ZIA NS002946-15/Intramural NIH HHS/United States&#xD;Howard Hughes Medical Institute/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, N.I.H., Intramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Curr Biol. 2012 Mar 20;22(6):545-52. doi: 10.1016/j.cub.2012.02.005. Epub 2012 Feb 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0960982212001224/1-s2.0-S0960982212001224-main.pdf?_tid=71178966-d7bd-11e6-a76c-00000aacb35e&amp;acdnat=1484112112_5d0e9ebc879929cef65c2b40a9d0f6b8</style></url></related-urls><pdf-urls><url>internal-pdf://2021256040/Cai-2012-Spatial parkin trans.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3313683</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms355385</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.cub.2012.02.005</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>274</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">274</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Caldeira, M. V.</style></author><author><style face="normal" font="default" size="100%">Salazar, I. L.</style></author><author><style face="normal" font="default" size="100%">Curcio, M.</style></author><author><style face="normal" font="default" size="100%">Canzoniero, L. M.</style></author><author><style face="normal" font="default" size="100%">Duarte, C. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Largo Marques de Pombal, 3004-517 Coimbra, Portugal; Department of Life Sciences, University of Coimbra, 3004-517 Coimbra, Portugal.&#xD;CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Largo Marques de Pombal, 3004-517 Coimbra, Portugal; Doctoral Programme in Experimental Biology and Biomedicine, Center for Neuroscience and Cell Biology, University of Coimbra, Portugal; Institute for Interdisciplinary Research, University of Coimbra (IIIUC), Portugal.&#xD;CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Largo Marques de Pombal, 3004-517 Coimbra, Portugal; Department of Science and Technology, University of Sannio, Benevento, Italy.&#xD;Department of Science and Technology, University of Sannio, Benevento, Italy.&#xD;CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Largo Marques de Pombal, 3004-517 Coimbra, Portugal; Department of Life Sciences, University of Coimbra, 3004-517 Coimbra, Portugal. Electronic address: cbduarte@ci.uc.pt.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Role of the ubiquitin-proteasome system in brain ischemia: friend or foe?</style></title><secondary-title><style face="normal" font="default" size="100%">Prog Neurobiol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Progress in neurobiology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Prog Neurobiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Progress in neurobiology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Prog Neurobiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Progress in neurobiology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">50-69</style></pages><volume><style face="normal" font="default" size="100%">112</style></volume><edition><style face="normal" font="default" size="100%">2013/10/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Proteasome Endopeptidase Complex/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Ubiquitinated Proteins/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Ubiquitination/ physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1873-5118 (Electronic)&#xD;0301-0082 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24157661</style></accession-num><abstract><style face="normal" font="default" size="100%">The ubiquitin-proteasome system (UPS) is a catalytic machinery that targets numerous cellular proteins for degradation, thus being essential to control a wide range of basic cellular processes and cell survival. Degradation of intracellular proteins via the UPS is a tightly regulated process initiated by tagging a target protein with a specific ubiquitin chain. Neurons are particularly vulnerable to any change in protein composition, and therefore the UPS is a key regulator of neuronal physiology. Alterations in UPS activity may induce pathological responses, ultimately leading to neuronal cell death. Brain ischemia triggers a complex series of biochemical and molecular mechanisms, such as an inflammatory response, an exacerbated production of misfolded and oxidized proteins, due to oxidative stress, and the breakdown of cellular integrity mainly mediated by excitotoxic glutamatergic signaling. Brain ischemia also damages protein degradation pathways which, together with the overproduction of damaged proteins and consequent upregulation of ubiquitin-conjugated proteins, contribute to the accumulation of ubiquitin-containing proteinaceous deposits. Despite recent advances, the factors leading to deposition of such aggregates after cerebral ischemic injury remain poorly understood. This review discusses the current knowledge on the role of the UPS in brain function and the molecular mechanisms contributing to UPS dysfunction in brain ischemia with consequent accumulation of ubiquitin-containing proteins. Chemical inhibitors of the proteasome and small molecule inhibitors of deubiquitinating enzymes, which promote the degradation of proteins by the proteasome, were both shown to provide neuroprotection in brain ischemia, and this apparent contradiction is also discussed in this review.</style></abstract><notes><style face="normal" font="default" size="100%">Caldeira, Margarida V&#xD;Salazar, Ivan L&#xD;Curcio, Michele&#xD;Canzoniero, Lorella M T&#xD;Duarte, Carlos B&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;England&#xD;Prog Neurobiol. 2014 Jan;112:50-69. doi: 10.1016/j.pneurobio.2013.10.003. Epub 2013 Oct 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0301008213001032/1-s2.0-S0301008213001032-main.pdf?_tid=6da1a1f4-d7bd-11e6-a3e4-00000aab0f02&amp;acdnat=1484112107_9a68ceb558edb0a8397d97ebf06460ce</style></url></related-urls><pdf-urls><url>internal-pdf://1858721004/Caldeira-2014-Role of the ubiquiti.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.pneurobio.2013.10.003</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>211</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">211</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Calias, P.</style></author><author><style face="normal" font="default" size="100%">Banks, W. A.</style></author><author><style face="normal" font="default" size="100%">Begley, D.</style></author><author><style face="normal" font="default" size="100%">Scarpa, M.</style></author><author><style face="normal" font="default" size="100%">Dickson, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Shire, Lexington, MA, USA. Electronic address: pcalias@shire.com.&#xD;Geriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care Center, Seattle, WA, USA; Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.&#xD;Institute of Pharmaceutical Science, King&apos;s College London, London, UK.&#xD;Department of Paediatrics, University of Padova, Padova, Italy.&#xD;Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, CA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Intrathecal delivery of protein therapeutics to the brain: a critical reassessment</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacol Ther</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Pharmacology &amp; therapeutics</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pharmacol Ther</style></full-title><abbr-1><style face="normal" font="default" size="100%">Pharmacology &amp; therapeutics</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Pharmacol Ther</style></full-title><abbr-1><style face="normal" font="default" size="100%">Pharmacology &amp; therapeutics</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">114-22</style></pages><volume><style face="normal" font="default" size="100%">144</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2014/05/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Biological Transport/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Central Nervous System Diseases/ drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrospinal Fluid/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrodynamics</style></keyword><keyword><style face="normal" font="default" size="100%">Injections, Spinal</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Proteins/ administration &amp; dosage</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1879-016X (Electronic)&#xD;0163-7258 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24854599</style></accession-num><abstract><style face="normal" font="default" size="100%">Disorders of the central nervous system (CNS), including stroke, neurodegenerative diseases, and brain tumors, are the world&apos;s leading causes of disability. Delivery of drugs to the CNS is complicated by the blood-brain barriers that protect the brain from the unregulated leakage and entry of substances, including proteins, from the blood. Yet proteins represent one of the most promising classes of therapeutics for the treatment of CNS diseases. Many strategies for overcoming these obstacles are in development, but the relatively straightforward approach of bypassing these barriers through direct intrathecal administration has been largely overlooked. Originally discounted because of its lack of usefulness for delivering small, lipid-soluble drugs to the brain, the intrathecal route has emerged as a useful, in some cases perhaps the ideal, route of administration for certain therapeutic protein and targeted disease combinations. Here, we review blood-brain barrier functions and cerebrospinal fluid dynamics and their relevance to drug delivery via the intrathecal route, discuss animal and human studies that have investigated intrathecal delivery of protein therapeutics, and outline several characteristics of protein therapeutics that can allow them to be successfully delivered intrathecally.</style></abstract><notes><style face="normal" font="default" size="100%">Calias, Pericles&#xD;Banks, William A&#xD;Begley, David&#xD;Scarpa, Maurizio&#xD;Dickson, Patricia&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;England&#xD;Pharmacol Ther. 2014 Nov;144(2):114-22. doi: 10.1016/j.pharmthera.2014.05.009. Epub 2014 May 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0163725814001041/1-s2.0-S0163725814001041-main.pdf?_tid=74092260-d7bd-11e6-9a85-00000aacb362&amp;acdnat=1484112117_f22c1f8082627ac142c1380a42ba2c06</style></url></related-urls><pdf-urls><url>internal-pdf://1189804271/Calias-2014-Intrathecal delivery.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.pharmthera.2014.05.009</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>261</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">261</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Camos, S.</style></author><author><style face="normal" font="default" size="100%">Gubern, C.</style></author><author><style face="normal" font="default" size="100%">Sobrado, M.</style></author><author><style face="normal" font="default" size="100%">Rodriguez, R.</style></author><author><style face="normal" font="default" size="100%">Romera, V. G.</style></author><author><style face="normal" font="default" size="100%">Moro, M. A.</style></author><author><style face="normal" font="default" size="100%">Lizasoain, I.</style></author><author><style face="normal" font="default" size="100%">Serena, J.</style></author><author><style face="normal" font="default" size="100%">Mallolas, J.</style></author><author><style face="normal" font="default" size="100%">Castellanos, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Servei de Neurologia, Institut d&apos;Investigacio Biomedica de Girona (IdIBGi), Hospital Universitari de Girona Dr. Josep Trueta, Av. Franca s/n, 17007, Girona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Oct-2 transcription factor binding activity and expression up-regulation in rat cerebral ischaemia is associated with a diminution of neuronal damage in vitro</style></title><secondary-title><style face="normal" font="default" size="100%">Neuromolecular Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuromolecular medicine</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuromolecular Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuromolecular medicine</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuromolecular Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuromolecular medicine</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">332-49</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2013/11/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Damage, Chronic/etiology/genetics/pathology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/genetics/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Chromatin Immunoprecipitation</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/genetics/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Attack, Transient/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Tissue Proteins/biosynthesis/genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Octamer Transcription Factor-2/biosynthesis/genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Binding</style></keyword><keyword><style face="normal" font="default" size="100%">RNA Interference</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/biosynthesis</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred F344</style></keyword><keyword><style face="normal" font="default" size="100%">Transcription, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-1174 (Electronic)&#xD;1535-1084 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24282026</style></accession-num><abstract><style face="normal" font="default" size="100%">Brain plasticity provides a mechanism to compensate for lesions produced as a result of stroke. The present study aims to identify new transcription factors (TFs) following focal cerebral ischaemia in rat as potential therapeutic targets. A transient focal cerebral ischaemia model was used for TF-binding activity and TF-TF interaction profile analysis. A permanent focal cerebral ischaemia model was used for the transcript gene analysis and for the protein study. The identification of TF variants, mRNA analysis, and protein study was performed using conventional polymerase chain reaction (PCR), qPCR, and Western blot and immunofluorescence, respectively. Rat cortical neurons were transfected with small interfering RNA against the TF in order to study its role. The TF-binding analysis revealed a differential binding activity of the octamer family in ischaemic brain in comparison with the control brain samples both in acute and late phases. In this study, we focused on Oct-2 TF. Five of the six putative Oct-2 transcript variants are expressed in both control and ischaemic rat brain, showing a significant increase in the late phase of ischaemia. Oct-2 protein showed neuronal localisation both in control and ischaemic rat brain cortical slices. Functional studies revealed that Oct-2 interacts with TFs involved in important brain processes (neuronal and vascular development) and basic cellular functions and that Oct-2 knockdown promotes neuronal injury. The present study shows that Oct-2 expression and binding activity increase in the late phase of cerebral ischaemia and finds Oct-2 to be involved in reducing ischaemic-mediated neuronal injury.</style></abstract><notes><style face="normal" font="default" size="100%">Camos, Susanna&#xD;Gubern, Carme&#xD;Sobrado, Monica&#xD;Rodriguez, Rocio&#xD;Romera, Victor G&#xD;Moro, Maria Angeles&#xD;Lizasoain, Ignacio&#xD;Serena, Joaquin&#xD;Mallolas, Judith&#xD;Castellanos, Mar&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Neuromolecular Med. 2014 Jun;16(2):332-49. doi: 10.1007/s12017-013-8279-1. Epub 2013 Nov 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/677/art%253A10.1007%252Fs12017-013-8279-1.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12017-013-8279-1&amp;token2=exp=1484113136~acl=%2Fstatic%2Fpdf%2F677%2Fart%25253A10.1007%25252Fs12017-013-8279-1.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs12017-013-8279-1*~hmac=5bf13d809412f4e85b5a7fb0aa04082be4269be220f6093baf404218c29677f0</style></url></related-urls><pdf-urls><url>internal-pdf://1578566070/Camos-2014-Oct-2 transcription.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12017-013-8279-1</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>29</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">29</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Capone, C.</style></author><author><style face="normal" font="default" size="100%">Cognat, E.</style></author><author><style face="normal" font="default" size="100%">Ghezali, L.</style></author><author><style face="normal" font="default" size="100%">Baron-Menguy, C.</style></author><author><style face="normal" font="default" size="100%">Aubin, D.</style></author><author><style face="normal" font="default" size="100%">Mesnard, L.</style></author><author><style face="normal" font="default" size="100%">Stohr, H.</style></author><author><style face="normal" font="default" size="100%">Domenga-Denier, V.</style></author><author><style face="normal" font="default" size="100%">Nelson, M. T.</style></author><author><style face="normal" font="default" size="100%">Joutel, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Genetics and Pathogenesis of Cerebrovascular Diseases, Inserm, U1161 and Univ Paris Diderot, Sorbonne Paris Cite, UMRS 1161, F-75010, Paris, France.&#xD;DHU NeuroVasc, Sorbonne Paris Cite, Paris, France.&#xD;Rare and Common Kidney Diseases, Matrix Remodeling and Tissue Repair, Inserm U1155 and Pierre and Marie Curie University, Sorbonne Universities UMR-S 1155, F-75020, Paris, France.&#xD;Department of Emergency Nephrological and Renal Transplantation, Tenon Hospital, AP-HP, F-75020, Paris, France.&#xD;Institute of Human Genetics, University of Regensburg, Regensburg, Germany.&#xD;Department of Pharmacology, College of Medicine, University of Vermont, Burlington, VT.&#xD;Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reducing Timp3 or vitronectin ameliorates disease manifestations in CADASIL mice</style></title><secondary-title><style face="normal" font="default" size="100%">Ann Neurol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Annals of neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Ann Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Annals of neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Ann Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Annals of neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">387-403</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2015/12/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/metabolism/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">CADASIL/ pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Tissue Inhibitor of Metalloproteinases/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Vitronectin/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1531-8249 (Electronic)&#xD;0364-5134 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26648042</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: CADASIL is a genetic paradigm of cerebral small vessel disease caused by NOTCH3 mutations that stereotypically lead to the extracellular deposition of NOTCH3 ectodomain (Notch3(ECD) ) on the vessels. TIMP3 and vitronectin are 2 extracellular matrix proteins that abnormally accumulate in Notch3(ECD) -containing deposits on brain vessels of mice and patients with CADASIL. Herein, we investigated whether increased levels of TIMP3 and vitronectin are responsible for aspects of CADASIL disease phenotypes. METHODS: Timp3 and vitronectin expression were genetically reduced in TgNotch3(R169C) mice, a well-established preclinical model of CADASIL. A mouse overexpressing human TIMP3 (TgBAC-TIMP3) was developed. Disease-related phenotypes, including cerebral blood flow (CBF) deficits, white matter lesions, and Notch3(ECD) deposition, were evaluated between 6 and 20 months of age. RESULTS: CBF responses to neural activity (functional hyperemia), topical application of vasodilators, and decreases in blood pressure (CBF autoregulation) were similarly reduced in TgNotch3(R169C) and TgBAC-TIMP3 mice, and myogenic responses of brain arteries were likewise attenuated. These defects were rescued in TgNotch3(R169C) mice by haploinsufficiency of Timp3, although the number of white matter lesions was unaffected. In contrast, haploinsufficiency or loss of vitronectin in TgNotch3(R169C) mice ameliorated white matter lesions, although CBF responses were unchanged. Amelioration of cerebrovascular reactivity or white matter lesions in these mice was not associated with reduced Notch3(ECD) deposition in brain vessels. INTERPRETATION: Elevated levels of TIMP3 and vitronectin, acting downstream of Notch3(ECD) deposition, play a role in CADASIL, producing divergent influences on early CBF deficits and later white matter lesions.</style></abstract><notes><style face="normal" font="default" size="100%">Capone, Carmen&#xD;Cognat, Emmanuel&#xD;Ghezali, Lamia&#xD;Baron-Menguy, Celine&#xD;Aubin, Deborah&#xD;Mesnard, Laurent&#xD;Stohr, Heidi&#xD;Domenga-Denier, Valerie&#xD;Nelson, Mark T&#xD;Joutel, Anne&#xD;R01 HL121706/HL/NHLBI NIH HHS/United States&#xD;P01 HL095488/HL/NHLBI NIH HHS/United States&#xD;R01HL121706/HL/NHLBI NIH HHS/United States&#xD;R37 DK053832/DK/NIDDK NIH HHS/United States&#xD;R37DK053832/DK/NIDDK NIH HHS/United States&#xD;P01HL095488/HL/NHLBI NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Ann Neurol. 2016 Mar;79(3):387-403. doi: 10.1002/ana.24573. Epub 2016 Feb 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1002/ana.24573/asset/ana24573.pdf?v=1&amp;t=ixshxjdz&amp;s=cd5036480212361858480b7817572165ef70c955</style></url></related-urls><pdf-urls><url>internal-pdf://2667061153/Capone-2016-Reducing Timp3 or vi.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/ana.24573</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>489</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">489</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Carlsson, Y.</style></author><author><style face="normal" font="default" size="100%">Schwendimann, L.</style></author><author><style face="normal" font="default" size="100%">Vontell, R.</style></author><author><style face="normal" font="default" size="100%">Rousset, C. I.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Lebon, S.</style></author><author><style face="normal" font="default" size="100%">Charriaut-Marlangue, C.</style></author><author><style face="normal" font="default" size="100%">Supramaniam, V.</style></author><author><style face="normal" font="default" size="100%">Hagberg, H.</style></author><author><style face="normal" font="default" size="100%">Gressens, P.</style></author><author><style face="normal" font="default" size="100%">Jacotot, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Perinatal Center, Department of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Genetic inhibition of caspase-2 reduces hypoxic-ischemic and excitotoxic neonatal brain injury</style></title><secondary-title><style face="normal" font="default" size="100%">Ann Neurol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Annals of neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Ann Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Annals of neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Ann Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Annals of neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">781-9</style></pages><volume><style face="normal" font="default" size="100%">70</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2011/06/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Animals, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/drug effects/ metabolism/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Caspase 2/deficiency/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia-Ischemia, Brain/genetics/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Ibotenic Acid</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Neurotoxins/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, N-Methyl-D-Aspartate/agonists</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1531-8249 (Electronic)&#xD;0364-5134 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">21674587</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: Perinatal brain injury is a major cause of neurodevelopmental handicaps. Multiple pathways of oxidant stress, inflammation, and excitotoxicity lead to cell damage and death, including caspase-dependent apoptosis. Caspase-2 (Casp2; Nedd-2, Ich-1) is a developmentally regulated initiator caspase, which poorly cleaves other caspases but can initiate mitochondrial outer membrane permeabilization. We have investigated if Casp2 could mediate perinatal ischemic brain damage. METHODS: Casp2 expression in human neonatal brains and developmental patterns in rats and mice were evaluated. Casp2-deficient (Casp2(-/-)), wild-type (WT), and heterozygous (Casp2(+/-)) newborn C57BL/6 mice were subjected to hypoxia-ischemia (unilateral carotid occlusion + exposure to 10% oxygen for 50 minutes) or intracerebral injection of the excitotoxic N-methyl-D-aspartate-receptor agonist ibotenate. In addition, Casp2 specific siRNAs were preinjected into the brain of WT newborn mice 24 hours before ibotenate treatment. Brain tissues were examined by immunohistochemical staining (cresyl violet, MAP2, NF68, Casp2, Casp3) and Western blotting. Lesion volumes and injury in the cortical plates and white matter were quantified together with activated Casp3. RESULTS: Casp2 is highly expressed in the neonatal brain. Casp2-deficient mice subjected to hypoxia-ischemia at postnatal day 9 present significantly lower cerebral infarction, reduced white matter injury, and reduced Casp3 activation in the thalamus and hippocampus. Both Casp2(-/-) mice and siRNA-administered WT mice conferred reduction of gray and white matter injury after excitotoxic insult at postnatal day 5. Casp3 activation was also found reduced in Casp2-deficient mice subjected to excitotoxicity. INTERPRETATION: These data suggest for the first time a role of Casp2 in neonatal brain damage.</style></abstract><notes><style face="normal" font="default" size="100%">Carlsson, Ylva&#xD;Schwendimann, Leslie&#xD;Vontell, Regina&#xD;Rousset, Catherine I&#xD;Wang, Xiaoyang&#xD;Lebon, Sophie&#xD;Charriaut-Marlangue, Christiane&#xD;Supramaniam, Veena&#xD;Hagberg, Henrik&#xD;Gressens, Pierre&#xD;Jacotot, Etienne&#xD;G0802853/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Ann Neurol. 2011 Nov;70(5):781-9. doi: 10.1002/ana.22431. Epub 2011 Jun 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1002/ana.22431/asset/22431_ftp.pdf?v=1&amp;t=ixshxppw&amp;s=2c164da7a99fcdc64a45fa6d6d6e038712361834</style></url></related-urls><pdf-urls><url>internal-pdf://3219735757/Carlsson-2011-Genetic inhibition o.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/ana.22431</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>333</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">333</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Castel, A.</style></author><author><style face="normal" font="default" size="100%">Helie, P.</style></author><author><style face="normal" font="default" size="100%">Beaudry, F.</style></author><author><style face="normal" font="default" size="100%">Vachon, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Veterinary Biomedicine, Saint-Hyacinthe, Quebec, Canada. pascal.vachon@umontreal.ca</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bilateral central pain sensitization in rats following a unilateral thalamic lesion may be treated with high doses of ketamine</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Vet Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">BMC veterinary research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMC Vet Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">BMC veterinary research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">BMC Vet Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">BMC veterinary research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">59</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><edition><style face="normal" font="default" size="100%">2013/03/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Analgesics/administration &amp; dosage/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Hemorrhage/complications/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperalgesia/ drug therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Ketamine/administration &amp; dosage/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Pain Measurement</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Rotarod Performance Test</style></keyword><keyword><style face="normal" font="default" size="100%">Thalamic Diseases/ complications/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Thalamus/pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 27</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1746-6148 (Electronic)&#xD;1746-6148 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23537119</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Central post-stroke pain is a neuropathic pain condition caused by a vascular lesion, of either ischemic or hemorrhagic origin, in the central nervous system and more precisely involving the spinothalamocortical pathway responsible for the transmission of painful sensations. Few animal models have been developed to study this problem. The objectives of this study were to evaluate different modalities of pain in a central neuropathic pain rat model and to assess the effects of ketamine administered at different doses. Animals were evaluated on the rotarod, Hargreaves, Von Frey and acetone tests. A very small hemorrhage was created by injecting a collagenase solution in the right ventral posterolateral thalamic nucleus. Following the establishment of the neuropathy, ketamine was evaluated as a therapeutic drug for this condition. RESULTS: Histopathological observations showed a well localized lesion with neuronal necrosis and astrocytosis following the collagenase injection that was localized within the VPL. No significant change in motor coordination was observed following surgery in either the saline or collagensae groups. In the collagenase group, a significant decrease in mechanical allodynia threshold was observed. A sporadic and transient cold allodynia was also noted. No thermal hyperalgesia was seen following the collagenase injection. Ketamine was then tested as a potential therapeutic drug. A significant decrease in motor coordination was seen only following the administration of 25 mg/kg of ketamine in both groups. An alleviation of mechanical allodynia was achieved only with the high ketamine dose. The minimal effective ketamine serum concentration (150 ng/mL) was only achieved in animals that received 25 mg/kg. CONCLUSIONS: An intrathalamic hemorrhage induced a bilateral mechanical allodynia in rats. Cold hyperalgesia was observed in 60% of these animals. Mechanical allodynia was alleviated with high doses of ketamine which corresponded with therapeutic plasmatic concentrations.</style></abstract><notes><style face="normal" font="default" size="100%">Castel, Aude&#xD;Helie, Pierre&#xD;Beaudry, Francis&#xD;Vachon, Pascal&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;BMC Vet Res. 2013 Mar 27;9:59. doi: 10.1186/1746-6148-9-59.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/47/art%253A10.1186%252F1746-6148-9-59.pdf?originUrl=http%3A%2F%2Fbmcvetres.biomedcentral.com%2Farticle%2F10.1186%2F1746-6148-9-59&amp;token2=exp=1484112245~acl=%2Fstatic%2Fpdf%2F47%2Fart%25253A10.1186%25252F1746-6148-9-59.pdf*~hmac=2ba74134cba2eee3ba5512a9f12ffdff6ccc4ae4c1b0726dc8b72bb0199352e7</style></url></related-urls><pdf-urls><url>internal-pdf://2188122692/Castel-2013-Bilateral central pa.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3618296</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/1746-6148-9-59</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>327</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">327</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cayabyab, F. S.</style></author><author><style face="normal" font="default" size="100%">Gowribai, K.</style></author><author><style face="normal" font="default" size="100%">Walz, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Physiology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada. frank.cayabyab@usask.ca</style></auth-address><titles><title><style face="normal" font="default" size="100%">Involvement of matrix metalloproteinases-2 and -9 in the formation of a lacuna-like cerebral cavity</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosci Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neuroscience research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosci Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroscience research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosci Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroscience research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">920-33</style></pages><volume><style face="normal" font="default" size="100%">91</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2013/04/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Analysis of Variance</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, CD11b/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Ectodysplasins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation, Enzymologic/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Glial Fibrillary Acidic Protein/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Matrix Metalloproteinase 2/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Matrix Metalloproteinase 9/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Microglia/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Minocycline/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Phenylalanine/analogs &amp; derivatives/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Protease Inhibitors/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/complications/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke, Lacunar/ enzymology/etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Thiophenes/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1097-4547 (Electronic)&#xD;0360-4012 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23606560</style></accession-num><abstract><style face="normal" font="default" size="100%">We used a modified pial vessel disruption (PVD) protocol with adult male Wistar rats to mimic small-vessel stroke in the cerebral cortex. Within 3 weeks, this lesion develops into a single lacuna-like cavity, which is fluid-filled and encapsulated by reactive astrocytes. Minocycline treatment that commences 1 hr after lesion and continues for 6 days prevents the cavitation and causes a filling of the lesion with reactive astrocytes and no barrier. Here, we determined whether inhibition of matrix metalloproteinases-2 and -9 (MMPs) mediates this minocycline action. Confocal microscopy revealed increased punctate staining of MMPs inside the lesion sites after 2 days of PVD. Astrocytes lined the lesion border but showed sparse localization inside the lesion. In contrast, increased MMP levels inside the lesion coincided with increased ED1 or OX-42 immunostaining, suggesting that MMP elevation reflected increased secretions from microglia/macrophages. Imaging analyses also revealed that minocycline administered for 2 days before animal euthanasia, significantly decreased MMP levels within the lesion. Moreover, Western blot analysis of cortical tissue extracts showed a significant 30-40% upregulation of MMPs 2 days after lesion. Minocycline administered 2 hr before the lesion significantly inhibited both MMP-9 and MMP-2 levels by approximately 40%. In contrast, minocycline administered 1 hr after the lesion only decreased MMP-9 levels by approximately 30%. Because MMP inhibition with batimastat injection also prevented cavity formation at 21 days, we conclude that minocycline prevented the creation of a lacuna-like cyst in the cerebral cortex by inhibiting the MMP secretion from microglia in the affected tissue.</style></abstract><notes><style face="normal" font="default" size="100%">Cayabyab, Francisco S&#xD;Gowribai, Krishnamoorty&#xD;Walz, Wolfgang&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Neurosci Res. 2013 Jul;91(7):920-33. doi: 10.1002/jnr.23223. Epub 2013 Apr 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1002/jnr.23223/asset/jnr23223.pdf?v=1&amp;t=ixshyb1m&amp;s=21161e36f62bd43ffa2abded7faf8f8f44b4921a</style></url></related-urls><pdf-urls><url>internal-pdf://2064688873/Cayabyab-2013-Involvement of matri.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/jnr.23223</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>222</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">222</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cebral, J. R.</style></author><author><style face="normal" font="default" size="100%">Raschi, M.</style></author><author><style face="normal" font="default" size="100%">Mut, F.</style></author><author><style face="normal" font="default" size="100%">Ding, Y. H.</style></author><author><style face="normal" font="default" size="100%">Dai, D.</style></author><author><style face="normal" font="default" size="100%">Kadirvel, R.</style></author><author><style face="normal" font="default" size="100%">Kallmes, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Computational Fluid Dynamics, College of Sciences, George Mason University, 4400 University Drive, MSN 6A2, Fairfax, VA, 22030, U.S.A.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Analysis of flow changes in side branches jailed by flow diverters in rabbit models</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Numer Method Biomed Eng</style></secondary-title><alt-title><style face="normal" font="default" size="100%">International journal for numerical methods in biomedical engineering</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Int J Numer Method Biomed Eng</style></full-title><abbr-1><style face="normal" font="default" size="100%">International journal for numerical methods in biomedical engineering</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Int J Numer Method Biomed Eng</style></full-title><abbr-1><style face="normal" font="default" size="100%">International journal for numerical methods in biomedical engineering</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">988-99</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2014/04/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Aorta/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Angiography/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Arteries/diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment Design</style></keyword><keyword><style face="normal" font="default" size="100%">Imaging, Three-Dimensional</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Aneurysm/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Biological</style></keyword><keyword><style face="normal" font="default" size="100%">Rabbits</style></keyword><keyword><style face="normal" font="default" size="100%">Stents</style></keyword><keyword><style face="normal" font="default" size="100%">Ultrasonography, Doppler, Transcranial</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2040-7947 (Electronic)&#xD;2040-7939 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24729467</style></accession-num><abstract><style face="normal" font="default" size="100%">Understanding the flow alteration in side branches during flow diversion treatment of cerebral aneurysms is important to prevent ischemic complications and improve device designs. Flow diverters were placed in the aorta of four rabbits crossing the origin of side arteries. Subject-specific computational models were constructed from 3D angiographies and Doppler ultrasounds (DUSs). Flow simulations were run before and after virtually deploying the flow diverters, assuming distal resistances remained unchanged after treatment. All jailed arteries remained patent angiographically 8 weeks after treatment. The computational models estimated decreases compared to pretreatment in the mean flow rates between 2% and 20% and in peak flow rates between 5% and 36%. The major changes were observed during systole. Flow patterns did not exhibit recirculation zones before treatment. Implantation of the flow diverters altered the flow structure only locally near the device wires. No major recirculation regions were created or destroyed. Flow diverters seem safe with respect to perforator or side branch occlusion. Relatively small changes in flow rates through jailed arteries are expected, even for moderate to large degrees of coverage of their origins. These results seem consistent with previous clinical experiences where no or very few complications related to perforator occlusion have been reported.</style></abstract><notes><style face="normal" font="default" size="100%">Cebral, Juan R&#xD;Raschi, Marcelo&#xD;Mut, Fernando&#xD;Ding, Yong-Hond&#xD;Dai, Daying&#xD;Kadirvel, Ramanathan&#xD;Kallmes, David&#xD;R01 NS076491/NS/NINDS NIH HHS/United States&#xD;NS076491/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;England&#xD;Int J Numer Method Biomed Eng. 2014 Oct;30(10):988-99. doi: 10.1002/cnm.2640. Epub 2014 Apr 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1002/cnm.2640/asset/cnm2640.pdf?v=1&amp;t=ixshxwqe&amp;s=d88585ebd31c86134a31c772eacf53acc8c5ed75</style></url></related-urls><pdf-urls><url>internal-pdf://1789693265/Cebral-2014-Analysis of flow cha.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4466553</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms598281</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/cnm.2640</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>42</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">42</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chakravarty, S.</style></author><author><style face="normal" font="default" size="100%">Maitra, S.</style></author><author><style face="normal" font="default" size="100%">Reddy, R. G.</style></author><author><style face="normal" font="default" size="100%">Das, T.</style></author><author><style face="normal" font="default" size="100%">Jhelum, P.</style></author><author><style face="normal" font="default" size="100%">Kootar, S.</style></author><author><style face="normal" font="default" size="100%">Rajan, W. D.</style></author><author><style face="normal" font="default" size="100%">Samanta, A.</style></author><author><style face="normal" font="default" size="100%">Samineni, R.</style></author><author><style face="normal" font="default" size="100%">Pabbaraja, S.</style></author><author><style face="normal" font="default" size="100%">Kernie, S. G.</style></author><author><style face="normal" font="default" size="100%">Mehta, G.</style></author><author><style face="normal" font="default" size="100%">Kumar, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Chemical Biology, CSIR- Indian Institute of Chemical Technology, Tarnaka, Uppal Road, Hyderabad 500007, India.&#xD;CSIR- Centre for Cellular and Molecular Biology, Habsiguda, Uppal Road, Hyderabad 500007, India.&#xD;Natural Products Chemistry, CSIR- Indian Institute of Chemical Technology, Tarnaka, Uppal Road, Hyderabad 500007, India.&#xD;Department of Pediatrics and Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.&#xD;School of Chemistry, University of Hyderabad, Hyderabad; 500046, India.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A novel natural product inspired scaffold with robust neurotrophic, neurogenic and neuroprotective action</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Rep</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Scientific reports</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Sci Rep</style></full-title><abbr-1><style face="normal" font="default" size="100%">Scientific reports</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Sci Rep</style></full-title><abbr-1><style face="normal" font="default" size="100%">Scientific reports</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">14134</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><edition><style face="normal" font="default" size="100%">2015/09/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Azepines/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Benzamides/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain-Derived Neurotrophic Factor/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Line</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Discovery</style></keyword><keyword><style face="normal" font="default" size="100%">Extracellular Signal-Regulated MAP Kinases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Flavonoids/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">MAP Kinase Signaling System/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mental Disorders/ drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Growth Factors/antagonists &amp; inhibitors/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Neurodegenerative Diseases/ drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/antagonists &amp; inhibitors/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, trkB/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Nerve Growth Factor/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Zebrafish</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 21</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2045-2322 (Electronic)&#xD;2045-2322 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26388493</style></accession-num><abstract><style face="normal" font="default" size="100%">In search for drugs to treat neuropsychiatric disorders wherein neurotrophic and neurogenic properties are affected, two neurotrophically active small molecules specially crafted following natural product leads based on 2-oxa-spiro[5.5]-undecane scaffold, have been thoroughly evaluated for their neurotrophic, neurogenic and neuroprotective potential in ex vivo primary culture and in vivo zebrafish and mouse models. The outcome of in vivo investigations suggest that one of these molecules is more neurotrophic than neurogenic while the other one is more neurogenic than neurotrophic and the former exhibits remarkable neuroprotection in a mouse acute ischemic stroke model. The molecular mechanisms of action of these compounds appear to be through the TrkB-MEK-ERK-CREB-BDNF pathway as pre-treatment with neurotrophin receptor TrkB inhibitor ANA-12 and MEK inhibitor PD98059 attenuates the neurotrophic action of compounds.</style></abstract><notes><style face="normal" font="default" size="100%">Chakravarty, Sumana&#xD;Maitra, Swati&#xD;Reddy, R Gajendra&#xD;Das, Tapatee&#xD;Jhelum, Priya&#xD;Kootar, Scherazad&#xD;Rajan, Wenson D&#xD;Samanta, Anumita&#xD;Samineni, Ramesh&#xD;Pabbaraja, Srihari&#xD;Kernie, Steven G&#xD;Mehta, Goverdhan&#xD;Kumar, Arvind&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Sci Rep. 2015 Sep 21;5:14134. doi: 10.1038/srep14134.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4585672</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/srep14134</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>108</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">108</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chaparro, R. E.</style></author><author><style face="normal" font="default" size="100%">Izutsu, M.</style></author><author><style face="normal" font="default" size="100%">Sasaki, T.</style></author><author><style face="normal" font="default" size="100%">Sheng, H.</style></author><author><style face="normal" font="default" size="100%">Zheng, Y.</style></author><author><style face="normal" font="default" size="100%">Sadeghian, H.</style></author><author><style face="normal" font="default" size="100%">Qin, T.</style></author><author><style face="normal" font="default" size="100%">von Bornstadt, D.</style></author><author><style face="normal" font="default" size="100%">Herisson, F.</style></author><author><style face="normal" font="default" size="100%">Duan, B.</style></author><author><style face="normal" font="default" size="100%">Li, J. S.</style></author><author><style face="normal" font="default" size="100%">Jiang, K.</style></author><author><style face="normal" font="default" size="100%">Pearlstein, M.</style></author><author><style face="normal" font="default" size="100%">Pearlstein, R. D.</style></author><author><style face="normal" font="default" size="100%">Smith, D. E.</style></author><author><style face="normal" font="default" size="100%">Goldberg, I. D.</style></author><author><style face="normal" font="default" size="100%">Ayata, C.</style></author><author><style face="normal" font="default" size="100%">Warner, D. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Anesthesiology, Multidisciplinary Neuroprotection Laboratories, Duke University Medical Center, Durham, North Carolina, USA.&#xD;Neurovascular Research Laboratory, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA.&#xD;Angion Biomedica Corporation, Uniondale, New York, USA.&#xD;Department of Surgery, Multidisciplinary Neuroprotection Laboratories, Duke University Medical Center, Durham, North Carolina, USA.&#xD;1] Neurovascular Research Laboratory, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA [2] Stroke Service and Neuroscience Intensive Care Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA.&#xD;1] Department of Anesthesiology, Multidisciplinary Neuroprotection Laboratories, Duke University Medical Center, Durham, North Carolina, USA [2] Department of Surgery, Multidisciplinary Neuroprotection Laboratories, Duke University Medical Center, Durham, North Carolina, USA [3] Department of Neurobiology, Multidisciplinary Neuroprotection Laboratories, Duke University Medical Center, Durham, North Carolina, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sustained functional improvement by hepatocyte growth factor-like small molecule BB3 after focal cerebral ischemia in rats and mice</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1044-53</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2015/02/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ blood supply/ drug effects/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Hepatocyte Growth Factor/ chemistry/pharmacokinetics/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ drug therapy/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Long-Evans</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25712497</style></accession-num><abstract><style face="normal" font="default" size="100%">Hepatocyte growth factor (HGF), efficacious in preclinical models of acute central nervous system injury, is burdened by administration of full-length proteins. A multiinstitutional consortium investigated the efficacy of BB3, a small molecule with HGF-like activity that crosses the blood-brain barrier in rodent focal ischemic stroke using Stroke Therapy Academic Industry Roundtable (STAIR) and Good Laboratory Practice guidelines. In rats, BB3, begun 6 hours after temporary middle cerebral artery occlusion (tMCAO) reperfusion, or permanent middle cerebral artery occlusion (pMCAO) onset, and continued for 14 days consistently improved long-term neurologic function independent of sex, age, or laboratory. BB3 had little effect on cerebral infarct size and no effect on blood pressure. BB3 increased HGF receptor c-Met phosphorylation and synaptophysin expression in penumbral tissue consistent with a neurorestorative mechanism from HGF-like activity. In mouse tMCAO, BB3 starting 10 minutes after reperfusion and continued for 14 days improved neurologic function that persisted for 8 weeks in some, but not all measures. Study in animals with comorbidities and those exposed to common stroke drugs are the next steps to complete preclinical assessment. These data, generated in independent, masked, and rigorously controlled settings, are the first to suggest that the HGF pathway can potentially be harnessed by BB3 for neurologic benefit after ischemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Chaparro, Rafael E&#xD;Izutsu, Miwa&#xD;Sasaki, Toshihiro&#xD;Sheng, Huaxin&#xD;Zheng, Yi&#xD;Sadeghian, Homa&#xD;Qin, Tao&#xD;von Bornstadt, Daniel&#xD;Herisson, Fanny&#xD;Duan, Bin&#xD;Li, Jing-Song&#xD;Jiang, Kai&#xD;Pearlstein, Molly&#xD;Pearlstein, Robert D&#xD;Smith, David E&#xD;Goldberg, Itzhak D&#xD;Ayata, Cenk&#xD;Warner, David S&#xD;5R44NS045373/NS/NINDS NIH HHS/United States&#xD;2R44NS045373/NS/NINDS NIH HHS/United States&#xD;P50 NS051343/NS/NINDS NIH HHS/United States&#xD;P01 NS055104/NS/NINDS NIH HHS/United States&#xD;R44 NS045373/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;United States&#xD;J Cereb Blood Flow Metab. 2015 Jun;35(6):1044-53. doi: 10.1038/jcbfm.2015.23. Epub 2015 Feb 25.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4640251</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2015.23</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>460</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">460</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chauveau, F.</style></author><author><style face="normal" font="default" size="100%">Cho, T. H.</style></author><author><style face="normal" font="default" size="100%">Riou, A.</style></author><author><style face="normal" font="default" size="100%">Langlois, J. B.</style></author><author><style face="normal" font="default" size="100%">Berthezene, Y.</style></author><author><style face="normal" font="default" size="100%">Nighoghossian, N.</style></author><author><style face="normal" font="default" size="100%">Wiart, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Universite de Lyon, CREATIS, CNRS UMR5220, Inserm U1044, INSA-Lyon, Universite Lyon 1, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Does acute behavioral testing reflect successful ischemia in rats with transient middle cerebral artery occlusion?</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">International journal of stroke : official journal of the International Stroke Society</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Int J Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">International journal of stroke : official journal of the International Stroke Society</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Int J Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">International journal of stroke : official journal of the International Stroke Society</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">465-72</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2011/12/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/pathology/ physiopathology/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/pathology/ physiopathology/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Ligation</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Angiography/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Psychomotor Performance/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reflex</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1747-4949 (Electronic)&#xD;1747-4930 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22151768</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Models of intraluminal middle cerebral artery occlusion present an intrinsic variability in infarct size. Behavioral evaluation is frequently performed during arterial occlusion to confirm success of surgery. AIMS AND/OR HYPOTHESIS: We compared the value of behavioral testing and multimodal magnetic resonance imaging performed during arterial occlusion for identifying successfully operated animals. METHODS: Rats were tested with behavioral assessment (using three scoring scales and the adhesive removal test) and multimodal magnetic resonance imaging (including magnetic resonance angiography, diffusion-weighted and perfusion-weighted imaging), both performed during the two-hours of middle cerebral artery occlusion using the intraluminal suture model. Behavioral assessment was repeated 24 h after reperfusion, followed by sacrifice. RESULTS: Acute apparent diffusion coefficient lesion volume was correlated with both 2,3,5-triphenyl tetrazolium chloride infarct size (r = 0.75, P = 0.02) and behavioral status (r = 0.66, P = 0.05) on day one. Conversely, no correlation was found between acute behavioral examination and day one outcomes (2,3,5-triphenyl tetrazolium chloride infarct volume, r = 0.40, P = 0.28; behavioral examination, r = 0.39, P = 0.30). Day zero apparent diffusion coefficient volumes (P = 0.04), but not behavioral assessment (P = 0.60), discriminated animals with day one corticostriatal infarcts from these with subcortical infarcts. CONCLUSIONS: Acute behavioral testing performed during arterial occlusion fails to identify successfully operated animals. Acute diffusion magnetic resonance imaging may be more appropriate to assess and reduce infarct size variability in this model.</style></abstract><notes><style face="normal" font="default" size="100%">Chauveau, Fabien&#xD;Cho, Tae-Hee&#xD;Riou, Adrien&#xD;Langlois, Jean-Baptiste&#xD;Berthezene, Yves&#xD;Nighoghossian, Norbert&#xD;Wiart, Marlene&#xD;United States&#xD;Int J Stroke. 2012 Aug;7(6):465-72. doi: 10.1111/j.1747-4949.2011.00710.x. Epub 2011 Dec 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/j.1747-4949.2011.00710.x/asset/ijs710.pdf?v=1&amp;t=ixshyfzh&amp;s=122f3e81ef7041a890afb8a77d547da1f511a2be</style></url></related-urls><pdf-urls><url>internal-pdf://3273573839/Chauveau-2012-Does acute behaviora.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1747-4949.2011.00710.x</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>156</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">156</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chechneva, O. V.</style></author><author><style face="normal" font="default" size="100%">Mayrhofer, F.</style></author><author><style face="normal" font="default" size="100%">Daugherty, D. J.</style></author><author><style face="normal" font="default" size="100%">Krishnamurty, R. G.</style></author><author><style face="normal" font="default" size="100%">Bannerman, P.</style></author><author><style face="normal" font="default" size="100%">Pleasure, D. E.</style></author><author><style face="normal" font="default" size="100%">Deng, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, CA 95817, USA.&#xD;Institute for Pediatric Regenerative Medicine, Shriners Hospitals for Children, 2425 Stockton Boulevard, Sacramento, CA 95817, USA.&#xD;1] Department of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, CA 95817, USA [2] Institute for Pediatric Regenerative Medicine, Shriners Hospitals for Children, 2425 Stockton Boulevard, Sacramento, CA 95817, USA.&#xD;1] Department of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, CA 95817, USA [2] Institute for Pediatric Regenerative Medicine, Shriners Hospitals for Children, 2425 Stockton Boulevard, Sacramento, CA 95817, USA [3] Medical College, Hubei University of Arts and Science, Xiangyang, Hubei 441053, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A Smoothened receptor agonist is neuroprotective and promotes regeneration after ischemic brain injury</style></title><secondary-title><style face="normal" font="default" size="100%">Cell Death Dis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Cell death &amp; disease</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cell Death Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Cell death &amp; disease</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Cell Death Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Cell death &amp; disease</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e1481</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><edition><style face="normal" font="default" size="100%">2014/10/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/complications/ drug therapy/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/drug effects/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Hedgehog Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Morpholines/ pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Regeneration/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Purines/ pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, G-Protein-Coupled/ agonists/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Smoothened Receptor</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/complications/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Tissue Plasminogen Activator/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation/drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 23</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2041-4889 (Electronic)</style></isbn><accession-num><style face="normal" font="default" size="100%">25341035</style></accession-num><abstract><style face="normal" font="default" size="100%">Ischemic stroke occurs as a result of blood supply interruption to the brain causing tissue degeneration, patient disabilities or death. Currently, treatment of ischemic stroke is limited to thrombolytic therapy with a narrow time window of administration. The sonic hedgehog (Shh) signaling pathway has a fundamental role in the central nervous system development, but its impact on neural cell survival and tissue regeneration/repair after ischemic stroke has not been well investigated. Here we report the neuroprotective properties of a small-molecule agonist of the Shh co-receptor Smoothened, purmorphamine (PUR), in the middle cerebral artery occlusion model of ischemic stroke. We found that intravenous administration of PUR at 6 h after injury was neuroprotective and restored neurological deficit after stroke. PUR promoted a transient upregulation of tissue-type plasminogen activator in injured neurons, which was associated with a reduction of apoptotic cell death in the ischemic cortex. We also observed a decrease in blood-brain barrier permeability after PUR treatment. At 14 d postinjury, attenuation of inflammation and reactive astrogliosis was found in PUR-treated animals. PUR increased the number of newly generated neurons in the peri-infarct and infarct area and promoted neovascularization in the ischemic zone. Notably, PUR treatment did not significantly alter the ischemia-induced level of Gli1, a Shh target gene of tumorigenic potential. Thus our study reports a novel pharmacological approach for postischemic treatment using a small-molecule Shh agonist, providing new insights into hedgehog signaling-mediated mechanisms of neuroprotection and regeneration after stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Chechneva, O V&#xD;Mayrhofer, F&#xD;Daugherty, D J&#xD;Krishnamurty, R G&#xD;Bannerman, P&#xD;Pleasure, D E&#xD;Deng, W&#xD;R01 ES015988/ES/NIEHS NIH HHS/United States&#xD;R01ES015988/ES/NIEHS NIH HHS/United States&#xD;R01NS061983/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Cell Death Dis. 2014 Oct 23;5:e1481. doi: 10.1038/cddis.2014.446.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.nature.com/cddis/journal/v5/n10/pdf/cddis2014446a.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://4047400931/Chechneva-2014-A Smoothened recepto.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4649529</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/cddis.2014.446</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>86</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">86</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chelluboina, B.</style></author><author><style face="normal" font="default" size="100%">Warhekar, A.</style></author><author><style face="normal" font="default" size="100%">Dillard, M.</style></author><author><style face="normal" font="default" size="100%">Klopfenstein, J. D.</style></author><author><style face="normal" font="default" size="100%">Pinson, D. M.</style></author><author><style face="normal" font="default" size="100%">Wang, D. Z.</style></author><author><style face="normal" font="default" size="100%">Veeravalli, K. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, Peoria, IL, USA.&#xD;1] Department of Neurosurgery, University of Illinois College of Medicine at Peoria, Peoria, IL, USA [2] Comprehensive Stroke Center, Illinois Neurological Institue, Peoria, IL, USA.&#xD;Department of Pathology, University of Illinois College of Medicine at Peoria, Peoria, IL, USA.&#xD;1] Department of Neurology, University of Illinois College of Medicine at Peoria, Peoria, IL, USA [2] Comprehensive Stroke Center, Illinois Neurological Institue, Peoria, IL, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Post-transcriptional inactivation of matrix metalloproteinase-12 after focal cerebral ischemia attenuates brain damage</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Rep</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Scientific reports</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Sci Rep</style></full-title><abbr-1><style face="normal" font="default" size="100%">Scientific reports</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Sci Rep</style></full-title><abbr-1><style face="normal" font="default" size="100%">Scientific reports</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">9504</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><edition><style face="normal" font="default" size="100%">2015/05/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/ enzymology/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ enzymology/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Line, Tumor</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Knockdown Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Silencing/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Matrix Metalloproteinase 12/ genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Matrix Metalloproteinase 9/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Myelin Basic Protein/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects/enzymology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmids/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Real-Time Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion</style></keyword><keyword><style face="normal" font="default" size="100%">Substrate Specificity/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Transcription, Genetic/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Tumor Necrosis Factor-alpha/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation/drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">May 08</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2045-2322 (Electronic)&#xD;2045-2322 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25955565</style></accession-num><abstract><style face="normal" font="default" size="100%">This study highlights the possible pathological role of MMP-12 in the context of ischemic stroke. Male rats were subjected to a two-hour middle cerebral artery occlusion (MCAO) procedure. MMP-12 shRNA expressing plasmid formulation was administered to these rats twenty-four hours after reperfusion. The results showed a predominant upregulation of MMP-12 (approximately 47, 58, 143, and 265 folds on days 1, 3, 5, 7 post-ischemia, respectively) in MCAO subjected rats. MMP-12 expression was localized to neurons, oligodendrocytes and microglia, but not astrocytes. Transcriptional inactivation of MMP-12 significantly reduced the infarct size. The percent infarct size was reduced from 62.87+/-4.13 to 34.67+/-5.39 after MMP-12 knockdown compared to untreated MCAO subjected rats. Expression of myelin basic protein was increased, and activity of MMP-9 was reduced in ischemic rat brains after MMP-12 knockdown. Furthermore, a significant reduction in the extent of apoptosis was noticed after MMP-12 knockdown. TNFalpha expression in the ipsilateral regions of MCAO-subjected rats was reduced after MMP-12 knockdown in addition to the reduced protein expression of apoptotic molecules that are downstream to TNFalpha signaling. Specific knockdown of MMP-12 after focal cerebral ischemia offers neuroprotection that could be mediated via reduced MMP-9 activation and myelin degradation as well as inhibition of apoptosis.</style></abstract><notes><style face="normal" font="default" size="100%">Chelluboina, Bharath&#xD;Warhekar, Aditi&#xD;Dillard, Matt&#xD;Klopfenstein, Jeffrey D&#xD;Pinson, David M&#xD;Wang, David Z&#xD;Veeravalli, Krishna Kumar&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Sci Rep. 2015 May 8;5:9504. doi: 10.1038/srep09504.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/srep09504</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>26</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">26</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, A.</style></author><author><style face="normal" font="default" size="100%">Akinyemi, R. O.</style></author><author><style face="normal" font="default" size="100%">Hase, Y.</style></author><author><style face="normal" font="default" size="100%">Firbank, M. J.</style></author><author><style face="normal" font="default" size="100%">Ndung&apos;u, M. N.</style></author><author><style face="normal" font="default" size="100%">Foster, V.</style></author><author><style face="normal" font="default" size="100%">Craggs, L. J.</style></author><author><style face="normal" font="default" size="100%">Washida, K.</style></author><author><style face="normal" font="default" size="100%">Okamoto, Y.</style></author><author><style face="normal" font="default" size="100%">Thomas, A. J.</style></author><author><style face="normal" font="default" size="100%">Polvikoski, T. M.</style></author><author><style face="normal" font="default" size="100%">Allan, L. M.</style></author><author><style face="normal" font="default" size="100%">Oakley, A. E.</style></author><author><style face="normal" font="default" size="100%">O&apos;Brien, J. T.</style></author><author><style face="normal" font="default" size="100%">Horsburgh, K.</style></author><author><style face="normal" font="default" size="100%">Ihara, M.</style></author><author><style face="normal" font="default" size="100%">Kalaria, R. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">1 Neurovascular Research Group, Institute of Neuroscience, Newcastle University, Campus for Ageing and Vitality, Newcastle Upon Tyne, UK.&#xD;2 Institute of Primate Research, National Museums of Kenya, Kenya.&#xD;3 Centre for Neuroregeneration, University of Edinburgh, Chancellor&apos;s Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK.&#xD;4 Department of Stroke and Cerebrovascular Diseases, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan.&#xD;1 Neurovascular Research Group, Institute of Neuroscience, Newcastle University, Campus for Ageing and Vitality, Newcastle Upon Tyne, UK raj.kalaria@ncl.ac.uk.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Frontal white matter hyperintensities, clasmatodendrosis and gliovascular abnormalities in ageing and post-stroke dementia</style></title><secondary-title><style face="normal" font="default" size="100%">Brain</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain : a journal of neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain : a journal of neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Brain</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain : a journal of neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">242-58</style></pages><volume><style face="normal" font="default" size="100%">139</style></volume><number><style face="normal" font="default" size="100%">Pt 1</style></number><edition><style face="normal" font="default" size="100%">2015/12/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Aging/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Aldehyde Dehydrogenase/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Aquaporin 4/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/metabolism/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition Disorders/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Dementia/ complications/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Frontal Lobe/blood supply/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Glial Fibrillary Acidic Protein/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroimaging</style></keyword><keyword><style face="normal" font="default" size="100%">Neuropsychological Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Papio anubis</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ complications/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">White Matter/blood supply/ pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1460-2156 (Electronic)&#xD;0006-8950 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26667280</style></accession-num><abstract><style face="normal" font="default" size="100%">White matter hyperintensities as seen on brain T2-weighted magnetic resonance imaging are associated with varying degrees of cognitive dysfunction in stroke, cerebral small vessel disease and dementia. The pathophysiological mechanisms within the white matter accounting for cognitive dysfunction remain unclear. With the hypothesis that gliovascular interactions are impaired in subjects with high burdens of white matter hyperintensities, we performed clinicopathological studies in post-stroke survivors, who had exhibited greater frontal white matter hyperintensities volumes that predicted shorter time to dementia onset. Histopathological methods were used to identify substrates in the white matter that would distinguish post-stroke demented from post-stroke non-demented subjects. We focused on the reactive cell marker glial fibrillary acidic protein (GFAP) to study the incidence and location of clasmatodendrosis, a morphological attribute of irreversibly injured astrocytes. In contrast to normal appearing GFAP+ astrocytes, clasmatodendrocytes were swollen and had vacuolated cell bodies. Other markers such as aldehyde dehydrogenase 1 family, member L1 (ALDH1L1) showed cytoplasmic disintegration of the astrocytes. Total GFAP+ cells in both the frontal and temporal white matter were not greater in post-stroke demented versus post-stroke non-demented subjects. However, the percentage of clasmatodendrocytes was increased by &gt;2-fold in subjects with post-stroke demented compared to post-stroke non-demented subjects (P = 0.026) and by 11-fold in older controls versus young controls (P &lt; 0.023) in the frontal white matter. High ratios of clasmotodendrocytes to total astrocytes in the frontal white matter were consistent with lower Mini-Mental State Examination and the revised Cambridge Cognition Examination scores in post-stroke demented subjects. Double immunofluorescent staining showed aberrant co-localization of aquaporin 4 (AQP4) in retracted GFAP+ astrocytes with disrupted end-feet juxtaposed to microvessels. To explore whether this was associated with the disrupted gliovascular interactions or blood-brain barrier damage, we assessed the co-localization of GFAP and AQP4 immunoreactivities in post-mortem brains from adult baboons with cerebral hypoperfusive injury, induced by occlusion of three major vessels supplying blood to the brain. Analysis of the frontal white matter in perfused brains from the animals surviving 1-28 days after occlusion revealed that the highest intensity of fibrinogen immunoreactivity was at 14 days. At this survival time point, we also noted strikingly similar redistribution of AQP4 and GFAP+ astrocytes transformed into clasmatodendrocytes. Our findings suggest novel associations between irreversible astrocyte injury and disruption of gliovascular interactions at the blood-brain barrier in the frontal white matter and cognitive impairment in elderly post-stroke survivors. We propose that clasmatodendrosis is another pathological substrate, linked to white matter hyperintensities and frontal white matter changes, which may contribute to post-stroke or small vessel disease dementia.</style></abstract><notes><style face="normal" font="default" size="100%">Chen, Aiqing&#xD;Akinyemi, Rufus O&#xD;Hase, Yoshiki&#xD;Firbank, Michael J&#xD;Ndung&apos;u, Michael N&#xD;Foster, Vincent&#xD;Craggs, Lucy J L&#xD;Washida, Kazuo&#xD;Okamoto, Yoko&#xD;Thomas, Alan J&#xD;Polvikoski, Tuomo M&#xD;Allan, Louise M&#xD;Oakley, Arthur E&#xD;O&apos;Brien, John T&#xD;Horsburgh, Karen&#xD;Ihara, Masafumi&#xD;Kalaria, Raj N&#xD;MR/L016451/1/Medical Research Council/United Kingdom&#xD;G1100540/Medical Research Council/United Kingdom&#xD;Biotechnology and Biological Sciences Research Council/United Kingdom&#xD;MR/K026992/1/Medical Research Council/United Kingdom&#xD;G0900652/Medical Research Council/United Kingdom&#xD;152/Alzheimer&apos;s Society/United Kingdom&#xD;G0502157/Medical Research Council/United Kingdom&#xD;G0400074/Medical Research Council/United Kingdom&#xD;G0500247/Medical Research Council/United Kingdom&#xD;R277/0213/The Dunhill Medical Trust/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Brain. 2016 Jan;139(Pt 1):242-58. doi: 10.1093/brain/awv328. Epub 2015 Dec 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://brain.oxfordjournals.org/content/brain/139/1/242.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0792905838/Chen-2016-Frontal white matter.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4905522</style></custom2><custom6><style face="normal" font="default" size="100%">Ems68159</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/brain/awv328</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>328</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">328</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, C.</style></author><author><style face="normal" font="default" size="100%">Mei, H.</style></author><author><style face="normal" font="default" size="100%">Shi, W.</style></author><author><style face="normal" font="default" size="100%">Deng, J.</style></author><author><style face="normal" font="default" size="100%">Zhang, B.</style></author><author><style face="normal" font="default" size="100%">Guo, T.</style></author><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Hu, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, PR China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">EGFP-EGF1-conjugated PLGA nanoparticles for targeted delivery of siRNA into injured brain microvascular endothelial cells for efficient RNA interference</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PloS one</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e60860</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2013/04/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Base Sequence</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Green Fluorescent Proteins/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lactic Acid/ chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Nanoparticles</style></keyword><keyword><style face="normal" font="default" size="100%">Polyglycolic Acid/ chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">RNA Interference</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/ administration &amp; dosage/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203 (Electronic)&#xD;1932-6203 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23593330</style></accession-num><abstract><style face="normal" font="default" size="100%">Injured endothelium is an important target for drug and/or gene therapy because brain microvascular endothelial cells (BMECs) play critical roles in various pathophysiological conditions. RNA-mediated gene silencing presents a new therapeutic approach for treating such diseases, but major challenge is to ensure minimal toxicity and target delivery of siRNA to injured BMECs. Injured BMECs overexpress tissue factor (TF), which the fusion protein EGFP-EGF1 could be targeted to. In this study, TNF alpha (TNF-alpha) was chosen as a stimulus for primary BMECs to produce injured endothelium in vitro. The EGFP-EGF1-PLGA nanoparticles (ENPs) with loaded TF-siRNA were used as a new carrier for targeted delivery to the injured BMECs. The nanoparticles then produced intracellular RNA interference against TF. We compared ENP-based transfections with NP-mediated transfections, and our studies show that the ENP-based transfections result in a more efficient downregulation of TF. Our findings also show that the TF siRNA-loaded ENPs had minimal toxicity, with almost 96% of the cells viable 24 h after transfection while Lipofectamine-based transfections resulted in only 75% of the cells. Therefore, ENP-based transfection could be used for efficient siRNA transfection to injured BMECs and for efficient RNA interference (RNAi). This transfection could serve as a potential treatment for diseases, such as stroke, atherosclerosis and cancer.</style></abstract><notes><style face="normal" font="default" size="100%">Chen, Chen&#xD;Mei, Heng&#xD;Shi, Wei&#xD;Deng, Jun&#xD;Zhang, Bo&#xD;Guo, Tao&#xD;Wang, Huafang&#xD;Hu, Yu&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;PLoS One. 2013 Apr 10;8(4):e60860. doi: 10.1371/journal.pone.0060860. Print 2013.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0060860&amp;type=printable</style></url></related-urls><pdf-urls><url>internal-pdf://2948774131/Chen-2013-EGFP-EGF1-conjugated.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3622655</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0060860</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>173</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">173</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, G. M.</style></author><author><style face="normal" font="default" size="100%">Lan, Y. Y.</style></author><author><style face="normal" font="default" size="100%">Wang, C. F.</style></author><author><style face="normal" font="default" size="100%">Zhan, H. X.</style></author><author><style face="normal" font="default" size="100%">Wang, W. R.</style></author><author><style face="normal" font="default" size="100%">Chen, J. H.</style></author><author><style face="normal" font="default" size="100%">Chen, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Fuzhou General Hospital of Nanjing Military Command, PLA, Clinical Medical College of Fujian Medical University in Fuzhou General Hospital of Nanjing Military Command, PLA, Dongfang Hospital Affiliated to Xiamen University, NO, 156, Xi Er-Huan North Road, Fuzhou 350025, Fujian Province, China. chenguangming39@126.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clearance of serum solutes by hemofiltration in dogs with severe heat stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Scand J Trauma Resusc Emerg Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Scandinavian journal of trauma, resuscitation and emergency medicine</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Scand J Trauma Resusc Emerg Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Scandinavian journal of trauma, resuscitation and emergency medicine</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Scand J Trauma Resusc Emerg Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Scandinavian journal of trauma, resuscitation and emergency medicine</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">49</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><edition><style face="normal" font="default" size="100%">2014/08/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/ blood</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Dogs</style></keyword><keyword><style face="normal" font="default" size="100%">Heat Stroke/blood/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Hemodialysis Solutions/ pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Hemofiltration/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 22</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1757-7241 (Electronic)&#xD;1757-7241 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25145441</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: We have previously reported that hemofiltration (HF) may be an effective additional means of treating heat stroke when rapid cooling is not effective. METHODS: Dogs were assigned to a heat stroke (control) or heat stroke + hemofiltration (HF) group (n = 8 each group). After heat stroke induction, dogs in the HF group received HF for 3 h. Serum concentrations of interleukin (IL)-10, tumor necrosis factor (TNF)-alpha, IL-6, blood urea nitrogen (BUN) and creatinine were measured at baseline and 1, 2, and 3 h after heat stroke. Clearance rates of solutes were determined 1, 2, and 3 h after the start of HF. RESULTS: Serum concentrations of all solutes tended to increase with time after heat stroke in the control group, but decreased (BUN, creatinine) or remained relatively unchanged (TNF-alpha, IL-6, IL-10) with time in the HF group. Concentrations of all solutes were significantly lower in the HF group compared with the control group at 2 and 3 h (P &lt; 0.05). Clearance rates for small molecular weight solutes were high, while those for larger molecular weight solutes were low. CONCLUSION: HF prevents heat stroke-induced increases in serum cytokine concentrations and is effective for clearing small molecular weight solutes from serum, but less effective for clearing larger molecular weight solutes, including TNF-alpha, IL-6, and IL-10.</style></abstract><notes><style face="normal" font="default" size="100%">Chen, Guang-Ming&#xD;Lan, Yu-Ying&#xD;Wang, Cheng-Feng&#xD;Zhan, Hai-Xia&#xD;Wang, Wen-Rui&#xD;Chen, Jin-Hua&#xD;Chen, Jian&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Scand J Trauma Resusc Emerg Med. 2014 Aug 22;22:49. doi: 10.1186/s13049-014-0049-z.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/627/art%253A10.1186%252Fs13049-014-0049-z.pdf?originUrl=http%3A%2F%2Fsjtrem.biomedcentral.com%2Farticle%2F10.1186%2Fs13049-014-0049-z&amp;token2=exp=1484112285~acl=%2Fstatic%2Fpdf%2F627%2Fart%25253A10.1186%25252Fs13049-014-0049-z.pdf*~hmac=612833568ba75558f1da32e7ff30f47f9c0d0840d7897a1c05ef9db10ae26d0f</style></url></related-urls><pdf-urls><url>internal-pdf://0984921481/Chen-2014-Clearance of serum s.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4237957</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s13049-014-0049-z</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>140</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">140</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, H.</style></author><author><style face="normal" font="default" size="100%">Tian, M.</style></author><author><style face="normal" font="default" size="100%">Jin, L.</style></author><author><style face="normal" font="default" size="100%">Jia, H.</style></author><author><style face="normal" font="default" size="100%">Jin, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Anesthesiology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu, PR China.&#xD;Department of Anesthesiology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu, PR China. Electronic address: jinyi2014@sogou.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">PUMA is invovled in ischemia/reperfusion-induced apoptosis of mouse cerebral astrocytes</style></title><secondary-title><style face="normal" font="default" size="100%">Neuroscience</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">824-32</style></pages><volume><style face="normal" font="default" size="100%">284</style></volume><edition><style face="normal" font="default" size="100%">2014/12/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Acetylcysteine/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Animals, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/drug effects/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis Regulatory Proteins/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/drug effects/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Caspase 3/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Caspase 9/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Hypoxia/drug effects/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Survival/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Cytochromes c/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Free Radical Scavengers/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Knockdown Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose/ deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering</style></keyword><keyword><style face="normal" font="default" size="100%">Reactive Oxygen Species/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/drug therapy/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Transfection</style></keyword><keyword><style face="normal" font="default" size="100%">Tumor Suppressor Proteins/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">bcl-2-Associated X Protein/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 22</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1873-7544 (Electronic)&#xD;0306-4522 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25451294</style></accession-num><abstract><style face="normal" font="default" size="100%">PUMA (p53-upregulated modulator of apoptosis), a BH3-only member of the Bcl-2 protein family, is required for p53-dependent and p53-independent forms of apoptosis. PUMA has been invovled in the onset and progress of several diseases, including cancer, acquired immunodeficiency syndrome, and ischemic brain disease. Although many studies have shown that ischemia and reperfusion (I/R) can induce the apoptosis of astrocytes, the role of PUMA in I/R-mediated apoptosis of cerebral astrocyte apoptosis remains unclear. To mimic in vivo I/R conditions, primary mouse cerebral astrocytes were incubated in a combinational cultural condition of oxygen, glucose, and serum deprivation (OSGD) for 1 h followed by reperfusion (OSGD/R). Cell death determination assays and cell viability assays indicated that OSGD and OSGD/R induce the apoptosis of primary cerebral astrocytes. The expression of PUMA was significantly elevated in primary cerebral astrocytes during OSGD/R. Moreover, targeted down-regulation of PUMA by siRNA transfection significantly decreased the OSGD/R-induced apoptosis of primary cerebral astrocytes. We also found that OSGD and OSGD/R triggered the release of cytochrome c in astrocytes, indicating the dependence on a mitochondrial apoptotic pathway. Reactive oxygen species (ROS) was extremely generated during OSGD and OSGD/R, and the elimination of ROS by treated with N-acetyl-L-cysteine (NAC) remarkably inhibited the expression of PUMA and the apoptosis of primary cerebral astrocytes. The activation of Caspase 3 and Caspase 9 was extremely elevated in primary cerebral astrocytes during OSGD. In addition, we found that knockdown of PUMA led to the depressed expression of Bax, cleaved caspase-9 and caspase-3 during OSGD/R. These results indicate that PUMA is invovled in the apoptosis of cerebral astrocytes upon I/R injury.</style></abstract><notes><style face="normal" font="default" size="100%">Chen, H&#xD;Tian, M&#xD;Jin, L&#xD;Jia, H&#xD;Jin, Y&#xD;United States&#xD;Neuroscience. 2015 Jan 22;284:824-32. doi: 10.1016/j.neuroscience.2014.10.059. Epub 2014 Nov 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0306452214009312/1-s2.0-S0306452214009312-main.pdf?_tid=951d6e34-d7bd-11e6-84c4-00000aacb35d&amp;acdnat=1484112173_c8f9f79dae138c5ab5bac227edc7cbfd</style></url></related-urls><pdf-urls><url>internal-pdf://3773944272/Chen-2015-PUMA is invovled in.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuroscience.2014.10.059</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>210</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">210</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, J.</style></author><author><style face="normal" font="default" size="100%">Li, J.</style></author><author><style face="normal" font="default" size="100%">Miao, Z.</style></author><author><style face="normal" font="default" size="100%">Xu, X.</style></author><author><style face="normal" font="default" size="100%">Liu, C. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou City, China; The Institute of Neuroscience, Soochow University, Suzhou City, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">XAV939, a small molecular inhibitor, provides neuroprotective effects on oligodentrocytes</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosci Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neuroscience research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosci Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroscience research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosci Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroscience research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1252-8</style></pages><volume><style face="normal" font="default" size="100%">92</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2014/05/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Animals, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Infarction/etiology/pathology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/complications/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Caspases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Line, Transformed</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Chromones/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme Inhibitors/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Heterocyclic Compounds, 3-Ring/ pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Morpholines/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Oligodendroglia/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Serum/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">beta Catenin/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1097-4547 (Electronic)&#xD;0360-4012 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24861203</style></accession-num><abstract><style face="normal" font="default" size="100%">White matter tracts are composed of axons and myelinating oligodendrocytes. Oligodendrocytes are the myelinating cells in the central nervous system that allow formation of myelin and saltatory nerve conduction. Cerebral white matter is highly vulnerable to ischemic injury in adults and neonates. White matter injury in newborn brains results in cerebral palsy and cognitive disability. In this study, we found that XAV939, a small-molecular inhibitor that stimulated beta-catenin degradation by stabilizing axin, protected against serum and glucose deprivation (SGD)-induced cell death in oligodentrocyte cell line OLN-93 cells in a concentration-dependent manner. We further showed that XAV939 reduced caspase-3 and caspase-8 levels and increased the expression of phosphorylated Akt in SGD-induced OLN-93 cells. Our data demonstrate that XAV939 protects against neonatal hypoxic/ischemic injury. In summary, our results demonstrate that XAV939 confers neuroprotection against SGD-induced injury in OLN-93 cells via its antiapoptotic activity and the loss of oligodendrocytes and neurons in neonatal hypoxic/ischemic injury.</style></abstract><notes><style face="normal" font="default" size="100%">Chen, Jing&#xD;Li, Jizhen&#xD;Miao, Zhigang&#xD;Xu, Xingshun&#xD;Liu, Chun-Feng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Neurosci Res. 2014 Oct;92(10):1252-8. doi: 10.1002/jnr.23415. Epub 2014 May 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1002/jnr.23415/asset/jnr23415.pdf?v=1&amp;t=ixshym8e&amp;s=e97a561c1f6fa3aea3688f7cbf4b32d4cf8a56f8</style></url></related-urls><pdf-urls><url>internal-pdf://2212487171/Chen-2014-XAV939, a small mole.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/jnr.23415</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>481</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">481</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, K. Y.</style></author><author><style face="normal" font="default" size="100%">Wu, C. C.</style></author><author><style face="normal" font="default" size="100%">Chang, C. F.</style></author><author><style face="normal" font="default" size="100%">Chen, Y. H.</style></author><author><style face="normal" font="default" size="100%">Chiu, W. T.</style></author><author><style face="normal" font="default" size="100%">Lou, Y. H.</style></author><author><style face="normal" font="default" size="100%">Chen, Y. H.</style></author><author><style face="normal" font="default" size="100%">Shih, H. M.</style></author><author><style face="normal" font="default" size="100%">Chiang, Y. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Taipei Medical University Hospital, Taipei, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Suppression of Etk/Bmx protects against ischemic brain injury</style></title><secondary-title><style face="normal" font="default" size="100%">Cell Transplant</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Cell transplantation</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cell Transplant</style></full-title><abbr-1><style face="normal" font="default" size="100%">Cell transplantation</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Cell Transplant</style></full-title><abbr-1><style face="normal" font="default" size="100%">Cell transplantation</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">345-54</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2011/09/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Amides/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ metabolism/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Caspase 3/biosynthesis</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Differentiation</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Line</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Proliferation</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Survival/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/cytology/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrogen Peroxide/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nitriles/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphorylation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Protein-Tyrosine Kinases/antagonists &amp; inhibitors/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA Interference</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">STAT1 Transcription Factor/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1555-3892 (Electronic)&#xD;0963-6897 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">21929872</style></accession-num><abstract><style face="normal" font="default" size="100%">Etk/Bmx (epithelial and endothelial tyrosine kinase, also known as BMX), a member of the Tec (tyrosine kinase expressed in hepatocellular carcinoma) family of protein-tyrosine kinases, is an important regulator of signal transduction for the activation of cell growth, differentiation, and development. We have previously reported that activation of Etk leads to apoptosis in MDA-MB-468 cells. The purpose of this study was to examine the role of Etk in neuronal injury induced by H(2)O(2) or ischemia. Using Western blot analysis and immunohistochemistry, we found that treatment with H(2)O(2) significantly enhanced phosphorylation of Etk and its downstream signaling molecule Stat1 in primary cortical neurons. Inhibiting Etk activity by LFM-A13 or knocking down Etk expression by a specific shRNA increased the survival of primary cortical neurons. Similarly, at 1 day after a 60-min middle cerebral artery occlusion (MCAo) in adult rats, both phosphorylated Etk and Stat1 were coexpressed with apoptotic markers in neurons in the penumbra. Pretreatment with LFM-A13 or an adenoviral vector encoding the kinase deletion mutant Etkk attenuated caspase-3 activity and infarct volume in ischemic brain. All together, our data suggest that Etk is activated after neuronal injury. Suppressing Etk activity protects against neurodegeneration in ischemic brain.</style></abstract><notes><style face="normal" font="default" size="100%">Chen, Kai-Yun&#xD;Wu, Chung-Che&#xD;Chang, Cheng-Fu&#xD;Chen, Yuan-Hao&#xD;Chiu, Wen-Ta&#xD;Lou, Ya-Hsin&#xD;Chen, Yen-Hua&#xD;Shih, Hsiu-Ming&#xD;Chiang, Yung-Hsiao&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Cell Transplant. 2012;21(1):345-54. doi: 10.3727/096368911X582741. Epub 2011 Sep 16.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3727/096368911x582741</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>419</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">419</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, R.</style></author><author><style face="normal" font="default" size="100%">Tan, S.</style></author><author><style face="normal" font="default" size="100%">Chen, J.</style></author><author><style face="normal" font="default" size="100%">Guo, Y.</style></author><author><style face="normal" font="default" size="100%">Li, C.</style></author><author><style face="normal" font="default" size="100%">Chen, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Zhujiang Hospital, Southern Medical University, Guangzhou, China. 1234567crq@163.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">[Role of CD4(+)CD25(+) regulatory T cells and Foxp3 in the pathophysiology of acute cerebral ischemia in rats]</style></title><secondary-title><style face="normal" font="default" size="100%">Nan Fang Yi Ke Da Xue Xue Bao</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Nan fang yi ke da xue xue bao = Journal of Southern Medical University</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nan Fang Yi Ke Da Xue Xue Bao</style></full-title><abbr-1><style face="normal" font="default" size="100%">Nan fang yi ke da xue xue bao = Journal of Southern Medical University</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Nan Fang Yi Ke Da Xue Xue Bao</style></full-title><abbr-1><style face="normal" font="default" size="100%">Nan fang yi ke da xue xue bao = Journal of Southern Medical University</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">659-63</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2012/05/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ immunology/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Forkhead Transcription Factors/immunology/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Regulatory/immunology/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1673-4254 (Print)&#xD;1673-4254 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22588919</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To investigate the dynamic changes in CD4(+)CD25(+) regulatory T cells and Foxp3 expression in peripheral blood and brain tissues of rats after acute cerebral ischemia and explore their role in the pathophysiological evolution of acute ischemic stroke. METHODS: Forty-eight Wistar rats were randomized equally into ischemia and sham-operated groups, and right middle cerebral artery occlusion was induced in the former group. Flow cytometry and immunohistochemistry were employed to detect CD4(+)CD25(+) T cells and Foxp3 expression, respectively, in the peripheral blood and brain tissue at 1, 3, 7, and 14 days after modeling. The behavioral changes of the rats were evaluated using an improved NSS neurological functional scoring system. RESULTS: The neurological function scores of the two groups both gradually declined after the operation, and showed significant differences between the two groups at all the time points of measurement (P&lt;0.01). The CD4(+)CD25 T cells in the peripheral blood were similar between the two group at 1 and 3 days after the operation (P&gt;0.05), but increased significantly in the ischemia group at 7 and 14 days (P&lt;0.05) with an inverse correlation to the neurological scores (r=-0.68, P=0.01). Immunohistochemistry detected the presence of Foxp3 primarily in the ischemic region of the brain tissue 1 day after cerebral ischemia; the contralateral hemisphere also showed a small quantity of Foxp3 expression. No Foxp3 expression was detected in the brain tissue of the sham-operated group. CONCLUSION: CD4(+)CD25 T regulatory cells participate in the inflammatory immune reactions as early as 1 day after acute cerebral ischemia in rats, which might be a protective mechanism of the brain cells.</style></abstract><notes><style face="normal" font="default" size="100%">Chen, Ruiqing&#xD;Tan, Sheng&#xD;Chen, Jian&#xD;Guo, Yang&#xD;Li, Can&#xD;Chen, Zhenzhou&#xD;English Abstract&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;China&#xD;Nan Fang Yi Ke Da Xue Xue Bao. 2012 May;32(5):659-63.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">chi</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>194</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">194</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, R. L.</style></author><author><style face="normal" font="default" size="100%">Ogunshola, O. O.</style></author><author><style face="normal" font="default" size="100%">Yeoh, K. K.</style></author><author><style face="normal" font="default" size="100%">Jani, A.</style></author><author><style face="normal" font="default" size="100%">Papadakis, M.</style></author><author><style face="normal" font="default" size="100%">Nagel, S.</style></author><author><style face="normal" font="default" size="100%">Schofield, C. J.</style></author><author><style face="normal" font="default" size="100%">Buchan, A. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Acute Stroke Programme, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.&#xD;Institute for Science and Technology in Medicine, School of Pharmacy, Keele University, Staffordshire, UK.&#xD;Institute of Veterinary Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.&#xD;Chemistry Research Laboratory, University of Oxford, Oxford, UK.&#xD;Department of Neurology, University of Heidelberg, Heidelberg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">HIF prolyl hydroxylase inhibition prior to transient focal cerebral ischaemia is neuroprotective in mice</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurochem</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neurochemistry</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurochem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurochemistry</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurochem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurochemistry</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">177-89</style></pages><volume><style face="normal" font="default" size="100%">131</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2014/07/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ metabolism/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Glycine/administration &amp; dosage/ analogs &amp; derivatives</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia-Inducible Factor 1, alpha Subunit/antagonists &amp; inhibitors/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia-Inducible Factor-Proline Dioxygenases/ antagonists &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">inhibitors/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Isoquinolines/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1471-4159 (Electronic)&#xD;0022-3042 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24974727</style></accession-num><abstract><style face="normal" font="default" size="100%">This study investigated the effects of 2-(1-chloro-4-hydroxyisoquinoline-3-carboxamido) acetic acid (IOX3), a selective small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylases, on mouse brains subject to transient focal cerebral ischaemia. Male, 8- to 12-week-old C57/B6 mice were subjected to 45 min of middle cerebral artery occlusion (MCAO) either immediately or 24 h after receiving IOX3. Mice receiving IOX3 at 20 mg/kg 24 h prior to the MCAO had better neuroscores and smaller blood-brain barrier (BBB) disruption and infarct volumes than mice receiving the vehicle, whereas those having IOX3 at 60 mg/kg showed no significant changes. IOX3 treatment immediately before MCAO was not neuroprotective. IOX3 up-regulated HIF-1alpha, and increased EPO expression in mouse brains. In an in vitro BBB model (RBE4 cell line), IOX3 up-regulated HIF-1alpha and delocalized ZO-1. Pre-treating IOX3 on RBE4 cells 24 h before oxygen-glucose deprivation had a protective effect on endothelial barrier preservation with ZO-1 being better localized, while immediate IOX3 treatment did not. Our study suggests that HIF stabilization with IOX3 before cerebral ischaemia is neuroprotective partially because of BBB protection, while immediate application could be detrimental. These results provide information for studies aimed at the therapeutic activation of HIF pathway for neurovascular protection from cerebral ischaemia. We show that IOX3, a selective small molecule (280.66 Da) HIF prolyl hydroxylase inhibitor, could up-regulate HIF-1alpha and increase erythropoietin expression in mice. We further demonstrate that HIF stabilization with IOX3 before cerebral ischaemia is neuroprotective partially because of blood-brain barrier (BBB) protection, while immediate application is detrimental both in vivo and in vitro. These findings provide new insights into the role of HIF stabilization in ischaemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Chen, Ruoli L&#xD;Ogunshola, O O&#xD;Yeoh, Karkheng K&#xD;Jani, Anant&#xD;Papadakis, Michalis&#xD;Nagel, Simon&#xD;Schofield, Christopher J&#xD;Buchan, Alastair M&#xD;British Heart Foundation/United Kingdom&#xD;Medical Research Council/United Kingdom&#xD;Biotechnology and Biological Sciences Research Council/United Kingdom&#xD;PG/12/33/29546/British Heart Foundation/United Kingdom&#xD;NF-SI-0508-10213/Department of Health/United Kingdom&#xD;G0500495/Medical Research Council/United Kingdom&#xD;Wellcome Trust/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Neurochem. 2014 Oct;131(2):177-89. doi: 10.1111/jnc.12804. Epub 2014 Jul 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/jnc.12804/asset/jnc12804.pdf?v=1&amp;t=ixshyqme&amp;s=39373f46f601536dbb913f77ce99bd90bae1ce4f</style></url></related-urls><pdf-urls><url>internal-pdf://1083897924/Chen-2014-HIF prolyl hydroxyla.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/jnc.12804</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>130</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">130</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, X.</style></author><author><style face="normal" font="default" size="100%">Dang, G.</style></author><author><style face="normal" font="default" size="100%">Dang, C.</style></author><author><style face="normal" font="default" size="100%">Liu, G.</style></author><author><style face="normal" font="default" size="100%">Xing, S.</style></author><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Xu, Q.</style></author><author><style face="normal" font="default" size="100%">Zeng, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology and Stroke Center, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.&#xD;Guangdong Landau Biotechnology Co. Ltd, Guangzhou, Guangdong, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An ischemic stroke model of nonhuman primates for remote lesion studies: a behavioral and neuroimaging investigation</style></title><secondary-title><style face="normal" font="default" size="100%">Restor Neurol Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Restorative neurology and neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Restor Neurol Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Restorative neurology and neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Restor Neurol Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Restorative neurology and neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">131-42</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2015/01/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Angiography</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery</style></keyword><keyword><style face="normal" font="default" size="100%">Macaca fascicularis</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Neurosurgical Procedures</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ pathology/ physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1878-3627 (Electronic)&#xD;0922-6028 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25588459</style></accession-num><abstract><style face="normal" font="default" size="100%">PURPOSE: We aimed to develop a nonhuman primate (NHP) stroke model for studies of secondary lesions in remote areas and to characterize its behavioral and neuroimaging features. METHODS: Monkeys were either subjected to middle cerebral artery occlusion (MCAO) distal to the M1 branch (n = 17) or sham operation (n = 7). Neurological assessment and magnetic resonance imaging (MRI) were performed before and 1 week after operation. RESULTS: After MCAO, six monkeys showed occlusion of the distal M1 segment and infarcts predominantly in the cortical and subcortical regions, without hippocampal and thalamic involvement. They had obvious neurological deficits. The other 11 monkeys showed blockage of the main trunk of the MCA, with infarcts extending into the hippocampus and thalamus, but no substantia nigra involvement. Their infarct volume were larger and neurological deficits were more severe than those after distal M1 occlusion. All sham-operated monkeys displayed normal behavior; however, MRI revealed small infarcts in three animals. CONCLUSIONS: MCAO or even sham operations might cause cerebral infarction in NHPs. Therefore, neurological assessment should be combined with MRI for screening candidate stroke models. Our model is suitable for studying secondary damage in remote regions, including the thalamus, hippocampus, and substantia nigra, after stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Chen, Xinran&#xD;Dang, Ge&#xD;Dang, Chao&#xD;Liu, Gang&#xD;Xing, Shihui&#xD;Chen, Yicong&#xD;Xu, Qiang&#xD;Zeng, Jinsheng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;Restor Neurol Neurosci. 2015;33(2):131-42. doi: 10.3233/RNN-140440.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://content.iospress.com/articles/restorative-neurology-and-neuroscience/rnn140440</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3233/rnn-140440</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>123</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">123</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, X.</style></author><author><style face="normal" font="default" size="100%">Zhang, X.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Lei, H.</style></author><author><style face="normal" font="default" size="100%">Su, H.</style></author><author><style face="normal" font="default" size="100%">Zeng, J.</style></author><author><style face="normal" font="default" size="100%">Pei, Z.</style></author><author><style face="normal" font="default" size="100%">Huang, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">1] Department of Neurology, National Key Clinical Department and Key Discipline of Neurology, Guangdong Key Laboratory for Diagnosis and Treatment of Major Neurological Diseases, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, PR China [2] Department of Neurology, Fujian Provincial Hospital, Fujian Medical University Shengli Clinical College, Fuzhou 350001, PR China.&#xD;Department of Neurology, Fujian Provincial Hospital, Fujian Medical University Shengli Clinical College, Fuzhou 350001, PR China.&#xD;Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, PR China.&#xD;Department of Neurology, National Key Clinical Department and Key Discipline of Neurology, Guangdong Key Laboratory for Diagnosis and Treatment of Major Neurological Diseases, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, PR China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inhibition of immunoproteasome reduces infarction volume and attenuates inflammatory reaction in a rat model of ischemic stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Cell Death Dis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Cell death &amp; disease</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cell Death Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Cell death &amp; disease</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Cell Death Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Cell death &amp; disease</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e1626</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><edition><style face="normal" font="default" size="100%">2015/01/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/ complications/metabolism/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cysteine Endopeptidases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Knockdown Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/complications/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-1beta/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Leupeptins/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Microglia/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">NF-kappa B/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Proteasome Endopeptidase Complex/ immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Proteasome Inhibitors/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Subunits/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Transport/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ complications/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Tumor Necrosis Factor-alpha/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Ubiquitinated Proteins/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 29</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2041-4889 (Electronic)</style></isbn><accession-num><style face="normal" font="default" size="100%">25633295</style></accession-num><abstract><style face="normal" font="default" size="100%">The detailed knowledge about the contribution of immunoproteasome to the neuroinflammation in ischemic stroke is still not available. The immunoreactivity of low molecular mass peptide 2 (LMP2) and low molecular mass peptide 7 (LMP7) was evident in the ipsilateral ischemic cerebral cortex and striatum following transient middle cerebral artery occlusion (MCAO). Both LMP2 and LMP7 increased as early as 4 h after the MCAO, further increased at 24 h, peaked at 72 h and decreased 7 days later. LMP2 and LMP7 were mainly present in astrocytes and microglia/macrophage cells, respectively. LMP2 knockdown by shRNA (short hairpin RNA) markedly reduced the levels of LMP2 and LMP7 protein and caused 75.5 and 78.6% decrease in the caspase-like (C-L) and chymotrypsin-like (CT-L) activities, respectively. Compared with cont-shRNA group (39.7%, infarction volumes/total ipsilateral hemisphere), the infarction volumes were reduced to 22.5% in LMP2-shRNA group. Additionally, LMP2 knockdown significantly reduced activated astrocytes and microglia, the expression nuclear factor kappa B (NF-kappaB) p65, tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) and caused less accumulation of ischemia-induced protein ubiquitination compared with MG132. These findings demonstrate that inhibition of LMP2 significantly attenuates inflammatory reaction and offers neuroprotection against focal cerebral ischemia in rats, suggesting that selective immunoproteasome inhibitors may be a promising strategy for stroke treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Chen, X&#xD;Zhang, X&#xD;Wang, Y&#xD;Lei, H&#xD;Su, H&#xD;Zeng, J&#xD;Pei, Z&#xD;Huang, R&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Cell Death Dis. 2015 Jan 29;6:e1626. doi: 10.1038/cddis.2014.586.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.nature.com/cddis/journal/v6/n1/pdf/cddis2014586a.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3311337582/Chen-2015-Inhibition of immuno.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4669779</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/cddis.2014.586</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>415</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">415</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, Y. T.</style></author><author><style face="normal" font="default" size="100%">Zang, X. F.</style></author><author><style face="normal" font="default" size="100%">Pan, J.</style></author><author><style face="normal" font="default" size="100%">Zhu, X. L.</style></author><author><style face="normal" font="default" size="100%">Chen, F.</style></author><author><style face="normal" font="default" size="100%">Chen, Z. B.</style></author><author><style face="normal" font="default" size="100%">Xu, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Expression patterns of histone deacetylases in experimental stroke and potential targets for neuroprotection</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Exp Pharmacol Physiol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Clinical and experimental pharmacology &amp; physiology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Exp Pharmacol Physiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Clinical and experimental pharmacology &amp; physiology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Clin Exp Pharmacol Physiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Clinical and experimental pharmacology &amp; physiology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">751-8</style></pages><volume><style face="normal" font="default" size="100%">39</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2012/06/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Survival/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/drug effects/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Embryo, Mammalian</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Histone Deacetylase Inhibitors/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Histone Deacetylases/chemistry/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Isoenzymes/antagonists &amp; inhibitors/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred Strains</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Targeted Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Tissue Proteins/antagonists &amp; inhibitors/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">RNA Interference</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/drug therapy/etiology/ metabolism/pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1440-1681 (Electronic)&#xD;0305-1870 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22651689</style></accession-num><abstract><style face="normal" font="default" size="100%">1. Histone deacetylase (HDAC) inhibitors exert neuroprotection in both cellular and animal models of ischaemic stroke. However, which HDAC isoform (or isoforms) mediates this beneficial effect has not yet been determined. 2. In the present study, gene levels of the HDAC isoforms were determined in the mouse cortex using reverse transcription-polymerase chain reaction (RT-PCR), whereas changes in the expression of individual zinc-dependent HDAC family members were evaluated by western blotting, 3, 12, 24 and 48 h after cerebral ischaemia induced by transient middle cerebral artery occlusion in male Kunming mice. 3. The HDAC isoforms HDAC1-11 were all expressed in the mouse cortex and differentially affected by cerebral ischaemia. Notably, there was a substantial increase in HDAC3, HDAC6 and HDAC11 expression during the early phases of experimental stroke, indicating their contribution to stroke pathogenesis. Furthermore, induction of HDAC3 and HDAC6 in cortical neurons by ischaemic stroke was confirmed in vivo and in vitro using double-labelled immunostaining and RT-PCR, respectively. Therefore, small hairpin (sh) RNAs were used to selectively knock down HDAC3 or HDAC6. This knockdown appreciably promoted the survival of cortical neurons subjected to oxygen and glucose deprivation. 4. The findings of the present study demonstrate the expression patterns of HDAC isoforms during experimental ischaemic stroke. Furthermore, HDAC3 and HDAC6 were identified as potential mediators in the neurotoxicity of ischaemic stroke, suggesting that specific therapeutic approaches may be considered according to HDAC subtype.</style></abstract><notes><style face="normal" font="default" size="100%">Chen, Yan-Ting&#xD;Zang, Xue-Feng&#xD;Pan, Jie&#xD;Zhu, Xiao-Lei&#xD;Chen, Fei&#xD;Chen, Zhi-Bin&#xD;Xu, Yun&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Australia&#xD;Clin Exp Pharmacol Physiol. 2012 Sep;39(9):751-8. doi: 10.1111/j.1440-1681.2012.05729.x.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/j.1440-1681.2012.05729.x/asset/cep5729.pdf?v=1&amp;t=ixshyx1j&amp;s=7bb1d5ee9ae6ccc02d58af71992db8e9240ac4d9</style></url></related-urls><pdf-urls><url>internal-pdf://0866195678/Chen-2012-Expression patterns.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1440-1681.2012.05729.x</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>349</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">349</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cheng, M. J.</style></author><author><style face="normal" font="default" size="100%">Huang, P. H.</style></author><author><style face="normal" font="default" size="100%">Liao, P. W.</style></author><author><style face="normal" font="default" size="100%">Chen, J. T.</style></author><author><style face="normal" font="default" size="100%">Chiang, T. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Cathay General Hospital, Taipei, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Multiple cerebral and cerebellar infarcts as the first clinical manifestation in a patient with Churg-Strauss syndrome: case report and literature review</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Neurol Taiwan</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Acta neurologica Taiwanica</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Neurol Taiwan</style></full-title><abbr-1><style face="normal" font="default" size="100%">Acta neurologica Taiwanica</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Acta Neurol Taiwan</style></full-title><abbr-1><style face="normal" font="default" size="100%">Acta neurologica Taiwanica</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">169-75</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2013/01/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Infarction/ etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebellum/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Churg-Strauss Syndrome/ complications/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Diffusion Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Echocardiography</style></keyword><keyword><style face="normal" font="default" size="100%">Endocardium/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1028-768X (Print)&#xD;1028-768X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23329548</style></accession-num><abstract><style face="normal" font="default" size="100%">PURPOSE: Churg-Strauss syndrome (CSS) is a rare autoimmune disease with small-vessel vasculitis. Neurological manifestation of CSS is common. Central nervous system is less frequently involved than that of peripheral nervous system. CASE REPORT: We report a case of 60-year-old man who presented with acute onset of right hemiparesis and impaired cognition. The presence of hypereosinophilia, asthma, sinusitis and extravascular eosinophil accumulation led to the diagnosis of Churg-Strauss syndrome. Brain magnetic resonance imaging (MRI) revealed multiple infarcts in bilateral cerebral and cerebellar hemispheres. The neurophysiology study did not reveal peripheral neuropathy. The patient was effectively treated with methylprednisolone, cyclophosphamide and warfarin. CONCLUSION: Symptoms and signs of central nervous system can be the initial neurological manifestation of CSS patients. CSS should be considered while patients have stroke and hypereosinophilia. In our patient, there is a good response to timely steroid, immunosuppressant and anticoagulant therapies.</style></abstract><notes><style face="normal" font="default" size="100%">Cheng, Meng-Ju&#xD;Huang, Pai-Hao&#xD;Liao, Pin-Wen&#xD;Chen, Jen-Tse&#xD;Chiang, Tsuey-Ru&#xD;Case Reports&#xD;Review&#xD;China (Republic : 1949- )&#xD;Acta Neurol Taiwan. 2012 Dec;21(4):169-75.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>13</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">13</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cheon, S. Y.</style></author><author><style face="normal" font="default" size="100%">Cho, K. J.</style></author><author><style face="normal" font="default" size="100%">Song, J.</style></author><author><style face="normal" font="default" size="100%">Kim, G. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Anaesthesiology and Pain Medicine, College of Medicine, Yonsei University, Seoul, Korea.&#xD;Department of Neurology, College of Medicine, Yonsei University, 50, Yonsei-ro, Seodaemun-gu, 120-752, Seoul, Korea.&#xD;Department of Biology, York University, Toronto, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Knockdown of apoptosis signal-regulating kinase 1 affects ischaemia-induced astrocyte activation and glial scar formation</style></title><secondary-title><style face="normal" font="default" size="100%">Eur J Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The European journal of neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The European journal of neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Eur J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The European journal of neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">912-22</style></pages><volume><style face="normal" font="default" size="100%">43</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2016/01/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Line</style></keyword><keyword><style face="normal" font="default" size="100%">Cicatrix/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Glial Fibrillary Acidic Protein/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">MAP Kinase Kinase Kinase 5/ genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">p38 Mitogen-Activated Protein Kinases/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1460-9568 (Electronic)&#xD;0953-816X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26797817</style></accession-num><abstract><style face="normal" font="default" size="100%">Reactive astrocytes play an essential role in determining the tissue response to ischaemia. Formation of a glial scar can block the neuronal outgrowth that is required for restoration of damaged tissue. Therefore, regulation of astrocyte activation is important; however, the mediator of this process has not been fully elucidated. Apoptosis signal-regulating kinase 1 (ASK1) is an early responder to oxidative stress, and plays a pivotal role in the intracellular signalling pathway of apoptosis, inflammation, and differentiation. To confirm whether ASK1 mediates astrocyte activation and leads to glial scar formation after cerebral ischaemia, we conducted in vivo and in vitro experiments. C57BL/6 mice were subjected to occlusion of the middle cerebral artery, and astrocyte cultures were exposed to oxygen-glucose deprivation. After silencing of ASK1 , astrocyte-associated genes were downregulated, as seen with the use of microarrays. The glial fibrillary acidic protein (GFAP) level was decreased, and correlated with the reduction in the ASK1 level. In astrocytes, reduction in the ASK1 level decreased the activity of the p38 pathway, and the levels of transcription factors for GFAP and GFAP transcripts after hypoxia. In the chronic phase, ASK1 depletion reduced glial scar formation and conserved neuronal structure, which may lead to better functional recovery. These data suggest that ASK1 may be an important mediator of ischaemia-induced astrocyte activation and scar formation, and could provide a potential therapeutic target for treatment after ischaemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Cheon, So Yeong&#xD;Cho, Kyoung Joo&#xD;Song, Juhyun&#xD;Kim, Gyung Whan&#xD;France&#xD;Eur J Neurosci. 2016 Apr;43(7):912-22. doi: 10.1111/ejn.13175. Epub 2016 Feb 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/ejn.13175/asset/ejn13175.pdf?v=1&amp;t=ixshzpe7&amp;s=5bdcbef3e48d2a95bafa4c37e4fdb080fc68e806</style></url></related-urls><pdf-urls><url>internal-pdf://0368427980/Cheon-2016-Knockdown of apoptos.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/ejn.13175</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>18</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">18</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chi, O. Z.</style></author><author><style face="normal" font="default" size="100%">Barsoum, S.</style></author><author><style face="normal" font="default" size="100%">Vega-Cotto, N. M.</style></author><author><style face="normal" font="default" size="100%">Jacinto, E.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Mellender, S. J.</style></author><author><style face="normal" font="default" size="100%">Weiss, H. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dept. of Anesthesiology, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ 08854, United States.&#xD;Dept. of Biochemistry and Molecular Biology, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ 08854, United States.&#xD;Dept. of Neuroscience and Cell Biology, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ 08854, United States. Electronic address: hweiss@rutgers.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of rapamycin on cerebral oxygen supply and consumption during reperfusion after cerebral ischemia</style></title><secondary-title><style face="normal" font="default" size="100%">Neuroscience</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">321-7</style></pages><volume><style face="normal" font="default" size="100%">316</style></volume><edition><style face="normal" font="default" size="100%">2016/01/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Antipyrine/analogs &amp; derivatives/pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Gas Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Carbon Isotopes/pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Hemodynamics/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Immunosuppressive Agents/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Oncogene Protein v-akt/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen Consumption/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred F344</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Sirolimus/ pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 01</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1873-7544 (Electronic)&#xD;0306-4522 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26742793</style></accession-num><abstract><style face="normal" font="default" size="100%">Activation of the mammalian target of rapamycin (mTOR) leads to cell growth and survival. We tested the hypothesis that inhibition of mTOR would increase infarct size and decrease microregional O2 supply/consumption balance after cerebral ischemia-reperfusion. This was tested in isoflurane-anesthetized rats with middle cerebral artery blockade for 1h and reperfusion for 2h with and without rapamycin (20mg/kg once daily for two days prior to ischemia). Regional cerebral blood flow was determined using a C(14)-iodoantipyrine autoradiographic technique. Regional small-vessel arterial and venous oxygen saturations were determined microspectrophotometrically. The control ischemic-reperfused cortex had a similar blood flow and O2 consumption to the contralateral cortex. However, microregional O2 supply/consumption balance was significantly reduced in the ischemic-reperfused cortex. Rapamycin significantly increased cerebral O2 consumption and further reduced O2 supply/consumption balance in the reperfused area. This was associated with an increased cortical infarct size (13.5+/-0.8% control vs. 21.5+/-0.9% rapamycin). We also found that ischemia-reperfusion increased AKT and S6K1 phosphorylation, while rapamycin decreased this phosphorylation in both the control and ischemic-reperfused cortex. This suggests that mTOR is important for not only cell survival, but also for the control of oxygen balance after cerebral ischemia-reperfusion.</style></abstract><notes><style face="normal" font="default" size="100%">Chi, O Z&#xD;Barsoum, S&#xD;Vega-Cotto, N M&#xD;Jacinto, E&#xD;Liu, X&#xD;Mellender, S J&#xD;Weiss, H R&#xD;R01 CA154674/CA/NCI NIH HHS/United States&#xD;United States&#xD;Neuroscience. 2016 Mar 1;316:321-7. doi: 10.1016/j.neuroscience.2015.12.045. Epub 2015 Dec 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0306452215011380/1-s2.0-S0306452215011380-main.pdf?_tid=a1155cec-d7bd-11e6-a8d1-00000aacb35e&amp;acdnat=1484112193_f810921f143b2416a8dc13610570069b</style></url></related-urls><pdf-urls><url>internal-pdf://2338398316/Chi-2016-Effects of rapamycin.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4881736</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms787839</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuroscience.2015.12.045</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>162</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">162</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chi, O. Z.</style></author><author><style face="normal" font="default" size="100%">Grayson, J.</style></author><author><style face="normal" font="default" size="100%">Barsoum, S.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Dinani, A.</style></author><author><style face="normal" font="default" size="100%">Weiss, H. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Anesthesiology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey. Electronic address: chi@rwjms.rutgers.edu.&#xD;Department of Anesthesiology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.&#xD;Department of Neuroscience and Cell Biology, Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of dexmedetomidine on microregional O2 balance during reperfusion after focal cerebral ischemia</style></title><secondary-title><style face="normal" font="default" size="100%">J Stroke Cerebrovasc Dis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Stroke Cerebrovasc Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Stroke Cerebrovasc Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">163-70</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2014/10/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic alpha-Agonists/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Gas Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ drug therapy/ metabolism/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Dexmedetomidine/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Hemodynamics</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen Consumption/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Pons/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred F344</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/ drug therapy/ metabolism/physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1532-8511 (Electronic)&#xD;1052-3057 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25294058</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: This study was performed to determine whether there is an association between microregional O2 balance and neuronal survival in cerebral ischemia-reperfusion using dexmedetomidine, an alpha2-adrenoreceptor agonist and a sedative. METHODS: Rats were subjected to 1 hour middle cerebral artery occlusion and a 2-hour reperfusion. During reperfusion, normal saline (n = 14) or dexmedetomidine 1 mug/kg/minute (n = 14) was infused intravenously. At 2 hours of reperfusion, regional cerebral blood flow using (14)C-iodoantipyrine autoradiography, microregional arterial and venous (20-60 mum in diameter) O2 saturation (SvO2) using cryomicrospectrophotometry, and the size of cortical infarction were determined. RESULTS: Ischemia-reperfusion decreased microregional SvO2 (52.9 +/- 3.7% vs. 61.1 +/- .6%, P &lt; .005) with increased variation or heterogeneity (P &lt; .0001) with similar regional cerebral blood flow and O2 consumption. Dexmedetomidine during reperfusion decreased the heterogeneity of SvO2 that was analyzed with an analysis of variance (P &lt; .01) and reported as coefficient of variation (100 x standard deviation/Mean) (11.8 vs. 16.4). The number of veins with O2 saturation less than 50% decreased with dexmedetomidine (13/80 vs. 27/81, P &lt; .01). The percentage of cortical infarct in total cortex was smaller with dexmedetomidine (8.3 +/- 2.2% vs. 12.6 +/- 1.5%, P &lt; .005). CONCLUSIONS: In the cerebral ischemic reperfused cortex, dexmedetomidine decreased the heterogeneity of SvO2 and the number of small veins with low O2 saturation suggesting improved microregional O2 supply/consumption balance. The improvement was accompanied by the reduced size of cortical infarction.</style></abstract><notes><style face="normal" font="default" size="100%">Chi, Oak Z&#xD;Grayson, Jeremy&#xD;Barsoum, Sylviana&#xD;Liu, Xia&#xD;Dinani, Aliraza&#xD;Weiss, Harvey R&#xD;United States&#xD;J Stroke Cerebrovasc Dis. 2015 Jan;24(1):163-70. doi: 10.1016/j.jstrokecerebrovasdis.2014.08.004. Epub 2014 Oct 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S1052305714004078/1-s2.0-S1052305714004078-main.pdf?_tid=bd24050a-d7bd-11e6-a0bb-00000aab0f26&amp;acdnat=1484112240_1c8b260f3355d379687a6418083eca84</style></url></related-urls><pdf-urls><url>internal-pdf://2865158104/Chi-2015-Effects of dexmedeto.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jstrokecerebrovasdis.2014.08.004</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>161</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">161</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chi, W.</style></author><author><style face="normal" font="default" size="100%">Meng, F.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Li, P.</style></author><author><style face="normal" font="default" size="100%">Wang, G.</style></author><author><style face="normal" font="default" size="100%">Cheng, H.</style></author><author><style face="normal" font="default" size="100%">Han, S.</style></author><author><style face="normal" font="default" size="100%">Li, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Anesthesiology, Weifang Medical University, Weifang City 261053, Shangdong Province, PR China.&#xD;Department of Anesthesiology, Shandong University Affiliated Jinan City Central Hospital, Jinan 250013, PR China. Electronic address: mfj15318816233@163.com.&#xD;Department of Anesthesiology, Shandong University Affiliated Jinan City Central Hospital, Jinan 250013, PR China.&#xD;Department of Burn Surgery, Shandong University Affiliated Jinan City Central Hospital, Jinan 250013, PR China.&#xD;Department of Neurobiology and Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, PR China.&#xD;Department of Neurobiology and Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, PR China. Electronic address: junfali@ccmu.edu.cn.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of microRNA-134 on neural cell survival against ischemic injury in primary cultured neuronal cells and mouse brain with ischemic stroke by targeting HSPA12B</style></title><secondary-title><style face="normal" font="default" size="100%">Brain Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">22-33</style></pages><volume><style face="normal" font="default" size="100%">1592</style></volume><edition><style face="normal" font="default" size="100%">2014/10/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Death</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Hypoxia/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Survival/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose/deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">HSP70 Heat-Shock Proteins/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">MicroRNAs/antagonists &amp; inhibitors/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/pathology/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/pathology/ physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 10</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-6240 (Electronic)&#xD;0006-8993 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25304362</style></accession-num><abstract><style face="normal" font="default" size="100%">As a newly discovered member of the HSP70 family, heat shock protein A12B (HSPA12B) is involved in brain ischemic injury. According to our previous study, microRNA-134 (miR-134) could target HSPA12B by binding to its 3&apos;-untranslated region (UTR). However, the regulation of miR-134 on HSPA12B and their role in protecting neuronal cells from ischemic injury are unclear. In this study, the miR-134 expression level was manipulated, and the HSPA12B protein levels were also determined in oxygen-glucose deprivation (OGD)-treated primary cultured neuronal cells in vitro and mouse brain after middle cerebral artery occlusion (MCAO)-induced ischemic stroke in vivo. The results showed that miR-134 expression levels increased in primary cultured neuronal cells and mouse brain from 12h to 7 day reoxygenation/reperfusion after 1h OGD or 1h MCAO treatment. miR-134 overexpression promoted neuronal cell death and apoptosis by decreasing HSPA12B protein levels. Conversely, downregulating miR-134 reduced neuronal cell death and apoptosis by enhancing HSPA12B protein levels. Also, HSPA12B siRNA could block miR-134 inhibitor-mediated neuroprotection against OGD-induced neuronal cell injury in vitro. Taken together, miR-134 might influence neuronal cell survival against ischemic injury in primary cultured neuronal cells and mouse brain with ischemic stroke by negatively modulating HSPA12B protein expression in a posttranscriptional manner.</style></abstract><notes><style face="normal" font="default" size="100%">Chi, Wenying&#xD;Meng, Fanjun&#xD;Li, Yan&#xD;Li, Peilong&#xD;Wang, Guizhi&#xD;Cheng, Hong&#xD;Han, Song&#xD;Li, Junfa&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;Brain Res. 2014 Dec 10;1592:22-33. doi: 10.1016/j.brainres.2014.09.072. Epub 2014 Oct 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0006899314013456/1-s2.0-S0006899314013456-main.pdf?_tid=b6e00cd4-d7bd-11e6-847b-00000aacb362&amp;acdnat=1484112229_de4f72716ff772947cf363dc2800d1a6</style></url></related-urls><pdf-urls><url>internal-pdf://2964369468/Chi-2014-Impact of microRNA-1.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.brainres.2014.09.072</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>193</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">193</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Christen, T.</style></author><author><style face="normal" font="default" size="100%">Bouzat, P.</style></author><author><style face="normal" font="default" size="100%">Pannetier, N.</style></author><author><style face="normal" font="default" size="100%">Coquery, N.</style></author><author><style face="normal" font="default" size="100%">Moisan, A.</style></author><author><style face="normal" font="default" size="100%">Lemasson, B.</style></author><author><style face="normal" font="default" size="100%">Thomas, S.</style></author><author><style face="normal" font="default" size="100%">Grillon, E.</style></author><author><style face="normal" font="default" size="100%">Detante, O.</style></author><author><style face="normal" font="default" size="100%">Remy, C.</style></author><author><style face="normal" font="default" size="100%">Payen, J. F.</style></author><author><style face="normal" font="default" size="100%">Barbier, E. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">1] Inserm, U836, Grenoble, France [2] Universite Grenoble Alpes, Grenoble Institut des Neurosciences, Grenoble, France.&#xD;1] Inserm, U836, Grenoble, France [2] Universite Grenoble Alpes, Grenoble Institut des Neurosciences, Grenoble, France [3] CHU Grenoble, Pole d&apos;Anesthesie-Reanimation, Grenoble, France.&#xD;1] Inserm, US 017, Grenoble, France [2] Universite Grenoble Alpes, IRMaGe, Grenoble, France [3] CHU Grenoble, IRMaGe, Grenoble, France [4] CNRS, UMS 3552, Grenoble, France.&#xD;1] Inserm, U836, Grenoble, France [2] Universite Grenoble Alpes, Grenoble Institut des Neurosciences, Grenoble, France [3] CHU Grenoble, Service de Neurologie, Grenoble, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tissue oxygen saturation mapping with magnetic resonance imaging</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1550-7</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2014/07/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Gas Analysis/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/ diagnostic imaging/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Radiography</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred F344</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ diagnostic imaging/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25005878</style></accession-num><abstract><style face="normal" font="default" size="100%">A quantitative estimate of cerebral blood oxygen saturation is of critical importance in the investigation of cerebrovascular disease. While positron emission tomography can map in vivo the oxygen level in blood, it has limited availability and requires ionizing radiation. Magnetic resonance imaging (MRI) offers an alternative through the blood oxygen level-dependent contrast. Here, we describe an in vivo and non-invasive approach to map brain tissue oxygen saturation (StO2) with high spatial resolution. StO2 obtained with MRI correlated well with results from blood gas analyses for various oxygen and hematocrit challenges. In a stroke model, the hypoxic areas delineated in vivo by MRI spatially matched those observed ex vivo by pimonidazole staining. In a model of diffuse traumatic brain injury, MRI was able to detect even a reduction in StO2 that was too small to be detected by histology. In a F98 glioma model, MRI was able to map oxygenation heterogeneity. Thus, the MRI technique may improve our understanding of the pathophysiology of several brain diseases involving impaired oxygenation.</style></abstract><notes><style face="normal" font="default" size="100%">Christen, Thomas&#xD;Bouzat, Pierre&#xD;Pannetier, Nicolas&#xD;Coquery, Nicolas&#xD;Moisan, Anaick&#xD;Lemasson, Benjamin&#xD;Thomas, Sebastien&#xD;Grillon, Emmanuelle&#xD;Detante, Olivier&#xD;Remy, Chantal&#xD;Payen, Jean-Francois&#xD;Barbier, Emmanuel Luc&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Cereb Blood Flow Metab. 2014 Sep;34(9):1550-7. doi: 10.1038/jcbfm.2014.116. Epub 2014 Jul 9.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4158672</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2014.116</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>158</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">158</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chung, B.</style></author><author><style face="normal" font="default" size="100%">Mut, F.</style></author><author><style face="normal" font="default" size="100%">Kadirvel, R.</style></author><author><style face="normal" font="default" size="100%">Lingineni, R.</style></author><author><style face="normal" font="default" size="100%">Kallmes, D. F.</style></author><author><style face="normal" font="default" size="100%">Cebral, J. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Bioengineering, Volgenau School of Engineering, George Mason University, 4400 University Drive, MSN 2A1, Fairfax, VA 22030, USA.&#xD;Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.&#xD;Department of Health Sciences and Research, Mayo Clinic, Rochester, Minnesota, USA.&#xD;Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hemodynamic analysis of fast and slow aneurysm occlusions by flow diversion in rabbits</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurointerv Surg</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neurointerventional surgery</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurointerv Surg</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurointerventional surgery</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurointerv Surg</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurointerventional surgery</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">931-5</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2014/10/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Flow Velocity/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Vessel Prosthesis</style></keyword><keyword><style face="normal" font="default" size="100%">Hemodynamics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Aneurysm/diagnostic imaging/ physiopathology/ surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Rabbits</style></keyword><keyword><style face="normal" font="default" size="100%">Radiography</style></keyword><keyword><style face="normal" font="default" size="100%">Stents</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1759-8486 (Electronic)&#xD;1759-8478 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25332410</style></accession-num><abstract><style face="normal" font="default" size="100%">PURPOSE: To assess hemodynamic differences between aneurysms that occlude rapidly and those occluding in delayed fashion after flow diversion in rabbits. METHODS: Thirty-six elastase-induced aneurysms in rabbits were treated with flow diverting devices. Aneurysm occlusion was assessed angiographically immediately before they were sacrificed at 1 (n=6), 2 (n=4), 4 (n=8) or 8 weeks (n=18) after treatment. The aneurysms were classified into a fast occlusion group if they were completely or near completely occluded at 4 weeks or earlier and a slow occlusion group if they remained incompletely occluded at 8 weeks. The immediate post-treatment flow conditions in aneurysms of each group were quantified using subject-specific computational fluid dynamics and statistically compared. RESULTS: Nine aneurysms were classified into the fast occlusion group and six into the slow occlusion group. Aneurysms in the fast occlusion group were on average significantly smaller (fast=0.9 cm, slow=1.393 cm, p=0.024) and had smaller ostia (fast=0.144 cm2, slow=0.365 cm2, p=0.015) than aneurysms in the slow occlusion group. They also had a lower mean post-treatment inflow rate (fast=0.047 mL/s, slow=0.155 mL/s, p=0.0239), kinetic energy (fast=0.519 erg, slow=1.283 erg, p=0.0468), and velocity (fast=0.221 cm/s, slow=0.506 cm/s, p=0.0582). However, the differences in the latter two variables were only marginally significant. CONCLUSIONS: Hemodynamic conditions after flow diversion treatment of cerebral aneurysms in rabbits are associated with the subsequent aneurysm occlusion time. Specifically, smaller inflow rate, kinetic energy, and velocity seem to promote faster occlusions, especially in smaller and small-necked aneurysms. These results are consistent with previous studies based on clinical series.</style></abstract><notes><style face="normal" font="default" size="100%">Chung, Bongjae&#xD;Mut, Fernando&#xD;Kadirvel, Ramanathan&#xD;Lingineni, Ravi&#xD;Kallmes, David F&#xD;Cebral, Juan R&#xD;R01 NS076491/NS/NINDS NIH HHS/United States&#xD;NS076491/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;England&#xD;J Neurointerv Surg. 2015 Dec;7(12):931-5. doi: 10.1136/neurintsurg-2014-011412. Epub 2014 Oct 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://jnis.bmj.com/content/neurintsurg/7/12/931.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3078219088/Chung-2015-Hemodynamic analysis.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4932851</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms797081</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/neurintsurg-2014-011412</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>309</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">309</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cipolla, M. J.</style></author><author><style face="normal" font="default" size="100%">Sweet, J. G.</style></author><author><style face="normal" font="default" size="100%">Gokina, N. I.</style></author><author><style face="normal" font="default" size="100%">White, S. L.</style></author><author><style face="normal" font="default" size="100%">Nelson, M. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">1] Department of Neurological Sciences, University of Vermont College of Medicine, Burlington, Vermont, USA [2] Department of Obstetrics, Gynecology and Reproductive Sciences, University of Vermont College of Medicine, Burlington, Vermont, USA [3] Department of Pharmacology, University of Vermont College of Medicine, Burlington, Vermont, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mechanisms of enhanced basal tone of brain parenchymal arterioles during early postischemic reperfusion: role of ET-1-induced peroxynitrite generation</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1486-92</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2013/06/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arterioles/drug effects/metabolism/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/complications/metabolism/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelin-1/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelium, Vascular/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Microcirculation/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle Tonus/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle, Smooth, Vascular/metabolism/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Peroxynitrous Acid/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Real-Time Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Endothelin B/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/complications/metabolism/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilation/physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23778163</style></accession-num><abstract><style face="normal" font="default" size="100%">The contributions of vasoconstrictors (endothelin-1 (ET-1), peroxynitrite) and endothelium-dependent vasodilatory mechanisms to basal tone were investigated in parenchymal arterioles (PAs) after early postischemic reperfusion. Transient middle cerebral artery occlusion (tMCAO) was induced for 2 hours with 30 minutes reperfusion in male Wistar rats and compared with ischemia alone (permanent MCAO (pMCAO); 2.5 hours) or sham controls. Changes in lumen diameter of isolated and pressurized PAs were compared. Quantitative PCR was used to measure endothelin type B (ETB) receptors. Constriction to intravascular pressure (&apos;basal tone&apos;) was not affected by tMCAO or pMCAO. However, constriction to inhibitors of endothelial cell, small- (SK) and intermediate- (IK) conductance, Ca(2+)-sensitive K(+) channels (apamin and TRAM-34, respectively) were significantly enhanced in PAs from tMCAO compared with pMCAO or sham. Addition of the ETB agonist sarafotoxin caused constriction in PAs from tMCAO but not from sham animals (21 +/- 4% versus 3 +/- 3% at 1 nmol/L; P&lt;0.01) that was inhibited by the peroxynitrite scavenger FeTMPyP (5,10,15,20-tetrakis (N-methyl-4&apos;-pyridyl) porphinato iron (III) chloride) (100 mumol/L). Expression of ETB receptors was not found on PA smooth muscle, suggesting that constriction to sarafotoxin after tMCAO was due to peroxynitrite and not ETB receptor expression. The maintenance of basal tone in PAs after tMCAO may restrict flow to the ischemic region and contribute to infarct expansion.</style></abstract><notes><style face="normal" font="default" size="100%">Cipolla, Marilyn J&#xD;Sweet, Julie G&#xD;Gokina, Natalia I&#xD;White, Sheryl L&#xD;Nelson, Mark T&#xD;5 P30 RR 032135/RR/NCRR NIH HHS/United States&#xD;P01 HL095488/HL/NHLBI NIH HHS/United States&#xD;P30 GM103498/GM/NIGMS NIH HHS/United States&#xD;R01 NS045940/NS/NINDS NIH HHS/United States&#xD;GMS 8 P30 GM 103498/PHS HHS/United States&#xD;P30 RR032135/RR/NCRR NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Cereb Blood Flow Metab. 2013 Oct;33(10):1486-92. doi: 10.1038/jcbfm.2013.99. Epub 2013 Jun 19.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3790940</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2013.99</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>346</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">346</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Clarkson, A. N.</style></author><author><style face="normal" font="default" size="100%">Lopez-Valdes, H. E.</style></author><author><style face="normal" font="default" size="100%">Overman, J. J.</style></author><author><style face="normal" font="default" size="100%">Charles, A. C.</style></author><author><style face="normal" font="default" size="100%">Brennan, K. C.</style></author><author><style face="normal" font="default" size="100%">Thomas Carmichael, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Multimodal examination of structural and functional remapping in the mouse photothrombotic stroke model</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">716-23</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2013/02/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/pathology/ physiopathology/ radiation effects</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Motor Activity</style></keyword><keyword><style face="normal" font="default" size="100%">Motor Cortex/pathology/physiopathology/radiation effects</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ etiology/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombosis/ complications/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Walking</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23385201</style></accession-num><abstract><style face="normal" font="default" size="100%">Recent studies show a limited capacity for neural repair after stroke, which includes remapping of sensorimotor functions and sprouting of new connections. However, physiologic and connectional plasticity of sensory maps during long-term functional recovery in the mouse have not been determined. Using a photothrombotic stroke model, we targeted the motor cortex, which we show results in lasting behavioral deficits on the grid-walking and in the cylinder tasks out to 8 weeks after stroke. Mice recovered performance in a skilled reaching task, showing no deficit from week 2 after stroke. Long-term optical intrinsic signal imaging revealed functional reorganization of sensory cortical maps for both forelimb and hindlimb, with more diffuse sensory physiologic maps. There was a small but significant increase in motor neuron projections within the areas of functional cortical reorganization as assessed using the neuroanatomic tracer biotinylated dextran amine. These findings show that the sensorimotor cortex undergoes remapping of cortical functions and axonal sprouting within the same regions during recovery after stroke. This suggests a linked structural and physiologic plasticity underlying recovery. Combined long-term structural and functional mapping after stroke in the mouse is practical and provides a rich data set for mechanistic analysis of stroke recovery.</style></abstract><notes><style face="normal" font="default" size="100%">Clarkson, Andrew N&#xD;Lopez-Valdes, Hector E&#xD;Overman, Justine J&#xD;Charles, Andrew C&#xD;Brennan, K C&#xD;Thomas Carmichael, S&#xD;K08 NS059072/NS/NINDS NIH HHS/United States&#xD;R21 NS070084/NS/NINDS NIH HHS/United States&#xD;K08 NS 059072/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Cereb Blood Flow Metab. 2013 May;33(5):716-23. doi: 10.1038/jcbfm.2013.7. Epub 2013 Feb 6.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3652691</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2013.7</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>249</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">249</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cognat, E.</style></author><author><style face="normal" font="default" size="100%">Baron-Menguy, C.</style></author><author><style face="normal" font="default" size="100%">Domenga-Denier, V.</style></author><author><style face="normal" font="default" size="100%">Cleophax, S.</style></author><author><style face="normal" font="default" size="100%">Fouillade, C.</style></author><author><style face="normal" font="default" size="100%">Monet-Lepretre, M.</style></author><author><style face="normal" font="default" size="100%">Dewerchin, M.</style></author><author><style face="normal" font="default" size="100%">Joutel, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From the INSERM, U740 and Univ Paris Diderot, Sorbonne Cite, UMR S740, Paris, France (E.C., C.B.-M., V.D.-D., S.C., C.F., M.M.-L., A.J.); and Laboratory of Angiogenesis &amp; Neurovascular Link, Vesalius Research Center, VIB-KU Leuven, Leuven, Belgium (M.D.).</style></auth-address><titles><title><style face="normal" font="default" size="100%">Archetypal Arg169Cys mutation in NOTCH3 does not drive the pathogenesis in cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy via a loss-of-function mechanism</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">842-9</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2014/01/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">CADASIL/ genetics/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Arteries/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Estrogen Antagonists/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">Image Processing, Computer-Assisted</style></keyword><keyword><style face="normal" font="default" size="100%">Immunohistochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation/ genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Real-Time Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Notch3</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Notch/ genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Tamoxifen/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Transcription, Genetic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24425116</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy, the most common heritable small vessel disease of the brain, is caused by dominant mutations in the NOTCH3 receptor that stereotypically lead to age-dependent Notch3ECD deposition in the vessels. NOTCH3 loss of function has been demonstrated for few mutations. However, whether this finding applies to all mutations and whether a loss-of-function mechanism drives the manifestations of the disease remain yet unknown. This study investigated the in vivo functionality of the Arg169Cys archetypal mutation. METHODS: We used mice with constitutive or conditional reduction of NOTCH3 activity, mice harboring the Arg169Cys mutation at the endogenous Notch3 locus (Notch3Arg170Cys), and mice overexpressing the Arg169Cys NOTCH3 mutant (TgPAC-Notch3R169C) on either a Notch3 wild-type or a null background. NOTCH3 activity was monitored in the brain arteries by measuring the expression of NOTCH3 target genes using real-time polymerase chain reaction. Notch3ECD deposits were assessed by immunohistochemistry. Brain parenchyma was analyzed for vacuolation and myelin debris in the white matter and infarcts. RESULTS: We identified a subset of genes appropriate to detect NOTCH3 haploinsufficiency in the adult. Expression of these genes was unaltered in Notch3Arg170Cys mice, despite marked Notch3ECD deposits. Elimination of wild-type NOTCH3 did not influence the onset and burden of white matter lesions in 20-month-old TgPAC-Notch3R169C mice, and 20-month-old Notch3-null mice exhibited neither infarct nor white matter changes. CONCLUSIONS: These data provide strong evidence that cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy can develop without impairment of NOTCH3 signaling and argue against a loss of NOTCH3 function as a general driving mechanism for white matter lesions in cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy.</style></abstract><notes><style face="normal" font="default" size="100%">Cognat, Emmanuel&#xD;Baron-Menguy, Celine&#xD;Domenga-Denier, Valerie&#xD;Cleophax, Sabine&#xD;Fouillade, Charles&#xD;Monet-Lepretre, Marie&#xD;Dewerchin, Mieke&#xD;Joutel, Anne&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Stroke. 2014 Mar;45(3):842-9. doi: 10.1161/STROKEAHA.113.003339. Epub 2014 Jan 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/45/3/842.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2293636760/Cognat-2014-Archetypal Arg169Cys.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.113.003339</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>205</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">205</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cognat, E.</style></author><author><style face="normal" font="default" size="100%">Cleophax, S.</style></author><author><style face="normal" font="default" size="100%">Domenga-Denier, V.</style></author><author><style face="normal" font="default" size="100%">Joutel, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Early white matter changes in CADASIL: evidence of segmental intramyelinic oedema in a pre-clinical mouse model</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Neuropathol Commun</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Acta neuropathologica communications</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Neuropathol Commun</style></full-title><abbr-1><style face="normal" font="default" size="100%">Acta neuropathologica communications</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Acta Neuropathol Commun</style></full-title><abbr-1><style face="normal" font="default" size="100%">Acta neuropathologica communications</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">49</style></pages><volume><style face="normal" font="default" size="100%">2</style></volume><edition><style face="normal" font="default" size="100%">2014/06/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, CD/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Differentiation, Myelomonocytic/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Axons/pathology/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Basic Helix-Loop-Helix Transcription Factors/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/ etiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">CADASIL/ complications/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium-Binding Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">Leukoencephalopathies/ etiology/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Microfilament Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Microglia/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Microscopy, Electron</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Myelin Sheath/pathology/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Tissue Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Notch3</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Notch/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Vacuoles/metabolism/ultrastructure</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 30</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2051-5960 (Electronic)&#xD;2051-5960 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24886907</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Small vessel disease (SVD) of the brain is a leading cause of age- and hypertension-related cognitive decline and disability. Cerebral white matter changes are a consistent manifestation of SVD on neuroimaging, progressing silently for many years before becoming clinically evident. The pathogenesis of these changes remains poorly understood, despite their importance. In particular, their pathological correlate at early stages remains largely undefined. Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), caused by dominant mutations of the NOTCH3 receptor, is regarded as a paradigm for the most common form of sporadic SVD. In this study, we used immunohistochemistry, confocal microscopy and electron microscopy, together with qualitative and quantitative analyses to assess oligodendroglial, axon and myelin damage in TgPAC-Notch3R169C mice, a model of preclinical CADASIL. RESULTS: The principal cerebral white matter changes in TgPAC-Notch3R169C mice are microvacuoles (&lt;/= 1 mum diameter) in the myelin sheaths associated with focal myelin degradation and occurring in the absence of oligodendrocyte loss. Half the damaged myelin sheaths still contain an apparently intact axon. Clearance of myelin debris appears inefficient, as demonstrated by the significant but mild microglial reaction, with occasional myelin debris either contacted or internalized by microglial cells. CONCLUSION: Our findings suggest that segmental intramyelinic oedema is an early, conspicuous white matter change in CADASIL. Brain white matter intramyelinic oedema is consistently found in patients and mouse models with compromised ion and water homeostasis. These data provide a starting point for novel mechanistic studies to investigate the pathogenesis of SVD-related white matter changes.</style></abstract><notes><style face="normal" font="default" size="100%">Cognat, Emmanuel&#xD;Cleophax, Sabine&#xD;Domenga-Denier, Valerie&#xD;Joutel, Anne&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Acta Neuropathol Commun. 2014 Apr 30;2:49. doi: 10.1186/2051-5960-2-49.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/222/art%253A10.1186%252F2051-5960-2-49.pdf?originUrl=http%3A%2F%2Factaneurocomms.biomedcentral.com%2Farticle%2F10.1186%2F2051-5960-2-49&amp;token2=exp=1484112367~acl=%2Fstatic%2Fpdf%2F222%2Fart%25253A10.1186%25252F2051-5960-2-49.pdf*~hmac=f3c4dcfb7926317cf0e0ec55d9521aace0c489237f11835cb45ae37fc0045698</style></url></related-urls><pdf-urls><url>internal-pdf://2495084643/Cognat-2014-Early white matter c.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4035092</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/2051-5960-2-49</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>208</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">208</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cognat, E.</style></author><author><style face="normal" font="default" size="100%">Herve, D.</style></author><author><style face="normal" font="default" size="100%">Joutel, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">INSERM, U1161, Paris, France.&#xD;CERVCO, Groupe Hospitalier Saint-Louis Lariboisiere-Fernand-Widal, Assistance Publique - Hopitaux de Paris, Paris, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Response to letter regarding article, &quot;Archetypal Arg169Cys mutation in NOTCH3 does not drive the pathogenesis in cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy via a loss-of-function mechanism&quot;</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e129</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2014/05/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">CADASIL/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation/ genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Notch/ genetics/ physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24867925</style></accession-num><notes><style face="normal" font="default" size="100%">Cognat, Emmanuel&#xD;Herve, Dominique&#xD;Joutel, Anne&#xD;Comment&#xD;Letter&#xD;United States&#xD;Stroke. 2014 Jul;45(7):e129. doi: 10.1161/STROKEAHA.114.005616. Epub 2014 May 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/45/7/e129.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2722575824/Cognat-2014-Response to letter r.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.114.005616</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>198</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">198</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Connor-Stroud, F. R.</style></author><author><style face="normal" font="default" size="100%">Hopkins, W. D.</style></author><author><style face="normal" font="default" size="100%">Preuss, T. M.</style></author><author><style face="normal" font="default" size="100%">Johnson, Z.</style></author><author><style face="normal" font="default" size="100%">Zhang, X.</style></author><author><style face="normal" font="default" size="100%">Sharma, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Animal Resources, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.&#xD;Division of Developmental and Cognitive Neuroscience, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.&#xD;Division of Neuropharmacology and Neurologic Diseases, Department of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA.&#xD;Division of Neuropharmacology and Neurologic Diseases, Yerkes Imaging Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.&#xD;Division of Pathology, Yerkes National Primate Research Center, Department of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA. psharm9@emory.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Extensive vascular mineralization in the brain of a chimpanzee (Pan troglodytes)</style></title><secondary-title><style face="normal" font="default" size="100%">Comp Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Comparative medicine</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Comp Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Comparative medicine</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Comp Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Comparative medicine</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">224-9</style></pages><volume><style face="normal" font="default" size="100%">64</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2014/06/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Ape Diseases/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Calcinosis/pathology/ veterinary</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Disorders/pathology/ veterinary</style></keyword><keyword><style face="normal" font="default" size="100%">Fatal Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging/veterinary</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Pan troglodytes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1532-0820 (Print)&#xD;1532-0820 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24956215</style></accession-num><abstract><style face="normal" font="default" size="100%">Spontaneous vascular mineralization (deposition of iron or calcium salts) has been observed in marble brain syndrome, mineralizing microangiopathy, hypothyroidism, Fahr syndrome, Sturge-Weber syndrome, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, and calciphylaxis in humans and as an aging or idiopathic lesion in the brains of horses, cats, nonhuman primates, mice, rats, cattle, white-tailed deer, and dogs. Here we present a 27-y-old, adult male chimpanzee (Pan troglodytes) with spontaneous, extensive vascular mineralization localized solely to the brain. The chimpanzee exhibited tremors and weakness of the limbs, which progressed to paralysis before euthanasia. Magnetic resonance brain imaging in 2002 and 2010 (immediately before euthanasia) revealed multiple hypointense foci, suggestive of iron- and calcium-rich deposits. At necropsy, the brain parenchyma had occasional petechial hemorrhage, and microscopically, the cerebral, cerebellar and brain stem, gray and white matter had moderate to severe mural aggregates of a granular, basophilic material (mineral) in the blood vessels. In addition, these regions often had moderate to severe medial to transmural deposition of mature collagen in the blood vessels. We ruled out common causes of brain mineralization in humans and animals, but an etiology for the mineralization could not be determined. To our knowledge, mineralization in brain has been reported only once to occur in a chimpanzee, but its chronicity in our case makes it particularly interesting.</style></abstract><notes><style face="normal" font="default" size="100%">Connor-Stroud, Fawn R&#xD;Hopkins, William D&#xD;Preuss, Todd M&#xD;Johnson, Zachary&#xD;Zhang, Xiaodong&#xD;Sharma, Prachi&#xD;P51 OD011132/OD/NIH HHS/United States&#xD;R01 NS042867/NS/NINDS NIH HHS/United States&#xD;P51OD11132/OD/NIH HHS/United States&#xD;P51RR165/RR/NCRR NIH HHS/United States&#xD;Case Reports&#xD;Research Support, N.I.H., Extramural&#xD;United States&#xD;Comp Med. 2014 Jun;64(3):224-9.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4067587</style></custom2><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>378</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">378</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cook, D. J.</style></author><author><style face="normal" font="default" size="100%">Teves, L.</style></author><author><style face="normal" font="default" size="100%">Tymianski, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Toronto Western Hospital Research Institute, Department of Physiology, University of Toronto, Toronto, Ontario M5T 2S8, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A translational paradigm for the preclinical evaluation of the stroke neuroprotectant Tat-NR2B9c in gyrencephalic nonhuman primates</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Transl Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Science translational medicine</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Sci Transl Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Science translational medicine</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Sci Transl Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Science translational medicine</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">154ra133</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">154</style></number><edition><style face="normal" font="default" size="100%">2012/10/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Peptides/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Primates</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ drug therapy/pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 03</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1946-6242 (Electronic)&#xD;1946-6234 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23035045</style></accession-num><abstract><style face="normal" font="default" size="100%">Over decades, all attempts to translate acute stroke neuroprotectants from discovery in lower-order species to human clinical use have failed. This raised concerns about the predictive validity of preclinical studies in animals for outcomes in human stroke trials. To bridge this translational gap, we used high-order gyrencephalic nonhuman primates subjected to an experimental protocol that mimicked that of a corresponding, separately reported, clinical trial in which the human subjects underwent endovascular cerebral aneurysm repair. Both placebo-controlled studies tested neuroprotection by Tat-NR2B9c, a prospective therapeutic compound, in anesthetized subjects. Embolic strokes were produced by small intra-arterial emboli caused by the endovascular procedure. We show that primates treated with Tat-NR2B9c after the onset of embolic strokes exhibited significantly reduced numbers and volumes of strokes, as visualized by diffusion- and T2-weighted magnetic resonance imaging. These results correctly anticipated the outcome of the corresponding human trial, thus validating this study design as a predictor of neuroprotective efficacy in humans. This strategy may facilitate the evaluation of promising neuroprotectants before undertaking similar studies in human subjects.</style></abstract><notes><style face="normal" font="default" size="100%">Cook, Douglas J&#xD;Teves, Lucy&#xD;Tymianski, Michael&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Sci Transl Med. 2012 Oct 3;4(154):154ra133. doi: 10.1126/scitranslmed.3003824.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stm.sciencemag.org/content/scitransmed/4/154/154ra133.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0854009351/Cook-2012-A translational para.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1126/scitranslmed.3003824</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>278</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">278</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cordova, C. A.</style></author><author><style face="normal" font="default" size="100%">Jackson, D.</style></author><author><style face="normal" font="default" size="100%">Langdon, K. D.</style></author><author><style face="normal" font="default" size="100%">Hewlett, K. A.</style></author><author><style face="normal" font="default" size="100%">Corbett, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of BioMedical Sciences, Memorial University, St. John&apos;s, NL, Canada; Heart and Stroke Foundation Centre for Stroke Recovery, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impaired executive function following ischemic stroke in the rat medial prefrontal cortex</style></title><secondary-title><style face="normal" font="default" size="100%">Behav Brain Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Behavioural brain research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Behav Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Behavioural brain research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Behav Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Behavioural brain research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">106-11</style></pages><volume><style face="normal" font="default" size="100%">258</style></volume><edition><style face="normal" font="default" size="100%">2013/10/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Attention/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Behavior, Animal/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/chemically induced/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Discrimination Learning/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelin-1</style></keyword><keyword><style face="normal" font="default" size="100%">Executive Function/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Prefrontal Cortex/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reversal Learning/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Set (Psychology)</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/chemically induced/ physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 01</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-7549 (Electronic)&#xD;0166-4328 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24144544</style></accession-num><abstract><style face="normal" font="default" size="100%">Small (lacunar) infarcts frequently arise in frontal and midline thalamic regions in the absence of major stroke. Damage to these areas often leads to impairment of executive function likely as a result of interrupting connections of the prefrontal cortex. Thus, patients experience frontal-like symptoms such as impaired ability to shift ongoing behavior and attention. In contrast, executive dysfunction has not been demonstrated in rodent models of stroke, thereby limiting the development of potential therapies for human executive dysfunction. Male Sprague-Dawley rats (n=40) underwent either sham surgery or bilateral endothelin-1 injections in the mediodorsal nucleus of the thalamus or in the medial prefrontal cortex. Executive function was assessed using a rodent attention set shifting test that requires animals to shift attention to stimuli in different stimulus dimensions. Medial prefrontal cortex ischemia impaired attention shift performance between different stimulus dimensions while sparing stimulus discrimination and attention shifts within a stimulus dimension, indicating a selective attention set-shift deficit. Rats with mediodorsal thalamic lacunar damage did not exhibit a cognitive impairment relative to sham controls. The selective attention set shift impairment observed in this study is consistent with clinical data demonstrating selective executive disorders following stroke within specific sub-regions of frontal cortex. These data contribute to the development and validation of a preclinical animal model of executive dysfunction, that can be employed to identify potential therapies for ameliorating cognitive deficits following stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Cordova, Chris A&#xD;Jackson, Danielle&#xD;Langdon, Kristopher D&#xD;Hewlett, Krista A&#xD;Corbett, Dale&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;Behav Brain Res. 2014 Jan 1;258:106-11. doi: 10.1016/j.bbr.2013.10.022. Epub 2013 Oct 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S016643281300630X/1-s2.0-S016643281300630X-main.pdf?_tid=ca3a4bb4-d7bd-11e6-93a7-00000aacb360&amp;acdnat=1484112262_1c634b9a242bf82f55a7aaeedc8932c2</style></url></related-urls><pdf-urls><url>internal-pdf://1262170633/Cordova-2014-Impaired executive f.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.bbr.2013.10.022</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>321</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">321</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cova, L.</style></author><author><style face="normal" font="default" size="100%">Gelosa, P.</style></author><author><style face="normal" font="default" size="100%">Mura, E.</style></author><author><style face="normal" font="default" size="100%">Mauro, A.</style></author><author><style face="normal" font="default" size="100%">Stramba-Badiale, M.</style></author><author><style face="normal" font="default" size="100%">Michailidis, G.</style></author><author><style face="normal" font="default" size="100%">Colonna, A.</style></author><author><style face="normal" font="default" size="100%">El Assawy, N.</style></author><author><style face="normal" font="default" size="100%">Pignieri, A.</style></author><author><style face="normal" font="default" size="100%">Busca, G.</style></author><author><style face="normal" font="default" size="100%">Tremoli, E.</style></author><author><style face="normal" font="default" size="100%">Silani, V.</style></author><author><style face="normal" font="default" size="100%">Sironi, L.</style></author><author><style face="normal" font="default" size="100%">Zanchetti, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Vascular and parenchymal lesions along with enhanced neurogenesis characterize the brain of asymptomatic stroke-prone spontaneous hypertensive rats</style></title><secondary-title><style face="normal" font="default" size="100%">J Hypertens</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of hypertension</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Hypertens</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of hypertension</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Hypertens</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of hypertension</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1618-28</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2013/05/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/cytology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Diseases/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Proliferation</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Edema/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Glial Fibrillary Acidic Protein/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunohistochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Microtubule-Associated Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neural Stem Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neuropeptides/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative Stress</style></keyword><keyword><style face="normal" font="default" size="100%">Proteinuria/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred SHR</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred WKY</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1473-5598 (Electronic)&#xD;0263-6352 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23666422</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND OBJECTIVES: Spontaneously hypertensive stroke-prone rats (SHRSPs) develop hypertension, cerebrovascular abnormalities and a stroke phenotype in association with higher levels of proteinuria. Here, we focus on cerebral abnormalities preceding lesions detectable by MRI. METHODS: Longitudinal assessment of brain histology was performed in salt-loaded male SHRSPs (n = 26) and Wistar-Kyoto (WKY) normotensive control animals (n = 27). Groups of rats were sacrificed at different time points: Time 0, before the salt diet administration; Time 1, when proteinuria achieved 40 mg/day; Time 2, when proteinuria exceeded 100 mg/day. RESULTS: At Time 0, no brain lesions were observed. At Time 1, changes of the cortical penetrating arteries, vasogenic oedema, lacunae and focal cell loss appeared in SHRSPs and worsened at Time 2, although no lesions were yet detected by MRI. Staining for proliferation markers revealed a significant boost of cellular mitosis in the subventricular zone (SVZ) of SHRSPs. Moreover, we observed higher immunopositivity for nestin, glial fibrillary acidic protein and doublecortin (markers for neural stem cells, astrocytes and immature neurons, respectively). At Time 2, apoptotic caspase-3 as well as 4-hydroxynonenal-positive neurons were associated to decreased nestin and doublecortin staining. High expression levels of glial fibrillary acidic protein were maintained in the SVZ. No comparative alterations and SVZ activation were recorded in WKYs. CONCLUSION: Appearance of vascular changes in SHRSPs, before any MRI-detectable brain lesion, is coupled to active neural proliferation in the SVZ. With disease progression, only newborn astrocytes can survive, likely because of the neurotoxicity triggered by brain oedema and oxidative stress.</style></abstract><notes><style face="normal" font="default" size="100%">Cova, Lidia&#xD;Gelosa, Paolo&#xD;Mura, Elena&#xD;Mauro, Alessandro&#xD;Stramba-Badiale, Marco&#xD;Michailidis, Georgios&#xD;Colonna, Alessandra&#xD;El Assawy, Nadia&#xD;Pignieri, Alice&#xD;Busca, Giuseppe&#xD;Tremoli, Elena&#xD;Silani, Vincenzo&#xD;Sironi, Luigi&#xD;Zanchetti, Alberto&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Hypertens. 2013 Aug;31(8):1618-28. doi: 10.1097/HJH.0b013e3283619d7f.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/HJH.0b013e3283619d7f</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>288</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">288</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Crobeddu, E.</style></author><author><style face="normal" font="default" size="100%">D&apos;Urso, P. I.</style></author><author><style face="normal" font="default" size="100%">Meyer, F. B.</style></author><author><style face="normal" font="default" size="100%">Lanzino, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Neurosurgery, Department of Neuroscience, University of Turin, Turin, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Intracranial aneurysms in patients with internal carotid artery occlusion: management and outcome in 22 cases</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Neurochir (Wien)</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Acta neurochirurgica</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Neurochir (Wien)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Acta neurochirurgica</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Acta Neurochir (Wien)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Acta neurochirurgica</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">2001-7</style></pages><volume><style face="normal" font="default" size="100%">155</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2013/09/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Aneurysm, Ruptured/complications/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arterial Occlusive Diseases/complications/ surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Artery, Internal/ surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Angiography/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Embolization, Therapeutic/adverse effects/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Aneurysm/complications/ surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0942-0940 (Electronic)&#xD;0001-6268 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24043416</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: There is little information about clinical characteristics, management, and outcome of patients with intracranial aneurysms and internal carotid artery occlusion. We will describe clinical characteristics, treatment and outcome of patients with coexistent internal carotid artery occlusion and intracranial aneurysms. METHODS: We conducted a retrospective chart review of 22 patients (eight males and 14 females) with coexistent internal carotid artery (ICA) occlusion and intracranial aneurysms. RESULTS: This series includes 14 females and eight males with a mean age of 63 years (range, 49 to 80). These patients harbored a total of 35 aneurysms, which were located on the same side of the ICA occlusion in five cases, on the contralateral side in 20 cases, while in ten cases the aneurysm had a midline location (AcomA 9, Basilar tip 1). Treatment consisted of surgery for eight aneurysms and endovascular embolization for 13 aneurysms. No invasive treatment was recommended for 14 aneurysms (eight patients with single aneurysm). No permanent perioperative or periprocedural complications occurred in the selected group of patients undergoing invasive treatment. At a mean follow-up of 57 months (range, 3-203), no patient had a subarachnoid hemorrhage and three patients had died of causes not related to the aneurysm. CONCLUSION: Surgical and endovascular treatment can be accomplished safely in selected patients with coexistent ICA occlusion and intracranial aneurysms. Conservative treatment is a valid alternative, especially in elderly patients or in patients with very small aneurysms, especially if not located along the collateral pathway.</style></abstract><notes><style face="normal" font="default" size="100%">Crobeddu, Emanuela&#xD;D&apos;Urso, Pietro I&#xD;Meyer, Fredric B&#xD;Lanzino, Giuseppe&#xD;Austria&#xD;Acta Neurochir (Wien). 2013 Nov;155(11):2001-7. doi: 10.1007/s00701-013-1879-6. Epub 2013 Sep 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/359/art%253A10.1007%252Fs00701-013-1879-6.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00701-013-1879-6&amp;token2=exp=1484113285~acl=%2Fstatic%2Fpdf%2F359%2Fart%25253A10.1007%25252Fs00701-013-1879-6.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs00701-013-1879-6*~hmac=c939a0cc4c74720ce2d4520ce168359693093e6b844e2c6488f37191913b463d</style></url></related-urls><pdf-urls><url>internal-pdf://2650290661/Crobeddu-2013-Intracranial aneurys.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00701-013-1879-6</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>454</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">454</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Csiszar, A.</style></author><author><style face="normal" font="default" size="100%">Sosnowska, D.</style></author><author><style face="normal" font="default" size="100%">Wang, M.</style></author><author><style face="normal" font="default" size="100%">Lakatta, E. G.</style></author><author><style face="normal" font="default" size="100%">Sonntag, W. E.</style></author><author><style face="normal" font="default" size="100%">Ungvari, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Reynolds Oklahoma Center on Aging, Department of Geriatric Medicine, University of Oklahoma Health Sciences Center, 975 North East 10th Street, Oklahoma City, OK 73104, USA. .anna-csiszar@ouhsc.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">Age-associated proinflammatory secretory phenotype in vascular smooth muscle cells from the non-human primate Macaca mulatta: reversal by resveratrol treatment</style></title><secondary-title><style face="normal" font="default" size="100%">J Gerontol A Biol Sci Med Sci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The journals of gerontology. Series A, Biological sciences and medical sciences</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Gerontol A Biol Sci Med Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The journals of gerontology. Series A, Biological sciences and medical sciences</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Gerontol A Biol Sci Med Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The journals of gerontology. Series A, Biological sciences and medical sciences</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">811-20</style></pages><volume><style face="normal" font="default" size="100%">67</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2012/01/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents, Non-Steroidal/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Aging/ drug effects/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Culture Media, Conditioned</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukins/secretion</style></keyword><keyword><style face="normal" font="default" size="100%">Macaca mulatta</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle, Smooth, Vascular/ cytology/ secretion</style></keyword><keyword><style face="normal" font="default" size="100%">Myocytes, Smooth Muscle/ physiology/ secretion</style></keyword><keyword><style face="normal" font="default" size="100%">NF-kappa B/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative Stress/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Phenanthridines</style></keyword><keyword><style face="normal" font="default" size="100%">Stilbenes/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Transcription, Genetic/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Tumor Necrosis Factor-alpha</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1758-535X (Electronic)&#xD;1079-5006 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22219513</style></accession-num><abstract><style face="normal" font="default" size="100%">There is increasing evidence that age-associated chronic low-grade inflammation promotes the development of both large-vessel disease (myocardial infarction, stroke, peripheral arterial disease) and small-vessel pathologies (including vascular cognitive impairment) in older persons. However, the source of age-related chronic vascular inflammation remains unclear. To test the hypothesis that cell-autonomous mechanisms contribute to the proinflammatory changes in vascular phenotype that accompanies advancing age, we analyzed the cytokine secretion profile of primary vascular smooth muscle cells (VSMCs) derived from young ( approximately 13 years old) and aged ( approximately 21 years old) Macaca mulatta. Aged VSMCs cultured in the absence of systemic factors exhibited significantly increased secretion of interleukin-1beta, MCP-1, and tumor necrosis factoralpha compared with young control cells. Secretion of interleukin-6 also tended to increase in aged VSMCs. This age-associated proinflammatory shift in the cellular secretory phenotype was associated with an increased mitochondrial O(2)(-) production and nuclear factor kappa-light-chain-enhancer of activated B cells activation. Treatment of aged VSMCs with a physiologically relevant concentration of resveratrol (1 muM) exerted significant anti-inflammatory effects, reversing aging-induced alterations in the cellular cytokine secretion profile and inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells. Resveratrol also attenuated mitochondrial O(2)(-) production and upregulated the transcriptional activity of Nrf2 in aged VSMCs. Thus, in non-human primates, cell-autonomous activation of nuclear factor kappa-light-chain-enhancer of activated B cells and expression of an inflammatory secretome likely contribute to vascular inflammation in aging. Resveratrol treatment prevents the proinflammatory properties of the aged VSMC secretome, an effect that likely contributes to the demonstrated vasoprotective action of resveratrol in animal models of aging.</style></abstract><notes><style face="normal" font="default" size="100%">Csiszar, Anna&#xD;Sosnowska, Danuta&#xD;Wang, Mingyi&#xD;Lakatta, Edward G&#xD;Sonntag, William E&#xD;Ungvari, Zoltan&#xD;AT006526/AT/NCCIH NIH HHS/United States&#xD;P01 AG11370/AG/NIA NIH HHS/United States&#xD;Intramural NIH HHS/United States&#xD;P01 AG011370/AG/NIA NIH HHS/United States&#xD;NS056218/NS/NINDS NIH HHS/United States&#xD;AG038747/AG/NIA NIH HHS/United States&#xD;R01 AT006526/AT/NCCIH NIH HHS/United States&#xD;R01 NS056218/NS/NINDS NIH HHS/United States&#xD;AG031085/AG/NIA NIH HHS/United States&#xD;R01 AG026607/AG/NIA NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, N.I.H., Intramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Gerontol A Biol Sci Med Sci. 2012 Aug;67(8):811-20. doi: 10.1093/gerona/glr228. Epub 2012 Jan 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://biomedgerontology.oxfordjournals.org/content/67/8/811.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1119709502/Csiszar-2012-Age-associated proin.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3536544</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/gerona/glr228</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>264</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">264</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cui, H.</style></author><author><style face="normal" font="default" size="100%">Yang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From the Beijing Friendship Hospital, Capital Medical University, Beijing 100050, People&apos;s Republic of China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Analysis of microRNA expression detected by microarray of the cerebral cortex after hypoxic-ischemic brain injury</style></title><secondary-title><style face="normal" font="default" size="100%">J Craniofac Surg</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The Journal of craniofacial surgery</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Craniofac Surg</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of craniofacial surgery</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Craniofac Surg</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of craniofacial surgery</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">2147-52</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2013/11/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Down-Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia-Ischemia, Brain/ genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">MicroRNAs/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Microarray Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1536-3732 (Electronic)&#xD;1049-2275 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24220425</style></accession-num><abstract><style face="normal" font="default" size="100%">Small and noncoding microRNAs (miRNAs) are known as key regulators of biological processes such as cell differentiation and tumor generation. They are also the important mediators of posttranscriptional gene silencing in both pathogenic and pathologic aspects of hypoxic-ischemic brain injury. miRNA microarray has been considered to be a high-throughput and precise analysis tool for detecting miRNA expression profiling, and it does greatly facilitate the research of the biological function of miRNAs. To investigate the changes of miRNA expression in cortex of neonatal rats with hypoxic-ischemic brain injury (HIBI) and the possible roles of miRNA in the pathogenesis of HIBI, we constructed the model of rat with HIBI and the cortex tissues were obtained 14 days after the HIBI operation. The large-scale miRNA microarrays and bioinformatics analysis were used to determine the differentially expressed miRNAs of HIBI rats compared with controls. Expression of 3 miRNAs (mir-429, mir-200b, and mir-182) was determined by quantitative real-time polymerase chain reaction. The results of miRNA expression profiles indicated that 5 miRNAs were up-regulated more than twice and 29 miRNAs were down-regulated more than twice compared with the normal control group. The results of the 3 miRNAs detected by quantitative real-time polymerase chain reaction were consistent with those detected by miRNA microarray. Hypoxic-ischemic brain injury rats have significant changes in miRNA expression, which demonstrated that miRNAs may play important roles in the pathogenesis of HIBI.</style></abstract><notes><style face="normal" font="default" size="100%">Cui, Hong&#xD;Yang, Lijun&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Craniofac Surg. 2013 Nov;24(6):2147-52. doi: 10.1097/SCS.0b013e3182a243f3.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/SCS.0b013e3182a243f3</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>4</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">4</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cuomo, O.</style></author><author><style face="normal" font="default" size="100%">Pignataro, G.</style></author><author><style face="normal" font="default" size="100%">Sirabella, R.</style></author><author><style face="normal" font="default" size="100%">Molinaro, P.</style></author><author><style face="normal" font="default" size="100%">Anzilotti, S.</style></author><author><style face="normal" font="default" size="100%">Scorziello, A.</style></author><author><style face="normal" font="default" size="100%">Sisalli, M. J.</style></author><author><style face="normal" font="default" size="100%">Di Renzo, G.</style></author><author><style face="normal" font="default" size="100%">Annunziato, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From the Division of Pharmacology, Department of Neuroscience, Reproductive and Odontostomatological Sciences, School of Medicine, Federico II University of Naples, Naples, Italy (O.C., G.P., P.M., A.S., M.J.S., G.D.R., L.A.); and SDN IRCCS, Naples, Italy (R.S., S.A.).&#xD;From the Division of Pharmacology, Department of Neuroscience, Reproductive and Odontostomatological Sciences, School of Medicine, Federico II University of Naples, Naples, Italy (O.C., G.P., P.M., A.S., M.J.S., G.D.R., L.A.); and SDN IRCCS, Naples, Italy (R.S., S.A.). lannunzi@unina.it.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sumoylation of LYS590 of NCX3 f-Loop by SUMO1 Participates in Brain Neuroprotection Induced by Ischemic Preconditioning</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1085-93</style></pages><volume><style face="normal" font="default" size="100%">47</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2016/03/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Preconditioning</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotection/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">SUMO-1 Protein/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium-Calcium Exchanger/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Sumoylation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26979866</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: The small ubiquitin-like modifier (SUMO), a ubiquitin-like protein involved in posttranslational protein modifications, is activated by several conditions, such as heat stress, hypoxia, and hibernation and confers neuroprotection. Sumoylation enzymes and substrates are expressed also at the plasma membrane level. Among the numerous plasma membrane proteins controlling ionic homeostasis during cerebral ischemia, 1 of the 3 brain sodium/calcium exchangers (NCX3), exerts a protective role during ischemic preconditioning. In this study, we evaluated whether NCX3 is a target for sumoylation and whether this posttranslational modification participates in ischemic preconditioning-induced neuroprotection. To test these hypotheses, we analyzed (1) SUMO1 conjugation pattern after ischemic preconditioning; (2) the effect of SUMO1 knockdown on the ischemic damage after transient middle cerebral artery occlusion and ischemic preconditioning, (3) the possible interaction between SUMO1 and NCX3 and (4) the molecular determinants of NCX3 sequence responsible for sumoylation. METHODS: Focal brain ischemia and ischemic preconditioning were induced in rats by middle cerebral artery occlusion. SUMOylation was evaluated by western blot and immunohistochemistry. SUMO1 and NCX3 interaction was analyzed by site-directed mutagenesis and immunoprecipitation assay. RESULTS: We found that (1) SUMO1 knockdown worsened ischemic damage and reduced the protective effect of preconditioning; (2) SUMO1 bound to NCX3 at lysine residue 590, and its silencing increased NCX3 degradation; and (3) NCX3 sumoylation participates in SUMO1 protective role during ischemic preconditioning. Thus, our results demonstrate that NCX3 sumoylation confers additional neuroprotection in ischemic preconditioning. CONCLUSIONS: Finally, this study suggests that NCX3 sumoylation might be a new target to enhance ischemic preconditioning-induced neuroprotection.</style></abstract><notes><style face="normal" font="default" size="100%">Cuomo, Ornella&#xD;Pignataro, Giuseppe&#xD;Sirabella, Rossana&#xD;Molinaro, Pasquale&#xD;Anzilotti, Serenella&#xD;Scorziello, Antonella&#xD;Sisalli, Maria Jose&#xD;Di Renzo, Gianfranco&#xD;Annunziato, Lucio&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Stroke. 2016 Apr;47(4):1085-93. doi: 10.1161/STROKEAHA.115.012514. Epub 2016 Mar 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/47/4/1085.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1714712687/Cuomo-2016-Sumoylation of LYS59.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.115.012514</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>120</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">120</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dabertrand, F.</style></author><author><style face="normal" font="default" size="100%">Kroigaard, C.</style></author><author><style face="normal" font="default" size="100%">Bonev, A. D.</style></author><author><style face="normal" font="default" size="100%">Cognat, E.</style></author><author><style face="normal" font="default" size="100%">Dalsgaard, T.</style></author><author><style face="normal" font="default" size="100%">Domenga-Denier, V.</style></author><author><style face="normal" font="default" size="100%">Hill-Eubanks, D. C.</style></author><author><style face="normal" font="default" size="100%">Brayden, J. E.</style></author><author><style face="normal" font="default" size="100%">Joutel, A.</style></author><author><style face="normal" font="default" size="100%">Nelson, M. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacology, College of Medicine, University of Vermont, Burlington, VT 05405;&#xD;INSERM, U1161 and Universite Paris Diderot, Sorbonne Cite, UMR S1161, Paris, F-75010, France; and.&#xD;Department of Pharmacology, College of Medicine, University of Vermont, Burlington, VT 05405; Institute of Cardiovascular Sciences, University of Manchester, Manchester M13 9NT, United Kingdom Mark.Nelson@uvm.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Potassium channelopathy-like defect underlies early-stage cerebrovascular dysfunction in a genetic model of small vessel disease</style></title><secondary-title><style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Proceedings of the National Academy of Sciences of the United States of America</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style></full-title><abbr-1><style face="normal" font="default" size="100%">Proceedings of the National Academy of Sciences of the United States of America</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style></full-title><abbr-1><style face="normal" font="default" size="100%">Proceedings of the National Academy of Sciences of the United States of America</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">E796-805</style></pages><volume><style face="normal" font="default" size="100%">112</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2015/02/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">4-Aminopyridine/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/blood supply/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Disorders/ genetics/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Heparin-binding EGF-like Growth Factor/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Membrane Potentials</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Potassium Channels/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Notch3</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Notch/genetics/physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 17</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1091-6490 (Electronic)&#xD;0027-8424 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25646445</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), caused by dominant mutations in the NOTCH3 receptor in vascular smooth muscle, is a genetic paradigm of small vessel disease (SVD) of the brain. Recent studies using transgenic (Tg)Notch3(R169C) mice, a genetic model of CADASIL, revealed functional defects in cerebral (pial) arteries on the surface of the brain at an early stage of disease progression. Here, using parenchymal arterioles (PAs) from within the brain, we determined the molecular mechanism underlying the early functional deficits associated with this Notch3 mutation. At physiological pressure (40 mmHg), smooth muscle membrane potential depolarization and constriction to pressure (myogenic tone) were blunted in PAs from TgNotch3(R169C) mice. This effect was associated with an approximately 60% increase in the number of voltage-gated potassium (KV) channels, which oppose pressure-induced depolarization. Inhibition of KV1 channels with 4-aminopyridine (4-AP) or treatment with the epidermal growth factor receptor agonist heparin-binding EGF (HB-EGF), which promotes KV1 channel endocytosis, reduced KV current density and restored myogenic responses in PAs from TgNotch3(R169C) mice, whereas pharmacological inhibition of other major vasodilatory influences had no effect. KV1 currents and myogenic responses were similarly altered in pial arteries from TgNotch3(R169C) mice, but not in mesenteric arteries. Interestingly, HB-EGF had no effect on mesenteric arteries, suggesting a possible mechanistic basis for the exclusive cerebrovascular manifestation of CADASIL. Collectively, our results indicate that increasing the number of KV1 channels in cerebral smooth muscle produces a mutant vascular phenotype akin to a channelopathy in a genetic model of SVD.</style></abstract><notes><style face="normal" font="default" size="100%">Dabertrand, Fabrice&#xD;Kroigaard, Christel&#xD;Bonev, Adrian D&#xD;Cognat, Emmanuel&#xD;Dalsgaard, Thomas&#xD;Domenga-Denier, Valerie&#xD;Hill-Eubanks, David C&#xD;Brayden, Joseph E&#xD;Joutel, Anne&#xD;Nelson, Mark T&#xD;R01 HL121706/HL/NHLBI NIH HHS/United States&#xD;P01 HL095488/HL/NHLBI NIH HHS/United States&#xD;R01HL121706/HL/NHLBI NIH HHS/United States&#xD;R37 DK053832/DK/NIDDK NIH HHS/United States&#xD;R37DK053832/DK/NIDDK NIH HHS/United States&#xD;R01HL44455/HL/NHLBI NIH HHS/United States&#xD;R01 HL044455/HL/NHLBI NIH HHS/United States&#xD;P01HL095488/HL/NHLBI NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):E796-805. doi: 10.1073/pnas.1420765112. Epub 2015 Feb 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.pnas.org/content/112/7/E796.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1691186449/Dabertrand-2015-Potassium channelopa.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4343103</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1073/pnas.1420765112</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>398</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">398</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dai, D.</style></author><author><style face="normal" font="default" size="100%">Ding, Y. H.</style></author><author><style face="normal" font="default" size="100%">Kadirvel, R.</style></author><author><style face="normal" font="default" size="100%">Rad, A. E.</style></author><author><style face="normal" font="default" size="100%">Lewis, D. A.</style></author><author><style face="normal" font="default" size="100%">Kallmes, D. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Neuroradiology Research Laboratory, Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Lack of aneurysm formation after carotid artery ligation in rabbits: a polymer MICROFIL(R) study</style></title><secondary-title><style face="normal" font="default" size="100%">Neuroradiology</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuroradiology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuroradiology</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroradiology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuroradiology</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroradiology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">65-70</style></pages><volume><style face="normal" font="default" size="100%">55</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2012/08/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aneurysm/diagnosis/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Artery Diseases/diagnosis/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Embolization, Therapeutic/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Hemostatics/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Ligation</style></keyword><keyword><style face="normal" font="default" size="100%">Rabbits</style></keyword><keyword><style face="normal" font="default" size="100%">Silicone Elastomers/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1432-1920 (Electronic)&#xD;0028-3940 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22847650</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Previous studies have noted formation of saccular aneurysms along the distal basilar artery/P1 segments after carotid ligation in rabbits. In this prospective study we employed MICROFIL(R), a polymer, which was used to fill the entire arterial tree, to examine the incidence of microaneurysm formation following right common carotid artery (RCCA) ligation in rabbits. METHODS: RCCA ligation was performed in 18 New Zealand White rabbits for 0 day (n = 2), 3 weeks (n = 6), or 16 weeks (n = 10). Three control rabbits without carotid surgery were sacrificed at 4 weeks. At the time of sacrifice, MICROFIL(R) MV-122 yellow was injected through left CCA to fill cerebral vasculature. After gross photographs were taken, specimens were embedded, sectioned, and stained for histopathological evaluation. Tissue and sections were carefully evaluated for microaneurysm formation, defined as a localized dilatation of the vessel wall, associated with fragmentation or complete loss of the internal elastic lamina (IEL), and/or medial degeneration. RESULTS: Gross examination with MICROFIL(R) opacification demonstrated no evidence of saccular aneurysm formation, but prominent perforating vessels were present in all 19 cases at, or adjacent to, the basilar terminus. Branches noted upon gross examination corresponded histologically to small, saccular contour defects, which demonstrated apparent loss of the IEL and apparent medial thinning. These observations, however, were a consequence of sectioning through the bases of perforating arteries, which simulated microaneurysm formation. CONCLUSIONS: Unilateral carotid ligation does not induce microaneurysm formation at the basilar terminus in rabbits. Prominent perforating arteries as well as tissue injury from the processing may simulate &quot;aneurysms&quot; histologically.</style></abstract><notes><style face="normal" font="default" size="100%">Dai, Daying&#xD;Ding, Yong Hong&#xD;Kadirvel, Ramanathan&#xD;Rad, Arash Ehteshami&#xD;Lewis, Debra A&#xD;Kallmes, David F&#xD;R01 NS042646/NS/NINDS NIH HHS/United States&#xD;NS42646/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Germany&#xD;Neuroradiology. 2013 Jan;55(1):65-70. doi: 10.1007/s00234-012-1070-4. Epub 2012 Jul 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/300/art%253A10.1007%252Fs00234-012-1070-4.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00234-012-1070-4&amp;token2=exp=1484113291~acl=%2Fstatic%2Fpdf%2F300%2Fart%25253A10.1007%25252Fs00234-012-1070-4.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs00234-012-1070-4*~hmac=822903e42f907d2c5232a799836638d5b7437de60ce6feb9d10bce0d63342523</style></url></related-urls><pdf-urls><url>internal-pdf://2861518852/Dai-2013-Lack of aneurysm for.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3910330</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms429211</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00234-012-1070-4</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>322</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">322</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Darling, W. G.</style></author><author><style face="normal" font="default" size="100%">Helle, N.</style></author><author><style face="normal" font="default" size="100%">Pizzimenti, M. A.</style></author><author><style face="normal" font="default" size="100%">Rotella, D. L.</style></author><author><style face="normal" font="default" size="100%">Hynes, S. M.</style></author><author><style face="normal" font="default" size="100%">Ge, J.</style></author><author><style face="normal" font="default" size="100%">Stilwell-Morecraft, K. S.</style></author><author><style face="normal" font="default" size="100%">Morecraft, R. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Health and Human Physiology, Motor Control Laboratories, The University of Iowa, Iowa City, IA 52242, USA. warren-darling@uiowa.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">Laterality affects spontaneous recovery of contralateral hand motor function following motor cortex injury in rhesus monkeys</style></title><secondary-title><style face="normal" font="default" size="100%">Exp Brain Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Experimental brain research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Exp Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Experimental brain research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Exp Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Experimental brain research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">9-24</style></pages><volume><style face="normal" font="default" size="100%">228</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2013/05/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnosis, Computer-Assisted</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Functional Laterality/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Hand/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Macaca mulatta</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Motor Cortex/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Psychomotor Performance/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery of Function</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1432-1106 (Electronic)&#xD;0014-4819 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23652723</style></accession-num><abstract><style face="normal" font="default" size="100%">The purpose of this study was to test whether brain laterality influences spontaneous recovery of hand motor function after controlled brain injuries to arm areas of M1 and lateral premotor cortex (LPMC) of the hemisphere contralateral to the preferred hand in rhesus monkeys. We hypothesized that monkeys with stronger hand preference would exhibit poorer recovery of skilled hand use after such brain injury. Degree of handedness was assessed using a standard dexterity board task in which subjects could use either hand to retrieve small food pellets. Fine hand/digit motor function was assessed using a modified dexterity board before and after the M1 and LPMC lesions in ten monkeys. We found a strong negative relationship between the degree of handedness and the recovery of manipulation skill, demonstrating that higher hand preference was associated with poorer recovery of hand fine motor function. We also observed that monkeys with larger lesions within M1 and LPMC had greater initial impairment of manipulation and poorer recovery of reaching skill. We conclude that monkeys with a stronger hand preference are likely to show poorer recovery of contralesional hand fine motor skill after isolated brain lesions affecting the lateral frontal motor areas. These data may be extended to suggest that humans who exhibit weak hand dominance, and perhaps individuals who use both hands for fine motor tasks, may have a more favorable potential for recovery after a unilateral stroke or brain injury affecting the lateral cortical motor areas than individuals with a high degree of hand dominance.</style></abstract><notes><style face="normal" font="default" size="100%">Darling, Warren G&#xD;Helle, Nicole&#xD;Pizzimenti, Marc A&#xD;Rotella, Diane L&#xD;Hynes, Stephanie M&#xD;Ge, Jizhi&#xD;Stilwell-Morecraft, Kimberly S&#xD;Morecraft, Robert J&#xD;R01 NS046367/NS/NINDS NIH HHS/United States&#xD;R56 NS046367/NS/NINDS NIH HHS/United States&#xD;NS 046367/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Germany&#xD;Exp Brain Res. 2013 Jul;228(1):9-24. doi: 10.1007/s00221-013-3533-1. Epub 2013 May 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/778/art%253A10.1007%252Fs00221-013-3533-1.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00221-013-3533-1&amp;token2=exp=1484113294~acl=%2Fstatic%2Fpdf%2F778%2Fart%25253A10.1007%25252Fs00221-013-3533-1.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs00221-013-3533-1*~hmac=64f56733d313c55762a1f019e8002f572029613d49602f6569c7cb0a9d12ca63</style></url></related-urls><pdf-urls><url>internal-pdf://1595760089/Darling-2013-Laterality affects s.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4799493</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms766896</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00221-013-3533-1</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>294</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">294</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Davis, M. F.</style></author><author><style face="normal" font="default" size="100%">Lay, C.</style></author><author><style face="normal" font="default" size="100%">Frostig, R. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurobiology &amp; Behavior, University of California, Irvine, Irvine, CA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Permanent cerebral vessel occlusion via double ligature and transection</style></title><secondary-title><style face="normal" font="default" size="100%">J Vis Exp</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of visualized experiments : JoVE</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Vis Exp</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of visualized experiments : JoVE</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Vis Exp</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of visualized experiments : JoVE</style></abbr-1></alt-periodical><number><style face="normal" font="default" size="100%">77</style></number><edition><style face="normal" font="default" size="100%">2013/08/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Ligation/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Cerebral Artery/ surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 21</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1940-087X (Electronic)&#xD;1940-087X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23912746</style></accession-num><abstract><style face="normal" font="default" size="100%">Stroke is a leading cause of death, disability, and socioeconomic loss worldwide. The majority of all strokes result from an interruption in blood flow (ischemia). Middle cerebral artery (MCA) delivers a great majority of blood to the lateral surface of the cortex, is the most common site of human stroke, and ischemia within its territory can result in extensive dysfunction or death. Survivors of ischemic stroke often suffer loss or disruption of motor capabilities, sensory deficits, and infarct. In an effort to capture these key characteristics of stroke, and thereby develop effective treatment, a great deal of emphasis is placed upon animal models of ischemia in MCA. Here we present a method of permanently occluding a cortical surface blood vessel. We will present this method using an example of a relevant vessel occlusion that models the most common type, location, and outcome of human stroke, permanent middle cerebral artery occlusion (pMCAO). In this model, we surgically expose MCA in the adult rat and subsequently occlude via double ligature and transection of the vessel. This pMCAO blocks the proximal cortical branch of MCA, causing ischemia in all of MCA cortical territory, a large portion of the cortex. This method of occlusion can also be used to occlude more distal portions of cortical vessels in order to achieve more focal ischemia targeting a smaller region of cortex. The primary disadvantages of pMCAO are that the surgical procedure is somewhat invasive as a small craniotomy is required to access MCA, though this results in minimal tissue damage. The primary advantages of this model, however, are: the site of occlusion is well defined, the degree of blood flow reduction is consistent, functional and neurological impairment occurs rapidly, infarct size is consistent, and the high rate of survival allows for long-term chronic assessment.</style></abstract><notes><style face="normal" font="default" size="100%">Davis, Melissa F&#xD;Lay, Christopher&#xD;Frostig, Ron D&#xD;R01 NS055832/NS/NINDS NIH HHS/United States&#xD;1T32DC010775-01/DC/NIDCD NIH HHS/United States&#xD;R01 NS066001/NS/NINDS NIH HHS/United States&#xD;NS-055832/NS/NINDS NIH HHS/United States&#xD;NS-066001/NS/NINDS NIH HHS/United States&#xD;T32 DC010775/DC/NIDCD NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Video-Audio Media&#xD;United States&#xD;J Vis Exp. 2013 Jul 21;(77). doi: 10.3791/50418.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.jove.com/pdf/50418/jove-protocol-50418-permanent-cerebral-vessel-occlusion-via-double-ligature</style></url></related-urls><pdf-urls><url>internal-pdf://1635617474/Davis-2013-Permanent cerebral v.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3845834</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3791/50418</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>425</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">425</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Deddens, L. H.</style></author><author><style face="normal" font="default" size="100%">Van Tilborg, G. A.</style></author><author><style face="normal" font="default" size="100%">Mulder, W. J.</style></author><author><style face="normal" font="default" size="100%">De Vries, H. E.</style></author><author><style face="normal" font="default" size="100%">Dijkhuizen, R. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Image Sciences Institute, University Medical Center Utrecht, Utrecht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Imaging neuroinflammation after stroke: current status of cellular and molecular MRI strategies</style></title><secondary-title><style face="normal" font="default" size="100%">Cerebrovasc Dis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Cerebrovascular diseases (Basel, Switzerland)</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cerebrovasc Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Cerebrovascular diseases (Basel, Switzerland)</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Cerebrovasc Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Cerebrovascular diseases (Basel, Switzerland)</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">392-402</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2012/03/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Coloring Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Contrast Media</style></keyword><keyword><style face="normal" font="default" size="100%">Ferric Compounds</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocytes/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroimaging/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1421-9786 (Electronic)&#xD;1015-9770 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22456323</style></accession-num><abstract><style face="normal" font="default" size="100%">Cellular and molecular magnetic resonance imaging (MRI) strategies for studying the spatiotemporal profile of neuroinflammatory processes after stroke are increasingly being explored since the first reports appeared about a decade ago. These strategies most often employ (super)paramagnetic contrast agents, such as (ultra)small particles of iron oxide and gadolinium chelates, for MRI-based detection of specific leukocyte populations or molecular inflammatory markers that are involved in the pathophysiology of stroke or plasticity. In this review we describe achievements, limitations and prospects in the field of cellular and molecular MRI of neuroinflammation in preclinical and clinical stroke. Several studies in rodent stroke models have demonstrated the application of MRI contrast agents for imaging of monocyte infiltration, which served as the foundation for pilot (small-scale proof-of-concept) cellular MRI studies in stroke patients. This may be achieved with isolated cells that are loaded with contrast agent through in vitro incubation prior to systemic administration. Alternatively, superparamagnetic iron oxide particles may be directly injected into the circulation to allow in vivo uptake by phagocytic cells. Both strategies have been successfully employed to measure the spatiotemporal profile of invasion of monocytes in and around cerebral ischemic lesions in experimental stroke models. Molecular MRI studies with target-specific contrast agents have shown the capability for in vivo detection of molecular markers after experimental stroke. For example, (super)paramagnetic micro- or nanoparticles that are functionalized with a ligand (e.g. an antibody) for specific cell adhesion molecules, such as E-selectin and vascular cell adhesion molecule 1 (VCAM-1), can target inflamed, activated endothelium, whose presence can subsequently be detected with MRI. Present applications remain limited as most of the currently available contrast agents provide relatively poor contrast enhancement, which is not easily discriminated from endogenous sources of tissue contrast. Nevertheless, current developments of more efficient particles, such as biocompatible liposomes, micelles and nanoemulsions that can contain high payloads of (super)paramagnetic material as well as other substances, such as dyes and drugs, may open a window of opportunities for promising translational multimodal imaging strategies that enable in vivo assessment of (neuroinflammatory) disease markers, therapeutic targets as well as drug delivery after stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Deddens, Lisette H&#xD;Van Tilborg, Geralda A F&#xD;Mulder, Willem J M&#xD;De Vries, Helga E&#xD;Dijkhuizen, Rick M&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Switzerland&#xD;Cerebrovasc Dis. 2012;33(4):392-402. doi: 10.1159/000336116. Epub 2012 Mar 28.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1159/000336116</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>7</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">7</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Della-Morte, D.</style></author><author><style face="normal" font="default" size="100%">Pacifici, F.</style></author><author><style face="normal" font="default" size="100%">Rundek, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">aDepartment of Neurology, Miller School of Medicine, University of Miami, Miami, Florida, USA bDepartment of Systems Medicine, School of Medicine, University of Rome Tor Vergata cIRCCS San Raffaele Pisana, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Genetic susceptibility to cerebrovascular disease</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Opin Lipidol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Current opinion in lipidology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Opin Lipidol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current opinion in lipidology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Curr Opin Lipidol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current opinion in lipidology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">187-95</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2016/03/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Disorders/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Dyslipidemias/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Genome-Wide Association Study</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lipid Metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1473-6535 (Electronic)&#xD;0957-9672 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26959706</style></accession-num><abstract><style face="normal" font="default" size="100%">PURPOSE OF REVIEW: Cerebrovascular disease (CeVD) remains a major cause of death and a leading cause of disability worldwide. CeVD is a complex and multifactorial disease caused by the interaction of vascular risk factors, environment, and genetic factors. In the present article, we discussed genetic susceptibility to CeVD, with particular emphasis on genetic studies of the associations between lipid traits and CeVD. RECENT FINDINGS: Several animal and clinical studies clearly defined genetic predisposition to atherosclerosis and CeVD, and particularly to ischemic stroke. Recent evidence has shown that traditional vascular risk factors explain only a small proportion of variance in atherosclerosis, suggesting that additional nontraditional factors and novel genetic determinants impact CeVD. With the help of genome-wide technology, novel genetic variants have been implicated in CeVD and lipid metabolism such as those in protein convertase subtilisin/kexin type 9 (PCSK9) gene in stroke and familial hypercholesterolemia. These studies are important as they contribute to our understanding of the genetic mechanisms underlying CeVD and to developing more effective CeVD prevention strategies. SUMMARY: CeVD is a complex and multifactorial disease and genetics likely plays an important role in its pathogenesis. The gene-gene and gene-environment interactions of genes involved in biology of vascular disease, including the lipid metabolism are important factors for individual susceptibility to CeVD. Accounting for individual variation in genes, environment and lifestyle will bring us closer to precision medicine, which is an emerging and recently introduced new approach for disease treatment and prevention in clinical practice.</style></abstract><notes><style face="normal" font="default" size="100%">Della-Morte, David&#xD;Pacifici, Francesca&#xD;Rundek, Tatjana&#xD;K24 NS062737/NS/NINDS NIH HHS/United States&#xD;K24 NS 062737/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;England&#xD;Curr Opin Lipidol. 2016 Apr;27(2):187-95. doi: 10.1097/MOL.0000000000000275.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC5138857</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms831798</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/mol.0000000000000275</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>136</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">136</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Deng, J.</style></author><author><style face="normal" font="default" size="100%">Xiong, L.</style></author><author><style face="normal" font="default" size="100%">Zuo, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Anesthesiology, University of Virginia, Charlottesville, Virginia; Department of Anesthesiology, Xijing Hospital, Fourth Military Medical University, Xi&apos;an, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Trans-sodium crocetinate provides neuroprotection against cerebral ischemia and reperfusion in obese mice</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosci Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neuroscience research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosci Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroscience research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosci Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroscience research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">615-22</style></pages><volume><style face="normal" font="default" size="100%">93</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2014/12/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aldehydes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Analysis of Variance</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/drug effects/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ complications/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Matrix Metalloproteinases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Nervous System Diseases/ drug therapy/ etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative Stress/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion</style></keyword><keyword><style face="normal" font="default" size="100%">Tyrosine/analogs &amp; derivatives/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamin A/ analogs &amp; derivatives/therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1097-4547 (Electronic)&#xD;0360-4012 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25491171</style></accession-num><abstract><style face="normal" font="default" size="100%">Trans-sodium crocetinate (TSC) is a novel synthetic carotenoid compound that improves diffusion of small molecules, including oxygen, in solutions. TSC provides neuroprotection in healthy rats and rabbits. This study seeks to determine whether TSC is neuroprotective in obese mice. Sixteen-week-old CD-1 male mice that had been fed a high-fat diet for 10 weeks were subjected to a 90-min middle cerebral arterial occlusion (MCAO). They received TSC by two boluses through a tail vein 10 min after the onset of MCAO and reperfusion, respectively, with doses of 0.14, 0.28, and 0.7 mg/kg or by a bolus-infusion-bolus strategy with a dose of 0.14 mg/kg during MCAO. The neurological outcome was evaluated 72 hr after MCAO. Brain tissues were harvested 24 hr after MCAO to measure nitrotyrosine-containing proteins, 4-hydroxy-2-nonenal, matrix metalloproteinase (MMP)-2 and -9 activity and expression, and inflammatory cytokines. TSC given in the two-bolus strategy did not improve the neurological outcome. The bolus-infusion-bolus strategy significantly reduced brain edema, infarct volume, and hemorrhagic transformation and improved neurological functions. TSC reduced nitrotyrosine-containing proteins, MMP-9 activity and expression, and inflammatory cytokines in ischemic brain tissues. Our results indicate that TSC delivered by the bolus-infusion-bolus strategy provides neuroprotection in obese mice. This protection may occur through reduction of oxidative stress, MMP-9 activity, or inflammatory cytokines in the ischemic brain tissues.</style></abstract><notes><style face="normal" font="default" size="100%">Deng, Jiao&#xD;Xiong, Lize&#xD;Zuo, Zhiyi&#xD;R01 GM065211/GM/NIGMS NIH HHS/United States&#xD;R01 GM098308/GM/NIGMS NIH HHS/United States&#xD;R01 NS045983/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Neurosci Res. 2015 Apr;93(4):615-22. doi: 10.1002/jnr.23522. Epub 2014 Dec 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1002/jnr.23522/asset/jnr23522.pdf?v=1&amp;t=ixsi0zqy&amp;s=2c89128ef50b0e1fe9929d2ce5668fdab7ec3c3f</style></url></related-urls><pdf-urls><url>internal-pdf://0330927660/Deng-2015-Trans-sodium croceti.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4329099</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms640869</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/jnr.23522</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>357</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">357</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Deng, Z.</style></author><author><style face="normal" font="default" size="100%">Wang, Z.</style></author><author><style face="normal" font="default" size="100%">Yang, X.</style></author><author><style face="normal" font="default" size="100%">Luo, Q.</style></author><author><style face="normal" font="default" size="100%">Gong, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology, Britton Chance Center for Biomedical Photonics, 1037 Luoyu Road, Wuhan 430074, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">In vivo imaging of hemodynamics and oxygen metabolism in acute focal cerebral ischemic rats with laser speckle imaging and functional photoacoustic microscopy</style></title><secondary-title><style face="normal" font="default" size="100%">J Biomed Opt</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of biomedical optics</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Biomed Opt</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of biomedical optics</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Biomed Opt</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of biomedical optics</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">081415-1</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2012/12/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Flow Velocity</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/diagnostic imaging/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Echoencephalography/instrumentation</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment Design</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment Failure Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Lasers</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Microscopy, Acoustic/ instrumentation</style></keyword><keyword><style face="normal" font="default" size="100%">Oximetry/instrumentation</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Photoacoustic Techniques/ instrumentation</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1560-2281 (Electronic)&#xD;1083-3668 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23224176</style></accession-num><abstract><style face="normal" font="default" size="100%">Stroke is a devastating disease. The changes in cerebral hemodynamics and oxygen metabolism associated with stroke play an important role in pathophysiology study. But the changes were difficult to describe with a single imaging modality. Here the changes in cerebral blood flow (CBF), cerebral blood volume (CBV), and oxygen saturation (SO2) were yielded with laser speckle imaging (LSI) and photoacoustic microscopy (PAM) during and after 3-h acute focal ischemic rats. These hemodynamic measures were further synthesized to deduce the changes in oxygen extraction fraction (OEF). The results indicate that all the hemodynamics except CBV had rapid declines within 40-min occlusion of middle cerebral artery (MCAO). CBV in arteries and veins first increased to the maximum value of 112.42 +/- 36.69% and 130.58 +/- 31.01% by 15 min MCAO; then all the hemodynamics had a persistent reduction with small fluctuations during the ischemic. When ischemia lasted for 3 h, CBF in arteries, veins decreased to 17 +/- 14.65%, 24.52 +/- 20.66%, respectively, CBV dropped to 62 +/- 18.56% and 59 +/- 18.48%. And the absolute SO2 decreased by 40.52 +/- 22.42% and 54.24 +/- 11.77%. After 180-min MCAO, the changes in hemodynamics and oxygen metabolism were also quantified. The study suggested that combining LSI and PAM provides an attractive approach for stroke detection in small animal studies.</style></abstract><notes><style face="normal" font="default" size="100%">Deng, Zilin&#xD;Wang, Zhen&#xD;Yang, Xiaoquan&#xD;Luo, Qingming&#xD;Gong, Hui&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Biomed Opt. 2012 Aug;17(8):081415-1. doi: 10.1117/1.JBO.17.8.081415.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://biomedicaloptics.spiedigitallibrary.org/pdfaccess.ashx?url=/data/journals/biomedo/24225/jbo_17_8_081415.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2400825358/Deng-2012-In vivo imaging of h.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1117/1.jbo.17.8.081415</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>306</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">306</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Deuchar, G. A.</style></author><author><style face="normal" font="default" size="100%">Brennan, D.</style></author><author><style face="normal" font="default" size="100%">Griffiths, H.</style></author><author><style face="normal" font="default" size="100%">Macrae, I. M.</style></author><author><style face="normal" font="default" size="100%">Santosh, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Wellcome Surgical Institute, Glasgow Experimental MRI Centre, Institute of Neuroscience and Psychology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Perfluorocarbons enhance a T2*-based MRI technique for identifying the penumbra in a rat model of acute ischemic stroke</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1422-8</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2013/06/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Substitutes/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/diagnostic imaging/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Contrast Media/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorocarbons/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Hemoglobins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Radiography</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/diagnostic imaging/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23801243</style></accession-num><abstract><style face="normal" font="default" size="100%">Accurate imaging of ischemic penumbra is crucial for improving the management of acute stroke patients. T2* magnetic resonance imaging (MRI) combined with a T2*oxygen challenge (T2*OC) is being developed to detect penumbra based on changes in blood deoxyhemoglobin. Using 100% O2, T2*OC-defined penumbra exhibits ongoing glucose metabolism and tissue recovery on reperfusion. However, potential limitations in translating this technique include a sinus artefact in human scans with delivery of 100% OC and relatively small signal changes. Here we investigate whether an oxygen-carrying perfluorocarbon (PFC) emulsion can enhance the sensitivity of the technique, enabling penumbra detection with lower levels of inspired oxygen. Stroke was induced in male Sprague-Dawley rats (n=17) with ischemic injury and perfusion deficit determined by diffusion and perfusion MRI, respectively. T2* signal change was measured in regions of interest (ROIs) located within ischemic core, T2*OC-defined penumbra and equivalent contralateral areas during 40% O2+/-prior PFC injection. Region of interest analyses between groups showed that PFC significantly enhanced the T2* response to 40% O2 in T2*-defined penumbra (mean increase of 10.6+/-2.3% compared to 5.6+/-1.5% with 40% O2, P&lt;0.001). This enhancement was specific to the penumbra ROI. Perfluorocarbon emulsions therefore enhances the translational potential of the T2*OC technique for identifying penumbra in acute stroke patients.</style></abstract><notes><style face="normal" font="default" size="100%">Deuchar, Graeme A&#xD;Brennan, David&#xD;Griffiths, Hugh&#xD;Macrae, I Mhairi&#xD;Santosh, Celestine&#xD;ETM/146/Chief Scientist Office/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Cereb Blood Flow Metab. 2013 Sep;33(9):1422-8. doi: 10.1038/jcbfm.2013.86. Epub 2013 Jun 26.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3764387</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2013.86</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>230</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">230</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Di, Y.</style></author><author><style face="normal" font="default" size="100%">Lei, Y.</style></author><author><style face="normal" font="default" size="100%">Yu, F.</style></author><author><style face="normal" font="default" size="100%">Changfeng, F.</style></author><author><style face="normal" font="default" size="100%">Song, W.</style></author><author><style face="normal" font="default" size="100%">Xuming, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Cardiothoracic Surgery, Nanjing Children&apos;s Hospital, Nanjing Medical University, Nanjing, 210008, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">MicroRNAs expression and function in cerebral ischemia reperfusion injury</style></title><secondary-title><style face="normal" font="default" size="100%">J Mol Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of molecular neuroscience : MN</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Mol Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of molecular neuroscience : MN</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Mol Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of molecular neuroscience : MN</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">242-50</style></pages><volume><style face="normal" font="default" size="100%">53</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2014/04/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">MicroRNAs/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-1166 (Electronic)&#xD;0895-8696 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24696166</style></accession-num><abstract><style face="normal" font="default" size="100%">MicroRNAs (miRNAs) are small (18 ~ 25 nt) noncoding single-stranded RNA molecules that act as negative regulators of gene expression and modulating the stability and/or the translational efficiency of target messenger RNAs. Studies have shown that miRNAs control diverse aspects of brain disease. Recently, several studies have suggested that miRNAs alter the response to ischemia reperfusion injury and regulate the expression of various key elements in cell survival and apoptosis. This review article gives a brief overview of some miRNAs (miR-15a/b, miR-21, miR-29b/c, miR-124, miR-145, miR-181, miR-200 family, miR-338, miR-422a, miR-497, and miR let 7 family) in cerebral ischemia reperfusion injury. Although miRNAs could be potential therapeutic targets for the treatment of ischemia reperfusion injury, their safety and other limitations need further confirmation.</style></abstract><notes><style face="normal" font="default" size="100%">Di, Yu&#xD;Lei, Yang&#xD;Yu, Feng&#xD;Changfeng, Fan&#xD;Song, Wang&#xD;Xuming, Mo&#xD;Review&#xD;United States&#xD;J Mol Neurosci. 2014 Jun;53(2):242-50. doi: 10.1007/s12031-014-0293-8. Epub 2014 Apr 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/423/art%253A10.1007%252Fs12031-014-0293-8.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12031-014-0293-8&amp;token2=exp=1484113311~acl=%2Fstatic%2Fpdf%2F423%2Fart%25253A10.1007%25252Fs12031-014-0293-8.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs12031-014-0293-8*~hmac=456b65d3783f394abe4ed454fd0533d7560fbc9eba36b69771aaa6322fb934ce</style></url></related-urls><pdf-urls><url>internal-pdf://0176791746/Di-2014-MicroRNAs expression.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12031-014-0293-8</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>316</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">316</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Diener, H. C.</style></author><author><style face="normal" font="default" size="100%">Foerch, C.</style></author><author><style face="normal" font="default" size="100%">Riess, H.</style></author><author><style face="normal" font="default" size="100%">Rother, J.</style></author><author><style face="normal" font="default" size="100%">Schroth, G.</style></author><author><style face="normal" font="default" size="100%">Weber, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology and Stroke Centre, University Hospital Essen, Essen, Germany. h.diener@uni-essen.de</style></auth-address><titles><title><style face="normal" font="default" size="100%">Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment</style></title><secondary-title><style face="normal" font="default" size="100%">Lancet Neurol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The Lancet. Neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lancet Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Lancet. Neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Lancet Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Lancet. Neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">677-88</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2013/06/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Anticoagulants/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/complications/ drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Fibrinolytic Agents/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Plasminogen Activators/adverse effects/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Platelet Aggregation Inhibitors/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ drug therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombectomy/adverse effects/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombolytic Therapy/adverse effects/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Tissue Plasminogen Activator/adverse effects/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Warfarin/therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1474-4465 (Electronic)&#xD;1474-4422 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23726849</style></accession-num><abstract><style face="normal" font="default" size="100%">Systemic thrombolysis with alteplase is the only approved medical treatment for patients with acute ischaemic stroke. Thrombectomy is also increasingly used to treat proximal occlusions of the cerebral arteries, but has not shown superiority over systemic thrombolysis with alteplase. Many patients with acute ischaemic stroke are pretreated with antiplatelet or anticoagulant drugs, which can increase the bleeding risk of thrombolysis or thrombectomy. Pretreatment with aspirin monotherapy increases the bleeding risk of alteplase in both observational and randomised trials with no effect on clinical outcome, and the risk of intracerebral haemorrhage is increased with the combination of aspirin and clopidogrel. Antiplatelet drugs should not be given in the first 24 h after alteplase treatment. Data from pooled randomised trials and a large observational study show that thrombolysis can probably be done safely in patients given vitamin-K antagonists if the international normalised ratio is less than 1.7, although bleeding risk is slightly raised. Almost no data are available for the safety of alteplase in patients with atrial fibrillation who have been given novel oral anticoagulants (NOAC) for stroke prevention. Some coagulation parameters could help to identify patients treated with NOAC who might be eligible for thrombolysis. Thrombectomy can be done in patients given antiplatelets and probably in those given anticoagulants; however, conclusions about anticoagulants are based on findings from observational studies with small patient numbers.</style></abstract><notes><style face="normal" font="default" size="100%">Diener, Hans-Christoph&#xD;Foerch, Christian&#xD;Riess, Hanno&#xD;Rother, Joachim&#xD;Schroth, Gerhard&#xD;Weber, Ralph&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;England&#xD;Lancet Neurol. 2013 Jul;12(7):677-88. doi: 10.1016/S1474-4422(13)70101-7. Epub 2013 May 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S1474442213701017/1-s2.0-S1474442213701017-main.pdf?_tid=dbe0b6fa-d7bd-11e6-b5aa-00000aab0f27&amp;acdnat=1484112292_22c858c17c7079dd4acfaa9ff4f54f7b</style></url></related-urls><pdf-urls><url>internal-pdf://2847122476/Diener-2013-Treatment of acute i.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/s1474-4422(13)70101-7</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>149</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">149</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ding, Y.</style></author><author><style face="normal" font="default" size="100%">Chen, M.</style></author><author><style face="normal" font="default" size="100%">Wang, M.</style></author><author><style face="normal" font="default" size="100%">Wang, M.</style></author><author><style face="normal" font="default" size="100%">Zhang, T.</style></author><author><style face="normal" font="default" size="100%">Park, J.</style></author><author><style face="normal" font="default" size="100%">Zhu, Y.</style></author><author><style face="normal" font="default" size="100%">Guo, C.</style></author><author><style face="normal" font="default" size="100%">Jia, Y.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Wen, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacy, Xijing Hospital, Fourth Military Medical University.&#xD;Department of Pharmacology, School of Pharmacy, Fourth Military Medical University.&#xD;Department of Pharmacology, Chungnam National University.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Neuroprotection by acetyl-11-keto-beta-Boswellic acid, in ischemic brain injury involves the Nrf2/HO-1 defense pathway</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Rep</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Scientific reports</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Sci Rep</style></full-title><abbr-1><style face="normal" font="default" size="100%">Scientific reports</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Sci Rep</style></full-title><abbr-1><style face="normal" font="default" size="100%">Scientific reports</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">7002</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><edition><style face="normal" font="default" size="100%">2014/11/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antioxidant Response Elements</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ drug therapy/genetics/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Hypoxia/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/cytology/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose/deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Heme Oxygenase-1/antagonists &amp; inhibitors/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">NF-E2-Related Factor 2/antagonists &amp; inhibitors/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/cytology/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen/metabolism/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Cell Culture</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ drug therapy/genetics/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Triterpenes/ pharmacology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 11</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2045-2322 (Electronic)&#xD;2045-2322 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25384416</style></accession-num><abstract><style face="normal" font="default" size="100%">Stroke is a complex disease involved oxidative stress-related pathways in its pathogenesis. The nuclear factor erythroid-2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) pathway has been considered a potential target for neuroprotection in stroke. Acetyl-11-Keto-beta-Boswellic Acid (AKBA) is an active triterpenoid compound from the extract of Boswellia serrate. The present study was to determine whether AKBA, a novel Nrf2 activator, can protect against cerebral ischemic injury. The stroke model was produced in Sprague-Dawley rats via middle cerebral artery occlusion. To model ischemia-like conditions in vitro, primary cultured cortical neurons were exposed to transient oxygen and glucose deprivation (OGD). Treatment of AKBA significantly reduced infarct volumes and apoptotic cells, and also increased neurologic scores by elevating the Nrf2 and HO-1 expression in brain tissues in middle cerebral artery occlusion (MCAO) rats at 48 hours post reperfusion. In primary cultured neurons, AKBA increased the Nrf2 and HO-1 expression, which provided protection against OGD-induced oxidative insult. Additionally, AKBA treatment increased Nrf2 binding activity to antioxidant-response elements (ARE). The protective effect of AKBA was attenuated by knockdown of Nrf2 or HO-1. In conclusion, these findings provide evidence that AKBA protects neurons against ischemic injury, and this neuroprotective effect involves the Nrf2/HO-1 pathway.</style></abstract><notes><style face="normal" font="default" size="100%">Ding, Yi&#xD;Chen, MinChun&#xD;Wang, Min&#xD;Wang, MingMing&#xD;Zhang, Tiejun&#xD;Park, Jongsun&#xD;Zhu, YanRong&#xD;Guo, Chao&#xD;Jia, YanYan&#xD;Li, YuWen&#xD;Wen, AiDong&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Sci Rep. 2014 Nov 11;4:7002. doi: 10.1038/srep07002.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4227012</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/srep07002</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>55</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">55</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Doeppner, T. R.</style></author><author><style face="normal" font="default" size="100%">Kaltwasser, B.</style></author><author><style face="normal" font="default" size="100%">Teli, M. K.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Mendoza, E. H.</style></author><author><style face="normal" font="default" size="100%">Kilic, E.</style></author><author><style face="normal" font="default" size="100%">Bahr, M.</style></author><author><style face="normal" font="default" size="100%">Hermann, D. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Duisburg-Essen Medical School, Department of Neurology, Essen, Germany; Istanbul Medipol University, Regenerative and Restorative Medical Research Center, Istanbul, Turkey. Electronic address: thorsten.doeppner@uk-essen.de.&#xD;University of Duisburg-Essen Medical School, Department of Neurology, Essen, Germany.&#xD;University of Duisburg-Essen Medical School, Department of Neurology, Essen, Germany; National Institute of Technology Calicut, Calicut, Kerala, India.&#xD;Istanbul Medipol University, Regenerative and Restorative Medical Research Center, Istanbul, Turkey.&#xD;University of Goettingen Medical School, Department of Neurology, Goettingen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Post-stroke transplantation of adult subventricular zone derived neural progenitor cells--A comprehensive analysis of cell delivery routes and their underlying mechanisms</style></title><secondary-title><style face="normal" font="default" size="100%">Exp Neurol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Experimental neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Exp Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Experimental neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Exp Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Experimental neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">45-56</style></pages><volume><style face="normal" font="default" size="100%">273</style></volume><edition><style face="normal" font="default" size="100%">2015/08/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, CD31/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/etiology/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Corpus Striatum/transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Functional Laterality</style></keyword><keyword><style face="normal" font="default" size="100%">Green Fluorescent Proteins/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Attack, Transient/complications/ surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Lateral Ventricles/ cytology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Matrix Metalloproteinase 9/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Microtubule-Associated Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Motor Activity</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle Strength</style></keyword><keyword><style face="normal" font="default" size="100%">Neural Stem Cells/ physiology/transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenesis/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuropeptides/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Psychomotor Performance</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery of Function/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Stem Cell Transplantation/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1090-2430 (Electronic)&#xD;0014-4886 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26253224</style></accession-num><abstract><style face="normal" font="default" size="100%">With neuroprotective approaches having failed until recently, current focus on experimental stroke research has switched towards manipulation of post-ischemic neuroregeneration. Transplantation of subventricular zone (SVZ) derived neural progenitor cells (NPCs) is a promising strategy for promotion of neurological recovery. Yet, fundamental questions including the optimal cell delivery route still have to be addressed. Consequently, male C57BL6 mice were exposed to transient focal cerebral ischemia and allowed to survive for as long as 84 days post-stroke. At 6h post-stroke, NPCs were grafted using six different cell delivery routes, i.e., intravenous, intraarterial, ipsilateral intrastriatal, contralateral intrastriatal, ipsilateral intraventricular and ipsilateral intracortical injection. Control mice received PBS only using the aforementioned delivery routes. Intralesional numbers of GFP(+) NPCs were high only after ipsilateral intrastriatal transplantation, whereas other injection paradigms only yielded comparatively small numbers of grafted cells. However, acute neuroprotection and improved functional outcome were observed after both systemic (i.e., intraarterial and intravenous) and ipsilateral intrastriatal transplantation only. Whereas systemic cell delivery induced acute and long-term neuroprotection, reduction of brain injury after ipsilateral intrastriatal cell grafting was only temporary, in line with the loss of transplanted NPCs in the brain. Both systemic and ipsilateral intrastriatal NPC delivery reduced microglial activation and leukocyte invasion, thus reducing free radical formation within the ischemic brain. On the contrary, only systemic NPC administration stabilized the blood-brain-barrier and reduced leukocytosis in the blood. Although intraarterial NPC transplantation was as effective as intravenous cell grafting, mortality of stroke mice was high using the intraarterial delivery route. Consequently, intravenous delivery of native NPCs in our experimental model is an attractive and effective strategy for stroke therapy that deserves further proof-of-concept studies.</style></abstract><notes><style face="normal" font="default" size="100%">Doeppner, Thorsten R&#xD;Kaltwasser, Britta&#xD;Teli, Mahesh K&#xD;Sanchez-Mendoza, Eduardo H&#xD;Kilic, Ertugrul&#xD;Bahr, Mathias&#xD;Hermann, Dirk M&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Exp Neurol. 2015 Nov;273:45-56. doi: 10.1016/j.expneurol.2015.07.023. Epub 2015 Aug 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0014488615300571/1-s2.0-S0014488615300571-main.pdf?_tid=de4f16d4-d7bd-11e6-961f-00000aacb35d&amp;acdnat=1484112296_02662c7c96f910ef04376ba274c7fd06</style></url></related-urls><pdf-urls><url>internal-pdf://1688319791/Doeppner-2015-Post-stroke transpla.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.expneurol.2015.07.023</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>367</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">367</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Doeppner, T. R.</style></author><author><style face="normal" font="default" size="100%">Mlynarczuk-Bialy, I.</style></author><author><style face="normal" font="default" size="100%">Kuckelkorn, U.</style></author><author><style face="normal" font="default" size="100%">Kaltwasser, B.</style></author><author><style face="normal" font="default" size="100%">Herz, J.</style></author><author><style face="normal" font="default" size="100%">Hasan, M. R.</style></author><author><style face="normal" font="default" size="100%">Hermann, D. M.</style></author><author><style face="normal" font="default" size="100%">Bahr, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, University of Duisburg-Essen Medical School, Essen, Germany. thorsten.doeppner@uk-essen.de</style></auth-address><titles><title><style face="normal" font="default" size="100%">The novel proteasome inhibitor BSc2118 protects against cerebral ischaemia through HIF1A accumulation and enhanced angioneurogenesis</style></title><secondary-title><style face="normal" font="default" size="100%">Brain</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain : a journal of neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain : a journal of neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Brain</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain : a journal of neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">3282-97</style></pages><volume><style face="normal" font="default" size="100%">135</style></volume><number><style face="normal" font="default" size="100%">Pt 11</style></number><edition><style face="normal" font="default" size="100%">2012/11/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Angiogenesis Inducing Agents/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Behavior, Animal/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ drug therapy/metabolism/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Butanes/administration &amp; dosage/antagonists &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">inhibitors/ pharmacology/therapeutic use/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Interactions</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Knockdown Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia-Inducible Factor 1, alpha Subunit/antagonists &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">inhibitors/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Matrix Metalloproteinase 9/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Microinjections</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenesis/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/administration &amp; dosage/ pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Oligopeptides/administration &amp; dosage/antagonists &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">inhibitors/ pharmacology/therapeutic use/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Proteasome Inhibitors/administration &amp; dosage/ pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Proteins/administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery of Function/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombolytic Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Tissue Plasminogen Activator/administration &amp; dosage/adverse effects/antagonists</style></keyword><keyword><style face="normal" font="default" size="100%">&amp; inhibitors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1460-2156 (Electronic)&#xD;0006-8950 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23169919</style></accession-num><abstract><style face="normal" font="default" size="100%">Only a minority of stroke patients receive thrombolytic therapy. Therefore, new therapeutic strategies focusing on neuroprotection are under review, among which, inhibition of the proteasome is attractive, as it affects multiple cellular pathways. As proteasome inhibitors like bortezomib have severe side effects, we applied the novel proteasome inhibitor BSc2118, which is putatively better tolerated, and analysed its therapeutic potential in a mouse model of cerebral ischaemia. Stroke was induced in male C57BL/6 mice using the intraluminal middle cerebral artery occlusion model. BSc2118 was intrastriatally injected 12 h post-stroke in mice that had received normal saline or recombinant tissue-plasminogen activator injections during early reperfusion. Brain injury, behavioural tests, western blotting, MMP9 zymography and analysis of angioneurogenesis were performed for up to 3 months post-stroke. Single injections of BSc2118 induced long-term neuroprotection, reduced functional impairment, stabilized blood-brain barrier through decreased MMP9 activity and enhanced angioneurogenesis when given no later than 12 h post-stroke. On the contrary, recombinant tissue-plasminogen activator enhanced brain injury, which was reversed by BSc2118. Protein expression of the transcription factor HIF1A was significantly increased in saline-treated and recombinant tissue-plasminogen activator-treated mice after BSc2118 application. In contrast, knock-down of HIF1A using small interfering RNA constructs or application of the HIF1A inhibitor YC1 (now known as RNA-binding motif, single-stranded-interacting protein 1 (RBMS1)) reversed BSc2118-induced neuroprotection. Noteworthy, loss of neuroprotection after combined treatment with BSc2118 and YC1 in recombinant tissue-plasminogen activator-treated animals was in the same order as in saline-treated mice, i.e. reduction of recombinant tissue-plasminogen activator toxicity through BSc2118 did not solely depend on HIF1A. Thus, the proteasome inhibitor BSc2118 is a promising new candidate for stroke therapy, which may in addition alleviate recombinant tissue-plasminogen activator-induced brain toxicity.</style></abstract><notes><style face="normal" font="default" size="100%">Doeppner, Thorsten R&#xD;Mlynarczuk-Bialy, Izabela&#xD;Kuckelkorn, Ulrike&#xD;Kaltwasser, Britta&#xD;Herz, Josephine&#xD;Hasan, Mohammad R&#xD;Hermann, Dirk M&#xD;Bahr, Mathias&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Brain. 2012 Nov;135(Pt 11):3282-97. doi: 10.1093/brain/aws269.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://brain.oxfordjournals.org/content/brain/135/11/3282.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2140593258/Doeppner-2012-The novel proteasome.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/brain/aws269</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>312</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">312</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dong, B.</style></author><author><style face="normal" font="default" size="100%">Cai, M.</style></author><author><style face="normal" font="default" size="100%">Fang, Z.</style></author><author><style face="normal" font="default" size="100%">Wei, H.</style></author><author><style face="normal" font="default" size="100%">Zhu, F.</style></author><author><style face="normal" font="default" size="100%">Li, G.</style></author><author><style face="normal" font="default" size="100%">Dong, H.</style></author><author><style face="normal" font="default" size="100%">Xiong, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Anesthesiology, Xijing Hospital, Fourth Military Medical University, Xi&apos;an, Shanxi 710032, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hemopexin induces neuroprotection in the rat subjected to focal cerebral ischemia</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">BMC neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMC Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">BMC neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">BMC Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">BMC neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">58</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><edition><style face="normal" font="default" size="100%">2013/06/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Glial Fibrillary Acidic Protein/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Hemopexin/metabolism/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ drug</style></keyword><keyword><style face="normal" font="default" size="100%">therapy/metabolism/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Injections, Intraventricular</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroglia/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurologic Examination</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/metabolism/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphopyruvate Hydratase/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/metabolism/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 10</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1471-2202 (Electronic)&#xD;1471-2202 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23758755</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The plasma protein hemopexin (HPX) exhibits the highest binding affinity to free heme. In vitro experiments and gene-knock out technique have suggested that HPX may have a neuroprotective effect. However, the expression of HPX in the brain was not well elucidated and its expression after cerebral ischemia-reperfusion injury was also poorly studied. Furthermore, no in vivo data were available on the effect of HPX given centrally on the prognosis of focal cerebral ischemia. RESULTS: In the present study, we systematically investigated expression of HPX in normal rat brain by immunofluorescent staining. The results showed that HPX was mainly expressed in vascular system and neurons, as well as in a small portion of astrocytes adjacent to the vessels in normal rat brain. Further, we determined the role of HPX in the process of focal cerebral ischemic injury and explored the effects of HPX treatment in a rat model of transient focal cerebral ischemia. After 2 h&apos; middle cerebral artery occlusion (MCAO) followed by 24 h&apos; reperfusion, the expression of HPX was increased in the neurons and astrocytes in the penumbra area, as demonstrated by immunohistochemistry and Western blot techniques. Intracerebroventricular injection of HPX at the onset of reperfusion dose-dependently reduced the infarct volumes and improved measurements of neurological function of the rat subjected to transient focal cerebral ischemia. The neuroprotective effects of HPX sustained for up to 7 days after experiments. CONCLUSIONS: Our study provides a new insight into the potential neuroprotective role of HPX as a contributing factor of endogenous protective mechanisms against focal cerebral ischemia injury, and HPX might be developed as a potential agent for treatment of ischemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Dong, Beibei&#xD;Cai, Min&#xD;Fang, Zongping&#xD;Wei, Haidong&#xD;Zhu, Fangyun&#xD;Li, Guochao&#xD;Dong, Hailong&#xD;Xiong, Lize&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;BMC Neurosci. 2013 Jun 10;14:58. doi: 10.1186/1471-2202-14-58.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/875/art%253A10.1186%252F1471-2202-14-58.pdf?originUrl=http%3A%2F%2Fbmcneurosci.biomedcentral.com%2Farticle%2F10.1186%2F1471-2202-14-58&amp;token2=exp=1484112420~acl=%2Fstatic%2Fpdf%2F875%2Fart%25253A10.1186%25252F1471-2202-14-58.pdf*~hmac=85a4b7e654260f443315965851362dd11ea35d0d932c78898a799e2ca0166798</style></url></related-urls><pdf-urls><url>internal-pdf://0869845913/Dong-2013-Hemopexin induces ne.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3694464</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/1471-2202-14-58</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>165</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">165</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dong, Y.</style></author><author><style face="normal" font="default" size="100%">Song, F.</style></author><author><style face="normal" font="default" size="100%">Ma, J.</style></author><author><style face="normal" font="default" size="100%">He, X.</style></author><author><style face="normal" font="default" size="100%">Amer, S.</style></author><author><style face="normal" font="default" size="100%">Gu, W.</style></author><author><style face="normal" font="default" size="100%">Tian, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310009, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Small-animal PET demonstrates brain metabolic change after using bevacizumab in a rat model of cerebral ischemic injury</style></title><secondary-title><style face="normal" font="default" size="100%">Neurosci Bull</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuroscience bulletin</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurosci Bull</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience bulletin</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurosci Bull</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience bulletin</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">838-44</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2014/09/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Angiogenesis Inhibitors/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Bevacizumab</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/diagnostic imaging/ drug effects/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorodeoxyglucose F18</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/diagnostic imaging/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Positron-Emission Tomography</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery of Function</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1995-8218 (Electronic)&#xD;1995-8218 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25260799</style></accession-num><abstract><style face="normal" font="default" size="100%">To evaluate the effect of bevacizumab on cerebral ischemia, we used 2-deoxy-2-(18)F-fluoro-D-glucose ((18)F-FDG) small-animal positron emission tomography (PET) in the middle cerebral artery occlusion (MCAO) rat model. After baseline neurologic function tests and PET studies, MCAO Sprague-Dawley rats received bevacizumab or normal saline (controls). Weekly PET imaging and neurologic function tests showed that the (18)F-FDG accumulation in the bevacizumab group was similar to that in the controls during the first 2 weeks, but lower than in controls at weeks 3 and 4. However, no difference was found in neurological scores between the groups. The number of von Willebrand factor-positive cells in the bevacizumab group was lower than that in controls. The expression of vascular endothelial growth factor was higher than in controls at week 4. These results suggested that bevacizumab does not influence functional recovery in this model of cerebral ischemia during a 4-week period, but inhibits vascular formation and metabolic recovery, which may be considered in cancer patients with a recent ischemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Dong, Ying&#xD;Song, Fahuan&#xD;Ma, Jianjuan&#xD;He, Xuexin&#xD;Amer, Said&#xD;Gu, Weizhong&#xD;Tian, Mei&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;China&#xD;Neurosci Bull. 2014 Oct;30(5):838-44. doi: 10.1007/s12264-014-1470-z. Epub 2014 Sep 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/855/art%253A10.1007%252Fs12264-014-1470-z.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12264-014-1470-z&amp;token2=exp=1484113320~acl=%2Fstatic%2Fpdf%2F855%2Fart%25253A10.1007%25252Fs12264-014-1470-z.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs12264-014-1470-z*~hmac=aff16d680d3549a15ec50551263d8131fa6a3d7d472153ed275760a81d131f29</style></url></related-urls><pdf-urls><url>internal-pdf://1111016677/Dong-2014-Small-animal PET dem.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12264-014-1470-z</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>100</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">100</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Drobyshevsky, A.</style></author><author><style face="normal" font="default" size="100%">Cotten, C. M.</style></author><author><style face="normal" font="default" size="100%">Shi, Z.</style></author><author><style face="normal" font="default" size="100%">Luo, K.</style></author><author><style face="normal" font="default" size="100%">Jiang, R.</style></author><author><style face="normal" font="default" size="100%">Derrick, M.</style></author><author><style face="normal" font="default" size="100%">Tracy, E. T.</style></author><author><style face="normal" font="default" size="100%">Gentry, T.</style></author><author><style face="normal" font="default" size="100%">Goldberg, R. N.</style></author><author><style face="normal" font="default" size="100%">Kurtzberg, J.</style></author><author><style face="normal" font="default" size="100%">Tan, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, NorthShore University HealthSystem, Evanston, Ill., USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Human Umbilical Cord Blood Cells Ameliorate Motor Deficits in Rabbits in a Cerebral Palsy Model</style></title><secondary-title><style face="normal" font="default" size="100%">Dev Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Developmental neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Dev Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Developmental neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Dev Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Developmental neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">349-62</style></pages><volume><style face="normal" font="default" size="100%">37</style></volume><number><style face="normal" font="default" size="100%">4-5</style></number><edition><style face="normal" font="default" size="100%">2015/03/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Behavior, Animal/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Palsy/etiology/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cord Blood Stem Cell Transplantation/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia-Ischemia, Brain/ complications</style></keyword><keyword><style face="normal" font="default" size="100%">Motor Activity/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Paracrine Communication</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Rabbits</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1421-9859 (Electronic)&#xD;0378-5866 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25791742</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebral palsy (CP) has a significant impact on both patients and society, but therapy is limited. Human umbilical cord blood cells (HUCBC), containing various stem and progenitor cells, have been used to treat various brain genetic conditions. In small animal experiments, HUCBC have improved outcomes after hypoxic-ischemic (HI) injury. Clinical trials using HUCBC are underway, testing feasibility, safety and efficacy for neonatal injury as well as CP. We tested HUCBC therapy in a validated rabbit model of CP after acute changes secondary to HI injury had subsided. Following uterine ischemia at 70% gestation, we infused HUCBC into newborn rabbit kits with either mild or severe neurobehavioral changes. Infusion of high-dose HUCBC (5 x 10(6) cells) dramatically altered the natural history of the injury, alleviating the abnormal phenotype including posture, righting reflex, locomotion, tone, and dystonia. Half the high dose showed lesser but still significant improvement. The swimming test, however, showed that joint function did not restore to naive control function in either group. Tracing HUCBC with either MRI biomarkers or PCR for human DNA found little penetration of HUCBC in the newborn brain in the immediate newborn period, suggesting that the beneficial effects were not due to cellular integration or direct proliferative effects but rather to paracrine signaling. This is the first study to show that HUCBC improve motor performance in a dose-dependent manner, perhaps by improving compensatory repair processes.</style></abstract><notes><style face="normal" font="default" size="100%">Drobyshevsky, Alexander&#xD;Cotten, C Michael&#xD;Shi, Zhongjie&#xD;Luo, Kehuan&#xD;Jiang, Rugang&#xD;Derrick, Matthew&#xD;Tracy, Elizabeth T&#xD;Gentry, Tracy&#xD;Goldberg, Ronald N&#xD;Kurtzberg, Joanne&#xD;Tan, Sidhartha&#xD;R01 NS051402/NS/NINDS NIH HHS/United States&#xD;R56 NS043285/NS/NINDS NIH HHS/United States&#xD;NS051402/NS/NINDS NIH HHS/United States&#xD;HD057307/HD/NICHD NIH HHS/United States&#xD;NS043285/NS/NINDS NIH HHS/United States&#xD;NS081936/NS/NINDS NIH HHS/United States&#xD;R01 NS043285/NS/NINDS NIH HHS/United States&#xD;K08 HD057307/HD/NICHD NIH HHS/United States&#xD;R01 NS081936/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Switzerland&#xD;Dev Neurosci. 2015;37(4-5):349-62. doi: 10.1159/000374107. Epub 2015 Mar 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.karger.com/Article/Pdf/374107</style></url></related-urls><pdf-urls><url>internal-pdf://3172852136/Drobyshevsky-2015-Human Umbilical Cord.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4908833</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms667795</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1159/000374107</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>260</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">260</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Duberstein, K. J.</style></author><author><style face="normal" font="default" size="100%">Platt, S. R.</style></author><author><style face="normal" font="default" size="100%">Holmes, S. P.</style></author><author><style face="normal" font="default" size="100%">Dove, C. R.</style></author><author><style face="normal" font="default" size="100%">Howerth, E. W.</style></author><author><style face="normal" font="default" size="100%">Kent, M.</style></author><author><style face="normal" font="default" size="100%">Stice, S. L.</style></author><author><style face="normal" font="default" size="100%">Hill, W. D.</style></author><author><style face="normal" font="default" size="100%">Hess, D. C.</style></author><author><style face="normal" font="default" size="100%">West, F. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Regenerative Bioscience Center, University of Georgia, Athens, GA 30602, USA; Department of Animal and Dairy Science, University of Georgia, Athens, GA 30602, USA.&#xD;Regenerative Bioscience Center, University of Georgia, Athens, GA 30602, USA; Department of Small Animal and Surgery, University of Georgia, Athens, GA 30602, USA.&#xD;Department of Veterinary Biosciences &amp; Diagnostic Imaging, University of Georgia, Athens, GA 30602, USA.&#xD;Department of Pathology, University of Georgia, Athens, GA 30602, USA.&#xD;Department of Small Animal and Surgery, University of Georgia, Athens, GA 30602, USA.&#xD;Department of Neurology, Georgia Regents University, Augusta, GA 30912, USA; Department of Cellular Biology &amp; Anatomy, Georgia Regents University, Augusta, GA 30912, USA.&#xD;Department of Neurology, Georgia Regents University, Augusta, GA 30912, USA.&#xD;Regenerative Bioscience Center, University of Georgia, Athens, GA 30602, USA; Department of Animal and Dairy Science, University of Georgia, Athens, GA 30602, USA. Electronic address: westf@uga.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Gait analysis in a pre- and post-ischemic stroke biomedical pig model</style></title><secondary-title><style face="normal" font="default" size="100%">Physiol Behav</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Physiology &amp; behavior</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Physiol Behav</style></full-title><abbr-1><style face="normal" font="default" size="100%">Physiology &amp; behavior</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Physiol Behav</style></full-title><abbr-1><style face="normal" font="default" size="100%">Physiology &amp; behavior</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">8-16</style></pages><volume><style face="normal" font="default" size="100%">125</style></volume><edition><style face="normal" font="default" size="100%">2013/11/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/complications/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Functional Laterality</style></keyword><keyword><style face="normal" font="default" size="100%">Gait/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Gait Disorders, Neurologic/complications/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/complications/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Swine/ physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 10</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1873-507X (Electronic)&#xD;0031-9384 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24286894</style></accession-num><abstract><style face="normal" font="default" size="100%">Severity of neural injury including stroke in human patients, as well as recovery from injury, can be assessed through changes in gait patterns of affected individuals. Similar quantification of motor function deficits has been measured in rodent animal models of such injuries. However, due to differences in fundamental structure of human and rodent brains, there is a need to develop a large animal model to facilitate treatment development for neurological conditions. Porcine brain structure is similar to that of humans, and therefore the pig may make a more clinically relevant animal model. The current study was undertaken to determine key gait characteristics in normal biomedical miniature pigs and dynamic changes that occur post-neural injury in a porcine middle cerebral artery (MCA) occlusion ischemic stroke model. Yucatan miniature pigs were trained to walk through a semi-circular track and were recorded with high speed cameras to detect changes in key gait parameters. Analysis of normal pigs showed overall symmetry in hindlimb swing and stance times, forelimb stance time, along with step length, step velocity, and maximum hoof height on both fore and hindlimbs. A subset of pigs were again recorded at 7, 5 and 3 days prior to MCA occlusion and then at 1, 3, 5, 7, 14 and 30 days following surgery. MRI analysis showed that MCA occlusion resulted in significant infarction. Gait analysis indicated that stroke resulted in notable asymmetries in both temporal and spatial variables. Pigs exhibited lower maximum front hoof height on the paretic side, as well as shorter swing time and longer stance time on the paretic hindlimb. These results support that gait analysis of stroke injury is a highly sensitive detection method for changes in gait parameters in pig.</style></abstract><notes><style face="normal" font="default" size="100%">Duberstein, Kylee Jo&#xD;Platt, Simon R&#xD;Holmes, Shannon P&#xD;Dove, C Robert&#xD;Howerth, Elizabeth W&#xD;Kent, Marc&#xD;Stice, Steven L&#xD;Hill, William D&#xD;Hess, David C&#xD;West, Franklin D&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Physiol Behav. 2014 Feb 10;125:8-16. doi: 10.1016/j.physbeh.2013.11.004. Epub 2013 Nov 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0031938413003879/1-s2.0-S0031938413003879-main.pdf?_tid=e8206d70-d7bd-11e6-a3e4-00000aab0f02&amp;acdnat=1484112312_94bf4f7b5e474d54f3ecc1af8eb7a386</style></url></related-urls><pdf-urls><url>internal-pdf://3727161224/Duberstein-2014-Gait analysis in a p.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.physbeh.2013.11.004</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>348</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">348</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dudhani, R. V.</style></author><author><style face="normal" font="default" size="100%">Kyle, M.</style></author><author><style face="normal" font="default" size="100%">Dedeo, C.</style></author><author><style face="normal" font="default" size="100%">Riordan, M.</style></author><author><style face="normal" font="default" size="100%">Deshaies, E. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, SUNY Upstate Medical University, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A low mortality rat model to assess delayed cerebral vasospasm after experimental subarachnoid hemorrhage</style></title><secondary-title><style face="normal" font="default" size="100%">J Vis Exp</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of visualized experiments : JoVE</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Vis Exp</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of visualized experiments : JoVE</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Vis Exp</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of visualized experiments : JoVE</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e4157</style></pages><number><style face="normal" font="default" size="100%">71</style></number><edition><style face="normal" font="default" size="100%">2013/01/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Subarachnoid Hemorrhage/ complications/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Vasospasm, Intracranial/ etiology/pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 17</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1940-087X (Electronic)&#xD;1940-087X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23353891</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To characterize and establish a reproducible model that demonstrates delayed cerebral vasospasm after aneurysmal subarachnoid hemorrhage (SAH) in rats, in order to identify the initiating events, pathophysiological changes and potential targets for treatment. METHODS: Twenty-eight male Sprague-Dawley rats (250 - 300 g) were arbitrarily assigned to one of two groups - SAH or saline control. Rat subarachnoid hemorrhage in the SAH group (n=15) was induced by double injection of autologous blood, 48 hr apart, into the cisterna magna. Similarly, normal saline (n=13) was injected into the cisterna magna of the saline control group. Rats were sacrificed on day five after the second blood injection and the brains were preserved for histological analysis. The degree of vasospasm was measured using sections of the basilar artery, by measuring the internal luminal cross sectional area using NIH Image-J software. The significance was tested using Tukey/Kramer&apos;s statistical analysis. RESULTS: After analysis of histological sections, basilar artery luminal cross sectional area were smaller in the SAH than in the saline group, consistent with cerebral vasospasm in the former group. In the SAH group, basilar artery internal area (.056 mum +/- 3) were significantly smaller from vasospasm five days after the second blood injection (seven days after the initial blood injection), compared to the saline control group with internal area (.069 +/- 3; p=0.004). There were no mortalities from cerebral vasospasm. CONCLUSION: The rat double SAH model induces a mild, survivable, basilar artery vasospasm that can be used to study the pathophysiological mechanisms of cerebral vasospasm in a small animal model. A low and acceptable mortality rate is a significant criterion to be satisfied for an ideal SAH animal model so that the mechanisms of vasospasm can be elucidated. Further modifications of the model can be made to adjust for increased severity of vasospasm and neurological exams.</style></abstract><notes><style face="normal" font="default" size="100%">Dudhani, Rahul V&#xD;Kyle, Michele&#xD;Dedeo, Christina&#xD;Riordan, Margaret&#xD;Deshaies, Eric M&#xD;Video-Audio Media&#xD;United States&#xD;J Vis Exp. 2013 Jan 17;(71):e4157. doi: 10.3791/4157.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.jove.com/pdf/4157/jove-protocol-4157-a-low-mortality-rat-model-to-assess-delayed-cerebral-vasospasm-after</style></url></related-urls><pdf-urls><url>internal-pdf://3017277659/Dudhani-2013-A low mortality rat.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3582678</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3791/4157</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>272</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">272</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dwyer, J. T.</style></author><author><style face="normal" font="default" size="100%">Peterson, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Office of Dietary Supplements, National Institutes of Health, Bethesda, MD (JTD); the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA (JTD); and the Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA (JP).</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tea and flavonoids: where we are, where to go next</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Clin Nutr</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The American journal of clinical nutrition</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Am J Clin Nutr</style></full-title><abbr-1><style face="normal" font="default" size="100%">The American journal of clinical nutrition</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Am J Clin Nutr</style></full-title><abbr-1><style face="normal" font="default" size="100%">The American journal of clinical nutrition</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1611S-1618S</style></pages><volume><style face="normal" font="default" size="100%">98</style></volume><number><style face="normal" font="default" size="100%">6 Suppl</style></number><edition><style face="normal" font="default" size="100%">2013/11/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Camellia sinensis/ chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Labeling</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence-Based Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Flavonoids/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Health</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Phytotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Extracts/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Tea/ chemistry</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1938-3207 (Electronic)&#xD;0002-9165 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24172298</style></accession-num><abstract><style face="normal" font="default" size="100%">There is a need to evaluate the evidence about the health effects of tea flavonoids and to provide valid, specific, and actionable tea consumption information to consumers. Emerging evidence suggests that the flavonoids in tea may be associated with beneficial health outcomes, whereas the benefits and risks of tea extracts and supplements are less well known. The next steps in developing tea science should include a focus on the most promising leads, such as reducing the risk of cardiovascular disease and stroke, rather than pursuing smaller, more diffuse studies of many different health outcomes. Future tea research should also include the use of common reference standards, better characterization of intervention products, and application of batteries of biomarkers of intakes and outcomes across studies, which will allow a common body of evidence to be developed. Mechanistic studies should determine which tea bioactive constituents have effects, whether they act alone or in combination, and how they influence health. Clinical studies should use well-characterized test products, better descriptions of baseline diets, and validated biomarkers of intake and disease risk reduction. There should be more attention to careful safety monitoring and adverse event reporting. Epidemiologic investigations should be of sufficient size and duration to detect small effects, involve populations most likely to benefit, use more complete tea exposure assessment, and include both intermediary markers of risk as well as morbidity and mortality outcomes. The construction of a strong foundation of scientific evidence on tea and health outcomes is essential for developing more specific and actionable messages on tea for consumers.</style></abstract><notes><style face="normal" font="default" size="100%">Dwyer, Johanna T&#xD;Peterson, Julia&#xD;United States&#xD;Am J Clin Nutr. 2013 Dec;98(6 Suppl):1611S-1618S. doi: 10.3945/ajcn.113.059584. Epub 2013 Oct 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ajcn.nutrition.org/content/91/5/1499S.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2600207476/Dwyer-2013-Tea and flavonoids_.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3831543</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3945/ajcn.113.059584</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>267</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">267</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eady, T. N.</style></author><author><style face="normal" font="default" size="100%">Khoutorova, L.</style></author><author><style face="normal" font="default" size="100%">Anzola, D. V.</style></author><author><style face="normal" font="default" size="100%">Hong, S. H.</style></author><author><style face="normal" font="default" size="100%">Obenaus, A.</style></author><author><style face="normal" font="default" size="100%">Mohd-Yusof, A.</style></author><author><style face="normal" font="default" size="100%">Bazan, N. G.</style></author><author><style face="normal" font="default" size="100%">Belayev, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Acute treatment with docosahexaenoic acid complexed to albumin reduces injury after a permanent focal cerebral ischemia in rats</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PloS one</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e77237</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2013/11/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Intravenous</style></keyword><keyword><style face="normal" font="default" size="100%">Albumins/administration &amp; dosage/metabolism/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Analysis of Variance</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Docosahexaenoic Acids/administration &amp; dosage/metabolism/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Histological Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ drug therapy/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203 (Electronic)&#xD;1932-6203 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24194876</style></accession-num><abstract><style face="normal" font="default" size="100%">Docosahexaenoic acid complexed to albumin (DHA-Alb) is highly neuroprotective after temporary middle cerebral artery occlusion (MCAo), but whether a similar effect occurs in permanent MCAo is unknown. Male Sprague-Dawley rats (270-330 g) underwent permanent MCAo. Neurological function was evaluated on days 1, 2 and 3 after MCAo. We studied six groups: DHA (5 mg/kg), Alb (0.63 or 1.25 g/kg), DHA-Alb (5 mg/kg+0.63 g/kg or 5 mg/kg+1.25 g/kg) or saline. Treatment was administered i.v. at 3 h after onset of stroke (n = 7-10 per group). Ex vivo imaging of brains and histopathology were conducted on day 3. Saline- and Alb-treated rats developed severe neurological deficits but were not significantly different from one another. In contrast, rats treated with low and moderate doses of DHA-Alb showed improved neurological score compared to corresponding Alb groups on days 2 and 3. Total, cortical and subcortical lesion volumes computed from T2 weighted images were reduced following a moderate dose of DHA-Alb (1.25 g/kg) by 25%, 22%, 34%, respectively, compared to the Alb group. The total corrected, cortical and subcortical infarct volumes were reduced by low (by 36-40%) and moderate doses (by 34-42%) of DHA-Alb treatment compared to the Alb groups. In conclusion, DHA-Alb therapy is highly neuroprotective in permanent MCAo in rats. This treatment can provide the basis for future therapeutics for patients suffering from ischemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Eady, Tiffany N&#xD;Khoutorova, Larissa&#xD;Anzola, Daniela V&#xD;Hong, Sung-Ha&#xD;Obenaus, Andre&#xD;Mohd-Yusof, Alena&#xD;Bazan, Nicolas G&#xD;Belayev, Ludmila&#xD;P30 GM103340/GM/NIGMS NIH HHS/United States&#xD;R01 NS065786/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;United States&#xD;PLoS One. 2013 Oct 23;8(10):e77237. doi: 10.1371/journal.pone.0077237. eCollection 2013.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0077237&amp;type=printable</style></url></related-urls><pdf-urls><url>internal-pdf://1452938955/Eady-2013-Acute treatment with.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3806755</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0077237</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>243</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">243</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Egea, J.</style></author><author><style face="normal" font="default" size="100%">Parada, E.</style></author><author><style face="normal" font="default" size="100%">Gomez-Rangel, V.</style></author><author><style face="normal" font="default" size="100%">Buendia, I.</style></author><author><style face="normal" font="default" size="100%">Negredo, P.</style></author><author><style face="normal" font="default" size="100%">Montell, E.</style></author><author><style face="normal" font="default" size="100%">Ruhi, R.</style></author><author><style face="normal" font="default" size="100%">Verges, J.</style></author><author><style face="normal" font="default" size="100%">Roda, J. M.</style></author><author><style face="normal" font="default" size="100%">Garcia, A. G.</style></author><author><style face="normal" font="default" size="100%">Lopez, M. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Instituto Teofilo Hernando and Department of Pharmacology, Universidad Autonoma de Madrid, Madrid, Spain; Instituto de Investigacion Sanitaria, Servicio de Farmacologia Clinica, Hospital Universitario de la Princesa, Universidad Autonoma de Madrid, Spain.&#xD;Instituto Teofilo Hernando and Department of Pharmacology, Universidad Autonoma de Madrid, Madrid, Spain.&#xD;Departamento de Anatomia, Histologia y Neurociencia, Universidad Autonoma de Madrid, Spain.&#xD;Pre-Clinical R&amp;D Area, Pharmascience Division, BIOIBERICA, S.A., Barcelona, Spain.&#xD;Pharmaceutical and Nutraceutical R&amp;D Department, BIOIBERICA, S.A., Barcelona, Spain.&#xD;Hospital La Paz Health Research Institute-IdiPAZ, Madrid, Spain.&#xD;Instituto Teofilo Hernando and Department of Pharmacology, Universidad Autonoma de Madrid, Madrid, Spain; Instituto de Investigacion Sanitaria, Servicio de Farmacologia Clinica, Hospital Universitario de la Princesa, Universidad Autonoma de Madrid, Spain. Electronic address: manuela.garcia@uam.es.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Small synthetic hyaluronan disaccharides afford neuroprotection in brain ischemia-related models</style></title><secondary-title><style face="normal" font="default" size="100%">Neuroscience</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">313-22</style></pages><volume><style face="normal" font="default" size="100%">265</style></volume><edition><style face="normal" font="default" size="100%">2014/02/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ drug therapy/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Survival/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Disaccharides/chemistry/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Hippocampus/ drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Hyaluronic Acid/chemistry/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative Stress/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reactive Oxygen Species/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 18</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1873-7544 (Electronic)&#xD;0306-4522 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24486437</style></accession-num><abstract><style face="normal" font="default" size="100%">High molecular weight (HMW) glycosaminoglycanes of the extracellular matrix have been implicated in tissue repair. The aim of this study was to evaluate if small synthetic hyaluronan disaccharides with different degrees of sulfation (methyl 2-acetamido-2-deoxy-3-O-(beta-d-glucopyranosyluronic acid)-O-sulfo-alpha-d-glucopyranoside, sodium salt (di0S), methyl 2-acetamido-2-deoxy-3-O-(beta-d-glucopyranosyluronic acid)-6-di-O-sulfo-alpha-d-glucopyranoside, disodium salt (di6S) and methyl 2-acetamido-2-deoxy-3-O-(beta-d-glucopyranosyluronic acid)-4,6-di-O-sulfo-alpha-d-glucopyranoside, trisodium salt (di4,6S)) could improve cell survival in in vitro and in vivo brain ischemia-related models. Rat hippocampal slices subjected to oxygen and glucose deprivation and a photothrombotic stroke model in mice were used. The three hyaluran disaccharides, incubated during the oxygen and glucose deprivation (15min) and re-oxygenation periods (120min), reduced cell death of hippocampal slices measured as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reduction, being the most potent di4,6S; in contrast, high molecular hyaluronan was ineffective. The protective actions of di4,6S against oxygen and glucose deprivation were related to activation of the PI3K/Akt survival pathway, reduction of p65 translocation to the nucleus, inhibition of inducible nitric oxide oxidase induction and reactive oxygen species production, and to an increase in glutathione levels. Administered 1h post-stroke, di4,6S reduced cerebral infarct size and improved motor activity in the beam walk test. In conclusion, di4,6S affords neuroprotection in in vitro and in vivo models of ischemic neuronal damage. Our results suggest that its neuroprotective effect could be exerted through its capability to reduce oxidative stress during ischemia. Its small molecular size makes it a more potential druggable drug to target the brain as compared with its HMW parent compound hyaluronan.</style></abstract><notes><style face="normal" font="default" size="100%">Egea, J&#xD;Parada, E&#xD;Gomez-Rangel, V&#xD;Buendia, I&#xD;Negredo, P&#xD;Montell, E&#xD;Ruhi, R&#xD;Verges, J&#xD;Roda, J M&#xD;Garcia, A G&#xD;Lopez, M G&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Neuroscience. 2014 Apr 18;265:313-22. doi: 10.1016/j.neuroscience.2014.01.032. Epub 2014 Jan 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0306452214000529/1-s2.0-S0306452214000529-main.pdf?_tid=f38e5406-d7bd-11e6-8f04-00000aab0f26&amp;acdnat=1484112331_2553c250dec7c7077bd0e9e518b01f1d</style></url></related-urls><pdf-urls><url>internal-pdf://1255227904/Egea-2014-Small synthetic hyal.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuroscience.2014.01.032</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>131</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">131</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ehret, F.</style></author><author><style face="normal" font="default" size="100%">Vogler, S.</style></author><author><style face="normal" font="default" size="100%">Pojar, S.</style></author><author><style face="normal" font="default" size="100%">Elliott, D. A.</style></author><author><style face="normal" font="default" size="100%">Bradke, F.</style></author><author><style face="normal" font="default" size="100%">Steiner, B.</style></author><author><style face="normal" font="default" size="100%">Kempermann, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">German Center for Neurodegenerative Diseases (DZNE) Dresden, 01307 Dresden, Germany.&#xD;CRTD - Center for Regenerative Therapies Dresden, Genomics of Regeneration, Technische Universitat Dresden, 01307 Dresden, Germany.&#xD;German Center for Neurodegenerative Diseases (DZNE) Bonn, 53175 Bonn, Germany.&#xD;Department of Neurology, Charite University Medicine Berlin, 10117 Berlin, Germany.&#xD;German Center for Neurodegenerative Diseases (DZNE) Dresden, 01307 Dresden, Germany; CRTD - Center for Regenerative Therapies Dresden, Genomics of Regeneration, Technische Universitat Dresden, 01307 Dresden, Germany. Electronic address: gerd.kempermann@dzne.de.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mouse model of CADASIL reveals novel insights into Notch3 function in adult hippocampal neurogenesis</style></title><secondary-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurobiology of disease</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurobiology of disease</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurobiology of disease</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">131-41</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><edition><style face="normal" font="default" size="100%">2015/01/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aging/pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">CADASIL/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Survival/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Arteries/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Hippocampus/blood supply/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation</style></keyword><keyword><style face="normal" font="default" size="100%">Neural Stem Cells/pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenesis/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Potassium Chloride/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Notch1/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Notch3</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Notch/genetics/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1095-953X (Electronic)&#xD;0969-9961 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25555543</style></accession-num><abstract><style face="normal" font="default" size="100%">Could impaired adult hippocampal neurogenesis be a relevant mechanism underlying CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy)? Memory symptoms in CADASIL, the most common hereditary form of vascular dementia, are usually thought to be primarily due to vascular degeneration and white matter lacunes. Since adult hippocampal neurogenesis, a process essential for the integration of new spatial memory occurs in a highly vascularized niche, we considered dysregulation of adult neurogenesis as a potential mechanism for the manifestation of dementia in CADASIL. Analysis in aged mice overexpressing Notch3 with a CADASIL mutation, revealed vascular deficits in arteries of the hippocampal fissure but not in the niche of the dentate gyrus. At 12 months of age, cell proliferation and survival of newborn neurons were reduced not only in CADASIL mice but also in transgenic controls overexpressing wild type Notch3. At 6 months, hippocampal neurogenesis was altered in CADASIL mice independent of overt vascular abnormalities in the fissure. Further, we identified Notch3 expression in hippocampal precursor cells and maturing neurons in vivo as well as in cultured hippocampal precursor cells. Overexpression and knockdown experiments showed that Notch3 signaling negatively regulated precursor cell proliferation. Notch3 overexpression also led to deficits in KCl-induced precursor cell activation. This suggests a cell-autonomous effect of Notch3 signaling in the regulation of precursor proliferation and activation and a loss-of-function effect in CADASIL. Consequently, besides vascular damage, aberrant precursor cell proliferation and differentiation due to Notch3 dysfunction might be an additional independent mechanism for the development of hippocampal dysfunction in CADASIL.</style></abstract><notes><style face="normal" font="default" size="100%">Ehret, Fanny&#xD;Vogler, Steffen&#xD;Pojar, Sherin&#xD;Elliott, David A&#xD;Bradke, Frank&#xD;Steiner, Barbara&#xD;Kempermann, Gerd&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Neurobiol Dis. 2015 Mar;75:131-41. doi: 10.1016/j.nbd.2014.12.018. Epub 2014 Dec 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0969996114003891/1-s2.0-S0969996114003891-main.pdf?_tid=0a1afba2-d7be-11e6-8a0f-00000aacb360&amp;acdnat=1484112369_a83ec6d520086cd11782fbd6291fb415</style></url></related-urls><pdf-urls><url>internal-pdf://3830304904/Ehret-2015-Mouse model of CADAS.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.nbd.2014.12.018</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>27</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">27</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eidizadeh, A.</style></author><author><style face="normal" font="default" size="100%">Khajehalichalehshtari, M.</style></author><author><style face="normal" font="default" size="100%">Freyer, D.</style></author><author><style face="normal" font="default" size="100%">Trendelenburg, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dept. of Neurology, University Medical Center Gottingen, Robert-Koch Str. 40, 37075, Gottingen, Germany.&#xD;Dept. of Neurology, Charite University Medical Center, Chariteplatz 1, 10117, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Assessment of the Therapeutic Potential of Metallothionein-II Application in Focal Cerebral Ischemia In Vitro and In Vivo</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PloS one</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e0144035</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2015/12/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">In Vitro Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation Mediators/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Metallothionein/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/pharmacology/ therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203 (Electronic)&#xD;1932-6203 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26658636</style></accession-num><abstract><style face="normal" font="default" size="100%">Metallothionein-II (MT-II) is an ubiquitously expressed small-molecular-weight protein and highly induced in various species and tissues upon stress, inflammation, and ischemia. MT-deficiency exacerbates ischemic injury in rodent stroke models in vitro and in vivo. However, there is conflicting data on the potential neuroprotective effect of exogenously applied metallothionein. Thus, we applied MT-II in an in vitro stroke model and intraperitoneally (i.p.) in two in vivo standard models of transient middle cerebral artery occlusion (MCAO) (a &apos;stringent&apos; one [60 min MCAO/48 h reperfusion] and a &apos;mild&apos; one [30 min MCAO/72 h reperfusion]), as well as i.v. together with recombinant tissue plasminogen activator (rtPA) to evaluate if exogenous MT-II-application protects against ischemic stroke. Whereas MT-II did not protect against 60 min MCAO, there was a significant reduction of direct and indirect infarct volumes and neurological deficit in the MT-II (i.p.) treated animals in the &apos;mild&apos; model at 3d after MCAO. Furthermore, MT-II also improved survival of the mice after MCAO, suppressed TNF-alpha mRNA induction in ischemic brain tissue, and protected primary neuronal cells against oxygen-glucose-deprivation in vitro. Thus, exogenous application of MT-II protects against ischemic injury in vitro and in vivo. However, long-term studies with different species and larger sampling sizes are required before a clinical use can be envisaged.</style></abstract><notes><style face="normal" font="default" size="100%">Eidizadeh, Abass&#xD;Khajehalichalehshtari, Manuel&#xD;Freyer, Dorette&#xD;Trendelenburg, George&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;PLoS One. 2015 Dec 14;10(12):e0144035. doi: 10.1371/journal.pone.0144035. eCollection 2015.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0144035&amp;type=printable</style></url></related-urls><pdf-urls><url>internal-pdf://1080110299/Eidizadeh-2015-Assessment of the Th.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4682799</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0144035</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>16</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">16</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ejaz, S.</style></author><author><style face="normal" font="default" size="100%">Emmrich, J. V.</style></author><author><style face="normal" font="default" size="100%">Sitnikov, S. L.</style></author><author><style face="normal" font="default" size="100%">Hong, Y. T.</style></author><author><style face="normal" font="default" size="100%">Sawiak, S. J.</style></author><author><style face="normal" font="default" size="100%">Fryer, T. D.</style></author><author><style face="normal" font="default" size="100%">Aigbirhio, F. I.</style></author><author><style face="normal" font="default" size="100%">Williamson, D. J.</style></author><author><style face="normal" font="default" size="100%">Baron, J. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">1 Stroke Research Group, Department of Clinical Neurosciences, University of Cambridge, UK.&#xD;1 Stroke Research Group, Department of Clinical Neurosciences, University of Cambridge, UK 2 Department of Neurology, Charite - Universitatsmedizin Berlin, Germany.&#xD;3 Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, UK.&#xD;1 Stroke Research Group, Department of Clinical Neurosciences, University of Cambridge, UK 4 INSERM U894, Hopital Sainte-Anne, Universite Paris Descartes, Sorbonne Paris Cite, Paris, France jean-claude.baron@inserm.fr.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Normobaric hyperoxia markedly reduces brain damage and sensorimotor deficits following brief focal ischaemia</style></title><secondary-title><style face="normal" font="default" size="100%">Brain</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain : a journal of neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain : a journal of neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Brain</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain : a journal of neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">751-64</style></pages><volume><style face="normal" font="default" size="100%">139</style></volume><number><style face="normal" font="default" size="100%">Pt 3</style></number><edition><style face="normal" font="default" size="100%">2016/01/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/metabolism/pathology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/metabolism/pathology/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Gait Disorders, Neurologic/metabolism/pathology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperbaric Oxygenation/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperoxia/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred SHR</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1460-2156 (Electronic)&#xD;0006-8950 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26767570</style></accession-num><abstract><style face="normal" font="default" size="100%">&apos;True&apos; transient ischaemic attacks are characterized not only clinically, but also radiologically by a lack of corresponding changes on magnetic resonance imaging. During a transient ischaemic attack it is assumed that the affected tissue is penumbral but rescued by early spontaneous reperfusion. There is, however, evidence from rodent studies that even brief focal ischaemia not resulting in tissue infarction can cause extensive selective neuronal loss associated with long-lasting sensorimotor impairment but normal magnetic resonance imaging. Selective neuronal loss might therefore contribute to the increasingly recognized cognitive impairment occurring in patients with transient ischaemic attacks. It is therefore relevant to consider treatments to reduce brain damage occurring with transient ischaemic attacks. As penumbral neurons are threatened by markedly constrained oxygen delivery, improving the latter by increasing arterial O2 content would seem logical. Despite only small increases in arterial O2 content, normobaric oxygen therapy experimentally induces significant increases in penumbral O2 pressure and by such may maintain the penumbra alive until reperfusion. Nevertheless, the effects of normobaric oxygen therapy on infarct volume in rodent models have been conflicting, although duration of occlusion appeared an important factor. Likewise, in the single randomized trial published to date, early-administered normobaric oxygen therapy had no significant effect on clinical outcome despite reduced diffusion-weighted imaging lesion growth during therapy. Here we tested the hypothesis that normobaric oxygen therapy prevents both selective neuronal loss and sensorimotor deficits in a rodent model mimicking true transient ischaemic attack. Normobaric oxygen therapy was applied from the onset and until completion of 15 min distal middle cerebral artery occlusion in spontaneously hypertensive rats, a strain representative of the transient ischaemic attack-prone population. Whereas normoxic controls showed normal magnetic resonance imaging but extensive cortical selective neuronal loss associated with microglial activation (present both at Day 14 in vivo and at Day 28 post-mortem) and marked and long-lasting sensorimotor deficits, normobaric oxygen therapy completely prevented sensorimotor deficit (P &lt; 0.02) and near-completely Day 28 selective neuronal loss (P &lt; 0.005). Microglial activation was substantially reduced at Day 14 and completely prevented at Day 28 (P = 0.002). Our findings document that normobaric oxygen therapy administered during ischaemia nearly completely prevents the neuronal death, microglial inflammation and sensorimotor impairment that characterize this rodent true transient ischaemic attack model. Taken together with the available literature, normobaric oxygen therapy appears a promising therapy for short-lasting ischaemia, and is attractive clinically as it could be started at home in at-risk patients or in the ambulance in subjects suspected of transient ischaemic attack/early stroke. It may also be a straightforward adjunct to reperfusion therapies, and help prevent subtle brain damage potentially contributing to long-term cognitive and sensorimotor impairment in at-risk populations.</style></abstract><notes><style face="normal" font="default" size="100%">Ejaz, Sohail&#xD;Emmrich, Julius V&#xD;Sitnikov, Sergey L&#xD;Hong, Young T&#xD;Sawiak, Stephen J&#xD;Fryer, Tim D&#xD;Aigbirhio, Franklin I&#xD;Williamson, David J&#xD;Baron, Jean-Claude&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Brain. 2016 Mar;139(Pt 3):751-64. doi: 10.1093/brain/awv391. Epub 2016 Jan 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://brain.oxfordjournals.org/content/brain/139/3/751.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2587314481/Ejaz-2016-Normobaric hyperoxia.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/brain/awv391</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>125</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">125</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ek, C. J.</style></author><author><style face="normal" font="default" size="100%">D&apos;Angelo, B.</style></author><author><style face="normal" font="default" size="100%">Baburamani, A. A.</style></author><author><style face="normal" font="default" size="100%">Lehner, C.</style></author><author><style face="normal" font="default" size="100%">Leverin, A. L.</style></author><author><style face="normal" font="default" size="100%">Smith, P. L.</style></author><author><style face="normal" font="default" size="100%">Nilsson, H.</style></author><author><style face="normal" font="default" size="100%">Svedin, P.</style></author><author><style face="normal" font="default" size="100%">Hagberg, H.</style></author><author><style face="normal" font="default" size="100%">Mallard, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Physiology, Institute for Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.&#xD;1] Department of Physiology, Institute for Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden [2] Centre for the Developing Brain, Division of Imaging Sciences and Biomedical Engineering, King&apos;s College London, King&apos;s Health Partners, St. Thomas&apos; Hospital, London, UK.&#xD;Spinal Cord Injury and Tissue Regeneration Center Salzburg, Department of Traumatology and Sport Injuries, Institute of Tendon and Bone Regeneration, Paracelsus Medical University, Salzburg, Austria; Austrian Cluster for Tissue Regeneration.&#xD;1] Centre for the Developing Brain, Division of Imaging Sciences and Biomedical Engineering, King&apos;s College London, King&apos;s Health Partners, St. Thomas&apos; Hospital, London, UK [2] Departments of Obstetrics and Gynecology, Institute for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Brain barrier properties and cerebral blood flow in neonatal mice exposed to cerebral hypoxia-ischemia</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">818-27</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2015/01/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Animals, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/embryology/metabolism/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Capillary Permeability</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Fetal Diseases/metabolism/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia-Ischemia, Brain/embryology/metabolism/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25627141</style></accession-num><abstract><style face="normal" font="default" size="100%">Insults to the developing brain often result in irreparable damage resulting in long-term deficits in motor and cognitive functions. The only treatment today for hypoxic-ischemic encephalopathy (HIE) in newborns is hypothermia, which has limited clinical benefit. We have studied changes to the blood-brain barriers (BBB) as well as regional cerebral blood flow (rCBF) in a neonatal model of HIE to further understand the underlying pathologic mechanisms. Nine-day old mice pups, brain roughly equivalent to the near-term human fetus, were subjected to hypoxia-ischemia. Hypoxia-ischemia increased BBB permeability to small and large molecules within hours after the insult, which normalized in the following days. The opening of the BBB was associated with changes to BBB protein expression whereas gene transcript levels were increased showing direct molecular damage to the BBB but also suggesting compensatory mechanisms. Brain pathology was closely related to reductions in rCBF during the hypoxia as well as the areas with compromised BBB showing that these are intimately linked. The transient opening of the BBB after the insult is likely to contribute to the pathology but at the same time provides an opportunity for therapeutics to better reach the infarcted areas in the brain.</style></abstract><notes><style face="normal" font="default" size="100%">Ek, C Joakim&#xD;D&apos;Angelo, Barbara&#xD;Baburamani, Ana A&#xD;Lehner, Christine&#xD;Leverin, Anna-Lena&#xD;Smith, Peter L P&#xD;Nilsson, Holger&#xD;Svedin, Pernilla&#xD;Hagberg, Henrik&#xD;Mallard, Carina&#xD;WT094823MA/Wellcome Trust/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Cereb Blood Flow Metab. 2015 May;35(5):818-27. doi: 10.1038/jcbfm.2014.255. Epub 2015 Jan 28.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4420855</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2014.255</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>62</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">62</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">El Amki, M.</style></author><author><style face="normal" font="default" size="100%">Clavier, T.</style></author><author><style face="normal" font="default" size="100%">Perzo, N.</style></author><author><style face="normal" font="default" size="100%">Bernard, R.</style></author><author><style face="normal" font="default" size="100%">Guichet, P. O.</style></author><author><style face="normal" font="default" size="100%">Castel, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institut National de la Sante et de la Recherche Medicale (Inserm), U982, Rouen University, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Mont-Saint-Aignan, France. Electronic address: mohamad.amki@gmail.com.&#xD;Institut National de la Sante et de la Recherche Medicale (Inserm), U982, Rouen University, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Mont-Saint-Aignan, France; Department of Anesthesiology and Critical Care, Rouen University Hospital, Rouen, France.&#xD;Institut National de la Sante et de la Recherche Medicale (Inserm), U982, Rouen University, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Mont-Saint-Aignan, France.&#xD;Department of Experimental Neurology, Charite University Medicine, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hypothalamic, thalamic and hippocampal lesions in the mouse MCAO model: Potential involvement of deep cerebral arteries?</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosci Methods</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neuroscience methods</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosci Methods</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroscience methods</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosci Methods</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroscience methods</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">80-5</style></pages><volume><style face="normal" font="default" size="100%">254</style></volume><edition><style face="normal" font="default" size="100%">2015/07/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Artery, Internal/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Arteries/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Hippocampus/blood supply/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Hypothalamus/blood supply/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/etiology/ pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Thalamus/blood supply/ pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 30</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-678X (Electronic)&#xD;0165-0270 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26213218</style></accession-num><abstract><style face="normal" font="default" size="100%">Intraluminal monofilament occlusion of the middle cerebral artery (MCAO) in mice is the most used rodent model to study the pathophysiology of stroke. However, this model often shows brain damage in regions not supplied by the MCA such as the hypothalamus, hippocampus and thalamus. Several studies have suggested some explanations on these localized infarcts. We aim to provide an alternative explanation which could allow each experimenter to better grasp the MCAO model. We propose that the MCA occlusion by the monofilament also occludes deep and small cerebral arteries arising directly from the internal carotid artery, proximally to the origin of MCA. Then, drawbacks and pitfalls of the MCAO model must be appreciated and the almost systematic risk of inducing lesions in some unwanted territories for neuroanatomical reasons, i.e. vascular connections between deep arteries and hypothalamic, thalamic and hippocampal areas in rodents has to be integrated.</style></abstract><notes><style face="normal" font="default" size="100%">El Amki, Mohamad&#xD;Clavier, Thomas&#xD;Perzo, Nicolas&#xD;Bernard, Rene&#xD;Guichet, Pierre-Olivier&#xD;Castel, Helene&#xD;Review&#xD;Netherlands&#xD;J Neurosci Methods. 2015 Oct 30;254:80-5. doi: 10.1016/j.jneumeth.2015.07.008. Epub 2015 Jul 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S016502701500254X/1-s2.0-S016502701500254X-main.pdf?_tid=fba91afe-d7bd-11e6-9a99-00000aacb360&amp;acdnat=1484112345_dcdae49d9c812965b6f11f7be8a8443c</style></url></related-urls><pdf-urls><url>internal-pdf://2647224790/El Amki-2015-Hypothalamic, thalam.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jneumeth.2015.07.008</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>340</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">340</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Engelter, S. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Neurorehabilitation Unit, Geriatric Competence Center, Felix Platter-Spital, Burgfelderstrasse 101, Basel, Switzerland. stefan.engelter@fps-basel.ch</style></auth-address><titles><title><style face="normal" font="default" size="100%">Safety in pharmacological enhancement of stroke rehabilitation</style></title><secondary-title><style face="normal" font="default" size="100%">Eur J Phys Rehabil Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">European journal of physical and rehabilitation medicine</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur J Phys Rehabil Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">European journal of physical and rehabilitation medicine</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Eur J Phys Rehabil Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">European journal of physical and rehabilitation medicine</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">261-7</style></pages><volume><style face="normal" font="default" size="100%">49</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2013/02/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Neuronal Plasticity/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Safety</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke Rehabilitation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1973-9095 (Electronic)&#xD;1973-9087 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23438654</style></accession-num><abstract><style face="normal" font="default" size="100%">Pharmacological enhancement of neurorehabilitation is based on the concept of neuroplasticity. Agents with probably unfavourable effects on recovery (e.g. classical antiepileptic drugs, butyrophenones) should be avoided. The findings of experimental studies in animal models, investigations in healthy subjects and the findings of neurophysiological studies indicate that there is scope for benefit from pharmacological enhancement in stroke rehabilitation in the clinical setting - in addition to rehabilitative therapies. Randomized controlled clinical trials have shown benefit of pharmacological enhancement in stroke rehabilitation for some agents. Nevertheless, the clinical evidence regarding benefits of this treatment approach is still considered weak for the following reason: First, the beneficial findings of some studies were not confirmed by others. Second, several studies were limited by small patient populations and narrow inclusion criteria. Third, there were concerns regarding safety of some agents (i.e., piracetam, and amphetamines). Dopaminergic agents, Selective Serotonin-Reuptake-Inhibitors (SSRI) and acetylcholinesterase-inhibitors are promising candidates. Their safety and efficacy should be further investigated; ideally in - sufficiently powered - large randomized controlled trials.</style></abstract><notes><style face="normal" font="default" size="100%">Engelter, S T&#xD;Review&#xD;Italy&#xD;Eur J Phys Rehabil Med. 2013 Apr;49(2):261-7. Epub 2013 Feb 26.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>223</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">223</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">English, J. D.</style></author><author><style face="normal" font="default" size="100%">Hetts, S. W.</style></author><author><style face="normal" font="default" size="100%">El-Ali, A.</style></author><author><style face="normal" font="default" size="100%">Kolli, P.</style></author><author><style face="normal" font="default" size="100%">Do, L.</style></author><author><style face="normal" font="default" size="100%">Wilson, M. W.</style></author><author><style face="normal" font="default" size="100%">Saeed, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departments of Radiology and Biomedical Imaging, San Francisco, California, USA Neurology University of California, San Francisco, California, USA.&#xD;Departments of Radiology and Biomedical Imaging, San Francisco, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A novel model of large vessel ischemic stroke in rabbits: microcatheter occlusion of the posterior cerebral artery</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurointerv Surg</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neurointerventional surgery</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurointerv Surg</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurointerventional surgery</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurointerv Surg</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurointerventional surgery</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">363-6</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2014/04/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Posterior Cerebral Artery/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Rabbits</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Access Devices/utilization</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1759-8486 (Electronic)&#xD;1759-8478 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24727130</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: The rabbit small clot embolic model for large vessel occlusion (LVO) is well established, yet has limitations. Blind introduction of autologous thrombus often fails to completely occlude a target vessel and, when successful, the precise timing of occlusion and revascularization is difficult to control. Studies of cellular biology and neuroimaging of acute reversible cerebral ischemia (ie, penumbral tissue) would benefit from a rabbit model in which LVO can be reliably induced, easily confirmed, and in which the time of occlusion and revascularization can be precisely controlled. METHODS: Transfemoral 1.5 F microcatheterization of the posterior cerebral artery (PCA) was performed in anesthetized rabbits (n=7) using fluoroscopic guidance. LVO with the wedged microcatheter was maintained for 30-210 min followed by reperfusion. Diffusion-weighted and T2 fluid-attenuated inversion recovery (FLAIR) MRI was performed 3 h after catheter removal on a 3 T scanner. Post-mortem histopathologic analysis of brain tissue was performed using triphenyltetrazolium chloride (TTC). RESULTS: Placing of the 1.5 F microcatheter tip in the PCA was successful in all seven animals. Infarct size on matched diffusion-weighted and TTC sections was strongly correlated (r(2)=0.86). Transient PCA occlusion of 30-60 min resulted in infarction of the ipsilateral hippocampus and thalamus, sparing the cortex, while more prolonged occlusion (180-210 min) resulted in cortical infarction as well. CONCLUSIONS: Image-guided microcatheter induction of PCA occlusion in rabbits can consistently produce time-dependent infarction of cortical and subcortical structures that is reliably detected by diffusion-weighted MRI, and thus may be a useful model for therapeutic studies in acute ischemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">English, Joey D&#xD;Hetts, Steven W&#xD;El-Ali, Alex&#xD;Kolli, Pallav&#xD;Do, Loi&#xD;Wilson, Mark W&#xD;Saeed, Maythem&#xD;UL1 RR024131/RR/NCRR NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Neurointerv Surg. 2015 May;7(5):363-6. doi: 10.1136/neurintsurg-2013-011063. Epub 2014 Apr 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://jnis.bmj.com/content/neurintsurg/7/5/363.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3717366845/English-2015-A novel model of lar.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/neurintsurg-2013-011063</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>163</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">163</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fanning, J. P.</style></author><author><style face="normal" font="default" size="100%">Wesley, A. J.</style></author><author><style face="normal" font="default" size="100%">Wong, A. A.</style></author><author><style face="normal" font="default" size="100%">Fraser, J. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From the School of Medicine (J.P.F., A.J.W., A.A.W., J.F.F.) and Critical Care Research Group (CCRG), The Prince Charles Hospital (J.P.F., J.F.F.), The University of Queensland, Brisbane, Queensland, Australia; Department of Medical Imaging (A.J.W.) and Adult Intensive Care Services (J.F.F.), The Prince Charles Hospital, Brisbane, Queensland, Australia; Department of Medical Imaging, Monash Medical Centre, Melbourne, Victoria, Australia (A.J.W.); and Department of Neurology, The Royal Brisbane and Women&apos;s Hospital, Brisbane, Queensland, Australia (A.A.W.). Jonathon_fanning@me.com.&#xD;From the School of Medicine (J.P.F., A.J.W., A.A.W., J.F.F.) and Critical Care Research Group (CCRG), The Prince Charles Hospital (J.P.F., J.F.F.), The University of Queensland, Brisbane, Queensland, Australia; Department of Medical Imaging (A.J.W.) and Adult Intensive Care Services (J.F.F.), The Prince Charles Hospital, Brisbane, Queensland, Australia; Department of Medical Imaging, Monash Medical Centre, Melbourne, Victoria, Australia (A.J.W.); and Department of Neurology, The Royal Brisbane and Women&apos;s Hospital, Brisbane, Queensland, Australia (A.A.W.).</style></auth-address><titles><title><style face="normal" font="default" size="100%">Emerging spectra of silent brain infarction</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">3461-71</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2014/10/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Infarction/ diagnosis/ metabolism/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative Stress/physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25293663</style></accession-num><notes><style face="normal" font="default" size="100%">Fanning, Jonathon P&#xD;Wesley, Allan J&#xD;Wong, Andrew A&#xD;Fraser, John F&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;United States&#xD;Stroke. 2014 Nov;45(11):3461-71. doi: 10.1161/STROKEAHA.114.005919. Epub 2014 Oct 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/45/11/3461.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0311792193/Fanning-2014-Emerging spectra of.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.114.005919</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>418</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">418</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Faraji, J.</style></author><author><style face="normal" font="default" size="100%">Kurio, K.</style></author><author><style face="normal" font="default" size="100%">Metz, G. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Canadian Centre for Behavioural Neuroscience, University of Lethbridge, Lethbridge, AB, Canada T1K 3M4. jamshid.faraji@uleth.ca</style></auth-address><titles><title><style face="normal" font="default" size="100%">Concurrent silent strokes impair motor function by limiting behavioral compensation</style></title><secondary-title><style face="normal" font="default" size="100%">Exp Neurol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Experimental neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Exp Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Experimental neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Exp Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Experimental neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">241-8</style></pages><volume><style face="normal" font="default" size="100%">236</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2012/05/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adaptation, Physiological/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Adaptation, Psychological/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Behavior, Animal/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Motor Skills Disorders/etiology/ physiopathology/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Long-Evans</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/complications/ physiopathology/psychology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1090-2430 (Electronic)&#xD;0014-4886 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22609330</style></accession-num><abstract><style face="normal" font="default" size="100%">Silent strokes occur more frequently than classic strokes; however, symptoms may go unreported in spite of lasting tissue damage. A silent stroke may indicate elevated susceptibility to recurrent stroke, which may eventually result in apparent and lasting impairments. Here we investigated if multiple silent strokes to the motor system challenge the compensatory capacity of the brain to cumulatively result in permanent functional deficits. Adult male rats with focal ischemia received single focal ischemic mini-lesions in the sensorimotor cortex (SMC) or the dorsolateral striatum (DLS), or multiple lesions affecting both SMC and DLS. The time course and outcome of motor compensation and recovery were determined by quantitative and qualitative assessment of skilled reaching and skilled walking. Rats with SMC or DLS lesion alone did not show behavioral deficits in either task. However, the combination of focal ischemic lesions in SMC and DLS perturbed skilled reaching accuracy and disrupted forelimb placement in the ladder rung walking task. These observations suggest that multiple focal infarcts, each resembling a silent stroke, gradually compromise the plastic capacity of the motor system to cause permanent motor deficits. Moreover, these findings support the notion that cortical and subcortical motor systems cooperate when adopting beneficial compensatory movement strategies.</style></abstract><notes><style face="normal" font="default" size="100%">Faraji, Jamshid&#xD;Kurio, Kristyn&#xD;Metz, Gerlinde A&#xD;Canadian Institutes of Health Research/Canada&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Exp Neurol. 2012 Aug;236(2):241-8. doi: 10.1016/j.expneurol.2012.05.007. Epub 2012 May 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0014488612002051/1-s2.0-S0014488612002051-main.pdf?_tid=fe8db7fc-d7bd-11e6-9c15-00000aab0f27&amp;acdnat=1484112350_f215a9b2519a7e67c521f19593371e9f</style></url></related-urls><pdf-urls><url>internal-pdf://0317099486/Faraji-2012-Concurrent silent st.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.expneurol.2012.05.007</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>477</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">477</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Faraji, J.</style></author><author><style face="normal" font="default" size="100%">Sutherland, R. J.</style></author><author><style face="normal" font="default" size="100%">Metz, G. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Canadian Centre for Behavioural Neuroscience, University of Lethbridge, Lethbridge, AB, Canada. jamshid.faraji@uleth.ca</style></auth-address><titles><title><style face="normal" font="default" size="100%">Stress precipitates functional deficits following striatal silent stroke: a synergistic effect</style></title><secondary-title><style face="normal" font="default" size="100%">Exp Neurol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Experimental neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Exp Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Experimental neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Exp Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Experimental neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">251-60</style></pages><volume><style face="normal" font="default" size="100%">232</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2011/09/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Corpus Striatum/ blood supply/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelin-1/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Microinjections</style></keyword><keyword><style face="normal" font="default" size="100%">Motor Activity/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Long-Evans</style></keyword><keyword><style face="normal" font="default" size="100%">Reaction Time/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Restraint, Physical</style></keyword><keyword><style face="normal" font="default" size="100%">Space Perception/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Stress, Physiological/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/chemically induced/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Vasoconstrictor Agents/toxicity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1090-2430 (Electronic)&#xD;0014-4886 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">21946265</style></accession-num><abstract><style face="normal" font="default" size="100%">Stress has been linked to structural and functional outcomes after stroke. Moreover, the striatum, both dorsal and ventral, is a vital regulator of stress perception and associated physiological responses. This study investigates potential synergistic effects of focal stroke in the ventrolateral striatum and restraint stress on motor and spatial performance. Adult male Long-Evans rats were pre-trained in a skilled reaching task and randomly assigned to sham, stroke-only, stress-only and stroke+stress conditions. Ventrolateral striatal focal ischemia was induced by endothelin-1 (ET-1) infusion. Rats in stress-only and stroke+stress groups received 21 days of mild restraint stress after stroke. All rats were tested in the skilled reaching task and the ziggurat task (ZT) for post-stroke motor and spatial performance. There was no effect of ventrolateral striatal ischemia or stress alone on motor and spatial performance. Notably, stroke and stress interacted synergistically to reduce reaching success and to disrupt qualitative aspects of movement performance in the absence of histological differences in lesion size. Thus, stress can precipitate behavioural deficits after focal ischemia even in the absence of significant functional deficits on its own. These results emphasize the importance of prevention programmes to control post-stroke levels of stress in clinical populations.</style></abstract><notes><style face="normal" font="default" size="100%">Faraji, Jamshid&#xD;Sutherland, Robert J&#xD;Metz, Gerlinde A&#xD;Canadian Institutes of Health Research/Canada&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Exp Neurol. 2011 Dec;232(2):251-60. doi: 10.1016/j.expneurol.2011.09.014. Epub 2011 Sep 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0014488611003220/1-s2.0-S0014488611003220-main.pdf?_tid=038aae0e-d7be-11e6-9074-00000aab0f26&amp;acdnat=1484112358_226878e059eb583283c874422067ecfa</style></url></related-urls><pdf-urls><url>internal-pdf://2988485110/Faraji-2011-Stress precipitates.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.expneurol.2011.09.014</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>9</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">9</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Feinberg, M. W.</style></author><author><style face="normal" font="default" size="100%">Moore, K. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From the Cardiovascular Division, Department of Medicine, Brigham and Women&apos;s Hospital, Harvard Medical School, Boston, MA (M.W.F.); and Departments of Medicine and Cell Biology, Leon H Charney Division of Cardiology, New York University Medical Center (K.J.M.). mfeinberg@partners.org kathryn.moore@nyumc.org.&#xD;From the Cardiovascular Division, Department of Medicine, Brigham and Women&apos;s Hospital, Harvard Medical School, Boston, MA (M.W.F.); and Departments of Medicine and Cell Biology, Leon H Charney Division of Cardiology, New York University Medical Center (K.J.M.).</style></auth-address><titles><title><style face="normal" font="default" size="100%">MicroRNA Regulation of Atherosclerosis</style></title><secondary-title><style face="normal" font="default" size="100%">Circ Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Circulation research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Circ Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Circulation research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Circ Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Circulation research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">703-20</style></pages><volume><style face="normal" font="default" size="100%">118</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2016/02/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arteries/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Atherosclerosis/diagnosis/genetics/ metabolism/pathology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Coronary Artery Disease/diagnosis/genetics/ metabolism/pathology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Markers</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Testing</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Therapy/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lipoproteins/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">MicroRNAs/genetics/ metabolism/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Plaque, Atherosclerotic</style></keyword><keyword><style face="normal" font="default" size="100%">Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 19</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4571 (Electronic)&#xD;0009-7330 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26892968</style></accession-num><abstract><style face="normal" font="default" size="100%">Atherosclerosis and its attendant clinical complications, such as myocardial infarction, stroke, and peripheral artery disease, are the leading cause of morbidity and mortality in Western societies. In response to biochemical and biomechanical stimuli, atherosclerotic lesion formation occurs from the participation of a range of cell types, inflammatory mediators, and shear stress. Over the past decade, microRNAs (miRNAs) have emerged as evolutionarily conserved, noncoding small RNAs that serve as important regulators and fine-tuners of a range of pathophysiological cellular effects and molecular signaling pathways involved in atherosclerosis. Accumulating studies reveal the importance of miRNAs in regulating key signaling and lipid homeostasis pathways that alter the balance of atherosclerotic plaque progression and regression. In this review, we highlight current paradigms of miRNA-mediated effects in atherosclerosis progression and regression. We provide an update on the potential use of miRNAs diagnostically for detecting increasing severity of coronary disease and clinical events. Finally, we provide a perspective on therapeutic opportunities and challenges for miRNA delivery in the field.</style></abstract><notes><style face="normal" font="default" size="100%">Feinberg, Mark W&#xD;Moore, Kathryn J&#xD;HL115141/HL/NHLBI NIH HHS/United States&#xD;R01 HL119047/HL/NHLBI NIH HHS/United States&#xD;HL117994/HL/NHLBI NIH HHS/United States&#xD;R01 HL108182/HL/NHLBI NIH HHS/United States&#xD;GM115605/GM/NIGMS NIH HHS/United States&#xD;HL108182/HL/NHLBI NIH HHS/United States&#xD;R01 HL115141/HL/NHLBI NIH HHS/United States&#xD;R01 GM115605/GM/NIGMS NIH HHS/United States&#xD;R01 HL117994/HL/NHLBI NIH HHS/United States&#xD;HL119047/HL/NHLBI NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;United States&#xD;Circ Res. 2016 Feb 19;118(4):703-20. doi: 10.1161/CIRCRESAHA.115.306300.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://circres.ahajournals.org/content/circresaha/118/4/703.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2512306056/Feinberg-2016-MicroRNA Regulation.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4762069</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms753671</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/circresaha.115.306300</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>40</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">40</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Feng, L.</style></author><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Ding, R.</style></author><author><style face="normal" font="default" size="100%">Fu, Z.</style></author><author><style face="normal" font="default" size="100%">Yang, S.</style></author><author><style face="normal" font="default" size="100%">Deng, X.</style></author><author><style face="normal" font="default" size="100%">Zeng, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, China. doctor_fengliang@163.com.&#xD;The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, China. yizhao_chen@hotmail.com.&#xD;Department of Neurosurgery, Jingmen No. 1 People&apos;s Hospital, Jingmen, 448000, Hubei, China. rui_ding@hotmail.com.&#xD;Department of Neurosurgery, The Fifth Affiliated Hospital of Southern Medical University, Guangzhou, 510900, China. 2474030376@qq.com.&#xD;Department of Neurosurgery, Gaoqing Campus of Central Hospital of Zibo, Gaoqing People&apos;s Hospital, Gaoqing, Zibo, 256300, Shandong, China. 343039756@qq.com.&#xD;Department of Neurosurgery, 999 Brain Hospital, Jinan University, Guangzhou, 510510, Guangdong, China. 1476494570@qq.com.&#xD;The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, China. 2405428@qq.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">P2X7R blockade prevents NLRP3 inflammasome activation and brain injury in a rat model of intracerebral hemorrhage: involvement of peroxynitrite</style></title><secondary-title><style face="normal" font="default" size="100%">J Neuroinflammation</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neuroinflammation</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neuroinflammation</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroinflammation</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neuroinflammation</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroinflammation</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">190</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><edition><style face="normal" font="default" size="100%">2015/10/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis Regulatory Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/drug therapy/ etiology/pathology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Carrier Proteins/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Caspase 1/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/ complications</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Membrane Glycoproteins/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">NADPH Oxidase/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">NLR Family, Pyrin Domain-Containing 3 Protein</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide Synthase Type II/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Peroxidase/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Peroxynitrous Acid/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Quaternary Ammonium Compounds/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Purinergic P2X7/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation/drug effects/physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 17</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1742-2094 (Electronic)&#xD;1742-2094 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26475134</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The NLR family, pyrin domain-containing 3 (NLRP3) inflammasome plays a key role in intracerebral hemorrhage (ICH)-induced inflammatory injury, and the purinergic 2X7 receptor (P2X7R) is upstream of NLRP3 activation. This study aimed to investigate how P2X7R functions in ICH-induced inflammatory injury and how the receptor interacts with the NLRP3 inflammasome. METHODS: Rats were treated with P2X7R small interfering RNA (siRNA) 24 h before undergoing collagenase-induced ICH. A selective P2X7R inhibitor (blue brilliant G, BBG) or a peroxynitrite (ONOO(-)) decomposition catalyst (5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron(III) [FeTPPS]) was injected 30 min after ICH. Brain water content, hemorrhagic lesion volume, and neurological deficits were evaluated, and western blot, immunofluorescence, and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) were carried out. RESULTS: Striatal P2X7R and NLRP3 inflammasomes were activated after ICH. Gene silencing of P2X7R suppressed NLRP3 inflammasome activation and interleukin (IL)-1beta/IL-18 release and significantly ameliorated brain edema and neurological deficits. Additionally, enhanced NADPH oxidase 2 (NOX2, gp91(phox)) and inducible nitric oxide synthase (iNOS), as well as their cytotoxic product (ONOO(-)) were markedly attenuated by BBG treatment following ICH. This was accompanied by downregulations of the inflammasome components, IL-1beta/IL-18 and myeloperoxidase (MPO, a neutrophil marker). Most importantly, inflammasome activation and IL-1beta/IL-18 release were significantly inhibited by ONOO(-) decomposition with FeTPPS. CONCLUSIONS: Our findings implicate that P2X7R exacerbated inflammatory progression and brain damage in ICH rats possibly via NLRP3 inflammasome-dependent IL-1beta/IL-18 release and neutrophil infiltration. ONOO(-), a potential downstream signaling molecule of P2X7R, may play a critical role in triggering NLRP3 inflammasome activation.</style></abstract><notes><style face="normal" font="default" size="100%">Feng, Liang&#xD;Chen, Yizhao&#xD;Ding, Rui&#xD;Fu, Zhenghao&#xD;Yang, Shuo&#xD;Deng, Xinqing&#xD;Zeng, Jun&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Neuroinflammation. 2015 Oct 17;12:190. doi: 10.1186/s12974-015-0409-2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/698/art%253A10.1186%252Fs12974-015-0409-2.pdf?originUrl=http%3A%2F%2Fjneuroinflammation.biomedcentral.com%2Farticle%2F10.1186%2Fs12974-015-0409-2&amp;token2=exp=1484112482~acl=%2Fstatic%2Fpdf%2F698%2Fart%25253A10.1186%25252Fs12974-015-0409-2.pdf*~hmac=3d82ea99be8a8ba72ad4bda7b3c6f883f33f18067dbfed1d3d7ab3c4b347ac55</style></url></related-urls><pdf-urls><url>internal-pdf://3264066376/Feng-2015-P2X7R blockade preve.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4609067</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12974-015-0409-2</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>403</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">403</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fernandez-Lopez, D.</style></author><author><style face="normal" font="default" size="100%">Faustino, J.</style></author><author><style face="normal" font="default" size="100%">Daneman, R.</style></author><author><style face="normal" font="default" size="100%">Zhou, L.</style></author><author><style face="normal" font="default" size="100%">Lee, S. Y.</style></author><author><style face="normal" font="default" size="100%">Derugin, N.</style></author><author><style face="normal" font="default" size="100%">Wendland, M. F.</style></author><author><style face="normal" font="default" size="100%">Vexler, Z. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, University of California San Francisco, San Francisco, California 94143-0633, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Blood-brain barrier permeability is increased after acute adult stroke but not neonatal stroke in the rat</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">9588-600</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">28</style></number><edition><style face="normal" font="default" size="100%">2012/07/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Animals, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/diagnostic imaging/growth &amp; development/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/growth &amp; development/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Capillary Permeability/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Collagen/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Dextrans/pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelial Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Evans Blue</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorescent Dyes</style></keyword><keyword><style face="normal" font="default" size="100%">Functional Laterality</style></keyword><keyword><style face="normal" font="default" size="100%">Gadolinium DTPA</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Image Processing, Computer-Assisted</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/diagnostic imaging/ pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Lectins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Angiography</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Membrane Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Radiography</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor Protein-Tyrosine Kinases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion</style></keyword><keyword><style face="normal" font="default" size="100%">Serum Albumin, Bovine</style></keyword><keyword><style face="normal" font="default" size="100%">Statistics, Nonparametric</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 11</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1529-2401 (Electronic)&#xD;0270-6474 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22787045</style></accession-num><abstract><style face="normal" font="default" size="100%">The immaturity of the CNS at birth greatly affects injury after stroke but the contribution of the blood-brain barrier (BBB) to the differential response to stroke in adults and neonates is poorly understood. We asked whether the structure and function of the BBB is disrupted differently in neonatal and adult rats by transient middle cerebral artery occlusion. In adult rats, albumin leakage into injured regions was markedly increased during 2-24 h reperfusion but leakage remained low in the neonates. Functional assays employing intravascular tracers in the neonates showed that BBB permeability to both large (70 kDa dextran) and small (3 kDa dextran), gadolinium (III)-diethyltriaminepentaacetic acid tracers remained largely undisturbed 24 h after reperfusion. The profoundly different functional integrity of the BBB was associated with the largely nonoverlapping patterns of regulated genes in endothelial cells purified from injured and uninjured adult and neonatal brain at 24 h (endothelial transcriptome, 31,042 total probe sets). Within significantly regulated 1266 probe sets in injured adults and 361 probe sets in neonates, changes in the gene expression of the basal lamina components, adhesion molecules, the tight junction protein occludin, and matrix metalloproteinase-9 were among the key differences. The protein expression of collagen-IV, laminin, claudin-5, occludin, and zonula occludens protein 1 was also better preserved in neonatal rats. Neutrophil infiltration remained low in acutely injured neonates but neutralization of cytokine-induced neutrophil chemoattractant-1 in the systemic circulation enhanced neutrophil infiltration, BBB permeability, and injury. The markedly more integrant BBB in neonatal brain than in adult brain after acute stroke may have major implications for the treatment of neonatal stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Fernandez-Lopez, David&#xD;Faustino, Joel&#xD;Daneman, Richard&#xD;Zhou, Lu&#xD;Lee, Sarah Y&#xD;Derugin, Nikita&#xD;Wendland, Michael F&#xD;Vexler, Zinaida S&#xD;R01 NS44025/NS/NINDS NIH HHS/United States&#xD;R01 NS055915/NS/NINDS NIH HHS/United States&#xD;R01 NS045621/NS/NINDS NIH HHS/United States&#xD;R01 NS044025/NS/NINDS NIH HHS/United States&#xD;P50 NS035902/NS/NINDS NIH HHS/United States&#xD;R01 NS55915/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Neurosci. 2012 Jul 11;32(28):9588-600. doi: 10.1523/JNEUROSCI.5977-11.2012.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.jneurosci.org/content/jneuro/32/28/9588.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3404988854/Fernandez-Lopez-2012-Blood-brain barrier.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3539825</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms393504</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1523/jneurosci.5977-11.2012</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>422</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">422</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Finsterer, J.</style></author><author><style face="normal" font="default" size="100%">Mahjoub, S. Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Danube University Krems, Krems, Postfach 20, 1180 Vienna, Austria. fipaps@yahoo.de</style></auth-address><titles><title><style face="normal" font="default" size="100%">Primary mitochondrial arteriopathy</style></title><secondary-title><style face="normal" font="default" size="100%">Nutr Metab Cardiovasc Dis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Nutrition, metabolism, and cardiovascular diseases : NMCD</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nutr Metab Cardiovasc Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Nutrition, metabolism, and cardiovascular diseases : NMCD</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Nutr Metab Cardiovasc Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Nutrition, metabolism, and cardiovascular diseases : NMCD</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">393-9</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2012/04/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arteries/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Arteries/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Microvessels/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Mitochondrial Diseases/ pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle, Skeletal/blood supply/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Retinal Artery/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Diseases/ etiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1590-3729 (Electronic)&#xD;0939-4753 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22520486</style></accession-num><abstract><style face="normal" font="default" size="100%">AIM: Whether arteries are affected in mitochondrial disorders (MIDs) was under debate for years but meanwhile there are strong indications that large and small arteries are primarily or secondarily affected in MIDs. DATA SYNTHESIS: When reviewing the literature for appropriate studies it turned out that vascular involvement in MIDs includes primary or secondary micro- or macroangiopathy of the cerebral, cervical, and retinal arteries, the aorta, the iliac arteries, the brachial arteries, or the muscular arteries. Arteriopathy in MIDs manifests as atherosclerosis, stenosis, occlusion, dissection, ectasia, aneurysm formation, or arteriovenous malformation. Direct evidence for primary cerebral microangiopathy comes from histological studies and indirect evidence from imaging and perfusion studies of the brain. Microangiopathy of the retina is highly prevalent in Leber&apos;s hereditary optic neuropathy. Macroangiopathy of the carotid arteries may be complicated by stroke. Arteriopathy of the aorta may result in ectasia, aneurysm formation, or even rupture. Further evidence for arteriopathy in MIDs comes from the frequent association of migraine with MIDs and the occurrence of premature atherosclerosis in MID patients without classical risk factors. CONCLUSIONS: Mitochondrial arteriopathy most frequently concerns the cerebral arteries and may result from the underlying metabolic defect or secondary from associated vascular risk factors. Vascular involvement in MIDs has a strong impact on the prognosis and outcome of these patients.</style></abstract><notes><style face="normal" font="default" size="100%">Finsterer, J&#xD;Mahjoub, S Zarrouk&#xD;Review&#xD;Netherlands&#xD;Nutr Metab Cardiovasc Dis. 2012 May;22(5):393-9. doi: 10.1016/j.numecd.2012.01.002.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0939475312000221/1-s2.0-S0939475312000221-main.pdf?_tid=0d5b3016-d7be-11e6-8a7c-00000aab0f01&amp;acdnat=1484112375_6dfc18220b610939dacc848f495518f3</style></url></related-urls><pdf-urls><url>internal-pdf://3965118431/Finsterer-2012-Primary mitochondria.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.numecd.2012.01.002</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>382</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">382</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fleg, J. L.</style></author><author><style face="normal" font="default" size="100%">Stone, G. W.</style></author><author><style face="normal" font="default" size="100%">Fayad, Z. A.</style></author><author><style face="normal" font="default" size="100%">Granada, J. F.</style></author><author><style face="normal" font="default" size="100%">Hatsukami, T. S.</style></author><author><style face="normal" font="default" size="100%">Kolodgie, F. D.</style></author><author><style face="normal" font="default" size="100%">Ohayon, J.</style></author><author><style face="normal" font="default" size="100%">Pettigrew, R.</style></author><author><style face="normal" font="default" size="100%">Sabatine, M. S.</style></author><author><style face="normal" font="default" size="100%">Tearney, G. J.</style></author><author><style face="normal" font="default" size="100%">Waxman, S.</style></author><author><style face="normal" font="default" size="100%">Domanski, M. J.</style></author><author><style face="normal" font="default" size="100%">Srinivas, P. R.</style></author><author><style face="normal" font="default" size="100%">Narula, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, Maryland 20892, USA. flegj@nhlbi.nih.gov</style></auth-address><titles><title><style face="normal" font="default" size="100%">Detection of high-risk atherosclerotic plaque: report of the NHLBI Working Group on current status and future directions</style></title><secondary-title><style face="normal" font="default" size="100%">JACC Cardiovasc Imaging</style></secondary-title><alt-title><style face="normal" font="default" size="100%">JACC. Cardiovascular imaging</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">JACC Cardiovasc Imaging</style></full-title><abbr-1><style face="normal" font="default" size="100%">JACC. Cardiovascular imaging</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">JACC Cardiovasc Imaging</style></full-title><abbr-1><style face="normal" font="default" size="100%">JACC. Cardiovascular imaging</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">941-55</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2012/09/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Artery Diseases/complications/ diagnosis/mortality/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Coronary Artery Disease/complications/ diagnosis/mortality/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Coronary Vessels/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnostic Imaging/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Embolism/etiology/mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Testing</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Infarction/etiology/mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Plaque, Atherosclerotic</style></keyword><keyword><style face="normal" font="default" size="100%">Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Rupture, Spontaneous</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/etiology/mortality</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1876-7591 (Electronic)&#xD;1876-7591 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22974808</style></accession-num><abstract><style face="normal" font="default" size="100%">The leading cause of major morbidity and mortality in most countries around the world is atherosclerotic cardiovascular disease, most commonly caused by thrombotic occlusion of a high-risk coronary plaque resulting in myocardial infarction or cardiac death, or embolization from a high-risk carotid plaque resulting in stroke. The lesions prone to result in such clinical events are termed vulnerable or high-risk plaques, and their identification may lead to the development of pharmacological and mechanical intervention strategies to prevent such events. Autopsy studies from patients dying of acute myocardial infarction or sudden death have shown that such events typically arise from specific types of atherosclerotic plaques, most commonly the thin-cap fibroatheroma. However, the search in human beings for vulnerable plaques before their becoming symptomatic has been elusive. Recently, the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) study demonstrated that coronary plaques that are likely to cause future cardiac events, regardless of angiographic severity, are characterized by large plaque burden and small lumen area and/or are thin-cap fibroatheromas verified by radiofrequency intravascular ultrasound imaging. This study opened the door to identifying additional invasive and noninvasive imaging modalities that may improve detection of high-risk atherosclerotic lesions and patients. Beyond classic risk factors, novel biomarkers and genetic profiling may identify those patients in whom noninvasive imaging for vulnerable plaque screening, followed by invasive imaging for risk confirmation is warranted, and in whom future pharmacological and/or device-based focal or regional therapies may be applied to improve long-term prognosis.</style></abstract><notes><style face="normal" font="default" size="100%">Fleg, Jerome L&#xD;Stone, Gregg W&#xD;Fayad, Zahi A&#xD;Granada, Juan F&#xD;Hatsukami, Thomas S&#xD;Kolodgie, Frank D&#xD;Ohayon, Jacques&#xD;Pettigrew, Roderic&#xD;Sabatine, Marc S&#xD;Tearney, Guillermo J&#xD;Waxman, Sergio&#xD;Domanski, Michael J&#xD;Srinivas, Pothur R&#xD;Narula, Jagat&#xD;Z99 HL999999/Intramural NIH HHS/United States&#xD;Review&#xD;United States&#xD;JACC Cardiovasc Imaging. 2012 Sep;5(9):941-55. doi: 10.1016/j.jcmg.2012.07.007.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S1936878X12005852/1-s2.0-S1936878X12005852-main.pdf?_tid=149f18c4-d7be-11e6-a58f-00000aab0f02&amp;acdnat=1484112387_9a76ea57d3a7840e69da6fd4dcdc8167</style></url></related-urls><pdf-urls><url>internal-pdf://1038556419/Fleg-2012-Detection of high-ri.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3646061</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms402001</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jcmg.2012.07.007</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>376</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">376</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Florczak-Rzepka, M.</style></author><author><style face="normal" font="default" size="100%">Grond-Ginsbach, C.</style></author><author><style face="normal" font="default" size="100%">Montaner, J.</style></author><author><style face="normal" font="default" size="100%">Steiner, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Medical University of Warsaw, PL-02-097Warsaw, Poland. malgorzata.florczak @ gmail.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">Matrix metalloproteinases in human spontaneous intracerebral hemorrhage: an update</style></title><secondary-title><style face="normal" font="default" size="100%">Cerebrovasc Dis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Cerebrovascular diseases (Basel, Switzerland)</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cerebrovasc Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Cerebrovascular diseases (Basel, Switzerland)</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Cerebrovasc Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Cerebrovascular diseases (Basel, Switzerland)</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">249-62</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2012/10/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/enzymology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/ enzymology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/enzymology</style></keyword><keyword><style face="normal" font="default" size="100%">Matrix Metalloproteinases/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/enzymology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1421-9786 (Electronic)&#xD;1015-9770 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23052179</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: In default of a plausible and satisfactory causal treatment for hemorrhagic stroke, a role of matrix metalloproteinases (MMPs) in the pathogenesis of cerebrovascular diseases has recently been widely discussed. The well-known impact of MMPs on extracellular matrix destruction triggered by inflammation as a foundation for several diseases, including stroke, is very much in evidence. Newly, some additional aspects of MMP function considering their intracellular activity crucial for neuronal death following ischemic brain damage have emerged. The effect of blood-brain barrier disruption caused by MMPs on the prognosis in patients suffering from spontaneous intracerebral hemorrhage (ICH) has been of interest since it throws a new light upon the pathogenesis, course and possible therapeutic approaches for this least treatable and at the same time most life-threatening form of stroke. Hence, we primarily aimed to review the current clinical knowledge on the significance of metalloproteinase activation in the course of spontaneous intracranial hemorrhage in humans. We also provide a brief characterization of the MMP enzyme family and report on the latest findings on issues arising from experimental studies. METHODS: A Medline search using the following key words was performed: matrix metalloproteinases + spontaneous intracerebral hemorrhage/intracranial hemorrhage/bleeding/hemorrhagic stroke. We accepted studies reporting on MMP expression in adult patients with spontaneous ICH, as well as its relation to radiological and clinical features and patients&apos; outcome. For the final review, 18 clinical studies were considered. MMP inhibition was reviewed on the basis of 11 relevant experimental studies. Also, some relevant reports on the biology of MMPs and their pathophysiology in ICH were reviewed. RESULTS AND CONCLUSIONS: Many studies provide convincing evidence of a detrimental role of MMPs in ICH, stressing their association with neuroinflammation. The role of MMPs in hemorrhagic stroke appears critical for hematoma and brain edema growth as well as for neuronal death, which are understood as secondary brain injury and may have a considerable clinical impact. Although data on human spontaneous ICH are scarce and mostly based on small populations, they reveal the apparent correlation between MMPs and clinical and radiological ICH features as well as the functional outcome, which might rationalize future therapeutic strategies. However, attempts at MMP inhibition in spontaneous ICH have solely been made under experimental conditions and were associated with a wide range of possible side effects. Therefore, further comprehensive, elucidating investigations in this field are vital before any conclusions could be translated to humans.</style></abstract><notes><style face="normal" font="default" size="100%">Florczak-Rzepka, M&#xD;Grond-Ginsbach, C&#xD;Montaner, J&#xD;Steiner, T&#xD;Review&#xD;Switzerland&#xD;Cerebrovasc Dis. 2012;34(4):249-62. doi: 10.1159/000341686. Epub 2012 Oct 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.karger.com/Article/Pdf/341686</style></url></related-urls><pdf-urls><url>internal-pdf://0197717948/Florczak-Rzepka-2012-Matrix metalloprotei.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1159/000341686</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>19</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">19</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Flores, J. J.</style></author><author><style face="normal" font="default" size="100%">Klebe, D.</style></author><author><style face="normal" font="default" size="100%">Rolland, W. B.</style></author><author><style face="normal" font="default" size="100%">Lekic, T.</style></author><author><style face="normal" font="default" size="100%">Krafft, P. R.</style></author><author><style face="normal" font="default" size="100%">Zhang, J. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Physiology &amp; Pharmacology, Loma Linda University School of Medicine, Loma Linda, CA, USA.&#xD;Department of Physiology &amp; Pharmacology, Loma Linda University School of Medicine, Loma Linda, CA, USA; Departments of Anesthesiology and Neurosurgery, Loma Linda University School of Medicine, Loma Linda, CA, USA. Electronic address: johnzhang3910@yahoo.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">PPARgamma-induced upregulation of CD36 enhances hematoma resolution and attenuates long-term neurological deficits after germinal matrix hemorrhage in neonatal rats</style></title><secondary-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurobiology of disease</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurobiology of disease</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurobiology of disease</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">124-33</style></pages><volume><style face="normal" font="default" size="100%">87</style></volume><edition><style face="normal" font="default" size="100%">2016/01/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anilides/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Animals, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, CD36/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/drug effects/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Central Nervous System Agents/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Knockdown Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Hematoma/drug therapy/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hemorrhages/drug therapy/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Macrophage Activation/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Microglia/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">PPAR gamma/antagonists &amp; inhibitors/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandin D2/analogs &amp; derivatives/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1095-953X (Electronic)&#xD;0969-9961 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26739391</style></accession-num><abstract><style face="normal" font="default" size="100%">Germinal matrix hemorrhage remains the leading cause of morbidity and mortality in preterm infants in the United States with little progress made in its clinical management. Survivors are often afflicted with long-term neurological sequelae, including cerebral palsy, mental retardation, hydrocephalus, and psychiatric disorders. Blood clots disrupting normal cerebrospinal fluid circulation and absorption after germinal matrix hemorrhage are thought to be important contributors towards post-hemorrhagic hydrocephalus development. We evaluated if upregulating CD36 scavenger receptor expression in microglia and macrophages through PPARgamma stimulation, which was effective in experimental adult cerebral hemorrhage models and is being evaluated clinically, will enhance hematoma resolution and ameliorate long-term brain sequelae using a neonatal rat germinal matrix hemorrhage model. PPARgamma stimulation (15d-PGJ2) increased short-term PPARgamma and CD36 expression levels as well as enhanced hematoma resolution, which was reversed by a PPARgamma antagonist (GW9662) and CD36 siRNA. PPARgamma stimulation (15d-PGJ2) also reduced long-term white matter loss and post-hemorrhagic ventricular dilation as well as improved neurofunctional outcomes, which were reversed by a PPARgamma antagonist (GW9662). PPARgamma-induced upregulation of CD36 in macrophages and microglia is, therefore, critical for enhancing hematoma resolution and ameliorating long-term brain sequelae.</style></abstract><notes><style face="normal" font="default" size="100%">Flores, Jerry J&#xD;Klebe, Damon&#xD;Rolland, William B&#xD;Lekic, Tim&#xD;Krafft, Paul R&#xD;Zhang, John H&#xD;P01 NS082184/NS/NINDS NIH HHS/United States&#xD;R01 NS078755/NS/NINDS NIH HHS/United States&#xD;United States&#xD;Neurobiol Dis. 2016 Mar;87:124-33. doi: 10.1016/j.nbd.2015.12.015. Epub 2015 Dec 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0969996115301169/1-s2.0-S0969996115301169-main.pdf?_tid=11da372c-d7be-11e6-9350-00000aacb360&amp;acdnat=1484112382_d2cc3ac35a5f789b850bb7728198d7bb</style></url></related-urls><pdf-urls><url>internal-pdf://1424558061/Flores-2016-PPARgamma-induced up.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4724557</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms749663</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.nbd.2015.12.015</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>166</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">166</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">French, C. R.</style></author><author><style face="normal" font="default" size="100%">Seshadri, S.</style></author><author><style face="normal" font="default" size="100%">Destefano, A. L.</style></author><author><style face="normal" font="default" size="100%">Fornage, M.</style></author><author><style face="normal" font="default" size="100%">Arnold, C. R.</style></author><author><style face="normal" font="default" size="100%">Gage, P. J.</style></author><author><style face="normal" font="default" size="100%">Skarie, J. M.</style></author><author><style face="normal" font="default" size="100%">Dobyns, W. B.</style></author><author><style face="normal" font="default" size="100%">Millen, K. J.</style></author><author><style face="normal" font="default" size="100%">Liu, T.</style></author><author><style face="normal" font="default" size="100%">Dietz, W.</style></author><author><style face="normal" font="default" size="100%">Kume, T.</style></author><author><style face="normal" font="default" size="100%">Hofker, M.</style></author><author><style face="normal" font="default" size="100%">Emery, D. J.</style></author><author><style face="normal" font="default" size="100%">Childs, S. J.</style></author><author><style face="normal" font="default" size="100%">Waskiewicz, A. J.</style></author><author><style face="normal" font="default" size="100%">Lehmann, O. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mutation of FOXC1 and PITX2 induces cerebral small-vessel disease</style></title><secondary-title><style face="normal" font="default" size="100%">J Clin Invest</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The Journal of clinical investigation</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Clin Invest</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of clinical investigation</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Clin Invest</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of clinical investigation</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">4877-81</style></pages><volume><style face="normal" font="default" size="100%">124</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2014/09/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Small Vessel Diseases/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Codon, Nonsense</style></keyword><keyword><style face="normal" font="default" size="100%">Forkhead Transcription Factors/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Genome-Wide Association Study</style></keyword><keyword><style face="normal" font="default" size="100%">Homeodomain Proteins/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Leukoencephalopathies/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Linkage Disequilibrium</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation, Missense</style></keyword><keyword><style face="normal" font="default" size="100%">Platelet-Derived Growth Factor/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword><keyword><style face="normal" font="default" size="100%">Quantitative Trait Loci</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">Transcription Factors/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Zebrafish</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1558-8238 (Electronic)&#xD;0021-9738 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25250569</style></accession-num><abstract><style face="normal" font="default" size="100%">Patients with cerebral small-vessel disease (CSVD) exhibit perturbed end-artery function and have an increased risk for stroke and age-related cognitive decline. Here, we used targeted genome-wide association (GWA) analysis and defined a CSVD locus adjacent to the forkhead transcription factor FOXC1. Moreover, we determined that the linked SNPs influence FOXC1 transcript levels and demonstrated that patients as young as 1 year of age with altered FOXC1 function exhibit CSVD. MRI analysis of patients with missense and nonsense mutations as well as FOXC1-encompassing segmental duplication and deletion revealed white matter hyperintensities, dilated perivascular spaces, and lacunar infarction. In a zebrafish model, overexpression or morpholino-induced suppression of foxc1 induced cerebral hemorrhage. Inhibition of foxc1 perturbed platelet-derived growth factor (Pdgf) signaling, impairing neural crest migration and the recruitment of mural cells, which are essential for vascular stability. GWA analysis also linked the FOXC1-interacting transcription factor PITX2 to CSVD, and both patients with PITX2 mutations and murine Pitx2-/- mutants displayed brain vascular phenotypes. Together, these results extend the genetic etiology of stroke and demonstrate an increasing developmental basis for human cerebrovascular disease.</style></abstract><notes><style face="normal" font="default" size="100%">French, Curtis R&#xD;Seshadri, Sudha&#xD;Destefano, Anita L&#xD;Fornage, Myriam&#xD;Arnold, Corey R&#xD;Gage, Philip J&#xD;Skarie, Jonathan M&#xD;Dobyns, William B&#xD;Millen, Kathleen J&#xD;Liu, Ting&#xD;Dietz, William&#xD;Kume, Tsutomu&#xD;Hofker, Marten&#xD;Emery, Derek J&#xD;Childs, Sarah J&#xD;Waskiewicz, Andrew J&#xD;Lehmann, Ordan J&#xD;R01 NS080390/NS/NINDS NIH HHS/United States&#xD;EY007003/EY/NEI NIH HHS/United States&#xD;EY014126/EY/NEI NIH HHS/United States&#xD;MOP-133658/Canadian Institutes of Health Research/Canada&#xD;R01 EY014126/EY/NEI NIH HHS/United States&#xD;MOP-114902/Canadian Institutes of Health Research/Canada&#xD;R01 EY019484/EY/NEI NIH HHS/United States&#xD;P30 EY007003/EY/NEI NIH HHS/United States&#xD;F31 EY007003/EY/NEI NIH HHS/United States&#xD;U01 AG049505/AG/NIA NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Clin Invest. 2014 Nov;124(11):4877-81. doi: 10.1172/JCI75109. Epub 2014 Sep 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://dm5migu4zj3pb.cloudfront.net/manuscripts/75000/75109/JCI75109.v2.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1376058192/French-2014-Mutation of FOXC1 an.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4347243</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1172/jci75109</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>444</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">444</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Frosini, M.</style></author><author><style face="normal" font="default" size="100%">Contartese, A.</style></author><author><style face="normal" font="default" size="100%">Zanardi, I.</style></author><author><style face="normal" font="default" size="100%">Travagli, V.</style></author><author><style face="normal" font="default" size="100%">Bocci, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dipartimento di Neuroscienze, Sezione di Farmacologia, Universit a degli Studi di Siena, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Selective ozone concentrations may reduce the ischemic damage after a stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Free Radic Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Free radical research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Free Radic Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Free radical research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Free Radic Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Free radical research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">612-8</style></pages><volume><style face="normal" font="default" size="100%">46</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2012/01/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebellum/blood supply/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Hippocampus/blood supply/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia-Ischemia, Brain/ drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">In Vitro Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Ozone/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ drug therapy/pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1029-2470 (Electronic)&#xD;1029-2470 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22263539</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract Stroke is one of the most debilitating diseases, and it is unfortunate that only a small percentage of patients can be treated with thrombolytic agents. Consequently, there is an urgent need of finding an alternative procedure for reoxygenating the so-called penumbra at the earliest time as possible for reducing morbidity and disability. A preliminary, preclinical study has been carried out by using rat hippocampal and cortical brain slices subjected to oxygen-glucose deprivation. Oxygen-ozone gaseous mixture appeared to be effective in reverting damage of brain tissues, supporting the evaluation of this approach in well-designed clinical trials in stroke patients.</style></abstract><notes><style face="normal" font="default" size="100%">Frosini, Maria&#xD;Contartese, Antonella&#xD;Zanardi, Iacopo&#xD;Travagli, Valter&#xD;Bocci, Velio&#xD;England&#xD;Free Radic Res. 2012 May;46(5):612-8. doi: 10.3109/10715762.2012.659247. Epub 2012 Feb 14.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3109/10715762.2012.659247</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>426</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">426</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fukuoka, T.</style></author><author><style face="normal" font="default" size="100%">Hattori, K.</style></author><author><style face="normal" font="default" size="100%">Maruyama, H.</style></author><author><style face="normal" font="default" size="100%">Hirayama, M.</style></author><author><style face="normal" font="default" size="100%">Tanahashi, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Saitama Medical University International Medical Center, Saitama, 350-1298, Japan. tfukuoka@saitama-med.ac.jp</style></auth-address><titles><title><style face="normal" font="default" size="100%">Laser-induced thrombus formation in mouse brain microvasculature: effect of clopidogrel</style></title><secondary-title><style face="normal" font="default" size="100%">J Thromb Thrombolysis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of thrombosis and thrombolysis</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Thromb Thrombolysis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of thrombosis and thrombolysis</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Thromb Thrombolysis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of thrombosis and thrombolysis</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">193-8</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2012/03/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Platelets/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ blood supply/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Arteries/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Thrombosis/etiology/pathology/ physiopathology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Lasers/ adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Platelet Aggregation Inhibitors/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Ticlopidine/ analogs &amp; derivatives/pharmacology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1573-742X (Electronic)&#xD;0929-5305 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22453683</style></accession-num><abstract><style face="normal" font="default" size="100%">Antiplatelet drugs have been evaluated by measuring platelet aggregation ex vivo, but in vivo studies were scanty. The purpose of this study was to observe the effects of an antiplatelet agent (clopidogrel) on the process of laser-induced thrombus formation in mice using intravital fluorescence microscopy. C57 BL/6J mice (n = 19) were anesthetized using chloral hydrate. The head of each mouse was fixed with a head holder, and a cranial window was made in the parietal region. Platelets were labeled in vivo by intravenous administration of carboxyfluorescein diacetate succinimidyl ester. Clopidogrel (1 mg/kg, n = 6; 10 mg/kg, n = 6) was administered orally for 2 days before the experiment. Another seven mice were used as controls. Laser irradiation (1,000 mA, 9.8 mW, diode-pumped solid-state (DPSS) laser 532 nm) was directed for 4 s at pial arteries to induce thrombus formation. Labeled platelets and thrombus were observed continuously under fluorescence microscopy. We recorded the area of thrombus after 30 min and determined the complete occlusion rate. After laser irradiation to the pial artery, complete occlusion rate was significantly lower in the clopidogrel (10 mg/kg) group (16%, 4/25 vessels) than in the control group (60%, 12/20 vessels) or clopidogrel (1 mg/kg) group (55%, 11/20 vessels). Area of platelet thrombus at 30 min after laser irradiation was significantly smaller in the clopidogrel (10 mg/kg) group (209 +/- 128 mum(2)) than in the control group (358 +/- 256 mum(2)) or clopidogrel (1 mg/kg) group (355 +/- 57 mum(2)). The apparatus which we developed is convenient for inducing thrombus formation by causing endothelial cell damage to the brain surface vasculature in small animals without damage of extravascular tissue. Clopidogrel significantly inhibited laser-induced thrombus formation in pial arteries of mice in a dose-dependent manner.</style></abstract><notes><style face="normal" font="default" size="100%">Fukuoka, Takuya&#xD;Hattori, Kimihiko&#xD;Maruyama, Hajime&#xD;Hirayama, Makiko&#xD;Tanahashi, Norio&#xD;Netherlands&#xD;J Thromb Thrombolysis. 2012 Aug;34(2):193-8. doi: 10.1007/s11239-012-0703-0.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/296/art%253A10.1007%252Fs11239-012-0703-0.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs11239-012-0703-0&amp;token2=exp=1484113406~acl=%2Fstatic%2Fpdf%2F296%2Fart%25253A10.1007%25252Fs11239-012-0703-0.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs11239-012-0703-0*~hmac=1dd29d17915dccfd580131ac641bc6a24bf93cc2e90ca95213d818b15674a2a1</style></url></related-urls><pdf-urls><url>internal-pdf://1809651435/Fukuoka-2012-Laser-induced thromb.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s11239-012-0703-0</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>279</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">279</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fukuoka, T.</style></author><author><style face="normal" font="default" size="100%">Hayashi, T.</style></author><author><style face="normal" font="default" size="100%">Hirayama, M.</style></author><author><style face="normal" font="default" size="100%">Maruyama, H.</style></author><author><style face="normal" font="default" size="100%">Tanahashi, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Saitama Medical University International Medical Center, Saitama, Japan. Electronic address: tfukuoka@saitama-med.ac.jp.&#xD;Department of Neurology, Saitama Medical University International Medical Center, Saitama, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cilostazol inhibits platelet-endothelial cell interaction in murine microvessels after transient bilateral common carotid artery occlusion</style></title><secondary-title><style face="normal" font="default" size="100%">J Stroke Cerebrovasc Dis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Stroke Cerebrovasc Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Stroke Cerebrovasc Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1056-61</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2013/10/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arterioles/drug effects/metabolism/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Platelets/ drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ blood supply</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/blood/physiopathology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Artery, Common/ drug effects/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Stenosis/blood/ drug therapy/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelial Cells/ drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Platelet Adhesiveness/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/blood/physiopathology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Tetrazoles/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Venules/drug effects/metabolism/physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">May-Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1532-8511 (Electronic)&#xD;1052-3057 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24135235</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The purpose of this study was to investigate the effects of cilostazol on platelet behavior (rolling and adhesion) in murine cerebral microvessels after transient bilateral carotid artery occlusion using intravital fluorescence microscopy. METHODS: We used 41 C57BL/6J mice for the experiment. Fourteen mice were used as sham group (no ischemia and reperfusion, no medication); an ischemia (induced by 15-minute occlusion of bilateral common carotid arteries) and reperfusion (I/R) group (n = 17); and an I/R + cilostazol (I/R + CZ) group (receiving 30 mg/kg of cilostazol orally at 30 minutes before ischemia) (n = 10). A cranial window was prepared in the right parietal region. Platelets obtained from donor mice were labeled with a fluorescent dye (carboxyfluorescein iodoacetate succinimidyl ester) in vitro. Labeled platelets were intravenously administered at 3 or 6 hours after reperfusion, and then platelet behavior (rolling and adhesion) in the brain microvessels was observed. The numbers of rolling and adhering platelets in the arteriole and venule were calculated. RESULTS: Numbers of rolling and adherent platelets at 3 and 6 hours after reperfusion were significantly higher in the I/R group than in the sham or I/R + CZ groups in both venule (P &lt; .05) and arteriole (P &lt; .05). CONCLUSIONS: Cilostazol inhibits platelet-endothelial interactions following cerebral ischemia and reperfusion.</style></abstract><notes><style face="normal" font="default" size="100%">Fukuoka, Takuya&#xD;Hayashi, Takeshi&#xD;Hirayama, Makiko&#xD;Maruyama, Hajime&#xD;Tanahashi, Norio&#xD;United States&#xD;J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):1056-61. doi: 10.1016/j.jstrokecerebrovasdis.2013.09.003. Epub 2013 Oct 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S1052305713003595/1-s2.0-S1052305713003595-main.pdf?_tid=18d8c2fa-d7be-11e6-9350-00000aacb360&amp;acdnat=1484112394_8c3a96fc506c136d3493d3a6498449a2</style></url></related-urls><pdf-urls><url>internal-pdf://3490133097/Fukuoka-2014-Cilostazol inhibits.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jstrokecerebrovasdis.2013.09.003</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>449</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">449</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fulkerson, C. V.</style></author><author><style face="normal" font="default" size="100%">Young, B. D.</style></author><author><style face="normal" font="default" size="100%">Jackson, N. D.</style></author><author><style face="normal" font="default" size="100%">Porter, B.</style></author><author><style face="normal" font="default" size="100%">Levine, J. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Large Animal Clinical Sciences, Texas A&amp;M University, College Station, TX 77843, USA. cvantass@purdue.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">MRI characteristics of cerebral microbleeds in four dogs</style></title><secondary-title><style face="normal" font="default" size="100%">Vet Radiol Ultrasound</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Veterinary radiology &amp; ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Vet Radiol Ultrasound</style></full-title><abbr-1><style face="normal" font="default" size="100%">Veterinary radiology &amp; ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Vet Radiol Ultrasound</style></full-title><abbr-1><style face="normal" font="default" size="100%">Veterinary radiology &amp; ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">389-93</style></pages><volume><style face="normal" font="default" size="100%">53</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2012/01/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/diagnosis/ veterinary</style></keyword><keyword><style face="normal" font="default" size="100%">Dog Diseases/ diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Dogs</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging/ veterinary</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul-Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1058-8183 (Print)&#xD;1058-8183 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22235951</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebral microbleeds in people are small foci of hemosiderin-containing macrophages in normal brain parenchyma. They are the remnant of previous hemorrhage and occur with greater frequency in older individuals. Our purpose was to describe the magnetic resonance (MR) appearance of cerebral microbleeds in four dogs. These lesions appeared as round, hypointense foci measuring &lt;/=4 mm on T2*-gradient-recalled echo images. They were less conspicuous or absent on T2-weighting, being iso- or hypointense, and uniformly invisible on T1-weighted images. No contrast enhancement was seen in any of the cerebral microbleeds. Necropsy-derived histopathologic analysis of one brain confirmed these lesions to be chronic cerebrocortical infarcts containing hemosiderin. The MR changes seen in dogs were analogous to what has been described in people and will be helpful in distinguishing cerebral microbleeds from other brain lesions.</style></abstract><notes><style face="normal" font="default" size="100%">Fulkerson, Caroline V&#xD;Young, Benjamin D&#xD;Jackson, Nicolette D&#xD;Porter, Brian&#xD;Levine, Jonathan M&#xD;England&#xD;Vet Radiol Ultrasound. 2012 Jul-Aug;53(4):389-93. doi: 10.1111/j.1740-8261.2011.01910.x. Epub 2012 Jan 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/j.1740-8261.2011.01910.x/asset/vru1910.pdf?v=1&amp;t=ixsi3brm&amp;s=8ace1af49388c7ff232ad90900589961a8d60682</style></url></related-urls><pdf-urls><url>internal-pdf://0664421082/Fulkerson-2012-MRI characteristics.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1740-8261.2011.01910.x</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>463</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">463</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fuster, J. J.</style></author><author><style face="normal" font="default" size="100%">Castillo, A. I.</style></author><author><style face="normal" font="default" size="100%">Zaragoza, C.</style></author><author><style face="normal" font="default" size="100%">Ibanez, B.</style></author><author><style face="normal" font="default" size="100%">Andres, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Epidemiology, Atherothrombosis and Imaging, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Animal models of atherosclerosis</style></title><secondary-title><style face="normal" font="default" size="100%">Prog Mol Biol Transl Sci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Progress in molecular biology and translational science</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Prog Mol Biol Transl Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Progress in molecular biology and translational science</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Prog Mol Biol Transl Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Progress in molecular biology and translational science</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1-23</style></pages><volume><style face="normal" font="default" size="100%">105</style></volume><edition><style face="normal" font="default" size="100%">2011/12/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Atherosclerosis/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1878-0814 (Electronic)&#xD;1877-1173 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22137427</style></accession-num><abstract><style face="normal" font="default" size="100%">Cardiovascular disease is currently the predominant cause of mortality worldwide and its incidence is expected to increase significantly during the next decades owing to the unhealthy effects of modern lifestyle habits (e.g., obesity and lack of physical exercise). Cardiovascular death is frequently associated with acute myocardial infarction or stroke, which are generally the ultimate consequence of an underlying atherosclerotic process. Small and big animal models are valuable tools to understand the molecular mechanisms underlying atherosclerotic plaque formation and progression, as well as the occurrence of associated ischemic events. Moreover, animal models of atherosclerosis are pivotal for testing mechanistic hypothesis and for translational research, including the assessment of dietary and/or pharmacological interventions and the development of imaging technologies and interventional devices. In this chapter, we will describe the most widely used animal models that have permitted major advances in atherosclerosis research and significant improvements in the treatment and diagnosis of atherosclerotic disease.</style></abstract><notes><style face="normal" font="default" size="100%">Fuster, Jose J&#xD;Castillo, Ana I&#xD;Zaragoza, Carlos&#xD;Ibanez, Borja&#xD;Andres, Vicente&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Netherlands&#xD;Prog Mol Biol Transl Sci. 2012;105:1-23. doi: 10.1016/B978-0-12-394596-9.00001-9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.sciencedirect.com/science/article/pii/B9780123945969000019</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/b978-0-12-394596-9.00001-9</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>298</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">298</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gabrielian, L.</style></author><author><style face="normal" font="default" size="100%">Helps, S. C.</style></author><author><style face="normal" font="default" size="100%">Thornton, E.</style></author><author><style face="normal" font="default" size="100%">Turner, R. J.</style></author><author><style face="normal" font="default" size="100%">Leonard, A. V.</style></author><author><style face="normal" font="default" size="100%">Vink, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Medical Sciences, University of Adelaide, Adelaide, SA, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Substance P antagonists as a novel intervention for brain edema and raised intracranial pressure</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Neurochir Suppl</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Acta neurochirurgica. Supplement</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Neurochir Suppl</style></full-title><abbr-1><style face="normal" font="default" size="100%">Acta neurochirurgica. Supplement</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Acta Neurochir Suppl</style></full-title><abbr-1><style face="normal" font="default" size="100%">Acta neurochirurgica. Supplement</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">201-4</style></pages><volume><style face="normal" font="default" size="100%">118</style></volume><edition><style face="normal" font="default" size="100%">2013/07/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/ complications/drug therapy/etiology/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hypertension/ etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Tachykinin/antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Substance P/antagonists &amp; inhibitors/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">0065-1419 (Print)&#xD;0065-1419 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23564132</style></accession-num><abstract><style face="normal" font="default" size="100%">Increased intracranial pressure (ICP) following acute brain injury requires the accumulation of additional water in the intracranial vault. One source of such water is the vasculature, although the mechanisms associated with control of blood-brain barrier permeability are unclear. We have recently shown that acute brain injury, such as neurotrauma and stroke, results in perivascular accumulation of the neuropeptide, substance P. This accumulation is associated with increased blood-brain barrier permeability and formation of vasogenic edema. Administration of a substance P antagonist targeting the tachykinin NK1 receptor profoundly reduced the increased blood-brain barrier permeability and edema formation, and in small animal models of acute brain injury, improved functional outcome. In a large, ovine model of experimental traumatic brain injury, trauma resulted in a significant increase in ICP. Administration of an NK1 antagonist caused a profound reduction in post--traumatic ICP, with levels returning to normal within 4 h of drug administration. Substance P NK1 antagonists offer a novel therapeutic approach to the treatment of acute brain injury.</style></abstract><notes><style face="normal" font="default" size="100%">Gabrielian, Levon&#xD;Helps, Stephen C&#xD;Thornton, Emma&#xD;Turner, Renee J&#xD;Leonard, Anna V&#xD;Vink, Robert&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Austria&#xD;Acta Neurochir Suppl. 2013;118:201-4. doi: 10.1007/978-3-7091-1434-6_37.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/765/chp%253A10.1007%252F978-3-7091-1434-6_37.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Fchapter%2F10.1007%2F978-3-7091-1434-6_37&amp;token2=exp=1484113423~acl=%2Fstatic%2Fpdf%2F765%2Fchp%25253A10.1007%25252F978-3-7091-1434-6_37.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Fchapter%252F10.1007%252F978-3-7091-1434-6_37*~hmac=6b229362464c323794faf2f16ff89768bc7c8813ffdafd84a5f7091197d76748</style></url></related-urls><pdf-urls><url>internal-pdf://2835960810/Gabrielian-2013-Substance P antagoni.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/978-3-7091-1434-6_37</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>110</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">110</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gailani, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Future prospects for contact factors as therapeutic targets</style></title><secondary-title><style face="normal" font="default" size="100%">Hematology Am Soc Hematol Educ Program</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Hematology. American Society of Hematology. Education Program</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hematology Am Soc Hematol Educ Program</style></full-title><abbr-1><style face="normal" font="default" size="100%">Hematology. American Society of Hematology. Education Program</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Hematology Am Soc Hematol Educ Program</style></full-title><abbr-1><style face="normal" font="default" size="100%">Hematology. American Society of Hematology. Education Program</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">52-9</style></pages><volume><style face="normal" font="default" size="100%">2014</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2015/02/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Coagulation Factors/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Targeted Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Small Molecule Libraries/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombosis/drug therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 05</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1520-4383 (Electronic)&#xD;1520-4383 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25696834</style></accession-num><abstract><style face="normal" font="default" size="100%">Anticoagulants currently used in clinical practice to treat or prevent thromboembolic disease are effective, but place patients at increased risk for serious bleeding because they interfere with plasma enzymes (thrombin and factor Xa) that are essential for hemostasis. In the past 10 years, work with genetically altered mice and studies in baboons and rabbits have demonstrated that the plasma contact proteases factor XI, factor XII, and prekallikrein contribute to the formation of occlusive thrombi despite having limited roles in hemostasis. In the case of factor XI, epidemiologic data from human populations indicate that elevated levels of this protein increase risk for stroke and venous thromboembolism and may also influence risk for myocardial infarction. These findings suggest that inhibiting contact activation may produce an antithrombotic effect without significantly compromising hemostasis. This chapter reviews strategies that are being developed for therapeutic targeting of factor XI and factor XII and their performances in preclinical and early human trials.</style></abstract><notes><style face="normal" font="default" size="100%">Gailani, David&#xD;R01 HL058837/HL/NHLBI NIH HHS/United States&#xD;R01 HL081326/HL/NHLBI NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;United States&#xD;Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):52-9. doi: 10.1182/asheducation-2014.1.52. Epub 2014 Nov 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://asheducationbook.hematologylibrary.org/content/2014/1/52.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0299209890/Gailani-2014-Future prospects for.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4364029</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms670485</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1182/asheducation-2014.1.52</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>262</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">262</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ganesh, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacology, Emory University School of Medicine , 1510 Clifton Road, Atlanta, Georgia, 30322, United States.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prostanoid receptor EP2 as a therapeutic target</style></title><secondary-title><style face="normal" font="default" size="100%">J Med Chem</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of medicinal chemistry</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Med Chem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of medicinal chemistry</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Med Chem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of medicinal chemistry</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">4454-65</style></pages><volume><style face="normal" font="default" size="100%">57</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2013/11/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents/ chemistry/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Eye Diseases/drug therapy/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Knockout Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Targeted Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Neurodegenerative Diseases/drug therapy/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandin-Endoperoxide Synthases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Prostaglandin E, EP2 Subtype/agonists/antagonists &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">inhibitors/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/drug therapy/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 12</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1520-4804 (Electronic)&#xD;0022-2623 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24279689</style></accession-num><abstract><style face="normal" font="default" size="100%">Cycoloxygenase-2 (COX-2) induction is prevalent in a variety of (brain and peripheral) injury models where COX-2 levels correlate with disease progression. Thus, COX-2 has been widely explored for anti-inflammatory therapy with COX-2 inhibitors, which proved to be effective in reducing the pain and inflammation in patients with arthritis and menstrual cramps, but they have not provided any benefit to patients with chronic inflammatory neurodegenerative disease. Recently, two COX-2 drugs, rofecoxib and valdecoxib, were withdrawn from the United States market due to cardiovascular side effects. Thus, future anti-inflammatory therapy could be targeted through a specific prostanoid receptor downstream of COX-2. The PGE2 receptor EP2 is emerging as a pro-inflammatory target in a variety of CNS and peripheral diseases. Here we highlight the latest developments on the role of EP2 in diseases, mechanism of activation, and small molecule discovery targeted either to enhance or to block the function of this receptor.</style></abstract><notes><style face="normal" font="default" size="100%">Ganesh, Thota&#xD;U01 NS058158/NS/NINDS NIH HHS/United States&#xD;U01NS058158/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Review&#xD;United States&#xD;J Med Chem. 2014 Jun 12;57(11):4454-65. doi: 10.1021/jm401431x. Epub 2013 Dec 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://pubs.acs.org/doi/pdfplus/10.1021/jm401431x</style></url></related-urls><pdf-urls><url>internal-pdf://3613813803/Ganesh-2014-Prostanoid receptor.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4045661</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms546595</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/jm401431x</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>277</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">277</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gasecki, D.</style></author><author><style face="normal" font="default" size="100%">Kwarciany, M.</style></author><author><style face="normal" font="default" size="100%">Nyka, W.</style></author><author><style face="normal" font="default" size="100%">Narkiewicz, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology of Adults, Medical University of Gdansk, Gdansk, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hypertension, brain damage and cognitive decline</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Hypertens Rep</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Current hypertension reports</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Hypertens Rep</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current hypertension reports</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Curr Hypertens Rep</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current hypertension reports</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">547-58</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2013/10/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aging</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Damage, Chronic/etiology/pathology/ physiopathology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition Disorders/etiology/pathology/ physiopathology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Dementia/etiology/pathology/ physiopathology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension/complications/pathology/ physiopathology/prevention &amp; control</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1534-3111 (Electronic)&#xD;1522-6417 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24146223</style></accession-num><abstract><style face="normal" font="default" size="100%">Loss of cognitive function is one the most devastating manifestations of ageing and vascular disease. Cognitive decline is rapidly becoming an important cause of disability worldwide and contributes significantly to increased mortality. There is growing evidence that hypertension is the most important modifiable vascular risk factor for development and progression of both cognitive decline and dementia. High blood pressure contributes to cerebral small and large vessel disease resulting in brain damage and dementia. A decline in cerebrovascular reserve capacity and emerging degenerative vascular wall changes underlie complete and incomplete brain infarcts, haemorrhages and white matter hyperintensities. This review discusses the complexity of factors linking hypertension to brain functional and structural changes, and to cognitive decline and dementia. The evidence for possible clinical markers useful for prevention of decreased cognitive ability, as well as recent data on vascular mechanism in the pathogenesis of cognitive decline, and the role of antihypertensive therapies in long-term prevention of late-life cognitive decline will be reviewed.</style></abstract><notes><style face="normal" font="default" size="100%">Gasecki, Dariusz&#xD;Kwarciany, Mariusz&#xD;Nyka, Walenty&#xD;Narkiewicz, Krzysztof&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;United States&#xD;Curr Hypertens Rep. 2013 Dec;15(6):547-58. doi: 10.1007/s11906-013-0398-4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/340/art%253A10.1007%252Fs11906-013-0398-4.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs11906-013-0398-4&amp;token2=exp=1484113426~acl=%2Fstatic%2Fpdf%2F340%2Fart%25253A10.1007%25252Fs11906-013-0398-4.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs11906-013-0398-4*~hmac=8d6ded367dd185f348f0758431c110b7b260a02ad41713d6f8543ea3c429b3a3</style></url></related-urls><pdf-urls><url>internal-pdf://1050239423/Gasecki-2013-Hypertension, brain.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3838597</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s11906-013-0398-4</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>404</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">404</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gaser, C.</style></author><author><style face="normal" font="default" size="100%">Schmidt, S.</style></author><author><style face="normal" font="default" size="100%">Metzler, M.</style></author><author><style face="normal" font="default" size="100%">Herrmann, K. H.</style></author><author><style face="normal" font="default" size="100%">Krumbein, I.</style></author><author><style face="normal" font="default" size="100%">Reichenbach, J. R.</style></author><author><style face="normal" font="default" size="100%">Witte, O. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Hans Berger Clinic for Neurology, Jena University Hospital, Erlanger Allee 101, 07747 Jena, Germany. christian.gaser@uni-jena.de</style></auth-address><titles><title><style face="normal" font="default" size="100%">Deformation-based brain morphometry in rats</style></title><secondary-title><style face="normal" font="default" size="100%">Neuroimage</style></secondary-title><alt-title><style face="normal" font="default" size="100%">NeuroImage</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuroimage</style></full-title><abbr-1><style face="normal" font="default" size="100%">NeuroImage</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuroimage</style></full-title><abbr-1><style face="normal" font="default" size="100%">NeuroImage</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">47-53</style></pages><volume><style face="normal" font="default" size="100%">63</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2012/07/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Diseases/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Computer Simulation</style></keyword><keyword><style face="normal" font="default" size="100%">Image Enhancement/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Image Interpretation, Computer-Assisted/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Anatomic</style></keyword><keyword><style face="normal" font="default" size="100%">Pattern Recognition, Automated/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Pilot Projects</style></keyword><keyword><style face="normal" font="default" size="100%">Programming Languages</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">Software</style></keyword><keyword><style face="normal" font="default" size="100%">Subtraction Technique</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1095-9572 (Electronic)&#xD;1053-8119 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22776449</style></accession-num><abstract><style face="normal" font="default" size="100%">Magnetic resonance imaging (MRI)-based morphometry provides in vivo evidence for macro-structural plasticity of the brain. Experiments on small animals using automated morphometric methods usually require expensive measurements with ultra-high field dedicated animal MRI systems. Here, we developed a novel deformation-based morphometry (DBM) tool for automated analyses of rat brain images measured on a 3-Tesla clinical whole body scanner with appropriate coils. A landmark-based transformation of our customized reference brain into the coordinates of the widely used rat brain atlas from Paxinos and Watson (Paxinos Atlas) guarantees the comparability of results to other studies. For cross-sectional data, we warped images onto the reference brain using the low-dimensional nonlinear registration implemented in the MATLAB software package SPM8. For the analysis of longitudinal data sets, we chose high-dimensional registrations of all images of one data set to the first baseline image which facilitate the identification of more subtle structural changes. Because all deformations were finally used to transform the data into the space of the Paxinos Atlas, Jacobian determinants could be used to estimate absolute local volumes of predefined regions-of-interest. Pilot experiments were performed to analyze brain structural changes due to aging or photothrombotically-induced cortical stroke. The results support the utility of DBM based on commonly available clinical whole-body scanners for highly sensitive morphometric studies on rats.</style></abstract><notes><style face="normal" font="default" size="100%">Gaser, Christian&#xD;Schmidt, Silvio&#xD;Metzler, Martin&#xD;Herrmann, Karl-Heinz&#xD;Krumbein, Ines&#xD;Reichenbach, Jurgen R&#xD;Witte, Otto W&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Neuroimage. 2012 Oct 15;63(1):47-53. doi: 10.1016/j.neuroimage.2012.06.066. Epub 2012 Jul 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S1053811912006829/1-s2.0-S1053811912006829-main.pdf?_tid=22a25dd2-d7be-11e6-93f6-00000aab0f01&amp;acdnat=1484112410_f6d752ae0b66fd675e9c8df62e89c95f</style></url></related-urls><pdf-urls><url>internal-pdf://1458402623/Gaser-2012-Deformation-based br.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuroimage.2012.06.066</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>49</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">49</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ghosh, M.</style></author><author><style face="normal" font="default" size="100%">Balbi, M.</style></author><author><style face="normal" font="default" size="100%">Hellal, F.</style></author><author><style face="normal" font="default" size="100%">Dichgans, M.</style></author><author><style face="normal" font="default" size="100%">Lindauer, U.</style></author><author><style face="normal" font="default" size="100%">Plesnila, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute for Stroke and Dementia Research, University of Munich Medical Center, Ludwig Maximilian University, Munich.&#xD;Experimental Neurosurgery, Department of Neurosurgery, Rechts der Isar Hospital, Technical University Munich, Munich.&#xD;Munich Cluster for Systems Neurology (SyNergy), Munich.&#xD;Graduate School of Systemic Neurosciences, Ludwig Maximilian University, Munich.&#xD;Translational Neurosurgery and Neurobiology, Department of Neurosurgery, Medical Faculty, RWTH Aachen University, Aachen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pericytes are involved in the pathogenesis of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy</style></title><secondary-title><style face="normal" font="default" size="100%">Ann Neurol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Annals of neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Ann Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Annals of neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Ann Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Annals of neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">887-900</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2015/08/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">CADASIL/ etiology/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Capillaries/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/ blood supply</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation</style></keyword><keyword><style face="normal" font="default" size="100%">Pericytes/metabolism/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Notch3</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Notch/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Single-Blind Method</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1531-8249 (Electronic)&#xD;0364-5134 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26312599</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), the most common inherited small-vessel disease, is associated with vascular aggregation of mutant Notch3 protein, dysfunction of cerebral vessels, and dementia. Pericytes, perivascular cells involved in microvascular function, express Notch3. Therefore, we hypothesize that these cells may play a role in the pathogenesis of CADASIL. METHODS: Two-, 7-, and 12-month-old CADASIL mutant mice (TgNotch3(R169C) ) and wild-type controls were examined regarding Notch3 aggregation in pericytes, the coverage of cerebral vessels by pericytes, pericyte numbers, capillary density, blood-brain barrier (BBB) integrity, astrocytic end-feet, and the expression of astrocytic gap junction and endothelial adherens junction protein using immunostaining and Western blot analysis. In addition, we examined cerebrovascular CO2 reactivity using laser Doppler fluxmetry and in vivo microscopy. RESULTS: With increasing age, mutated Notch3 aggregated around pericytes and smooth muscle cells. Notch3 aggregation caused significant reduction of pericyte number and coverage of capillaries by pericyte processes (p &lt; 0.01). These changes were associated with detachment of astrocytic end-feet from cerebral microvessels, leakage of plasma proteins, reduction in expression of endothelial adherens junction protein, and reduced microvascular reactivity to CO2 . Smooth muscle cells were not affected by Notch3 accumulation. INTERPRETATION: Our results show that pericytes are the first cells affected by Notch3 aggregation in CADASIL mice. Pericyte pathology causes opening of the BBB and microvascular dysfunction. Therefore, protecting pericytes may represent a novel therapeutic strategy for vascular dementia.</style></abstract><notes><style face="normal" font="default" size="100%">Ghosh, Mitrajit&#xD;Balbi, Matilde&#xD;Hellal, Farida&#xD;Dichgans, Martin&#xD;Lindauer, Ute&#xD;Plesnila, Nikolaus&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Ann Neurol. 2015 Dec;78(6):887-900. doi: 10.1002/ana.24512. Epub 2015 Oct 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1002/ana.24512/asset/ana24512.pdf?v=1&amp;t=ixsi3p63&amp;s=95a687168347fbdb10ecc4b4558c3ff565a4edaa</style></url></related-urls><pdf-urls><url>internal-pdf://0514752099/Ghosh-2015-Pericytes are involv.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/ana.24512</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>388</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">388</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Giannopoulos, S.</style></author><author><style face="normal" font="default" size="100%">Katsanos, A. H.</style></author><author><style face="normal" font="default" size="100%">Tsivgoulis, G.</style></author><author><style face="normal" font="default" size="100%">Marshall, R. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Columbia University Medical Center, New York, NY, USA. sgiannop@uoi.gr</style></auth-address><titles><title><style face="normal" font="default" size="100%">Statins and cerebral hemodynamics</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1973-6</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2012/08/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/drug therapy/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Small Vessel Diseases/drug therapy/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Disorders/drug therapy/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Hemodynamics/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hydroxymethylglutaryl-CoA Reductase Inhibitors/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle Contraction/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle, Smooth, Vascular/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide Synthase Type III/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Subarachnoid Hemorrhage/drug therapy/physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22929438</style></accession-num><abstract><style face="normal" font="default" size="100%">HMG-CoA reductase inhibitors (statins) are associated with improved stroke outcome. This observation has been attributed in part to the palliative effect of statins on cerebral hemodynamics and cerebral autoregulation (CA), which are mediated mainly through the upregulation of endothelium nitric oxide synthase (eNOS). Several animal studies indicate that statin pretreatment enhances cerebral blood flow after ischemic stroke, although this finding is not further supported in clinical settings. Cerebral vasomotor reactivity, however, is significantly improved after long-term statin administration in most patients with severe small vessel disease, aneurysmal subarachnoid hemorrhage, or impaired baseline CA.</style></abstract><notes><style face="normal" font="default" size="100%">Giannopoulos, Sotirios&#xD;Katsanos, Aristeidis H&#xD;Tsivgoulis, Georgios&#xD;Marshall, Randolph S&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;United States&#xD;J Cereb Blood Flow Metab. 2012 Nov;32(11):1973-6. doi: 10.1038/jcbfm.2012.122. Epub 2012 Aug 29.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3494001</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2012.122</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>240</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">240</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gong, G.</style></author><author><style face="normal" font="default" size="100%">Bai, S.</style></author><author><style face="normal" font="default" size="100%">Wu, W.</style></author><author><style face="normal" font="default" size="100%">Hu, L.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Niu, J.</style></author><author><style face="normal" font="default" size="100%">Dai, X.</style></author><author><style face="normal" font="default" size="100%">Yin, L.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Anesthesia, General Hospital of Chengdu Military Area Command, Chengdu, 610000, Sichuan, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Lrg participates in lipopolysaccharide preconditioning-induced brain ischemia injury via TLR4 signaling pathway</style></title><secondary-title><style face="normal" font="default" size="100%">J Mol Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of molecular neuroscience : MN</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Mol Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of molecular neuroscience : MN</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Mol Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of molecular neuroscience : MN</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">20-6</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2014/02/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Glycoproteins/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interferon Regulatory Factor-3/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-1 Receptor-Associated Kinases/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lipopolysaccharides/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">Toll-Like Receptor 4/agonists/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Transcription Factor RelA/genetics/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-1166 (Electronic)&#xD;0895-8696 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24526448</style></accession-num><abstract><style face="normal" font="default" size="100%">Lipopolysaccharide (LPS) preconditioning is a powerful neuroprotective phenomenon by which an injurious stimulus renders the brain resistant to a subsequent damaging ischemic insult. The LPS response gene (Lrg) is a recently identified gene in human dental pulp cells treated with LPS. However, the role and mechanism of Lrg in brain ischemia injury have not yet been demonstrated. Here, we sought to determine whether Lrg participates in LPS preconditioning-induced brain ischemia injury. The Lrg protein accumulates in brain tissue after middle cerebral artery occlusion (MCAO). Furthermore, knockdown of Lrg by small interfering RNA (siRNA) significantly increased the infarct size of brain injury. In addition, we investigated the mechanism of Lrg in brain ischemia injury. Lrg-siRNA could regulate inflammatory cytokine expression. Moreover, interleukin-1 receptor-associated kinase 1 (IRAK-1) and nuclear factor Kappa B (NF-kappaB) p65 protein levels were significantly increased by Lrg-siRNA in mice after MCAO. Conversely, interferon regulatory factor 3 (IRF3) protein level was decreased by Lrg-siRNA. Taken together, these results suggest that Lrg regulates the expression of inflammatory cytokines in LPS preconditioning-induced brain ischemia injury via the toll-like receptor 4 (TLR4) signaling pathway. Lrg may therefore serve as a novel therapeutic target for brain ischemia injury.</style></abstract><notes><style face="normal" font="default" size="100%">Gong, Gu&#xD;Bai, Shurong&#xD;Wu, Wei&#xD;Hu, Ling&#xD;Liu, Yinghai&#xD;Niu, Jie&#xD;Dai, Xuemei&#xD;Yin, Liang&#xD;Wang, Xiaowu&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Mol Neurosci. 2014 Sep;54(1):20-6. doi: 10.1007/s12031-014-0240-8. Epub 2014 Feb 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/261/art%253A10.1007%252Fs12031-014-0240-8.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12031-014-0240-8&amp;token2=exp=1484113434~acl=%2Fstatic%2Fpdf%2F261%2Fart%25253A10.1007%25252Fs12031-014-0240-8.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs12031-014-0240-8*~hmac=1751743a3a2b9d3b18f608600b903993d54cf0f2714bc90820aaec082b948023</style></url></related-urls><pdf-urls><url>internal-pdf://2949743849/Gong-2014-Lrg participates in.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12031-014-0240-8</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>220</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">220</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Grabmaier, U.</style></author><author><style face="normal" font="default" size="100%">Theiss, H. D.</style></author><author><style face="normal" font="default" size="100%">Keithahn, A.</style></author><author><style face="normal" font="default" size="100%">Kreiner, J.</style></author><author><style face="normal" font="default" size="100%">Brenner, C.</style></author><author><style face="normal" font="default" size="100%">Huber, B.</style></author><author><style face="normal" font="default" size="100%">von der Helm, C.</style></author><author><style face="normal" font="default" size="100%">Gross, L.</style></author><author><style face="normal" font="default" size="100%">Klingel, K.</style></author><author><style face="normal" font="default" size="100%">Franz, W. M.</style></author><author><style face="normal" font="default" size="100%">Brunner, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine I, Ludwig-Maximilians-University, Campus Grosshadern, Munich, Germany.&#xD;Department of Nuclear Medicine, Klinikum Rechts der Isar, Munich, Germany.&#xD;Department of Dermatology, Klinikum Augsburg, Augsburg, Germany.&#xD;Department of Molecular Pathology, University of Tubingen, Tubingen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The role of 1.5 tesla MRI and anesthetic regimen concerning cardiac analysis in mice with cardiomyopathy</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PloS one</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e94615</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2014/04/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anesthetics/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiomyopathies/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Heart/ drug effects/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Function Tests/instrumentation/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke Volume/drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203 (Electronic)&#xD;1932-6203 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24747816</style></accession-num><abstract><style face="normal" font="default" size="100%">Accurate assessment of left ventricular function in rodent models is essential for the evaluation of new therapeutic approaches for cardiac diseases. In our study, we provide new insights regarding the role of a 1.5 Tesla (T) magnetic resonance imaging (MRI) device and different anesthetic regimens on data validity. As dedicated small animal MRI and echocardiographic devices are not broadly available, we evaluated whether monitoring cardiac function in small rodents with a clinical 1.5 T MRI device is feasible. On a clinical electrocardiogram (ECG) synchronized 1.5 T MRI scanner we therefore studied cardiac function parameters of mice with chronic virus-induced cardiomyopathy. Thus, reduced left ventricular ejection fraction (LVEF) could be verified compared to healthy controls. However, our results showed a high variability. First, anesthesia with medetomidine, midazolam and fentanyl (MMF) led to depressed cardiac function parameters and more variability than isoflurane gas inhalation anesthesia, especially at high concentrations. Furthermore, calculation of an average ejection fraction value from sequenced scans significantly reduced the variance of the results. To sum up, we introduce the clinical 1.5 T MRI device as a new tool for effective analysis of left ventricular function in mice with cardiomyopathy. Besides, we suggest isoflurane gas inhalation anesthesia at high concentrations for variance reduction and recommend calculation of an average ejection fraction value from multiple sequenced MRI scans to provide valid data and a solid basis for further clinical testing.</style></abstract><notes><style face="normal" font="default" size="100%">Grabmaier, Ulrich&#xD;Theiss, Hans D&#xD;Keithahn, Alexandra&#xD;Kreiner, Julia&#xD;Brenner, Christoph&#xD;Huber, Bruno&#xD;von der Helm, Christine&#xD;Gross, Lisa&#xD;Klingel, Karin&#xD;Franz, Wolfgang-M&#xD;Brunner, Stefan&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;PLoS One. 2014 Apr 18;9(4):e94615. doi: 10.1371/journal.pone.0094615. eCollection 2014.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0094615&amp;type=printable</style></url></related-urls><pdf-urls><url>internal-pdf://2306657614/Grabmaier-2014-The role of 1.5 tesl.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3991627</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0094615</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>359</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">359</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gredal, H.</style></author><author><style face="normal" font="default" size="100%">Toft, N.</style></author><author><style face="normal" font="default" size="100%">Westrup, U.</style></author><author><style face="normal" font="default" size="100%">Motta, L.</style></author><author><style face="normal" font="default" size="100%">Gideon, P.</style></author><author><style face="normal" font="default" size="100%">Arlien-Soborg, P.</style></author><author><style face="normal" font="default" size="100%">Skerritt, G. C.</style></author><author><style face="normal" font="default" size="100%">Berendt, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Small Animal Clinical Sciences, Faculty of Life Sciences, University of Copenhagen, Dyrlaegevej 16, DK-1870 Frederiksberg C, Denmark. hbg@life.ku.dk</style></auth-address><titles><title><style face="normal" font="default" size="100%">Survival and clinical outcome of dogs with ischaemic stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Vet J</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Veterinary journal (London, England : 1997)</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Vet J</style></full-title><abbr-1><style face="normal" font="default" size="100%">Veterinary journal (London, England : 1997)</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Vet J</style></full-title><abbr-1><style face="normal" font="default" size="100%">Veterinary journal (London, England : 1997)</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">408-13</style></pages><volume><style face="normal" font="default" size="100%">196</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2012/12/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Dog Diseases/mortality/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Dogs</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemia/mortality/pathology/ veterinary</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/mortality/pathology/ veterinary</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1532-2971 (Electronic)&#xD;1090-0233 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23206661</style></accession-num><abstract><style face="normal" font="default" size="100%">The objectives of the present study were to investigate survival time, possible predictors of survival and clinical outcome in dogs with ischaemic stroke. A retrospective study of dogs with a previous diagnosis of ischaemic stroke diagnosed by magnetic resonance imaging (MRI) was performed. The association between survival and the hypothesised risk factors was examined using univariable exact logistic regression. Survival was examined using Kaplan-Meier and Cox regression. Twenty-two dogs were identified. Five dogs (23%) died within the first 30days of the stroke event. Median survival in 30-day survivors was 505days. Four dogs (18%) were still alive by the end of the study. Right-sided lesions posed a significantly increased risk of mortality with a median survival time in dogs with right-sided lesions of 24days vs. 602days in dogs with left sided lesions (P=0.006). Clinical outcome was considered excellent in seven of 17 (41%) 30-day survivors. Another seven 30-day survivors experienced new acute neurological signs within 6-17months of the initial stroke event; in two of those cases a new ischaemic stroke was confirmed by MRI. In conclusion, dogs with ischaemic stroke have a fair to good prognosis in terms of survival and clinical outcome. However, owners should be informed of the risk of acute death within 30days and of the possibility of new neurological events in survivors. Mortality was increased in dogs with right-sided lesions in this study.</style></abstract><notes><style face="normal" font="default" size="100%">Gredal, H&#xD;Toft, N&#xD;Westrup, U&#xD;Motta, L&#xD;Gideon, P&#xD;Arlien-Soborg, P&#xD;Skerritt, G C&#xD;Berendt, M&#xD;England&#xD;Vet J. 2013 Jun;196(3):408-13. doi: 10.1016/j.tvjl.2012.10.018. Epub 2012 Dec 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S1090023312004534/1-s2.0-S1090023312004534-main.pdf?_tid=2827d6ce-d7be-11e6-a0cd-00000aacb361&amp;acdnat=1484112420_ad58157fe359d03f5533db61ddfed0ac</style></url></related-urls><pdf-urls><url>internal-pdf://0128752376/Gredal-2013-Survival and clinica.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.tvjl.2012.10.018</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>28</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">28</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gu, W. W.</style></author><author><style face="normal" font="default" size="100%">Lu, S. Q.</style></author><author><style face="normal" font="default" size="100%">Ni, Y.</style></author><author><style face="normal" font="default" size="100%">Liu, Z. H.</style></author><author><style face="normal" font="default" size="100%">Zhou, X. Y.</style></author><author><style face="normal" font="default" size="100%">Zhu, Y. M.</style></author><author><style face="normal" font="default" size="100%">Luo, Y.</style></author><author><style face="normal" font="default" size="100%">Li, X.</style></author><author><style face="normal" font="default" size="100%">Li, L. S.</style></author><author><style face="normal" font="default" size="100%">Sun, W. Z.</style></author><author><style face="normal" font="default" size="100%">Zhang, H. L.</style></author><author><style face="normal" font="default" size="100%">Ao, G. Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases, Department of Pharmacology, Laboratory of Cerebrovascular Pharmacology, College of Pharmaceutical Science, Soochow University, Suzhou 215123, China; Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, School of Public Health, Soochow University, Suzhou 215123, China.&#xD;Department of Emergency, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.&#xD;Guangzhou Institute of Traumatic Surgery, Guangzhou Red Cross Hospital, Medical College, Jinan University, Guangzhou 510220, China.&#xD;The Second High School Attached to Beijing Normal University, Beijing 100091, China.&#xD;Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases, Department of Pharmacology, Laboratory of Cerebrovascular Pharmacology, College of Pharmaceutical Science, Soochow University, Suzhou 215123, China; Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, School of Public Health, Soochow University, Suzhou 215123, China. Electronic address: huilingzhang07@hotmail.com.&#xD;Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases, Department of Pharmacology, Laboratory of Cerebrovascular Pharmacology, College of Pharmaceutical Science, Soochow University, Suzhou 215123, China; Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, School of Public Health, Soochow University, Suzhou 215123, China. Electronic address: aoguizhen@suda.edu.cn.</style></auth-address><titles><title><style face="normal" font="default" size="100%">2-(3&apos;,5&apos;-Dimethoxybenzylidene) cyclopentanone, a novel synthetic small-molecule compound, provides neuroprotective effects against ischemic stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Neuroscience</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">26-40</style></pages><volume><style face="normal" font="default" size="100%">316</style></volume><edition><style face="normal" font="default" size="100%">2015/12/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Benzylidene Compounds/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/cytology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclopentanes/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Glial Fibrillary Acidic Protein/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose/deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle Strength/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Neurologic Examination</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Psychomotor Performance/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 01</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1873-7544 (Electronic)&#xD;0306-4522 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26656221</style></accession-num><abstract><style face="normal" font="default" size="100%">2-(3&apos;,5&apos;-Dimethoxybenzylidene) cyclopentanone (DMBC) is a novel small-molecule compound synthesized by our group. Here, we found that in rat models of permanent middle cerebral artery occlusion (pMCAO), intraperitoneal injection (ip) of DMBC at 1h after ischemia reduced infarct volume, improved neurological deficits and increased the protein levels of microtubule-associated protein 2 (MAP 2) and glial fibrillary acid protein (GFAP) in the ischemic cortex. Post-treatment of DMBC still produced neuroprotective effects even when administered at 6h after ischemia. In the oxygen-glucose deprivation (OGD)-induced astrocytes or HT22 cell injury, DMBC treatment decreased the OGD-induced lactate dehydrogenase (LDH) leakage and increased the GFAP levels in astrocytes. In addition, Annexin-V-Fluos staining analysis revealed that DMBC treatment attenuated both OGD-induced apoptosis and necrosis in astrocytes. Western blotting analysis showed DMBC treatment inhibited the ischemia or OGD-induced increases in active cathepsin B in the ischemic cortex or in astrocytes or HT22 cells. Immunofluorescence analysis demonstrated that DMBC treatment blocked the ischemia or OGD-induced release of cathepsin B from the lysosomes into the cytoplasm in the ischemic cortex or in astrocytes or HT22 cells. Taken together, our results indicate that DMBC can offer neuroprotective effects against cerebral ischemia with an extended therapeutic window and its mechanism might be associated with inhibition of the cathepsin B activation.</style></abstract><notes><style face="normal" font="default" size="100%">Gu, W W&#xD;Lu, S Q&#xD;Ni, Y&#xD;Liu, Z H&#xD;Zhou, X Y&#xD;Zhu, Y M&#xD;Luo, Y&#xD;Li, X&#xD;Li, L S&#xD;Sun, W Z&#xD;Zhang, H L&#xD;Ao, G Z&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Neuroscience. 2016 Mar 1;316:26-40. doi: 10.1016/j.neuroscience.2015.11.052. Epub 2015 Nov 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0306452215010519/1-s2.0-S0306452215010519-main.pdf?_tid=34477810-d7be-11e6-961f-00000aacb35d&amp;acdnat=1484112440_02506f1d8fe53adfa13adcf9f769969c</style></url></related-urls><pdf-urls><url>internal-pdf://4288800002/Gu-2016-2-(3&apos;,5&apos;-Dimethoxybe.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuroscience.2015.11.052</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>440</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">440</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gu, X.</style></author><author><style face="normal" font="default" size="100%">Liu, X. Y.</style></author><author><style face="normal" font="default" size="100%">Fagan, A.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Toledo, M. E.</style></author><author><style face="normal" font="default" size="100%">Zhao, L. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathology, Louisiana State University Health Sciences Center, Shreveport, LA 71130-3932, USA. XGu@lsuhsc.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">Ultrastructural changes in cerebral capillary pericytes in aged Notch3 mutant transgenic mice</style></title><secondary-title><style face="normal" font="default" size="100%">Ultrastruct Pathol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Ultrastructural pathology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Ultrastruct Pathol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Ultrastructural pathology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Ultrastruct Pathol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Ultrastructural pathology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">48-55</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2012/02/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aging/genetics/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">CADASIL/genetics/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Capillaries/ ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/ blood supply/ ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Microscopy, Electron, Transmission</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle, Smooth, Vascular/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Pericytes/ ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Notch3</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Notch/ genetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1521-0758 (Electronic)&#xD;0191-3123 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22292737</style></accession-num><abstract><style face="normal" font="default" size="100%">Pericytes, the specialized vascular smooth muscle cells (VSMCs), play an important role in supporting and maintaining the structure of capillaries. Pericytes show biochemical and physiologic features similar to VSMC, usually containing smooth muscle actin fibers and rich endoplasm reticulum. Studies have indicated that degeneration of VSMCs due to Notch3 mutations is the cause of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). However, it remains unclear whether the Notch3 mutation also affects cerebral cortex capillary pericytes. In this ultrastructural morphologic study, the authors have observed pathological changes in the cerebral cortex capillary pericytes in aged mice that carry human mutant Notch3 genes. The number of abnormal pericytes in the cerebral cortex in Notch3 gene mutant mice was slightly increased when compared to an age-matched control group. Morphologically, the pericytes in the brains of Notch3 gene mutant mice showed more severe cellular injury, such as the presence of damaged mitochondria, secondary lysosomes, and large cytoplasmic vesicles. In addition, morphologic structures related to autophagy were also present in the pericytes of Notch3 gene mutant group. These ultrastructural morphologic alterations suggest that Notch3 mutation precipitates age-related pericytic degeneration that might result in cellular injury and trigger autophagic apoptosis. Microvascular dysfunction due to pericyte degeneration could initiate secondary neurodegenerative changes in brain parenchyma. These findings provide new insight into understanding the role of pericyte degeneration in the phathogenesis of CADASIL disease.</style></abstract><notes><style face="normal" font="default" size="100%">Gu, Xin&#xD;Liu, Xiao-Yun&#xD;Fagan, Austin&#xD;Gonzalez-Toledo, Maria E&#xD;Zhao, Li-Ru&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Ultrastruct Pathol. 2012 Feb;36(1):48-55. doi: 10.3109/01913123.2011.620220.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3109/01913123.2011.620220</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>238</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">238</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gu, Y.</style></author><author><style face="normal" font="default" size="100%">Chen, J.</style></author><author><style face="normal" font="default" size="100%">Shen, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, 10 Sassoon Road, Pokfulam, Hong Kong, SAR, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Herbal medicines for ischemic stroke: combating inflammation as therapeutic targets</style></title><secondary-title><style face="normal" font="default" size="100%">J Neuroimmune Pharmacol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neuroimmune Pharmacol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neuroimmune Pharmacol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">313-39</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2014/02/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ drug therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Delivery Systems/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Herbal Medicine/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/immunology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation Mediators/ antagonists &amp; inhibitors/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Preparations/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ drug therapy/immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1557-1904 (Electronic)&#xD;1557-1890 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24562591</style></accession-num><abstract><style face="normal" font="default" size="100%">Stroke is a debilitating disease for which limited therapeutic approaches are available currently. Thus, there is an urgent need for developing novel therapies for stroke. Astrocytes, endothelial cells and pericytes constitute a neurovascular network for metabolic requirement of neurons. During ischemic stroke, these cells contribute to post-ischemic inflammation at multiple stages of ischemic cascades. Upon ischemia onset, activated resident microglia and astrocytes, and infiltrated immune cells release multiple inflammation factors including cytokines, chemokines, enzymes, free radicals and other small molecules, not only inducing brain damage but affecting brain repair. Recent progress indicates that anti-inflammation is an important therapeutic strategy for stroke. Given a long history with direct experience in the treatment of human subjects, Traditional Chinese Medicine and its related natural compounds are recognized as important sources for drug discovery. Last decade, a great progress has been made to identify active compounds from herbal medicines with the properties of modulating post-ischemic inflammation for neuroprotection. Herein, we discuss the inflammatory pathway in early stage and secondary response to injured tissues after stroke from initial artery occlusion to brain repair, and review the active ingredients from natural products with anti-inflammation and neuroprotection effects as therapeutic agents for ischemic stroke. Further studies on the post-ischemic inflammatory mechanisms and corresponding drug candidates from herbal medicine may lead to the development of novel therapeutic strategies in stroke treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Gu, Yong&#xD;Chen, Jianping&#xD;Shen, Jiangang&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;United States&#xD;J Neuroimmune Pharmacol. 2014 Jun;9(3):313-39. doi: 10.1007/s11481-014-9525-5. Epub 2014 Feb 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/486/art%253A10.1007%252Fs11481-014-9525-5.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs11481-014-9525-5&amp;token2=exp=1484113445~acl=%2Fstatic%2Fpdf%2F486%2Fart%25253A10.1007%25252Fs11481-014-9525-5.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs11481-014-9525-5*~hmac=3cb9bc4962061890260ebc1354eb99856fa8cce2c19911c6c867e134811476d5</style></url></related-urls><pdf-urls><url>internal-pdf://0986950789/Gu-2014-Herbal medicines for.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s11481-014-9525-5</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>354</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">354</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Halder, S. K.</style></author><author><style face="normal" font="default" size="100%">Matsunaga, H.</style></author><author><style face="normal" font="default" size="100%">Yamaguchi, H.</style></author><author><style face="normal" font="default" size="100%">Ueda, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Molecular Pharmacology and Neuroscience, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8521, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Novel neuroprotective action of prothymosin alpha-derived peptide against retinal and brain ischemic damages</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurochem</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neurochemistry</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurochem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurochemistry</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurochem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurochemistry</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">713-23</style></pages><volume><style face="normal" font="default" size="100%">125</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2013/01/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Amino Acid Sequence</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/pathology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Survival/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Sequence Data</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Precursors/genetics/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Retinal Diseases/pathology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Thymosin/ analogs &amp; derivatives/genetics/pharmacology/therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1471-4159 (Electronic)&#xD;0022-3042 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23278181</style></accession-num><abstract><style face="normal" font="default" size="100%">Prothymosin alpha (ProTalpha), a nuclear protein, is implicated in the inhibition of ischemia-induced necrosis as well as apoptosis in the brain and retina. Although ProTalpha has multiple biological functions through distinct regions in its sequence, it has remained which region is involved in this neuroprotection. This study reported that the active core peptide sequence P30 (amino acids 49-78) of ProTalpha exerts its full survival effect in cultured cortical neurons against ischemic stress. Our in vivo study revealed that intravitreous administration of P30 at 24 h after retinal ischemia significantly blocks the ischemia-induced functional damages of retina at day 7. In addition, P30 completely rescued the retinal ischemia-induced ganglion cell damages at day 7 after the ischemic stress, along with partial blockade of the loss of bipolar, amacrine, and photoreceptor cells. On the other hand, intracerebroventricular (3 nmol) or systemic (1 mg/kg; i.v.) injection of P30 at 1 h after cerebral ischemia (1 h tMCAO) significantly blocked the ischemia-induced brain damages and disruption of blood vessels. Systemic P30 delivery (1 mg/kg; i.v.) also significantly ameliorated the ischemic brain caused by photochemically induced thrombosis. Taken together, this study confers a precise demonstration about the novel protective activity of ProTalpha-derived small peptide P30 against the ischemic damages in vitro and in vivo.</style></abstract><notes><style face="normal" font="default" size="100%">Halder, Sebok Kumar&#xD;Matsunaga, Hayato&#xD;Yamaguchi, Haruka&#xD;Ueda, Hiroshi&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Neurochem. 2013 Jun;125(5):713-23. doi: 10.1111/jnc.12132. Epub 2013 Jan 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/jnc.12132/asset/jnc12132.pdf?v=1&amp;t=ixsi47h7&amp;s=ae1e3753f022b49bd7a12ab0e9720870dd3bae77</style></url></related-urls><pdf-urls><url>internal-pdf://2504387494/Halder-2013-Novel neuroprotectiv.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/jnc.12132</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>231</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">231</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hall, C. N.</style></author><author><style face="normal" font="default" size="100%">Reynell, C.</style></author><author><style face="normal" font="default" size="100%">Gesslein, B.</style></author><author><style face="normal" font="default" size="100%">Hamilton, N. B.</style></author><author><style face="normal" font="default" size="100%">Mishra, A.</style></author><author><style face="normal" font="default" size="100%">Sutherland, B. A.</style></author><author><style face="normal" font="default" size="100%">O&apos;Farrell, F. M.</style></author><author><style face="normal" font="default" size="100%">Buchan, A. M.</style></author><author><style face="normal" font="default" size="100%">Lauritzen, M.</style></author><author><style face="normal" font="default" size="100%">Attwell, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">1] Department of Neuroscience, Physiology and Pharmacology, University College London, Gower Street, London, WC1E 6BT, UK [2].&#xD;1] Department of Neuroscience and Pharmacology and Center for Healthy Aging, University of Copenhagen, DK-2200 Copenhagen N, Denmark [2].&#xD;Acute Stroke Programme, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DU, UK.&#xD;Department of Neuroscience, Physiology and Pharmacology, University College London, Gower Street, London, WC1E 6BT, UK.&#xD;1] Department of Neuroscience and Pharmacology and Center for Healthy Aging, University of Copenhagen, DK-2200 Copenhagen N, Denmark [2] Department of Clinical Neurophysiology, Glostrup University Hospital, DK-2600 Glostrup, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Capillary pericytes regulate cerebral blood flow in health and disease</style></title><secondary-title><style face="normal" font="default" size="100%">Nature</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Nature</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nature</style></full-title><abbr-1><style face="normal" font="default" size="100%">Nature</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Nature</style></full-title><abbr-1><style face="normal" font="default" size="100%">Nature</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">55-60</style></pages><volume><style face="normal" font="default" size="100%">508</style></volume><number><style face="normal" font="default" size="100%">7494</style></number><edition><style face="normal" font="default" size="100%">2014/03/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arterioles/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Capillaries/ cytology/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Death</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebellum/blood supply</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/blood supply/cytology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/drug effects/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Dinoprostone/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Excitatory Amino Acid Antagonists/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Functional Neuroimaging</style></keyword><keyword><style face="normal" font="default" size="100%">Glutamic Acid/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Hydroxyeicosatetraenoic Acids/biosynthesis</style></keyword><keyword><style face="normal" font="default" size="100%">In Vitro Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Pericytes/cytology/drug effects/pathology/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Glutamate/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Vasoconstriction</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilation/drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 03</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1476-4687 (Electronic)&#xD;0028-0836 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24670647</style></accession-num><abstract><style face="normal" font="default" size="100%">Increases in brain blood flow, evoked by neuronal activity, power neural computation and form the basis of BOLD (blood-oxygen-level-dependent) functional imaging. Whether blood flow is controlled solely by arteriole smooth muscle, or also by capillary pericytes, is controversial. We demonstrate that neuronal activity and the neurotransmitter glutamate evoke the release of messengers that dilate capillaries by actively relaxing pericytes. Dilation is mediated by prostaglandin E2, but requires nitric oxide release to suppress vasoconstricting 20-HETE synthesis. In vivo, when sensory input increases blood flow, capillaries dilate before arterioles and are estimated to produce 84% of the blood flow increase. In pathology, ischaemia evokes capillary constriction by pericytes. We show that this is followed by pericyte death in rigor, which may irreversibly constrict capillaries and damage the blood-brain barrier. Thus, pericytes are major regulators of cerebral blood flow and initiators of functional imaging signals. Prevention of pericyte constriction and death may reduce the long-lasting blood flow decrease that damages neurons after stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Hall, Catherine N&#xD;Reynell, Clare&#xD;Gesslein, Bodil&#xD;Hamilton, Nicola B&#xD;Mishra, Anusha&#xD;Sutherland, Brad A&#xD;O&apos;Farrell, Fergus M&#xD;Buchan, Alastair M&#xD;Lauritzen, Martin&#xD;Attwell, David&#xD;075232/Wellcome Trust/United Kingdom&#xD;G0500495/Medical Research Council/United Kingdom&#xD;Medical Research Council/United Kingdom&#xD;Wellcome Trust/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Nature. 2014 Apr 3;508(7494):55-60. doi: 10.1038/nature13165. Epub 2014 Mar 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.nature.com/nature/journal/v508/n7494/pdf/nature13165.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3779838175/Hall-2014-Capillary pericytes.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3976267</style></custom2><custom6><style face="normal" font="default" size="100%">Ems57101</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/nature13165</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>145</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">145</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Han, J. E.</style></author><author><style face="normal" font="default" size="100%">Lee, E. J.</style></author><author><style face="normal" font="default" size="100%">Moon, E.</style></author><author><style face="normal" font="default" size="100%">Ryu, J. H.</style></author><author><style face="normal" font="default" size="100%">Choi, J. W.</style></author><author><style face="normal" font="default" size="100%">Kim, H. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Neuropharmacology, College of Pharmacy and Gachon Institute of Pharmaceutical Sciences, Gachon University, 191 Hambakmoero, Yeonsu-gu, Incheon, 406-799, Republic of Korea.&#xD;Department of Molecular Medicine and Tissue Injury Defense Research Center, Ewha Womans University Medical School, Mok-6-dong 911-1, Yangchun-Ku, Seoul, 158-710, Republic of Korea.&#xD;Department of Life and Nanopharmaceutical Sciences, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea.&#xD;Laboratory of Neuropharmacology, College of Pharmacy and Gachon Institute of Pharmaceutical Sciences, Gachon University, 191 Hambakmoero, Yeonsu-gu, Incheon, 406-799, Republic of Korea. pharmchoi@gachon.ac.kr.&#xD;Department of Molecular Medicine and Tissue Injury Defense Research Center, Ewha Womans University Medical School, Mok-6-dong 911-1, Yangchun-Ku, Seoul, 158-710, Republic of Korea. hskimp@ewha.ac.kr.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Matrix Metalloproteinase-8 is a Novel Pathogenetic Factor in Focal Cerebral Ischemia</style></title><secondary-title><style face="normal" font="default" size="100%">Mol Neurobiol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Molecular neurobiology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Mol Neurobiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Molecular neurobiology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Mol Neurobiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Molecular neurobiology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">231-9</style></pages><volume><style face="normal" font="default" size="100%">53</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2014/11/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/drug effects/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/drug effects/enzymology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/complications/ enzymology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Claudin-5/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Down-Regulation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/complications/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Lentivirus/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Matrix Metalloproteinase 8/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred ICR</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation/drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-1182 (Electronic)&#xD;0893-7648 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25421209</style></accession-num><abstract><style face="normal" font="default" size="100%">The neutrophil collagenase matrix metalloproteinase-8 (MMP8) is a recently identified member of MMPs that have important roles in various inflammation-related disorders. Previously, we identified MMP8 as a new neuroinflammatory mediator in activated microglia by regulating TNF-alpha productivity. Here, we present evidence that MMP8 is a critical factor for brain damage in transient focal cerebral ischemia by modulating neuroinflammation likely microglial activation and TNF-alpha production. Biochemical analyses showed upregulation of MMP8 expression at mRNA and protein levels in transient middle cerebral artery occlusion/reperfusion (M/R)-challenged brains. Furthermore, double immunolabeling showed that MMP8 expression was upregulated in the activated microglia of M/R-challenged brains. Assessment of infarct volume, neurological score, and survival/death of neural cells revealed that administration of an MMP8 inhibitor (M8I) immediately after reperfusion reduced brain damage. Histological analyses showed that microglial activation and TNF-alpha expression in ischemic conditions was abrogated by exposure to M8I, as demonstrated in our previous study using cultured microglia. These outcomes from a pharmacological approach were reaffirmed by a genetic approach using a lentiviral system. Intracerebroventricular microinjection of MMP8-specific shRNA lentivirus reduced the extent of ischemia-induced brain damage, as assessed by infarct volume, neurological score, microglial activation, and TNF-alpha expression. These results suggest a novel pathogenetic role of MMP8 and implicate modulation of its activity as a tractable strategy for therapies against cerebral ischemia.</style></abstract><notes><style face="normal" font="default" size="100%">Han, Jeong Eun&#xD;Lee, Eun-Jung&#xD;Moon, Eunjung&#xD;Ryu, Jong Hoon&#xD;Choi, Ji Woong&#xD;Kim, Hee-Sun&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Mol Neurobiol. 2016 Jan;53(1):231-9. doi: 10.1007/s12035-014-8996-y. Epub 2014 Nov 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/292/art%253A10.1007%252Fs12035-014-8996-y.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12035-014-8996-y&amp;token2=exp=1484113457~acl=%2Fstatic%2Fpdf%2F292%2Fart%25253A10.1007%25252Fs12035-014-8996-y.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs12035-014-8996-y*~hmac=52d5d22cac1003c1fa133b482bd86b95100701464c6ca7f13df5d202652c88b1</style></url></related-urls><pdf-urls><url>internal-pdf://0325310924/Han-2016-Matrix Metalloprotei.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12035-014-8996-y</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>339</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">339</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Harms, C.</style></author><author><style face="normal" font="default" size="100%">Datwyler, A. L.</style></author><author><style face="normal" font="default" size="100%">Wiekhorst, F.</style></author><author><style face="normal" font="default" size="100%">Trahms, L.</style></author><author><style face="normal" font="default" size="100%">Lindquist, R.</style></author><author><style face="normal" font="default" size="100%">Schellenberger, E.</style></author><author><style face="normal" font="default" size="100%">Mueller, S.</style></author><author><style face="normal" font="default" size="100%">Schutz, G.</style></author><author><style face="normal" font="default" size="100%">Roohi, F.</style></author><author><style face="normal" font="default" size="100%">Ide, A.</style></author><author><style face="normal" font="default" size="100%">Fuchtemeier, M.</style></author><author><style face="normal" font="default" size="100%">Gertz, K.</style></author><author><style face="normal" font="default" size="100%">Kronenberg, G.</style></author><author><style face="normal" font="default" size="100%">Harms, U.</style></author><author><style face="normal" font="default" size="100%">Endres, M.</style></author><author><style face="normal" font="default" size="100%">Dirnagl, U.</style></author><author><style face="normal" font="default" size="100%">Farr, T. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Experimental Neurology, Center for Stroke Research Berlin, Charite University Medicine, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Certain types of iron oxide nanoparticles are not suited to passively target inflammatory cells that infiltrate the brain in response to stroke</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e1-9</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2013/02/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ blood supply/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Contrast Media/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocytes/cytology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetite Nanoparticles/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Particle Size</style></keyword><keyword><style face="normal" font="default" size="100%">Phagocytosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23443176</style></accession-num><abstract><style face="normal" font="default" size="100%">Intravenous administration of iron oxide nanoparticles during the acute stage of experimental stroke can produce signal intensity changes in the ischemic region. This has been attributed, albeit controversially, to the infiltration of iron-laden blood-borne macrophages. The properties of nanoparticles that render them most suitable for phagocytosis is a matter of debate, as is the most relevant timepoint for administration. Both of these questions are examined in the present study. Imaging experiments were performed in mice with 30 minutes of middle cerebral artery occlusion (MCAO). Iron oxide nanoparticles with different charges and sizes were used, and mice received 300 mumol Fe/kg intravenously: either superparamagnetic iron oxide nanoparticles (SPIOs), ultrasmall SPIOs, or very small SPIOs. The particles were administered 7 days before MCAO, at the time of reperfusion, or 72 hours after MCAO. Interestingly, there was no observable signal change in the ischemic brains that could be attributed to iron. Furthermore, no Prussian blue-positive cells were found in the brains or blood leukocytes, despite intense staining in the livers and spleens. This implies that the nanoparticles selected for this study are not phagocytosed by blood-borne leukocytes and do not enter the ischemic mouse brain.</style></abstract><notes><style face="normal" font="default" size="100%">Harms, Christoph&#xD;Datwyler, Anna Lena&#xD;Wiekhorst, Frank&#xD;Trahms, Lutz&#xD;Lindquist, Randall&#xD;Schellenberger, Eyk&#xD;Mueller, Susanne&#xD;Schutz, Gunnar&#xD;Roohi, Farnoosh&#xD;Ide, Andreas&#xD;Fuchtemeier, Martina&#xD;Gertz, Karen&#xD;Kronenberg, Golo&#xD;Harms, Ulrike&#xD;Endres, Matthias&#xD;Dirnagl, Ulrich&#xD;Farr, Tracy D&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Cereb Blood Flow Metab. 2013 May;33(5):e1-9. doi: 10.1038/jcbfm.2013.22. Epub 2013 Feb 27.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3652690</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2013.22</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>467</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">467</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hartz, A. M.</style></author><author><style face="normal" font="default" size="100%">Bauer, B.</style></author><author><style face="normal" font="default" size="100%">Soldner, E. L.</style></author><author><style face="normal" font="default" size="100%">Wolf, A.</style></author><author><style face="normal" font="default" size="100%">Boy, S.</style></author><author><style face="normal" font="default" size="100%">Backhaus, R.</style></author><author><style face="normal" font="default" size="100%">Mihaljevic, I.</style></author><author><style face="normal" font="default" size="100%">Bogdahn, U.</style></author><author><style face="normal" font="default" size="100%">Klunemann, H. H.</style></author><author><style face="normal" font="default" size="100%">Schuierer, G.</style></author><author><style face="normal" font="default" size="100%">Schlachetzki, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmaceutical Sciences, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Amyloid-beta contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">514-23</style></pages><volume><style face="normal" font="default" size="100%">43</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2011/11/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Amyloid beta-Peptides/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Amyloid beta-Protein Precursor/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apolipoproteins E/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Blotting, Western</style></keyword><keyword><style face="normal" font="default" size="100%">Capillaries/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Membrane/pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Amyloid Angiopathy/ genetics/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/etiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorescent Dyes</style></keyword><keyword><style face="normal" font="default" size="100%">Hemosiderosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Matrix Metalloproteinases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Selection</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/classification/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Tight Junctions/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Tomography, X-Ray Computed</style></keyword><keyword><style face="normal" font="default" size="100%">Xanthenes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22116809</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: Cerebral amyloid angiopathy (CAA) is a degenerative disorder characterized by amyloid-beta (Abeta) deposition in the blood-brain barrier (BBB). CAA contributes to injuries of the neurovasculature including lobar hemorrhages, cortical microbleeds, ischemia, and superficial hemosiderosis. We postulate that CAA pathology is partially due to Abeta compromising the BBB. METHODS: We characterized 19 patients with acute stroke with &quot;probable CAA&quot; for neurovascular pathology based on MRI and clinical findings. Also, we studied the effect of Abeta on the expression of tight junction proteins and matrix metalloproteases (MMPs) in isolated rat brain microvessels. RESULTS: Two of 19 patients with CAA had asymptomatic BBB leakage and posterior reversible encephalopathic syndrome indicating increased BBB permeability. In addition to white matter changes, diffusion abnormality suggesting lacunar ischemia was found in 4 of 19 patients with CAA; superficial hemosiderosis was observed in 7 of 9 patients. Abeta(40) decreased expression of the tight junction proteins claudin-1 and claudin-5 and increased expression of MMP-2 and MMP-9. Analysis of brain microvessels from transgenic mice overexpressing human amyloid precursor protein revealed the same expression pattern for tight junction and MMP proteins. Consistent with reduced tight junction and increased MMP expression and activity, permeability was increased in brain microvessels from human amyloid precursor protein mice compared with microvessels from wild-type controls. CONCLUSIONS: Our findings indicate that Abeta contributes to changes in brain microvessel tight junction and MMP expression, which compromises BBB integrity. We conclude that Abeta causes BBB leakage and that assessing BBB permeability could potentially help characterize CAA progression and be a surrogate marker for treatment response.</style></abstract><notes><style face="normal" font="default" size="100%">Hartz, Anika M S&#xD;Bauer, Bjorn&#xD;Soldner, Emma L B&#xD;Wolf, Andrea&#xD;Boy, Sandra&#xD;Backhaus, Roland&#xD;Mihaljevic, Ivan&#xD;Bogdahn, Ulrich&#xD;Klunemann, Hans H&#xD;Schuierer, Gerhard&#xD;Schlachetzki, Felix&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Stroke. 2012 Feb;43(2):514-23. doi: 10.1161/STROKEAHA.111.627562. Epub 2011 Nov 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/43/2/514.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2212829983/Hartz-2012-Amyloid-beta contrib.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.111.627562</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>469</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">469</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hattori, H.</style></author><author><style face="normal" font="default" size="100%">Suzuki, S.</style></author><author><style face="normal" font="default" size="100%">Okazaki, Y.</style></author><author><style face="normal" font="default" size="100%">Suzuki, N.</style></author><author><style face="normal" font="default" size="100%">Kuwana, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Intracranial transplantation of monocyte-derived multipotential cells enhances recovery after ischemic stroke in rats</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosci Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neuroscience research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosci Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroscience research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosci Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroscience research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">479-88</style></pages><volume><style face="normal" font="default" size="100%">90</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2011/11/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/pathology/physiopathology/ surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Injections, Intraventricular</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Monocytes/cytology/ transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Multipotent Stem Cells/pathology/ transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery of Function/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Stem Cell Transplantation/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/pathology/physiopathology/ surgery</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1097-4547 (Electronic)&#xD;0360-4012 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22057655</style></accession-num><abstract><style face="normal" font="default" size="100%">Cell transplantation has emerged as a potential therapy to reduce the neurological deficits caused by ischemic stroke. We previously reported a primitive cell population, monocyte-derived multipotential cells (MOMCs), which can differentiate into mesenchymal, neuronal, and endothelial lineages. In this study, MOMCs and macrophages were prepared from rat peripheral blood and transplanted intracranially into the ischemic core of syngeneic rats that had undergone a left middle cerebral artery occlusion procedure. Neurological deficits, as evaluated by the corner test, were less severe in the MOMC-transplanted rats than in macrophage-transplanted or mock-treated rats. Histological evaluations revealed that the number of microvessels that had formed in the ischemic boundary area by 4 weeks after transplantation was significantly greater in the MOMC-transplanted rats than in the control groups. The blood vessel formation was preceded by the appearance of round CD31(+) cells, which we confirmed were derived from the transplanted MOMCs. Small numbers of bloodvessels incorporating MOMC-derived endothelial cells expressing a mature endothelial marker RECA-1 were detected at 4 weeks after transplantation. In addition, MOMCs expressed a series of angiogenic factors, including vascular endothelial growth factor, angiopoetin-1, and placenta growth factor (PlGF). These findings provide evidence that the intracranial delivery of MOMCs enhances functional recovery by promoting neovascularization in a rat model for ischemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Hattori, Hidenori&#xD;Suzuki, Shigeaki&#xD;Okazaki, Yuka&#xD;Suzuki, Norihiro&#xD;Kuwana, Masataka&#xD;Comparative Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Neurosci Res. 2012 Feb;90(2):479-88. doi: 10.1002/jnr.22755. Epub 2011 Nov 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1002/jnr.22755/asset/22755_ftp.pdf?v=1&amp;t=ixsi4g0e&amp;s=6e7d57ca532fef15bc372da6474e8f3d268a5f14</style></url></related-urls><pdf-urls><url>internal-pdf://2607154183/Hattori-2012-Intracranial transpl.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/jnr.22755</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>106</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">106</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hattori, Y.</style></author><author><style face="normal" font="default" size="100%">Enmi, J.</style></author><author><style face="normal" font="default" size="100%">Kitamura, A.</style></author><author><style face="normal" font="default" size="100%">Yamamoto, Y.</style></author><author><style face="normal" font="default" size="100%">Saito, S.</style></author><author><style face="normal" font="default" size="100%">Takahashi, Y.</style></author><author><style face="normal" font="default" size="100%">Iguchi, S.</style></author><author><style face="normal" font="default" size="100%">Tsuji, M.</style></author><author><style face="normal" font="default" size="100%">Yamahara, K.</style></author><author><style face="normal" font="default" size="100%">Nagatsuka, K.</style></author><author><style face="normal" font="default" size="100%">Iida, H.</style></author><author><style face="normal" font="default" size="100%">Ihara, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departments of Regenerative Medicine and.&#xD;Investigative Radiology, National Cerebral and Cardiovascular Center, Suita, Osaka 565-8565 Japan.&#xD;Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto 606-8507 Japan, and.&#xD;Departments of Regenerative Medicine and Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto 606-8507 Japan, and.&#xD;Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto 606-8507 Japan, and Department of Stroke and Cerebrovascular Diseases, National Cerebral and Cardiovascular Center, Osaka 565-8565 Japan.&#xD;Department of Stroke and Cerebrovascular Diseases, National Cerebral and Cardiovascular Center, Osaka 565-8565 Japan.&#xD;Departments of Regenerative Medicine and Department of Stroke and Cerebrovascular Diseases, National Cerebral and Cardiovascular Center, Osaka 565-8565 Japan ihara@ncvc.go.jp.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A novel mouse model of subcortical infarcts with dementia</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">3915-28</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2015/03/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/pathology/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/ pathology/ psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Constriction, Pathologic</style></keyword><keyword><style face="normal" font="default" size="100%">Dementia/ pathology/ psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Dementia, Vascular/pathology/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Maze Learning</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Postural Balance</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke, Lacunar/pathology/psychology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 04</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1529-2401 (Electronic)&#xD;0270-6474 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25740520</style></accession-num><abstract><style face="normal" font="default" size="100%">Subcortical white matter (WM) is a frequent target of ischemic injury and extensive WM lesions are important substrates of vascular cognitive impairment (VCI) in humans. However, ischemic stroke rodent models have been shown to mainly induce cerebral infarcts in the gray matter, while cerebral hypoperfusion models show only WM rarefaction without infarcts. The lack of animal models consistently replicating WM infarct damage may partially explain why many neuroprotective drugs for ischemic stroke or VCI have failed clinically, despite earlier success in preclinical experiments. Here, we report a novel animal model of WM infarct damage with cognitive impairment can be generated by surgical implantation of different devices to the right and left common carotid artery (CCA) in C57BL/6J mice. Implantation of an ameroid constrictor to the right CCA resulted in gradual occlusion of the vessel over 28 d, whereas placement of a microcoil to the left CCA induced approximately 50% arterial stenosis. Arterial spin labeling showed a gradual reduction of cerebral blood flow over 28 d post operation. Such reductions were more marked in the right, compared with the left, hemisphere and in subcortical, rather than the cortical, areas. Histopathological analysis showed multiple infarct damage in right subcortical regions, including the corpus callosum, internal capsule, hippocampal fimbria, and caudoputamen, in 81% of mice. Mice displaying such damage performed significantly poorer in locomotor and cognitive tests. The current mouse model replicates the phenotypes of human subcortical VCI, including multiple WM infarcts with motor and cognitive impairment.</style></abstract><notes><style face="normal" font="default" size="100%">Hattori, Yorito&#xD;Enmi, Jun-ichiro&#xD;Kitamura, Akihiro&#xD;Yamamoto, Yumi&#xD;Saito, Satoshi&#xD;Takahashi, Yukako&#xD;Iguchi, Satoshi&#xD;Tsuji, Masahiro&#xD;Yamahara, Kenichi&#xD;Nagatsuka, Kazuyuki&#xD;Iida, Hidehiro&#xD;Ihara, Masafumi&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Neurosci. 2015 Mar 4;35(9):3915-28. doi: 10.1523/JNEUROSCI.3970-14.2015.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.jneurosci.org/content/jneuro/35/9/3915.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1888703232/Hattori-2015-A novel mouse model.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1523/jneurosci.3970-14.2015</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>356</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">356</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hayakawa, K.</style></author><author><style face="normal" font="default" size="100%">Miyamoto, N.</style></author><author><style face="normal" font="default" size="100%">Seo, J. H.</style></author><author><style face="normal" font="default" size="100%">Pham, L. D.</style></author><author><style face="normal" font="default" size="100%">Kim, K. W.</style></author><author><style face="normal" font="default" size="100%">Lo, E. H.</style></author><author><style face="normal" font="default" size="100%">Arai, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Neuroprotection Research Laboratory, Departments of Radiology and Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.&#xD;NeuroVascular Coordination Research Center, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea.&#xD;Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">High-mobility group box 1 from reactive astrocytes enhances the accumulation of endothelial progenitor cells in damaged white matter</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurochem</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neurochemistry</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurochem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurochemistry</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurochem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurochemistry</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">273-80</style></pages><volume><style face="normal" font="default" size="100%">125</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2012/12/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Blotting, Western</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelial Progenitor Cells/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Flow Cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">HMGB1 Protein/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunohistochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">White Matter/ injuries/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1471-4159 (Electronic)&#xD;0022-3042 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23227954</style></accession-num><abstract><style face="normal" font="default" size="100%">High-mobility group box 1 (HMGB1) was initially described as a damage-associated-molecular-pattern (DAMP) mediator that worsens acute brain injury after stroke. But, recent findings suggest that HMGB1 can play a surprisingly beneficial role during stroke recovery by promoting endothelial progenitor cell (EPC) function and vascular remodeling in cortical gray matter. Here, we ask whether HMGB1 may also influence EPC responses in white matter injury. The standard lysophosphatidylcholine (LPC) injection model was used to induce focal demyelination in the corpus callosum of mice. Immunostaining showed that within the focal white matter lesions, HMGB1 was up-regulated in GFAP-positive reactive astrocytes, along with the accumulation of Flk1/CD34-double-positive EPCs that expressed pro-recovery mediators such as brain-derived neurotrophic factor and basic fibroblast growth factor. Astrocyte-EPC signaling required the HMGB1 receptor RAGE as treatment with RAGE-neutralizing antibody significantly decreased EPC accumulation. Moreover, suppression of HMGB1 with siRNA in vivo significantly decreased EPC numbers in damaged white matter as well as proliferated endothelial cell numbers. Finally, in vitro cell culture systems confirmed that HMGB1 directly affected EPC function such as migration and tube formation. Taken together, our findings suggest that HMGB1 from reactive astrocytes may attract EPCs to promote recovery after white matter injury.</style></abstract><notes><style face="normal" font="default" size="100%">Hayakawa, Kazuhide&#xD;Miyamoto, Nobukazu&#xD;Seo, Ji Hae&#xD;Pham, Loc-Duyen D&#xD;Kim, Kyu-Won&#xD;Lo, Eng H&#xD;Arai, Ken&#xD;R01 NS076694/NS/NINDS NIH HHS/United States&#xD;R37 NS037074/NS/NINDS NIH HHS/United States&#xD;R01 NS065089/NS/NINDS NIH HHS/United States&#xD;P50 NS010828/NS/NINDS NIH HHS/United States&#xD;P01 NS055104/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Neurochem. 2013 Apr;125(2):273-80. doi: 10.1111/jnc.12120. Epub 2012 Dec 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/jnc.12120/asset/jnc12120.pdf?v=1&amp;t=ixsi4ko2&amp;s=b0cdbb0ed55421364785cbb98864e1c32190be6e</style></url></related-urls><pdf-urls><url>internal-pdf://2231510832/Hayakawa-2013-High-mobility group.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3604050</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms427665</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/jnc.12120</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>22</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">22</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">He, G. Q.</style></author><author><style face="normal" font="default" size="100%">Xu, W. M.</style></author><author><style face="normal" font="default" size="100%">Li, J. F.</style></author><author><style face="normal" font="default" size="100%">Li, S. S.</style></author><author><style face="normal" font="default" size="100%">Liu, B.</style></author><author><style face="normal" font="default" size="100%">Tan, X. D.</style></author><author><style face="normal" font="default" size="100%">Li, C. Q.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China. heguoqian2011@163.com.&#xD;Department of Obstetrics and Gynecology, Joint Laboratory of Reproductive Medicine, Sichuan University-The Chinese University of Hongkong Joint Laboratory for Reproductive Medicine (SCU-CUHK), Institute of Women and Children&apos;s Health, West China Second University Hospital, Sichuan University, Chengdu, 610041, China. xuwenming1973@163.com.&#xD;Department of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China. lijf331@sina.com.&#xD;Department of Obstetrics and Gynecology, Joint Laboratory of Reproductive Medicine, Sichuan University-The Chinese University of Hongkong Joint Laboratory for Reproductive Medicine (SCU-CUHK), Institute of Women and Children&apos;s Health, West China Second University Hospital, Sichuan University, Chengdu, 610041, China. 2413395687@qq.com.&#xD;Department of Neurology, Shandong Provincial Qianfoshan Hospital, Jinan, 250000, China. 443726389@qq.com.&#xD;Department of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China. 554692849@qq.com.&#xD;Department of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China. licq9217@cqmu.edu.cn.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Huwe1 interacts with Gadd45b under oxygen-glucose deprivation and reperfusion injury in primary Rat cortical neuronal cells</style></title><secondary-title><style face="normal" font="default" size="100%">Mol Brain</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Molecular brain</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Mol Brain</style></full-title><abbr-1><style face="normal" font="default" size="100%">Molecular brain</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Mol Brain</style></full-title><abbr-1><style face="normal" font="default" size="100%">Molecular brain</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">88</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><edition><style face="normal" font="default" size="100%">2015/12/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Differentiation/biosynthesis/genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain-Derived Neurotrophic Factor/biosynthesis/genetics/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/cytology/embryology</style></keyword><keyword><style face="normal" font="default" size="100%">CpG Islands</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclic AMP Response Element-Binding Protein/biosynthesis/genetics/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">DNA Methylation</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia-Ischemia, Brain</style></keyword><keyword><style face="normal" font="default" size="100%">In Vitro Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Tissue Proteins/biosynthesis/genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Proteasome Endopeptidase Complex</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Interaction Mapping</style></keyword><keyword><style face="normal" font="default" size="100%">RNA Interference</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">Ubiquitin/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Ubiquitin-Protein Ligases/biosynthesis/genetics/ physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 23</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1756-6606 (Electronic)&#xD;1756-6606 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26698301</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Growth arrest and DNA-damage inducible protein 45 beta (Gadd45b) is serving as a neuronal activity sensor. Brain ischemia induces the expression of Gadd45b, which stimulates recovery after stroke and may play a protective role in cerebral ischemia. However, little is known of the molecular mechanisms of how Gadd45b expression regulated and the down-stream targets in brain ischemia. Here, using an oxygen-glucose deprivation and reperfusion (OGD/R) model, we identified Huwe1/Mule/ARF-BP1, a HECT domain containing ubiquitin ligase, involved in the control of Gadd45b protein level. In this study, we also investigated the role of Huwe1-Gadd45b mediated pathway in BDNF methylation. RESULTS: We found that the depletion of Huwe1 by lentivirus shRNA mediated interference significantly increased the expression of Gadd45b and BDNF at 24 h after OGD. Moreover, treatment with Cycloheximide (CHX) inhibited endogenous expression of Gadd45b, and promoted expression of Gadd45b after co-treated with lentivirus shRNA-Huwe1. Inhibition of Gadd45b by lentivirus shRNA decreased the expression levels of brain derived neurotrophic factor (BDNF) and phosphorylated cAMP response element-binding protein (p-CREB) pathway, while inhibition of Huwe1 increased the expression levels of BDNF and p-CREB. Moreover, shRNA-Huwe1 treatment decreased the methylation level of the fifth CpG islands (123 bp apart from BDNF IXa), while shRNA-Gadd45b treatment increased the methylation level of the forth CpG islands (105 bp apart from BDNF IXa). CONCLUSIONS: These findings suggested that Huwe1 involved in the regulation of Gadd45b expression under OGD/R, providing a novel route for neurons following cerebral ischemia-reperfusion injury. It also indicated that the methylation of BDNF IXa was affected by Gadd45b as well as Huwe1 in the OGD/R model.</style></abstract><notes><style face="normal" font="default" size="100%">He, Guo-qian&#xD;Xu, Wen-ming&#xD;Li, Jin-fang&#xD;Li, Shuai-shuai&#xD;Liu, Bin&#xD;Tan, Xiao-dan&#xD;Li, Chang-qing&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Mol Brain. 2015 Dec 23;8:88. doi: 10.1186/s13041-015-0178-y.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/14/art%253A10.1186%252Fs13041-015-0178-y.pdf?originUrl=http%3A%2F%2Fmolecularbrain.biomedcentral.com%2Farticle%2F10.1186%2Fs13041-015-0178-y&amp;token2=exp=1484112571~acl=%2Fstatic%2Fpdf%2F14%2Fart%25253A10.1186%25252Fs13041-015-0178-y.pdf*~hmac=2495c34e23b21d578bb59869983e4bc66d4db3842663d47ea26f047e4434af0e</style></url></related-urls><pdf-urls><url>internal-pdf://2296582323/He-2015-Huwe1 interacts with.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4690333</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s13041-015-0178-y</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>355</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">355</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">He, Y.</style></author><author><style face="normal" font="default" size="100%">Fujii, M.</style></author><author><style face="normal" font="default" size="100%">Inoue, T.</style></author><author><style face="normal" font="default" size="100%">Nomura, S.</style></author><author><style face="normal" font="default" size="100%">Maruta, Y.</style></author><author><style face="normal" font="default" size="100%">Oka, F.</style></author><author><style face="normal" font="default" size="100%">Shirao, S.</style></author><author><style face="normal" font="default" size="100%">Owada, Y.</style></author><author><style face="normal" font="default" size="100%">Kida, H.</style></author><author><style face="normal" font="default" size="100%">Kunitsugu, I.</style></author><author><style face="normal" font="default" size="100%">Yamakawa, T.</style></author><author><style face="normal" font="default" size="100%">Tokiwa, T.</style></author><author><style face="normal" font="default" size="100%">Yamakawa, T.</style></author><author><style face="normal" font="default" size="100%">Suzuki, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Graduate School of Medicine, Yamaguchi University, 1-1-1 Minami-kogushi, Ube, Yamaguchi 755 8505, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Neuroprotective effects of focal brain cooling on photochemically-induced cerebral infarction in rats: analysis from a neurophysiological perspective</style></title><secondary-title><style face="normal" font="default" size="100%">Brain Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">53-60</style></pages><volume><style face="normal" font="default" size="100%">1497</style></volume><edition><style face="normal" font="default" size="100%">2012/12/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Analysis of Variance</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/complications/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Waves/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/etiology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Electroencephalography</style></keyword><keyword><style face="normal" font="default" size="100%">Hand Strength/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Hypothermia, Induced/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Photochemical Processes</style></keyword><keyword><style face="normal" font="default" size="100%">Photochemistry/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Statistics, Nonparametric</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 25</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-6240 (Electronic)&#xD;0006-8993 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23268352</style></accession-num><abstract><style face="normal" font="default" size="100%">Although systemic hypothermia provides favorable outcomes in stroke patients, it has only been adopted in a limited number of patients because of fatal complications. To resolve these issues, focal brain cooling (FBC) has recently drawn attention as a less-invasive treatment for brain injuries. Therefore, we investigated whether FBC has a favorable effect on focal cerebral ischemia (FCI). Male-adult-Wistar rats were used. Under general anesthesia, a small burr hole was made and FCI was induced in the primary sensorimotor area (SI-MI) using photothrombosis. An additional craniotomy was made over the SI-MI and FBC was performed at a temperature of 15 degrees C for 5h. Electrocorticograms (ECoG) were recorded on the border cortex of the ischemic focus. Thereafter, rats were sacrificed and the infarct area was measured. In another experiment, rats were allowed to recover for 5 days after cooling and neurobehavioral function was evaluated. FBC suppressed all ECoG frequency bands during and after cooling (p&lt;0.05), except for the delta frequency band in the precooling versus rewarming periods. The injured areas in the cooling and non-cooling groups were 0.99+/-0.30 and 1.71+/-0.54 mm(2), respectively (p&lt;0.03). The grip strength at 2 days after surgery was preserved in the cooling group (p&lt;0.05). We report the novel finding that epileptiform discharges were suppressed in the ischemic border, the infarct area was reduced and neurobehaviour was preserved by FBC. These results indicate that FBC is neuroprotective in the ischemic brain and has demonstrated therapeutic potential for cerebral infarction.</style></abstract><notes><style face="normal" font="default" size="100%">He, Yeting&#xD;Fujii, Masami&#xD;Inoue, Takao&#xD;Nomura, Sadahiro&#xD;Maruta, Yuichi&#xD;Oka, Fumiaki&#xD;Shirao, Satoshi&#xD;Owada, Yuji&#xD;Kida, Hiroyuki&#xD;Kunitsugu, Ichiro&#xD;Yamakawa, Toshitaka&#xD;Tokiwa, Tatsuji&#xD;Yamakawa, Takeshi&#xD;Suzuki, Michiyasu&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;Brain Res. 2013 Feb 25;1497:53-60. doi: 10.1016/j.brainres.2012.11.041. Epub 2012 Dec 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0006899312018355/1-s2.0-S0006899312018355-main.pdf?_tid=6af6f598-d7be-11e6-baec-00000aacb361&amp;acdnat=1484112532_698a171968751941e11ea0c1fc056ce8</style></url></related-urls><pdf-urls><url>internal-pdf://2233421594/He-2013-Neuroprotective effe.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.brainres.2012.11.041</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>386</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">386</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">He, Z.</style></author><author><style face="normal" font="default" size="100%">Ostrowski, R. P.</style></author><author><style face="normal" font="default" size="100%">Sun, X.</style></author><author><style face="normal" font="default" size="100%">Ma, Q.</style></author><author><style face="normal" font="default" size="100%">Tang, J.</style></author><author><style face="normal" font="default" size="100%">Zhang, J. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, First Affiliated Hospital of Chongqing Medical University, 1 Friendship Road, 400016 Chongqing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Targeting C/EBP homologous protein with siRNA attenuates cerebral vasospasm after experimental subarachnoid hemorrhage</style></title><secondary-title><style face="normal" font="default" size="100%">Exp Neurol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Experimental neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Exp Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Experimental neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Exp Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Experimental neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">218-24</style></pages><volume><style face="normal" font="default" size="100%">238</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2012/09/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Analysis of Variance</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis Regulatory Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Basilar Artery/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Bcl-2-Like Protein 11</style></keyword><keyword><style face="normal" font="default" size="100%">Caspase 3/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Count</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelial Cells/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelium/drug effects/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">In Situ Nick-End Labeling</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Membrane Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Proto-Oncogene Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Proto-Oncogene Proteins c-bcl-2/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Subarachnoid Hemorrhage/ complications</style></keyword><keyword><style face="normal" font="default" size="100%">Transcription Factor CHOP/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Vasospasm, Intracranial/ etiology/pathology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">von Willebrand Factor/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1090-2430 (Electronic)&#xD;0014-4886 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22944263</style></accession-num><abstract><style face="normal" font="default" size="100%">Endothelial apoptosis plays a major role in the development of cerebral vascular spasm after subarachnoid hemorrhage (SAH). C/EBP homologous protein (CHOP) orchestrates apoptosis in a variety of cell types in response to endoplasmic reticulum (ER) stress, implicated in the brain injury after SAH. However, the role of CHOP in the mechanism of cerebral vasospasm (CVS) after SAH remains unexplored. The aim of this study was to evaluate the effect of CHOP silencing on endothelial apoptosis and CVS following subarachnoid hemorrhage in the rat. The study was conducted on 65 rats and employed endovascular perforation model of SAH. CHOP siRNAs were injected 24 h prior to the hemorrhage. At 72 h after SAH brains with basilar arteries (BA) were collected from euthanized rats for laboratory investigations. Triple fluorescence stain revealed expression of CHOP in cerebral vascular endothelia after SAH. Marked reduction of CHOP protein and the reduction of its downstream signaling effectors, bim and caspase-3, were found in BA with Western blot analysis. CHOP silencing reduced number of apoptotic endothelial cells in BA, and increased BA diameter after SAH. The amelioration of CVS was associated with reduced neuronal injury in cerebral tissues. In conclusion, CHOP siRNA treatment can effectively combat apoptotic mechanisms of cerebral vasospasm set in motion by subarachnoid bleeding.</style></abstract><notes><style face="normal" font="default" size="100%">He, Zhaohui&#xD;Ostrowski, Robert P&#xD;Sun, Xiaochuan&#xD;Ma, Qingyi&#xD;Tang, Jiping&#xD;Zhang, John H&#xD;R01 NS045694/NS/NINDS NIH HHS/United States&#xD;R01 NS053407/NS/NINDS NIH HHS/United States&#xD;NS53407/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;United States&#xD;Exp Neurol. 2012 Dec;238(2):218-24. doi: 10.1016/j.expneurol.2012.08.025. Epub 2012 Aug 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0014488612003342/1-s2.0-S0014488612003342-main.pdf?_tid=3fe94f5e-d7be-11e6-9c92-00000aacb35d&amp;acdnat=1484112459_6037e91aafe4b2f470bc43b93342fa88</style></url></related-urls><pdf-urls><url>internal-pdf://1979987423/He-2012-Targeting C_EBP homo.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3498605</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms404042</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.expneurol.2012.08.025</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>391</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">391</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Henry-Feugeas, M. C.</style></author><author><style face="normal" font="default" size="100%">Koskas, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Henri Huchard, Paris cedex, France. marie-cecile.henry-feugeas@bch.aphp.fr</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cerebral vascular aging: extending the concept of pulse wave encephalopathy through capillaries to the cerebral veins</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Aging Sci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Current aging science</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Aging Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current aging science</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Curr Aging Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current aging science</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">157-67</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2012/08/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Aging/ pathology/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arterial Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ blood supply</style></keyword><keyword><style face="normal" font="default" size="100%">Capillaries/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Veins/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Disorders/etiology/ pathology/physiopathology/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition</style></keyword><keyword><style face="normal" font="default" size="100%">Collagen Diseases/etiology/ pathology/physiopathology/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Dilatation, Pathologic</style></keyword><keyword><style face="normal" font="default" size="100%">Elasticity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pulsatile Flow</style></keyword><keyword><style face="normal" font="default" size="100%">Pulse Wave Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Stress, Mechanical</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1874-6128 (Electronic)&#xD;1874-6098 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22894741</style></accession-num><abstract><style face="normal" font="default" size="100%">The recent concept of pulse wave encephalopathy helps understanding the cerebral venous remodeling in aging. This so-called periventricular venous collagenosis is an expected mechanical consequence of the age-related changes in arterial pulsations and the mechanical fatigue of vascular smooth muscles. Unlike arteriolar mechanical stress, venular mechanical stress depends on both the blood pulse wave amplitude and the mechanical properties of the environment tissue. Thereby, there is a preferential periventricular location of venous collagenosis and a mechanistic link between venous collagenosis and foci of white matter rarefaction or leukoaraiosis. The recent concept of pulse wave encephalopathy also helps understanding the widening of retinal venules, the &quot;mirror&quot; of cerebral venules, in various manifestations of pulse wave encephalopathy, including progressive leukoaraosis, lacunar and hemorrhagic &quot;pulse wave&quot; strokes, and dementia. Indeed, the age-related chronic increase in arterial pulsations explains subsequent arteriolar myogenic &quot;fatigue&quot;, marked attenuation in the arteriolar myogenic tone and abnormal penetration of the insufficiently dampened arterial pulse wave into the venules. Thus, retinal venular widening, a biomarker of advanced pulse wave encephalopathy, is also increasingly recognized as a biomarker for high cardiovascular risk. All these data support a shift in the concept of chronic cerebrovascular disease, from the classical model which is restricted to steno-occlusive cerebrovascular diseases to an enlarged model which would include the pulse wave encephalopathy concept. Thereby, preventing damage to the cerebral microvasculature by an undampened arterial pulse wave will become a logical target for the prevention and treatment of late-onset cognitive decline.</style></abstract><notes><style face="normal" font="default" size="100%">Henry-Feugeas, Marie Cecile&#xD;Koskas, Pierre&#xD;Review&#xD;United Arab Emirates&#xD;Curr Aging Sci. 2012 Jul;5(2):157-67.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>57</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">57</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Herbert, W. J.</style></author><author><style face="normal" font="default" size="100%">Powell, K.</style></author><author><style face="normal" font="default" size="100%">Buford, J. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Physical Therapy, School of Health and Rehabilitation Sciences,, The Ohio State University, 453 W. 10th Ave., Rm. 516G, Columbus, OH, 43210-1234, USA.&#xD;Health and Rehabilitation Sciences PhD Program, The Ohio State University, Columbus, OH, 43210, USA.&#xD;Department of Physical Therapy Education, Elon University, Campus Box 2085, Elon, NC, 27244, USA.&#xD;Small Animal Imaging Core, Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, 43210, USA.&#xD;Division of Physical Therapy, School of Health and Rehabilitation Sciences,, The Ohio State University, 453 W. 10th Ave., Rm. 516G, Columbus, OH, 43210-1234, USA. Buford.5@osu.edu.&#xD;Health and Rehabilitation Sciences PhD Program, The Ohio State University, Columbus, OH, 43210, USA. Buford.5@osu.edu.&#xD;Center for Brain and Spinal Cord Repair, The Ohio State University, Columbus, OH, 43210, USA. Buford.5@osu.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evidence for a role of the reticulospinal system in recovery of skilled reaching after cortical stroke: initial results from a model of ischemic cortical injury</style></title><secondary-title><style face="normal" font="default" size="100%">Exp Brain Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Experimental brain research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Exp Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Experimental brain research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Exp Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Experimental brain research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">3231-51</style></pages><volume><style face="normal" font="default" size="100%">233</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2015/08/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Afferent Pathways</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/pathology/ physiopathology/rehabilitation</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Electric Stimulation</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelin-1/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Functional Laterality</style></keyword><keyword><style face="normal" font="default" size="100%">Macaca fascicularis</style></keyword><keyword><style face="normal" font="default" size="100%">Motor Cortex/injuries/ pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Motor Skills Disorders/ etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Pilot Projects</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery of Function/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Reticular Formation/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Spinal Cord/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Upper Extremity/physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1432-1106 (Electronic)&#xD;0014-4819 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26231990</style></accession-num><abstract><style face="normal" font="default" size="100%">The purposes of this pilot study were to create a model of focal cortical ischemia in Macaca fascicularis and to explore contributions of the reticulospinal system in recovery of reaching. Endothelin-1 was used to create a focal lesion in the shoulder/elbow representation of left primary motor cortex (M1) of two adult female macaques. Repetitive microstimulation was used to map upper limb motor outputs from right and left cortical motor areas and from the pontomedullary reticular formation (PMRF). In subject 1 with a small lesion and spontaneous recovery, reaching was mildly impaired. Changes were evident in the shoulder/elbow representations of both the lesioned and contralesional M1, and there appeared to be fewer than expected upper limb responses from the left (ipsilesional) PMRF. In subject 2 with a substantial lesion, reaching was severely impaired immediately after the lesion. After 12 weeks of intensive rehabilitative training, reach performance recovered to near-baseline levels, but movement times remained about 50% slower. Surprisingly, the shoulder/elbow representation in the lesioned M1 remained completely absent after recovery, and there was a little change in the contralesional M1. There was a definite difference in motor output patterns for left versus right PMRF for this subject, with an increase in right arm responses from right PMRF and a paucity of left arm responses from left PMRF. The results are consistent with increased reliance on PMRF motor outputs for recovery of voluntary upper limb motor control after significant cortical ischemic injury.</style></abstract><notes><style face="normal" font="default" size="100%">Herbert, Wendy J&#xD;Powell, Kimerly&#xD;Buford, John A&#xD;NS045758/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Germany&#xD;Exp Brain Res. 2015 Nov;233(11):3231-51. doi: 10.1007/s00221-015-4390-x. Epub 2015 Aug 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/43/art%253A10.1007%252Fs00221-015-4390-x.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00221-015-4390-x&amp;token2=exp=1484113483~acl=%2Fstatic%2Fpdf%2F43%2Fart%25253A10.1007%25252Fs00221-015-4390-x.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs00221-015-4390-x*~hmac=708c8ef3f179e7c5110155736db7018bed4b49065358863315a8603150011079</style></url></related-urls><pdf-urls><url>internal-pdf://0666910920/Herbert-2015-Evidence for a role.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00221-015-4390-x</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>433</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">433</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hetze, S.</style></author><author><style face="normal" font="default" size="100%">Romer, C.</style></author><author><style face="normal" font="default" size="100%">Teufelhart, C.</style></author><author><style face="normal" font="default" size="100%">Meisel, A.</style></author><author><style face="normal" font="default" size="100%">Engel, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center of Stroke Research Berlin, Neurocure Clinical Research Center, Department for Experimental Neurology, Charite Universitaetsmedizin Berlin, Chariteplatz 1, 10117 Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Gait analysis as a method for assessing neurological outcome in a mouse model of stroke</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosci Methods</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neuroscience methods</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosci Methods</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroscience methods</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosci Methods</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroscience methods</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">7-14</style></pages><volume><style face="normal" font="default" size="100%">206</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2012/02/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Gait/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Neurologic Examination/ methods/standards</style></keyword><keyword><style face="normal" font="default" size="100%">Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ diagnosis/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 30</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-678X (Electronic)&#xD;0165-0270 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22343052</style></accession-num><abstract><style face="normal" font="default" size="100%">Ameliorating stroke induced neurological deficits is one of the most important goals of stroke therapy. In order to improve stroke outcome, novel treatment approaches as well as animal stroke models predictive for the clinical setting are of urgent need. One of the main obstacles in experimental stroke research is measuring long-term outcome, in particular in mouse models of stroke. On the other hand, assessing functional deficits in animal models of stroke is critical to improve the prediction of preclinical findings. Automated gait analysis provides a sensitive tool to examine locomotion and limb coordination in small rodents. Comparing mice before and 10 days after experimental stroke (60 min MCAo) we observed a significant decrease in maximum contact area, stride length and swing speed in the hind limbs, especially the contralateral one. Mice showed a disturbed interlimb coordination represented by changes in regularity index and phase dispersion. To assess whether gait analysis is applicable to assess improvements by neuroprotective compounds, we applied a model calculation and approached common statistical problems. In conclusion, gait analysis is a promising tool to assess mid- to long-term outcome in experimental stroke research.</style></abstract><notes><style face="normal" font="default" size="100%">Hetze, Susann&#xD;Romer, Christine&#xD;Teufelhart, Carena&#xD;Meisel, Andreas&#xD;Engel, Odilo&#xD;Comparative Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;J Neurosci Methods. 2012 Apr 30;206(1):7-14. doi: 10.1016/j.jneumeth.2012.02.001. Epub 2012 Feb 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0165027012000350/1-s2.0-S0165027012000350-main.pdf?_tid=44c1a314-d7be-11e6-a0cd-00000aacb361&amp;acdnat=1484112467_55634df6424e2dea1829698d00796ab7</style></url></related-urls><pdf-urls><url>internal-pdf://3679017802/Hetze-2012-Gait analysis as a m.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jneumeth.2012.02.001</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>176</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">176</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hewlett, K. A.</style></author><author><style face="normal" font="default" size="100%">Kelly, M. H.</style></author><author><style face="normal" font="default" size="100%">Corbett, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of BioMedical Sciences, Memorial University, St. John&apos;s, NL, Canada.&#xD;Division of BioMedical Sciences, Memorial University, St. John&apos;s, NL, Canada; Heart &amp; Stroke Foundation Canadian Partnership for Stroke Recovery, Canada; Dept Cellular &amp; Molecular Medicine, University of Ottawa, Ottawa, ON, Canada; Dept of Medicine, University of Toronto, Toronto, ON, Canada. Electronic address: dcorbett@uottawa.ca.</style></auth-address><titles><title><style face="normal" font="default" size="100%">&apos;Not-so-minor&apos; stroke: Lasting psychosocial consequences of anterior cingulate cortical ischemia in the rat</style></title><secondary-title><style face="normal" font="default" size="100%">Exp Neurol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Experimental neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Exp Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Experimental neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Exp Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Experimental neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">543-50</style></pages><volume><style face="normal" font="default" size="100%">261</style></volume><edition><style face="normal" font="default" size="100%">2014/08/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Analysis of Variance</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Infarction/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Dexamethasone</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Exploratory Behavior/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Gyrus Cinguli/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Interpersonal Relations</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemia/complications/ pathology/ psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Maze Learning/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Movement Disorders/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Porphyrins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Radioimmunoassay</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Steroids/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Stress, Psychological/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Vocalization, Animal/physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1090-2430 (Electronic)&#xD;0014-4886 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25131641</style></accession-num><abstract><style face="normal" font="default" size="100%">Patients with small, non-debilitating strokes often report a reduction in quality of life due to persistent cognitive and emotional alterations. Stroke may directly damage limbic circuitry resulting in an impaired stress response, however the possibility that this may in part explain the prevalence of stroke comorbidity with mood disorders has yet to be determined. Here we systematically examine psychosocial consequences of prefrontal lesions targeting the left anterior cingulate cortex (ACC) using hormone assays and a behavioral test battery in adult rats to probe whether a small stroke could alter stress behavior or response to psychosocial stress (chronic mild stress (CMS) or subordination stress). Minor stroke produced chronic hyperactivity in an open field but did not alter fear-related inhibition in the elevated plus maze. Novelty-induced defecation was increased by the combination of CMS, subordination and stroke. Anterior cingulate lesions alone increased distress vocalizations in the water maze. Interestingly, ACC stroke caused hyper-secretion of porphyrin and long-term hormonal alterations that resulted in adrenal hypertrophy and enhanced dexamethasone suppression of the HPA axis. We propose that this behavioral profile is consistent with an animal model of post-stroke distress-like syndrome which could be useful in understanding how stroke affects the capacity to cope with psychological stress.</style></abstract><notes><style face="normal" font="default" size="100%">Hewlett, Krista A&#xD;Kelly, Meighan H&#xD;Corbett, Dale&#xD;Canadian Institutes of Health Research/Canada&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Exp Neurol. 2014 Nov;261:543-50. doi: 10.1016/j.expneurol.2014.07.024. Epub 2014 Aug 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0014488614002568/1-s2.0-S0014488614002568-main.pdf?_tid=489eaf18-d7be-11e6-b72e-00000aacb362&amp;acdnat=1484112474_9206c9f969caffa31a9303575d006eb4</style></url></related-urls><pdf-urls><url>internal-pdf://2678680104/Hewlett-2014-&apos;Not-so-minor&apos; strok.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.expneurol.2014.07.024</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>216</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">216</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hill, J. W.</style></author><author><style face="normal" font="default" size="100%">Thompson, J. F.</style></author><author><style face="normal" font="default" size="100%">Carter, M. B.</style></author><author><style face="normal" font="default" size="100%">Edwards, B. S.</style></author><author><style face="normal" font="default" size="100%">Sklar, L. A.</style></author><author><style face="normal" font="default" size="100%">Rosenberg, G. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of New Mexico Health Sciences Center, Department of Neurology, Albuquerque, New Mexico, United States of America.&#xD;Center for Molecular Discovery, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States of America.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Identification of isoxsuprine hydrochloride as a neuroprotectant in ischemic stroke through cell-based high-throughput screening</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PloS one</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e96761</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2014/05/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Isoxsuprine/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred SHR</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ drug therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203 (Electronic)&#xD;1932-6203 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24804769</style></accession-num><abstract><style face="normal" font="default" size="100%">Stroke is a leading cause of death and disability and treatment options are limited. A promising approach to accelerate the development of new therapeutics is the use of high-throughput screening of chemical libraries. Using a cell-based high-throughput oxygen-glucose deprivation (OGD) model, we evaluated 1,200 small molecules for repurposed application in stroke therapy. Isoxsuprine hydrochloride was identified as a potent neuroprotective compound in primary neurons exposed to OGD. Isoxsuprine, a beta2-adrenergic agonist and NR2B subtype-selective N-methyl-D-aspartate (NMDA) receptor antagonist, demonstrated no loss of efficacy when administered up to an hour after reoxygenation in an in vitro stroke model. In an animal model of transient focal ischemia, isoxsuprine significantly reduced infarct volume compared to vehicle (137 +/- 18 mm3 versus 279 +/- 25 mm3, p &lt; 0.001). Isoxsuprine, a peripheral vasodilator, was FDA approved for the treatment of cerebrovascular insufficiency and peripheral vascular disease. Our demonstration of the significant and novel neuroprotective action of isoxsuprine hydrochloride in an in vivo stroke model and its history of human use suggest that isoxsuprine may be an ideal candidate for further investigation as a potential stroke therapeutic.</style></abstract><notes><style face="normal" font="default" size="100%">Hill, Jeff W&#xD;Thompson, Jeffrey F&#xD;Carter, Mark B&#xD;Edwards, Bruce S&#xD;Sklar, Larry A&#xD;Rosenberg, Gary A&#xD;1 UL1RR031977-01/RR/NCRR NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;PLoS One. 2014 May 7;9(5):e96761. doi: 10.1371/journal.pone.0096761. eCollection 2014.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0096761&amp;type=printable</style></url></related-urls><pdf-urls><url>internal-pdf://2252312155/Hill-2014-Identification of is.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4013073</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0096761</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>147</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">147</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hill, M. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Stroke Unit, Foothills Hospital, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada. Electronic address: hillmd@ucalgary.ca.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Stroke and diabetes mellitus</style></title><secondary-title><style face="normal" font="default" size="100%">Handb Clin Neurol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Handbook of clinical neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Handb Clin Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Handbook of clinical neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Handb Clin Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Handbook of clinical neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">167-74</style></pages><volume><style face="normal" font="default" size="100%">126</style></volume><edition><style face="normal" font="default" size="100%">2014/11/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/diagnosis/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/diagnosis/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus/ diagnosis/ epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperglycemia/diagnosis/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Microvessels/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ diagnosis/ epidemiology/therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">0072-9752 (Print)&#xD;0072-9752 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25410221</style></accession-num><abstract><style face="normal" font="default" size="100%">Diabetes is a condition of accelerated vascular aging. Patients with diabetes have approximately twice the risk of stroke compared to nondiabetics. Hyperglycemia is a strong risk factor for poor outcome after stroke, but it may be simply a marker of poor outcome rather than a cause. Glucose lowering has not been shown to be associated with improved prognosis. Similarly, long-term prevention of stroke risk among diabetic patients is not improved with glucose-lowering therapies. Stroke prevention and treatment remains generic among diabetic patients. The future, however, may be brighter, with multiple new agents recently available. We await the outcome of these agents on macrovascular complications such as stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Hill, Michael D&#xD;Review&#xD;Netherlands&#xD;Handb Clin Neurol. 2014;126:167-74. doi: 10.1016/B978-0-444-53480-4.00012-6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/B9780444534804000126/1-s2.0-B9780444534804000126-main.pdf?_tid=4aa0fc62-d7be-11e6-a419-00000aacb360&amp;acdnat=1484112477_61efaa8e5510242f5b9bd1b42884a974</style></url></related-urls><pdf-urls><url>internal-pdf://3872750424/Hill-2014-Stroke and diabetes.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/b978-0-444-53480-4.00012-6</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>154</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">154</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hochrainer, K.</style></author><author><style face="normal" font="default" size="100%">Jackman, K.</style></author><author><style face="normal" font="default" size="100%">Benakis, C.</style></author><author><style face="normal" font="default" size="100%">Anrather, J.</style></author><author><style face="normal" font="default" size="100%">Iadecola, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Feil Family Brain and Mind Research Institute, Weill Cornell Medical College, New York, NY, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">SUMO2/3 is associated with ubiquitinated protein aggregates in the mouse neocortex after middle cerebral artery occlusion</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1-5</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2014/10/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blotting, Western</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Electrophoresis, Polyacrylamide Gel</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoprecipitation</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Neocortex/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Aggregates</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">SUMO-1 Protein/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Small Ubiquitin-Related Modifier Proteins/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Sumoylation</style></keyword><keyword><style face="normal" font="default" size="100%">Ubiquitin/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25352045</style></accession-num><abstract><style face="normal" font="default" size="100%">Protein modifications cooperatively act to protect the proteome from cellular stress. Focal cerebral ischemia increases protein ubiquitination, resulting in formation of ubiquitin-rich aggregates. A concurrent elevation in small ubiquitin-related modifier (SUMO)-conjugated proteins has also been reported, but a potential connection to ubiquitin remains unexplored. Here we show that SUMO2/3 conjugates are present in postischemic ubiquitin-rich aggregates, physically associated with ubiquitin. The coaggregation of SUMO2/3 and ubiquitin is induced rapidly after ischemia, depends on reperfusion, and is also observed in the absence of ischemic damage. The association between SUMO and ubiquitin suggests overlapping functional roles after ischemia/reperfusion.</style></abstract><notes><style face="normal" font="default" size="100%">Hochrainer, Karin&#xD;Jackman, Katherine&#xD;Benakis, Corinne&#xD;Anrather, Josef&#xD;Iadecola, Costantino&#xD;R01 NS034179/NS/NINDS NIH HHS/United States&#xD;R37 NS034179/NS/NINDS NIH HHS/United States&#xD;R37-NS34179/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Cereb Blood Flow Metab. 2015 Jan;35(1):1-5. doi: 10.1038/jcbfm.2014.180. Epub 2014 Oct 29.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4294403</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2014.180</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>221</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">221</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoffmann, A.</style></author><author><style face="normal" font="default" size="100%">Stoffel, M. H.</style></author><author><style face="normal" font="default" size="100%">Nitzsche, B.</style></author><author><style face="normal" font="default" size="100%">Lobsien, D.</style></author><author><style face="normal" font="default" size="100%">Seeger, J.</style></author><author><style face="normal" font="default" size="100%">Schneider, H.</style></author><author><style face="normal" font="default" size="100%">Boltze, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Anatomy, Histology and Embryology, Faculty of Veterinary Medicine, University of Leipzig, Leipzig, Germany.&#xD;Division of Veterinary Anatomy, Vetsuisse Faculty, University of Bern, Bern, Switzerland.&#xD;Fraunhofer Institute of Cell Therapy and Immunology, Department of Cell Therapy, Leipzig, Germany.&#xD;Department of Neuroradiology, University Hospital of Leipzig, Leipzig, Germany.&#xD;Department of Pediatrics, University Hospital Erlangen, Erlangen, Germany.&#xD;Fraunhofer Institute of Cell Therapy and Immunology, Department of Cell Therapy, Leipzig, Germany; Translational Centre for Regenerative Medicine, University of Leipzig, Leipzig, Germany; Massachusetts General Hospital and Harvard Medical School, Neurovascular Regulation Laboratory at Neuroscience Center, Charlestown, Massachusetts, United States of America.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The ovine cerebral venous system: comparative anatomy, visualization, and implications for translational research</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PloS one</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e92990</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2014/04/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anatomy, Comparative</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ anatomy &amp; histology/ blood supply</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Angiography</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Veins/anatomy &amp; histology/diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Cranial Sinuses/anatomy &amp; histology/diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Sheep</style></keyword><keyword><style face="normal" font="default" size="100%">Translational Medical Research</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203 (Electronic)&#xD;1932-6203 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24736654</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebrovascular diseases are significant causes of death and disability in humans. Improvements in diagnostic and therapeutic approaches strongly rely on adequate gyrencephalic, large animal models being demanded for translational research. Ovine stroke models may represent a promising approach but are currently limited by insufficient knowledge regarding the venous system of the cerebral angioarchitecture. The present study was intended to provide a comprehensive anatomical analysis of the intracranial venous system in sheep as a reliable basis for the interpretation of experimental results in such ovine models. We used corrosion casts as well as contrast-enhanced magnetic resonance venography to scrutinize blood drainage from the brain. This combined approach yielded detailed and, to some extent, novel findings. In particular, we provide evidence for chordae Willisii and lateral venous lacunae, and report on connections between the dorsal and ventral sinuses in this species. For the first time, we also describe venous confluences in the deep cerebral venous system and an &apos;anterior condylar confluent&apos; as seen in humans. This report provides a detailed reference for the interpretation of venous diagnostic imaging findings in sheep, including an assessment of structure detectability by in vivo (imaging) versus ex vivo (corrosion cast) visualization methods. Moreover, it features a comprehensive interspecies-comparison of the venous cerebral angioarchitecture in man, rodents, canines and sheep as a relevant large animal model species, and describes possible implications for translational cerebrovascular research.</style></abstract><notes><style face="normal" font="default" size="100%">Hoffmann, Anke&#xD;Stoffel, Michael H&#xD;Nitzsche, Bjorn&#xD;Lobsien, Donald&#xD;Seeger, Johannes&#xD;Schneider, Holm&#xD;Boltze, Johannes&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;PLoS One. 2014 Apr 15;9(4):e92990. doi: 10.1371/journal.pone.0092990. eCollection 2014.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0092990&amp;type=printable</style></url></related-urls><pdf-urls><url>internal-pdf://2854556451/Hoffmann-2014-The ovine cerebral v.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3988027</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0092990</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>273</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">273</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoh, B. L.</style></author><author><style face="normal" font="default" size="100%">Hosaka, K.</style></author><author><style face="normal" font="default" size="100%">Downes, D. P.</style></author><author><style face="normal" font="default" size="100%">Nowicki, K. W.</style></author><author><style face="normal" font="default" size="100%">Wilmer, E. N.</style></author><author><style face="normal" font="default" size="100%">Velat, G. J.</style></author><author><style face="normal" font="default" size="100%">Scott, E. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departments of Neurological Surgery and.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Stromal cell-derived factor-1 promoted angiogenesis and inflammatory cell infiltration in aneurysm walls</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosurg</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neurosurgery</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosurg</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurosurgery</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosurg</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurosurgery</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">73-86</style></pages><volume><style face="normal" font="default" size="100%">120</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2013/10/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aneurysm/metabolism/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Arteries/drug effects/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Artery Diseases/metabolism/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Movement/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Proliferation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Chemokine CXCL12/metabolism/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelial Cells/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Aneurysm/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Neovascularization, Pathologic/metabolism/ pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1933-0693 (Electronic)&#xD;0022-3085 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24160472</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECT: A small percentage of cerebral aneurysms rupture, but when they do, the effects are devastating. Current management of unruptured aneurysms consists of surgery, endovascular treatment, or watchful waiting. If the biology of how aneurysms grow and rupture were better known, a novel drug could be developed to prevent unruptured aneurysms from rupturing. Ruptured cerebral aneurysms are characterized by inflammation-mediated wall remodeling. The authors studied the role of stromal cell-derived factor-1 (SDF-1) in inflammation-mediated wall remodeling in cerebral aneurysms. METHODS: Human aneurysms, murine carotid artery aneurysms, and murine intracranial aneurysms were studied using immunohistochemistry. Flow cytometry analysis was performed on blood from mice developing carotid or intracranial aneurysms. The effect of SDF-1 on endothelial cells and macrophages was studied by chemotaxis cell migration assay and capillary tube formation assay. Anti-SDF-1 blocking antibody was given to mice and compared with control (vehicle)-administered mice for its effects on the walls of carotid aneurysms and the development of intracranial aneurysms. RESULTS: Human aneurysms, murine carotid aneurysms, and murine intracranial aneurysms all expressed SDF-1, and mice with developing carotid or intracranial aneurysms had increased progenitor cells expressing CXCR4, the receptor for SDF-1 (p &lt; 0.01 and p &lt; 0.001, respectively). Human aneurysms and murine carotid aneurysms had endothelial cells, macrophages, and capillaries in the walls of the aneurysms, and the presence of capillaries in the walls of human aneurysms was associated with the presence of macrophages (p = 0.01). Stromal cell-derived factor-1 promoted endothelial cell and macrophage migration (p &lt; 0.01 for each), and promoted capillary tube formation (p &lt; 0.001). When mice were given anti-SDF-1 blocking antibody, there was a significant reduction in endothelial cells (p &lt; 0.05), capillaries (p &lt; 0.05), and cell proliferation (p &lt; 0.05) in the aneurysm wall. Mice given anti-SDF-1 blocking antibody developed significantly fewer intracranial aneurysms (33% vs 89% in mice given control immunoglobulin G, respectively; p &lt; 0.05). CONCLUSIONS: These data suggest SDF-1 is associated with angiogenesis and inflammatory cell migration and proliferation in the walls of aneurysms, and may have a role in the development of intracranial aneurysms.</style></abstract><notes><style face="normal" font="default" size="100%">Hoh, Brian L&#xD;Hosaka, Koji&#xD;Downes, Daniel P&#xD;Nowicki, Kamil W&#xD;Wilmer, Erin N&#xD;Velat, Gregory J&#xD;Scott, Edward W&#xD;K08 NS067058/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Neurosurg. 2014 Jan;120(1):73-86. doi: 10.3171/2013.9.JNS122074. Epub 2013 Oct 25.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3877706</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms505348</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.3171/2013.9.jns122074</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>117</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">117</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Holland, P. R.</style></author><author><style face="normal" font="default" size="100%">Searcy, J. L.</style></author><author><style face="normal" font="default" size="100%">Salvadores, N.</style></author><author><style face="normal" font="default" size="100%">Scullion, G.</style></author><author><style face="normal" font="default" size="100%">Chen, G.</style></author><author><style face="normal" font="default" size="100%">Lawson, G.</style></author><author><style face="normal" font="default" size="100%">Scott, F.</style></author><author><style face="normal" font="default" size="100%">Bastin, M. E.</style></author><author><style face="normal" font="default" size="100%">Ihara, M.</style></author><author><style face="normal" font="default" size="100%">Kalaria, R.</style></author><author><style face="normal" font="default" size="100%">Wood, E. R.</style></author><author><style face="normal" font="default" size="100%">Smith, C.</style></author><author><style face="normal" font="default" size="100%">Wardlaw, J. M.</style></author><author><style face="normal" font="default" size="100%">Horsburgh, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Neuroregeneration, Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK.&#xD;Centre for Neuroregeneration, University of Edinburgh, Edinburgh, UK.&#xD;Centre for Cognitive Ageing and Cognitive Epidemiology, Scottish Imaging Network, A Platform for Scientific Collaboration (SINAPSE), Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.&#xD;Department of Stroke and Cerebrovascular Diseases, National Cerebral and Cardiovascular Center Hospital, Osaka, Japan.&#xD;Institute of Neuroscience, Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne, UK.&#xD;Centre for Cognitive and Neural Systems and Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK.&#xD;Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Gliovascular disruption and cognitive deficits in a mouse model with features of small vessel disease</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1005-14</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2015/02/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Atrophy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Small Vessel Diseases/complications/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition</style></keyword><keyword><style face="normal" font="default" size="100%">Diffusion Tensor Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Microvessels/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroglia/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">White Matter/pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25669904</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebral small vessel disease (SVD) is a major cause of age-related cognitive impairment and dementia. The pathophysiology of SVD is not well understood and is hampered by a limited range of relevant animal models. Here, we describe gliovascular alterations and cognitive deficits in a mouse model of sustained cerebral hypoperfusion with features of SVD (microinfarcts, hemorrhage, white matter disruption) induced by bilateral common carotid stenosis. Multiple features of SVD were determined on T2-weighted and diffusion-tensor magnetic resonance imaging scans and confirmed by pathologic assessment. These features, which were absent in sham controls, included multiple T2-hyperintense infarcts and T2-hypointense hemosiderin-like regions in subcortical nuclei plus increased cerebral atrophy compared with controls. Fractional anisotropy was also significantly reduced in several white matter structures including the corpus callosum. Investigation of gliovascular changes revealed a marked increase in microvessel diameter, vascular wall disruption, fibrinoid necrosis, hemorrhage, and blood-brain barrier alterations. Widespread reactive gliosis, including displacement of the astrocytic water channel, aquaporin 4, was observed. Hypoperfused mice also demonstrated deficits in spatial working and reference memory tasks. Overall, gliovascular disruption is a prominent feature of this mouse, which could provide a useful model for early-phase testing of potential SVD treatment strategies.</style></abstract><notes><style face="normal" font="default" size="100%">Holland, Philip R&#xD;Searcy, James L&#xD;Salvadores, Natalia&#xD;Scullion, Gillian&#xD;Chen, Guiquan&#xD;Lawson, Greig&#xD;Scott, Fiona&#xD;Bastin, Mark E&#xD;Ihara, Masafumi&#xD;Kalaria, Rajesh&#xD;Wood, Emma R&#xD;Smith, Colin&#xD;Wardlaw, Joanna M&#xD;Horsburgh, Karen&#xD;152/Alzheimer&apos;s Society/United Kingdom&#xD;MR/K026992/1/Medical Research Council/United Kingdom&#xD;CI/05/004/British Heart Foundation/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Cereb Blood Flow Metab. 2015 Jun;35(6):1005-14. doi: 10.1038/jcbfm.2015.12. Epub 2015 Feb 11.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4640247</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2015.12</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>487</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">487</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Holly, S. P.</style></author><author><style face="normal" font="default" size="100%">Parise, L. V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7260, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Big science for small cells: systems approaches for platelets</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Drug Targets</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Current drug targets</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Drug Targets</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current drug targets</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Curr Drug Targets</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current drug targets</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1859-70</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2011/07/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Platelets/drug effects/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Discovery/trends</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Targeted Therapy/trends</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmacogenetics/trends</style></keyword><keyword><style face="normal" font="default" size="100%">Platelet Aggregation Inhibitors/adverse effects/ pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics/trends</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment/trends</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Systems Biology/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombosis/drug therapy/etiology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Translational Medical Research</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1873-5592 (Electronic)&#xD;1389-4501 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">21718236</style></accession-num><abstract><style face="normal" font="default" size="100%">Platelets are dynamic blood cells that form life-threatening thrombi in response to a variety of pathological conditions such as atherosclerosis, diabetes, metastatic cancer, sickle cell disease and obesity. These thrombi can lead directly to myocardial infarction (MI), stroke and other thrombotic events that contribute to over a million deaths every year in the United States. Even though multiple, effective drugs have been developed to combat these pathologies by antagonizing platelet receptors and their ligands, clinical use of these drugs can result in serious bleeding consequences. With the advent of increasingly powerful and accessible systems biology approaches, however, new opportunities are available to identify novel platelet targets and elucidate potentially safer antiplatelet strategies. Here we provide an overview of some of these exciting systems approaches ranging from genomics to aptamer discovery and emphasize the importance of identifying and exploiting novel platelet targets for therapeutic benefit.</style></abstract><notes><style face="normal" font="default" size="100%">Holly, Stephen P&#xD;Parise, Leslie V&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Netherlands&#xD;Curr Drug Targets. 2011 Nov;12(12):1859-70.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>105</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">105</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Horie, N.</style></author><author><style face="normal" font="default" size="100%">Hiu, T.</style></author><author><style face="normal" font="default" size="100%">Nagata, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Nagasaki University School of Medicine.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Stem cell transplantation enhances endogenous brain repair after experimental stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Neurol Med Chir (Tokyo)</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurologia medico-chirurgica</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurol Med Chir (Tokyo)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurologia medico-chirurgica</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurol Med Chir (Tokyo)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurologia medico-chirurgica</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">107-12</style></pages><volume><style face="normal" font="default" size="100%">55</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2015/03/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Axons/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/blood supply/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Neovascularization, Physiologic</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Regeneration/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenesis/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuronal Plasticity/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Stem Cell Transplantation/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ physiopathology/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Synapses/physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1349-8029 (Electronic)&#xD;0470-8105 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25746304</style></accession-num><abstract><style face="normal" font="default" size="100%">Stem cell transplantation for stroke treatment has been a promising therapy in small and large animal models, and many clinical trials are ongoing to establish this strategy in a clinical setting. However, the mechanism underlying functional recovery after stem cell transplantation has not been fully established and there is still a need to determine the ideal subset of stem cells for such therapy. We herein reviewed the recent evidences showing the underlying mechanism of functional recovery after cell transplantation, focusing on endogenous brain repair. First, angiogenesis/neovascularization is promoted by trophic factors including vascular endothelial growth factor secreted from stem cells, and stem cells migrated to the lesion along with the vessels. Second, axonal sprouting, dendritic branching, and synaptogenesis were enhanced altogether in the both ipsilateral and contralateral hemisphere remapping the pyramidal tract across the board. Finally, endogenous neurogenesis was also enhanced although little is known how much these neurogenesis contribute to the functional recovery. Taken together, it is clear that stem cell transplantation provides functional recovery via endogenous repair enhancement from multiple ways. This is important to maximize the effect of stem cell therapy after stroke, although it is still undetermined which repair mechanism is mostly contributed.</style></abstract><notes><style face="normal" font="default" size="100%">Horie, Nobutaka&#xD;Hiu, Takeshi&#xD;Nagata, Izumi&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Japan&#xD;Neurol Med Chir (Tokyo). 2015;55(2):107-12. doi: 10.2176/nmc.ra.2014-0271. Epub 2015 Jan 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.jstage.jst.go.jp/article/nmc/55/2/55_ra.2014-0271/_pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3068514737/Horie-2015-Stem cell transplant.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4533406</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.2176/nmc.ra.2014-0271</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>5</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">5</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hsieh, M. C.</style></author><author><style face="normal" font="default" size="100%">Tsai, C. Y.</style></author><author><style face="normal" font="default" size="100%">Liao, M. C.</style></author><author><style face="normal" font="default" size="100%">Yang, J. L.</style></author><author><style face="normal" font="default" size="100%">Su, C. H.</style></author><author><style face="normal" font="default" size="100%">Chen, J. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Graduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University, Taipei 106, Taiwan.&#xD;Molecular Imaging Center, National Taiwan University, Taipei 106, Taiwan.&#xD;Department of Electrical Engineering, National Taiwan University, Taipei 106, Taiwan.&#xD;Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan.&#xD;Department of Biomedical Imaging and Radiological Sciences, National Yang Ming University, Taipei 112, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Quantitative Susceptibility Mapping-Based Microscopy of Magnetic Resonance Venography (QSM-mMRV) for In Vivo Morphologically and Functionally Assessing Cerebromicrovasculature in Rat Stroke Model</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PloS one</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e0149602</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2016/03/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Angiography/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Microcirculation</style></keyword><keyword><style face="normal" font="default" size="100%">Oximetry/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen/ administration &amp; dosage/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Phlebography</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/blood/diagnostic imaging/physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203 (Electronic)&#xD;1932-6203 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26974842</style></accession-num><abstract><style face="normal" font="default" size="100%">Abnormal cerebral oxygenation and vessel structure is a crucial feature of stroke. An imaging method with structural and functional information is necessary for diagnosis of stroke. This study applies QSM-mMRV (quantitative susceptibility mapping-based microscopic magnetic resonance venography) for noninvasively detecting small cerebral venous vessels in rat stroke model. First, susceptibility mapping is optimized and calculated from magnetic resonance (MR) phase images of a rat brain. Subsequently, QSM-mMRV is used to simultaneously provide information on microvascular architecture and venous oxygen saturation (SvO2), both of which can be used to evaluate the physiological and functional characteristics of microvascular changes for longitudinally monitoring and therapeutically evaluating a disease model. Morphologically, the quantification of vessel sizes using QSM-mMRV was 30% smaller than that of susceptibility-weighted imaging (SWI), which eliminated the overestimation of conventional SWI. Functionally, QSM-mMRV estimated an average SvO2 ranging from 73% to 85% for healthy rats. Finally, we also applied QSM to monitor the revascularization of post-stroke vessels from 3 to 10 days after reperfusion. QSM estimations of SvO2 were comparable to those calculated using the pulse oximeter standard metric. We conclude that QSM-mMRV is useful for longitudinally monitoring blood oxygen and might become clinically useful for assessing cerebrovascular diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Hsieh, Meng-Chi&#xD;Tsai, Ching-Yi&#xD;Liao, Min-Chiao&#xD;Yang, Jenq-Lin&#xD;Su, Chia-Hao&#xD;Chen, Jyh-Horng&#xD;United States&#xD;PLoS One. 2016 Mar 14;11(3):e0149602. doi: 10.1371/journal.pone.0149602. eCollection 2016.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0149602&amp;type=printable</style></url></related-urls><pdf-urls><url>internal-pdf://1863183099/Hsieh-2016-Quantitative Suscept.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4790912</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0149602</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>439</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">439</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Huber, V. J.</style></author><author><style face="normal" font="default" size="100%">Tsujita, M.</style></author><author><style face="normal" font="default" size="100%">Nakada, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Integrated Human Brain Science, Brain Research Institute, University of Niigata, 1 Asahi Machi-dori, Chuo-ku, Niigata 951-8585, Japan. vjhuber@bri.niigata-u.ac.jp</style></auth-address><titles><title><style face="normal" font="default" size="100%">Aquaporins in drug discovery and pharmacotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Mol Aspects Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Molecular aspects of medicine</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Mol Aspects Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Molecular aspects of medicine</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Mol Aspects Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Molecular aspects of medicine</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">691-703</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">5-6</style></number><edition><style face="normal" font="default" size="100%">2012/02/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Acetazolamide/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Aquaporins/antagonists &amp; inhibitors/chemistry/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Biological Transport/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/ drug therapy/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Bumetanide/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Discovery</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Targeted Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Neoplasms/ drug therapy/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Niacinamide/analogs &amp; derivatives/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Thiadiazoles/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Water/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Water-Electrolyte Balance/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Water-Electrolyte Imbalance/ drug therapy/metabolism/pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct-Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-9452 (Electronic)&#xD;0098-2997 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22293138</style></accession-num><abstract><style face="normal" font="default" size="100%">Identification of the aquaporin (AQP) protein family more than twenty years ago has ushered in an era where water and neutral solute trafficking is considered a prime target for pharmacological intervention. Using AQP modulation as a basis for the treatment of human disorders has been suggested by phenotype analysis involving specific AQP-null animals, as well as by pathohistological studies. Based on those reports, a wide variety of disorders, such as cerebral edema, cancer and malaria, are considered indications for AQP modulators. Recent studies have also identified several small molecule AQP modulators that can be used to test those hypotheses in disease models. We believe these studies and compounds form the basis from which future treatments and diagnostic protocols of aquaporin-based disorders will be developed.</style></abstract><notes><style face="normal" font="default" size="100%">Huber, Vincent J&#xD;Tsujita, Mika&#xD;Nakada, Tsutomu&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;England&#xD;Mol Aspects Med. 2012 Oct-Dec;33(5-6):691-703. doi: 10.1016/j.mam.2012.01.002. Epub 2012 Jan 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0098299712000039/1-s2.0-S0098299712000039-main.pdf?_tid=60a2c0f4-d7be-11e6-883b-00000aacb35f&amp;acdnat=1484112514_069b95496b28f82a064a36e33959165f</style></url></related-urls><pdf-urls><url>internal-pdf://0363072920/Huber-2012-Aquaporins in drug d.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.mam.2012.01.002</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>385</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">385</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Huisa, B. N.</style></author><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Meyer, B. C.</style></author><author><style face="normal" font="default" size="100%">Tafreshi, G. M.</style></author><author><style face="normal" font="default" size="100%">Zivin, J. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, MSC10 5620, Health Sciences Center 1, University of New Mexico, Albuquerque, NM 87131, USA. bhuisagarate@salud.unm.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">Incremental treatments with laser therapy augments good behavioral outcome in the rabbit small clot embolic stroke model</style></title><secondary-title><style face="normal" font="default" size="100%">Lasers Med Sci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Lasers in medical science</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lasers Med Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Lasers in medical science</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Lasers Med Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Lasers in medical science</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1085-9</style></pages><volume><style face="normal" font="default" size="100%">28</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2012/09/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Behavior, Animal/ radiation effects</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Infrared Rays/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Embolism/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Low-Level Light Therapy/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Rabbits</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/etiology/ psychology/ radiotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1435-604X (Electronic)&#xD;0268-8921 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22945539</style></accession-num><abstract><style face="normal" font="default" size="100%">Transcranial near-infrared laser therapy (TLT) improves behavioral outcome in animal stroke models when applied as single treatment within the 24 h of the stroke onset. It is unknown if the multiple TLT treatments have an added beneficial effect. We aim to determine whether multiple irradiations with TLT would have further improvement in behavioral outcomes in the rabbit small clot embolic stroke model (RSCEM). Using the RSCEM, two and three TLT treatments (7.5-20 mW/cm(2)) were compared against single laser treatment alone (7.5-10.8 mW/cm(2)). Two sham irradiation groups were added for the control curves. The double treatment group received TLT at 3 and 5 h and the triple treatment group at 2, 3, and 4 h after embolization. Behavioral analysis was conducted 24 h after embolization using a dichotomized behavioral score. The determination of the effective clot amount (milligrams) that produces neurological deficits in 50 % of the rabbits (P 50) was used to compare TLT treatments with the sham. The P 50 for double treatment was 5.47 +/- 0.90, with n = 39; the corresponding P 50 value for a single treatment was 3.87 +/- 0.73, with n = 38; and the corresponding control curve was 3.25 +/- 0.4, n = 32. The P 50 for triple treatment was 5.91 +/- 0.49, with n = 23; the corresponding P 50 value for a single treatment was 3.09 +/- 0.59, with n = 15, and the corresponding control curve was 1.71 +/- 0.26, with n = 17. The triple treatment had 91 % improvement when compared with the single treatment and 245 % improvement when compared with the sham. The present study suggests that the additional TLT treatments provide further behavioral improvement when given during the acute ischemic stroke phase.</style></abstract><notes><style face="normal" font="default" size="100%">Huisa, Branko N&#xD;Chen, Yongmei&#xD;Meyer, Brett C&#xD;Tafreshi, Gilda M&#xD;Zivin, Justin A&#xD;P50 NS044148/NS/NINDS NIH HHS/United States&#xD;5P50NS044148/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;England&#xD;Lasers Med Sci. 2013 Jul;28(4):1085-9. doi: 10.1007/s10103-012-1193-1. Epub 2012 Sep 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/171/art%253A10.1007%252Fs10103-012-1193-1.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs10103-012-1193-1&amp;token2=exp=1484113532~acl=%2Fstatic%2Fpdf%2F171%2Fart%25253A10.1007%25252Fs10103-012-1193-1.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs10103-012-1193-1*~hmac=4dff4d33b11c6311ba7e105f1f8866423ae1568c09104d42b5f56be169222fd8</style></url></related-urls><pdf-urls><url>internal-pdf://1841233406/Huisa-2013-Incremental treatmen.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3538923</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms406161</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s10103-012-1193-1</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>168</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">168</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Huisa, B. N.</style></author><author><style face="normal" font="default" size="100%">Rosenberg, G. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, University of New Mexico Health Sciences Center, MSC10 5620, Albuquerque, NM 87131, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Binswanger&apos;s disease: toward a diagnosis agreement and therapeutic approach</style></title><secondary-title><style face="normal" font="default" size="100%">Expert Rev Neurother</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Expert review of neurotherapeutics</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Expert Rev Neurother</style></full-title><abbr-1><style face="normal" font="default" size="100%">Expert review of neurotherapeutics</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Expert Rev Neurother</style></full-title><abbr-1><style face="normal" font="default" size="100%">Expert review of neurotherapeutics</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1203-13</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2014/09/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Vessels/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/blood supply/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cognitive Dysfunction/diagnosis/pathology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Dementia, Vascular/ diagnosis/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelium/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging/methods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1744-8360 (Electronic)&#xD;1473-7175 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25201523</style></accession-num><abstract><style face="normal" font="default" size="100%">Binswanger&apos;s disease (BD) is a progressive form of cerebral small vessel disease affecting the white matter and other subcortical structures. Clinical and imaging characteristics, neuropsychological profile and cerebrospinal fluid analysis aid in making the diagnosis. BD shares features of other small vessel diseases and degenerative neurological conditions, which makes diagnosis difficult. However, with recent developments in MRI methods and serum/cerebrospinal fluid biomarkers, we have gained a greater understanding of the complex pathophysiology of the disease that will guide us to a more certain diagnosis. There is growing evidence that the white matter injury in BD is related to endothelial dysfunction with a secondary inflammatory response leading to breakdown of the neurovascular unit. This review summarizes current and future research directions, including pathophysiological mechanisms and potential therapeutic approaches.</style></abstract><notes><style face="normal" font="default" size="100%">Huisa, Branko N&#xD;Rosenberg, Gary A&#xD;R01 NS052305/NS/NINDS NIH HHS/United States&#xD;UL1 TR000041/TR/NCATS NIH HHS/United States&#xD;Review&#xD;England&#xD;Expert Rev Neurother. 2014 Oct;14(10):1203-13. doi: 10.1586/14737175.2014.956726. Epub 2014 Sep 9.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4545265</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms636349</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1586/14737175.2014.956726</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>63</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">63</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Iijima, K.</style></author><author><style face="normal" font="default" size="100%">Kurachi, M.</style></author><author><style face="normal" font="default" size="100%">Shibasaki, K.</style></author><author><style face="normal" font="default" size="100%">Naruse, M.</style></author><author><style face="normal" font="default" size="100%">Puentes, S.</style></author><author><style face="normal" font="default" size="100%">Imai, H.</style></author><author><style face="normal" font="default" size="100%">Yoshimoto, Y.</style></author><author><style face="normal" font="default" size="100%">Mikuni, M.</style></author><author><style face="normal" font="default" size="100%">Ishizaki, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.&#xD;Department of Molecular and Cellular Neurobiology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.&#xD;Department of Neurosurgery, Tokyo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan.&#xD;Department of Psychiatry and Neuroscience, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transplanted microvascular endothelial cells promote oligodendrocyte precursor cell survival in ischemic demyelinating lesions</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurochem</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neurochemistry</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurochem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurochemistry</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurochem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurochemistry</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">539-50</style></pages><volume><style face="normal" font="default" size="100%">135</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2015/07/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/pathology/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Survival/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Demyelinating Diseases/pathology/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelial Cells/ transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Microvessels/cytology/ transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Oligodendroglia/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Stem Cells/ physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1471-4159 (Electronic)&#xD;0022-3042 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26212499</style></accession-num><abstract><style face="normal" font="default" size="100%">We previously showed that transplantation of brain microvascular endothelial cells (MVECs) greatly stimulated remyelination in the white matter infarct of the internal capsule (IC) induced by endothelin-1 injection and improved the behavioral outcome. In the present study, we examined the effect of MVEC transplantation on the infarct volume using intermittent magnetic resonance image and on the behavior of oligodendrocyte lineage cells histochemically. Our results in vivo show that MVEC transplantation reduced the infarct volume in IC and apoptotic death of oligodendrocyte precursor cells (OPCs). These results indicate that MVECs have a survival effect on OPCs, and this effect might contribute to the recovery of the white matter infarct. The conditioned-medium from cultured MVECs reduced apoptosis of cultured OPCs, while the conditioned medium from cultured fibroblasts did not show such effect. These results suggest a possibility that transplanted MVECs increased the number of OPCs through the release of humoral factors that prevent their apoptotic death. Identification of such humoral factors may lead to the new therapeutic strategy against ischemic demyelinating diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Iijima, Keiya&#xD;Kurachi, Masashi&#xD;Shibasaki, Koji&#xD;Naruse, Masae&#xD;Puentes, Sandra&#xD;Imai, Hideaki&#xD;Yoshimoto, Yuhei&#xD;Mikuni, Masahiko&#xD;Ishizaki, Yasuki&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Neurochem. 2015 Nov;135(3):539-50. doi: 10.1111/jnc.13262. Epub 2015 Sep 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/jnc.13262/asset/jnc13262.pdf?v=1&amp;t=ixsi62v1&amp;s=048b96fc15c2e1674d5deb70a164c149231f1793</style></url></related-urls><pdf-urls><url>internal-pdf://2589671905/Iijima-2015-Transplanted microva.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/jnc.13262</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>256</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">256</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Inaba, Y.</style></author><author><style face="normal" font="default" size="100%">Davidson, B. P.</style></author><author><style face="normal" font="default" size="100%">Kim, S.</style></author><author><style face="normal" font="default" size="100%">Liu, Y. N.</style></author><author><style face="normal" font="default" size="100%">Packwood, W.</style></author><author><style face="normal" font="default" size="100%">Belcik, J. T.</style></author><author><style face="normal" font="default" size="100%">Xie, A.</style></author><author><style face="normal" font="default" size="100%">Lindner, J. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Knight Cardiovascular Institute, Oregon Health &amp; Science University, Portland, Oregon.&#xD;Knight Cardiovascular Institute, Oregon Health &amp; Science University, Portland, Oregon. Electronic address: linderj@ohsu.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Echocardiographic evaluation of the effects of stem cell therapy on perfusion and function in ischemic cardiomyopathy</style></title><secondary-title><style face="normal" font="default" size="100%">J Am Soc Echocardiogr</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Am Soc Echocardiogr</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Am Soc Echocardiogr</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">192-9</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2013/12/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Echocardiography</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Nude</style></keyword><keyword><style face="normal" font="default" size="100%">Multipotent Stem Cells/transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Ischemia/complications/ diagnostic imaging/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Perfusion Imaging/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Ventricular Dysfunction, Left/ diagnostic imaging/etiology/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Ventricular Remodeling</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1097-6795 (Electronic)&#xD;0894-7317 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24315764</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Small animal models of ischemic left ventricular (LV) dysfunction are important for the preclinical optimization of stem cell therapy. The aim of this study was to test the hypothesis that temporal changes in LV function and regional perfusion after cell therapy can be assessed in mice using echocardiographic imaging. METHODS: Wild-type mice (n = 25) were studied 7 and 28 days after permanent ligation of the left anterior descending coronary artery. Animals were randomized to receive closed-chest ultrasound-guided intramyocardial delivery of saline (n = 13) or 5 x 10(5) multipotential adult progenitor cells (MAPCs; n = 12) on day 7. LV end-diastolic and end-systolic volumes, LV ejection fraction, and stroke volume were measured using high-frequency echocardiography. Multiplanar assessments of perfusion and defect area size were made using myocardial contrast echocardiography. RESULTS: Between days 7 and 28, MAPC-treated animals had 40% to 50% reductions in defect size (P &lt; .001) and 20% to 30% increases in total perfusion (P &lt; .01). Perfusion did not change in nontreated controls. Both LV end-diastolic and end-systolic volumes increased between days 7 and 28 in both groups, but LV end-systolic volume increased to a lesser degree in MAPC-treated compared with control mice (+4.2 +/- 7.9 vs +19.2 +/- 22.0 muL, P &lt; .05). LV ejection fraction increased in the MAPC-treated mice and decreased in control mice (+3.0 +/- 4.3% vs -5.6 +/- 5.9%, P &lt; .01). There was a significant linear relation between the change in LV ejection fraction and the change in either defect area size or total perfusion. CONCLUSIONS: High-frequency echocardiography and myocardial contrast echocardiography in murine models of ischemic LV dysfunction can be used to assess the response to stem cell therapy and to characterize the relationship among spatial flow, ventricular function, and ventricular remodeling.</style></abstract><notes><style face="normal" font="default" size="100%">Inaba, Yoichi&#xD;Davidson, Brian P&#xD;Kim, Sajeevani&#xD;Liu, Ya Ni&#xD;Packwood, William&#xD;Belcik, J Todd&#xD;Xie, Aris&#xD;Lindner, Jonathan R&#xD;R01 DK063508/DK/NIDDK NIH HHS/United States&#xD;R01 HL074443/HL/NHLBI NIH HHS/United States&#xD;R01 HL111969/HL/NHLBI NIH HHS/United States&#xD;RC1-HL-100659/HL/NHLBI NIH HHS/United States&#xD;T32 HL094294/HL/NHLBI NIH HHS/United States&#xD;T32-HL094294/HL/NHLBI NIH HHS/United States&#xD;RC1 HL100659/HL/NHLBI NIH HHS/United States&#xD;R01 HL078610/HL/NHLBI NIH HHS/United States&#xD;R01-HL111969/HL/NHLBI NIH HHS/United States&#xD;R01-HL-078610/HL/NHLBI NIH HHS/United States&#xD;Evaluation Studies&#xD;Research Support, N.I.H., Extramural&#xD;Validation Studies&#xD;United States&#xD;J Am Soc Echocardiogr. 2014 Feb;27(2):192-9. doi: 10.1016/j.echo.2013.10.011. Epub 2013 Dec 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0894731713008328/1-s2.0-S0894731713008328-main.pdf?_tid=67501186-d7be-11e6-98ef-00000aacb35f&amp;acdnat=1484112526_e85ba42736b5a4c5ff8c4d6b6035f874</style></url></related-urls><pdf-urls><url>internal-pdf://2446080111/Inaba-2014-Echocardiographic ev.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3946830</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms537251</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.echo.2013.10.011</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>236</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">236</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Irmady, K.</style></author><author><style face="normal" font="default" size="100%">Jackman, K. A.</style></author><author><style face="normal" font="default" size="100%">Padow, V. A.</style></author><author><style face="normal" font="default" size="100%">Shahani, N.</style></author><author><style face="normal" font="default" size="100%">Martin, L. A.</style></author><author><style face="normal" font="default" size="100%">Cerchietti, L.</style></author><author><style face="normal" font="default" size="100%">Unsicker, K.</style></author><author><style face="normal" font="default" size="100%">Iadecola, C.</style></author><author><style face="normal" font="default" size="100%">Hempstead, B. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine and Brain and Mind Research Institute, Weill Cornell Medical College, New York, New York 10065, and Interdisciplinary Center for Neurosciences, Department of Neuroanatomy, University of Heidelberg, INF 307, D69120 Heidelberg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mir-592 regulates the induction and cell death-promoting activity of p75NTR in neuronal ischemic injury</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">3419-28</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2014/02/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/drug effects/genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation/genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose/deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Hippocampus/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia</style></keyword><keyword><style face="normal" font="default" size="100%">In Vitro Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">MicroRNAs/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Growth Factor/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Precursors/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Nerve Growth Factor/genetics/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 26</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1529-2401 (Electronic)&#xD;0270-6474 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24573298</style></accession-num><abstract><style face="normal" font="default" size="100%">The neurotrophin receptor p75(NTR) has been implicated in mediating neuronal apoptosis after injury to the CNS. Despite its frequent induction in pathologic states, there is limited understanding of the mechanisms that regulate p75(NTR) expression after injury. Here, we show that after focal cerebral ischemia in vivo or oxygen-glucose deprivation in organotypic hippocampal slices or neurons, p75(NTR) is rapidly induced. A concomitant induction of proNGF, a ligand for p75(NTR), is also observed. Induction of this ligand/receptor system is pathologically relevant, as a decrease in apoptosis, after oxygen-glucose deprivation, is observed in hippocampal neurons or slices after delivery of function-blocking antibodies to p75(NTR) or proNGF and in p75(NTR) and ngf haploinsufficient slices. Furthermore, a significant decrease in infarct volume was noted in p75(NTR)-/- mice compared with the wild type. We also investigated the regulatory mechanisms that lead to post-ischemic induction of p75(NTR). We demonstrate that induction of p75(NTR) after ischemic injury is independent of transcription but requires active translation. Basal levels of p75(NTR) in neurons are maintained in part by the expression of microRNA miR-592, and an inverse correlation is seen between miR-592 and p75(NTR) levels in the adult brain. After cerebral ischemia, miR-592 levels fall, with a corresponding increase in p75(NTR) levels. Importantly, overexpression of miR-592 in neurons decreases the level of ischemic injury-induced p75(NTR) and attenuates activation of pro-apoptotic signaling and cell death. These results identify miR-592 as a key regulator of p75(NTR) expression and point to a potential therapeutic candidate to limit neuronal apoptosis after ischemic injury.</style></abstract><notes><style face="normal" font="default" size="100%">Irmady, Krithi&#xD;Jackman, Katherine A&#xD;Padow, Victoria A&#xD;Shahani, Neelam&#xD;Martin, Laura Andres&#xD;Cerchietti, Leandro&#xD;Unsicker, Klaus&#xD;Iadecola, Costantino&#xD;Hempstead, Barbara L&#xD;NS30687/NS/NINDS NIH HHS/United States&#xD;R01 NS073666/NS/NINDS NIH HHS/United States&#xD;R01 NS034179/NS/NINDS NIH HHS/United States&#xD;NS73666/NS/NINDS NIH HHS/United States&#xD;R01 NS030687/NS/NINDS NIH HHS/United States&#xD;R37 NS034179/NS/NINDS NIH HHS/United States&#xD;NS34179/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Neurosci. 2014 Feb 26;34(9):3419-28. doi: 10.1523/JNEUROSCI.1982-13.2014.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.jneurosci.org/content/jneuro/34/9/3419.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1062949788/Irmady-2014-Mir-592 regulates th.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3935094</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1523/jneurosci.1982-13.2014</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>431</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">431</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jalal, F. Y.</style></author><author><style face="normal" font="default" size="100%">Yang, Y.</style></author><author><style face="normal" font="default" size="100%">Thompson, J.</style></author><author><style face="normal" font="default" size="100%">Lopez, A. C.</style></author><author><style face="normal" font="default" size="100%">Rosenberg, G. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, MSC10 5620, 1 University of New Mexico, Albuquerque, NM 87131, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Myelin loss associated with neuroinflammation in hypertensive rats</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1115-22</style></pages><volume><style face="normal" font="default" size="100%">43</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2012/03/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Caspase 3/biosynthesis</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Matrix Metalloproteinase 2/biosynthesis</style></keyword><keyword><style face="normal" font="default" size="100%">Matrix Metalloproteinase 3/biosynthesis</style></keyword><keyword><style face="normal" font="default" size="100%">Matrix Metalloproteinase 9/biosynthesis</style></keyword><keyword><style face="normal" font="default" size="100%">Microglia/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Myelin Basic Protein/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Myelin Sheath/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred SHR</style></keyword><keyword><style face="normal" font="default" size="100%">Tumor Necrosis Factor-alpha/biosynthesis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22363061</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: Small vessel disease is the major cause of white matter injury in patients with vascular cognitive impairment. Matrix metalloproteinase (MMP)-mediated inflammation may be involved in the white matter damage with oligodendrocyte (Ol) death. Therefore, we used spontaneously hypertensive stroke-prone rats to study the role of neuroinflammation in white matter damage. METHODS: Permanent unilateral carotid artery occlusion was performed at 12 weeks of age in spontaneously hypertensive stroke-prone rats. Following surgery, rats were placed on a Japanese permissive diet and received 1% NaCl in drinking water. MRI, histology, biochemistry, and ELISA characterized white matter lesions, and cognitive impairment was tested by Morris water maze. RESULTS: White matter damage was observed 4 to 5 weeks following permanent unilateral carotid artery occlusion/Japanese permissive diet. Immunoblotting showed marked reduction in myelin basic protein and upregulation of immature Ols. Mature Ols underwent caspase-3-mediated apoptosis. Morris water maze showed cognitive impairment. Abnormally appearing vessels were observed and surrounded by inflammatory-like cells. IgG extravasation and hemorrhage, indicating blood-brain barrier (BBB) disruption, was closely associated with MMP-9 expression. Lesions in white matter showed reactive astrocytosis and activated microglia that expressed tumor necrosis factor-alpha. MMP-3 and MMP-9 were significantly increased, and MMP-2 was reduced in both astrocytes and Ol. CONCLUSIONS: We found apoptosis of mature Ols with an increase in immature Ols. Increased MMP-3, MMP-9, and tumor necrosis factor-alpha were associated with myelin breakdown and BBB disruption. Neuroinflammation is an important factor in white matter damage and Ol death, and studies using this new model can be performed to assess agents to block inflammation.</style></abstract><notes><style face="normal" font="default" size="100%">Jalal, Fakhreya Y&#xD;Yang, Yi&#xD;Thompson, Jeffrey&#xD;Lopez, Anita C&#xD;Rosenberg, Gary A&#xD;R01 NS045847/NS/NINDS NIH HHS/United States&#xD;R21 NS066418/NS/NINDS NIH HHS/United States&#xD;2 R01 NS045847-05A2/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;United States&#xD;Stroke. 2012 Apr;43(4):1115-22. doi: 10.1161/STROKEAHA.111.643080. Epub 2012 Feb 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/43/4/1115.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://4266818922/Jalal-2012-Myelin loss associat.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3598597</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms355337</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.111.643080</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>107</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">107</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jalal, F. Y.</style></author><author><style face="normal" font="default" size="100%">Yang, Y.</style></author><author><style face="normal" font="default" size="100%">Thompson, J. F.</style></author><author><style face="normal" font="default" size="100%">Roitbak, T.</style></author><author><style face="normal" font="default" size="100%">Rosenberg, G. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.&#xD;Department of Neurosurgery, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.&#xD;1] Department of Neurology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA [2] Department of Neurosciences, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA [3] Department of Cell Biology and Physiology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hypoxia-induced neuroinflammatory white-matter injury reduced by minocycline in SHR/SP</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1145-53</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2015/02/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/drug effects/immunology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia/ complications/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia-Inducible Factor 1, alpha Subunit/analysis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/complications/ drug therapy/immunology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Matrix Metalloproteinase 2/analysis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Matrix Metalloproteinase 9/analysis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Minocycline/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred SHR</style></keyword><keyword><style face="normal" font="default" size="100%">White Matter/ drug effects/immunology/injuries/ pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25712499</style></accession-num><abstract><style face="normal" font="default" size="100%">Hypertensive small vessel disease is a major cause of vascular cognitive impairment (VCI). Spontaneously hypertensive/stroke prone rats (SHR/SP) with unilateral carotid artery occlusion (UCAO) and a Japanese permissive diet (JPD) have white-matter (WM) damage similar to that seen in VCI. We hypothesized that WM injury was due to hypoxia-mediated, blood-brain barrier (BBB) disruption. Twelve-week-old SHR/SP had UCAO/JPD and were studied with immunohistochemistry, biochemistry, multimodal magnetic resonance imaging (MRI), and Morris water maze (MWM) testing. One week after UCAO/JPD, WM showed a significant increase in hypoxia inducible factor-1alpha (HIF-1alpha), which increased further by 3 weeks. Prolyl hydroxylase-2 (PHD2) expression decreased at 1 and 3 weeks. Infiltrating T cells and neutrophils appeared around endothelial cells from 1 to 3 weeks after UCAO/JPD, and matrix metalloproteinase-9 (MMP-9) colocalized with inflammatory cells. At 3 weeks, WM immunostained for IgG, indicating BBB leakage. Minocycline (50 mg/kg intraperitoneally) was given every other day from weeks 12 to 20. Multimodal MRI showed that treatment with minocycline significantly reduced lesion size and improved cerebral blood flow. Minocycline improved performance in the MWM and prolonged survival. We propose that BBB disruption occurred secondary to hypoxia, which induced an MMP-9-mediated infiltration of leukocytes. Minocycline significantly reduced WM damage, improved behavior, and prolonged life.</style></abstract><notes><style face="normal" font="default" size="100%">Jalal, Fakhreya Y&#xD;Yang, Yi&#xD;Thompson, Jeffrey F&#xD;Roitbak, Tamara&#xD;Rosenberg, Gary A&#xD;R01 NS045847/NS/NINDS NIH HHS/United States&#xD;R01NS045847/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;United States&#xD;J Cereb Blood Flow Metab. 2015 Jul;35(7):1145-53. doi: 10.1038/jcbfm.2015.21. Epub 2015 Feb 25.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4640265</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2015.21</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>103</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">103</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jeanne, M.</style></author><author><style face="normal" font="default" size="100%">Jorgensen, J.</style></author><author><style face="normal" font="default" size="100%">Gould, D. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From Departments of Ophthalmology and Anatomy, Institute for Human Genetics, University of California, San Francisco (UCSF).&#xD;From Departments of Ophthalmology and Anatomy, Institute for Human Genetics, University of California, San Francisco (UCSF). GouldD@vision.ucsf.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Molecular and Genetic Analyses of Collagen Type IV Mutant Mouse Models of Spontaneous Intracerebral Hemorrhage Identify Mechanisms for Stroke Prevention</style></title><secondary-title><style face="normal" font="default" size="100%">Circulation</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Circulation</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Circulation</style></full-title><abbr-1><style face="normal" font="default" size="100%">Circulation</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Circulation</style></full-title><abbr-1><style face="normal" font="default" size="100%">Circulation</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1555-65</style></pages><volume><style face="normal" font="default" size="100%">131</style></volume><number><style face="normal" font="default" size="100%">18</style></number><edition><style face="normal" font="default" size="100%">2015/03/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Vessels/abnormalities/embryology</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/blood supply/embryology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/genetics/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Collagen/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Collagen Type IV/deficiency/ genetics/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelial Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Gene-Environment Interaction</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Heterogeneity</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Mutant Strains</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation</style></keyword><keyword><style face="normal" font="default" size="100%">Neovascularization, Physiologic/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Peptide Fragments/deficiency/ genetics/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Pericytes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Physical Conditioning, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Porencephaly/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Retinal Vessels/embryology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">May 05</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4539 (Electronic)&#xD;0009-7322 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25753534</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Collagen type IV alpha1 (COL4A1) and alpha2 (COL4A2) form heterotrimers critical for vascular basement membrane stability and function. Patients with COL4A1 or COL4A2 mutations suffer from diverse cerebrovascular diseases, including cerebral microbleeds, porencephaly, and fatal intracerebral hemorrhage (ICH). However, the pathogenic mechanisms remain unknown, and there is a lack of effective treatment. METHODS AND RESULTS: Using Col4a1 and Col4a2 mutant mouse models, we investigated the genetic complexity and cellular mechanisms underlying the disease. We found that Col4a1 mutations cause abnormal vascular development, which triggers small-vessel disease, recurrent hemorrhagic strokes, and age-related macroangiopathy. We showed that allelic heterogeneity, genetic context, and environmental factors such as intense exercise or anticoagulant medication modulated disease severity and contributed to phenotypic heterogeneity. We found that intracellular accumulation of mutant collagen in vascular endothelial cells and pericytes was a key triggering factor of ICH. Finally, we showed that treatment of mutant mice with a US Food and Drug Administration-approved chemical chaperone resulted in a decreased collagen intracellular accumulation and a significant reduction in ICH severity. CONCLUSIONS: Our data are the first to show therapeutic prevention in vivo of ICH resulting from Col4a1 mutation and imply that a mechanism-based therapy promoting protein folding might also prevent ICH in patients with COL4A1 and COL4A2 mutations.</style></abstract><notes><style face="normal" font="default" size="100%">Jeanne, Marion&#xD;Jorgensen, Jeff&#xD;Gould, Douglas B&#xD;P30 EY002162/EY/NEI NIH HHS/United States&#xD;R01 NS083830/NS/NINDS NIH HHS/United States&#xD;EY02162/EY/NEI NIH HHS/United States&#xD;NS083830/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Circulation. 2015 May 5;131(18):1555-65. doi: 10.1161/CIRCULATIONAHA.114.013395. Epub 2015 Mar 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://circ.ahajournals.org/content/circulationaha/131/18/1555.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0705300383/Jeanne-2015-Molecular and Geneti.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4497509</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms703379</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/circulationaha.114.013395</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>402</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">402</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jeon, S. J.</style></author><author><style face="normal" font="default" size="100%">Han, S. H.</style></author><author><style face="normal" font="default" size="100%">Yang, S. I.</style></author><author><style face="normal" font="default" size="100%">Choi, J. W.</style></author><author><style face="normal" font="default" size="100%">Kwon, K. J.</style></author><author><style face="normal" font="default" size="100%">Park, S. H.</style></author><author><style face="normal" font="default" size="100%">Kim, H. Y.</style></author><author><style face="normal" font="default" size="100%">Cheong, J. H.</style></author><author><style face="normal" font="default" size="100%">Ryu, J. H.</style></author><author><style face="normal" font="default" size="100%">Ko, K. H.</style></author><author><style face="normal" font="default" size="100%">Wells, D. G.</style></author><author><style face="normal" font="default" size="100%">Shin, C. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacology, College of Pharmacy, Seoul National University, Seoul, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Positive feedback regulation of Akt-FMRP pathway protects neurons from cell death</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurochem</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neurochemistry</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurochem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurochemistry</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurochem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurochemistry</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">226-38</style></pages><volume><style face="normal" font="default" size="100%">123</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2012/07/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Death/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Survival/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Feedback, Physiological/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Fragile X Mental Retardation Protein/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/metabolism/pathology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/pathology/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Proto-Oncogene Proteins c-akt/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/ physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1471-4159 (Electronic)&#xD;0022-3042 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22817682</style></accession-num><abstract><style face="normal" font="default" size="100%">J. Neurochem. (2012) 123, 226-238. ABSTRACT: Fragile X syndrome (FXS), the most common single genetic cause of mental retardation and autistic spectrum disease, occurs when FMR1 gene is mutated. FMR1 encodes fragile X mental retardation protein (FMRP) which regulates translation of mRNAs playing important roles in the development of neurons as well as formation and maintenance of synapses. To examine whether FMRP regulates cell viability, we induced apoptosis in rat primary cortical neurons with glutamate in vitro and with middle cerebral artery occlusion (MCAO) in striatal neurons in vivo. Both conditions elicited a rapid, but transient FMRP expression in neurons. This up-regulated FMRP expression was abolished by pre-treatment with PI3K and Protein Kinase B (Akt) inhibitors: LY294002, Akt inhibitor IV, and VIII. Reduced FMRP expression in vitro or in vivo using small hairpin Fmr1 virus exacerbated cell death by glutamate or MCAO, presumably via hypophosphorylation of Akt and reduced expression of B-cell lymphoma-extra large (Bcl-xL). However, over-expression of FMRP using enhanced green fluorescent protein (eGFP)-FMRP constructs alleviated cell death, increased Akt activity, and enhanced Bcl-xL production. The pro-survival role of Akt-dependent up-regulation of FMRP in glutamate-stimulated cultured neuron as well as in ischemic brain may have a clinical importance in FXS as well as in neurodegenerative disorders and traumatic brain injury.</style></abstract><notes><style face="normal" font="default" size="100%">Jeon, Se Jin&#xD;Han, Seol-Heui&#xD;Yang, Sung-Il&#xD;Choi, Ji Woong&#xD;Kwon, Kyoung Ja&#xD;Park, Seung Hwa&#xD;Kim, Hahn Young&#xD;Cheong, Jae Hoon&#xD;Ryu, Jong Hoon&#xD;Ko, Kwang Ho&#xD;Wells, David G&#xD;Shin, Chan Young&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Neurochem. 2012 Oct;123(2):226-38. doi: 10.1111/j.1471-4159.2012.07886.x. Epub 2012 Aug 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/j.1471-4159.2012.07886.x/asset/jnc7886.pdf?v=1&amp;t=ixsi6erg&amp;s=5ae9af19172ee4a65651d9b0174c840f133fead9</style></url></related-urls><pdf-urls><url>internal-pdf://2280024335/Jeon-2012-Positive feedback re.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1471-4159.2012.07886.x</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>81</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">81</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ji, Y.</style></author><author><style face="normal" font="default" size="100%">Zhou, Y.</style></author><author><style face="normal" font="default" size="100%">Pan, J.</style></author><author><style face="normal" font="default" size="100%">Li, X.</style></author><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">a Department of Neurology, Sun Yat-Sen Memorial Hospital , Sun Yat-Sen University , Guangzhou , China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Temporal pattern of Toll-like receptor 9 upregulation in neurons and glial cells following cerebral ischemia reperfusion in mice</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The International journal of neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Int J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The International journal of neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Int J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The International journal of neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">269-77</style></pages><volume><style face="normal" font="default" size="100%">126</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2015/05/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroglia/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Toll-Like Receptor 9/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">1563-5279 (Electronic)&#xD;0020-7454 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26000727</style></accession-num><abstract><style face="normal" font="default" size="100%">PURPOSE: The family of Toll-like receptors (TLRs) has recently been reported to play a role in ischemic injury, but the time course and cell types of the post-stroke TLR9 upregulation remain unclear. In this study, we investigated the dynamic changes of TLR9 expression and the expression of TLR9 in neurons and glial cells after cerebral ischemia reperfusion in mice. METHODS: Focal cerebral ischemia was induced by middle cerebral artery occlusion for 90 min in male C57BL/6 mice. The TLR9 expression levels in the tissue surrounding the infarct were detected by Western Blot at 6 h, 3 d, 7 d, 14 d, 21 d, and 28 d after reperfusion. The expression of TLR9 in neurons and glial cells was observed by immunofluorescence staining. RESULTS: The expression of TLR9 protein first increased and then decreased, with the peak observed at 14 d-21 d. Only small punctate intracellular TLR9 was occasionally observed in the neurons at each time point, and the TLR9-positive rate showed no difference at different time points. By contrast, the activated microglia gathered at the margin of the infarct, and the intracellular TLR9 changed from scattered small punctate to coarse and lumpy. The TLR9-positive rate of microglia was first increased and then decreased with time, with the peak observed at 3 d. No positive TLR9 staining was found in the astrocytes and oligodendrocytes. CONCLUSIONS: TLR9 expression showed dynamic changes for a long period of time and microglias were the main brain cells to express TLR9 after cerebral ischemia and reperfusion.</style></abstract><notes><style face="normal" font="default" size="100%">Ji, Yuan&#xD;Zhou, Ying&#xD;Pan, Jingrui&#xD;Li, Xiangpen&#xD;Wang, Hongxuan&#xD;Wang, Yidong&#xD;England&#xD;Int J Neurosci. 2016;126(3):269-77. doi: 10.3109/00207454.2015.1010649. Epub 2015 Jun 5.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3109/00207454.2015.1010649</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>281</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">281</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ji, Y. F.</style></author><author><style face="normal" font="default" size="100%">Zhou, L.</style></author><author><style face="normal" font="default" size="100%">Xie, Y. J.</style></author><author><style face="normal" font="default" size="100%">Xu, S. M.</style></author><author><style face="normal" font="default" size="100%">Zhu, J.</style></author><author><style face="normal" font="default" size="100%">Teng, P.</style></author><author><style face="normal" font="default" size="100%">Shao, C. Y.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Luo, J. H.</style></author><author><style face="normal" font="default" size="100%">Shen, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurobiology, Key Laboratory of Medical Neurobiology of Ministry of Health of China, Zhejiang Province Key Laboratory of Neurobiology, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People&apos;s Republic of China; Department of Neurology, Second Clinical College, North Sichuan Medical College, Nanchong, Sichuan, People&apos;s Republic of China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Upregulation of glutamate transporter GLT-1 by mTOR-Akt-NF-small ka, CyrillicB cascade in astrocytic oxygen-glucose deprivation</style></title><secondary-title><style face="normal" font="default" size="100%">Glia</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Glia</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Glia</style></full-title><abbr-1><style face="normal" font="default" size="100%">Glia</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Glia</style></full-title><abbr-1><style face="normal" font="default" size="100%">Glia</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1959-75</style></pages><volume><style face="normal" font="default" size="100%">61</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2013/10/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/drug effects/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Excitatory Amino Acid Transporter 2/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">NF-kappa B/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphorylation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Proto-Oncogene Proteins c-akt/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Sirolimus/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">TOR Serine-Threonine Kinases/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1098-1136 (Electronic)&#xD;0894-1491 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24108520</style></accession-num><abstract><style face="normal" font="default" size="100%">Excessive extracellular glutamate leads to neuronal death in central nervous system. Excitatory glutamate transporter subtype 2 (GLT-1) carries bulk of glutamate reuptake in cerebral ischemia. Although GLT-1 expression fluctuates during the period of ischemia, little is known about its regulatory mechanism. Here we show an up-regulation of GLT-1 via mammalian target of rapamycin (mTOR)-Akt-nuclear factor-small ka, CyrillicB (NF-small ka, CyrillicB) signaling cascade in oxygen glucose deprivation (OGD). We found that brief rapamycin treatment significantly increased GLT-1 expression in cultured astrocytes. Rapamycin increased phosphorylation of raptor at Ser792 and decreased phosphorylation of rictor at Thr1135, suggesting that both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) are involved in GLT-1 expression. This conclusion was further confirmed by raptor and rictor disruption experiments. Akt was activated by mTORC1 inhibition and required for GLT-1 expression because triciribine, a specific inhibitor of Akt, blocked the increase of GLT-1 expression. mTOR-Akt cascade then activated NF-small ka, CyrillicB and increased small ka, CyrillicB-motif-binding phosphoprotein (KBBP) expression and GLT-1 transcription. We next demonstrated that mTOR-Akt-NF-small ka, CyrillicB cascade was activated in OGD and subsequently caused the upregulation of GLT-1. Supporting evidence included: (1) inhibition of Akt or NF-small ka, CyrillicB occluded OGD-induced GLT-1 upregulation; (2) Raptor knock-down plus OGD did not add to the increase of GLT-1 expression; (3) Intact mTORC2 was required for GLT-1 enhancement. In summary, our data first showed that mTOR-Akt-NF-small ka, CyrillicB cascade played critical roles to up-regulate GLT-1 in OGD. This signaling cascade may work to promote glutamate uptake in brain ischemia and neurodegenerative diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Ji, Yi-Fei&#xD;Zhou, Liang&#xD;Xie, Ya-Jun&#xD;Xu, Si-Min&#xD;Zhu, Jia&#xD;Teng, Peng&#xD;Shao, Chong-Yu&#xD;Wang, Yin&#xD;Luo, Jian-Hong&#xD;Shen, Ying&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Glia. 2013 Dec;61(12):1959-75. doi: 10.1002/glia.22566. Epub 2013 Sep 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1002/glia.22566/asset/glia22566.pdf?v=1&amp;t=ixsi6jc6&amp;s=d35c447c52f51ddefdb13fac586276bf1d08a9c1</style></url></related-urls><pdf-urls><url>internal-pdf://3493038162/Ji-2013-Upregulation of glut.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/glia.22566</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>491</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">491</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jia, J.</style></author><author><style face="normal" font="default" size="100%">Verma, S.</style></author><author><style face="normal" font="default" size="100%">Nakayama, S.</style></author><author><style face="normal" font="default" size="100%">Quillinan, N.</style></author><author><style face="normal" font="default" size="100%">Grafe, M. R.</style></author><author><style face="normal" font="default" size="100%">Hurn, P. D.</style></author><author><style face="normal" font="default" size="100%">Herson, P. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Anesthesiology and Peri-Operative Medicine, Oregon Health and Science University, Portland, Oregon 97201, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sex differences in neuroprotection provided by inhibition of TRPM2 channels following experimental stroke</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">2160-8</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2011/05/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Culture Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Death/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Hypoxia</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Clotrimazole/administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Culture Media/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Vectors</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lentivirus/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Microinjections</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/ drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/administration &amp; dosage/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/administration &amp; dosage/genetics/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Sex Characteristics</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/metabolism/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">TRPM Cation Channels/ antagonists &amp; inhibitors/genetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">21587268</style></accession-num><abstract><style face="normal" font="default" size="100%">The calcium-permeable transient receptor potential M2 (TRPM2) ion channel is activated following oxidative stress and has been implicated in ischemic damage; however, little experimental evidence exists linking TRPM2 channel activation to damage following cerebral ischemia. We directly assessed the involvement of TRPM2 channels in ischemic brain injury using pharmacological inhibitors and short-hairpin RNA (shRNA)-mediated knockdown of TRPM2 expression. Each of the four TRPM2 inhibitors tested provided significant protection to male neurons following in vitro ischemia (oxygen-glucose deprivation, OGD), while having no effect in female neurons. Similarly, TRPM2 knockdown by TRPM2 shRNA resulted in significantly reduced neuronal cell death following OGD only in male neurons. The TRPM2 inhibitor clotrimazole reduced infarct volume in male mice, while having no effect on female infarct volume. Finally, intrastriatal injection of lentivirus expressing shRNA against TRPM2 resulted in significantly smaller striatal infarcts only in male mice following middle cerebral artery occlusion, having no significant effect in female mice. Data presented in the current study demonstrate that TRPM2 inhibition and knockdown preferentially protects male neurons and brain against ischemia in vitro and in vivo, indicating that TRPM2 inhibitors may provide a new therapeutic approach to the treatment of stroke in men.</style></abstract><notes><style face="normal" font="default" size="100%">Jia, Jia&#xD;Verma, Saurabh&#xD;Nakayama, Shin&#xD;Quillinan, Nidia&#xD;Grafe, Marjorie R&#xD;Hurn, Patricia D&#xD;Herson, Paco S&#xD;R01 NR003521/NR/NINR NIH HHS/United States&#xD;R01 NS058792/NS/NINDS NIH HHS/United States&#xD;R01 NS058792-05/NS/NINDS NIH HHS/United States&#xD;NS058792/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;United States&#xD;J Cereb Blood Flow Metab. 2011 Nov;31(11):2160-8. doi: 10.1038/jcbfm.2011.77. Epub 2011 May 18.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3210342</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2011.77</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>89</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">89</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jiang, L.</style></author><author><style face="normal" font="default" size="100%">Tu, Y.</style></author><author><style face="normal" font="default" size="100%">Kimura, R. H.</style></author><author><style face="normal" font="default" size="100%">Habte, F.</style></author><author><style face="normal" font="default" size="100%">Chen, H.</style></author><author><style face="normal" font="default" size="100%">Cheng, K.</style></author><author><style face="normal" font="default" size="100%">Shi, H.</style></author><author><style face="normal" font="default" size="100%">Gambhir, S. S.</style></author><author><style face="normal" font="default" size="100%">Cheng, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China; and Molecular Imaging Program at Stanford (MIPS), Department of Radiology and Bio-X Program, Canary Center at Stanford for Cancer Early Detection, Stanford University, Stanford, California.&#xD;Molecular Imaging Program at Stanford (MIPS), Department of Radiology and Bio-X Program, Canary Center at Stanford for Cancer Early Detection, Stanford University, Stanford, California.&#xD;Molecular Imaging Program at Stanford (MIPS), Department of Radiology and Bio-X Program, Canary Center at Stanford for Cancer Early Detection, Stanford University, Stanford, California zcheng@stanford.edu.&#xD;Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China; and.</style></auth-address><titles><title><style face="normal" font="default" size="100%">64Cu-Labeled Divalent Cystine Knot Peptide for Imaging Carotid Atherosclerotic Plaques</style></title><secondary-title><style face="normal" font="default" size="100%">J Nucl Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Nucl Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Nucl Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">939-44</style></pages><volume><style face="normal" font="default" size="100%">56</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2015/04/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Amino Acid Sequence</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Arteries/ diagnostic imaging/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Artery Diseases/ diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Coordination Complexes/ chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Cysteine/ chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Heterocyclic Compounds/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Integrin alphaVbeta3/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Macrophages/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">Microscopy, Fluorescence</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Sequence Data</style></keyword><keyword><style face="normal" font="default" size="100%">Peptides/ chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Plaque, Atherosclerotic/ diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Positron-Emission Tomography</style></keyword><keyword><style face="normal" font="default" size="100%">Rupture</style></keyword><keyword><style face="normal" font="default" size="100%">Tomography, X-Ray Computed</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1535-5667 (Electronic)&#xD;0161-5505 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25908832</style></accession-num><abstract><style face="normal" font="default" size="100%">The rupture of vulnerable atherosclerotic plaques that lead to stroke and myocardial infarction may be induced by macrophage infiltration and augmented by the expression of integrin alphavbeta3. Indeed, atherosclerotic angiogenesis may be a promising marker of inflammation. In this study, an engineered integrin alphavbeta3-targeting PET probe, (64)Cu-NOTA-3-4A, derived from a divalent knottin miniprotein was evaluated in a mouse model for carotid atherosclerotic plaques. METHODS: Atherosclerotic plaques in BALB/C mice, maintained on a high-fat diet, were induced with streptozotocin injection and carotid artery ligation and verified by MR imaging. Knottin 3-4A was synthesized by solid-phase peptide synthesis chemistry and coupled to 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) before radiolabeling with (64)Cu. PET probe stability in mouse serum was evaluated. Mice with carotid atherosclerotic plaques were injected via the tail vein with (64)Cu-NOTA-3-4A or (18)F-FDG, followed by small-animal PET/CT imaging at different time points. Receptor targeting specificity of the probe was verified by coinjection of c(RGDyK) administered in molar excess. Subsequently, carotid artery dissection and immunofluorescence staining were performed to evaluate target expression. RESULTS: (64)Cu-NOTA-3-4A was synthesized in high radiochemical purity and yield and demonstrated molecular stability in both phosphate-buffered saline and mouse serum at 4 h. Small-animal PET/CT showed that (64)Cu-NOTA-3-4A accumulated at significantly higher levels in the neovasculature of carotid atherosclerotic plaques (7.41 +/- 1.44 vs. 0.67 +/- 0.23 percentage injected dose/gram, P &lt; 0.05) than healthy or normal vessels at 1 h after injection. (18)F-FDG also accumulated in atherosclerotic lesions at 0.5 and 1 h after injection but at lower plaque-to-normal tissue ratios than (64)Cu-NOTA-3-4A. For example, plaque-to-normal carotid artery ratios for (18)F-FDG and (64)Cu-NOTA-3-4A at 1 h after injection were 3.75 and 14.71 (P &lt; 0.05), respectively. Furthermore, uptake of (64)Cu-NOTA-3-4A in atherosclerotic plaques was effectively blocked ( approximately 90% at 1 h after injection) by coinjection of c(RGDyK). Immunostaining confirmed integrin alphavbeta3 expression in both the infiltrating macrophages and the neovasculature of atherosclerotic plaques. CONCLUSION: (64)Cu-NOTA-3-4A demonstrates specific accumulation in carotid atherosclerotic plaques in which macrophage infiltration and angiogenesis are responsible for elevated integrin alphavbeta3 levels. Therefore, (64)Cu-NOTA-3-4A may demonstrate clinical utility as a PET probe for atherosclerosis imaging or for the evaluation of therapies used to treat atherosclerosis.</style></abstract><notes><style face="normal" font="default" size="100%">Jiang, Lei&#xD;Tu, Yingfeng&#xD;Kimura, Richard H&#xD;Habte, Frezghi&#xD;Chen, Hao&#xD;Cheng, Kai&#xD;Shi, Hongcheng&#xD;Gambhir, Sanjiv Sam&#xD;Cheng, Zhen&#xD;P50 CA114747/CA/NCI NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United States&#xD;J Nucl Med. 2015 Jun;56(6):939-44. doi: 10.2967/jnumed.115.155176. Epub 2015 Apr 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://jnm.snmjournals.org/content/56/6/939.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0624926649/Jiang-2015-64Cu-Labeled Divalen.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2967/jnumed.115.155176</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>72</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">72</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jiang, Y.</style></author><author><style face="normal" font="default" size="100%">Fan, X.</style></author><author><style face="normal" font="default" size="100%">Yu, Z.</style></author><author><style face="normal" font="default" size="100%">Cheng, C.</style></author><author><style face="normal" font="default" size="100%">Wang, X. S.</style></author><author><style face="normal" font="default" size="100%">Lo, E. H.</style></author><author><style face="normal" font="default" size="100%">Sun, X.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China; Neuroprotection Research Laboratory, Departments of Neurology and Radiology, Massachusetts General Hospital, Neuroscience Program, Harvard Medical School. Boston, MA, USA.&#xD;Research Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; Neuroprotection Research Laboratory, Departments of Neurology and Radiology, Massachusetts General Hospital, Neuroscience Program, Harvard Medical School. Boston, MA, USA.&#xD;Neuroprotection Research Laboratory, Departments of Neurology and Radiology, Massachusetts General Hospital, Neuroscience Program, Harvard Medical School. Boston, MA, USA.&#xD;Department of Neurosurgery, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China.&#xD;Department of Neurosurgery, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China; Neuroprotection Research Laboratory, Departments of Neurology and Radiology, Massachusetts General Hospital, Neuroscience Program, Harvard Medical School. Boston, MA, USA. Electronic address: wangxi@helix.mgh.harvard.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Low dose tPA plus annexin A2 combination attenuates tPA delayed treatment-associated hemorrhage and improves recovery in rat embolic focal stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Neurosci Lett</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuroscience letters</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurosci Lett</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience letters</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurosci Lett</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience letters</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">73-8</style></pages><volume><style face="normal" font="default" size="100%">602</style></volume><edition><style face="normal" font="default" size="100%">2015/07/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Annexin A2/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/blood supply/drug effects/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Infarction/drug therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/ drug therapy/etiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Embolism/ complications</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ drug therapy/etiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Tissue Plasminogen Activator/ therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 18</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-7972 (Electronic)&#xD;0304-3940 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26149229</style></accession-num><abstract><style face="normal" font="default" size="100%">We previously have shown that tissue type plasminogen activator (tPA) in combination with its receptor annexin A2 (rA2) protein significantly improved tPA thrombolytic efficacy. In this study we aimed to examine the therapeutic effects of the combination when treated at delayed 4-hour window after stroke compared to standard conventional tPA alone in an embolic focal stroke rat model. We compared effects of intravenous tPA alone (10 mg/kg) versus a combination of low-dose tPA (5 mg/kg) plus 10 mg/kg rA2. Totally 152 rats were used. Our results showed that: (1) at 24 h after stroke, the combination slightly reduced brain infarction compared to saline (9.2% reduction), and tPA (7.4% reduction), although the reductions did not reach statistical significance; while the combination significantly reduced (22.2% reduction) the conventional tPA-elevated intracerebral hemorrhagic (ICH) transformation; (2) at 7 days after stroke, the combination significantly attenuated conventional tPA alone-elevated iron deposition at peri-lesion area (68.2% reduction); (3) at 28 days after stroke, the combination significantly improved performance of adhesive tape-removal test, which was accompanied by a significantly higher micro vessel density at peri- infarct areas compared to conventional tPA alone group.In conclusion, compared to conventional tPA alone, when treated at delayed 4-hour after stroke, the combination of low-dose tPA plus rA2 therapy provides a safer profile by lowering risk of ICH transformation and improves neurological function recovery after stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Jiang, Yinghua&#xD;Fan, Xiang&#xD;Yu, Zhanyang&#xD;Cheng, Chongjie&#xD;Wang, Xiao-Shu&#xD;Lo, Eng H&#xD;Sun, Xiaochuan&#xD;Wang, Xiaoying&#xD;R01 NS065998/NS/NINDS NIH HHS/United States&#xD;U01 NS072324/NS/NINDS NIH HHS/United States&#xD;R01-NS065998/NS/NINDS NIH HHS/United States&#xD;U01-NS072324/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Ireland&#xD;Neurosci Lett. 2015 Aug 18;602:73-8. doi: 10.1016/j.neulet.2015.06.050. Epub 2015 Jul 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0304394015300082/1-s2.0-S0304394015300082-main.pdf?_tid=76ee1bf6-d7be-11e6-9187-00000aab0f27&amp;acdnat=1484112552_507e8c349b5c36ee3a09f87c86e08b2f</style></url></related-urls><pdf-urls><url>internal-pdf://1868470689/Jiang-2015-Low dose tPA plus an.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4739853</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms708956</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neulet.2015.06.050</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>127</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">127</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jiang, Y.</style></author><author><style face="normal" font="default" size="100%">Li, L.</style></author><author><style face="normal" font="default" size="100%">Liu, B.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Chen, Q.</style></author><author><style face="normal" font="default" size="100%">Li, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China (mainland).</style></auth-address><titles><title><style face="normal" font="default" size="100%">PPARgamma upregulation induced by vagus nerve stimulation exerts anti-inflammatory effect in cerebral ischemia/reperfusion rats</style></title><secondary-title><style face="normal" font="default" size="100%">Med Sci Monit</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Medical science monitor : international medical journal of experimental and clinical research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Med Sci Monit</style></full-title><abbr-1><style face="normal" font="default" size="100%">Medical science monitor : international medical journal of experimental and clinical research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Med Sci Monit</style></full-title><abbr-1><style face="normal" font="default" size="100%">Medical science monitor : international medical journal of experimental and clinical research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">268-75</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><edition><style face="normal" font="default" size="100%">2015/01/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Central Nervous System/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Silencing</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Microscopy, Fluorescence</style></keyword><keyword><style face="normal" font="default" size="100%">PPAR gamma/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">Vagus Nerve/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Vagus Nerve Stimulation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 21</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1643-3750 (Electronic)&#xD;1234-1010 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25619160</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: It is well known that peroxisome proliferator-activated receptor gamma (PPARgamma), a ligand-activated transcription factor, plays a protective role in anti-inflammatory responses in both acute and chronic central nerve system (CNS) insults. Emerging evidence in rats suggests that vagus nerve stimulation (VNS), while restraining inflammatory cytokine production in the peripheral nervous system, also exerts a significant CNS neuroprotective function against ischemic stroke injury. The aim of this study was to explore the role of PPARgamma in VNS-mediated anti-inflammatory protection against ischemic stroke damage. MATERIAL/METHODS: Adult male Sprague-Dawley rats (total n=160) preconditioned through transfection with either PPARgamma small interfering RNA (siRNA) or lentiviral vector without siRNA and surgically subjected to middle cerebral artery occlusion and reperfusion subsequently received VNS treatment at 30 min post-occlusion. The expression of PPARgamma after VNS treatment was measured by real-time PCR and Western blotting, also supported by immunofluorescence staining. Subsequently, the neurological deficits scores, the infarct volume, and the brain histopathology were all evaluated. Additionally, the influence on the pro-inflammatory cytokines expression and neuro-immune cells activation was determined by ELISA and immunofluorescence staining. RESULTS: We found that VNS upregulated expression of PPARgamma in ischemia penumbra, diminished the extent of ischemic infarct, alleviated neuronal injury, and suppressed pro-inflammatory cytokine expression and immune cell activation (P&lt;0.05). However, rats with PPARgamma silencing failed to manifest significant neuroprotection and anti-inflammatory effect induced by VNS treatment (p&gt;0.05). CONCLUSIONS: PPARgamma may participate in the process by which VNS modulates the neuro-inflammatory response following ischemia/reperfusion in rats.</style></abstract><notes><style face="normal" font="default" size="100%">Jiang, Ying&#xD;Li, Longling&#xD;Liu, Bin&#xD;Zhang, Yanhong&#xD;Chen, Qian&#xD;Li, Changqing&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Med Sci Monit. 2015 Jan 21;21:268-75. doi: 10.12659/MSM.891407.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.medscimonit.com/abstract/index/idArt/891407</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4310716</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.12659/msm.891407</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>234</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">234</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jiang, Z.</style></author><author><style face="normal" font="default" size="100%">Chen, C. H.</style></author><author><style face="normal" font="default" size="100%">Chen, Y. Y.</style></author><author><style face="normal" font="default" size="100%">Han, J. Y.</style></author><author><style face="normal" font="default" size="100%">Riley, J.</style></author><author><style face="normal" font="default" size="100%">Zhou, C. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Anatomy and Embryology, Peking University Health Science Center, Beijing, China.&#xD;Peking University Center for Human Disease Genomics, Beijing, China.&#xD;Key Laboratory of Stasis and Phlegm of State Administration of Traditional Chinese Medicine, Beijing, China.&#xD;Department of Anesthesiology and Critical Care, Hospital of University of Pennsylvania, Philadelphia, PA, USA.&#xD;Department of Anatomy and Embryology, Peking University Health Science Center, Beijing, China. Electronic address: changmanzhou@hotmail.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Autophagic effect of programmed cell death 5 (PDCD5) after focal cerebral ischemic reperfusion injury in rats</style></title><secondary-title><style face="normal" font="default" size="100%">Neurosci Lett</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuroscience letters</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurosci Lett</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience letters</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurosci Lett</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience letters</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">298-303</style></pages><volume><style face="normal" font="default" size="100%">566</style></volume><edition><style face="normal" font="default" size="100%">2014/03/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis Regulatory Proteins/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Autophagy</style></keyword><keyword><style face="normal" font="default" size="100%">Beclin-1</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Infarction/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Attack, Transient/etiology/metabolism/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Microtubule-Associated Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/etiology/metabolism/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Sirolimus/pharmacology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 30</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-7972 (Electronic)&#xD;0304-3940 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24614334</style></accession-num><abstract><style face="normal" font="default" size="100%">Former studies indicated that programmed cell death 5 (PDCD5) protein could accelerate the process of apoptosis in response to some stimuli in various kinds of cells via the intrinsic or extrinsic pathway. In this study, we aimed to demonstrate for the first time that protein level of PDCD5 are related to autophagic activity after focal ischemic brain injury in rats. One hundred and twenty-five Sprague-Dawley rats (male) were randomly divided into the following groups: Sham operated, Middle Cerebral Artery Occlusion/Reperfusion (MCAO), MCAO+Control siRNA and MCAO+PDCD5 siRNA. Outcome measurements include neurobehavioral outcomes, brain infarct volume, brain water content, BBB disruption, MRI and double fluorescence labeling. Western blot and histopathophysiological techniques were used to measure the expression of PDCD5 and some pro-autophagic proteins such as Beclin 1 and the LC3-II/LC3-I ratio. The study found that decreased PDCD5 expression via intracerebroventricular injection of PDCD5 siRNA significantly improved the neurobehavioral outcome, reduced the infarct ratio, cerebral edema and BBB disruption. These results were associated with decreased expression of Beclin 1 and the LC3-II/LC3-I ratio in the penumbra area. Rapamycin, an inducer of autophagy, partially weakened the effect of PDCD5 siRNA. In conclusion, this study suggested that PDCD5 was a key regulator of autophagy that might play an important role following MCAO injury.</style></abstract><notes><style face="normal" font="default" size="100%">Jiang, Zhao&#xD;Chen, Chun-Hua&#xD;Chen, Ying-Yu&#xD;Han, Jing-Yan&#xD;Riley, John&#xD;Zhou, Chang-Man&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Ireland&#xD;Neurosci Lett. 2014 Apr 30;566:298-303. doi: 10.1016/j.neulet.2014.02.066. Epub 2014 Mar 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0304394014001797/1-s2.0-S0304394014001797-main.pdf?_tid=7a36c2b8-d7be-11e6-93a7-00000aacb360&amp;acdnat=1484112557_7d63d23be96477885127b36f5655df4b</style></url></related-urls><pdf-urls><url>internal-pdf://1619768604/Jiang-2014-Autophagic effect of.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neulet.2014.02.066</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>374</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">374</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jing, Yh</style></author><author><style face="normal" font="default" size="100%">Hou, Yp</style></author><author><style face="normal" font="default" size="100%">Song, Yf</style></author><author><style face="normal" font="default" size="100%">Yin, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, Lanzhou University. PR China. jingyh@lzu.edu.cn</style></auth-address><titles><title><style face="normal" font="default" size="100%">Methylprednisolone improves the survival of new neurons following transient cerebral ischemia in rats</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Neurobiol Exp (Wars)</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Acta neurobiologiae experimentalis</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Neurobiol Exp (Wars)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Acta neurobiologiae experimentalis</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Acta Neurobiol Exp (Wars)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Acta neurobiologiae experimentalis</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">240-52</style></pages><volume><style face="normal" font="default" size="100%">72</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2012/10/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Analysis of Variance</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Bromodeoxyuridine/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Count</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Differentiation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Proliferation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/ etiology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default" size="100%">Functional Laterality</style></keyword><keyword><style face="normal" font="default" size="100%">In Situ Nick-End Labeling</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ complications/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-6/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Methylprednisolone/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Tissue Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenesis/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion</style></keyword><keyword><style face="normal" font="default" size="100%">Statistics, Nonparametric</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Tumor Necrosis Factor-alpha/genetics/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1689-0035 (Electronic)&#xD;0065-1400 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23093011</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebral ischemia induced the proliferation and differentiation of neural stem cells in discrete regions of brain. However, only a small fraction of the neural stem/progenitor cells survives. In this report, the effects of methylprednisolone (MP) on proliferation, differentiation and survival of neural progenitor cells were explored through early MP administration after occlusion of the middle cerebral artery (MCAo). Transient cerebral ischemia was induced by middle cerebral artery occlusion in Sprague Dawley male rats. One hour, 1 day, 3 days, 14 days, and 28 days after MCAo, neurological examination was performed to evaluate the neurological deficit. MCAo rats were randomly divided into two groups, MP-group was injected MP (30 mg/kg, i.p.) at 3 h, 12 h, and 24 h after MCAo, and vehicle group was injected equal saline (i.p.). Animals were sacrificed at 3 days, 14 days, and 28 days after MCAo. MP was found to decrease apoptosis and TNF-alpha and IL-6 expression at 3 days after MCAo in the ipsilateral striatum. Moreover, MP significantly increased the migrated new neurons (BrdU+/ DCX+) and immature neurons (BrdU+/Tuj1+) at day 14 after MCAo in the ipsilateral striatum. Likewise, MP increased the number of mature neurons (BrdU+/MAP2+) at 28 days after MCAo. However, MP did not affect the progenitor cell proliferation (BrdU+ and Nestin+) at day 3 after MCAo in the subventricular zone (SVZ), but improved the neurological deficit at day 1 and day 3 after MCAo. These results indicate that early MP administration can improve the neurological deficit and enhance the survival of new neurons in the ipsilateral striatum by inhibiting apoptosis and downregulation of inflammatory response after transient cerebral ischemia in rats.</style></abstract><notes><style face="normal" font="default" size="100%">Jing, Yu hong&#xD;Hou, Yi ping&#xD;Song, Yan feng&#xD;Yin, Jie&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Poland&#xD;Acta Neurobiol Exp (Wars). 2012;72(3):240-52.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>409</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">409</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jo, H.</style></author><author><style face="normal" font="default" size="100%">Mondal, S.</style></author><author><style face="normal" font="default" size="100%">Tan, D.</style></author><author><style face="normal" font="default" size="100%">Nagata, E.</style></author><author><style face="normal" font="default" size="100%">Takizawa, S.</style></author><author><style face="normal" font="default" size="100%">Sharma, A. K.</style></author><author><style face="normal" font="default" size="100%">Hou, Q.</style></author><author><style face="normal" font="default" size="100%">Shanmugasundaram, K.</style></author><author><style face="normal" font="default" size="100%">Prasad, A.</style></author><author><style face="normal" font="default" size="100%">Tung, J. K.</style></author><author><style face="normal" font="default" size="100%">Tejeda, A. O.</style></author><author><style face="normal" font="default" size="100%">Man, H.</style></author><author><style face="normal" font="default" size="100%">Rigby, A. C.</style></author><author><style face="normal" font="default" size="100%">Luo, H. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathology, Harvard Medical School, Dana-Farber/Harvard Cancer Center, Boston, MA 02115, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Small molecule-induced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death</style></title><secondary-title><style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Proceedings of the National Academy of Sciences of the United States of America</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style></full-title><abbr-1><style face="normal" font="default" size="100%">Proceedings of the National Academy of Sciences of the United States of America</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style></full-title><abbr-1><style face="normal" font="default" size="100%">Proceedings of the National Academy of Sciences of the United States of America</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">10581-6</style></pages><volume><style face="normal" font="default" size="100%">109</style></volume><number><style face="normal" font="default" size="100%">26</style></number><edition><style face="normal" font="default" size="100%">2012/06/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/enzymology/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Death</style></keyword><keyword><style face="normal" font="default" size="100%">Cytosol/ enzymology</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme Activation</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphorylation</style></keyword><keyword><style face="normal" font="default" size="100%">Proto-Oncogene Proteins c-akt/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 26</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1091-6490 (Electronic)&#xD;0027-8424 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22689977</style></accession-num><abstract><style face="normal" font="default" size="100%">Elevating Akt activation is an obvious clinical strategy to prevent progressive neuronal death in neurological diseases. However, this endeavor has been hindered because of the lack of specific Akt activators. Here, from a cell-based high-throughput chemical genetic screening, we identified a small molecule SC79 that inhibits Akt membrane translocation, but paradoxically activates Akt in the cytosol. SC79 specifically binds to the PH domain of Akt. SC79-bound Akt adopts a conformation favorable for phosphorylation by upstream protein kinases. In a hippocampal neuronal culture system and a mouse model for ischemic stroke, the cytosolic activation of Akt by SC79 is sufficient to recapitulate the primary cellular function of Akt signaling, resulting in augmented neuronal survival. Thus, SC79 is a unique specific Akt activator that may be used to enhance Akt activity in various physiological and pathological conditions.</style></abstract><notes><style face="normal" font="default" size="100%">Jo, Hakryul&#xD;Mondal, Subhanjan&#xD;Tan, Dewar&#xD;Nagata, Eiichiro&#xD;Takizawa, Shunya&#xD;Sharma, Alok K&#xD;Hou, Qingming&#xD;Shanmugasundaram, Kumaran&#xD;Prasad, Amit&#xD;Tung, Joe K&#xD;Tejeda, Alexander O&#xD;Man, Hengye&#xD;Rigby, Alan C&#xD;Luo, Hongbo R&#xD;R01 GM076084/GM/NIGMS NIH HHS/United States&#xD;HL092020/HL/NHLBI NIH HHS/United States&#xD;R01 HL085100/HL/NHLBI NIH HHS/United States&#xD;R01 HL092020/HL/NHLBI NIH HHS/United States&#xD;GM076084/GM/NIGMS NIH HHS/United States&#xD;AI076471/AI/NIAID NIH HHS/United States&#xD;R01 AI076471/AI/NIAID NIH HHS/United States&#xD;HL085100/HL/NHLBI NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;United States&#xD;Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10581-6. doi: 10.1073/pnas.1202810109. Epub 2012 Jun 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.pnas.org/content/109/26/10581.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0067493158/Jo-2012-Small molecule-induc.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3387065</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1073/pnas.1202810109</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>170</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">170</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Joerk, A.</style></author><author><style face="normal" font="default" size="100%">Seidel, R. A.</style></author><author><style face="normal" font="default" size="100%">Walter, S. G.</style></author><author><style face="normal" font="default" size="100%">Wiegand, A.</style></author><author><style face="normal" font="default" size="100%">Kahnes, M.</style></author><author><style face="normal" font="default" size="100%">Klopfleisch, M.</style></author><author><style face="normal" font="default" size="100%">Kirmse, K.</style></author><author><style face="normal" font="default" size="100%">Pohnert, G.</style></author><author><style face="normal" font="default" size="100%">Westerhausen, M.</style></author><author><style face="normal" font="default" size="100%">Witte, O. W.</style></author><author><style face="normal" font="default" size="100%">Holthoff, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Hans-Berger Department of Neurology, University Hospital Jena, Germany (A.J., S.G.W., A.W., K.K., O.W.W., K.H.).&#xD;Institute of Inorganic and Analytical Chemistry, Friedrich-Schiller University, Jena, Germany (R.A.S., M.K., M.K., G.P., M.W.) Department of Anesthesiology and Intensive Care Medicine/Center for Sepsis Control and Care, University Hospital, Friedrich Schiller University, Jena, Germany (R.A.S.).&#xD;Institute of Inorganic and Analytical Chemistry, Friedrich-Schiller University, Jena, Germany (R.A.S., M.K., M.K., G.P., M.W.).</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of heme and heme degradation products on vascular diameter in mouse visual cortex</style></title><secondary-title><style face="normal" font="default" size="100%">J Am Heart Assoc</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of the American Heart Association</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Am Heart Assoc</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of the American Heart Association</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Am Heart Assoc</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of the American Heart Association</style></abbr-1></alt-periodical><volume><style face="normal" font="default" size="100%">3</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2014/08/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arterioles/ drug effects/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Bilirubin/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Heme/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Hemin/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Indoles/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Large-Conductance Calcium-Activated Potassium Channels/antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Microscopy, Interference</style></keyword><keyword><style face="normal" font="default" size="100%">Peptides/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Potassium Channel Blockers</style></keyword><keyword><style face="normal" font="default" size="100%">Pyrroles</style></keyword><keyword><style face="normal" font="default" size="100%">Subarachnoid Hemorrhage/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Vasoconstriction/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Vasospasm, Intracranial/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Visual Cortex/ blood supply/drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 28</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2047-9980 (Electronic)&#xD;2047-9980 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25169792</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Delayed cerebral vasospasm is the most common cause of mortality and severe neurological impairment in patients who survive subarachnoid hemorrhage. Despite improvements in the field of diagnostic imaging, options for prevention and medical treatment-primarily with the calcium channel antagonist nimodipine or hemodynamic manipulations-are insufficient. Previous studies have suggested that heme and bilirubin oxidation end products, originating from degraded hemoglobin around ruptured blood vessels, are involved in the development of vasospasm by inhibiting large conductance BKC a potassium channels in vascular smooth muscle cells. In this study, we identify individual heme degradation products regulating arteriolar diameter in dependence of BKC a channel activity. METHODS AND RESULTS: Using differential interference contrast video microscopy in acute brain slices, we determined diameter changes of intracerebral arterioles in mouse visual cortex. In preconstricted vessels, the specific BKC a channel blockers paxilline and iberiotoxin as well as iron-containing hemin caused vasoconstriction. In addition, the bilirubin oxidation end product Z-BOX A showed a stronger vasoconstrictive potency than its regio-isomer Z-BOX B. Importantly, Z-BOX A had the same vasoconstrictive effect, independent of its origin from oxidative degradation or chemical synthesis. Finally, in slices of Slo1-deficient knockout mice, paxilline and Z-BOX A remained ineffective in changing arteriole diameter. CONCLUSIONS: We identified individual components of the oxidative bilirubin degradation that led to vasoconstriction of cerebral arterioles. The vasoconstrictive effect of Z-BOX A and Z-BOX B was mediated by BKC a channel activity that might represent a signaling pathway in the occurrence of delayed cerebral vasospasm in subarachnoid hemorrhage patients.</style></abstract><notes><style face="normal" font="default" size="100%">Joerk, Alexander&#xD;Seidel, Raphael Andreas&#xD;Walter, Sebastian Gottfried&#xD;Wiegand, Anne&#xD;Kahnes, Marcel&#xD;Klopfleisch, Maurice&#xD;Kirmse, Knut&#xD;Pohnert, Georg&#xD;Westerhausen, Matthias&#xD;Witte, Otto Wilhelm&#xD;Holthoff, Knut&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Am Heart Assoc. 2014 Aug 28;3(4). pii: e001220. doi: 10.1161/JAHA.114.001220.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://jaha.ahajournals.org/content/ahaoa/3/4/e001220.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0303967934/Joerk-2014-Impact of heme and h.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4310418</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/jaha.114.001220</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>392</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">392</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Johnston, S. M.</style></author><author><style face="normal" font="default" size="100%">Johnson, G. A.</style></author><author><style face="normal" font="default" size="100%">Badea, C. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for In Vivo Microscopy, Duke University Medical Center, Durham, North Carolina 27710, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Temporal and spectral imaging with micro-CT</style></title><secondary-title><style face="normal" font="default" size="100%">Med Phys</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Medical physics</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Med Phys</style></full-title><abbr-1><style face="normal" font="default" size="100%">Medical physics</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Med Phys</style></full-title><abbr-1><style face="normal" font="default" size="100%">Medical physics</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">4943-58</style></pages><volume><style face="normal" font="default" size="100%">39</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2012/08/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Computer Graphics</style></keyword><keyword><style face="normal" font="default" size="100%">Computer Simulation</style></keyword><keyword><style face="normal" font="default" size="100%">Computers</style></keyword><keyword><style face="normal" font="default" size="100%">Image Processing, Computer-Assisted</style></keyword><keyword><style face="normal" font="default" size="100%">Iodine/chemistry/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Statistical</style></keyword><keyword><style face="normal" font="default" size="100%">Normal Distribution</style></keyword><keyword><style face="normal" font="default" size="100%">Radiographic Image Interpretation, Computer-Assisted/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Water/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">X-Ray Microtomography/ methods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0094-2405 (Print)&#xD;0094-2405 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22894420</style></accession-num><abstract><style face="normal" font="default" size="100%">PURPOSE: Micro-CT is widely used for small animal imaging in preclinical studies of cardiopulmonary disease, but further development is needed to improve spatial resolution, temporal resolution, and material contrast. We present a technique for visualizing the changing distribution of iodine in the cardiac cycle with dual source micro-CT. METHODS: The approach entails a retrospectively gated dual energy scan with optimized filters and voltages, and a series of computational operations to reconstruct the data. Projection interpolation and five-dimensional bilateral filtration (three spatial dimensions + time + energy) are used to reduce noise and artifacts associated with retrospective gating. We reconstruct separate volumes corresponding to different cardiac phases and apply a linear transformation to decompose these volumes into components representing concentrations of water and iodine. Since the resulting material images are still compromised by noise, we improve their quality in an iterative process that minimizes the discrepancy between the original acquired projections and the projections predicted by the reconstructed volumes. The values in the voxels of each of the reconstructed volumes represent the coefficients of linear combinations of basis functions over time and energy. We have implemented the reconstruction algorithm on a graphics processing unit (GPU) with CUDA. We tested the utility of the technique in simulations and applied the technique in an in vivo scan of a C57BL6 mouse injected with blood pool contrast agent at a dose of 0.01 mlg body weight. Postreconstruction, at each cardiac phase in the iodine images, we segmented the left ventricle and computed its volume. Using the maximum and minimum volumes in the left ventricle, we calculated the stroke volume, the ejection fraction, and the cardiac output. RESULTS: Our proposed method produces five-dimensional volumetric images that distinguish different materials at different points in time, and can be used to segment regions containing iodinated blood and compute measures of cardiac function. CONCLUSIONS: We believe this combined spectral and temporal imaging technique will be useful for future studies of cardiopulmonary disease in small animals.</style></abstract><notes><style face="normal" font="default" size="100%">Johnston, Samuel M&#xD;Johnson, G Allan&#xD;Badea, Cristian T&#xD;P41 EB015897/EB/NIBIB NIH HHS/United States&#xD;U24 CA092656/CA/NCI NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Med Phys. 2012 Aug;39(8):4943-58. doi: 10.1118/1.4736809.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1118/1.4736809/abstract?systemMessage=Wiley+Online+Library+Journal+subscribe+and+renew+pages+for+some+journals+will+be+unavailable+on+Wednesday+11th+January+2017+from+06%3A00-12%3A00+GMT+%2F+01%3A00-07%3A00+EST+%2F+14%3A00-20%3A00+SGT+for+essential+maintenance.+Apologies+for+the+inconvenience</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3416878</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1118/1.4736809</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>242</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">242</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Joutel, A.</style></author><author><style face="normal" font="default" size="100%">Faraci, F. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From INSERM, U1161 and Univ Paris Diderot, Sorbonne Paris Cite, UMRS 1161, Paris, France (A.J.); and Departments of Internal Medicine and Pharmacology, Francois M. Abboud Cardiovascular Center, University of Iowa College of Medicine, Iowa City Veterans Affairs Healthcare System, Iowa City, IA (F.M.F.).</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cerebral small vessel disease: insights and opportunities from mouse models of collagen IV-related small vessel disease and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1215-21</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2014/02/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">CADASIL/epidemiology/ genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/epidemiology/ genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Disorders/epidemiology/ genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Collagen Type IV/ genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Genes, Dominant</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Leukoencephalopathies/epidemiology/ genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Microcirculation/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24503668</style></accession-num><notes><style face="normal" font="default" size="100%">Joutel, Anne&#xD;Faraci, Frank M&#xD;HL-113863/HL/NHLBI NIH HHS/United States&#xD;P01 HL062984/HL/NHLBI NIH HHS/United States&#xD;I01 BX001399/BX/BLRD VA/United States&#xD;HL-62984/HL/NHLBI NIH HHS/United States&#xD;R01 HL113863/HL/NHLBI NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;Review&#xD;United States&#xD;Stroke. 2014 Apr;45(4):1215-21. doi: 10.1161/STROKEAHA.113.002878. Epub 2014 Feb 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/45/4/1215.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0951273574/Joutel-2014-Cerebral small vesse.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3966958</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms557707</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.113.002878</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>98</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">98</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Joutel, A.</style></author><author><style face="normal" font="default" size="100%">Haddad, I.</style></author><author><style face="normal" font="default" size="100%">Ratelade, J.</style></author><author><style face="normal" font="default" size="100%">Nelson, M. T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Perturbations of the cerebrovascular matrisome: A convergent mechanism in small vessel disease of the brain?</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">143-57</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2015/04/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ blood supply/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Small Vessel Diseases/genetics/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Extracellular Matrix/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Extracellular Matrix Proteins/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Microvessels/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25853907</style></accession-num><abstract><style face="normal" font="default" size="100%">The term matrisome refers to the ensemble of proteins constituting the extracellular matrix (ECM) (core matrisome) as well as the proteins associated with the ECM. Every organ has an ECM with a unique composition that not only provides the support and anchorage for cells, but also controls fundamental cellular processes as diverse as differentiation, survival, proliferation, and polarity. The current knowledge of the matrisome of small brain vessels is reviewed with a focus on the basement membrane (BM), a specialized form of ECM located at the interface between endothelial cells, contractile cells (smooth muscle cells and pericytes), and astrocyte endfeet-a very strategic location in the communication pathway between the cerebral microcirculation and astrocytes. We discuss some of the most recent genetic data and relevant findings from experimental models of nonamyloid cerebral small vessel disease (SVD). We propose the concept that perturbations of the cerebrovascular matrisome is a convergent pathologic pathway in monogenic forms of SVD, and is likely relevant to the sporadic disease.</style></abstract><notes><style face="normal" font="default" size="100%">Joutel, Anne&#xD;Haddad, Iman&#xD;Ratelade, Julien&#xD;Nelson, Mark T&#xD;R01-HL-098243/HL/NHLBI NIH HHS/United States&#xD;P01 HL095488/HL/NHLBI NIH HHS/United States&#xD;P01-HL-095488/HL/NHLBI NIH HHS/United States&#xD;R01-HL-044455/HL/NHLBI NIH HHS/United States&#xD;R01 HL098243/HL/NHLBI NIH HHS/United States&#xD;R01 HL044455/HL/NHLBI NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;United States&#xD;J Cereb Blood Flow Metab. 2016 Jan;36(1):143-57.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4758555</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2015.62</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>297</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">297</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Juenemann, M.</style></author><author><style face="normal" font="default" size="100%">Goegel, S.</style></author><author><style face="normal" font="default" size="100%">Obert, M.</style></author><author><style face="normal" font="default" size="100%">Schleicher, N.</style></author><author><style face="normal" font="default" size="100%">Ritschel, N.</style></author><author><style face="normal" font="default" size="100%">Doenges, S.</style></author><author><style face="normal" font="default" size="100%">Eitenmueller, I.</style></author><author><style face="normal" font="default" size="100%">Schwarz, N.</style></author><author><style face="normal" font="default" size="100%">Kastaun, S.</style></author><author><style face="normal" font="default" size="100%">Yeniguen, M.</style></author><author><style face="normal" font="default" size="100%">Tschernatsch, M.</style></author><author><style face="normal" font="default" size="100%">Gerriets, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Justus-Liebig-University Giessen, Klinikstrasse 33, 35392 Giessen, Germany. martin.juenemann@neuro.med.uni-giessen.de</style></auth-address><titles><title><style face="normal" font="default" size="100%">Flat-panel volumetric computed tomography in cerebral perfusion: evaluation of three rat stroke models</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosci Methods</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neuroscience methods</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosci Methods</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroscience methods</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosci Methods</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroscience methods</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">113-23</style></pages><volume><style face="normal" font="default" size="100%">219</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2013/07/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cone-Beam Computed Tomography/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Functional Laterality/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Hemodynamics/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Image Processing, Computer-Assisted</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Postural Balance/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Psychomotor Performance/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ diagnostic imaging/ physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 30</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-678X (Electronic)&#xD;0165-0270 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23880321</style></accession-num><abstract><style face="normal" font="default" size="100%">Flat-panel volumetric computed tomography (fpVCT) is a non-invasive approach to three-dimensional small animal imaging. The capability of volumetric scanning and a high resolution in time and space enables whole organ perfusion studies. We aimed to assess feasibility and validity of fpVCT in cerebral perfusion measurement with impaired hemodynamics by evaluation of three well-established rat stroke models for temporary and permanent middle cerebral artery occlusion (MCAO). Male Wistar rats were randomly assigned to temporary (group I: suture model) and permanent (group II: suture model; III: macrosphere model) MCAO and to a control group. Perfusion scans with respect to cerebral blood flow (CBF) and volume (CBV) were performed 24h post intervention by fpVCT, using a Gantry rotation time of 1s and a total scanning time of 30s. Postmortem analysis included infarct-size calculation by 2,3,5-triphenyltetrazolium chloride (TTC) staining. Infarct volumes did not differ significantly throughout intervention groups. After permanent MCAO, CBF significantly decreased in subcortical regions to 78.2% (group II, p=0.005) and 79.9% (group III, p=0.012) and in total hemisphere to 77.4% (group II, p=0.010) and 82.0% (group III, p=0.049). CBF was less impaired with temporary vessel occlusion. CBV measurement revealed no significant differences. Results demonstrate feasibility of cerebral perfusion quantification in rats with the fpVCT, which can be a useful tool for non-invasive dynamic imaging of cerebral perfusion in rodent stroke models. In addition to methodological advantages, CBF data confirm the macrosphere model as a useful alternative to the suture model for permanent experimental MCAO.</style></abstract><notes><style face="normal" font="default" size="100%">Juenemann, Martin&#xD;Goegel, Sinja&#xD;Obert, Martin&#xD;Schleicher, Nadine&#xD;Ritschel, Nouha&#xD;Doenges, Simone&#xD;Eitenmueller, Inka&#xD;Schwarz, Niko&#xD;Kastaun, Sabrina&#xD;Yeniguen, Mesut&#xD;Tschernatsch, Marlene&#xD;Gerriets, Tibo&#xD;Netherlands&#xD;J Neurosci Methods. 2013 Sep 30;219(1):113-23. doi: 10.1016/j.jneumeth.2013.07.010. Epub 2013 Jul 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0165027013002483/1-s2.0-S0165027013002483-main.pdf?_tid=9035be66-d7be-11e6-a76c-00000aacb35e&amp;acdnat=1484112594_fb32b7e8d8fc1104f7bc8dc65c57d420</style></url></related-urls><pdf-urls><url>internal-pdf://3569177048/Juenemann-2013-Flat-panel volumetri.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jneumeth.2013.07.010</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>203</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">203</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jun Hong, S.</style></author><author><style face="normal" font="default" size="100%">Rogers, P. I.</style></author><author><style face="normal" font="default" size="100%">Kihlken, J.</style></author><author><style face="normal" font="default" size="100%">Warfel, J.</style></author><author><style face="normal" font="default" size="100%">Bull, C.</style></author><author><style face="normal" font="default" size="100%">Deuter-Reinhard, M.</style></author><author><style face="normal" font="default" size="100%">Feng, D.</style></author><author><style face="normal" font="default" size="100%">Xie, J.</style></author><author><style face="normal" font="default" size="100%">Kyle, A.</style></author><author><style face="normal" font="default" size="100%">Merfeld-Clauss, S.</style></author><author><style face="normal" font="default" size="100%">Johnstone, B. H.</style></author><author><style face="normal" font="default" size="100%">Traktuev, D. O.</style></author><author><style face="normal" font="default" size="100%">Chen, P. S.</style></author><author><style face="normal" font="default" size="100%">Lindner, J. R.</style></author><author><style face="normal" font="default" size="100%">March, K. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Krannert Institute of Cardiology, Indiana University, Indianapolis, Indiana.&#xD;Indiana Center for Vascular Biology and Medicine, Indianapolis, Indiana.&#xD;Indiana University School of Medicine, Indianapolis, Indiana.&#xD;R.L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana.&#xD;Korea University Anam Hospital, Seoul, Korea.&#xD;Oregon Health and Science University, Portland, Oregon.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Intravenous xenogeneic transplantation of human adipose-derived stem cells improves left ventricular function and microvascular integrity in swine myocardial infarction model</style></title><secondary-title><style face="normal" font="default" size="100%">Catheter Cardiovasc Interv</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography &amp; Interventions</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Catheter Cardiovasc Interv</style></full-title><abbr-1><style face="normal" font="default" size="100%">Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography &amp; Interventions</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Catheter Cardiovasc Interv</style></full-title><abbr-1><style face="normal" font="default" size="100%">Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography &amp; Interventions</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">E38-48</style></pages><volume><style face="normal" font="default" size="100%">86</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2014/06/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adipose Tissue/ cytology</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">CD4 Lymphocyte Count</style></keyword><keyword><style face="normal" font="default" size="100%">CD4-Positive T-Lymphocytes/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">CD8-Positive T-Lymphocytes/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Coronary Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Coronary Vessels/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Heterografts</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Microcirculation</style></keyword><keyword><style face="normal" font="default" size="100%">Microvessels/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Infarction/diagnosis/immunology/physiopathology/ surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Perfusion Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Neovascularization, Physiologic</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery of Function</style></keyword><keyword><style face="normal" font="default" size="100%">Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke Volume</style></keyword><keyword><style face="normal" font="default" size="100%">Sus scrofa</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Ventricular Function, Left</style></keyword><keyword><style face="normal" font="default" size="100%">Ventricular Premature Complexes/physiopathology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1522-726X (Electronic)&#xD;1522-1946 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24905889</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVES: The potential for beneficial effects of adipose-derived stem cells (ASCs) on myocardial perfusion and left ventricular dysfunction in myocardial ischemia (MI) has not been tested following intravenous delivery. METHODS: Surviving pigs following induction of MI were randomly assigned to 1 of 3 different groups: the placebo group (n = 7), the single bolus group (SB) (n = 7, 15 x 10(7) ASCs), or the divided dose group (DD) (n = 7, 5 x 10(7) ASCs/day for three consecutive days). Myocardial perfusion defect area and coronary flow reserve (CFR) were compared during the 28-day follow-up. Also, serial changes in the absolute number of circulating CD4(+) T and CD8(+) T cells were measured. RESULTS: The increases in ejection fraction were significantly greater in both the SB and the DD groups compared to the placebo group (5.4 +/- 0.9%, 3.7 +/- 0.7%, and -0.4 +/- 0.6%, respectively), and the decrease in the perfusion defect area was significantly greater in the SB group than the placebo group (-36.3 +/- 1.8 and -11.5 +/- 2.8). CFR increased to a greater degree in the SB and the DD groups than in the placebo group (0.9 +/- 0.2, 0.8 +/- 0.1, and 0.2 +/- 0.2, respectively). The circulating number of CD8(+) T cells was significantly greater in the SB and DD groups than the placebo group at day 7 (3,687 +/- 317/microL, 3,454 +/- 787/microL, and 1,928 +/- 457/microL, respectively). The numbers of small vessels were significantly greater in the SB and the DD groups than the placebo group in the peri-infarct area. CONCLUSIONS: Both intravenous SB and DD delivery of ASCs are effective modalities for the treatment of MI in swine. Intravenous delivery of ASCs, with its immunomodulatory and angiogenic effects, is an attractive noninvasive approach for myocardial rescue.</style></abstract><notes><style face="normal" font="default" size="100%">Jun Hong, Soon&#xD;Rogers, Pamela I&#xD;Kihlken, John&#xD;Warfel, Jessica&#xD;Bull, Chris&#xD;Deuter-Reinhard, Maja&#xD;Feng, Dongni&#xD;Xie, Jie&#xD;Kyle, Aaron&#xD;Merfeld-Clauss, Stephanie&#xD;Johnstone, Brian H&#xD;Traktuev, Dmitry O&#xD;Chen, Peng-Sheng&#xD;Lindner, Jonathan R&#xD;March, Keith L&#xD;R01 HL077688/HL/NHLBI NIH HHS/United States&#xD;Comparative Study&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United States&#xD;Catheter Cardiovasc Interv. 2015 Aug;86(2):E38-48. doi: 10.1002/ccd.25566. Epub 2015 Apr 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1002/ccd.25566/asset/ccd25566.pdf?v=1&amp;t=ixsi7mxm&amp;s=94281be22632f377e6308aad15fe0ec5a17cea86</style></url></related-urls><pdf-urls><url>internal-pdf://3302968318/Jun Hong-2015-Intravenous xenogene.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/ccd.25566</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>479</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">479</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jung, J. E.</style></author><author><style face="normal" font="default" size="100%">Kim, G. S.</style></author><author><style face="normal" font="default" size="100%">Chan, P. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Stanford University School of Medicine, 1201 Welch Road, MSLS #P314, Stanford, CA 94305-5487, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Neuroprotection by interleukin-6 is mediated by signal transducer and activator of transcription 3 and antioxidative signaling in ischemic stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">3574-9</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2011/09/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ drug therapy/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Death/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokine Receptor gp130/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-6/metabolism/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/metabolism/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphorylation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">STAT3 Transcription Factor/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ drug therapy/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Superoxide Dismutase/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">21940958</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: Interleukin-6 (IL-6) has been shown to have a neuroprotective effect in brain ischemic injury. However, its molecular mechanisms are still poorly understood. In this study, we investigated the neuroprotective role of the IL-6 receptor (IL-6R) by IL-6 in the reactive oxygen species defense system after transient focal cerebral ischemia (tFCI). METHODS: IL-6 was injected in mice before and after middle cerebral artery occlusion. Coimmunoprecipitation assays were performed for analysis of an IL-6R association after tFCI. Primary mouse cerebral cortical neurons were transfected with small interfering RNA probes targeted to IL-6Ralpha or gp130 and were used for chromatin-immunoprecipitation assay, luciferase promoter assay, and cell viability assay. Reduction in infarct volumes by IL-6 was measured after tFCI. RESULTS: IL-6R was disrupted through a disassembly between IL-6Ralpha and gp130 associated by protein oxidation after reperfusion after tFCI. This suppressed phosphorylation of signal transducer and activator of transcription 3 (STAT3) and finally induced neuronal cell death through a decrease in manganese-superoxide dismutase. However, IL-6 injections prevented disruption of IL-6R against reperfusion after tFCI, consequently restoring activity of STAT3 through recovery of the binding of STAT3 to gp130. Moreover, IL-6 injections restored the transcriptional activity of the manganese-superoxide dismutase promoter through recovery of the recruitment of STAT3 to the manganese-superoxide dismutase promoter and reduced infarct volume after tFCI. CONCLUSIONS: This study demonstrates that IL-6 has a neuroprotective effect against cerebral ischemic injury through IL-6R-mediated STAT3 activation and manganese-superoxide dismutase expression.</style></abstract><notes><style face="normal" font="default" size="100%">Jung, Joo Eun&#xD;Kim, Gab Seok&#xD;Chan, Pak H&#xD;R01 NS025372/NS/NINDS NIH HHS/United States&#xD;R01 NS038653/NS/NINDS NIH HHS/United States&#xD;P01 NS014543/NS/NINDS NIH HHS/United States&#xD;P01 NS014543-33/NS/NINDS NIH HHS/United States&#xD;R01 NS036147-14/NS/NINDS NIH HHS/United States&#xD;R01 NS038653-14/NS/NINDS NIH HHS/United States&#xD;R01 NS036147/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Stroke. 2011 Dec;42(12):3574-9. doi: 10.1161/STROKEAHA.111.626648. Epub 2011 Sep 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/42/12/3574.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3285943576/Jung-2011-Neuroprotection by i.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3395465</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms311865</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.111.626648</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>134</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">134</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kaiser, D.</style></author><author><style face="normal" font="default" size="100%">Weise, G.</style></author><author><style face="normal" font="default" size="100%">Moller, K.</style></author><author><style face="normal" font="default" size="100%">Scheibe, J.</style></author><author><style face="normal" font="default" size="100%">Posel, C.</style></author><author><style face="normal" font="default" size="100%">Baasch, S.</style></author><author><style face="normal" font="default" size="100%">Gawlitza, M.</style></author><author><style face="normal" font="default" size="100%">Lobsien, D.</style></author><author><style face="normal" font="default" size="100%">Diederich, K.</style></author><author><style face="normal" font="default" size="100%">Minnerup, J.</style></author><author><style face="normal" font="default" size="100%">Kranz, A.</style></author><author><style face="normal" font="default" size="100%">Boltze, J.</style></author><author><style face="normal" font="default" size="100%">Wagner, D. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Fraunhofer Institute for Cell Therapy and Immunology, Perlickstrasse 1, 04103, Leipzig, Germany. daniel.kaiser@izi.fraunhofer.de.&#xD;Fraunhofer Institute for Cell Therapy and Immunology, Perlickstrasse 1, 04103, Leipzig, Germany. gesa.weise@izi.fraunhofer.de.&#xD;Department of Neurology, University of Leipzig, Leipzig, Germany. gesa.weise@izi.fraunhofer.de.&#xD;Translational Centre for Regenerative Medicine, Leipzig, Germany. gesa.weise@izi.fraunhofer.de.&#xD;Fraunhofer Institute for Cell Therapy and Immunology, Perlickstrasse 1, 04103, Leipzig, Germany. karoline.moeller@izi.fraunhofer.de.&#xD;Fraunhofer Institute for Cell Therapy and Immunology, Perlickstrasse 1, 04103, Leipzig, Germany. johanna.scheibe@izi.fraunhofer.de.&#xD;Fraunhofer Institute for Cell Therapy and Immunology, Perlickstrasse 1, 04103, Leipzig, Germany. claudia.poesel@izi.fraunhofer.de.&#xD;Fraunhofer Institute for Cell Therapy and Immunology, Perlickstrasse 1, 04103, Leipzig, Germany. sebastian.baasch@izi.fraunhofer.de.&#xD;Department of Radiology, University of Leipzig, Leipzig, Germany. Matthias.Gawlitza@medizin.uni-leipzig.de.&#xD;Department of Neuroradiology, University of Leipzig, Leipzig, Germany. donald.lobsien@medizin.uni-leipzig.de.&#xD;Department of Neurology, University of Munster, Munster, Germany. kai.diederich@uni-muenster.de.&#xD;Department of Neurology, University of Munster, Munster, Germany. minnerup@uni-muenster.de.&#xD;Fraunhofer Institute for Cell Therapy and Immunology, Perlickstrasse 1, 04103, Leipzig, Germany. alexander.kranz@izi.fraunhofer.de.&#xD;Translational Centre for Regenerative Medicine, Leipzig, Germany. alexander.kranz@izi.fraunhofer.de.&#xD;Fraunhofer Institute for Cell Therapy and Immunology, Perlickstrasse 1, 04103, Leipzig, Germany. johannes.boltze@izi.fraunhofer.de.&#xD;Translational Centre for Regenerative Medicine, Leipzig, Germany. johannes.boltze@izi.fraunhofer.de.&#xD;Fraunhofer Institute for Cell Therapy and Immunology, Perlickstrasse 1, 04103, Leipzig, Germany. daniel-christoph.wagner@izi.fraunhofer.de.&#xD;Translational Centre for Regenerative Medicine, Leipzig, Germany. daniel-christoph.wagner@izi.fraunhofer.de.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Spontaneous white matter damage, cognitive decline and neuroinflammation in middle-aged hypertensive rats: an animal model of early-stage cerebral small vessel disease</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Neuropathol Commun</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Acta neuropathologica communications</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Neuropathol Commun</style></full-title><abbr-1><style face="normal" font="default" size="100%">Acta neuropathologica communications</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Acta Neuropathol Commun</style></full-title><abbr-1><style face="normal" font="default" size="100%">Acta neuropathologica communications</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">169</style></pages><volume><style face="normal" font="default" size="100%">2</style></volume><edition><style face="normal" font="default" size="100%">2014/12/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, CD45/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Atrophy</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Small Vessel Diseases/pathology/ physiopathology/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition Disorders/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Gliosis/immunology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-10/cerebrospinal fluid</style></keyword><keyword><style face="normal" font="default" size="100%">Killer Cells, Natural/pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocytes/pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Memory Disorders/immunology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroimmunomodulation/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Organ Size</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred SHR</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred WKY</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes/pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">White Matter/ pathology/physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 18</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2051-5960 (Electronic)&#xD;2051-5960 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25519173</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Cerebral small vessel disease (cSVD) is one of the most prevalent neurological disorders. The progressive remodeling of brain microvessels due to arterial hypertension or other vascular risk factors causes subtle, but constant cognitive decline through to manifest dementia and substantially increases the risk for stroke. Preliminary evidence suggests the contribution of the immune system to disease initiation and progression, but a more detailed understanding is impaired by the unavailability of appropriate animal models. Here, we introduce the spontaneously hypertensive rat (SHR) as a model for early onset cSVD and unveiled substantial immune changes in conjunction with brain abnormalities that resemble clinical findings. RESULTS: In contrast to age-matched normotensive Wistar Kyoto (WKY) rats, male SHR exhibited non-spatial memory deficits. Magnetic resonance imaging showed brain atrophy and a reduction of white matter volumes in SHR. Histological analyses confirmed white matter demyelination and unveiled a circumscribed blood brain barrier dysfunction in conjunction with micro- and macrogliosis in deep cortical regions. Flow cytometry and histological analyses further revealed substantial disparities in cerebral CD45high leukocyte counts and distribution patterns between SHR and WKY. SHR showed lower counts of T cells in the choroid plexus and meningeal spaces as well as decreased interleukin-10 levels in the cerebrospinal fluid. On the other hand, both T and NK cells were significantly augmented in the SHR brain microvasculature. CONCLUSIONS: Our results indicate that SHR share behavioral and neuropathological characteristics with human cSVD patients and further undergird the relevance of immune responses for the initiation and progression of cSVD.</style></abstract><notes><style face="normal" font="default" size="100%">Kaiser, Daniel&#xD;Weise, Gesa&#xD;Moller, Karoline&#xD;Scheibe, Johanna&#xD;Posel, Claudia&#xD;Baasch, Sebastian&#xD;Gawlitza, Matthias&#xD;Lobsien, Donald&#xD;Diederich, Kai&#xD;Minnerup, Jens&#xD;Kranz, Alexander&#xD;Boltze, Johannes&#xD;Wagner, Daniel-Christoph&#xD;England&#xD;Acta Neuropathol Commun. 2014 Dec 18;2:169. doi: 10.1186/s40478-014-0169-8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/108/art%253A10.1186%252Fs40478-014-0169-8.pdf?originUrl=http%3A%2F%2Factaneurocomms.biomedcentral.com%2Farticle%2F10.1186%2Fs40478-014-0169-8&amp;token2=exp=1484112724~acl=%2Fstatic%2Fpdf%2F108%2Fart%25253A10.1186%25252Fs40478-014-0169-8.pdf*~hmac=ba03d879f5508142a453fdda0021d0acde157726a413e59dd12a4afb8d62cda0</style></url></related-urls><pdf-urls><url>internal-pdf://1286628930/Kaiser-2014-Spontaneous white ma.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4279586</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s40478-014-0169-8</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>319</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">319</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kalappa, B. I.</style></author><author><style face="normal" font="default" size="100%">Sun, F.</style></author><author><style face="normal" font="default" size="100%">Johnson, S. R.</style></author><author><style face="normal" font="default" size="100%">Jin, K.</style></author><author><style face="normal" font="default" size="100%">Uteshev, V. V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacology, Southern Illinois University School of Medicine, Springfield, IL, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A positive allosteric modulator of alpha7 nAChRs augments neuroprotective effects of endogenous nicotinic agonists in cerebral ischaemia</style></title><secondary-title><style face="normal" font="default" size="100%">Br J Pharmacol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">British journal of pharmacology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Br J Pharmacol</style></full-title><abbr-1><style face="normal" font="default" size="100%">British journal of pharmacology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Br J Pharmacol</style></full-title><abbr-1><style face="normal" font="default" size="100%">British journal of pharmacology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1862-78</style></pages><volume><style face="normal" font="default" size="100%">169</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2013/05/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ drug therapy/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Choline/metabolism/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Hippocampus/cytology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">In Vitro Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Isoxazoles/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Nicotinic Agonists/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Patch-Clamp Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Phenylurea Compounds/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">alpha7 Nicotinic Acetylcholine Receptor/ drug effects/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1476-5381 (Electronic)&#xD;0007-1188 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23713819</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: Activation of alpha7 nicotinic acetylcholine receptors (nAChRs) can be neuroprotective. However, endogenous choline and ACh have not been regarded as potent neuroprotective agents because physiological levels of choline/ACh do not produce neuroprotective levels of alpha7 activation. This limitation may be overcome by the use of type-II positive allosteric modulators (PAMs-II) of alpha7 nAChRs, such as 1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)-urea (PNU-120596). This proof-of-concept study presents a novel neuroprotective paradigm that converts endogenous choline/ACh into potent neuroprotective agents in cerebral ischaemia by inhibiting alpha7 nAChR desensitization using PNU-120596. EXPERIMENTAL APPROACH: An electrophysiological ex vivo cell injury assay (to quantify the susceptibility of hippocampal neurons to acute injury by complete oxygen and glucose deprivation; COGD) and an in vivo middle cerebral artery occlusion model of ischaemia were used in rats. KEY RESULTS: Choline (20-200 muM) in the presence, but not absence of 1 muM PNU-120596 significantly delayed anoxic depolarization/injury of hippocampal CA1 pyramidal neurons, but not CA1 stratum radiatum interneurons, subjected to COGD in acute hippocampal slices and these effects were blocked by 20 nM methyllycaconitine, a selective alpha7 antagonist, thus, activation of alpha7 nAChRs was required. PNU-120596 alone was ineffective ex vivo. In in vivo experiments, both pre- and post-ischaemia treatments with PNU-120596 (30 mg.kg(-1) , s.c. and 1 mg.kg(-1) , i.v., respectively) significantly reduced the cortical/subcortical infarct volume caused by transient focal cerebral ischaemia. PNU-120596 (1 mg.kg(-1) , i.v., 30 min post-ischaemia) remained neuroprotective in rats subjected to a choline-deficient diet for 14 days prior to experiments. CONCLUSIONS AND IMPLICATIONS: PNU-120596 and possibly other PAMs-II significantly improved neuronal survival in cerebral ischaemia by augmenting neuroprotective effects of endogenous choline/ACh.</style></abstract><notes><style face="normal" font="default" size="100%">Kalappa, Bopanna I&#xD;Sun, Fen&#xD;Johnson, Stephen R&#xD;Jin, Kunlin&#xD;Uteshev, Victor V&#xD;R01 DK082625/DK/NIDDK NIH HHS/United States&#xD;DK-082625/DK/NIDDK NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Br J Pharmacol. 2013 Aug;169(8):1862-78. doi: 10.1111/bph.12247.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/bph.12247/asset/bph12247.pdf?v=1&amp;t=ixsi7wmu&amp;s=64c71740dbc4eb369c9e3d69c169920059fb02bc</style></url></related-urls><pdf-urls><url>internal-pdf://3333390782/Kalappa-2013-A positive allosteri.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3753841</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/bph.12247</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>96</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">96</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kang, H. M.</style></author><author><style face="normal" font="default" size="100%">Sohn, I.</style></author><author><style face="normal" font="default" size="100%">Park, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Anatomy and Neurobiology, Biomedical Science Institute, School of Medicine, Kyung Hee University, No. 1 Hoeki-dong, Dongdaemun-gu, Seoul, Republic of Korea.&#xD;Department of Anatomy and Neurobiology, Biomedical Science Institute, School of Medicine, Kyung Hee University, No. 1 Hoeki-dong, Dongdaemun-gu, Seoul, Republic of Korea. Electronic address: psychan@khu.ac.kr.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Use of indocyanine green for optical analysis of cortical infarcts in photothrombotic ischemic brains</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosci Methods</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neuroscience methods</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosci Methods</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroscience methods</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosci Methods</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroscience methods</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">46-50</style></pages><volume><style face="normal" font="default" size="100%">248</style></volume><edition><style face="normal" font="default" size="100%">2015/04/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/blood supply/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorescence</style></keyword><keyword><style face="normal" font="default" size="100%">Indocyanine Green</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Optical Imaging/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Pia Mater/blood supply/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Regional Blood Flow/physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-678X (Electronic)&#xD;0165-0270 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25857614</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Currently used techniques for diagnosing ischemic injury, such as magnetic resonance imaging and computed tomography, are not easily accessible for basic research using small animals due to their high cost and low availability. NEW METHOD: We investigated the dynamic recovery of infarct regions in ischemia-injured brains using indocyanine green (ICG), which is inexpensive and readily available. This dye was used to visualize blood vessels and infarct area, and to measure blood flow after a photothrombotic ischemic operation (PIO). Mice were injected with ICG via the tail vein, and a time-series of fluorescence signal images was acquired before and after PIO. We then applied color codes to arteries and veins in the images and analyzed ICG intensity and dynamics. RESULTS: These time-series stacked images showed changes in pial vessel morphology after PIO. Further, a map of maximum fluorescence intensity showed an infarct in the dorsal cortical region. Changes in the blood flow index and mean transit time were also observed in the infarct region after PIO. COMPARISON WITH EXISTING METHOD(S): Our application of ICG imaging provided a range of information on PIO-induced infarcts in mice with relative ease and in a cost-effective manner. CONCLUSION: Our results show that optical imaging using ICG combined with a time-series analysis of molecular dynamics can be a useful tool for the anatomical and physiological monitoring of cortical ischemia.</style></abstract><notes><style face="normal" font="default" size="100%">Kang, Hye-Min&#xD;Sohn, Inkyung&#xD;Park, Chan&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;J Neurosci Methods. 2015 Jun 15;248:46-50. doi: 10.1016/j.jneumeth.2015.03.033. Epub 2015 Apr 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S016502701500134X/1-s2.0-S016502701500134X-main.pdf?_tid=99044b20-d7be-11e6-846b-00000aab0f01&amp;acdnat=1484112609_2a59ea9bd67fb85a7e16c1d4583bba88</style></url></related-urls><pdf-urls><url>internal-pdf://0867989767/Kang-2015-Use of indocyanine g.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jneumeth.2015.03.033</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>383</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">383</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kang, S. S.</style></author><author><style face="normal" font="default" size="100%">Keasey, M. P.</style></author><author><style face="normal" font="default" size="100%">Arnold, S. A.</style></author><author><style face="normal" font="default" size="100%">Reid, R.</style></author><author><style face="normal" font="default" size="100%">Geralds, J.</style></author><author><style face="normal" font="default" size="100%">Hagg, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Kentucky Spinal Cord Injury Research Center, University of Louisville, KY 40292, USA; Department of Neurological Surgery, University of Louisville, KY 40292, USA.&#xD;Kentucky Spinal Cord Injury Research Center, University of Louisville, KY 40292, USA; Department of Neurological Surgery, University of Louisville, KY 40292, USA; Department of Pharmacology and Toxicology, University of Louisville, KY 40292, USA.&#xD;Kentucky Spinal Cord Injury Research Center, University of Louisville, KY 40292, USA; Department of Neurological Surgery, University of Louisville, KY 40292, USA; Department of Pharmacology and Toxicology, University of Louisville, KY 40292, USA. Electronic address: theo.hagg@louisville.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Endogenous CNTF mediates stroke-induced adult CNS neurogenesis in mice</style></title><secondary-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurobiology of disease</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurobiology of disease</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurobiology of disease</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">68-78</style></pages><volume><style face="normal" font="default" size="100%">49</style></volume><edition><style face="normal" font="default" size="100%">2012/09/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Ciliary Neurotrophic Factor/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocytes/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, 129 Strain</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Neural Stem Cells/pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenesis/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroimmunomodulation/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Stem Cell Niche/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/pathology/ physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1095-953X (Electronic)&#xD;0969-9961 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22960105</style></accession-num><abstract><style face="normal" font="default" size="100%">Focal brain ischemia in adult rats rapidly and robustly induces neurogenesis in the subventricular zone (SVZ) but there are few and inconsistent reports in mice, presenting a hurdle to genetically investigate the endogenous neurogenic regulators such as ciliary neurotrophic factor (CNTF). Here, we first provide a platform for further studies by showing that middle cerebral artery occlusion in adult male C57BL/6 mice robustly enhances neurogenesis in the SVZ only under very specific conditions, i.e., 14days after a 30min occlusion. CNTF expression paralleled changes in the number of proliferated, BrdU-positive, SVZ cells. Stroke-induced proliferation was absent in CNTF-/- mice, suggesting that it is mediated by CNTF. MCAO-increased CNTF appears to act on C cell proliferation and by inducing FGF2 expression but not via EGF expression or Notch1 signaling of neural stem cells in the SVZ. CNTF is unique, as expression of other gp130 ligands, IL-6 and LIF, did not predict SVZ proliferation or showed no or only small compensatory increases in CNTF-/- mice. Expression of tumor necrosis factor-alpha, which can inhibit neurogenesis, and the presence of leukocytes in the SVZ were inversely correlated with neurogenesis, but pro-inflammatory cytokines did not affect CNTF expression in cultured astrocytes. These results suggest that slowly up-regulated CNTF in the SVZ mediates stroke-induced neurogenesis and is counteracted by inflammation. Further pharmacological stimulation of endogenous CNTF might be a good therapeutic strategy for cell replacement after stroke as CNTF regulates normal patterns of neurogenesis and is expressed almost exclusively in the nervous system.</style></abstract><notes><style face="normal" font="default" size="100%">Kang, Seong Su&#xD;Keasey, Matthew P&#xD;Arnold, Sheila A&#xD;Reid, Rollie&#xD;Geralds, Justin&#xD;Hagg, Theo&#xD;P30 GM103507/GM/NIGMS NIH HHS/United States&#xD;R01 AG029493/AG/NIA NIH HHS/United States&#xD;AG29493/AG/NIA NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;United States&#xD;Neurobiol Dis. 2013 Jan;49:68-78. doi: 10.1016/j.nbd.2012.08.020. Epub 2012 Aug 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0969996112003075/1-s2.0-S0969996112003075-main.pdf?_tid=9cc297a8-d7be-11e6-9d59-00000aacb35e&amp;acdnat=1484112615_a78f271c0b140f3d2aa4ed3d649c5c38</style></url></related-urls><pdf-urls><url>internal-pdf://2743375930/Kang-2013-Endogenous CNTF medi.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3657597</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms404966</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.nbd.2012.08.020</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>405</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">405</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kang, S. S.</style></author><author><style face="normal" font="default" size="100%">Keasey, M. P.</style></author><author><style face="normal" font="default" size="100%">Cai, J.</style></author><author><style face="normal" font="default" size="100%">Hagg, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Kentucky Spinal Cord Injury Research Center and Department of Neurological Surgery, University of Louisville, Louisville, Kentucky 40292, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Loss of neuron-astroglial interaction rapidly induces protective CNTF expression after stroke in mice</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">9277-87</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">27</style></number><edition><style face="normal" font="default" size="100%">2012/07/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/metabolism/ pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Communication/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Line, Tumor</style></keyword><keyword><style face="normal" font="default" size="100%">Ciliary Neurotrophic Factor/biosynthesis/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Coculture Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia, Brain/genetics/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/genetics/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, 129 Strain</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Degeneration/genetics/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/metabolism/ pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Cell Culture</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 04</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1529-2401 (Electronic)&#xD;0270-6474 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22764235</style></accession-num><abstract><style face="normal" font="default" size="100%">Ciliary neurotrophic factor (CNTF) is a potent neural cytokine with very low expression in the CNS, predominantly by astrocytes. CNTF increases rapidly and greatly following traumatic or ischemic injury. Understanding the underlying mechanisms would help to design pharmacological treatments to increase endogenous CNTF levels for neuroprotection. Here, we show that astroglial CNTF expression in the adult mouse striatum is increased twofold within 1 h and increases up to &gt;30-fold over 2 weeks following a focal stroke caused by a transient middle cerebral artery occlusion (MCAO). Selective neuronal loss caused by intrastriatal injection of quinolinic acid resulted in a comparable increase. Cocultured neurons reduced CNTF expression in astrocytes, which was prevented by light trypsinization. RGD (arginine-glycine-aspartic acid) blocking peptides induced CNTF expression, which was dependent on transcription. Astroglial CNTF expression was not affected by diffusible neuronal molecules or by neurotransmitters. The transient ischemia does not seem to directly increase CNTF, as intrastriatal injection of an ischemic solution or exposure of naive mice or cultured cells to severe hypoxia had minimal effects. Inflammatory mechanisms were probably also not involved, as intrastriatal injection of proinflammatory cytokines (IFNgamma, IL6) in naive mice had no or small effects, and anti-inflammatory treatments did not diminish the increase in CNTF after MCAO. CNTF-/- mice had more extensive tissue loss and similar astrocyte activation after MCAO than their wild-type littermates. These data suggest that contact-mediated integrin signaling between neurons and astrocytes normally represses CNTF expression and that neuronal dysfunction causes a rapid protective response by the CNS.</style></abstract><notes><style face="normal" font="default" size="100%">Kang, Seong Su&#xD;Keasey, Matthew P&#xD;Cai, Jun&#xD;Hagg, Theo&#xD;GM103507/GM/NIGMS NIH HHS/United States&#xD;AG29493/AG/NIA NIH HHS/United States&#xD;R01 AG029493/AG/NIA NIH HHS/United States&#xD;P30 GM103507/GM/NIGMS NIH HHS/United States&#xD;RR031159/RR/NCRR NIH HHS/United States&#xD;P30 RR031159/RR/NCRR NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Neurosci. 2012 Jul 4;32(27):9277-87. doi: 10.1523/JNEUROSCI.1746-12.2012.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.jneurosci.org/content/jneuro/32/27/9277.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3025776607/Kang-2012-Loss of neuron-astro.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3403837</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms391455</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1523/jneurosci.1746-12.2012</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>396</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">396</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Karczewski, P.</style></author><author><style face="normal" font="default" size="100%">Pohlmann, A.</style></author><author><style face="normal" font="default" size="100%">Wagenhaus, B.</style></author><author><style face="normal" font="default" size="100%">Wisbrun, N.</style></author><author><style face="normal" font="default" size="100%">Hempel, P.</style></author><author><style face="normal" font="default" size="100%">Lemke, B.</style></author><author><style face="normal" font="default" size="100%">Kunze, R.</style></author><author><style face="normal" font="default" size="100%">Niendorf, T.</style></author><author><style face="normal" font="default" size="100%">Bimmler, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">ERDE-AAK-Diagnostik GmbH, Berlin, Germany. karczewski@aak-diagnostik.de</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antibodies to the alpha1-adrenergic receptor cause vascular impairments in rat brain as demonstrated by magnetic resonance angiography</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PloS one</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e41602</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2012/08/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Autoantibodies/blood/ immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ blood supply/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Angiography</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Adrenergic, alpha-1/ immunology/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203 (Electronic)&#xD;1932-6203 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22860001</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Circulating agonistic autoantibodies acting at G protein-coupled receptors have been associated with numerous sever pathologies in humans. Antibodies directed predominantly against the alpha(1)-adrenergig receptor were detected in patients suffering from widespread diseases such as hypertension and type 2 diabetes. Their deleterious action has been demonstrated for peripheral organs. We postulate that antibodies to the alpha(1)-adrenergig receptor are relevant pathomolecules in diseases of the central nervous system associated with vascular impairments. METHODOLOGY/PRINCIPAL FINDINGS: Using a rat model we studied the long-term action of antibodies against the alpha(1)-adrenergig receptor either induced by immunization with a receptor peptide or applied by intravenous injection. The vasculature in the rat brains was investigated by time-of-flight magnetic resonance angiography using a 9.4 Tesla small animal MR imaging system. Visual examination of maximum-intensity-projections (MIPs) of brain angiographs revealed the development of vascular defects in antibody- exposed animals between three and eight months of treatment. Relative vascular areas were derived from representative MIP image sections by grayscale analysis and used to form an index of vascular circulation. Animals exposed to the action of alpha(1)-adrenergig receptor antibodies showed significantly reduced vascular areas (p&lt;0.05). Calculated index values indicated attenuated blood flow in both antibody-treated cohorts compared to their respective controls reaching with (relative units +/- standard error, n = 10) 0.839 +/- 0.026 versus 0.919 +/- 0.026 statistical significance (p&lt;0.05) for peptide-immunized rats. CONCLUSION/SIGNIFICANCE: We present evidence that antibodies to the alpha(1)-adrenergig receptor cause cerebrovascular impairments in the rat. Our findings suggest the pathological significance of these antibodies in pathologies of the human central nervous system linked to impairments of brain vasculature such as stroke and dementia.</style></abstract><notes><style face="normal" font="default" size="100%">Karczewski, Peter&#xD;Pohlmann, Andreas&#xD;Wagenhaus, Babette&#xD;Wisbrun, Natali&#xD;Hempel, Petra&#xD;Lemke, Bernd&#xD;Kunze, Rudolf&#xD;Niendorf, Thoralf&#xD;Bimmler, Marion&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;PLoS One. 2012;7(7):e41602. doi: 10.1371/journal.pone.0041602. Epub 2012 Jul 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0041602&amp;type=printable</style></url></related-urls><pdf-urls><url>internal-pdf://3293170086/Karczewski-2012-Antibodies to the al.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3408502</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0041602</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>406</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">406</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kato, T.</style></author><author><style face="normal" font="default" size="100%">Nishizawa, M.</style></author><author><style face="normal" font="default" size="100%">Onodera, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Clinical Neuroscience Branch, Niigata University Brain Research Institute.</style></auth-address><titles><title><style face="normal" font="default" size="100%">[CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) and CARASIL (Cerebral Autosomal Recessive Arteriopathy with Subcortical Infarcts and Leukoencephalopathy)]</style></title><secondary-title><style face="normal" font="default" size="100%">Nihon Rinsho</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Nihon rinsho. Japanese journal of clinical medicine</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nihon Rinsho</style></full-title><abbr-1><style face="normal" font="default" size="100%">Nihon rinsho. Japanese journal of clinical medicine</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Nihon Rinsho</style></full-title><abbr-1><style face="normal" font="default" size="100%">Nihon rinsho. Japanese journal of clinical medicine</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">320-4</style></pages><volume><style face="normal" font="default" size="100%">69 Suppl 10 Pt 2</style></volume><edition><style face="normal" font="default" size="100%">2012/07/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">CADASIL/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Arterial Diseases/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Genes, Recessive</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0047-1852 (Print)&#xD;0047-1852 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22755206</style></accession-num><notes><style face="normal" font="default" size="100%">Kato, Taisuke&#xD;Nishizawa, Masatoyo&#xD;Onodera, Makoto&#xD;Japan&#xD;Nihon Rinsho. 2011 Dec;69 Suppl 10 Pt 2:320-4.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">jpn</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>472</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">472</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kawachi, K.</style></author><author><style face="normal" font="default" size="100%">Iso, Y.</style></author><author><style face="normal" font="default" size="100%">Sato, T.</style></author><author><style face="normal" font="default" size="100%">Wakabayashi, K.</style></author><author><style face="normal" font="default" size="100%">Kobayashi, Y.</style></author><author><style face="normal" font="default" size="100%">Takeyama, Y.</style></author><author><style face="normal" font="default" size="100%">Suzuki, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Cardiology, Department of Internal Medicine, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa, 227-8501, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of erythropoietin on angiogenesis after myocardial infarction in porcine</style></title><secondary-title><style face="normal" font="default" size="100%">Heart Vessels</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Heart and vessels</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Heart Vessels</style></full-title><abbr-1><style face="normal" font="default" size="100%">Heart and vessels</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Heart Vessels</style></full-title><abbr-1><style face="normal" font="default" size="100%">Heart and vessels</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">79-88</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2011/11/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Angiogenesis Inducing Agents/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Erythropoietin/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fibroblast Growth Factors/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Hepatocyte Growth Factor/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunohistochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Infarction/blood/ drug therapy/genetics/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardium/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Neovascularization, Physiologic/ drug effects/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Proteins/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery of Function</style></keyword><keyword><style face="normal" font="default" size="100%">Reverse Transcriptase Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default" size="100%">Somatomedins/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke Volume</style></keyword><keyword><style face="normal" font="default" size="100%">Sus scrofa</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Endothelial Growth Factor A/blood/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Ventricular Function, Left</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1615-2573 (Electronic)&#xD;0910-8327 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22038108</style></accession-num><abstract><style face="normal" font="default" size="100%">Erythropoietin (EPO) has recently been shown to confer cardioprotective effects via angiogenesis and antiapoptosis. The administration of EPO after myocardial infarction (MI) reduces infarct size and improves cardiac function in small animals. The purpose of this study is to investigate the protective effects of EPO in porcine MI. Each animal in the EPO group received four injections of recombinant human EPO (rhEPO; 6000 U per injection) at 2-day intervals, starting after coronary occlusion. Animals in the control group received saline. Left ventriculography was performed just after coronary occlusion and at 28 days. Time-course changes in serum levels of vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and fibroblast growth factor (FGF) were measured. The number of vessels was calculated, and the mRNA expressions of VEGF and insulin-like growth factor (IGF) were examined. Left ventricular function was similar between the groups. The numbers of cells positive for anti-alpha-smooth muscle actin, von Willebrand factor, and c-kit were significantly higher in the EPO group than in the controls (P &lt; 0.05). The EPO group exhibited significantly higher HGF and FGF concentrations (P &lt; 0.05) and higher expression of VEGF and IGF mRNA (P &lt; 0.05) compared with the controls. In conclusion, EPO accelerates angiogenesis via the upregulation of systemic levels such as HGF and FGF, and the local expression of VEGF and IGF, in porcine MI.</style></abstract><notes><style face="normal" font="default" size="100%">Kawachi, Keisuke&#xD;Iso, Yoshitaka&#xD;Sato, Takatoshi&#xD;Wakabayashi, Kohei&#xD;Kobayashi, Youichi&#xD;Takeyama, Youichi&#xD;Suzuki, Hiroshi&#xD;Japan&#xD;Heart Vessels. 2012 Jan;27(1):79-88. doi: 10.1007/s00380-011-0197-2. Epub 2011 Oct 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/471/art%253A10.1007%252Fs00380-011-0197-2.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00380-011-0197-2&amp;token2=exp=1484113669~acl=%2Fstatic%2Fpdf%2F471%2Fart%25253A10.1007%25252Fs00380-011-0197-2.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs00380-011-0197-2*~hmac=b73f08459ff2a66d0be8b3754cfcd921e65e5d16f472a126c32d25be0f0c7005</style></url></related-urls><pdf-urls><url>internal-pdf://3457947761/Kawachi-2012-Effects of erythropo.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00380-011-0197-2</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>345</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">345</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ke, K.</style></author><author><style face="normal" font="default" size="100%">Li, L.</style></author><author><style face="normal" font="default" size="100%">Rui, Y.</style></author><author><style face="normal" font="default" size="100%">Zheng, H.</style></author><author><style face="normal" font="default" size="100%">Tan, X.</style></author><author><style face="normal" font="default" size="100%">Xu, W.</style></author><author><style face="normal" font="default" size="100%">Cao, J.</style></author><author><style face="normal" font="default" size="100%">Xu, J.</style></author><author><style face="normal" font="default" size="100%">Cui, G.</style></author><author><style face="normal" font="default" size="100%">Xu, G.</style></author><author><style face="normal" font="default" size="100%">Cao, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, People&apos;s Republic of China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Increased expression of small heat shock protein alphaB-crystallin after intracerebral hemorrhage in adult rats</style></title><secondary-title><style face="normal" font="default" size="100%">J Mol Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of molecular neuroscience : MN</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Mol Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of molecular neuroscience : MN</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Mol Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of molecular neuroscience : MN</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">159-69</style></pages><volume><style face="normal" font="default" size="100%">51</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2013/02/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/metabolism/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Caspase 3/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Proliferation</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/metabolism/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">PC12 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Proliferating Cell Nuclear Antigen/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">alpha-Crystallin B Chain/genetics/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-1166 (Electronic)&#xD;0895-8696 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23386121</style></accession-num><abstract><style face="normal" font="default" size="100%">alphaB-crystallin (alphaBC) is involved in diverse cellular activities. Previous studies demonstrated that alphaBC had anti-apoptotic and proliferation-promoting effects in multiple diseases. Here, we explored the alphaBC&apos;s roles in the pathophysiology of intracerebral hemorrhage (ICH). An ICH rat model was established and assessed by behavioral tests. Using Western blot and immunohistochemistry, significant up-regulation of alphaBC was found in neurons and astrocytes in brain areas surrounding the hematoma following ICH. Increase of alphaBC expression was found to be accompanied by the increased expression of proliferating cell nuclear antigen (PCNA), p53, Bax, and active-caspase-3. alphaBC was co-localized with PCNA in astrocytes or active-caspase-3 in neurons, suggesting its role in astrocyte proliferation and neuronal apoptosis. Our in vitro study, using alphaBC RNA interference in PC12 cells, indicated that alphaBC might exert its anti-apoptotic function in neuronal apoptosis. Thus, alphaBC may play a role in protecting the brain from secondary damage following ICH.</style></abstract><notes><style face="normal" font="default" size="100%">Ke, Kaifu&#xD;Li, Lei&#xD;Rui, Ying&#xD;Zheng, Heyi&#xD;Tan, Xiang&#xD;Xu, Wei&#xD;Cao, Jianhua&#xD;Xu, Jian&#xD;Cui, Gang&#xD;Xu, Guangfei&#xD;Cao, Maohong&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Mol Neurosci. 2013 Sep;51(1):159-69. doi: 10.1007/s12031-013-9970-2. Epub 2013 Feb 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/999/art%253A10.1007%252Fs12031-013-9970-2.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12031-013-9970-2&amp;token2=exp=1484113641~acl=%2Fstatic%2Fpdf%2F999%2Fart%25253A10.1007%25252Fs12031-013-9970-2.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs12031-013-9970-2*~hmac=4f3cafe7c164ff3b2b265f748beae069280de87cc66e9dbd7a11c4cf7622f200</style></url></related-urls><pdf-urls><url>internal-pdf://1418115222/Ke-2013-Increased expression.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12031-013-9970-2</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>199</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">199</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kent, M.</style></author><author><style face="normal" font="default" size="100%">Glass, E. N.</style></author><author><style face="normal" font="default" size="100%">Haley, A. C.</style></author><author><style face="normal" font="default" size="100%">March, P.</style></author><author><style face="normal" font="default" size="100%">Rozanski, E. A.</style></author><author><style face="normal" font="default" size="100%">Galban, E. M.</style></author><author><style face="normal" font="default" size="100%">Bertalan, A.</style></author><author><style face="normal" font="default" size="100%">Platt, S. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA 30602.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Ischemic stroke in Greyhounds: 21 cases (2007-2013)</style></title><secondary-title><style face="normal" font="default" size="100%">J Am Vet Med Assoc</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of the American Veterinary Medical Association</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Am Vet Med Assoc</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of the American Veterinary Medical Association</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Am Vet Med Assoc</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of the American Veterinary Medical Association</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">113-7</style></pages><volume><style face="normal" font="default" size="100%">245</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2014/06/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/pathology/ veterinary</style></keyword><keyword><style face="normal" font="default" size="100%">Dog Diseases/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Dogs</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/pathology/ veterinary</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 01</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1943-569X (Electronic)&#xD;0003-1488 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24941395</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To determine the prevalence of ischemic stroke in Greyhounds and determine whether affected dogs had coagulation abnormalities and hypertension. DESIGN: Multi-institutional, retrospective study. ANIMALS: 21 dogs. PROCEDURES: Medical records (including diagnostic testing results) and MRI images of the brain were reviewed for Greyhounds with ischemic stroke that had been evaluated at 4 institutions. The proportion of Greyhounds with ischemic stroke was compared with the proportion of non-Greyhound dogs with ischemic stroke. Demographic information for dogs evaluated at each institution was obtained to determine the proportion of Greyhounds in the hospital populations. RESULTS: 21 Greyhounds with ischemic stroke were identified. Abnormalities in coagulation were not identified in the 14 Greyhounds that underwent such testing. Systemic hypertension was identified in 6 of 14 Greyhounds that underwent such testing. No other abnormalities were identified by means of other routine diagnostic tests for Greyhounds. For all institutions combined, the prevalence of ischemic stroke in Greyhounds was 0.66% (21/3,161 Greyhounds). Greyhounds were significantly more likely to be evaluated because of ischemic stroke, compared with all other dog breeds combined (OR, 6.6; 95% confidence interval, 4.2 to 10.2). CONCLUSIONS AND CLINICAL RELEVANCE: Results of this study suggested that Greyhounds were predisposed to ischemic stroke, compared with all other breeds combined. Coagulation abnormalities did not seem to contribute to ischemic stroke. Hypertension may have contributed to the development of ischemic stroke. Greyhounds with ischemic stroke should undergo measurement of systolic arterial blood pressure. Antihypertensive treatments may be warranted for such dogs.</style></abstract><notes><style face="normal" font="default" size="100%">Kent, Marc&#xD;Glass, Eric N&#xD;Haley, Allison C&#xD;March, Phillip&#xD;Rozanski, Elizabeth A&#xD;Galban, Evelyn M&#xD;Bertalan, Abagail&#xD;Platt, Simon R&#xD;Multicenter Study&#xD;United States&#xD;J Am Vet Med Assoc. 2014 Jul 1;245(1):113-7. doi: 10.2460/javma.245.1.113.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2460/javma.245.1.113</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>325</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">325</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Khanna, S.</style></author><author><style face="normal" font="default" size="100%">Rink, C.</style></author><author><style face="normal" font="default" size="100%">Ghoorkhanian, R.</style></author><author><style face="normal" font="default" size="100%">Gnyawali, S.</style></author><author><style face="normal" font="default" size="100%">Heigel, M.</style></author><author><style face="normal" font="default" size="100%">Wijesinghe, D. S.</style></author><author><style face="normal" font="default" size="100%">Chalfant, C. E.</style></author><author><style face="normal" font="default" size="100%">Chan, Y. C.</style></author><author><style face="normal" font="default" size="100%">Banerjee, J.</style></author><author><style face="normal" font="default" size="100%">Huang, Y.</style></author><author><style face="normal" font="default" size="100%">Roy, S.</style></author><author><style face="normal" font="default" size="100%">Sen, C. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Surgery, Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Loss of miR-29b following acute ischemic stroke contributes to neural cell death and infarct size</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1197-206</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2013/05/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antioxidants/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Arachidonate 12-Lipoxygenase/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Blotting, Western</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ genetics/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Death/ genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Survival/genetics/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/ genetics/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Eicosanoids/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorescent Antibody Technique</style></keyword><keyword><style face="normal" font="default" size="100%">Glutathione/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Membrane Potential, Mitochondrial/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">MicroRNAs/antagonists &amp; inhibitors/ genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">RNA/biosynthesis/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Real-Time Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ genetics/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Tocotrienols/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Transfection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23632968</style></accession-num><abstract><style face="normal" font="default" size="100%">Glutathione depletion and 12-lipoxygenase-dependent metabolism of arachidonic acid are known to be implicated in neurodegeneration associated with acute ischemic stroke. The objective of this study was to investigate the significance of miR-29 in neurodegeneration associated with acute ischemic stroke. Neural cell death caused by arachidonic acid insult of glutathione-deficient cells was preceded by a 12-lipoxygenase-dependent loss of miR-29b. Delivery of miR-29b mimic to blunt such loss was neuroprotective. miR-29b inhibition potentiated such neural cell death. 12-Lipoxygenase knockdown and inhibitors attenuated the loss of miR-29b in challenged cells. In vivo, stroke caused by middle-cerebral artery occlusion was followed by higher 12-lipoxygenase activity and loss of miR-29b as detected in laser-captured infarct site tissue. 12-Lipoxygenase knockout mice demonstrated protection against such miR loss. miR-29b gene delivery markedly attenuated stroke-induced brain lesion. Oral supplementation of alpha-tocotrienol, a vitamin E 12-lipoxygenase inhibitor, rescued stroke-induced loss of miR-29b and minimized lesion size. This work provides the first evidence demonstrating that loss of miR-29b at the infarct site is a key contributor to stroke lesion. Such loss is contributed by activity of the 12-lipoxygenase pathway providing maiden evidence linking arachidonic acid metabolism to miR-dependent mechanisms in stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Khanna, Savita&#xD;Rink, Cameron&#xD;Ghoorkhanian, Reza&#xD;Gnyawali, Surya&#xD;Heigel, Mallory&#xD;Wijesinghe, Dayanjan S&#xD;Chalfant, Charles E&#xD;Chan, Yuk Cheung&#xD;Banerjee, Jaideep&#xD;Huang, Yue&#xD;Roy, Sashwati&#xD;Sen, Chandan K&#xD;UL1 TR000090/TR/NCATS NIH HHS/United States&#xD;R01 NS042617/NS/NINDS NIH HHS/United States&#xD;I01 BX001792/BX/BLRD VA/United States&#xD;HL072925/HL/NHLBI NIH HHS/United States&#xD;R01 CA154314/CA/NCI NIH HHS/United States&#xD;NS42617/NS/NINDS NIH HHS/United States&#xD;CA154314/CA/NCI NIH HHS/United States&#xD;R01 HL072925/HL/NHLBI NIH HHS/United States&#xD;P30 CA016058/CA/NCI NIH HHS/United States&#xD;P30 CA016059/CA/NCI NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United States&#xD;J Cereb Blood Flow Metab. 2013 Aug;33(8):1197-206. doi: 10.1038/jcbfm.2013.68. Epub 2013 May 1.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3734770</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2013.68</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>153</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">153</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, D.</style></author><author><style face="normal" font="default" size="100%">Kim, R. G.</style></author><author><style face="normal" font="default" size="100%">Kim, H. S.</style></author><author><style face="normal" font="default" size="100%">Kim, J. M.</style></author><author><style face="normal" font="default" size="100%">Jun, S. C.</style></author><author><style face="normal" font="default" size="100%">Lee, B.</style></author><author><style face="normal" font="default" size="100%">Jo, H. J.</style></author><author><style face="normal" font="default" size="100%">Neto, P. R.</style></author><author><style face="normal" font="default" size="100%">Lee, M. C.</style></author><author><style face="normal" font="default" size="100%">Kim, H. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Information and Communication, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea.&#xD;Department of Medical System Engineering and School of Mechatronics, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea.&#xD;Department of Pathology, Chonnam National University Medical School, Gwangju, Republic of Korea.&#xD;Section on Functional Imaging Methods, Laboratory of Brain and Cognition, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.&#xD;Translational Neuroimaging Laboratory, McGill Center for Studies in Aging, Douglas Mental Health University Institute, Montreal, Quebec, Canada.&#xD;1] Department of Medical System Engineering and School of Mechatronics, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea [2] Department of Neurosurgery, Presbyterian Medical Center, Jeonju, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Longitudinal changes in resting-state brain activity in a capsular infarct model</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">11-9</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2014/10/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Behavior, Animal/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/diagnostic imaging/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Infarction/diagnostic imaging/metabolism/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Data Interpretation, Statistical</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorodeoxyglucose F18</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Image Processing, Computer-Assisted</style></keyword><keyword><style face="normal" font="default" size="100%">Internal Capsule/diagnostic imaging/metabolism/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Motor Activity/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Positron-Emission Tomography</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery of Function/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25352047</style></accession-num><abstract><style face="normal" font="default" size="100%">Strokes attributable to subcortical infarcts have been increasing recently in elderly patients. To gain insight how this lesion influences the motor outcome and responds to rehabilitative training, we used circumscribed photothrombotic capsular infarct models on 36 Sprague-Dawley rats (24 experimental and 12 sham-operated). We used 2-deoxy-2-[(18)F]-fluoro-D-glucose-micro positron emission tomography (FDG-microPET) to assess longitudinal changes in resting-state brain activity (rs-BA) and daily single-pellet reaching task (SPRT) trainings to evaluate motor recovery. Longitudinal FDG-microPET results showed that capsular infarct resulted in a persistent decrease in rs-BA in bilateral sensory and auditory cortices, and ipsilesional motor cortex, thalamus, and inferior colliculus (P&lt;0.0025, false discovery rate (FDR) q&lt;0.05). The decreased rs-BA is compatible with diaschisis and contributes to manifest the malfunctions of lesion-specific functional connectivity. In contrast, capsular infarct resulted in increase of rs-BA in the ipsilesional internal capsule, and contralesional red nucleus and ventral hippocampus in recovery group (P&lt;0.0025, FDR q&lt;0.05), implying that remaining subcortical structures have an important role in conducting the recovery process in capsular infarct. The SPRT training facilitated motor recovery only in rats with an incomplete destruction of the posterior limb of the internal capsule (PLIC) (Pearson&apos;s correlation, P&lt;0.05). Alternative therapeutic interventions are required to enhance the potential for recovery in capsular infarct with complete destruction of PLIC.</style></abstract><notes><style face="normal" font="default" size="100%">Kim, Donghyeon&#xD;Kim, Ra Gyung&#xD;Kim, Hyung-Sun&#xD;Kim, Jin-Myung&#xD;Jun, Sung Chan&#xD;Lee, Boreom&#xD;Jo, Hang Joon&#xD;Neto, Pedro R&#xD;Lee, Min-Cheol&#xD;Kim, Hyoung-Ihl&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Cereb Blood Flow Metab. 2015 Jan;35(1):11-9. doi: 10.1038/jcbfm.2014.178. Epub 2014 Oct 29.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4814054</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2014.178</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>474</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">474</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, D. E.</style></author><author><style face="normal" font="default" size="100%">Kim, J. Y.</style></author><author><style face="normal" font="default" size="100%">Nahrendorf, M.</style></author><author><style face="normal" font="default" size="100%">Lee, S. K.</style></author><author><style face="normal" font="default" size="100%">Ryu, J. H.</style></author><author><style face="normal" font="default" size="100%">Kim, K.</style></author><author><style face="normal" font="default" size="100%">Kwon, I. C.</style></author><author><style face="normal" font="default" size="100%">Schellingerhout, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">MINER Laboratory at Department of Neurology, Dongguk University Ilsan Hospital, 814 Siksa-dong, Goyang, Korea. kdongeog@duih.org</style></auth-address><titles><title><style face="normal" font="default" size="100%">Direct thrombus imaging as a means to control the variability of mouse embolic infarct models: the role of optical molecular imaging</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">3566-73</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2011/10/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Infarction/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Thrombosis/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Imaging/ methods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22020025</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: High experimental variability in mouse embolic stroke models could mask the effects of experimental treatments. We hypothesized that imaging thrombus directly would allow this variability to be controlled. METHODS: We optically labeled thrombi with a near-infrared fluorescent (NIRF) probe C15 that is covalently linked to fibrin by factor-XIIIa. Labeled thrombus was injected into the left distal internal carotid artery (ICA) of C57/BL6 mice (n=47), near its bifurcation, and laser-Doppler cerebral-blood-flow (CBF) was assessed for 30 minutes. NIRF thrombus imaging was done ex vivo at 24 hours. RESULTS: CBF variably decreased to 43.9+/-17.3% at 5 minutes (rCBF; 11.2 approximately 80.4%). NIRF thrombus imaging at 24 hours showed variability in distribution (ICA bifurcation, adjacent and/or remote areas) and burden (2279+/-1270 pixels; 0 approximately 5940 pixels). Final infarct size was also variable (21.0+/-10.3%; 4.7 approximately 60.3% of the bihemispheric volume). Despite this heterogeneity, a strong thrombus-infarct correlation was maintained. The left hemispheric target infarct size (% of the hemisphere) correlated with thrombus burden, as a stronger predictor of infarct volume (P&lt;0.001, r=0.50) than rCBF (P=0.02, r=-0.34). The infarct size was best predicted by a combination of thrombus imaging and CBF: left-hemispheric big-thrombi (&gt;1865 pixels)/low-rCBF (&lt;/=42%) had an infarct volume of 56.9+/-10.4% (n=12), big-thrombi/high-rCBF had 45.9+/-23.5% (n=11), small-thrombi/low-rCBF 35.7+/-17.3% (n=11) and small-thrombi/ high-rCBF 27.3+/-16.4% (n=12). CONCLUSIONS: This is the first study to demonstrate that the highly heterogeneous nature of the mouse embolic stroke model can be characterized and managed by using near-infrared fluorescent thrombus imaging combined with CBF monitoring to stratify animals into useful subgroups.</style></abstract><notes><style face="normal" font="default" size="100%">Kim, Dong-Eog&#xD;Kim, Jeong-Yeon&#xD;Nahrendorf, Matthias&#xD;Lee, Su-Kyoung&#xD;Ryu, Ju Hee&#xD;Kim, Kwangmeyung&#xD;Kwon, Ick Chan&#xD;Schellingerhout, Dawid&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Stroke. 2011 Dec;42(12):3566-73. doi: 10.1161/STROKEAHA.111.629428. Epub 2011 Oct 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/42/12/3566.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0990838847/Kim-2011-Direct thrombus imag.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.111.629428</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>430</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">430</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, G. S.</style></author><author><style face="normal" font="default" size="100%">Jung, J. E.</style></author><author><style face="normal" font="default" size="100%">Narasimhan, P.</style></author><author><style face="normal" font="default" size="100%">Sakata, H.</style></author><author><style face="normal" font="default" size="100%">Chan, P. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, and Program in Neurosciences, Stanford University School of Medicine, Stanford, CA 94305-5487, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Induction of thioredoxin-interacting protein is mediated by oxidative stress, calcium, and glucose after brain injury in mice</style></title><secondary-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurobiology of disease</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurobiology of disease</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurobiology of disease</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">440-9</style></pages><volume><style face="normal" font="default" size="100%">46</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2012/03/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis Regulatory Proteins/biosynthesis</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Signaling/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Carrier Proteins/ biosynthesis</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperglycemia/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative Stress/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Thioredoxins/ biosynthesis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1095-953X (Electronic)&#xD;0969-9961 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22366181</style></accession-num><abstract><style face="normal" font="default" size="100%">Oxidative stress and glucose affect the expression of various genes that contribute to both reactive oxygen species generation and antioxidant systems. However, systemic alteration of oxidative stress-related gene expression in normal brains and in brains with a high-glucose status after ischemic-reperfusion has not been explored. Using a polymerase chain reaction array system, we demonstrate that thioredoxin-interacting protein (Txnip) is induced by both oxidative stress and glucose. We found that Txnip mRNA is induced by ischemic-reperfusion injury and that Txnip is located in the cytoplasm of neurons. Moreover, in vitro oxygen-glucose deprivation (OGD) and subsequent reoxygenation without glucose and in vivo administration of 3-nitropropionic acid also promoted an increase in Txnip in a time-dependent manner, indicating that oxidative stress without glucose can induce Txnip expression in the brain. However, calcium channel blockers inhibit induction of Txnip after OGD and reoxygenation. Using the polymerase chain reaction array with ischemic and hyperglycemic-ischemic samples, we confirmed that enhanced expression of Txnip was observed in hyperglycemic-ischemic brains after middle cerebral artery occlusion. Finally, transfection of Txnip small interfering RNA into primary neurons reduced lactate dehydrogenase release after OGD and reoxygenation. This is the first report showing that Txnip expression is induced in neurons after oxidative or glucose stress under either ischemic or hyperglycemic-ischemic conditions, and that Txnip is proapoptotic under these conditions.</style></abstract><notes><style face="normal" font="default" size="100%">Kim, Gab Seok&#xD;Jung, Joo Eun&#xD;Narasimhan, Purnima&#xD;Sakata, Hiroyuki&#xD;Chan, Pak H&#xD;R01 NS038653/NS/NINDS NIH HHS/United States&#xD;P01 NS014543/NS/NINDS NIH HHS/United States&#xD;R01 NS025372-23/NS/NINDS NIH HHS/United States&#xD;P01 NS014543-33/NS/NINDS NIH HHS/United States&#xD;R01 NS038653-15/NS/NINDS NIH HHS/United States&#xD;R01 NS025372/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Neurobiol Dis. 2012 May;46(2):440-9. doi: 10.1016/j.nbd.2012.02.008. Epub 2012 Feb 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0969996112000502/1-s2.0-S0969996112000502-main.pdf?_tid=b209b574-d7be-11e6-a0cd-00000aacb361&amp;acdnat=1484112651_7bff66748b9517111592d364828a7f6b</style></url></related-urls><pdf-urls><url>internal-pdf://2515738982/Kim-2012-Induction of thiored.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3323710</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms358205</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.nbd.2012.02.008</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>447</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">447</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, I. D.</style></author><author><style face="normal" font="default" size="100%">Shin, J. H.</style></author><author><style face="normal" font="default" size="100%">Kim, S. W.</style></author><author><style face="normal" font="default" size="100%">Choi, S.</style></author><author><style face="normal" font="default" size="100%">Ahn, J.</style></author><author><style face="normal" font="default" size="100%">Han, P. L.</style></author><author><style face="normal" font="default" size="100%">Park, J. S.</style></author><author><style face="normal" font="default" size="100%">Lee, J. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Anatomy and Center for Advanced Medical Education (BK21 project), Inha University School of Medicine, Inchon, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain</style></title><secondary-title><style face="normal" font="default" size="100%">Mol Ther</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Molecular therapy : the journal of the American Society of Gene Therapy</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Mol Ther</style></full-title><abbr-1><style face="normal" font="default" size="100%">Molecular therapy : the journal of the American Society of Gene Therapy</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Mol Ther</style></full-title><abbr-1><style face="normal" font="default" size="100%">Molecular therapy : the journal of the American Society of Gene Therapy</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">829-39</style></pages><volume><style face="normal" font="default" size="100%">20</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2012/01/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Intranasal</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/drug therapy/metabolism/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">HMGB1 Protein/ antagonists &amp; inhibitors/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoblotting</style></keyword><keyword><style face="normal" font="default" size="100%">Immunohistochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ administration &amp; dosage/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/ administration &amp; dosage/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Real-Time Polymerase Chain Reaction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1525-0024 (Electronic)&#xD;1525-0016 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22252450</style></accession-num><abstract><style face="normal" font="default" size="100%">Noninvasive intranasal drug administration has been noted to allow direct delivery of drugs to the brain. In the present study, the therapeutic efficacy of intranasal small interfering RNA (siRNA) delivery was investigated in the postischemic rat brain. Fluorescein isothiocyanate (FITC)-labeled control siRNA was delivered intranasally in normal adult rats using e-PAM-R, a biodegradable PAMAM dendrimer, as gene carrier. Florescence-tagged siRNA was found in the cytoplasm and processes of neurons and of glial cells in many brain regions, including the hypothalamus, amygdala, cerebral cortex, and striatum, in 1 hour after infusion, and the FITC-fluorescence was continuously detected for at least 12 hours. When siRNA for high mobility group box 1 (HMGB1), which functions as an endogenous danger molecule and aggravates inflammation, was delivered intranasally, the target gene was significantly depleted in many brain regions, including the prefrontal cortex and striatum. More importantly, intranasal delivery of HMGB1 siRNA markedly suppressed infarct volume in the postischemic rat brain (maximal reduction to 42.8 +/- 5.6% at 48 hours after 60 minutes middle cerebral artery occlusion (MCAO)) and this protective effect was manifested by recoveries from neurological and behavioral deficits. These results indicate that the intranasal delivery of HMGB1 siRNA offers an efficient means of gene knockdown-mediated therapy in the ischemic brain.</style></abstract><notes><style face="normal" font="default" size="100%">Kim, Il-Doo&#xD;Shin, Joo-Hyun&#xD;Kim, Seung-Woo&#xD;Choi, Sunghyun&#xD;Ahn, Junseong&#xD;Han, Pyung-Lim&#xD;Park, Jong-Sang&#xD;Lee, Ja-Kyeong&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Mol Ther. 2012 Apr;20(4):829-39. doi: 10.1038/mt.2011.291. Epub 2012 Jan 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S1525001616305470/1-s2.0-S1525001616305470-main.pdf?_tid=ac3c4710-d7be-11e6-9350-00000aacb360&amp;acdnat=1484112641_9e1e782a0589406deb477ea6107f63af</style></url></related-urls><pdf-urls><url>internal-pdf://1317341477/Kim-2012-Intranasal delivery.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3321593</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/mt.2011.291</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>361</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">361</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kirchhoff, F.</style></author><author><style face="normal" font="default" size="100%">Debarbieux, F.</style></author><author><style face="normal" font="default" size="100%">Kronland-Martinet, C.</style></author><author><style face="normal" font="default" size="100%">Cojocaru, G. R.</style></author><author><style face="normal" font="default" size="100%">Popa-Wagner, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Molecular Physiology, University of Saarland, Homburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Combined two-photon laser-scanning microscopy and spectral microCT X-ray imaging to characterize the cellular signature and evolution of microstroke foci</style></title><secondary-title><style face="normal" font="default" size="100%">Rom J Morphol Embryol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Rom J Morphol Embryol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Rom J Morphol Embryol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">671-5</style></pages><volume><style face="normal" font="default" size="100%">53</style></volume><number><style face="normal" font="default" size="100%">3 Suppl</style></number><edition><style face="normal" font="default" size="100%">2012/12/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/diagnostic imaging/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Image Processing, Computer-Assisted/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Microscopy, Confocal/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Radiography</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/diagnostic imaging/ pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1220-0522 (Print)&#xD;1220-0522 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23188424</style></accession-num><abstract><style face="normal" font="default" size="100%">Occlusive brain ischemia and micro-strokes are the most frequent brain pathologies, particularly in older patients and a major cause of dementia. Currently, we are missing appropriate methodology to study micro-strokes in experimental animals. In vivo two-photon laser-scanning microscopy (2P-LSM) and transgenic mouse models expressing cell type specific reporters have been used to examine ischemia-related insults, e.g. perturbations of neuronal process morphology and local blood flow in the MCAO - middle cerebral artery occlusion-model. Glia and pericytes can be visualized by selective fluorescent protein expression, e.g. astrocytes by their cyan-fluorescent ECFP, pericytes by red-fluorescent tdtomato and microglia by green fluorescent EGFP expression. In these mice, the breakdown of the blood brain barrier and the immediate as well as long-term cellular responses can be monitored. A new prototype of microCT incorporating a fast X-ray XPAD3 camera has been recently set up to allow cerebral angiography at high sampling rate. Preliminary data indicate that it is useful to monitor blood perfusion disturbance (i.e. lateralization) in the brain of tumor-bearing mice following retro-orbital injection of iodinated contrast agent. We expect this technology to be adequate to assess in real time the impact of acute stroke models on brain blood perfusion. By localizing perfusion anomalies, we will evaluate the extent of non-perfused areas and correlate these observations with subsequent behavioral deficits, and with local changes in myelin content in white matter tracks. The spectral properties of the XPAD3 detector moreover allow for the simultaneous identification and localization of several contrast agents opening the way to whole body multicolor imaging of vessels and inflammatory cells in the context of microstrokes.</style></abstract><notes><style face="normal" font="default" size="100%">Kirchhoff, F&#xD;Debarbieux, F&#xD;Kronland-Martinet, Carine&#xD;Cojocaru, G R&#xD;Popa-Wagner, A&#xD;Review&#xD;Romania&#xD;Rom J Morphol Embryol. 2012;53(3 Suppl):671-5.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>437</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">437</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Klohs, J.</style></author><author><style face="normal" font="default" size="100%">Baltes, C.</style></author><author><style face="normal" font="default" size="100%">Princz-Kranz, F.</style></author><author><style face="normal" font="default" size="100%">Ratering, D.</style></author><author><style face="normal" font="default" size="100%">Nitsch, R. M.</style></author><author><style face="normal" font="default" size="100%">Knuesel, I.</style></author><author><style face="normal" font="default" size="100%">Rudin, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute for Biomedical Engineering, Swiss Federal Institute of Technology and University of Zurich, CH-8093 Zurich, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Contrast-enhanced magnetic resonance microangiography reveals remodeling of the cerebral microvasculature in transgenic ArcAbeta mice</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1705-13</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2012/02/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Amyloid beta-Peptides/ genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Amyloid Angiopathy/genetics/metabolism/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Contrast Media</style></keyword><keyword><style face="normal" font="default" size="100%">Cytoskeletal Proteins/ genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fibrinogen/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Angiography/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Microvessels/diagnostic imaging/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Tissue Proteins/ genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Radiography</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 01</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1529-2401 (Electronic)&#xD;0270-6474 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22302811</style></accession-num><abstract><style face="normal" font="default" size="100%">Amyloid-beta (Abeta) deposition in the cerebral vasculature is accompanied by remodeling which has a profound influence on vascular integrity and function. In the current study we have quantitatively assessed the age-dependent changes of the cortical vasculature in the arcAbeta model of cerebral amyloidosis. To estimate the density of the cortical microvasculature in vivo, we used contrast-enhanced magnetic resonance microangiography (CE-muMRA). Three-dimensional gradient echo datasets with 60 mum isotropic resolution were acquired in 4- and 24-month-old arcAbeta mice and compared with wild-type (wt) control mice of the same age before and after administration of superparamagnetic iron oxide nanoparticles. After segmentation of the cortical vasculature from difference images, an automated algorithm was applied for assessing the number and size distribution of intracortical vessels. With CE-muMRA, cerebral arteries and veins with a diameter of less than the nominal pixel resolution (60 mum) can be visualized. A significant age-dependent reduction in the number of functional intracortical microvessels (radii of 20-80 mum) has been observed in 24-month-old arcAbeta mice compared with age-matched wt mice, whereas there was no difference between transgenic and wt mice of 4 months of age. Immunohistochemistry demonstrated strong fibrinogen and Abeta deposition in small- and medium-sized vessels, but not in large cerebral arteries, of 24-month-old arcAbeta mice. The reduced density of transcortical vessels may thus be attributed to impaired perfusion and vascular occlusion caused by deposition of Abeta and fibrin. The study demonstrated that remodeling of the cerebrovasculature can be monitored noninvasively with CE-muMRA in mice.</style></abstract><notes><style face="normal" font="default" size="100%">Klohs, Jan&#xD;Baltes, Christof&#xD;Princz-Kranz, Felicitas&#xD;Ratering, David&#xD;Nitsch, Roger M&#xD;Knuesel, Irene&#xD;Rudin, Markus&#xD;Comparative Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Neurosci. 2012 Feb 1;32(5):1705-13. doi: 10.1523/JNEUROSCI.5626-11.2012.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.jneurosci.org/content/jneuro/32/5/1705.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0203961870/Klohs-2012-Contrast-enhanced ma.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1523/jneurosci.5626-11.2012</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>484</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">484</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kobayashi, M.</style></author><author><style face="normal" font="default" size="100%">Mori, T.</style></author><author><style face="normal" font="default" size="100%">Kiyono, Y.</style></author><author><style face="normal" font="default" size="100%">Tiwari, V. N.</style></author><author><style face="normal" font="default" size="100%">Maruyama, R.</style></author><author><style face="normal" font="default" size="100%">Kawai, K.</style></author><author><style face="normal" font="default" size="100%">Okazawa, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Biomedical Imaging Research Center, University of Fukui, Eiheiji-cho, Fukui, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cerebral oxygen metabolism of rats using injectable (15)O-oxygen with a steady-state method</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">33-40</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2011/08/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Volume/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/blood supply/diagnostic imaging/ metabolism/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/diagnostic imaging/ metabolism/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen Radioisotopes</style></keyword><keyword><style face="normal" font="default" size="100%">Positron-Emission Tomography/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">21863038</style></accession-num><abstract><style face="normal" font="default" size="100%">To develop a less-stressful and simple method for measurement of the cerebral metabolic rate of oxygen (CMRO(2)) in small animals, the steady-state method was applied to injectable (15)O(2)-PET ((15)O(2)-positron emission tomography) using hemoglobin-containing vesicles ((15)O(2)-HbV). Ten normal rats and 10 with middle cerebral arterial occlusion (MCAO) were studied using a small animal PET scanner. A series of (15)O-PET scans with C(15)O-labeled HbV, H(2)(15)O, and (15)O(2)-HbV were performed with 10 to 15 minutes intervals to measure cerebral blood volume (CBV), cerebral blood flow (CBF), and CMRO(2). Positron emission tomography scans were started with a tracer injection using a multiprogramming syringe pump, which provides a slowly increasing injection volume to achieve steady-state radioactivity for H(2)(15)O and (15)O(2)-HbV scans. The radioactivity concentration of (15)O rapidly achieved equilibrium in the blood and whole brain at about 2 minutes after H(2)(15)O and (15)O(2)-HbV administration, which was stable during the scans. The whole brain mean values of CBF, CBV, and CMRO(2) were 54.3+/-2.0 mL per 100 g per minute, 4.9+/-0.4 mL/100 g, and 2.8+/-0.2 mumoL per g per minute (6.2+/-0.4 mL per 100 g per minute) in the normal rats, respectively. In the MCAO model rats, all hemodynamic parameters of the infarction area on the occlusion side significantly decreased. The steady-state method with (15)O-labeled HbV is simple and useful to analyze hemodynamic changes in studies with model animals.</style></abstract><notes><style face="normal" font="default" size="100%">Kobayashi, Masato&#xD;Mori, Tetsuya&#xD;Kiyono, Yasushi&#xD;Tiwari, Vijay Narayan&#xD;Maruyama, Rikiya&#xD;Kawai, Keiichi&#xD;Okazawa, Hidehiko&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Cereb Blood Flow Metab. 2012 Jan;32(1):33-40. doi: 10.1038/jcbfm.2011.125. Epub 2011 Aug 24.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3323301</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2011.125</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>456</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">456</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Koga, S.</style></author><author><style face="normal" font="default" size="100%">Kojima, S.</style></author><author><style face="normal" font="default" size="100%">Kishimoto, T.</style></author><author><style face="normal" font="default" size="100%">Kuwabara, S.</style></author><author><style face="normal" font="default" size="100%">Yamaguchi, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurobiology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Over-expression of map kinase phosphatase-1 (MKP-1) suppresses neuronal death through regulating JNK signaling in hypoxia/re-oxygenation</style></title><secondary-title><style face="normal" font="default" size="100%">Brain Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">137-46</style></pages><volume><style face="normal" font="default" size="100%">1436</style></volume><edition><style face="normal" font="default" size="100%">2011/12/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Line, Tumor</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Dual Specificity Phosphatase 1/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">MAP Kinase Kinase 4/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 03</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-6240 (Electronic)&#xD;0006-8993 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22197701</style></accession-num><abstract><style face="normal" font="default" size="100%">A pivotal role of c-jun N-terminal kinase (JNK) on neuronal apoptosis has been demonstrated in a rodent stroke model. MAP kinase phosphatase 1 (MKP-1) is an archetypal member of the dual-specificity protein phosphatase (DUSP) family, which inactivates mitogen-activated protein kinase (MAPK) including JNK through dephosphorylation. MKP-1, one of immediate early genes in stress conditions, was induced at transcriptional level in hypoxia/re-oxygenation (H/R) in neuroblastoma N1E115 cells, however the activation of JNK was not suppressed in the acute phase of re-oxygenation. Small interference RNA-mediated knock-down of MKP-1 enhanced phospho-JNK and neuronal death that is rescued by JNK inhibitor in H/R. Conversely, conditional over-expression of MKP-1 suppressed phospho-JNK, the expression of proapoptotic genes, and neuronal death in H/R. Further the immunoreactivity of MKP-1 was detected in the neurons and partially co-localized with that of phospho-JNK in the surrounding zone of ischemia in rat MCA-O (middle cerebral artery occlusion) reperfusion model. These findings indicate that over-expression of MKP-1 could suppress neuronal death possibly through regulating JNK signaling in vitro and be a prominent neuroprotective target for the treatment of acute cerebral infarction.</style></abstract><notes><style face="normal" font="default" size="100%">Koga, Shunsuke&#xD;Kojima, Shunsuke&#xD;Kishimoto, Takashi&#xD;Kuwabara, Satoshi&#xD;Yamaguchi, Atsushi&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;Brain Res. 2012 Feb 3;1436:137-46. doi: 10.1016/j.brainres.2011.12.004. Epub 2011 Dec 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S000689931102155X/1-s2.0-S000689931102155X-main.pdf?_tid=bdcc4548-d7be-11e6-8b14-00000aab0f26&amp;acdnat=1484112671_3b607247337784fe3c52a11194ff884a</style></url></related-urls><pdf-urls><url>internal-pdf://0608792048/Koga-2012-Over-expression of m.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.brainres.2011.12.004</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>369</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">369</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Koh, E. J.</style></author><author><style face="normal" font="default" size="100%">Kim, S. K.</style></author><author><style face="normal" font="default" size="100%">Wang, K. C.</style></author><author><style face="normal" font="default" size="100%">Chai, J. Y.</style></author><author><style face="normal" font="default" size="100%">Chong, S.</style></author><author><style face="normal" font="default" size="100%">Park, S. H.</style></author><author><style face="normal" font="default" size="100%">Cheon, J. E.</style></author><author><style face="normal" font="default" size="100%">Phi, J. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pediatric Neurosurgery, Seoul National University Children&apos;s Hospital, Seoul, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The return of an old worm: cerebral paragonimiasis presenting with intracerebral hemorrhage</style></title><secondary-title><style face="normal" font="default" size="100%">J Korean Med Sci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of Korean medical science</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Korean Med Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of Korean medical science</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Korean Med Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of Korean medical science</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1428-32</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2012/11/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Anthelmintics/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/parasitology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/ etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Dysarthria/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Facial Paralysis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Paragonimiasis/ diagnosis/drug therapy/parasitology</style></keyword><keyword><style face="normal" font="default" size="100%">Paragonimus/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Praziquantel/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Tomography, X-Ray Computed</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Malformations/etiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1598-6357 (Electronic)&#xD;1011-8934 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23166429</style></accession-num><abstract><style face="normal" font="default" size="100%">Paragonimiasis is caused by ingesting crustaceans, which are the intermediate hosts of Paragonimus. The involvement of the brain was a common presentation in Korea decades ago, but it becomes much less frequent in domestic medical practices. We observed a rare case of cerebral paragonimiasis manifesting with intracerebral hemorrhage. A 10-yr-old girl presented with sudden-onset dysarthria, right facial palsy and clumsiness of the right hand. Brain imaging showed acute intracerebral hemorrhage in the left frontal area. An occult vascular malformation or small arteriovenous malformation compressed by the hematoma was initially suspected. The lesion progressed for over 2 months until a delayed surgery was undertaken. Pathologic examination was consistent with cerebral paragonimiasis. After chemotherapy with praziquantel, the patient was monitored without neurological deficits or seizure attacks for 6 months. This case alerts practicing clinicians to the domestic transmission of a forgotten parasitic disease due to environmental changes.</style></abstract><notes><style face="normal" font="default" size="100%">Koh, Eun Jung&#xD;Kim, Seung-Ki&#xD;Wang, Kyu-Chang&#xD;Chai, Jong-Yil&#xD;Chong, Sangjoon&#xD;Park, Sung-Hye&#xD;Cheon, Jung-Eun&#xD;Phi, Ji Hoon&#xD;Case Reports&#xD;Korea (South)&#xD;J Korean Med Sci. 2012 Nov;27(11):1428-32. doi: 10.3346/jkms.2012.27.11.1428. Epub 2012 Oct 30.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3492682</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3346/jkms.2012.27.11.1428</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>32</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">32</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Koh, S.</style></author><author><style face="normal" font="default" size="100%">Kim, N.</style></author><author><style face="normal" font="default" size="100%">Yin, H. H.</style></author><author><style face="normal" font="default" size="100%">Harris, I. R.</style></author><author><style face="normal" font="default" size="100%">Dejneka, N. S.</style></author><author><style face="normal" font="default" size="100%">Eroglu, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departments of Cell Biology.&#xD;Neurobiology.&#xD;Neurobiology, Psychology and Neuroscience, and Duke Institute for Brain Sciences, Duke University, Durham, North Carolina 27710, and.&#xD;Janssen Research and Development, Spring House, Pennsylvania 19477.&#xD;Departments of Cell Biology, Neurobiology, Duke Institute for Brain Sciences, Duke University, Durham, North Carolina 27710, and c.eroglu@cellbio.duke.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Human Umbilical Tissue-Derived Cells Promote Synapse Formation and Neurite Outgrowth via Thrombospondin Family Proteins</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">15649-65</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">47</style></number><edition><style face="normal" font="default" size="100%">2015/11/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Survival/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Coculture Techniques/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Culture Media, Conditioned</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">HEK293 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Neurites/physiology/ secretion</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenesis/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Synapses/physiology/ secretion</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombospondins/ secretion</style></keyword><keyword><style face="normal" font="default" size="100%">Umbilical Cord/ cytology/physiology/ secretion</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 25</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1529-2401 (Electronic)&#xD;0270-6474 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26609158</style></accession-num><abstract><style face="normal" font="default" size="100%">Cell therapy demonstrates great potential for the treatment of neurological disorders. Human umbilical tissue-derived cells (hUTCs) were previously shown to have protective and regenerative effects in animal models of stroke and retinal degeneration, but the underlying therapeutic mechanisms are unknown. Because synaptic dysfunction, synapse loss, degeneration of neuronal processes, and neuronal death are hallmarks of neurological diseases and retinal degenerations, we tested whether hUTCs contribute to tissue repair and regeneration by stimulating synapse formation, neurite outgrowth, and neuronal survival. To do so, we used a purified rat retinal ganglion cell culture system and found that hUTCs secrete factors that strongly promote excitatory synaptic connectivity and enhance neuronal survival. Additionally, we demonstrated that hUTCs support neurite outgrowth under normal culture conditions and in the presence of the growth-inhibitory proteins chondroitin sulfate proteoglycan, myelin basic protein, or Nogo-A (reticulon 4). Furthermore, through biochemical fractionation and pharmacology, we identified the major hUTC-secreted synaptogenic factors as the thrombospondin family proteins (TSPs), TSP1, TSP2, and TSP4. Silencing TSP expression in hUTCs, using small RNA interference, eliminated both the synaptogenic function of these cells and their ability to promote neurite outgrowth. However, the majority of the prosurvival functions of hUTC-conditioned media was spared after TSP knockdown, indicating that hUTCs secrete additional neurotrophic factors. Together, our findings demonstrate that hUTCs affect multiple aspects of neuronal health and connectivity through secreted factors, and each of these paracrine effects may individually contribute to the therapeutic function of these cells. SIGNIFICANCE STATEMENT: Human umbilical tissue-derived cells (hUTC) are currently under clinical investigation for the treatment of geographic atrophy secondary to age-related macular degeneration. These cells show great promise for the treatment of neurological disorders; however, the therapeutic effects of these cells on CNS neurons are not fully understood. Here we provide compelling evidence that hUTCs secrete multiple factors that work synergistically to enhance synapse formation and function, and support neuronal growth and survival. Moreover, we identified thrombospondins (TSPs) as the hUTC-secreted factors that mediate the synaptogenic and growth-promoting functions of these cells. Our findings highlight novel paracrine effects of hUTC on CNS neuron health and connectivity and begin to unravel potential therapeutic mechanisms by which these cells elicit their effects.</style></abstract><notes><style face="normal" font="default" size="100%">Koh, Sehwon&#xD;Kim, Namsoo&#xD;Yin, Henry H&#xD;Harris, Ian R&#xD;Dejneka, Nadine S&#xD;Eroglu, Cagla&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Neurosci. 2015 Nov 25;35(47):15649-65. doi: 10.1523/JNEUROSCI.1364-15.2015.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.jneurosci.org/content/jneuro/35/47/15649.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1783072445/Koh-2015-Human Umbilical Tiss.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4659827</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1523/jneurosci.1364-15.2015</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>313</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">313</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Koutsis, G.</style></author><author><style face="normal" font="default" size="100%">Siasos, G.</style></author><author><style face="normal" font="default" size="100%">Spengos, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Neurogenetics Unit, 1st Department of Neurology, University of Athens Medical School, Eginition Hospital, Athens, Greece.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The emerging role of microRNA in stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Top Med Chem</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Current topics in medicinal chemistry</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Top Med Chem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current topics in medicinal chemistry</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Curr Top Med Chem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current topics in medicinal chemistry</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1573-88</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">13</style></number><edition><style face="normal" font="default" size="100%">2013/06/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers/blood/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">MicroRNAs/blood/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/diagnosis/ metabolism/physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">1873-4294 (Electronic)&#xD;1568-0266 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23745809</style></accession-num><abstract><style face="normal" font="default" size="100%">MicroRNAs (miRNAs) are small non-coding RNAs approximately 22 nucleotides in length that play a pivotal role in post-transcriptional gene regulation by binding to complementary sites in the 3&apos;-untranslated region of messenger RNAs. In the past decade, their role in several human diseases, from cancer to cardiovascular disease, has been established by a wealth of evidence. Stroke is responsible for 10% of deaths worldwide and is one of the leading causes of disability. MiRNAs are involved in stroke risk factors including hypertension, atherosclerosis, atrial fibrillation, diabetes and dyslipidemia. The role of miRNAs in the pathophysiology of stroke has been the subject of more recent investigations. Animal studies, which dominate the field, have demonstrated the differential expression of miRNAs in brain and blood following ischemic or hemorrhagic insult and the potential use of miRNA antagonists to reduce focal cerebral damage. In particular, antagomirs to miR-145, -497, -181a, -1 and let-7f have been found to be neuroprotective in vivo. The discovery of circulating miRNAs in peripheral blood, which are unexpectedly stable, has allowed the recent completion of several studies in human stroke patients that have confirmed the differential expression of specific miRNAs following stroke and have addressed their potential use as diagnostic and prognostic markers. With miRNA research in stroke still in its infancy, it is anticipated that in the next few years significant discoveries that may have important therapeutic implications will emerge.</style></abstract><notes><style face="normal" font="default" size="100%">Koutsis, Georgios&#xD;Siasos, Gerasimos&#xD;Spengos, Konstantinos&#xD;Review&#xD;Netherlands&#xD;Curr Top Med Chem. 2013;13(13):1573-88.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>315</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">315</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kozoriz, M. G.</style></author><author><style face="normal" font="default" size="100%">Lai, S.</style></author><author><style face="normal" font="default" size="100%">Vega, J. L.</style></author><author><style face="normal" font="default" size="100%">Saez, J. C.</style></author><author><style face="normal" font="default" size="100%">Sin, W. C.</style></author><author><style face="normal" font="default" size="100%">Bechberger, J. F.</style></author><author><style face="normal" font="default" size="100%">Naus, C. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Cellular and Physiological Sciences, Life Sciences Institute, University of British Columbia, Vancouver, BC, Canada.&#xD;Experimental Physiology Laboratory (EPhyL), Instituto Antofagasta, Antofagasta, Chile; Departamento de Fisiologia, Pontificia Universidad Catolica de Chile, Santiago, Chile.&#xD;Departamento de Fisiologia, Pontificia Universidad Catolica de Chile, Santiago, Chile; Instituto Milenio, Centro Interdiciplinario de Neurociencias de Valparaiso, Valparaiso, Chile.&#xD;Department of Cellular and Physiological Sciences, Life Sciences Institute, University of British Columbia, Vancouver, BC, Canada. Electronic address: cnaus@interchange.ubc.ca.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cerebral ischemic injury is enhanced in a model of oculodentodigital dysplasia</style></title><secondary-title><style face="normal" font="default" size="100%">Neuropharmacology</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuropharmacology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuropharmacology</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuropharmacology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuropharmacology</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuropharmacology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">549-56</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><edition><style face="normal" font="default" size="100%">2013/06/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Infarction/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Death/drug effects/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Connexin 43/antagonists &amp; inhibitors/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Craniofacial Abnormalities/ complications/genetics/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme Inhibitors/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Eye Abnormalities/ complications/genetics/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Foot Deformities, Congenital/ complications/genetics/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Gap Junctions/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Glutamic Acid/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Serine/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Syndactyly/ complications/genetics/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Tooth Abnormalities/ complications/genetics/pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1873-7064 (Electronic)&#xD;0028-3908 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23727526</style></accession-num><abstract><style face="normal" font="default" size="100%">Oculodentodigital dysplasia (ODDD) is a rare autosomal dominant disease that results in visible developmental anomalies of the limbs, face, eyes and teeth. Recently analysis of human connexin43 (Cx43) DNA sequences has revealed a number of different missense, duplication and frame shift mutations resulting in this phenotype. A mouse model of this disorder has been created with a missense point mutation of the glycine amino acid at position 60 to serine (G60S). Heterozygote +/G60S mice exhibit a similar ODDD phenotype as observed in humans. In addition to the malformations listed above, ODDD patients often have neurological findings. In the brain, Cx43 is highly expressed in astrocytes and has been shown to play a role in neuroprotection. We were interested in determining the effect of the +/G60S mutation following stroke. Four days after middle cerebral artery occlusion the volume of infarct was larger in mice with the +/G60S mutation. In astrocyte-neuron co-cultures, exposure to glutamate also resulted in greater cellular death in the +/G60S mutants. Protein levels of Cx43 in the mutant mouse were found to be reduced when compared to the normal tissue. Cx43 protein was observed as a continual line of small punctate aggregates in the plasma membrane with increased intracellular localization, which is distinct from the larger plaques seen in the normal mouse astrocytes. Functionally, primary +/G60S astrocytes exhibited reduced gap junctional coupling and increased hemichannel activity, which may underlie the mechanism of increased damage during stroke. This article is part of the Special Issue Section entitled &apos;Current Pharmacology of Gap Junction Channels and Hemichannels&apos;.</style></abstract><notes><style face="normal" font="default" size="100%">Kozoriz, Michael G&#xD;Lai, Simon&#xD;Vega, Jose L&#xD;Saez, Juan C&#xD;Sin, Wun Chey&#xD;Bechberger, John F&#xD;Naus, Christian C&#xD;Canadian Institutes of Health Research/Canada&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Neuropharmacology. 2013 Dec;75:549-56. doi: 10.1016/j.neuropharm.2013.05.003. Epub 2013 May 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0028390813002128/1-s2.0-S0028390813002128-main.pdf?_tid=ba9d0538-d7be-11e6-b066-00000aab0f6b&amp;acdnat=1484112665_b1a369cc9de50c9c0b818d1f2cc3ba1e</style></url></related-urls><pdf-urls><url>internal-pdf://1308318803/Kozoriz-2013-Cerebral ischemic in.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuropharm.2013.05.003</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>291</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">291</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kramer, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Biochemistry, Biocenter Goethe-Universitat Frankfurt, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Novel drug approaches in development for the treatment of lipid disorders</style></title><secondary-title><style face="normal" font="default" size="100%">Exp Clin Endocrinol Diabetes</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Experimental and clinical endocrinology &amp; diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Exp Clin Endocrinol Diabetes</style></full-title><abbr-1><style face="normal" font="default" size="100%">Experimental and clinical endocrinology &amp; diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Exp Clin Endocrinol Diabetes</style></full-title><abbr-1><style face="normal" font="default" size="100%">Experimental and clinical endocrinology &amp; diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">567-80</style></pages><volume><style face="normal" font="default" size="100%">121</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2013/09/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases/blood/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cholesterol, LDL/ blood</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Discovery</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lipid Metabolism Disorders/blood/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Lipoproteins, HDL/ blood</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1439-3646 (Electronic)&#xD;0947-7349 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24002899</style></accession-num><abstract><style face="normal" font="default" size="100%">Lipid-lowering drug therapy with statins has become a cornerstone to reduce and prevent atherosclerosis and its detrimental complications like cardiovascular diseases and stroke. Due to the multifactorial pathogenesis of atherosclerosis the search for novel lipid-modifying drugs is still one of the most active areas in research and development in the pharmaceutical industry. Currently, the focus lies on novel LDL-cholesterol lowering drugs with a higher efficacy and improved safety profile as well as on approaches to increase plasma levels and functionality of high-density lipoproteins (HDL) based on the inverse relationship between high plasma HDL-levels and the risk for cardiovascular diseases. Whereas the today clinically used lipid-modifying drugs are predominantly small molecules for oral drug therapy a significant percentage of the drug candidates currently in development are biological drugs such as monoclonal antibodies and antisense oligonucleotides. Up-to-date around 70 novel drug molecules acting on about 20 different molecular targets are in clinical and preclinical development with antibodies inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) being the most intensively investigated and competitive approach. The clinical results reported so far with these antibodies are very promising whereas the clinical benefit for prevention of atherosclerosis and cardiovascular diseases by pharmacologically increasing of plasma high-density lipoproteins still remains to be demonstrated. However, with the recent approval of 2 innovative drugs for the treatment of familial hypercholesterolemia and the promising clinical results of several novel drug candidates for LDL cholesterol lowering and high-density lipoprotein modulation one can expect the appearance of new drug breakthroughs for the treatment of dyslipidemia in the near future.</style></abstract><notes><style face="normal" font="default" size="100%">Kramer, W&#xD;Review&#xD;Germany&#xD;Exp Clin Endocrinol Diabetes. 2013 Nov;121(10):567-80. doi: 10.1055/s-0033-1351258. Epub 2013 Sep 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.thieme-connect.de/DOI/DOI?10.1055/s-0033-1351258</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1055/s-0033-1351258</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>61</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">61</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Krey, L.</style></author><author><style face="normal" font="default" size="100%">Luhder, F.</style></author><author><style face="normal" font="default" size="100%">Kusch, K.</style></author><author><style face="normal" font="default" size="100%">Czech-Zechmeister, B.</style></author><author><style face="normal" font="default" size="100%">Konnecke, B.</style></author><author><style face="normal" font="default" size="100%">Fleming Outeiro, T.</style></author><author><style face="normal" font="default" size="100%">Trendelenburg, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, University Medical Center Gottingen, Gottingen, Germany.&#xD;Department of Neuroimmunology, Institute for Multiple Sclerosis Research, University Medical Center Gottingen, Gottingen, Germany.&#xD;Department of Neurogenetics, Max Planck Institute of Experimental Medicine, Gottingen, Germany.&#xD;Center for Nanoscale Microscopy and Molecular Physiology of the Brain, Department of Neurodegeneration and Restorative Research, University Medical Center Gottingen, Gottingen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Knockout of silent information regulator 2 (SIRT2) preserves neurological function after experimental stroke in mice</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">2080-8</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2015/07/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/complications/ genetics/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Count</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Attack, Transient/genetics/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Nervous System Diseases/etiology/ physiopathology/ psychology</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/biosynthesis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Sirtuin 2/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Sirtuins/biosynthesis</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/complications/ genetics/ pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26219598</style></accession-num><abstract><style face="normal" font="default" size="100%">Sirtuin-2 (Sirt2) is a member of the NAD(+)-dependent protein deacetylase family. Various members of the sirtuin class have been found to be involved in processes related to longevity, regulation of inflammation, and neuroprotection. Induction of Sirt2 mRNA was found in the whole hemisphere after experimental stroke in a recent screening approach. Moreover, Sirt2 protein is highly expressed in myelin-rich brain regions after stroke. To examine the effects of Sirt2 on ischemic stroke, we induced transient focal cerebral ischemia in adult male Sirt2-knockout and wild-type mice. Two stroke models with different occlusion times were applied: a severe ischemia (45 minutes of middle cerebral artery occlusion (MCAO)) and a mild one (15 minutes of MCAO), which was used to focus on subcortical infarcts. Neurological deficit was determined at 48 hours after 45 minutes of MCAO, and up to 7 days after induction of 15 minutes of cerebral ischemia. In contrast to recent data on Sirt1, Sirt2(-/-) mice showed less neurological deficits in both models of experimental stroke, with the strongest manifestation after 48 hours of reperfusion. However, we did not observe a significant difference of stroke volumes or inflammatory cell count between Sirt2-deficient and wild-type mice. Thus we postulate that Sirt2 mediates myelin-dependent neuronal dysfunction during the early phase after ischemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Krey, Lea&#xD;Luhder, Fred&#xD;Kusch, Kathrin&#xD;Czech-Zechmeister, Bozena&#xD;Konnecke, Birte&#xD;Fleming Outeiro, Tiago&#xD;Trendelenburg, George&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Cereb Blood Flow Metab. 2015 Dec;35(12):2080-8. doi: 10.1038/jcbfm.2015.178. Epub 2015 Jul 29.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4671131</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2015.178</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>115</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">115</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Krishna, S. M.</style></author><author><style face="normal" font="default" size="100%">Trollope, A. F.</style></author><author><style face="normal" font="default" size="100%">Golledge, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">*Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, QLD, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The relevance of epigenetics to occlusive cerebral and peripheral arterial disease</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Sci (Lond)</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Clinical science (London, England : 1979)</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Sci (Lond)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Clinical science (London, England : 1979)</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Clin Sci (Lond)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Clinical science (London, England : 1979)</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">537-58</style></pages><volume><style face="normal" font="default" size="100%">128</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2015/02/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Chromatin Assembly and Disassembly</style></keyword><keyword><style face="normal" font="default" size="100%">DNA Methylation</style></keyword><keyword><style face="normal" font="default" size="100%">Epigenesis, Genetic/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Hemodynamics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Arteriosclerosis/drug therapy/ genetics/metabolism/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">MicroRNAs/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Peripheral Arterial Disease/drug therapy/ genetics/metabolism/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1470-8736 (Electronic)&#xD;0143-5221 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25671777</style></accession-num><abstract><style face="normal" font="default" size="100%">Athero-thrombosis of the arteries supplying the brain and lower limb are the main causes of stroke and limb loss. New therapies are needed to improve the outcomes of athero-thrombosis. Recent evidence suggests a role for epigenetic changes in the development and progression of ischaemic injury due to atherosclerotic occlusion of peripheral arteries. DNA hypermethylation have been associated with cardiovascular diseases. Histone post-translational modifications have also been implicated in atherosclerosis. Oxidized low-density lipoprotein regulated pro-inflammatory gene expression within endothelial cells is controlled by phosphorylation/acetylation of histone H3 and acetylation of histone H4 for example. There are a number of challenges in translating the growing evidence implicating epigenetics in atherosclerosis to improved therapies for patients. These include the small therapeutic window in conditions such as acute stroke and critical limb ischaemia, since interventions introduced in such patients need to act rapidly and be safe in elderly patients with many co-morbidities. Pre-clinical animal experiments have also reported conflicting effects of some novel epigenetic drugs, which suggest that further in-depth studies are required to better understand their efficacy in resolving ischaemic injury. Effective ways of dealing with these challenges are needed before epigenetic approaches to therapy can be introduced into practice.</style></abstract><notes><style face="normal" font="default" size="100%">Krishna, Smriti Murali&#xD;Trollope, Alexandra Fay&#xD;Golledge, Jonathan&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;England&#xD;Clin Sci (Lond). 2015 May;128(9):537-58. doi: 10.1042/CS20140491.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.clinsci.org/content/ppclinsci/128/9/537.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1670093654/Krishna-2015-The relevance of epi.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1042/cs20140491</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>372</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">372</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ku, T.</style></author><author><style face="normal" font="default" size="100%">Choi, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Graduate School of Medical Science and Engineering, KAIST, Daejeon, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Noninvasive optical measurement of cerebral blood flow in mice using molecular dynamics analysis of indocyanine green</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PloS one</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e48383</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2012/11/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/diagnosis/metabolism/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Indocyanine Green/chemistry/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred ICR</style></keyword><keyword><style face="normal" font="default" size="100%">Optical Imaging/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Spectrometry, Fluorescence</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203 (Electronic)&#xD;1932-6203 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23119000</style></accession-num><abstract><style face="normal" font="default" size="100%">In preclinical studies of ischemic brain disorders, it is crucial to measure cerebral blood flow (CBF); however, this requires radiological techniques with heavy instrumentation or invasive procedures. Here, we propose a noninvasive and easy-to-use optical imaging technique for measuring CBF in experimental small animals. Mice were injected with indocyanine green (ICG) via tail-vein catheterization. Time-series near-infrared fluorescence signals excited by 760 nm light-emitting diodes were imaged overhead by a charge-coupled device coupled with an 830 nm bandpass-filter. We calculated four CBF parameters including arrival time, rising time and mean transit time of a bolus and blood flow index based on time and intensity information of ICG fluorescence dynamics. CBF maps were generated using the parameters to estimate the status of CBF, and they dominantly represented intracerebral blood flows in mice even in the presence of an intact skull and scalp. We demonstrated that this noninvasive optical imaging technique successfully detected reduced local CBF during middle cerebral artery occlusion. We further showed that the proposed method is sufficiently sensitive to detect the differences between CBF status in mice anesthetized with either isoflurane or ketamine-xylazine, and monitor the dynamic changes in CBF after reperfusion during transient middle cerebral artery occlusion. The near-infrared optical imaging of ICG fluorescence combined with a time-series analysis of the molecular dynamics can be a useful noninvasive tool for preclinical studies of brain ischemia.</style></abstract><notes><style face="normal" font="default" size="100%">Ku, Taeyun&#xD;Choi, Chulhee&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;PLoS One. 2012;7(10):e48383. doi: 10.1371/journal.pone.0048383. Epub 2012 Oct 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0048383&amp;type=printable</style></url></related-urls><pdf-urls><url>internal-pdf://1633207150/Ku-2012-Noninvasive optical.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3485229</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0048383</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>336</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">336</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kull, F. J.</style></author><author><style face="normal" font="default" size="100%">Endow, S. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chemistry, Dartmouth College, Hanover, NH 03755, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Force generation by kinesin and myosin cytoskeletal motor proteins</style></title><secondary-title><style face="normal" font="default" size="100%">J Cell Sci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cell science</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cell Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cell science</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cell Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cell science</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">9-19</style></pages><volume><style face="normal" font="default" size="100%">126</style></volume><number><style face="normal" font="default" size="100%">Pt 1</style></number><edition><style face="normal" font="default" size="100%">2013/03/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adenosine Triphosphate/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Biomechanical Phenomena</style></keyword><keyword><style face="normal" font="default" size="100%">Cytoskeletal Proteins/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Kinesin/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Biological</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Motor Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Myosins/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 01</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1477-9137 (Electronic)&#xD;0021-9533 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23487037</style></accession-num><abstract><style face="normal" font="default" size="100%">Kinesins and myosins hydrolyze ATP, producing force that drives spindle assembly, vesicle transport and muscle contraction. How do motors do this? Here we discuss mechanisms of motor force transduction, based on their mechanochemical cycles and conformational changes observed in crystal structures. Distortion or twisting of the central beta-sheet - proposed to trigger actin-induced Pi and ADP release by myosin, and microtubule-induced ADP release by kinesins - is shown in a movie depicting the transition between myosin ATP-like and nucleotide-free states. Structural changes in the switch I region form a tube that governs ATP hydrolysis and Pi release by the motors, explaining the essential role of switch I in hydrolysis. Comparison of the motor power strokes reveals that each stroke begins with the force-amplifying structure oriented opposite to the direction of rotation or swing. Motors undergo changes in their mechanochemical cycles in response to small-molecule inhibitors, several of which bind to kinesins by induced fit, trapping the motors in a state that resembles a force-producing conformation. An unusual motor activator specifically increases mechanical output by cardiac myosin, potentially providing valuable information about its mechanism of function. Further study is essential to understand motor mechanochemical coupling and energy transduction, and could lead to new therapies to treat human disease.</style></abstract><notes><style face="normal" font="default" size="100%">Kull, F Jon&#xD;Endow, Sharyn A&#xD;R01 GM046225/GM/NIGMS NIH HHS/United States&#xD;R01 GM097079/GM/NIGMS NIH HHS/United States&#xD;GM046225/GM/NIGMS NIH HHS/United States&#xD;GM097079/GM/NIGMS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;England&#xD;J Cell Sci. 2013 Jan 1;126(Pt 1):9-19. doi: 10.1242/jcs.103911. Epub 2013 Mar 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://jcs.biologists.org/content/joces/126/1/9.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3321521590/Kull-2013-Force generation by.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3603507</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1242/jcs.103911</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>299</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">299</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuroiwa, T.</style></author><author><style face="normal" font="default" size="100%">Xi, G.</style></author><author><style face="normal" font="default" size="100%">Hua, Y.</style></author><author><style face="normal" font="default" size="100%">Nagaraja, T. N.</style></author><author><style face="normal" font="default" size="100%">Fenstermacher, J. D.</style></author><author><style face="normal" font="default" size="100%">Keep, R. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Namegata District General Hospital, Namegata, Ibaraki, Japan. tkuroiwa-nsu@umin.ac.jp</style></auth-address><titles><title><style face="normal" font="default" size="100%">Brain edema and blood-brain barrier opening after photothrombotic ischemia in rat</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Neurochir Suppl</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Acta neurochirurgica. Supplement</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Neurochir Suppl</style></full-title><abbr-1><style face="normal" font="default" size="100%">Acta neurochirurgica. Supplement</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Acta Neurochir Suppl</style></full-title><abbr-1><style face="normal" font="default" size="100%">Acta neurochirurgica. Supplement</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">11-5</style></pages><volume><style face="normal" font="default" size="100%">118</style></volume><edition><style face="normal" font="default" size="100%">2013/07/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/pathology/ physiopathology/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/ etiology/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ complications/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Evans Blue</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Thrombosis/complications/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Rose Bengal</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">0065-1419 (Print)&#xD;0065-1419 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23564097</style></accession-num><abstract><style face="normal" font="default" size="100%">We have examined the time course of brain edema and the blood-brain barrier opening in rat after basal ganglia ischemia induced by photothrombotic occlusion of the small vessels within the caudate-putamen. Male SD rats were anesthetized, and Rose Bengal dye was intravenously injected. The left caudo-putamen was exposed to cold white light for 5-10 min via a stereotaxically implanted optic fiber. Ischemic brain edema and the blood-brain barrier, as well as the histological changes, were assessed at various times during the following 6 weeks. Local cerebral blood flow was measured 90 min after photothrombosis by quantitative autoradiography. A round infarct with thrombosed parenchymal vessels surrounded by a layer of selective neuronal death was formed within the caudo-putamen. The ischemic lesion turned into a lacune over a period of 6 weeks. A central zone of markedly reduced blood flow and a surrounding oligemic zone were observed 90 min after light exposure. Early blood-brain barrier opening with edema was observed as early as 4 h after photothrombosis, peaked at day 1, and disappeared at 7 days after photothrombosis. In a model of lacunar infarction, we observed an early and transient brain edema and blood-brain opening after onset of ischemia.</style></abstract><notes><style face="normal" font="default" size="100%">Kuroiwa, Toshihiko&#xD;Xi, Guohua&#xD;Hua, Ya&#xD;Nagaraja, Tavarekere N&#xD;Fenstermacher, Joseph D&#xD;Keep, Richard F&#xD;Austria&#xD;Acta Neurochir Suppl. 2013;118:11-5. doi: 10.1007/978-3-7091-1434-6_2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/941/chp%253A10.1007%252F978-3-7091-1434-6_2.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Fchapter%2F10.1007%2F978-3-7091-1434-6_2&amp;token2=exp=1484113705~acl=%2Fstatic%2Fpdf%2F941%2Fchp%25253A10.1007%25252F978-3-7091-1434-6_2.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Fchapter%252F10.1007%252F978-3-7091-1434-6_2*~hmac=5d4507aeecb862693eb28394d97aed897da7176410c0c61e307598176f7a9037</style></url></related-urls><pdf-urls><url>internal-pdf://0750625399/Kuroiwa-2013-Brain edema and bloo.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/978-3-7091-1434-6_2</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>75</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">75</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuzenkov, V. S.</style></author><author><style face="normal" font="default" size="100%">Krushinskii, A. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Biological Faculty, M. V. Lomonosov Moscow State University, Moscow, Russia, kouzenkov@mail.ru.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of Sodium Nitrite and L-NNA on the Outcome of Experimental Ischemic Stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Bull Exp Biol Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Bulletin of experimental biology and medicine</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bull Exp Biol Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Bulletin of experimental biology and medicine</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Bull Exp Biol Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Bulletin of experimental biology and medicine</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">217-20</style></pages><volume><style face="normal" font="default" size="100%">159</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2015/06/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Arteries/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Evaluation, Preclinical</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide Synthase/antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Nitroarginine/adverse effects/ pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Nitrite/administration &amp; dosage/ pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Statistics, Nonparametric</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1573-8221 (Electronic)&#xD;0007-4888 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26085355</style></accession-num><abstract><style face="normal" font="default" size="100%">We studied the effect of sodium nitrite in doses of 5 and 50 mg/kg and NO synthase inhibitor L-NNA in a dose of 20 mg/kg on the course of experimental ischemic stroke caused by occlusion of both carotid arteries. Sodium nitrite and NO synthase inhibitor were administered 1 h prior to occlusion of small ie, Cyrillicsmall er, Cyrillicsmall u, Cyrillic carotid arteries and 5 sec after brain ischemia. Sodium nitrite in a dose of 5 mg/kg had a protective effect on the time course of neurological disorders and reduced animal mortality. NO synthase inhibitor L-NNA aggravated the neurological symptoms.</style></abstract><notes><style face="normal" font="default" size="100%">Kuzenkov, V S&#xD;Krushinskii, A L&#xD;United States&#xD;Bull Exp Biol Med. 2015 Jun;159(2):217-20. doi: 10.1007/s10517-015-2926-5. Epub 2015 Jun 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/257/art%253A10.1007%252Fs10517-015-2926-5.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs10517-015-2926-5&amp;token2=exp=1484113708~acl=%2Fstatic%2Fpdf%2F257%2Fart%25253A10.1007%25252Fs10517-015-2926-5.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs10517-015-2926-5*~hmac=836eed674cc77c6cd1bc8fe5aca9dd7af4d3dd98bb50578bd53ed8025f65632c</style></url></related-urls><pdf-urls><url>internal-pdf://1586278055/Kuzenkov-2015-Effect of Sodium Nit.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s10517-015-2926-5</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>310</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">310</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Labat-gest, V.</style></author><author><style face="normal" font="default" size="100%">Tomasi, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neuroscience, University of Turin. vivien.labatgest@unito.it</style></auth-address><titles><title><style face="normal" font="default" size="100%">Photothrombotic ischemia: a minimally invasive and reproducible photochemical cortical lesion model for mouse stroke studies</style></title><secondary-title><style face="normal" font="default" size="100%">J Vis Exp</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of visualized experiments : JoVE</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Vis Exp</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of visualized experiments : JoVE</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Vis Exp</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of visualized experiments : JoVE</style></abbr-1></alt-periodical><number><style face="normal" font="default" size="100%">76</style></number><edition><style face="normal" font="default" size="100%">2013/06/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/blood/ etiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Thrombosis/blood/ etiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Neuronal Plasticity/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Photochemical Processes</style></keyword><keyword><style face="normal" font="default" size="100%">Rose Bengal/administration &amp; dosage/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/blood/ etiology/pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 09</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1940-087X (Electronic)&#xD;1940-087X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23770844</style></accession-num><abstract><style face="normal" font="default" size="100%">The photothrombotic stroke model aims to induce an ischemic damage within a given cortical area by means of photo-activation of a previously injected light-sensitive dye. Following illumination, the dye is activated and produces singlet oxygen that damages components of endothelial cell membranes, with subsequent platelet aggregation and thrombi formation, which eventually determines the interruption of local blood flow. This approach, initially proposed by Rosenblum and El-Sabban in 1977, was later improved by Watson in 1985 in rat brain and set the basis of the current model. Also, the increased availability of transgenic mouse lines further contributed to raise the interest on the photothrombosis model. Briefly, a photosensitive dye (Rose Bengal) is injected intraperitoneally and enters the blood stream. When illuminated by a cold light source, the dye becomes activated and induces endothelial damage with platelet activation and thrombosis, resulting in local blood flow interruption. The light source can be applied on the intact skull with no need of craniotomy, which allows targeting of any cortical area of interest in a reproducible and non-invasive way. The mouse is then sutured and allowed to wake up. The evaluation of ischemic damage can be quickly accomplished by triphenyl-tetrazolium chloride or cresyl violet staining. This technique produces infarction of small size and well-delimited boundaries, which is highly advantageous for precise cell characterization or functional studies. Furthermore, it is particularly suitable for studying cellular and molecular responses underlying brain plasticity in transgenic mice.</style></abstract><notes><style face="normal" font="default" size="100%">Labat-gest, Vivien&#xD;Tomasi, Simone&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Video-Audio Media&#xD;United States&#xD;J Vis Exp. 2013 Jun 9;(76). doi: 10.3791/50370.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.jove.com/pdf/50370/jove-protocol-50370-photothrombotic-ischemia-minimally-invasive-reproducible</style></url></related-urls><pdf-urls><url>internal-pdf://1790557760/Labat-gest-2013-Photothrombotic isch.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3727176</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3791/50370</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>245</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">245</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Laloux, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, CHU Mont-Godinne, Institute of Neurosciences, Avenue Therasse 1, B- 5530 Yvoir, Belgium. patrice.laloux@uclouvain.be.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Risk and benefit of statins in stroke secondary prevention</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Vasc Pharmacol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Current vascular pharmacology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Vasc Pharmacol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current vascular pharmacology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Curr Vasc Pharmacol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current vascular pharmacology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">812-6</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2014/02/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/blood/chemically induced</style></keyword><keyword><style face="normal" font="default" size="100%">Cholesterol, LDL/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic/methods/trends</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hydroxymethylglutaryl-CoA Reductase Inhibitors/ administration &amp; dosage/ adverse</style></keyword><keyword><style face="normal" font="default" size="100%">effects</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Secondary Prevention/methods/ trends</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/blood/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1875-6212 (Electronic)&#xD;1570-1611 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24484462</style></accession-num><abstract><style face="normal" font="default" size="100%">Statin is now recommended in secondary prevention after stroke or transient ischemic attacks to reduce the risk of a new stroke or major cardiovascular events. However, some issues about the extent of the benefit in some stroke patients and the risk of cerebral hemorrhage remain debated. This review shows that statins are significantly effective in decreasing the risk of further strokes despite an increase in the risk of brain hemorrhage. A significant benefit was observed in men and women, in aged patients and possibly to a greater extent in patients with carotid artery stenosis. Intensive statin therapy lowering the LDL-cholesterol beyond the cut-off value of 1.8 mmol/L (70 mg/dl) seems to be more effective than less intensive treatment and without an increased risk of side effects. Overall, statins are well tolerated. Further prospective studies should clarify whether the effect is of the same magnitude in small vessel disease and how to select the patients to reduce the risk of cerebral hemorrhage.</style></abstract><notes><style face="normal" font="default" size="100%">Laloux, Patrice&#xD;Review&#xD;United Arab Emirates&#xD;Curr Vasc Pharmacol. 2013 Nov;11(6):812-6.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>128</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">128</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lan, L. F.</style></author><author><style face="normal" font="default" size="100%">Zheng, L.</style></author><author><style face="normal" font="default" size="100%">Yang, X.</style></author><author><style face="normal" font="default" size="100%">Ji, X. T.</style></author><author><style face="normal" font="default" size="100%">Fan, Y. H.</style></author><author><style face="normal" font="default" size="100%">Zeng, J. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Peroxisome proliferator-activated receptor-gamma agonist pioglitazone ameliorates white matter lesion and cognitive impairment in hypertensive rats</style></title><secondary-title><style face="normal" font="default" size="100%">CNS Neurosci Ther</style></secondary-title><alt-title><style face="normal" font="default" size="100%">CNS neuroscience &amp; therapeutics</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">CNS Neurosci Ther</style></full-title><abbr-1><style face="normal" font="default" size="100%">CNS neuroscience &amp; therapeutics</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">CNS Neurosci Ther</style></full-title><abbr-1><style face="normal" font="default" size="100%">CNS neuroscience &amp; therapeutics</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">410-6</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2015/01/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ drug effects/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition Disorders/ drug therapy/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Maze Learning/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroimmunomodulation/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Nootropic Agents/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">PPAR gamma/agonists/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Thiazolidinediones/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">White Matter/ drug effects/metabolism/pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1755-5949 (Electronic)&#xD;1755-5930 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25611692</style></accession-num><abstract><style face="normal" font="default" size="100%">AIMS: Cerebrovascular white matter lesion (WML) is a major subtype of cerebral small vessel disease. Clinical drugs are not available for WML. We investigated whether peroxisome proliferator-activated receptor-gamma agonist pioglitazone, with properties of vascular protection and antiinflammation, exerts beneficial effect in hypertensive WML rats. METHODS: Stroke-prone renovascular hypertensive rats (RHRSP) were treated with pioglitazone for 12 weeks. Morris water maze experiment was conducted to assess cognition. WML was observed by Luxol fast blue staining. Smooth muscle actin-alpha, collagen I, collagen IV, glial fibrillary acidic protein, and ionized calcium-binding adaptor molecule-1 were evaluated by immunohistochemistry. Interleukin-1 beta (IL-1beta) and tumor necrosis factor alpha (TNF-alpha) in brain and soluble intercellular adhesion molecule-1 (sICAM-1) in serum were detected. RESULTS: Pioglitazone significantly attenuated WML in corpus callosum, caudate putamen, external capsule, and internal capsule. Cognitive impairment in RHRSP was ameliorated by pioglitazone. Pioglitazone attenuated arteriolar remodeling and reduced sICAM-1 level in serum. Pioglitazone decreased the proliferation of microglia and astrocyte and lowered the expression of proinflammatory cytokines IL-1beta and TNF-alpha in the white matter. CONCLUSIONS: Long-term treatment of pioglitazone has beneficial effect on hypertension-induced WML and cognition decline, which may partly through its effect on attenuation of arteriolar remodeling, endothelial activation, and brain inflammation.</style></abstract><notes><style face="normal" font="default" size="100%">Lan, Lin-Fang&#xD;Zheng, Lu&#xD;Yang, Xian&#xD;Ji, Xiao-Tan&#xD;Fan, Yu-Hua&#xD;Zeng, Jin-Sheng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;CNS Neurosci Ther. 2015 May;21(5):410-6. doi: 10.1111/cns.12374. Epub 2015 Jan 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/cns.12374/asset/cns12374.pdf?v=1&amp;t=ixsi9tbc&amp;s=f5171a1fd58e711d210c5720f1806dab7003d2f3</style></url></related-urls><pdf-urls><url>internal-pdf://0512744305/Lan-2015-Peroxisome prolifera.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/cns.12374</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>337</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">337</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leak, R. K.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Stetler, R. A.</style></author><author><style face="normal" font="default" size="100%">Weng, Z.</style></author><author><style face="normal" font="default" size="100%">Li, P.</style></author><author><style face="normal" font="default" size="100%">Atkins, G. B.</style></author><author><style face="normal" font="default" size="100%">Gao, Y.</style></author><author><style face="normal" font="default" size="100%">Chen, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, S507 Biomedical Science Tower, University of Pittsburgh, Pittsburgh PA 15213, USA. chenj2@upmc.edu;yqgao@shmu.edu.cn.</style></auth-address><titles><title><style face="normal" font="default" size="100%">HSP27 protects the blood-brain barrier against ischemia-induced loss of integrity</style></title><secondary-title><style face="normal" font="default" size="100%">CNS Neurol Disord Drug Targets</style></secondary-title><alt-title><style face="normal" font="default" size="100%">CNS &amp; neurological disorders drug targets</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">CNS Neurol Disord Drug Targets</style></full-title><abbr-1><style face="normal" font="default" size="100%">CNS &amp; neurological disorders drug targets</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">CNS Neurol Disord Drug Targets</style></full-title><abbr-1><style face="normal" font="default" size="100%">CNS &amp; neurological disorders drug targets</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">325-37</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2013/03/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/genetics/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Survival/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/secretion</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelial Cells/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">HSP27 Heat-Shock Proteins/genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Cell Culture</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation/physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">May 01</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1996-3181 (Electronic)&#xD;1871-5273 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23469858</style></accession-num><abstract><style face="normal" font="default" size="100%">Loss of integrity of the blood-brain barrier (BBB) in stroke victims initiates a devastating cascade of events including extravasation of blood-borne molecules, water, and inflammatory cells deep into brain parenchyma. Thus, it is important to identify mechanisms by which BBB integrity can be maintained in the face of ischemic injury in experimental stroke. We previously demonstrated that the phylogenetically conserved small heat shock protein 27 (HSP27) protects against transient middle cerebral artery occlusion (tMCAO). Here we show that HSP27 transgenic overexpression also maintains the integrity of the BBB in mice subjected to tMCAO. Extravasation of endogenous IgG antibodies and exogenous FITC-albumin into the brain following tMCAO was reduced in transgenic mice, as was total brain water content. HSP27 overexpression abolished the appearance of TUNEL-positive profiles in microvessel walls. Transgenics also exhibited less loss of microvessel proteins following tMCAO. Notably, primary endothelial cell cultures were rescued from oxygen-glucose deprivation (OGD) by lentiviral HSP27 overexpression according to four viability assays, supporting a direct effect on this cell type. Finally, HSP27 overexpression reduced the appearance of neutrophils in the brain and inhibited the secretion of five cytokines. These findings reveal a novel role for HSP27 in attenuating ischemia/reperfusion injury - the maintenance of BBB integrity. Endogenous upregulation of HSP27 after ischemia in wild-type animals may exert similar protective functions and warrants further investigation. Exogenous enhancement of HSP27 by rational drug design may lead to future therapies against a host of injuries, including but not limited to a harmful breach in brain vasculature.</style></abstract><notes><style face="normal" font="default" size="100%">Leak, Rehana K&#xD;Zhang, Lili&#xD;Stetler, R Anne&#xD;Weng, Zhongfang&#xD;Li, Peiying&#xD;Atkins, G Brandon&#xD;Gao, Yanqin&#xD;Chen, Jun&#xD;NS036736/NS/NINDS NIH HHS/United States&#xD;NS056118./NS/NINDS NIH HHS/United States&#xD;NS043802/NS/NINDS NIH HHS/United States&#xD;R01 NS056118/NS/NINDS NIH HHS/United States&#xD;R01 NS043802/NS/NINDS NIH HHS/United States&#xD;NS045048/NS/NINDS NIH HHS/United States&#xD;R01 NS036736/NS/NINDS NIH HHS/United States&#xD;R01 NS045048/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United Arab Emirates&#xD;CNS Neurol Disord Drug Targets. 2013 May 1;12(3):325-37.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4061290</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms594280</style></custom6><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>462</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">462</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, J. H.</style></author><author><style face="normal" font="default" size="100%">Bacskai, B. J.</style></author><author><style face="normal" font="default" size="100%">Ayata, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Radiology, Neurovascular Research Laboratory, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Genetic animal models of cerebral vasculopathies</style></title><secondary-title><style face="normal" font="default" size="100%">Prog Mol Biol Transl Sci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Progress in molecular biology and translational science</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Prog Mol Biol Transl Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Progress in molecular biology and translational science</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Prog Mol Biol Transl Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Progress in molecular biology and translational science</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">25-55</style></pages><volume><style face="normal" font="default" size="100%">105</style></volume><edition><style face="normal" font="default" size="100%">2011/12/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Animals, Genetically Modified</style></keyword><keyword><style face="normal" font="default" size="100%">CADASIL/genetics/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Amyloid Angiopathy/genetics/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Disorders/ genetics/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Genetic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1878-0814 (Electronic)&#xD;1877-1173 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22137428</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebral amyloid angiopathy (CAA) and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) are genetic cerebrovasculopathies associated with neurodegeneration and vascular cognitive impairment. Linked to autosomal dominant mutations in diverse genes that encode cell-surface receptors (i.e., amyloid precursor protein in CAA and NOTCH3 in CADASIL), both diseases are associated with accumulation of abnormal material around cerebral vessels, such as amyloid in CAA or granular osmiophilic material in CADASIL. Both CAA and CADASIL share clinical features of white matter degeneration and infarcts, and vascular dementia in the human adult; microbleeds occur in both CADASIL and CAA, but large intracerebral hemorrhages are more characteristic for the latter. While the mechanisms are poorly understood, wall thickening, luminal narrowing, and eventual loss of vascular smooth muscle cells are overlapping pathologies involving leptomeningeal, and pial or penetrating small arteries and arterioles in CAA and CADASIL. Dysregulation of cerebral blood flow and eventual hypoperfusion are believed to be the key pathophysiological steps in neurodegeneration and cognitive impairment. Although animal models expressing CAA or CADASIL mutations have partially reproduced the human pathology, there has been marked heterogeneity in the phenotypic spectrum, possibly due to genetic background differences among mouse models, and obvious species differences between mouse and man. Here, we provide an overview of animal models of CAA and CADASIL and the insight on molecular and physiological mechanisms of disease gained from these models.</style></abstract><notes><style face="normal" font="default" size="100%">Lee, Jeong Hyun&#xD;Bacskai, Brian J&#xD;Ayata, Cenk&#xD;NS061505/NS/NINDS NIH HHS/United States&#xD;R01 EB000768/EB/NIBIB NIH HHS/United States&#xD;AG021084/AG/NIA NIH HHS/United States&#xD;R01 NS061505/NS/NINDS NIH HHS/United States&#xD;NS055104/NS/NINDS NIH HHS/United States&#xD;UL1 RR025758/RR/NCRR NIH HHS/United States&#xD;UL1 RR 025758/RR/NCRR NIH HHS/United States&#xD;P01 NS055104/NS/NINDS NIH HHS/United States&#xD;R01 AG021084/AG/NIA NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Netherlands&#xD;Prog Mol Biol Transl Sci. 2012;105:25-55. doi: 10.1016/B978-0-12-394596-9.00002-0.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.sciencedirect.com/science/article/pii/B9780123945969000020</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3910291</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms509853</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/b978-0-12-394596-9.00002-0</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>285</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">285</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, K. H.</style></author><author><style face="normal" font="default" size="100%">Kim, J. H.</style></author><author><style face="normal" font="default" size="100%">Choi, D. H.</style></author><author><style face="normal" font="default" size="100%">Lee, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Neuroscience Research, SMART Institute of Advanced Biomedical Science, Konkuk University, Seoul, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of task-specific training on functional recovery and corticospinal tract plasticity after stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Restor Neurol Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Restorative neurology and neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Restor Neurol Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Restorative neurology and neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Restor Neurol Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Restorative neurology and neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">773-85</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2013/09/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Biotin/analogs &amp; derivatives</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/physiopathology/rehabilitation</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/rehabilitation</style></keyword><keyword><style face="normal" font="default" size="100%">Corpus Callosum/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Dextrans</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorescent Dyes</style></keyword><keyword><style face="normal" font="default" size="100%">Immunohistochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Thrombosis/complications/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Motor Cortex/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Regeneration</style></keyword><keyword><style face="normal" font="default" size="100%">Neuronal Plasticity/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Postural Balance/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Psychomotor Performance/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Pyramidal Tracts/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery of Function/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Somatosensory Cortex/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke Rehabilitation</style></keyword><keyword><style face="normal" font="default" size="100%">Video Recording</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">1878-3627 (Electronic)&#xD;0922-6028 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24056148</style></accession-num><abstract><style face="normal" font="default" size="100%">PURPOSE: To determine the optimal timing of rehabilitation and its role in corticospinal tract (CST) plasticity after stroke. METHODS: Rats were subjected to photothrombotic infarct. The large stroke (LS) and small stroke (SS) groups were subdivided and task-specific training (TST) was initiated at 1, 5, or 14 days poststroke. Behavioral tests were performed at 2, 7, 14, 21, 28, and 35 days poststroke. The differences of axonal sprouting in the cortex, red nucleus, cerebral peduncle, and pyramid level were compared by immunohistochemistry. RESULTS: SS groups with TST starting at 1 day and 5 days showed significantly better recovery in the behavioral tests. LS group with TST starting at 5 days showed better recovery, while those with TST starting at 1 day showed worse recovery. Contralesional axonal sprouting was increased in both groups with TST starting at 5 days. However, it was decreased in the LS group with TST starting at 1 day. Transcallosal axonal sprouting from the contralesional motor cortex was increased in the LS group with TST starting at 5 days. CONCLUSIONS: Functional recovery after stroke may vary, depending on the lesion size and the timing of rehabilitation. The underlying mechanism may involve contralesional CST plasticity and transcallosal axonal sprouting.</style></abstract><notes><style face="normal" font="default" size="100%">Lee, Kyoung-Hee&#xD;Kim, Ji-Hye&#xD;Choi, Dong-Hee&#xD;Lee, Jongmin&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;Restor Neurol Neurosci. 2013;31(6):773-85. doi: 10.3233/RNN-130336.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://content.iospress.com/articles/restorative-neurology-and-neuroscience/rnn130336</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3233/rnn-130336</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>296</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">296</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, O. H.</style></author><author><style face="normal" font="default" size="100%">Kim, J.</style></author><author><style face="normal" font="default" size="100%">Kim, J. M.</style></author><author><style face="normal" font="default" size="100%">Lee, H.</style></author><author><style face="normal" font="default" size="100%">Kim, E. H.</style></author><author><style face="normal" font="default" size="100%">Bae, S. K.</style></author><author><style face="normal" font="default" size="100%">Choi, Y.</style></author><author><style face="normal" font="default" size="100%">Nam, H. S.</style></author><author><style face="normal" font="default" size="100%">Heo, J. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Severance Integrative Research Institute for Cerebral and Cardiovascular Diseases, Yonsei University Health System, Seoul 120-752, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Decreased expression of sirtuin 6 is associated with release of high mobility group box-1 after cerebral ischemia</style></title><secondary-title><style face="normal" font="default" size="100%">Biochem Biophys Res Commun</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Biochemical and biophysical research communications</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Biochem Biophys Res Commun</style></full-title><abbr-1><style face="normal" font="default" size="100%">Biochemical and biophysical research communications</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Biochem Biophys Res Commun</style></full-title><abbr-1><style face="normal" font="default" size="100%">Biochemical and biophysical research communications</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">388-94</style></pages><volume><style face="normal" font="default" size="100%">438</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2013/08/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/cytology/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Death</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Line, Tumor</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">HEK293 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">HMGB1 Protein/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Cerebral Artery/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">Sirtuins/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 23</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1090-2104 (Electronic)&#xD;0006-291X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23899523</style></accession-num><abstract><style face="normal" font="default" size="100%">Sirtuin 6 (SIRT6) belongs to the sirtuin family of NAD(+)-dependent deacetylases and has been implicated in the regulation of metabolism, inflammation, and aging. Here, we found that SIRT6 was predominantly expressed in neuronal cells throughout the entire brain. Ischemia models using transient middle cerebral artery occlusion in rats and oxygen/glucose deprivation (OGD) in SH-SY5Y neuronal cells showed that ischemia reduced SIRT6 expression and induced the release of high mobility group box-1 (HMGB1) from cell nuclei. The reduced expression of SIRT6 via treatment with SIRT6 siRNA dramatically enhanced the OGD-induced release of HMGB1 in SH-SY5Y cells. Together, our data suggest that SIRT6 may serve as a potential therapeutic target for HMGB1-mediated inflammation after cerebral ischemia.</style></abstract><notes><style face="normal" font="default" size="100%">Lee, Ok-Hee&#xD;Kim, Jayoung&#xD;Kim, Jin-Moo&#xD;Lee, Hyunji&#xD;Kim, Eun Hee&#xD;Bae, Soo-Kyung&#xD;Choi, Youngsok&#xD;Nam, Hyo Suk&#xD;Heo, Ji Hoe&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Biochem Biophys Res Commun. 2013 Aug 23;438(2):388-94. doi: 10.1016/j.bbrc.2013.07.085. Epub 2013 Jul 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0006291X13012473/1-s2.0-S0006291X13012473-main.pdf?_tid=d6ea00ce-d7be-11e6-aa58-00000aacb35d&amp;acdnat=1484112713_dc0a6108a88b02f9d3d19423fc2f88cf</style></url></related-urls><pdf-urls><url>internal-pdf://2039616884/Lee-2013-Decreased expression.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.bbrc.2013.07.085</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>187</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">187</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lei, B.</style></author><author><style face="normal" font="default" size="100%">Sheng, H.</style></author><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Lascola, C. D.</style></author><author><style face="normal" font="default" size="100%">Warner, D. S.</style></author><author><style face="normal" font="default" size="100%">Laskowitz, D. T.</style></author><author><style face="normal" font="default" size="100%">James, M. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Multidisciplinary Neuroprotection Laboratories, Department of Anesthesiology, Duke University.&#xD;Department of Neurology, Duke University.&#xD;Department of Radiology, Duke University.&#xD;Multidisciplinary Neuroprotection Laboratories, Department of Anesthesiology, Duke University; Department of Neurobiology, Duke University.&#xD;Multidisciplinary Neuroprotection Laboratories, Department of Anesthesiology, Duke University; Department of Neurology, Duke University; Department of Neurobiology, Duke University.&#xD;Multidisciplinary Neuroprotection Laboratories, Department of Anesthesiology, Duke University; Department of Neurology, Duke University; michael.james@duke.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Intrastriatal injection of autologous blood or clostridial collagenase as murine models of intracerebral hemorrhage</style></title><secondary-title><style face="normal" font="default" size="100%">J Vis Exp</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of visualized experiments : JoVE</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Vis Exp</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of visualized experiments : JoVE</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Vis Exp</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of visualized experiments : JoVE</style></abbr-1></alt-periodical><number><style face="normal" font="default" size="100%">89</style></number><edition><style face="normal" font="default" size="100%">2014/07/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/ etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Clostridium/enzymology</style></keyword><keyword><style face="normal" font="default" size="100%">Collagenases/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 03</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1940-087X (Electronic)&#xD;1940-087X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25046028</style></accession-num><abstract><style face="normal" font="default" size="100%">Intracerebral hemorrhage (ICH) is a common form of cerebrovascular disease and is associated with significant morbidity and mortality. Lack of effective treatment and failure of large clinical trials aimed at hemostasis and clot removal demonstrate the need for further mechanism-driven investigation of ICH. This research may be performed through the framework provided by preclinical models. Two murine models in popular use include intrastriatal (basal ganglia) injection of either autologous whole blood or clostridial collagenase. Since, each model represents distinctly different pathophysiological features related to ICH, use of a particular model may be selected based on what aspect of the disease is to be studied. For example, autologous blood injection most accurately represents the brain&apos;s response to the presence of intraparenchymal blood, and may most closely replicate lobar hemorrhage. Clostridial collagenase injection most accurately represents the small vessel rupture and hematoma evolution characteristic of deep hemorrhages. Thus, each model results in different hematoma formation, neuroinflammatory response, cerebral edema development, and neurobehavioral outcomes. Robustness of a purported therapeutic intervention can be best assessed using both models. In this protocol, induction of ICH using both models, immediate post-operative demonstration of injury, and early post-operative care techniques are demonstrated. Both models result in reproducible injuries, hematoma volumes, and neurobehavioral deficits. Because of the heterogeneity of human ICH, multiple preclinical models are needed to thoroughly explore pathophysiologic mechanisms and test potential therapeutic strategies.</style></abstract><notes><style face="normal" font="default" size="100%">Lei, Beilei&#xD;Sheng, Huaxin&#xD;Wang, Haichen&#xD;Lascola, Christopher D&#xD;Warner, David S&#xD;Laskowitz, Daniel T&#xD;James, Michael L&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Video-Audio Media&#xD;United States&#xD;J Vis Exp. 2014 Jul 3;(89). doi: 10.3791/51439.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.jove.com/pdf/51439/jove-protocol-51439-intrastriatal-injection-autologous-blood-or-clostridial-collagenase</style></url></related-urls><pdf-urls><url>internal-pdf://0377944303/Lei-2014-Intrastriatal inject.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4211435</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3791/51439</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>362</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">362</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lei, C.</style></author><author><style face="normal" font="default" size="100%">Lin, S.</style></author><author><style face="normal" font="default" size="100%">Zhang, C.</style></author><author><style face="normal" font="default" size="100%">Tao, W.</style></author><author><style face="normal" font="default" size="100%">Dong, W.</style></author><author><style face="normal" font="default" size="100%">Hao, Z.</style></author><author><style face="normal" font="default" size="100%">Liu, M.</style></author><author><style face="normal" font="default" size="100%">Wu, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Stroke Clinical Research Unit, Department of Neurology, West China Hospital, Sichuan University, 610041 Chengdu, PR China. leichunyan328@163.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">Activation of cerebral recovery by matrix metalloproteinase-9 after intracerebral hemorrhage</style></title><secondary-title><style face="normal" font="default" size="100%">Neuroscience</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">86-93</style></pages><volume><style face="normal" font="default" size="100%">230</style></volume><edition><style face="normal" font="default" size="100%">2012/12/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Bromodeoxyuridine/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Proliferation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/drug effects/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/chemically induced/drug therapy/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Collagenases/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Matrix Metalloproteinase 9/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Microtubule-Associated Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Growth Factor/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neuropeptides/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery of Function/drug effects/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Endothelial Growth Factor A/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 29</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1873-7544 (Electronic)&#xD;0306-4522 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23201258</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebral ischemia, traumatic brain injury, intracerebral hemorrhage and other brain insults trigger neurogenesis in the subventricular zone and hippocampal subgranular zone, and newly formed blood vessels promote the migration of these new neuronal cells to damaged brain regions. The molecular steps involved in brain injury-induced angiogenesis and neurogenesis are unclear. Here we used a rat model of collagenase-induced intracerebral hemorrhage (ICH) to examine whether matrix metalloproteinase-9 (MMP-9), a zinc endopeptidase that regulates growth factor levels during recovery from brain injury, is involved in neurogenesis and angiogenesis following ICH. Induction of ICH led to significant increases in the levels of MMP-9, vascular endothelial growth factor (VEGF), and nerve growth factor (NGF), as well as in the numbers of 5-bromo-2-deoxyuridine (BrdU)- and doublecortin (DCX)-positive cells, in the ipsilateral brain. Intracerebroventricular injection of MMP-9 siRNA reduced these ICH-induced increases. These findings suggest that MMP-9 may promote angiogenesis and neurogenesis during recovery from ICH.</style></abstract><notes><style face="normal" font="default" size="100%">Lei, C&#xD;Lin, S&#xD;Zhang, C&#xD;Tao, W&#xD;Dong, W&#xD;Hao, Z&#xD;Liu, M&#xD;Wu, B&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Neuroscience. 2013 Jan 29;230:86-93. doi: 10.1016/j.neuroscience.2012.11.008. Epub 2012 Nov 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0306452212011141/1-s2.0-S0306452212011141-main.pdf?_tid=d3c4e5c6-d7be-11e6-a9dd-00000aab0f01&amp;acdnat=1484112707_d404f811b91495b1485b623c118e1601</style></url></related-urls><pdf-urls><url>internal-pdf://0826278076/Lei-2013-Activation of cerebr.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuroscience.2012.11.008</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>227</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">227</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leroux, P.</style></author><author><style face="normal" font="default" size="100%">Omouendze, P. L.</style></author><author><style face="normal" font="default" size="100%">Roy, V.</style></author><author><style face="normal" font="default" size="100%">Dourmap, N.</style></author><author><style face="normal" font="default" size="100%">Gonzalez, B. J.</style></author><author><style face="normal" font="default" size="100%">Brasse-Lagnel, C.</style></author><author><style face="normal" font="default" size="100%">Carmeliet, P.</style></author><author><style face="normal" font="default" size="100%">Leroux-Nicollet, I.</style></author><author><style face="normal" font="default" size="100%">Marret, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From the Laboratory of Microvascular Endothelium and Neonate Brain Lesions (PL, PLO, ND, BJG, CB-L, IL-N, SM), INSERM-Region Haute-Normandie Team ERI-28, Institute for Research and Innovation in Biomedicine and Laboratory of Psychology and Neuroscience of Cognition and Affects (VR), PSY-NCA, University of Rouen, Rouen; Department of Biochemistry (CB-L), IBC and Department of Neonatal Pediatrics and Intensive Care (SM), Rouen University Hospital, Rouen, France; and Laboratory of Angiogenesis and Neurovascular Link (PC), Vesalius Research Center, VIB and Laboratory of Angiogenesis and Neurovascular Link (PC), Department of Oncology, KU Leuven, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Age-dependent neonatal intracerebral hemorrhage in plasminogen activator inhibitor 1 knockout mice</style></title><secondary-title><style face="normal" font="default" size="100%">J Neuropathol Exp Neurol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neuropathology and experimental neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neuropathol Exp Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuropathology and experimental neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neuropathol Exp Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuropathology and experimental neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">387-402</style></pages><volume><style face="normal" font="default" size="100%">73</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2014/04/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Aging/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Aminocaproic Acid/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Animals, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Aprotinin/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/genetics/ metabolism/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, 129 Strain</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Motor Activity/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Serpin E2/antagonists &amp; inhibitors/ deficiency/physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1554-6578 (Electronic)&#xD;0022-3069 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24709679</style></accession-num><abstract><style face="normal" font="default" size="100%">Intracerebral-intraventricular hemorrhages (ICH/IVH) in very preterm neonates are responsible for high mortality and subsequent disabilities. In humans, tissue plasminogen activator (t-PA) initiates fibrinolysis and activates endoluminal-endothelial receptors; dysfunction of the t-PA inhibitor (PAI-1) results in recurrent hemorrhages. We used PAI-1 knockout (PAI-1) mice to examine the role of t-PA in age-dependent intracranial hemorrhages as a possible model of preterm ICH/IVH. Intracortical injection of 2 muL of phosphate-buffered saline produced a small traumatic injury and a high rate of hemorrhage in PAI-1 pups at postnatal day 3 (P3) or P5, whereas it had no effect in wild-type neonates. This resulted in white matter and cortical lesions, ventricle enlargement, hyperlocomotion, and altered cortical levels of serotonin and dopamine in the adult PAI mice. N-methyl-D-aspartate receptor blockers, plasmin- and matrix metalloproteinases inhibitors reduced hemorrhage and tissue lesions. In contrast to P3 to P5, no significant hemorrhages were induced in P10 PAI-1 pups and there were no behavioral or neurochemical alterations in adulthood. These data suggest that microvascular immaturity up to P5 in mice is a determinant factor required for t-PA-dependent vascular rupture. Neonatal PAI-1 mice could be a useful ICH/IVH model for studying the ontogenic window of vascular immaturity and vascular protection against later neurodisabilities.</style></abstract><notes><style face="normal" font="default" size="100%">Leroux, Philippe&#xD;Omouendze, Priscilla L&#xD;Roy, Vincent&#xD;Dourmap, Nathalie&#xD;Gonzalez, Bruno J&#xD;Brasse-Lagnel, Carole&#xD;Carmeliet, Peter&#xD;Leroux-Nicollet, Isabelle&#xD;Marret, Stephane&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Neuropathol Exp Neurol. 2014 May;73(5):387-402. doi: 10.1097/NEN.0000000000000062.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://jnen.oxfordjournals.org/content/jnen/73/5/387.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://4219285104/Leroux-2014-Age-dependent neonat.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/nen.0000000000000062</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>452</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">452</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, L.</style></author><author><style face="normal" font="default" size="100%">Khatibi, N. H.</style></author><author><style face="normal" font="default" size="100%">Hu, Q.</style></author><author><style face="normal" font="default" size="100%">Yan, J.</style></author><author><style face="normal" font="default" size="100%">Chen, C.</style></author><author><style face="normal" font="default" size="100%">Han, J.</style></author><author><style face="normal" font="default" size="100%">Ma, D.</style></author><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Zhou, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Anatomy and Histology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transmembrane protein 166 regulates autophagic and apoptotic activities following focal cerebral ischemic injury in rats</style></title><secondary-title><style face="normal" font="default" size="100%">Exp Neurol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Experimental neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Exp Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Experimental neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Exp Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Experimental neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">181-90</style></pages><volume><style face="normal" font="default" size="100%">234</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2012/01/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis Regulatory Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Autophagy/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Beclin-1</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation/drug effects/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Glial Fibrillary Acidic Protein/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Green Fluorescent Proteins/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">In Situ Nick-End Labeling</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/drug therapy/ pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Membrane Proteins/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Microtubule-Associated Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Tetrazolium Salts</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Transduction, Genetic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1090-2430 (Electronic)&#xD;0014-4886 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22227058</style></accession-num><abstract><style face="normal" font="default" size="100%">Transmembrane protein 166 (TMEM166) is a lysosomal/endoplasmic reticulum-associated protein found in various species where it acts as a regulator of programmed cell death, mediating both autophagy and apoptosis. In the present study, we investigated the role of TMEM166 following MCAO injury in rats to determine whether the structural damages following injury were orchestrated in part by TMEM166. One hundred and fifty six male Sprague-Dawley rats were randomly divided into 4 groups: Sham, MCAO, MCAO+control siRNA, MCAO+TMEM166 siRNA. Outcomes were measured including mortality rate, brain edema, BBB disruption, and neurobehavioral testing. Western blotting techniques measured the expression of key pro-autophagic and apoptotic proteins such as TMEM166, Beclin-1, cleaved casepase-3 and Bcl-2/Bax. The study found that TMEM166 siRNA treatment significantly reduced the mortality rate, cerebral edema, neurobehavioral deficits, and BBB disruption as measured by Evan&apos;s blue assay following MCAO injury. Immunohistochemical staining and western blotting analysis demonstrated an increased expressions of TMEM166, Beclin-1, LC3, cleaved casepase-3 and Bcl-2/Bax in the infarcted areas. This study suggests that TMEM166 induces autophagy and apoptosis may in fact play a significant role in cell death following MCAO injury and its mediation may be through the crosstalk of Bcl-2. By blocking the activity of TMEM166 using siRNA, we were able to prevent the cell loss that occured following cerebral ischemia injury. This translated into a preservation of functional integrity and an improvement in mortality.</style></abstract><notes><style face="normal" font="default" size="100%">Li, Li&#xD;Khatibi, Nikan H&#xD;Hu, Qin&#xD;Yan, Junhao&#xD;Chen, Chunhua&#xD;Han, Jingyan&#xD;Ma, Dalong&#xD;Chen, Yinyu&#xD;Zhou, Changman&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Exp Neurol. 2012 Mar;234(1):181-90. doi: 10.1016/j.expneurol.2011.12.038. Epub 2011 Dec 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0014488611004900/1-s2.0-S0014488611004900-main.pdf?_tid=da1231a4-d7be-11e6-98ef-00000aacb35f&amp;acdnat=1484112718_7be91aa25a25cfe61f4342cf7834359e</style></url></related-urls><pdf-urls><url>internal-pdf://2289772866/Li-2012-Transmembrane protei.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.expneurol.2011.12.038</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>76</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">76</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, L.</style></author><author><style face="normal" font="default" size="100%">Liu, Z. T.</style></author><author><style face="normal" font="default" size="100%">Chu, L. S.</style></author><author><style face="normal" font="default" size="100%">Yu, T. H.</style></author><author><style face="normal" font="default" size="100%">Qu, T. B.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Ren, C. C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">[Buyang Huanwu decoction promotes neuroblast migration from subventricular zone via inducing angiogenesis after ischemia]</style></title><secondary-title><style face="normal" font="default" size="100%">Zhongguo Zhong Yao Za Zhi</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Zhongguo Zhong Yao Za Zhi</style></full-title><abbr-1><style face="normal" font="default" size="100%">Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Zhongguo Zhong Yao Za Zhi</style></full-title><abbr-1><style face="normal" font="default" size="100%">Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">298-302</style></pages><volume><style face="normal" font="default" size="100%">40</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2015/06/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Angiogenesis Inducing Agents/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain-Derived Neurotrophic Factor/analysis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Movement/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Ventricles/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Chemokine CXCL12/analysis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Drugs, Chinese Herbal/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred ICR</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/ drug effects/physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1001-5302 (Print)&#xD;1001-5302 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26080562</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To study the effect of Buyang Huanwu decoction (BYHWD) inducing angiogenesis on the neuroblast migration from the subventricular zone and its mechanisms after focal cerebral ischemia. METHOD: The middle cerebral artery occlusion (MCAO) was performed to mice for 30 minutes to establish the model. The rats were divided into sham group, model group, BYHWD group and endostatin group. BYHWD (20 g x kg(-1), ig) and endostatin (10 mug, sc) were administered 24 h after ischemia once a day for consecutively 14 days. At 14 d after ischemia, the density of micro-vessel and the number of neuroblasts in the ischemia border zone were determined by immunofluorescence staining. The mRNA and protein expression of cell-derived factor-1 (SDF-1) and brain-derived neurotrophic (BDNF) were examined by real-time PCR and Western blot. RESULT: Compared with the model group, BYHWD significantly increased the density of micro-vessel and the number of DCX positive cells in the ischemia border zone (P &lt; 0.01), and significantly increased the SDF-1 and BDNF mRNA and protein expression (P &lt; 0.01). Compared with BYHWD group, endostatin significantly reduced the density of micro-vessel and the number of DCX positive cells in the ischemia border zone (P &lt; 0.01), as well as the SDF-1, BDNF mRNA and protein expression (P &lt; 0.01). CONCLUSION: BYHWD could promote the neuroblast migration from the subventricular zone via inducing angiogenesis after cerebral ischemia, the mechanism may be correlated with up-regulating the expression of SDF-1 and BDNF.</style></abstract><notes><style face="normal" font="default" size="100%">Li, Lin&#xD;Liu, Zhi-ting&#xD;Chu, Li-sheng&#xD;Yu, Tian-hong&#xD;Qu, Tie-bing&#xD;Wang, Jun&#xD;Ren, Cui-cui&#xD;English Abstract&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;China&#xD;Zhongguo Zhong Yao Za Zhi. 2015 Jan;40(2):298-302.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">chi</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>141</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">141</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, L.</style></author><author><style face="normal" font="default" size="100%">Zhu, K.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Wu, X.</style></author><author><style face="normal" font="default" size="100%">Wu, J.</style></author><author><style face="normal" font="default" size="100%">Zhao, Y.</style></author><author><style face="normal" font="default" size="100%">Zhao, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathophysiology, Chongqing Medical University, Chongqing, People&apos;s Republic of China; Institute of Neuroscience, Chongqing Medical University, Chongqing, People&apos;s Republic of China.&#xD;Department of Pathology, Chongqing Medical University, Chongqing, People&apos;s Republic of China; Institute of Neuroscience, Chongqing Medical University, Chongqing, People&apos;s Republic of China.&#xD;Department of Pathophysiology, Chongqing Medical University, Chongqing, People&apos;s Republic of China; Institute of Neuroscience, Chongqing Medical University, Chongqing, People&apos;s Republic of China. Electronic address: zjbingsheng@sina.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Targeting thioredoxin-1 with siRNA exacerbates oxidative stress injury after cerebral ischemia/reperfusion in rats</style></title><secondary-title><style face="normal" font="default" size="100%">Neuroscience</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">815-23</style></pages><volume><style face="normal" font="default" size="100%">284</style></volume><edition><style face="normal" font="default" size="100%">2014/12/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Knockdown Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Malondialdehyde/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">NF-E2-Related Factor 2/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative Stress/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Peroxiredoxins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Superoxide Dismutase/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Thioredoxins/genetics/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 22</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1873-7544 (Electronic)&#xD;0306-4522 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25451293</style></accession-num><abstract><style face="normal" font="default" size="100%">Reactive oxygen species and their detrimental effects on the brain after transient ischemia/reperfusion (I/R) have been implicated in the pathogenesis of ischemic reperfusion injury. Thioredoxin-1 (Trx-1) is an endogenous antioxidant protein that has neuroprotective effects. We hypothesized that Trx-1 plays a crucial role in regulating cerebral I/R injury. To be able to test this, 190 Sprague-Dawley rats were subjected to transient middle cerebral artery occlusion (tMCAO) with Trx-1 siRNA (small interference RNA) injected 24 h prior to ischemia. At 24 h after tMCAO, we measured neurological deficits, infarct volume, and brain water content, and found that neurological dysfunction, brain infarct size, and brain edema were worse in the Trx-1 siRNA group than in the control group. Oxidative stress was evaluated by measuring superoxide dismutase activity and malondialdehyde level. The levels of Trx-1 and its cofactor, peroxiredoxin (Prdx), were significantly decreased after Trx-1 down-regulated. However, there is no significant difference in the Prdx mRNA level after administration of Trx-1 siRNA. In contrast, Prdx-SO3 protein levels were significantly increased in the Trx-1 siRNA group. We also investigated the specific role of nuclear factor erythroid 2-related factor 2 (Nrf2) in Trx-1 induction by knocking down Nrf2. Nrf2 siRNA injection decreased Trx-1 mRNA and protein expression. Our results suggest that the exacerbation of brain damage was associated with enhanced cerebral peroxidation in brain tissues. Moreover, these results revealed that Trx-1, which is more likely regulated by Nrf2, exerts a neuroprotective role probably through maintaining the reduction activity of Prdx1-4.</style></abstract><notes><style face="normal" font="default" size="100%">Li, L&#xD;Zhu, K&#xD;Liu, Y&#xD;Wu, X&#xD;Wu, J&#xD;Zhao, Y&#xD;Zhao, J&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Neuroscience. 2015 Jan 22;284:815-23. doi: 10.1016/j.neuroscience.2014.10.066. Epub 2014 Nov 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0306452214009385/1-s2.0-S0306452214009385-main.pdf?_tid=dfad0b16-d7be-11e6-8bfb-00000aab0f6c&amp;acdnat=1484112727_ce2793861ccaba8dd4e590536914be12</style></url></related-urls><pdf-urls><url>internal-pdf://4104275976/Li-2015-Targeting thioredoxi.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuroscience.2014.10.066</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>217</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">217</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, L. J.</style></author><author><style face="normal" font="default" size="100%">Huang, Q.</style></author><author><style face="normal" font="default" size="100%">Zhang, N.</style></author><author><style face="normal" font="default" size="100%">Wang, G. B.</style></author><author><style face="normal" font="default" size="100%">Liu, Y. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">miR-376b-5p regulates angiogenesis in cerebral ischemia</style></title><secondary-title><style face="normal" font="default" size="100%">Mol Med Rep</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Molecular medicine reports</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Mol Med Rep</style></full-title><abbr-1><style face="normal" font="default" size="100%">Molecular medicine reports</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Mol Med Rep</style></full-title><abbr-1><style face="normal" font="default" size="100%">Molecular medicine reports</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">527-35</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2014/05/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ genetics/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Hypoxia</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Down-Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">Human Umbilical Vein Endothelial Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia-Inducible Factor 1, alpha Subunit/antagonists &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">inhibitors/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ genetics/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">MicroRNAs/antagonists &amp; inhibitors/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neovascularization, Physiologic</style></keyword><keyword><style face="normal" font="default" size="100%">Oligonucleotides, Antisense/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA Interference</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Notch1/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Endothelial Growth Factor A/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">von Willebrand Factor/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1791-3004 (Electronic)&#xD;1791-2997 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24789343</style></accession-num><abstract><style face="normal" font="default" size="100%">The profile of microRNAs (miRNAs) altered following middle cerebral artery occlusion (MCAO) and miRNAs are involved in angiogenesis following cerebral ischemia. miR376b5p was decreased following MCAO, however, whether miR376b5p is important in angiogenesis remains to be elucidated. The present study was designed to identify whether miR376b5p is involved in angiogenesis following cerebral ischemia and to elucidate the underlying mechanisms. A rat MCAO model was established and quantitative polymerase chain reaction was performed to analyze the mRNA expression level of miR376b5p for 1 to 7 days. In addition, the density of microvessels and the relative mRNA and protein levels of hypoxiainducible factor1 alpha (HIF1alpha), vascular endothelial growth factor A (VEGFA) and Notch1 were measured. The miR376b5p mimic or the miR376b5p inhibitor were transfected into hypoxic human umbilical vein endothelial cells (HUVECs), and the proliferation, migration and tube formation were measured. To further examine the underlying mechanisms, shRNA was transfected into cells to knock down HIF1alpha, and angiogenesis and the expression of associated molecules, including HIF1alpha, VEGFA and Notch1 were compared between each group. Our results demonstrated that miR376b5p repressed angiogenesis in vivo and in vitro, and miR376b5p inhibited angiogenesis in HUVECs by targeting the HIF1alphamediated VEGFA/Notch1 signaling pathway. These findings provide new insights into angiogenesis therapy for cerebral ischemia.</style></abstract><notes><style face="normal" font="default" size="100%">Li, Ling-Juan&#xD;Huang, Qing&#xD;Zhang, Ning&#xD;Wang, Gui-Bin&#xD;Liu, Yun-Hai&#xD;Greece&#xD;Mol Med Rep. 2014 Jul;10(1):527-35. doi: 10.3892/mmr.2014.2172. Epub 2014 Apr 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.spandidos-publications.com/mmr/10/1/527/download</style></url></related-urls><pdf-urls><url>internal-pdf://1339440775/Li-2014-miR-376b-5p regulate.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3892/mmr.2014.2172</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>85</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">85</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, L. L.</style></author><author><style face="normal" font="default" size="100%">Melero-Fernandez de Mera, R. M.</style></author><author><style face="normal" font="default" size="100%">Chen, J.</style></author><author><style face="normal" font="default" size="100%">Ba, W.</style></author><author><style face="normal" font="default" size="100%">Kasri, N. N.</style></author><author><style face="normal" font="default" size="100%">Zhang, M.</style></author><author><style face="normal" font="default" size="100%">Courtney, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurobiology, A. I. Virtanen Institute, University of Eastern Finland, Kuopio, FIN 70210, Finland.&#xD;Division of Life Science, Center for Systems Biology and Human Health, Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong.&#xD;Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Department of Cognitive Neuroscience, Nijmegen 6500 HB, The Netherlands, and.&#xD;Department of Neurobiology, A. I. Virtanen Institute, University of Eastern Finland, Kuopio, FIN 70210, Finland, Turku Centre for Biotechnology, Abo Akademi University and University of Turku, Turku, FIN 20521, Finland miccou@utu.fi.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Unexpected Heterodivalent Recruitment of NOS1AP to nNOS Reveals Multiple Sites for Pharmacological Intervention in Neuronal Disease Models</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">7349-64</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">19</style></number><edition><style face="normal" font="default" size="100%">2015/05/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adaptor Proteins, Signal Transducing/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Animals, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">COS Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Death/drug effects/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Cercopithecus aethiops</style></keyword><keyword><style face="normal" font="default" size="100%">Excitatory Amino Acid Agonists/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Guanine Nucleotide Exchange Factors/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">In Vitro Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Membrane Proteins/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Molecular</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">N-Methylaspartate/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide Synthase Type I/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Organ Culture Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Structure, Tertiary</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Proteins/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Tumor Suppressor Proteins/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">p38 Mitogen-Activated Protein Kinases/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">May 13</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1529-2401 (Electronic)&#xD;0270-6474 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25972165</style></accession-num><abstract><style face="normal" font="default" size="100%">The protein NOS1AP/CAPON mediates signaling from a protein complex of NMDA receptor, PSD95 and nNOS. The only stroke trial for neuroprotectants that showed benefit to patients targeted this ternary complex. NOS1AP/nNOS interaction regulates small GTPases, iron transport, p38MAPK-linked excitotoxicity, and anxiety. Moreover, the nos1ap gene is linked to disorders from schizophrenia, post-traumatic stress disorder, and autism to cardiovascular disorders and breast cancer. Understanding protein interactions required for NOS1AP function, therefore, has broad implications for numerous diseases. Here we show that the interaction of NOS1AP with nNOS differs radically from the classical PDZ docking assumed to be responsible. The NOS1AP PDZ motif does not bind nNOS as measured by multiple methods. In contrast, full-length NOS1AP forms an unusually stable interaction with nNOS. We mapped the discrepancy between full-length and C-terminal PDZ motif to a novel internal region we call the ExF motif. The C-terminal PDZ motif, although neither sufficient nor necessary for binding, nevertheless promotes the stability of the complex. It therefore potentially affects signal transduction and suggests that functional interaction of nNOS with NOS1AP might be targetable at two distinct sites. We demonstrate that excitotoxic pathways can be regulated, in cortical neuron and organotypic hippocampal slice cultures from rat, either by the previously described PDZ ligand TAT-GESV or by the ExF motif-bearing region of NOS1AP, even when lacking the critical PDZ residues as long as the ExF motif is intact and not mutated. This previously unrecognized heterodivalent interaction of nNOS with NOS1AP may therefore provide distinct opportunities for pharmacological intervention in NOS1AP-dependent signaling and excitotoxicity.</style></abstract><notes><style face="normal" font="default" size="100%">Li, Li-Li&#xD;Melero-Fernandez de Mera, Raquel M&#xD;Chen, Jia&#xD;Ba, Wei&#xD;Kasri, Nael Nadif&#xD;Zhang, Mingjie&#xD;Courtney, Michael J&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Neurosci. 2015 May 13;35(19):7349-64. doi: 10.1523/JNEUROSCI.0037-15.2015.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.jneurosci.org/content/jneuro/35/19/7349.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2202816407/Li-2015-Unexpected Heterodiv.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1523/jneurosci.0037-15.2015</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>90</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">90</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, S.</style></author><author><style face="normal" font="default" size="100%">Hu, X.</style></author><author><style face="normal" font="default" size="100%">Zhang, M.</style></author><author><style face="normal" font="default" size="100%">Zhou, F.</style></author><author><style face="normal" font="default" size="100%">Lin, N.</style></author><author><style face="normal" font="default" size="100%">Xia, Q.</style></author><author><style face="normal" font="default" size="100%">Zhou, Y.</style></author><author><style face="normal" font="default" size="100%">Qi, W.</style></author><author><style face="normal" font="default" size="100%">Zong, Y.</style></author><author><style face="normal" font="default" size="100%">Yang, H.</style></author><author><style face="normal" font="default" size="100%">Wang, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Morphology Lab, Chengdu Medical College, Sichuan 610500, China. Electronic address: 734862297@qq.com.&#xD;Department of Morphology Lab, Chengdu Medical College, Sichuan 610500, China. Electronic address: woodwind@sohu.com.&#xD;Department of Morphology Lab, Chengdu Medical College, Sichuan 610500, China.&#xD;Institute of Neuroscience, Kunming Medical University, Kunming 650031, China.&#xD;State Key Laboratory of Biotherapy, Translational Neuroscience Center, Sichuan University, Sichuan 610041, China.&#xD;Institute of Neuroscience, Kunming Medical University, Kunming 650031, China; State Key Laboratory of Biotherapy, Translational Neuroscience Center, Sichuan University, Sichuan 610041, China. Electronic address: neuron@yahoo.com.cn.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Remote ischemic post-conditioning improves neurological function by AQP4 down-regulation in astrocytes</style></title><secondary-title><style face="normal" font="default" size="100%">Behav Brain Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Behavioural brain research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Behav Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Behavioural brain research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Behav Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Behavioural brain research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1-8</style></pages><volume><style face="normal" font="default" size="100%">289</style></volume><edition><style face="normal" font="default" size="100%">2015/04/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Aquaporin 4/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ blood supply/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/pathology/physiopathology/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Down-Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Postconditioning</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 01</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-7549 (Electronic)&#xD;0166-4328 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25907740</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebral ischemia is a primary cause of human death and long-term disability. Previous studies have suggested that remote ischemic post-conditioning (RIPC) is a potential useful tool for cerebral ischemic treatment. However, the protective mechanism of RIPC is not very clear. This study verified the hypothesis that, in remote post-conditioning of cerebral ischemic rats, down-regulation of aquaporin 4 (AQP4), which is an important player for water hemostasis in astrocytes, could attenuate cerebral damage after transient middle cerebral artery occlusion (MCAO). In this study, RIPC model was established after MCAO. Each hind limb of rat was clamped by small rubber tubes for 10 min, and then the tubes were opened for 10 min. The clamping and opening were operated for a total of three cycles to block the hind limbs blood flow. The results showed that, RIPC could significantly improve neurological function, decrease the percentage of the infarct volume and edema, and elevate the integrity of blood-brain barrier (BBB). In addition, the numbers of AQP4 and glial fibrillary acidic protein (GFAP) positive cells were significantly lower in the RIPC group. Moreover, we found that AQP4 expression decreased in response to ischemia/reperfusion in the RIPC group. Our findings indicated that RIPC could attenuate focal cerebral ischemia/reperfusion injury, and the neuroprotective mechanism was related with the down-regulation of AQP4 in astrocytes.</style></abstract><notes><style face="normal" font="default" size="100%">Li, Shuai&#xD;Hu, Xiaosong&#xD;Zhang, Mingxiao&#xD;Zhou, Fangfang&#xD;Lin, Na&#xD;Xia, Qingjie&#xD;Zhou, Yu&#xD;Qi, Wenqian&#xD;Zong, Yonghua&#xD;Yang, Huijun&#xD;Wang, Tinghua&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Netherlands&#xD;Behav Brain Res. 2015 Aug 1;289:1-8. doi: 10.1016/j.bbr.2015.04.024. Epub 2015 Apr 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0166432815002661/1-s2.0-S0166432815002661-main.pdf?_tid=e2e136ea-d7be-11e6-8dda-00000aab0f6b&amp;acdnat=1484112733_c397cceb593f9f69c50619418f952183</style></url></related-urls><pdf-urls><url>internal-pdf://1322999117/Li-2015-Remote ischemic post.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.bbr.2015.04.024</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>276</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">276</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, T.</style></author><author><style face="normal" font="default" size="100%">Pang, S.</style></author><author><style face="normal" font="default" size="100%">Yu, Y.</style></author><author><style face="normal" font="default" size="100%">Wu, X.</style></author><author><style face="normal" font="default" size="100%">Guo, J.</style></author><author><style face="normal" font="default" size="100%">Zhang, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Life Sciences, Lanzhou University, Lanzhou 73000, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Proliferation of parenchymal microglia is the main source of microgliosis after ischaemic stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Brain</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain : a journal of neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain : a journal of neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Brain</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain : a journal of neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">3578-88</style></pages><volume><style face="normal" font="default" size="100%">136</style></volume><number><style face="normal" font="default" size="100%">Pt 12</style></number><edition><style face="normal" font="default" size="100%">2013/10/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/metabolism/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium-Binding Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Caspase 3/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Proliferation</style></keyword><keyword><style face="normal" font="default" size="100%">Connective Tissue/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation/genetics/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Gliosis/ etiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Green Fluorescent Proteins/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Microfilament Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Microglia/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Photic Stimulation</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, CCR2/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Chemokine</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1460-2156 (Electronic)&#xD;0006-8950 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24154617</style></accession-num><abstract><style face="normal" font="default" size="100%">Stroke induces rapid activation and expansion of microglia, but the main source of microgliosis is controversial. Here we investigated the formation of microgliosis and infiltration of circulating cells in a photothrombosis stroke model by taking advantage of parabiosis and two-photon microscopy. We found that a small population of blood-derived CX3CR1(GFP/+) cells infiltrated the cerebral parenchyma, but these cells did not proliferate and were phenotypically distinguishable from resident microglia. CX3CR1(GFP/+) infiltrating cells also displayed different kinetics from reactive microglia. The number of CX3CR1(GFP/+) infiltrating cells peaked on Day 5 after stroke and then decreased. The decline of these infiltrating cells was associated with an active apoptotic process. In contrast, reactive microglia were recruited to the ischaemic area continuously during the first week after stroke induction. Immunohistology and in vivo two-photon imaging revealed that cells involved in the process of microgliosis were mainly derived from proliferating resident microglia. Expansion of microglia exhibited a consistent pattern and our in vivo data demonstrated for the first time that microglia underwent active division in regions surrounding the ischaemic core. Together, these results indicated that CX3CR1(GFP/+) infiltrating cells and reactive microglia represented two distinct populations of cells with different functions and therapeutic potentials for the treatment of stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Li, Ting&#xD;Pang, Shengru&#xD;Yu, Yongping&#xD;Wu, Xiaoqian&#xD;Guo, Jing&#xD;Zhang, Shengxiang&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Brain. 2013 Dec;136(Pt 12):3578-88. doi: 10.1093/brain/awt287. Epub 2013 Oct 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://brain.oxfordjournals.org/content/brain/136/12/3578.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1876198836/Li-2013-Proliferation of par.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/brain/awt287</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>209</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">209</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, X.</style></author><author><style face="normal" font="default" size="100%">Luo, P.</style></author><author><style face="normal" font="default" size="100%">Wang, F.</style></author><author><style face="normal" font="default" size="100%">Yang, Q.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Zhao, M.</style></author><author><style face="normal" font="default" size="100%">Wang, S.</style></author><author><style face="normal" font="default" size="100%">Wang, Q.</style></author><author><style face="normal" font="default" size="100%">Xiong, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From the Department of Anesthesiology (X.L., F.W., Q.Y., Y.L., S.W., Q.W., L.X.) and Department of Neurosurgery (P.L., M.Z.), Xijing Hospital, Fourth Military Medical University, Xi&apos;an, China; and Department of Anesthesiology, Shaanxi Provincial Maternal and Child Health Hospital, Xi&apos;an, China (Y.L.).</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inhibition of N-myc downstream-regulated gene-2 is involved in an astrocyte-specific neuroprotection induced by sevoflurane preconditioning</style></title><secondary-title><style face="normal" font="default" size="100%">Anesthesiology</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Anesthesiology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Anesthesiology</style></full-title><abbr-1><style face="normal" font="default" size="100%">Anesthesiology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Anesthesiology</style></full-title><abbr-1><style face="normal" font="default" size="100%">Anesthesiology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">549-62</style></pages><volume><style face="normal" font="default" size="100%">121</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2014/05/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Active Transport, Cell Nucleus</style></keyword><keyword><style face="normal" font="default" size="100%">Anesthetics, Inhalation/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Preconditioning</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Methyl Ethers/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Tissue Proteins/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1528-1175 (Electronic)&#xD;0003-3022 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24866406</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Mechanism of sevoflurane preconditioning-induced cerebral ischemic tolerance is unclear. This study investigates the role of N-myc downstream-regulated gene-2 (NDRG2) in the neuroprotection of sevoflurane preconditioning in ischemic model both in vivo and in vitro. METHODS: At 2 h after sevoflurane (2%) preconditioning for 1 h, rats were subjected to middle cerebral artery occlusion for 120 min. Neurobehavioral scores (n = 10), infarct volumes (n = 10), cellular apoptosis (n = 6), and NDRG2 expression (n = 6) were determined at 24 h after reperfusion. In vitro, cultural astrocytes were exposed to oxygen-glucose deprivation for 4 h. Cellular viability, cytotoxicity, apoptosis, and NDRG2 expression (n = 6) were evaluated in the presence or absence of NDRG2-specific small interfering RNA or NDRG2 overexpression plasmid. RESULTS: Sevoflurane preconditioning decreased apoptosis (terminal deoxynucleotidyl transferase-mediated 2&apos;-deoxyuridine 5&apos;-triphosphate nick-end labeling-positive cells reduced to 31.2 +/- 5.3% and cleaved Caspase-3 reduced to 1.42 +/- 0.21 fold) and inhibited NDRG2 expression (1.28 +/- 0.15 fold) and nuclear translocation (2.21 +/- 0.29 fold) in ischemic penumbra. Similar effects were observed in cultural astrocytes exposed to oxygen-glucose deprivation. NDRG2 knockdown by small interfering RNA attenuated oxygen-glucose deprivation-induced injury (cell viability increased to 80.5 +/- 4.1%; lactate dehydrogenase release reduced to 30.5 +/- 4.0%) and cellular apoptosis (cleaved Caspase-3 reduced to 1.55 +/- 0.21 fold; terminal deoxynucleotidyl transferase-mediated 2&apos;-deoxyuridine 5&apos;-triphosphate nick-end labeling-positive cells reduced to 18.2 +/- 4.3%), whereas NDRG2 overexpression reversed the protective effects of sevoflurane preconditioning. All the data are presented as mean +/- SD. CONCLUSION: Sevoflurane preconditioning inhibits NDRG2 up-regulation and nuclear translocation in astrocytes to induce cerebral ischemic tolerance via antiapoptosis, which represents one new mechanism of sevoflurane preconditioning and provides a novel target for neuroprotection.</style></abstract><notes><style face="normal" font="default" size="100%">Li, Xin&#xD;Luo, Peng&#xD;Wang, Feng&#xD;Yang, Qianzi&#xD;Li, Yan&#xD;Zhao, Mingming&#xD;Wang, Shiquan&#xD;Wang, Qiang&#xD;Xiong, Lize&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Anesthesiology. 2014 Sep;121(3):549-62. doi: 10.1097/ALN.0000000000000314.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://anesthesiology.pubs.asahq.org/article.aspx?articleid=1921506</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/aln.0000000000000314</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>175</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">175</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liang, X.</style></author><author><style face="normal" font="default" size="100%">Hu, Q.</style></author><author><style face="normal" font="default" size="100%">Li, B.</style></author><author><style face="normal" font="default" size="100%">McBride, D.</style></author><author><style face="normal" font="default" size="100%">Bian, H.</style></author><author><style face="normal" font="default" size="100%">Spagnoli, P.</style></author><author><style face="normal" font="default" size="100%">Chen, D.</style></author><author><style face="normal" font="default" size="100%">Tang, J.</style></author><author><style face="normal" font="default" size="100%">Zhang, J. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From the Departments of Physiology and Pharmacology (X.L., Q.H., B.L., D.M., H.B., P.S., D.C., J.T., J.H.Z.) and Neurosurgery (J.H.Z.), Loma Linda University School of Medicine, CA; and Department of Neurology, Chongqing Medical University, Chongqing, China (X.L.).&#xD;From the Departments of Physiology and Pharmacology (X.L., Q.H., B.L., D.M., H.B., P.S., D.C., J.T., J.H.Z.) and Neurosurgery (J.H.Z.), Loma Linda University School of Medicine, CA; and Department of Neurology, Chongqing Medical University, Chongqing, China (X.L.). johnzhang3910@yahoo.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Follistatin-like 1 attenuates apoptosis via disco-interacting protein 2 homolog A/Akt pathway after middle cerebral artery occlusion in rats</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">3048-54</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2014/08/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Blotting, Western</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Survival/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorescent Antibody Technique</style></keyword><keyword><style face="normal" font="default" size="100%">Follistatin-Related Proteins/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Knockdown Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">In Situ Nick-End Labeling</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Proto-Oncogene Proteins c-akt/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25139876</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: Follistatin-like 1 (FSTL1), an extracellular glycoprotein, has been reported to decrease apoptosis in ischemic cardiac diseases, but its effect in ischemic stroke has not been examined. We hypothesized that recombinant FSTL1 attenuates neuronal apoptosis through its receptor disco-interacting protein 2 homolog A (DIP2A) and the Akt pathway after middle cerebral artery occlusion (MCAO) in rats. METHODS: One hundred forty male Sprague-Dawley rats were subjected to 2 hours of MCAO followed by reperfusion. In a subset of animals, the time course and location of FSTL1 and DIP2A were detected by Western blot and immunofluorescence double staining. Another set of animals were intracerebroventricularly given either recombinant FSTL1 1 hour after reperfusion or FSTL1-small interfering RNA (siRNA) 48 hours before reperfusion. Additionally, DIP2A was knockdown by siRNA in some animals. Infarction volume and neurological deficits were measured, and the expression of FSTL1, DIP2A, phosphorylated Akt, cleaved caspase-3, and terminal deoxynucleotidyl transferase dUTP nick end labeling were quantified using Western blot. RESULTS: The expression of FSTL1 and DIP2A was increased in neurons and peaked 24 hours after MCAO. Recombinant FSTL1 reduced brain infarction and improved neurological deficits 24 and 72 hours after MCAO via activation of its receptor DIP2A and downstream phosphorylation of Akt. These effects were reversed by DIP2A-siRNA and FSTL1-siRNA. CONCLUSIONS: Recombinant FSTL1 decreases neuronal apoptosis and improves neurological deficits through phosphorylation of Akt by activation of its receptor DIP2A after MCAO in rats. Thus, FSTL1 may have potentials as a treatment for patients with ischemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Liang, Xiping&#xD;Hu, Qin&#xD;Li, Bo&#xD;McBride, Devin&#xD;Bian, Hetao&#xD;Spagnoli, Pierre&#xD;Chen, Di&#xD;Tang, Jiping&#xD;Zhang, John H&#xD;R01 NS043338/NS/NINDS NIH HHS/United States&#xD;NS043338/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;United States&#xD;Stroke. 2014 Oct;45(10):3048-54. doi: 10.1161/STROKEAHA.114.006092. Epub 2014 Aug 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/45/10/3048.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1722722291/Liang-2014-Follistatin-like 1 a.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4174959</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms617877</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.114.006092</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>38</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">38</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liao, R. J.</style></author><author><style face="normal" font="default" size="100%">Jiang, L.</style></author><author><style face="normal" font="default" size="100%">Wang, R. R.</style></author><author><style face="normal" font="default" size="100%">Zhao, H. W.</style></author><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, L.</style></author><author><style face="normal" font="default" size="100%">Jie, L. Y.</style></author><author><style face="normal" font="default" size="100%">Zhou, Y. D.</style></author><author><style face="normal" font="default" size="100%">Zhang, X. N.</style></author><author><style face="normal" font="default" size="100%">Chen, Z.</style></author><author><style face="normal" font="default" size="100%">Hu, W. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacology, Key Laboratory of Medical Neurobiology of the Ministry of Health of China, School of Basic Medical Sciences, School of Medicine, Zhejiang University, Hangzhou, 310058, China.&#xD;Department of Pharmacology, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.&#xD;Department of Pharmacology, Children&apos;s Hospital of Zhejiang University, Hangzhou 310006, China.&#xD;Department of Radiology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Histidine provides long-term neuroprotection after cerebral ischemia through promoting astrocyte migration</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Rep</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Scientific reports</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Sci Rep</style></full-title><abbr-1><style face="normal" font="default" size="100%">Scientific reports</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Sci Rep</style></full-title><abbr-1><style face="normal" font="default" size="100%">Scientific reports</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">15356</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><edition><style face="normal" font="default" size="100%">2015/10/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/drug effects/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/drug therapy/ metabolism/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Movement/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cicatrix/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Histidine/ metabolism/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotection/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Histamine H2/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery of Function/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Wound Healing/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">rac1 GTP-Binding Protein/antagonists &amp; inhibitors/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 20</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2045-2322 (Electronic)&#xD;2045-2322 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26481857</style></accession-num><abstract><style face="normal" font="default" size="100%">The formation of glial scar impedes the neurogenesis and neural functional recovery following cerebral ischemia. Histamine showed neuroprotection at early stage after cerebral ischemia, however, its long-term effect, especially on glial scar formation, hasn&apos;t been characterized. With various administration regimens constructed for histidine, a precursor of histamine, we found that histidine treatment at a high dose at early stage and a low dose at late stage demonstrated the most remarkable long-term neuroprotection with decreased infarct volume and improved neurological function. Notably, this treatment regimen also robustly reduced the glial scar area and facilitated the astrocyte migration towards the infarct core. In wound-healing assay and transwell test, histamine significantly promoted astrocyte migration. H2 receptor antagonists reversed the promotion of astrocyte migration and the neuroprotection provided by histidine. Moreover, histamine upregulated the GTP-bound small GTPase Rac1, while a Rac1 inhibitor, NSC23766, abrogated the neuroprotection of histidine and its promotion of astrocyte migration. Our data indicated that a dose/stage-dependent histidine treatment, mediated by H2 receptor, promoted astrocyte migration towards the infarct core, which benefited long-term post-cerebral ischemia neurological recovery. Therefore, targeting histaminergic system may be an effective therapeutic strategy for long-term cerebral ischemia injury through its actions on astrocytes.</style></abstract><notes><style face="normal" font="default" size="100%">Liao, Ru-jia&#xD;Jiang, Lei&#xD;Wang, Rong-rong&#xD;Zhao, Hua-wei&#xD;Chen, Ying&#xD;Li, Ya&#xD;Wang, Lu&#xD;Jie, Li-Yong&#xD;Zhou, Yu-dong&#xD;Zhang, Xiang-nan&#xD;Chen, Zhong&#xD;Hu, Wei-wei&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Sci Rep. 2015 Oct 20;5:15356. doi: 10.1038/srep15356.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4611873</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/srep15356</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>259</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">259</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liao, Y. C.</style></author><author><style face="normal" font="default" size="100%">Wang, Y. S.</style></author><author><style face="normal" font="default" size="100%">Guo, Y. C.</style></author><author><style face="normal" font="default" size="100%">Lin, W. L.</style></author><author><style face="normal" font="default" size="100%">Chang, M. H.</style></author><author><style face="normal" font="default" size="100%">Juo, S. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Section of Neurology, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Neurology, National Yang-Ming University School of Medicine, Taipei, Taiwan.&#xD;Department of Genome Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.&#xD;Neuroscience Laboratory, Department of Neurology, China Medical University Hospital, Taichung, Taiwan; School of Medicine, Medical College, China Medical University, Taichung, Taiwan.&#xD;Department of Genome Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Medical Research and Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. Electronic address: hjuo@kmu.edu.tw.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Let-7g improves multiple endothelial functions through targeting transforming growth factor-beta and SIRT-1 signaling</style></title><secondary-title><style face="normal" font="default" size="100%">J Am Coll Cardiol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of the American College of Cardiology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Am Coll Cardiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of the American College of Cardiology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Am Coll Cardiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of the American College of Cardiology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1685-94</style></pages><volume><style face="normal" font="default" size="100%">63</style></volume><number><style face="normal" font="default" size="100%">16</style></number><edition><style face="normal" font="default" size="100%">2013/12/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases/genetics/metabolism/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelium, Vascular/metabolism/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">MicroRNAs/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default" size="100%">RNA/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">Sirtuin 1/biosynthesis/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Transforming Growth Factor beta/biosynthesis/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilation/ genetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 29</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1558-3597 (Electronic)&#xD;0735-1097 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24291274</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVES: The present study aimed to explore the role of microribonucleic acid (miRNA) Let-7g in regulating endothelial functions. BACKGROUND: Derangement of miRNAs is implicated in the pathogenesis of cardiovascular diseases. Because the transforming growth factor (TGF)-beta pathway plays a regulatory role in endothelial functions, miRNAs targeted at TGF-beta signal cascade might affect vascular health. METHODS: Bioinformatics software predicted that Let-7g can influence the TGF-beta pathway by targeting 3 genes. The Let-7g&apos;s effects on multiple endothelial functions were first tested in endothelial cells (ECs) and then in apolipoprotein E knockout mice. Blood samples from lacunar stroke patients were also examined to further support Let-7g&apos;s effects on human subjects. RESULTS: Let-7g was experimentally confirmed to knock down the THBS1, TGFBR1, and SMAD2 genes in the TGF-beta pathway. PAI-I, one of the downstream effectors of the TGF-beta pathway, was also down-regulated by Let-7g. Let-7g decreased EC inflammation and monocyte adhesion and increased angiogenesis via the TGF-beta pathway. Furthermore, Let-7g reduced EC senescence through increasing SIRT-1 protein. Venous injection of Let-7g inhibitor into apolipoprotein E knockout mice caused overgrowth of vascular intima-media, overexpression of PAI-1, increased macrophage infiltration, and up-regulation of TGF-beta downstream genes in the carotid arteries. Let-7g&apos;s beneficial effects on EC were reduced, whereas the TGF-beta pathway was suppressed by ribonucleic acid interference. Restoration of the TGF-beta pathway also attenuated the effects of Let-7g overexpression. Low serum levels of Let-7g were associated with increased circulating PAI-1 levels. CONCLUSIONS: Decreased Let-7g levels impair endothelial function and increase the risks of cardiovascular diseases through targeting TGF-beta and SIRT-1 signaling.</style></abstract><notes><style face="normal" font="default" size="100%">Liao, Yi-Chu&#xD;Wang, Yung-Song&#xD;Guo, Yuh-Cherng&#xD;Lin, Wen-Lien&#xD;Chang, Ming-Hung&#xD;Juo, Suh-Hang Hank&#xD;Comparative Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Am Coll Cardiol. 2014 Apr 29;63(16):1685-94. doi: 10.1016/j.jacc.2013.09.069. Epub 2013 Nov 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0735109713060828/1-s2.0-S0735109713060828-main.pdf?_tid=ee57d754-d7be-11e6-9350-00000aacb360&amp;acdnat=1484112752_6b36f49f2aba1728a04ca0c438abeb8f</style></url></related-urls><pdf-urls><url>internal-pdf://2368712593/Liao-2014-Let-7g improves mult.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jacc.2013.09.069</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>39</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">39</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lin, C. M.</style></author><author><style face="normal" font="default" size="100%">Chang, C. K.</style></author><author><style face="normal" font="default" size="100%">Chang, C. P.</style></author><author><style face="normal" font="default" size="100%">Hsu, Y. C.</style></author><author><style face="normal" font="default" size="100%">Lin, M. T.</style></author><author><style face="normal" font="default" size="100%">Lin, J. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.&#xD;Department of Surgery, College of Medicine, Taipei Medical University, Taipei, Taiwan.&#xD;Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan.&#xD;Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Protecting against ischaemic stroke in rats by heat shock protein 20-mediated exercise</style></title><secondary-title><style face="normal" font="default" size="100%">Eur J Clin Invest</style></secondary-title><alt-title><style face="normal" font="default" size="100%">European journal of clinical investigation</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur J Clin Invest</style></full-title><abbr-1><style face="normal" font="default" size="100%">European journal of clinical investigation</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Eur J Clin Invest</style></full-title><abbr-1><style face="normal" font="default" size="100%">European journal of clinical investigation</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1297-305</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2015/10/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/metabolism/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Infarction/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Frontal Lobe/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">HSP20 Heat-Shock Proteins/metabolism/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Ligation</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Cerebral Artery</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroglia/metabolism/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/metabolism/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Physical Conditioning, Animal/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery of Function/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ prevention &amp; control</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1365-2362 (Electronic)&#xD;0014-2972 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26479875</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Exercise preconditioning (EP(+) ) has been widely accepted as a being of safe and effective preventive measure for stroke. The purpose of this study was to investigate whether EP(+) improves outcomes of ischaemic stroke by promoting neuronal and glial expression of heat shock protein (HSP) 20. MATERIALS AND METHODS: Adult male Sprague-Dawley rats (288 in number) were used to investigate the contribution of HSP20-containing neurons and HSP20-containing glial cells in the exercise-mediated neuroprotection in the stroke condition using middle cerebral artery occlusion. RESULTS: Exercise preconditioning, in addition to increasing the numbers of both the HSP20-containg neurons (88 +/- 8 vs. 43 +/- 4; n = 8 each group; P &lt; 0.05) and the HSP20-containg astrocytes (102 +/- 10 vs. 56 +/- 5; n = 8; P &lt; 0.05) significantly attenuated stroke-induced brain infarct (140 +/- 9 vs. 341 +/- 20 mm(3) ; n = 8 per group; P &lt; 0.01), neuronal apoptosis (20 +/- 5 vs. 87 +/- 7; n = 8 per group; n = 8; P &lt; 0.01), glial apoptosis (29 +/- 5 vs. 101 +/- 4; n = 8; P &lt; 0.01), and neurological deficits (6.6 +/- 0.3 vs. 11.7 +/- 0.8; n = 8 per group; P &lt; 0.01). Reducing the numbers of both HSP20-containing neurons and HSP20-contaiing glia by intracerebral injection of pSUPER small interfering RNAiota expressing HSP20 significantly reversed the beneficial effects of EP(+) in attenuating stroke-induced cerebral infarct, neuronal and glial apoptosis, and neurological deficits. CONCLUSIONS: The numbers of both the HSP20-containing neurons and the HSP20-containing glia inversely correlated with the outcomes of ischaemic stroke. In addition, preischaemic treadmill exercise improves outcomes of ischaemic stroke by increasing the numbers of both the HSP20-containing neurons and the HSP20-containing glia.</style></abstract><notes><style face="normal" font="default" size="100%">Lin, Chien-Min&#xD;Chang, Cheng-Kuei&#xD;Chang, Ching-Ping&#xD;Hsu, Yu-Chih&#xD;Lin, Mao-Tsun&#xD;Lin, Jia-Wei&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Eur J Clin Invest. 2015 Dec;45(12):1297-305. doi: 10.1111/eci.12551. Epub 2015 Nov 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/eci.12551/asset/eci12551.pdf?v=1&amp;t=ixsiawjb&amp;s=1be3de702b5b42f7f41b4fdb7dac0b581b4bbe6a</style></url></related-urls><pdf-urls><url>internal-pdf://1561763394/Lin-2015-Protecting against i.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/eci.12551</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>124</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">124</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lin, X.</style></author><author><style face="normal" font="default" size="100%">Miao, P.</style></author><author><style face="normal" font="default" size="100%">Mu, Z.</style></author><author><style face="normal" font="default" size="100%">Jiang, Z.</style></author><author><style face="normal" font="default" size="100%">Lu, Y.</style></author><author><style face="normal" font="default" size="100%">Guan, Y.</style></author><author><style face="normal" font="default" size="100%">Chen, X.</style></author><author><style face="normal" font="default" size="100%">Xiao, T.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Yang, G. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, People&apos;s Republic of China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Development of functional in vivo imaging of cerebral lenticulostriate artery using novel synchrotron radiation angiography</style></title><secondary-title><style face="normal" font="default" size="100%">Phys Med Biol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Physics in medicine and biology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Phys Med Biol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Physics in medicine and biology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Phys Med Biol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Physics in medicine and biology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1655-65</style></pages><volume><style face="normal" font="default" size="100%">60</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2015/01/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Angiography/instrumentation/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Elasticity Imaging Techniques/instrumentation/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Synchrotrons</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 21</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1361-6560 (Electronic)&#xD;0031-9155 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25632958</style></accession-num><abstract><style face="normal" font="default" size="100%">The lenticulostriate artery plays a vital role in the onset and development of cerebral ischemia. However, current imaging techniques cannot assess the in vivo functioning of small arteries such as the lenticulostriate artery in the brain of rats. Here, we report a novel method to achieve a high resolution multi-functional imaging of the cerebrovascular system using synchrotron radiation angiography, which is based on spatio-temporal analysis of contrast density in the arterial cross section. This method provides a unique tool for studying the sub-cortical vascular elasticity after cerebral ischemia in rats. Using this technique, we demonstrated that the vascular elasticity of the lenticulostriate artery decreased from day 1 to day 7 after transient middle cerebral artery occlusion in rats and recovered from day 7 to day 28 compared to the controls (p &lt; 0.001), which paralleled with brain edema formation and inversely correlated with blood flow velocity (p &lt; 0.05). Our results demonstrated that the change of vascular elasticity was related to the levels of brain edema and the velocity of focal blood flow, suggesting that reducing brain edema is important for the improvement of the function of the lenticulostriate artery in the ischemic brain.</style></abstract><notes><style face="normal" font="default" size="100%">Lin, Xiaojie&#xD;Miao, Peng&#xD;Mu, Zhihao&#xD;Jiang, Zhen&#xD;Lu, Yifan&#xD;Guan, Yongjing&#xD;Chen, Xiaoyan&#xD;Xiao, Tiqiao&#xD;Wang, Yongting&#xD;Yang, Guo-Yuan&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Phys Med Biol. 2015 Feb 21;60(4):1655-65. doi: 10.1088/0031-9155/60/4/1655. Epub 2015 Jan 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://iopscience.iop.org/article/10.1088/0031-9155/60/4/1655/pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1507308610/Lin-2015-Development of funct.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1088/0031-9155/60/4/1655</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>301</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">301</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lin, Z. J.</style></author><author><style face="normal" font="default" size="100%">Ren, M.</style></author><author><style face="normal" font="default" size="100%">Li, L.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Su, J.</style></author><author><style face="normal" font="default" size="100%">Yang, S. H.</style></author><author><style face="normal" font="default" size="100%">Liu, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Bioengineering, Joint Graduate Program between University of Texas at Arlington and University of Texas Southwestern Medical Center, University of Texas at Arlington, TX 76019, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Interleaved imaging of cerebral hemodynamics and blood flow index to monitor ischemic stroke and treatment in rat by volumetric diffuse optical tomography</style></title><secondary-title><style face="normal" font="default" size="100%">Neuroimage</style></secondary-title><alt-title><style face="normal" font="default" size="100%">NeuroImage</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuroimage</style></full-title><abbr-1><style face="normal" font="default" size="100%">NeuroImage</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuroimage</style></full-title><abbr-1><style face="normal" font="default" size="100%">NeuroImage</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">566-82</style></pages><volume><style face="normal" font="default" size="100%">85 Pt 1</style></volume><edition><style face="normal" font="default" size="100%">2013/07/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Atlases as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ pathology/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Coloring Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Data Interpretation, Statistical</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Functional Neuroimaging/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Image Processing, Computer-Assisted</style></keyword><keyword><style face="normal" font="default" size="100%">Indocyanine Green</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Embolism/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Spectroscopy, Near-Infrared/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ pathology/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Tomography, Optical/ methods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1095-9572 (Electronic)&#xD;1053-8119 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23872158</style></accession-num><abstract><style face="normal" font="default" size="100%">Diffuse optical tomography (DOT) has been used by several groups to assess cerebral hemodynamics of cerebral ischemia in humans and animals. In this study, we combined DOT with an indocyanine green (ICG)-tracking method to achieve interleaved images of cerebral hemodynamics and blood flow index (BFI) using two middle cerebral artery occlusion (MCAO) rat models. To achieve volumetric images with high-spatial resolution, we first integrated a depth compensation algorithm (DCA) with a volumetric mesh-based rat head model to generate three-dimensional (3D) DOT on a rat brain atlas. Then, the experimental DOT data from two rat models were collected using interleaved strategy for cerebral hemodynamics and BFI during and after ischemic stroke, with and without a thrombolytic therapy for the embolic MCAO model. The acquired animal data were further analyzed using the integrated rat-atlas-guided DOT method to form time-evolving 3D images of both cerebral hemodynamics and BFI. In particular, we were able to show and identify therapeutic outcomes of a thrombolytic treatment applied to the embolism-induced ischemic model. This paper demonstrates that volumetric DOT is capable of providing high-quality, interleaved images of cerebral hemodynamics and blood perfusion in small animals during and after ischemic stroke, with excellent 3D visualization and quantifications.</style></abstract><notes><style face="normal" font="default" size="100%">Lin, Zi-Jing&#xD;Ren, Ming&#xD;Li, Lin&#xD;Liu, Yueming&#xD;Su, Jianzhong&#xD;Yang, Shao-Hua&#xD;Liu, Hanli&#xD;R33 CA101098/CA/NCI NIH HHS/United States&#xD;R33 NS052850/NS/NINDS NIH HHS/United States&#xD;5R33CA101098/CA/NCI NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;United States&#xD;Neuroimage. 2014 Jan 15;85 Pt 1:566-82. doi: 10.1016/j.neuroimage.2013.07.020. Epub 2013 Jul 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S1053811913007751/1-s2.0-S1053811913007751-main.pdf?_tid=f2f1fd80-d7be-11e6-883b-00000aacb35f&amp;acdnat=1484112760_dfb64d9e97cceb708e3d689e40705a80</style></url></related-urls><pdf-urls><url>internal-pdf://0397135494/Lin-2014-Interleaved imaging.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4524538</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms506603</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuroimage.2013.07.020</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>160</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">160</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, B.</style></author><author><style face="normal" font="default" size="100%">Li, L. L.</style></author><author><style face="normal" font="default" size="100%">Tan, X. D.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y. H.</style></author><author><style face="normal" font="default" size="100%">Jiang, Y.</style></author><author><style face="normal" font="default" size="100%">He, G. Q.</style></author><author><style face="normal" font="default" size="100%">Chen, Q.</style></author><author><style face="normal" font="default" size="100%">Li, C. Q.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.&#xD;Department of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. licq9218@163.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Gadd45b Mediates Axonal Plasticity and Subsequent Functional Recovery After Experimental Stroke in Rats</style></title><secondary-title><style face="normal" font="default" size="100%">Mol Neurobiol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Molecular neurobiology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Mol Neurobiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Molecular neurobiology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Mol Neurobiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Molecular neurobiology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1245-56</style></pages><volume><style face="normal" font="default" size="100%">52</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2014/10/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Differentiation/genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Axons/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain-Derived Neurotrophic Factor/biosynthesis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclic AMP Response Element-Binding Protein/biosynthesis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Regeneration/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuronal Plasticity/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">RNA Interference</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/biosynthesis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery of Function</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">rho-Associated Kinases/biosynthesis/genetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-1182 (Electronic)&#xD;0893-7648 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25324012</style></accession-num><abstract><style face="normal" font="default" size="100%">Stroke causes devastating and irreversible losses of neurological function with subsequent slow and incomplete recovery of lost brain functions, because of the brain&apos;s limited capacity for brain plasticity. Growth arrest and DNA-damage-inducible protein 45 beta (Gadd45b) has recently been demonstrated as a candidate plasticity-related gene, making it an excellent candidate molecule that has therapeutic potential. Here, we examine whether in vivo blockage of Gadd45b affects axonal plasticity and subsequent functional recovery after focal brain infarction. Adult male Sprague-Dawley rats were subjected to cerebral ischemia by middle cerebral artery occlusion (MCAO). We adopted RNA interference (RNAi) mediated by a lentiviral vector (LV) as a means of suppressing the expression of Gadd45b. Functional recovery was assessed with a battery of tests that measured skilled forelimb reaching and forelimb balance controlling. Axonal reorganization at the level of the red nucleus was revealed by anatomical studies. Axonal regeneration was measured by elevated expression of growth-associated protein 43 (GAP-43). The levels of brain-derived neurotrophic factor (BDNF), cyclic AMP (cAMP), protein kinase A (PKA), and Rho-kinase (ROCK) were determined. Gadd45b-RNAi significantly inhibited axonal plasticity (axonal regeneration and axonal reorganization) after MCAO. This inhibition was paralleled by worse functional recovery performance on several behavioral measures. Gadd45b-RNAi also significantly decreased the expression levels of both BDNF and cAMP/PKA/phosphorylated cAMP response element-binding protein (pCREB) pathway and promoted ROCK expression. We conclude that Gadd45b stimulates recovery after stroke by enhancing axonal plasticity required for brain repair. Pharmacological targeting of Gadd45b provides new opportunities for stroke treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Liu, Bin&#xD;Li, Long-ling&#xD;Tan, Xiao-dan&#xD;Zhang, Yan-hong&#xD;Jiang, Ying&#xD;He, Guo-qian&#xD;Chen, Qian&#xD;Li, Chang-qing&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Mol Neurobiol. 2015 Dec;52(3):1245-56. doi: 10.1007/s12035-014-8909-0. Epub 2014 Oct 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/601/art%253A10.1007%252Fs12035-014-8909-0.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12035-014-8909-0&amp;token2=exp=1484122523~acl=%2Fstatic%2Fpdf%2F601%2Fart%25253A10.1007%25252Fs12035-014-8909-0.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs12035-014-8909-0*~hmac=57bd32251c72bbe234a16a6261b3ff8cd47da573460154765a164338a92e08f4</style></url></related-urls><pdf-urls><url>internal-pdf://0774389011/Liu-2015-Gadd45b Mediates Axo.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12035-014-8909-0</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>407</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">407</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, S.</style></author><author><style face="normal" font="default" size="100%">Hu, W. X.</style></author><author><style face="normal" font="default" size="100%">Zu, Q. Q.</style></author><author><style face="normal" font="default" size="100%">Lu, S. S.</style></author><author><style face="normal" font="default" size="100%">Xu, X. Q.</style></author><author><style face="normal" font="default" size="100%">Sun, L.</style></author><author><style face="normal" font="default" size="100%">Zhou, W. Z.</style></author><author><style face="normal" font="default" size="100%">Shi, H. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A novel embolic stroke model resembling lacunar infarction following proximal middle cerebral artery occlusion in beagle dogs</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosci Methods</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neuroscience methods</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosci Methods</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroscience methods</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosci Methods</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroscience methods</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">90-6</style></pages><volume><style face="normal" font="default" size="100%">209</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2012/06/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Dogs</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ complications/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Angiography</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke, Lacunar/ etiology/ pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 30</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-678X (Electronic)&#xD;0165-0270 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22722089</style></accession-num><abstract><style face="normal" font="default" size="100%">It is estimated that lacunar infarcts account for 25% of all ischemic strokes, but its exact etiology is still on debating. The existing controversies include whether the embolisms can indeed cause lacunar stroke in humans or animal models. We hypothesized that lacunar infarction can be induced by the proximal middle cerebral artery (MCA) segmental occlusion involving the orifices of lenticulostriate arteries in animal models, which have abundant distal cerebral collateral anastomosis. Our work here establishes a proximal MCA occlusion model using thrombi (autologous blood clots about 1.7 mm in diameter and 5 mm in length) in 8 beagle dogs, evaluates the progression of ischemic lesions at 30 min interval within 6 h after embolization using the diffusion weighted imaging (DWI), and discusses the potential mechanisms of lacunar infarction. Our results indicate that the left proximal MCAs can be successfully occluded in all dogs using interventional single-thrombus method. The small solitary or multiple ischemic lesions shown in DWI were observed in the deep brain area, with the mean detecting time of 1.21 +/- 0.45 h using DWI and diameter of 6.62 +/- 0.60mm in 6h-DWI after procedure. In conclusion, our method established an ischemic model which can recapitulate the radiologic and histologic changes in lacunar infarcts, suggesting that emboli can cause lacunar infarcts in animal model.</style></abstract><notes><style face="normal" font="default" size="100%">Liu, Sheng&#xD;Hu, Wei-Xing&#xD;Zu, Qing-Quan&#xD;Lu, Shan-Shan&#xD;Xu, Xiao-Quan&#xD;Sun, Lei&#xD;Zhou, Wei-Zhong&#xD;Shi, Hai-Bin&#xD;Netherlands&#xD;J Neurosci Methods. 2012 Jul 30;209(1):90-6. doi: 10.1016/j.jneumeth.2012.06.009. Epub 2012 Jun 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0165027012002221/1-s2.0-S0165027012002221-main.pdf?_tid=4f7bf114-d7d3-11e6-848b-00000aacb35d&amp;acdnat=1484121505_678f29ee1746f8e165b47580cab2d61e</style></url></related-urls><pdf-urls><url>internal-pdf://0276581283/Liu-2012-A novel embolic stro.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jneumeth.2012.06.009</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>202</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">202</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, T.</style></author><author><style face="normal" font="default" size="100%">Zhang, T.</style></author><author><style face="normal" font="default" size="100%">Yu, H.</style></author><author><style face="normal" font="default" size="100%">Shen, H.</style></author><author><style face="normal" font="default" size="100%">Xia, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Road, Shanghai 200127, China. wlxia@sjtu.edu.cn.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Adjudin protects against cerebral ischemia reperfusion injury by inhibition of neuroinflammation and blood-brain barrier disruption</style></title><secondary-title><style face="normal" font="default" size="100%">J Neuroinflammation</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neuroinflammation</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neuroinflammation</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroinflammation</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neuroinflammation</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroinflammation</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">107</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><edition><style face="normal" font="default" size="100%">2014/06/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, CD11b/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/ drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/drug effects/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Infarction/drug therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrazines/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Indazoles/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Matrix Metalloproteinase 9/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Microglia/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurologic Examination</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide Synthase Type II/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Occludin/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/complications/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Zonula Occludens-1 Protein/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 14</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1742-2094 (Electronic)&#xD;1742-2094 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24927761</style></accession-num><abstract><style face="normal" font="default" size="100%">Neuroinflammation mediated by activation of microglia and interruption of the blood-brain barrier (BBB) is an important factor that contributes to neuron death and infarct area diffusion in ischemia reperfusion injury. Finding novel molecules to regulate neuroinflammation is of significant clinical value. We have previously shown that adjudin, a small molecule compound known to possess antispermatogenic function, attenuates microglia activation by suppression of the NF-kappaB pathway. In this study we continued to explore whether adjudin could be neuroprotective by using the transient middle cerebral artery occlusion (tMCAO) model. Adjudin treatment after reperfusion significantly decreased the infarction volume and neuroscore compared to the vehicle group. Staining of CD11b showed that adjudin markedly inhibited microglial activation in both the cortex and the striatum, accompanied by a reduction in the expression and release of cytokines TNF-alpha, IL-1beta and IL-6. Concomitantly, adjudin noticeably prevented BBB disruption after ischemia and reperfusion, as indicated by the reduction of IgG detection in the brain cortex and striatum versus the vehicle group. This finding was also corroborated by immunofluorescence staining and immunoblotting of tight junction-related proteins ZO-1, JAM-A and Occludin, where the reduction of these proteins could be attenuated by adjudin treatment. Moreover, adjudin obviously inhibited the elevated MMP-9 activity after stroke. Together these data demonstrate that adjudin protects against cerebral ischemia reperfusion injury, and we present an effective neuroinflammation modulator with clinical potential.</style></abstract><notes><style face="normal" font="default" size="100%">Liu, Tengyuan&#xD;Zhang, Tingting&#xD;Yu, Hemei&#xD;Shen, Hailian&#xD;Xia, Weiliang&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Neuroinflammation. 2014 Jun 14;11:107. doi: 10.1186/1742-2094-11-107.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/572/art%253A10.1186%252F1742-2094-11-107.pdf?originUrl=http%3A%2F%2Fjneuroinflammation.biomedcentral.com%2Farticle%2F10.1186%2F1742-2094-11-107&amp;token2=exp=1484121633~acl=%2Fstatic%2Fpdf%2F572%2Fart%25253A10.1186%25252F1742-2094-11-107.pdf*~hmac=b8765e3282d1ba066bd60d6368d7847501a3d442d4c6faa0c90adda55a7ae16d</style></url></related-urls><pdf-urls><url>internal-pdf://3861143363/Liu-2014-Adjudin protects aga.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4132223</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/1742-2094-11-107</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>464</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">464</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Cheng, C.</style></author><author><style face="normal" font="default" size="100%">Shao, B.</style></author><author><style face="normal" font="default" size="100%">Wu, X.</style></author><author><style face="normal" font="default" size="100%">Ji, Y.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Lu, X.</style></author><author><style face="normal" font="default" size="100%">Shen, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Medical College, Nantong University, Nantong 226001, Jiangsu, People&apos;s Republic of China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">CDK11(p58) promotes rat astrocyte inflammatory response via activating p38 and JNK pathways induced by lipopolysaccharide</style></title><secondary-title><style face="normal" font="default" size="100%">Neurochem Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurochemical research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurochem Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurochemical research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurochem Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurochemical research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">563-73</style></pages><volume><style face="normal" font="default" size="100%">37</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2011/11/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/drug effects/enzymology/ immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Base Sequence</style></keyword><keyword><style face="normal" font="default" size="100%">Blotting, Western</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclin-Dependent Kinases/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">DNA Primers</style></keyword><keyword><style face="normal" font="default" size="100%">Flow Cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">Lipopolysaccharides/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">MAP Kinase Kinase 4/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reverse Transcriptase Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default" size="100%">p38 Mitogen-Activated Protein Kinases/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1573-6903 (Electronic)&#xD;0364-3190 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22120654</style></accession-num><abstract><style face="normal" font="default" size="100%">In response to a variety of neural damages in the CNS, quiescent astrocytes become reactive astrocytes. Astrocytes are the major glial subtype and are important effectors that participate in the pathogenesis of numerous neural disorders, including trauma, stroke, aging, and developmental, genetic, idiopathic or acquired neurodegenerative diseases. CDK11(p58) (Cyclin-dependent kinases 11 protein 58/PITSLRE) is a p34cdc2-related protein kinase that plays an important role in normal cell cycle progression. In the process of LPS stimulus, the expression of CDK11(p58) in astrocytes was increased. Induced CDK11(p58) was parallel to astrocyte inflammatory response. Knockdown of CDK11(p58) by small-interfering RNAs (siRNAs) reduced the LPS-induced astrocyte inflammatory response, while overexpression CDK11(p58) enhanced the process. CDK11(p58) exerted its functions via activating p38 and JNK MAPK pathways. This study delineates that CDK11(p58) may be a significant regulatory factor for host defenses in central nervous system (CNS) inflammation.</style></abstract><notes><style face="normal" font="default" size="100%">Liu, Xiaojuan&#xD;Cheng, Chun&#xD;Shao, Bai&#xD;Wu, Xiaohong&#xD;Ji, Yuhong&#xD;Liu, Yichang&#xD;Lu, Xiang&#xD;Shen, Aiguo&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Neurochem Res. 2012 Mar;37(3):563-73. doi: 10.1007/s11064-011-0643-7. Epub 2011 Nov 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/957/art%253A10.1007%252Fs11064-011-0643-7.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs11064-011-0643-7&amp;token2=exp=1484122532~acl=%2Fstatic%2Fpdf%2F957%2Fart%25253A10.1007%25252Fs11064-011-0643-7.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs11064-011-0643-7*~hmac=eae3f585bcbd57dcf8ba4c8a1df6e959019b0d862126109b88bb73cef87ec862</style></url></related-urls><pdf-urls><url>internal-pdf://2017482208/Liu-2012-CDK11(p58) promotes.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s11064-011-0643-7</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>188</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">188</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Zhao, S.</style></author><author><style face="normal" font="default" size="100%">Liu, F.</style></author><author><style face="normal" font="default" size="100%">Kang, J.</style></author><author><style face="normal" font="default" size="100%">Xiao, A.</style></author><author><style face="normal" font="default" size="100%">Li, F.</style></author><author><style face="normal" font="default" size="100%">Zhang, C.</style></author><author><style face="normal" font="default" size="100%">Yan, F.</style></author><author><style face="normal" font="default" size="100%">Zhao, H.</style></author><author><style face="normal" font="default" size="100%">Luo, M.</style></author><author><style face="normal" font="default" size="100%">Luo, Y.</style></author><author><style face="normal" font="default" size="100%">Ji, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Cerebrovascular Diseases Research Institute, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Beijing, 100053, People&apos;s Republic of China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Remote ischemic postconditioning alleviates cerebral ischemic injury by attenuating endoplasmic reticulum stress-mediated apoptosis</style></title><secondary-title><style face="normal" font="default" size="100%">Transl Stroke Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Translational stroke research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Transl Stroke Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Translational stroke research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Transl Stroke Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Translational stroke research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">692-700</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2014/07/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ blood supply/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Endoplasmic Reticulum Stress</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/metabolism/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Preconditioning</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/metabolism/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/metabolism/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Transcription Factor CHOP/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1868-601X (Electronic)&#xD;1868-4483 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25043802</style></accession-num><abstract><style face="normal" font="default" size="100%">Remote ischemic postconditioning (RIPostC) has been proved to protect the brain from stroke, but the precise mechanism remains not fully understood. In the present study, we aimed to investigate whether RIPostC attenuates cerebral ischemia-reperfusion injury by abating endoplasmic reticulum (ER) stress response. CHOP, a multifunctional transcription factor in ER stress, regulates the expression of genes related to apoptosis, such as Bim and Bcl-2. Male SD rats were subjected to right middle cerebral artery occlusion (MCAO) for 2 h followed by reperfusion, and RIPostC was induced by three cycles of 10 min ischemia and 10 min reperfusion on bilateral femoral arteries immediately after ischemia. CHOP siRNA (CHOPi) and control siRNA (Coni) were injected into the right lateral ventricle 30 min before the beginning of ischemia. RIPostC, CHOPi, or RIPostC + CHOPi application reduced infarct volume, improved the neurological function, and decreased cell apoptosis. RIPostC increased the protein level of glucose-regulated protein 78 (GRP78) and decreased the protein level of phosphorylated-EIF2alpha, caspase-12, and CHOP. Furthermore, the expression of CHOP, Bim and cleaved-caspase-3 was decreased, while Bcl-2 expression was increased in response to application of RIPostC, CHOPi, or RIPostC + CHOPi. In sum, RIPostC protects against ischemia-reperfusion brain injury in rats by attenuating ER stress response-induced apoptosis.</style></abstract><notes><style face="normal" font="default" size="100%">Liu, Xiangrong&#xD;Zhao, Shangfeng&#xD;Liu, Fang&#xD;Kang, Jun&#xD;Xiao, Ao&#xD;Li, Fang&#xD;Zhang, Chencheng&#xD;Yan, Feng&#xD;Zhao, Haiping&#xD;Luo, Mei&#xD;Luo, Yumin&#xD;Ji, Xunming&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Transl Stroke Res. 2014 Dec;5(6):692-700. doi: 10.1007/s12975-014-0359-5. Epub 2014 Jul 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/864/art%253A10.1007%252Fs12975-014-0359-5.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12975-014-0359-5&amp;token2=exp=1484122537~acl=%2Fstatic%2Fpdf%2F864%2Fart%25253A10.1007%25252Fs12975-014-0359-5.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs12975-014-0359-5*~hmac=397aa863597c34acd262f4d198d0315bde24d87fc653ebf5ad3a2a2bc478430d</style></url></related-urls><pdf-urls><url>internal-pdf://2736745502/Liu-2014-Remote ischemic post.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12975-014-0359-5</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>56</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">56</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Llovera, G.</style></author><author><style face="normal" font="default" size="100%">Hofmann, K.</style></author><author><style face="normal" font="default" size="100%">Roth, S.</style></author><author><style face="normal" font="default" size="100%">Salas-Perdomo, A.</style></author><author><style face="normal" font="default" size="100%">Ferrer-Ferrer, M.</style></author><author><style face="normal" font="default" size="100%">Perego, C.</style></author><author><style face="normal" font="default" size="100%">Zanier, E. R.</style></author><author><style face="normal" font="default" size="100%">Mamrak, U.</style></author><author><style face="normal" font="default" size="100%">Rex, A.</style></author><author><style face="normal" font="default" size="100%">Party, H.</style></author><author><style face="normal" font="default" size="100%">Agin, V.</style></author><author><style face="normal" font="default" size="100%">Fauchon, C.</style></author><author><style face="normal" font="default" size="100%">Orset, C.</style></author><author><style face="normal" font="default" size="100%">Haelewyn, B.</style></author><author><style face="normal" font="default" size="100%">De Simoni, M. G.</style></author><author><style face="normal" font="default" size="100%">Dirnagl, U.</style></author><author><style face="normal" font="default" size="100%">Grittner, U.</style></author><author><style face="normal" font="default" size="100%">Planas, A. M.</style></author><author><style face="normal" font="default" size="100%">Plesnila, N.</style></author><author><style face="normal" font="default" size="100%">Vivien, D.</style></author><author><style face="normal" font="default" size="100%">Liesz, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute for Stroke and Dementia Research, Klinikum der Universitat Munchen, Feodor-Lynen-Strasse 17, 81377 Munich, Germany. Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.&#xD;Department of Brain Ischemia and Neurodegeneration, Institut d&apos;Investigacions Biomediques de Barcelona (IIBB), Consejo Superior de Investigaciones Cientificas (CSIC), 08036 Barcelona, Spain. Area de Neurociencies, Institut d&apos;Investigacions Biomediques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.&#xD;Neuroscience Department, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, 20156 Milan, Italy.&#xD;Department of Experimental Neurology and Center for Stroke Research Berlin (CSB), Charite-Universitatsmedizin Berlin; German Center for Neurodegenerative Diseases (DZNE) and German Center for Cardiovascular Diseases (DZHK), Berlin sites; Excellence Cluster NeuroCure, 10117 Berlin, Germany.&#xD;INSERM, UMR-S U919, Universite de Caen Basse-Normandie, team Serine Proteases and Pathophysiology of the neurovascular Unit, GIP Cyceron, F-14074 Caen Cedex, France.&#xD;Experimental Stroke Research Platform (ESRP), IBiSA platform, Centre Universitaire de Ressources Biologiques (CURB), Universite de Caen Basse-Normandie, F-14074 Caen Cedex, France.&#xD;INSERM, UMR-S U919, Universite de Caen Basse-Normandie, team Serine Proteases and Pathophysiology of the neurovascular Unit, GIP Cyceron, F-14074 Caen Cedex, France. Experimental Stroke Research Platform (ESRP), IBiSA platform, Centre Universitaire de Ressources Biologiques (CURB), Universite de Caen Basse-Normandie, F-14074 Caen Cedex, France.&#xD;Department of Biostatistics and Clinical Epidemiology, Charite-Universitatsmedizin Berlin, 12203 Berlin, Germany.&#xD;Institute for Stroke and Dementia Research, Klinikum der Universitat Munchen, Feodor-Lynen-Strasse 17, 81377 Munich, Germany. Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany. arthur.liesz@med.uni-muenchen.de.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Results of a preclinical randomized controlled multicenter trial (pRCT): Anti-CD49d treatment for acute brain ischemia</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Transl Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Science translational medicine</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Sci Transl Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Science translational medicine</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Sci Transl Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Science translational medicine</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">299ra121</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">299</style></number><edition><style face="normal" font="default" size="100%">2015/08/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Acute Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ drug therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Evaluation, Preclinical</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Integrin alpha4/ immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 05</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1946-6242 (Electronic)&#xD;1946-6234 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26246166</style></accession-num><abstract><style face="normal" font="default" size="100%">Numerous treatments have been reported to provide a beneficial outcome in experimental animal stroke models; however, these treatments (with the exception of tissue plasminogen activator) have failed in clinical trials. To improve the translation of treatment efficacy from bench to bedside, we have performed a preclinical randomized controlled multicenter trial (pRCT) to test a potential stroke therapy under circumstances closer to the design and rigor of a clinical randomized control trial. Anti-CD49d antibodies, which inhibit the migration of leukocytes into the brain, were previously investigated in experimental stroke models by individual laboratories. Despite the conflicting results from four positive and one inconclusive preclinical studies, a clinical trial was initiated. To confirm the preclinical results and to test the feasibility of conducting a pRCT, six independent European research centers investigated the efficacy of anti-CD49d antibodies in two distinct mouse models of stroke in a centrally coordinated, randomized, and blinded approach. The results pooled from all research centers revealed that treatment with CD49d-specific antibodies significantly reduced both leukocyte invasion and infarct volume after the permanent distal occlusion of the middle cerebral artery, which causes a small cortical infarction. In contrast, anti-CD49d treatment did not reduce lesion size or affect leukocyte invasion after transient proximal occlusion of the middle cerebral artery, which induces large lesions. These results suggest that the benefits of immune-targeted approaches may depend on infarct severity and localization. This study supports the feasibility of performing pRCTs.</style></abstract><notes><style face="normal" font="default" size="100%">Llovera, Gemma&#xD;Hofmann, Kerstin&#xD;Roth, Stefan&#xD;Salas-Perdomo, Angelica&#xD;Ferrer-Ferrer, Maura&#xD;Perego, Carlo&#xD;Zanier, Elisa R&#xD;Mamrak, Uta&#xD;Rex, Andre&#xD;Party, Helene&#xD;Agin, Veronique&#xD;Fauchon, Claudine&#xD;Orset, Cyrille&#xD;Haelewyn, Benoit&#xD;De Simoni, Maria-Grazia&#xD;Dirnagl, Ulrich&#xD;Grittner, Ulrike&#xD;Planas, Anna M&#xD;Plesnila, Nikolaus&#xD;Vivien, Denis&#xD;Liesz, Arthur&#xD;Multicenter Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Sci Transl Med. 2015 Aug 5;7(299):299ra121. doi: 10.1126/scitranslmed.aaa9853.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stm.sciencemag.org/content/scitransmed/7/299/299ra121.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1661303939/Llovera-2015-Results of a preclin.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1126/scitranslmed.aaa9853</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>174</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">174</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Llovera, G.</style></author><author><style face="normal" font="default" size="100%">Roth, S.</style></author><author><style face="normal" font="default" size="100%">Plesnila, N.</style></author><author><style face="normal" font="default" size="100%">Veltkamp, R.</style></author><author><style face="normal" font="default" size="100%">Liesz, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute for Stroke and Dementia Research, University Hospital Munich; Munich Cluster for Systems Neurology (SyNergy).&#xD;Department of Neurology, University Heidelberg; Imperial College, Charing Cross Hospital.&#xD;Institute for Stroke and Dementia Research, University Hospital Munich; Munich Cluster for Systems Neurology (SyNergy); Arthur.Liesz@med.uni-muenchen.de.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Modeling stroke in mice: permanent coagulation of the distal middle cerebral artery</style></title><secondary-title><style face="normal" font="default" size="100%">J Vis Exp</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of visualized experiments : JoVE</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Vis Exp</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of visualized experiments : JoVE</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Vis Exp</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of visualized experiments : JoVE</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e51729</style></pages><number><style face="normal" font="default" size="100%">89</style></number><edition><style face="normal" font="default" size="100%">2014/08/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Coagulation</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Coagulation Disorders/ blood/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ blood/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ blood/pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 31</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1940-087X (Electronic)&#xD;1940-087X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25145316</style></accession-num><abstract><style face="normal" font="default" size="100%">Stroke is the third most common cause of death and a main cause of acquired adult disability in developed countries. Only very limited therapeutical options are available for a small proportion of stroke patients in the acute phase. Current research is intensively searching for novel therapeutic strategies and is increasingly focusing on the sub-acute and chronic phase after stroke because more patients might be eligible for therapeutic interventions in a prolonged time window. These delayed mechanisms include important pathophysiological pathways such as post-stroke inflammation, angiogenesis, neuronal plasticity and regeneration. In order to analyze these mechanisms and to subsequently evaluate novel drug targets, experimental stroke models with clinical relevance, low mortality and high reproducibility are sought after. Moreover, mice are the smallest mammals in which a focal stroke lesion can be induced and for which a broad spectrum of transgenic models are available. Therefore, we describe here the mouse model of transcranial, permanent coagulation of the middle cerebral artery via electrocoagulation distal of the lenticulostriatal arteries, the so-called &quot;coagulation model&quot;. The resulting infarct in this model is located mainly in the cortex; the relative infarct volume in relation to brain size corresponds to the majority of human strokes. Moreover, the model fulfills the above-mentioned criteria of reproducibility and low mortality. In this video we demonstrate the surgical methods of stroke induction in the &quot;coagulation model&quot; and report histological and functional analysis tools.</style></abstract><notes><style face="normal" font="default" size="100%">Llovera, Gemma&#xD;Roth, Stefan&#xD;Plesnila, Nikolaus&#xD;Veltkamp, Roland&#xD;Liesz, Arthur&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Video-Audio Media&#xD;United States&#xD;J Vis Exp. 2014 Jul 31;(89):e51729. doi: 10.3791/51729.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.jove.com/pdf/51729/jove-protocol-51729-modeling-stroke-mice-permanent-coagulation-distal-middle-cerebral</style></url></related-urls><pdf-urls><url>internal-pdf://2951508987/Llovera-2014-Modeling stroke in m.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4692348</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3791/51729</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>54</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">54</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lloyd, E. E.</style></author><author><style face="normal" font="default" size="100%">Durgan, D. J.</style></author><author><style face="normal" font="default" size="100%">Martini, S. R.</style></author><author><style face="normal" font="default" size="100%">Bryan, R. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From the Departments of Anesthesiology (E.E.L., D.J.D., R.M.B.), Molecular Physiology and Biophysics (R.M.B.), Medicine (Cardiovascular Section) (R.M.B.), and Neurology (S.R.M.), Baylor College of Medicine, Houston, TX; and Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX (S.R.M.).&#xD;From the Departments of Anesthesiology (E.E.L., D.J.D., R.M.B.), Molecular Physiology and Biophysics (R.M.B.), Medicine (Cardiovascular Section) (R.M.B.), and Neurology (S.R.M.), Baylor College of Medicine, Houston, TX; and Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX (S.R.M.). rbryan@bcm.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pathological effects of obstructive apneas during the sleep cycle in an animal model of cerebral small vessel disease</style></title><secondary-title><style face="normal" font="default" size="100%">Hypertension</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Hypertension (Dallas, Tex. : 1979)</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hypertension</style></full-title><abbr-1><style face="normal" font="default" size="100%">Hypertension (Dallas, Tex. : 1979)</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Hypertension</style></full-title><abbr-1><style face="normal" font="default" size="100%">Hypertension (Dallas, Tex. : 1979)</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">913-7</style></pages><volume><style face="normal" font="default" size="100%">66</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2015/08/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Small Vessel Diseases/etiology/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred SHR</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred WKY</style></keyword><keyword><style face="normal" font="default" size="100%">Sleep</style></keyword><keyword><style face="normal" font="default" size="100%">Sleep Apnea, Obstructive/ complications/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">White Matter/ pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4563 (Electronic)&#xD;0194-911X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26259594</style></accession-num><abstract><style face="normal" font="default" size="100%">We tested the hypothesis that apneas during the sleep cycle exacerbate hypertension and accelerate changes that occur with cerebral small vessel disease. Obstructive sleep apnea was modeled by intermittent inflations of a chronically implanted tracheal balloon to occlude the airway during the sleep cycle (termed OSA) in spontaneously hypertensive stroke-prone (SHRSP) rats, a model of cerebral small vessel disease. SHRSP rats and their parent strain, Wistar Kyoto (WKY) rats, were exposed to OSA for 2 weeks (from 9 to 11 or from 18 to 20 weeks). At 9 weeks, hypertension was developing in the SHRSP rats and was firmly established by 18 weeks. OSA exposure increased systolic blood pressure in SHRSP rats by approximately 30 mm Hg in both age groups compared with shams that were surgically prepared but not exposed to OSA (P&lt;0.05). OSA exposure also increased systolic blood pressure in WKY rats by 20 and 37 mm Hg at 11 and 20 weeks, respectively (P&lt;0.05). OSA exposure in SHRSP rats compromised blood-brain barrier integrity in white matter at both 11 and 20 weeks of age when compared with SHRSP sham rats (P&lt;0.05). Microglia were activated in SHRSP rats exposed to OSA but not in sham rats at 11 weeks (P&lt;0.05). At 20 weeks, microglia were activated in sham SHRSP rats (P&lt;0.05) compared with WKY sham rats and were not further activated by OSA. Neither was blood-brain barrier integrity altered nor microglia activated in any of the WKY groups. We conclude that OSA accelerates the onset of the cerebral pathologies associated with cerebral small vessel disease in SHRSP, but not WKY, rats.</style></abstract><notes><style face="normal" font="default" size="100%">Lloyd, Eric E&#xD;Durgan, David J&#xD;Martini, Sharyl R&#xD;Bryan, Robert M&#xD;R21 NS094806/NS/NINDS NIH HHS/United States&#xD;R01 NS080531/NS/NINDS NIH HHS/United States&#xD;P30 DK056338/DK/NIDDK NIH HHS/United States&#xD;UL1 TR001425/TR/NCATS NIH HHS/United States&#xD;5R01NS080531/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;United States&#xD;Hypertension. 2015 Oct;66(4):913-7. doi: 10.1161/HYPERTENSIONAHA.115.05764. Epub 2015 Aug 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://hyper.ahajournals.org/content/hypertensionaha/66/4/913.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3026224114/Lloyd-2015-Pathological effects.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4567494</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms709889</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/hypertensionaha.115.05764</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>320</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">320</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lobsien, D.</style></author><author><style face="normal" font="default" size="100%">Dreyer, A. Y.</style></author><author><style face="normal" font="default" size="100%">Stroh, A.</style></author><author><style face="normal" font="default" size="100%">Boltze, J.</style></author><author><style face="normal" font="default" size="100%">Hoffmann, K. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neuroradiology, University Hospital Leipzig, Leipzig, Germany. donald.lobsien@medizin.uni-leipzig.de</style></auth-address><titles><title><style face="normal" font="default" size="100%">Imaging of VSOP labeled stem cells in agarose phantoms with susceptibility weighted and T2* weighted MR Imaging at 3T: determination of the detection limit</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PloS one</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e62644</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2013/05/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Ferric Compounds/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Limit of Detection</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Mesenchymal Stromal Cells/metabolism/ ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Particle Size</style></keyword><keyword><style face="normal" font="default" size="100%">Phantoms, Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Sepharose</style></keyword><keyword><style face="normal" font="default" size="100%">Sheep</style></keyword><keyword><style face="normal" font="default" size="100%">Staining and Labeling/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Stem Cell Transplantation/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203 (Electronic)&#xD;1932-6203 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23667503</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVES: This study aimed to evaluate the detectability of stem cells labeled with very small iron oxide particles (VSOP) at 3T with susceptibility weighted (SWI) and T2* weighted imaging as a methodological basis for subsequent examinations in a large animal stroke model (sheep). MATERIALS AND METHODS: We examined ovine mesenchymal stem cells labeled with VSOP in agarose layer phantoms. The experiments were performed in 2 different groups, with quantities of 0-100,000 labeled cells per layer. 15 different SWI- and T2*-weighted sequences and 3 RF coils were used. All measurements were carried out on a clinical 3T MRI. Images of Group A were analyzed by four radiologists blinded for the number of cells, and rated for detectability according to a four-step scale. Images of Group B were subject to a ROI-based analysis of signal intensities. Signal deviations of more than the 0.95 confidence interval in cell containing layers as compared to the mean of the signal intensity of non cell bearing layers were considered significant. RESULTS: GROUP A: 500 or more labeled cells were judged as confidently visible when examined with a SWI-sequence with 0.15 mm slice thickness. Group B: 500 or more labeled cells showed a significant signal reduction in SWI sequences with a slice thickness of 0.25 mm. Slice thickness and cell number per layer had a significant influence on the amount of detected signal reduction. CONCLUSION: 500 VSOP labeled stem cells could be detected with SWI imaging at 3 Tesla using an experimental design suitable for large animal models.</style></abstract><notes><style face="normal" font="default" size="100%">Lobsien, Donald&#xD;Dreyer, Antje Y&#xD;Stroh, Albrecht&#xD;Boltze, Johannes&#xD;Hoffmann, Karl-Titus&#xD;United States&#xD;PLoS One. 2013 May 8;8(5):e62644. doi: 10.1371/journal.pone.0062644. Print 2013.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0062644&amp;type=printable</style></url></related-urls><pdf-urls><url>internal-pdf://1986328475/Lobsien-2013-Imaging of VSOP labe.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3648551</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0062644</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>287</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">287</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Loh, K. P.</style></author><author><style face="normal" font="default" size="100%">Ng, G.</style></author><author><style face="normal" font="default" size="100%">Yu, C. Y.</style></author><author><style face="normal" font="default" size="100%">Fhu, C. K.</style></author><author><style face="normal" font="default" size="100%">Yu, D.</style></author><author><style face="normal" font="default" size="100%">Vennekens, R.</style></author><author><style face="normal" font="default" size="100%">Nilius, B.</style></author><author><style face="normal" font="default" size="100%">Soong, T. W.</style></author><author><style face="normal" font="default" size="100%">Liao, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Calcium Signaling Laboratory, National Neuroscience Institute, 11 Jalan Tan Tock Seng, 308433, Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">TRPM4 inhibition promotes angiogenesis after ischemic stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Pflugers Arch</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Pflugers Archiv : European journal of physiology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pflugers Arch</style></full-title><abbr-1><style face="normal" font="default" size="100%">Pflugers Archiv : European journal of physiology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Pflugers Arch</style></full-title><abbr-1><style face="normal" font="default" size="100%">Pflugers Archiv : European journal of physiology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">563-76</style></pages><volume><style face="normal" font="default" size="100%">466</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2013/09/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Hypoxia</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelium, Vascular/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Human Umbilical Vein Endothelial Cells/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ metabolism/physiopathology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Locomotion</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Neovascularization, Physiologic</style></keyword><keyword><style face="normal" font="default" size="100%">Phenanthrenes/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">RNA Interference</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">TRPM Cation Channels/antagonists &amp; inhibitors/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1432-2013 (Electronic)&#xD;0031-6768 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24043570</style></accession-num><abstract><style face="normal" font="default" size="100%">Transient receptor potential melastatin 4 (TRPM4) is a voltage-dependent, nonselective cation channel. Under pathological conditions, sustained activation of TRPM4 leads to oncotic cell death. Here, we report the upregulation of TRPM4 in vascular endothelium following hypoxia/ischemia in vitro and in vivo. In human umbilical vein endothelial cells, TRPM4 expression was increased at both the mRNA and protein levels following oxygen-glucose deprivation. Blocking TRPM4 with 9-phenanthrol greatly enhanced tube formation on Matrigel. In a rat permanent middle cerebral artery occlusion model, TRPM4 was upregulated in the vascular endothelium within the penumbra region after stroke. TRPM4 expression peaked 1 day post-occlusion and gradually decreased. In vivo siRNA-mediated TRPM4 silencing enhanced angiogenesis and improved capillary integrity. A twofold reduction in infarct volume and a substantial recovery of motor function were observed in animals receiving the siRNA treatment. Interestingly, the protective effect of TRPM4 suppression disappeared 5 days after stroke induction, indicating that TRPM4 upregulation is critical for cerebral damage during the acute phase of stroke. TRPM4 could be a potential therapeutic target for ischemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Loh, Kok Poh&#xD;Ng, Gandi&#xD;Yu, Chye Yun&#xD;Fhu, Chee Kong&#xD;Yu, Dejie&#xD;Vennekens, Rudi&#xD;Nilius, Bernd&#xD;Soong, Tuck Wah&#xD;Liao, Ping&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Germany&#xD;Pflugers Arch. 2014 Mar;466(3):563-76. doi: 10.1007/s00424-013-1347-4. Epub 2013 Sep 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/566/art%253A10.1007%252Fs00424-013-1347-4.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00424-013-1347-4&amp;token2=exp=1484122547~acl=%2Fstatic%2Fpdf%2F566%2Fart%25253A10.1007%25252Fs00424-013-1347-4.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs00424-013-1347-4*~hmac=7c6cc9589c3ad0c61276a173c52c94bf00d39ed00939870de4fcdc2f3a44cff7</style></url></related-urls><pdf-urls><url>internal-pdf://1502385004/Loh-2014-TRPM4 inhibition pro.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00424-013-1347-4</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>215</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">215</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Longden, T. A.</style></author><author><style face="normal" font="default" size="100%">Dabertrand, F.</style></author><author><style face="normal" font="default" size="100%">Hill-Eubanks, D. C.</style></author><author><style face="normal" font="default" size="100%">Hammack, S. E.</style></author><author><style face="normal" font="default" size="100%">Nelson, M. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departments of Pharmacology and.&#xD;Psychology, University of Vermont, Burlington, VT 05405; and.&#xD;Departments of Pharmacology andInstitute of Cardiovascular Sciences, University of Manchester, Manchester M13 9PL, United Kingdom Mark.Nelson@uvm.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Stress-induced glucocorticoid signaling remodels neurovascular coupling through impairment of cerebrovascular inwardly rectifying K+ channel function</style></title><secondary-title><style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Proceedings of the National Academy of Sciences of the United States of America</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style></full-title><abbr-1><style face="normal" font="default" size="100%">Proceedings of the National Academy of Sciences of the United States of America</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style></full-title><abbr-1><style face="normal" font="default" size="100%">Proceedings of the National Academy of Sciences of the United States of America</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">7462-7</style></pages><volume><style face="normal" font="default" size="100%">111</style></volume><number><style face="normal" font="default" size="100%">20</style></number><edition><style face="normal" font="default" size="100%">2014/05/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Amygdala/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arterioles/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/drug effects/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Corticosterone/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Glucocorticoids/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Hormone Antagonists/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Limbic System/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mifepristone/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Potassium Channels, Inwardly Rectifying/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">Stress, Psychological</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilation/drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">May 20</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1091-6490 (Electronic)&#xD;0027-8424 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24808139</style></accession-num><abstract><style face="normal" font="default" size="100%">Studies of stress effects on the brain have traditionally focused on neurons, without considering the cerebral microcirculation. Here we report that stress impairs neurovascular coupling (NVC), the process that matches neuronal activity with increased local blood flow. A stressed phenotype was induced in male rats by administering a 7-d heterotypical stress paradigm. NVC was modeled by measuring parenchymal arteriole (PA) vasodilation in response to neuronal stimulation in amygdala brain slices. After stress, vasodilation of PAs to neuronal stimulation was greatly reduced, and dilation of isolated PAs to external K(+) was diminished, suggesting a defect in smooth muscle inwardly rectifying K(+) (KIR) channel function. Consistent with these observations, stress caused a reduction in PA KIR2.1 mRNA and smooth muscle KIR current density, and blocking KIR channels significantly inhibited NVC in control, but not in stressed, slices. Delivery of corticosterone for 7 d (without stressors) or RU486 (before stressors) mimicked and abrogated NVC impairment by stress, respectively. We conclude that stress causes a glucocorticoid-mediated decrease in functional KIR channels in amygdala PA myocytes. This renders arterioles less responsive to K(+) released from astrocytic endfeet during NVC, leading to impairment of this process. Because the fidelity of NVC is essential for neuronal health, the impairment characterized here may contribute to the pathophysiology of brain disorders with a stress component.</style></abstract><notes><style face="normal" font="default" size="100%">Longden, Thomas A&#xD;Dabertrand, Fabrice&#xD;Hill-Eubanks, David C&#xD;Hammack, Sayamwong E&#xD;Nelson, Mark T&#xD;R01-MH-097988/MH/NIMH NIH HHS/United States&#xD;R01-HL-098243/HL/NHLBI NIH HHS/United States&#xD;P01 HL095488/HL/NHLBI NIH HHS/United States&#xD;P30 GM103498/GM/NIGMS NIH HHS/United States&#xD;P01-HL-095488/HL/NHLBI NIH HHS/United States&#xD;P20 RR016435/RR/NCRR NIH HHS/United States&#xD;R01-HL-044455/HL/NHLBI NIH HHS/United States&#xD;R01 MH097988/MH/NIMH NIH HHS/United States&#xD;R37 DK053832/DK/NIDDK NIH HHS/United States&#xD;R01 HL098243/HL/NHLBI NIH HHS/United States&#xD;P20-RR-16435/RR/NCRR NIH HHS/United States&#xD;R01 HL044455/HL/NHLBI NIH HHS/United States&#xD;R37-DK-053832/DK/NIDDK NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Proc Natl Acad Sci U S A. 2014 May 20;111(20):7462-7. doi: 10.1073/pnas.1401811111. Epub 2014 May 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.pnas.org/content/111/20/7462.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1024371036/Longden-2014-Stress-induced gluco.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4034203</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1073/pnas.1401811111</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>453</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">453</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lu, H.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">He, X.</style></author><author><style face="normal" font="default" size="100%">Yuan, F.</style></author><author><style face="normal" font="default" size="100%">Lin, X.</style></author><author><style face="normal" font="default" size="100%">Xie, B.</style></author><author><style face="normal" font="default" size="100%">Tang, G.</style></author><author><style face="normal" font="default" size="100%">Huang, J.</style></author><author><style face="normal" font="default" size="100%">Tang, Y.</style></author><author><style face="normal" font="default" size="100%">Jin, K.</style></author><author><style face="normal" font="default" size="100%">Chen, S.</style></author><author><style face="normal" font="default" size="100%">Yang, G. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Netrin-1 hyperexpression in mouse brain promotes angiogenesis and long-term neurological recovery after transient focal ischemia</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">838-43</style></pages><volume><style face="normal" font="default" size="100%">43</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2012/01/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Behavior, Animal/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Blotting, Western</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Chemistry/genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Capillaries/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Death/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Angiography/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Dependovirus/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorescent Antibody Technique</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Therapy/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Vectors</style></keyword><keyword><style face="normal" font="default" size="100%">Immunohistochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Attack, Transient/pathology/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Microscopy, Fluorescence</style></keyword><keyword><style face="normal" font="default" size="100%">Neovascularization, Physiologic/genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Growth Factors/biosynthesis/genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Postural Balance/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery of Function</style></keyword><keyword><style face="normal" font="default" size="100%">Tumor Suppressor Proteins/biosynthesis/genetics/ physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22223243</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: Netrin-1 (NT-1) stimulates endothelial cell proliferation and migration in vitro and promotes focal neovascularization in the adult brain in vivo. This in vivo study in mice investigated the effect of NT-1 hyperexpression on focal angiogenesis and long-term functional outcome after transient middle cerebral artery occlusion (tMCAO). METHODS: Adeno-associated viral vectors carrying either the NT-1 gene (AAV-NT-1) or GFP (AAV-GFP) were generated and injected into the brains of separate groups of 93 mice. Seven days later, tMCAO followed by 7-28 days of reperfusion were carried out. Histological outcomes and behavioral deficits were quantified 7-28 days after tMCAO. Small cerebral vessel network and angiogenesis were assessed 28 days after tMCAO, using synchrotron radiation microangiography and immunohistochemistry. RESULTS: Western blot and immunohistochemistry showed that on the day of tMCAO, NT-1 hyperexpression had been achieved in both normal and ischemic hemispheres. Immunofluorescence imaging showed that NT-1 expression was primarily in neurons and astrocytes. Ischemia-induced infarction in the NT-1 hyperexpression group was attenuated in comparison to saline or AAV-GFP-treated groups (P&lt;0.01). Similarly, neurological deficits were greatly improved in AAV-NT-1-treated mice compared with mice in saline or AAV-GFP-treated groups (P&lt;0.05). In addition, angiogenesis was increased in AAV-NT-1-treated mice compared with the other 2 groups (P&lt;0.05). In vivo synchrotron radiation microangiography 28 days after tMCAO revealed more branches in AAV-NT-1-treated mice than in other groups. CONCLUSIONS: AAV-NT-1 induced NT-1 hyperexpression before tMCAO reduced infarct size, enhanced neovascularization, and improved long-term functional recovery.</style></abstract><notes><style face="normal" font="default" size="100%">Lu, Haiyan&#xD;Wang, Yongting&#xD;He, Xiaosong&#xD;Yuan, Falei&#xD;Lin, Xiaojie&#xD;Xie, Bohua&#xD;Tang, Guanghui&#xD;Huang, Jun&#xD;Tang, Yaohui&#xD;Jin, Kunlin&#xD;Chen, Shengdi&#xD;Yang, Guo-Yuan&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Stroke. 2012 Mar;43(3):838-43. doi: 10.1161/STROKEAHA.111.635235. Epub 2012 Jan 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/43/3/838.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2659107978/Lu-2012-Netrin-1 hyperexpres.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.111.635235</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>451</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">451</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lu, H. T.</style></author><author><style face="normal" font="default" size="100%">Zhao, J. G.</style></author><author><style face="normal" font="default" size="100%">Li, M. H.</style></author><author><style face="normal" font="default" size="100%">Li, Y. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Interventional and Diagnostic Radiology, The Sixth Affiliated People&apos;s Hospital, Shanghai Jiao Tong University, No. 600, Yi Shan Road, Shanghai 200233, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Application of albumin prior to delayed thrombolysis reduces brain edema and blood brain barrier permeability in an embolic stroke model</style></title><secondary-title><style face="normal" font="default" size="100%">Brain Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">75-84</style></pages><volume><style face="normal" font="default" size="100%">1438</style></volume><edition><style face="normal" font="default" size="100%">2012/01/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Fibrinolytic Agents/ administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/complications/ drug therapy/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Embolism/complications/ drug therapy/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Permeability</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Proteins/administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Serum Albumin/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombolytic Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Tissue Plasminogen Activator/ administration &amp; dosage/therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-6240 (Electronic)&#xD;0006-8993 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22227456</style></accession-num><abstract><style face="normal" font="default" size="100%">To explore whether human albumin (Alb) administration prior to thrombolysis with recombinant tissue plasminogen activator (rt-PA) can eliminate brain damage induced by this treatment given after the effective and safe window of 3h after stroke onset. Rats were subjected to embolic stroke by unilateral embolic middle cerebral artery occlusion (MCAO). Three or six hours after the onset of stroke, rats were administered intravenously with saline (control), rt-PA (thrombolysis) or rt-PA+Alb (additional Alb 3h after MCAO, combination). Cerebral blood flow, infarct volume, space-occupying effect and blood brain barrier (BBB) leakage of gadopentetate dimeglumine (Gd-DTPA) were assessed dynamically by magnetic resonance imaging (MRI) at 24h, 7 and 14days after treatment. BBB leakage of both fluoro-isothiocyanate dextran (FITC-dextran) and erythrocytes was also evaluated 14days after treatment. The space-occupying effect in the combination group at 7days after treatment declined significantly compared with that at 24h after treatment (P&lt;0.05), but additional Alb treatment failed to reduce the infarct volumes or improve cerebral blood volume. Furthermore, BBB leakage of both small (Gd-DTPA) and large (FITC-dextran and erythrocytes) molecules decreased significantly in the combination compared to the saline or thrombolysis groups (P&lt;0.05). Alb administration prior to thrombolysis (3h after stroke) can reduce delayed rt-PA treatment-induced brain edema and BBB permeability.</style></abstract><notes><style face="normal" font="default" size="100%">Lu, Hai-Tao&#xD;Zhao, Jun-Gong&#xD;Li, Ming-Hua&#xD;Li, Yong-Dong&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;Brain Res. 2012 Feb 15;1438:75-84. doi: 10.1016/j.brainres.2011.12.026. Epub 2011 Dec 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S000689931102227X/1-s2.0-S000689931102227X-main.pdf?_tid=606d4658-d7d3-11e6-be8a-00000aacb361&amp;acdnat=1484121533_11a5832bdc7b56bf3205130195898a30</style></url></related-urls><pdf-urls><url>internal-pdf://0117747526/Lu-2012-Application of album.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.brainres.2011.12.026</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>490</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">490</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lu, J.</style></author><author><style face="normal" font="default" size="100%">Ng, K. C.</style></author><author><style face="normal" font="default" size="100%">Ling, G.</style></author><author><style face="normal" font="default" size="100%">Wu, J.</style></author><author><style face="normal" font="default" size="100%">Poon, D. J.</style></author><author><style face="normal" font="default" size="100%">Kan, E. M.</style></author><author><style face="normal" font="default" size="100%">Tan, M. H.</style></author><author><style face="normal" font="default" size="100%">Wu, Y. J.</style></author><author><style face="normal" font="default" size="100%">Li, P.</style></author><author><style face="normal" font="default" size="100%">Moochhala, S.</style></author><author><style face="normal" font="default" size="100%">Yap, E.</style></author><author><style face="normal" font="default" size="100%">Lee, L. K.</style></author><author><style face="normal" font="default" size="100%">Teo, M.</style></author><author><style face="normal" font="default" size="100%">Yeh, I. B.</style></author><author><style face="normal" font="default" size="100%">Sergio, D. M.</style></author><author><style face="normal" font="default" size="100%">Chua, F.</style></author><author><style face="normal" font="default" size="100%">Kumar, S. D.</style></author><author><style face="normal" font="default" size="100%">Ling, E. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Defence Medical and Environmental Research Institute, DSO National Laboratories, Singapore 117510. ljia@dso.org.sg</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of blast exposure on the brain structure and cognition in Macaca fascicularis</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurotrauma</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neurotrauma</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurotrauma</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurotrauma</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurotrauma</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurotrauma</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1434-54</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2011/06/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blast Injuries/ pathology/ physiopathology/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ pathology/physiology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/ pathology/ physiopathology/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition Disorders/pathology/physiopathology/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Macaca fascicularis</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">May 01</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1557-9042 (Electronic)&#xD;0897-7151 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">21639720</style></accession-num><abstract><style face="normal" font="default" size="100%">Blast injury to the brain is one of the major causes of death and can also significantly affect cognition and physical and psychological skills in survivors of blast. The complex mechanisms via which blast injury causes impairment of cognition and other symptoms are poorly understood. In this study, we investigated the effects of varying degrees of primary blast overpressure (BOP; 80 and 200 kPa) on the pathophysiological and magnetic resonance imaging (MRI) changes and neurocognitive performance as assessed by the monkey Cambridge Neuropsychological Test Automated Battery (mCANTAB) in non-human primates (NHP). The study aimed to examine the effects of neurobehavioral and histopathological changes in NHP. MRI and histopathology revealed ultrastructural changes in the brain, notably in the Purkinje neurons in the cerebellum and pyramidal neurons in the hippocampus, which were most vulnerable to the blast. The results correlated well with the behavioral changes and changes in motor coordination and working memory of the affected monkeys. In addition, there was white matter damage affecting myelinated axons, astrocytic hypertrophy, and increased aquaporin-4 (AQP-4) expression in astrocytes, suggesting cerebral edema. Increased apoptosis appeared to involve astrocytes and oligodendrocytes in the animals following blast exposure. The small sample size could have contributed to the non-significant outcome in cognitive performance post-blast and limited quantitative analyses. Nevertheless, the study has provided initial descriptive changes for establishing a primary BOP threshold for brain injury to serve as a useful platform for future investigations that aim to estimate brain injury potential and set safe limits of exposure.</style></abstract><notes><style face="normal" font="default" size="100%">Lu, Jia&#xD;Ng, Kian Chye&#xD;Ling, Geoffrey&#xD;Wu, Jian&#xD;Poon, David Jia Fei&#xD;Kan, Enci Mary&#xD;Tan, Mui Hong&#xD;Wu, Ya Jun&#xD;Li, Ping&#xD;Moochhala, Shabbir&#xD;Yap, Eric&#xD;Lee, Lionel Kim Hock&#xD;Teo, Melissa&#xD;Yeh, Ing Berne&#xD;Sergio, Darvi Michell Bufete&#xD;Chua, Frederic&#xD;Kumar, Srinivasan Dinesh&#xD;Ling, Eng-Ang&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United States&#xD;J Neurotrauma. 2012 May 1;29(7):1434-54. doi: 10.1089/neu.2010.1591. Epub 2011 Nov 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://online.liebertpub.com/doi/abs/10.1089/neu.2010.1591</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1089/neu.2010.1591</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>351</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">351</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lu, S. S.</style></author><author><style face="normal" font="default" size="100%">Liu, S.</style></author><author><style face="normal" font="default" size="100%">Zu, Q. Q.</style></author><author><style face="normal" font="default" size="100%">Xu, X. Q.</style></author><author><style face="normal" font="default" size="100%">Wang, J. W.</style></author><author><style face="normal" font="default" size="100%">Yu, J.</style></author><author><style face="normal" font="default" size="100%">Sun, L.</style></author><author><style face="normal" font="default" size="100%">Shi, H. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Radiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Multimodal magnetic resonance imaging for assessing lacunar infarction after proximal middle cerebral artery occlusion in a canine model</style></title><secondary-title><style face="normal" font="default" size="100%">Chin Med J (Engl)</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Chinese medical journal</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Chin Med J (Engl)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Chinese medical journal</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Chin Med J (Engl)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Chinese medical journal</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">311-7</style></pages><volume><style face="normal" font="default" size="100%">126</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2013/01/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Diffusion Magnetic Resonance Imaging/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Dogs</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ complications</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Angiography/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke, Lacunar/ diagnosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0366-6999 (Print)&#xD;0366-6999 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23324283</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: A new lacunar infarction model was recently established in beagle dogs through proximal middle cerebral artery (MCA) occlusion by thrombus. This study aimed to characterize the model by multimodal magnetic resonance imaging (MRI) and to investigate its potential role for the future stroke research. METHODS: The left proximal MCA was embolized with an autologous thrombus in six beagles. Diffusion-weighted imaging (DWI) and T2-weighted imaging (T2WI) were performed every half hour during the first six hours after occlusion, followed by three time points at 12 hours, 24 hours, and one week. Perfusion-weighted imaging (PWI) and magnetic resonance angiography (MRA) were carried out at six hours, 24 hours and one week. The PWI-DWI mismatch ratio was defined as (PWI-DWI)/DWI ischemic volume. RESULTS: Lacunar infarcts induced by MCA occlusion were located in the left caudate nucleus and internal capsule. All the lesions could be detected within two hours by DWI. Lesion volume on DWI increased in a time dependent manner, from (87.19 +/- 67.16) mm(3) at one hour up to (368.98 +/- 217.05) mm(3) at 24 hours (P = 0.009), while that on PWI gradually decreased from (7315.00 +/- 2054.38) mm(3) at six hours to (4900.33 +/- 1319.71) mm(3) at 24 hours and (3334.33 +/- 1195.11) mm(3) at one week (P = 0.002). The mismatch ratio was 41.93 +/- 22.75 at six hours after ischemia, showing &quot;extensive mismatch&quot;, and decreased to 18.10 +/- 13.74 at 24 hours (P = 0.002). No MCA recanalization was observed within 24 hours after MCA occlusion. CONCLUSIONS: Lacunar infarction induced by proximal MCA occlusion could be detected early by DWI and was characterized by extensive PWI-DWI mismatch. Multimodal MRI is useful to demonstrate the natural evolution of PWI-DWI mismatch. This ischemic model could be further used for investigating early thrombolysis in lacunar stroke showing extensive mismatch.</style></abstract><notes><style face="normal" font="default" size="100%">Lu, Shan-Shan&#xD;Liu, Sheng&#xD;Zu, Qing-Quan&#xD;Xu, Xiao-Quan&#xD;Wang, Jian-Wei&#xD;Yu, Jing&#xD;Sun, Lei&#xD;Shi, Hai-Bin&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;China&#xD;Chin Med J (Engl). 2013 Jan;126(2):311-7.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>232</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">232</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lv, W.</style></author><author><style face="normal" font="default" size="100%">Lin, Y.</style></author><author><style face="normal" font="default" size="100%">Song, W.</style></author><author><style face="normal" font="default" size="100%">Sun, K.</style></author><author><style face="normal" font="default" size="100%">Yu, H.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, C.</style></author><author><style face="normal" font="default" size="100%">Li, L.</style></author><author><style face="normal" font="default" size="100%">Suo, M.</style></author><author><style face="normal" font="default" size="100%">Hui, R.</style></author><author><style face="normal" font="default" size="100%">Chen, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sino-German Laboratory for Molecular Medicine, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishilu, Beijing, 100037, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Variants of COL3A1 are associated with the risk of stroke recurrence and prognosis in the Chinese population: a prospective study</style></title><secondary-title><style face="normal" font="default" size="100%">J Mol Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of molecular neuroscience : MN</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Mol Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of molecular neuroscience : MN</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Mol Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of molecular neuroscience : MN</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">196-203</style></pages><volume><style face="normal" font="default" size="100%">53</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2014/03/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">China</style></keyword><keyword><style face="normal" font="default" size="100%">Collagen Type III/ genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">NIH 3T3 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/diagnosis/ genetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-1166 (Electronic)&#xD;0895-8696 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24664438</style></accession-num><abstract><style face="normal" font="default" size="100%">Type III collagen plays an important role in activating platelets, forming thrombus, and maintaining the mechanical properties of arteries. This study aimed to test the hypothesis that genetic variants of COL3A1 (gene encoding type III collagen) contribute to recurrence and prognosis of stroke. We investigated the associations of three variants (rs2138533, rs11887092, and rs1800255) in the COL3A1 gene with stroke recurrence and prognosis in 1,544 patients with three subtypes of stroke: lacunar infarction (n = 442), atherothrombotic infarction (n = 670), and hemorrhage (n = 432). These associations were evaluated by Kaplan-Meier analysis and Cox regression models. Patients were followed up for 4.5 years. The A allele of rs1800255 in the COL3A1 gene coding region was significantly associated with a reduced risk of stroke recurrence in patients with lacunar infarction (adjusted hazard ratio [HR] 0.58, 95 % confidence interval [CI] 0.36-0.93, P = 0.024), but there was an increased risk of all-cause mortality of atherothrombotic patients (adjusted HR 1.43, 95 % CI 1.01-2.00, P = 0.044). The TT genotype of rs2138533 showed a significantly increased risk of death caused by cardiovascular disease or stroke in lacunar infarct patients (adjusted HR 2.98, 95 % CI 1.27-6.98, P = 0.012), but there was a reduced risk of all-cause mortality for patients with intracerebral hemorrhage (adjusted HR 0.34, 95 % CI 0.12-0.93, P = 0.036). The G allele of rs11887092 increased the risk of stroke recurrence in patients with atherothrombotic stroke (adjusted HR 1.59, 95 % CI 1.04-2.44, P = 0.035). In conclusion, variants of COL3A1 might play a vital role in determining the risk of recurrence and prognosis after stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Lv, Wenfei&#xD;Lin, Yahui&#xD;Song, Weihua&#xD;Sun, Kai&#xD;Yu, Hui&#xD;Zhang, Yinhui&#xD;Zhang, Channa&#xD;Li, Liang&#xD;Suo, Miaomiao&#xD;Hui, Rutai&#xD;Chen, Jingzhou&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Mol Neurosci. 2014 Jun;53(2):196-203. doi: 10.1007/s12031-014-0283-x. Epub 2014 Mar 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/150/art%253A10.1007%252Fs12031-014-0283-x.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12031-014-0283-x&amp;token2=exp=1484122561~acl=%2Fstatic%2Fpdf%2F150%2Fart%25253A10.1007%25252Fs12031-014-0283-x.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs12031-014-0283-x*~hmac=0f6d91768da1e8875fcaffe84a6a8744cbb3a26fdeb02cda228a071573c015c6</style></url></related-urls><pdf-urls><url>internal-pdf://4111387516/Lv-2014-Variants of COL3A1 a.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12031-014-0283-x</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>36</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">36</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lv, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, B.</style></author><author><style face="normal" font="default" size="100%">Zhai, C.</style></author><author><style face="normal" font="default" size="100%">Qiu, J.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Yao, W.</style></author><author><style face="normal" font="default" size="100%">Zhang, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.&#xD;Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. Electronic address: wlyao82@126.com.&#xD;Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. Electronic address: chzhang@tjh.tjmu.edu.cn.</style></auth-address><titles><title><style face="normal" font="default" size="100%">PFKFB3-mediated glycolysis is involved in reactive astrocyte proliferation after oxygen-glucose deprivation/reperfusion and is regulated by Cdh1</style></title><secondary-title><style face="normal" font="default" size="100%">Neurochem Int</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurochemistry international</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurochem Int</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurochemistry international</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurochem Int</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurochemistry international</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">26-33</style></pages><volume><style face="normal" font="default" size="100%">91</style></volume><edition><style face="normal" font="default" size="100%">2015/10/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apc1 Subunit, Anaphase-Promoting Complex-Cyclosome/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cadherins/biosynthesis/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Hypoxia</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Proliferation</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Knockdown Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose/deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Glycolysis</style></keyword><keyword><style face="normal" font="default" size="100%">Lactic Acid/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphofructokinase-2/biosynthesis/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-9754 (Electronic)&#xD;0197-0186 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26498254</style></accession-num><abstract><style face="normal" font="default" size="100%">Reactive astrocyte proliferation is involved in many central degenerative diseases. The enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase isoform 3 (PFKFB3), an allosteric activator of 6-phosphofructo-1-kinase (PFK1), controls glycolytic flux. Furthermore, APC/C-Cdh1 plays a crucial role in brain metabolism by regulating PFKFB3 expression. Previous studies have defined the roles of PFKFB3-mediated glycolysis in pathological angiogenesis, cell autophagy, and amyloid plaque deposition in proliferating cells. However, the role of PFKFB3 in reactive astrocyte proliferation after cerebral ischemia is unknown. In this study, we cultured rat primary cortical astrocytes and established an oxygen-glucose deprivation/reperfusion (OGD/R) model to mimic cerebral ischemia in vivo. Astrocyte proliferation was measured by western blotting for proliferating cell nuclear antigen (PCNA) and by EdU incorporation. We found that OGD/R up-regulated PFKFB3 and PFK1 expression, which was accompanied by reactive astrocyte proliferation. Knockdown of PFKFB3 by siRNA transfection significantly inhibited reactive astrocyte proliferation and lactate release, an indicator of glycolysis. We found that PFKFB3 and PFK1 expression were down-regulated and lactate release was decreased when OGD/R-induced astrocyte proliferation was inhibited by a Cdh1-expressing lentivirus. Thus, reactive astrocyte proliferation can be effectively suppressed by down-regulation of PFKFB3 through control of glycolytic flux, which is downstream of APC/C-Cdh1.</style></abstract><notes><style face="normal" font="default" size="100%">Lv, Youyou&#xD;Zhang, Bo&#xD;Zhai, Chunchun&#xD;Qiu, Jin&#xD;Zhang, Yue&#xD;Yao, Wenlong&#xD;Zhang, Chuanhan&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Neurochem Int. 2015 Dec;91:26-33. doi: 10.1016/j.neuint.2015.10.006. Epub 2015 Oct 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0197018615300565/1-s2.0-S0197018615300565-main.pdf?_tid=68171d5c-d7d3-11e6-8348-00000aab0f27&amp;acdnat=1484121546_525975b88e4768b89a025647945a09e3</style></url></related-urls><pdf-urls><url>internal-pdf://2171919984/Lv-2015-PFKFB3-mediated glyc.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuint.2015.10.006</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>263</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">263</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ma, Q.</style></author><author><style face="normal" font="default" size="100%">Chen, S.</style></author><author><style face="normal" font="default" size="100%">Hu, Q.</style></author><author><style face="normal" font="default" size="100%">Feng, H.</style></author><author><style face="normal" font="default" size="100%">Zhang, J. H.</style></author><author><style face="normal" font="default" size="100%">Tang, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Physiology and Pharmacology, Loma Linda University, Loma Linda, CA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">NLRP3 inflammasome contributes to inflammation after intracerebral hemorrhage</style></title><secondary-title><style face="normal" font="default" size="100%">Ann Neurol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Annals of neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Ann Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Annals of neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Ann Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Annals of neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">209-19</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2013/11/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antioxidants/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Carrier Proteins/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/ complications/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Cholestenones/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme Inhibitors/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation/drug effects/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Hematoma/drug therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/ etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Injections, Intraventricular</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">NLR Family, Pyrin Domain-Containing 3 Protein</style></keyword><keyword><style face="normal" font="default" size="100%">Neutrophil Infiltration/drug effects/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Organophosphorus Compounds/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Piperidines/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1531-8249 (Electronic)&#xD;0364-5134 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24273204</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: The NLRP3 (NALP3, cryopyrin) inflammasome, a key component of the innate immune system, facilitates caspase-1 and interleukin (IL)-1beta processing, which amplifies the inflammatory response. Here, we investigated whether NLRP3 knockdown decreases neutrophil infiltration, reduces brain edema, and improves neurological function in an intracerebral hemorrhage (ICH) mouse model. We also determined whether mitochondrial reactive oxygen species (ROS) governed by mitochondrial permeability transition pores (mPTPs) would trigger NLRP3 inflammasome activation following ICH. METHODS: ICH was induced by injecting autologous arterial blood (30mul) into a mouse brain. NLRP3 small interfering RNAs were administered 24 hours before ICH. A mPTP inhibitor (TRO-19622) or a specific mitochondria ROS scavenger (Mito-TEMPO) was coinjected with the blood. In naive animals, rotenone, which is a respiration chain complex I inhibitor, was applied to induce mitochondrial ROS production, and followed by TRO-19622 or Mito-TEMPO treatment. Neurological deficits, brain edema, enzyme-linked immunosorbent assay, Western blot, in vivo chemical cross-linking, ROS assay, and immunofluorescence were evaluated. RESULTS: ICH activated the NLRP3 inflammasome. NLRP3 knockdown reduced brain edema and decreased myeloperoxidase (MPO) levels at 24 hours, and improved neurological functions from 24 to 72 hours following ICH. TRO-19622 or Mito-TEMPO reduced ROS, NLRP3 inflammasome components, and MPO levels following ICH. In naive animals, rotenone administration induced mPTP formation, ROS generation, and NLRP3 inflammasome activation, which were then reduced by TRO-19622 or Mito-TEMPO. INTERPRETATION: The NLRP3 inflammasome amplified the inflammatory response by releasing IL-1beta and promoting neutrophil infiltration following ICH. Mitochondria ROS may be a major trigger of NLRP3 inflammasome activation. The results of our study suggest that the inhibition of the NLRP3 inflammasome may effectively reduce the inflammatory response following ICH.ANN NEUROL 2014;75:209-219.</style></abstract><notes><style face="normal" font="default" size="100%">Ma, Qingyi&#xD;Chen, Sheng&#xD;Hu, Qin&#xD;Feng, Hua&#xD;Zhang, John H&#xD;Tang, Jiping&#xD;NS053407/NS/NINDS NIH HHS/United States&#xD;R01 NS078755/NS/NINDS NIH HHS/United States&#xD;P01 NS082184/NS/NINDS NIH HHS/United States&#xD;R01 NS053407/NS/NINDS NIH HHS/United States&#xD;R01 NS060936/NS/NINDS NIH HHS/United States&#xD;NS060936/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Ann Neurol. 2014 Feb;75(2):209-19. doi: 10.1002/ana.24070. Epub 2014 Jan 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1002/ana.24070/asset/ana24070.pdf?v=1&amp;t=ixsnjizd&amp;s=dd58a3475c7f88c71b9d2d95782d2d3f749142b5</style></url></related-urls><pdf-urls><url>internal-pdf://0612167287/Ma-2014-NLRP3 inflammasome c.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4386653</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms672276</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/ana.24070</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>24</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">24</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ma, Y. Z.</style></author><author><style face="normal" font="default" size="100%">Li, L.</style></author><author><style face="normal" font="default" size="100%">Song, J. K.</style></author><author><style face="normal" font="default" size="100%">Niu, Z. R.</style></author><author><style face="normal" font="default" size="100%">Liu, H. F.</style></author><author><style face="normal" font="default" size="100%">Zhou, X. S.</style></author><author><style face="normal" font="default" size="100%">Xie, F. S.</style></author><author><style face="normal" font="default" size="100%">Du, G. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Beijing Key Laboratory of Drug Target and Screening Research, Institute of Materia Medica, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100050, China.&#xD;Shandong Ehua Biopharmaceutical Co., Ltd., Shandong 252201, China; Shandong Dong-e E-Jiao Co., Ltd., Shandong 252201, China.&#xD;Shandong Dong-e E-Jiao Co., Ltd., Shandong 252201, China.&#xD;Shandong Ehua Biopharmaceutical Co., Ltd., Shandong 252201, China.&#xD;Beijing Key Laboratory of Drug Target and Screening Research, Institute of Materia Medica, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100050, China. Electronic address: dugh@imm.ac.cn.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A novel embolic middle cerebral artery occlusion model induced by thrombus formed in common carotid artery in rat</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurol Sci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of the neurological sciences</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurol Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of the neurological sciences</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurol Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of the neurological sciences</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">275-9</style></pages><volume><style face="normal" font="default" size="100%">359</style></volume><number><style face="normal" font="default" size="100%">1-2</style></number><edition><style face="normal" font="default" size="100%">2015/12/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Analysis of Variance</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Infarction/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Artery Diseases/ complications</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Fibrinolytic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Forelimb/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ etiology/mortality/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nervous System Diseases/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Postural Balance</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Rotarod Performance Test</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Tissue Plasminogen Activator/therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1878-5883 (Electronic)&#xD;0022-510X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26671127</style></accession-num><abstract><style face="normal" font="default" size="100%">Stroke is a major cause of death and disability worldwide. However, treatment options to date are very limited. To meet the need for validating the novel therapeutic approaches and understanding the physiopathology of the ischemic brain injury, experimental stroke models were critical for preclinical research. However, commonly used embolic stroke models are reluctant to mimic the clinical situation and not suitable for thrombolytic timing studies. In this paper, we established a standard method for producing a rat embolic stroke model with autologous thrombus formed within the common carotid artery (CCA) by constant galvanic stimulation. Then the thrombus was shattered and channeled into the origin of the MCA and small (lacunar) artery. To identify the success of MCA occlusion, regional cerebral blood flow was monitored, neurological deficits and infarct volumes were measured at 2, 4 and 6h postischemia. This model developed a predictable infarct volume (38.37 +/- 2.88%) and gradually reduced blood flow (20% of preischemic baselines) within the middle cerebral artery (MCA) territory. The thrombus occluded in the MCA was able to be lysed by a tissue-type plasminogen activator (t-PA) within 4h postischemia. The techniques presented in this paper would help investigators to overcome technical problems for stroke research.</style></abstract><notes><style face="normal" font="default" size="100%">Ma, Yin-Zhong&#xD;Li, Li&#xD;Song, Jun-Ke&#xD;Niu, Zi-Ran&#xD;Liu, Hai-Feng&#xD;Zhou, Xiang-Shan&#xD;Xie, Fu-Sheng&#xD;Du, Guan-Hua&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;J Neurol Sci. 2015 Dec 15;359(1-2):275-9. doi: 10.1016/j.jns.2015.09.362. Epub 2015 Oct 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0022510X15024508/1-s2.0-S0022510X15024508-main.pdf?_tid=76da57dc-d7d3-11e6-88a9-00000aacb35e&amp;acdnat=1484121571_5dffc3d0b837fab1834b57a5d3d5fa8a</style></url></related-urls><pdf-urls><url>internal-pdf://3757785259/Ma-2015-A novel embolic midd.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jns.2015.09.362</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>389</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">389</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Machicao, F.</style></author><author><style face="normal" font="default" size="100%">Muresanu, D. F.</style></author><author><style face="normal" font="default" size="100%">Hundsberger, H.</style></author><author><style face="normal" font="default" size="100%">Pfluger, M.</style></author><author><style face="normal" font="default" size="100%">Guekht, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Molecular Genetics and Diagnosis, Department of Internal Medicine IV, Otfried Muller Str. 10, University Hospital, D-72076 Tubingen, Germany. fausto.machicao@med.uni-tuebingen.de</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pleiotropic neuroprotective and metabolic effects of Actovegin&apos;s mode of action</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurol Sci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of the neurological sciences</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurol Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of the neurological sciences</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurol Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of the neurological sciences</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">222-7</style></pages><volume><style face="normal" font="default" size="100%">322</style></volume><number><style face="normal" font="default" size="100%">1-2</style></number><edition><style face="normal" font="default" size="100%">2012/08/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/drug effects/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Heme/ analogs &amp; derivatives/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">NF-kappa B/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nervous System Diseases/ metabolism/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1878-5883 (Electronic)&#xD;0022-510X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22910148</style></accession-num><abstract><style face="normal" font="default" size="100%">This article reviews the mechanisms of action of Actovegin in the context of its preclinical effects and new concepts in the pharmacological treatment of neurological disorders. Actovegin is an ultrafiltrate of calf blood, composed of more than 200 biological substances. The drug is used for a broad spectrum of diseases, including disturbances of peripheral and cerebral blood circulation, burns, impaired wound healing, radiation-induced damage and diabetic polyneuropathy. Actovegin is composed of small molecules present under normal physiological conditions, therefore pharmacokinetic and pharmacodynamic studies to determine its active substance are not feasible. Preclinical data have revealed that it improves metabolic balance by increasing glucose uptake and improving oxygen uptake under conditions of ischemia. Actovegin also resists the effects of gamma-irradiation and stimulates wound healing. More recent preclinical studies have suggested that anti-oxidative and anti-apoptotic mechanisms of action specifically underlie the neuroprotective properties of Actovegin. The drug has been found to exert these beneficial effects experimentally, in primary rat hippocampal neurons and in an STZ-rat model of diabetic polyneuropathy, while also providing evidence that it positively affects the functional recovery of neurons. Latest data suggest that Actovegin also has a positive influence on the NF-kappaB pathway, but many molecular and cellular pathways remain unexplored. In particular, Actovegin&apos;s influence on neuroplasticity, neurogenesis and neurotrophicity are questions that ideally should be answered by future research. Nevertheless, it is clear that the multifactorial and complex nature of Actovegin underlies its pleiotropic neuroprotective mechanisms of action and positive effect on clinical outcomes.</style></abstract><notes><style face="normal" font="default" size="100%">Machicao, Fausto&#xD;Muresanu, Dafin Fior&#xD;Hundsberger, Harald&#xD;Pfluger, Maren&#xD;Guekht, Alla&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Netherlands&#xD;J Neurol Sci. 2012 Nov 15;322(1-2):222-7. doi: 10.1016/j.jns.2012.07.069. Epub 2012 Aug 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0022510X12004236/1-s2.0-S0022510X12004236-main.pdf?_tid=7094a9b8-d7d3-11e6-9af7-00000aab0f6c&amp;acdnat=1484121560_9ada0814f90130b2c83f5bddb25413ca</style></url></related-urls><pdf-urls><url>internal-pdf://2993099496/Machicao-2012-Pleiotropic neuropro.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jns.2012.07.069</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>31</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">31</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mao, M.</style></author><author><style face="normal" font="default" size="100%">Alavi, M. V.</style></author><author><style face="normal" font="default" size="100%">Labelle-Dumais, C.</style></author><author><style face="normal" font="default" size="100%">Gould, D. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departments of Ophthalmology and Anatomy, Institute for Human Genetics, UCSF School of Medicine, San Francisco, CA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Type IV Collagens and Basement Membrane Diseases: Cell Biology and Pathogenic Mechanisms</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Top Membr</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Current topics in membranes</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Top Membr</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current topics in membranes</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Curr Top Membr</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current topics in membranes</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">61-116</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><edition><style face="normal" font="default" size="100%">2015/11/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Basement Membrane/metabolism/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Biology</style></keyword><keyword><style face="normal" font="default" size="100%">Collagen Type IV/chemistry/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Genomics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1063-5823 (Print)&#xD;1063-5823 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26610912</style></accession-num><abstract><style face="normal" font="default" size="100%">Basement membranes are highly specialized extracellular matrices. Once considered inert scaffolds, basement membranes are now viewed as dynamic and versatile environments that modulate cellular behaviors to regulate tissue development, function, and repair. Increasing evidence suggests that, in addition to providing structural support to neighboring cells, basement membranes serve as reservoirs of growth factors that direct and fine-tune cellular functions. Type IV collagens are a major component of all basement membranes. They evolved along with the earliest multicellular organisms and have been integrated into diverse fundamental biological processes as time and evolution shaped the animal kingdom. The roles of basement membranes in humans are as complex and diverse as their distributions and molecular composition. As a result, basement membrane defects result in multisystem disorders with ambiguous and overlapping boundaries that likely reflect the simultaneous interplay and integration of multiple cellular pathways and processes. Consequently, there will be no single treatment for basement membrane disorders, and therapies are likely to be as varied as the phenotypes. Understanding tissue-specific pathology and the underlying molecular mechanism is the present challenge; personalized medicine will rely upon understanding how a given mutation impacts diverse cellular functions.</style></abstract><notes><style face="normal" font="default" size="100%">Mao, Mao&#xD;Alavi, Marcel V&#xD;Labelle-Dumais, Cassandre&#xD;Gould, Douglas B&#xD;Review&#xD;United States&#xD;Curr Top Membr. 2015;76:61-116. doi: 10.1016/bs.ctm.2015.09.002. Epub 2015 Oct 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.sciencedirect.com/science/article/pii/S1063582315000642</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/bs.ctm.2015.09.002</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>44</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">44</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Marcuzzi, A.</style></author><author><style face="normal" font="default" size="100%">Piscianz, E.</style></author><author><style face="normal" font="default" size="100%">Valencic, E.</style></author><author><style face="normal" font="default" size="100%">Monasta, L.</style></author><author><style face="normal" font="default" size="100%">Vecchi Brumatti, L.</style></author><author><style face="normal" font="default" size="100%">Tommasini, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Surgery and Health Sciences, University of Trieste, Piazzale Europa 1, Trieste 34128, Italy. annalisa.marcuzzi@burlo.trieste.it.&#xD;Institute for Maternal and Child Health - IRCCS &quot;Burlo Garofolo&quot; - , via dell&apos;Istria, 65/1, Trieste 34137, Italy. elisa.piscianz@gmail.com.&#xD;Institute for Maternal and Child Health - IRCCS &quot;Burlo Garofolo&quot; - , via dell&apos;Istria, 65/1, Trieste 34137, Italy. erica.valencic@gmail.com.&#xD;Institute for Maternal and Child Health - IRCCS &quot;Burlo Garofolo&quot; - , via dell&apos;Istria, 65/1, Trieste 34137, Italy. lorenzo.monasta@burlo.trieste.it.&#xD;Institute for Maternal and Child Health - IRCCS &quot;Burlo Garofolo&quot; - , via dell&apos;Istria, 65/1, Trieste 34137, Italy. liza.vecchibrumatti@burlo.trieste.it.&#xD;Institute for Maternal and Child Health - IRCCS &quot;Burlo Garofolo&quot; - , via dell&apos;Istria, 65/1, Trieste 34137, Italy. alberto.tommasini@burlo.trieste.it.</style></auth-address><titles><title><style face="normal" font="default" size="100%">To Extinguish the Fire from Outside the Cell or to Shutdown the Gas Valve Inside? Novel Trends in Anti-Inflammatory Therapies</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Mol Sci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">International journal of molecular sciences</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Int J Mol Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">International journal of molecular sciences</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Int J Mol Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">International journal of molecular sciences</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">21277-93</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2015/09/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Biological Products/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Cryopyrin-Associated Periodic Syndromes/diagnosis/drug</style></keyword><keyword><style face="normal" font="default" size="100%">therapy/etiology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/diagnosis/drug therapy/ etiology/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mevalonate Kinase Deficiency/diagnosis/drug therapy/etiology/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 07</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1422-0067 (Electronic)&#xD;1422-0067 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26370962</style></accession-num><abstract><style face="normal" font="default" size="100%">Cytokines are the most important soluble mediators of inflammation. Rare pediatric diseases provided exemplar conditions to study the anti-inflammatory efficacy of new generation therapies (biologics/biopharmaceuticals) selectively targeting single cytokines. Monoclonal antibodies and recombinant proteins have revolutionized anti-inflammatory therapies in the last two decades, allowing the specific targeting of single cytokines. They are very effective in extinguishing inflammation from outside the cell, even with the risk of an excessive and prolonged immunosuppression. Small molecules can enter the cell and shutdown the valve of inflammation by directly targeting signal proteins involved in cytokine release or in response to cytokines. They are orally-administrable drugs whose dosage can be easily adjusted to obtain the desired anti-inflammatory effect. This could make these drugs more suitable for a wide range of diseases as stroke, gout, or neurological impairment, where inflammatory activation plays a pivotal role as trigger. Autoinflammatory diseases, which have previously put anti-cytokine proteins in the limelight, can again provide a valuable model to measure the real potential of small inhibitors as anti-inflammatory agents.</style></abstract><notes><style face="normal" font="default" size="100%">Marcuzzi, Annalisa&#xD;Piscianz, Elisa&#xD;Valencic, Erica&#xD;Monasta, Lorenzo&#xD;Vecchi Brumatti, Liza&#xD;Tommasini, Alberto&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Switzerland&#xD;Int J Mol Sci. 2015 Sep 7;16(9):21277-93. doi: 10.3390/ijms160921277.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.mdpi.com/1422-0067/16/9/21277/pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3073777432/Marcuzzi-2015-To Extinguish the Fi.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4613252</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3390/ijms160921277</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>155</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">155</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Markus, H. S.</style></author><author><style face="normal" font="default" size="100%">Bevan, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Stroke Research Group, Department of Neurology, R3, Box 83, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mechanisms and treatment of ischaemic stroke--insights from genetic associations</style></title><secondary-title><style face="normal" font="default" size="100%">Nat Rev Neurol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Nature reviews. Neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nat Rev Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Nature reviews. Neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Nat Rev Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Nature reviews. Neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">723-30</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2014/10/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/diagnosis/ genetics/physiopathology/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Genome-Wide Association Study</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/diagnosis/ genetics/physiopathology/ therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1759-4766 (Electronic)&#xD;1759-4758 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25348005</style></accession-num><abstract><style face="normal" font="default" size="100%">The precise pathophysiology of ischaemic stroke is unclear, and a greater understanding of the different mechanisms that underlie large-artery, cardioembolic and lacunar ischaemic stroke subtypes would enable the development of more-effective, subtype-specific therapies. Genome-wide association studies (GWASs) are identifying novel genetic variants that associate with the risk of stroke. These associations provide insight into the pathophysiological mechanisms, and present opportunities for novel therapeutic approaches. In this Review, we summarize the genetic variants that have been linked to ischaemic stroke in GWASs to date and discuss the implications of these associations for both our understanding and treatment of ischaemic stroke. The majority of genetic variants identified are associated with specific subtypes of ischaemic stroke, implying that these subtypes have distinct genetic architectures and pathophysiological mechanisms. The findings from the GWASs highlight the need to consider whether therapies should be subtype-specific. Further GWASs that include large cohorts are likely to provide further insights, and emerging technologies will complement and build on the GWAS findings.</style></abstract><notes><style face="normal" font="default" size="100%">Markus, Hugh S&#xD;Bevan, Steve&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;England&#xD;Nat Rev Neurol. 2014 Dec;10(12):723-30. doi: 10.1038/nrneurol.2014.196. Epub 2014 Oct 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.nature.com/nrneurol/journal/v10/n12/pdf/nrneurol.2014.196.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3482331055/Markus-2014-Mechanisms and treat.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/nrneurol.2014.196</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>152</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">152</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Matsumoto, N.</style></author><author><style face="normal" font="default" size="100%">Suzuki, E.</style></author><author><style face="normal" font="default" size="100%">Ishikawa, M.</style></author><author><style face="normal" font="default" size="100%">Shirafuji, T.</style></author><author><style face="normal" font="default" size="100%">Hasumi, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From the Department of Applied Biological Science, Tokyo Noko University, 3-5-8 Saiwaicho, Fuchu, Tokyo 183-8509, Japan.&#xD;Pharmaceutical Research Laboratory, Nihon Pharmaceutical, 34 Shin-izumi, Narita, Chiba 286-0825, Japan, and.&#xD;From the Department of Applied Biological Science, Tokyo Noko University, 3-5-8 Saiwaicho, Fuchu, Tokyo 183-8509, Japan, TMS Co., Ltd., 1-32-1-102 Fuchucho, Fuchu, Tokyo 183-0055, Japan hasumi@cc.tuat.ac.jp.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Soluble epoxide hydrolase as an anti-inflammatory target of the thrombolytic stroke drug SMTP-7</style></title><secondary-title><style face="normal" font="default" size="100%">J Biol Chem</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The Journal of biological chemistry</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Biol Chem</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of biological chemistry</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Biol Chem</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of biological chemistry</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">35826-38</style></pages><volume><style face="normal" font="default" size="100%">289</style></volume><number><style face="normal" font="default" size="100%">52</style></number><edition><style face="normal" font="default" size="100%">2014/11/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Amino Acid Sequence</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Benzopyrans/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Colitis, Ulcerative/drug therapy/enzymology</style></keyword><keyword><style face="normal" font="default" size="100%">Crohn Disease/drug therapy/enzymology</style></keyword><keyword><style face="normal" font="default" size="100%">Epoxide Hydrolases/ antagonists &amp; inhibitors/blood/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Fibrinolytic Agents/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Guillain-Barre Syndrome/drug therapy/enzymology</style></keyword><keyword><style face="normal" font="default" size="100%">Hep G2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Kinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Sequence Data</style></keyword><keyword><style face="normal" font="default" size="100%">Plasminogen/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Pyrrolidinones/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred Lew</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 26</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1083-351X (Electronic)&#xD;0021-9258 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25361765</style></accession-num><abstract><style face="normal" font="default" size="100%">Although ischemic stroke is a major cause of death and disability worldwide, only a small fraction of patients benefit from the current thrombolytic therapy due to a risk of cerebral hemorrhage caused by inflammation. Thus, the development of a new strategy to combat inflammation during thrombolysis is an urgent demand. The small molecule thrombolytic SMTP-7 effectively treats ischemic stroke in several animal models with reducing cerebral hemorrhage. Here we revealed that SMTP-7 targeted soluble epoxide hydrolase (sEH) to suppress inflammation. SMTP-7 inhibited both of the two sEH enzyme activities: epoxide hydrolase (which inactivates anti-inflammatory epoxy-fatty acids) and lipid phosphate phosphatase. SMTP-7 suppressed epoxy-fatty acid hydrolysis in HepG2 cells in culture, implicating the sEH inhibition in the anti-inflammatory mechanism. The sEH inhibition by SMTP-7 was independent of its thrombolytic activity. The simultaneous targeting of thrombolysis and sEH by a single molecule is a promising strategy to revolutionize the current stroke therapy.</style></abstract><notes><style face="normal" font="default" size="100%">Matsumoto, Naoki&#xD;Suzuki, Eriko&#xD;Ishikawa, Makoto&#xD;Shirafuji, Takumi&#xD;Hasumi, Keiji&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Biol Chem. 2014 Dec 26;289(52):35826-38. doi: 10.1074/jbc.M114.588087. Epub 2014 Oct 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.jbc.org/content/289/52/35826.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3069081273/Matsumoto-2014-Soluble epoxide hydr.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4276851</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1074/jbc.M114.588087</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>331</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">331</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maucler, C.</style></author><author><style face="normal" font="default" size="100%">Pernot, P.</style></author><author><style face="normal" font="default" size="100%">Vasylieva, N.</style></author><author><style face="normal" font="default" size="100%">Pollegioni, L.</style></author><author><style face="normal" font="default" size="100%">Marinesco, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">INSERM U1028; CNRS UMR5292 Lyon Neuroscience Research Center, AniRA-Neurochem technological platform, team WAKING, Lyon, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">In vivo D-serine hetero-exchange through alanine-serine-cysteine (ASC) transporters detected by microelectrode biosensors</style></title><secondary-title><style face="normal" font="default" size="100%">ACS Chem Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">ACS chemical neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">ACS Chem Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">ACS chemical neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">ACS Chem Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">ACS chemical neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">772-81</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2013/04/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Amino Acid Transport System ASC/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Biosensing Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Frontal Lobe/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Microelectrodes</style></keyword><keyword><style face="normal" font="default" size="100%">Minor Histocompatibility Antigens</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Serine/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">May 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1948-7193 (Electronic)&#xD;1948-7193 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23581544</style></accession-num><abstract><style face="normal" font="default" size="100%">D-serine, a co-agonist of N-methyl D-aspartate (NMDA) receptors, has been implicated in neurological and psychiatric disorders such as cerebral ischemia, lateral amyotrophic sclerosis, or schizophrenia. D-serine signaling represents an important pharmacological target for treating these diseases; however, the biochemical mechanisms controlling extracellular D-serine levels in vivo are still unclear. D-serine heteroexchange through small neutral amino acid transporters has been shown in cell cultures and brain slices and could provide a biochemical mechanism for the control of D-serine extracellular concentration in vivo. Alternatively, exocytotic D-serine release has also been proposed. In this study, the dynamics of D-serine release and clearance were explored in vivo on a second-by-second time scale using microelectrode biosensors. The rate of D-serine clearance in the rat frontal cortex after a microionophoretic injection revealed a transporter-mediated uptake mechanism. D-serine uptake was blocked by small neutral l-amino acids, implicating alanine-serine-cysteine (ASC) transporters, in particular high affinity Asc-1 and low affinity ASCT2 transporters. Interestingly, changes in alanine, serine, or threonine levels resulted in D-serine release through ASC transporters. Asc-1, but not ASCT2, appeared to release D-serine in response to changes in amino acid concentrations. Finally, neuronal silencing by tetrodotoxin increased D-serine extracellular concentration by an ASC-transporter-dependent mechanism. Together, these results indicate that D-serine heteroexchange through ASC transporters is present in vivo and may constitute a key component in the regulation of D-serine extracellular concentration.</style></abstract><notes><style face="normal" font="default" size="100%">Maucler, Caroline&#xD;Pernot, Pierre&#xD;Vasylieva, Natalia&#xD;Pollegioni, Loredano&#xD;Marinesco, Stephane&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;ACS Chem Neurosci. 2013 May 15;4(5):772-81. doi: 10.1021/cn4000549. Epub 2013 Apr 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://pubs.acs.org/doi/pdfplus/10.1021/cn4000549</style></url></related-urls><pdf-urls><url>internal-pdf://1077558141/Maucler-2013-In vivo D-serine het.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3656752</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/cn4000549</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>307</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">307</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mauri-Capdevila, G.</style></author><author><style face="normal" font="default" size="100%">Jove, M.</style></author><author><style face="normal" font="default" size="100%">Suarez-Luis, I.</style></author><author><style face="normal" font="default" size="100%">Portero-Otin, M.</style></author><author><style face="normal" font="default" size="100%">Purroy, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Unidad de Ictus, Hospital Universitari Arnaude Vilanova, Grupo de Neurociencias Clinicas, Universitat de Lleida, Avda. Rovira Roure 80, Lleida, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">[Metabolomics in ischaemic stroke, new diagnostic and prognostic biomarkers]</style></title><secondary-title><style face="normal" font="default" size="100%">Rev Neurol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Revista de neurologia</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Rev Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Revista de neurologia</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Rev Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Revista de neurologia</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">29-36</style></pages><volume><style face="normal" font="default" size="100%">57</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2013/06/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/diagnosis/ metabolism/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases/blood/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Early Diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolomics</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosticos y pronosticos. El estudio de biomarcadores relacionados con el ictus</style></keyword><keyword><style face="normal" font="default" size="100%">isquemico esta adquiriendo una mayor importancia en vistas de conocer mejor los</style></keyword><keyword><style face="normal" font="default" size="100%">cambios fisiopatologicos de la enfermedad cerebrovascular y facilitar un</style></keyword><keyword><style face="normal" font="default" size="100%">diagnostico precoz. Dentro de este campo, la metabolomica ofrece un nuevo</style></keyword><keyword><style face="normal" font="default" size="100%">abordaje. Se define como el estudio de los metabolitos moleculares de pequeno</style></keyword><keyword><style face="normal" font="default" size="100%">tamano derivados del metabolismo celular. Su interes radica en que, a partir de</style></keyword><keyword><style face="normal" font="default" size="100%">una muestra biologica, ofrece una instantanea de los cambios celulares que estan</style></keyword><keyword><style face="normal" font="default" size="100%">aconteciendo. Actualmente, la aplicacion de la metabolomica requiere una</style></keyword><keyword><style face="normal" font="default" size="100%">metodologia compleja que incluye la aplicacion de tecnicas de separacion de</style></keyword><keyword><style face="normal" font="default" size="100%">laboratorio, analisis estadisticos multivariantes y el empleo de herramientas</style></keyword><keyword><style face="normal" font="default" size="100%">bioinformaticas. Son multiples los estudios en el ambito de la enfermedad</style></keyword><keyword><style face="normal" font="default" size="100%">cardiovascular que se han centrado en aplicar este abordaje. En los ultimos anos</style></keyword><keyword><style face="normal" font="default" size="100%">ha ido en aumento el numero de publicaciones referentes a los cambios metabolicos</style></keyword><keyword><style face="normal" font="default" size="100%">relacionados con el ictus isquemico, tanto en modelos animales como en pacientes.</style></keyword><keyword><style face="normal" font="default" size="100%">La metabolomica permite la obtencion de perfiles de metabolitos que identifican a</style></keyword><keyword><style face="normal" font="default" size="100%">los pacientes que han sufrido un ictus isquemico. Ademas, dado que se han llevado</style></keyword><keyword><style face="normal" font="default" size="100%">a cabo estudios que relacionan metabolitos concretos con las etiologias mas</style></keyword><keyword><style face="normal" font="default" size="100%">frecuentes del ictus isquemico, la metabolomica puede llegar a adquirir un papel</style></keyword><keyword><style face="normal" font="default" size="100%">significativo en el estudio del ictus criptogenico. El conocimiento mas minucioso</style></keyword><keyword><style face="normal" font="default" size="100%">de los cambios en las vias metabolicas implicadas en la enfermedad</style></keyword><keyword><style face="normal" font="default" size="100%">cerebrovascular podria sentar las bases para el desarrollo de nuevas estrategias</style></keyword><keyword><style face="normal" font="default" size="100%">de neuroproteccion.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 01</style></date></pub-dates></dates><orig-pub><style face="normal" font="default" size="100%">La metabolomica en el ictus isquemico, nuevos biomarcadores diagnosticos y pronosticos.</style></orig-pub><isbn><style face="normal" font="default" size="100%">1576-6578 (Electronic)&#xD;0210-0010 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23799599</style></accession-num><abstract><style face="normal" font="default" size="100%">The study of biomarkers related with ischaemic stroke is becoming increasingly more important as a way to further our knowledge of the pathophysiological changes that occur in cerebrovascular disease and to make it easier to reach an early diagnosis. Within this field, metabolomics offers a novel approach. The field is defined as the study of the small-molecule metabolites derived from cell metabolism. Its interest lies in the fact that, using a biological sample, it offers a snapshot of the cellular changes that are taking place. Today, the application of metabolomics requires a complex methodology that includes the application of laboratory separation techniques, multivariant statistical analyses and the use of bioinformatic tools. A number of studies conducted within the field of cardiovascular disease have focused on the application of this approach. In recent years there has been a steady growth in the number of publications referring to the metabolic changes related with ischaemic stroke, both in animal models and in patients. Metabolomics makes it possible to obtain the profiles of metabolites that identify patients who have suffered an ischaemic stroke. Furthermore, since studies have been carried out that relate certain metabolites with the most common causations of ischaemic stroke, metabolomics may eventually play a significant role in the study of cryptogenic stroke. The most exhaustive knowledge of the changes in the metabolic pathways involved in cerebrovascular disease could lay the foundations for the development of new neuroprotector strategies.</style></abstract><notes><style face="normal" font="default" size="100%">Mauri-Capdevila, Gerard&#xD;Jove, Mariona&#xD;Suarez-Luis, Idalmis&#xD;Portero-Otin, Manuel&#xD;Purroy, Francisco&#xD;English Abstract&#xD;Review&#xD;Spain&#xD;Rev Neurol. 2013 Jul 1;57(1):29-36.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">spa</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>486</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">486</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McAuley, G.</style></author><author><style face="normal" font="default" size="100%">Schrag, M.</style></author><author><style face="normal" font="default" size="100%">Barnes, S.</style></author><author><style face="normal" font="default" size="100%">Obenaus, A.</style></author><author><style face="normal" font="default" size="100%">Dickson, A.</style></author><author><style face="normal" font="default" size="100%">Kirsch, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Neurosurgery Center for Research, Training and Education, Loma Linda University, Loma Linda, California 92354, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">In vivo iron quantification in collagenase-induced microbleeds in rat brain</style></title><secondary-title><style face="normal" font="default" size="100%">Magn Reson Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Magnetic resonance in medicine</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Magn Reson Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Magnetic resonance in medicine</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Magn Reson Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Magnetic resonance in medicine</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">711-7</style></pages><volume><style face="normal" font="default" size="100%">67</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2011/07/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Collagenases</style></keyword><keyword><style face="normal" font="default" size="100%">Image Processing, Computer-Assisted</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hemorrhages/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Iron/ analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Linear Models</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Spectrophotometry, Atomic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1522-2594 (Electronic)&#xD;0740-3194 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">21721041</style></accession-num><abstract><style face="normal" font="default" size="100%">Brain microbleeds (BMB) are associated with chronic and acute cerebrovascular disease. Because BMB present in the brain is a source of potentially cytotoxic iron proportional to the volume of extravasated blood, BMB iron content is a potentially valuable biomarker both to assess tissue risk and small cerebral vessel health. We recently reported methods to quantify focal iron sources using phase images that were tested in phantoms and BMB in postmortem tissue. In this study, we applied our methods to small hemorrhagic lesions induced in the in vivo rat brain using bacterial collagenase. As expected by theory, measurements of geometric features in phase images correlated with lesion iron content measured by graphite furnace atomic absorption spectrometry. Iron content estimation following BMB in an in vivo rodent model could shed light on the role and temporal evolution of iron-mediated tissue damage and efficacy of potential treatments in cerebrovascular diseases associated with BMB.</style></abstract><notes><style face="normal" font="default" size="100%">McAuley, Grant&#xD;Schrag, Matthew&#xD;Barnes, Samuel&#xD;Obenaus, Andre&#xD;Dickson, April&#xD;Kirsch, Wolff&#xD;United States&#xD;Magn Reson Med. 2012 Mar;67(3):711-7. doi: 10.1002/mrm.23045. Epub 2011 Jun 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1002/mrm.23045/asset/23045_ftp.pdf?v=1&amp;t=ixsnk6qa&amp;s=90cc46b98687f6c3c7e0a7cd593c28a664e0bd2d</style></url></related-urls><pdf-urls><url>internal-pdf://4022954601/McAuley-2012-In vivo iron quantif.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/mrm.23045</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>87</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">87</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McBride, D. W.</style></author><author><style face="normal" font="default" size="100%">Klebe, D.</style></author><author><style face="normal" font="default" size="100%">Tang, J.</style></author><author><style face="normal" font="default" size="100%">Zhang, J. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Physiology &amp; Pharmacology, Loma Linda University School of Medicine, Loma Linda, CA, 92350, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Correcting for Brain Swelling&apos;s Effects on Infarct Volume Calculation After Middle Cerebral Artery Occlusion in Rats</style></title><secondary-title><style face="normal" font="default" size="100%">Transl Stroke Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Translational stroke research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Transl Stroke Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Translational stroke research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Transl Stroke Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Translational stroke research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">323-38</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2015/05/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/complications/etiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Functional Laterality</style></keyword><keyword><style face="normal" font="default" size="100%">Image Processing, Computer-Assisted</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ complications/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion</style></keyword><keyword><style face="normal" font="default" size="100%">Tetrazolium Salts/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1868-601X (Electronic)&#xD;1868-4483 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25933988</style></accession-num><abstract><style face="normal" font="default" size="100%">Evaluating infarct volume is the primary outcome for experimental ischemic stroke studies and is a major factor in determining translation of a drug into clinical trials. Numerous algorithms are available for evaluating this critical value, but a major limitation of current algorithms is that brain swelling is not appropriately considered. The model by Lin et al. is widely used, but overestimates swelling within the infarction, yielding infarct volumes which do not reflect the true infarct size. Herein, a new infarct volume algorithm is developed to minimize the effects of both peri-infarct and infarct core swelling on infarct volume measurement. 2,3,5-Triphenyl-2H-tetrazolium chloride-stained brain tissue of adult rats subjected to middle cerebral artery occlusion was used for infarct volume analysis. When both peri-infarct swelling and infarction core swelling are removed from infarct volume calculations, such as accomplished by our algorithm, larger infarct volumes are estimated than those of Lin et al.&apos;s algorithm. Furthermore, the infarct volume difference between the two algorithms is the greatest for small infarcts (&lt;10% of brain volume) when peri-infarct swelling is the greatest. Finally, using data from four published studies, our algorithm is compared to Lin et al.&apos;s algorithm. Our algorithm offers a more reliable estimation of the infarct volume after ischemic brain injury, and thus may provide the foundation for comparing infarct volumes between experimental studies and standardizing infarct volume quantification to aid in the selection of the best candidates for clinical trials.</style></abstract><notes><style face="normal" font="default" size="100%">McBride, Devin W&#xD;Klebe, Damon&#xD;Tang, Jiping&#xD;Zhang, John H&#xD;P01 NS082184/NS/NINDS NIH HHS/United States&#xD;R01 NS043338/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;United States&#xD;Transl Stroke Res. 2015 Aug;6(4):323-38. doi: 10.1007/s12975-015-0400-3. Epub 2015 May 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/890/art%253A10.1007%252Fs12975-015-0400-3.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12975-015-0400-3&amp;token2=exp=1484122599~acl=%2Fstatic%2Fpdf%2F890%2Fart%25253A10.1007%25252Fs12975-015-0400-3.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs12975-015-0400-3*~hmac=c769e039de159e97d16888c067b441b5a75d30387633d5f03e48285cdbd0de70</style></url></related-urls><pdf-urls><url>internal-pdf://0242114511/McBride-2015-Correcting for Brain.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4765329</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms757035</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12975-015-0400-3</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>318</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">318</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Megill, A.</style></author><author><style face="normal" font="default" size="100%">Lee, T.</style></author><author><style face="normal" font="default" size="100%">DiBattista, A. M.</style></author><author><style face="normal" font="default" size="100%">Song, J. M.</style></author><author><style face="normal" font="default" size="100%">Spitzer, M. H.</style></author><author><style face="normal" font="default" size="100%">Rubinshtein, M.</style></author><author><style face="normal" font="default" size="100%">Habib, L. K.</style></author><author><style face="normal" font="default" size="100%">Capule, C. C.</style></author><author><style face="normal" font="default" size="100%">Mayer, M.</style></author><author><style face="normal" font="default" size="100%">Turner, R. S.</style></author><author><style face="normal" font="default" size="100%">Kirkwood, A.</style></author><author><style face="normal" font="default" size="100%">Yang, J.</style></author><author><style face="normal" font="default" size="100%">Pak, D. T.</style></author><author><style face="normal" font="default" size="100%">Lee, H. K.</style></author><author><style face="normal" font="default" size="100%">Hoe, H. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neuroscience, Johns Hopkins University, Baltimore, Maryland 20218, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A tetra(ethylene glycol) derivative of benzothiazole aniline enhances Ras-mediated spinogenesis</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">9306-18</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">22</style></number><edition><style face="normal" font="default" size="100%">2013/05/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Amyloid beta-Protein Precursor/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Aniline Compounds/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Benzothiazoles/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Biotinylation</style></keyword><keyword><style face="normal" font="default" size="100%">COS Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Cercopithecus aethiops</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition Disorders/chemically induced/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Dendritic Spines/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default" size="100%">Ethylene Glycols/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Excitatory Postsynaptic Potentials/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Genes, ras/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Immunohistochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Long-Term Potentiation/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Maze Learning/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenesis/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, AMPA/drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">May 29</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1529-2401 (Electronic)&#xD;0270-6474 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23719799</style></accession-num><abstract><style face="normal" font="default" size="100%">The tetra(ethylene glycol) derivative of benzothiazole aniline, BTA-EG4, is a novel amyloid-binding small molecule that can penetrate the blood-brain barrier and protect cells from Abeta-induced toxicity. However, the effects of Abeta-targeting molecules on other cellular processes, including those that modulate synaptic plasticity, remain unknown. We report here that BTA-EG4 decreases Abeta levels, alters cell surface expression of amyloid precursor protein (APP), and improves memory in wild-type mice. Interestingly, the BTA-EG4-mediated behavioral improvement is not correlated with LTP, but with increased spinogenesis. The higher dendritic spine density reflects an increase in the number of functional synapses as determined by increased miniature EPSC (mEPSC) frequency without changes in presynaptic parameters or postsynaptic mEPSC amplitude. Additionally, BTA-EG4 requires APP to regulate dendritic spine density through a Ras signaling-dependent mechanism. Thus, BTA-EG4 may provide broad therapeutic benefits for improving neuronal and cognitive function, and may have implications in neurodegenerative disease therapy.</style></abstract><notes><style face="normal" font="default" size="100%">Megill, Andrea&#xD;Lee, Taehee&#xD;DiBattista, Amanda Marie&#xD;Song, Jung Min&#xD;Spitzer, Matthew H&#xD;Rubinshtein, Mark&#xD;Habib, Lila K&#xD;Capule, Christina C&#xD;Mayer, Michael&#xD;Turner, R Scott&#xD;Kirkwood, Alfredo&#xD;Yang, Jerry&#xD;Pak, Daniel T S&#xD;Lee, Hey-Kyoung&#xD;Hoe, Hyang-Sook&#xD;3P50 AG005131/AG/NIA NIH HHS/United States&#xD;R01-AG034606/AG/NIA NIH HHS/United States&#xD;P50 AG005131/AG/NIA NIH HHS/United States&#xD;AG039708/AG/NIA NIH HHS/United States&#xD;R03 AG039708/AG/NIA NIH HHS/United States&#xD;R01 AG026478/AG/NIA NIH HHS/United States&#xD;R01 AG034606/AG/NIA NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Neurosci. 2013 May 29;33(22):9306-18. doi: 10.1523/JNEUROSCI.1615-12.2013.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.jneurosci.org/content/jneuro/33/22/9306.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3350181947/Megill-2013-A tetra(ethylene gly.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3865503</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1523/jneurosci.1615-12.2013</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>51</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">51</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Meng, S.</style></author><author><style face="normal" font="default" size="100%">Su, Z.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author><author><style face="normal" font="default" size="100%">Wang, N.</style></author><author><style face="normal" font="default" size="100%">Wang, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Harbin Medical University, Harbin 150001, China.&#xD;Harbin Medical University, Harbin 150001, China. Electronic address: zhiqiangsu70@163.com.&#xD;The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, China.&#xD;The Fourth Hospital of Harbin, Harbin 150001, China.&#xD;Department of Pharmacology, the Fourth Military Medical University, Xi&apos;an 710032, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Rac1 contributes to cerebral ischemia reperfusion-induced injury in mice by regulation of Notch2</style></title><secondary-title><style face="normal" font="default" size="100%">Neuroscience</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">100-14</style></pages><volume><style face="normal" font="default" size="100%">306</style></volume><edition><style face="normal" font="default" size="100%">2015/08/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ physiopathology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Self Renewal/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">NF-kappa B/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neuropeptides/antagonists &amp; inhibitors/ metabolism/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Pyrimidines/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Reactive Oxygen Species/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Notch2/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/ physiopathology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">rac1 GTP-Binding Protein/antagonists &amp; inhibitors/ metabolism/ physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1873-7544 (Electronic)&#xD;0306-4522 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26299339</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Cerebral ischemia-reperfusion (IR) injury is a complex pathological process that can cause irreversible brain damage, neuronal injury or death from brain ischemia. Rac1 GTPase is involved in cellular protection from IR injury. However, the mechanism of protection and the molecules affected by Rac1 remain to be defined. METHODS AND RESULTS: C57BL/6 mice were subjected to middle cerebral artery occlusion for 1h, followed by 24-h reperfusion. In this in vivo model of cerebral IR injury, mice treated with the Rac GTPase inhibitor NSC23766 or Rac1 small interfering RNA (siRNA) had better short-term (72 h) neurologic scores, less infarction volume, higher production of antioxidant enzymes, lower lipid peroxide, and reduced apoptosis compared with a vehicle-treated group or a control-siRNA group. However, long-term (14 day) neurologic scores were worse for the two treatments compared to controls. Microarray and quantitative polymerase chain reaction (PCR) revealed that Notch2 was downregulated under NSC23766 treatment. Notch2 protein levels decreased with NSC23766 and Rac1 siRNA in vitro and in vivo. Cell survival increased with the Notch signaling inhibitor DAPT or Notch2 siRNA and NICD2 attenuated the NSC23766 effect. In addition, immunoblotting showed that DAPT and Notch2 siRNA changed the levels of apoptosis-regulating proteins. NFkB mediated Rac1, which regulated Notch2 in an oxygen glucose deprivation model. Both inhibitors of Notch2 and Rac1 enhanced neural stem cell differentiation. CONCLUSIONS: This study demonstrated the importance of Rac1 regulation of Notch2 in mediating cerebral IR-induced production of injurious reactive oxygen species and cell death in vitro and in vivo in the short term. Targeted inhibition of Rac1 or Notch2 is new avenue for in vivo therapy aimed at protecting organs at risk from IR injury.</style></abstract><notes><style face="normal" font="default" size="100%">Meng, S&#xD;Su, Z&#xD;Liu, Z&#xD;Wang, N&#xD;Wang, Z&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Neuroscience. 2015 Oct 15;306:100-14. doi: 10.1016/j.neuroscience.2015.08.014. Epub 2015 Aug 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S030645221500737X/1-s2.0-S030645221500737X-main.pdf?_tid=81e98dfa-d7d3-11e6-a765-00000aacb35f&amp;acdnat=1484121590_a5ab3c11a7ad32379c6506de4f8e4870</style></url></related-urls><pdf-urls><url>internal-pdf://1565952163/Meng-2015-Rac1 contributes to.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuroscience.2015.08.014</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>47</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">47</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Menyhart, A.</style></author><author><style face="normal" font="default" size="100%">Makra, P.</style></author><author><style face="normal" font="default" size="100%">Szepes, B. E.</style></author><author><style face="normal" font="default" size="100%">Toth, O. M.</style></author><author><style face="normal" font="default" size="100%">Hertelendy, P.</style></author><author><style face="normal" font="default" size="100%">Bari, F.</style></author><author><style face="normal" font="default" size="100%">Farkas, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Physics and Informatics, Faculty of Medicine, Faculty of Science and Informatics, University of Szeged, Szeged, Hungary.&#xD;Department of Medical Physics and Informatics, Faculty of Medicine, Faculty of Science and Informatics, University of Szeged, Szeged, Hungary. Electronic address: farkas.eszter.1@med.u-szeged.hu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">High incidence of adverse cerebral blood flow responses to spreading depolarization in the aged ischemic rat brain</style></title><secondary-title><style face="normal" font="default" size="100%">Neurobiol Aging</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurobiology of aging</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurobiol Aging</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurobiology of aging</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurobiol Aging</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurobiology of aging</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">3269-77</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2015/09/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aging/ pathology/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ blood supply/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Electrocorticography</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1558-1497 (Electronic)&#xD;0197-4580 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26346140</style></accession-num><abstract><style face="normal" font="default" size="100%">Spreading depolarizations (SDs) occur spontaneously in the brain after stroke, exacerbate ischemic injury, and thus emerge as a potential target of intervention. Aging predicts worse outcome from stroke; yet, the impact of age on SD evolution is not clear. Cerebral ischemia was induced by bilateral common carotid artery occlusion in young (8-9 weeks old, n = 8) and old (2 year olds, n = 6) anesthetized rats. Sham-operated animals of both age groups served as control (n = 12). Electrocorticogram, direct current potential, and cerebral blood flow (CBF) variations were acquired via a small craniotomy above the parietal cortex. SDs were elicited by KCl through a second craniotomy distal to the recording site. Ischemia and age delayed the recovery from SD. CBF decreased progressively during ischemia in the old animals selectively, and inverse neurovascular coupling with SD evolved in the old but not in the young ischemic group. We propose that (mal)adaptation of cerebrovascular function with aging impairs the SD-related CBF response, which is implicated in the intensified expansion of ischemic damage in the old brain.</style></abstract><notes><style face="normal" font="default" size="100%">Menyhart, Akos&#xD;Makra, Peter&#xD;Szepes, Borbala E&#xD;Toth, Orsolya M&#xD;Hertelendy, Peter&#xD;Bari, Ferenc&#xD;Farkas, Eszter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Neurobiol Aging. 2015 Dec;36(12):3269-77. doi: 10.1016/j.neurobiolaging.2015.08.014. Epub 2015 Aug 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S019745801500425X/1-s2.0-S019745801500425X-main.pdf?_tid=85bf51da-d7d3-11e6-abfb-00000aab0f6b&amp;acdnat=1484121596_b96c8a72823ceec4593f48baa50469e6</style></url></related-urls><pdf-urls><url>internal-pdf://3281232880/Menyhart-2015-High incidence of ad.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neurobiolaging.2015.08.014</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>292</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">292</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Meyer, D. M.</style></author><author><style face="normal" font="default" size="100%">Compton, P.</style></author><author><style face="normal" font="default" size="100%">Eastwood, J. A.</style></author><author><style face="normal" font="default" size="100%">Gylys, K.</style></author><author><style face="normal" font="default" size="100%">Zivin, J. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From the Department of Neurosciences, University of California, San Diego, La Jolla, CA (D.M.M., J.A.Z.); and School of Nursing, University of California, Los Angeles, CA (D.M.M., P.C., J.-A.E., K.G.).</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antiplatelet loading improves behavioral outcome in a rabbit model of stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">3246-8</style></pages><volume><style face="normal" font="default" size="100%">44</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2013/08/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adenosine Diphosphate/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arachidonic Acid/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Aspirin/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Platelets/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Collagen/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Embolization, Therapeutic</style></keyword><keyword><style face="normal" font="default" size="100%">Fibrinolytic Agents/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Platelet Aggregation Inhibitors/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Rabbits</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23982714</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: No approved acute therapy exists for thousands of patients with ischemic stroke who present ineligible for thrombolytics. The purpose of this proof-of-concept study was to evaluate the efficacy of acute antiplatelet loading on stroke outcome in the rabbit small clot embolic model. METHODS: Sixty male New Zealand white rabbits were embolized via small clots into the middle cerebral artery. Two hours later, animals were treated with (1) aspirin (5 mg/kg; n=20); (2) usual dual antiplatelet loading (aspirin 10 mg/kg+clopidogrel 10 mg/kg; n=20); or (3) high-dose dual antiplatelet loading (aspirin 10 mg/kg+clopidogrel 30 mg/kg; n=20). The coprimary outcomes were as follows: (1) platelet inhibition and (2) behavioral outcome as measured by the P50 (milligrams of clot that leads to neurological dysfunction in 50% of animals in a group). RESULTS: There was a significant difference in 3-hour arachidonic acid and ADP (P&lt;0.011); 6-hour collagen and ADP (P&lt;0.01, P&lt;0.01); and 24-hour collagen, arachidonic acid, and ADP (P=0.02, P&lt;0.01, P&lt;0.01) platelet inhibition. The behavioral outcome was significantly better in the usual dual antiplatelet loading versus aspirin group (P=0.02). CONCLUSIONS: This study suggests that usual dual antiplatelet loading is clinically beneficial in a validated model of acute stroke. Study of usual dual antiplatelet loading in acute stroke is warranted to provide treatment to stroke victims ineligible for current therapies.</style></abstract><notes><style face="normal" font="default" size="100%">Meyer, Dawn M&#xD;Compton, Peggy&#xD;Eastwood, Jo-Ann&#xD;Gylys, Karen&#xD;Zivin, Justin A&#xD;F31 NR011120/NR/NINR NIH HHS/United States&#xD;1F31NR011120-01/NR/NINR NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;United States&#xD;Stroke. 2013 Nov;44(11):3246-8. doi: 10.1161/STROKEAHA.113.002565. Epub 2013 Aug 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/44/11/3246.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0716938260/Meyer-2013-Antiplatelet loading.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.113.002565</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>432</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">432</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Milot, M. R.</style></author><author><style face="normal" font="default" size="100%">James, J. S.</style></author><author><style face="normal" font="default" size="100%">Merali, Z.</style></author><author><style face="normal" font="default" size="100%">Plamondon, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Ottawa, School of Psychology, Behavioral Neuroscience Group, Ottawa, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A refined blood collection method for quantifying corticosterone</style></title><secondary-title><style face="normal" font="default" size="100%">Lab Anim (NY)</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Lab animal</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lab Anim (NY)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Lab animal</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Lab Anim (NY)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Lab animal</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">77-83</style></pages><volume><style face="normal" font="default" size="100%">41</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2012/02/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Specimen Collection/ methods/veterinary</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/veterinary</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrum/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Corticosterone/ blood</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Metyrapone/administration &amp; dosage/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Radioimmunoassay/veterinary</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Glucocorticoid/antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Regression Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Stress, Physiological</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1548-4475 (Electronic)&#xD;0093-7355 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22343460</style></accession-num><abstract><style face="normal" font="default" size="100%">In many rodent laboratories, blood samples are collected from rats using the tail vein nick procedure and analyzed to quantify blood corticosterone levels as an indicator of stress. The standard method of corticosterone quantification often requires the collection of a relatively large volume of blood, followed by the extraction of the blood plasma. An alternative blood sampling method requires the collection of only a drop of blood on paper (the &apos;drop&apos; method), minimizing handling of the animals, and does not require plasma extraction. The authors aimed to validate the drop method of blood sampling for use in corticosterone quantification. They induced stress in rats by cerebral ischemia, collected blood samples at various intervals using both the drop method and the plasma extraction method and then quantified corticosterone by radioimmunoassay. Corticosterone levels of the ischemic rats were compared with those of sham-operated rats and those of ischemic rats that had been given metyrapone, a glucocorticoid synthesis inhibitor, prior to vessel occlusion. Blood corticosterone levels in the samples obtained from the same animal using the two different methods were highly correlated for all rats. The authors further provide a regression model that can be used to predict plasma corticosterone values from those obtained from the drop blood samples. Quantification of corticosterone from only a small drop of blood has many practical and ethical advantages and should be considered as an alternative to standard methods.</style></abstract><notes><style face="normal" font="default" size="100%">Milot, Marc R&#xD;James, Jonathan S&#xD;Merali, Zul&#xD;Plamondon, Helene&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Validation Studies&#xD;United States&#xD;Lab Anim (NY). 2012 Mar;41(3):77-83. doi: 10.1038/laban0312-77.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/laban0312-77</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>411</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">411</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mizuno, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Kyoto Prefectural University of Medicine.</style></auth-address><titles><title><style face="normal" font="default" size="100%">[Diagnosis, pathomechanism and treatment of CADASIL]</style></title><secondary-title><style face="normal" font="default" size="100%">Rinsho Shinkeigaku</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Rinsho shinkeigaku = Clinical neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Rinsho Shinkeigaku</style></full-title><abbr-1><style face="normal" font="default" size="100%">Rinsho shinkeigaku = Clinical neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Rinsho Shinkeigaku</style></full-title><abbr-1><style face="normal" font="default" size="100%">Rinsho shinkeigaku = Clinical neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">303-13</style></pages><volume><style face="normal" font="default" size="100%">52</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2012/06/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Age of Onset</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">CADASIL/ diagnosis/epidemiology/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation</style></keyword><keyword><style face="normal" font="default" size="100%">Pathology, Molecular</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Notch3</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Notch/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Reference Standards</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke</style></keyword><keyword><style face="normal" font="default" size="100%">Tomography, X-Ray Computed</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1882-0654 (Electronic)&#xD;0009-918X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22688109</style></accession-num><abstract><style face="normal" font="default" size="100%">During the past 10 years, our understanding of the pathomechanism and pathophysiology of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) has improved through clinical examination, imaging studies, pathological studies, cell experiments and the development of transgenic mice. Although epidemiological studies of CADASIL in Japan have been limited, more than 100 cases of this condition have been diagnosed in Japan. In our laboratory, we diagnosed 37 CADASIL cases genetically and identified three features common to Japanese cases. One is the wide distribution of onset age for clinical symptoms other than migraine, with the onset of symptoms being later than age 60 in 22% of cases. Second, the majority (65%) of Japanese CADASIL cases have stroke risk factors, such as hypertension, hyperlipidemia, or smoking. Third, in 22% cases there was no definite family history of stroke. However, the previous diagnostic criteria proposed by Dabous excluded several definite cases in our cohort. Therefore, to avoid missing undiagnosed cases of CADASIL, we have generated new diagnostic criteria for Japanese CADASIL based on the knowledge accumulated during the past 10 years, and compared sensitivity of two criteria. In our diagnosed Japanese CADASIL cases, the sensitivity of the new criteria was 19% and 78% for probable and possible cases, respectively, and only one case was (Fig. 3) missed when using the new criteria. In comparison, the sensitivity of Dabous&apos;s was 11% and 51% for probable and possible cases, respectively, and 24% cases were excluded due to hypertension, elderly onset or no family history, although these cases showed recurrent strokes, white matter lesions and NOTCH3 mutations. Using our new criteria, diagnosis of CADASIL can be made even in cases with elderly onset, stroke risk factors, and obscure family history.</style></abstract><notes><style face="normal" font="default" size="100%">Mizuno, Toshiki&#xD;Review&#xD;Japan&#xD;Rinsho Shinkeigaku. 2012;52(5):303-13.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">jpn</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>99</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">99</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mizuno, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine.</style></auth-address><titles><title><style face="normal" font="default" size="100%">[Subcortical ischemic vascular dementia: lesson from hereditary cerebral small vessel disease]</style></title><secondary-title><style face="normal" font="default" size="100%">Brain Nerve</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain and nerve = Shinkei kenkyu no shinpo</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain Nerve</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain and nerve = Shinkei kenkyu no shinpo</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Brain Nerve</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain and nerve = Shinkei kenkyu no shinpo</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">403-12</style></pages><volume><style face="normal" font="default" size="100%">67</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2015/04/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Small Vessel Diseases/genetics/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Dementia, Vascular/diagnosis/genetics/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Susceptibility</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lewy Bodies/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation/genetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1881-6096 (Print)&#xD;1881-6096 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25846589</style></accession-num><abstract><style face="normal" font="default" size="100%">Subcortical ischemic vascular dementia (SIVD) is a main subgroup of vascular dementia related to cerebral small vessel disease. Risk factors for SIVD include hypertension, ageing, and diabetes mellitus, but the specific contribution of each factor to the development of cerebral small vessel disease remains obscure. This is mainly because SIVD in the elderly might be affected by many factors related to the ageing process. Hereditary cerebral small vessel diseases, including cerebral autosomal-dominant or autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL or CARASIL) and cerebral amyloid angiopathy, are affected by different pathomechanisms, but these diseases indicate a clear a role of the cerebral small vessel on subcortical dementia. CADASIL is caused by a cysteine residue-related mutation in the EGF-like repeat on the extracellular domain of Notch3. Pathological examination of a CADASIL brain indicated abnormal accumulation of the extracellular domain of Notch3 with extracellular matrix proteins, including tissue inhibitor of metalloproteinase 3 and vitronectin, around vascular smooth muscle cells. CARASIL is caused by a mutation in HTAR1, a serine protease that regulates transforming growth factor (TGF)-beta signaling. The mutation in HTAR1 related to CARASIL fails to repress TGF-beta signaling and induces the accumulation of extracellular matrix, including the extra domain-A region of fibronectin and versican. The individual and common pathomechanisms of hereditary cerebral small vessel disease are discussed in this review.</style></abstract><notes><style face="normal" font="default" size="100%">Mizuno, Toshiki&#xD;English Abstract&#xD;Review&#xD;Japan&#xD;Brain Nerve. 2015 Apr;67(4):403-12. doi: 10.11477/mf.1416200156.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.11477/mf.1416200156</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">jpn</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>164</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">164</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moccia, M.</style></author><author><style face="normal" font="default" size="100%">Mosca, L.</style></author><author><style face="normal" font="default" size="100%">Erro, R.</style></author><author><style face="normal" font="default" size="100%">Cervasio, M.</style></author><author><style face="normal" font="default" size="100%">Allocca, R.</style></author><author><style face="normal" font="default" size="100%">Vitale, C.</style></author><author><style face="normal" font="default" size="100%">Leonardi, A.</style></author><author><style face="normal" font="default" size="100%">Caranci, F.</style></author><author><style face="normal" font="default" size="100%">Del Basso-De Caro, M. L.</style></author><author><style face="normal" font="default" size="100%">Barone, P.</style></author><author><style face="normal" font="default" size="100%">Penco, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neuroscience, Reproductive Science and Odontostomatology, Federico II University, Naples, Italy.&#xD;Medical Genetics Unit, Department of Laboratory Medicine, Niguarda Ca&apos;Granda Hospital, Milan, Italy.&#xD;Sobell Department of Motor Neuroscience and Movement Disorders, University College London (UCL) Institute of Neurology, Queen Square, London, UK.&#xD;Department of Advanced Biomedical Sciences, Anatomopathology Unit, Federico II University, Naples, Italy.&#xD;Department of Motor Sciences, University of Naples &quot;Parthenope,&quot; Naples, Italy; Istituto di Diagnosi e Cura (IDC) Hermitage-Capodimonte, Naples, Italy.&#xD;Department of Molecular and Biotechnological Medicine, Federico II University, Naples, Italy.&#xD;Department of Advanced Biomedical Sciences, Neuroradiology Unit, Federico II University, Naples, Italy.&#xD;Center for Neurodegenerative Diseases (CEMAND), Neuroscience Section, Department of Medicine, University of Salerno, Salerno, Italy.&#xD;Medical Genetics Unit, Department of Laboratory Medicine, Niguarda Ca&apos;Granda Hospital, Milan, Italy. Electronic address: silvana.penco@ospedaleniguarda.it.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hypomorphic NOTCH3 mutation in an Italian family with CADASIL features</style></title><secondary-title><style face="normal" font="default" size="100%">Neurobiol Aging</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurobiology of aging</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurobiol Aging</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurobiology of aging</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurobiol Aging</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurobiology of aging</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">547 e5-11</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2014/09/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">CADASIL/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Codon, Nonsense</style></keyword><keyword><style face="normal" font="default" size="100%">Exons/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Italy</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Notch3</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Notch/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/genetics/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1558-1497 (Electronic)&#xD;0197-4580 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25260852</style></accession-num><abstract><style face="normal" font="default" size="100%">The cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) is because of NOTCH3 mutations affecting the number of cysteine residues. In this view, the role of atypical NOTCH3 mutations is still debated. Therefore, we investigated a family carrying a NOTCH3 nonsense mutation, with dominantly inherited recurrent cerebrovascular disorders. Among 7 family members, 4 received a clinical diagnosis of CADASIL. A heterozygous truncating mutation in exon 3 (c.307C&gt;T, p.Arg103X) was found in the 4 clinically affected subjects and in one 27-year old lady, only complaining of migraine with aura. Magnetic resonance imaging scans found typical signs of small-vessel disease in the 4 affected subjects, supporting the clinical diagnosis. Skin biopsies did not show the typical granular osmiophilic material, but only nonspecific signs of vascular damage, resembling those previously described in Notch3 knockout mice. Interestingly, messenger RNA (mRNA) analysis supports the hypothesis of an atypical NOTCH3 mutation, suggesting a nonsense-mediated mRNA decay. In conclusion, the present study broadens the spectrum of CADASIL mutations, and, therefore, opens new insights about Notch3 signaling.</style></abstract><notes><style face="normal" font="default" size="100%">Moccia, Marcello&#xD;Mosca, Lorena&#xD;Erro, Roberto&#xD;Cervasio, Mariarosaria&#xD;Allocca, Roberto&#xD;Vitale, Carmine&#xD;Leonardi, Antonio&#xD;Caranci, Ferdinando&#xD;Del Basso-De Caro, Maria Laura&#xD;Barone, Paolo&#xD;Penco, Silvana&#xD;United States&#xD;Neurobiol Aging. 2015 Jan;36(1):547.e5-11. doi: 10.1016/j.neurobiolaging.2014.08.021. Epub 2014 Aug 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S019745801400534X/1-s2.0-S019745801400534X-main.pdf?_tid=9188a534-d7d3-11e6-8695-00000aab0f26&amp;acdnat=1484121624_4798fe3d78ecec6d9cec42a85d047f9e</style></url></related-urls><pdf-urls><url>internal-pdf://0309595905/Moccia-2015-Hypomorphic NOTCH3 m.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neurobiolaging.2014.08.021</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>207</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">207</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moccia, M.</style></author><author><style face="normal" font="default" size="100%">Penco, S.</style></author><author><style face="normal" font="default" size="100%">Barone, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neuroscience, Reproductive Science and Odontostomatology, Federico II University, Naples, Italy.&#xD;Department of Laboratory Medicine, Medical Genetics, Niguarda Ca&apos; Granda Hospital, Milan, Italy.&#xD;Center for Neurodegenerative Diseases (CEMAND), Neuroscience Section, Department of Medicine, University of Salerno, Salerno, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Letter by Moccia et al regarding article, &quot;Archetypal Arg169Cys mutation in NOTCH3 does not drive the pathogenesis in cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy via a loss-of-function mechanism&quot;</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e128</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2014/05/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">CADASIL/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation/ genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Notch/ genetics/ physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24867927</style></accession-num><notes><style face="normal" font="default" size="100%">Moccia, Marcello&#xD;Penco, Silvana&#xD;Barone, Paolo&#xD;Comment&#xD;Letter&#xD;United States&#xD;Stroke. 2014 Jul;45(7):e128. doi: 10.1161/STROKEAHA.114.005593. Epub 2014 May 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/45/7/e128.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0614782986/Moccia-2014-Letter by Moccia et.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.114.005593</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>323</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">323</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Monet-Lepretre, M.</style></author><author><style face="normal" font="default" size="100%">Haddad, I.</style></author><author><style face="normal" font="default" size="100%">Baron-Menguy, C.</style></author><author><style face="normal" font="default" size="100%">Fouillot-Panchal, M.</style></author><author><style face="normal" font="default" size="100%">Riani, M.</style></author><author><style face="normal" font="default" size="100%">Domenga-Denier, V.</style></author><author><style face="normal" font="default" size="100%">Dussaule, C.</style></author><author><style face="normal" font="default" size="100%">Cognat, E.</style></author><author><style face="normal" font="default" size="100%">Vinh, J.</style></author><author><style face="normal" font="default" size="100%">Joutel, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">INSERM, U740, Paris, F-75010, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Abnormal recruitment of extracellular matrix proteins by excess Notch3 ECD: a new pathomechanism in CADASIL</style></title><secondary-title><style face="normal" font="default" size="100%">Brain</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain : a journal of neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain : a journal of neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Brain</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain : a journal of neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1830-45</style></pages><volume><style face="normal" font="default" size="100%">136</style></volume><number><style face="normal" font="default" size="100%">Pt 6</style></number><edition><style face="normal" font="default" size="100%">2013/05/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">CADASIL/ diagnosis/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Extracellular Matrix Proteins/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Homeostasis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Transport/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Notch3</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Notch/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Tissue Inhibitor of Metalloproteinase-3/genetics/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1460-2156 (Electronic)&#xD;0006-8950 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23649698</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, or CADASIL, one of the most common inherited small vessel diseases of the brain, is characterized by a progressive loss of vascular smooth muscle cells and extracellular matrix accumulation. The disease is caused by highly stereotyped mutations within the extracellular domain of the NOTCH3 receptor (Notch3(ECD)) that result in an odd number of cysteine residues. While CADASIL-associated NOTCH3 mutations differentially affect NOTCH3 receptor function and activity, they all are associated with early accumulation of Notch3(ECD)-containing aggregates in small vessels. We still lack mechanistic explanation to link NOTCH3 mutations with small vessel pathology. Herein, we hypothesized that excess Notch3(ECD) could recruit and sequester functionally important proteins within small vessels of the brain. We performed biochemical, nano-liquid chromatography-tandem mass spectrometry and immunohistochemical analyses, using cerebral and arterial tissue derived from patients with CADASIL and mouse models of CADASIL that exhibit vascular lesions in the end- and early-stage of the disease, respectively. Biochemical fractionation of brain and artery samples demonstrated that mutant Notch3(ECD) accumulates in disulphide cross-linked detergent-insoluble aggregates in mice and patients with CADASIL. Further proteomic and immunohistochemical analyses identified two functionally important extracellular matrix proteins, tissue inhibitor of metalloproteinases 3 (TIMP3) and vitronectin (VTN) that are sequestered into Notch3(ECD)-containing aggregates. Using cultured cells, we show that increased levels or aggregation of Notch3 enhances the formation of Notch3(ECD)-TIMP3 complex, promoting TIMP3 recruitment and accumulation. In turn, TIMP3 promotes complex formation including NOTCH3 and VTN. In vivo, brain vessels from mice and patients with CADASIL exhibit elevated levels of both insoluble cross-linked and soluble TIMP3 species. Moreover, reverse zymography assays show a significant elevation of TIMP3 activity in the brain vessels from mice and patients with CADASIL. Collectively, our findings lend support to a Notch3(ECD) cascade hypothesis in CADASIL disease pathology, which posits that aggregation/accumulation of Notch3(ECD) in the brain vessels is a central event, promoting the abnormal recruitment of functionally important extracellular matrix proteins that may ultimately cause multifactorial toxicity. Specifically, our results suggest a dysregulation of TIMP3 activity, which could contribute to mutant Notch3(ECD) toxicity by impairing extracellular matrix homeostasis in small vessels.</style></abstract><notes><style face="normal" font="default" size="100%">Monet-Lepretre, Marie&#xD;Haddad, Iman&#xD;Baron-Menguy, Celine&#xD;Fouillot-Panchal, Mai&#xD;Riani, Meriem&#xD;Domenga-Denier, Valerie&#xD;Dussaule, Claire&#xD;Cognat, Emmanuel&#xD;Vinh, Joelle&#xD;Joutel, Anne&#xD;R01 NS054122/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Brain. 2013 Jun;136(Pt 6):1830-45. doi: 10.1093/brain/awt092. Epub 2013 May 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://brain.oxfordjournals.org/content/brain/136/6/1830.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2713775844/Monet-Lepretre-2013-Abnormal recruitment.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3673461</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/brain/awt092</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>324</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">324</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Monteith, S. J.</style></author><author><style face="normal" font="default" size="100%">Kassell, N. F.</style></author><author><style face="normal" font="default" size="100%">Goren, O.</style></author><author><style face="normal" font="default" size="100%">Harnof, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, University of Virginia Health System, Charlottesville, Virginia 22908, USA. stephen.monteith@gmail.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transcranial MR-guided focused ultrasound sonothrombolysis in the treatment of intracerebral hemorrhage</style></title><secondary-title><style face="normal" font="default" size="100%">Neurosurg Focus</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurosurgical focus</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurosurg Focus</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurosurgical focus</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurosurg Focus</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurosurgical focus</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">E14</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2013/05/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/diagnostic imaging/pathology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombectomy/instrumentation/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Ultrasonic Surgical Procedures/instrumentation/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Ultrasonography</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1092-0684 (Electronic)&#xD;1092-0684 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23634918</style></accession-num><abstract><style face="normal" font="default" size="100%">Intracerebral hemorrhage remains a significant cause of morbidity and mortality. Current surgical therapies aim to use a minimally invasive approach to remove as much of the clot as possible without causing undue disruption to surrounding neural structures. Transcranial MR-guided focused ultrasound (MRgFUS) surgery is an emerging technology that permits a highly concentrated focal point of ultrasound energy to be deposited to a target deep within the brain without an incision or craniotomy. With appropriate ultrasound parameters it has been shown that MRgFUS can effectively liquefy large-volume blood clots through the human calvaria. In this review the authors discuss the rationale for using MRgFUS to noninvasively liquefy intracerebral hemorrhage (ICH), thereby permitting minimally invasive aspiration of the liquefied clot via a small drainage tube. The mechanism of action of MRgFUS sonothrombolysis; current investigational work with in vitro, in vivo, and cadaveric models of ICH; and the potential clinical application of this disruptive technology for the treatment of ICH are discussed.</style></abstract><notes><style face="normal" font="default" size="100%">Monteith, Stephen J&#xD;Kassell, Neal F&#xD;Goren, Oded&#xD;Harnof, Sagi&#xD;Review&#xD;United States&#xD;Neurosurg Focus. 2013 May;34(5):E14. doi: 10.3171/2013.2.FOCUS1313.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3171/2013.2.focus1313</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>330</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">330</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Morowski, M.</style></author><author><style face="normal" font="default" size="100%">Vogtle, T.</style></author><author><style face="normal" font="default" size="100%">Kraft, P.</style></author><author><style face="normal" font="default" size="100%">Kleinschnitz, C.</style></author><author><style face="normal" font="default" size="100%">Stoll, G.</style></author><author><style face="normal" font="default" size="100%">Nieswandt, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Experimental Biomedicine, University Hospital and Rudolf Virchow Center, Deutsche Forschungsgemeinschaft (DFG) Research Center for Experimental Biomedicine, University of Wurzburg, Wurzburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Only severe thrombocytopenia results in bleeding and defective thrombus formation in mice</style></title><secondary-title><style face="normal" font="default" size="100%">Blood</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Blood</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Blood</style></full-title><abbr-1><style face="normal" font="default" size="100%">Blood</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Blood</style></full-title><abbr-1><style face="normal" font="default" size="100%">Blood</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">4938-47</style></pages><volume><style face="normal" font="default" size="100%">121</style></volume><number><style face="normal" font="default" size="100%">24</style></number><edition><style face="normal" font="default" size="100%">2013/04/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Aorta/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Platelets/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Arteries/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Hemorrhage/ blood/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Platelet Count</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ blood/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombocytopenia/ blood/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombosis/ blood/pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 13</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1528-0020 (Electronic)&#xD;0006-4971 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23584880</style></accession-num><abstract><style face="normal" font="default" size="100%">Platelets are essential mediators of hemostasis and thrombosis. Platelet counts (PCs) in humans average 250 platelets/nL, but it is not entirely clear how platelet numbers affect hemostasis and occurrence of thrombotic events. Mice, displaying PCs of ~1000 platelets/nL, are widely used to assess platelet function in (patho-)physiology, but also in this species, the significance of PC for hemostasis and thrombotic disease is not established. We reduced PCs in mice to defined ranges between 0 and 1000 platelets/nL by platelet-depleting antibodies and challenged them in different arterial thrombosis models: the transient middle cerebral artery occlusion (tMCAO) stroke model and tail bleeding experiments. We show that thrombotic occlusion of the injured aorta and the carotid artery were partially impaired when PCs were reduced by 70% or 80%, respectively. In contrast, tail bleeding times and thrombus formation in small arterioles were largely unaffected by reductions of PC up to 97.5%. Similarly, infarct growth and neurological deficits after tMCAO were unaffected by reductions of PCs up to 90%, whereas a further reduction was protective. These results reveal that arterial thrombosis, cerebral infarction, and hemostasis in mice efficiently occur at unexpectedly low PCs, which may have implications for humans at risk of thrombotic or hemorrhagic disease.</style></abstract><notes><style face="normal" font="default" size="100%">Morowski, Martina&#xD;Vogtle, Timo&#xD;Kraft, Peter&#xD;Kleinschnitz, Christoph&#xD;Stoll, Guido&#xD;Nieswandt, Bernhard&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Blood. 2013 Jun 13;121(24):4938-47. doi: 10.1182/blood-2012-10-461459. Epub 2013 Apr 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.bloodjournal.org/content/bloodjournal/121/24/4938.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1505495461/Morowski-2013-Only severe thromboc.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1182/blood-2012-10-461459</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>475</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">475</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mortimer, A. M.</style></author><author><style face="normal" font="default" size="100%">Bradley, M.</style></author><author><style face="normal" font="default" size="100%">Renowden, S. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neuroradiology, Frenchay Hospital, North Bristol NHS Trust, Bristol, UK. alex_mortimer@hotmail.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">Endovascular therapy for acute basilar artery occlusion: a review of the literature</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurointerv Surg</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neurointerventional surgery</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurointerv Surg</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurointerventional surgery</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurointerv Surg</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurointerventional surgery</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">266-73</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2011/10/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Acute Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Basilar Artery/ pathology/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Disorders/ diagnosis/ surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Endovascular Procedures/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic/methods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1759-8486 (Electronic)&#xD;1759-8478 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">21990530</style></accession-num><abstract><style face="normal" font="default" size="100%">Basilar artery occlusion is an infrequent form of acute stroke; clinical outcomes are heterogeneous, but the condition can be fatal. There is a lack of randomized controlled trial data in this field. Case series suggest that patients who are recanalized have much better outcomes than those who are not, and it is generally accepted that intra-arterial techniques achieve high rates of recanalization. Controversially, several studies, including a meta-analysis and registry-based investigation, that have compared intravenous thrombolysis (IVT) and intra-arterial treatment suggest similar outcomes. However, there are many potential sources of bias in each of these studies, precluding a firm conclusion. Indeed, there are many confounding factors that can influence the outcome including severity of presentation, site of occlusion, clot load, degree of collateral flow, timing of therapy, agent used for recanalization and dose of thrombolytic agent. Additionally, pretreatment infarct core imaging using diffusion-weighted imaging and the posterior circulation Acute Stroke Prognosis Early CT Score (pc-ASPECTS) scoring systems have been shown to predict outcome and therefore may be useful in selecting patients for aggressive therapy. Protocols combining intravenous agents such as glycoprotein IIb/IIIa receptor antagonists or thombolytics agents with intra-arterial techniques (&apos;bridging&apos; therapy) have shown encouraging improvements in neurological outcome and survival. Furthermore, initial case series describing the use of mechanical clot extraction devices or aspiration catheters suggest high rates of recanalization. What would be useful is a randomized trial comparing IVT, endovascular approaches and a combined IVT/endovascular approach. However, the small numbers of patients and multiple confounding factors are barriers to the development of such a trial.</style></abstract><notes><style face="normal" font="default" size="100%">Mortimer, A M&#xD;Bradley, M&#xD;Renowden, S A&#xD;Review&#xD;England&#xD;J Neurointerv Surg. 2012 Jul;4(4):266-73. doi: 10.1136/neurintsurg-2011-010090. Epub 2011 Jul 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://jnis.bmj.com/content/neurintsurg/4/4/266.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2158238576/Mortimer-2012-Endovascular therapy.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/neurintsurg-2011-010090</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>180</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">180</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moyes, A. J.</style></author><author><style face="normal" font="default" size="100%">Khambata, R. S.</style></author><author><style face="normal" font="default" size="100%">Villar, I.</style></author><author><style face="normal" font="default" size="100%">Bubb, K. J.</style></author><author><style face="normal" font="default" size="100%">Baliga, R. S.</style></author><author><style face="normal" font="default" size="100%">Lumsden, N. G.</style></author><author><style face="normal" font="default" size="100%">Xiao, F.</style></author><author><style face="normal" font="default" size="100%">Gane, P. J.</style></author><author><style face="normal" font="default" size="100%">Rebstock, A. S.</style></author><author><style face="normal" font="default" size="100%">Worthington, R. J.</style></author><author><style face="normal" font="default" size="100%">Simone, M. I.</style></author><author><style face="normal" font="default" size="100%">Mota, F.</style></author><author><style face="normal" font="default" size="100%">Rivilla, F.</style></author><author><style face="normal" font="default" size="100%">Vallejo, S.</style></author><author><style face="normal" font="default" size="100%">Peiro, C.</style></author><author><style face="normal" font="default" size="100%">Sanchez Ferrer, C. F.</style></author><author><style face="normal" font="default" size="100%">Djordjevic, S.</style></author><author><style face="normal" font="default" size="100%">Caulfield, M. J.</style></author><author><style face="normal" font="default" size="100%">MacAllister, R. J.</style></author><author><style face="normal" font="default" size="100%">Selwood, D. L.</style></author><author><style face="normal" font="default" size="100%">Ahluwalia, A.</style></author><author><style face="normal" font="default" size="100%">Hobbs, A. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Endothelial C-type natriuretic peptide maintains vascular homeostasis</style></title><secondary-title><style face="normal" font="default" size="100%">J Clin Invest</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The Journal of clinical investigation</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Clin Invest</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of clinical investigation</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Clin Invest</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of clinical investigation</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">4039-51</style></pages><volume><style face="normal" font="default" size="100%">124</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2014/08/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Aortic Aneurysm/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Atherosclerosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Platelets/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelium, Vascular/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Homeostasis</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocytes/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle, Smooth, Vascular/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Natriuretic Peptide, C-Type/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilation/drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1558-8238 (Electronic)&#xD;0021-9738 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25105365</style></accession-num><abstract><style face="normal" font="default" size="100%">The endothelium plays a fundamental role in maintaining vascular homeostasis by releasing factors that regulate local blood flow, systemic blood pressure, and the reactivity of leukocytes and platelets. Accordingly, endothelial dysfunction underpins many cardiovascular diseases, including hypertension, myocardial infarction, and stroke. Herein, we evaluated mice with endothelial-specific deletion of Nppc, which encodes C-type natriuretic peptide (CNP), and determined that this mediator is essential for multiple aspects of vascular regulation. Specifically, disruption of CNP leads to endothelial dysfunction, hypertension, atherogenesis, and aneurysm. Moreover, we identified natriuretic peptide receptor-C (NPR-C) as the cognate receptor that primarily underlies CNP-dependent vasoprotective functions and developed small-molecule NPR-C agonists to target this pathway. Administration of NPR-C agonists promotes a vasorelaxation of isolated resistance arteries and a reduction in blood pressure in wild-type animals that is diminished in mice lacking NPR-C. This work provides a mechanistic explanation for genome-wide association studies that have linked the NPR-C (Npr3) locus with hypertension by demonstrating the importance of CNP/NPR-C signaling in preserving vascular homoeostasis. Furthermore, these results suggest that the CNP/NPR-C pathway has potential as a disease-modifying therapeutic target for cardiovascular disorders.</style></abstract><notes><style face="normal" font="default" size="100%">Moyes, Amie J&#xD;Khambata, Rayomand S&#xD;Villar, Inmaculada&#xD;Bubb, Kristen J&#xD;Baliga, Reshma S&#xD;Lumsden, Natalie G&#xD;Xiao, Fang&#xD;Gane, Paul J&#xD;Rebstock, Anne-Sophie&#xD;Worthington, Roberta J&#xD;Simone, Michela I&#xD;Mota, Filipa&#xD;Rivilla, Fernando&#xD;Vallejo, Susana&#xD;Peiro, Concepcion&#xD;Sanchez Ferrer, Carlos F&#xD;Djordjevic, Snezana&#xD;Caulfield, Mark J&#xD;MacAllister, Raymond J&#xD;Selwood, David L&#xD;Ahluwalia, Amrita&#xD;Hobbs, Adrian J&#xD;G9521010/Medical Research Council/United Kingdom&#xD;MR/K006584/1/Medical Research Council/United Kingdom&#xD;078496/Z/05/Z/Wellcome Trust/United Kingdom&#xD;084449/Z/07/Z/Wellcome Trust/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Clin Invest. 2014 Sep;124(9):4039-51. doi: 10.1172/JCI74281. Epub 2014 Aug 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://dm5migu4zj3pb.cloudfront.net/manuscripts/74000/74281/JCI74281.v2.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3157791635/Moyes-2014-Endothelial C-type n.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4151218</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1172/jci74281</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>12</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">12</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mu, Z. H.</style></author><author><style face="normal" font="default" size="100%">Jiang, Z.</style></author><author><style face="normal" font="default" size="100%">Lin, X. J.</style></author><author><style face="normal" font="default" size="100%">Wang, L. P.</style></author><author><style face="normal" font="default" size="100%">Xi, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, Z. J.</style></author><author><style face="normal" font="default" size="100%">Wang, Y. T.</style></author><author><style face="normal" font="default" size="100%">Yang, G. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.&#xD;Med-X Research Institute and School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.&#xD;Center for Biotechnology and Interdisciplinary Studies, Department of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, NY, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Vessel Dilation Attenuates Endothelial Dysfunction Following Middle Cerebral Artery Occlusion in Hyperglycemic Rats</style></title><secondary-title><style face="normal" font="default" size="100%">CNS Neurosci Ther</style></secondary-title><alt-title><style face="normal" font="default" size="100%">CNS neuroscience &amp; therapeutics</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">CNS Neurosci Ther</style></full-title><abbr-1><style face="normal" font="default" size="100%">CNS neuroscience &amp; therapeutics</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">CNS Neurosci Ther</style></full-title><abbr-1><style face="normal" font="default" size="100%">CNS neuroscience &amp; therapeutics</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">316-24</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2016/02/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/ analogs &amp; derivatives/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/diagnostic imaging/drug effects/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Angiography</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Arteries/diagnostic imaging/drug effects/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/drug therapy/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Experimental/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelium, Vascular/diagnostic imaging/drug effects/pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperglycemia/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/drug therapy/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">NG-Nitroarginine Methyl Ester</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Organ Size</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents/ pharmacology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1755-5949 (Electronic)&#xD;1755-5930 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26842484</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVES: Dynamically observe cerebral vascular changes in hyperglycemic rats in vivo and explore the effect of diabetes on endothelial function after ischemic stroke. BACKGROUND: Diabetes affects both large and small vessels in the brain, but the dynamic process and mechanism are unclear. METHODS: We investigated the structural and functional changes of brain vasculature in living hyperglycemic rats and their impact on stroke outcomes via a novel technique: synchrotron radiation angiography. We also examined the effect of prolonged fasudil treatment on arterial reactivity and hemorrhagic transformation. Adult Sprague Dawley rats were treated by streptozotocin to induce type 1 diabetes. These hyperglycemic rats received fasudil pretreatment and then underwent transient middle cerebral artery occlusion. RESULTS: We found that diabetes caused arteries narrowing in the circus Willis as early as 2 weeks after streptozotocin injection (P &lt; 0.05). These vessels were further constricted after middle cerebral artery occlusion. L-NAME could induce regional constrictions and impaired relaxation in hyperglycemic animals. Furthermore, hemorrhagic transformation was also increased in the hyperglycemic rats compared to the control (P &lt; 0.05). In fasudil-treated rats, the internal carotid artery narrowing was ameliorated and L-NAME-induced regional constriction was abolished. Importantly, stroke prognosis was improved in fasudil-treated rats compared to the control (P &lt; 0.05). CONCLUSIONS: Our dynamic angiographic data demonstrated that diabetes could impair the cerebral arterial reactivity. Prolonged fasudil treatment could attenuate arterial dysfunction and improve the prognosis of ischemic stroke by affecting both the large and small vasculature.</style></abstract><notes><style face="normal" font="default" size="100%">Mu, Zhi-Hao&#xD;Jiang, Zhen&#xD;Lin, Xiao-Jie&#xD;Wang, Li-Ping&#xD;Xi, Yan&#xD;Zhang, Zhi-Jun&#xD;Wang, Yong-Ting&#xD;Yang, Guo-Yuan&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;CNS Neurosci Ther. 2016 Apr;22(4):316-24. doi: 10.1111/cns.12500. Epub 2016 Feb 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/cns.12500/asset/cns12500.pdf?v=1&amp;t=ixsnlbej&amp;s=da18f821becfa4f0746f5ddbf7ce1a8e3498e68e</style></url></related-urls><pdf-urls><url>internal-pdf://0385560039/Mu-2016-Vessel Dilation Atte.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/cns.12500</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>289</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">289</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Murtha, L. A.</style></author><author><style face="normal" font="default" size="100%">McLeod, D. D.</style></author><author><style face="normal" font="default" size="100%">McCann, S. K.</style></author><author><style face="normal" font="default" size="100%">Pepperall, D.</style></author><author><style face="normal" font="default" size="100%">Chung, S.</style></author><author><style face="normal" font="default" size="100%">Levi, C. R.</style></author><author><style face="normal" font="default" size="100%">Calford, M. B.</style></author><author><style face="normal" font="default" size="100%">Spratt, N. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Newcastle and Hunter Medical Research Institute, School of Biomedical Sciences &amp; Pharmacy, University of Newcastle, Callaghan, NSW, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Short-duration hypothermia after ischemic stroke prevents delayed intracranial pressure rise</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">International journal of stroke : official journal of the International Stroke Society</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Int J Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">International journal of stroke : official journal of the International Stroke Society</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Int J Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">International journal of stroke : official journal of the International Stroke Society</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">553-9</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2013/09/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Hypothermia, Induced/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/pathology/physiopathology/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hypertension/physiopathology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Pressure/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Long-Evans</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Rewarming/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Species Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1747-4949 (Electronic)&#xD;1747-4930 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24025084</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Intracranial pressure elevation, peaking three to seven post-stroke is well recognized following large strokes. Data following small-moderate stroke are limited. Therapeutic hypothermia improves outcome after cardiac arrest, is strongly neuroprotective in experimental stroke, and is under clinical trial in stroke. Hypothermia lowers elevated intracranial pressure; however, rebound intracranial pressure elevation and neurological deterioration may occur during rewarming. HYPOTHESES: (1) Intracranial pressure increases 24 h after moderate and small strokes. (2) Short-duration hypothermia-rewarming, instituted before intracranial pressure elevation, prevents this 24 h intracranial pressure elevation. METHODS: Long-Evans rats with two hour middle cerebral artery occlusion or outbred Wistar rats with three hour middle cerebral artery occlusion had intracranial pressure measured at baseline and 24 h. Wistars were randomized to 2.5 h hypothermia (32.5 degrees C) or normothermia, commencing 1 h after stroke. RESULTS: In Long-Evans rats (n = 5), intracranial pressure increased from 10.9 +/- 4.6 mmHg at baseline to 32.4 +/- 11.4 mmHg at 24 h, infarct volume was 84.3 +/- 15.9 mm(3) . In normothermic Wistars (n = 10), intracranial pressure increased from 6.7 +/- 2.3 mmHg to 31.6 +/- 9.3 mmHg, infarct volume was 31.3 +/- 18.4 mm(3) . In hypothermia-treated Wistars (n = 10), 24 h intracranial pressure did not increase (7.0 +/- 2.8 mmHg, P &lt; 0.001 vs. normothermia), and infarct volume was smaller (15.4 +/- 11.8 mm(3) , P &lt; 0.05). CONCLUSIONS: We saw major intracranial pressure elevation 24 h after stroke in two rat strains, even after small strokes. Short-duration hypothermia prevented the intracranial pressure rise, an effect sustained for at least 18 h after rewarming. The findings have potentially important implications for design of future clinical trials.</style></abstract><notes><style face="normal" font="default" size="100%">Murtha, L A&#xD;McLeod, D D&#xD;McCann, S K&#xD;Pepperall, D&#xD;Chung, S&#xD;Levi, C R&#xD;Calford, M B&#xD;Spratt, N J&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Int J Stroke. 2014 Jul;9(5):553-9. doi: 10.1111/ijs.12181. Epub 2013 Sep 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/ijs.12181/asset/ijs12181.pdf?v=1&amp;t=ixsnlg83&amp;s=fc6ef77be35b12f3fd2d329836783d61d073662e</style></url></related-urls><pdf-urls><url>internal-pdf://3314697284/Murtha-2014-Short-duration hypot.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/ijs.12181</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>377</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">377</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nada, S. E.</style></author><author><style face="normal" font="default" size="100%">Tulsulkar, J.</style></author><author><style face="normal" font="default" size="100%">Raghavan, A.</style></author><author><style face="normal" font="default" size="100%">Hensley, K.</style></author><author><style face="normal" font="default" size="100%">Shah, Z. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicinal and Biological Chemistry, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, OH, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A derivative of the CRMP2 binding compound lanthionine ketimine provides neuroprotection in a mouse model of cerebral ischemia</style></title><secondary-title><style face="normal" font="default" size="100%">Neurochem Int</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurochemistry international</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurochem Int</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurochemistry international</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurochem Int</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurochemistry international</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1357-63</style></pages><volume><style face="normal" font="default" size="100%">61</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2012/10/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Amino Acids, Sulfur/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Damage, Chronic/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Evaluation, Preclinical</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Hand Strength</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/complications/ drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Intercellular Signaling Peptides and Proteins/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Tissue Proteins/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Poly (ADP-Ribose) Polymerase-1</style></keyword><keyword><style face="normal" font="default" size="100%">Poly(ADP-ribose) Polymerases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Cell Culture</style></keyword><keyword><style face="normal" font="default" size="100%">Rotarod Performance Test</style></keyword><keyword><style face="normal" font="default" size="100%">Single-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Sirtuin 1/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">tert-Butylhydroperoxide/toxicity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-9754 (Electronic)&#xD;0197-0186 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23036362</style></accession-num><abstract><style face="normal" font="default" size="100%">Lanthionines are novel neurotrophic and neuroprotective small molecules that show promise for the treatment of neurodegenerative diseases. In particular, a recently developed, cell permeable lanthionine derivative known as LKE (lanthionine ketimine 5-ethyl ester) promotes neurite growth at low nanomolar concentrations. LKE also has neuroprotective, anti-apoptotic, and anti-inflammatory properties. Its therapeutic potential in cerebral ischemia and its mechanisms of neurotrophic action remain to be fully elucidated. Here, we hypothesize that the neuroprotective actions of LKE could result from induction or modulation of CRMP2. We found that treating primary cultured mouse neurons with LKE provided significant protection against t-butyl hydroperoxide-induced neuronal death possibly through CRMP2 upregulation. Similarly, in vivo studies showed that LKE pre and/or post-treatment protects mice against permanent distal middle cerebral artery occlusion (p-MCAO) as evidenced by lower stroke lesions and improved functional outcomes in terms of rotarod, grip strength and neurologic deficit scores in treated groups. Protein expression levels of CRMP2 were higher in brain cortices of LKE pretreated mice, suggesting that LKE&apos;s neuroprotective activity may be CRMP2 dependent. Lower activity of cleaved PARP-1 and higher activity of SIRT-1 was also observed in LKE treated group suggesting its anti-apoptotic properties. Our results suggest that LKE has potential as a therapeutic intervention in cerebral ischemia and that part of its protective mechanism may be attributed to CRMP2 mediated action and PARP-1/SIRT-1 modulation.</style></abstract><notes><style face="normal" font="default" size="100%">Nada, Shadia E&#xD;Tulsulkar, Jatin&#xD;Raghavan, Aparna&#xD;Hensley, Kenneth&#xD;Shah, Zahoor A&#xD;R21-NS066279/NS/NINDS NIH HHS/United States&#xD;R00-AT004197/AT/NCCIH NIH HHS/United States&#xD;R00 AT004197/AT/NCCIH NIH HHS/United States&#xD;R01-AE031553/AE/ASPE HHS/United States&#xD;R21 NS066279/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;England&#xD;Neurochem Int. 2012 Dec;61(8):1357-63. doi: 10.1016/j.neuint.2012.09.013. Epub 2012 Oct 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0197018612002987/1-s2.0-S0197018612002987-main.pdf?_tid=9b9fd722-d7d3-11e6-949f-00000aab0f26&amp;acdnat=1484121633_7fc831e31ccb9983e1fdb70e4e9d4f89</style></url></related-urls><pdf-urls><url>internal-pdf://1836331531/Nada-2012-A derivative of the.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3513634</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms412080</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuint.2012.09.013</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>379</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">379</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nahab, F.</style></author><author><style face="normal" font="default" size="100%">Kass-Hout, T.</style></author><author><style face="normal" font="default" size="100%">Shaltoni, H. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Emory University, Atlanta, GA, USA. fnahab@emory.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">Periprocedural antithrombotic strategies in acute ischemic stroke interventional therapy</style></title><secondary-title><style face="normal" font="default" size="100%">Neurology</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurology</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurology</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">S174-81</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">13 Suppl 1</style></number><edition><style face="normal" font="default" size="100%">2012/10/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/diagnosis/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Early Medical Intervention/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Fibrinolytic Agents/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/diagnosis/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombolytic Therapy/ methods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 25</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1526-632X (Electronic)&#xD;0028-3878 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23008395</style></accession-num><abstract><style face="normal" font="default" size="100%">In patients undergoing endovascular therapy for acute ischemic stroke, antithrombotic therapies are utilized to prevent distal embolization, arterial reocclusion, or catheter-related embolism. However, this must be weighed against the risk of hemorrhagic complications secondary to existing and ongoing ischemia or silent vessel perforation. In this article, we present an overview of the available literature evaluating antithrombotic therapy in patients undergoing endovascular therapy for acute ischemic stroke and discuss the emerging role of these agents.</style></abstract><notes><style face="normal" font="default" size="100%">Nahab, Fadi&#xD;Kass-Hout, Tareq&#xD;Shaltoni, Hashem M&#xD;Review&#xD;United States&#xD;Neurology. 2012 Sep 25;79(13 Suppl 1):S174-81.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.neurology.org/content/79/13_Supplement_1/S174.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3322428114/Nahab-2012-Periprocedural antit.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1212/WNL.0b013e31826959af</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>485</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">485</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nakka, V. P.</style></author><author><style face="normal" font="default" size="100%">Lang, B. T.</style></author><author><style face="normal" font="default" size="100%">Lenschow, D. J.</style></author><author><style face="normal" font="default" size="100%">Zhang, D. E.</style></author><author><style face="normal" font="default" size="100%">Dempsey, R. J.</style></author><author><style face="normal" font="default" size="100%">Vemuganti, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurological Surgery, Madison, Wisconsin 53792, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Increased cerebral protein ISGylation after focal ischemia is neuroprotective</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">2375-84</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2011/08/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Blotting, Western</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Electrophoresis, Gel, Two-Dimensional</style></keyword><keyword><style face="normal" font="default" size="100%">Immunohistochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Attack, Transient/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Psychomotor Performance/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">SUMO-1 Protein/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Ubiquitin-Activating Enzymes/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Ubiquitination</style></keyword><keyword><style face="normal" font="default" size="100%">Ubiquitins/genetics/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">21847135</style></accession-num><abstract><style face="normal" font="default" size="100%">Addition of a small peptide called ISG15 is known as ISGylation, which is an ubiquitin (ub)-like posttranslational modification. We currently show that focal ischemia induced by transient middle cerebral artery occlusion (MCAO) in adult mice significantly induces cortical protein ISGylation between 6 and 24 hours reperfusion. With two-dimensional western blotting, 45 proteins were observed to be significantly increased in ISGylation (by 1.8- to 9.7-fold) after focal ischemia compared with sham control. Immunochemistry showed that ISGylated proteins are localized in neurons within the ipsilateral striatum and in astroglia within the peri-infarct cortex of ischemic mice. When subjected to transient MCAO, ISG15(-/-) mice showed increased mortality, exacerbated infarction, and worsened neurologic recovery than did wild-type controls. In addition, mice lacking UBE1L (ub-activating enzyme E1-like protein, the first enzyme of the ISGylation cycle) also showed bigger infarcts when subjected to transient MCAO. Regional cerebral blood flow or other physiologic parameters were not significantly different in both knockouts compared with wild-type controls. These studies indicate that increased protein ISGylation might be an endogenous neuroprotective adaptation to minimize poststroke brain damage.</style></abstract><notes><style face="normal" font="default" size="100%">Nakka, Venkata P&#xD;Lang, Bradley T&#xD;Lenschow, Deborah J&#xD;Zhang, Dong-Er&#xD;Dempsey, Robert J&#xD;Vemuganti, Raghu&#xD;R01 GM066955/GM/NIGMS NIH HHS/United States&#xD;GM66955/GM/NIGMS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Cereb Blood Flow Metab. 2011 Dec;31(12):2375-84. doi: 10.1038/jcbfm.2011.103. Epub 2011 Aug 17.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3323186</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2011.103</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>84</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">84</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nampoothiri, S. S.</style></author><author><style face="normal" font="default" size="100%">Menon, H. V.</style></author><author><style face="normal" font="default" size="100%">Das, D.</style></author><author><style face="normal" font="default" size="100%">Krishnamurthy, R. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Biotechnology, Coordinator, DBT - Centre for Bioinformatics, National Institute of Technology Calicut, Calicut 673601, India. rajanikant@nitc.ac.in.</style></auth-address><titles><title><style face="normal" font="default" size="100%">ISCHEMIRs: Finding a Way Through the Obstructed Cerebral Arteries</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Drug Targets</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Current drug targets</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Drug Targets</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current drug targets</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Curr Drug Targets</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current drug targets</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">800-10</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2015/05/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antagomirs/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Disorders/drug therapy/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Computational Biology/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Regulatory Networks</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Markers/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">MicroRNAs/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Transcription Factors/genetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">1873-5592 (Electronic)&#xD;1389-4501 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25981603</style></accession-num><abstract><style face="normal" font="default" size="100%">MicroRNAs (miRNAs) are small (19-25 nucleotides) non-coding single-stranded RNAs that control post-transcriptional gene expression. miRNAs are abundantly expressed in the brain, where they play key roles during neuronal differentiation, synaptogenesis, and plasticity. It is also becoming increasingly evident that miRNAs are involved in the etiology of several neurological disorders. Mounting evidence indicates that miRNAs have the ability to regulate the expression profiles of genes in signaling pathways associated with cerebrovascular diseases such as ischemic stroke, subarachnoid hemorrhage, and vascular dementia. For instance, miR-21 is involved in ischemic stroke pathology through atherosclerosis and provides neuroprotection by its anti-apoptotic features. miR-497 induces neuronal death and miR-210 is upregulated in hypoxic cells. Deregulated expression of miRNAs in response to ischemic stroke has enabled the use of miRNA as an efficient non-invasive biomarker. Antagomirs are often effective against neuronal apoptosis and can induce neuroregeneration following ischemia. Moreover, the advent of systems biology has introduced novel computational tools to identify the link between miRNAs, target genes and transcription factors involved in the stroke pathology and its treatment. This review describes the emerging role of miRNAs in neuroprotection and focuses on a subset of miRNAs that act as central players in ischemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Nampoothiri, Sreekala S&#xD;Menon, Hari Vinayak&#xD;Das, Debashish&#xD;Krishnamurthy, Rajanikant Golgodu&#xD;Review&#xD;Netherlands&#xD;Curr Drug Targets. 2016;17(7):800-10.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>387</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">387</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nance, E. A.</style></author><author><style face="normal" font="default" size="100%">Woodworth, G. F.</style></author><author><style face="normal" font="default" size="100%">Sailor, K. A.</style></author><author><style face="normal" font="default" size="100%">Shih, T. Y.</style></author><author><style face="normal" font="default" size="100%">Xu, Q.</style></author><author><style face="normal" font="default" size="100%">Swaminathan, G.</style></author><author><style face="normal" font="default" size="100%">Xiang, D.</style></author><author><style face="normal" font="default" size="100%">Eberhart, C.</style></author><author><style face="normal" font="default" size="100%">Hanes, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Transl Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Science translational medicine</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Sci Transl Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Science translational medicine</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Sci Transl Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Science translational medicine</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">149ra119</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">149</style></number><edition><style face="normal" font="default" size="100%">2012/08/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Chemistry, Pharmaceutical</style></keyword><keyword><style face="normal" font="default" size="100%">Coated Materials, Biocompatible</style></keyword><keyword><style face="normal" font="default" size="100%">Diffusion</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Carriers</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Microscopy, Confocal</style></keyword><keyword><style face="normal" font="default" size="100%">Microscopy, Fluorescence</style></keyword><keyword><style face="normal" font="default" size="100%">Microscopy, Video</style></keyword><keyword><style face="normal" font="default" size="100%">Nanoparticles</style></keyword><keyword><style face="normal" font="default" size="100%">Nanotechnology</style></keyword><keyword><style face="normal" font="default" size="100%">Paclitaxel/chemistry/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Particle Size</style></keyword><keyword><style face="normal" font="default" size="100%">Permeability</style></keyword><keyword><style face="normal" font="default" size="100%">Polyethylene Glycols/ chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Polystyrenes/administration &amp; dosage/chemistry/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Surface Properties</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 29</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1946-6242 (Electronic)&#xD;1946-6234 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22932224</style></accession-num><abstract><style face="normal" font="default" size="100%">Prevailing opinion suggests that only substances up to 64 nm in diameter can move at appreciable rates through the brain extracellular space (ECS). This size range is large enough to allow diffusion of signaling molecules, nutrients, and metabolic waste products, but too small to allow efficient penetration of most particulate drug delivery systems and viruses carrying therapeutic genes, thereby limiting effectiveness of many potential therapies. We analyzed the movements of nanoparticles of various diameters and surface coatings within fresh human and rat brain tissue ex vivo and mouse brain in vivo. Nanoparticles as large as 114 nm in diameter diffused within the human and rat brain, but only if they were densely coated with poly(ethylene glycol) (PEG). Using these minimally adhesive PEG-coated particles, we estimated that human brain tissue ECS has some pores larger than 200 nm and that more than one-quarter of all pores are &gt;/= 100 nm. These findings were confirmed in vivo in mice, where 40- and 100-nm, but not 200-nm, nanoparticles spread rapidly within brain tissue, only if densely coated with PEG. Similar results were observed in rat brain tissue with paclitaxel-loaded biodegradable nanoparticles of similar size (85 nm) and surface properties. The ability to achieve brain penetration with larger nanoparticles is expected to allow more uniform, longer-lasting, and effective delivery of drugs within the brain, and may find use in the treatment of brain tumors, stroke, neuroinflammation, and other brain diseases where the blood-brain barrier is compromised or where local delivery strategies are feasible.</style></abstract><notes><style face="normal" font="default" size="100%">Nance, Elizabeth A&#xD;Woodworth, Graeme F&#xD;Sailor, Kurt A&#xD;Shih, Ting-Yu&#xD;Xu, Qingguo&#xD;Swaminathan, Ganesh&#xD;Xiang, Dennis&#xD;Eberhart, Charles&#xD;Hanes, Justin&#xD;5T32CA130840-02/CA/NCI NIH HHS/United States&#xD;T32 CA130840/CA/NCI NIH HHS/United States&#xD;T32 EY017203/EY/NEI NIH HHS/United States&#xD;R01 CA164789/CA/NCI NIH HHS/United States&#xD;U54 CA151838/CA/NCI NIH HHS/United States&#xD;U54CA151838/CA/NCI NIH HHS/United States&#xD;R01CA164789/CA/NCI NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;United States&#xD;Sci Transl Med. 2012 Aug 29;4(149):149ra119. doi: 10.1126/scitranslmed.3003594.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stm.sciencemag.org/content/scitransmed/4/149/149ra119.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1672371691/Nance-2012-A dense poly(ethylen.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3718558</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms448252</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1126/scitranslmed.3003594</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>104</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">104</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Naylor, A. R.</style></author><author><style face="normal" font="default" size="100%">Sillesen, H.</style></author><author><style face="normal" font="default" size="100%">Schroeder, T. V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Vascular Surgery at Leicester Royal Infirmary, Leicester, UK. Electronic address: ross.naylor@uhl-tr.nhs.uk.&#xD;Department of Vascular Surgery at Rigshospitalet, Copenhagen, Denmark.&#xD;Centre for Clinical Education at Rigshospitalet and University of Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical and imaging features associated with an increased risk of early and late stroke in patients with symptomatic carotid disease</style></title><secondary-title><style face="normal" font="default" size="100%">Eur J Vasc Endovasc Surg</style></secondary-title><alt-title><style face="normal" font="default" size="100%">European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur J Vasc Endovasc Surg</style></full-title><abbr-1><style face="normal" font="default" size="100%">European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Eur J Vasc Endovasc Surg</style></full-title><abbr-1><style face="normal" font="default" size="100%">European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">513-23</style></pages><volume><style face="normal" font="default" size="100%">49</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2015/03/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Stenosis/ surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Endarterectomy, Carotid/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ surgery</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1532-2165 (Electronic)&#xD;1078-5884 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25747345</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: The aim of this review was to identify clinical and/or imaging parameters that are associated with an increased (decreased) risk of early/late stroke in patients with symptomatic carotid disease. IN THE FIRST 14 DAYS: Natural history studies suggest that 8-15% of patients with 50-99% stenoses will suffer a stroke within 72 hours of their index symptom. Currently, there are insufficient validated data to identify highest-risk patients for emergency carotid endarterectomy (CEA), but an increased risk of stroke appears to be predicted by (i) an ABCD(2) score of 4-7; (ii) the presence of acute cerebral injury on CT/MRI; (iii) Gray Scale Median (GSM) &lt;15, (iv) spontaneous embolisation on Transcranial Doppler (TCD); and (v) increased fluorodeoxyglucose (FDG) uptake in the carotid plaque on positron emission tomography (PET). A future goal must be to develop predictive algorithms (based on accessible imaging strategies) for identifying acutely symptomatic patients with highly unstable plaques for emergency CEA. MEDIUM TO LONG TERM: In the randomised trials, about 70% of patients with symptomatic 70-99% stenoses were stroke-free on &quot;best medical therapy&quot; at 5 years. Clinical predictors of increased stroke risk include (i) male gender; (ii) age &gt;75; (iii) hemispheric symptoms; and (iv) increasing comorbidity. Imaging features associated with increased stroke risk include (i) irregular stenoses; (ii) contralateral occlusion; (iii) increasing stenosis severity, but not subocclusion; (iv) tandem intracranial disease; (v) a failure to recruit intracranial collaterals; (vi) low GSM; (vii) MR diagnosis of intra-plaque haemorrhage; (vii) spontaneous embolisation on TCD; and (viii) increased FDG uptake in the carotid plaque on PET. Clinical/imaging parameters associated with a lower risk of stroke include (i) female gender, especially those with 50-99% stenoses; (ii) ocular symptoms/lacunar stroke; (iii) smooth stenoses; and (iv) chronic subocclusion.</style></abstract><notes><style face="normal" font="default" size="100%">Naylor, A R&#xD;Sillesen, H&#xD;Schroeder, T V&#xD;Review&#xD;England&#xD;Eur J Vasc Endovasc Surg. 2015 May;49(5):513-23. doi: 10.1016/j.ejvs.2015.01.011. Epub 2015 Mar 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S1078588415000520/1-s2.0-S1078588415000520-main.pdf?_tid=a242823c-d7d3-11e6-bb6d-00000aab0f27&amp;acdnat=1484121644_db9b70043f2e7b05cb0bad76178eefd1</style></url></related-urls><pdf-urls><url>internal-pdf://0862279979/Naylor-2015-Clinical and imaging.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ejvs.2015.01.011</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>488</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">488</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nguyen, J.</style></author><author><style face="normal" font="default" size="100%">Nishimura, N.</style></author><author><style face="normal" font="default" size="100%">Fetcho, R. N.</style></author><author><style face="normal" font="default" size="100%">Iadecola, C.</style></author><author><style face="normal" font="default" size="100%">Schaffer, C. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biomedical Engineering, Cornell University, Ithaca, New York 14853, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Occlusion of cortical ascending venules causes blood flow decreases, reversals in flow direction, and vessel dilation in upstream capillaries</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">2243-54</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2011/06/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Flow Velocity/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Capillaries/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Veins/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Data Interpretation, Statistical</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Microscopy, Fluorescence, Multiphoton</style></keyword><keyword><style face="normal" font="default" size="100%">Neocortex/blood supply</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Venous Thrombosis/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Venules/pathology/ physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">21712834</style></accession-num><abstract><style face="normal" font="default" size="100%">The accumulation of small strokes has been linked to cognitive dysfunction. Although most animal models have focused on the impact of arteriole occlusions, clinical evidence indicates that venule occlusions may also be important. We used two-photon excited fluorescence microscopy to quantify changes in blood flow and vessel diameter in capillaries after occlusion of single ascending or surface cortical venules as a function of the connectivity between the measured capillary and the occluded venule. Clotting was induced by injuring the target vessel wall with femtosecond laser pulses. After an ascending venule (AV) occlusion, upstream capillaries showed decreases in blood flow speed, high rates of reversal in flow direction, and increases in vessel diameter. Surface venule occlusions produced similar effects, unless a collateral venule provided a new drain. Finally, we showed that AVs and penetrating arterioles have different nearest-neighbor spacing but capillaries branching from them have similar topology, which together predicted the severity and spatial extent of blood flow reduction after occlusion of either one. These results provide detailed insights into the widespread hemodynamic changes produced by cortical venule occlusions and may help elucidate the role of venule occlusions in the development of cognitive disorders and other brain diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Nguyen, John&#xD;Nishimura, Nozomi&#xD;Fetcho, Robert N&#xD;Iadecola, Costantino&#xD;Schaffer, Chris B&#xD;F32 AG031620/AG/NIA NIH HHS/United States&#xD;R01 NS037853/NS/NINDS NIH HHS/United States&#xD;1F32AG031620-01A2/AG/NIA NIH HHS/United States&#xD;NS37853/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United States&#xD;J Cereb Blood Flow Metab. 2011 Nov;31(11):2243-54. doi: 10.1038/jcbfm.2011.95. Epub 2011 Jun 29.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3210348</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2011.95</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>347</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">347</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nijboer, C. H.</style></author><author><style face="normal" font="default" size="100%">Bonestroo, H. J.</style></author><author><style face="normal" font="default" size="100%">Zijlstra, J.</style></author><author><style face="normal" font="default" size="100%">Kavelaars, A.</style></author><author><style face="normal" font="default" size="100%">Heijnen, C. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Neuroimmunology and Developmental Origins of Disease (NIDOD), University Medical Center Utrecht, Utrecht, The Netherlands. C.Nijboer@umcutrecht.nl</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mitochondrial JNK phosphorylation as a novel therapeutic target to inhibit neuroinflammation and apoptosis after neonatal ischemic brain damage</style></title><secondary-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurobiology of disease</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurobiology of disease</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurobiology of disease</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">432-44</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><edition><style face="normal" font="default" size="100%">2013/02/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Animals, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Blotting, Western</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/complications/ metabolism/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Electrophoretic Mobility Shift Assay</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme Inhibitors/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/etiology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">MAP Kinase Kinase 4/ antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Mitochondria/drug effects/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative Stress/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Peptides/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphorylation</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Real-Time Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default" size="100%">Reverse Transcriptase Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1095-953X (Electronic)&#xD;0969-9961 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23376684</style></accession-num><abstract><style face="normal" font="default" size="100%">Neonatal encephalopathy is associated with high mortality and life-long developmental consequences. Therapeutic options are very limited. We assessed the effects of D-JNKi, a small peptide c-Jun N-terminal kinase (JNK) MAP kinase inhibitor, on neuroinflammation, mitochondrial integrity and neuronal damage in a neonatal rat model of ischemic brain damage. Hypoxic-ischemic (HI) brain injury was induced in postnatal-day 7 rats by unilateral carotid artery occlusion and hypoxia, and was followed by intraperitoneal D-JNKi treatment. We demonstrate here for the first time that a single intraperitoneal injection with D-JNKi directly after HI strongly reduces neonatal brain damage by &gt;85% with a therapeutic window of at least 6h. D-JNKi treatment also restored cognitive and motor function as analyzed at 9weeks post-insult. Neuroprotective D-JNKi treatment inhibited phosphorylation of nuclear c-Jun (P-c-Jun), and consequently reduced activity of the AP-1 transcription factor and production of cerebral cytokines/chemokines as determined at 3 and 24h post-HI. Inhibition of P-c-Jun by D-JNKi is thought to be mediated via inhibition of the upstream phosphorylation of cytosolic and nuclear JNK and/or by preventing the direct interaction of phosphorylated (P-)JNK with c-Jun. Surprisingly, however, HI did not induce a detectable increase in P-JNK in cytosol or nucleus. Notably, we show here for the first time that HI induces P-JNK only in the mitochondrial fraction, which was completely prevented by D-JNKi treatment. The hypothesis that mitochondrial JNK activation is key to HI brain injury was supported by data showing that treatment of rat pups with SabKIM1 peptide, a specific mitochondrial JNK inhibitor, is also neuroprotective. Inhibition of HI-induced mitochondrial JNK activation was associated with preservation of mitochondrial integrity as evidenced by prevention of ATP loss and inhibition of lipid peroxidation. The HI-induced increase in apoptotic markers (cytochrome c release and caspase 3 activation) as analyzed at 24h post-HI were also strongly reduced by D-JNKi and the mitochondrial anti-apoptotic proteins Bcl-2 and Bcl-xL were upregulated. Neuroprotection was lost after repeated 0+3h D-JNKi treatment which was associated with complete inhibition of the second peak of AP-1 activity and disability to upregulate mitochondrial Bcl-2 and Bcl-xL. We show here for the first time that D-JNKi treatment efficiently protects the neonatal brain against ischemic brain damage and subsequent cognitive and motor impairment. We propose that inhibition of phosphorylation of mitochondrial JNK is a pivotal step in preventing early loss of mitochondrial integrity leading to reduced neuroinflammation and inhibition of apoptotic neuronal loss. Moreover we show the crucial role of upregulation of mitochondrial anti-apoptotic proteins to maintain neuroprotection.</style></abstract><notes><style face="normal" font="default" size="100%">Nijboer, Cora H&#xD;Bonestroo, Hilde J C&#xD;Zijlstra, Jitske&#xD;Kavelaars, Annemieke&#xD;Heijnen, Cobi J&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Neurobiol Dis. 2013 Jun;54:432-44. doi: 10.1016/j.nbd.2013.01.017. Epub 2013 Jan 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0969996113000417/1-s2.0-S0969996113000417-main.pdf?_tid=acc89ac0-d7d3-11e6-b21a-00000aab0f01&amp;acdnat=1484121661_49425338091006663e93b6eaf9762342</style></url></related-urls><pdf-urls><url>internal-pdf://3828981738/Nijboer-2013-Mitochondrial JNK ph.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.nbd.2013.01.017</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>352</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">352</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nijboer, C. H.</style></author><author><style face="normal" font="default" size="100%">Heijnen, C. J.</style></author><author><style face="normal" font="default" size="100%">Degos, V.</style></author><author><style face="normal" font="default" size="100%">Willemen, H. L.</style></author><author><style face="normal" font="default" size="100%">Gressens, P.</style></author><author><style face="normal" font="default" size="100%">Kavelaars, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Neuroimmunology and Developmental Origins of Disease (NIDOD), University Medical Center Utrecht, KC03.068.0, Lundlaan 6, 3584 EA, Utrecht, The Netherlands. C.Nijboer@umcutrecht.nl</style></auth-address><titles><title><style face="normal" font="default" size="100%">Astrocyte GRK2 as a novel regulator of glutamate transport and brain damage</style></title><secondary-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurobiology of disease</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurobiology of disease</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurobiology of disease</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">206-15</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><edition><style face="normal" font="default" size="100%">2013/01/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Amino Acid Transport System X-AG/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Animals, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Blotting, Western</style></keyword><keyword><style face="normal" font="default" size="100%">Cytoskeletal Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorescent Antibody Technique</style></keyword><keyword><style face="normal" font="default" size="100%">G-Protein-Coupled Receptor Kinase 2/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Glutamic Acid/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia-Ischemia, Brain/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoprecipitation</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1095-953X (Electronic)&#xD;0969-9961 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23313319</style></accession-num><abstract><style face="normal" font="default" size="100%">G protein-coupled receptor (GPCR) kinase 2 (GRK2) regulates cellular signaling via desensitization of GPCRs and by direct interaction with intracellular signaling molecules. We recently described that ischemic brain injury decreases cerebral GRK2 levels. Here we studied the effect of astrocyte GRK2-deficiency on neonatal brain damage in vivo. As astrocytes protect neurons by taking up glutamate via plasma-membrane transporters, we also studied the effect of GRK2 on the localization of the GLutamate ASpartate Transporter (GLAST). Brain damage induced by hypoxia-ischemia was significantly reduced in GFAP-GRK2(+/-) mice, which have a 60% reduction in astrocyte GRK2 compared to GFAP-WT littermates. In addition, GRK2-deficient astrocytes have higher plasma-membrane levels of GLAST and an increased capacity to take up glutamate in vitro. In search for the mechanism by which GRK2 regulates GLAST expression, we observed increased GFAP levels in GRK2-deficient astrocytes. GFAP and the cytoskeletal protein ezrin are known regulators of GLAST localization. In line with this evidence, GRK2-deficiency reduced phosphorylation of the GRK2 substrate ezrin and enforced plasma-membrane GLAST association after stimulation with the group I mGluR-agonist DHPG. When ezrin was silenced, the enhanced plasma-membrane GLAST association in DHPG-exposed GRK2-deficient astrocytes was prevented. In conclusion, we identified a novel role of astrocyte GRK2 in regulating plasma-membrane GLAST localization via an ezrin-dependent route. We demonstrate that the 60% reduction in astrocyte GRK2 protein level that is observed in GFAP-GRK2(+/-) mice is sufficient to significantly reduce neonatal ischemic brain damage. These findings underline the critical role of GRK2 regulation in astrocytes for dampening the extent of brain damage after ischemia.</style></abstract><notes><style face="normal" font="default" size="100%">Nijboer, Cora H&#xD;Heijnen, Cobi J&#xD;Degos, Vincent&#xD;Willemen, Hanneke L D M&#xD;Gressens, Pierre&#xD;Kavelaars, Annemieke&#xD;R01 NS073939/NS/NINDS NIH HHS/United States&#xD;R01 NS074999/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Neurobiol Dis. 2013 Jun;54:206-15. doi: 10.1016/j.nbd.2012.12.013. Epub 2013 Jan 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0969996113000041/1-s2.0-S0969996113000041-main.pdf?_tid=a79d930c-d7d3-11e6-beb0-00000aacb360&amp;acdnat=1484121653_b105e0e9462274a457e4ae290bcb101d</style></url></related-urls><pdf-urls><url>internal-pdf://1932426745/Nijboer-2013-Astrocyte GRK2 as a.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3628971</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms434143</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.nbd.2012.12.013</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>185</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">185</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nishibe, M.</style></author><author><style face="normal" font="default" size="100%">Urban, E. T., 3rd</style></author><author><style face="normal" font="default" size="100%">Barbay, S.</style></author><author><style face="normal" font="default" size="100%">Nudo, R. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Osaka University, Osaka, Japan.&#xD;University of Kansas Medical Center, Kansas City, KS, USA.&#xD;University of Kansas Medical Center, Kansas City, KS, USA rnudo@kumc.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Rehabilitative training promotes rapid motor recovery but delayed motor map reorganization in a rat cortical ischemic infarct model</style></title><secondary-title><style face="normal" font="default" size="100%">Neurorehabil Neural Repair</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurorehabilitation and neural repair</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurorehabil Neural Repair</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurorehabilitation and neural repair</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurorehabil Neural Repair</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurorehabilitation and neural repair</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">472-82</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2014/07/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Biomechanical Phenomena</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/chemically induced/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Mapping</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/etiology/ rehabilitation</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Electric Stimulation</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelin-1/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Forelimb/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Motor Activity/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Physical Conditioning, Animal/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Psychomotor Performance/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Long-Evans</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery of Function/ physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1552-6844 (Electronic)&#xD;1545-9683 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25055836</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: In preclinical stroke models, improvement in motor performance is associated with reorganization of cortical motor maps. However, the temporal relationship between performance gains and map plasticity is not clear. OBJECTIVE: This study was designed to assess the effects of rehabilitative training on the temporal dynamics of behavioral and neurophysiological endpoints in a rat model of focal cortical infarct. METHODS: Eight days after an ischemic infarct in primary motor cortex, adult rats received either rehabilitative training or were allowed to recover spontaneously. Motor performance and movement quality of the paretic forelimb was assessed on a skilled reach task. Intracortical microstimulation mapping procedures were conducted to assess the topography of spared forelimb representations either at the end of training (post-lesion day 18) or at the end of a 3-week follow-up period (post-lesion day 38). RESULTS: Rats receiving rehabilitative training demonstrated more rapid improvement in motor performance and movement quality during the training period that persisted through the follow-up period. Motor maps in both groups were unusually small on post-lesion day 18. On post-lesion day 38, forelimb motor maps in the rehabilitative training group were significantly enlarged compared with the no-rehab group, and within the range of normal maps. CONCLUSIONS: Postinfarct rehabilitative training rapidly improves motor performance and movement quality after an ischemic infarct in motor cortex. However, training-induced motor improvements are not reflected in spared motor maps until substantially later, suggesting that early motor training after stroke can help shape the evolving poststroke neural network.</style></abstract><notes><style face="normal" font="default" size="100%">Nishibe, Mariko&#xD;Urban, Edward T R 3rd&#xD;Barbay, Scott&#xD;Nudo, Randolph J&#xD;R37 NS030853/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;United States&#xD;Neurorehabil Neural Repair. 2015 Jun;29(5):472-82. doi: 10.1177/1545968314543499. Epub 2014 Jul 22.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4303553</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms608798</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/1545968314543499</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>159</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">159</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Niu, G.</style></author><author><style face="normal" font="default" size="100%">Ye, T.</style></author><author><style face="normal" font="default" size="100%">Qin, L.</style></author><author><style face="normal" font="default" size="100%">Bourbon, P. M.</style></author><author><style face="normal" font="default" size="100%">Chang, C.</style></author><author><style face="normal" font="default" size="100%">Zhao, S.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Zhou, L.</style></author><author><style face="normal" font="default" size="100%">Cui, P.</style></author><author><style face="normal" font="default" size="100%">Rabinovitz, I.</style></author><author><style face="normal" font="default" size="100%">Mercurio, A. M.</style></author><author><style face="normal" font="default" size="100%">Zhao, D.</style></author><author><style face="normal" font="default" size="100%">Zeng, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Vascular Biology Research and Division of Molecular and Vascular Biology, Department of Medicine and Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, People&apos;s Republic of China;&#xD;Center for Vascular Biology Research and Division of Molecular and Vascular Biology, Department of Medicine and Department of Obstetrics &amp; Gynecology, Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, People&apos;s Republic of China;&#xD;Department of Pathology.&#xD;Department of Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts, USA;&#xD;Center for Vascular Biology Research and Division of Molecular and Vascular Biology, Department of Medicine and Department of Gastroenterology, Provincial Hospital Affiliated to Shandong University, Ji-nan, People&apos;s Republic of China;&#xD;Center for Vascular Biology Research and Division of Molecular and Vascular Biology, Department of Medicine and Departments of Hepatobiliary Surgery and General Surgery, the First Affiliated Hospital, School of Medicine, Xi&apos;an Jiaotong University, Xi&apos;an, People&apos;s Republic of China;&#xD;Center for Vascular Biology Research and Division of Molecular and Vascular Biology, Department of Medicine and Department of General Surgery, Pancreatic Disease Institute, Union Hospital, Huazhong University of Science &amp; Technology (HUST), Wuhan, People&apos;s Republic of China.&#xD;Center for Vascular Biology Research and Division of Molecular and Vascular Biology, Department of Medicine and Department of Pathology.&#xD;Center for Vascular Biology Research and Division of Molecular and Vascular Biology, Department of Medicine and Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA;&#xD;Center for Vascular Biology Research and Division of Molecular and Vascular Biology, Department of Medicine and hzeng@caregroup.harvard.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Orphan nuclear receptor TR3/Nur77 improves wound healing by upregulating the expression of integrin beta4</style></title><secondary-title><style face="normal" font="default" size="100%">FASEB J</style></secondary-title><alt-title><style face="normal" font="default" size="100%">FASEB journal : official publication of the Federation of American Societies for Experimental Biology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">FASEB J</style></full-title><abbr-1><style face="normal" font="default" size="100%">FASEB journal : official publication of the Federation of American Societies for Experimental Biology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">FASEB J</style></full-title><abbr-1><style face="normal" font="default" size="100%">FASEB journal : official publication of the Federation of American Societies for Experimental Biology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">131-40</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2014/10/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Movement</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Proliferation</style></keyword><keyword><style face="normal" font="default" size="100%">Human Umbilical Vein Endothelial Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Integrin beta4/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Neovascularization, Pathologic</style></keyword><keyword><style face="normal" font="default" size="100%">Neovascularization, Physiologic</style></keyword><keyword><style face="normal" font="default" size="100%">Nuclear Receptor Subfamily 4, Group A, Member 1/deficiency/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Promoter Regions, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/injuries/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">Wound Healing/genetics/ physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1530-6860 (Electronic)&#xD;0892-6638 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25326539</style></accession-num><abstract><style face="normal" font="default" size="100%">Tissue repair/wound healing, in which angiogenesis plays an important role, is a critical step in many diseases including chronic wound, myocardial infarction, stroke, cancer, and inflammation. Recently, we were the first to report that orphan nuclear receptor TR3/Nur77 is a critical mediator of angiogenesis and its associated microvessel permeability. Tumor growth and angiogenesis induced by VEGF-A, histamine, and serotonin are almost completely inhibited in Nur77 knockout mice. However, it is not known whether TR3/Nur77 plays any roles in wound healing. In these studies, skin wound-healing assay was performed in 3 types of genetically modified mice having various Nur77 activities. We found that ectopic induction of Nur77 in endothelial cells of mice is sufficient to improve skin wound healing. Although skin wound healing in Nur77 knockout mice is comparable to the wild-type control mice, the process is significantly delayed in the EC-Nur77-DN mice, in which a dominant negative Nur77 mutant is inducibly and specifically expressed in mouse endothelial cells. By a loss-of-function assay, we elucidate a novel feed-forward signaling pathway, integrin beta4 --&gt; PI3K --&gt; Akt --&gt; FAK, by which TR3 mediates HUVEC migration. Furthermore, TR3/Nur77 regulates the expression of integrin beta4 by targeting its promoter activity. In conclusion, expression of TR3/Nur77 improves wound healing by targeting integrin beta4. TR3/Nur77 is a potential candidate for proangiogenic therapy. The results further suggest that TR3/Nur77 is required for pathologic angiogenesis but not for developmental/physiologic angiogenesis and that Nur77 and its family members play a redundant role in normal skin wound healing.</style></abstract><notes><style face="normal" font="default" size="100%">Niu, Gengming&#xD;Ye, Taiyang&#xD;Qin, Liuliang&#xD;Bourbon, Pierre M&#xD;Chang, Cheng&#xD;Zhao, Shengqiang&#xD;Li, Yan&#xD;Zhou, Lei&#xD;Cui, Pengfei&#xD;Rabinovitz, Issac&#xD;Mercurio, Arthur M&#xD;Zhao, Dezheng&#xD;Zeng, Huiyan&#xD;R01 DK095873/DK/NIDDK NIH HHS/United States&#xD;R01DK095873/DK/NIDDK NIH HHS/United States&#xD;R21DK080970/DK/NIDDK NIH HHS/United States&#xD;R01 CA133235/CA/NCI NIH HHS/United States&#xD;R01CA133235/CA/NCI NIH HHS/United States&#xD;R21 DK080970/DK/NIDDK NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;FASEB J. 2015 Jan;29(1):131-40. doi: 10.1096/fj.14-257550. Epub 2014 Oct 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.fasebj.org/content/29/1/131.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2942349453/Niu-2015-Orphan nuclear recep.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4285545</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1096/fj.14-257550</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>179</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">179</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nozaki, H.</style></author><author><style face="normal" font="default" size="100%">Nishizawa, M.</style></author><author><style face="normal" font="default" size="100%">Onodera, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From the Department of Medical Technology, School of Health Sciences Faculty of Medicine (H.N.), Department of Neurology, Clinical Neuroscience Branch, Brain Research Institute (M.N.), and Department of Molecular Neuroscience, Resource Branch for Brain Disease, Brain Research Institute (O.O.), Niigata University, Niigata, Japan.&#xD;From the Department of Medical Technology, School of Health Sciences Faculty of Medicine (H.N.), Department of Neurology, Clinical Neuroscience Branch, Brain Research Institute (M.N.), and Department of Molecular Neuroscience, Resource Branch for Brain Disease, Brain Research Institute (O.O.), Niigata University, Niigata, Japan. onodera@bri.niigata-u.ac.jp.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Features of cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">3447-53</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2014/08/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Alopecia/ diagnosis/ genetics/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/ diagnosis/ genetics/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Leukoencephalopathies/ diagnosis/ genetics/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Serine Endopeptidases/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Spinal Diseases/ diagnosis/ genetics/therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25116877</style></accession-num><notes><style face="normal" font="default" size="100%">Nozaki, Hiroaki&#xD;Nishizawa, Masatoyo&#xD;Onodera, Osamu&#xD;Review&#xD;United States&#xD;Stroke. 2014 Nov;45(11):3447-53. doi: 10.1161/STROKEAHA.114.004236. Epub 2014 Aug 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/45/11/3447.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1006151124/Nozaki-2014-Features of cerebral.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.114.004236</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>2</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">2</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nunez, S.</style></author><author><style face="normal" font="default" size="100%">Doroudchi, M. M.</style></author><author><style face="normal" font="default" size="100%">Gleichman, A. J.</style></author><author><style face="normal" font="default" size="100%">Ng, K. L.</style></author><author><style face="normal" font="default" size="100%">Llorente, I. L.</style></author><author><style face="normal" font="default" size="100%">Sozmen, E. G.</style></author><author><style face="normal" font="default" size="100%">Carmichael, S. T.</style></author><author><style face="normal" font="default" size="100%">Hinman, J. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">JHinman@mednet.ucla.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A Versatile Murine Model of Subcortical White Matter Stroke for the Study of Axonal Degeneration and White Matter Neurobiology</style></title><secondary-title><style face="normal" font="default" size="100%">J Vis Exp</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of visualized experiments : JoVE</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Vis Exp</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of visualized experiments : JoVE</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Vis Exp</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of visualized experiments : JoVE</style></abbr-1></alt-periodical><number><style face="normal" font="default" size="100%">109</style></number><edition><style face="normal" font="default" size="100%">2016/03/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Axons/drug effects/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme Inhibitors/ toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Degeneration/chemically induced/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide Synthase Type III/antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Ornithine/ analogs &amp; derivatives/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/chemically induced/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">White Matter/ drug effects/pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 17</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1940-087X (Electronic)&#xD;1940-087X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">27023377</style></accession-num><abstract><style face="normal" font="default" size="100%">Stroke affecting white matter accounts for up to 25% of clinical stroke presentations, occurs silently at rates that may be 5-10 fold greater, and contributes significantly to the development of vascular dementia. Few models of focal white matter stroke exist and this lack of appropriate models has hampered understanding of the neurobiologic mechanisms involved in injury response and repair after this type of stroke. The main limitation of other subcortical stroke models is that they do not focally restrict the infarct to the white matter or have primarily been validated in non-murine species. This limits the ability to apply the wide variety of murine research tools to study the neurobiology of white matter stroke. Here we present a methodology for the reliable production of a focal stroke in murine white matter using a local injection of an irreversible eNOS inhibitor. We also present several variations on the general protocol including two unique stereotactic variations, retrograde neuronal tracing, as well as fresh tissue labeling and dissection that greatly expand the potential applications of this technique. These variations allow for multiple approaches to analyze the neurobiologic effects of this common and understudied form of stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Nunez, Stefanie&#xD;Doroudchi, M Mehdi&#xD;Gleichman, Amy J&#xD;Ng, Kwan L&#xD;Llorente, Irene L&#xD;Sozmen, Elif G&#xD;Carmichael, S Thomas&#xD;Hinman, Jason D&#xD;F32 NS087783/NS/NINDS NIH HHS/United States&#xD;K08 NS083740/NS/NINDS NIH HHS/United States&#xD;R01 NS071481/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Vis Exp. 2016 Mar 17;(109). doi: 10.3791/53404.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.jove.com/pdf/53404/jove-protocol-53404-a-versatile-murine-model-subcortical-white-matter-stroke-for-study</style></url></related-urls><pdf-urls><url>internal-pdf://2417153200/Nunez-2016-A Versatile Murine M.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4829029</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3791/53404</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>3</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">3</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nyberg, C.</style></author><author><style face="normal" font="default" size="100%">Karlsson, T.</style></author><author><style face="normal" font="default" size="100%">Hillered, L.</style></author><author><style face="normal" font="default" size="100%">Stridsberg, M.</style></author><author><style face="normal" font="default" size="100%">Ronne Engstrom, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neuroscience, Section of Neurosurgery, Uppsala University, Uppsala, Sweden.&#xD;Department of Surgical Sciences, Section of Anesthesiology and Intensive care, Uppsala University, Uppsala, Sweden.&#xD;Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Early Endocrine Stress Response in Experimental Subarachnoid Hemorrhage</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PloS one</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e0151457</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2016/03/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adrenocorticotropic Hormone/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Aldosterone/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Catecholamines/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrocortisone/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Hypothalamo-Hypophyseal System</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Pituitary-Adrenal System</style></keyword><keyword><style face="normal" font="default" size="100%">Stress, Physiological</style></keyword><keyword><style face="normal" font="default" size="100%">Subarachnoid Hemorrhage/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Swine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203 (Electronic)&#xD;1932-6203 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">27007694</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: In patients with severe illness, such as aneurysmal subarachnoid hemorrhage (SAH), a physiologic stress response is triggered. This includes activation of the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system. The aim of this study was to investigate the very early responses of these systems. METHODS: A porcine animal model of aneurysmal SAH was used. In this model, blood is injected slowly to the basal cisterns above the anterior skull base until the cerebral perfusion pressure is 0 mm Hg. Sampling was done from blood and urine at -10, +15, +75 and +135 minutes from time of induction of SAH. Analyses of adrenocorticotropic hormone (ACTH), cortisol, aldosterone, catecholamines and chromogranin-A were performed. RESULTS: Plasma ACTH, serum cortisol and plasma aldosterone increased in the samples following induction of SAH, and started to decline after 75 minutes. Urine cortisol also increased after SAH. Urine catecholamines and their metabolites were found to increase after SAH. Many samples were however below detection level, not allowing for statistical analysis. Plasma chromogranin-A peaked at 15 minutes after SAH, and thereafter decreased. CONCLUSIONS: The endocrine stress response after aneurysmal SAH was found to start within 15 minutes in the HPA axis with early peak values of ACTH, cortisol and aldosterone. The fact that the concentrations of the HPA axis hormones decreased 135 minutes after SAH may suggest that a similar pattern exists in SAH patients, thus making it difficult to catch these early peak values. There were also indications of early activation of the sympathetic nervous system, but the small number of valid samples made interpretation difficult.</style></abstract><notes><style face="normal" font="default" size="100%">Nyberg, Christoffer&#xD;Karlsson, Torbjorn&#xD;Hillered, Lars&#xD;Stridsberg, Mats&#xD;Ronne Engstrom, Elisabeth&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;PLoS One. 2016 Mar 23;11(3):e0151457. doi: 10.1371/journal.pone.0151457. eCollection 2016.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0151457&amp;type=printable</style></url></related-urls><pdf-urls><url>internal-pdf://1145817762/Nyberg-2016-The Early Endocrine.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4805209</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0151457</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>53</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">53</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ohkubo, K.</style></author><author><style face="normal" font="default" size="100%">Sakai, Y.</style></author><author><style face="normal" font="default" size="100%">Inoue, H.</style></author><author><style face="normal" font="default" size="100%">Akamine, S.</style></author><author><style face="normal" font="default" size="100%">Ishizaki, Y.</style></author><author><style face="normal" font="default" size="100%">Matsushita, Y.</style></author><author><style face="normal" font="default" size="100%">Sanefuji, M.</style></author><author><style face="normal" font="default" size="100%">Torisu, H.</style></author><author><style face="normal" font="default" size="100%">Ihara, K.</style></author><author><style face="normal" font="default" size="100%">Sardiello, M.</style></author><author><style face="normal" font="default" size="100%">Hara, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.&#xD;1] Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan [2] Section of Pediatrics, Department of Medicine, Fukuoka Dental College, Fukuoka 814-0193, Japan.&#xD;1] Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan [2] Department of Pediatrics, Faculty of Medicine, Oita University, Yufu 879-5593, Japan.&#xD;Department of Molecular and Human Genetics, Baylor College of Medicine, Jan and Dan Duncan Neurological Research Institute, Texas Children&apos;s Hospital, Houston 77030, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Moyamoya disease susceptibility gene RNF213 links inflammatory and angiogenic signals in endothelial cells</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Rep</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Scientific reports</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Sci Rep</style></full-title><abbr-1><style face="normal" font="default" size="100%">Scientific reports</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Sci Rep</style></full-title><abbr-1><style face="normal" font="default" size="100%">Scientific reports</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">13191</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><edition><style face="normal" font="default" size="100%">2015/08/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adenosine Triphosphatases</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Line</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Proliferation</style></keyword><keyword><style face="normal" font="default" size="100%">Chromones/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Down-Regulation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Human Umbilical Vein Endothelial Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interferon-gamma/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Matrix Metalloproteinase 1/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Morpholines/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Moyamoya Disease/ genetics/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Neovascularization, Physiologic</style></keyword><keyword><style face="normal" font="default" size="100%">Proto-Oncogene Proteins c-akt/antagonists &amp; inhibitors/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA Interference</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Transcription, Genetic/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Tumor Necrosis Factor-alpha/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Ubiquitin-Protein Ligases/antagonists &amp; inhibitors/ genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">eIF-2 Kinase/antagonists &amp; inhibitors/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 17</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2045-2322 (Electronic)&#xD;2045-2322 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26278786</style></accession-num><abstract><style face="normal" font="default" size="100%">Moyamoya disease (MMD) is a cerebrovascular disorder characterized by occlusive lesions of the circle of Willis. To date, both environmental and genetic factors have been implicated for pathogenesis of MMD. Allelic variations in RNF213 are known to confer the risk of MMD; however, functional roles of RNF213 remain to be largely elusive. We herein report that pro-inflammatory cytokines, IFNG and TNFA, synergistically activated transcription of RNF213 both in vitro and in vivo. Using various chemical inhibitors, we found that AKT and PKR pathways contributed to the transcriptional activation of RNF213. Transcriptome-wide analysis and subsequent validation with quantitative PCR supported that endogenous expression of cell cycle-promoting genes were significantly decreased with knockdown of RNF213 in cultured endothelial cells. Consistently, these cells showed less proliferative and less angiogenic profiles. Chemical inhibitors for AKT (LY294002) and PKR (C16) disrupted their angiogenic potentials, suggesting that RNF213 and its upstream pathways cooperatively organize the process of angiogenesis. Furthermore, RNF213 down-regulated expressions of matrix metalloproteases in endothelial cells, but not in fibroblasts or other cell types. Altogether, our data illustrate that RNF213 plays unique roles in endothelial cells for proper gene expressions in response to inflammatory signals from environments.</style></abstract><notes><style face="normal" font="default" size="100%">Ohkubo, Kazuhiro&#xD;Sakai, Yasunari&#xD;Inoue, Hirosuke&#xD;Akamine, Satoshi&#xD;Ishizaki, Yoshito&#xD;Matsushita, Yuki&#xD;Sanefuji, Masafumi&#xD;Torisu, Hiroyuki&#xD;Ihara, Kenji&#xD;Sardiello, Marco&#xD;Hara, Toshiro&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Sci Rep. 2015 Aug 17;5:13191. doi: 10.1038/srep13191.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4538604</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/srep13191</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>353</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">353</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ong, E.</style></author><author><style face="normal" font="default" size="100%">Mechtouff, L.</style></author><author><style face="normal" font="default" size="100%">Bernard, E.</style></author><author><style face="normal" font="default" size="100%">Cho, T. H.</style></author><author><style face="normal" font="default" size="100%">Diallo, L. L.</style></author><author><style face="normal" font="default" size="100%">Nighoghossian, N.</style></author><author><style face="normal" font="default" size="100%">Derex, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Stroke Unit, Neurology Department, Neurological Hospital, Lyon, 59, boulevard Pinel, 69677 Bron Cedex, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Thrombolysis for stroke caused by infective endocarditis: an illustrative case and review of the literature</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1339-42</style></pages><volume><style face="normal" font="default" size="100%">260</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2013/01/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Small Vessel Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Endocarditis, Bacterial/ complications</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/complications/ etiology/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombolytic Therapy/ adverse effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1432-1459 (Electronic)&#xD;0340-5354 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23292203</style></accession-num><abstract><style face="normal" font="default" size="100%">Infective endocarditis represents a classical contra-indication to thrombolysis for acute ischemic stroke due to a potential increased risk of intracranial hemorrhage. However, some case reports have suggested safety and potential efficacy of intravenous or intra-arterial thrombolysis in stroke related to infective endocarditis. We present a case of ischemic stroke related to infective endocarditis who was treated with intravenous tissue plasminogen activator within the first 3 h of symptoms onset and subsequently developed symptomatic multifocal intracerebral hemorrhages, and summarize currently available data on this issue.</style></abstract><notes><style face="normal" font="default" size="100%">Ong, Elodie&#xD;Mechtouff, Laura&#xD;Bernard, Emilien&#xD;Cho, Tae-Hee&#xD;Diallo, Lansana Laho&#xD;Nighoghossian, Norbert&#xD;Derex, Laurent&#xD;Case Reports&#xD;Review&#xD;Germany&#xD;J Neurol. 2013 May;260(5):1339-42. doi: 10.1007/s00415-012-6802-1. Epub 2013 Jan 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/915/art%253A10.1007%252Fs00415-012-6802-1.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00415-012-6802-1&amp;token2=exp=1484122690~acl=%2Fstatic%2Fpdf%2F915%2Fart%25253A10.1007%25252Fs00415-012-6802-1.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs00415-012-6802-1*~hmac=8d274574ed3a52f19b797f985da431d6539ef8433049b6dd23db7766292a823f</style></url></related-urls><pdf-urls><url>internal-pdf://0157794390/Ong-2013-Thrombolysis for str.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00415-012-6802-1</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>420</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">420</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Onodera, H.</style></author><author><style face="normal" font="default" size="100%">Oshio, K.</style></author><author><style face="normal" font="default" size="100%">Uchida, M.</style></author><author><style face="normal" font="default" size="100%">Tanaka, Y.</style></author><author><style face="normal" font="default" size="100%">Hashimoto, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, St. Marianna University School of Medicine, Kawasaki, Japan. dera@marianna-u.ac.jp</style></auth-address><titles><title><style face="normal" font="default" size="100%">Analysis of intracranial pressure pulse waveform and brain capillary morphology in type 2 diabetes mellitus rats</style></title><secondary-title><style face="normal" font="default" size="100%">Brain Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">73-7</style></pages><volume><style face="normal" font="default" size="100%">1460</style></volume><edition><style face="normal" font="default" size="100%">2012/05/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Capillaries/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Small Vessel Diseases/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetic Angiopathies/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Elasticity</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelial Cells/pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Pressure/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Mutant Strains</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-6240 (Electronic)&#xD;0006-8993 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22583857</style></accession-num><abstract><style face="normal" font="default" size="100%">Diabetes mellitus in neurosurgical patients is known to be a disease with high risks and severe outcomes. However, the mechanism by which diabetes mellitus induces dysfunction of brain tissue is not well known. The hypothesis of this study was that the damage to brain microvasculature in diabetes mellitus results in impaired compliance of the brain. Pathological changes associated with type II diabetes were investigated using a rat model. Pathophysiological changes in diabetic brain tissue were also investigated to confirm cerebral compliance by analyzing intracranial pressure waveforms. Pathologic findings revealed thickening of the basement membrane and fibrous collagen infiltration into the inner basement membrane of the brain microvasculature in diabetes mellitus. Analysis of intracranial pressure waveforms revealed that the P2 portion increased in diabetic rats compared to the control and was increased further with the increase in intracranial pressure. Analysis of the differential pressure curve, with respect to time, demonstrated that intracranial elasticity showed a concomitant increase. Pathologic findings and intracranial pressure waveforms were consistent with changes in brain microvasculature in diabetes mellitus. The increase of elasticity of brain tissue in diabetes mellitus may exacerbate the damage of intracranial disease.</style></abstract><notes><style face="normal" font="default" size="100%">Onodera, Hidetaka&#xD;Oshio, Kotaro&#xD;Uchida, Masashi&#xD;Tanaka, Yuichiro&#xD;Hashimoto, Takuo&#xD;Netherlands&#xD;Brain Res. 2012 Jun 15;1460:73-7. doi: 10.1016/j.brainres.2012.03.061. Epub 2012 Apr 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0006899312005951/1-s2.0-S0006899312005951-main.pdf?_tid=b6f7cf48-d7d3-11e6-b83e-00000aacb35f&amp;acdnat=1484121679_3ccacc6845c1ef20c2a2d6082c227a4d</style></url></related-urls><pdf-urls><url>internal-pdf://3297960020/Onodera-2012-Analysis of intracra.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.brainres.2012.03.061</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>442</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">442</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Onodera, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Molecular Neuroscience, Resource Branch for Brain Disease, Niigata University.</style></auth-address><titles><title><style face="normal" font="default" size="100%">[TGF-beta family signaling contributes to human cerebral small vessel disease]</style></title><secondary-title><style face="normal" font="default" size="100%">Rinsho Shinkeigaku</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Rinsho shinkeigaku = Clinical neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Rinsho Shinkeigaku</style></full-title><abbr-1><style face="normal" font="default" size="100%">Rinsho shinkeigaku = Clinical neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Rinsho Shinkeigaku</style></full-title><abbr-1><style face="normal" font="default" size="100%">Rinsho shinkeigaku = Clinical neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">943-4</style></pages><volume><style face="normal" font="default" size="100%">51</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2012/01/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Small Vessel Diseases/drug therapy/ genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Serine Endopeptidases/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">Transforming Growth Factor beta/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1882-0654 (Electronic)&#xD;0009-918X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22277429</style></accession-num><abstract><style face="normal" font="default" size="100%">The discovery of the causative gene for hereditary cerebral small vessel disease (CARASIL: Cerebral Autosomal Recessive Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) opens a new avenue for exploring the pathogenesis of cerebral small vessel disease. The causative gene for CARASIL is HTRA1 (high-temperature requirement A1). HTRA1 is a serine protease and inhibits TGF-beta signaling in their protease activity-dependent manner. The CARASIL-associated mutant HTRA1s lost their protease activity and increase the TGF-beta family signaling. However the precious molecular mechanism for inhibition of TGF-beta signaling by HTRA1 has not been elucidated. We have found that HTRA1 aberrantly cleaved pro-TGF-beta in an endoplasmic reticulum and the cleaved products were degraded by the endoplasmic reticulum-associated degradation pathway. The result reconfirms the importance of HTRA1 for TGF-beta signaling. The study for Marfan syndrome, which is caused by the increasing TGF-beta signaling in aortic artery, indicates that the angiotensin I receptor antagonist, a drug already in clinical use for hypertension, inhibits TGF-beta signaling and ameliorates the disease progression in model mouse as well as patients with Marfan syndrome. In human brain, angiotensin I receptor antagonist also inhibits TGF-beta signaling. Therefore angiotensin I receptor antagonist warrants investigation as a therapeutic strategy for patients with CARASIL.</style></abstract><notes><style face="normal" font="default" size="100%">Onodera, Osamu&#xD;English Abstract&#xD;Japan&#xD;Rinsho Shinkeigaku. 2011 Nov;51(11):943-4.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">jpn</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>186</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">186</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Orakcioglu, B.</style></author><author><style face="normal" font="default" size="100%">Kentar, M. M.</style></author><author><style face="normal" font="default" size="100%">Schiebel, P.</style></author><author><style face="normal" font="default" size="100%">Uozumi, Y.</style></author><author><style face="normal" font="default" size="100%">Unterberg, A.</style></author><author><style face="normal" font="default" size="100%">Sakowitz, O. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Ruprecht-Karls-University, Heidelberg, Germany, berk.orakcioglu@med.uni-heidelberg.de.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Perihemorrhagic ischemia occurs in a volume-dependent manner as assessed by multimodal cerebral monitoring in a porcine model of intracerebral hemorrhage</style></title><secondary-title><style face="normal" font="default" size="100%">Neurocrit Care</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurocritical care</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurocrit Care</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurocritical care</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurocrit Care</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurocritical care</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">133-9</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2014/07/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ metabolism/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/ metabolism/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Neurophysiological Monitoring/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Swine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1556-0961 (Electronic)&#xD;1541-6933 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25052158</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Changes in the perihemorrhagic zone (PHZ) of intracerebral hemorrhage (ICH) are variable. Different mechanisms contribute to secondary neuronal injury after ICH. This multimodal monitoring study investigated early changes in the PHZ of ICH. METHODS: Twenty-four swine were anesthetized, ventilated, and underwent monitoring of vital parameters. Next to an intracranial pressure-probe (ICP), microdialysis (MD), thermodiffusion cerebral blood flow (td-CBF), and oxygen probes (PbrO2) were placed into the gray white matter junction for 12 h of monitoring. ICH was induced using the autologous blood injection model. Pre-defined volumes were 0 ml (sham), 1.5 ml ipsilateral (1.5 ml), 3.0 ml ipsilateral (3.0 ml), and 3.0 ml contralateral (3.0 ml contra). RESULTS: ICP equally increased in all groups after ICH. In the 3.0 ml group tissue oxygenation decreased to ischemic values of 9 +/- 7 mmHg early after 6 h of monitoring. This decrease was associated with a significant perfusion reduction from 36 +/- 8 ml/100 g/min to 20 +/- 10 ml/100 g/min. MD correlated with a threefold lactate/pyruvate ratio increase. Measurements in all other groups were unchanged. CONCLUSION: Multimodal monitoring demonstrates volume-dependent changes of tissue oxygenation, blood flow, and ischemic MD markers in the PHZ independent of increased ICP suggesting early moderate ischemia. No evidence was found for the existence of a perihemorrhagic ischemia in the small hematoma groups.</style></abstract><notes><style face="normal" font="default" size="100%">Orakcioglu, Berk&#xD;Kentar, Modar M&#xD;Schiebel, Patrick&#xD;Uozumi, Yoichi&#xD;Unterberg, Andreas&#xD;Sakowitz, Oliver W&#xD;United States&#xD;Neurocrit Care. 2015 Feb;22(1):133-9. doi: 10.1007/s12028-014-0027-3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/99/art%253A10.1007%252Fs12028-014-0027-3.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12028-014-0027-3&amp;token2=exp=1484122699~acl=%2Fstatic%2Fpdf%2F99%2Fart%25253A10.1007%25252Fs12028-014-0027-3.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs12028-014-0027-3*~hmac=2b061effd58b5bd072ffd19552f31308c9d899f391a46f1b92c3c93fdaf494a1</style></url></related-urls><pdf-urls><url>internal-pdf://1687610660/Orakcioglu-2015-Perihemorrhagic isch.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12028-014-0027-3</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>73</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">73</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ortega, S. B.</style></author><author><style face="normal" font="default" size="100%">Noorbhai, I.</style></author><author><style face="normal" font="default" size="100%">Poinsatte, K.</style></author><author><style face="normal" font="default" size="100%">Kong, X.</style></author><author><style face="normal" font="default" size="100%">Anderson, A.</style></author><author><style face="normal" font="default" size="100%">Monson, N. L.</style></author><author><style face="normal" font="default" size="100%">Stowe, A. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology and Neurotherapeutics, UT Southwestern Medical Center, Dallas, TX 75390, USA.&#xD;Department of Neuroscience, UT Southwestern Medical Center, Dallas, TX 75390, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Stroke induces a rapid adaptive autoimmune response to novel neuronal antigens</style></title><secondary-title><style face="normal" font="default" size="100%">Discov Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Discovery medicine</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Discov Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Discovery medicine</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Discov Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Discovery medicine</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">381-92</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">106</style></number><edition><style face="normal" font="default" size="100%">2015/06/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adaptive Immunity/ immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Amino Acid Sequence</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens/ immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Autoimmunity/ immunology</style></keyword><keyword><style face="normal" font="default" size="100%">B-Lymphocytes/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">CD4-Positive T-Lymphocytes/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">CD8-Positive T-Lymphocytes/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lymph Nodes</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Sequence Data</style></keyword><keyword><style face="normal" font="default" size="100%">Myelin Sheath/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Peptides/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery of Function</style></keyword><keyword><style face="normal" font="default" size="100%">Spleen/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1944-7930 (Electronic)&#xD;1539-6509 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26105701</style></accession-num><abstract><style face="normal" font="default" size="100%">Stroke affects millions of people worldwide every year. Despite this prevalence, mechanisms of long-term injury and repair within the ischemic brain are still understudied. Sterile inflammation occurs in the injured brain after stroke, with damaged tissue exposing central nervous system (CNS)-derived antigen that could initiate potential autoimmune responses. We used a standard immunology-based recall response assay for murine immune cells, isolated from the cervical lymph nodes and spleen after transient stroke, to determine if stroke induces autoreactivity to CNS target antigens. Our assays included novel neuronal peptides, in addition to myelin-, nuclear-, glial-, and endothelial-derived peptides. Autoimmune responses to an antigen were considered positive based on proliferation and activation over non-stimulated conditions. Stroke induced a significant increase in autoreactive CD4+ and CD8+ T cells, as well as autoreactive CD19+ B cells, as early as 4 days after stroke onset. Mice with large infarct volumes exhibited early T and B cell autoreactivity to NR2A, an NMDA receptor subunit, in cells isolated from lymph nodes but not spleen. Mice with small infarct volumes exhibited high autoreactivity to MAP2, a dendritic cytoskeletal protein, as well as myelin-derived peptides. This autoimmunity was maintained through 10 days post-stroke in both lymph nodes and spleen for all lymphocyte subsets. Sham surgery also induced early autoreactive B cell responses to MAP2 and myelin. Based on these observations, we hypothesize that stroke induces a secondary, complex, and dynamic autoimmune response to neuronal antigens with the potential to potentiate, or perhaps even ameliorate, long-term neuroinflammation.</style></abstract><notes><style face="normal" font="default" size="100%">Ortega, Sterling B&#xD;Noorbhai, Ibrahim&#xD;Poinsatte, Katie&#xD;Kong, Xiangmei&#xD;Anderson, Ashley&#xD;Monson, Nancy L&#xD;Stowe, Ann M&#xD;R01 NS088555/NS/NINDS NIH HHS/United States&#xD;NS088555/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Discov Med. 2015 May;19(106):381-92.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4692161</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms744450</style></custom6><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>266</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">266</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Otani, N.</style></author><author><style face="normal" font="default" size="100%">Ishihara, M.</style></author><author><style face="normal" font="default" size="100%">Nakai, K.</style></author><author><style face="normal" font="default" size="100%">Fujita, M.</style></author><author><style face="normal" font="default" size="100%">Wada, K.</style></author><author><style face="normal" font="default" size="100%">Mori, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, National Defense Medical College.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Uncooled infrared camera for the noninvasive visualization of the vascular flow in an anastomotic vessel during neurological surgery: technical note</style></title><secondary-title><style face="normal" font="default" size="100%">Neurol Med Chir (Tokyo)</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurologia medico-chirurgica</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurol Med Chir (Tokyo)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurologia medico-chirurgica</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurol Med Chir (Tokyo)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurologia medico-chirurgica</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">502-6</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2013/11/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Angiography</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Revascularization/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Computer Systems</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment Design</style></keyword><keyword><style face="normal" font="default" size="100%">Feasibility Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Imaging, Three-Dimensional</style></keyword><keyword><style face="normal" font="default" size="100%">Infrared Rays</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Aneurysm/diagnostic imaging/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Arteriosclerosis/diagnostic imaging/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Monitoring, Intraoperative/ instrumentation/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Moyamoya Disease/diagnostic imaging/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Photography/ instrumentation/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Radiometry/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Temperature</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Patency</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 17</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1349-8029 (Electronic)&#xD;0470-8105 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24201104</style></accession-num><abstract><style face="normal" font="default" size="100%">We herein present our experience to assess intraoperative confirmation of vascular patency with an uncooled infrared camera in extracranial-intracranial (EC-IC) bypass surgery. This camera had distinguishing characteristics, including its small size, light weight, and adequate temperature resolution (&lt; 0.022 degrees). We used a simplified zoom germanium lens as a preliminary study to verify the potential of using this camera to assess the vascular flow of the end-to-side anastomosis model in rats. In addition, we evaluated the vascular flow in continuous clinical series using this infrared camera during EC-IC bypass in 14 patients (17 sides). This infrared camera offers real-time information on the vascular patency of end-to-side anastomosis vessels of all relevant diameters. The spatial resolution and image quality are satisfactory, and the procedure can be safely repeatable. We have shown that the infrared camera could be a new and feasible technology for intraoperative imaging of the vascular flow and is considered to be clinically useful during cerebrovascular surgery.</style></abstract><notes><style face="normal" font="default" size="100%">Otani, Naoki&#xD;Ishihara, Miya&#xD;Nakai, Kanji&#xD;Fujita, Masanori&#xD;Wada, Kojiro&#xD;Mori, Kentaro&#xD;Case Reports&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Japan&#xD;Neurol Med Chir (Tokyo). 2014 Jun 17;54(6):502-6. Epub 2013 Nov 8.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4533455</style></custom2><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>448</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">448</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Otero, L.</style></author><author><style face="normal" font="default" size="100%">Zurita, M.</style></author><author><style face="normal" font="default" size="100%">Bonilla, C.</style></author><author><style face="normal" font="default" size="100%">Rico, M. A.</style></author><author><style face="normal" font="default" size="100%">Aguayo, C.</style></author><author><style face="normal" font="default" size="100%">Rodriguez, A.</style></author><author><style face="normal" font="default" size="100%">Vaquero, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Neuroscience Research Unit, Puerta de Hierro-Majadahonda Hospital, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Endogenous neurogenesis after intracerebral hemorrhage</style></title><secondary-title><style face="normal" font="default" size="100%">Histol Histopathol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Histology and histopathology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Histol Histopathol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Histology and histopathology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Histol Histopathol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Histology and histopathology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">303-15</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2012/01/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Proliferation</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Survival</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/chemically induced/metabolism/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Collagenases</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Glial Fibrillary Acidic Protein/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Immunohistochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Intermediate Filament Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Ki-67 Antigen/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Microtubule-Associated Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Tissue Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nestin</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/metabolism/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuropeptides/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1699-5848 (Electronic)&#xD;0213-3911 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22237708</style></accession-num><abstract><style face="normal" font="default" size="100%">Currently, it is accepted that brain injury promotes endogenous neurogenesis in mammals, primarily in the subventricular zone (SVZ), and newborn cells can migrate to the injured area. We examined the pattern of endogenous neurogenesis in adult rats after intracerebral hemorrhage (ICH) that was caused by intrastrial administration of collagenase type IV. Our results showed that ICH induced strong endogenous neurogenesis between 72 hours and 7 days after injury, but that the majority of newborn cells did not survive longer than 3 weeks due to apoptosis-mediated cell death. Furthermore, endogenous neurogenesis remained into a small extent at least 1 year after ICH. Because of the growing interest in new strategies for brain regeneration, these data suggest endogenous neurogenesis and inhibiting apoptosis of newborn neuroblasts as potential strategies to improve the consequences of hemorrhagic stroke in humans.</style></abstract><notes><style face="normal" font="default" size="100%">Otero, L&#xD;Zurita, M&#xD;Bonilla, C&#xD;Rico, M A&#xD;Aguayo, C&#xD;Rodriguez, A&#xD;Vaquero, J&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Spain&#xD;Histol Histopathol. 2012 Mar;27(3):303-15.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>74</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">74</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Otero-Ortega, L.</style></author><author><style face="normal" font="default" size="100%">Gutierrez-Fernandez, M.</style></author><author><style face="normal" font="default" size="100%">Ramos-Cejudo, J.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Frutos, B.</style></author><author><style face="normal" font="default" size="100%">Fuentes, B.</style></author><author><style face="normal" font="default" size="100%">Sobrino, T.</style></author><author><style face="normal" font="default" size="100%">Hernanz, T. N.</style></author><author><style face="normal" font="default" size="100%">Campos, F.</style></author><author><style face="normal" font="default" size="100%">Lopez, J. A.</style></author><author><style face="normal" font="default" size="100%">Cerdan, S.</style></author><author><style face="normal" font="default" size="100%">Vazquez, J.</style></author><author><style face="normal" font="default" size="100%">Diez-Tejedor, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology and Stroke Center, Neuroscience and Cerebrovascular Research Laboratory, La Paz University Hospital, Neuroscience Area of IdiPAZ Health Research Institute, Autonoma University of Madrid, Paseo de la Castellana 261, 28046, Madrid, Spain. laura.otero@salud.madrid.org.&#xD;Department of Neurology and Stroke Center, Neuroscience and Cerebrovascular Research Laboratory, La Paz University Hospital, Neuroscience Area of IdiPAZ Health Research Institute, Autonoma University of Madrid, Paseo de la Castellana 261, 28046, Madrid, Spain. mgutierrezfernandez@salud.madrid.org.&#xD;Department of Neurology and Stroke Center, Neuroscience and Cerebrovascular Research Laboratory, La Paz University Hospital, Neuroscience Area of IdiPAZ Health Research Institute, Autonoma University of Madrid, Paseo de la Castellana 261, 28046, Madrid, Spain. Jaime.ramos@idipaz.es.&#xD;Department of Neurology and Stroke Center, Neuroscience and Cerebrovascular Research Laboratory, La Paz University Hospital, Neuroscience Area of IdiPAZ Health Research Institute, Autonoma University of Madrid, Paseo de la Castellana 261, 28046, Madrid, Spain. berta.rodriguez@salud.madrid.org.&#xD;Department of Neurology and Stroke Center, Neuroscience and Cerebrovascular Research Laboratory, La Paz University Hospital, Neuroscience Area of IdiPAZ Health Research Institute, Autonoma University of Madrid, Paseo de la Castellana 261, 28046, Madrid, Spain. blanca.fuentes@salud.madrid.org.&#xD;Department of Neurology, Clinical Neurosciences Research Laboratory, Hospital Clinico Universitario, Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela, Travesia de Choupana, s/n, 15706, Santiago de Compostela, Spain. tomas.sobrino.moreiras@sergas.es.&#xD;Laboratory for Imaging and Spectroscopy by Magnetic Resonance (LISMAR), Institute of Biomedical Research Alberto Sols, CSIC-UAM, Arturo Duperier, 4, 28029, Madrid, Spain. tnavarro@iib.uam.es.&#xD;Department of Neurology, Clinical Neurosciences Research Laboratory, Hospital Clinico Universitario, Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela, Travesia de Choupana, s/n, 15706, Santiago de Compostela, Spain. francisco.campos.perez@sergas.es.&#xD;Cardiovascular Proteomics Laboratory &amp; Proteomics Unit, Centro Nacional de Investigaciones Cardiovasculares, CNIC, Melchor Fernandez, Almagro, 3, 28029, Madrid, Spain. jalopez@cnic.es.&#xD;Laboratory for Imaging and Spectroscopy by Magnetic Resonance (LISMAR), Institute of Biomedical Research Alberto Sols, CSIC-UAM, Arturo Duperier, 4, 28029, Madrid, Spain. scerdan@iib.uam.es.&#xD;Cardiovascular Proteomics Laboratory &amp; Proteomics Unit, Centro Nacional de Investigaciones Cardiovasculares, CNIC, Melchor Fernandez, Almagro, 3, 28029, Madrid, Spain. jvazquez@cnic.es.&#xD;Department of Neurology and Stroke Center, Neuroscience and Cerebrovascular Research Laboratory, La Paz University Hospital, Neuroscience Area of IdiPAZ Health Research Institute, Autonoma University of Madrid, Paseo de la Castellana 261, 28046, Madrid, Spain. exuperio.diez@salud.madrid.org.</style></auth-address><titles><title><style face="normal" font="default" size="100%">White matter injury restoration after stem cell administration in subcortical ischemic stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Stem Cell Res Ther</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stem cell research &amp; therapy</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stem Cell Res Ther</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stem cell research &amp; therapy</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stem Cell Res Ther</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stem cell research &amp; therapy</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">121</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><edition><style face="normal" font="default" size="100%">2015/06/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis</style></keyword><keyword><style face="normal" font="default" size="100%">Basic Helix-Loop-Helix Transcription Factors/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Differentiation</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Movement</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Proliferation</style></keyword><keyword><style face="normal" font="default" size="100%">Diffusion Tensor Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelin-1/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mesenchymal Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Mesenchymal Stromal Cells/ cytology</style></keyword><keyword><style face="normal" font="default" size="100%">Myelin Basic Protein/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Myelin Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Tissue Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nogo Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Oligodendroglia/cytology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Proteome/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery of Function</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/etiology/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">White Matter/ physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 19</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1757-6512 (Electronic)&#xD;1757-6512 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26088123</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Despite its high incidence, nerve fiber (axon and myelin) damage after cerebral infarct has not yet been extensively investigated. The aim of this study was to investigate white matter repair after adipose-derived mesenchymal stem cell (ADMSC) administration in an experimental model of subcortical stroke. Furthermore, we aimed to analyze the ADMSC secretome and whether this could be implicated in this repair function. METHODS: An animal model of subcortical ischemic stroke with white matter affectation was induced in rats by injection of endothelin-1. At 24 hours, 2 x 10(6) ADMSC were administered intravenously to the treatment group. Functional evaluation, lesion size, fiber tract integrity, cell death, proliferation, white matter repair markers (Olig-2, NF, and MBP) and NogoA were all studied after sacrifice (7 days and 28 days). ADMSC migration and implantation in the brain as well as proteomics analysis and functions of the secretome were also analyzed. RESULTS: Neither ADMSC migration nor implantation to the brain was observed after ADMSC administration. In contrast, ADMSC implantation was detected in peripheral organs. The treatment group showed a smaller functional deficit, smaller lesion area, less cell death, more oligodendrocyte proliferation, more white matter connectivity and higher amounts of myelin formation. The treated animals also showed higher levels of white matter-associated markers in the injured area than the control group. Proteomics analysis of the ADMSC secretome identified 2,416 proteins, not all of them previously described to be involved in brain plasticity. CONCLUSIONS: White matter integrity in subcortical stroke is in part restored by ADMSC treatment; this is mediated by repair molecular factors implicated in axonal sprouting, remyelination and oligodendrogenesis. These findings are associated with improved functional recovery after stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Otero-Ortega, Laura&#xD;Gutierrez-Fernandez, Maria&#xD;Ramos-Cejudo, Jaime&#xD;Rodriguez-Frutos, Berta&#xD;Fuentes, Blanca&#xD;Sobrino, Tomas&#xD;Hernanz, Teresa Navarro&#xD;Campos, Francisco&#xD;Lopez, Juan Antonio&#xD;Cerdan, Sebastian&#xD;Vazquez, Jesus&#xD;Diez-Tejedor, Exuperio&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Stem Cell Res Ther. 2015 Jun 19;6:121. doi: 10.1186/s13287-015-0111-4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/502/art%253A10.1186%252Fs13287-015-0111-4.pdf?originUrl=http%3A%2F%2Fstemcellres.biomedcentral.com%2Farticle%2F10.1186%2Fs13287-015-0111-4&amp;token2=exp=1484121810~acl=%2Fstatic%2Fpdf%2F502%2Fart%25253A10.1186%25252Fs13287-015-0111-4.pdf*~hmac=fb3bbaf154a0a43af14d84dddf4d87081786bf0841ef6493952bce97f415c693</style></url></related-urls><pdf-urls><url>internal-pdf://3254720737/Otero-Ortega-2015-White matter injury.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4513704</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s13287-015-0111-4</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>446</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">446</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Palomo, V.</style></author><author><style face="normal" font="default" size="100%">Perez, D. I.</style></author><author><style face="normal" font="default" size="100%">Perez, C.</style></author><author><style face="normal" font="default" size="100%">Morales-Garcia, J. A.</style></author><author><style face="normal" font="default" size="100%">Soteras, I.</style></author><author><style face="normal" font="default" size="100%">Alonso-Gil, S.</style></author><author><style face="normal" font="default" size="100%">Encinas, A.</style></author><author><style face="normal" font="default" size="100%">Castro, A.</style></author><author><style face="normal" font="default" size="100%">Campillo, N. E.</style></author><author><style face="normal" font="default" size="100%">Perez-Castillo, A.</style></author><author><style face="normal" font="default" size="100%">Gil, C.</style></author><author><style face="normal" font="default" size="100%">Martinez, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Instituto de Quimica Medica-CSIC, Juan de la Cierva 3, 28006 Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3</style></title><secondary-title><style face="normal" font="default" size="100%">J Med Chem</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of medicinal chemistry</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Med Chem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of medicinal chemistry</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Med Chem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of medicinal chemistry</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1645-61</style></pages><volume><style face="normal" font="default" size="100%">55</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2012/01/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents, Non-Steroidal/ chemical</style></keyword><keyword><style face="normal" font="default" size="100%">synthesis/chemistry/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/cytology/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Death/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Differentiation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Membrane Permeability</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Glycogen Synthase Kinase 3/ antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Hippocampus/cytology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Imines/ chemical synthesis/chemistry/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">In Vitro Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Lipopolysaccharides/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Membranes, Artificial</style></keyword><keyword><style face="normal" font="default" size="100%">Microglia/cytology/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Molecular</style></keyword><keyword><style face="normal" font="default" size="100%">Neural Stem Cells/cytology/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenesis/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/cytology/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ chemical synthesis/chemistry/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Nitrites/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Binding</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Structure-Activity Relationship</style></keyword><keyword><style face="normal" font="default" size="100%">Substrate Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">Swine</style></keyword><keyword><style face="normal" font="default" size="100%">Thiadiazoles/ chemical synthesis/chemistry/pharmacology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 23</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1520-4804 (Electronic)&#xD;0022-2623 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22257026</style></accession-num><abstract><style face="normal" font="default" size="100%">Cumulative evidence strongly supports that glycogen synthase kinase-3 (GSK-3) is a pathogenic molecule when it is up-dysregulated, emerging as an important therapeutic target in severe unmet human diseases. GSK-3 specific inhibitors might be promising effective drugs for the treatment of devastating pathologies such as neurodegenerative diseases, stroke, and mood disorders. As GSK-3 has the ability to phosphorylate primed substrates, small molecules able to bind to this site should be perfect drug candidates, able to partially block the activity of the enzyme over some specific substrates. Here, we report substituted 5-imino-1,2,4-thiadiazoles as the first small molecules able to inhibit GSK-3 in a substrate competitive manner. These compounds are cell permeable, able to decrease inflammatory activation and to selectively differentiate neural stem cells. Overall, 5-imino-1,2,4-thiadiazoles are presented here as new molecules able to decrease neuronal cell death and to increase endogenous neurogenesis blocking the GSK-3 substrate site.</style></abstract><notes><style face="normal" font="default" size="100%">Palomo, Valle&#xD;Perez, Daniel I&#xD;Perez, Concepcion&#xD;Morales-Garcia, Jose A&#xD;Soteras, Ignacio&#xD;Alonso-Gil, Sandra&#xD;Encinas, Arantxa&#xD;Castro, Ana&#xD;Campillo, Nuria E&#xD;Perez-Castillo, Ana&#xD;Gil, Carmen&#xD;Martinez, Ana&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Med Chem. 2012 Feb 23;55(4):1645-61. doi: 10.1021/jm201463v. Epub 2012 Feb 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://pubs.acs.org/doi/pdfplus/10.1021/jm201463v</style></url></related-urls><pdf-urls><url>internal-pdf://3875024374/Palomo-2012-5-imino-1,2,4-thiadi.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/jm201463v</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>101</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">101</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pang, X. M.</style></author><author><style face="normal" font="default" size="100%">Liu, J. L.</style></author><author><style face="normal" font="default" size="100%">Li, J. P.</style></author><author><style face="normal" font="default" size="100%">Huang, L. G.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Xiang, H. Y.</style></author><author><style face="normal" font="default" size="100%">Feng, L. B.</style></author><author><style face="normal" font="default" size="100%">Chen, C. Y.</style></author><author><style face="normal" font="default" size="100%">Li, S. H.</style></author><author><style face="normal" font="default" size="100%">Su, S. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, The First Affiliated Hospital, Guangxi Medical University, Nanning, China.&#xD;Department of Neurology, Dongguan Kanghua Hospital, Dongguan, Guangdong, China.&#xD;Department of Neurology, The First People&apos;s Hospital of Yichang, Yichang, Hubei, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Fastigial nucleus stimulation regulates neuroprotection via induction of a novel microRNA, rno-miR-676-1, in middle cerebral artery occlusion rats</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurochem</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neurochemistry</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurochem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurochemistry</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurochem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurochemistry</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">926-34</style></pages><volume><style face="normal" font="default" size="100%">133</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2015/03/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebellar Nuclei/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Electric Stimulation Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">High-Throughput Nucleotide Sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">In Situ Nick-End Labeling</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">MicroRNAs/ biosynthesis</style></keyword><keyword><style face="normal" font="default" size="100%">Oligonucleotide Array Sequence Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reverse Transcriptase Polymerase Chain Reaction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1471-4159 (Electronic)&#xD;0022-3042 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25783478</style></accession-num><abstract><style face="normal" font="default" size="100%">Previous studies have shown that fastigial nucleus stimulation (FNS) reduces tissue damage resulting from focal cerebral ischemia. Although the mechanisms of neuroprotection induced by FNS are not entirely understood, important data have been presented in the past two decades. MicroRNAs (miRNAs) are a newly discovered group of non-coding small RNA molecules that negatively regulate target gene expression and are involved in the regulation of cell proliferation and cell apoptosis. To date, no studies have demonstrated whether miRNAs can serve as mediators of the brain&apos;s response to FNS, which leads to endogenous neuroprotection. Therefore, this study investigated the profiles of FNS-mediated miRNAs. Using a combination of deep sequencing and microarray with computational analysis, we identified a novel miRNA in the rat ischemic cortex after 1 h of FNS. This novel miRNA (PC-3p-3469_406), herein referred to as rno-miR-676-1, was upregulated in rats with cerebral ischemia after FNS. In vivo observations indicate that this novel miRNA may have antiapoptotic effects and contribute to neuroprotection induced by FNS. Our study provides a better understanding of neuroprotection induced by FNS. MicroRNA (miRNA) is defined as a small non-coding RNA that fulfills both the expression and biogenesis criteria. Here, we describe a novel miRNA in the rat ischemic cortex expressed after 1 h of fastigial nucleus stimulation (FNS). The miRNA was functionally characterized by secondary structure, quantitative expression, the conservation analysis, target gene analysis, and biological functions. We consider rno-miR-676-1 to be a true microRNA and present evidence for its neuroprotective effects exerted after induction by FNS.</style></abstract><notes><style face="normal" font="default" size="100%">Pang, Xiao-Min&#xD;Liu, Jing-Li&#xD;Li, Jin-Pin&#xD;Huang, Li-Gang&#xD;Zhang, Lei&#xD;Xiang, Hui-Yao&#xD;Feng, Ling-Bo&#xD;Chen, Chun-Yong&#xD;Li, Sheng-Hua&#xD;Su, Sheng-You&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Neurochem. 2015 Jun;133(6):926-34. doi: 10.1111/jnc.13094. Epub 2015 Apr 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/jnc.13094/asset/jnc13094.pdf?v=1&amp;t=ixsnmtc4&amp;s=60f55eb597f4f10328cfb854e6adf8846fdf34a6</style></url></related-urls><pdf-urls><url>internal-pdf://1200242048/Pang-2015-Fastigial nucleus st.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/jnc.13094</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>190</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">190</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Park, J. Y.</style></author><author><style face="normal" font="default" size="100%">Lee, S. K.</style></author><author><style face="normal" font="default" size="100%">Kim, J. Y.</style></author><author><style face="normal" font="default" size="100%">Je, K. H.</style></author><author><style face="normal" font="default" size="100%">Schellingerhout, D.</style></author><author><style face="normal" font="default" size="100%">Kim, D. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From the Molecular Imaging and Neurovascular Research (MINER) Laboratory, Department of Neurology, Dongguk University Ilsan Hospital, Goyang, Korea (J.-Y.P., S.-K.L., J.-Y.K., K.-H.J., D.-E.K.); and Departments of Radiology and Experimental Diagnostic Imaging, University of Texas MD Anderson Cancer Center, Houston (D.S.).&#xD;From the Molecular Imaging and Neurovascular Research (MINER) Laboratory, Department of Neurology, Dongguk University Ilsan Hospital, Goyang, Korea (J.-Y.P., S.-K.L., J.-Y.K., K.-H.J., D.-E.K.); and Departments of Radiology and Experimental Diagnostic Imaging, University of Texas MD Anderson Cancer Center, Houston (D.S.). kdongeog@duih.org.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A new micro-computed tomography-based high-resolution blood-brain barrier imaging technique to study ischemic stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">2480-4</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2014/07/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/ diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">X-Ray Microtomography/ methods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25013021</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: Micro-computed tomography (mCT) offers high-resolution images, but it suffers from low contrast sensitivity and poor soft tissue contrast. We introduce a new mCT imaging technique with improved sensitivity for the dynamic spatial and temporal characterization of poststroke blood-brain barrier (BBB) dysfunction in small animals in vivo. METHODS: Transient middle cerebral artery occlusion was induced for 1 hour in 10- to 12-week-old C57BL/6 mice (n=35). At 4, 24, and 48 hours after ischemic stroke, serial in vivo mCT imaging was performed 5 minutes after intravenous infusion (n=3) or intracarotid infusion of iopromide (240 muL) for 5 minutes (n=32). After intravenous injection of 2% Evans blue, we performed ex vivo near-infrared fluorescent imaging of parenchymal Evans blue leakage, visual assessment of poststroke parenchymal hematoma, triphenyltetrazolium chloride staining of the brain tissue, and quantitative mapping of stroke-related brain lesions. RESULTS: Infarct-related BBB dysfunction could be demonstrated with intra-arterial but not with intravenous infusion of iopromide. Iopromide leakage across the dysfunctional BBB showed a monophasic (not biphasic) course for 48 hours after ischemic insult in both the parenchymal hematoma (n=5) and the non-parenchymal hematoma (n=24) groups, with relatively severe leakiness and greater hemispheric midline shift in animals with hemorrhage. Parenchymal staining on in vivo mCT overlapped with ex vivo fluorescent staining because of Evans blue. Multivariable analyses showed that midline shift and the amount of iopromide leakage at each of the 3 time points predicted the final infarct size at 48 hours. CONCLUSIONS: The new mCT BBB imaging technique, based on the intra-arterial infusion of clinically available iopromide, allows serial quantitative visualization of poststroke BBB dysfunction in mice, with high resolution and in a sensitive manner.</style></abstract><notes><style face="normal" font="default" size="100%">Park, Jin-Yong&#xD;Lee, Su-Kyoung&#xD;Kim, Jeong-Yeon&#xD;Je, Kang-Hoon&#xD;Schellingerhout, Dawid&#xD;Kim, Dong-Eog&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Stroke. 2014 Aug;45(8):2480-4. doi: 10.1161/STROKEAHA.114.006297. Epub 2014 Jul 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/45/8/2480.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1883269145/Park-2014-A new micro-computed.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.114.006297</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>254</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">254</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Park, S.</style></author><author><style face="normal" font="default" size="100%">Hwang, S. M.</style></author><author><style face="normal" font="default" size="100%">Song, J. S.</style></author><author><style face="normal" font="default" size="100%">Suh, D. C.</style></author><author><style face="normal" font="default" size="100%">Lee, D. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Radiology and Research Institute of Radiology; University of Ulsan College of Medicine, Asan Medical Center; Songpa-gu, Seoul, Korea - dhlee2000@gmail.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evaluation of the Solitaire system in a canine arterial thromboembolic occlusion model: is it safe for the endothelium?</style></title><secondary-title><style face="normal" font="default" size="100%">Interv Neuroradiol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Interv Neuroradiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Interv Neuroradiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">417-24</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2013/12/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Artery Thrombosis/complications/diagnosis/ surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Stenosis/complications/diagnosis/ surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Dogs</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelium, Vascular/diagnostic imaging/ injuries/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment Design</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment Failure Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment Safety</style></keyword><keyword><style face="normal" font="default" size="100%">Radiography</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombectomy/ adverse effects/ instrumentation</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1591-0199 (Print)&#xD;1591-0199 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24355144</style></accession-num><abstract><style face="normal" font="default" size="100%">The Solitaire system has recently been increasingly used for acute stroke treatment in which the endothelial safety immediately after its use has not been evaluated. This study was performed to evaluate the endothelial status when using a Solitaire system in a canine arterial occlusion model. Thromboembolic occlusion of both internal maxillary arteries was achieved in five mongrel dogs. In each animal, the Solitaire system (ev3, Irvine, CA, USA) was used for primary thrombectomy on the right side and for temporary stenting on the left side. Efficacy was assessed by comparing the recanalization rates, and safety was assessed using angiographic and microscopic assessments. Endothelial injuries were evaluated with light microscopy (LM) and scanning electron microscopy (SEM). Successful revascularizations were observed following primary thrombectomy in all five animals (100%) and after temporary stenting in two (40%). There was no incidence of vasospasm or vessel perforation in either group. Distal migration of the clot occurred in two animals that underwent primary thrombectomy. Endothelial injury was seen after primary thrombectomy in two animals (40%) and after temporary stenting in one (20%). The lesions presented as defects of the internal elastic lamina on LM and denudation of the wavy endothelial surface on SEM. During mechanical thrombectomy, the Solitaire system can cause endothelial injury both in primary thrombectomy and temporary stenting. Primary thrombectomy is likely to have a higher recanalization rate with increased endothelial injury.</style></abstract><notes><style face="normal" font="default" size="100%">Park, Soonchan&#xD;Hwang, Seon Moon&#xD;Song, Joon Seon&#xD;Suh, Dae Chul&#xD;Lee, Deok Hee&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Interv Neuroradiol. 2013 Dec;19(4):417-24. Epub 2013 Dec 18.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3902739</style></custom2><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>251</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">251</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pedder, H.</style></author><author><style face="normal" font="default" size="100%">Vesterinen, H. M.</style></author><author><style face="normal" font="default" size="100%">Macleod, M. R.</style></author><author><style face="normal" font="default" size="100%">Wardlaw, J. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From the Department of Clinical Neurosciences, Western General Hospital, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, Scotland, United Kingdom.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Systematic review and meta-analysis of interventions tested in animal models of lacunar stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">563-70</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2014/01/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Behavior, Animal/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Data Interpretation, Statistical</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Thrombosis/physiopathology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Microspheres</style></keyword><keyword><style face="normal" font="default" size="100%">Publication Bias</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Research Design</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke, Lacunar/ therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24385271</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: A total of 25% of strokes are lacunar, and these are pathophysiologically different from large artery strokes. Despite emerging evidence of a substantial impact on physical disability and dementia, little attention has been paid to the development of specific treatments. The optimal use of the animal models of lacunar stroke used to test candidate interventions is not known. METHODS: We conducted a systematic review and meta-analysis of studies testing candidate interventions in animal models of lacunar stroke. We used random-effects meta-analysis to assess the impact of study characteristics and trim and fill to seek evidence of publication bias. RESULTS: The efficacy of 43 distinct interventions was described in 57 publications. The median number of quality checklist items scored was 3 of 8 (interquartile range, 2-4). Many models reflected mechanisms of limited relevance to lacunar stroke. Meta-analysis of results from 27 studies showed that on average, infarct size and neurobehavioral outcome were improved by 34.2% (24.1-44.2) and 0.82 standardized mean difference (0.51-1.14), respectively. Four interventions improved both infarct size and neurobehavioral outcome but there were insufficient data for this finding to be considered robust. For infarct size, efficacy was lower in studies reporting blinding and higher in studies reporting randomization. For neurobehavior, efficacy was lower in randomized studies. For infarct size there was evidence of publication bias. CONCLUSIONS: No intervention has yet been tested in sufficient range and depth to support translation to clinical trial. There is limited reporting of measures to reduce the risk of bias and evidence for a substantial publications bias.</style></abstract><notes><style face="normal" font="default" size="100%">Pedder, Hugo&#xD;Vesterinen, Hanna M&#xD;Macleod, Malcolm R&#xD;Wardlaw, Joanna M&#xD;MR/K026992/1/Medical Research Council/United Kingdom&#xD;NC/L000970/1/National Centre for the Replacement, Refinement and Reduction of Animals in Research/United Kingdom&#xD;Medical Research Council/United Kingdom&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;United States&#xD;Stroke. 2014 Feb;45(2):563-70. doi: 10.1161/STROKEAHA.113.003128. Epub 2014 Jan 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/45/2/563.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2438437455/Pedder-2014-Systematic review an.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.113.003128</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>15</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">15</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Peres, R.</style></author><author><style face="normal" font="default" size="100%">De Guio, F.</style></author><author><style face="normal" font="default" size="100%">Chabriat, H.</style></author><author><style face="normal" font="default" size="100%">Jouvent, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Univ Paris Diderot, Sorbonne Paris Cite, UMR-S 1161 INSERM, Paris, France DHU NeuroVasc Sorbonne Paris Cite, Paris, France.&#xD;Univ Paris Diderot, Sorbonne Paris Cite, UMR-S 1161 INSERM, Paris, France DHU NeuroVasc Sorbonne Paris Cite, Paris, France Department of Neurology, AP-HP, Lariboisiere Hosp, F-75475 Paris, France.&#xD;Univ Paris Diderot, Sorbonne Paris Cite, UMR-S 1161 INSERM, Paris, France DHU NeuroVasc Sorbonne Paris Cite, Paris, France Department of Neurology, AP-HP, Lariboisiere Hosp, F-75475 Paris, France eric.jouvent@aphp.fr.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Alterations of the cerebral cortex in sporadic small vessel disease: A systematic review of in vivo MRI data</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">681-95</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2016/01/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Small Vessel Diseases/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Image Processing, Computer-Assisted</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging/ methods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26787108</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebral small vessel diseases of the brain are a major determinant of cognitive impairment in the elderly. In small vessel diseases, the most easily identifiable lesions, both at post-mortem evaluation and magnetic resonance imaging, lie in subcortical areas. However, recent results obtained post-mortem, particularly in severe cases, have highlighted the burden of cortex lesions such as microinfarcts and diffuse neuronal loss. The recent development of image post-processing methods allows now assessing in vivo multiple aspects of the cerebral cortex. This systematic review aimed to analyze in vivo magnetic resonance imaging studies evaluating cortex alterations at different stages of small vessel diseases. Studies assessing the relationships between small vessel disease magnetic resonance imaging markers obtained at the subcortical level and cortex estimates were reviewed both in community-dwelling elderly and in patients with symptomatic small vessel diseases. Thereafter, studies analyzing cortex estimates in small vessel disease patients compared with healthy subjects were evaluated. The results support that important cortex alterations develop along the course of small vessel diseases independently of concomitant neurodegenerative processes. Easy detection and quantification of cortex changes in small vessel diseases as well as understanding their underlying mechanisms are challenging tasks for better understanding cognitive decline in small vessel diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Peres, Roxane&#xD;De Guio, Francois&#xD;Chabriat, Hugues&#xD;Jouvent, Eric&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;United States&#xD;J Cereb Blood Flow Metab. 2016 Apr;36(4):681-95. doi: 10.1177/0271678X15625352. Epub 2016 Jan 19.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4821027</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/0271678x15625352</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>332</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">332</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Perez-de-Puig, I.</style></author><author><style face="normal" font="default" size="100%">Martin, A.</style></author><author><style face="normal" font="default" size="100%">Gorina, R.</style></author><author><style face="normal" font="default" size="100%">de la Rosa, X.</style></author><author><style face="normal" font="default" size="100%">Martinez, E.</style></author><author><style face="normal" font="default" size="100%">Planas, A. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Brain Ischemia and Neurodegeneration, Institut d&apos;Investigacions Biomediques de Barcelona (IIBB)-Consejo Superior de Investigaciones Cientificas (CSIC), Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Induction of hemeoxygenase-1 expression after inhibition of hemeoxygenase activity promotes inflammation and worsens ischemic brain damage in mice</style></title><secondary-title><style face="normal" font="default" size="100%">Neuroscience</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">22-32</style></pages><volume><style face="normal" font="default" size="100%">243</style></volume><edition><style face="normal" font="default" size="100%">2013/04/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Basic-Leucine Zipper Transcription Factors/ biosynthesis</style></keyword><keyword><style face="normal" font="default" size="100%">Blotting, Western</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ enzymology/genetics/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme Inhibitors/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorescent Antibody Technique</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Heme Oxygenase-1/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/enzymology/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Membrane Proteins/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Protoporphyrins/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Real-Time Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default" size="100%">Reverse Transcriptase Polymerase Chain Reaction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 23</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1873-7544 (Electronic)&#xD;0306-4522 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23562577</style></accession-num><abstract><style face="normal" font="default" size="100%">Hemeoxygenase (HO) is an enzymatic system that degrades heme. HO-1 is an inducible isoform whereas HO-2 is constitutive. Stroke strongly induces HO-1 expression but the underlying mechanisms are not fully elucidated. Cytokines that are up-regulated after ischemia, like interleukin (IL)-10, can induce HO-1 gene expression, which is positively regulated by the transcriptional activator nuclear factor erythroid 2-related factor 2 (Nrf2) and negatively regulated by the transcriptional repressor breast cancer type 1 susceptibility protein (BRCA1) associated C-terminal helicase 1 (Bach-1). While Nrf2 is activated after ischemia and drugs promoting Nrf2 activation increase HO-1 and are beneficial, the involvement of Bach-1 is unknown. Here we investigated mechanisms involved in HO-1 induction and evaluated the effects of HO activity inhibition in mouse permanent middle cerebral artery occlusion (pMCAO). HO-1 was induced after ischemia in IL-10-deficient mice suggesting that post-ischemic HO-1 induction was IL-10-independent. Attenuation of Bach-1 gene repression after ischemia was associated to enhanced HO-1 induction. Administration of the HO activity inhibitor zinc proto-porphyrin IX (ZnPP) i.p. 24h before pMCAO exacerbated ischemia-induced tumor necrosis factor-alpha (TNF-alpha) and IL-1beta, nitro-oxidative stress, and the presence of neutrophils at 8h, and increased infarct volume at day 4. However, ZnPP did not worsen ischemic damage when given 30min before pMCAO. ZnPP induced HO-1 expression in the cerebral vasculature at 24h, when it was still detected by high-performance liquid chromatography (HPLC) in plasma. While ZnPP was not found in brain tissue extracts of controls, it could be detected after ischemia, supporting that a small fraction of the injected drug can reach the tissue following blood-brain barrier breakdown. The deleterious effect of inhibiting HO activity in ischemia became apparent in the presence of ZnPP-induced HO-1, which is known to exert effects independent of its enzymatic activity. In conclusion, HO-1 induction after ischemia was associated to down-regulation of transcriptional repressor Bach-1, and induction of HO-1 when HO enzymatic activity was inhibited was related to worst outcome after brain ischemia.</style></abstract><notes><style face="normal" font="default" size="100%">Perez-de-Puig, I&#xD;Martin, A&#xD;Gorina, R&#xD;de la Rosa, X&#xD;Martinez, E&#xD;Planas, A M&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Neuroscience. 2013 Jul 23;243:22-32. doi: 10.1016/j.neuroscience.2013.03.046. Epub 2013 Apr 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0306452213003011/1-s2.0-S0306452213003011-main.pdf?_tid=cbf0b63a-d7d3-11e6-b5ab-00000aab0f27&amp;acdnat=1484121714_6b93123b516930719039b17e2207cfe5</style></url></related-urls><pdf-urls><url>internal-pdf://0714174750/Perez-de-Puig-2013-Induction of hemeoxy.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuroscience.2013.03.046</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>468</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">468</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pezzini, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dipartimento di Scienze Mediche e Chirurgiche, Clinica Neurologica, Universita degli Studi di Brescia, Brescia, Italia. ale_pezzini@hotmail.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">Genetic determinants of juvenile stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Thromb Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Thrombosis research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Thromb Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Thrombosis research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Thromb Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Thrombosis research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">330-5</style></pages><volume><style face="normal" font="default" size="100%">129</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2011/11/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Age of Onset</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">DNA, Mitochondrial/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Association Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Variation</style></keyword><keyword><style face="normal" font="default" size="100%">Genome-Wide Association Study</style></keyword><keyword><style face="normal" font="default" size="100%">Heredity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation</style></keyword><keyword><style face="normal" font="default" size="100%">Pedigree</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/epidemiology/ genetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1879-2472 (Electronic)&#xD;0049-3848 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22113147</style></accession-num><abstract><style face="normal" font="default" size="100%">Stroke is a heterogeneous multifactorial disorder. Although epidemiological data from twin and family studies provide substantial evidence for a genetic basis for stroke, the contribution of genetic factors identified so far is small. Large progress has been made in single-gene disorders associated with ischemic stroke, particularly at young age. The identification of NOTCH3 mutations in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) and of TREX1 mutations in retinal vasculopathy with cerebral leukodystrophy (RVCL) have led to new insights on lacunar stroke and small-vessel disease. Studies of sickle-cell disease have drawn attention to the importance of modifier genes and of gene-gene interactions in determining stroke risk, while there is now evidence that Fabry disease is an underdiagnosed cause of stroke. Furthermore, stroke is a well-known complication of several heritable connective tissue disorders, including Marfan&apos;s syndrome (FBN1 mutations) and Ehlers-Danlos syndrome type IV (COL3A1 mutations), which predispose to cervical artery dissection, the most frequent cause of cerebral ischemia at young age. By contrast, little is known about the genes associated with multifactorial stroke. The reported genome-wide association studies of ischemic stroke have shown that no single common genetic variant imparts major risk. Pharmacogenomic studies have uncovered genetic determinants of response to warfarin, statins and clopidogrel. Larger studies with samples numbering in the thousands are ongoing to identify common variants with smaller effects on risk. This approach will contribute to the identification of additional genes, novel pathways, and eventually novel therapeutic approaches to cerebrovascular disorders.</style></abstract><notes><style face="normal" font="default" size="100%">Pezzini, Alessandro&#xD;Review&#xD;United States&#xD;Thromb Res. 2012 Mar;129(3):330-5. doi: 10.1016/j.thromres.2011.10.035. Epub 2011 Nov 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0049384811005755/1-s2.0-S0049384811005755-main.pdf?_tid=d0348e6a-d7d3-11e6-8c8e-00000aacb361&amp;acdnat=1484121721_e2f8551dfab25e5f9c99675590ba220b</style></url></related-urls><pdf-urls><url>internal-pdf://3293742331/Pezzini-2012-Genetic determinants.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.thromres.2011.10.035</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>414</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">414</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pinto, D. J.</style></author><author><style face="normal" font="default" size="100%">Qiao, J. X.</style></author><author><style face="normal" font="default" size="100%">Knabb, R. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Bristol-Myers Squibb Co., Research and Development, 311 Pennington-Rocky Hill Road, Pennington, NJ 08534 , USA. donald.pinto@bms.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review</style></title><secondary-title><style face="normal" font="default" size="100%">Expert Opin Ther Pat</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Expert opinion on therapeutic patents</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Expert Opin Ther Pat</style></full-title><abbr-1><style face="normal" font="default" size="100%">Expert opinion on therapeutic patents</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Expert Opin Ther Pat</style></full-title><abbr-1><style face="normal" font="default" size="100%">Expert opinion on therapeutic patents</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">645-61</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2012/06/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Anticoagulants/adverse effects/chemistry/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Binding Sites</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Coagulation/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases/blood/ drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Design</style></keyword><keyword><style face="normal" font="default" size="100%">Factor Xa/chemistry/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Factor Xa Inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Structure</style></keyword><keyword><style face="normal" font="default" size="100%">Patents as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Structure-Activity Relationship</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1744-7674 (Electronic)&#xD;1354-3776 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22655676</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Factor Xa (FXa) is a critical enzyme in the coagulation cascade responsible for thrombin generation, the final enzyme that leads to fibrin clot formation. Significant success has recently been reported with compounds such as rivaroxaban, apixaban and edoxaban in the treatment and prevention of venous thromboembolism (VTE) and more recently in the prevention of stroke in atrial fibrillation (AF). The success these agents have demonstrated is now being reflected by a narrowing of new FXa patents over the past few years. The new patents appear to be structural modifications of previously published, small molecule inhibitors and bind in a similar manner to the FXa enzyme. AREAS COVERED: SciFinder(R), PubMed and Google websites were used as the main source of literature retrieval. Patent searches were conducted in the patent databases: HCAPlus, WPIX and the full text databases (USPAT2, USPATFULL, EPFULL, PCTFULL) using the following keywords: ((FXa) OR (F OR factor) (W) (Xa)) (S) (inhibit? or block? or modulat? or antagonist? or regulat?). The search was restricted to patent documents with the entry date on or after 1 January 2009. Literature and information related to clinical development was retrieved from Thomson Reuter&apos;s Pharma. EXPERT OPINION: A large body of Phase II and Phase III data is now available for FXa inhibitors such as rivaroxaban, apixaban, edoxaban and betrixaban. The clinical data demonstrate favorable benefit-risk profiles compared with the standards of care for short- and long-term anticoagulation (i.e., low molecular weight heparins (LMWHs) and wafarin). The potential exists that these agents will eventually be the agents of choice for the treatment of a host of cardiovascular disease states, offering improved efficacy, safety, and ease of use compared with existing anticoagulants.</style></abstract><notes><style face="normal" font="default" size="100%">Pinto, Donald J P&#xD;Qiao, Jennifer X&#xD;Knabb, Robert M&#xD;Review&#xD;England&#xD;Expert Opin Ther Pat. 2012 Jun;22(6):645-61. doi: 10.1517/13543776.2012.680438. Epub 2012 Jun 3.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1517/13543776.2012.680438</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>471</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">471</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pleines, I.</style></author><author><style face="normal" font="default" size="100%">Hagedorn, I.</style></author><author><style face="normal" font="default" size="100%">Gupta, S.</style></author><author><style face="normal" font="default" size="100%">May, F.</style></author><author><style face="normal" font="default" size="100%">Chakarova, L.</style></author><author><style face="normal" font="default" size="100%">van Hengel, J.</style></author><author><style face="normal" font="default" size="100%">Offermanns, S.</style></author><author><style face="normal" font="default" size="100%">Krohne, G.</style></author><author><style face="normal" font="default" size="100%">Kleinschnitz, C.</style></author><author><style face="normal" font="default" size="100%">Brakebusch, C.</style></author><author><style face="normal" font="default" size="100%">Nieswandt, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Chair of Vascular Medicine, University Hospital Wurzburg and Rudolf Virchow Center, DFG-Research Center for Experimental Biomedicine, Josef-Schneider-Strasse 2,Wurzburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Megakaryocyte-specific RhoA deficiency causes macrothrombocytopenia and defective platelet activation in hemostasis and thrombosis</style></title><secondary-title><style face="normal" font="default" size="100%">Blood</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Blood</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Blood</style></full-title><abbr-1><style face="normal" font="default" size="100%">Blood</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Blood</style></full-title><abbr-1><style face="normal" font="default" size="100%">Blood</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1054-63</style></pages><volume><style face="normal" font="default" size="100%">119</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2011/11/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Bleeding Time</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Platelets/drug effects/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Infarction/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Signaling</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Shape</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Size</style></keyword><keyword><style face="normal" font="default" size="100%">Clot Retraction</style></keyword><keyword><style face="normal" font="default" size="100%">GTP-Binding Protein alpha Subunits, G12-G13/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">GTP-Binding Protein alpha Subunits, Gq-G11/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Hemostasis/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Kinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Megakaryocytes/drug effects/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Platelet Activation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Platelet Count</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombocytopenia/blood/metabolism/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombosis/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">rho GTP-Binding Proteins/genetics/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 26</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1528-0020 (Electronic)&#xD;0006-4971 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22045984</style></accession-num><abstract><style face="normal" font="default" size="100%">Vascular injury initiates rapid platelet activation that is critical for hemostasis, but it also may cause thrombotic diseases, such as myocardial infarction or ischemic stroke. Reorganizations of the platelet cytoskeleton are crucial for platelet shape change and secretion and are thought to involve activation of the small GTPase RhoA. In this study, we analyzed the in vitro and in vivo consequences of megakaryocyte- and platelet-specific RhoA gene deletion in mice. We found a pronounced macrothrombocytopenia in RhoA-deficient mice, with platelet counts of approximately half that of wild-type controls. The mutant cells displayed an altered shape but only a moderately reduced life span. Shape change of RhoA-deficient platelets in response to G(13)-coupled agonists was abolished, and it was impaired in response to G(q) stimulation. Similarly, RhoA was required for efficient secretion of alpha and dense granules downstream of G(13) and G(q). Furthermore, RhoA was essential for integrin-mediated clot retraction but not for actomyosin rearrangements and spreading of activated platelets on fibrinogen. In vivo, RhoA deficiency resulted in markedly prolonged tail bleeding times but also significant protection in different models of arterial thrombosis and in a model of ischemic stroke. Together, these results establish RhoA as an important regulator of platelet function in thrombosis and hemostasis.</style></abstract><notes><style face="normal" font="default" size="100%">Pleines, Irina&#xD;Hagedorn, Ina&#xD;Gupta, Shuchi&#xD;May, Frauke&#xD;Chakarova, Lidija&#xD;van Hengel, Jolanda&#xD;Offermanns, Stefan&#xD;Krohne, Georg&#xD;Kleinschnitz, Christoph&#xD;Brakebusch, Cord&#xD;Nieswandt, Bernhard&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Blood. 2012 Jan 26;119(4):1054-63. doi: 10.1182/blood-2011-08-372193. Epub 2011 Nov 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.bloodjournal.org/content/bloodjournal/119/4/1054.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3267416047/Pleines-2012-Megakaryocyte-specif.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1182/blood-2011-08-372193</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>151</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">151</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Prabhakar, P.</style></author><author><style face="normal" font="default" size="100%">Zhang, H.</style></author><author><style face="normal" font="default" size="100%">Chen, D.</style></author><author><style face="normal" font="default" size="100%">Faber, J. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Cell Biology and Physiology, McAllister Heart Institute, 6309 MBRB, University of North Carolina, Chapel Hill, NC, 27599-7545, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Genetic variation in retinal vascular patterning predicts variation in pial collateral extent and stroke severity</style></title><secondary-title><style face="normal" font="default" size="100%">Angiogenesis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Angiogenesis</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Angiogenesis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Angiogenesis</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Angiogenesis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Angiogenesis</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">97-114</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2014/11/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Arteries/anatomy &amp; histology</style></keyword><keyword><style face="normal" font="default" size="100%">Collateral Circulation/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Variation</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Multivariate Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Regression Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Retinal Vessels/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Species Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/genetics/ physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1573-7209 (Electronic)&#xD;0969-6970 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25369734</style></accession-num><abstract><style face="normal" font="default" size="100%">The presence of a native collateral circulation in tissues lessens injury in occlusive vascular diseases. However, differences in genetic background cause wide variation in collateral number and diameter in mice, resulting in large variation in protection. Indirect estimates of collateral perfusion suggest that wide variation also exists in humans. Unfortunately, methods used to obtain these estimates are invasive and not widely available. We sought to determine whether differences in genetic background in mice result in variation in branch patterning of the retinal arterial circulation, and whether these differences predict strain-dependent differences in pial collateral extent and severity of ischemic stroke. Retinal patterning metrics, collateral extent, and infarct volume were obtained for 10 strains known to differ widely in collateral extent. Multivariate regression was conducted, and model performance was assessed using K-fold cross-validation. Twenty-one metrics varied with strain (p&lt;0.01). Ten metrics (e.g., bifurcation angle, lacunarity, optimality) predicted collateral number and diameter across seven regression models, with the best model closely predicting (p&lt;0.0001) number (+/-1.2-3.4 collaterals, K-fold R2=0.83-0.98), diameter (+/-1.2-1.9 mum, R2=0.73-0.88), and infarct volume (+/-5.1 mm3, R2=0.85-0.87). An analogous set of the most predictive metrics, obtained for the middle cerebral artery (MCA) tree in a subset of the above strains, also predicted (p&lt;0.0001) collateral number (+/-3.3 collaterals, K-fold R2=0.78) and diameter (+/-1.6 mum, R2=0.86). Thus, differences in arterial branch patterning in the retina and the MCA trees are specified by genetic background and predict variation in collateral extent and stroke severity. If also true in human, and since genetic variation in cerebral collaterals extends to other tissues at least in mice, a similar &quot;retinal predictor index&quot; could serve as a non- or minimally invasive biomarker for collateral extent in brain and other tissues. This could aid prediction of severity of tissue injury in the event of an occlusive event or development of obstructive disease and in patient stratification for treatment options and clinical studies.</style></abstract><notes><style face="normal" font="default" size="100%">Prabhakar, Pranay&#xD;Zhang, Hua&#xD;Chen, De&#xD;Faber, James E&#xD;NS083633/NS/NINDS NIH HHS/United States&#xD;R01 NS083633/NS/NINDS NIH HHS/United States&#xD;HL090655/HL/NHLBI NIH HHS/United States&#xD;T35-DK007386/DK/NIDDK NIH HHS/United States&#xD;R01 HL090655/HL/NHLBI NIH HHS/United States&#xD;HL111070/HL/NHLBI NIH HHS/United States&#xD;HHSN261200800001E/PHS HHS/United States&#xD;T35 DK007386/DK/NIDDK NIH HHS/United States&#xD;HHSN261200800001C/RC/CCR NIH HHS/United States&#xD;R01 HL111070/HL/NHLBI NIH HHS/United States&#xD;HHSN261200800001E/CA/NCI NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Germany&#xD;Angiogenesis. 2015 Jan;18(1):97-114. doi: 10.1007/s10456-014-9449-y. Epub 2014 Nov 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/468/art%253A10.1007%252Fs10456-014-9449-y.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs10456-014-9449-y&amp;token2=exp=1484122746~acl=%2Fstatic%2Fpdf%2F468%2Fart%25253A10.1007%25252Fs10456-014-9449-y.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs10456-014-9449-y*~hmac=8620607b89824da39f33a704f605ace7cc080dd00fe413cde34857c567b8fc9d</style></url></related-urls><pdf-urls><url>internal-pdf://2987303842/Prabhakar-2015-Genetic variation in.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4422395</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms683877</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s10456-014-9449-y</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>65</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">65</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Prokai, L.</style></author><author><style face="normal" font="default" size="100%">Nguyen, V.</style></author><author><style face="normal" font="default" size="100%">Szarka, S.</style></author><author><style face="normal" font="default" size="100%">Garg, P.</style></author><author><style face="normal" font="default" size="100%">Sabnis, G.</style></author><author><style face="normal" font="default" size="100%">Bimonte-Nelson, H. A.</style></author><author><style face="normal" font="default" size="100%">McLaughlin, K. J.</style></author><author><style face="normal" font="default" size="100%">Talboom, J. S.</style></author><author><style face="normal" font="default" size="100%">Conrad, C. D.</style></author><author><style face="normal" font="default" size="100%">Shughrue, P. J.</style></author><author><style face="normal" font="default" size="100%">Gould, T. D.</style></author><author><style face="normal" font="default" size="100%">Brodie, A.</style></author><author><style face="normal" font="default" size="100%">Merchenthaler, I.</style></author><author><style face="normal" font="default" size="100%">Koulen, P.</style></author><author><style face="normal" font="default" size="100%">Prokai-Tatrai, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA. AgyPharma LLC, Mansfield, TX 76063, USA. laszlo.prokai@unthsc.edu.&#xD;Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.&#xD;Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA. Vision Research Center and Departments of Ophthalmology and Basic Medical Science, University of Missouri-Kansas City, School of Medicine, Kansas City, MO 64108, USA.&#xD;Department of Pharmacology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.&#xD;Department of Psychology, Arizona State University, Tempe, AZ 85287, USA. Arizona Alzheimer&apos;s Consortium, Tempe, AZ 85014, USA.&#xD;Department of Psychology, Arizona State University, Tempe, AZ 85287, USA.&#xD;Department of Pharmacology, Elan Pharmaceuticals Inc., South San Francisco, CA 94080, USA.&#xD;Department of Pharmacology, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.&#xD;Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA.&#xD;Vision Research Center and Departments of Ophthalmology and Basic Medical Science, University of Missouri-Kansas City, School of Medicine, Kansas City, MO 64108, USA.&#xD;Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA. AgyPharma LLC, Mansfield, TX 76063, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The prodrug DHED selectively delivers 17beta-estradiol to the brain for treating estrogen-responsive disorders</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Transl Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Science translational medicine</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Sci Transl Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Science translational medicine</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Sci Transl Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Science translational medicine</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">297ra113</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">297</style></number><edition><style face="normal" font="default" size="100%">2015/07/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Androstenediols/ pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antidepressive Agents/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/drug effects/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/complications/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Breast Neoplasms/drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Proliferation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Estradiol/chemistry/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Estrogens/chemistry/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">MCF-7 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotection/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Prodrugs/metabolism/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/complications/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Uterus/drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 22</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1946-6242 (Electronic)&#xD;1946-6234 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26203081</style></accession-num><abstract><style face="normal" font="default" size="100%">Many neurological and psychiatric maladies originate from the deprivation of the human brain from estrogens. However, current hormone therapies cannot be used safely to treat these conditions commonly associated with menopause because of detrimental side effects in the periphery. The latter also prevents the use of the hormone for neuroprotection. We show that a small-molecule bioprecursor prodrug, 10beta,17beta-dihydroxyestra-1,4-dien-3-one (DHED), converts to 17beta-estradiol in the brain after systemic administration but remains inert in the rest of the body. The localized and rapid formation of estrogen from the prodrug was revealed by a series of in vivo bioanalytical assays and through in vivo imaging in rodents. DHED treatment efficiently alleviated symptoms that originated from brain estrogen deficiency in animal models of surgical menopause and provided neuroprotection in a rat stroke model. Concomitantly, we determined that 17beta-estradiol formed in the brain from DHED elicited changes in gene expression and neuronal morphology identical to those obtained after direct 17beta-estradiol treatment. Together, complementary functional and mechanistic data show that our approach is highly relevant therapeutically, because administration of the prodrug selectively produces estrogen in the brain independently from the route of administration and treatment regimen. Therefore, peripheral responses associated with the use of systemic estrogens, such as stimulation of the uterus and estrogen-responsive tumor growth, were absent. Collectively, our brain-selective prodrug approach may safely provide estrogen neuroprotection and medicate neurological and psychiatric symptoms developing from estrogen deficiency, particularly those encountered after surgical menopause, without the adverse side effects of current hormone therapies.</style></abstract><notes><style face="normal" font="default" size="100%">Prokai, Laszlo&#xD;Nguyen, Vien&#xD;Szarka, Szabolcs&#xD;Garg, Puja&#xD;Sabnis, Gauri&#xD;Bimonte-Nelson, Heather A&#xD;McLaughlin, Katie J&#xD;Talboom, Joshua S&#xD;Conrad, Cheryl D&#xD;Shughrue, Paul J&#xD;Gould, Todd D&#xD;Brodie, Angela&#xD;Merchenthaler, Istvan&#xD;Koulen, Peter&#xD;Prokai-Tatrai, Katalin&#xD;R21 AG031421/AG/NIA NIH HHS/United States&#xD;R01 NS044765/NS/NINDS NIH HHS/United States&#xD;P01 AG027956/AG/NIA NIH HHS/United States&#xD;R21 MH100700/MH/NIMH NIH HHS/United States&#xD;R01 AG028084/AG/NIA NIH HHS/United States&#xD;S10 RR012023/RR/NCRR NIH HHS/United States&#xD;R01 AG031535/AG/NIA NIH HHS/United States&#xD;United States&#xD;Sci Transl Med. 2015 Jul 22;7(297):297ra113. doi: 10.1126/scitranslmed.aab1290.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stm.sciencemag.org/content/scitransmed/7/297/297ra113.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0145479160/Prokai-2015-The prodrug DHED sel.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4591937</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms724359</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1126/scitranslmed.aab1290</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>195</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">195</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Qi, Q.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Zhang, G.</style></author><author><style face="normal" font="default" size="100%">He, W.</style></author><author><style face="normal" font="default" size="100%">Ma, R.</style></author><author><style face="normal" font="default" size="100%">Cong, B.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Basic Medicine, Hebei Medical University Shijiazhuang 050017, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Morphological changes of cerebral vessels and expression patterns of MMP-2 and MMP-9 on cerebrovascular wall of alcoholic rats</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Clin Exp Pathol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">International journal of clinical and experimental pathology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Int J Clin Exp Pathol</style></full-title><abbr-1><style face="normal" font="default" size="100%">International journal of clinical and experimental pathology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Int J Clin Exp Pathol</style></full-title><abbr-1><style face="normal" font="default" size="100%">International journal of clinical and experimental pathology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1880-8</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2014/06/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Alcohol Drinking</style></keyword><keyword><style face="normal" font="default" size="100%">Alcoholism/ complications</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Basilar Artery/enzymology/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ blood supply</style></keyword><keyword><style face="normal" font="default" size="100%">Capillaries/enzymology/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Disorders/enzymology/ etiology/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelial Cells/enzymology/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Matrix Metalloproteinase 2/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Matrix Metalloproteinase 9/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle, Smooth, Vascular/enzymology/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Myocytes, Smooth Muscle/enzymology/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Remodeling</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">1936-2625 (Electronic)&#xD;1936-2625 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24966898</style></accession-num><abstract><style face="normal" font="default" size="100%">Alcohol abuse increases the incidence of cerebral accidents, which correlates with cerebrovascular structural changes. The present study was designed to observe the cerebrovascular remodeling of drinking rats with light microscopy and transmission electron microscopy (TEM). Short-term alcohol administration induced apparent amplification of perivascular spaces around small vessels in brain tissue, while long-term administration caused pathological changes of basilar arteries (BAs), including endothelial exfoliation, inner elastic lamina (IEL) fragmentation and thickening of tunica media and adventitia. In addition, the relationship between cerebrovascular remodeling and MMP-2 and MMP-9 synthesized by endothelial cells and vascular smooth muscle cells was explored by immunohistochemistry. The two protein expression in cerebral vessels changed dynamically, peaking at 1-2 weeks after treatment, and decreasing as treatment continued. These results suggest that MMP-2 and MMP-9 may play a significant role in blood-brain barrier disruption after alcohol abuse. But the chronic changes of cerebral arteries resulted from drinking are not coincident with time course of MMP-2 and MMP-9 expression in situ.</style></abstract><notes><style face="normal" font="default" size="100%">Qi, Qian&#xD;Liu, Xia&#xD;Zhang, Guozhong&#xD;He, Wenjing&#xD;Ma, Rufei&#xD;Cong, Bin&#xD;Li, Yingmin&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Int J Clin Exp Pathol. 2014 Apr 15;7(5):1880-8. eCollection 2014.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4069940</style></custom2><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">1</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Qi, W.</style></author><author><style face="normal" font="default" size="100%">Zhou, F.</style></author><author><style face="normal" font="default" size="100%">Li, S.</style></author><author><style face="normal" font="default" size="100%">Zong, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, M.</style></author><author><style face="normal" font="default" size="100%">Lin, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, X.</style></author><author><style face="normal" font="default" size="100%">Yang, H.</style></author><author><style face="normal" font="default" size="100%">Zou, Y.</style></author><author><style face="normal" font="default" size="100%">Qi, C.</style></author><author><style face="normal" font="default" size="100%">Wang, T.</style></author><author><style face="normal" font="default" size="100%">Hu, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">aDepartment of Morphology Lab, Chengdu Medical College bState Key Laboratory of Medical Neurobiology, Sichuan University, Chengdu cDepartment of Anatomy Lab, North Sichuan Medical College, Nanchong, Sichuan dInstitute of Neuroscience, Kunming Medical University, Kunming, Yunnan eDepartment of Anatomy, Qinghai University, Xining, Qinghai, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Remote ischemic postconditioning protects ischemic brain from injury in rats with focal cerebral ischemia/reperfusion associated with suppression of TLR4 and NF-small ka, CyrillicB expression</style></title><secondary-title><style face="normal" font="default" size="100%">Neuroreport</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuroreport</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuroreport</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroreport</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuroreport</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroreport</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">469-75</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2016/04/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/ complications</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/etiology/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Postconditioning</style></keyword><keyword><style face="normal" font="default" size="100%">NF-kappa B/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury</style></keyword><keyword><style face="normal" font="default" size="100%">Toll-Like Receptor 4/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">May 04</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1473-558X (Electronic)&#xD;0959-4965 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">27031871</style></accession-num><abstract><style face="normal" font="default" size="100%">Remote ischemic postconditioning (RIPC) has been proven to be a promising protective method for brain damage caused by transient focal ischemia/reperfusion (I/R) injury. However, the underlying mechanism of RIPC remains elusive. To address whether RIPC protects against brain damage by regulating TLR4 and the NF-kappaB pathway, focal I/R rat (SD) model induced by 1 h transient middle cerebral artery occlusion was used in this study. RIPC treatment was generated by three cycles of 10 min occlusion and 10 min release of the bilateral hind femoral arteries. The Garcia JH score was used to evaluate neurobehavioral function and triphenyltetrazolium chloride staining was used to estimate the infarct size of the brain. The expression levels of TLR4 and NF-kappaB were determined by quantitative PCR and immunohistochemistry. The results showed that RIPC treatment significantly improved neurological deficits and decreased infarct volume. Furthermore, it also inhibited the overexpression of TLR4 and NF-kappaB induced by middle cerebral artery occlusion reperfusion. Thus, we suggested that RIPC might protect ischemic brain against I/R injury in rats by suppressing the TLR4/NF-small ka, CyrillicB pathway.</style></abstract><notes><style face="normal" font="default" size="100%">Qi, Wenqian&#xD;Zhou, Fangfang&#xD;Li, Shuai&#xD;Zong, Yonghua&#xD;Zhang, Mingxiao&#xD;Lin, Yousheng&#xD;Zhang, Xiao&#xD;Yang, Huijun&#xD;Zou, Yu&#xD;Qi, Cunfang&#xD;Wang, Tinghua&#xD;Hu, Xiaosong&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Neuroreport. 2016 May 4;27(7):469-75. doi: 10.1097/WNR.0000000000000553.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/wnr.0000000000000553</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>311</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">311</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Qiu, B.</style></author><author><style face="normal" font="default" size="100%">Hu, S.</style></author><author><style face="normal" font="default" size="100%">Liu, L.</style></author><author><style face="normal" font="default" size="100%">Chen, M.</style></author><author><style face="normal" font="default" size="100%">Wang, L.</style></author><author><style face="normal" font="default" size="100%">Zeng, X.</style></author><author><style face="normal" font="default" size="100%">Zhu, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, People&apos;s Republic of China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">CART attenuates endoplasmic reticulum stress response induced by cerebral ischemia and reperfusion through upregulating BDNF synthesis and secretion</style></title><secondary-title><style face="normal" font="default" size="100%">Biochem Biophys Res Commun</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Biochemical and biophysical research communications</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Biochem Biophys Res Commun</style></full-title><abbr-1><style face="normal" font="default" size="100%">Biochemical and biophysical research communications</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Biochem Biophys Res Commun</style></full-title><abbr-1><style face="normal" font="default" size="100%">Biochemical and biophysical research communications</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">655-9</style></pages><volume><style face="normal" font="default" size="100%">436</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2013/06/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Base Sequence</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain-Derived Neurotrophic Factor/ biosynthesis</style></keyword><keyword><style face="normal" font="default" size="100%">DNA Primers</style></keyword><keyword><style face="normal" font="default" size="100%">Endoplasmic Reticulum/ drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Tissue Proteins/genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Real-Time Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default" size="100%">Stress, Physiological</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 12</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1090-2104 (Electronic)&#xD;0006-291X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23770418</style></accession-num><abstract><style face="normal" font="default" size="100%">Cocaine and amphetamine regulated transcript (CART), a neuropeptide, has shown strong neuroprotective effects against cerebral ischemia and reperfusion (I/R) injury in vivo and in vitro. Here, we report a new effect of CART on ER stress which is induced by cerebral I/R in a rat model of middle cerebral artery occlusion (MCAO) or by oxygen and glucose deprivation (OGD) in cultured cortical neurons, as well as a new functionality of BDNF in the neuroprotection by CART against the ER stress in cerebral I/R. The results showed that CART was effective in reducing the neuronal apoptosis and expression of ER stress markers (GRP78, CHOP and cleaved caspase12), and increasing the BDNF expression in I/R injury rat cortex both in vivo and in vitro. In addition, the effects of CART on ischemia-induced neuronal apoptosis and ER stress were suppressed by tyrosine receptor kinase B (TrkB) IgG, whereas the effects of CART on BDNF transcription, synthesis and secretion were abolished by CREB siRNA. This work suggests that CART is functional in inhibiting the cerebral I/R-induced ER stress and neuronal apoptosis by facilitating the transcription, synthesis and secretion of BDNF in a CREB-dependent way.</style></abstract><notes><style face="normal" font="default" size="100%">Qiu, Bin&#xD;Hu, Shengdi&#xD;Liu, Libing&#xD;Chen, Man&#xD;Wang, Lai&#xD;Zeng, Xianwei&#xD;Zhu, Shigong&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Biochem Biophys Res Commun. 2013 Jul 12;436(4):655-9. doi: 10.1016/j.bbrc.2013.05.142. Epub 2013 Jun 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0006291X13009844/1-s2.0-S0006291X13009844-main.pdf?_tid=dbd36188-d7d3-11e6-80ed-00000aacb362&amp;acdnat=1484121740_bf5c46fd9dd5ade5097da0088d5bdf92</style></url></related-urls><pdf-urls><url>internal-pdf://0793436228/Qiu-2013-CART attenuates endo.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.bbrc.2013.05.142</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>235</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">235</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ragoschke-Schumm, A.</style></author><author><style face="normal" font="default" size="100%">Walter, S.</style></author><author><style face="normal" font="default" size="100%">Haass, A.</style></author><author><style face="normal" font="default" size="100%">Balucani, C.</style></author><author><style face="normal" font="default" size="100%">Lesmeister, M.</style></author><author><style face="normal" font="default" size="100%">Nasreldein, A.</style></author><author><style face="normal" font="default" size="100%">Sarlon, L.</style></author><author><style face="normal" font="default" size="100%">Bachhuber, A.</style></author><author><style face="normal" font="default" size="100%">Licina, T.</style></author><author><style face="normal" font="default" size="100%">Grunwald, I. Q.</style></author><author><style face="normal" font="default" size="100%">Fassbender, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, University Hospital of the Saarland, Homburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Translation of the &apos;time is brain&apos; concept into clinical practice: focus on prehospital stroke management</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">International journal of stroke : official journal of the International Stroke Society</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Int J Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">International journal of stroke : official journal of the International Stroke Society</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Int J Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">International journal of stroke : official journal of the International Stroke Society</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">333-40</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2014/03/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">Emergency Medical Services</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/diagnosis/pathology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombolytic Therapy/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Translational Medical Research</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1747-4949 (Electronic)&#xD;1747-4930 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24593156</style></accession-num><abstract><style face="normal" font="default" size="100%">Acute stroke is one of the main causes of death and chronic disability. Thrombolysis with recombinant tissue plasminogen activator within the first hours after onset of symptoms is an effective therapeutic option for ischemic stroke. However, fewer than 2% to 7% of patients receive this treatment, primarily because most patients reach the hospital too late for the initiation of successful therapy. Several measures can reduce detrimental delay until treatment. It is of importance to use continual public awareness campaigns to reduce delays in patients&apos; alarm of emergency medical services. Further relevant measures are repetitive education of emergency medical services teams to ensure the systematic use of scales designed for recognition of stroke symptoms and the proper triage of patients to stroke centers. A most important time-saving measure is prenotification of the receiving hospital by the emergency medical services team. In the future, treatment already at the emergency site may allow more than a small minority of patients to benefit from available treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Ragoschke-Schumm, A&#xD;Walter, S&#xD;Haass, A&#xD;Balucani, C&#xD;Lesmeister, M&#xD;Nasreldein, A&#xD;Sarlon, L&#xD;Bachhuber, A&#xD;Licina, T&#xD;Grunwald, I Q&#xD;Fassbender, K&#xD;Review&#xD;United States&#xD;Int J Stroke. 2014 Apr;9(3):333-40. doi: 10.1111/ijs.12252. Epub 2014 Mar 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/ijs.12252/asset/ijs12252.pdf?v=1&amp;t=ixsnnup1&amp;s=c196db32f7eee6ab9db7b15e1162b1c023eb0c58</style></url></related-urls><pdf-urls><url>internal-pdf://3192977619/Ragoschke-Schumm-2014-Translation of the &apos;.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4374710</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/ijs.12252</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>148</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">148</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ramos-Cejudo, J.</style></author><author><style face="normal" font="default" size="100%">Gutierrez-Fernandez, M.</style></author><author><style face="normal" font="default" size="100%">Otero-Ortega, L.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Frutos, B.</style></author><author><style face="normal" font="default" size="100%">Fuentes, B.</style></author><author><style face="normal" font="default" size="100%">Vallejo-Cremades, M. T.</style></author><author><style face="normal" font="default" size="100%">Hernanz, T. N.</style></author><author><style face="normal" font="default" size="100%">Cerdan, S.</style></author><author><style face="normal" font="default" size="100%">Diez-Tejedor, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From the Department of Neurology and Stroke Center, Neuroscience and Cerebrovascular Research Laboratory, La Paz University Hospital, Neuroscience Area of IdiPAZ Health Research Institute, Autonoma University of Madrid, Madrid, Spain (J.R.-C., M.G.-F., L.O.-O., B.R.-F., B.F., M.T.V.-C., E.D.-T.); and Laboratory for Imaging and Spectroscopy by Magnetic Resonance (LISMAR), Institute of Biomedical Research Alberto Sols, CSIC-UAM, Madrid, Spain (T.N.H., S.C.).&#xD;From the Department of Neurology and Stroke Center, Neuroscience and Cerebrovascular Research Laboratory, La Paz University Hospital, Neuroscience Area of IdiPAZ Health Research Institute, Autonoma University of Madrid, Madrid, Spain (J.R.-C., M.G.-F., L.O.-O., B.R.-F., B.F., M.T.V.-C., E.D.-T.); and Laboratory for Imaging and Spectroscopy by Magnetic Resonance (LISMAR), Institute of Biomedical Research Alberto Sols, CSIC-UAM, Madrid, Spain (T.N.H., S.C.). exuperio.diez@salud.madrid.org mariagutierrezfdez@hotmail.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Brain-derived neurotrophic factor administration mediated oligodendrocyte differentiation and myelin formation in subcortical ischemic stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">221-8</style></pages><volume><style face="normal" font="default" size="100%">46</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2014/11/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">2&apos;,3&apos;-Cyclic-Nucleotide Phosphodiesterases/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Adenomatous Polyposis Coli Protein/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Basic Helix-Loop-Helix Transcription Factors/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/drug effects/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/complications/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain-Derived Neurotrophic Factor/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Differentiation/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Diffusion Tensor Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Myelin Basic Protein/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Myelin Sheath/ drug effects/pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Oligodendroglia/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Platelet-Derived Growth Factor alpha/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/etiology/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">White Matter/ drug effects/pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25395417</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: Translational research is beginning to reveal the importance of trophic factors as a therapy for cellular brain repair. The purpose of this study was to analyze whether brain-derived neurotrophic factor (BDNF) administration could mediate oligodendrogenesis and remyelination after white matter injury in subcortical stroke. METHODS: Ischemia was induced in rats by injection of endothelin-1. At 24 hours, 0.4 mug/kg of BDNF or saline was intravenously administered to the treatment and control groups, respectively. Functional evaluation, MRI, and fiber tract integrity on tractography images were analyzed. Proliferation (KI-67) and white matter repair markers (A2B5, 2&apos;,3&apos;-cyclic-nucleotide 3&apos;-phosphodiesterase [CNPase], adenomatous polyposis coli [APC], platelet-derived growth factor receptor alpha [PDGFR-alpha], oligodendrocyte marker O4 [O4], oligodendrocyte transcription factor [Olig-2], and myelin basic protein [MBP]) were analyzed at 7 and 28 days. RESULTS: The BDNF-treated animals showed less functional deficit at 28 days after treatment than the controls (P&lt;0.05). Although T2-MRI did not show differences in lesion size at 7 and 28 days between groups, diffusion tensor imaging tractography analysis revealed significantly better tract connectivity at 28 days in the BDNF group than in the controls (P&lt;0.05). Increased proliferation of oligodendrocyte progenitors was observed in treated animals at 7 days (P&lt;0.05). Finally, the levels of white matter repair markers (A2B5, CNPase, and O4 at 7 days; Olig-2 and MBP at 28 days) were higher in the BDNF group than in the controls (P&lt;0.05). CONCLUSIONS: BDNF administration exerted better functional outcome, oligodendrogenesis, remyelination, and fiber connectivity than controls in rats subjected to subcortical damage in ischemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Ramos-Cejudo, Jaime&#xD;Gutierrez-Fernandez, Maria&#xD;Otero-Ortega, Laura&#xD;Rodriguez-Frutos, Berta&#xD;Fuentes, Blanca&#xD;Vallejo-Cremades, Maria Teresa&#xD;Hernanz, Teresa Navarro&#xD;Cerdan, Sebastian&#xD;Diez-Tejedor, Exuperio&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Stroke. 2015 Jan;46(1):221-8. doi: 10.1161/STROKEAHA.114.006692. Epub 2014 Nov 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/46/1/221.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1660175475/Ramos-Cejudo-2015-Brain-derived neurot.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.114.006692</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>370</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">370</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Raymond, J.</style></author><author><style face="normal" font="default" size="100%">Darsaut, T. E.</style></author><author><style face="normal" font="default" size="100%">Kotowski, M.</style></author><author><style face="normal" font="default" size="100%">Makoyeva, A.</style></author><author><style face="normal" font="default" size="100%">Gevry, G.</style></author><author><style face="normal" font="default" size="100%">Berthelet, F.</style></author><author><style face="normal" font="default" size="100%">Salazkin, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Radiology, Centre Hospitalier de l&apos;Universite de Montreal, Notre-Dame Hospital, Montreal, Quebec, Canada H2L 4M1. jean.raymond@umontreal.ca</style></auth-address><titles><title><style face="normal" font="default" size="100%">Thrombosis heralding aneurysmal rupture: an exploration of potential mechanisms in a novel giant swine aneurysm model</style></title><secondary-title><style face="normal" font="default" size="100%">AJNR Am J Neuroradiol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">AJNR. American journal of neuroradiology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">AJNR Am J Neuroradiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">AJNR. American journal of neuroradiology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">AJNR Am J Neuroradiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">AJNR. American journal of neuroradiology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">346-53</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2012/11/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aneurysm, Ruptured/complications/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Biopsy</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Arteries/diagnostic imaging/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Artery Diseases/complications/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Angiography</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Aneurysm/complications/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Sus scrofa</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombosis/complications/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Vasculitis/complications/pathology/physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1936-959X (Electronic)&#xD;0195-6108 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23153870</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: The relationship between aneurysm dimensions, flow, thrombosis, and rupture remains poorly understood. We attempted to clarify this relationship by exploring various swine aneurysm models. MATERIALS AND METHODS: Bilateral carotid aneurysms were constructed according to 3 protocols in 24 animals: small aneurysms with wide necks (group 1; n = 6 animals); small aneurysms with small necks (group 2; n = 4 animals), and giant aneurysms with large necks (group 3; n = 14 animals). Group 3 included 3 subgroups, related to testing the model in various experimental conditions: The neck was clipped in 3 animals; venous pouches lacked an endothelial lining in 4 animals; and 7 were control animals. Animals were followed until rupture, or for 1-4 weeks. Angiography was performed postoperatively and before euthanasia. We studied lesion pathology, paying attention to thrombosis, recanalization, wall composition, and perianeurysmal hemorrhage. RESULTS: Groups differed significantly in aneurysm dimensions and aspect ratio (P = .002). Ruptures occurred more frequently in animals with untreated giant aneurysms (7/7) than in animals with small wide-neck (0/6) or small-neck (2/4) aneurysms (P = .002). Ruptures occurred only in animals with thrombosed aneurysms. Lesions lacking an endothelial lining and 5 of 6 clipped venous pouches thrombosed but did not rupture. One giant lesion ruptured despite complete clipping. The wall was deficient in alpha-actin and was infiltrated with inflammatory cells and erythrocytes in all thrombosed cases, ruptured or not. Ruptures were associated with recanalizing channels in 9 of 10 cases. CONCLUSIONS: Thrombosis, inflammation, and recanalization may precipitate aneurysmal ruptures in a swine model.</style></abstract><notes><style face="normal" font="default" size="100%">Raymond, J&#xD;Darsaut, T E&#xD;Kotowski, M&#xD;Makoyeva, A&#xD;Gevry, G&#xD;Berthelet, F&#xD;Salazkin, I&#xD;Canadian Institutes of Health Research/Canada&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;AJNR Am J Neuroradiol. 2013 Feb;34(2):346-53. doi: 10.3174/ajnr.A3407. Epub 2012 Nov 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.ajnr.org/content/34/2/346.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1685476380/Raymond-2013-Thrombosis heralding.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3174/ajnr.A3407</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>270</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">270</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Reddy, R.</style></author><author><style face="normal" font="default" size="100%">Duong, T. T.</style></author><author><style face="normal" font="default" size="100%">Fairhall, J. M.</style></author><author><style face="normal" font="default" size="100%">Smee, R. I.</style></author><author><style face="normal" font="default" size="100%">Stoodley, M. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Prince of Wales Medical Research Institute;</style></auth-address><titles><title><style face="normal" font="default" size="100%">Durable thrombosis in a rat model of arteriovenous malformation treated with radiosurgery and vascular targeting</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosurg</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neurosurgery</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosurg</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurosurgery</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosurg</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurosurgery</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">113-9</style></pages><volume><style face="normal" font="default" size="100%">120</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2013/11/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Angiography</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Arteriovenous Malformations/diagnostic imaging/ surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Radiosurgery/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombosis/diagnostic imaging/ surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1933-0693 (Electronic)&#xD;0022-3085 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24180569</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECT: Radiosurgical treatment of brain arteriovenous malformations (AVMs) has the significant shortcomings of being limited to lesions smaller than 3 cm in diameter and of a latency-to-cure time of up to 3 years. A possible method of overcoming these limitations is stimulation of thrombosis by using vascular targeting. Using an animal model of AVM, the authors examined the durability of the thrombosis induced by the vascular-targeting agents lipopolysaccharide and soluble tissue factor conjugate (LPS/sTF). METHODS: Stereotactic radiosurgery or sham radiation was administered to 32 male Sprague-Dawley rats serving as an animal model of AVM; 24 hours after this intervention, the rats received an intravenous injection of LPS/sTF or normal saline. The animals were killed at 1, 7, 30, or 90 days after treatment. Immediately beforehand, angiography was performed, and model AVM tissue was harvested for histological analysis to assess rates of vessel thrombosis. RESULTS: Among rats that received radiosurgery and LPS/sTF, induced thrombosis occurred in 58% of small AVM vessels; among those that received radiosurgery and saline, thrombosis occurred in 12% of small AVM vessels (diameter &lt; 200 mum); and among those that received LPS/sTF but no radiosurgery, thrombosis occurred at an intermediate rate of 43%. No systemic toxicity or intravascular thrombosis remote from the target region was detected in any of the animals. CONCLUSIONS: Vascular targeting can increase intravascular thrombosis after radiosurgery, and the vessel occlusion is durable. Further work is needed to refine this approach to AVM treatment, which shows promise as a way to overcome the limitations of radiosurgery.</style></abstract><notes><style face="normal" font="default" size="100%">Reddy, Rajesh&#xD;Duong, T T Hong&#xD;Fairhall, Jacob M&#xD;Smee, Robert I&#xD;Stoodley, Marcus A&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Neurosurg. 2014 Jan;120(1):113-9. doi: 10.3171/2013.9.JNS122056. Epub 2013 Nov 1.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3171/2013.9.jns122056</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>305</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">305</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ren, T. J.</style></author><author><style face="normal" font="default" size="100%">Qiang, R.</style></author><author><style face="normal" font="default" size="100%">Jiang, Z. L.</style></author><author><style face="normal" font="default" size="100%">Wang, G. H.</style></author><author><style face="normal" font="default" size="100%">Sun, L.</style></author><author><style face="normal" font="default" size="100%">Jiang, R.</style></author><author><style face="normal" font="default" size="100%">Zhao, G. W.</style></author><author><style face="normal" font="default" size="100%">Han, L. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neuropharmacology, Institute of Nautical Medicine, Nantong University, Nantong, Jiangsu Province, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Improvement in regional CBF by L-serine contributes to its neuroprotective effect in rats after focal cerebral ischemia</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PloS one</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e67044</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2013/07/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apamin/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Charybdotoxin/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Interactions</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelium, Vascular/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/metabolism/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Potassium Channels, Calcium-Activated/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Serine/antagonists &amp; inhibitors/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203 (Electronic)&#xD;1932-6203 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23825613</style></accession-num><abstract><style face="normal" font="default" size="100%">To investigate the mechanisms underlying the neuroprotective effect of L-serine, permanent focal cerebral ischemia was induced by occlusion of the middle cerebral artery while monitoring cerebral blood flow (CBF). Rats were divided into control and L-serine-treated groups after middle cerebral artery occlusion. The neurological deficit score and brain infarct volume were assessed. Nissl staining was used to quantify the cortical injury. L-serine and D-serine levels in the ischemic cortex were analyzed with high performance liquid chromatography. We found that L-serine treatment: 1) reduced the neurological deficit score, infarct volume and cortical neuron loss in a dose-dependent manner; 2) improved CBF in the cortex, and this effect was inhibited in the presence of apamin plus charybdotoxin while the alleviation of both neurological deficit score and infarct volume was blocked; and 3) increased the amount of L-serine and D-serine in the cortex, and inhibition of the conversion of L-serine into D-serine by aminooxyacetic acid did not affect the reduction of neurological deficit score and infarct volume by L-serine. In conclusion, improvement in regional CBF by L-serine may contribute to its neuroprotective effect on the ischemic brain, potentially through vasodilation which is mediated by the small- and intermediate-conductance Ca(2+)-activated K(+) channels on the cerebral blood vessel endothelium.</style></abstract><notes><style face="normal" font="default" size="100%">Ren, Tao-Jie&#xD;Qiang, Ren&#xD;Jiang, Zheng-Lin&#xD;Wang, Guo-Hua&#xD;Sun, Li&#xD;Jiang, Rui&#xD;Zhao, Guang-Wei&#xD;Han, Le-Yang&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;PLoS One. 2013 Jun 25;8(6):e67044. doi: 10.1371/journal.pone.0067044. Print 2013.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0067044&amp;type=printable</style></url></related-urls><pdf-urls><url>internal-pdf://3531637091/Ren-2013-Improvement in regio.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3692549</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0067044</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>443</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">443</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ritz, M. F.</style></author><author><style face="normal" font="default" size="100%">Grond-Ginsbach, C.</style></author><author><style face="normal" font="default" size="100%">Engelter, S.</style></author><author><style face="normal" font="default" size="100%">Lyrer, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biomedicine, Brain Tumor Biology Laboratory, Pharmazentrum, Klingelbergstrasse 50, 4056 Basel, Switzerland. marie-francoise.ritz@unibas.ch</style></auth-address><titles><title><style face="normal" font="default" size="100%">Gene expression suggests spontaneously hypertensive rats may have altered metabolism and reduced hypoxic tolerance</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Neurovasc Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Current neurovascular research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Neurovasc Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current neurovascular research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Curr Neurovasc Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current neurovascular research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">10-9</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2012/01/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/blood supply/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Hypoxia/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Small Vessel Diseases/etiology/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension/complications/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Oligonucleotide Array Sequence Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred SHR</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Real-Time Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default" size="100%">Reverse Transcriptase Polymerase Chain Reaction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1875-5739 (Electronic)&#xD;1567-2026 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22272763</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebral small vessel disease (SVD) is an important cause of stroke, cognitive decline and vascular dementia (VaD). It is associated with diffuse white matter abnormalities and small deep cerebral ischemic infarcts. The molecular mechanisms involved in the development and progression of SVD are unclear. As hypertension is a major risk factor for developing SVD, Spontaneously Hypertensive Rats (SHR) are considered an appropriate experimental model for SVD. Prior work suggested an imbalance between the number of blood microvessels and astrocytes at the level of the neurovascular unit in 2-month-old SHR, leading to neuronal hypoxia in the brain of 9-month-old animals. To identify genes and pathways involved in the development of SVD, we compared the gene expression profile in the cortex of 2 and 9-month-old of SHR with age-matched normotensive Wistar Kyoto (WKY) rats using microarray-based technology. The results revealed significant differences in expression of genes involved in energy and lipid metabolisms, mitochondrial functions, oxidative stress and ischemic responses between both groups. These results strongly suggest that SHR suffer from chronic hypoxia, and therefore are unable to tolerate ischemia-like conditions, and are more vulnerable to high-energy needs than WKY. This molecular analysis gives new insights about pathways accounting for the development of SVD.</style></abstract><notes><style face="normal" font="default" size="100%">Ritz, Marie-Francoise&#xD;Grond-Ginsbach, Caspar&#xD;Engelter, Stefan&#xD;Lyrer, Philippe&#xD;Netherlands&#xD;Curr Neurovasc Res. 2012 Feb;9(1):10-9.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3296125</style></custom2><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>82</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">82</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Roome, R. B.</style></author><author><style face="normal" font="default" size="100%">Vanderluit, J. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">BioMedical Sciences, Faculty of Medicine, Memorial University of Newfoundland; Neurosciences, Faculty of Medicine, McGill University.&#xD;BioMedical Sciences, Faculty of Medicine, Memorial University of Newfoundland; jvanderl@mun.ca.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Paw-dragging: a novel, sensitive analysis of the mouse cylinder test</style></title><secondary-title><style face="normal" font="default" size="100%">J Vis Exp</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of visualized experiments : JoVE</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Vis Exp</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of visualized experiments : JoVE</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Vis Exp</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of visualized experiments : JoVE</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e52701</style></pages><number><style face="normal" font="default" size="100%">98</style></number><edition><style face="normal" font="default" size="100%">2015/05/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/chemically induced/ diagnosis/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/chemically induced/diagnosis/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelin-1</style></keyword><keyword><style face="normal" font="default" size="100%">Forelimb/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Motor Cortex/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery of Function</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/chemically induced/diagnosis/physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 29</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1940-087X (Electronic)&#xD;1940-087X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25993447</style></accession-num><abstract><style face="normal" font="default" size="100%">The cylinder test is routinely used to predict focal ischemic damage to the forelimb motor cortex in rodents. When placed in the cylinder, rodents explore by rearing and touching the walls of the cylinder with their forelimb paws for postural support. Following ischemic injury to the forelimb sensorimotor cortex, rats rely more heavily on their unaffected forelimb paw for postural support resulting in fewer touches with their affected paw which is termed forelimb asymmetry. In contrast, focal ischemic damage in the mouse brain fails to result in comparable consistent deficits in forelimb asymmetry. While forelimb asymmetry deficits are infrequently observed, mice do demonstrate a novel behaviour post stroke termed &quot;paw-dragging&quot;. Paw-dragging is the tendency for a mouse to drag its affected paw along the cylinder wall rather than directly push off from the wall when dismounting from a rear to a four-legged stance. We have previously demonstrated that paw-dragging behaviour is highly sensitive to small cortical ischemic injuries to the forelimb motor cortex. Here we provide a detailed protocol for paw-dragging analysis. We define what a paw-drag is and demonstrate how to quantify paw-dragging behaviour. The cylinder test is a simple and inexpensive test to administer and does not require pre-training or food deprivation strategies. In using paw-dragging analysis with the cylinder test, it fills a niche for predicting cortical ischemic injuries such as photothrombosis and Endothelin-1 (ET-1)-induced ischemia--two models that are ever-increasing in popularity and produce smaller focal injuries than middle cerebral artery occlusion. Finally, measuring paw-dragging behaviour in the cylinder test will allow studies of functional recovery after cortical injury using a wide cohort of transgenic mouse strains where previous forelimb asymmetry analysis has failed to detect consistent deficits.</style></abstract><notes><style face="normal" font="default" size="100%">Roome, R Brian&#xD;Vanderluit, Jacqueline L&#xD;Canadian Institutes of Health Research/Canada&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Video-Audio Media&#xD;United States&#xD;J Vis Exp. 2015 Apr 29;(98):e52701. doi: 10.3791/52701.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.jove.com/pdf/52701/jove-protocol-52701-paw-dragging-a-novel-sensitive-analysis-of-the-mouse-cylinder-test</style></url></related-urls><pdf-urls><url>internal-pdf://3243055812/Roome-2015-Paw-dragging_ a nove.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3791/52701</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>473</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">473</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rosidi, N. L.</style></author><author><style face="normal" font="default" size="100%">Zhou, J.</style></author><author><style face="normal" font="default" size="100%">Pattanaik, S.</style></author><author><style face="normal" font="default" size="100%">Wang, P.</style></author><author><style face="normal" font="default" size="100%">Jin, W.</style></author><author><style face="normal" font="default" size="100%">Brophy, M.</style></author><author><style face="normal" font="default" size="100%">Olbricht, W. L.</style></author><author><style face="normal" font="default" size="100%">Nishimura, N.</style></author><author><style face="normal" font="default" size="100%">Schaffer, C. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biomedical Engineering, Cornell University, Ithaca, New York, United States of America.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cortical microhemorrhages cause local inflammation but do not trigger widespread dendrite degeneration</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PloS one</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e26612</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2011/10/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arterioles/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Coagulation</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Count</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/blood supply/metabolism/ pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/etiology/metabolism/ pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Dendrites/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Erythrocytes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Glial Fibrillary Acidic Protein</style></keyword><keyword><style face="normal" font="default" size="100%">Hematoma/metabolism/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/etiology/metabolism/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Laser Therapy/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Macrophages/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Microglia/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Tissue Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Plasma/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203 (Electronic)&#xD;1932-6203 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22028924</style></accession-num><abstract><style face="normal" font="default" size="100%">Microhemorrhages are common in the aging brain, and their incidence is correlated with increased risk of neurodegenerative disease. Past work has shown that occlusion of individual cortical microvessels as well as large-scale hemorrhages can lead to degeneration of neurons and increased inflammation. Using two-photon excited fluorescence microscopy in anesthetized mice, we characterized the acute and chronic dynamics of vessel bleeding, tissue compression, blood flow change, neural degeneration, and inflammation following a microhemorrhage caused by rupturing a single penetrating arteriole with tightly-focused femtosecond laser pulses. We quantified the extravasation of red blood cells (RBCs) and blood plasma into the brain and determined that the bleeding was limited by clotting. The vascular bleeding formed a RBC-filled core that compressed the surrounding parenchymal tissue, but this compression was not sufficient to crush nearby brain capillaries, although blood flow speeds in these vessels was reduced by 20%. Imaging of cortical dendrites revealed no degeneration of the large-scale structure of the dendritic arbor up to 14 days after the microhemorrhage. Dendrites close to the RBC core were displaced by extravasating RBCs but began to relax back one day after the lesion. Finally, we observed a rapid inflammatory response characterized by morphology changes in microglia/macrophages up to 200 microm from the microhemorrhage as well as extension of cellular processes into the RBC core. This inflammation persisted over seven days. Taken together, our data suggest that a cortical microhemorrhage does not directly cause significant neural pathology but does trigger a sustained, local inflammatory response.</style></abstract><notes><style face="normal" font="default" size="100%">Rosidi, Nathanael L&#xD;Zhou, Joan&#xD;Pattanaik, Sanket&#xD;Wang, Peng&#xD;Jin, Weiyang&#xD;Brophy, Morgan&#xD;Olbricht, William L&#xD;Nishimura, Nozomi&#xD;Schaffer, Chris B&#xD;F32 AG031620/AG/NIA NIH HHS/United States&#xD;1F32AG031620-01A2/AG/NIA NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United States&#xD;PLoS One. 2011;6(10):e26612. doi: 10.1371/journal.pone.0026612. Epub 2011 Oct 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0026612&amp;type=printable</style></url></related-urls><pdf-urls><url>internal-pdf://0522394698/Rosidi-2011-Cortical microhemorr.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3197572</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0026612</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>438</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">438</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Roth, C.</style></author><author><style face="normal" font="default" size="100%">Junk, D.</style></author><author><style face="normal" font="default" size="100%">Papanagiotou, P.</style></author><author><style face="normal" font="default" size="100%">Keuler, A.</style></author><author><style face="normal" font="default" size="100%">Korner, H.</style></author><author><style face="normal" font="default" size="100%">Schumacher, M.</style></author><author><style face="normal" font="default" size="100%">Reith, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinic for Diagnostic and Interventional Neuroradiology, Saarland University Hospital, Homburg/Saar, Germany. Christian.roth@uks.eu</style></auth-address><titles><title><style face="normal" font="default" size="100%">A comparison of 2 stroke devices: the new Aperio clot-removal device and the solitaire AB/FR</style></title><secondary-title><style face="normal" font="default" size="100%">AJNR Am J Neuroradiol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">AJNR. American journal of neuroradiology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">AJNR Am J Neuroradiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">AJNR. American journal of neuroradiology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">AJNR Am J Neuroradiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">AJNR. American journal of neuroradiology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1317-20</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2012/02/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/complications/ diagnostic imaging/ surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment Design</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment Failure Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Mechanical Thrombolysis/ instrumentation</style></keyword><keyword><style face="normal" font="default" size="100%">Radiography</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ diagnostic imaging/etiology/ surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Swine</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1936-959X (Electronic)&#xD;0195-6108 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22300938</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: Several studies have shown promising results for the use of self-expandable intracranial stents for the treatment of acute ischemic stroke. This new technique combines immediate flow restoration after stent deployment with high recanalization rates. In the present study, the safety and efficacy of the new Aperio clot-removal device was tested in comparison with the Solitaire AB device. MATERIALS AND METHODS: The experiments were performed in swine with a weight of 35-50 kg following established models. The experimental thrombi were prepared by using a new flow model (Thrombus Loop) to produce radiopaque thrombi. Thrombi were cut into lengths of 10 mm and injected into the target vessel. The occlusion was verified by DSA and rated with the help of the TICI score. A microcatheter was placed distal to the thrombus. The devices were placed with the proximal third within the thrombus and were retrieved under continuous aspiration in their released state into the guiding sheath. We performed 23 procedures with the Aperio device and 18 procedures with the Solitaire AB and FR devices. Control angiograms were obtained 3 and 5 minutes after device deployment to evaluate the flow restoration. The number of attempts to reach a TICI 2/3 score was recorded as well as the time to recanalization and the device-related complications. Vasospasm, vascular perforation, intramural arterial dissection, or embolization of a previously uninvolved territory was defined as a device-related complication. RESULTS: Defined radiopaque thrombi from whole blood could reliably be created by using the Thrombus Loop. Both devices demonstrated a high recanalization rate of 100% (TICI 3) in the target vessel with no device-related complications. No significant differences were found between the 2 devices. CONCLUSIONS: In this small study, we could show that radiopaque thrombi of whole blood with a defined diameter could be reliably created by using the Thrombus Loop. The new &quot;stent-retriever&quot; (Aperio System) seems to be a very efficient and safe addition to the existing repertoire of clot-removal devices.</style></abstract><notes><style face="normal" font="default" size="100%">Roth, C&#xD;Junk, D&#xD;Papanagiotou, P&#xD;Keuler, A&#xD;Korner, H&#xD;Schumacher, M&#xD;Reith, W&#xD;Comparative Study&#xD;United States&#xD;AJNR Am J Neuroradiol. 2012 Aug;33(7):1317-20. doi: 10.3174/ajnr.A2962. Epub 2012 Feb 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.ajnr.org/content/33/7/1317.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3229053557/Roth-2012-A comparison of 2 st.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3174/ajnr.A2962</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>326</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">326</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rother, J.</style></author><author><style face="normal" font="default" size="100%">Ford, G. A.</style></author><author><style face="normal" font="default" size="100%">Thijs, V. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Asklepios Klinik Altona, Hamburg, Germany. j.roether@asklepios.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">Thrombolytics in acute ischaemic stroke: historical perspective and future opportunities</style></title><secondary-title><style face="normal" font="default" size="100%">Cerebrovasc Dis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Cerebrovascular diseases (Basel, Switzerland)</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cerebrovasc Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Cerebrovascular diseases (Basel, Switzerland)</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Cerebrovasc Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Cerebrovascular diseases (Basel, Switzerland)</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">313-9</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2013/04/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/diagnosis/ drug therapy/history</style></keyword><keyword><style face="normal" font="default" size="100%">Fibrinolytic Agents/ administration &amp; dosage/adverse effects/history</style></keyword><keyword><style face="normal" font="default" size="100%">Forecasting</style></keyword><keyword><style face="normal" font="default" size="100%">History, 20th Century</style></keyword><keyword><style face="normal" font="default" size="100%">History, 21st Century</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/diagnosis/ drug therapy/history</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombolytic Therapy/adverse effects/history/trends</style></keyword><keyword><style face="normal" font="default" size="100%">Time-to-Treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Tissue Plasminogen Activator/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">1421-9786 (Electronic)&#xD;1015-9770 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23615379</style></accession-num><abstract><style face="normal" font="default" size="100%">The discovery of thrombolytic agents goes back to the 1930s, when it was shown that substances derived from bacteria (streptokinase, staphylokinase), tissue (fibrinokinase), urine (urokinase) or bat saliva could activate the fibrinolytic system. The potential to treat arterial thrombosis with plasmin was recognized, but it was not until 1958 that its first use in acute ischaemic stroke (AIS) was described. However, since computer tomography (CT) was not available until the mid 1970s, optimal selection of patients was not possible. Early studies with streptokinase in AIS showed an increased risk of intracranial haemorrhage and lack of efficacy, which was associated with low fibrin specificity. The search for new agents with a better risk-benefit profile continued until 1979 when tissue plasminogen activator (t-PA) was discovered. In 1983 it became possible to produce recombinant t-PA (rt-PA) by expression of a cloned gene which enabled clinical trials to be started, mainly for coronary thrombolysis. In 1995, the National Institute of Neurological Disorders and Stroke study showed that rt-PA was an effective treatment for AIS, nowadays for use up to 4.5 h after onset. However, rt-PA still often fails in achieving rapid reperfusion, has relatively low recanalization rates and is associated with an increased bleeding risk. Several attempts have been made to develop thrombolytics with a better risk-benefit profile than rt-PA, but no real impact on clinical practice was observed. In 1994, it was shown that tenecteplase (rt-PA-TNK) had a higher fibrin specificity than rt-PA, but its clinical use in AIS was described only in 2005. The recently reported results of a small phase 2B trial showed significantly better reperfusion and clinical outcome with rt-PA-TNK compared to rt-PA; patients were selected by CT perfusion and angiography, and treated within 6 h after stroke onset. Currently, a phase 3 trial of rt-PA-TNK versus rt-PA is being planned in patients at an onset up to 4.5 h. The most fibrin-specific recombinant plasminogen activator desmoteplase originates from 1991, and its clinical development in AIS started in 2005. Desmoteplase is in phase 3 development for the treatment of AIS between 3 and 9 h after onset in AIS patients presenting with occlusion or high-grade stenosis.</style></abstract><notes><style face="normal" font="default" size="100%">Rother, Joachim&#xD;Ford, Gary A&#xD;Thijs, Vincent N S&#xD;Historical Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Switzerland&#xD;Cerebrovasc Dis. 2013;35(4):313-9. doi: 10.1159/000348705. Epub 2013 Apr 23.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1159/000348705</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>21</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">21</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rutten, J. W.</style></author><author><style face="normal" font="default" size="100%">Klever, R. R.</style></author><author><style face="normal" font="default" size="100%">Hegeman, I. M.</style></author><author><style face="normal" font="default" size="100%">Poole, D. S.</style></author><author><style face="normal" font="default" size="100%">Dauwerse, H. G.</style></author><author><style face="normal" font="default" size="100%">Broos, L. A.</style></author><author><style face="normal" font="default" size="100%">Breukel, C.</style></author><author><style face="normal" font="default" size="100%">Aartsma-Rus, A. M.</style></author><author><style face="normal" font="default" size="100%">Verbeek, J. S.</style></author><author><style face="normal" font="default" size="100%">van der Weerd, L.</style></author><author><style face="normal" font="default" size="100%">van Duinen, S. G.</style></author><author><style face="normal" font="default" size="100%">van den Maagdenberg, A. M.</style></author><author><style face="normal" font="default" size="100%">Lesnik Oberstein, S. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands. j.w.rutten@lumc.nl.&#xD;Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands. r.r.klever@lumc.nl.&#xD;Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. i.m.hegeman@lumc.nl.&#xD;Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands. d.poole@lumc.nl.&#xD;Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands. j.g.dauwerse@lumc.nl.&#xD;Department of Clinical Genetics, K5-R, Leiden University Medical Center, PO Box 9600, 2300, RC, Leiden, The Netherlands. j.g.dauwerse@lumc.nl.&#xD;Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands. l.a.m.broos@lumc.nl.&#xD;Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands. c.breukel@lumc.nl.&#xD;Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands. a.m.aartsma-rus@lumc.nl.&#xD;Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands. j.s.verbeek@lumc.nl.&#xD;Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands. L.van_der_Weerd@lumc.nl.&#xD;Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands. L.van_der_Weerd@lumc.nl.&#xD;Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. S.G.van_Duinen@lumc.nl.&#xD;Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands. A.M.J.M.van_den_Maagdenberg@lumc.nl.&#xD;Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands. A.M.J.M.van_den_Maagdenberg@lumc.nl.&#xD;Department of Clinical Genetics, K5-R, Leiden University Medical Center, PO Box 9600, 2300, RC, Leiden, The Netherlands. lesnik@lumc.nl.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The NOTCH3 score: a pre-clinical CADASIL biomarker in a novel human genomic NOTCH3 transgenic mouse model with early progressive vascular NOTCH3 accumulation</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Neuropathol Commun</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Acta neuropathologica communications</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Neuropathol Commun</style></full-title><abbr-1><style face="normal" font="default" size="100%">Acta neuropathologica communications</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Acta Neuropathol Commun</style></full-title><abbr-1><style face="normal" font="default" size="100%">Acta neuropathologica communications</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">89</style></pages><volume><style face="normal" font="default" size="100%">3</style></volume><edition><style face="normal" font="default" size="100%">2015/12/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Analysis of Variance</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/metabolism/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">CADASIL/ genetics/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">DNA Mutational Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Microscopy, Electron</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Notch3</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Notch/ genetics/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 29</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2051-5960 (Electronic)&#xD;2051-5960 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26715087</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is a hereditary small vessel disease caused by mutations in the NOTCH3 gene, leading to toxic NOTCH3 protein accumulation in the small- to medium sized arterioles. The accumulation is systemic but most pronounced in the brain vasculature where it leads to clinical symptoms of recurrent stroke and dementia. There is no therapy for CADASIL, and therapeutic development is hampered by a lack of feasible clinical outcome measures and biomarkers, both in mouse models and in CADASIL patients. To facilitate pre-clinical therapeutic interventions for CADASIL, we aimed to develop a novel, translational CADASIL mouse model. RESULTS: We generated transgenic mice in which we overexpressed the full length human NOTCH3 gene from a genomic construct with the archetypal c.544C &gt; T, p.Arg182Cys mutation. The four mutant strains we generated have respective human NOTCH3 RNA expression levels of 100, 150, 200 and 350 % relative to endogenous mouse Notch3 RNA expression. Immunohistochemistry on brain sections shows characteristic vascular human NOTCH3 accumulation in all four mutant strains, with human NOTCH3 RNA expression levels correlating with age at onset and progression of NOTCH3 accumulation. This finding was the basis for developing the &apos;NOTCH3 score&apos;, a quantitative measure for the NOTCH3 accumulation load. This score proved to be a robust and sensitive method to assess the progression of NOTCH3 accumulation, and a feasible biomarker for pre-clinical therapeutic testing. CONCLUSIONS: This novel, translational CADASIL mouse model is a suitable model for pre-clinical testing of therapeutic strategies aimed at delaying or reversing NOTCH3 accumulation, using the NOTCH3 score as a biomarker.</style></abstract><notes><style face="normal" font="default" size="100%">Rutten, Julie W&#xD;Klever, Roselin R&#xD;Hegeman, Ingrid M&#xD;Poole, Dana S&#xD;Dauwerse, Hans G&#xD;Broos, Ludo A M&#xD;Breukel, Cor&#xD;Aartsma-Rus, Annemieke M&#xD;Verbeek, J Sjef&#xD;van der Weerd, Louise&#xD;van Duinen, Sjoerd G&#xD;van den Maagdenberg, Arn M J M&#xD;Lesnik Oberstein, Saskia A J&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Acta Neuropathol Commun. 2015 Dec 29;3:89. doi: 10.1186/s40478-015-0268-1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/772/art%253A10.1186%252Fs40478-015-0268-1.pdf?originUrl=http%3A%2F%2Factaneurocomms.biomedcentral.com%2Farticle%2F10.1186%2Fs40478-015-0268-1&amp;token2=exp=1484121905~acl=%2Fstatic%2Fpdf%2F772%2Fart%25253A10.1186%25252Fs40478-015-0268-1.pdf*~hmac=ae820565ebe6182123b97787ec02d2c1c15d4729668aff2e17fe55702ce2f15b</style></url></related-urls><pdf-urls><url>internal-pdf://3573583220/Rutten-2015-The NOTCH3 score_ a.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4696336</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s40478-015-0268-1</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>350</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">350</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ryg-Cornejo, V.</style></author><author><style face="normal" font="default" size="100%">Ioannidis, L. J.</style></author><author><style face="normal" font="default" size="100%">Hansen, D. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Walter and Eliza Hall Institute of Medical Research.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Isolation and analysis of brain-sequestered leukocytes from Plasmodium berghei ANKA-infected mice</style></title><secondary-title><style face="normal" font="default" size="100%">J Vis Exp</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of visualized experiments : JoVE</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Vis Exp</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of visualized experiments : JoVE</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Vis Exp</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of visualized experiments : JoVE</style></abbr-1></alt-periodical><number><style face="normal" font="default" size="100%">71</style></number><edition><style face="normal" font="default" size="100%">2013/01/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/blood supply/pathology/ surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Movement/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocytes/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/blood/parasitology/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium berghei/isolation &amp; purification</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 02</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1940-087X (Electronic)&#xD;1940-087X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23329000</style></accession-num><abstract><style face="normal" font="default" size="100%">We describe a method for isolation and characterization of adherent inflammatory cells from brain blood vessels of P. berghei ANKA-infected mice. Infection of susceptible mouse-strains with this parasite strain results in the induction of experimental cerebral malaria, a neurologic syndrome that recapitulates certain important aspects of Plasmodium falciparum-mediated severe malaria in humans. Mature forms of blood-stage malaria express parasitic proteins on the surface of the infected erythrocyte, which allows them to bind to vascular endothelial cells. This process induces obstructions in blood flow, resulting in hypoxia and haemorrhages and also stimulates the recruitment of inflammatory leukocytes to the site of parasite sequestration. Unlike other infections, i.e neutrotopic viruses, both malaria-parasitized red blood cells (pRBC) as well as associated inflammatory leukocytes remain sequestered within blood vessels rather than infiltrating the brain parenchyma. Thus to avoid contamination of sequestered leukocytes with non-inflammatory circulating cells, extensive intracardial perfusion of infected-mice prior to organ extraction and tissue processing is required in this procedure to remove the blood compartment. After perfusion, brains are harvested and dissected in small pieces. The tissue structure is further disrupted by enzymatic treatment with Collagenase D and DNAse I. The resulting brain homogenate is then centrifuged on a Percoll gradient that allows separation of brain-sequestered leukocytes (BSL) from myelin and other tissue debris. Isolated cells are then washed, counted using a hemocytometer and stained with fluorescent antibodies for subsequent analysis by flow cytometry. This procedure allows comprehensive phenotypic characterization of inflammatory leukocytes migrating to the brain in response to various stimuli, including stroke as well as viral or parasitic infections. The method also provides a useful tool for assessment of novel anti-inflammatory treatments in pre-clinical animal models.</style></abstract><notes><style face="normal" font="default" size="100%">Ryg-Cornejo, Victoria&#xD;Ioannidis, Lisa J&#xD;Hansen, Diana S&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Video-Audio Media&#xD;United States&#xD;J Vis Exp. 2013 Jan 2;(71). pii: 50112. doi: 10.3791/50112.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.jove.com/pdf/50112/jove-protocol-50112-isolation-analysis-brain-sequestered-leukocytes-from-plasmodium</style></url></related-urls><pdf-urls><url>internal-pdf://2754976195/Ryg-Cornejo-2013-Isolation and analys.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3582690</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3791/50112</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>441</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">441</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ryou, M. G.</style></author><author><style face="normal" font="default" size="100%">Liu, R.</style></author><author><style face="normal" font="default" size="100%">Ren, M.</style></author><author><style face="normal" font="default" size="100%">Sun, J.</style></author><author><style face="normal" font="default" size="100%">Mallet, R. T.</style></author><author><style face="normal" font="default" size="100%">Yang, S. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, 3500 Camp Bowie Boulevard, Fort Worth, TX 76107-2699, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pyruvate protects the brain against ischemia-reperfusion injury by activating the erythropoietin signaling pathway</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1101-7</style></pages><volume><style face="normal" font="default" size="100%">43</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2012/01/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Line, Tumor</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Erythropoietin/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia-Inducible Factor 1, alpha Subunit/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Proto-Oncogene Proteins c-akt/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Pyruvic Acid/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Erythropoietin/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/pathology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/metabolism/ therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22282883</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: Pyruvate is known to be cytoprotective through antioxidant and anti-inflammatory mechanisms. We tested the hypothesis that pyruvate protects the brain against ischemia-reperfusion injury by inducing endogenous erythropoietin (EPO) expression. METHODS: Pyruvate&apos;s protective effect was evaluated in C6 glioma cells and HT22 neuronal cells subjected to transient oxygen glucose deprivation. Cell viability (calcein AM assay) and expression of hypoxia-inducible factor-1alpha, EPO, Akt and Erk (immunoblot), and EPO receptor (reverse transcription-polymerase chain reaction) were analyzed. Transient focal cerebral ischemia in rats was induced by 2 hours middle cerebral artery occlusion followed by 24 hours reperfusion. Pyruvate or saline was infused from 60 minutes occlusion until 30 minutes reperfusion. Lesion volume and DNA fragmentation were assessed by 2,3,5-triphenyltetrazolium staining and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling assay, respectively. Immunoblots were conducted to determine cerebral EPO contents. RESULTS: Pyruvate increased cell viability, hypoxia-inducible factor-1alpha, EPO, and Akt phosphorylation. Small interfering RNA suppression of hypoxia-inducible factor-1alpha and EPO abolished pyruvate-induced cytoprotection. In the rat stroke model, pyruvate reduced lesion volume by 84% and DNA fragmentation by 77% versus controls; increased EPO content paralleled these cerebroprotective actions of pyruvate. CONCLUSIONS: Pyruvate activation of the hypoxia-inducible factor-1alpha-EPO signaling cascade in neurons and glia could protect the brain from ischemia-reperfusion injury.</style></abstract><notes><style face="normal" font="default" size="100%">Ryou, Myoung-Gwi&#xD;Liu, Ran&#xD;Ren, Ming&#xD;Sun, Jie&#xD;Mallet, Robert T&#xD;Yang, Shao-Hua&#xD;R01 NS076975-01/NS/NINDS NIH HHS/United States&#xD;R01 NS054687-03/NS/NINDS NIH HHS/United States&#xD;AG020494/AG/NIA NIH HHS/United States&#xD;NS054687/NS/NINDS NIH HHS/United States&#xD;T32 AG020494/AG/NIA NIH HHS/United States&#xD;R01 NS054687/NS/NINDS NIH HHS/United States&#xD;R01 NS054651-02/NS/NINDS NIH HHS/United States&#xD;R01 NS054651-05/NS/NINDS NIH HHS/United States&#xD;R01 NS054651-01A2/NS/NINDS NIH HHS/United States&#xD;R01 NS076975-02/NS/NINDS NIH HHS/United States&#xD;R01 NS054651/NS/NINDS NIH HHS/United States&#xD;R01 NS054687-02/NS/NINDS NIH HHS/United States&#xD;R01 NS054651-03/NS/NINDS NIH HHS/United States&#xD;R01 NS054687-04/NS/NINDS NIH HHS/United States&#xD;R01 NS076975/NS/NINDS NIH HHS/United States&#xD;R01 NS054651-04/NS/NINDS NIH HHS/United States&#xD;NS076975/NS/NINDS NIH HHS/United States&#xD;NS054651/NS/NINDS NIH HHS/United States&#xD;R01 NS054687-01A2/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;United States&#xD;Stroke. 2012 Apr;43(4):1101-7. doi: 10.1161/STROKEAHA.111.620088. Epub 2012 Jan 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/43/4/1101.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2510604525/Ryou-2012-Pyruvate protects th.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3314723</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms350318</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.111.620088</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>366</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">366</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sakata, H.</style></author><author><style face="normal" font="default" size="100%">Narasimhan, P.</style></author><author><style face="normal" font="default" size="100%">Niizuma, K.</style></author><author><style face="normal" font="default" size="100%">Maier, C. M.</style></author><author><style face="normal" font="default" size="100%">Wakai, T.</style></author><author><style face="normal" font="default" size="100%">Chan, P. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Neurosurgical Laboratories, Stanford University, Stanford, CA 94305-5487, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Interleukin 6-preconditioned neural stem cells reduce ischaemic injury in stroke mice</style></title><secondary-title><style face="normal" font="default" size="100%">Brain</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain : a journal of neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain : a journal of neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Brain</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain : a journal of neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">3298-310</style></pages><volume><style face="normal" font="default" size="100%">135</style></volume><number><style face="normal" font="default" size="100%">Pt 11</style></number><edition><style face="normal" font="default" size="100%">2012/11/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Angiogenesis Inducing Agents/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/metabolism/physiopathology/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Death/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Survival/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-6/antagonists &amp; inhibitors/ pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Neural Stem Cells/ drug effects/ transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Neurologic Examination/methods/statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery of Function/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">STAT3 Transcription Factor/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/physiopathology/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Superoxide Dismutase/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Endothelial Growth Factor A/secretion</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1460-2156 (Electronic)&#xD;0006-8950 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23169920</style></accession-num><abstract><style face="normal" font="default" size="100%">Transplantation of neural stem cells provides a promising therapy for stroke. Its efficacy, however, might be limited because of massive grafted-cell death after transplantation, and its insufficient capability for tissue repair. Interleukin 6 is a pro-inflammatory cytokine involved in the pathogenesis of various neurological disorders. Paradoxically, interleukin 6 promotes a pro-survival signalling pathway through activation of signal transducer and activator of transcription 3. In this study, we investigated whether cellular reprogramming of neural stem cells with interleukin 6 facilitates the effectiveness of cell transplantation therapy in ischaemic stroke. Neural stem cells harvested from the subventricular zone of foetal mice were preconditioned with interleukin 6 in vitro and transplanted into mouse brains 6 h or 7 days after transient middle cerebral artery occlusion. Interleukin 6 preconditioning protected the grafted neural stem cells from ischaemic reperfusion injury through signal transducer and activator of transcription 3-mediated upregulation of manganese superoxide dismutase, a primary mitochondrial antioxidant enzyme. In addition, interleukin 6 preconditioning induced secretion of vascular endothelial growth factor from the neural stem cells through activation of signal transducer and activator of transcription 3, resulting in promotion of angiogenesis in the ischaemic brain. Furthermore, transplantation of interleukin 6-preconditioned neural stem cells significantly attenuated infarct size and improved neurological performance compared with non-preconditioned neural stem cells. This interleukin 6-induced amelioration of ischaemic insults was abolished by transfecting the neural stem cells with signal transducer and activator of transcription 3 small interfering RNA before transplantation. These results indicate that preconditioning with interleukin 6, which reprograms neural stem cells to tolerate oxidative stress after ischaemic reperfusion injury and to induce angiogenesis through activation of signal transducer and activator of transcription 3, is a simple and beneficial approach for enhancing the effectiveness of cell transplantation therapy in ischaemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Sakata, Hiroyuki&#xD;Narasimhan, Purnima&#xD;Niizuma, Kuniyasu&#xD;Maier, Carolina M&#xD;Wakai, Takuma&#xD;Chan, Pak H&#xD;R01 NS025372/NS/NINDS NIH HHS/United States&#xD;P01 NS014543/NS/NINDS NIH HHS/United States&#xD;R01 NS038653/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Brain. 2012 Nov;135(Pt 11):3298-310. doi: 10.1093/brain/aws259.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://brain.oxfordjournals.org/content/brain/135/11/3298.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://4137206563/Sakata-2012-Interleukin 6-precon.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3501976</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/brain/aws259</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>428</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">428</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sakata, H.</style></author><author><style face="normal" font="default" size="100%">Niizuma, K.</style></author><author><style face="normal" font="default" size="100%">Yoshioka, H.</style></author><author><style face="normal" font="default" size="100%">Kim, G. S.</style></author><author><style face="normal" font="default" size="100%">Jung, J. E.</style></author><author><style face="normal" font="default" size="100%">Katsu, M.</style></author><author><style face="normal" font="default" size="100%">Narasimhan, P.</style></author><author><style face="normal" font="default" size="100%">Maier, C. M.</style></author><author><style face="normal" font="default" size="100%">Nishiyama, Y.</style></author><author><style face="normal" font="default" size="100%">Chan, P. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Department of Neurology and Neurological Sciences, and Program in Neurosciences and Department of Neurosurgery, Stanford University School of Medicine, Stanford, California 94305, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Minocycline-preconditioned neural stem cells enhance neuroprotection after ischemic stroke in rats</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">3462-73</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2012/03/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/pathology/ prevention &amp; control/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Death/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Preconditioning/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Minocycline/ pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Neural Stem Cells/drug effects/ transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Stem Cell Transplantation/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/pathology/ prevention &amp; control/surgery</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 07</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1529-2401 (Electronic)&#xD;0270-6474 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22399769</style></accession-num><abstract><style face="normal" font="default" size="100%">Transplantation of neural stem cells (NSCs) offers a novel therapeutic strategy for stroke; however, massive grafted cell death following transplantation, possibly due to a hostile host brain environment, lessens the effectiveness of this approach. Here, we have investigated whether reprogramming NSCs with minocycline, a broadly used antibiotic also known to possess cytoprotective properties, enhances survival of grafted cells and promotes neuroprotection in ischemic stroke. NSCs harvested from the subventricular zone of fetal rats were preconditioned with minocycline in vitro and transplanted into rat brains 6 h after transient middle cerebral artery occlusion. Histological and behavioral tests were examined from days 0-28 after stroke. For in vitro experiments, NSCs were subjected to oxygen-glucose deprivation and reoxygenation. Cell viability and antioxidant gene expression were analyzed. Minocycline preconditioning protected the grafted NSCs from ischemic reperfusion injury via upregulation of Nrf2 and Nrf2-regulated antioxidant genes. Additionally, preconditioning with minocycline induced the NSCs to release paracrine factors, including brain-derived neurotrophic factor, nerve growth factor, glial cell-derived neurotrophic factor, and vascular endothelial growth factor. Moreover, transplantation of the minocycline-preconditioned NSCs significantly attenuated infarct size and improved neurological performance, compared with non-preconditioned NSCs. Minocycline-induced neuroprotection was abolished by transfecting the NSCs with Nrf2-small interfering RNA before transplantation. Thus, preconditioning with minocycline, which reprograms NSCs to tolerate oxidative stress after ischemic reperfusion injury and express higher levels of paracrine factors through Nrf2 up-regulation, is a simple and safe approach to enhance the effectiveness of transplantation therapy in ischemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Sakata, Hiroyuki&#xD;Niizuma, Kuniyasu&#xD;Yoshioka, Hideyuki&#xD;Kim, Gab Seok&#xD;Jung, Joo Eun&#xD;Katsu, Masataka&#xD;Narasimhan, Purnima&#xD;Maier, Carolina M&#xD;Nishiyama, Yasuhiro&#xD;Chan, Pak H&#xD;R01 NS038653/NS/NINDS NIH HHS/United States&#xD;R01NS038653/NS/NINDS NIH HHS/United States&#xD;P01 NS014543/NS/NINDS NIH HHS/United States&#xD;R01 NS025372-23/NS/NINDS NIH HHS/United States&#xD;P01 NS014543-33/NS/NINDS NIH HHS/United States&#xD;R01 NS038653-15/NS/NINDS NIH HHS/United States&#xD;R01 NS025372/NS/NINDS NIH HHS/United States&#xD;Comparative Study&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Neurosci. 2012 Mar 7;32(10):3462-73. doi: 10.1523/JNEUROSCI.5686-11.2012.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.jneurosci.org/content/jneuro/32/10/3462.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1007145208/Sakata-2012-Minocycline-precondi.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3315362</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms362348</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1523/jneurosci.5686-11.2012</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>94</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">94</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sam, C.</style></author><author><style face="normal" font="default" size="100%">Li, F. F.</style></author><author><style face="normal" font="default" size="100%">Liu, S. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Genomics Research Center (One of the State-Province Key Laboratory of Biopharmaceutical Engineering, China), Harbin, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inherited neurovascular diseases affecting cerebral blood vessels and smooth muscle</style></title><secondary-title><style face="normal" font="default" size="100%">Metab Brain Dis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Metabolic brain disease</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Metab Brain Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Metabolic brain disease</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Metab Brain Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Metabolic brain disease</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1105-16</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2015/04/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/blood supply/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">CADASIL/diagnosis/genetics/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Arteries/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Veins/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Dwarfism/diagnosis/genetics/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Fetal Growth Retardation/diagnosis/genetics/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Leukoencephalopathies/diagnosis/genetics/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Marfan Syndrome/diagnosis/genetics/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Microcephaly/diagnosis/genetics/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Moyamoya Disease/diagnosis/genetics/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle, Smooth, Vascular/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Osteochondrodysplasias/diagnosis/genetics/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Telangiectasia, Hereditary Hemorrhagic/diagnosis/genetics/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Diseases/ diagnosis/ genetics/therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1573-7365 (Electronic)&#xD;0885-7490 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25893882</style></accession-num><abstract><style face="normal" font="default" size="100%">Neurovascular diseases are among the leading causes of mortality and permanent disability due to stroke, aneurysm, and other cardiovascular complications. Cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) and Marfan syndrome are two neurovascular disorders that affect smooth muscle cells through accumulation of granule and osmiophilic materials and defective elastic fiber formations respectively. Moyamoya disease, hereditary hemorrhagic telangiectasia (HHT), microcephalic osteodysplastic primordial dwarfism type II (MOPD II), and Fabry&apos;s disease are disorders that affect the endothelium cells of blood vessels through occlusion or abnormal development. While much research has been done on mapping out mutations in these diseases, the exact mechanisms are still largely unknown. This paper briefly introduces the pathogenesis, genetics, clinical symptoms, and current methods of treatment of the diseases in the hope that it can help us better understand the mechanism of these diseases and work on ways to develop better diagnosis and treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Sam, Christine&#xD;Li, Fei-Feng&#xD;Liu, Shu-Lin&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;United States&#xD;Metab Brain Dis. 2015 Oct;30(5):1105-16. doi: 10.1007/s11011-015-9668-y. Epub 2015 Apr 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/917/art%253A10.1007%252Fs11011-015-9668-y.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs11011-015-9668-y&amp;token2=exp=1484122828~acl=%2Fstatic%2Fpdf%2F917%2Fart%25253A10.1007%25252Fs11011-015-9668-y.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs11011-015-9668-y*~hmac=f2753917720a27869a2006f0e0bbfbaaa46f6221613f7875291c2a042db3fbb2</style></url></related-urls><pdf-urls><url>internal-pdf://0413391077/Sam-2015-Inherited neurovascu.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s11011-015-9668-y</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>139</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">139</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sarbu, N.</style></author><author><style face="normal" font="default" size="100%">Alobeidi, F.</style></author><author><style face="normal" font="default" size="100%">Toledano, P.</style></author><author><style face="normal" font="default" size="100%">Espinosa, G.</style></author><author><style face="normal" font="default" size="100%">Giles, I.</style></author><author><style face="normal" font="default" size="100%">Rahman, A.</style></author><author><style face="normal" font="default" size="100%">Yousry, T.</style></author><author><style face="normal" font="default" size="100%">Capurro, S.</style></author><author><style face="normal" font="default" size="100%">Jager, R.</style></author><author><style face="normal" font="default" size="100%">Cervera, R.</style></author><author><style face="normal" font="default" size="100%">Bargallo, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neuroradiology, Hospital Clinic, Barcelona, Catalonia, Spain.&#xD;Department of Neuroradiology, The National Hospital of Neurology and Neurosurgery, London, UK.&#xD;Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Catalonia, Spain.&#xD;Department of Rheumatology, University College Hospital, London, UK.&#xD;Department of Neuroradiology, Hospital Clinic, Barcelona, Catalonia, Spain; Magnetic Resonance Imaging Core Facility, Institut d&apos;Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain. Electronic address: bargallo@clinic.cat.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Autoimmun Rev</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Autoimmunity reviews</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Autoimmun Rev</style></full-title><abbr-1><style face="normal" font="default" size="100%">Autoimmunity reviews</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Autoimmun Rev</style></full-title><abbr-1><style face="normal" font="default" size="100%">Autoimmunity reviews</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">153-9</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2014/12/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lupus Vasculitis, Central Nervous System/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1873-0183 (Electronic)&#xD;1568-9972 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25461835</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVES: To describe brain magnetic resonance imaging (MRI) abnormalities in newly diagnosed neuropsychiatric lupus (NPSLE). To correlate them with clinical and laboratory data. METHODS: This retrospective cross-sectional study included patients presenting NPSLE undergoing brain MRI within 6 months after onset between 2003 and 2012. Clinical and laboratory data were recorded. MRI findings were defined as inflammatory-like, large-vessel disease (LVD), and small-vessel disease (SVD); SVD was classified as white-matter hyperintensities (WMH), recent small subcortical infarcts, lacunes, microbleeds, and brain atrophy. RESULTS: We included 108 patients (mean 40.6 +/- 14.2 years; range 14-77), 91.7% women. The most frequent syndromes were headache (28.5%), cerebrovascular disease (15.5%), seizure (15.5%), and cognitive dysfunction (11.4%). Brain abnormalities were found in 59.3%. SVD was the most common (55.6%), followed by LVD (13%) and inflammatory-like lesions (6.5%). The most frequent SVD findings were WMH (53.7%), atrophy (18.5%), microbleeds (13.7%) and lacunes (11.1%). Cerebrovascular syndrome correlated with LVD (p = 0.001) and microbleeds (p = 0.002), cognitive dysfunction with WMH (p = 0.045) and myelopathy with inflammatory-like lesions (p = 0.020). Low C4 and CH50 correlated with inflammatory-like lesions (p &lt; 0.001, p = 0.019) and lupus anticoagulant with WMH (p = 0.018), microbleeds (p = 0.002) and atrophy (p = 0.008). CONCLUSIONS: Vascular disease is the hallmark of NPSLE. Certain syndromes and immunological patterns are prone to more extensive brain damage. MRI could provide significant clinical information and insights into the pathological substrate.</style></abstract><notes><style face="normal" font="default" size="100%">Sarbu, Nicolae&#xD;Alobeidi, Farah&#xD;Toledano, Pilar&#xD;Espinosa, Gerard&#xD;Giles, Ian&#xD;Rahman, Anisur&#xD;Yousry, Tarek&#xD;Capurro, Sebastian&#xD;Jager, Rolf&#xD;Cervera, Ricard&#xD;Bargallo, Nuria&#xD;Review&#xD;Netherlands&#xD;Autoimmun Rev. 2015 Feb;14(2):153-9. doi: 10.1016/j.autrev.2014.11.001. Epub 2014 Nov 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S1568997214002596/1-s2.0-S1568997214002596-main.pdf?_tid=061d503e-d7d4-11e6-8348-00000aab0f27&amp;acdnat=1484121811_5369565e7befdebf3624729299c306d2</style></url></related-urls><pdf-urls><url>internal-pdf://0854517496/Sarbu-2015-Brain abnormalities.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.autrev.2014.11.001</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>268</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">268</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sawada, H.</style></author><author><style face="normal" font="default" size="100%">Nishimura, N.</style></author><author><style face="normal" font="default" size="100%">Suzuki, E.</style></author><author><style face="normal" font="default" size="100%">Zhuang, J.</style></author><author><style face="normal" font="default" size="100%">Hasegawa, K.</style></author><author><style face="normal" font="default" size="100%">Takamatsu, H.</style></author><author><style face="normal" font="default" size="100%">Honda, K.</style></author><author><style face="normal" font="default" size="100%">Hasumi, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Research and Development, TMS Co., Ltd., Tokyo, Japan.&#xD;Department of Applied Biological Science, Tokyo Noko University, Tokyo, Japan.&#xD;Hamamatsu Pharma Research, Hamamatsu, Japan.&#xD;Department of Pharmacology, Showa University, Tokyo, Japan.&#xD;1] Division of Research and Development, TMS Co., Ltd., Tokyo, Japan [2] Department of Applied Biological Science, Tokyo Noko University, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">SMTP-7, a novel small-molecule thrombolytic for ischemic stroke: a study in rodents and primates</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">235-41</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2013/11/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/ drug therapy/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Evaluation, Preclinical</style></keyword><keyword><style face="normal" font="default" size="100%">Fibrinolytic Agents/chemistry/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ drug therapy/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Macaca fascicularis</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred ICR</style></keyword><keyword><style face="normal" font="default" size="100%">Phenols/chemistry/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Stachybotrys/ chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ drug therapy/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombolytic Therapy/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombosis/drug therapy/physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24192639</style></accession-num><abstract><style face="normal" font="default" size="100%">SMTP-7 (Stachybotrys microspora triprenyl phenol-7), a small molecule that promotes plasminogen activation through the modulation of plasminogen conformation, has excellent therapeutic activity against cerebral infarction in several rodent models. Detailed evaluations of SMTP-7 in a primate stroke model are needed for effective, safe drug development. Here we evaluated SMTP-7 in a monkey photochemical-induced thrombotic middle cerebral artery (MCA) occlusion model (n=6), in which MCA occlusion was followed by recanalization/reocclusion. SMTP-7 (10 mg/kg, intravenous infusion) significantly increased the postinfusion MCA recanalization rate (32.5-fold, P=0.043) and ameliorated the post-24-h neurologic deficit (by 29%, P=0.02), cerebral infarct (by 46%, P=0.033), and cerebral hemorrhage (by 51%, P=0.013) compared with the vehicle control animals. In normal monkeys, SMTP-7 did not affect general physiologic or hemostatic variables, including coagulation and platelet parameters. Investigations in rodent models of transient and permanent focal cerebral ischemia, as well as arterial thrombosis and bleeding tests, suggest a role for SMTP-7&apos;s regulated profibrinolytic action and neuroprotective properties in the monkey MCA occlusion model. In conclusion, SMTP-7 is effective in treating thrombotic stroke in monkeys. SMTP-7 is thus a promising candidate for the development of alternative therapy for ischemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Sawada, Hironobu&#xD;Nishimura, Naoko&#xD;Suzuki, Eriko&#xD;Zhuang, Jie&#xD;Hasegawa, Keiko&#xD;Takamatsu, Hiroyuki&#xD;Honda, Kazuo&#xD;Hasumi, Keiji&#xD;United States&#xD;J Cereb Blood Flow Metab. 2014 Feb;34(2):235-41. doi: 10.1038/jcbfm.2013.191. Epub 2013 Nov 6.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3915202</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2013.191</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>483</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">483</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schreiber, S.</style></author><author><style face="normal" font="default" size="100%">Bueche, C. Z.</style></author><author><style face="normal" font="default" size="100%">Garz, C.</style></author><author><style face="normal" font="default" size="100%">Kropf, S.</style></author><author><style face="normal" font="default" size="100%">Angenstein, F.</style></author><author><style face="normal" font="default" size="100%">Goldschmidt, J.</style></author><author><style face="normal" font="default" size="100%">Neumann, J.</style></author><author><style face="normal" font="default" size="100%">Heinze, H. J.</style></author><author><style face="normal" font="default" size="100%">Goertler, M.</style></author><author><style face="normal" font="default" size="100%">Reymann, K. G.</style></author><author><style face="normal" font="default" size="100%">Braun, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Klinik fur Neurologie, Otto-von-Guericke Universitat, Magdeburg, Germany. stefanie.schreiber@med.ovgu.de</style></auth-address><titles><title><style face="normal" font="default" size="100%">The pathologic cascade of cerebrovascular lesions in SHRSP: is erythrocyte accumulation an early phase?</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">278-90</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2011/09/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ blood supply/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Small Vessel Diseases/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Erythrocytes/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Microvessels/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred SHR</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Tomography, Emission-Computed, Single-Photon</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">21878945</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebral small vessel disease (CSVD) is associated with vessel wall changes, microbleeds, blood-brain barrier (BBB) disturbances, and reduced cerebral blood flow (CBF). As spontaneously hypertensive stroke-prone rats (SHRSP) may be a valid model of some aspects of human CSVD, we aimed to identify whether those changes occur in definite temporal stages and whether there is an initial phenomenon beyond those common vascular alterations. Groups of 51 SHRSP were examined simultaneously by histologic (Hematoxylin-Eosin, IgG-Immunohistochemistry, vessel diameter measurement) and imaging methods (Magnetic Resonance Imaging, 201-Thallium-Diethyldithiocarbamate/99m-Technetium-HMPAO Single Photon Emission Computed Tomography conducted as pilot study) at different stages of age. Vascular pathology in SHRSP proceeds in definite stages, whereas an age-dependent accumulation of erythrocytes in capillaries and arterioles represents the homogeneous initial step of the disease. Erythrocyte accumulations are followed by BBB disturbances and microbleeds, both also increasing with age. Microthromboses, tissue infarctions with CBF reduction, and disturbed potassium uptake represent the final stage of vascular pathology in SHRSP. Erythrocyte accumulations--we parsimoniously interpreted as stases--without cerebral tissue damage represent the first step of vascular pathology in SHRSP. If that initial phenomenon could be identified in patients, these erythrocyte accumulations might be a promising target for implementing prophylactic and therapeutic strategies in human CSVD.</style></abstract><notes><style face="normal" font="default" size="100%">Schreiber, Stefanie&#xD;Bueche, Celine Z&#xD;Garz, Cornelia&#xD;Kropf, Siegfried&#xD;Angenstein, Frank&#xD;Goldschmidt, Juergen&#xD;Neumann, Jens&#xD;Heinze, Hans-Jochen&#xD;Goertler, Michael&#xD;Reymann, Klaus G&#xD;Braun, Holger&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Cereb Blood Flow Metab. 2012 Feb;32(2):278-90. doi: 10.1038/jcbfm.2011.122. Epub 2011 Aug 31.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3272595</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2011.122</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>466</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">466</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schrigten, D.</style></author><author><style face="normal" font="default" size="100%">Breyholz, H. J.</style></author><author><style face="normal" font="default" size="100%">Wagner, S.</style></author><author><style face="normal" font="default" size="100%">Hermann, S.</style></author><author><style face="normal" font="default" size="100%">Schober, O.</style></author><author><style face="normal" font="default" size="100%">Schafers, M.</style></author><author><style face="normal" font="default" size="100%">Haufe, G.</style></author><author><style face="normal" font="default" size="100%">Kopka, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Nuclear Medicine, University Hospital Munster, Albert-Schweitzer-Campus 1, Building A1, D-48149 Munster, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography</style></title><secondary-title><style face="normal" font="default" size="100%">J Med Chem</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of medicinal chemistry</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Med Chem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of medicinal chemistry</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Med Chem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of medicinal chemistry</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">223-32</style></pages><volume><style face="normal" font="default" size="100%">55</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2011/11/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Stability</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorine Radioisotopes</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Matrix Metalloproteinase Inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Matrix Metalloproteinases/chemistry/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">Polyethylene Glycols/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Positron-Emission Tomography</style></keyword><keyword><style face="normal" font="default" size="100%">Pyrimidines/ chemical synthesis/chemistry/pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Radiopharmaceuticals/ chemical synthesis/chemistry/pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Structure-Activity Relationship</style></keyword><keyword><style face="normal" font="default" size="100%">Tissue Distribution</style></keyword><keyword><style face="normal" font="default" size="100%">Triazoles/chemical synthesis/chemistry/pharmacology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 12</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1520-4804 (Electronic)&#xD;0022-2623 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22118188</style></accession-num><abstract><style face="normal" font="default" size="100%">Radiolabeled C-5-disubstituted pyrimidine-2,4,6-triones have recently been suggested by our group as a class of potent matrix metalloproteinase (MMP) targeted radiotracers that can noninvasively visualize activated MMPs by means of positron emission tomography (PET). MMPs belong to the zinc- and calcium-dependent endopeptidases which are involved in the proteolytic degradation of components of the extracellular matrix (ECM) but also are capable of processing and releasing bioactive molecules such as growth factors, proteinase inhibitors, and cytokines. Locally increased levels of activated MMPs modulate and contribute to the progression of various diseases, such as cancer, atherosclerosis, stroke, arthritis, and others. Therefore, activated MMPs are suitable biological targets for the specific and noninvasive visualization of aforementioned pathologies in vivo. On the basis of our recent results, we here describe a series of new fluorinated pyrimidine-2,4,6-triones of the second generation with maintained MMP inhibition potencies (IC(50) = 4-605 nM), which are fine-tuned toward more hydrophilic versions, and show the improved biodistribution behavior of one selected radiofluorinated pyrimidine-2,4,6-trione by means of small-animal PET.</style></abstract><notes><style face="normal" font="default" size="100%">Schrigten, Daniela&#xD;Breyholz, Hans-Jorg&#xD;Wagner, Stefan&#xD;Hermann, Sven&#xD;Schober, Otmar&#xD;Schafers, Michael&#xD;Haufe, Gunter&#xD;Kopka, Klaus&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Med Chem. 2012 Jan 12;55(1):223-32. doi: 10.1021/jm201142w. Epub 2011 Dec 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://pubs.acs.org/doi/pdfplus/10.1021/jm201142w</style></url></related-urls><pdf-urls><url>internal-pdf://0495515531/Schrigten-2012-A new generation of.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/jm201142w</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>30</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">30</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Selhub, J.</style></author><author><style face="normal" font="default" size="100%">Troen, A. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Jean Mayer Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts.&#xD;Nutrition and Brain Health Laboratory, The Institute of Biochemistry Food and Nutrition Science, The Robert H. Smith Faculty of Agriculture Food and the Environment, The Hebrew University of Jerusalem, Israel.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sulfur amino acids and atherosclerosis: a role for excess dietary methionine</style></title><secondary-title><style face="normal" font="default" size="100%">Ann N Y Acad Sci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Annals of the New York Academy of Sciences</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Ann N Y Acad Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Annals of the New York Academy of Sciences</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Ann N Y Acad Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Annals of the New York Academy of Sciences</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">18-25</style></pages><volume><style face="normal" font="default" size="100%">1363</style></volume><edition><style face="normal" font="default" size="100%">2015/12/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Amino Acids, Sulfur/blood/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apolipoproteins E/deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Atherosclerosis/blood/ etiology/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Chemical Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Homocysteine/blood/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolic Networks and Pathways</style></keyword><keyword><style face="normal" font="default" size="100%">Methionine/blood/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Plaque, Atherosclerotic/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1749-6632 (Electronic)&#xD;0077-8923 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26647293</style></accession-num><abstract><style face="normal" font="default" size="100%">The homocysteine theory of arteriosclerosis received credence when it was shown that after a methionine load, circulating homocysteine-cysteine concentrations were higher in cardiovascular disease patients than in healthy controls. Subsequent studies showing associations between homocysteine and coronary artery disease, stroke and cognitive impairment, relied on small increases in homocysteine concentration unlike the very high homocysteine seen in the rare genetic disorders that lead to homocystinuria and much higher homocysteine levels. Subsequent studies in cell culture, animals, and humans showed that a variety of cardiovascular adverse effects of &quot;high homocysteine&quot; introduced either as a nonphysiological bolus or as a methionine load led to high homocysteine. We fed apolipoprotein E-deficient mice diets designed to achieve three conditions: (1) high methionine intake with normal blood homocysteine, (2) high methionine intake with B vitamin deficiency and hyperhomocysteinemia, and (3) normal methionine intake with both B vitamin deficiency and hyperhomocysteinemia. We found that the mice fed methionine-rich diets had significant atheromatous pathology in the aortic arch even with normal plasma homocysteine levels. Mice fed B vitamin-deficient diets developed severe hyperhomocysteinemia but without any increase in vascular pathology. Our findings suggest that even moderate increases in methionine intake are atherogenic in susceptible mice while high plasma homocysteine is not.</style></abstract><notes><style face="normal" font="default" size="100%">Selhub, Jacob&#xD;Troen, Aron M&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Ann N Y Acad Sci. 2016 Jan;1363:18-25. doi: 10.1111/nyas.12962. Epub 2015 Dec 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/nyas.12962/asset/nyas12962.pdf?v=1&amp;t=ixsnpddy&amp;s=924b9e093f5e1dee90fd629eb623ebeac60f0e5b</style></url></related-urls><pdf-urls><url>internal-pdf://3240429661/Selhub-2016-Sulfur amino acids a.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/nyas.12962</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>248</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">248</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Selvamani, A.</style></author><author><style face="normal" font="default" size="100%">Williams, M. H.</style></author><author><style face="normal" font="default" size="100%">Miranda, R. C.</style></author><author><style face="normal" font="default" size="100%">Sohrabji, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">*Women&apos;s Health in Neuroscience Program, Neuroscience and Experimental Therapeutics, Texas A&amp;M College of Medicine, Bryan, TX 77807, U.S.A.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Circulating miRNA profiles provide a biomarker for severity of stroke outcomes associated with age and sex in a rat model</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Sci (Lond)</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Clinical science (London, England : 1979)</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Sci (Lond)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Clinical science (London, England : 1979)</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Clin Sci (Lond)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Clinical science (London, England : 1979)</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">77-89</style></pages><volume><style face="normal" font="default" size="100%">127</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2014/01/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aging</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling/methods</style></keyword><keyword><style face="normal" font="default" size="100%">MicroRNAs/ genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Oligonucleotide Array Sequence Analysis/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphatidylinositol 3-Kinases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Sex Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1470-8736 (Electronic)&#xD;0143-5221 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24428837</style></accession-num><abstract><style face="normal" font="default" size="100%">Small non-coding RNA [miRNA (microRNA)] found in the circulation have been used successfully as biomarkers and mechanistic targets for chronic and acute disease. The present study investigated the impact of age and sex on miRNA expression following ischaemic stroke in an animal model. Adult (6 month) and middle-aged (11-12 months) female and male rats were subject to MCAo (middle cerebral artery occlusion) using ET-1 (endothelin-1). Circulating miRNAs were analysed in blood samples at 2 and 5 days post-stroke, and brain miRNAs were analysed at 5 days post-stroke. Although stroke-associated infarction was observed in all groups, infarct volume and sensory-motor deficits were significantly reduced in adult females compared with middle-aged females, adult males or middle-aged males. At 2 days post-stroke, 21 circulating miRNAs were differentially regulated and PCA (principal component analysis) confirmed that most of the variance was due to age. At 5 days post-stroke, 78 circulating miRNAs exhibited significantly different regulation, and most of the variance was associated with sex. A small cohort (five) of miRNAs, miR-15a, miR-19b, miR-32 miR-136 and miR-199a-3p, were found to be highly expressed exclusively in adult females compared with middle-aged females, adult males and middle-aged males. Predicted gene targets for these five miRNAs analysed for KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways revealed that the top ten KEGG pathways were related to growth factor signalling, cell structure and PI3K (phosphoinositide 3-kinase)/Akt and mTOR (mammalian target of rapamycin) signalling. Overall, the pattern of circulating miRNA expression suggests an early influence of age in stroke pathology, with a later emergence of sex as a factor for stroke severity.</style></abstract><notes><style face="normal" font="default" size="100%">Selvamani, Amutha&#xD;Williams, Madison H&#xD;Miranda, Rajesh C&#xD;Sohrabji, Farida&#xD;R01 AG042189/AG/NIA NIH HHS/United States&#xD;R01 NS074895/NS/NINDS NIH HHS/United States&#xD;AG042189/AG/NIA NIH HHS/United States&#xD;NS074895/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Clin Sci (Lond). 2014 Jul;127(2):77-89. doi: 10.1042/CS20130565.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.clinsci.org/content/ppclinsci/127/2/77.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1532439290/Selvamani-2014-Circulating miRNA pr.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4386587</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms576534</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1042/cs20130565</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>450</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">450</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sharma, A.</style></author><author><style face="normal" font="default" size="100%">Muresanu, D. F.</style></author><author><style face="normal" font="default" size="100%">Mossler, H.</style></author><author><style face="normal" font="default" size="100%">Sharma, H. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Cerebrovascular Research, Department of Surgical Sciences, Anesthesiology and Intensive Care Medicine, University Hospital, Uppsala University, SE-75185 Uppsala, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Superior neuroprotective effects of cerebrolysin in nanoparticle-induced exacerbation of hyperthermia-induced brain pathology</style></title><secondary-title><style face="normal" font="default" size="100%">CNS Neurol Disord Drug Targets</style></secondary-title><alt-title><style face="normal" font="default" size="100%">CNS &amp; neurological disorders drug targets</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">CNS Neurol Disord Drug Targets</style></full-title><abbr-1><style face="normal" font="default" size="100%">CNS &amp; neurological disorders drug targets</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">CNS Neurol Disord Drug Targets</style></full-title><abbr-1><style face="normal" font="default" size="100%">CNS &amp; neurological disorders drug targets</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">7-25</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2012/01/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Amino Acids/administration &amp; dosage/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Anticonvulsants/administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/chemically induced/ drug therapy/ etiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/drug effects/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Heat Stroke/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Metal Nanoparticles/ toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/administration &amp; dosage/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1996-3181 (Electronic)&#xD;1871-5273 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22229316</style></accession-num><abstract><style face="normal" font="default" size="100%">In recent years, the incidence of heat stroke and associated brain pathology are increasing Worldwide. More than half of the world&apos;s population are living in areas associated with high environmental heat especially during the summer seasons. Thus, new research is needed using novel drug targets to achieve neuroprotection in heat-induced brain pathology. Previous research from our laboratory showed that the pathophysiology of brain injuries following heat stroke are exacerbated by chronic intoxication of engineered nanoparticles of small sizes (50-60 nm) following identical heat exposure in rats. Interestingly, in nanoparticle-intoxicated animals the known neuroprotective agents in standard doses failed to induce effective neuroprotection. This suggests that the dose-response of the drugs either requires modification or new therapeutic agents are needed to provide better neuroprotection in nanoparticle-intoxicated animals after heat stroke. This review is focused on the use of cerebrolysin, a mixture of several neurotrophic factors and active peptide fragments, in relation to other neuroprotective agents normally used to treat ischemic stroke in clinics in nanoparticle-induced exacerbation of brain damage in heat stroke. It appears that cerebrolysin exerts the most superior neuroprotective effects in heat stress as compared to other neuroprotective agents on brain pathology in normal rats. Interestingly, to induce effective neuroprotection in nanoparticle-induced exacerbation of brain pathology a double dose of cerebrolysin is needed. On the other hand, double doses of the other drugs were quite ineffective in reducing brain damage. These observations suggest that the drug type and doses are important factors in attenuating nanoparticle-induced exacerbation of brain pathology in heat stroke. The functional significance and possible mechanisms of drug-induced neuroprotection in nanoparticle-treated, heat-stressed rats are discussed.</style></abstract><notes><style face="normal" font="default" size="100%">Sharma, Aruna&#xD;Muresanu, Dafin Fior&#xD;Mossler, Herbert&#xD;Sharma, Hari Shanker&#xD;Comparative Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, P.H.S.&#xD;Review&#xD;United Arab Emirates&#xD;CNS Neurol Disord Drug Targets. 2012 Feb;11(1):7-25.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>60</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">60</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shen, H.</style></author><author><style face="normal" font="default" size="100%">Chen, Z.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Gao, A.</style></author><author><style face="normal" font="default" size="100%">Li, H.</style></author><author><style face="normal" font="default" size="100%">Cui, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Xu, X.</style></author><author><style face="normal" font="default" size="100%">Wang, Z.</style></author><author><style face="normal" font="default" size="100%">Chen, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From the Department of Neurosurgery &amp; Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, China (H.S., Z.C., Y.W., A.G., H.L., Y.C., L.Z., X.X., Z.W., G.C.); and Department of Neurosurgery, Anhui Provincial Hospital Affiliated to Anhui Medical University, Anhui Province Key Laboratory of Brain Function and Brain Disease, Hefei, Anhui, China (Y.W.).&#xD;From the Department of Neurosurgery &amp; Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, China (H.S., Z.C., Y.W., A.G., H.L., Y.C., L.Z., X.X., Z.W., G.C.); and Department of Neurosurgery, Anhui Provincial Hospital Affiliated to Anhui Medical University, Anhui Province Key Laboratory of Brain Function and Brain Disease, Hefei, Anhui, China (Y.W.). nju_neurosurgery@163.com dr_zhongwang@126.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Role of Neurexin-1beta and Neuroligin-1 in Cognitive Dysfunction After Subarachnoid Hemorrhage in Rats</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">2607-15</style></pages><volume><style face="normal" font="default" size="100%">46</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2015/07/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Behavior, Animal/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Adhesion Molecules, Neuronal/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition Disorders/ metabolism/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Tissue Proteins/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Subarachnoid Hemorrhage/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26219651</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: Neurexin-1beta and neuroligin-1 play an important role in the formation, maintenance, and regulation of synaptic structures. This study is to estimate the potential role of neurexin-1beta and neuroligin-1 in subarachnoid hemorrhage (SAH)-induced cognitive dysfunction. METHODS: In vivo, 228 Sprague-Dawley rats were used. An experimental SAH model was induced by single blood injection to prechiasmatic cistern. Primary cultured hippocampal neurons were exposed to oxyhemoglobin to mimic SAH in vitro. Specific small interfering RNAs and expression plasmids for neurexin-1beta and neuroligin-1 were exploited both in vivo and in vitro. Western blot, immunofluorescence, immunoprecipitation, neurological scoring, and Morris water maze were performed to evaluate the mechanism of neurexin-1beta and neuroligin-1, as well as neurological outcome. RESULTS: Both in vivo and in vitro experiments showed SAH-induced decrease in the expressions of neurexin-1beta and neuroligin-1 and the interaction between neurexin-1beta and neuroligin-1 in neurons. In addition, the interaction between neurexin-1beta and neuroligin-1 was reduced by their knockdown and increased by their overexpression. The formation of excitatory synapses was inhibited by oxyhemoglobin treatment, which was significantly ameliorated by overexpression of neurexin-1beta and neuroligin-1 and aggravated by the knockdown of neurexin-1beta and neuroligin-1. More importantly, neurexin-1beta and neuroligin-1 overexpression ameliorated SAH-induced cognitive dysfunction, whereas neurexin-1beta and neuroligin-1 knockdown induced an opposite effect. CONCLUSIONS: Enhancing the expressions of neurexin-1beta and neuroligin-1 could promote the interaction between them and the formation of excitatory synapses, which is helpful to improve cognitive dysfunction after SAH. Neurexin-1beta and neuroligin-1 might be good targets for improving cognitive function after SAH.</style></abstract><notes><style face="normal" font="default" size="100%">Shen, Haitao&#xD;Chen, Zhouqing&#xD;Wang, Yang&#xD;Gao, Anju&#xD;Li, Haiying&#xD;Cui, Yonghua&#xD;Zhang, Li&#xD;Xu, Xiang&#xD;Wang, Zhong&#xD;Chen, Gang&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Stroke. 2015 Sep;46(9):2607-15. doi: 10.1161/STROKEAHA.115.009729. Epub 2015 Jul 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/46/9/2607.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3939731385/Shen-2015-Role of Neurexin-1be.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4542569</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.115.009729</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>137</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">137</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shen, J.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Song, Y.</style></author><author><style face="normal" font="default" size="100%">Li, L.</style></author><author><style face="normal" font="default" size="100%">Duan, C.</style></author><author><style face="normal" font="default" size="100%">Zhou, Y.</style></author><author><style face="normal" font="default" size="100%">Ke, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China; Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Medical College of Nantong University, Nantong, Jiangsu Province 226001, China.&#xD;Department of Pathogen Biology, Medical College, Nantong University, Nantong 226001, Jiangsu Province, China; Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Medical College of Nantong University, Nantong, Jiangsu Province 226001, China.&#xD;Department of Neurology, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China.&#xD;The Jiangsu Province Key Laboratory of Neuroregeneration, Nantong University, Nantong, China; Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Medical College of Nantong University, Nantong, Jiangsu Province 226001, China.&#xD;Department of Neurology, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China; Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Medical College of Nantong University, Nantong, Jiangsu Province 226001, China. Electronic address: kekaifu_ntfy@126.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">CHMP4B, ESCRT-III associating protein, associated with neuronal apoptosis following intracerebral hemorrhage</style></title><secondary-title><style face="normal" font="default" size="100%">Brain Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1-13</style></pages><volume><style face="normal" font="default" size="100%">1597</style></volume><edition><style face="normal" font="default" size="100%">2014/12/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, CD95/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Blotting, Western</style></keyword><keyword><style face="normal" font="default" size="100%">Caspase 3/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Caspase 8/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Fas Ligand Protein/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorescent Antibody Technique</style></keyword><keyword><style face="normal" font="default" size="100%">Hematoma/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Hemin</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Motor Activity/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/pathology/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">PC12 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">RNA Interference</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Vesicular Transport Proteins/genetics/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 09</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-6240 (Electronic)&#xD;0006-8993 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25478783</style></accession-num><abstract><style face="normal" font="default" size="100%">Charged multivesicular body protein (CHMP) represents a family of small helical proteins that contain an N-terminal basically charged region and a smaller C-terminal acidic region, which are highly conserved in all eukaryotes. CHMP4B, a core component of the endosomal sorting complex required for transport (ESCRT)-III, is requisite for endosomal sorting and other biological processes. Here, we demonstrate that CHMP4B may be involved in neuronal apoptosis in the processes of intracerebral hemorrhage (ICH). From the results of Western blot, immunohistochemistry and immunofluorescence, we obtained a significant up-regulation of CHMP4B in neurons adjacent to the hematoma following ICH. Increasing CHMP4B level was found to be accompanied by the up-regulation of Fas receptor (Fas), Fas ligand (FasL), active caspase-8, and active caspase-3. Besides, CHMP4B co-localized well with Fas and active caspase-3 in neurons, indicating its potential role in neuronal apoptosis. What&apos;s more, our in vitro study, using CHMP4B RNA interference in PC12 cells, further confirmed that CHMP4B might exert its pro-apoptotic function on neuronal apoptosis through extrinsic pathway. Thus, CHMP4B may play a role in promoting the brain damage following ICH.</style></abstract><notes><style face="normal" font="default" size="100%">Shen, Jiabing&#xD;Liu, Yonghua&#xD;Song, Yan&#xD;Li, Lei&#xD;Duan, Chengwei&#xD;Zhou, Ying&#xD;Ke, Kaifu&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;Brain Res. 2015 Feb 9;1597:1-13. doi: 10.1016/j.brainres.2014.11.043. Epub 2014 Dec 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0006899314016278/1-s2.0-S0006899314016278-main.pdf?_tid=13269baa-d7d4-11e6-9033-00000aab0f01&amp;acdnat=1484121833_db5ff55e4288fcad6598a04451468e1c</style></url></related-urls><pdf-urls><url>internal-pdf://1912490447/Shen-2015-CHMP4B, ESCRT-III as.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.brainres.2014.11.043</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>77</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">77</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sheth, S. A.</style></author><author><style face="normal" font="default" size="100%">Iavarone, A. T.</style></author><author><style face="normal" font="default" size="100%">Liebeskind, D. S.</style></author><author><style face="normal" font="default" size="100%">Won, S. J.</style></author><author><style face="normal" font="default" size="100%">Swanson, R. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Comprehensive Stroke Center and Department of Neurology, University of California Los Angeles, Los Angeles, California, United States of America.&#xD;QB3/Chemistry Mass Spectrometry Facility, University of California, Berkeley, California, United States of America.&#xD;Neurology and Rehabilitation Service, San Francisco Veterans Affairs Medical Center and Department of Neurology, University of California San Francisco, San Francisco, California, United States of America.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Targeted Lipid Profiling Discovers Plasma Biomarkers of Acute Brain Injury</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PloS one</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e0129735</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2015/06/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/ blood/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Lipid Metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lipids/ blood</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Sphingolipids/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203 (Electronic)&#xD;1932-6203 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26076478</style></accession-num><abstract><style face="normal" font="default" size="100%">Prior efforts to identify a blood biomarker of brain injury have relied almost exclusively on proteins; however their low levels at early time points and poor correlation with injury severity have been limiting. Lipids, on the other hand, are the most abundant molecules in the brain and readily cross the blood-brain barrier. We previously showed that certain sphingolipid (SL) species are highly specific to the brain. Here we examined the feasibility of using SLs as biomarkers for acute brain injury. A rat model of traumatic brain injury (TBI) and a mouse model of stroke were used to identify candidate SL species though our mass-spectrometry based lipid profiling approach. Plasma samples collected after TBI in the rat showed large increases in many circulating SLs following injury, and larger lesions produced proportionately larger increases. Plasma samples collected 24 hours after stroke in mice similarly revealed a large increase in many SLs. We constructed an SL score (sum of the two SL species showing the largest relative increases in the mouse stroke model) and then evaluated the diagnostic value of this score on a small sample of patients (n = 14) who presented with acute stroke symptoms. Patients with true stroke had significantly higher SL scores than patients found to have non-stroke causes of their symptoms. The SL score correlated with the volume of ischemic brain tissue. These results demonstrate the feasibility of using lipid biomarkers to diagnose brain injury. Future studies will be needed to further characterize the diagnostic utility of this approach and to transition to an assay method applicable to clinical settings.</style></abstract><notes><style face="normal" font="default" size="100%">Sheth, Sunil A&#xD;Iavarone, Anthony T&#xD;Liebeskind, David S&#xD;Won, Seok Joon&#xD;Swanson, Raymond A&#xD;R01 NS081149/NS/NINDS NIH HHS/United States&#xD;NS041421/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United States&#xD;PLoS One. 2015 Jun 15;10(6):e0129735. doi: 10.1371/journal.pone.0129735. eCollection 2015.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0129735&amp;type=printable</style></url></related-urls><pdf-urls><url>internal-pdf://3403186032/Sheth-2015-Targeted Lipid Profi.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4468135</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0129735</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>113</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">113</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shi, Q. J.</style></author><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Liu, Z. X.</style></author><author><style face="normal" font="default" size="100%">Fang, S. H.</style></author><author><style face="normal" font="default" size="100%">Song, X. M.</style></author><author><style face="normal" font="default" size="100%">Lu, Y. B.</style></author><author><style face="normal" font="default" size="100%">Zhang, W. P.</style></author><author><style face="normal" font="default" size="100%">Sa, X. Y.</style></author><author><style face="normal" font="default" size="100%">Ying, H. Z.</style></author><author><style face="normal" font="default" size="100%">Wei, E. Q.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacology, School of Medicine, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058, China; Experimental Animal Center, Zhejiang Academy of Medical Sciences, 182 Tianmushan Road, Hangzhou 310013, China.&#xD;Department of Neurology, Tongde Hospital of Zhejiang Province, Hangzhou 310012, China.&#xD;Department of Pharmacology, School of Medicine, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058, China.&#xD;Experimental Animal Center, Zhejiang Academy of Medical Sciences, 182 Tianmushan Road, Hangzhou 310013, China.&#xD;Department of Pharmacology, School of Medicine, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058, China. Electronic address: weieq2006@zju.edu.cn.</style></auth-address><titles><title><style face="normal" font="default" size="100%">HAMI 3379, a CysLT2R antagonist, dose- and time-dependently attenuates brain injury and inhibits microglial inflammation after focal cerebral ischemia in rats</style></title><secondary-title><style face="normal" font="default" size="100%">Neuroscience</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">53-69</style></pages><volume><style face="normal" font="default" size="100%">291</style></volume><edition><style face="normal" font="default" size="100%">2015/02/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Acute Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/drug effects/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/drug therapy/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ drug therapy/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Chromones/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclohexanecarboxylic Acids/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery</style></keyword><keyword><style face="normal" font="default" size="100%">Leukotriene Antagonists/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Microglia/ drug effects/immunology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Phthalic Acids/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">RNA Interference</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Leukotriene/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ drug therapy/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 16</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1873-7544 (Electronic)&#xD;0306-4522 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25681271</style></accession-num><abstract><style face="normal" font="default" size="100%">Cysteinyl leukotrienes (CysLTs) induce inflammatory responses by activating their receptors, CysLT1R and CysLT2R. We have reported that CysLT2R is involved in neuronal injury, astrocytosis, and microgliosis, and that intracerebroventricular (i.c.v.) injection of the selective CysLT2R antagonist HAMI 3379 protects against acute brain injury after focal cerebral ischemia in rats. In the present study, we clarified features of the protective effect of intraperitoneally-injected HAMI 3379 in rats. We found that HAMI 3379 attenuated the acute brain injury 24 h after middle cerebral artery occlusion (MCAO) with effective doses of 0.1-0.4 mg/kg and a therapeutic window of approximately 1h. It attenuated the neurological deficits, and reduced infarct volume, brain edema, and neuronal loss and degeneration 24 and 72h after MCAO. RNA interference with i.c.v. injection of CysLT2R short hairpin RNA (shRNA) attenuated the acute injury as well. Also, HAMI 3379 inhibited release of the cytokines IL-1beta, interferon-gamma (IFN-gamma), and tumor necrosis factor-alpha (TNF-alpha) into the serum and cerebrospinal fluid 24h after MCAO. Moreover, HAMI 3379 ameliorated the microglial activation and neutrophil accumulation in the ischemic regions, but did not affect astrocyte proliferation 72h after MCAO. In comparison, the CysLT1R antagonist pranlukast did not affect microglial activation and IFN-gamma release, but inhibited astrocyte proliferation and reduced serum IL-4. Thus, we conclude that HAMI 3379 has a protective effect on acute and subacute ischemic brain injury, and attenuates microglia-related inflammation. CysLT2R antagonist(s) alone or in combination with CysLT1R antagonists may be a novel class of therapeutic agents in the treatment of ischemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Shi, Q J&#xD;Wang, H&#xD;Liu, Z X&#xD;Fang, S H&#xD;Song, X M&#xD;Lu, Y B&#xD;Zhang, W P&#xD;Sa, X Y&#xD;Ying, H Z&#xD;Wei, E Q&#xD;Comparative Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Neuroscience. 2015 Apr 16;291:53-69. doi: 10.1016/j.neuroscience.2015.02.002. Epub 2015 Feb 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S030645221500144X/1-s2.0-S030645221500144X-main.pdf?_tid=1af4d220-d7d4-11e6-abfb-00000aab0f6b&amp;acdnat=1484121846_e9f8a8613cec6ad2c0f9c877fe5aedd1</style></url></related-urls><pdf-urls><url>internal-pdf://1725593351/Shi-2015-HAMI 3379, a CysLT2R.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuroscience.2015.02.002</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>257</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">257</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shih, A. Y.</style></author><author><style face="normal" font="default" size="100%">Nishimura, N.</style></author><author><style face="normal" font="default" size="100%">Nguyen, J.</style></author><author><style face="normal" font="default" size="100%">Friedman, B.</style></author><author><style face="normal" font="default" size="100%">Lyden, P. D.</style></author><author><style face="normal" font="default" size="100%">Schaffer, C. B.</style></author><author><style face="normal" font="default" size="100%">Kleinfeld, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Optically induced occlusion of single blood vessels in rodent neocortex</style></title><secondary-title><style face="normal" font="default" size="100%">Cold Spring Harb Protoc</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Cold Spring Harbor protocols</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cold Spring Harb Protoc</style></full-title><abbr-1><style face="normal" font="default" size="100%">Cold Spring Harbor protocols</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Cold Spring Harb Protoc</style></full-title><abbr-1><style face="normal" font="default" size="100%">Cold Spring Harbor protocols</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1153-60</style></pages><volume><style face="normal" font="default" size="100%">2013</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2013/12/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Vessels/ radiation effects</style></keyword><keyword><style face="normal" font="default" size="100%">Hemostatic Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Light</style></keyword><keyword><style face="normal" font="default" size="100%">Neocortex/ radiation effects</style></keyword><keyword><style face="normal" font="default" size="100%">Photosensitizing Agents/radiation effects</style></keyword><keyword><style face="normal" font="default" size="100%">Rodentia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 01</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-6095 (Electronic)&#xD;1559-6095 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24298038</style></accession-num><abstract><style face="normal" font="default" size="100%">The ability to form targeted vascular occlusions in small vessels of the brain is an important technique for studying the microscopic basis of cerebral ischemia. We describe two complementary methods that enable targeted occlusion of any single blood vessel within the upper 500 microm of adult rodent neocortex. Our goal is to generate highly localized regions of ischemia by blocking penetrating arterioles and ascending venules, which are bottlenecks of flow in the cortical angioarchitecture. One method, termed photothrombosis, makes use of linear optical absorption by a photosensitizer, transiently circulated in the blood stream, to induce a clot in a surface or near-surface segment of a vessel. The second method, termed plasma-mediated ablation, makes use of nonlinear optical interactions, without the need to introduce an exogenous absorber, to induce clots in subsurface segments of penetrating vessels, as well as subsurface microvessels and capillaries. The choice of the method for occlusion of individual vessels depends on the location of the vessels being studied and the objectives of the study. Here we describe concurrent high resolution in vivo imaging and auxiliary laser setups, occlusion protocols, and post hoc histological procedures.</style></abstract><notes><style face="normal" font="default" size="100%">Shih, Andy Y&#xD;Nishimura, Nozomi&#xD;Nguyen, John&#xD;Friedman, Beth&#xD;Lyden, Patrick D&#xD;Schaffer, Chris B&#xD;Kleinfeld, David&#xD;EB003832/EB/NIBIB NIH HHS/United States&#xD;MH085499/MH/NIMH NIH HHS/United States&#xD;NS052565/NS/NINDS NIH HHS/United States&#xD;NS059832/NS/NINDS NIH HHS/United States&#xD;NS43300/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United States&#xD;Cold Spring Harb Protoc. 2013 Dec 1;2013(12):1153-60. doi: 10.1101/pdb.prot079509.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://cshprotocols.cshlp.org/content/2013/12/pdb.prot079509.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0224303336/Shih-2013-Optically induced oc.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1101/pdb.prot079509</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>88</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">88</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shindo, A.</style></author><author><style face="normal" font="default" size="100%">Liang, A. C.</style></author><author><style face="normal" font="default" size="100%">Maki, T.</style></author><author><style face="normal" font="default" size="100%">Miyamoto, N.</style></author><author><style face="normal" font="default" size="100%">Tomimoto, H.</style></author><author><style face="normal" font="default" size="100%">Lo, E. H.</style></author><author><style face="normal" font="default" size="100%">Arai, K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Subcortical ischemic vascular disease: Roles of oligodendrocyte function in experimental models of subcortical white-matter injury</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">187-98</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2015/04/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/complications/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Communication</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Proliferation</style></keyword><keyword><style face="normal" font="default" size="100%">Dementia, Vascular/etiology/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Oligodendroglia/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke, Lacunar/etiology/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">White Matter/ pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25920960</style></accession-num><abstract><style face="normal" font="default" size="100%">Oligodendrocytes are one of the major cell types in cerebral white matter. Under normal conditions, they form myelin sheaths that encircle axons to support fast nerve conduction. Under conditions of cerebral ischemia, oligodendrocytes tend to die, resulting in white-matter dysfunction. Repair of white matter involves the ability of oligodendrocyte precursors to proliferate and mature. However, replacement of lost oligodendrocytes may not be the only mechanism for white-matter recovery. Emerging data now suggest that coordinated signaling between neural, glial, and vascular cells in the entire neurovascular unit may be required. In this mini-review, we discuss how oligodendrocyte lineage cells participate in signaling and crosstalk with other cell types to underlie function and recovery in various experimental models of subcortical white-matter injury.</style></abstract><notes><style face="normal" font="default" size="100%">Shindo, Akihiro&#xD;Liang, Anna C&#xD;Maki, Takakuni&#xD;Miyamoto, Nobukazu&#xD;Tomimoto, Hidekazu&#xD;Lo, Eng H&#xD;Arai, Ken&#xD;P01 NS055104/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Review&#xD;United States&#xD;J Cereb Blood Flow Metab. 2016 Jan;36(1):187-98.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4758561</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2015.80</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>412</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">412</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shirakawa, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Japan. shirakaw@pharm.kyoto-u.ac.jp</style></auth-address><titles><title><style face="normal" font="default" size="100%">[Pathophysiological significance of the canonical transient receptor potential (TRPC) subfamily in astrocyte activation]</style></title><secondary-title><style face="normal" font="default" size="100%">Yakugaku Zasshi</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Yakugaku Zasshi</style></full-title><abbr-1><style face="normal" font="default" size="100%">Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Yakugaku Zasshi</style></full-title><abbr-1><style face="normal" font="default" size="100%">Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">587-93</style></pages><volume><style face="normal" font="default" size="100%">132</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2012/06/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/cytology/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytoma/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/etiology/pathology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Signaling/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Proliferation</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Targeted Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Growth Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Pyrazoles/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">S100 Calcium Binding Protein beta Subunit</style></keyword><keyword><style face="normal" font="default" size="100%">S100 Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">TRPC Cation Channels/antagonists &amp; inhibitors/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Theophylline/analogs &amp; derivatives</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombin/adverse effects/physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1347-5231 (Electronic)&#xD;0031-6903 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22687694</style></accession-num><abstract><style face="normal" font="default" size="100%">Astrocytes, the most abundant cells in the central nervous system (CNS), play diverse roles in the regulation of neuronal activity, vascular function and gliotransmitter release. In neurodegenerative diseases, pathologically activated astrocytes show astrogliosis, which is clinically characterized by an abnormal cell morphology and excessive astrocyte proliferation. Thrombin, a crucial factor for brain injury after intracerebral hemorrhage, activates astrocytic Ca2+ signaling through a specific subtype of the thrombin receptor, termed the proteinase-activated receptor (PAR). In this study, we demonstrate a novel pathophysiological role for transient receptor potential canonical 3 (TRPC3) Ca2+-permeable nonselective cation channels in thrombin-activated astrocytes. In 1321N1 human astrocytoma cells and cultured rat cortical astrocytes, thrombin induced heterogeneous Ca2+ responses with asynchronous repetitive peaks. These oscillations were found to be the result of repetitive Ca2+ release from intracellular stores followed by replenishment of the stores with Ca2+ from the extracellular region. The oscillations occurred without a direct [Ca2+]i increase and were inhibited by the selective TRPC3 inhibitor pyrazole-3. Pharmacological manipulation with BAPTA-AM, cyclopiazonic acid, 2-aminoethoxydiphenyl borate and pyrazole-3 indicated that Ca2+ mobilization through TRPC3 was involved in thrombin-induced changes in the morphology of astrocytes. Moreover, thrombin-induced upregulation of S100B, a marker of reactive astrocytes, at 20 h and increased astrocytic proliferation at 72 h were inhibited by Ca2+ signaling blockers and knockdown of TRPC3 with specific siRNA. Taken together, these results suggest that TRPC3 may constitute a new therapeutic target for brain injury after intracerebral hemorrhage.</style></abstract><notes><style face="normal" font="default" size="100%">Shirakawa, Hisashi&#xD;Review&#xD;Japan&#xD;Yakugaku Zasshi. 2012;132(5):587-93.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>360</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">360</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shmonin, A.</style></author><author><style face="normal" font="default" size="100%">Melnikova, E.</style></author><author><style face="normal" font="default" size="100%">Galagudza, M.</style></author><author><style face="normal" font="default" size="100%">Vlasov, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Experimental Medicine, V.A. Almazov Federal Heart, Blood and Endocrinology Center, St-Petersburg, Russian Federation; Department of Neurology, I.P. Pavlov Federal Medical University, St-Petersburg, Russian Federation.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Characteristics of cerebral ischemia in major rat stroke models of middle cerebral artery ligation through craniectomy</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">International journal of stroke : official journal of the International Stroke Society</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Int J Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">International journal of stroke : official journal of the International Stroke Society</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Int J Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">International journal of stroke : official journal of the International Stroke Society</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">793-801</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2012/12/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Flow Velocity</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Craniotomy</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Functional Laterality</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/mortality/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Ligation</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Tetrazolium Salts</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1747-4949 (Electronic)&#xD;1747-4930 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23205677</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The refinement of experimental stroke models is important for further development of neuroprotective interventions. AIMS AND/OR HYPOTHESIS: Our goal was to study the reproducibility of outcomes obtained in five rat models of middle cerebral artery (MCA) ligation in order to identify the optimal model for the preclinical studies. METHODS: In Part 1 of the experiments, systolic blood flow velocity (sBFV) and cerebral area at risk (AR) were determined immediately after the onset of brain ischemia induced in different ways in Wistar rats. After that, another set of experiments was performed (Part 2 of the experiments), now aimed at the assessment of the delayed outcome of five different models of cerebral ischemia designated as Versions 1-5. The versions were: Version 1 - 40-minute left MCA (LMCA) occlusion with reperfusion; Version 2 - permanent LMCA ligation; Version 3 - permanent ligation of both LMCA and left common carotid artery (CCA); Version 4 - permanent LMCA and bilateral CCA (bCCA) ligation; Version 5 - permanent LMCA ligation and 40-minute bCCA occlusion. The infarct size (IS) was quantified using triphenyltetrazolium chloride staining. The severity of neurological deficit was assessed by the Garcia score. The extent of brain edema was determined by calculating the difference in volumes of affected and contralateral hemispheres. RESULTS: Within a relatively big AR, Versions 1 and 2 resulted in a small IS [0.2 (0.0; 0.4)% and 0.3 (0.0; 0.7)%, respectively, P &gt; 0.05]. Unlike that and comparable with AR, Version 3 resulted in a greater, albeit more variable IS [5.9 (2.1; 8.3)%, P &lt; 0.0001 vs. Version 2]. Also comparable with AR, Versions 4 and 5 produced greatest values of IS [14.5 (11.4; 17.9)% and 11.3 (10.1; 14.2)%, respectively]; this parameter was most reproducible in Version 5. A significant decrease in neurological deficit score was found in Versions 4 and 5. Again, the reproducibility of the data on neurological outcome was higher in Version 5 versus Version 4. CONCLUSIONS: Comparative analysis of several Versions of focal cerebral ischemia within a single study might be helpful in better understanding of the mechanisms underlying the development and aftermath of stroke. Permanent LMCA ligation plus transient bilateral CCA occlusion produced most consistent results and might be recommended for preclinical studies.</style></abstract><notes><style face="normal" font="default" size="100%">Shmonin, Alexey&#xD;Melnikova, Elena&#xD;Galagudza, Michael&#xD;Vlasov, Timur&#xD;Comparative Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Int J Stroke. 2014 Aug;9(6):793-801. doi: 10.1111/j.1747-4949.2012.00947.x. Epub 2012 Dec 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/j.1747-4949.2012.00947.x/asset/ijs947.pdf?v=1&amp;t=ixsnqbk2&amp;s=a0ef4fa286327b13b302d957da71c2c7f55a5a77</style></url></related-urls><pdf-urls><url>internal-pdf://2123020222/Shmonin-2014-Characteristics of c.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1747-4949.2012.00947.x</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>111</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">111</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Silasi, G.</style></author><author><style face="normal" font="default" size="100%">She, J.</style></author><author><style face="normal" font="default" size="100%">Boyd, J. D.</style></author><author><style face="normal" font="default" size="100%">Xue, S.</style></author><author><style face="normal" font="default" size="100%">Murphy, T. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">1] Department of Psychiatry, Kinsmen Laboratory of Neurological Research, Vancouver, British Columbia, Canada [2] Brain Research Centre, University of British Columbia, Vancouver, British Columbia, Canada.&#xD;Department of Psychiatry, Kinsmen Laboratory of Neurological Research, Vancouver, British Columbia, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A mouse model of small-vessel disease that produces brain-wide-identified microocclusions and regionally selective neuronal injury</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">734-8</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2015/02/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arterial Occlusive Diseases/chemically</style></keyword><keyword><style face="normal" font="default" size="100%">induced/metabolism/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Arterioles/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Axons/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Disorders/chemically induced/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Hippocampus/blood supply/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Microspheres</style></keyword><keyword><style face="normal" font="default" size="100%">White Matter/blood supply/metabolism/pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25690472</style></accession-num><abstract><style face="normal" font="default" size="100%">We developed a mouse model of small-vessel disease where occlusions are produced through endovascular injection of fluorescent microspheres that target ~12 mum diameter penetrating arterioles and can be localized in histology. Using Thy1-GFP transgenic mice, we visualized the impact of microocclusions on neuronal structure. Microocclusions in the hippocampus produce cell loss or neuronal atrophy (~7% of lodged microspheres led to microinfarcts), while axons within white matter tracts, as well as the striatum and thalamus became blebbed or disrupted. Although the neocortex contained more occlusions than other structures, labeled layer 5 neurons were relatively resistant to structural damage, with &lt;2% of the lodged microspheres producing obvious neuronal damage.</style></abstract><notes><style face="normal" font="default" size="100%">Silasi, Gergely&#xD;She, Jennifer&#xD;Boyd, Jamie D&#xD;Xue, Songchao&#xD;Murphy, Timothy H&#xD;MOP-111009/Canadian Institutes of Health Research/Canada&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Cereb Blood Flow Metab. 2015 May;35(5):734-8. doi: 10.1038/jcbfm.2015.8. Epub 2015 Feb 18.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4420872</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2015.8</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>368</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">368</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Silva, J.</style></author><author><style face="normal" font="default" size="100%">Polesskaya, O.</style></author><author><style face="normal" font="default" size="100%">Knight, W.</style></author><author><style face="normal" font="default" size="100%">Zheng, J. T.</style></author><author><style face="normal" font="default" size="100%">Granger, M.</style></author><author><style face="normal" font="default" size="100%">Lopez, T.</style></author><author><style face="normal" font="default" size="100%">Ontiveros, F.</style></author><author><style face="normal" font="default" size="100%">Feng, C.</style></author><author><style face="normal" font="default" size="100%">Yan, C.</style></author><author><style face="normal" font="default" size="100%">Kasischke, K. A.</style></author><author><style face="normal" font="default" size="100%">Dewhurst, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiology and Immunology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 672, Rochester, NY 14642, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transient hypercapnia reveals an underlying cerebrovascular pathology in a murine model for HIV-1 associated neuroinflammation: role of NO-cGMP signaling and normalization by inhibition of cyclic nucleotide phosphodiesterase-5</style></title><secondary-title><style face="normal" font="default" size="100%">J Neuroinflammation</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neuroinflammation</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neuroinflammation</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroinflammation</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neuroinflammation</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroinflammation</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">253</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><edition><style face="normal" font="default" size="100%">2012/11/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arterioles/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Biopterin/analogs &amp; derivatives/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Circulation Time</style></keyword><keyword><style face="normal" font="default" size="100%">COS Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Carbon Dioxide/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular System/ pathology/virology</style></keyword><keyword><style face="normal" font="default" size="100%">Cercopithecus aethiops</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclic GMP/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclic Nucleotide Phosphodiesterases, Type 5/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Encephalitis/ complications/etiology/ pathology/virology</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation, Enzymologic/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">HIV Infections/complications/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lectins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilation/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">tat Gene Products, Human Immunodeficiency Virus/genetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 20</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1742-2094 (Electronic)&#xD;1742-2094 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23167821</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Cerebral blood flow (CBF) is known to be dysregulated in persons with human immunodeficiency virus 1 (HIV-1), for uncertain reasons. This is an important issue because impaired vasoreactivity has been associated with increased risk of ischemic stroke, elevated overall cardiovascular risk and cognitive impairment. METHODS: To test whether dysregulation of CBF might be due to virally-induced neuroinflammation, we used a well-defined animal model (GFAP-driven, doxycycline-inducible HIV-1 Tat transgenic (Tat-tg) mice). We then exposed the mice to a brief hypercapnic stimulus, and assessed cerebrovascular reactivity by measuring 1) changes in cerebral blood flow, using laser Doppler flowmetry and 2) changes in vascular dilation, using in vivo two-photon imaging. RESULTS: Exposure to brief hypercapnia revealed an underlying cerebrovascular pathology in Tat-tg mice. In control animals, brief hypercapnia induced a brisk increase in cortical flow (20.8% above baseline) and vascular dilation, as measured by laser Doppler flowmetry and in vivo two-photon microscopy. These responses were significantly attenuated in Tat-tg mice (11.6% above baseline), but cortical microvascular morphology and capillary density were unaltered, suggesting that the functional pathology was not secondary to vascular remodeling. To examine the mechanistic basis for the diminished cerebrovascular response to brief hypercapnia, Tat-tg mice were treated with 1) gisadenafil, a phosphodiesterase 5 (PDE5) inhibitor and 2) tetrahydrobiopterin (BH4). Gisadenafil largely restored the normal increase in cortical flow following hypercapnia in Tat-tg mice (17.5% above baseline), whereas BH4 had little effect. Gisadenafil also restored the dilation of small (&lt;25 mum) arterioles following hypercapnia (19.1% versus 20.6% diameter increase in control and Tat-tg plus gisadenafil, respectively), although it failed to restore full dilation of larger (&gt;25 mum) vessels. CONCLUSIONS: Taken together, these data show that HIV-associated neuroinflammation can cause cerebrovascular pathology through effects on cyclic guanosine monophosphate (cGMP) metabolism and possibly on PDE5 metabolism.</style></abstract><notes><style face="normal" font="default" size="100%">Silva, Jharon&#xD;Polesskaya, Oksana&#xD;Knight, Walter&#xD;Zheng, Johnny Ting&#xD;Granger, Megan&#xD;Lopez, Tenee&#xD;Ontiveros, Fernando&#xD;Feng, Changyong&#xD;Yan, Chen&#xD;Kasischke, Karl A&#xD;Dewhurst, Stephen&#xD;T32GM007356/GM/NIGMS NIH HHS/United States&#xD;P30AI078498/AI/NIAID NIH HHS/United States&#xD;R01DA026325/DA/NIDA NIH HHS/United States&#xD;Howard Hughes Medical Institute/United States&#xD;T32DA007232/DA/NIDA NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Neuroinflammation. 2012 Nov 20;9:253. doi: 10.1186/1742-2094-9-253.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/474/art%253A10.1186%252F1742-2094-9-253.pdf?originUrl=http%3A%2F%2Fjneuroinflammation.biomedcentral.com%2Farticle%2F10.1186%2F1742-2094-9-253&amp;token2=exp=1484122004~acl=%2Fstatic%2Fpdf%2F474%2Fart%25253A10.1186%25252F1742-2094-9-253.pdf*~hmac=c24f5858ef83e91a5a5c96befbcc786555e02bea65bada50da923da15ce967a1</style></url></related-urls><pdf-urls><url>internal-pdf://1610809301/Silva-2012-Transient hypercapni.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3526511</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/1742-2094-9-253</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>11</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">11</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Siniscalchi, A.</style></author><author><style face="normal" font="default" size="100%">Sztajzel, R.</style></author><author><style face="normal" font="default" size="100%">Bonci, A.</style></author><author><style face="normal" font="default" size="100%">Malferrari, G.</style></author><author><style face="normal" font="default" size="100%">De Sarro, G.</style></author><author><style face="normal" font="default" size="100%">Gallelli, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Annunziata Hospital Via F. Migliori, 1; 87100 Cosenza, Italy. anto.siniscalchi@libero.it.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Editorial: Cocaine and Cerebral Small Vessel: Is it a Negative Factor for Intravenous Thrombolysis?</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Vasc Pharmacol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Current vascular pharmacology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Vasc Pharmacol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current vascular pharmacology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Curr Vasc Pharmacol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current vascular pharmacology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">304-6</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2016/02/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ blood supply/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cocaine/ adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Fibrinolysis/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Fibrinolytic Agents/ adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/chemically induced</style></keyword><keyword><style face="normal" font="default" size="100%">Substance-Related Disorders/complications</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">1875-6212 (Electronic)&#xD;1570-1611 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26845684</style></accession-num><notes><style face="normal" font="default" size="100%">Siniscalchi, Antonio&#xD;Sztajzel, Roman&#xD;Bonci, Antonello&#xD;Malferrari, Giovanni&#xD;De Sarro, Giovambattista&#xD;Gallelli, Luca&#xD;Editorial&#xD;United Arab Emirates&#xD;Curr Vasc Pharmacol. 2016;14(3):304-6.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>157</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">157</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sleiman, S. F.</style></author><author><style face="normal" font="default" size="100%">Olson, D. E.</style></author><author><style face="normal" font="default" size="100%">Bourassa, M. W.</style></author><author><style face="normal" font="default" size="100%">Karuppagounder, S. S.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y. L.</style></author><author><style face="normal" font="default" size="100%">Gale, J.</style></author><author><style face="normal" font="default" size="100%">Wagner, F. F.</style></author><author><style face="normal" font="default" size="100%">Basso, M.</style></author><author><style face="normal" font="default" size="100%">Coppola, G.</style></author><author><style face="normal" font="default" size="100%">Pinto, J. T.</style></author><author><style face="normal" font="default" size="100%">Holson, E. B.</style></author><author><style face="normal" font="default" size="100%">Ratan, R. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Burke Medical Research Institute, White Plains, New York 10605, Department of Natural Sciences, Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, New York 10021, Lebanese American University, Byblos, Lebanon, sama.sleiman01@lau.edu.lb rrr2001@med.cornell.edu.&#xD;Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, New York 10021.&#xD;Department of Natural Sciences, Lebanese American University, Byblos, Lebanon, Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts 02142.&#xD;Centre for Integrative Biology, University of Trento, Trento, Italy.&#xD;Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095, and.&#xD;Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, New York 10595.&#xD;Burke Medical Research Institute, White Plains, New York 10605, Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, New York 10021, sama.sleiman01@lau.edu.lb rrr2001@med.cornell.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hydroxamic acid-based histone deacetylase (HDAC) inhibitors can mediate neuroprotection independent of HDAC inhibition</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of neuroscience : the official journal of the Society for Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">14328-37</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><number><style face="normal" font="default" size="100%">43</style></number><edition><style face="normal" font="default" size="100%">2014/10/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/ drug effects/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Histone Deacetylase Inhibitors/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/ drug effects/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 22</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1529-2401 (Electronic)&#xD;0270-6474 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25339746</style></accession-num><abstract><style face="normal" font="default" size="100%">Histone deacetylase (HDAC) inhibition improves function and extends survival in rodent models of a host of neurological conditions, including stroke, and neurodegenerative diseases. Our understanding, however, of the contribution of individual HDAC isoforms to neuronal death is limited. In this study, we used selective chemical probes to assess the individual roles of the Class I HDAC isoforms in protecting Mus musculus primary cortical neurons from oxidative death. We demonstrated that the selective HDAC8 inhibitor PCI-34051 is a potent neuroprotective agent; and by taking advantage of both pharmacological and genetic tools, we established that HDAC8 is not critically involved in PCI-34051&apos;s mechanism of action. We used BRD3811, an inactive ortholog of PCI-34051, and showed that, despite its inability to inhibit HDAC8, it exhibits robust neuroprotective properties. Furthermore, molecular deletion of HDAC8 proved insufficient to protect neurons from oxidative death, whereas both PCI-34051 and BRD3811 were able to protect neurons derived from HDAC8 knock-out mice. Finally, we designed and synthesized two new, orthogonal negative control compounds, BRD9715 and BRD8461, which lack the hydroxamic acid motif and showed that they stably penetrate cell membranes but are not neuroprotective. These results indicate that the protective effects of these hydroxamic acid-containing small molecules are likely unrelated to direct epigenetic regulation via HDAC inhibition, but rather due to their ability to bind metals. Our results suggest that hydroxamic acid-based HDAC inhibitors may mediate neuroprotection via HDAC-independent mechanisms and affirm the need for careful structure-activity relationship studies when using pharmacological approaches.</style></abstract><notes><style face="normal" font="default" size="100%">Sleiman, Sama F&#xD;Olson, David E&#xD;Bourassa, Megan W&#xD;Karuppagounder, Saravanan S&#xD;Zhang, Yan-Ling&#xD;Gale, Jennifer&#xD;Wagner, Florence F&#xD;Basso, Manuela&#xD;Coppola, Giovanni&#xD;Pinto, John T&#xD;Holson, Edward B&#xD;Ratan, Rajiv R&#xD;P01 AG014930/AG/NIA NIH HHS/United States&#xD;P01 NIA AG014930/AG/NIA NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Neurosci. 2014 Oct 22;34(43):14328-37. doi: 10.1523/JNEUROSCI.1010-14.2014.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.jneurosci.org/content/jneuro/34/43/14328.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1563152991/Sleiman-2014-Hydroxamic acid-base.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4205555</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1523/jneurosci.1010-14.2014</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>138</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">138</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Song, D.</style></author><author><style face="normal" font="default" size="100%">Xu, J.</style></author><author><style face="normal" font="default" size="100%">Du, T.</style></author><author><style face="normal" font="default" size="100%">Yan, E.</style></author><author><style face="normal" font="default" size="100%">Hertz, L.</style></author><author><style face="normal" font="default" size="100%">Walz, W.</style></author><author><style face="normal" font="default" size="100%">Peng, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Brain Metabolic Diseases, Institute of Metabolic Disease Research and Drug Development China Medical University, No. 92 Beier Road, Heping District, Shenyang 110001, China.&#xD;Laboratory of Brain Metabolic Diseases, Institute of Metabolic Disease Research and Drug Development China Medical University, No. 92 Beier Road, Heping District, Shenyang 110001, China ; Departments of Psychiatry and Pharmacology, University of Saskatchewan, Saskatoon, SK, Canada.&#xD;Departments of Psychiatry and Pharmacology, University of Saskatchewan, Saskatoon, SK, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inhibition of brain swelling after ischemia-reperfusion by beta-adrenergic antagonists: correlation with increased K+ and decreased Ca2+ concentrations in extracellular fluid</style></title><secondary-title><style face="normal" font="default" size="100%">Biomed Res Int</style></secondary-title><alt-title><style face="normal" font="default" size="100%">BioMed research international</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Biomed Res Int</style></full-title><abbr-1><style face="normal" font="default" size="100%">BioMed research international</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Biomed Res Int</style></full-title><abbr-1><style face="normal" font="default" size="100%">BioMed research international</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">873590</style></pages><volume><style face="normal" font="default" size="100%">2014</style></volume><edition><style face="normal" font="default" size="100%">2014/12/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-1 Receptor Antagonists/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/drug effects/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/ drug therapy/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Death/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Extracellular Fluid/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Potassium/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/ drug therapy/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium-Potassium-Exchanging ATPase/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Solute Carrier Family 12, Member 2/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">2314-6141 (Electronic)</style></isbn><accession-num><style face="normal" font="default" size="100%">25478577</style></accession-num><abstract><style face="normal" font="default" size="100%">Infarct size and brain edema following ischemia/reperfusion are reduced by inhibitors of the Na+, K+, 2Cl-, and water cotransporter NKCC1 and by beta1-adrenoceptor antagonists. NKCC1 is a secondary active transporter, mainly localized in astrocytes, driven by transmembrane Na+/K+ gradients generated by the Na+,K+-ATPase. The astrocytic Na+,K+-ATPase is stimulated by small increases in extracellular K+ concentration and by the beta-adrenergic agonist isoproterenol. Larger K+ increases, as occurring during ischemia, also stimulate NKCC1, creating cell swelling. This study showed no edema after 3 hr medial cerebral artery occlusion but pronounced edema after 8 hr reperfusion. The edema was abolished by inhibitors of specifically beta1-adrenergic pathways, indicating failure of K+-mediated, but not beta1-adrenoceptor-mediated, stimulation of Na+,K+-ATPase/NKCC1 transport during reoxygenation. Ninety percent reduction of extracellular Ca2+ concentration occurs in ischemia. Ca2+ omission abolished K+ uptake in normoxic cultures of astrocytes after addition of 5 mM KCl. A large decrease in ouabain potency on K+ uptake in cultured astrocytes was also demonstrated in Ca2+-depleted media, and endogenous ouabains are needed for astrocytic K+ uptake. Thus, among the ionic changes induced by ischemia, the decrease in extracellular Ca2+ causes failure of the high-K+-stimulated Na+,K+-ATPase/NKCC1 ion/water uptake, making beta1-adrenergic activation the only stimulus and its inhibition effective against edema.</style></abstract><notes><style face="normal" font="default" size="100%">Song, Dan&#xD;Xu, Junnan&#xD;Du, Ting&#xD;Yan, Enzhi&#xD;Hertz, Leif&#xD;Walz, Wolfgang&#xD;Peng, Liang&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Biomed Res Int. 2014;2014:873590. doi: 10.1155/2014/873590. Epub 2014 Nov 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://downloads.hindawi.com/journals/bmri/2014/873590.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1862981845/Song-2014-Inhibition of brain.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4247955</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1155/2014/873590</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>142</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">142</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Song, J.</style></author><author><style face="normal" font="default" size="100%">Cheon, S. Y.</style></author><author><style face="normal" font="default" size="100%">Lee, W. T.</style></author><author><style face="normal" font="default" size="100%">Park, K. A.</style></author><author><style face="normal" font="default" size="100%">Lee, J. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Anatomy, Yonsei University College of Medicine, Seoul, South Korea.&#xD;Department of Anatomy, Yonsei University College of Medicine, Seoul, South Korea; BK21 Plus Project for Medical Sciences, and Brain Research Institute, Yonsei University College of Medicine, Seoul, South Korea.&#xD;Department of Anatomy, Yonsei University College of Medicine, Seoul, South Korea; BK21 Plus Project for Medical Sciences, and Brain Research Institute, Yonsei University College of Medicine, Seoul, South Korea. Electronic address: jelee@yuhs.ac.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The effect of ASK1 on vascular permeability and edema formation in cerebral ischemia</style></title><secondary-title><style face="normal" font="default" size="100%">Brain Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">143-55</style></pages><volume><style face="normal" font="default" size="100%">1595</style></volume><edition><style face="normal" font="default" size="100%">2014/12/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Aquaporin 1/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/drug therapy/ etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ complications/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Capillary Permeability/drug effects/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Hypoxia/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelial Cells/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation/drug effects/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose/deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Endothelial Growth Factor A/genetics/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 21</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-6240 (Electronic)&#xD;0006-8993 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25446452</style></accession-num><abstract><style face="normal" font="default" size="100%">Apoptosis signal-regulating kinase-1 (ASK1) is the mitogen-activated protein kinase kinase kinase (MAPKKK) and participates in the various central nervous system (CNS) signaling pathways. In cerebral ischemia, vascular permeability in the brain is an important issue because regulation failure of it results in edema formation and blood-brain barrier (BBB) disruption. To determine the role of ASK1 on vascular permeability and edema formation following cerebral ischemia, we first investigated ASK1-related gene expression using microarray analyses of ischemic brain tissue. We then measured protein levels of ASK1 and vascular endothelial growth factor (VEGF) in brain endothelial cells after hypoxia injury. We also examined protein expression of ASK1 and VEGF, edema formation, and morphological alteration through cresyl violet staining in ischemic brain tissue using ASK1-small interference RNA (ASK1-siRNA). Finally, immunohistochemistry was performed to examine VEGF and aquaporin-1 (AQP-1) expression in ischemic brain injury. Based on our findings, we propose that ASK1 is a regulating factor of vascular permeability and edema formation in cerebral ischemia.</style></abstract><notes><style face="normal" font="default" size="100%">Song, Juhyun&#xD;Cheon, So Yeong&#xD;Lee, Won Taek&#xD;Park, Kyung Ah&#xD;Lee, Jong Eun&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;Brain Res. 2015 Jan 21;1595:143-55. doi: 10.1016/j.brainres.2014.11.024. Epub 2014 Nov 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0006899314016084/1-s2.0-S0006899314016084-main.pdf?_tid=76182b7a-d7d4-11e6-8c8e-00000aacb361&amp;acdnat=1484121999_1e209781f7e6fc2256fc7353a0939508</style></url></related-urls><pdf-urls><url>internal-pdf://2864434871/Song-2015-The effect of ASK1 o.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.brainres.2014.11.024</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>284</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">284</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Soria, G.</style></author><author><style face="normal" font="default" size="100%">Tudela, R.</style></author><author><style face="normal" font="default" size="100%">Marquez-Martin, A.</style></author><author><style face="normal" font="default" size="100%">Camon, L.</style></author><author><style face="normal" font="default" size="100%">Batalle, D.</style></author><author><style face="normal" font="default" size="100%">Munoz-Moreno, E.</style></author><author><style face="normal" font="default" size="100%">Eixarch, E.</style></author><author><style face="normal" font="default" size="100%">Puig, J.</style></author><author><style face="normal" font="default" size="100%">Pedraza, S.</style></author><author><style face="normal" font="default" size="100%">Vila, E.</style></author><author><style face="normal" font="default" size="100%">Prats-Galino, A.</style></author><author><style face="normal" font="default" size="100%">Planas, A. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Experimental 7T MRI Unit, Institut d&apos;Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain ; Department of Brain Ischemia and Neurodegeneration, Institut d&apos;Investigacions Biomediques de Barcelona (IIBB), Consejo Superior de Investigaciones Cientificas (CSIC), Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The ins and outs of the BCCAo model for chronic hypoperfusion: a multimodal and longitudinal MRI approach</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PloS one</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e74631</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2013/09/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arterial Occlusive Diseases/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Basilar Artery/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Behavior, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/blood supply/pathology/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Artery, Common/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Contrast Media</style></keyword><keyword><style face="normal" font="default" size="100%">Diffusion Tensor Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Immunohistochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Multimodal Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Perfusion</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Visual Pathways/pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203 (Electronic)&#xD;1932-6203 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24058609</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebral hypoperfusion induced by bilateral common carotid artery occlusion (BCCAo) in rodents has been proposed as an experimental model of white matter damage and vascular dementia. However, the histopathological and behavioral alterations reported in this model are variable and a full characterization of the dynamic alterations is not available. Here we implemented a longitudinal multimodal magnetic resonance imaging (MRI) design, including time-of-flight angiography, high resolution T1-weighted images, T2 relaxometry mapping, diffusion tensor imaging, and cerebral blood flow measurements up to 12 weeks after BCCAo or sham-operation in Wistar rats. Changes in MRI were related to behavioral performance in executive function tasks and histopathological alterations in the same animals. MRI frequently (70%) showed various degrees of acute ischemic lesions, ranging from very small to large subcortical infarctions. Independently, delayed MRI changes were also apparent. The patterns of MRI alterations were related to either ischemic necrosis or gliosis. Progressive microstructural changes revealed by diffusion tensor imaging in white matter were confirmed by observation of myelinated fiber degeneration, including severe optic tract degeneration. The latter interfered with the visually cued learning paradigms used to test executive functions. Independently of brain damage, BCCAo induced progressive arteriogenesis in the vertebrobasilar tree, a process that was associated with blood flow recovery after 12 weeks. The structural alterations found in the basilar artery were compatible with compensatory adaptive changes driven by shear stress. In summary, BCCAo in rats induces specific signatures in multimodal MRI that are compatible with various types of histological lesion and with marked adaptive arteriogenesis.</style></abstract><notes><style face="normal" font="default" size="100%">Soria, Guadalupe&#xD;Tudela, Raul&#xD;Marquez-Martin, Ana&#xD;Camon, Lluisa&#xD;Batalle, Dafnis&#xD;Munoz-Moreno, Emma&#xD;Eixarch, Elisenda&#xD;Puig, Josep&#xD;Pedraza, Salvador&#xD;Vila, Elisabet&#xD;Prats-Galino, Alberto&#xD;Planas, Anna M&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;PLoS One. 2013 Sep 18;8(9):e74631. doi: 10.1371/journal.pone.0074631. eCollection 2013.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0074631&amp;type=printable</style></url></related-urls><pdf-urls><url>internal-pdf://0855450366/Soria-2013-The ins and outs of.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3776744</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0074631</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>265</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">265</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Spalletti, C.</style></author><author><style face="normal" font="default" size="100%">Lai, S.</style></author><author><style face="normal" font="default" size="100%">Mainardi, M.</style></author><author><style face="normal" font="default" size="100%">Panarese, A.</style></author><author><style face="normal" font="default" size="100%">Ghionzoli, A.</style></author><author><style face="normal" font="default" size="100%">Alia, C.</style></author><author><style face="normal" font="default" size="100%">Gianfranceschi, L.</style></author><author><style face="normal" font="default" size="100%">Chisari, C.</style></author><author><style face="normal" font="default" size="100%">Micera, S.</style></author><author><style face="normal" font="default" size="100%">Caleo, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">1CNR Neuroscience Institute, Pisa, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A robotic system for quantitative assessment and poststroke training of forelimb retraction in mice</style></title><secondary-title><style face="normal" font="default" size="100%">Neurorehabil Neural Repair</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurorehabilitation and neural repair</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurorehabil Neural Repair</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurorehabilitation and neural repair</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurorehabil Neural Repair</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurorehabilitation and neural repair</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">188-96</style></pages><volume><style face="normal" font="default" size="100%">28</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2013/11/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/rehabilitation</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment Design</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Forelimb/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Motor Activity/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Robotics/ instrumentation</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke Rehabilitation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1552-6844 (Electronic)&#xD;1545-9683 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24213954</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Neurorehabilitation protocols based on the use of robotic devices have recently shown to provide promising clinical results. However, their efficacy is still limited because of the poor comprehension of the mechanisms at the basis of functional enhancements. OBJECTIVE: To increase basic understanding of robot-mediated neurorehabilitation by performing experiments on a rodent model of stroke. METHODS: Mice were trained to pull back a handle on a robotic platform and their performances in the task were evaluated before and after a focal cortical ischemic stroke. The platform was designed for the quantitative assessment of forelimb function via a series of parameters (time needed to complete the task, t-target; average force; number of sub-movements). RESULTS: The animals rapidly learned the retraction task and reached asymptotic performance by the fifth session of training. Within 2 to 6 days after a small, endothelin-1-induced lesion in the caudal forelimb area, mice showed an increase in t-target and number of sub-movements and a corresponding decrease in the average force exerted. These parameters returned to baseline, pre-lesion values with continued platform training (10-14 days after stroke). CONCLUSIONS: These results highlight the utility of the devised platform for characterizing post-infarct deficits and improvements of forelimb performance. Further research is warranted to widen the understanding of device-dependent rehabilitation effects.</style></abstract><notes><style face="normal" font="default" size="100%">Spalletti, Cristina&#xD;Lai, Stefano&#xD;Mainardi, Marco&#xD;Panarese, Alessandro&#xD;Ghionzoli, Alessio&#xD;Alia, Claudia&#xD;Gianfranceschi, Laura&#xD;Chisari, Carmelo&#xD;Micera, Silvestro&#xD;Caleo, Matteo&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Neurorehabil Neural Repair. 2014 Feb;28(2):188-96. doi: 10.1177/1545968313506520. Epub 2013 Nov 8.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/1545968313506520</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>91</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">91</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Spescha, R. D.</style></author><author><style face="normal" font="default" size="100%">Klohs, J.</style></author><author><style face="normal" font="default" size="100%">Semerano, A.</style></author><author><style face="normal" font="default" size="100%">Giacalone, G.</style></author><author><style face="normal" font="default" size="100%">Derungs, R. S.</style></author><author><style face="normal" font="default" size="100%">Reiner, M. F.</style></author><author><style face="normal" font="default" size="100%">Rodriguez Gutierrez, D.</style></author><author><style face="normal" font="default" size="100%">Mendez-Carmona, N.</style></author><author><style face="normal" font="default" size="100%">Glanzmann, M.</style></author><author><style face="normal" font="default" size="100%">Savarese, G.</style></author><author><style face="normal" font="default" size="100%">Krankel, N.</style></author><author><style face="normal" font="default" size="100%">Akhmedov, A.</style></author><author><style face="normal" font="default" size="100%">Keller, S.</style></author><author><style face="normal" font="default" size="100%">Mocharla, P.</style></author><author><style face="normal" font="default" size="100%">Kaufmann, M. R.</style></author><author><style face="normal" font="default" size="100%">Wenger, R. H.</style></author><author><style face="normal" font="default" size="100%">Vogel, J.</style></author><author><style face="normal" font="default" size="100%">Kulic, L.</style></author><author><style face="normal" font="default" size="100%">Nitsch, R. M.</style></author><author><style face="normal" font="default" size="100%">Beer, J. H.</style></author><author><style face="normal" font="default" size="100%">Peruzzotti-Jametti, L.</style></author><author><style face="normal" font="default" size="100%">Sessa, M.</style></author><author><style face="normal" font="default" size="100%">Luscher, T. F.</style></author><author><style face="normal" font="default" size="100%">Camici, G. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Molecular Cardiology, University of Zurich, Wagistrasse 12, Schlieren CH-8952, Switzerland Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Zurich, Switzerland.&#xD;Institute for Biomedical Engineering, Swiss Federal Institute of Technology Zurich (ETHZ), Zurich, Switzerland.&#xD;Department of Neurology, San Raffaele Scientific Institute, Milan, Italy.&#xD;Division of Psychiatry Research, University of Zurich, Schlieren, Switzerland.&#xD;Center for Molecular Cardiology, University of Zurich, Wagistrasse 12, Schlieren CH-8952, Switzerland.&#xD;Center for Molecular Cardiology, University of Zurich, Wagistrasse 12, Schlieren CH-8952, Switzerland Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Zurich, Switzerland Department of Cardiology, Charite - Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.&#xD;Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Zurich, Switzerland Institute of Physiology, University of Zurich, Zurich, Switzerland.&#xD;Institute of Veterinary Physiology, University of Zurich, Zurich, Switzerland.&#xD;Department of Internal Medicine, Cantonal Hospital of Baden, Baden, Switzerland.&#xD;Center for Molecular Cardiology, University of Zurich, Wagistrasse 12, Schlieren CH-8952, Switzerland Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Zurich, Switzerland Cardiology, University Heart Center, University Hospital, Zurich, Switzerland.&#xD;Center for Molecular Cardiology, University of Zurich, Wagistrasse 12, Schlieren CH-8952, Switzerland Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Zurich, Switzerland giovanni.camici@uzh.ch giovannicamici@hotmail.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Post-ischaemic silencing of p66Shc reduces ischaemia/reperfusion brain injury and its expression correlates to clinical outcome in stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Eur Heart J</style></secondary-title><alt-title><style face="normal" font="default" size="100%">European heart journal</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur Heart J</style></full-title><abbr-1><style face="normal" font="default" size="100%">European heart journal</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Eur Heart J</style></full-title><abbr-1><style face="normal" font="default" size="100%">European heart journal</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1590-600</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><number><style face="normal" font="default" size="100%">25</style></number><edition><style face="normal" font="default" size="100%">2015/04/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Analysis of Variance</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Claudin-5/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelial Cells/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Knockdown Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Silencing/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Postconditioning/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Microcirculation/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Reactive Oxygen Species/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Shc Signaling Adaptor Proteins/ genetics/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Src Homology 2 Domain-Containing, Transforming Protein 1</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 01</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1522-9645 (Electronic)&#xD;0195-668X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25904764</style></accession-num><abstract><style face="normal" font="default" size="100%">AIM: Constitutive genetic deletion of the adaptor protein p66(Shc) was shown to protect from ischaemia/reperfusion injury. Here, we aimed at understanding the molecular mechanisms underlying this effect in stroke and studied p66(Shc) gene regulation in human ischaemic stroke. METHODS AND RESULTS: Ischaemia/reperfusion brain injury was induced by performing a transient middle cerebral artery occlusion surgery on wild-type mice. After the ischaemic episode and upon reperfusion, small interfering RNA targeting p66(Shc) was injected intravenously. We observed that post-ischaemic p66(Shc) knockdown preserved blood-brain barrier integrity that resulted in improved stroke outcome, as identified by smaller lesion volumes, decreased neurological deficits, and increased survival. Experiments on primary human brain microvascular endothelial cells demonstrated that silencing of the adaptor protein p66(Shc) preserves claudin-5 protein levels during hypoxia/reoxygenation by reducing nicotinamide adenine dinucleotide phosphate oxidase activity and reactive oxygen species production. Further, we found that in peripheral blood monocytes of acute ischaemic stroke patients p66(Shc) gene expression is transiently increased and that this increase correlates with short-term neurological outcome. CONCLUSION: Post-ischaemic silencing of p66(Shc) upon reperfusion improves stroke outcome in mice while the expression of p66(Shc) gene correlates with short-term outcome in patients with ischaemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Spescha, R D&#xD;Klohs, J&#xD;Semerano, A&#xD;Giacalone, G&#xD;Derungs, R S&#xD;Reiner, M F&#xD;Rodriguez Gutierrez, D&#xD;Mendez-Carmona, N&#xD;Glanzmann, M&#xD;Savarese, G&#xD;Krankel, N&#xD;Akhmedov, A&#xD;Keller, S&#xD;Mocharla, P&#xD;Kaufmann, M R&#xD;Wenger, R H&#xD;Vogel, J&#xD;Kulic, L&#xD;Nitsch, R M&#xD;Beer, J H&#xD;Peruzzotti-Jametti, L&#xD;Sessa, M&#xD;Luscher, T F&#xD;Camici, G G&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Eur Heart J. 2015 Jul 1;36(25):1590-600. doi: 10.1093/eurheartj/ehv140. Epub 2015 Apr 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://eurheartj.oxfordjournals.org/content/ehj/36/25/1590.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1305050992/Spescha-2015-Post-ischaemic silen.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/eurheartj/ehv140</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>343</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">343</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Srejic, L. R.</style></author><author><style face="normal" font="default" size="100%">Valiante, T. A.</style></author><author><style face="normal" font="default" size="100%">Aarts, M. M.</style></author><author><style face="normal" font="default" size="100%">Hutchison, W. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Medical Sciences, University of Toronto, Toronto, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">High-frequency cortical activity associated with postischemic epileptiform discharges in an in vivo rat focal stroke model</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosurg</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neurosurgery</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosurg</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurosurgery</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosurg</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurosurgery</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1098-106</style></pages><volume><style face="normal" font="default" size="100%">118</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2013/02/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Waves/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Electrophysiological Phenomena</style></keyword><keyword><style face="normal" font="default" size="100%">Epilepsies, Partial/ etiology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Anterior Cerebral Artery/ complications</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Microelectrodes</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1933-0693 (Electronic)&#xD;0022-3085 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23413946</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECT: The postischemic brain has greater susceptibility to epileptogenic activity than physiologically healthy tissue. Epileptiform discharges are thought to exacerbate postischemic brain function. The aim of this study was to develop an in vivo focal stroke model in rats to characterize epileptiform activity. METHODS: The authors developed a parasagittal 8-channel intracortical microelectrode array to obtain recordings of cortical oscillations of local field potentials following partial middle and anterior cerebral artery occlusion. All experiments were done in urethane-anesthetized Sprague-Dawley rats. RESULTS: Theta runs (TRs), ranging in duration from 5 seconds to 5 minutes, were observed in 62% of animals within 1 hour of occlusion. High-frequency oscillations (HFOs) in the high gamma range (80-120 Hz) were observed 5-15 seconds before each TR and terminated at the onset of the discharge. Periodic epileptiform discharges (PEDs) were detected in 54% of rats following ischemia. The PEDs consisted of an early negative slow wave, a high-amplitude positive spike, and a short negative slow wave. Transient HFOs in the low gamma range (30-70 Hz) occurred during the first negative wave and the rising phase of the positive spike of the PED. CONCLUSIONS: These recordings provide the first intracortical evidence of a high-frequency component that could be an important element for diagnosis and intervention in postischemic epileptogenic activity. The early onset also suggests that HFOs could serve as a reliable method of detecting small epileptiform events and could be used as a consideration in deciding whether antiepileptic medications are appropriate as part of a patient&apos;s poststroke care.</style></abstract><notes><style face="normal" font="default" size="100%">Srejic, Luka R&#xD;Valiante, Taufik A&#xD;Aarts, Michelle M&#xD;Hutchison, William D&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Neurosurg. 2013 May;118(5):1098-106. doi: 10.3171/2013.1.JNS121059. Epub 2013 Feb 15.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3171/2013.1.jns121059</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>258</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">258</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stanczyk, F. Z.</style></author><author><style face="normal" font="default" size="100%">Bhavnani, B. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Obstetrics and Gynecology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA; Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA. Electronic address: fstanczyk@att.net.&#xD;Department of Obstetrics and Gynecology, University of Toronto and The Keenan Research Center of Li Ka Shing Knowledge Institute, St. Michael&apos;s Hospital, Toronto, Ont., Canada M5B 1W8.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: is it safe?</style></title><secondary-title><style face="normal" font="default" size="100%">J Steroid Biochem Mol Biol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The Journal of steroid biochemistry and molecular biology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Steroid Biochem Mol Biol</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of steroid biochemistry and molecular biology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Steroid Biochem Mol Biol</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of steroid biochemistry and molecular biology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">30-8</style></pages><volume><style face="normal" font="default" size="100%">142</style></volume><edition><style face="normal" font="default" size="100%">2013/12/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Coagulation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Breast Neoplasms/chemically induced</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases/chemically induced</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Estrogen Replacement Therapy/ adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Medroxyprogesterone Acetate/ adverse effects/pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Postmenopause</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1879-1220 (Electronic)&#xD;0960-0760 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24291402</style></accession-num><abstract><style face="normal" font="default" size="100%">Medroxyprogesterone acetate (MPA) has been in clinical use for over 30 years, and was generally considered to be safe until the results of long-term studies of postmenopausal hormone therapy (HT) using treatment with conjugated equine estrogens (CEE) combined with MPA and CEE alone suggested that MPA, and perhaps other progestogens, may play a role in the increased risk of breast cancer and cardiovascular diseases. This review examines critically the safety of MPA in terms of breast cancer and cardiovascular disease risk, and its effects on brain function. Research into mechanisms by which MPA might cause adverse effects in these areas, combined with the available clinical evidence, suggests a small increase in relative risk for breast cancer and stroke, and a decline in cognitive function, in older women using MPA with an estrogen for postmenopausal HT. However, short-term (less than 5 years) use of MPA with an estrogen in the years immediately after the onset of menopause for the management of vasomotor symptoms does not appear to be associated with any increased risk of these disorders.</style></abstract><notes><style face="normal" font="default" size="100%">Stanczyk, Frank Z&#xD;Bhavnani, Bhagu R&#xD;Review&#xD;England&#xD;J Steroid Biochem Mol Biol. 2014 Jul;142:30-8. doi: 10.1016/j.jsbmb.2013.11.011. Epub 2013 Nov 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0960076013002665/1-s2.0-S0960076013002665-main.pdf?_tid=3becd392-d7d4-11e6-8c8e-00000aacb361&amp;acdnat=1484121902_035ccb269e9e4ef9f308d80861b1efa7</style></url></related-urls><pdf-urls><url>internal-pdf://3528018259/Stanczyk-2014-Use of medroxyproges.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jsbmb.2013.11.011</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>302</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">302</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stegner, D.</style></author><author><style face="normal" font="default" size="100%">Thielmann, I.</style></author><author><style face="normal" font="default" size="100%">Kraft, P.</style></author><author><style face="normal" font="default" size="100%">Frohman, M. A.</style></author><author><style face="normal" font="default" size="100%">Stoll, G.</style></author><author><style face="normal" font="default" size="100%">Nieswandt, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University Hospital Wurzburg, Rudolf Virchow Center, DFG Research Center for Experimental Biomedicine, University of Wurzburg, Wurzburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pharmacological inhibition of phospholipase D protects mice from occlusive thrombus formation and ischemic stroke--brief report</style></title><secondary-title><style face="normal" font="default" size="100%">Arterioscler Thromb Vasc Biol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Arteriosclerosis, thrombosis, and vascular biology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Arterioscler Thromb Vasc Biol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Arteriosclerosis, thrombosis, and vascular biology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Arterioscler Thromb Vasc Biol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Arteriosclerosis, thrombosis, and vascular biology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">2212-7</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2013/07/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Platelets/ drug effects/enzymology</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Artery Diseases/blood/enzymology/genetics/physiopathology/ prevention &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Domperidone/ analogs &amp; derivatives/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme Inhibitors/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Fibrinolytic Agents/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Hemostasis/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Indoles/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral</style></keyword><keyword><style face="normal" font="default" size="100%">Artery/blood/enzymology/genetics/physiopathology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Integrins/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Phospholipase D/ antagonists &amp; inhibitors/deficiency/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery of Function</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombosis/blood/enzymology/genetics/physiopathology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4636 (Electronic)&#xD;1079-5642 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23868933</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: We recently showed that mice lacking the lipid signaling enzyme phospholipase (PL) D1 or both PLD isoforms (PLD1 and PLD2) were protected from pathological thrombus formation and ischemic stroke, whereas hemostasis was not impaired in these animals. We sought to assess whether pharmacological inhibition of PLD activity affects hemostasis, thrombosis, and thrombo-inflammatory brain infarction in mice. APPROACH AND RESULTS: Treatment of platelets with the reversible, small molecule PLD inhibitor, 5-fluoro-2-indolyl des-chlorohalopemide (FIPI), led to a specific blockade of PLD activity that was associated with reduced alpha-granule release and integrin activation. Mice that received FIPI at a dose of 3 mg/kg displayed reduced occlusive thrombus formation upon chemical injury of carotid arteries or mesenterial arterioles. Similarly, FIPI-treated mice had smaller infarct sizes and significantly better motor and neurological function 24 hours after transient middle cerebral artery occlusion. This protective effect was not associated with major intracerebral hemorrhage or prolonged tail bleeding times. CONCLUSIONS: These results provide the first evidence that pharmacological PLD inhibition might provide a safe therapeutic strategy to prevent arterial thrombosis and ischemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Stegner, David&#xD;Thielmann, Ina&#xD;Kraft, Peter&#xD;Frohman, Michael A&#xD;Stoll, Guido&#xD;Nieswandt, Bernhard&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Arterioscler Thromb Vasc Biol. 2013 Sep;33(9):2212-7. doi: 10.1161/ATVBAHA.113.302030. Epub 2013 Jul 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://atvb.ahajournals.org/content/atvbaha/33/9/2212.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0214258170/Stegner-2013-Pharmacological inhi.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/atvbaha.113.302030</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>394</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">394</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stemmer, N.</style></author><author><style face="normal" font="default" size="100%">Mehnert, J.</style></author><author><style face="normal" font="default" size="100%">Steinbrink, J.</style></author><author><style face="normal" font="default" size="100%">Wunder, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Stroke Research Berlin, Small Animal Imaging Center, Department of Experimental Neurology, Charite - University Medicine Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Noninvasive fluorescence imaging in animal models of stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Med Chem</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Current medicinal chemistry</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Med Chem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current medicinal chemistry</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Curr Med Chem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current medicinal chemistry</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">4786-93</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">28</style></number><edition><style face="normal" font="default" size="100%">2012/08/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorescent Dyes/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Luminescent Measurements</style></keyword><keyword><style face="normal" font="default" size="100%">Matrix Metalloproteinases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Quantum Dots</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Tomography, Optical</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1875-533X (Electronic)&#xD;0929-8673 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22873664</style></accession-num><abstract><style face="normal" font="default" size="100%">Noninvasive fluorescence imaging (NFI) is a powerful tool to study physiology and pathophysiology in animal disease models. NFI has been successfully applied in a number of animal disease models including cancer, arthritis, and stroke. Furthermore, several applications in humans have been described. NFI is widely available in research laboratories because it has a number of advantages: It uses non-ionizing radiation and requires comparably simple, inexpensive instrumentation, and easy to handle. Fluorochromes can be detected with high sensitivity, and image acquisition time is relatively short. Furthermore, a plethora of fluorescent imaging agents is available including unspecific, target-specific, and activatable imaging probes. With these probes, biological processes such as inflammation, cell death or enzyme activity, and many others can be visualized in living animals. This review offers an overview of current approaches in NFI of stroke pathophysiology in animal models of cerebral ischemia. First, the instrumentation and the different types of imaging agents for NFI are described. Second, a short introduction to animal models of stroke is provided. Third, examples for NFI in animal models of stroke are given. Finally, the use of NFI in human stroke is critically discussed.</style></abstract><notes><style face="normal" font="default" size="100%">Stemmer, N&#xD;Mehnert, J&#xD;Steinbrink, J&#xD;Wunder, A&#xD;Review&#xD;Netherlands&#xD;Curr Med Chem. 2012;19(28):4786-93.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>271</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">271</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Strom, J. O.</style></author><author><style face="normal" font="default" size="100%">Ingberg, E.</style></author><author><style face="normal" font="default" size="100%">Theodorsson, E.</style></author><author><style face="normal" font="default" size="100%">Theodorsson, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinical Chemistry, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, Department of Clinical Chemistry, County Council of Ostergotland, Linkoping, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of high and low 17beta-estradiol doses on focal cerebral ischemia: negative results</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Rep</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Scientific reports</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Sci Rep</style></full-title><abbr-1><style face="normal" font="default" size="100%">Scientific reports</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Sci Rep</style></full-title><abbr-1><style face="normal" font="default" size="100%">Scientific reports</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">3111</style></pages><volume><style face="normal" font="default" size="100%">3</style></volume><edition><style face="normal" font="default" size="100%">2013/11/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Body Weight</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ drug therapy/mortality/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/drug therapy/mortality/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Estradiol/ administration &amp; dosage/pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 01</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2045-2322 (Electronic)&#xD;2045-2322 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24177749</style></accession-num><abstract><style face="normal" font="default" size="100%">The reasons why some animal studies indicate that estrogens increase focal cerebral ischemic damage while others show estrogen-induced neuroprotection has hitherto not been fully elucidated. Recent evidence indicates that discrepancies in hormone administration paradigms, resulting in highly different serum hormone concentrations, may account for the dichotomy. The current study aimed to test this hypothesis. Sixty ovariectomized female rats were randomized into three groups differing in 17beta-estradiol regimens, and transient focal cerebral ischemia was subsequently induced. All animals were subjected to a small functional testing battery, and three days after MCAo they were sacrificed for infarct size assessment. Infarct sizes did not differ between groups, however clear discrepancies were seen in body weight and feeding behavior. In comparison to sham-operated animals, ovariectomized rats rapidly increased in body weight, whereas the opposite was seen in rats receiving 17beta-estradiol. The weight gain in the ovariectomized rats was paralleled by an increased food intake.</style></abstract><notes><style face="normal" font="default" size="100%">Strom, Jakob O&#xD;Ingberg, Edvin&#xD;Theodorsson, Elvar&#xD;Theodorsson, Annette&#xD;England&#xD;Sci Rep. 2013 Nov 1;3:3111. doi: 10.1038/srep03111.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/srep03111</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>41</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">41</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Struzyna, L. A.</style></author><author><style face="normal" font="default" size="100%">Wolf, J. A.</style></author><author><style face="normal" font="default" size="100%">Mietus, C. J.</style></author><author><style face="normal" font="default" size="100%">Adewole, D. O.</style></author><author><style face="normal" font="default" size="100%">Chen, H. I.</style></author><author><style face="normal" font="default" size="100%">Smith, D. H.</style></author><author><style face="normal" font="default" size="100%">Cullen, D. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">1 Center for Brain Injury and Repair, Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania , Philadelphia, Pennsylvania.&#xD;2 Philadelphia Veterans Affairs Medical Center , Philadelphia, Pennsylvania.&#xD;3 Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania , Philadelphia, Pennsylvania.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Rebuilding Brain Circuitry with Living Micro-Tissue Engineered Neural Networks</style></title><secondary-title><style face="normal" font="default" size="100%">Tissue Eng Part A</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Tissue engineering. Part A</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Tissue Eng Part A</style></full-title><abbr-1><style face="normal" font="default" size="100%">Tissue engineering. Part A</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Tissue Eng Part A</style></full-title><abbr-1><style face="normal" font="default" size="100%">Tissue engineering. Part A</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">2744-56</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">21-22</style></number><edition><style face="normal" font="default" size="100%">2015/09/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ cytology/physiology/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Guided Tissue Regeneration/instrumentation/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Net/ cytology/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Regeneration/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/ cytology/ transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Neurosurgical Procedures/instrumentation/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Tissue Engineering/instrumentation/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Tissue Scaffolds</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1937-335X (Electronic)&#xD;1937-3341 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26414439</style></accession-num><abstract><style face="normal" font="default" size="100%">Prominent neuropathology following trauma, stroke, and various neurodegenerative diseases includes neuronal degeneration as well as loss of long-distance axonal connections. While cell replacement and axonal pathfinding strategies are often explored independently, there is no strategy capable of simultaneously replacing lost neurons and re-establishing long-distance axonal connections in the central nervous system. Accordingly, we have created micro-tissue engineered neural networks (micro-TENNs), which are preformed constructs consisting of long integrated axonal tracts spanning discrete neuronal populations. These living micro-TENNs reconstitute the architecture of long-distance axonal tracts, and thus may serve as an effective substrate for targeted neurosurgical reconstruction of damaged pathways in the brain. Cerebral cortical neurons or dorsal root ganglia neurons were precisely delivered into the tubular constructs, and properties of the hydrogel exterior and extracellular matrix internal column (180-500 mum diameter) were optimized for robust neuronal survival and to promote axonal extensions across the 2.0 cm tube length. The very small diameter permits minimally invasive delivery into the brain. In this study, preformed micro-TENNs were stereotaxically injected into naive rats to bridge deep thalamic structures with the cerebral cortex to assess construct survival and integration. We found that micro-TENN neurons survived at least 1 month and maintained their long axonal architecture along the cortical-thalamic axis. Notably, we also found neurite penetration from micro-TENN neurons into the host cortex, with evidence of synapse formation. These micro-TENNs represent a new strategy to facilitate nervous system repair by recapitulating features of neural pathways to restore or modulate damaged brain circuitry.</style></abstract><notes><style face="normal" font="default" size="100%">Struzyna, Laura A&#xD;Wolf, John A&#xD;Mietus, Constance J&#xD;Adewole, Dayo O&#xD;Chen, H Isaac&#xD;Smith, Douglas H&#xD;Cullen, D Kacy&#xD;T32-NS043126/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United States&#xD;Tissue Eng Part A. 2015 Nov;21(21-22):2744-56. doi: 10.1089/ten.TEA.2014.0557. Epub 2015 Oct 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://online.liebertpub.com/doi/10.1089/ten.tea.2014.0557</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4652241</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1089/ten.TEA.2014.0557</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>247</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">247</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Su, J. J.</style></author><author><style face="normal" font="default" size="100%">Pan, H.</style></author><author><style face="normal" font="default" size="100%">Zhou, H. G.</style></author><author><style face="normal" font="default" size="100%">Tang, Y. P.</style></author><author><style face="normal" font="default" size="100%">Dong, Q.</style></author><author><style face="normal" font="default" size="100%">Liu, J. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Shanghai Ninth People&apos;s Hospital, Shanghai Jiao Tong University, Shanghai, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Acid-sensing ion channels activation and hypoxia upregulate Homer1a expression</style></title><secondary-title><style face="normal" font="default" size="100%">CNS Neurosci Ther</style></secondary-title><alt-title><style face="normal" font="default" size="100%">CNS neuroscience &amp; therapeutics</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">CNS Neurosci Ther</style></full-title><abbr-1><style face="normal" font="default" size="100%">CNS neuroscience &amp; therapeutics</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">CNS Neurosci Ther</style></full-title><abbr-1><style face="normal" font="default" size="100%">CNS neuroscience &amp; therapeutics</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">264-74</style></pages><volume><style face="normal" font="default" size="100%">20</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2014/01/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">6-Cyano-7-nitroquinoxaline-2,3-dione/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Acid Sensing Ion Channel Blockers/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Acid Sensing Ion Channels/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Amiloride/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Carrier Proteins/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Survival</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Dizocilpine Maleate/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Excitatory Amino Acid Antagonists/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Homer Scaffolding Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ metabolism/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Peptides/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Spider Venoms/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation/drug effects/ physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1755-5949 (Electronic)&#xD;1755-5930 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24433527</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Recent studies have indicated that dynamic alterations in the structure of postsynaptic density (PSD) are involved in the pathogenesis of many central nervous system disorders, including ischemic stroke. Homer is the newly identified scaffolding protein located at PSD and regulates synaptic function. Homer1a, an immediate early gene, has been shown to be induced by several stimulations, such as glutamate, brain-derived neurotrophic factor, and trauma. However, whether acidosis mediated by acid-sensing ion channels (ASICs) and hypoxia during cerebral ischemia can change Homer1a expression remains to be determined. RESULTS: We investigated that acidosis and hypoxia selectively and rapidly upregulated Homer1a expression, but not Homer1b/c in cultured cortical neurons. We also found that Homer1a exhibited induction expression in brain cortex of the middle cerebral artery occlusion (MCAO) rats. Additionally, acid-evoked Homer1a mRNA induction depended on extracellular signal-regulated kinase1/2 (ERK1/2) and Akt activity, and ASIC1a-mediated calcium influx whereas hypoxia depended only on ERK1/2 activity. Also, we demonstrated that continuous acidosis and hypoxia resulted in pronounced cell injury and Homer1a knockdown with small interfering RNA aggravated this damage induced by 3 h acid and hypoxia incubation in neuro-2a cells. CONCLUSION: Homer1a might act as an activity-dependent regulator responding to extracellular stimuli during cerebral ischemia.</style></abstract><notes><style face="normal" font="default" size="100%">Su, Jing-Jing&#xD;Pan, Hui&#xD;Zhou, Hou-Guang&#xD;Tang, Yu-Ping&#xD;Dong, Qiang&#xD;Liu, Jian-Ren&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;CNS Neurosci Ther. 2014 Mar;20(3):264-74. doi: 10.1111/cns.12206. Epub 2014 Jan 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/cns.12206/asset/cns12206.pdf?v=1&amp;t=ixsnrjq4&amp;s=5e0d0e1e13d7abbfd65b9efa4f55fe520e4bd9e3</style></url></related-urls><pdf-urls><url>internal-pdf://4276000392/Su-2014-Acid-sensing ion cha.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/cns.12206</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>408</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">408</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sumbria, R. K.</style></author><author><style face="normal" font="default" size="100%">Boado, R. J.</style></author><author><style face="normal" font="default" size="100%">Pardridge, W. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, UCLA, Los Angeles, California 90024, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Brain protection from stroke with intravenous TNFalpha decoy receptor-Trojan horse fusion protein</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1933-8</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2012/06/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Intravenous</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal/administration &amp; dosage/immunology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/drug effects/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">CHO Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Cricetinae</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin gamma-Chains/administration &amp; dosage/immunology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/pathology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/administration &amp; dosage/immunology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Transferrin/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Tumor Necrosis Factor/administration &amp; dosage/immunology/ therapeutic</style></keyword><keyword><style face="normal" font="default" size="100%">use</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Fusion Proteins/administration &amp; dosage/immunology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/pathology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Tumor Necrosis Factor-alpha/ antagonists &amp; inhibitors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22714051</style></accession-num><abstract><style face="normal" font="default" size="100%">Tumor necrosis factor (TNF)-alpha is produced in brain in response to acute cerebral ischemia, and promotes neuronal apoptosis. Biologic TNF inhibitors (TNFIs), such as the etanercept, cannot be developed as new stroke treatments because these large molecule drugs do not cross the blood-brain barrier (BBB). A BBB-penetrating biologic TNFI was engineered by fusion of the type II human TNF receptor (TNFR) to each heavy chain of a genetically engineered chimeric monoclonal antibody (MAb) against the mouse transferrin receptor (TfR), designated as cTfRMAb-TNFR fusion protein. The cTfRMAb domain of the fusion protein acts as a molecular Trojan horse to deliver the fused TNFR across the BBB. Etanercept or the cTfRMAb-TNFR fusion protein (1 mg/kg) was administered intravenously in adult mice subjected to 1-hour reversible middle cerebral artery occlusion up to 90 minutes after the occlusion. Neuroprotection was assessed at 24 hours or 7 days after occlusion. The cTfRMAb-TNFR fusion protein treatment caused a significant 45%, 48%, 42%, and 54% reduction in hemispheric, cortical, and subcortical stroke volumes, and neural deficit, respectively. Intravenous etanercept had no therapeutic effect. Biologic TNFIs can be reengineered for BBB penetration, and the IgG-TNFR fusion protein is therapeutic after delayed intravenous administration in experimental stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Sumbria, Rachita K&#xD;Boado, Ruben J&#xD;Pardridge, William M&#xD;United States&#xD;J Cereb Blood Flow Metab. 2012 Oct;32(10):1933-8. doi: 10.1038/jcbfm.2012.97. Epub 2012 Jun 20.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3463885</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2012.97</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>341</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">341</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sumbria, R. K.</style></author><author><style face="normal" font="default" size="100%">Boado, R. J.</style></author><author><style face="normal" font="default" size="100%">Pardridge, W. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, UCLA, Los Angeles, CA 90024, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Combination stroke therapy in the mouse with blood-brain barrier penetrating IgG-GDNF and IgG-TNF decoy receptor fusion proteins</style></title><secondary-title><style face="normal" font="default" size="100%">Brain Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">91-6</style></pages><volume><style face="normal" font="default" size="100%">1507</style></volume><edition><style face="normal" font="default" size="100%">2013/02/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Glial Cell Line-Derived Neurotrophic Factor/genetics/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, TNF-Related Apoptosis-Inducing Ligand/genetics/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Fusion Proteins/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ drug therapy/pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 24</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-6240 (Electronic)&#xD;0006-8993 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23428543</style></accession-num><abstract><style face="normal" font="default" size="100%">Stroke therapy may be optimized by combination therapy with both a neuroprotective neurotrophin and an anti-inflammatory agent. In the present work, the model neurotrophin is glial cell line-derived neurotrophic factor (GDNF), and the model anti-inflammatory agent is the type II tumor necrosis factor receptor (TNFR) decoy receptor. Both the GDNF and the TNFR are large molecules that do not cross the blood-brain barrier (BBB), which is intact in the early hours after stroke when neural rescue is still possible. The GDNF and the TNFR decoy receptor were re-engineered for BBB transport as IgG fusion proteins, wherein the GDNF or the TNFR are fused to the heavy chain of a chimeric monoclonal antibody (MAb) against the mouse transferrin receptor (TfR), and these fusion proteins are designated cTfRMAb-GDNF and cTfRMAb-TNFR, respectively. Mice were treated intravenously with (a) saline, (b) GDNF alone, (c) the cTfRMAb-GDNF fusion protein alone, or (d) the combined cTfRMAb-GDNF and cTfRMAb-TNFR fusion proteins, following a 1-h reversible middle cerebral artery occlusion (MCAO). The cTfRMAb-GDNF fusion protein alone caused a significant 25% and 30% reduction in hemispheric and cortical stroke volumes. Combined treatment with the cTfRMAb-GDNF and cTfRMAb-TNFR fusion proteins caused a significant 54%, 69% and 30% reduction in hemispheric, cortical and subcortical stroke volumes. Conversely, intravenous GDNF had no therapeutic effect. In conclusion, combination treatment with BBB penetrating IgG-GDNF and IgG-TNFR fusion proteins enhances the therapeutic effect of single treatment with the IgG-GDNF fusion protein following delayed intravenous administration in acute stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Sumbria, Rachita K&#xD;Boado, Ruben J&#xD;Pardridge, William M&#xD;R01 NS065917/NS/NINDS NIH HHS/United States&#xD;Netherlands&#xD;Brain Res. 2013 Apr 24;1507:91-6. doi: 10.1016/j.brainres.2013.02.022. Epub 2013 Feb 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0006899313002552/1-s2.0-S0006899313002552-main.pdf?_tid=534797fc-d7d4-11e6-be82-00000aacb35d&amp;acdnat=1484121941_719126cae0afe213e21a66fbc25d321d</style></url></related-urls><pdf-urls><url>internal-pdf://3446728908/Sumbria-2013-Combination stroke t.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.brainres.2013.02.022</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>143</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">143</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sun, S.</style></author><author><style face="normal" font="default" size="100%">Chen, X.</style></author><author><style face="normal" font="default" size="100%">Gao, Y.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author><author><style face="normal" font="default" size="100%">Zhai, Q.</style></author><author><style face="normal" font="default" size="100%">Xiong, L.</style></author><author><style face="normal" font="default" size="100%">Cai, M.</style></author><author><style face="normal" font="default" size="100%">Wang, Q.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Anesthesiology Xijing Hospital, Fourth Military Medical University, Xi&apos;an, 710032, Shaanxi Province, China.&#xD;Department of Physiology, Fourth Military Medical University, Xi&apos;an, 710032, China.&#xD;Department of Psychiatry, Xijing Hospital, Fourth Military Medical University, Xi&apos;an, 710032, Shaanxi Province, China. caimin@fmmu.edu.cn.&#xD;Department of Anesthesiology Xijing Hospital, Fourth Military Medical University, Xi&apos;an, 710032, Shaanxi Province, China. wangqiang@fmmu.edu.cn.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mn-SOD Upregulation by Electroacupuncture Attenuates Ischemic Oxidative Damage via CB1R-Mediated STAT3 Phosphorylation</style></title><secondary-title><style face="normal" font="default" size="100%">Mol Neurobiol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Molecular neurobiology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Mol Neurobiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Molecular neurobiology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Mol Neurobiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Molecular neurobiology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">331-43</style></pages><volume><style face="normal" font="default" size="100%">53</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2014/11/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/enzymology/pathology/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Electroacupuncture</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Knockdown Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Biological</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotection</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative Stress</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphorylation</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Cannabinoid, CB1/agonists/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">STAT3 Transcription Factor/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Superoxide Dismutase/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-1182 (Electronic)&#xD;0893-7648 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25432886</style></accession-num><abstract><style face="normal" font="default" size="100%">Electroacupuncture (EA) pretreatment elicits the neuroprotective effect against cerebral ischemic injury through cannabinoid receptor type 1 receptor (CB1R). In current study, we aimed to investigate whether the signal transducer and activator of transcription 3 (STAT3) and manganese superoxide dismutase (Mn-SOD) were involved in the antioxidant effect of EA pretreatment through CB1R. At 2 h after EA pretreatment, focal cerebral ischemic injury was induced by transient middle cerebral artery occlusion for 60 min in C57BL/6 mice. The expression of Mn-SOD in the penumbra was assessed by Western blot and immunoflourescent staining at 2 h after reperfusion. In the presence or absence of Mn-SOD small interfering RNA (siRNA), the neurological deficit score, the infarct volume, the terminal deoxynucleotidyl transferase-mediated dUDP-biotin nick end labeling (TUNEL) staining, and oxidative stress were evaluated. Furthermore, the Mn-SOD protein expression and phosphorylation of STAT3 at Y705 were also determined in the presence and absence of CB1R antagonists (AM251, SR141716) and CB1R agonists (arachidonyl-2-chloroethylamide (ACEA), WIN 55,212-2). EA pretreatment upregulated the Mn-SOD protein expression and Mn-SOD-positive neuronal cells at 2 h after reperfusion. EA pretreatment also attenuated oxidative stress, inhibited cellular apoptosis, and induced neuroprotection against ischemic damage, whereas these beneficial effects of EA pretreatment were reversed by knockdown of Mn-SOD. Mn-SOD upregulation and STAT3 phosphorylation by EA pretreatment were abolished by two CB1R antagonists, while pretreatment with two CB1R agonists increased the expression of Mn-SOD and phosphorylation level of STAT3. Mn-SOD upregulation by EA attenuates ischemic oxidative damage through CB1R-mediated STAT3 phosphorylation in stroke mice, which may represent one new mechanism of EA pretreatment-induced neuroprotection against cerebral ischemia.</style></abstract><notes><style face="normal" font="default" size="100%">Sun, Sisi&#xD;Chen, Xiyao&#xD;Gao, Yang&#xD;Liu, Zhaoyu&#xD;Zhai, Qian&#xD;Xiong, Lize&#xD;Cai, Min&#xD;Wang, Qiang&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Mol Neurobiol. 2016 Jan;53(1):331-43. doi: 10.1007/s12035-014-8971-7. Epub 2014 Nov 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/745/art%253A10.1007%252Fs12035-014-8971-7.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12035-014-8971-7&amp;token2=exp=1484122949~acl=%2Fstatic%2Fpdf%2F745%2Fart%25253A10.1007%25252Fs12035-014-8971-7.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs12035-014-8971-7*~hmac=11df4b3d3f01209a14588dde66807428208a560c601f04a38f3d8e163876cc44</style></url></related-urls><pdf-urls><url>internal-pdf://1470411580/Sun-2016-Mn-SOD Upregulation.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12035-014-8971-7</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>476</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">476</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sun, Y. Y.</style></author><author><style face="normal" font="default" size="100%">Yang, D.</style></author><author><style face="normal" font="default" size="100%">Kuan, C. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Developmental Biology, Division of Neurology, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, OH 45229, United States.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mannitol-facilitated perfusion staining with 2,3,5-triphenyltetrazolium chloride (TTC) for detection of experimental cerebral infarction and biochemical analysis</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosci Methods</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neuroscience methods</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosci Methods</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroscience methods</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosci Methods</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroscience methods</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">122-9</style></pages><volume><style face="normal" font="default" size="100%">203</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2011/10/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Coloring Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoblotting</style></keyword><keyword><style face="normal" font="default" size="100%">Immunohistochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mannitol/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Perfusion</style></keyword><keyword><style face="normal" font="default" size="100%">Reverse Transcriptase Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default" size="100%">Staining and Labeling/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Tetrazolium Salts</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-678X (Electronic)&#xD;0165-0270 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">21982741</style></accession-num><abstract><style face="normal" font="default" size="100%">A simple method to quantify cerebral infarction has great value for mechanistic and therapeutic studies in experimental stroke research. Immersion staining of unfixed brain slices with 2,3,5-triphenyltetrazolium chloride (TTC) is a popular method to determine cerebral infarction in preclinical studies. However, it is often difficult to apply immersion TTC-labeling to severely injured or soft newborn brains in rodents. Here we report an in vivo TTC perfusion-labeling method based on osmotic opening of blood-brain-barrier with mannitol-pretreatment. This new method delineates cortical infarction correlated with the boundary of morphological cell injury, differentiates the induction or subcellular redistribution of apoptosis-related factors between viable and damaged areas, and easily determines the size of cerebral infarction in both adult and newborn mice. Using this method, we confirmed that administration of lipopolysaccharide 72 h before hypoxia-ischemia increases the damage in neonatal mouse brains, in contrast to its effect of protective preconditioning in adults. These results demonstrate a fast and inexpensive method that simplifies the task of quantifying cerebral infarction in small or severely injured brains and assists biochemical analysis of experimental cerebral ischemia.</style></abstract><notes><style face="normal" font="default" size="100%">Sun, Yu-Yo&#xD;Yang, Dianer&#xD;Kuan, Chia-Yi&#xD;R21 NS074559/NS/NINDS NIH HHS/United States&#xD;R21 NS074559-01/NS/NINDS NIH HHS/United States&#xD;NS 074559/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;J Neurosci Methods. 2012 Jan 15;203(1):122-9. doi: 10.1016/j.jneumeth.2011.09.029. Epub 2011 Oct 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0165027011005966/1-s2.0-S0165027011005966-main.pdf?_tid=5082dae0-d7d4-11e6-bb6e-00000aab0f27&amp;acdnat=1484121936_3058b5b36860af70577ef2f09fa76f94</style></url></related-urls><pdf-urls><url>internal-pdf://2895564487/Sun-2012-Mannitol-facilitated.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3268057</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms332422</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jneumeth.2011.09.029</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>393</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">393</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Suzuki, H.</style></author><author><style face="normal" font="default" size="100%">Shiba, M.</style></author><author><style face="normal" font="default" size="100%">Fujimoto, M.</style></author><author><style face="normal" font="default" size="100%">Kawamura, K.</style></author><author><style face="normal" font="default" size="100%">Nanpei, M.</style></author><author><style face="normal" font="default" size="100%">Tekeuchi, E.</style></author><author><style face="normal" font="default" size="100%">Matsushima, S.</style></author><author><style face="normal" font="default" size="100%">Kanamaru, K.</style></author><author><style face="normal" font="default" size="100%">Imanaka-Yoshida, K.</style></author><author><style face="normal" font="default" size="100%">Yoshida, T.</style></author><author><style face="normal" font="default" size="100%">Taki, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Mie University Graduate School of Medicine, Mie, Japan. suzuki02@clin.medic.mie-u.ac.jp</style></auth-address><titles><title><style face="normal" font="default" size="100%">Matricellular protein: a new player in cerebral vasospasm following subarachnoid hemorrhage</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Neurochir Suppl</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Acta neurochirurgica. Supplement</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Neurochir Suppl</style></full-title><abbr-1><style face="normal" font="default" size="100%">Acta neurochirurgica. Supplement</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Acta Neurochir Suppl</style></full-title><abbr-1><style face="normal" font="default" size="100%">Acta neurochirurgica. Supplement</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">213-8</style></pages><volume><style face="normal" font="default" size="100%">115</style></volume><edition><style face="normal" font="default" size="100%">2012/08/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Basilar Artery/drug effects/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Carbon</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Angiography</style></keyword><keyword><style face="normal" font="default" size="100%">Cisterna Magna/drug effects/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Neurologic Examination</style></keyword><keyword><style face="normal" font="default" size="100%">Osteopontin/ metabolism/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Statistics, Nonparametric</style></keyword><keyword><style face="normal" font="default" size="100%">Subarachnoid Hemorrhage/ complications/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Tenascin/ metabolism/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Vasoconstriction/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Vasospasm, Intracranial/ etiology/pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">0065-1419 (Print)&#xD;0065-1419 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22890671</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Matricellular protein (MCP) is a class of nonstructural and secreted extracellular matrix proteins that exert diverse functions, but its role in vascular smooth muscle contraction has not been investigated. MATERIAL AND METHODS: First, rat subarachnoid hemorrhage (SAH) models were produced by endovascular perforation and examined for tenascin-C (TNC) and osteopontin (OPN) induction (representatives of MCPs) in vasospastic cerebral arteries using immunostaining. Second, recombinant TNC (r-TNC), recombinant OPN (r-OPN), or both were injected into a cisterna magna in healthy rats, and the effects on the diameter of basilar arteries were determined using India ink angiography. RESULTS: In SAH rats, TNC immunoreactivity was markedly induced in the smooth muscle cell layers of spastic cerebral arteries on day 1 but not in control animals. The TNC immunoreactivity decreased on day 3 as vasospasm improved: OPN immunoreactivity, on the other hand, was more induced in the arterial wall on day 3. r-TNC injections caused prolonged contractions of rat basilar arteries, which were reversed by r-OPN, although r-OPN itself had no effect on the vessel diameter. CONCLUSIONS: MCPs, including TNC and OPN, may contribute to the pathophysiology of cerebral vasospasm and provide a novel therapeutic approach against it.</style></abstract><notes><style face="normal" font="default" size="100%">Suzuki, Hidenori&#xD;Shiba, Masato&#xD;Fujimoto, Masashi&#xD;Kawamura, Kengo&#xD;Nanpei, Mai&#xD;Tekeuchi, Eriko&#xD;Matsushima, Satoshi&#xD;Kanamaru, Kenji&#xD;Imanaka-Yoshida, Kyoko&#xD;Yoshida, Toshimichi&#xD;Taki, Waro&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Austria&#xD;Acta Neurochir Suppl. 2013;115:213-8. doi: 10.1007/978-3-7091-1192-5_39.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/103/chp%253A10.1007%252F978-3-7091-1192-5_39.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Fchapter%2F10.1007%2F978-3-7091-1192-5_39&amp;token2=exp=1484122954~acl=%2Fstatic%2Fpdf%2F103%2Fchp%25253A10.1007%25252F978-3-7091-1192-5_39.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Fchapter%252F10.1007%252F978-3-7091-1192-5_39*~hmac=17cd413f9839b22ef0b8403d58d5ee8650fda6bd7b23d69b06295aa0cd11d6c8</style></url></related-urls><pdf-urls><url>internal-pdf://4134716695/Suzuki-2013-Matricellular protei.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/978-3-7091-1192-5_39</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>52</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">52</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sweet, J. G.</style></author><author><style face="normal" font="default" size="100%">Chan, S. L.</style></author><author><style face="normal" font="default" size="100%">Cipolla, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departments of Neurological Sciences, Obstetrics, Gynecology &amp; Reproductive Sciences, and Pharmacology, University of Vermont College of Medicine, Burlington, Vermont.&#xD;Departments of Neurological Sciences, Obstetrics, Gynecology &amp; Reproductive Sciences, and Pharmacology, University of Vermont College of Medicine, Burlington, Vermont marilyn.cipolla@uvm.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of hypertension and carotid occlusion on brain parenchymal arteriole structure and reactivity</style></title><secondary-title><style face="normal" font="default" size="100%">J Appl Physiol (1985)</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of applied physiology (Bethesda, Md. : 1985)</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Appl Physiol (1985)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of applied physiology (Bethesda, Md. : 1985)</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Appl Physiol (1985)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of applied physiology (Bethesda, Md. : 1985)</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">817-23</style></pages><volume><style face="normal" font="default" size="100%">119</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2015/08/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arterioles/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Stenosis/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle Tonus/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle, Smooth, Vascular/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Perfusion</style></keyword><keyword><style face="normal" font="default" size="100%">Potassium Channels/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred SHR</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred WKY</style></keyword><keyword><style face="normal" font="default" size="100%">Vasoconstriction/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilation/physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 01</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1522-1601 (Electronic)&#xD;0161-7567 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26294749</style></accession-num><abstract><style face="normal" font="default" size="100%">We studied the effect of hypertension and chronic hypoperfusion on brain parenchymal arteriole (PA) structure and function. PAs were studied isolated and pressurized from 18-wk-old Wistar-Kyoto (WKY18; n = 8) and spontaneously hypertensive stroke prone (SHRSP18; n = 8) and 5-wk-old prehypertensive (SHRSP5; n = 8) rats. In separate groups, unilateral common carotid artery occlusion (UCCAo) was performed for 4 wk to cause chronic hypoperfusion in 18-wk-old WKY (WKY18-CH; n = 8) and SHRSP (SHRSP18-CH; n = 8). UCCAo caused PAs to have significantly diminished myogenic tone (31 +/- 3 vs. 14 +/- 6% at 60 mmHg; P &lt; 0.05) and reactivity to pressure from WKY18-CH vs. WKY18 animals. The effect of UCCAo was limited to normotensive animals, as there was little effect of chronic hypoperfusion on vascular reactivity or percent tone in PAs from SHRSP18 vs. SHRSP18-CH animals (53 +/- 4 vs. 41 +/- 3%; P &gt; 0.05). However, PAs from SHRSP18 and SHRSP5 animals had significantly greater tone compared with WKY18, suggesting an effect of strain and not hypertension per se on PA vasoconstriction. Structurally, PAs from SHRSP18 and SHRSP5 animals had similar sized lumen diameters, but increased wall thickness and distensibility compared with WKY18. Interestingly, chronic hypoperfusion did not affect the structure of PAs from either WKY18-CH or SHRSP18-CH animals. Thus PAs responded to UCCAo with active vasodilation, but not structural remodeling, an effect that was absent in SHRSP. The increased tone of PAs from SHRSP animals, combined with lack of response to chronic hypoperfusion, may contribute to the propensity for ischemic lesions and increased perfusion deficit during hypertension.</style></abstract><notes><style face="normal" font="default" size="100%">Sweet, Julie G&#xD;Chan, Siu-Lung&#xD;Cipolla, Marilyn J&#xD;R01 NS045940/NS/NINDS NIH HHS/United States&#xD;P01 HL-095488/HL/NHLBI NIH HHS/United States&#xD;R01 NS-045940/NS/NINDS NIH HHS/United States&#xD;R01 NS-093289/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Appl Physiol (1985). 2015 Oct 1;119(7):817-23. doi: 10.1152/japplphysiol.00467.2015. Epub 2015 Aug 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://jap.physiology.org/content/jap/119/7/817.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0876471011/Sweet-2015-Effect of hypertensi.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4593811</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1152/japplphysiol.00467.2015</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>364</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">364</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Takizawa, S.</style></author><author><style face="normal" font="default" size="100%">Nagata, E.</style></author><author><style face="normal" font="default" size="100%">Luo, H. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Tokai University.</style></auth-address><titles><title><style face="normal" font="default" size="100%">[Novel neuroprotective agents: a HIF activator and an Akt activator]</style></title><secondary-title><style face="normal" font="default" size="100%">Rinsho Shinkeigaku</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Rinsho shinkeigaku = Clinical neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Rinsho Shinkeigaku</style></full-title><abbr-1><style face="normal" font="default" size="100%">Rinsho shinkeigaku = Clinical neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Rinsho Shinkeigaku</style></full-title><abbr-1><style face="normal" font="default" size="100%">Rinsho shinkeigaku = Clinical neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">911-2</style></pages><volume><style face="normal" font="default" size="100%">52</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2012/12/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Basic Helix-Loop-Helix Transcription Factors/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme Activators/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Protein-Serine-Threonine Kinases/physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1882-0654 (Electronic)&#xD;0009-918X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23196464</style></accession-num><abstract><style face="normal" font="default" size="100%">We here presented two new neuroprotective agents; a HIF activator and an Akt activator. Hypoxia inducible factor (HIF) plays a pivotal role in the adaptation to ischemic conditions, and its activity is modulated by an oxygen-dependent hydroxylation of proline residues by prolyl hydroxylases (PHD). We discovered a unique compound TM6008, which inhibited PHD and stabilized HIF activity in vitro. Oral administration of TM6008 protected neurons in forebrain as well as focal ischemia. The protection was associated with amelioration of apoptosis but independent of enhanced angiogenesis. Next, elevating Akt activation is an obvious clinical strategy to prevent progressive neuronal death in neurological diseases. We identified a small molecule SC79 that inhibits Akt membrane translocation, but paradoxically activates Akt in the cytosol. SC79 specifically binds to the PH domain of Akt. SC79-bound Akt adopts a conformation favorable for phosphorylation by upstream protein kinases. In a hippocampal neuronal culture system and a mouse model for ischemic stroke, the cytosolic activation of Akt by SC79 is sufficient to recapitulate the primary cellular function of Akt signaling, resulting in augmented neuronal survival. Thus, HIF and Akt activators may be the new therapeutic strategy against cerebral infarction, and be expanded the therapeutic time window for hemolysis.</style></abstract><notes><style face="normal" font="default" size="100%">Takizawa, Shunya&#xD;Nagata, Eiichiro&#xD;Luo, Hongbo R&#xD;P01 HL095489/HL/NHLBI NIH HHS/United States&#xD;R01 HL085100/HL/NHLBI NIH HHS/United States&#xD;English Abstract&#xD;Japan&#xD;Rinsho Shinkeigaku. 2012;52(11):911-2.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">jpn</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>181</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">181</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tang, G.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, Z.</style></author><author><style face="normal" font="default" size="100%">Lu, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Huang, J.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Chen, X.</style></author><author><style face="normal" font="default" size="100%">Gu, X.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Yang, G. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Neuroscience and Neuroengineering Research Center, Med-X Research Institute and School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, People&apos;s Republic of China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mesenchymal stem cells maintain blood-brain barrier integrity by inhibiting aquaporin-4 upregulation after cerebral ischemia</style></title><secondary-title><style face="normal" font="default" size="100%">Stem Cells</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stem cells (Dayton, Ohio)</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stem Cells</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stem cells (Dayton, Ohio)</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stem Cells</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stem cells (Dayton, Ohio)</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">3150-62</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2014/08/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Aquaporin 4/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mesenchymal Stromal Cells/ cytology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1549-4918 (Electronic)&#xD;1066-5099 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25100404</style></accession-num><abstract><style face="normal" font="default" size="100%">RATIONALE: Cerebral ischemia upregulates aquaporin-4 expression, increases blood-brain barrier (BBB) permeability, and induces brain edema. Mesenchymal stem cells (MSCs) can repress inflammatory cytokines and show great potential for ischemic stroke therapy. However, the effect of MSCs regarding the protection of ischemia-induced BBB break down is unknown. OBJECTIVE: We test whether MSCs therapy protects BBB integrity and explore the molecular mechanisms of aquaporin-4 on BBB integrity. METHODS AND RESULTS: Two hundred and twenty-eight adult CD1 male mice underwent 90 minutes transient middle cerebral artery occlusion and received 2 x 10(5) MSCs intracranial transplantation. The neurological severity score was improved and both ischemia-induced brain edema and BBB leakage were reduced in MSC-treated mice. MSCs therapy reduced astrocyte apoptosis and inhibited ischemia-induced aquaporin-4 upregulation. In addition, small-interfering RNA knockdown of aquaporin-4 after cerebral ischemia effectively reduced aquaporin-4 expression, brain edema, BBB leakage, and astrocyte apoptosis. Conditional medium from lipopolysaccharide (LPS)-activated microglia enhanced aquaporin-4 expression, p38 and JNK phosphorylation, and apoptosis of cultured astrocytes. MSC treatment reduced the expression of inflammatory cytokines in LPS-activated microglia, and subsequently reduced aquaporin-4 expression and apoptosis of astrocytes. Knockdown of aquaporin-4 in cultured astrocytes also reduced apoptosis. Treatment with p38 and JNK inhibitors showed that p38, but not the JNK signaling pathway, was responsible for the aquaporin-4 upregulation. CONCLUSION: MSCs protected BBB integrity by reducing the apoptosis of astrocytes after ischemic attack, which was due to the attenuation of inflammatory response and downregulation of aquaporin-4 expression via p38 signaling pathway.</style></abstract><notes><style face="normal" font="default" size="100%">Tang, Guanghui&#xD;Liu, Yanqun&#xD;Zhang, Zhijun&#xD;Lu, Yifan&#xD;Wang, Yang&#xD;Huang, Jun&#xD;Li, Yaning&#xD;Chen, Xiaoyan&#xD;Gu, Xiang&#xD;Wang, Yongting&#xD;Yang, Guo-Yuan&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Stem Cells. 2014 Dec;32(12):3150-62. doi: 10.1002/stem.1808.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1002/stem.1808/asset/stem1808.pdf?v=1&amp;t=ixsns4tw&amp;s=106668a60542610b8ff61cca5bf36e07c15dbae4</style></url></related-urls><pdf-urls><url>internal-pdf://4188210497/Tang-2014-Mesenchymal stem cel.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/stem.1808</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>95</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">95</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tang, J.</style></author><author><style face="normal" font="default" size="100%">Hu, Q.</style></author><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Liu, F.</style></author><author><style face="normal" font="default" size="100%">Zheng, Y.</style></author><author><style face="normal" font="default" size="100%">Tang, J.</style></author><author><style face="normal" font="default" size="100%">Zhang, J.</style></author><author><style face="normal" font="default" size="100%">Zhang, J. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; Departments of Physiology and Pharmacology, Loma Linda University, Loma Linda, CA, USA.&#xD;Departments of Physiology and Pharmacology, Loma Linda University, Loma Linda, CA, USA.&#xD;Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. Electronic address: zjm135@vip.sina.com.&#xD;Departments of Physiology and Pharmacology, Loma Linda University, Loma Linda, CA, USA. Electronic address: johnzhang3910@yahoo.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Neuroprotective role of an N-acetyl serotonin derivative via activation of tropomyosin-related kinase receptor B after subarachnoid hemorrhage in a rat model</style></title><secondary-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurobiology of disease</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurobiology of disease</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurobiology of disease</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">126-33</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><edition><style face="normal" font="default" size="100%">2015/04/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain-Derived Neurotrophic Factor/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">MAP Kinase Signaling System/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphorylation</style></keyword><keyword><style face="normal" font="default" size="100%">Proto-Oncogene Proteins c-bcl-2/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, trkB/agonists/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Serotonin/ administration &amp; dosage/ analogs &amp; derivatives</style></keyword><keyword><style face="normal" font="default" size="100%">Subarachnoid Hemorrhage/ metabolism/ prevention &amp; control</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1095-953X (Electronic)&#xD;0969-9961 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25862938</style></accession-num><abstract><style face="normal" font="default" size="100%">N-[2-(5-hydroxy-1H-indol-3-yl) ethyl]-2-oxopiperidine-3-carboxamide (HIOC), an N-acetyl serotonin derivative, selectively activates tropomyosin-related kinase receptor B (TrkB). This study is to investigate a potential role of HIOC on ameliorating early brain injury after experimental subarachnoid hemorrhage (SAH). One hundred and fifty-six adult male Sprague-Dawley rats were used. SAH model was induced by endovascular perforation. TrkB small interfering RNA (siRNA) or scramble siRNA was injected intracerebroventricularly 24h before SAH. HIOC was administrated intracerebroventricularly 3h after SAH and compared with brain-derived neurotrophic factor (BDNF). SAH grade and neurologic scores were evaluated for the outcome study. For the mechanism study, the expression of TrkB, phosphorylated TrkB (p-TrkB), phosphorylated extracellular signal regulated kinase (p-ERK), B-cell lymphoma 2 (Bcl-2) and cleaved caspase 3 (CC3) was detected by Western blots, and neuronal injury was determined by double immunofluorescence staining of neuronal nuclei and terminal deoxynucleotidyl transferase-mediated uridine 5&apos;-triphosphate-biotin nick end-labeling. Knocking down of TrkB decreased the expression of Bcl-2 and aggravated neurologic deficits 24h after SAH. HIOC activated TrkB/ERK pathway, decreased neuronal cell death, and improved neurobehavioral outcome, and these effects were abolished by TrkB siRNA. HIOC was more potent than BDNF in reduction of apoptosis 24h post-SAH. Thus, we conclude that administration of HIOC activated TrkB/ERK signaling cascade and attenuated early brain injury after SAH. HIOC may be a promising agent for further treatment for SAH and other stroke events.</style></abstract><notes><style face="normal" font="default" size="100%">Tang, Junjia&#xD;Hu, Qin&#xD;Chen, Yujie&#xD;Liu, Fei&#xD;Zheng, Yun&#xD;Tang, Jiping&#xD;Zhang, Jianmin&#xD;Zhang, John H&#xD;R01 NS081740/NS/NINDS NIH HHS/United States&#xD;R01 NS084921/NS/NINDS NIH HHS/United States&#xD;NS081740/NS/NINDS NIH HHS/United States&#xD;NS084921/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Neurobiol Dis. 2015 Jun;78:126-33. doi: 10.1016/j.nbd.2015.01.009. Epub 2015 Apr 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0969996115001072/1-s2.0-S0969996115001072-main.pdf?_tid=68351b6c-d7d4-11e6-bcc5-00000aab0f6b&amp;acdnat=1484121976_1f8fa4af8764432a3b66097b38cede85</style></url></related-urls><pdf-urls><url>internal-pdf://4086198277/Tang-2015-Neuroprotective role.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4545490</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms679235</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.nbd.2015.01.009</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>69</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">69</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tang, J.</style></author><author><style face="normal" font="default" size="100%">Xiao, W.</style></author><author><style face="normal" font="default" size="100%">Li, Q.</style></author><author><style face="normal" font="default" size="100%">Deng, Q.</style></author><author><style face="normal" font="default" size="100%">Chu, X.</style></author><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Pan, D.</style></author><author><style face="normal" font="default" size="100%">Fu, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Pudong, Shanghai 201399, China. jianhuifu@126.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A Cyclooxygenase-2 Inhibitor Reduces Vascular Wall Thickness and Ameliorates Cognitive Impairment in a Cerebral Small Vessel Diseases Rat Model</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Alzheimer Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Current Alzheimer research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Alzheimer Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current Alzheimer research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Curr Alzheimer Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current Alzheimer research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">704-10</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2015/07/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ blood supply/ drug effects/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Celecoxib/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Small Vessel Diseases/ drug therapy/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition Disorders/ drug therapy/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Collagen Type I/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclooxygenase 2/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclooxygenase 2 Inhibitors/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Down-Regulation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Fibronectins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Maze Learning/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Organ Size</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred SHR</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1875-5828 (Electronic)&#xD;1567-2050 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26159203</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebral small vessel disease (CSVD) is a group of diseases that originate from changes in cerebral small vessels and that cause many conditions, such as cognitive impairment. However, there is no effective therapy for these diseases. Recent studies have suggested that inflammation is associated with this disease. Cyclooxygenase-2 (cox-2) is an inflammatory mediator; however, whether a cox-2 inhibitor could protect against the CSVD progression remains unknown. In the present study, stroke-prone spontaneously hypertensive rats (SHRsp) were used as a model of CSVD, and Sprague Dawley (SD) rats served as the control. SHRsp were treated with the cox-2 inhibitor celecoxib or vehicle. The Morris water maze test was performed, and vascular morphometry and the expression of collagen I and fibronectin were examined in cerebral small vessels and cerebral tissue. The results revealed that thickened small veesel walls, increased expression of collagen I and fibronectin and impaired cognitive function in SHRsp compared with SD rats. Additionally, celecoxib significantly down-regulated the expression of collagen I and fibronectin, attenuated the increase in vascular wall thickness and ameliorates the cognitive impairment. Our study indicated that this cox-2 inhibitor may serve as a promising candidate for the pharmacological intervention of CSVD.</style></abstract><notes><style face="normal" font="default" size="100%">Tang, Jie&#xD;Xiao, Weizhong&#xD;Li, Qinghua&#xD;Deng, Qiuqiong&#xD;Chu, Xinquan&#xD;Chen, Yang&#xD;Pan, Danhong&#xD;Fu, Jianhui&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United Arab Emirates&#xD;Curr Alzheimer Res. 2015;12(7):704-10.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>167</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">167</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Temma, T.</style></author><author><style face="normal" font="default" size="100%">Koshino, K.</style></author><author><style face="normal" font="default" size="100%">Moriguchi, T.</style></author><author><style face="normal" font="default" size="100%">Enmi, J.</style></author><author><style face="normal" font="default" size="100%">Iida, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Investigative Radiology, National Cerebral and Cardiovascular Center Research Institute, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">PET quantification of cerebral oxygen metabolism in small animals</style></title><secondary-title><style face="normal" font="default" size="100%">ScientificWorldJournal</style></secondary-title><alt-title><style face="normal" font="default" size="100%">TheScientificWorldJournal</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">ScientificWorldJournal</style></full-title><abbr-1><style face="normal" font="default" size="100%">TheScientificWorldJournal</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">ScientificWorldJournal</style></full-title><abbr-1><style face="normal" font="default" size="100%">TheScientificWorldJournal</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">159103</style></pages><volume><style face="normal" font="default" size="100%">2014</style></volume><edition><style face="normal" font="default" size="100%">2014/09/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Inhalation</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/blood supply/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Infarction/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/blood supply/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen/administration &amp; dosage/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen Consumption</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen Radioisotopes/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Positron-Emission Tomography</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">1537-744X (Electronic)&#xD;1537-744X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25202714</style></accession-num><abstract><style face="normal" font="default" size="100%">Understanding cerebral oxygen metabolism is of great importance in both clinical diagnosis and animal experiments because oxygen is a fundamental source of brain energy and supports brain functional activities. Since small animals such as rats are widely used to study various diseases including cerebral ischemia, cerebrovascular diseases, and neurodegenerative diseases, the development of a noninvasive in vivo measurement method of cerebral oxygen metabolic parameters such as oxygen extraction fraction (OEF) and cerebral metabolic rate of oxygen (CMRO2) as well as cerebral blood flow (CBF) and cerebral blood volume (CBV) has been a priority. Although positron emission tomography (PET) with (15)O labeled gas tracers has been recognized as a powerful way to evaluate cerebral oxygen metabolism in humans, this method could not be applied to rats due to technical problems and there were no reports of PET measurement of cerebral oxygen metabolism in rats until an (15)O-O2 injection method was developed a decade ago. Herein, we introduce an intravenous administration method using two types of injectable (15)O-O2 and an (15)O-O2 gas inhalation method through an airway placed in the trachea, which enables oxygen metabolism measurements in rats.</style></abstract><notes><style face="normal" font="default" size="100%">Temma, Takashi&#xD;Koshino, Kazuhiro&#xD;Moriguchi, Tetsuaki&#xD;Enmi, Jun-ichiro&#xD;Iida, Hidehiro&#xD;Review&#xD;United States&#xD;ScientificWorldJournal. 2014;2014:159103. doi: 10.1155/2014/159103. Epub 2014 Aug 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://downloads.hindawi.com/journals/tswj/2014/159103.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3385858475/Temma-2014-PET quantification o.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4151541</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1155/2014/159103</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>308</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">308</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Teramoto, S.</style></author><author><style face="normal" font="default" size="100%">Shimura, H.</style></author><author><style face="normal" font="default" size="100%">Tanaka, R.</style></author><author><style face="normal" font="default" size="100%">Shimada, Y.</style></author><author><style face="normal" font="default" size="100%">Miyamoto, N.</style></author><author><style face="normal" font="default" size="100%">Arai, H.</style></author><author><style face="normal" font="default" size="100%">Urabe, T.</style></author><author><style face="normal" font="default" size="100%">Hattori, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Human-derived physiological heat shock protein 27 complex protects brain after focal cerebral ischemia in mice</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PloS one</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e66001</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2013/06/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/drug effects/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Infarction/metabolism/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">DNA Damage/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">HSP27 Heat-Shock Proteins/administration &amp; dosage/isolation &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">purification/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lipid Peroxidation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroglia/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/administration &amp; dosage/isolation &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">purification/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative Stress/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphorylation</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/metabolism/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ metabolism/ prevention &amp; control</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203 (Electronic)&#xD;1932-6203 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23785464</style></accession-num><abstract><style face="normal" font="default" size="100%">Although challenging, neuroprotective therapies for ischemic stroke remain an interesting strategy for countering ischemic injury and suppressing brain tissue damage. Among potential neuroprotective molecules, heat shock protein 27 (HSP27) is a strong cell death suppressor. To assess the neuroprotective effects of HSP27 in a mouse model of transient middle cerebral artery occlusion, we purified a &quot;physiological&quot; HSP27 (hHSP27) from normal human lymphocytes. hHSP27 differed from recombinant HSP27 in that it formed dimeric, tetrameric, and multimeric complexes, was phosphorylated, and contained small amounts of alphabeta-crystallin and HSP20. Mice received intravenous injections of hHSP27 following focal cerebral ischemia. Infarct volume, neurological deficit scores, physiological parameters, and immunohistochemical analyses were evaluated 24 h after reperfusion. Intravenous injections of hHSP27 1 h after reperfusion significantly reduced infarct size and improved neurological deficits. Injected hHSP27 was localized in neurons on the ischemic side of the brain. hHSP27 suppressed neuronal cell death resulting from cytochrome c-mediated caspase activation, oxidative stress, and inflammatory responses. Recombinant HSP27 (rHSP27), which was artificially expressed and purified from Escherichia coli, and dephosphorylated hHSP27 did not have brain protective effects, suggesting that the phosphorylation of hHSP27 may be important for neuroprotection after ischemic insults. The present study suggests that hHSP27 with posttranslational modifications provided neuroprotection against ischemia/reperfusion injury and that the protection was mediated through the inhibition of apoptosis, oxidative stress, and inflammation. Intravenously injected human HSP27 should be explored for the treatment of acute ischemic strokes.</style></abstract><notes><style face="normal" font="default" size="100%">Teramoto, Shinichiro&#xD;Shimura, Hideki&#xD;Tanaka, Ryota&#xD;Shimada, Yoshiaki&#xD;Miyamoto, Nobukazu&#xD;Arai, Hajime&#xD;Urabe, Takao&#xD;Hattori, Nobutaka&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;PLoS One. 2013 Jun 13;8(6):e66001. doi: 10.1371/journal.pone.0066001. Print 2013.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0066001&amp;type=printable</style></url></related-urls><pdf-urls><url>internal-pdf://1227185269/Teramoto-2013-Human-derived physio.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3681760</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0066001</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>132</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">132</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thatipamula, S.</style></author><author><style face="normal" font="default" size="100%">Al Rahim, M.</style></author><author><style face="normal" font="default" size="100%">Zhang, J.</style></author><author><style face="normal" font="default" size="100%">Hossain, M. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Hugo W. Moser Research Institute at Kennedy Krieger, Baltimore, MD 21205, USA.&#xD;Hugo W. Moser Research Institute at Kennedy Krieger, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.&#xD;Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.&#xD;Hugo W. Moser Research Institute at Kennedy Krieger, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Electronic address: hossain@kennedykrieger.org.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Genetic deletion of neuronal pentraxin 1 expression prevents brain injury in a neonatal mouse model of cerebral hypoxia-ischemia</style></title><secondary-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurobiology of disease</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurobiology of disease</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurobiology of disease</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">15-30</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><edition><style face="normal" font="default" size="100%">2015/01/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Animals, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">C-Reactive Protein/ deficiency/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Caspase 3/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Death/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Hypoxia/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose/deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia-Ischemia, Brain/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Mitochondria/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Tissue Proteins/ deficiency/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering</style></keyword><keyword><style face="normal" font="default" size="100%">bcl-2-Associated X Protein/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1095-953X (Electronic)&#xD;0969-9961 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25554688</style></accession-num><abstract><style face="normal" font="default" size="100%">Neonatal hypoxic-ischemic (HI) brain injury is a leading cause of mortality and morbidity in infants and children for which there is no promising therapy at present. Previously, we reported induction of neuronal pentraxin 1 (NP1), a novel neuronal protein of the long-pentraxin family, following HI injury in neonatal brain. Here, we report that genetic deletion of NP1 expression prevents HI injury in neonatal brain. Elevated expression of NP1 was observed in neurons, not in astrocytes, of the ipsilateral cortical layers (I-IV) and in the hippocampal CA1 and CA3 areas of WT brains following hypoxia-ischemia; brain areas that developed infarcts (at 24-48 h), showed significantly increased numbers of TUNEL-(+) cells and tissue loss (at 7 days). In contrast, NP1-KO mice showed no evidence of brain infarction and tissue loss after HI. The immunofluorescence staining of brain sections with mitochondrial protein COX IV and subcellular fractionation analysis showed increased accumulation of NP1 in mitochondria, pro-death protein Bax activation and NP1 co-localization with activated caspase-3 in WT, but not in the NP1-KO brains; corroborating NP1 interactions with the mitochondria-derived pro-death pathways. Disruption of NP1 translocation to mitochondria by NP1-siRNA in primary cortical cultures significantly reduced ischemic neuronal death. NP1 was immunoprecipitated with activated Bax [6A7] proteins; HI caused increased interactions of NP1 with Bax, thereby, facilitating Bax translocation to mitochondrial and neuronal death. To further delineate the specificity of NPs, we found that NP1 but not the NP2 induction is specifically involved in brain injury mechanisms and that knockdown of NP1 only results in neuroprotection. Furthermore, live in vivo T2-weighted magnetic resonance imaging (MRI) including fractional anisotropy (FA) mapping showed no sign of delayed brain injury or tissue loss in the NP1-KO mice as compared to the WT at different post-HI periods (4-24 weeks) examined; indicating a long-term neuroprotective efficacy of NP1 gene deletion. Collectively, our results demonstrate a novel mechanism of neuronal death and predict that inhibition of NP1 expression is a promising strategy to prevent hypoxic-ischemic injury in immature brain.</style></abstract><notes><style face="normal" font="default" size="100%">Thatipamula, Shabarish&#xD;Al Rahim, Md&#xD;Zhang, Jiangyang&#xD;Hossain, Mir Ahamed&#xD;R01 NS046030/NS/NINDS NIH HHS/United States&#xD;R01 NS046030-09/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;United States&#xD;Neurobiol Dis. 2015 Mar;75:15-30. doi: 10.1016/j.nbd.2014.12.016. Epub 2014 Dec 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0969996114003878/1-s2.0-S0969996114003878-main.pdf?_tid=630d8f5c-d7d4-11e6-8710-00000aab0f26&amp;acdnat=1484121967_a5199290ee54000e50f38018b1cc8c40</style></url></related-urls><pdf-urls><url>internal-pdf://1980714297/Thatipamula-2015-Genetic deletion of.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4351118</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms656567</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.nbd.2014.12.016</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>384</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">384</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tikka, S.</style></author><author><style face="normal" font="default" size="100%">Ng, Y. P.</style></author><author><style face="normal" font="default" size="100%">Di Maio, G.</style></author><author><style face="normal" font="default" size="100%">Mykkanen, K.</style></author><author><style face="normal" font="default" size="100%">Siitonen, M.</style></author><author><style face="normal" font="default" size="100%">Lepikhova, T.</style></author><author><style face="normal" font="default" size="100%">Poyhonen, M.</style></author><author><style face="normal" font="default" size="100%">Viitanen, M.</style></author><author><style face="normal" font="default" size="100%">Virtanen, I.</style></author><author><style face="normal" font="default" size="100%">Kalimo, H.</style></author><author><style face="normal" font="default" size="100%">Baumann, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Protein Chemistry Unit, Institute of Biomedicine/Anatomy, University of Helsinki, Helsinki, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">CADASIL mutations and shRNA silencing of NOTCH3 affect actin organization in cultured vascular smooth muscle cells</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">2171-80</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2012/09/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Actin Cytoskeleton/genetics/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Actins/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Aging/genetics/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Amino Acid Substitution</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">CADASIL/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Line</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Silencing</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle, Smooth, Vascular/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation, Missense</style></keyword><keyword><style face="normal" font="default" size="100%">Myocytes, Smooth Muscle/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Organ Specificity/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/ biosynthesis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Notch3</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Notch/ biosynthesis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Transduction, Genetic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22948298</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common hereditary vascular dementia caused by mutations in NOTCH3 gene. Pathology is manifested in small- and middle-sized arteries throughout the body, though primarily in cerebral white matter. Hemodynamics is altered in CADASIL and NOTCH3 is suggested to regulate actin filament polymerization and thereby vascular tone. We analyzed NOTCH3 expression and morphology of actin cytoskeleton in genetically genuine cultured human CADASIL vascular smooth muscle cells (VSMCs) (including a cell line homozygous for p.Arg133Cys mutation) derived from different organs, and in control VSMCs with short hairpin RNA (shRNA)-silenced NOTCH3. NOTCH3 protein level was higher in VSMCs derived from adult than newborn arteries in both CADASIL and control VSMCs. CADASIL VSMCs showed altered actin cytoskeleton including increased branching and node formation, and more numerous and smaller adhesion sites than control VSMCs. Alterations in actin cytoskeleton in shRNA-silenced VSMCs were similar as in CADASIL VSMCs. Severity of the alterations in actin filaments corresponded to NOTCH3 expression level being most severe in VSMCs derived from adult cerebral arteries. These observations suggest that hypomorphic NOTCH3 activity causes alterations in actin organization in CADASIL. Furthermore, arteries from different organs have specific characteristics, which modify the effects of the NOTCH3 mutation and which is one explanation for the exceptional susceptibility of cerebral white matter arteries.</style></abstract><notes><style face="normal" font="default" size="100%">Tikka, Saara&#xD;Ng, Yan Peng&#xD;Di Maio, Giuseppe&#xD;Mykkanen, Kati&#xD;Siitonen, Maija&#xD;Lepikhova, Tatiana&#xD;Poyhonen, Minna&#xD;Viitanen, Matti&#xD;Virtanen, Ismo&#xD;Kalimo, Hannu&#xD;Baumann, Marc&#xD;Clinical Trial&#xD;Multicenter Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Cereb Blood Flow Metab. 2012 Dec;32(12):2171-80. doi: 10.1038/jcbfm.2012.123. Epub 2012 Sep 5.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3519411</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2012.123</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>70</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">70</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tiwari, A. K.</style></author><author><style face="normal" font="default" size="100%">Ji, B.</style></author><author><style face="normal" font="default" size="100%">Yui, J.</style></author><author><style face="normal" font="default" size="100%">Fujinaga, M.</style></author><author><style face="normal" font="default" size="100%">Yamasaki, T.</style></author><author><style face="normal" font="default" size="100%">Xie, L.</style></author><author><style face="normal" font="default" size="100%">Luo, R.</style></author><author><style face="normal" font="default" size="100%">Shimoda, Y.</style></author><author><style face="normal" font="default" size="100%">Kumata, K.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Hatori, A.</style></author><author><style face="normal" font="default" size="100%">Maeda, J.</style></author><author><style face="normal" font="default" size="100%">Higuchi, M.</style></author><author><style face="normal" font="default" size="100%">Wang, F.</style></author><author><style face="normal" font="default" size="100%">Zhang, M. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">1. Molecular Imaging Centre, National Institute of Radiological Sciences, Chiba, Japan ; 2. Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, Delhi, India.&#xD;1. Molecular Imaging Centre, National Institute of Radiological Sciences, Chiba, Japan.&#xD;3. Department of Nuclear Medicine, Nanjing Hospital, Affiliated to Nanjing Medical University, Nanjing, China .</style></auth-address><titles><title><style face="normal" font="default" size="100%">[18F]FEBMP: Positron Emission Tomography Imaging of TSPO in a Model of Neuroinflammation in Rats, and in vitro Autoradiograms of the Human Brain</style></title><secondary-title><style face="normal" font="default" size="100%">Theranostics</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Theranostics</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Theranostics</style></full-title><abbr-1><style face="normal" font="default" size="100%">Theranostics</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Theranostics</style></full-title><abbr-1><style face="normal" font="default" size="100%">Theranostics</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">961-9</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2015/07/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Acetanilides/administration &amp; dosage/pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Benzoxazoles/administration &amp; dosage/pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/diagnostic imaging/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ diagnosis/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Carrier Proteins/ analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorine Radioisotopes/ administration &amp; dosage/pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/ diagnosis/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroimaging/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Positron-Emission Tomography/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Radiography</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, GABA/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, GABA-A/ analysis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1838-7640 (Electronic)&#xD;1838-7640 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26155312</style></accession-num><abstract><style face="normal" font="default" size="100%">We evaluated the efficacy of 2-[5-(4-[(18)F]fluoroethoxy-2-oxo-1,3-benzoxazol-3(2H)-yl)-N-methyl-N-phenylaceta mide] ([(18)F]FEBMP) for positron emission tomography (PET) imaging of translocator protein (18 kDa, TSPO). Dissection was used to determine the distribution of [(18)F]FEBMP in mice, while small-animal PET and metabolite analysis were used for a rat model of focal cerebral ischemia. [(18)F]FEBMP showed high radioactivity uptake in mouse peripheral organs enriched with TSPO, and relatively high initial brain uptake (2.67 +/- 0.12% ID/g). PET imaging revealed an increased accumulation of radioactivity in the infarcted striatum, with a maximum ratio of 3.20 +/- 0.12, compared to non-injured striatum. Displacement with specific TSPO ligands lowered the accumulation levels in infarcts to those on the contralateral side. This suggests that the increased accumulation reflected TPSO-specific binding of [(18)F]FEBMP in vivo. Using a simplified reference tissue model, the binding potential on the infarcted area was 2.72 +/- 0.27. Metabolite analysis in brain tissues showed that 83.2 +/- 7.4% and 76.4 +/- 2.1% of radioactivity was from intact [(18)F]FEBMP at 30 and 60 min, respectively, and that this ratio was higher than in plasma (8.6 +/- 1.9% and 3.9 +/- 1.1%, respectively). In vitro autoradiography on postmortem human brains showed that TSPO rs6971 polymorphism did not affect binding sites for [(18)F]FEBMP. These findings suggest that [(18)F]FEBMP is a promising new tool for visualization of neuroinflammation.</style></abstract><notes><style face="normal" font="default" size="100%">Tiwari, Anjani K&#xD;Ji, Bin&#xD;Yui, Joji&#xD;Fujinaga, Masayuki&#xD;Yamasaki, Tomoteru&#xD;Xie, Lin&#xD;Luo, Rui&#xD;Shimoda, Yoko&#xD;Kumata, Katsushi&#xD;Zhang, Yiding&#xD;Hatori, Akiko&#xD;Maeda, Jun&#xD;Higuchi, Makoto&#xD;Wang, Feng&#xD;Zhang, Ming-Rong&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Australia&#xD;Theranostics. 2015 May 26;5(9):961-9. doi: 10.7150/thno.12027. eCollection 2015.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4493534</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.7150/thno.12027</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>275</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">275</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tong, L.</style></author><author><style face="normal" font="default" size="100%">Cai, M.</style></author><author><style face="normal" font="default" size="100%">Huang, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, H.</style></author><author><style face="normal" font="default" size="100%">Su, B.</style></author><author><style face="normal" font="default" size="100%">Li, Z.</style></author><author><style face="normal" font="default" size="100%">Dong, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Anesthesiology, Xijing Hospital, Xi&apos;an, Shanxi 710032, China.&#xD;Department of Anesthesiology, Xijing Hospital, Xi&apos;an, Shanxi 710032, China hldong6@hotmail.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Activation of K(2)P channel-TREK1 mediates the neuroprotection induced by sevoflurane preconditioning</style></title><secondary-title><style face="normal" font="default" size="100%">Br J Anaesth</style></secondary-title><alt-title><style face="normal" font="default" size="100%">British journal of anaesthesia</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Br J Anaesth</style></full-title><abbr-1><style face="normal" font="default" size="100%">British journal of anaesthesia</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Br J Anaesth</style></full-title><abbr-1><style face="normal" font="default" size="100%">British journal of anaesthesia</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">157-67</style></pages><volume><style face="normal" font="default" size="100%">113</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2013/10/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/metabolism/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Carbon Monoxide/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Differentiation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Hypoxia/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Survival/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/metabolism/pathology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Knockdown Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Preconditioning/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Methyl Ethers/ pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Partial Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Potassium Channels, Tandem Pore Domain/biosynthesis/genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/metabolism/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Tumor Cells, Cultured</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1471-6771 (Electronic)&#xD;0007-0912 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24154701</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Preconditioning with volatile anaesthetic agents induces tolerance to focal cerebral ischaemia, although the underlying mechanisms have not been clearly defined. The present study analyses whether TREK-1, a two-pore domain K(+) channel and target for volatile anaesthetics, plays a role in mediating neuroprotection by sevoflurane. METHODS: Differentiated SH-SY5Y cells were preconditioning with sevoflurane and challenged by oxygen-glucose deprivation (OGD). Cell viability and expression of caspase-3 and TREK-1 were evaluated. Rats that were preconditioned with sevoflurane were subjected to middle cerebral artery occlusion (MCAO), and the expression of TREK-1 protein and mRNA was analysed. Neurological scores were evaluated and infarction volume was examined. RESULTS: Sevoflurane preconditioning reduced cell death in differentiated SH-SY5Y cells challenged by OGD. Sevoflurane preconditioning reduced infarct volume and improved neurological outcome in rats subjected to MCAO. Sevoflurane preconditioning increased levels of TREK-1 mRNA and protein. Knockdown of TREK-1 significantly attenuated sevoflurane preconditioning-induced neuroprotective effects in vitro and in vivo. CONCLUSIONS: Sevoflurane preconditioning-induced neuroprotective effects against transient cerebral ischaemic injuries involve TREK-1 channels. These results suggest a novel mechanism for sevoflurane preconditioning-induced tolerance to focal cerebral ischaemia.</style></abstract><notes><style face="normal" font="default" size="100%">Tong, L&#xD;Cai, M&#xD;Huang, Y&#xD;Zhang, H&#xD;Su, B&#xD;Li, Z&#xD;Dong, H&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Br J Anaesth. 2014 Jul;113(1):157-67. doi: 10.1093/bja/aet338. Epub 2013 Oct 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://bja.oxfordjournals.org/content/113/1/157.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1051433598/Tong-2014-Activation of K(2)P.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4062297</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/bja/aet338</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>197</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">197</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tong, L.</style></author><author><style face="normal" font="default" size="100%">Wu, Z.</style></author><author><style face="normal" font="default" size="100%">Ran, M.</style></author><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Yang, L.</style></author><author><style face="normal" font="default" size="100%">Zhang, H.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Dong, H.</style></author><author><style face="normal" font="default" size="100%">Xiong, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Anesthesiology, Xijing Hospital, Xi&apos;an, Shaanxi, 710032, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Role of SUMO-Conjugating Enzyme Ubc9 in the Neuroprotection of Isoflurane Preconditioning Against Ischemic Neuronal Injury</style></title><secondary-title><style face="normal" font="default" size="100%">Mol Neurobiol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Molecular neurobiology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Mol Neurobiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Molecular neurobiology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Mol Neurobiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Molecular neurobiology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1221-31</style></pages><volume><style face="normal" font="default" size="100%">51</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2014/06/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anesthetics, Inhalation/administration &amp; dosage/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Preconditioning/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Isoflurane/administration &amp; dosage/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotection/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">SUMO-1 Protein/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Sumoylation/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Ubiquitin-Conjugating Enzymes/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1559-1182 (Electronic)&#xD;0893-7648 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24961570</style></accession-num><abstract><style face="normal" font="default" size="100%">Preconditioning with volatile anesthetics can create an ischemia tolerance against cerebral ischemia-reperfusion injury. We investigated whether ubiquitin conjugase 9 (Ubc9), the E2 conjugase for SUMOylation, is associated with neuroprotection induced by isoflurane preconditioning (IsoPC). In vitro, Ubc9 protein expression was evaluated at 4 and 24 h after reoxygenation. The role of Ubc9 in the neuroprotective effect was assessed in the presence or absence of Ubc9 small interfering RNA (siRNA). In vivo, rats were preconditionally exposed for 1 h to 2% isoflurane for five consecutive days followed by middle cerebral artery occlusion. Neurobehavioral scores and infarction volume were determined at different times after reperfusion. The role of Ubc9 in ischemic tolerance was evaluated by intracerebroventricular microinjection with the Ubc9 siRNA. We showed that isoflurane preconditioning improved the cell viability of the SH-SY5Y cells that were challenged by oxygen-glucose deprivation. It also reduced brain infarct volumes and improved neurologic outcomes in the focal cerebral ischemic rat. The expression of Ubc9 was upregulated by isoflurane preconditioning. Knockdown of Ubc9 significantly attenuated the isoflurane preconditioning-induced neuroprotective effects. Isoflurane preconditioning-induced neuroprotection against ischemic injuries is mediated by Ubc9. These results suggest a novel mechanism for isoflurane preconditioning-induced tolerance to cerebral ischemia.</style></abstract><notes><style face="normal" font="default" size="100%">Tong, Li&#xD;Wu, Zhixin&#xD;Ran, Mingzi&#xD;Chen, Yu&#xD;Yang, Lujia&#xD;Zhang, Haopeng&#xD;Zhang, Lina&#xD;Dong, Hailong&#xD;Xiong, Lize&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Mol Neurobiol. 2015;51(3):1221-31. doi: 10.1007/s12035-014-8797-3. Epub 2014 Jun 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/443/art%253A10.1007%252Fs12035-014-8797-3.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12035-014-8797-3&amp;token2=exp=1484123003~acl=%2Fstatic%2Fpdf%2F443%2Fart%25253A10.1007%25252Fs12035-014-8797-3.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs12035-014-8797-3*~hmac=0f7ea4d7970fd675ce9aca077e20aa56e54ff67b6d29012d2459fea88da700fe</style></url></related-urls><pdf-urls><url>internal-pdf://3789720308/Tong-2015-The Role of SUMO-Con.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4435903</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12035-014-8797-3</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>114</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">114</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Toth, P.</style></author><author><style face="normal" font="default" size="100%">Tarantini, S.</style></author><author><style face="normal" font="default" size="100%">Springo, Z.</style></author><author><style face="normal" font="default" size="100%">Tucsek, Z.</style></author><author><style face="normal" font="default" size="100%">Gautam, T.</style></author><author><style face="normal" font="default" size="100%">Giles, C. B.</style></author><author><style face="normal" font="default" size="100%">Wren, J. D.</style></author><author><style face="normal" font="default" size="100%">Koller, A.</style></author><author><style face="normal" font="default" size="100%">Sonntag, W. E.</style></author><author><style face="normal" font="default" size="100%">Csiszar, A.</style></author><author><style face="normal" font="default" size="100%">Ungvari, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Reynolds Oklahoma Center on Aging, Department of Geriatric Medicine, University of Oklahoma Health Sciences Center, 975 NE 10th Street, Oklahoma City, OK, 73104, USA; Department of Pathophysiology and Gerontology and Szentagothai Research Center, University of Pecs, Szigeti Street 12, 7624, Pecs, Hungary.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Aging exacerbates hypertension-induced cerebral microhemorrhages in mice: role of resveratrol treatment in vasoprotection</style></title><secondary-title><style face="normal" font="default" size="100%">Aging Cell</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Aging cell</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Aging Cell</style></full-title><abbr-1><style face="normal" font="default" size="100%">Aging cell</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Aging Cell</style></full-title><abbr-1><style face="normal" font="default" size="100%">Aging cell</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">400-8</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2015/02/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aging</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension/ complications/ drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hemorrhages/drug therapy/ etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidation-Reduction/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative Stress/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Stilbenes/ pharmacology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1474-9726 (Electronic)&#xD;1474-9718 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25677910</style></accession-num><abstract><style face="normal" font="default" size="100%">Recent studies demonstrate that aging exacerbates hypertension-induced cognitive decline, but the specific age-related mechanisms remain elusive. Cerebral microhemorrhages (CMHs) are associated with rupture of small intracerebral vessels and are thought to progressively impair neuronal function. To determine whether aging exacerbates hypertension-induced CMHs young (3 months) and aged (24 months) mice were treated with angiotensin II plus L-NAME. We found that the same level of hypertension leads to significantly earlier onset and increased incidence of CMHs in aged mice than in young mice, as shown by neurological examination, gait analysis, and histological assessment of CMHs in serial brain sections. Hypertension-induced cerebrovascular oxidative stress and redox-sensitive activation of matrix metalloproteinases (MMPs) were increased in aging. Treatment of aged mice with resveratrol significantly attenuated hypertension-induced oxidative stress, inhibited vascular MMP activation, significantly delayed the onset, and reduced the incidence of CMHs. Collectively, aging promotes CMHs in mice likely by exacerbating hypertension-induced oxidative stress and MMP activation. Therapeutic strategies that reduce microvascular oxidative stress and MMP activation may be useful for the prevention of CMHs, protecting neurocognitive function in high-risk elderly patients.</style></abstract><notes><style face="normal" font="default" size="100%">Toth, Peter&#xD;Tarantini, Stefano&#xD;Springo, Zsolt&#xD;Tucsek, Zsuzsanna&#xD;Gautam, Tripti&#xD;Giles, Cory B&#xD;Wren, Jonathan D&#xD;Koller, Akos&#xD;Sonntag, William E&#xD;Csiszar, Anna&#xD;Ungvari, Zoltan&#xD;R01 AG038747/AG/NIA NIH HHS/United States&#xD;U54 GM104938/GM/NIGMS NIH HHS/United States&#xD;R01-AG038747/AG/NIA NIH HHS/United States&#xD;P30 AG028718/AG/NIA NIH HHS/United States&#xD;R01 AG047879/AG/NIA NIH HHS/United States&#xD;R01-AT006526/AT/NCCIH NIH HHS/United States&#xD;1R01AG047879-01/AG/NIA NIH HHS/United States&#xD;R01 AT006526/AT/NCCIH NIH HHS/United States&#xD;R01 NS056218/NS/NINDS NIH HHS/United States&#xD;R01-NS056218/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Aging Cell. 2015 Jun;14(3):400-8. doi: 10.1111/acel.12315. Epub 2015 Feb 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/acel.12315/asset/acel12315.pdf?v=1&amp;t=ixsnt29b&amp;s=c15acd444d5146793d26edd30f471e8ba4200c54</style></url></related-urls><pdf-urls><url>internal-pdf://1452063013/Toth-2015-Aging exacerbates hy.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4406669</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/acel.12315</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>252</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">252</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Toyama, K.</style></author><author><style face="normal" font="default" size="100%">Koibuchi, N.</style></author><author><style face="normal" font="default" size="100%">Uekawa, K.</style></author><author><style face="normal" font="default" size="100%">Hasegawa, Y.</style></author><author><style face="normal" font="default" size="100%">Kataoka, K.</style></author><author><style face="normal" font="default" size="100%">Katayama, T.</style></author><author><style face="normal" font="default" size="100%">Sueta, D.</style></author><author><style face="normal" font="default" size="100%">Ma, M. J.</style></author><author><style face="normal" font="default" size="100%">Nakagawa, T.</style></author><author><style face="normal" font="default" size="100%">Yasuda, O.</style></author><author><style face="normal" font="default" size="100%">Tomimoto, H.</style></author><author><style face="normal" font="default" size="100%">Ichijo, H.</style></author><author><style face="normal" font="default" size="100%">Ogawa, H.</style></author><author><style face="normal" font="default" size="100%">Kim-Mitsuyama, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From the Department of Pharmacology and Molecular Therapeutics (K.T., N.K., K.U., Y.H., K.K., T.K., D.S., M.J.M., T.N., S.K.-M.) and Department of Cardiovascular Medicine, Faculty of Life Science (K.T., H.O.), Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan; Research Fellowship of the Japan Society for the Promotion of Science, Tokyo, Japan (K.T.); Department of Cardiovascular Clinical and Translational Research, Kumamoto University Hospital, Kumamoto, Japan (O.Y.); Department of Neurology, Graduate School of Medicine, Mie University, Tsu, Japan (H.T.); and Laboratory of Cell Signaling, Graduate School of Pharmaceutical Sciences, and Global Center of Excellence (GCOE) Program, The University of Tokyo, Tokyo, Japan (H.I.).</style></auth-address><titles><title><style face="normal" font="default" size="100%">Apoptosis signal-regulating kinase 1 is a novel target molecule for cognitive impairment induced by chronic cerebral hypoperfusion</style></title><secondary-title><style face="normal" font="default" size="100%">Arterioscler Thromb Vasc Biol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Arteriosclerosis, thrombosis, and vascular biology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Arterioscler Thromb Vasc Biol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Arteriosclerosis, thrombosis, and vascular biology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Arterioscler Thromb Vasc Biol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Arteriosclerosis, thrombosis, and vascular biology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">616-25</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2013/12/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/etiology/physiopathology/prevention &amp; control/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Stenosis/ complications/physiopathology/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Conditioning, Operant/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Corpus Callosum/blood supply</style></keyword><keyword><style face="normal" font="default" size="100%">Dementia, Vascular/enzymology/ etiology/physiopathology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelial Cells/enzymology</style></keyword><keyword><style face="normal" font="default" size="100%">Exploratory Behavior</style></keyword><keyword><style face="normal" font="default" size="100%">MAP Kinase Kinase Kinase 5/antagonists &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">inhibitors/deficiency/genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Maze Learning/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroglia/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative Stress</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphorylation</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Kinase Inhibitors/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Processing, Post-Translational</style></keyword><keyword><style face="normal" font="default" size="100%">Recognition (Psychology)</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Tight Junctions</style></keyword><keyword><style face="normal" font="default" size="100%">Tumor Necrosis Factor-alpha/pharmacology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4636 (Electronic)&#xD;1079-5642 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24371084</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: There are currently no specific strategies for the treatment or prevention of vascular dementia. White matter lesions, a common pathology in cerebral small vessel disease, are a major cause of vascular dementia. We investigated whether apoptosis signal-regulating kinase 1 (ASK1) might be a key molecule in cerebral hypoperfusion, associated with blood-brain barrier breakdown and white matter lesions. APPROACH AND RESULTS: A mouse model of cognitive impairment was developed by inducing chronic cerebral hypoperfusion in white matter including the corpus callosum via bilateral common carotid artery stenosis (BCAS) surgery. BCAS-induced white matter lesions caused cognitive decline in C57BL/6J (wild-type) mice but not in ASK1-deficient (ASK1(-/-)) mice. Phosphorylated ASK1 increased in wild-type mouse brains, and phosphorylated p38 and tumor necrosis factor-alpha expression increased in corpus callosum cerebral endothelial cells after BCAS in wild-type mice but not in ASK1(-/-) mice. BCAS decreased claudin-5 expression and disrupted blood-brain barrier in the corpus callosum of wild-type but not ASK1(-/-) mice. Cerebral nitrotyrosine was increased in wild-type and ASK1(-/-) BCAS mice. Cerebral phosphorylated ASK1 did not increase in wild-type mice treated with NADPH-oxidase inhibitor. A p38 inhibitor and NADPH-oxidase inhibitor mimicked the protective effect of ASK1 deficiency against cognitive impairment. Specific ASK1 inhibitor prevented cognitive decline in BCAS mice. In vitro oxygen-glucose deprivation and tumor necrosis factor-alpha stimulation caused the disruption of endothelial tight junctions from wild-type mice but not ASK1(-/-) mice. CONCLUSIONS: Oxidative stress-ASK1-p38 cascade plays a role in the pathogenesis of cognitive impairment, through blood-brain barrier breakdown via the disruption of endothelial tight junctions. ASK1 might be a promising therapeutic target for chronic cerebral hypoperfusion-induced cognitive impairment.</style></abstract><notes><style face="normal" font="default" size="100%">Toyama, Kensuke&#xD;Koibuchi, Nobutaka&#xD;Uekawa, Ken&#xD;Hasegawa, Yu&#xD;Kataoka, Keiichiro&#xD;Katayama, Tetsuji&#xD;Sueta, Daisuke&#xD;Ma, Ming Jie&#xD;Nakagawa, Takashi&#xD;Yasuda, Osamu&#xD;Tomimoto, Hidekazu&#xD;Ichijo, Hidenori&#xD;Ogawa, Hisao&#xD;Kim-Mitsuyama, Shokei&#xD;United States&#xD;Arterioscler Thromb Vasc Biol. 2014 Mar;34(3):616-25. doi: 10.1161/ATVBAHA.113.302440. Epub 2013 Dec 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://atvb.ahajournals.org/content/atvbaha/34/3/616.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3394046217/Toyama-2014-Apoptosis signal-reg.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/atvbaha.113.302440</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>293</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">293</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Toyooka, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, National Hospital Organization Toneyama National Hospital, Toyonaka, Osaka, Japan. Electronic address: ktoyooka@toneyama.go.jp.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Fabry disease</style></title><secondary-title><style face="normal" font="default" size="100%">Handb Clin Neurol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Handbook of clinical neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Handb Clin Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Handbook of clinical neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Handb Clin Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Handbook of clinical neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">629-42</style></pages><volume><style face="normal" font="default" size="100%">115</style></volume><edition><style face="normal" font="default" size="100%">2013/08/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Fabry Disease/diagnosis/epidemiology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Peripheral Nerves/pathology/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">alpha-Galactosidase/genetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">0072-9752 (Print)&#xD;0072-9752 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23931807</style></accession-num><abstract><style face="normal" font="default" size="100%">Fabry disease results from deficient activity of the enzyme alpha-galactosidase A and progressive lysosomal deposition of globotriaosylceramide (GL-3) in cells throughout the body. The main neurological presentations of Fabry disease patients are painful neuropathy, hypohidrosis, and stroke. Fabry neuropathy is characterized as a length-dependent peripheral neuropathy affecting mainly the small myelinated (Adelta) fibers and unmyelinated (C) fibers. Enzyme replacement therapy (ERT) has been shown to have some positive effects on the reduction of neuropathic pain, the improvement of detection threshold for thermal sensation, and sweat function. On the contrary, the effect of ERT on the central nervous system has not been established. Early initiation of ERT before irreversible organ failure is extremely important, and alternative therapeutic approaches are currently being explored. Heterozygotes suffer from peripheral neuropathy at a higher rate than previously shown, significant multisystemic disease, and severely decreased quality of life. As well as being carriers, heterozygotes also display symptoms of Fabry disease, and should be carefully monitored and given adequate therapy.</style></abstract><notes><style face="normal" font="default" size="100%">Toyooka, Keiko&#xD;Review&#xD;Netherlands&#xD;Handb Clin Neurol. 2013;115:629-42. doi: 10.1016/B978-0-444-52902-2.00037-0.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/B9780444529022000370/1-s2.0-B9780444529022000370-main.pdf?_tid=726e38fc-d7d4-11e6-bc98-00000aacb35f&amp;acdnat=1484121993_149c0a1b8b94b6cd088b4a551353fab4</style></url></related-urls><pdf-urls><url>internal-pdf://2516693305/Toyooka-2013-Fabry disease.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/b978-0-444-52902-2.00037-0</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>201</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">201</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tress, E. E.</style></author><author><style face="normal" font="default" size="100%">Clark, R. S.</style></author><author><style face="normal" font="default" size="100%">Foley, L. M.</style></author><author><style face="normal" font="default" size="100%">Alexander, H.</style></author><author><style face="normal" font="default" size="100%">Hickey, R. W.</style></author><author><style face="normal" font="default" size="100%">Drabek, T.</style></author><author><style face="normal" font="default" size="100%">Kochanek, P. M.</style></author><author><style face="normal" font="default" size="100%">Manole, M. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Pittsburgh, Department of Pediatrics, 4401 Penn Avenue, Pittsburgh, PA 15224, USA. Electronic address: Erika.Tress@UHhospitals.org.&#xD;University of Pittsburgh, Department of Pediatrics, 4401 Penn Avenue, Pittsburgh, PA 15224, USA; University of Pittsburgh, Critical Care Medicine, 3434 Fifth Avenue, Pittsburgh, PA 15260, USA; University of Pittsburgh, Safar Center for Resuscitation Research, 3434 Fifth Avenue, Pittsburgh, PA 15260, USA. Electronic address: clarkrs@ccm.upmc.edu.&#xD;Carnegie Mellon University, NMR Center for Biomedical Research, 4400 Fifth Avenue, Pittsburgh, PA 15213, USA. Electronic address: lmfoley@andrew.cmu.edu.&#xD;University of Pittsburgh, Critical Care Medicine, 3434 Fifth Avenue, Pittsburgh, PA 15260, USA; University of Pittsburgh, Safar Center for Resuscitation Research, 3434 Fifth Avenue, Pittsburgh, PA 15260, USA. Electronic address: AlexanderHL@anes.upmc.edu.&#xD;University of Pittsburgh, Department of Pediatrics, 4401 Penn Avenue, Pittsburgh, PA 15224, USA. Electronic address: Robert.Hickey@chp.edu.&#xD;University of Pittsburgh, Safar Center for Resuscitation Research, 3434 Fifth Avenue, Pittsburgh, PA 15260, USA; University of Pittsburgh Department of Anesthesiology, 3434 Fifth Avenue, Pittsburgh, PA 15260, USA. Electronic address: drabtx@upmc.edu.&#xD;University of Pittsburgh, Department of Pediatrics, 4401 Penn Avenue, Pittsburgh, PA 15224, USA; University of Pittsburgh, Critical Care Medicine, 3434 Fifth Avenue, Pittsburgh, PA 15260, USA; University of Pittsburgh, Safar Center for Resuscitation Research, 3434 Fifth Avenue, Pittsburgh, PA 15260, USA. Electronic address: kochanekpm@ccm.upmc.edu.&#xD;University of Pittsburgh, Department of Pediatrics, 4401 Penn Avenue, Pittsburgh, PA 15224, USA; University of Pittsburgh, Safar Center for Resuscitation Research, 3434 Fifth Avenue, Pittsburgh, PA 15260, USA. Electronic address: mioara.manole@chp.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Blood brain barrier is impermeable to solutes and permeable to water after experimental pediatric cardiac arrest</style></title><secondary-title><style face="normal" font="default" size="100%">Neurosci Lett</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuroscience letters</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurosci Lett</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience letters</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurosci Lett</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience letters</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">17-21</style></pages><volume><style face="normal" font="default" size="100%">578</style></volume><edition><style face="normal" font="default" size="100%">2014/06/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Asphyxia/complications/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Body Water/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorescein/metabolism/pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Gadolinium/metabolism/pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Arrest/etiology/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Heterocyclic Compounds/metabolism/pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Organometallic Compounds/metabolism/pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Permeability</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Water/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 22</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-7972 (Electronic)&#xD;0304-3940 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24937271</style></accession-num><abstract><style face="normal" font="default" size="100%">Pediatric asphyxial cardiac arrest (CA) results in unfavorable neurological outcome in most survivors. Development of neuroprotective therapies is contingent upon understanding the permeability of intravenously delivered medications through the blood brain barrier (BBB). In a model of pediatric CA we sought to characterize BBB permeability to small and large molecular weight substances. Additionally, we measured the percent brain water after CA. Asphyxia of 9 min was induced in 16-18 day-old rats. The rats were resuscitated and the BBB permeability to small (sodium fluorescein and gadoteridol) and large (immunoglobulin G, IgG) molecules was assessed at 1, 4, and 24 h after asphyxial CA or sham surgery. Percent brain water was measured post-CA and in shams using wet-to-dry brain weight. Fluorescence, gadoteridol uptake, or IgG staining at 1, 4h and over the entire 24 h post-CA did not differ from shams, suggesting absence of BBB permeability to these solutes. Cerebral water content was increased at 3h post-CA vs. sham. In conclusion, after 9 min of asphyxial CA there is no BBB permeability over 24h to conventional small or large molecule tracers despite the fact that cerebral water content is increased early post-CA indicating the development of brain edema. Evaluation of novel therapies targeting neuronal death after pediatric CA should include their capacity to cross the BBB.</style></abstract><notes><style face="normal" font="default" size="100%">Tress, Erika E&#xD;Clark, Robert S B&#xD;Foley, Lesley M&#xD;Alexander, Henry&#xD;Hickey, Robert W&#xD;Drabek, Tomas&#xD;Kochanek, Patrick M&#xD;Manole, Mioara D&#xD;P41 EB001977/EB/NIBIB NIH HHS/United States&#xD;R01 HD075760/HD/NICHD NIH HHS/United States&#xD;R01 NS084604/NS/NINDS NIH HHS/United States&#xD;P41-EB001977/EB/NIBIB NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Ireland&#xD;Neurosci Lett. 2014 Aug 22;578:17-21. doi: 10.1016/j.neulet.2014.06.020. Epub 2014 Jun 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0304394014004923/1-s2.0-S0304394014004923-main.pdf?_tid=7b190c84-d7d4-11e6-bcd3-00000aacb35f&amp;acdnat=1484122008_3eba4c73a6d8c4cb492d794e80b420a9</style></url></related-urls><pdf-urls><url>internal-pdf://2944788123/Tress-2014-Blood brain barrier.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4246011</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms611909</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neulet.2014.06.020</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>233</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">233</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Trzepizur, W.</style></author><author><style face="normal" font="default" size="100%">Martinez, M. C.</style></author><author><style face="normal" font="default" size="100%">Priou, P.</style></author><author><style face="normal" font="default" size="100%">Andriantsitohaina, R.</style></author><author><style face="normal" font="default" size="100%">Gagnadoux, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">INSERM U1063, Angers Dept of Respiratory Diseases, Angers University Hospital, Angers, France wotrzepizur@chu-angers.fr.&#xD;INSERM U1063, Angers.&#xD;INSERM U1063, Angers Dept of Respiratory Diseases, Angers University Hospital, Angers, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Microparticles and vascular dysfunction in obstructive sleep apnoea</style></title><secondary-title><style face="normal" font="default" size="100%">Eur Respir J</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The European respiratory journal</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur Respir J</style></full-title><abbr-1><style face="normal" font="default" size="100%">The European respiratory journal</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Eur Respir J</style></full-title><abbr-1><style face="normal" font="default" size="100%">The European respiratory journal</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">207-16</style></pages><volume><style face="normal" font="default" size="100%">44</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2014/03/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Atherosclerosis/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Membrane/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell-Derived Microparticles</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelium, Vascular/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocytes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative Stress</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Sleep Apnea, Obstructive/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1399-3003 (Electronic)&#xD;0903-1936 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24627532</style></accession-num><abstract><style face="normal" font="default" size="100%">Obstructive sleep apnoea (OSA) is independently associated with various cardiovascular diseases, including myocardial infarction and stroke. OSA may promote atherosclerosis risk factors such as hypertension, diabetes and dyslipidaemia, and may have direct proatherogenic effects on the vascular wall. A growing number of studies have recently focused on the role of microparticles (MPs) in the atherogenic process. MPs are small plasma membrane vesicles that can be released by a variety of vascular or blood cells, and contain both membrane and cytosolic elements. Case-control studies have shown that platelet-, endothelium- and leukocyte-derived MP levels are increased in OSA. Experimental evidence has demonstrated that MPs from OSA patients induce endothelial dysfunction, inflammation and vascular hyperreactivity when injected into mice. In this review, we provide an overview of the main characteristics of MPs, their expression in OSA and their potential role in the atherogenic process associated with OSA.</style></abstract><notes><style face="normal" font="default" size="100%">Trzepizur, Wojciech&#xD;Martinez, Maria Carmen&#xD;Priou, Pascaline&#xD;Andriantsitohaina, Ramaroson&#xD;Gagnadoux, Frederic&#xD;Review&#xD;England&#xD;Eur Respir J. 2014 Jul;44(1):207-16. doi: 10.1183/09031936.00197413. Epub 2014 Mar 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://erj.ersjournals.com/content/erj/44/1/207.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1481497226/Trzepizur-2014-Microparticles and v.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1183/09031936.00197413</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>200</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">200</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tsai, M. J.</style></author><author><style face="normal" font="default" size="100%">Kuo, Y. M.</style></author><author><style face="normal" font="default" size="100%">Tsai, Y. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, China Medical University Hospital, Taichung, Taiwan; School of Medicine, Medical College, China Medical University, Taichung, Taiwan; Department of Neurology, Tainan Municipal An-Nan Hospital-China Medical University, Tainan, Taiwan.&#xD;Department of Cell Biology and Anatomy, National Cheng Kung University, Tainan, Taiwan. Electronic address: kuoym@mail.ncku.edu.tw.&#xD;Graduate Institute of Clinical Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: yhtsai@kmu.edu.tw.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transient ischemic attack induced by melted solid lipid microparticles protects rat brains from permanent focal ischemia</style></title><secondary-title><style face="normal" font="default" size="100%">Neuroscience</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">136-45</style></pages><volume><style face="normal" font="default" size="100%">275</style></volume><edition><style face="normal" font="default" size="100%">2014/06/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/physiopathology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Cell-Derived Microparticles</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Attack, Transient/ etiology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Preconditioning/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Lipids/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 05</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1873-7544 (Electronic)&#xD;0306-4522 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24937754</style></accession-num><abstract><style face="normal" font="default" size="100%">This study aims to develop a transient ischemic attack (TIA) model in conscious animals and uses this model to investigate the effect of TIA on subsequent permanent ischemia. TIA was induced by injecting designed temperature-sensitive melted solid lipid microparticles with a melting point around body temperature into male Wistar rats via arterial cannulation. Neurologic deficit was monitored immediately after the injection without anesthesia. According to the clinical definition of TIA, rats were divided into neurologic symptom durations &lt;24-h, 24-48-h and &gt;/=48-h groups. The lipid microparticle-induced infarct volumes were small in the &lt;24-h and 24-48-h groups, while the volumes were five times larger in the &gt;/=48-h group. Permanent ischemic stroke was induced 3d after the induction of TIA by injecting a different kind of embolic particle manufactured by blending chitin and PLGA. The &lt;24-h group had less severe neurologic deficits and smaller infarct volumes than that of 24-48-h and control (without prior lipid microparticle treatment) rats. Taken together, we successfully develop a TIA animal model which allows us to monitor the neurologic deficit in real-time. By adopting this model, we validate that TIA (&lt;24h) preconditioning protects the brain from subsequent permanent ischemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Tsai, M-J&#xD;Kuo, Y-M&#xD;Tsai, Y-H&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Neuroscience. 2014 Sep 5;275:136-45. doi: 10.1016/j.neuroscience.2014.06.014. Epub 2014 Jun 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0306452214004990/1-s2.0-S0306452214004990-main.pdf?_tid=7daf5732-d7d4-11e6-a765-00000aacb35f&amp;acdnat=1484122012_8e0f77e89e35f44d3a08fb4b07f1e5c4</style></url></related-urls><pdf-urls><url>internal-pdf://2845636975/Tsai-2014-Transient ischemic a.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuroscience.2014.06.014</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>46</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">46</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tsygan, N. V.</style></author><author><style face="normal" font="default" size="100%">Trashkov, A. P.</style></author><author><style face="normal" font="default" size="100%">Yakovleva, V. A.</style></author><author><style face="normal" font="default" size="100%">Malkova, V. M.</style></author><author><style face="normal" font="default" size="100%">Gracheva, E. V.</style></author><author><style face="normal" font="default" size="100%">Kovalenko, A. L.</style></author><author><style face="normal" font="default" size="100%">Vasiliev, A. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Kirov Military Medical Academy, St. Petersburg.&#xD;St. Petersburg State Pediatric Medical University, St. Petersburg.&#xD;Institute of Toxicology of the Federal Medical-Biological Agency, St. Petersburg.</style></auth-address><titles><title><style face="normal" font="default" size="100%">[Characteristics of the regulation of neurotrophic mechanisms in ischemic stroke]</style></title><secondary-title><style face="normal" font="default" size="100%">Zh Nevrol Psikhiatr Im S S Korsakova</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Zh Nevrol Psikhiatr Im S S Korsakova</style></full-title><abbr-1><style face="normal" font="default" size="100%">Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Zh Nevrol Psikhiatr Im S S Korsakova</style></full-title><abbr-1><style face="normal" font="default" size="100%">Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">112-6</style></pages><volume><style face="normal" font="default" size="100%">115</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2015/09/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Combinations</style></keyword><keyword><style face="normal" font="default" size="100%">Flavin Mononucleotide/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Inosine Diphosphate/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Growth Factors/analysis/blood/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Niacinamide/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide/analysis/blood/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphopyruvate Hydratase/analysis/blood/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ drug therapy/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Succinates/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Endothelial Growth Factor A/analysis/blood/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">sign, Cyrillic small i, Cyrillicsmall es, Cyrillicsmall es, Cyrillicsmall el,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall de, Cyrillicsmall o, Cyrillicsmall ve,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall a, Cyrillicsmall en, Cyrillicsmall i, Cyrillicsmall ya, Cyrillic -</style></keyword><keyword><style face="normal" font="default" size="100%">small i, Cyrillicsmall ze, Cyrillicsmall u, Cyrillicsmall che, Cyrillicsmall ie,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall en, Cyrillicsmall i, Cyrillicsmall ie, Cyrillic small o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall es, Cyrillicsmall o, Cyrillicsmall be, Cyrillicsmall ie,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall en, Cyrillicsmall en, Cyrillicsmall o, Cyrillicsmall es,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall te, Cyrillicsmall ie, Cyrillicsmall short i, Cyrillic small e,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall en, Cyrillicsmall de, Cyrillicsmall o, Cyrillicsmall ghe,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall en, Cyrillicsmall en, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall short i, Cyrillic small i, Cyrillic small ef, Cyrillicsmall a,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall er, Cyrillicsmall em, Cyrillicsmall a, Cyrillicsmall ka,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall o, Cyrillicsmall el, Cyrillicsmall o, Cyrillicsmall ghe,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall i, Cyrillicsmall che, Cyrillicsmall ie, Cyrillicsmall es,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ka, Cyrillicsmall o, Cyrillicsmall short i, Cyrillic small a,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ka, Cyrillicsmall te, Cyrillicsmall i, Cyrillicsmall ve,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall a, Cyrillicsmall tse, Cyrillicsmall i, Cyrillicsmall i, Cyrillic</style></keyword><keyword><style face="normal" font="default" size="100%">small en, Cyrillicsmall ie, Cyrillicsmall short i, Cyrillicsmall er,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall o, Cyrillicsmall te, Cyrillicsmall er, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ef, Cyrillicsmall i, Cyrillicsmall che, Cyrillicsmall ie,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall es, Cyrillicsmall ka, Cyrillicsmall i, Cyrillicsmall ha, Cyrillic</style></keyword><keyword><style face="normal" font="default" size="100%">small em, Cyrillicsmall ie, Cyrillicsmall ha, Cyrillicsmall a, Cyrillic-small en,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall i, Cyrillicsmall ze, Cyrillicsmall em, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ve, Cyrillic small pe, Cyrillicsmall er, Cyrillicsmall i, Cyrillic</style></keyword><keyword><style face="normal" font="default" size="100%">small em, Cyrillicsmall o, Cyrillicsmall de, Cyrillicsmall ie, Cyrillicsmall el,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall i, Cyrillicsmall er, Cyrillicsmall o, Cyrillicsmall ve,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall a, Cyrillicsmall en, Cyrillicsmall i, Cyrillicsmall i, Cyrillic</style></keyword><keyword><style face="normal" font="default" size="100%">small o, Cyrillicsmall es, Cyrillicsmall te, Cyrillicsmall er, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ghe, Cyrillicsmall o, Cyrillic small i, Cyrillicsmall sha,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall em, Cyrillicsmall i, Cyrillicsmall che,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall es, Cyrillicsmall ka, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ghe, Cyrillicsmall o, Cyrillic small pe, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ve, Cyrillicsmall er, Cyrillicsmall ie, Cyrillicsmall zhe,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall de, Cyrillicsmall ie, Cyrillicsmall en, Cyrillicsmall i,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ya, Cyrillic small ghe, Cyrillicsmall o, Cyrillicsmall el,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall o, Cyrillicsmall ve, Cyrillicsmall en, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ghe, Cyrillicsmall o, Cyrillic small em, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ze, Cyrillicsmall ghe, Cyrillicsmall a, Cyrillic small u, Cyrillic</style></keyword><keyword><style face="normal" font="default" size="100%">small ka, Cyrillicsmall er, Cyrillicsmall yeru, Cyrillicsmall es, Cyrillic.</style></keyword><keyword><style face="normal" font="default" size="100%">capital EM, Cyrillicsmall a, Cyrillicsmall te, Cyrillicsmall ie, Cyrillicsmall</style></keyword><keyword><style face="normal" font="default" size="100%">er, Cyrillicsmall i, Cyrillicsmall a, Cyrillicsmall el, Cyrillic small i,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillic small em, Cyrillicsmall ie, Cyrillicsmall te, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall de, Cyrillicsmall yeru, Cyrillic. capital I, Cyrillicsmall es,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall es, Cyrillicsmall el, Cyrillicsmall ie, Cyrillicsmall de,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall o, Cyrillicsmall ve, Cyrillicsmall a, Cyrillicsmall en,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall i, Cyrillicsmall ie, Cyrillic small be, Cyrillicsmall yeru,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall el, Cyrillicsmall o, Cyrillic small ve, Cyrillicsmall yeru,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall pe, Cyrillicsmall o, Cyrillicsmall el, Cyrillicsmall en,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall en, Cyrillicsmall o, Cyrillic small en,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall a, Cyrillic 170 small es, Cyrillicsmall a, Cyrillicsmall em,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall tse, Cyrillicsmall a, Cyrillicsmall ha, Cyrillic-small a,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall el, Cyrillicsmall soft sign, Cyrillicsmall be, Cyrillicsmall i,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall en, Cyrillicsmall o, Cyrillicsmall es, Cyrillicsmall a,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ha, Cyrillic small es, Cyrillicsmall ie, Cyrillicsmall er,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall yeru, Cyrillicsmall ha, Cyrillic small ka, Cyrillicsmall er,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall yeru, Cyrillicsmall es, Cyrillic. capital I, Cyrillicsmall sha,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall em, Cyrillicsmall i, Cyrillicsmall che,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall es, Cyrillicsmall ka, Cyrillicsmall i,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall short i, Cyrillic small em, Cyrillicsmall o, Cyrillicsmall ze,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ghe, Cyrillicsmall o, Cyrillicsmall ve, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall short i, Cyrillic small i, Cyrillicsmall en, Cyrillicsmall es,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall u, Cyrillicsmall el, Cyrillicsmall soft sign, Cyrillicsmall te,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillic small em, Cyrillicsmall o, Cyrillicsmall de, Cyrillicsmall ie,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall el, Cyrillicsmall i, Cyrillicsmall er, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ve, Cyrillicsmall a, Cyrillicsmall el, Cyrillicsmall i, Cyrillic</style></keyword><keyword><style face="normal" font="default" size="100%">small pe, Cyrillicsmall u, Cyrillicsmall te, Cyrillicsmall ie, Cyrillicsmall em,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillic small e, Cyrillicsmall el, Cyrillicsmall ie, Cyrillicsmall ka,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall te, Cyrillicsmall er, Cyrillicsmall o, Cyrillicsmall ka,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall o, Cyrillicsmall a, Cyrillicsmall ghe, Cyrillicsmall u,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall el, Cyrillicsmall ya, Cyrillicsmall tse, Cyrillicsmall i,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall i, Cyrillic small pe, Cyrillicsmall er, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ka, Cyrillicsmall es, Cyrillicsmall i, Cyrillicsmall em,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall a, Cyrillicsmall el, Cyrillicsmall soft sign, Cyrillicsmall en,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall o, Cyrillicsmall ghe, Cyrillicsmall o, Cyrillic small es,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall ghe, Cyrillicsmall em, Cyrillicsmall ie,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall en, Cyrillicsmall te, Cyrillicsmall a, Cyrillic small el,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall ve, Cyrillicsmall o, Cyrillicsmall short i,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillic small es, Cyrillicsmall er, Cyrillicsmall ie, Cyrillicsmall de,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall en, Cyrillicsmall ie, Cyrillicsmall short i, Cyrillic small em,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall o, Cyrillicsmall ze, Cyrillicsmall ghe, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ve, Cyrillicsmall o, Cyrillicsmall short i, Cyrillic small a,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall er, Cyrillicsmall te, Cyrillicsmall ie, Cyrillicsmall er,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall i, Cyrillicsmall i, Cyrillic small es, Cyrillic small o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall de, Cyrillicsmall en, Cyrillicsmall o, Cyrillicsmall ve,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall er, Cyrillicsmall ie, Cyrillicsmall em, Cyrillicsmall ie,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall en, Cyrillicsmall en, Cyrillicsmall yeru, Cyrillicsmall em,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillic small en, Cyrillicsmall a, Cyrillicsmall el, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall zhe, Cyrillicsmall ie, Cyrillicsmall en, Cyrillicsmall i,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall em, Cyrillic small pe, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall es, Cyrillicsmall te, Cyrillicsmall o, Cyrillicsmall ya,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall en, Cyrillicsmall en, Cyrillicsmall o, Cyrillicsmall short i,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillic small el, Cyrillicsmall i, Cyrillicsmall ghe, Cyrillicsmall a,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall te, Cyrillicsmall u, Cyrillicsmall er, Cyrillicsmall yeru, Cyrillic</style></keyword><keyword><style face="normal" font="default" size="100%">small en, Cyrillicsmall a, Cyrillic small el, Cyrillicsmall ie, Cyrillicsmall ve,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall u, Cyrillicsmall yu, Cyrillic small o, Cyrillicsmall be,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall shcha, Cyrillicsmall u, Cyrillicsmall yu, Cyrillic small es,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall o, Cyrillicsmall en, Cyrillicsmall en, Cyrillicsmall u,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall yu, Cyrillic small a, Cyrillicsmall er, Cyrillicsmall te,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall er, Cyrillicsmall i, Cyrillicsmall yu, Cyrillic.</style></keyword><keyword><style face="normal" font="default" size="100%">capital ER, Cyrillicsmall ie, Cyrillicsmall ze, Cyrillicsmall u, Cyrillicsmall</style></keyword><keyword><style face="normal" font="default" size="100%">el, Cyrillicsmall soft sign, Cyrillicsmall te, Cyrillicsmall a, Cyrillicsmall te,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall yeru, Cyrillic small i, Cyrillic small ze, Cyrillicsmall a,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ka, Cyrillicsmall el, Cyrillicsmall yu, Cyrillicsmall che,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall en, Cyrillicsmall i, Cyrillicsmall ie, Cyrillic.</style></keyword><keyword><style face="normal" font="default" size="100%">capital O, Cyrillicsmall tse, Cyrillicsmall ie, Cyrillicsmall en, Cyrillicsmall</style></keyword><keyword><style face="normal" font="default" size="100%">ka, Cyrillicsmall a, Cyrillic small es, Cyrillicsmall o, Cyrillicsmall de,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall er, Cyrillicsmall zhe, Cyrillicsmall a,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall en, Cyrillicsmall i, Cyrillicsmall ya, Cyrillic NSE, NO, VEGF, NGF</style></keyword><keyword><style face="normal" font="default" size="100%">small ve, Cyrillic small tse, Cyrillicsmall i, Cyrillicsmall te, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall el, Cyrillicsmall i, Cyrillicsmall ze, Cyrillicsmall a,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall te, Cyrillicsmall ie, Cyrillic small ghe, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall el, Cyrillicsmall o, Cyrillicsmall ve, Cyrillicsmall en,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall o, Cyrillicsmall ghe, Cyrillicsmall o, Cyrillic small em,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall o, Cyrillicsmall ze, Cyrillicsmall ghe, Cyrillicsmall a, Cyrillic</style></keyword><keyword><style face="normal" font="default" size="100%">small i, Cyrillic small pe, Cyrillicsmall el, Cyrillicsmall a, Cyrillicsmall ze,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall em, Cyrillicsmall ie, Cyrillic small ka, Cyrillicsmall er,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall o, Cyrillicsmall ve, Cyrillicsmall i, Cyrillic small ve,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall yeru, Cyrillicsmall ya, Cyrillicsmall ve, Cyrillicsmall i,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall el, Cyrillicsmall a, Cyrillic small o, Cyrillicsmall te,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall es, Cyrillicsmall er, Cyrillicsmall o, Cyrillicsmall che,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall en, Cyrillicsmall en, Cyrillicsmall u,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall yu, Cyrillic small a, Cyrillicsmall ka, Cyrillicsmall te,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall i, Cyrillicsmall ve, Cyrillicsmall a, Cyrillicsmall tse,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall i, Cyrillicsmall yu, Cyrillic small en, Cyrillicsmall ie,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall short i, Cyrillicsmall er, Cyrillicsmall o, Cyrillicsmall te,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall er, Cyrillicsmall o, Cyrillicsmall ef, Cyrillicsmall i,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall che, Cyrillicsmall ie, Cyrillicsmall es, Cyrillicsmall ka,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall i, Cyrillicsmall ha, Cyrillic small em, Cyrillicsmall ie,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ha, Cyrillicsmall a, Cyrillicsmall en, Cyrillicsmall i,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ze, Cyrillicsmall em, Cyrillicsmall o, Cyrillicsmall ve, Cyrillic</style></keyword><keyword><style face="normal" font="default" size="100%">small ve, Cyrillic small a, Cyrillicsmall es, Cyrillicsmall te, Cyrillicsmall er,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall o, Cyrillicsmall tse, Cyrillicsmall i, Cyrillicsmall te,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall a, Cyrillicsmall ha, Cyrillic, small es, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall pe, Cyrillicsmall er, Cyrillicsmall o, Cyrillicsmall ve,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall o, Cyrillicsmall zhe, Cyrillicsmall de, Cyrillicsmall a,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall yu, Cyrillicsmall shcha, Cyrillicsmall u, Cyrillicsmall yu,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall es, Cyrillicsmall ya, Cyrillic small u, Cyrillicsmall em,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall en, Cyrillicsmall soft sign, Cyrillicsmall sha,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall en, Cyrillicsmall i, Cyrillicsmall ie,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall em, Cyrillic small o, Cyrillicsmall te, Cyrillicsmall es,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall er, Cyrillicsmall o, Cyrillicsmall che, Cyrillicsmall ie,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall en, Cyrillicsmall en, Cyrillicsmall o, Cyrillicsmall ghe,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall o, Cyrillic small pe, Cyrillicsmall o, Cyrillicsmall ve,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall er, Cyrillicsmall ie, Cyrillicsmall zhe, Cyrillicsmall de,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall en, Cyrillicsmall i, Cyrillicsmall ya, Cyrillic</style></keyword><keyword><style face="normal" font="default" size="100%">small en, Cyrillicsmall ie, Cyrillicsmall short i, Cyrillicsmall er,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall o, Cyrillicsmall en, Cyrillicsmall o, Cyrillicsmall ve, Cyrillic.</style></keyword><keyword><style face="normal" font="default" size="100%">capital PE, Cyrillicsmall er, Cyrillicsmall i, Cyrillicsmall em, Cyrillicsmall</style></keyword><keyword><style face="normal" font="default" size="100%">ie, Cyrillicsmall en, Cyrillicsmall ie, Cyrillicsmall en, Cyrillicsmall i,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillic small tse, Cyrillicsmall i, Cyrillicsmall te,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall o, Cyrillicsmall ef, Cyrillicsmall el, Cyrillicsmall a,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ve, Cyrillicsmall i, Cyrillicsmall en, Cyrillicsmall a, Cyrillic</style></keyword><keyword><style face="normal" font="default" size="100%">small ve, Cyrillic small el, Cyrillicsmall ie, Cyrillicsmall che, Cyrillicsmall</style></keyword><keyword><style face="normal" font="default" size="100%">ie, Cyrillicsmall en, Cyrillicsmall i, Cyrillicsmall i, Cyrillic small i,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall en, Cyrillicsmall es, Cyrillicsmall u, Cyrillicsmall el,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall soft sign, Cyrillicsmall te, Cyrillicsmall a, Cyrillic small ve,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillic small e, Cyrillicsmall ka, Cyrillicsmall es, Cyrillicsmall pe,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall er, Cyrillicsmall i, Cyrillicsmall em,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall en, Cyrillicsmall te, Cyrillicsmall ie, Cyrillic</style></keyword><keyword><style face="normal" font="default" size="100%">small es, Cyrillicsmall o, Cyrillicsmall pe, Cyrillicsmall er, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ve, Cyrillicsmall o, Cyrillicsmall zhe, Cyrillicsmall de,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall a, Cyrillicsmall el, Cyrillicsmall o, Cyrillicsmall es,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall soft sign, Cyrillic small be, Cyrillicsmall o, Cyrillicsmall el,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall ie, Cyrillic small er, Cyrillicsmall a,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall en, Cyrillicsmall en, Cyrillicsmall ie, Cyrillicsmall short i,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillic small i, Cyrillic small be, Cyrillicsmall o, Cyrillicsmall el,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall ie, Cyrillic small i, Cyrillicsmall en,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall te, Cyrillicsmall ie, Cyrillicsmall en, Cyrillicsmall es,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall i, Cyrillicsmall ve, Cyrillicsmall en, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall short i, Cyrillic small a, Cyrillicsmall ka, Cyrillicsmall te,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall i, Cyrillicsmall ve, Cyrillicsmall a, Cyrillicsmall tse,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall i, Cyrillicsmall ie, Cyrillicsmall short i, Cyrillic small en,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall short i, Cyrillicsmall er, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall te, Cyrillicsmall er, Cyrillicsmall o, Cyrillicsmall ef,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall i, Cyrillicsmall che, Cyrillicsmall ie, Cyrillicsmall es,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ka, Cyrillicsmall i, Cyrillicsmall ha, Cyrillic small em,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall ha, Cyrillicsmall a, Cyrillicsmall en,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall i, Cyrillicsmall ze, Cyrillicsmall em, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ve, Cyrillic small ve, Cyrillic small a, Cyrillicsmall es,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall te, Cyrillicsmall er, Cyrillicsmall o, Cyrillicsmall tse,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall i, Cyrillicsmall te, Cyrillicsmall a, Cyrillicsmall ha, Cyrillic,</style></keyword><keyword><style face="normal" font="default" size="100%">small o, Cyrillicsmall te, Cyrillicsmall es, Cyrillicsmall er, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall che, Cyrillicsmall ie, Cyrillicsmall en, Cyrillicsmall en,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall o, Cyrillicsmall short i, Cyrillic small a, Cyrillicsmall ka,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall te, Cyrillicsmall i, Cyrillicsmall ve, Cyrillicsmall a,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall tse, Cyrillicsmall i, Cyrillicsmall ie, Cyrillicsmall short i,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillic small en, Cyrillicsmall ie, Cyrillicsmall short i, Cyrillicsmall er,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall o, Cyrillicsmall te, Cyrillicsmall er, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ef, Cyrillicsmall i, Cyrillicsmall che, Cyrillicsmall ie,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall es, Cyrillicsmall ka, Cyrillicsmall i, Cyrillicsmall ha, Cyrillic</style></keyword><keyword><style face="normal" font="default" size="100%">small em, Cyrillicsmall ie, Cyrillicsmall ha, Cyrillicsmall a, Cyrillicsmall en,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall i, Cyrillicsmall ze, Cyrillicsmall em, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ve, Cyrillic small ve, Cyrillic small e, Cyrillicsmall en,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall de, Cyrillicsmall o, Cyrillicsmall te, Cyrillicsmall ie,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall el, Cyrillicsmall i, Cyrillicsmall o, Cyrillicsmall tse,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall i, Cyrillicsmall te, Cyrillicsmall a, Cyrillicsmall ha, Cyrillic,</style></keyword><keyword><style face="normal" font="default" size="100%">small che, Cyrillicsmall te, Cyrillicsmall o, Cyrillic small pe, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ze, Cyrillicsmall ve, Cyrillicsmall o, Cyrillicsmall el,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ya, Cyrillicsmall el, Cyrillicsmall o, Cyrillic small en,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall a, Cyrillic small be, Cyrillicsmall o, Cyrillicsmall el,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall ie, Cyrillic small er, Cyrillicsmall a,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall en, Cyrillicsmall en, Cyrillicsmall i, Cyrillicsmall ha, Cyrillic</style></keyword><keyword><style face="normal" font="default" size="100%">small es, Cyrillicsmall er, Cyrillicsmall o, Cyrillicsmall ka, Cyrillicsmall a,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ha, Cyrillic small o, Cyrillicsmall be, Cyrillicsmall ie,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall es, Cyrillicsmall pe, Cyrillicsmall ie, Cyrillicsmall che,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall i, Cyrillicsmall te, Cyrillicsmall soft sign, Cyrillic small en,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall short i, Cyrillicsmall er, Cyrillicsmall o,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall pe, Cyrillicsmall er, Cyrillicsmall o, Cyrillicsmall te,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall ie, Cyrillicsmall ka, Cyrillicsmall tse, Cyrillicsmall i,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall yu, Cyrillic small pe, Cyrillicsmall er, Cyrillicsmall i, Cyrillic</style></keyword><keyword><style face="normal" font="default" size="100%">small er, Cyrillicsmall a, Cyrillicsmall ze, Cyrillicsmall ve, Cyrillicsmall i,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall te, Cyrillicsmall i, Cyrillicsmall i, Cyrillic small i,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall sha, Cyrillicsmall ie, Cyrillicsmall em, Cyrillicsmall i,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall che, Cyrillicsmall ie, Cyrillicsmall es, Cyrillicsmall ka,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall o, Cyrillicsmall ghe, Cyrillicsmall o, Cyrillic small i,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall en, Cyrillicsmall es, Cyrillicsmall u, Cyrillicsmall el,</style></keyword><keyword><style face="normal" font="default" size="100%">Cyrillicsmall soft sign, Cyrillicsmall te, Cyrillicsmall a, Cyrillic.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1997-7298 (Print)&#xD;1997-7298 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26356524</style></accession-num><abstract><style face="normal" font="default" size="100%">AIM: To explore the endogenous and pharmacological activation of neurotrophic mechanisms in a model of brain ischemic lesion in rats. MATERIAL AND METHODS: The study was performed on 170 male albino rats (195-205 g). The model of ischemic stroke was accomplished by the electrocoagulation of the proximal segment of the left middle cerebral artery and simultaneous permanent ligation of the left common carotid artery. RESULTS AND CONCLUSION: The evaluation of NSE, NO, VEGF, NGF levels in the brain cytoplasmic lysate and plasma showed the delayed activation of neurotrophic mechanisms in astrocytes accompanied by a decrease in delayed alteration of neurons. The use of cytoflavin in the treatment of stroke was accompanied by the earlier and more intense activation of neurotrophic mechanisms in astrocytes, delayed activation of neurotrophic mechanisms in endothelial cells, which promoted neuroprotection in acute ischemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Tsygan, N V&#xD;Trashkov, A P&#xD;Yakovleva, V A&#xD;Malkova, V M&#xD;Gracheva, E V&#xD;Kovalenko, A L&#xD;Vasiliev, A G&#xD;English Abstract&#xD;Russia (Federation)&#xD;Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(7):112-6.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">rus</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>429</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">429</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tuttolomondo, A.</style></author><author><style face="normal" font="default" size="100%">Di Raimondo, D.</style></author><author><style face="normal" font="default" size="100%">Pecoraro, R.</style></author><author><style face="normal" font="default" size="100%">Arnao, V.</style></author><author><style face="normal" font="default" size="100%">Pinto, A.</style></author><author><style face="normal" font="default" size="100%">Licata, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dipartimento Biomedico di Medicina Interna e Specialistica, Universita degli Studi di Palermo, Italy. bruno.tuttolomondo@unipa.it</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inflammation in ischemic stroke subtypes</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Pharm Des</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Current pharmaceutical design</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Pharm Des</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current pharmaceutical design</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Curr Pharm Des</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current pharmaceutical design</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">4289-310</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><number><style face="normal" font="default" size="100%">28</style></number><edition><style face="normal" font="default" size="100%">2012/03/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/diagnosis/drug therapy/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">C-Reactive Protein/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/diagnosis/drug therapy/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-6/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Outcome Assessment (Health Care)</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/diagnosis/drug therapy/ physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1873-4286 (Electronic)&#xD;1381-6128 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22390641</style></accession-num><abstract><style face="normal" font="default" size="100%">Determining the cause of stroke does influence choices for management. categorization of subtypes of ischemic stroke has had considerable study, but definitions are hard to formulate and their application for diagnosis in an individual patient is often problematic. Cerebral ischemia initiates a complex cascade of events at genomic, molecular, and cellular levels, and inflammation is important in this cascade. In 1993 for For the Trial of Org 10172 in Acute Stroke Treatment (TOAST), Adams et al] conducted a placebo-controlled, randomized, blinded study of the low-molecular-weight heparinoid given to patients within 24 hours after stroke and developed a system for diagnosis of subtype of ischemic stroke that uses components of existing diagnostic schemes. The type of acute ischemic stroke was classified according to the TOAST classification: 1) Large Artery AtheroSclerosis (LAAS); 2) CardioEmbolic Infarct (CEI); 3) LACunar infarct (LAC); 4) stroke of Other Determined Etiology (ODE); 5) stroke of UnDetermined Etiology (UDE) (see Fig. (1)). On the basis of pathophysiologic differences of each stroke subtype it&apos;s possible to hypothesize a different pattern of immuno-inflammatory activation in relation of ischemic stroke subtype. A nonspecific systemic inflammatory response occurs after both ischemic and hemorrhagic stroke, either as part of the process of brain damage or in response to complications such as deep venous thrombosis. Several studies have reported that higher levels of inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6) are associated with worse outcome after ischemic stroke. Our group reported that patients with cardioembolic subtype showed significantly higher median plasma levels of TNF-alpha, IL-6, IL-1beta whereas the lacunar subtype showed significantly lower median plasma levels of TNF-alpha, IL-6 and IL-1beta. Our findings underlined the significant association was noted between the severity of neurological deficit at admission, the diagnostic subtype and some inflammatory variables.</style></abstract><notes><style face="normal" font="default" size="100%">Tuttolomondo, Antonino&#xD;Di Raimondo, Domenico&#xD;Pecoraro, Rosaria&#xD;Arnao, Valentina&#xD;Pinto, Antonio&#xD;Licata, Giuseppe&#xD;Review&#xD;Netherlands&#xD;Curr Pharm Des. 2012;18(28):4289-310.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>244</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">244</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tuttolomondo, A.</style></author><author><style face="normal" font="default" size="100%">Pecoraro, R.</style></author><author><style face="normal" font="default" size="100%">Di Raimondo, D.</style></author><author><style face="normal" font="default" size="100%">Arnao, V.</style></author><author><style face="normal" font="default" size="100%">Clemente, G.</style></author><author><style face="normal" font="default" size="100%">Della Corte, V.</style></author><author><style face="normal" font="default" size="100%">Maida, C.</style></author><author><style face="normal" font="default" size="100%">Simonetta, I.</style></author><author><style face="normal" font="default" size="100%">Licata, G.</style></author><author><style face="normal" font="default" size="100%">Pinto, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dipartimento Biomedico di Medicina Interna e Specialistica, Universita degli Studi di Palermo, Palermo, Italy. brunotutto@unipa.it.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Stroke subtypes and their possible implication in stroke prevention drug strategies</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Vasc Pharmacol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Current vascular pharmacology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Vasc Pharmacol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current vascular pharmacology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Curr Vasc Pharmacol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current vascular pharmacology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">824-37</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2014/02/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Aspirin/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Atherosclerosis/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Dipyridamole/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Platelet Aggregation Inhibitors/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ classification/diagnosis/ prevention &amp; control</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1875-6212 (Electronic)&#xD;1570-1611 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24484464</style></accession-num><abstract><style face="normal" font="default" size="100%">Thrombotic strokes can affect large or small arteries in the brain. Drugs to prevent atherosclerosis complication such as thrombotic strokes, should be drugs able to prevent the accumulation of intravascular fat, reduce vascular proliferation, decrease blood pressure levels with the resulting shear stress, reduce platelet aggregation, and possibly partially or totally reverse carotid plaques. Any of the commonly used antihypertensive drugs lower the incidence of stroke, with larger reductions in BP resulting in larger reductions in risk. Experimental and clinical data suggest that reducing the activity of the renin-angiotensin aldosterone system (RAAS) may have beneficial effects beyond the lowering of blood pressure to reduce stroke incidence. In clinical trials, statins consistently reduced the risk of ischemic stroke in patients with or without CHD whereas the data on the effects of other lipid modifying drugs on stroke risk are limited. Approximately 25% of strokes are recurrent. Antiplatelet therapy is indicated for the prevention of recurrent stroke in patients with a history of noncardioembolic minor stroke or transient ischemic attack (TIA). Although clinicians may choose acetylsalicylic acid (ASA) as first-line therapy for secondary prevention, clinical guidelines and evidence from trials suggest that ASA may not be the most effective strategy. A recent review discussed results from clinical trials that have compared the efficacy of ASA monotherapy versus ASA + extended release dipyridamole in secondary stroke prevention. Therefore it is difficult to extrapolate the real benefit of pharmacological prevention strategies against atherothrombotic subtype for excellence in the TOAST classification subtype that is represented by the LAAS and also with regard to lacunar subtype as an expression of lipohyalinosis process which is a further aspect of atherosclerosis.</style></abstract><notes><style face="normal" font="default" size="100%">Tuttolomondo, Antonino&#xD;Pecoraro, Rosaria&#xD;Di Raimondo, Domenico&#xD;Arnao, Valentina&#xD;Clemente, Giuseppe&#xD;Della Corte, Vittoriano&#xD;Maida, Carlo&#xD;Simonetta, Irene&#xD;Licata, Giuseppe&#xD;Pinto, Antonio&#xD;Review&#xD;United Arab Emirates&#xD;Curr Vasc Pharmacol. 2013 Nov;11(6):824-37.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>35</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">35</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Uchida, H.</style></author><author><style face="normal" font="default" size="100%">Sakata, H.</style></author><author><style face="normal" font="default" size="100%">Fujimura, M.</style></author><author><style face="normal" font="default" size="100%">Niizuma, K.</style></author><author><style face="normal" font="default" size="100%">Kushida, Y.</style></author><author><style face="normal" font="default" size="100%">Dezawa, M.</style></author><author><style face="normal" font="default" size="100%">Tominaga, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Miyagi, Japan; Department of Anatomy and Anthropology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan. Electronic address: h.uchida0206@gmail.com.&#xD;Department of Neurosurgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Miyagi, Japan. Electronic address: sakata@nsg.med.tohoku.ac.jp.&#xD;Department of Neurosurgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Miyagi, Japan. Electronic address: fujimur@nsg.med.tohoku.ac.jp.&#xD;Department of Neurosurgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Miyagi, Japan. Electronic address: niizuma@nsg.med.tohoku.ac.jp.&#xD;Department of Anatomy and Anthropology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan. Electronic address: y-kushida@med.tohoku.ac.jp.&#xD;Department of Anatomy and Anthropology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan; Department of Stem Cell Biology and Histology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan. Electronic address: mdezawa@med.tohoku.ac.jp.&#xD;Department of Neurosurgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Miyagi, Japan. Electronic address: tomi@nsg.med.tohoku.ac.jp.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Experimental model of small subcortical infarcts in mice with long-lasting functional disabilities</style></title><secondary-title><style face="normal" font="default" size="100%">Brain Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">318-28</style></pages><volume><style face="normal" font="default" size="100%">1629</style></volume><edition><style face="normal" font="default" size="100%">2015/11/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/ chemically induced/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelin-1/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Internal Capsule/drug effects/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, SCID</style></keyword><keyword><style face="normal" font="default" size="100%">NG-Nitroarginine Methyl Ester/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Psychomotor Performance/drug effects/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ chemically induced/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 10</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-6240 (Electronic)&#xD;0006-8993 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26522346</style></accession-num><abstract><style face="normal" font="default" size="100%">Small subcortical infarcts account for 25% of all ischemic strokes. Although once considered to be a small vessel disease with a favorable outcome, recent studies have reported relatively poor long-term prognoses following small subcortical infarcts. Limited pre-clinical modeling has hampered understanding of the etiology and development of treatments for this disease. Therefore, we attempted to develop a new experimental model of small subcortical infarcts in mice to investigate pathophysiological changes in the corticospinal tract and assess long-term behavioral performance. The vasoconstrictor peptide, endothlin-1 (ET-1), in combination with the nitric oxide synthase inhibitor, N(G)-nitro-l-arginine methyl ester (l-NAME), were injected into the internal capsule of mice. Histological and behavioral tests were performed 0-8 weeks after the injection. The ET-1/l-NAME injection resulted in severe neurological deficits that continued for up to 8 weeks. The loss of axons and myelin surrounded by reactive gliosis was identified in the region of the injection, in which the vasoconstriction of microvessels was also observed. Moreover, a tract-tracing study revealed an interruption in axonal flow at the internal capsule. The present model of small subcortical infarcts is unique and novel due to the reproduction of neurological deficits that continue for a long period, up to 8 weeks, as well as the use of mice as experimental animals. The reproducibility, simplicity, and easy adoptability make the present model highly appealing for use in further pre-clinical studies on small subcortical infarcts.</style></abstract><notes><style face="normal" font="default" size="100%">Uchida, Hiroki&#xD;Sakata, Hiroyuki&#xD;Fujimura, Miki&#xD;Niizuma, Kuniyasu&#xD;Kushida, Yoshihiro&#xD;Dezawa, Mari&#xD;Tominaga, Teiji&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;Brain Res. 2015 Dec 10;1629:318-28. doi: 10.1016/j.brainres.2015.10.039. Epub 2015 Oct 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0006899315008100/1-s2.0-S0006899315008100-main.pdf?_tid=843da77a-d7d4-11e6-9351-00000aacb360&amp;acdnat=1484122023_01bbeba022bf191f126dc99be2364a8a</style></url></related-urls><pdf-urls><url>internal-pdf://0115288951/Uchida-2015-Experimental model o.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.brainres.2015.10.039</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>196</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">196</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ueda, Y.</style></author><author><style face="normal" font="default" size="100%">Masuda, T.</style></author><author><style face="normal" font="default" size="100%">Ishida, A.</style></author><author><style face="normal" font="default" size="100%">Misumi, S.</style></author><author><style face="normal" font="default" size="100%">Shimizu, Y.</style></author><author><style face="normal" font="default" size="100%">Jung, C. G.</style></author><author><style face="normal" font="default" size="100%">Hida, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurophysiology and Brain Science, Nagoya City University Graduate School of Medical Science, Nagoya, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Enhanced electrical responsiveness in the cerebral cortex with oral melatonin administration after a small hemorrhage near the internal capsule in rats</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosci Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neuroscience research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosci Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroscience research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurosci Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroscience research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1499-508</style></pages><volume><style face="normal" font="default" size="100%">92</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2014/06/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antioxidants/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/complications/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Deep Brain Stimulation/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Functional Laterality/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrogen Peroxide/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Internal Capsule/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Melatonin/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Motor Activity/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Movement Disorders/drug therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative Stress/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Pyramidal Tracts/drug effects/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1097-4547 (Electronic)&#xD;0360-4012 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24964396</style></accession-num><abstract><style face="normal" font="default" size="100%">Intracerebral hemorrhage (ICH) can cause direct brain injury at the insult site and indirect damage in remote brain areas. Although a protective effect of melatonin (ML) has been reported for ICH, its detailed mechanisms and effects on remote brain injury remain unclear. To clarify the mechanism of indirect neuroprotection after ICH, we first investigated whether ML improved motor function after ICH and then examined the underlying mechanisms. The ICH model rat was made by collagenase injection into the left globus pallidus, adjacent to the internal capsule. ML oral administration (15 mg/kg) for 7 days after ICH resulted in significant recovery of motor function. Retrograde labeling of the corticospinal tract by Fluoro-Gold revealed a significant increase in numbers of positive neurons in the cerebral cortex. Immunohistological analysis showed that ML treatment induced no difference in OX41-positive activated microglia/macrophage at day 1 (D1) but a significant reduction in 8-hydroxydeoxyguanosin-positive cells at D7. Neutral red assay revealed that ML significantly prevented H2 O2 -induced cell death in cultured oligodendrocytes and astrocytes but not in neurons. Electrophysiological response in the cerebral cortex area where the number of Fluoro-Gold-positive cells was increased was significantly improved in ML-treated rats. These data suggest that ML improves motor abilities after ICH by protecting oligodendrocytes and astrocytes in the vicinity of the lesion in the corticospinal tract from oxidative stress and causes enhanced electrical responsiveness in the cerebral cortex remote to the ICH pathology.</style></abstract><notes><style face="normal" font="default" size="100%">Ueda, Yoshitomo&#xD;Masuda, Tadashi&#xD;Ishida, Akimasa&#xD;Misumi, Sachiyo&#xD;Shimizu, Yuko&#xD;Jung, Cha-Gyun&#xD;Hida, Hideki&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Neurosci Res. 2014 Nov;92(11):1499-508. doi: 10.1002/jnr.23434. Epub 2014 Jun 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1002/jnr.23434/asset/jnr23434.pdf?v=1&amp;t=ixsntpos&amp;s=df9c94364676d9ab2b24c4a29b4f088c8ab9a781</style></url></related-urls><pdf-urls><url>internal-pdf://1190536808/Ueda-2014-Enhanced electrical.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/jnr.23434</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>67</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">67</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">van der Vorst, E. P.</style></author><author><style face="normal" font="default" size="100%">Doring, Y.</style></author><author><style face="normal" font="default" size="100%">Weber, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Pettenkoferstr 9, 80336, Munich, Germany. Emiel.Van_der_Vorst@med.uni-muenchen.de.&#xD;Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Pettenkoferstr 9, 80336, Munich, Germany. yvonne.doering@med.uni-muenchen.de.&#xD;Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Pettenkoferstr 9, 80336, Munich, Germany. christian.weber@med.uni-muenchen.de.&#xD;DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany. christian.weber@med.uni-muenchen.de.&#xD;Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands. christian.weber@med.uni-muenchen.de.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Chemokines and their receptors in Atherosclerosis</style></title><secondary-title><style face="normal" font="default" size="100%">J Mol Med (Berl)</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of molecular medicine (Berlin, Germany)</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Mol Med (Berl)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of molecular medicine (Berlin, Germany)</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Mol Med (Berl)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of molecular medicine (Berlin, Germany)</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">963-71</style></pages><volume><style face="normal" font="default" size="100%">93</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2015/07/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Atherosclerosis/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Chemokine CXCL12/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Macrophage Migration-Inhibitory Factors/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Biological</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1432-1440 (Electronic)&#xD;0946-2716 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26175090</style></accession-num><abstract><style face="normal" font="default" size="100%">Atherosclerosis, a chronic inflammatory disease of the medium- and large-sized arteries, is the main underlying cause of cardiovascular diseases (CVDs) most often leading to a myocardial infarction or stroke. However, atherosclerosis can also develop without this clinical manifestation. The pathophysiology of atherosclerosis is very complex and consists of many cells and molecules interacting with each other. Over the last years, chemokines (small 8-12 kDa cytokines with chemotactic properties) have been identified as key players in atherogenesis. However, this remains a very active and dynamic field of research. Here, we will give an overview of the current knowledge about the involvement of chemokines in all phases of atherosclerotic lesion development. Furthermore, we will focus on two chemokines that recently have been associated with atherogenesis, CXCL12, and macrophage migration inhibitory factor (MIF). Both chemokines play a crucial role in leukocyte recruitment and arrest, a critical step in atherosclerosis development. MIF has shown to be a more pro-inflammatory and thus pro-atherogenic chemokine, instead CXCL12 seems to have a more protective function. However, results about this protective role are still quite debatable. Future research will further elucidate the precise role of these chemokines in atherosclerosis and determine the potential of chemokine-based therapies.</style></abstract><notes><style face="normal" font="default" size="100%">van der Vorst, Emiel P C&#xD;Doring, Yvonne&#xD;Weber, Christian&#xD;249929/European Research Council/International&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Germany&#xD;J Mol Med (Berl). 2015 Sep;93(9):963-71. doi: 10.1007/s00109-015-1317-8. Epub 2015 Jul 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/746/art%253A10.1007%252Fs00109-015-1317-8.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00109-015-1317-8&amp;token2=exp=1484123042~acl=%2Fstatic%2Fpdf%2F746%2Fart%25253A10.1007%25252Fs00109-015-1317-8.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs00109-015-1317-8*~hmac=f043b6b0e4c4bf893edc6ec3a86b90ee8b3c33628c2489a21a3b1c54563c1d6d</style></url></related-urls><pdf-urls><url>internal-pdf://1687494393/van der Vorst-2015-Chemokines and their.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4577534</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00109-015-1317-8</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>390</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">390</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vandeputte, C.</style></author><author><style face="normal" font="default" size="100%">Casteels, C.</style></author><author><style face="normal" font="default" size="100%">Struys, T.</style></author><author><style face="normal" font="default" size="100%">Koole, M.</style></author><author><style face="normal" font="default" size="100%">van Veghel, D.</style></author><author><style face="normal" font="default" size="100%">Evens, N.</style></author><author><style face="normal" font="default" size="100%">Gerits, A.</style></author><author><style face="normal" font="default" size="100%">Dresselaers, T.</style></author><author><style face="normal" font="default" size="100%">Lambrichts, I.</style></author><author><style face="normal" font="default" size="100%">Himmelreich, U.</style></author><author><style face="normal" font="default" size="100%">Bormans, G.</style></author><author><style face="normal" font="default" size="100%">Van Laere, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Nuclear Medicine, KU Leuven, Leuven, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Small-animal PET imaging of the type 1 and type 2 cannabinoid receptors in a photothrombotic stroke model</style></title><secondary-title><style face="normal" font="default" size="100%">Eur J Nucl Med Mol Imaging</style></secondary-title><alt-title><style face="normal" font="default" size="100%">European journal of nuclear medicine and molecular imaging</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur J Nucl Med Mol Imaging</style></full-title><abbr-1><style face="normal" font="default" size="100%">European journal of nuclear medicine and molecular imaging</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Eur J Nucl Med Mol Imaging</style></full-title><abbr-1><style face="normal" font="default" size="100%">European journal of nuclear medicine and molecular imaging</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1796-806</style></pages><volume><style face="normal" font="default" size="100%">39</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2012/08/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Positron-Emission Tomography</style></keyword><keyword><style face="normal" font="default" size="100%">Pyridines</style></keyword><keyword><style face="normal" font="default" size="100%">Quinolines</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Cannabinoid, CB1/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Cannabinoid, CB2/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ diagnostic imaging/etiology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombosis/complications</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1619-7089 (Electronic)&#xD;1619-7070 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22895861</style></accession-num><abstract><style face="normal" font="default" size="100%">PURPOSE: Recent ex vivo and pharmacological evidence suggests involvement of the endocannabinoid system in the pathophysiology of stroke, but conflicting roles for type 1 and 2 cannabinoid receptors (CB(1) and CB(2)) have been suggested. The purpose of this study was to evaluate CB(1) and CB(2) receptor binding over time in vivo in a rat photothrombotic stroke model using PET. METHODS: CB(1) and CB(2) microPET imaging was performed at regular time-points up to 2 weeks after stroke using [(18)F]MK-9470 and [(11)C]NE40. Stroke size was measured using MRI at 9.4 T. Ex vivo validation was performed via immunostaining for CB(1) and CB(2). Immunofluorescent double stainings were also performed with markers for astrocytes (GFAP) and macrophages/microglia (CD68). RESULTS: [(18)F]MK-9470 PET showed a strong increase in CB(1) binding 24 h and 72 h after stroke in the cortex surrounding the lesion, extending to the insular cortex 24 h after surgery. These alterations were consistently confirmed by CB(1) immunohistochemical staining. [(11)C]NE40 did not show any significant differences between stroke and sham-operated animals, although staining for CB(2) revealed minor immunoreactivity at 1 and 2 weeks after stroke in this model. Both CB (1) (+) and CB (2) (+) cells showed minor immunoreactivity for CD68. CONCLUSION: Time-dependent and regionally strongly increased CB(1), but not CB(2), binding are early consequences of photothrombotic stroke. Pharmacological interventions should primarily aim at CB(1) signalling as the role of CB(2) seems minor in the acute and subacute phases of stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Vandeputte, Caroline&#xD;Casteels, Cindy&#xD;Struys, Tom&#xD;Koole, Michel&#xD;van Veghel, Daisy&#xD;Evens, Nele&#xD;Gerits, Anneleen&#xD;Dresselaers, Tom&#xD;Lambrichts, Ivo&#xD;Himmelreich, Uwe&#xD;Bormans, Guy&#xD;Van Laere, Koen&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Germany&#xD;Eur J Nucl Med Mol Imaging. 2012 Nov;39(11):1796-806. doi: 10.1007/s00259-012-2209-6. Epub 2012 Aug 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/287/art%253A10.1007%252Fs00259-012-2209-6.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00259-012-2209-6&amp;token2=exp=1484123049~acl=%2Fstatic%2Fpdf%2F287%2Fart%25253A10.1007%25252Fs00259-012-2209-6.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs00259-012-2209-6*~hmac=3b6d1bf32bd753909bb960b5a984894cf23a819f2bbe9cca9ae1f72286700cff</style></url></related-urls><pdf-urls><url>internal-pdf://1561344488/Vandeputte-2012-Small-animal PET ima.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00259-012-2209-6</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>206</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">206</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vandeputte, C.</style></author><author><style face="normal" font="default" size="100%">Reumers, V.</style></author><author><style face="normal" font="default" size="100%">Aelvoet, S. A.</style></author><author><style face="normal" font="default" size="100%">Thiry, I.</style></author><author><style face="normal" font="default" size="100%">De Swaef, S.</style></author><author><style face="normal" font="default" size="100%">Van den Haute, C.</style></author><author><style face="normal" font="default" size="100%">Pascual-Brazo, J.</style></author><author><style face="normal" font="default" size="100%">Farr, T. D.</style></author><author><style face="normal" font="default" size="100%">Vande Velde, G.</style></author><author><style face="normal" font="default" size="100%">Hoehn, M.</style></author><author><style face="normal" font="default" size="100%">Himmelreich, U.</style></author><author><style face="normal" font="default" size="100%">Van Laere, K.</style></author><author><style face="normal" font="default" size="100%">Debyser, Z.</style></author><author><style face="normal" font="default" size="100%">Gijsbers, R.</style></author><author><style face="normal" font="default" size="100%">Baekelandt, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">KU Leuven, Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences, 3000 Leuven, Flanders, Belgium; KU Leuven, Molecular Small Animal Imaging Center, MOSAIC, KU Leuven, 3000 Leuven, Flanders, Belgium; Division of Nuclear Medicine, University Hospital and KU Leuven, 3000 Leuven, Flanders, Belgium.&#xD;KU Leuven, Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences, 3000 Leuven, Flanders, Belgium.&#xD;KU Leuven, Laboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, 3000 Leuven, Flanders, Belgium.&#xD;KU Leuven, Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences, 3000 Leuven, Flanders, Belgium; KU Leuven, Leuven Viral Vector Core, 3000 Leuven, Flanders, Belgium.&#xD;In-vivo-NMR Laboratory, Max Planck Institute for Neurological Research, 50931 Cologne, Germany.&#xD;KU Leuven, Molecular Small Animal Imaging Center, MOSAIC, KU Leuven, 3000 Leuven, Flanders, Belgium; KU Leuven, Biomedical MRI, Department of Imaging and Pathology, 3000 Leuven, Flanders, Belgium.&#xD;KU Leuven, Molecular Small Animal Imaging Center, MOSAIC, KU Leuven, 3000 Leuven, Flanders, Belgium; Division of Nuclear Medicine, University Hospital and KU Leuven, 3000 Leuven, Flanders, Belgium.&#xD;KU Leuven, Molecular Small Animal Imaging Center, MOSAIC, KU Leuven, 3000 Leuven, Flanders, Belgium; KU Leuven, Laboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, 3000 Leuven, Flanders, Belgium.&#xD;KU Leuven, Laboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, 3000 Leuven, Flanders, Belgium; KU Leuven, Leuven Viral Vector Core, 3000 Leuven, Flanders, Belgium. Electronic address: rik.gijsbers@med.kuleuven.be.&#xD;KU Leuven, Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences, 3000 Leuven, Flanders, Belgium; KU Leuven, Molecular Small Animal Imaging Center, MOSAIC, KU Leuven, 3000 Leuven, Flanders, Belgium. Electronic address: veerle.baekelandt@med.kuleuven.be.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bioluminescence imaging of stroke-induced endogenous neural stem cell response</style></title><secondary-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurobiology of disease</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurobiology of disease</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurobiol Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurobiology of disease</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">144-55</style></pages><volume><style face="normal" font="default" size="100%">69</style></volume><edition><style face="normal" font="default" size="100%">2014/06/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Movement/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Luminescent Measurements/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Neural Stem Cells/pathology/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Optical Imaging/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1095-953X (Electronic)&#xD;0969-9961 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24878507</style></accession-num><abstract><style face="normal" font="default" size="100%">Brain injury following stroke affects neurogenesis in the adult mammalian brain. However, a complete understanding of the origin and fate of the endogenous neural stem cells (eNSCs) in vivo is missing. Tools and technology that allow non-invasive imaging and tracking of eNSCs in living animals will help to overcome this hurdle. In this study, we aimed to monitor eNSCs in a photothrombotic (PT) stroke model using in vivo bioluminescence imaging (BLI). In a first strategy, inducible transgenic mice expressing firefly luciferase (Fluc) in the eNSCs were generated. In animals that received stroke, an increased BLI signal originating from the infarct region was observed. However, due to histological limitations, the identity and exact origin of cells contributing to the increased BLI signal could not be revealed. To overcome this limitation, we developed an alternative strategy employing stereotactic injection of conditional lentiviral vectors (Cre-Flex LVs) encoding Fluc and eGFP in the subventricular zone (SVZ) of Nestin-Cre transgenic mice, thereby specifically labeling the eNSCs. Upon induction of stroke, increased eNSC proliferation resulted in a significant increase in BLI signal between 2days and 2weeks after stroke, decreasing after 3months. Additionally, the BLI signal relocalized from the SVZ towards the infarct region during the 2weeks following stroke. Histological analysis at 90days post stroke showed that in the peri-infarct area, 36% of labeled eNSC progeny differentiated into astrocytes, while 21% differentiated into mature neurons. In conclusion, we developed and validated a novel imaging technique that unequivocally demonstrates that nestin(+) eNSCs originating from the SVZ respond to stroke injury by increased proliferation, migration towards the infarct region and differentiation into both astrocytes and neurons. In addition, this new approach allows non-invasive and specific monitoring of eNSCs over time, opening perspectives for preclinical evaluation of candidate stroke therapeutics.</style></abstract><notes><style face="normal" font="default" size="100%">Vandeputte, Caroline&#xD;Reumers, Veerle&#xD;Aelvoet, Sarah-Ann&#xD;Thiry, Irina&#xD;De Swaef, Sylvie&#xD;Van den Haute, Chris&#xD;Pascual-Brazo, Jesus&#xD;Farr, Tracy D&#xD;Vande Velde, Greetje&#xD;Hoehn, Mathias&#xD;Himmelreich, Uwe&#xD;Van Laere, Koen&#xD;Debyser, Zeger&#xD;Gijsbers, Rik&#xD;Baekelandt, Veerle&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Validation Studies&#xD;United States&#xD;Neurobiol Dis. 2014 Sep;69:144-55. doi: 10.1016/j.nbd.2014.05.014. Epub 2014 May 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0969996114001326/1-s2.0-S0969996114001326-main.pdf?_tid=8d618a38-d7d4-11e6-9351-00000aacb360&amp;acdnat=1484122038_08e4915f56099c295994927399d664b5</style></url></related-urls><pdf-urls><url>internal-pdf://2602263088/Vandeputte-2014-Bioluminescence imag.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.nbd.2014.05.014</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>78</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">78</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vanhoutte, L.</style></author><author><style face="normal" font="default" size="100%">Gallez, B.</style></author><author><style face="normal" font="default" size="100%">Feron, O.</style></author><author><style face="normal" font="default" size="100%">Balligand, J. L.</style></author><author><style face="normal" font="default" size="100%">Esfahani, H.</style></author><author><style face="normal" font="default" size="100%">d&apos;Hoore, W.</style></author><author><style face="normal" font="default" size="100%">Moniotte, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Paediatric Cardiology, Department of Paediatrics, Cliniques Universitaires St. Luc, Universite Catholique de Louvain (UCL), Avenue Hippocrate 10/1380, B-1200, Brussels, Belgium, laetitia.vanhoutte@uclouvain.be.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Variability of Mouse Left Ventricular Function Assessment by 11.7 Tesla MRI</style></title><secondary-title><style face="normal" font="default" size="100%">J Cardiovasc Transl Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cardiovascular translational research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cardiovasc Transl Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cardiovascular translational research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cardiovasc Transl Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cardiovascular translational research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">362-71</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2015/06/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging, Cine/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke Volume</style></keyword><keyword><style face="normal" font="default" size="100%">Ventricular Dysfunction, Left/ physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1937-5395 (Electronic)&#xD;1937-5387 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26070905</style></accession-num><abstract><style face="normal" font="default" size="100%">We studied intraobserver (n = 24), interobserver (n = 24) and interexperiment (n = 12) reproducibility of left ventricular (LV) mass and volume measurements in mice using an 11.7 T MRI system. The LV systolic function was assessed with a short-axis FLASH-cine sequence in 29 mice, including animals having undergone transverse aortic constriction. Bland-Altman and regression analysis were used to compare the different data sets. Reproducibility was excellent for the LV mass and end-diastolic volume (coefficient of variability (CoV) between 5.4 and 11.8 %), good for end-systolic volume (CoV 15.2-19.4 %) and moderate for stroke volume and ejection fraction (CoV 14.7-20.9 %). We found an excellent correlation between LV mass determined by MRI and ex vivo morphometric data (r = 0.92). In conclusion, LV systolic function can be assessed on an 11.7 T MRI scanner with high reproducibility for most parameters, as needed in longitudinal studies. However, data should be interpreted taking into account the moderate reproducibility of small volumes.</style></abstract><notes><style face="normal" font="default" size="100%">Vanhoutte, Laetitia&#xD;Gallez, Bernard&#xD;Feron, Olivier&#xD;Balligand, Jean-Luc&#xD;Esfahani, Hrag&#xD;d&apos;Hoore, William&#xD;Moniotte, Stephane&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Cardiovasc Transl Res. 2015 Aug;8(6):362-71. doi: 10.1007/s12265-015-9638-0. Epub 2015 Jun 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/212/art%253A10.1007%252Fs12265-015-9638-0.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12265-015-9638-0&amp;token2=exp=1484123053~acl=%2Fstatic%2Fpdf%2F212%2Fart%25253A10.1007%25252Fs12265-015-9638-0.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs12265-015-9638-0*~hmac=284974c8e8d4c74ba8385b7c279922e4840496e0952fdbc8a3be5a3d648ccdbe</style></url></related-urls><pdf-urls><url>internal-pdf://1121669283/Vanhoutte-2015-Variability of Mouse.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12265-015-9638-0</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>381</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">381</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Varon, D.</style></author><author><style face="normal" font="default" size="100%">Hayon, Y.</style></author><author><style face="normal" font="default" size="100%">Dashevsky, O.</style></author><author><style face="normal" font="default" size="100%">Shai, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Coagulation Unit, Department of Hematology, Hadassah University Hospital, Jerusalem, Israel. Dvaron@hadassah.org.il</style></auth-address><titles><title><style face="normal" font="default" size="100%">Involvement of platelet derived microparticles in tumor metastasis and tissue regeneration</style></title><secondary-title><style face="normal" font="default" size="100%">Thromb Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Thrombosis research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Thromb Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Thrombosis research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Thromb Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Thrombosis research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">S98-9</style></pages><volume><style face="normal" font="default" size="100%">130 Suppl 1</style></volume><edition><style face="normal" font="default" size="100%">2012/10/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Platelets/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/blood supply/ metabolism/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Proliferation</style></keyword><keyword><style face="normal" font="default" size="100%">Cell-Derived Microparticles/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ blood/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Lung Neoplasms/ blood/blood supply/secondary</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Neoplasm Invasiveness</style></keyword><keyword><style face="normal" font="default" size="100%">Neovascularization, Pathologic</style></keyword><keyword><style face="normal" font="default" size="100%">Neovascularization, Physiologic</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">Platelet Activation</style></keyword><keyword><style face="normal" font="default" size="100%">Prostatic Neoplasms/ blood/blood supply/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneration</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1879-2472 (Electronic)&#xD;0049-3848 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23026678</style></accession-num><abstract><style face="normal" font="default" size="100%">Platelets play a major role in hemostasis, but are also involved in vascular biology processes such as angiogenesis and tumor metastasis. Activated platelets release many proteins favoring wound healing and promoting angiogenesis. Microparticles (MP) are small plasma membrane vesicles shed from cells upon their activation or apoptosis. Platelet-derived microparticles (PMP) constitute the majority of the pool of MP circulating in the blood. PMP express and may transfer functional receptors, stimulate the release of cytokines, activate intracellular signaling pathways, promote angiogenesis, and are involved in tissue regeneration and cancer metastasis. We investigated the effect of PMP on cancer cells metastasis and their potential beneficial effect in an ischemic stroke model.</style></abstract><notes><style face="normal" font="default" size="100%">Varon, David&#xD;Hayon, Yael&#xD;Dashevsky, Olga&#xD;Shai, Ela&#xD;United States&#xD;Thromb Res. 2012 Oct;130 Suppl 1:S98-9. doi: 10.1016/j.thromres.2012.08.289.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0049384812006615/1-s2.0-S0049384812006615-main.pdf?_tid=90e8412e-d7d4-11e6-bcd3-00000aacb35f&amp;acdnat=1484122044_fbc56a8affdd9a06dab5835d3460a92a</style></url></related-urls><pdf-urls><url>internal-pdf://1920889757/Varon-2012-Involvement of plate.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.thromres.2012.08.289</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>436</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">436</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Verbeek, E.</style></author><author><style face="normal" font="default" size="100%">Meuwissen, M. E.</style></author><author><style face="normal" font="default" size="100%">Verheijen, F. W.</style></author><author><style face="normal" font="default" size="100%">Govaert, P. P.</style></author><author><style face="normal" font="default" size="100%">Licht, D. J.</style></author><author><style face="normal" font="default" size="100%">Kuo, D. S.</style></author><author><style face="normal" font="default" size="100%">Poulton, C. J.</style></author><author><style face="normal" font="default" size="100%">Schot, R.</style></author><author><style face="normal" font="default" size="100%">Lequin, M. H.</style></author><author><style face="normal" font="default" size="100%">Dudink, J.</style></author><author><style face="normal" font="default" size="100%">Halley, D. J.</style></author><author><style face="normal" font="default" size="100%">de Coo, R. I.</style></author><author><style face="normal" font="default" size="100%">den Hollander, J. C.</style></author><author><style face="normal" font="default" size="100%">Oegema, R.</style></author><author><style face="normal" font="default" size="100%">Gould, D. B.</style></author><author><style face="normal" font="default" size="100%">Mancini, G. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">COL4A2 mutation associated with familial porencephaly and small-vessel disease</style></title><secondary-title><style face="normal" font="default" size="100%">Eur J Hum Genet</style></secondary-title><alt-title><style face="normal" font="default" size="100%">European journal of human genetics : EJHG</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur J Hum Genet</style></full-title><abbr-1><style face="normal" font="default" size="100%">European journal of human genetics : EJHG</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Eur J Hum Genet</style></full-title><abbr-1><style face="normal" font="default" size="100%">European journal of human genetics : EJHG</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">844-51</style></pages><volume><style face="normal" font="default" size="100%">20</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2012/02/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Base Sequence</style></keyword><keyword><style face="normal" font="default" size="100%">Basement Membrane/pathology/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Diseases/diagnosis/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Collagen Type IV/deficiency/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Consanguinity</style></keyword><keyword><style face="normal" font="default" size="100%">Endoplasmic Reticulum Stress</style></keyword><keyword><style face="normal" font="default" size="100%">Exons</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Hemiplegia/diagnosis/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Heterozygote</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Aneurysm/diagnosis/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation</style></keyword><keyword><style face="normal" font="default" size="100%">Pedigree</style></keyword><keyword><style face="normal" font="default" size="100%">Porencephaly</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/pathology/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1476-5438 (Electronic)&#xD;1018-4813 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22333902</style></accession-num><abstract><style face="normal" font="default" size="100%">Familial porencephaly, leukoencephalopathy and small-vessel disease belong to the spectrum of disorders ascribed to dominant mutations in the gene encoding for type IV collagen alpha-1 (COL4A1). Mice harbouring mutations in either Col4a1 or Col4a2 suffer from porencephaly, hydrocephalus, cerebral and ocular bleeding and developmental defects. We observed porencephaly and white matter lesions in members from two families that lack COL4A1 mutations. We hypothesized that COL4A2 mutations confer genetic predisposition to porencephaly, therefore we sequenced COL4A2 in the family members and characterized clinical, neuroradiological and biochemical phenotypes. Genomic sequencing of COL4A2 identified the heterozygous missense G1389R in exon 44 in one family and the c.3206delC change in exon 34 leading to frame shift and premature stop, in the second family. Fragmentation and duplication of epidermal basement membranes were observed by electron microscopy in a c.3206delC patient skin biopsy, consistent with abnormal collagen IV network. Collagen chain accumulation and endoplasmic reticulum (ER) stress have been proposed as cellular mechanism in COL4A1 mutations. In COL4A2 (3206delC) fibroblasts we detected increased rates of apoptosis and no signs of ER stress. Mutation phenotypes varied, including porencephaly, white matter lesions, cerebellar and optic nerve hypoplasia and unruptured carotid aneurysm. In the second family however, we found evidence for additional factors contributing to the phenotype. We conclude that dominant COL4A2 mutations are a novel major risk factor for familial cerebrovascular disease, including porencephaly and small-vessel disease with reduced penetrance and variable phenotype, which might also be modified by other contributing factors.</style></abstract><notes><style face="normal" font="default" size="100%">Verbeek, Elly&#xD;Meuwissen, Marije E C&#xD;Verheijen, Frans W&#xD;Govaert, Paul P&#xD;Licht, Daniel J&#xD;Kuo, Debbie S&#xD;Poulton, Cathryn J&#xD;Schot, Rachel&#xD;Lequin, Maarten H&#xD;Dudink, Jeroen&#xD;Halley, Dicky J&#xD;de Coo, Rene I F&#xD;den Hollander, Jan C&#xD;Oegema, Renske&#xD;Gould, Douglas B&#xD;Mancini, Grazia M S&#xD;England&#xD;Eur J Hum Genet. 2012 Aug;20(8):844-51. doi: 10.1038/ejhg.2012.20. Epub 2012 Feb 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.nature.com/ejhg/journal/v20/n8/pdf/ejhg201220a.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1460094660/Verbeek-2012-COL4A2 mutation asso.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3400734</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/ejhg.2012.20</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>280</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">280</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Virtanen, J. K.</style></author><author><style face="normal" font="default" size="100%">Siscovick, D. S.</style></author><author><style face="normal" font="default" size="100%">Lemaitre, R. N.</style></author><author><style face="normal" font="default" size="100%">Longstreth, W. T.</style></author><author><style face="normal" font="default" size="100%">Spiegelman, D.</style></author><author><style face="normal" font="default" size="100%">Rimm, E. B.</style></author><author><style face="normal" font="default" size="100%">King, I. B.</style></author><author><style face="normal" font="default" size="100%">Mozaffarian, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Eastern Finland, Institute of Public Health and Clinical Nutrition, Kuopio, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Circulating omega-3 polyunsaturated fatty acids and subclinical brain abnormalities on MRI in older adults: the Cardiovascular Health Study</style></title><secondary-title><style face="normal" font="default" size="100%">J Am Heart Assoc</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of the American Heart Association</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Am Heart Assoc</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of the American Heart Association</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Am Heart Assoc</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of the American Heart Association</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e000305</style></pages><volume><style face="normal" font="default" size="100%">2</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2013/10/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Fatty Acids, Omega-3/ blood</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fishes</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 10</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2047-9980 (Electronic)&#xD;2047-9980 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24113325</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Consumption of tuna or other broiled or baked fish, but not fried fish, is associated with fewer subclinical brain abnormalities on magnetic resonance imaging (MRI). We investigated the association between plasma phospholipid omega-3 polyunsaturated fatty acids (PUFAs), objective biomarkers of exposure, and subclinical brain abnormalities on MRI. METHODS AND RESULTS: In the community-based Cardiovascular Health Study, 3660 participants aged &gt;/= 65 underwent brain MRI in 1992-1994, and 2313 were rescanned 5 years later. MRIs were centrally read by neuroradiologists in a standardized, blinded manner. Participants with recognized transient ischemic attacks or stroke were excluded. Phospholipid PUFAs were measured in stored plasma collected in 1992-1993 and related to cross-sectional and longitudinal MRI findings. After multivariable adjustment, the odds ratio for having a prevalent subclinical infarct was 0.60 (95% CI, 0.44 to 0.82; P for trend = 0.001) in the highest versus lowest long-chain omega-3 PUFA quartile. Higher long-chain omega-3 PUFA content was also associated with better white matter grade, but not with sulcal or ventricular grades, markers of brain atrophy, or with incident subclinical infarcts. The phospholipid intermediate-chain omega-3 PUFA alpha-linolenic acid was associated only with modestly better sulcal and ventricular grades. However, this finding was not supported in the analyses with alpha-linolenic acid intake. CONCLUSIONS: Among older adults, higher phospholipid long-chain omega-3 PUFA content was associated with lower prevalence of subclinical infarcts and better white matter grade on MRI. Our results support the beneficial effects of fish consumption, the major source of long-chain omega-3 PUFAs, on brain health in later life. The role of plant-derived alpha-linolenic acid in brain health requires further investigation.</style></abstract><notes><style face="normal" font="default" size="100%">Virtanen, Jyrki K&#xD;Siscovick, David S&#xD;Lemaitre, Rozenn N&#xD;Longstreth, William T&#xD;Spiegelman, Donna&#xD;Rimm, Eric B&#xD;King, Irena B&#xD;Mozaffarian, Dariush&#xD;N01-HC-85085/HC/NHLBI NIH HHS/United States&#xD;R01-HL-085710/HL/NHLBI NIH HHS/United States&#xD;N01-HC-85081/HC/NHLBI NIH HHS/United States&#xD;U01-HL080295/HL/NHLBI NIH HHS/United States&#xD;AG-15928/AG/NIA NIH HHS/United States&#xD;AG-20098/AG/NIA NIH HHS/United States&#xD;N01-HC-85086/HC/NHLBI NIH HHS/United States&#xD;AG-027058/AG/NIA NIH HHS/United States&#xD;N01-HC-85082/HC/NHLBI NIH HHS/United States&#xD;AG-023692/AG/NIA NIH HHS/United States&#xD;N01-HC-35129/HC/NHLBI NIH HHS/United States&#xD;N01 HC-55222/HC/NHLBI NIH HHS/United States&#xD;HHSN268201200036C/HL/NHLBI NIH HHS/United States&#xD;N01-HC-85083/HC/NHLBI NIH HHS/United States&#xD;N01-HC-75150/HC/NHLBI NIH HHS/United States&#xD;N01-HC-85080/HC/NHLBI NIH HHS/United States&#xD;N01 HC-15103/HC/NHLBI NIH HHS/United States&#xD;N01-HC-45133/HC/NHLBI NIH HHS/United States&#xD;N01-HC-85079/HC/NHLBI NIH HHS/United States&#xD;HHSN268201200036C/PHS HHS/United States&#xD;N01-HC-85239/HC/NHLBI NIH HHS/United States&#xD;N01-HC-85084/HC/NHLBI NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Am Heart Assoc. 2013 Oct 10;2(5):e000305. doi: 10.1161/JAHA.113.000305.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://jaha.ahajournals.org/content/ahaoa/2/5/e000305.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0237172011/Virtanen-2013-Circulating omega-3.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3835236</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/jaha.113.000305</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>480</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">480</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wallays, G.</style></author><author><style face="normal" font="default" size="100%">Nuyens, D.</style></author><author><style face="normal" font="default" size="100%">Silasi-Mansat, R.</style></author><author><style face="normal" font="default" size="100%">Souffreau, J.</style></author><author><style face="normal" font="default" size="100%">Callaerts-Vegh, Z.</style></author><author><style face="normal" font="default" size="100%">Van Nuffelen, A.</style></author><author><style face="normal" font="default" size="100%">Moons, L.</style></author><author><style face="normal" font="default" size="100%">D&apos;Hooge, R.</style></author><author><style face="normal" font="default" size="100%">Lupu, F.</style></author><author><style face="normal" font="default" size="100%">Carmeliet, P.</style></author><author><style face="normal" font="default" size="100%">Collen, D.</style></author><author><style face="normal" font="default" size="100%">Dewerchin, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Vesalius Research Center, Flanders Institute for Biotechnology (VIB), Leuven, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Notch3 Arg170Cys knock-in mice display pathologic and clinical features of the neurovascular disorder cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy</style></title><secondary-title><style face="normal" font="default" size="100%">Arterioscler Thromb Vasc Biol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Arteriosclerosis, thrombosis, and vascular biology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Arterioscler Thromb Vasc Biol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Arteriosclerosis, thrombosis, and vascular biology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Arterioscler Thromb Vasc Biol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Arteriosclerosis, thrombosis, and vascular biology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">2881-8</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2011/09/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arginine</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">CADASIL/ genetics/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Capillaries/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cystine</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Fertility/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Knock-In Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Motor Activity/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle, Smooth, Vascular/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Notch3</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Notch/ genetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4636 (Electronic)&#xD;1079-5642 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">21940951</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an adult-onset neurovascular disorder caused by stereotyped mutations in the NOTCH3 receptor. Elucidation of its pathobiology is still incomplete and remains a challenge, in part because the available preclinical mouse models to date do not reproduce the full spectrum of CADASIL pathology and clinical disease. METHODS AND RESULTS: Here, we report a novel knock-in mouse with Arg170Cys substitution in murine Notch3, corresponding to the prevalent Arg169Cys substitution in CADASIL. The Notch3(Arg170Cys) mice displayed late-onset, dominant CADASIL arteriopathy with typical granular osmiophilic material deposition and developed brain histopathology including thrombosis, microbleeds, gliosis, and microinfarction. Furthermore, Notch3(Arg170Cys) mice experienced neurological symptoms with motor defects such as staggering gait and limb paresis. CONCLUSIONS: This model, for the first time, phenocopies the arteriopathy and the histopathologic as well as clinical features of CADASIL and may offer novel opportunities to investigate disease pathogenesis.</style></abstract><notes><style face="normal" font="default" size="100%">Wallays, Goedele&#xD;Nuyens, Dieter&#xD;Silasi-Mansat, Robert&#xD;Souffreau, Joris&#xD;Callaerts-Vegh, Zsuzsanna&#xD;Van Nuffelen, An&#xD;Moons, Lieve&#xD;D&apos;Hooge, Rudi&#xD;Lupu, Florea&#xD;Carmeliet, Peter&#xD;Collen, Desire&#xD;Dewerchin, Mieke&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Arterioscler Thromb Vasc Biol. 2011 Dec;31(12):2881-8. doi: 10.1161/ATVBAHA.111.237859. Epub 2011 Sep 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://atvb.ahajournals.org/content/atvbaha/31/12/2881.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0998477203/Wallays-2011-Notch3 Arg170Cys kno.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/atvbaha.111.237859</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>109</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">109</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Walter, H. L.</style></author><author><style face="normal" font="default" size="100%">Walberer, M.</style></author><author><style face="normal" font="default" size="100%">Rueger, M. A.</style></author><author><style face="normal" font="default" size="100%">Backes, H.</style></author><author><style face="normal" font="default" size="100%">Wiedermann, D.</style></author><author><style face="normal" font="default" size="100%">Hoehn, M.</style></author><author><style face="normal" font="default" size="100%">Neumaier, B.</style></author><author><style face="normal" font="default" size="100%">Graf, R.</style></author><author><style face="normal" font="default" size="100%">Fink, G. R.</style></author><author><style face="normal" font="default" size="100%">Schroeter, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, University Hospital Cologne, Kerpener Strasse 62, 50937 Cologne, Germany; Max-Planck-Institute for Neurological Research, Gleueler Strasse 50, 50931 Cologne, Germany. Electronic address: helene.walter@uk-koeln.de.&#xD;Department of Neurology, University Hospital Cologne, Kerpener Strasse 62, 50937 Cologne, Germany.&#xD;Department of Neurology, University Hospital Cologne, Kerpener Strasse 62, 50937 Cologne, Germany; Max-Planck-Institute for Neurological Research, Gleueler Strasse 50, 50931 Cologne, Germany.&#xD;Max-Planck-Institute for Neurological Research, Gleueler Strasse 50, 50931 Cologne, Germany.&#xD;Max-Planck-Institute for Neurological Research, Gleueler Strasse 50, 50931 Cologne, Germany; Department of Radiology, Leiden University Medical Center, Einthovenweg 20, 2333 ZC Leiden, Netherlands.&#xD;Department of Neurology, University Hospital Cologne, Kerpener Strasse 62, 50937 Cologne, Germany; Institute of Neuroscience and Medicine (INM-3), Cognitive Neuroscience, Research Centre Julich, 52425 Julich, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">In vivo analysis of neuroinflammation in the late chronic phase after experimental stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Neuroscience</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">71-80</style></pages><volume><style face="normal" font="default" size="100%">292</style></volume><edition><style face="normal" font="default" size="100%">2015/02/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, CD/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Differentiation, Myelomonocytic/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/diagnostic imaging/ immunology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/diagnostic imaging/ immunology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium-Binding Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Carbon Radioisotopes</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Ferric Compounds</style></keyword><keyword><style face="normal" font="default" size="100%">Immunohistochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery</style></keyword><keyword><style face="normal" font="default" size="100%">Isoquinolines</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Microfilament Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Microglia/pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Phagocytosis/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Positron-Emission Tomography</style></keyword><keyword><style face="normal" font="default" size="100%">Radiopharmaceuticals</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/diagnostic imaging/ immunology/pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 30</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1873-7544 (Electronic)&#xD;0306-4522 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25701708</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: In vivo imaging of inflammatory processes is a valuable tool in stroke research. We here investigated the combination of two imaging modalities in the chronic phase after cerebral ischemia: magnetic resonance imaging (MRI) using intravenously applied ultra small supraparamagnetic iron oxide particles (USPIO), and positron emission tomography (PET) with the tracer [(11)C]PK11195. METHODS: Rats were subjected to permanent middle cerebral artery occlusion (pMCAO) by the macrosphere model and monitored by MRI and PET for 28 or 56 days, followed by immunohistochemical endpoint analysis. To our knowledge, this is the first study providing USPIO-MRI data in the chronic phase up to 8 weeks after stroke. RESULTS: Phagocytes with internalized USPIOs induced MRI-T2( *) signal alterations in the brain. Combined analysis with [(11)C]PK11195-PET allowed quantification of phagocytic activity and other neuroinflammatory processes. From 4 weeks after induction of ischemia, inflammation was dominated by phagocytes. Immunohistochemistry revealed colocalization of Iba1+ microglia with [(11)C]PK11195 and ED1/CD68 with USPIOs. USPIO-related iron was distinguished from alternatively deposited iron by assessing MRI before and after USPIO application. Tissue affected by non-phagocytic inflammation during the first week mostly remained in a viably vital but remodeled state after 4 or 8 weeks, while phagocytic activity was associated with severe injury and necrosis accordingly. CONCLUSIONS: We conclude that the combined approach of USPIO-MRI and [(11)C]PK11195-PET allows to observe post-stroke inflammatory processes in the living animal in an intraindividual and longitudinal fashion, predicting long-term tissue fate. The non-invasive imaging methods do not affect the immune system and have been applied to human subjects before. Translation into clinical applications is therefore feasible.</style></abstract><notes><style face="normal" font="default" size="100%">Walter, H L&#xD;Walberer, M&#xD;Rueger, M A&#xD;Backes, H&#xD;Wiedermann, D&#xD;Hoehn, M&#xD;Neumaier, B&#xD;Graf, R&#xD;Fink, G R&#xD;Schroeter, M&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Neuroscience. 2015 Apr 30;292:71-80. doi: 10.1016/j.neuroscience.2015.02.024. Epub 2015 Feb 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0306452215001761/1-s2.0-S0306452215001761-main.pdf?_tid=93dae562-d7d4-11e6-9e7e-00000aab0f6b&amp;acdnat=1484122049_60595d18c51a67b28b95d85fcc0f0d5f</style></url></related-urls><pdf-urls><url>internal-pdf://0725325027/Walter-2015-In vivo analysis of.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuroscience.2015.02.024</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>286</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">286</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, B.</style></author><author><style face="normal" font="default" size="100%">Wu, N.</style></author><author><style face="normal" font="default" size="100%">Liang, F.</style></author><author><style face="normal" font="default" size="100%">Zhang, S.</style></author><author><style face="normal" font="default" size="100%">Ni, W.</style></author><author><style face="normal" font="default" size="100%">Cao, Y.</style></author><author><style face="normal" font="default" size="100%">Xia, D.</style></author><author><style face="normal" font="default" size="100%">Xi, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Human Anatomy, Histology and Embryology, China Medical University, 92 Bei&apos;er Road, Shenyang, 110001, Liaoning, People&apos;s Republic of China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">7,8-dihydroxyflavone, a small-molecule tropomyosin-related kinase B (TrkB) agonist, attenuates cerebral ischemia and reperfusion injury in rats</style></title><secondary-title><style face="normal" font="default" size="100%">J Mol Histol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of molecular histology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Mol Histol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of molecular histology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Mol Histol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of molecular histology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">129-40</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2013/09/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Evaluation, Preclinical</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme Activation</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme Activators/ pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Flavones/ pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Glutathione/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Glutathione Peroxidase/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Malondialdehyde/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative Stress</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, trkB/agonists/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Superoxide Dismutase/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1567-2387 (Electronic)&#xD;1567-2379 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24045895</style></accession-num><abstract><style face="normal" font="default" size="100%">7,8-dihydroxyflavone (7,8-DHF) is a recently identified potent agonist of tropomyosin-related kinase B that can cross the blood-brain barrier after oral or intraperitoneal administration. The aim of the present study was to determine whether 7,8-DHF has neuroprotective effects against cerebral ischemia and reperfusion (I/R) injury and, if so, to investigate the possible underlying mechanisms. Cerebral I/R injury rats were induced by middle cerebral artery occlusion for 90 min followed by reperfusion for 24 h. 7,8-DHF was administered intraperitoneally at a dose of 5 mg/kg immediately after ischemia. Our results showed that 7,8-DHF significantly reduced neurological deficit scores, infarct volumes, and neuronal apoptosis in brains of I/R rats. Meanwhile, 7,8-DHF also increased Bcl-2 expression, decreased expression of cleaved caspase-3, Bax and inducible nitric oxide synthase, and inhibited nuclear factor-kappaB activation in ischemic cortex. Finally, malondialdehyde and nitric oxide contents were reduced, but activities of glutathione, glutathione peroxidase and superoxide dismutase were restored in ischemic cortex treated with 7,8-DHF. Taken together, our findings demonstrated that 7,8-DHF is able to protect against cerebral I/R injury, which may be, at least in part, attributable to its anti-apoptotic, anti-oxidative and anti-inflammatory actions.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Bing&#xD;Wu, Nan&#xD;Liang, Feng&#xD;Zhang, Shuqin&#xD;Ni, Weimin&#xD;Cao, Yunxing&#xD;Xia, Dongjian&#xD;Xi, Huanjiu&#xD;Netherlands&#xD;J Mol Histol. 2014 Apr;45(2):129-40. doi: 10.1007/s10735-013-9539-y. Epub 2013 Sep 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/604/art%253A10.1007%252Fs10735-013-9539-y.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs10735-013-9539-y&amp;token2=exp=1484123068~acl=%2Fstatic%2Fpdf%2F604%2Fart%25253A10.1007%25252Fs10735-013-9539-y.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs10735-013-9539-y*~hmac=7b52cfd7602229df15bd990ad81edf03acb750af2903afc90427f8e35f8d1d24</style></url></related-urls><pdf-urls><url>internal-pdf://4186604967/Wang-2014-7,8-dihydroxyflavone.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s10735-013-9539-y</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>184</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">184</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, C.</style></author><author><style face="normal" font="default" size="100%">Pan, Y.</style></author><author><style face="normal" font="default" size="100%">Cheng, B.</style></author><author><style face="normal" font="default" size="100%">Chen, J.</style></author><author><style face="normal" font="default" size="100%">Bai, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Neurobiology Institute, Jining Medical University, Jining, 272067, People&apos;s Republic of China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Identification of conserved and novel microRNAs in cerebral ischemia-reperfusion injury of rat using deep sequencing</style></title><secondary-title><style face="normal" font="default" size="100%">J Mol Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of molecular neuroscience : MN</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Mol Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of molecular neuroscience : MN</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Mol Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of molecular neuroscience : MN</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">671-83</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2014/07/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">High-Throughput Nucleotide Sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">MAP Kinase Signaling System</style></keyword><keyword><style face="normal" font="default" size="100%">MicroRNAs/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">NF-kappa B/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Growth Factors/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Sequence Analysis, DNA</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-1166 (Electronic)&#xD;0895-8696 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25063377</style></accession-num><abstract><style face="normal" font="default" size="100%">MicroRNAs are a class of noncoding small RNAs that regulate gene expression by inhibiting target genes at post-transcriptional levels. MicroRNAs have been highlighted in many organs and tissues, including the brain. To identify special microRNAs involved in ischemia-reperfusion injury, we performed a comprehensive small RNA profiling in rat model and the control using Illumina high-throughput sequencing. A total of 9,444,562 and 10,290,391 clean reads were sequenced from two small RNA libraries constructed, respectively. Three hundred fifty-eight known microRNAs were identified, in which 78 microRNAs exhibited significantly differential expression between model and control. In addition, 62 and 68 novel miRNAs were found in model and control, respectively. Comparative analysis showed that 24 novel microRNAs were differentially expressed with greater than six-fold change. The GO annotation suggested that predicted targets of microRNAs were enriched into the category of metabolic process, cell part, cell-extracellular communications, and so on. KEGG pathway analysis suggested that these genes were involved in many important pathways, mainly including signaling transduction, MAPK signaling pathway, NF-kappaB signaling pathway, and neurotrophin signaling pathway. Our findings provided a deeper understanding to the regulatory mechanism of microRNAs underlying cerebral ischemia, therefore benefitting the improvement of the protection and treatment strategies of this disease.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Chunmei&#xD;Pan, Yanyou&#xD;Cheng, Baohua&#xD;Chen, Jing&#xD;Bai, Bo&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Mol Neurosci. 2014 Dec;54(4):671-83. doi: 10.1007/s12031-014-0383-7. Epub 2014 Jul 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/694/art%253A10.1007%252Fs12031-014-0383-7.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12031-014-0383-7&amp;token2=exp=1484123076~acl=%2Fstatic%2Fpdf%2F694%2Fart%25253A10.1007%25252Fs12031-014-0383-7.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs12031-014-0383-7*~hmac=397bbd58f92a31468e45a2fe70e314edc29be870164abb344d8aee4f47c4e8df</style></url></related-urls><pdf-urls><url>internal-pdf://2358682655/Wang-2014-Identification of co.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12031-014-0383-7</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>282</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">282</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, C. P.</style></author><author><style face="normal" font="default" size="100%">Li, J. L.</style></author><author><style face="normal" font="default" size="100%">Zhang, L. Z.</style></author><author><style face="normal" font="default" size="100%">Zhang, X. C.</style></author><author><style face="normal" font="default" size="100%">Yu, S.</style></author><author><style face="normal" font="default" size="100%">Liang, X. M.</style></author><author><style face="normal" font="default" size="100%">Ding, F.</style></author><author><style face="normal" font="default" size="100%">Wang, Z. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Jiangsu Key Laboratory of Neuroregeneration, Nantong University, Nantong 226001, PR China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Isoquercetin protects cortical neurons from oxygen-glucose deprivation-reperfusion induced injury via suppression of TLR4-NF-small ka, CyrillicB signal pathway</style></title><secondary-title><style face="normal" font="default" size="100%">Neurochem Int</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurochemistry international</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurochem Int</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurochemistry international</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurochem Int</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurochemistry international</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">741-9</style></pages><volume><style face="normal" font="default" size="100%">63</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2013/10/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Base Sequence</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/cytology/ drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">DNA Primers</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">NF-kappa B/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/ drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Quercetin/chemistry/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Real-Time Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Reverse Transcriptase Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Toll-Like Receptor 4/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-9754 (Electronic)&#xD;0197-0186 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24099731</style></accession-num><abstract><style face="normal" font="default" size="100%">In the present study, oxygen-glucose deprivation followed by reperfusion (OGD/R), an in vitro model of ischemia, was used to evaluate the neuroprotective effect of isoquercetin in primary culture of rat cortical neuronal cells. It was found that isoquercetin administered prior to the insult could prevent OGD/R-induced intracellular calcium concentrations ([Ca(2+)]i) increase, lactate dehydrogenase (LDH) release and cell viability decrease. For the first time, isoquercetin is described as a neuroprotective agent that potentially explains the alleviation and prevention from OGD/R-induced injury in neurons. Mechanistic studies showed that the neuroprotective effect of isoquercetin was carried out by anti-inflammatory signaling pathway of inhibiting protein expression of toll-like receptor 4 (TLR4) and nuclear factor-kappa B (NF-kappaB), and mRNA expression of TNF-alpha and IL-6, accompanied by the anti-apoptotic signaling pathway of deactivation of extracellular-regulated kinase (ERK), Jun kinase (JNK) and p38, and inhibition of activity of caspase-3. Therefore, these studies highlighted the confirmation of isoquercetin, a flavonoid compound, as an anti-inflammation and anti-apoptosis factor which might be used as a therapeutic strategy for the ischemia/reperfusion (I/R) brain injury and related diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Cai-Ping&#xD;Li, Jian-Long&#xD;Zhang, Lu-Zhong&#xD;Zhang, Xiao-Chuan&#xD;Yu, Shu&#xD;Liang, Xin-Miao&#xD;Ding, Fei&#xD;Wang, Zhi-Wei&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Neurochem Int. 2013 Dec;63(8):741-9. doi: 10.1016/j.neuint.2013.09.018. Epub 2013 Oct 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0197018613002465/1-s2.0-S0197018613002465-main.pdf?_tid=98705ba2-d7d4-11e6-a984-00000aacb362&amp;acdnat=1484122057_066d84266a6963bd985da1cb131cf37d</style></url></related-urls><pdf-urls><url>internal-pdf://1726720754/Wang-2013-Isoquercetin protect.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuint.2013.09.018</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>129</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">129</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, C. X.</style></author><author><style face="normal" font="default" size="100%">Lin, Y. X.</style></author><author><style face="normal" font="default" size="100%">Xie, G. B.</style></author><author><style face="normal" font="default" size="100%">Shi, J. X.</style></author><author><style face="normal" font="default" size="100%">Zhou, M. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210002, Jiangsu Province, China.&#xD;Department of Neurosurgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210002, Jiangsu Province, China. Electronic address: mengliangzhou@yahoo.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Constriction and dysfunction of pial arterioles after regional hemorrhage in the subarachnoid space</style></title><secondary-title><style face="normal" font="default" size="100%">Brain Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">85-91</style></pages><volume><style face="normal" font="default" size="100%">1601</style></volume><edition><style face="normal" font="default" size="100%">2015/01/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Acetylcholine/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arterioles/drug effects/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Hypercapnia/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Microvessels/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Parietal Lobe/drug effects/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Pia Mater/ blood supply/drug effects/ pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">S-Nitroso-N-Acetylpenicillamine/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Subarachnoid Hemorrhage/ pathology/ physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 19</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-6240 (Electronic)&#xD;0006-8993 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25598204</style></accession-num><abstract><style face="normal" font="default" size="100%">Increasing evidence indicates that poor outcomes after brain hemorrhage, especially after subarachnoid hemorrhage (SAH), can be attributed largely to dysfunction of the cerebral microcirculation. However, the cause of this dysfunction remains unclear. Here, we investigated changes in the cerebral microcirculation after regional hemorrhage in the subarachnoid space using the closed cranial window technique in mice. A single pial arteriole on the surface of the brain was punctured to induce a regional hemorrhage in the subarachnoid space. Physiological parameters were monitored during the procedure, and microvessel diameter was measured after hemorrhage. The vasoreactivity of the arterioles in response to hypercapnia as well as to topical application of the vasodilator acetylcholine (ACh) and S-nitroso-N-acetyl-penicillamine (SNAP) were assessed. The constriction of pial arterioles was detected without changes in other physiological parameters. Decreased reactivity of pial arterioles to all of the applied vasodilatory stimuli was observed after hemorrhage. Our results indicate that regional hemorrhage in the subarachnoid space can induce the vasospasm of microvessels and also reduce the vasoreactivity of pial arterioles.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Chun-xi&#xD;Lin, Yi-xing&#xD;Xie, Guang-bin&#xD;Shi, Ji-xin&#xD;Zhou, Meng-liang&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;Brain Res. 2015 Mar 19;1601:85-91. doi: 10.1016/j.brainres.2015.01.012. Epub 2015 Jan 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0006899315000232/1-s2.0-S0006899315000232-main.pdf?_tid=9becfb46-d7d4-11e6-9f37-00000aab0f02&amp;acdnat=1484122063_4b199beaaee2bdc09a2022ba7c689cb9</style></url></related-urls><pdf-urls><url>internal-pdf://4269784612/Wang-2015-Constriction and dys.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.brainres.2015.01.012</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>358</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">358</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Anderson, L. G.</style></author><author><style face="normal" font="default" size="100%">Lascola, C. D.</style></author><author><style face="normal" font="default" size="100%">James, M. L.</style></author><author><style face="normal" font="default" size="100%">Venkatraman, T. N.</style></author><author><style face="normal" font="default" size="100%">Bennett, E. R.</style></author><author><style face="normal" font="default" size="100%">Acheson, S. K.</style></author><author><style face="normal" font="default" size="100%">Vitek, M. P.</style></author><author><style face="normal" font="default" size="100%">Laskowitz, D. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine (Neurology), Duke University School of Medicine, Durham, NC 27710, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">ApolipoproteinE mimetic peptides improve outcome after focal ischemia</style></title><secondary-title><style face="normal" font="default" size="100%">Exp Neurol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Experimental neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Exp Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Experimental neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Exp Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Experimental neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">67-74</style></pages><volume><style face="normal" font="default" size="100%">241</style></volume><edition><style face="normal" font="default" size="100%">2012/12/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Analysis of Variance</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apolipoproteins E/ chemistry/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Infarction/etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Chromatography, Liquid</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Encephalitis/etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Functional Laterality/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/complications/ drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mass Spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Movement Disorders/drug therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery of Function/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Tumor Necrosis Factor-alpha/genetics/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1090-2430 (Electronic)&#xD;0014-4886 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23219883</style></accession-num><abstract><style face="normal" font="default" size="100%">Growing clinical evidence implicates isoform-specific effects of apolipoprotein E (apoE) in reducing neuroinflammation and mediating adaptive responses following ischemic and traumatic brain injury. However, the intact apoE holoprotein does not cross the blood-brain barrier and thus has limited therapeutic potential. We have created a small peptide, COG1410 (acetyl-AS-Aib-LRKL-Aib-KRLL-amide), derived from the apoE receptor-binding region. COG1410 retains the anti-inflammatory and neuroprotective biological properties of the intact holoprotein and penetrates the blood-brain barrier. In the current study, we utilized a murine model of transient focal cerebral ischemia and reperfusion to demonstrate that intravenous (IV) administration of COG1410 reduces infarct volume and radiographic progression of infarct, and improves functional outcome as assessed by rotarod when delivered up to 4h after ischemia onset.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Haichen&#xD;Anderson, Lauren G&#xD;Lascola, Christopher D&#xD;James, Michael L&#xD;Venkatraman, Talaignair N&#xD;Bennett, Ellen R&#xD;Acheson, Shawn K&#xD;Vitek, Michael P&#xD;Laskowitz, Daniel T&#xD;IK2 BX001267/BX/BLRD VA/United States&#xD;United States&#xD;Exp Neurol. 2013 Mar;241:67-74. doi: 10.1016/j.expneurol.2012.11.027. Epub 2012 Dec 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S001448861200444X/1-s2.0-S001448861200444X-main.pdf?_tid=9ed0bbae-d7d4-11e6-84f1-00000aab0f6c&amp;acdnat=1484122068_c9d419441680f8202477200dc5d744a5</style></url></related-urls><pdf-urls><url>internal-pdf://2345389939/Wang-2013-ApolipoproteinE mime.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.expneurol.2012.11.027</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>335</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">335</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Chao, F.</style></author><author><style face="normal" font="default" size="100%">Han, F.</style></author><author><style face="normal" font="default" size="100%">Zhang, G.</style></author><author><style face="normal" font="default" size="100%">Xi, Q.</style></author><author><style face="normal" font="default" size="100%">Li, J.</style></author><author><style face="normal" font="default" size="100%">Jiang, H.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Yu, G.</style></author><author><style face="normal" font="default" size="100%">Tian, M.</style></author><author><style face="normal" font="default" size="100%">Zhang, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Nuclear Medicine, Second Hospital of Zhejiang University School of Medicine, Hangzhou, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">PET demonstrates functional recovery after transplantation of induced pluripotent stem cells in a rat model of cerebral ischemic injury</style></title><secondary-title><style face="normal" font="default" size="100%">J Nucl Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Nucl Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Nucl Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">785-92</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2013/03/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/diagnostic imaging/ physiopathology/ surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Embryonic Stem Cells/transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorodeoxyglucose F18</style></keyword><keyword><style face="normal" font="default" size="100%">Induced Pluripotent Stem Cells/ transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Positron-Emission Tomography</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery of Function</style></keyword><keyword><style face="normal" font="default" size="100%">Stem Cell Transplantation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1535-5667 (Electronic)&#xD;0161-5505 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23503731</style></accession-num><abstract><style face="normal" font="default" size="100%">The purpose of this study was to determine the functionality of the transplanted induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) in a rat model of cerebral ischemia with use of (18)F-FDG small-animal PET imaging. METHODS: Middle cerebral artery occlusion was used to establish cerebral ischemia. Twenty-four male rats were randomly assigned to 1 of 3 groups: iPSC treatment, ESC treatment, and the control phosphate-buffered saline (PBS) injection. After neurologic function tests and baseline (18)F-FDG small-animal PET had been performed, 1.0 x 10(6) suspended iPSCs or ESCs were injected stereotactically into the left lateral ventricle. The treatment response was evaluated weekly by (18)F-FDG PET scans and neurologic function tests. Histologic analyses and autoradiographic imaging were performed 4 wk after stem cell transplantation. RESULTS: Compared with the PBS injection group, higher (18)F-FDG accumulation in the ipsilateral cerebral infarction was observed in both the iPSC and the ESC treatment groups during the 4-wk period (P &lt; 0.05). (18)F-FDG accumulation in the ipsilateral cerebral infarction increased steadily over time in the iPSC treatment group. At 1 and 2 wk after stem cell transplantation, significant recovery of glucose metabolism was found in the ESC treatment group (P &lt; 0.05) and then decreased gradually. The neurologic score in both stem cell-treated groups was significantly lower than that in the PBS group, indicating functional improvement. Immunohistochemical analysis demonstrated that transplanted stem cells survived and migrated close to the ischemic region, and most of the stem cells expressed protein markers for cells of interest. CONCLUSION: (18)F-FDG small-animal PET demonstrated metabolic recovery after iPSC and ESC transplantation in the rat model of cerebral ischemia. iPSCs could be considered a potentially better therapeutic approach than ESCs and are worthy of further translational investigation.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Jiachuan&#xD;Chao, Fangfang&#xD;Han, Feng&#xD;Zhang, Gensheng&#xD;Xi, Qunying&#xD;Li, Jinhui&#xD;Jiang, Han&#xD;Wang, Jing&#xD;Yu, Gang&#xD;Tian, Mei&#xD;Zhang, Hong&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Nucl Med. 2013 May;54(5):785-92. doi: 10.2967/jnumed.112.111112. Epub 2013 Mar 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://jnm.snmjournals.org/content/54/5/785.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0593286648/Wang-2013-PET demonstrates fun.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2967/jnumed.112.111112</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>338</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">338</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, L. M.</style></author><author><style face="normal" font="default" size="100%">Wang, Y. J.</style></author><author><style face="normal" font="default" size="100%">Cui, M.</style></author><author><style face="normal" font="default" size="100%">Luo, W. J.</style></author><author><style face="normal" font="default" size="100%">Wang, X. J.</style></author><author><style face="normal" font="default" size="100%">Barber, P. A.</style></author><author><style face="normal" font="default" size="100%">Chen, Z. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurobiology, Shandong Provincial Key Laboratory of Mental Disorders, School of Medicine, Shandong University, Jinan, Shandong, 250012, China. limeiwang@sdu.edu.cn</style></auth-address><titles><title><style face="normal" font="default" size="100%">A dietary polyphenol resveratrol acts to provide neuroprotection in recurrent stroke models by regulating AMPK and SIRT1 signaling, thereby reducing energy requirements during ischemia</style></title><secondary-title><style face="normal" font="default" size="100%">Eur J Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The European journal of neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The European journal of neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Eur J Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">The European journal of neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1669-81</style></pages><volume><style face="normal" font="default" size="100%">37</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2013/03/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">AMP-Activated Protein Kinases/antagonists &amp; inhibitors/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/cytology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Energy Metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme Inhibitors/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">NAD/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">Sirtuin 1/antagonists &amp; inhibitors/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Stilbenes/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ drug therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1460-9568 (Electronic)&#xD;0953-816X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23461657</style></accession-num><abstract><style face="normal" font="default" size="100%">Polyphenol resveratrol (RSV) has been associated with Silent Information Regulator T1 (SIRT1) and AMP-activated protein kinase (AMPK) metabolic stress sensors and probably responds to the intracellular energy status. Our aim here was to investigate the neuroprotective effects of RSV and its association with SIRT1 and AMPK signaling in recurrent ischemia models. In this study, elderly male Wistar rats received a combination of two mild transient middle cerebral artery occlusions (tMCAOs) as an in vivo recurrent ischemic model. Primary cultured cortical neuronal cells subjected to combined oxygen-glucose deprivation (OGD) were used as an in vitro recurrent ischemic model. RSV administration significantly reduced infarct volumes, improved behavioral deficits and protected neuronal cells from cell death in recurrent ischemic stroke models in vivo and in vitro. RSV treatments significantly increased the intracellular NAD(+) /NADH ratio, AMPK and SIRT1 activities, decreased energy assumption and restored cell energy ATP level. SIRT1 and AMPK inhibitors and specific small interfering RNA (siRNA) for SIRT1 and AMPK significantly abrogated the neuroprotection induced by RSV. AMPK-siRNA and inhibitor decreased SIRT1 activities; however, SIRT1-siRNA and inhibitor had no impact on phospho-AMPK (p-AMPK) levels. These results indicated that the neuroprotective effects of RSV increased the intracellular NAD(+) /NADH ratio as well as AMPK and SIRT1 activities, thereby reducing energy ATP requirements during ischemia. SIRT1 is a downstream target of p-AMPK signaling induced by RSV in the recurrent ischemic stroke model.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Li-Mei&#xD;Wang, Yong-Jiu&#xD;Cui, Min&#xD;Luo, Wen-Juan&#xD;Wang, Xiao-Ji&#xD;Barber, Philip A&#xD;Chen, Zhe-Yu&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Retracted Publication&#xD;France&#xD;Eur J Neurosci. 2013 May;37(10):1669-81. doi: 10.1111/ejn.12162. Epub 2013 Mar 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/ejn.12162/asset/ejn12162.pdf?v=1&amp;t=ixsnupn1&amp;s=994082176ec8b30407d6e44830308e1739126ab1</style></url></related-urls><pdf-urls><url>internal-pdf://2405034173/Wang-2013-A dietary polyphenol.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/ejn.12162</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>6</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">6</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, R.</style></author><author><style face="normal" font="default" size="100%">Wang, S. T.</style></author><author><style face="normal" font="default" size="100%">Wang, Y. D.</style></author><author><style face="normal" font="default" size="100%">Wu, G.</style></author><author><style face="normal" font="default" size="100%">Du, Y.</style></author><author><style face="normal" font="default" size="100%">Qian, M. Q.</style></author><author><style face="normal" font="default" size="100%">Liang, X. G.</style></author><author><style face="normal" font="default" size="100%">Elbatreek, M. H.</style></author><author><style face="normal" font="default" size="100%">Yang, H. Y.</style></author><author><style face="normal" font="default" size="100%">Liu, Z. R.</style></author><author><style face="normal" font="default" size="100%">Fukunaga, K.</style></author><author><style face="normal" font="default" size="100%">Liu, J. X.</style></author><author><style face="normal" font="default" size="100%">Lu, Y. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">aSchool of Medicine, Zhejiang University City College bInstitute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University cDepartment of Pharmacy, First Affiliated Hospital of Zhejiang University, School of Medicine dDepartment of Neurology, Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China eDepartment of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Stress-responsive heme oxygenase-1 isoenzyme participates in Toll-like receptor 4-induced inflammation during brain ischemia</style></title><secondary-title><style face="normal" font="default" size="100%">Neuroreport</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuroreport</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuroreport</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroreport</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuroreport</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroreport</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">445-54</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2016/03/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Analysis of Variance</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Annexin A5/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ complications</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/cytology</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition Disorders/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Embryo, Mammalian</style></keyword><keyword><style face="normal" font="default" size="100%">Encephalitis/ etiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Flow Cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Heme Oxygenase-1/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lipopolysaccharides/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">NF-E2-Related Factor 2/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Stress, Psychological/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Toll-Like Receptor 4/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Transfection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 13</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1473-558X (Electronic)&#xD;0959-4965 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26966782</style></accession-num><abstract><style face="normal" font="default" size="100%">Toll-like receptors (TLRs) are involved in the progression of ischemic brain injury and hence vascular dementia; however, the underlying mechanisms are largely unknown. Here, we have investigated the interrelationship between stress-responsive heme oxygenase (HO)-1 isoenzyme and TLR4 during chronic brain hypoperfusion. The right unilateral common carotid artery occlusion was performed by ligation of the right common carotid artery in C57BL/6J mice. The brain cortex or hippocampus was removed for western blotting and confocal immunofluorescence analysis. The link between HO-1 and TLR4 was further examined by silencing TLR4 and pharmacological inhibition of HO-1 in primary cultured cortical neurons. Cognitive dysfunction and decrease in cerebral blood flow in mice were observed 4 weeks after the occlusion. Our data further show that common carotid artery occlusion induced an increase in TLR4 and HO-1 protein levels. Although the administration of CoPP (10 mg/kg), HO-1 agonist, improved the cognitive dysfunction in a mice model of occlusion, western blot analysis in primary cultured cortical neurons showed that HO-1 was upregulated after lipopolysaccharide treatment; this was partially abolished by the TLR4 siRNA interference. The flow cytometry analysis showed that pharmacological inhibition of HO-1 by ZnPP (100 muM) further exaggerated lipopolysaccharide-induced neuronal cell death. Hence, stress-responsive HO-1 isoenzyme participates in TLR4-induced inflammation during chronic brain ischemia. The pharmacological manipulation of TLR4 or the HO-1 antioxidant defense pathway may represent a novel treatment strategy for neuronal protection in vascular dementia.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Rui&#xD;Wang, Shu-Ting&#xD;Wang, Yu-Di&#xD;Wu, Gang&#xD;Du, Yan&#xD;Qian, Man-Qing&#xD;Liang, Xing-Guang&#xD;Elbatreek, Mahmoud H&#xD;Yang, Hong-Yu&#xD;Liu, Zhi-Rong&#xD;Fukunaga, Kohji&#xD;Liu, Jian-Xiang&#xD;Lu, Ying-Mei&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Neuroreport. 2016 Apr 13;27(6):445-54. doi: 10.1097/WNR.0000000000000561.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/wnr.0000000000000561</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>427</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">427</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, S.</style></author><author><style face="normal" font="default" size="100%">Zhang, H.</style></author><author><style face="normal" font="default" size="100%">Wiltshire, T.</style></author><author><style face="normal" font="default" size="100%">Sealock, R.</style></author><author><style face="normal" font="default" size="100%">Faber, J. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Physiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Genetic dissection of the Canq1 locus governing variation in extent of the collateral circulation</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PloS one</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e31910</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2012/03/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Chromosome Mapping</style></keyword><keyword><style face="normal" font="default" size="100%">Chromosomes, Mammalian</style></keyword><keyword><style face="normal" font="default" size="100%">Cluster Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Collateral Circulation/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">Genome-Wide Association Study</style></keyword><keyword><style face="normal" font="default" size="100%">Hemostasis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword><keyword><style face="normal" font="default" size="100%">Quantitative Trait Loci</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203 (Electronic)&#xD;1932-6203 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22412848</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Native (pre-existing) collaterals are arteriole-to-arteriole anastomoses that interconnect adjacent arterial trees and serve as endogenous bypass vessels that limit tissue injury in ischemic stroke, myocardial infarction, coronary and peripheral artery disease. Their extent (number and diameter) varies widely among mouse strains and healthy humans. We previously identified a major quantitative trait locus on chromosome 7 (Canq1, LOD = 29) responsible for 37% of the heritable variation in collateral extent between C57BL/6 and BALB/c mice. We sought to identify candidate genes in Canq1 responsible for collateral variation in the cerebral pial circulation, a tissue whose strain-dependent variation is shared by similar variation in other tissues. METHODS AND FINDINGS: Collateral extent was intermediate in a recombinant inbred line that splits Canq1 between the C57BL/6 and BALB/c strains. Phenotyping and SNP-mapping of an expanded panel of twenty-one informative inbred strains narrowed the Canq1 locus, and genome-wide linkage analysis of a SWRxSJL-F2 cross confirmed its haplotype structure. Collateral extent, infarct volume after cerebral artery occlusion, bleeding time, and re-bleeding time did not differ in knockout mice for two vascular-related genes located in Canq1, IL4ra and Itgal. Transcript abundance of 6 out of 116 genes within the 95% confidence interval of Canq1 were differentially expressed &gt;2-fold (p-value&lt;0.05/150) in the cortical pia mater from C57BL/6 and BALB/c embryos at E14.5, E16.5 and E18.5 time-points that span the period of collateral formation. CONCLUSIONS: These findings refine the Canq1 locus and identify several genes as high-priority candidates important in specifying native collateral formation and its wide variation.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Shiliang&#xD;Zhang, Hua&#xD;Wiltshire, Tim&#xD;Sealock, Robert&#xD;Faber, James E&#xD;HL090655/HL/NHLBI NIH HHS/United States&#xD;R01 HL090655/HL/NHLBI NIH HHS/United States&#xD;R01 HL062584/HL/NHLBI NIH HHS/United States&#xD;HL062584/HL/NHLBI NIH HHS/United States&#xD;R01 HL111070/HL/NHLBI NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;United States&#xD;PLoS One. 2012;7(3):e31910. doi: 10.1371/journal.pone.0031910. Epub 2012 Mar 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0031910&amp;type=printable</style></url></related-urls><pdf-urls><url>internal-pdf://0575999870/Wang-2012-Genetic dissection o.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3295810</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0031910</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>241</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">241</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Palasubramaniam, J.</style></author><author><style face="normal" font="default" size="100%">Gkanatsas, Y.</style></author><author><style face="normal" font="default" size="100%">Hohmann, J. D.</style></author><author><style face="normal" font="default" size="100%">Westein, E.</style></author><author><style face="normal" font="default" size="100%">Kanojia, R.</style></author><author><style face="normal" font="default" size="100%">Alt, K.</style></author><author><style face="normal" font="default" size="100%">Huang, D.</style></author><author><style face="normal" font="default" size="100%">Jia, F.</style></author><author><style face="normal" font="default" size="100%">Ahrens, I.</style></author><author><style face="normal" font="default" size="100%">Medcalf, R. L.</style></author><author><style face="normal" font="default" size="100%">Peter, K.</style></author><author><style face="normal" font="default" size="100%">Hagemeyer, C. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From Atherothrombosis and Vascular Biology Laboratory (X.W., J.P., Y.G., J.D.H., E.W., K.A., D.H., F.J., I.A., K.P.), and Vascular Biotechnology Laboratory (R.K., K.A., C.E.H.), Baker IDI, Melbourne, Australia; Department of Cardiology and Angiology, University Hospital Freiburg, Germany (I.A.); Fibrinolysis and Gene Regulation Laboratory, Australian Centre for Blood Diseases, Melbourne, Australia (R.L.M.); and Central Clinical School, Monash University, Melbourne, Australia (R.L.M., K.P., C.E.H.).</style></auth-address><titles><title><style face="normal" font="default" size="100%">Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets</style></title><secondary-title><style face="normal" font="default" size="100%">Circ Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Circulation research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Circ Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Circulation research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Circ Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Circulation research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1083-93</style></pages><volume><style face="normal" font="default" size="100%">114</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2014/02/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Platelets/ drug effects/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">CHO Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Arteries/ diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Cricetinae</style></keyword><keyword><style face="normal" font="default" size="100%">Cricetulus</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Evaluation, Preclinical</style></keyword><keyword><style face="normal" font="default" size="100%">Fibrinolytic Agents/adverse effects/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Integrin alpha2/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Plasminogen/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Platelet Activation</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Fusion Proteins/genetics/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Single-Chain Antibodies/genetics/immunology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Thromboembolism/ drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombolytic Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Ultrasonography</style></keyword><keyword><style face="normal" font="default" size="100%">Urokinase-Type Plasminogen Activator/genetics/ therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 28</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4571 (Electronic)&#xD;0009-7330 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24508759</style></accession-num><abstract><style face="normal" font="default" size="100%">RATIONALE: Fibrinolysis is a valuable alternative for the treatment of myocardial infarction when percutaneous coronary intervention is not available in a timely fashion. For acute ischemic stroke, fibrinolysis is the only treatment option with a very narrow therapeutic window. Clinically approved thrombolytics have significant drawbacks, including bleeding complications. Thus their use is highly restricted, leaving many patients untreated. OBJECTIVE: We developed a novel targeted fibrinolytic drug that is directed against activated platelets. METHODS AND RESULTS: We fused single-chain urokinase plasminogen activator (scuPA) to a small recombinant antibody (scFvSCE5), which targets the activated form of the platelet-integrin glycoprotein IIb/IIIa. Antibody binding and scuPA activity of this recombinant fusion protein were on par with the parent molecules. Prophylactic in vivo administration of scFvSCE5-scuPA (75 U/g body weight) prevented carotid artery occlusion after ferric chloride injury in a plasminogen-dependent process compared with saline (P&lt;0.001), and blood flow recovery was similar to high-dose nontargeted urokinase (500 U/g body weight). Tail bleeding time was significantly prolonged with this high dose of nontargeted urokinase, but not with equally effective targeted scFvSCE5-scuPA at 75 U/g body weight. Real-time in vivo molecular ultrasound imaging demonstrates significant therapeutic reduction of thrombus size after administration of 75 U/g body weight scFvSCE5-scuPA as compared with the same dose of a mutated, nontargeting scFv-scuPA or vehicle. The ability of scFvSCE5-scuPA to lyse thrombi was lost in plasminogen-deficient mice, but could be restored by intravenous injection of plasminogen. CONCLUSIONS: Targeting of scuPA to activated glycoprotein IIb/IIIa allows effective thrombolysis and the potential novel use as a fibrinolytic agent for thromboprophylaxis without bleeding complications.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Xiaowei&#xD;Palasubramaniam, Jathushan&#xD;Gkanatsas, Yannik&#xD;Hohmann, Jan David&#xD;Westein, Erik&#xD;Kanojia, Ruchi&#xD;Alt, Karen&#xD;Huang, Dexing&#xD;Jia, Fu&#xD;Ahrens, Ingo&#xD;Medcalf, Robert L&#xD;Peter, Karlheinz&#xD;Hagemeyer, Christoph E&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Circ Res. 2014 Mar 28;114(7):1083-93. doi: 10.1161/CIRCRESAHA.114.302514. Epub 2014 Feb 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://circres.ahajournals.org/content/circresaha/114/7/1083.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3102286949/Wang-2014-Towards effective an.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/circresaha.114.302514</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>80</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">80</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Ma, W.</style></author><author><style face="normal" font="default" size="100%">Jia, A.</style></author><author><style face="normal" font="default" size="100%">Guo, Q.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Anesthesiology, Xiangya Hospital of Central South University, 87 Xiangya Road, Changsha City, 410008, Hunan Province, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Parecoxib Protects Mouse Cortical Neurons Against OGD/R Induced Neurotoxicity by Up-Regulating Bcl-2</style></title><secondary-title><style face="normal" font="default" size="100%">Neurochem Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurochemical research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurochem Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurochemical research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurochem Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurochemical research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1294-302</style></pages><volume><style face="normal" font="default" size="100%">40</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2015/06/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adenosine Triphosphate/biosynthesis</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Death/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclic AMP Response Element-Binding Protein/biosynthesis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclooxygenase 2 Inhibitors/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Knockdown Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose/ deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia, Brain/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Isoxazoles/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Membrane Potential, Mitochondrial/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Nervous System Diseases/etiology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Proto-Oncogene Proteins c-bcl-2/ biosynthesis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/pathology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation/drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1573-6903 (Electronic)&#xD;0364-3190 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26033681</style></accession-num><abstract><style face="normal" font="default" size="100%">Ischemic stroke remains a significant problem that is the major cause of death and disability worldwide. Parecoxib is clinically used for short-term management of postoperative pain. Administration of parecoxib in rats has been reported to protect against the cerebral ischemia/reperfusion. However, the neuroprotective mechanism of parecoxib is still largely unknown. In this study, we found parecoxib could protect against neurotoxicity induced by 4 h oxygen-glucose deprivation (OGD) plus reoxgenation for 20 h, a widely used in vitro model of ischemia/reperfusion. In addition, we characterized the molecular mechanism of parecoxib&apos;s neuroprotection. We found parecoxib was able to activate CREB, and subsequently maintained the expression of Bcl-2, which is an important mitochondria-associated protein. Inhibition of endogenous Bcl-2 expression by transfection of Bcl-2-shRNA significantly attenuated the neuroprotective effects of parecoxib treatment. Furthermore, ATP production assay and mitochondrial membrane potential (DeltaPsim) assay suggested that parecoxib exerted neuroprotective effect against OGD/R by maintaining the function of mitochondria. These data suggested that parecoxib treatment is a potential therapeutic approach for protecting against ischemia/reperfusion injury.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Yueling&#xD;Ma, Wenjuan&#xD;Jia, Aijun&#xD;Guo, Qulian&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Neurochem Res. 2015 Jun;40(6):1294-302. doi: 10.1007/s11064-015-1580-7. Epub 2015 Jun 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/312/art%253A10.1007%252Fs11064-015-1580-7.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs11064-015-1580-7&amp;token2=exp=1484123101~acl=%2Fstatic%2Fpdf%2F312%2Fart%25253A10.1007%25252Fs11064-015-1580-7.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs11064-015-1580-7*~hmac=cc83e3b2fad19d785755ba80e3ad95b431e82ab9653cdcf6c487d357d57d9939</style></url></related-urls><pdf-urls><url>internal-pdf://0679347646/Wang-2015-Parecoxib Protects M.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s11064-015-1580-7</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>192</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">192</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Qiu, B.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Zhu, W. G.</style></author><author><style face="normal" font="default" size="100%">Zhu, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, People&apos;s Republic of China; Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, People&apos;s Republic of China.&#xD;Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, People&apos;s Republic of China.&#xD;Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, People&apos;s Republic of China.&#xD;Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, People&apos;s Republic of China. Electronic address: sgzhu@bjmu.edu.cn.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cocaine- and amphetamine-regulated transcript facilitates the neurite outgrowth in cortical neurons after oxygen and glucose deprivation through PTN-dependent pathway</style></title><secondary-title><style face="normal" font="default" size="100%">Neuroscience</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">103-10</style></pages><volume><style face="normal" font="default" size="100%">277</style></volume><edition><style face="normal" font="default" size="100%">2014/07/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Carrier Proteins/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Hypoxia/ drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Survival/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">GAP-43 Protein/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Knockdown Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose/ deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Tissue Proteins/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Neurites/ drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/ drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 26</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1873-7544 (Electronic)&#xD;0306-4522 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25010400</style></accession-num><abstract><style face="normal" font="default" size="100%">Cocaine- and amphetamine-regulated transcript (CART) is a neuropeptide that plays neuroprotective roles in cerebral ischemia and reperfusion (I/R) injury in animal models or oxygen and glucose deprivation (OGD) in cultured neurons. Recent data suggest that intranasal CART treatment facilitates neuroregeneration in stroke brain. However, little is known about the effects of post-treatment with CART during the neuronal recovery after OGD and reoxygenation in cultured primary cortical neurons. The present study was to investigate the role of CART treated after OGD injury in neurons. Primary mouse cortical neurons were subjected to OGD and then treated with CART. Our data show that post-treatment with CART reduced the neuronal apoptosis caused by OGD injury. In addition, CART repaired OGD-impaired cortical neurons by increasing the expression of growth-associated protein 43 (GAP43), which promotes neurite outgrowth. This effect depends on pleiotrophin (PTN) as siRNA-mediated PTN knockdown totally abolished the increase in CART-stimulated GAP43 protein levels. In summary, our findings demonstrate that CART repairs the neuronal injury after OGD by facilitating neurite outgrowth through PTN-dependent pathway. The role for CART in neurite outgrowth makes it a new potential therapeutic agent for the treatment of neurodegenerative diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Y&#xD;Qiu, B&#xD;Liu, J&#xD;Zhu, Wei-Guo&#xD;Zhu, S&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Neuroscience. 2014 Sep 26;277:103-10. doi: 10.1016/j.neuroscience.2014.06.064. Epub 2014 Jul 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0306452214005491/1-s2.0-S0306452214005491-main.pdf?_tid=aec8e32e-d7d4-11e6-87fe-00000aab0f6b&amp;acdnat=1484122094_63ad63da7686a0e684a1f1d5f37e69e5</style></url></related-urls><pdf-urls><url>internal-pdf://0503724520/Wang-2014-Cocaine- and ampheta.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuroscience.2014.06.064</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>177</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">177</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Yoshimura, R.</style></author><author><style face="normal" font="default" size="100%">Manabe, H.</style></author><author><style face="normal" font="default" size="100%">Schretter, C.</style></author><author><style face="normal" font="default" size="100%">Clarke, R.</style></author><author><style face="normal" font="default" size="100%">Cai, Y.</style></author><author><style face="normal" font="default" size="100%">Fitzgerald, M.</style></author><author><style face="normal" font="default" size="100%">Lee, K. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neuroscience, University of Virginia, Charlottesville, VA, USA.&#xD;Department of Neuroscience, University of Virginia, Charlottesville, VA, USA; Neuroscience Graduate Program, University of Virginia, Charlottesville, VA, USA.&#xD;Department of Neuroscience, University of Virginia, Charlottesville, VA, USA; Neuroscience Graduate Program, University of Virginia, Charlottesville, VA, USA; Department of Neurological Surgery, University of Virginia, Charlottesville, VA, USA. Electronic address: ksl3h@virginia.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Trans-sodium crocetinate improves outcomes in rodent models of occlusive and hemorrhagic stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Brain Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">245-54</style></pages><volume><style face="normal" font="default" size="100%">1583</style></volume><edition><style face="normal" font="default" size="100%">2014/08/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Biomechanical Phenomena</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ drug effects/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/drug therapy/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ drug therapy/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/ drug therapy/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Gait/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Pattern Recognition, Automated</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ drug therapy/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamin A/ analogs &amp; derivatives/pharmacology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 02</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-6240 (Electronic)&#xD;0006-8993 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25128603</style></accession-num><abstract><style face="normal" font="default" size="100%">Trans-sodium crocetinate (TSC) is a novel carotenoid compound capable of enhancing the diffusion of small molecules in aqueous solutions. TSC improves the diffusion of oxygen and glucose, and increases oxygenation in ischemic brain tissue. TSC also dampens the intensity of an ischemic challenge during an ongoing ischemic event. The current study examined the impact of TSC in rat models of ischemic and hemorrhagic stroke. Rat three vessel occlusion (3VO), and combined 3VO and one vessel occlusion (3VO/1VO) models of ischemic stroke were evaluated for structural and behavioral outcomes. The effects of TSC were also tested in a rat model of intracerebral hemorrhage (ICH). Delayed treatment with TSC reduced infarct volume in a rodent model of transient focal ischemia involving either 2 or 6h of ischemia. Neurological outcomes, based on a multi-scale assessment and automated gait analysis, also were improved by TSC treatment. Additionally, TSC reduced edema and hemorrhagic volume in a rat model of ICH. An optimal therapeutic candidate for early intervention in ischemic stroke should be effective when administered on a delayed basis and should not aggravate outcomes associated with hemorrhagic stroke. The current findings demonstrate that delayed TSC treatment improves outcomes in experimental models of both ischemic and hemorrhagic stroke. Together, these findings suggest that TSC may be a safe and beneficial therapeutic modality for early stroke intervention, irrespective of the type of stroke involved.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Yi&#xD;Yoshimura, Ryo&#xD;Manabe, Hiroaki&#xD;Schretter, Catherine&#xD;Clarke, Ryon&#xD;Cai, Yu&#xD;Fitzgerald, Mark&#xD;Lee, Kevin S&#xD;R01 NS057168/NS/NINDS NIH HHS/United States&#xD;T32 GM008328/GM/NIGMS NIH HHS/United States&#xD;Netherlands&#xD;Brain Res. 2014 Oct 2;1583:245-54. doi: 10.1016/j.brainres.2014.08.013. Epub 2014 Aug 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0006899314010774/1-s2.0-S0006899314010774-main.pdf?_tid=e283a51e-d7d4-11e6-a73f-00000aab0f02&amp;acdnat=1484122181_aef4d1ec5f98ea5d243af6698a5f6cee</style></url></related-urls><pdf-urls><url>internal-pdf://3652882263/Wang-2014-Trans-sodium croceti.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4170841</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms623121</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.brainres.2014.08.013</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>228</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">228</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Huang, J.</style></author><author><style face="normal" font="default" size="100%">Chen, X.</style></author><author><style face="normal" font="default" size="100%">Gu, X.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Zeng, L.</style></author><author><style face="normal" font="default" size="100%">Yang, G. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of neurology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, 197 Ruijin Er Road, 200025 Shanghai, China. llzeng@126.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Increase of circulating miR-223 and insulin-like growth factor-1 is associated with the pathogenesis of acute ischemic stroke in patients</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Neurol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">BMC neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMC Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">BMC neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">BMC Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">BMC neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">77</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><edition><style face="normal" font="default" size="100%">2014/04/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Insulin-Like Growth Factor I/analysis/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">MicroRNAs/ blood</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Real-Time Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default" size="100%">Reverse Transcriptase Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ blood/genetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 08</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1471-2377 (Electronic)&#xD;1471-2377 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24708646</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The relationship between circulating microRNA-223 and pathogenesis of acute ischemic stroke is unknown. Here we investigated the roles and possible targets of circulating microRNA-223 in human ischemic stroke within the first 72 hours. METHODS: Blood samples were collected from patients within 72 hours after cerebral ischemia (n = 79) and compared with healthy control samples (n = 75). The level of possible downstream factors of microRNA-223 including insulin-like growth factor-1, insulin-like growth factor-1 receptor and interleukin-6 was examined by ELISA assay. The relationship between the microRNA-223 level and NIHSS scores, TOAST subtypes, and infarct volume was analyzed respectively. In addition, twelve adult male CD-1 mice underwent middle cerebral artery occlusion using the suture technique. Circulating blood and brain tissue in the ischemic ipsilateral hemisphere were collected at 24 hours after middle cerebral artery occlusion. microRNA-223 was detected by real-time polymerase chain reactions. RESULTS: microRNA-223 levels in the circulating blood of acute ischemic stroke patients were greatly increased compared to the control (p &lt; 0.05). microRNA-223, which were negatively correlated with NIHSS scores (r = -0.531, p &lt; 0.01) and infarct volume (r = -0.265, p = 0.039), was significantly up-regulated in large artery and small artery strokes. The plasma level of insulin-like growth factor-1 was positively associated with that of microRNA-223 (r = 0.205, p = 0.022). Moreover, microRNA-223 in blood and brain were positively correlated (r = 0.834, p &lt; 0.05), and they were up-regulated significantly in mice that underwent middle cerebral artery occlusion (p &lt; 0.05). CONCLUSIONS: Our results suggest that microRNA-223 is associated with acute ischemic stroke and possibly plays a role in stroke through up-regulating growth factor such as insulin-like growth factor-1 gene.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Yang&#xD;Zhang, Yu&#xD;Huang, Jun&#xD;Chen, Xiaoyan&#xD;Gu, Xiang&#xD;Wang, Yongting&#xD;Zeng, Lili&#xD;Yang, Guo-Yuan&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;BMC Neurol. 2014 Apr 8;14:77. doi: 10.1186/1471-2377-14-77.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/559/art%253A10.1186%252F1471-2377-14-77.pdf?originUrl=http%3A%2F%2Fbmcneurol.biomedcentral.com%2Farticle%2F10.1186%2F1471-2377-14-77&amp;token2=exp=1484122218~acl=%2Fstatic%2Fpdf%2F559%2Fart%25253A10.1186%25252F1471-2377-14-77.pdf*~hmac=d8b0ec6cc3f30116f10a865626168c973d4db75415bcaa8be0281c9a8886452b</style></url></related-urls><pdf-urls><url>internal-pdf://2125088296/Wang-2014-Increase of circulat.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4234389</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/1471-2377-14-77</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>219</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">219</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, Y. C.</style></author><author><style face="normal" font="default" size="100%">Zhou, Y.</style></author><author><style face="normal" font="default" size="100%">Fang, H.</style></author><author><style face="normal" font="default" size="100%">Lin, S.</style></author><author><style face="normal" font="default" size="100%">Wang, P. F.</style></author><author><style face="normal" font="default" size="100%">Xiong, R. P.</style></author><author><style face="normal" font="default" size="100%">Chen, J.</style></author><author><style face="normal" font="default" size="100%">Xiong, X. Y.</style></author><author><style face="normal" font="default" size="100%">Lv, F. L.</style></author><author><style face="normal" font="default" size="100%">Liang, Q. L.</style></author><author><style face="normal" font="default" size="100%">Yang, Q. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Xinqiao Hospital and Second Affiliated Hospital, Third Military Medical University, Chongqing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Toll-like receptor 2/4 heterodimer mediates inflammatory injury in intracerebral hemorrhage</style></title><secondary-title><style face="normal" font="default" size="100%">Ann Neurol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Annals of neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Ann Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Annals of neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Ann Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Annals of neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">876-89</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2014/04/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/ complications</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclooxygenase 2/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Encephalitis/ etiology/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">HEK293 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Tissue Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nervous System Diseases/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroglia/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Toll-Like Receptor 2/chemistry/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Toll-Like Receptor 4/chemistry/genetics/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1531-8249 (Electronic)&#xD;0364-5134 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24752976</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: Inflammatory injury plays a critical role in intracerebral hemorrhage (ICH)-induced secondary brain injury. However, the upstream events that initiate inflammatory responses following ICH remain elusive. Our previous studies suggested that Toll-like receptor 4 (TLR4) may be the upstream signal that triggers inflammatory injury in ICH. In addition, recent clinical findings indicated that both TLR2 and TLR4 may participate in ICH-induced brain injury. However, it is unclear how TLR2 functions in ICH-induced inflammatory injury and how TLR2 interacts with TLR4. METHODS: The role of TLR2 and TLR2/TLR4 heterodimerization in ICH-induced inflammatory injury was investigated in both in vivo and in vitro models of ICH. RESULTS: TLR2 mediated ICH-induced inflammatory injury, which forms a heterodimer with TLR4 in both in vivo and in vitro models of ICH. Hemoglobin (Hb), but not other blood components, triggered inflammatory injury in ICH via assembly of TLR2/TLR4 heterodimers. MyD88 (myeloid differentiation primary response gene 88), but not TRIF (Toll/IR-1 domain-containing adaptor protein inducing interferon-beta), was required for ICH-induced TLR2/TLR4 heterodimerization. Mutation of MyD88 Arg196 abolished the TLR2/TLR4 heterodimerization. INTERPRETATION: Our results suggest that a novel TLR2/TLR4 heterodimer induced by Hb initiates inflammatory injury in ICH. Interfering with the assembly of the TLR2/TLR4 heterodimer may be a novel target for developing effective treatment of ICH.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Yan-Chun&#xD;Zhou, Yu&#xD;Fang, Huang&#xD;Lin, Sen&#xD;Wang, Peng-Fei&#xD;Xiong, Ren-Ping&#xD;Chen, Jing&#xD;Xiong, Xiao-Yi&#xD;Lv, Feng-Lin&#xD;Liang, Qiao-Li&#xD;Yang, Qing-Wu&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Ann Neurol. 2014 Jun;75(6):876-89. doi: 10.1002/ana.24159. Epub 2014 May 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1002/ana.24159/asset/ana24159.pdf?v=1&amp;t=ixsnvac1&amp;s=243c8feb2e49014060502423f7648380a4a99c10</style></url></related-urls><pdf-urls><url>internal-pdf://1762480306/Wang-2014-Toll-like receptor 2.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/ana.24159</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>43</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">43</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, Y. Y.</style></author><author><style face="normal" font="default" size="100%">Gao, Y. X.</style></author><author><style face="normal" font="default" size="100%">Gao, W.</style></author><author><style face="normal" font="default" size="100%">Xu, Y.</style></author><author><style face="normal" font="default" size="100%">Xu, Y. Z.</style></author><author><style face="normal" font="default" size="100%">Wang, Y. J.</style></author><author><style face="normal" font="default" size="100%">Chang, S.</style></author><author><style face="normal" font="default" size="100%">Yu, L. G.</style></author><author><style face="normal" font="default" size="100%">Zhang, L. Y.</style></author><author><style face="normal" font="default" size="100%">Liao, H.</style></author><author><style face="normal" font="default" size="100%">Yang, L. F.</style></author><author><style face="normal" font="default" size="100%">Pang, T.</style></author><author><style face="normal" font="default" size="100%">Qiu, W. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chemistry, School of Chemistry and Molecular Engineering, East China Normal University, 500 Dongchuan Road, Shanghai 200241, China.&#xD;Jiangsu Key Laboratory of Drug Screening, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.&#xD;Jiangsu Key Laboratory of Drug Screening, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China. Electronic address: tpang@cpu.edu.cn.&#xD;Department of Chemistry, School of Chemistry and Molecular Engineering, East China Normal University, 500 Dongchuan Road, Shanghai 200241, China. Electronic address: wwqiu@chem.ecnu.edu.cn.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Design, synthesis and biological evaluation of tricyclic diterpene derivatives as novel neuroprotective agents against ischemic brain injury</style></title><secondary-title><style face="normal" font="default" size="100%">Eur J Med Chem</style></secondary-title><alt-title><style face="normal" font="default" size="100%">European journal of medicinal chemistry</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur J Med Chem</style></full-title><abbr-1><style face="normal" font="default" size="100%">European journal of medicinal chemistry</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Eur J Med Chem</style></full-title><abbr-1><style face="normal" font="default" size="100%">European journal of medicinal chemistry</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">396-408</style></pages><volume><style face="normal" font="default" size="100%">103</style></volume><edition><style face="normal" font="default" size="100%">2015/09/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/chemically induced/ drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Survival/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Diterpenes/chemical synthesis/chemistry/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Design</style></keyword><keyword><style face="normal" font="default" size="100%">Glutamic Acid/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Structure</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/chemical synthesis/chemistry/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Structure-Activity Relationship</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 20</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1768-3254 (Electronic)&#xD;0223-5234 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26375352</style></accession-num><abstract><style face="normal" font="default" size="100%">Lead compound 7 has neuroprotective effects, and it was discovered by screening a small synthetic natural product-like (NPL) library. Based on the lead, a series of tricyclic diterpene derivatives was designed and synthesized, and their neuroprotective effects were further evaluated against glutamate-, oxygen and glucose deprivation (OGD)- and nutrient deprivation-induced neuronal injury using cell-based assays. To our delight, most of these synthetic compounds exhibited increased neuroprotective effects and blood-brain barrier (BBB) permeability without cellular toxicity. The most potent compound, compound 30, showed significantly improved neuroprotection against neuronal injury in primary neurons. Furthermore, compound 30 exhibited remarkable neuroprotection in transient middle cerebral artery occlusion (tMCAO) rats by reducing their infarct sizes and neurological deficit scores. A mechanistic exploration using in vitro and in vivo experiments showed that the neuroprotection of these compounds was at least partly mediated by improving the levels of glutathione (GSH), superoxide dismutase (SOD) and heme oxygenase-1 (HO-1) protein. Therefore, these tricyclic diterpene derivatives could be used as promising leads for the development of a new type of neuroprotective agents against ischemic brain injury.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Ying-Ying&#xD;Gao, Yuan-Xue&#xD;Gao, Wei&#xD;Xu, Yuan&#xD;Xu, Ya-Zhou&#xD;Wang, Yun-Jie&#xD;Chang, Sai&#xD;Yu, Li-Gang&#xD;Zhang, Lu-Yong&#xD;Liao, Hong&#xD;Yang, Lian-Fang&#xD;Pang, Tao&#xD;Qiu, Wen-Wei&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;France&#xD;Eur J Med Chem. 2015 Oct 20;103:396-408. doi: 10.1016/j.ejmech.2015.08.057. Epub 2015 Sep 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0223523415302403/1-s2.0-S0223523415302403-main.pdf?_tid=b4f7b2a2-d7d4-11e6-8695-00000aab0f26&amp;acdnat=1484122105_03f97e3baf66d8ec9c936d97f792f6c2</style></url></related-urls><pdf-urls><url>internal-pdf://2592630746/Wang-2015-Design, synthesis an.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ejmech.2015.08.057</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>410</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">410</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, Z. W.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Huang, L. Y.</style></author><author><style face="normal" font="default" size="100%">Guan, Q. K.</style></author><author><style face="normal" font="default" size="100%">Xu, D. W.</style></author><author><style face="normal" font="default" size="100%">Zhou, W. K.</style></author><author><style face="normal" font="default" size="100%">Zhang, X. Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, The First Affiliated Hospital of Xinxiang Medical University, Health Road No. 88, Weihui, Henan, People&apos;s Republic of China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Helicobacter pylori infection contributes to high risk of ischemic stroke: evidence from a meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">2527-37</style></pages><volume><style face="normal" font="default" size="100%">259</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2012/06/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/diagnosis/ epidemiology/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Helicobacter Infections/diagnosis/ epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Helicobacter pylori</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/diagnosis/ epidemiology/microbiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1432-1459 (Electronic)&#xD;0340-5354 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22688569</style></accession-num><abstract><style face="normal" font="default" size="100%">Chronic infection of Helicobacter pylori (H. pylori) in ischemic stroke (IS) incidence has been previously studied in several publications; however, conflicting results have been reported. A meta-analysis was used to assess whether chronic infection of H. pylori was associated with risk of IS, and which of the following was more effective for predication of IS risk, antibody IgG of H. pylori (anti-H. pylori IgG), antibody IgG of cytotoxin-associated gene-A (anti-Cag A IgG) or the (13)C-urea breath test. We searched the databases of Medline and Embase, and latest update was January 1, 2012. Case-control studies were considered to be eligible. The odds ratio (OR) and 95 % confidence interval (95 % CI) were calculated using the random-effect model. A total of 13 studies including 4,041 participants were included in this meta-analysis. Of these studies, ten, four and four studies were for anti-H. pylori IgG, anti-Cag A IgG and the (13)C-urea breath test, respectively. Combined analysis indicated that positive anti-H. pylori IgG, anti-Cag A IgG and (13)C-urea breath test were significantly associated with increased risk of IS, respectively, and positive anti-Cag A IgG was more effective for predication of IS risk [OR (95 % CI) = 1.60 (1.21-2.11), P (heterogeneity) = 0.001 for positive versus negative anti-H. pylori IgG; 2.33 (1.76-3.09), P (heterogeneity) = 0.71 for positive versus negative anti-Cag A IgG and 1.65 (1.11-2.47), P (heterogeneity) = 0.17 for positive versus negative (13)C-urea breath test]. In addition, we found that positive anti-H. pylori IgG was closely associated with risk of IS caused by atherosclerosis and small artery disease, but not for cardioembolic IS. This meta-analysis indicated that chronic H. pylori infection was significantly associated with an increased risk of IS, especially for non-cardioembolic IS. Compared with anti-H. pylori IgG and the (13)C-urea breath test, anti-Cag A IgG seemed more effective for prediction of risk of IS.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Zhong Wei&#xD;Li, Yan&#xD;Huang, Li Yong&#xD;Guan, Qing Kai&#xD;Xu, Da Wei&#xD;Zhou, Wen Ke&#xD;Zhang, Xin Zhong&#xD;Meta-Analysis&#xD;Germany&#xD;J Neurol. 2012 Dec;259(12):2527-37. doi: 10.1007/s00415-012-6558-7. Epub 2012 Jun 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/79/art%253A10.1007%252Fs00415-012-6558-7.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00415-012-6558-7&amp;token2=exp=1484123124~acl=%2Fstatic%2Fpdf%2F79%2Fart%25253A10.1007%25252Fs00415-012-6558-7.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs00415-012-6558-7*~hmac=0966e95ff1b46f335030a9b7878a14c586d032897d4891b56aacd74e6ed2e333</style></url></related-urls><pdf-urls><url>internal-pdf://4195508238/Wang-2012-Helicobacter pylori.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00415-012-6558-7</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>482</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">482</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wassermann, E. M.</style></author><author><style face="normal" font="default" size="100%">Zimmermann, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Behavioral Neurology Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. eric.wassermann@nih.gov</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transcranial magnetic brain stimulation: therapeutic promises and scientific gaps</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacol Ther</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Pharmacology &amp; therapeutics</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pharmacol Ther</style></full-title><abbr-1><style face="normal" font="default" size="100%">Pharmacology &amp; therapeutics</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Pharmacol Ther</style></full-title><abbr-1><style face="normal" font="default" size="100%">Pharmacology &amp; therapeutics</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">98-107</style></pages><volume><style face="normal" font="default" size="100%">133</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2011/09/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Diseases/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mental Disorders/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Transcranial Magnetic Stimulation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1879-016X (Electronic)&#xD;0163-7258 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">21924290</style></accession-num><abstract><style face="normal" font="default" size="100%">Since its commercial advent in 1985, transcranial magnetic stimulation (TMS), a technique for stimulating neurons in the cerebral cortex through the scalp, safely and with minimal discomfort, has captured the imaginations of scientists, clinicians and lay observers. Initially a laboratory tool for neurophysiologists studying the human motor system, TMS now has a growing list of applications in clinical and basic neuroscience. Although we understand many of its effects at the system level, detailed knowledge of its actions, particularly as a modulator of neural activity, has lagged, due mainly to the lack of suitable non-human models. Nevertheless, these gaps have not blocked the therapeutic application of TMS in brain disorders. Moderate success has been achieved in treating disorders such as depression, where the U.S. Food and Drug Administration has cleared a TMS system for therapeutic use. In addition, there are small, but promising, bodies of data on the treatment of schizophrenic auditory hallucinations, tinnitus, anxiety disorders, neurodegenerative diseases, hemiparesis, and pain syndromes. Some other nascent areas of study also exist. While the fate of TMS as a therapeutic modality depends on continued innovation and experimentation, economic and other factors may be decisive.</style></abstract><notes><style face="normal" font="default" size="100%">Wassermann, Eric M&#xD;Zimmermann, Trelawny&#xD;ZIA NS002977-12/Intramural NIH HHS/United States&#xD;Research Support, N.I.H., Intramural&#xD;Review&#xD;England&#xD;Pharmacol Ther. 2012 Jan;133(1):98-107. doi: 10.1016/j.pharmthera.2011.09.003. Epub 2011 Sep 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0163725811001811/1-s2.0-S0163725811001811-main.pdf?_tid=b9b10f46-d7d4-11e6-9a99-00000aacb360&amp;acdnat=1484122113_1e984cda05003a05d17733babd73dfd2</style></url></related-urls><pdf-urls><url>internal-pdf://2697559670/Wassermann-2012-Transcranial magneti.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3241868</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms329236</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.pharmthera.2011.09.003</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>239</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">239</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Weaver, J.</style></author><author><style face="normal" font="default" size="100%">Jalal, F. Y.</style></author><author><style face="normal" font="default" size="100%">Yang, Y.</style></author><author><style face="normal" font="default" size="100%">Thompson, J.</style></author><author><style face="normal" font="default" size="100%">Rosenberg, G. A.</style></author><author><style face="normal" font="default" size="100%">Liu, K. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmaceutical Sciences, College of Pharmacy, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.&#xD;1] Department of Neurology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA [2] Departments of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, UAE.&#xD;Department of Neurology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.&#xD;1] Department of Neurology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA [2] Department of Neuroscience, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA [3] Department of Cell Biology and Physiology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.&#xD;1] Department of Pharmaceutical Sciences, College of Pharmacy, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA [2] Department of Neurology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tissue oxygen is reduced in white matter of spontaneously hypertensive-stroke prone rats: a longitudinal study with electron paramagnetic resonance</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">890-6</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2014/02/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/blood supply/metabolism/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Infarction/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Stenosis/ complications/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Electron Spin Resonance Spectroscopy</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension/ complications/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Longitudinal Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Fibers, Myelinated/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Oximetry</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred SHR</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred WKY</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ complications/metabolism/pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24549186</style></accession-num><abstract><style face="normal" font="default" size="100%">Small vessel disease is associated with white-matter (WM) magnetic resonance imaging (MRI) hyperintensities (WMHs) in patients with vascular cognitive impairment (VCI) and subsequent damage to the WM. Although WM is vulnerable to hypoxic-ischemic injury and O(2) is critical in brain physiology, tissue O(2) level in the WM has not been measured and explored in vivo. We hypothesized that spontaneously hypertensive stroke-prone rat (SHR/SP) fed a Japanese permissive diet (JPD) and subjected to unilateral carotid artery occlusion (UCAO), a model to study VCI, would lead to reduced tissue oxygen (pO(2)) in the deep WM. We tested this hypothesis by monitoring WM tissue pO(2) using in vivo electron paramagnetic resonance (EPR) oximetry in SHR/SP rats over weeks before and after JPD/UCAO. The SHR/SP rats experienced an increase in WM pO(2) from 9 to 12 weeks with a maximal 32% increase at week 12, followed by a dramatic decrease in WM pO(2) to near hypoxic conditions during weeks 13 to 16 after JPD/UCAO. The decreased WM pO(2) was accompanied with WM damage and hemorrhages surrounding microvessels. Our findings suggest that changes in WM pO(2) may contribute to WM damage in SHR/SP rat model, and that EPR oximetry can monitor brain pO(2) in the WM of small animals.</style></abstract><notes><style face="normal" font="default" size="100%">Weaver, John&#xD;Jalal, Fakhreya Y&#xD;Yang, Yi&#xD;Thompson, Jeffrey&#xD;Rosenberg, Gary A&#xD;Liu, Ke J&#xD;P30GM103400/GM/NIGMS NIH HHS/United States&#xD;R01 NS045847/NS/NINDS NIH HHS/United States&#xD;UL1 TR000041/TR/NCATS NIH HHS/United States&#xD;R01NS045847/NS/NINDS NIH HHS/United States&#xD;P30 GM103400/GM/NIGMS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;United States&#xD;J Cereb Blood Flow Metab. 2014 May;34(5):890-6. doi: 10.1038/jcbfm.2014.35. Epub 2014 Feb 19.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4013771</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2014.35</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>93</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">93</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wehrum, T.</style></author><author><style face="normal" font="default" size="100%">Kams, M.</style></author><author><style face="normal" font="default" size="100%">Gunther, F.</style></author><author><style face="normal" font="default" size="100%">Beryl, P.</style></author><author><style face="normal" font="default" size="100%">Vach, W.</style></author><author><style face="normal" font="default" size="100%">Dragonu, I.</style></author><author><style face="normal" font="default" size="100%">Harloff, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, University Medical Center Freiburg, Freiburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Quantification of Retrograde Blood Flow in the Descending Aorta Using Transesophageal Echocardiography in Comparison to 4D Flow MRI</style></title><secondary-title><style face="normal" font="default" size="100%">Cerebrovasc Dis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Cerebrovascular diseases (Basel, Switzerland)</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cerebrovasc Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Cerebrovascular diseases (Basel, Switzerland)</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Cerebrovasc Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Cerebrovascular diseases (Basel, Switzerland)</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">287-92</style></pages><volume><style face="normal" font="default" size="100%">39</style></volume><number><style face="normal" font="default" size="100%">5-6</style></number><edition><style face="normal" font="default" size="100%">2015/04/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Aorta, Thoracic/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Aortic Diseases/diagnosis/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Echocardiography, Transesophageal/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Hemodynamics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Embolism/ diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Angiography/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1421-9786 (Electronic)&#xD;1015-9770 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25896851</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Retrograde diastolic blood flow in the proximal descending aorta (DAo), which connects plaques &gt;/=4 mm thickness with brain-supplying arteries, has previously been identified as a possible source of brain embolism. Currently, only 4D flow MRI is able to visualize and quantify potential retrograde embolization pathways in the DAo in-vivo. Hence, it was our aim to test if the extent of retrograde flow could be estimated by routine 2D transesophageal echocardiography (TEE). METHODS: Forty-eight acute stroke patients were prospectively included and they underwent Doppler examinations of the transition zone between the aortic arch and the DAo using a 20 mm 2D sample volume in longitudinal section at 90-140 degrees Doppler angle during routine TEE. Velocity-time-integrals (VTI) were studied for antegrade and retrograde velocities and the ratio (VTIratio) was calculated and correlated with the length of retrograde pathlines at that site, which were visualized using 4D flow MRI at 3-Tesla. A receiver operating characteristic (ROC) curve was used to evaluate a threshold value of VTIratio in differentiating large (&gt;/=3 cm) from small (&lt;3 cm) retrograde flow extent. RESULTS: At the TEE measurement site, the mean VTIratio was 0.53 +/- 0.16 and the mean length of retrograde pathlines reaching back into the aortic arch was 3.1 +/- 1.4 cm. VTIratio was an independent predictor of retrograde pathline length (r = 0.44; p = 0.002). ROC analysis identified a VTIratio threshold value of 0.6012 with a sensitivity of 0.5, a specificity of 0.92, and positive and negative predictive values of 0.84 and 0.68, respectively. Accordingly, 11 (22.91%) patients had a VTIratio cutoff value &gt;/=0.6012 and corresponding retrograde pathline length &gt;/=3 cm in 4D flow MRI. CONCLUSIONS: TEE allows predicting the length of retrograde pathlines. Hence, it may offer a cost-effective way to investigate independent predictors of DAo flow reversal in large-scale studies. However, TEE is only of limited value as a screening tool for high retrograde flow in a clinical setting, as only approximately 23% of patients can be spared 4D flow MRI, which remains indispensable for the exact assessment of individual embolization pathways from plaques of the DAo in-vivo.</style></abstract><notes><style face="normal" font="default" size="100%">Wehrum, Thomas&#xD;Kams, Miriam&#xD;Gunther, Felix&#xD;Beryl, Primrose&#xD;Vach, Werner&#xD;Dragonu, Iulius&#xD;Harloff, Andreas&#xD;Comparative Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Switzerland&#xD;Cerebrovasc Dis. 2015;39(5-6):287-92. doi: 10.1159/000381682. Epub 2015 Apr 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.karger.com/Article/Pdf/381682</style></url></related-urls><pdf-urls><url>internal-pdf://1251182053/Wehrum-2015-Quantification of Re.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1159/000381682</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>58</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">58</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Weinl, C.</style></author><author><style face="normal" font="default" size="100%">Castaneda Vega, S.</style></author><author><style face="normal" font="default" size="100%">Riehle, H.</style></author><author><style face="normal" font="default" size="100%">Stritt, C.</style></author><author><style face="normal" font="default" size="100%">Calaminus, C.</style></author><author><style face="normal" font="default" size="100%">Wolburg, H.</style></author><author><style face="normal" font="default" size="100%">Mauel, S.</style></author><author><style face="normal" font="default" size="100%">Breithaupt, A.</style></author><author><style face="normal" font="default" size="100%">Gruber, A. D.</style></author><author><style face="normal" font="default" size="100%">Wasylyk, B.</style></author><author><style face="normal" font="default" size="100%">Olson, E. N.</style></author><author><style face="normal" font="default" size="100%">Adams, R. H.</style></author><author><style face="normal" font="default" size="100%">Pichler, B. J.</style></author><author><style face="normal" font="default" size="100%">Nordheim, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Molecular Biology, Interfaculty Institute of Cell Biology, University of Tuebingen, 72076 Tuebingen, Germany; alfred.nordheim@uni-tuebingen.de christine.weinl@uni-tuebingen.de Eric.Olson@utsouthwestern.edu.&#xD;Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University Hospital Tuebingen, 72076 Tuebingen, Germany;&#xD;Department of Molecular Biology, Interfaculty Institute of Cell Biology, University of Tuebingen, 72076 Tuebingen, Germany;&#xD;Department of Pathology and Neuropathology, University of Tuebingen, 72076 Tuebingen, Germany;&#xD;Institute for Animal Pathology, Department of Veterinary Pathology, Free University Berlin, 14163 Berlin, Germany;&#xD;Institut de Genetique et de Biologie Moleculaire et Cellulaire, 67400 Illkirch, France; Centre National de la Recherche Scientifique, UMR 7104, 67404 Illkirch, France; Institut National de la Sante et de la Recherche Medicale, U964, 67400 Illkirch, France; Universite de Strasbourg, 67400 Illkirch, France;&#xD;Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390; alfred.nordheim@uni-tuebingen.de christine.weinl@uni-tuebingen.de Eric.Olson@utsouthwestern.edu.&#xD;Department of Tissue Morphogenesis, Max-Planck-Institute for Molecular Biomedicine and Faculty of Medicine, University of Muenster, 48149 Muenster, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Endothelial depletion of murine SRF/MRTF provokes intracerebral hemorrhagic stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Proceedings of the National Academy of Sciences of the United States of America</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style></full-title><abbr-1><style face="normal" font="default" size="100%">Proceedings of the National Academy of Sciences of the United States of America</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style></full-title><abbr-1><style face="normal" font="default" size="100%">Proceedings of the National Academy of Sciences of the United States of America</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">9914-9</style></pages><volume><style face="normal" font="default" size="100%">112</style></volume><number><style face="normal" font="default" size="100%">32</style></number><edition><style face="normal" font="default" size="100%">2015/07/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Animals, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Basement Membrane/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/blood supply/metabolism/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cadherins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/ complications/metabolism/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Collagen Type IV/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Down-Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelial Cells/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Evans Blue/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Exploratory Behavior</style></keyword><keyword><style face="normal" font="default" size="100%">Extravasation of Diagnostic and Therapeutic Materials</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Deletion</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Microvessels/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Motor Activity</style></keyword><keyword><style face="normal" font="default" size="100%">Permeability</style></keyword><keyword><style face="normal" font="default" size="100%">Serum Response Factor/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ etiology/ metabolism/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Tight Junctions/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Trans-Activators/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Transcription Factors/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 11</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1091-6490 (Electronic)&#xD;0027-8424 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26221020</style></accession-num><abstract><style face="normal" font="default" size="100%">Intracerebral hemorrhagic stroke and vascular dementia are age- and hypertension-associated manifestations of human cerebral small vessel disease (SVD). Cerebral microvessels are formed by endothelial cells (ECs), which are connected through tight junctions, adherens junctions, and stabilizing basement membrane structures. These endothelial connections ensure both vessel stability and blood-brain barrier (BBB) functions, the latter enabling selective exchange of ions, bioactive molecules, and cells between the bloodstream and brain tissue. Srf(iECKO) mice, permitting conditional EC-specific depletion of the transcription factor Serum Response Factor (SRF), suffer from loss of BBB integrity and intracerebral hemorrhaging. Cerebral microbleeds and larger hemorrhages developed upon postnatal and adult depletion of either SRF or its cofactors Myocardin Related Transcription Factor (MRTF-A/-B), revealing essential requirements of ongoing SRF/MRTF activity for maintenance of cerebral small vessel integrity. In vivo magnetic resonance imaging allowed detection, localization, and time-resolved quantification of BBB permeability and hemorrhage formation in Srf(iECKO) brains. At the molecular level, direct and indirect SRF/MRTF target genes, encoding structural components of tight junctions (Claudins and ZO proteins), adherens junctions (VE-cadherin, alpha-Actinin), and the basement membrane (Collagen IV), were down-regulated upon SRF depletion. These results identify SRF and its MRTF cofactors as major transcriptional regulators of EC junctional stability, guaranteeing physiological functions of the cerebral microvasculature. We hypothesize that impairments in SRF/MRTF activity contribute to human SVD pathology.</style></abstract><notes><style face="normal" font="default" size="100%">Weinl, Christine&#xD;Castaneda Vega, Salvador&#xD;Riehle, Heidemarie&#xD;Stritt, Christine&#xD;Calaminus, Carsten&#xD;Wolburg, Hartwig&#xD;Mauel, Susanne&#xD;Breithaupt, Angele&#xD;Gruber, Achim D&#xD;Wasylyk, Bohdan&#xD;Olson, Eric N&#xD;Adams, Ralf H&#xD;Pichler, Bernd J&#xD;Nordheim, Alfred&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Proc Natl Acad Sci U S A. 2015 Aug 11;112(32):9914-9. doi: 10.1073/pnas.1509047112. Epub 2015 Jul 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.pnas.org/content/112/32/9914.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3224345245/Weinl-2015-Endothelial depletio.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4538672</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1073/pnas.1509047112</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>304</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">304</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Weiss, H. R.</style></author><author><style face="normal" font="default" size="100%">Grayson, J.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Barsoum, S.</style></author><author><style face="normal" font="default" size="100%">Shah, H.</style></author><author><style face="normal" font="default" size="100%">Chi, O. Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neuroscience and Cell Biology, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ, USA. hweiss@rwjms.rutgers.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cerebral ischemia and reperfusion increases the heterogeneity of local oxygen supply/consumption balance</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">2553-8</style></pages><volume><style face="normal" font="default" size="100%">44</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2013/07/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/blood/diagnostic imaging/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Microspectrophotometry</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Cerebral Artery/injuries/physiology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen/blood/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen Consumption/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Radiography</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred F344</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/blood/ metabolism/ physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23839504</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: After cerebral vessel blockage, local blood flow and O2 consumption becomes lower and oxygen extraction increases. With reperfusion, blood flow is partially restored. We examined the effects of ischemia-reperfusion on the heterogeneity of local venous oxygen saturation in rats in order to determine the pattern of microregional O2 supply/consumption balance in reperfusion. METHODS: The middle cerebral artery was blocked for 1 hour using the internal carotid approach in 1 group (n=9) and was then reperfused for 2 hours in another group (n=9) of isoflurane-anesthetized rats. Regional cerebral blood flow was determined using a C(14)-iodoantipyrine autoradiographic technique. Regional small vessel arterial and venous oxygen saturations were determined microspectrophotometrically. RESULTS: After 1 hour of ischemia, local cerebral blood flow (92+/-10 versus 50+/-10 mL/min per 100 g) and O2 consumption (4.5+/-0.6 versus 2.7+/-0.5 mL O2/min per 100 g) decreased compared with the contralateral cortex. Oxygen extraction increased (4.7+/-0.2 versus 5.4+/-0.3 mL O2/100 mL) and the variation in small vein (20-60 mum) O2 saturation as determined by its coefficient of variation (=100xSD/mean) increased (5.5 versus 10.5). With 2 hours of reperfusion, the blood flow decrement was reduced and O2 consumption returned to the value in the contralateral cortex. Oxygen extraction remained elevated in the ischemic-reperfused area and the coefficient of variation of small vein O2 saturation increased further (17.3). CONCLUSIONS: These data indicated continued reduction of O2 supply/consumption balance with reperfusion. They also demonstrated many small regions of low oxygenation within the reperfused cortical region.</style></abstract><notes><style face="normal" font="default" size="100%">Weiss, Harvey R&#xD;Grayson, Jeremy&#xD;Liu, Xia&#xD;Barsoum, Sylviana&#xD;Shah, Harsh&#xD;Chi, Oak Z&#xD;United States&#xD;Stroke. 2013 Sep;44(9):2553-8. doi: 10.1161/STROKEAHA.113.001172. Epub 2013 Jul 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/44/9/2553.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0491303412/Weiss-2013-Cerebral ischemia an.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.113.001172</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>395</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">395</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">White, R. E.</style></author><author><style face="normal" font="default" size="100%">Palm, C.</style></author><author><style face="normal" font="default" size="100%">Xu, L.</style></author><author><style face="normal" font="default" size="100%">Ling, E.</style></author><author><style face="normal" font="default" size="100%">Ginsburg, M.</style></author><author><style face="normal" font="default" size="100%">Daigle, B. J.</style></author><author><style face="normal" font="default" size="100%">Han, R.</style></author><author><style face="normal" font="default" size="100%">Patterson, A.</style></author><author><style face="normal" font="default" size="100%">Altman, R. B.</style></author><author><style face="normal" font="default" size="100%">Giffard, R. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">*Department of Anesthesia, Stanford University, 300 Pasteur Drive, Grant Building S282, Stanford, CA 94305, U.S.A.&#xD;daggerGenome Technology Center, Stanford University, 855 S. California Avenue, Palo Alto, CA 94305, U.S.A.&#xD;double daggerDepartment of Computer Science, University of California Santa Barbara, Santa Barbara, CA 931065070, U.S.A.&#xD;paragraph signDepartment of Bioengineering, Stanford University, 318 Campus Drive S172, Stanford, CA 94305, U.S.A.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mice lacking the beta2 adrenergic receptor have a unique genetic profile before and after focal brain ischaemia</style></title><secondary-title><style face="normal" font="default" size="100%">ASN Neuro</style></secondary-title><alt-title><style face="normal" font="default" size="100%">ASN neuro</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">ASN Neuro</style></full-title><abbr-1><style face="normal" font="default" size="100%">ASN neuro</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">ASN Neuro</style></full-title><abbr-1><style face="normal" font="default" size="100%">ASN neuro</style></abbr-1></alt-periodical><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2012/08/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Death</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Regulatory Networks</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Microarray Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">NF-kappa B/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Tissue Proteins/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Proto-Oncogene Proteins c-bcl-2/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Adrenergic, beta-2/ deficiency/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, G-Protein-Coupled/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Tumor Necrosis Factor-alpha/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">rab GTP-Binding Proteins</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 07</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1759-0914 (Electronic)&#xD;1759-0914 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22867428</style></accession-num><abstract><style face="normal" font="default" size="100%">The role of the beta2AR (beta2 adrenergic receptor) after stroke is unclear as pharmacological manipulations of the beta2AR have produced contradictory results. We previously showed that mice deficient in the beta2AR (beta2KO) had smaller infarcts compared with WT (wild-type) mice (FVB) after MCAO (middle cerebral artery occlusion), a model of stroke. To elucidate mechanisms of this neuroprotection, we evaluated changes in gene expression using microarrays comparing differences before and after MCAO, and differences between genotypes. Genes associated with inflammation and cell deaths were enriched after MCAO in both genotypes, and we identified several genes not previously shown to increase following ischaemia (Ccl9, Gem and Prg4). In addition to networks that were similar between genotypes, one network with a central core of GPCR (G-protein-coupled receptor) and including biological functions such as carbohydrate metabolism, small molecule biochemistry and inflammation was identified in FVB mice but not in beta2KO mice. Analysis of differences between genotypes revealed 11 genes differentially expressed by genotype both before and after ischaemia. We demonstrate greater Glo1 protein levels and lower Pmaip/Noxa mRNA levels in beta2KO mice in both sham and MCAO conditions. As both genes are implicated in NF-kappaB (nuclear factor kappaB) signalling, we measured p65 activity and TNFalpha (tumour necrosis factor alpha) levels 24 h after MCAO. MCAO-induced p65 activation and post-ischaemic TNFalpha production were both greater in FVB compared with beta2KO mice. These results suggest that loss of beta2AR signalling results in a neuroprotective phenotype in part due to decreased NF-kappaB signalling, decreased inflammation and decreased apoptotic signalling in the brain.</style></abstract><notes><style face="normal" font="default" size="100%">White, Robin E&#xD;Palm, Curtis&#xD;Xu, Lijun&#xD;Ling, Evelyn&#xD;Ginsburg, Mitchell&#xD;Daigle, Bernie J&#xD;Han, Ruquan&#xD;Patterson, Andrew&#xD;Altman, Russ B&#xD;Giffard, Rona G&#xD;R24 GM061374/GM/NIGMS NIH HHS/United States&#xD;T32GM089626/GM/NIGMS NIH HHS/United States&#xD;GM61374/GM/NIGMS NIH HHS/United States&#xD;U01 GM061374/GM/NIGMS NIH HHS/United States&#xD;T32 GM089626/GM/NIGMS NIH HHS/United States&#xD;GM49831/GM/NIGMS NIH HHS/United States&#xD;R01 GM049831/GM/NIGMS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;United States&#xD;ASN Neuro. 2012 Sep 7;4(5). pii: e00096. doi: 10.1042/AN20110020.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3436074</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1042/an20110020</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>8</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">8</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wiggers, G. A.</style></author><author><style face="normal" font="default" size="100%">Furieri, L. B.</style></author><author><style face="normal" font="default" size="100%">Briones, A. M.</style></author><author><style face="normal" font="default" size="100%">Avendano, M. S.</style></author><author><style face="normal" font="default" size="100%">Pecanha, F. M.</style></author><author><style face="normal" font="default" size="100%">Vassallo, D. V.</style></author><author><style face="normal" font="default" size="100%">Salaices, M.</style></author><author><style face="normal" font="default" size="100%">Alonso, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Postgraduate Program in Biochemistry, Universidade Federal do Pampa, Rio Grande do Sul, Unipampa, Campus Uruguaiana, BR 472, km 592, PO Box 118, Uruguaiana, RS 97500-970, Brazil; Department of Pharmacology, School of Medicine, Universidad Autonoma de Madrid, Calle Arzobispo Morcillo s/n, 28029 Madrid, Spain. Electronic address: giuliawp@gmail.com.&#xD;Department of Physiological Sciences, Universidade Federal do Espirito Santo, Vitoria, Espirito Santo, Avenida Marechal Campos, 1468, Vitoria, ES 29040-090, Brazil; Department of Pharmacology, School of Medicine, Universidad Autonoma de Madrid, Calle Arzobispo Morcillo s/n, 28029 Madrid, Spain. Electronic address: lorena.furieri@ufes.br.&#xD;Department of Pharmacology, School of Medicine, Universidad Autonoma de Madrid, Calle Arzobispo Morcillo s/n, 28029 Madrid, Spain. Electronic address: ana.briones@uam.es.&#xD;Department of Pharmacology, School of Medicine, Universidad Autonoma de Madrid, Calle Arzobispo Morcillo s/n, 28029 Madrid, Spain. Electronic address: marisol.avendanno@uam.es.&#xD;Postgraduate Program in Biochemistry, Universidade Federal do Pampa, Rio Grande do Sul, Unipampa, Campus Uruguaiana, BR 472, km 592, PO Box 118, Uruguaiana, RS 97500-970, Brazil; Department of Pharmacology, School of Medicine, Universidad Autonoma de Madrid, Calle Arzobispo Morcillo s/n, 28029 Madrid, Spain.&#xD;Department of Physiological Sciences, Universidade Federal do Espirito Santo, Vitoria, Espirito Santo, Avenida Marechal Campos, 1468, Vitoria, ES 29040-090, Brazil. Electronic address: daltonv2@terra.com.br.&#xD;Department of Pharmacology, School of Medicine, Universidad Autonoma de Madrid, Calle Arzobispo Morcillo s/n, 28029 Madrid, Spain. Electronic address: mercedes.salaices@uam.es.&#xD;Department of Ciencias Basicas de la Salud, Universidad Rey Juan Carlos, Avenida de Atenas s/n, 28922 Alcorcon, Madrid, Spain. Electronic address: mariajesus.alonso@urjc.es.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cerebrovascular endothelial dysfunction induced by mercury exposure at low concentrations</style></title><secondary-title><style face="normal" font="default" size="100%">Neurotoxicology</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurotoxicology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurotoxicology</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurotoxicology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurotoxicology</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurotoxicology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">282-9</style></pages><volume><style face="normal" font="default" size="100%">53</style></volume><edition><style face="normal" font="default" size="100%">2016/03/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Analysis of Variance</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Basilar Artery/cytology</style></keyword><keyword><style face="normal" font="default" size="100%">Body Weight/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Bradykinin/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Disorders/ chemically induced/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Drinking/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Eating/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelial Cells/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrazines/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mercuric Chloride/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">NG-Nitroarginine Methyl Ester/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide Donors/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Serotonin/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Superoxides/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Vasoconstriction/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents/pharmacology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-9711 (Electronic)&#xD;0161-813X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26945730</style></accession-num><abstract><style face="normal" font="default" size="100%">Mercury (Hg) has many harmful vascular effects by increasing oxidative stress, inflammation and vascular/endothelial dysfunction, all of which may contribute to cerebrovascular diseases development. We aimed to explore the effects of chronic low-mercury concentration on vascular function in cerebral arteries and the mechanisms involved. Basilar arteries from control (vehicle-saline solution, im) and mercury chloride (HgCl2)-treated rats for 30 days (first dose 4.6mug/kg, subsequent dose 0.07mug/kg/day, im, to cover daily loss) were used. Vascular reactivity, protein expression, nitric oxide (NO) levels and superoxide anion (O2(-)) production were analyzed. HgCl2 exposure increased serotonin contraction and reduced the endothelium-dependent vasodilatation to bradykinin. After NO synthase inhibition, serotonin responses were enhanced more in control than in mercury-treated rats while bradykinin-induced relaxation was abolished. NO levels were greater in control than Hg-treated rats. Tiron and indomethacin reduced vasoconstriction and increased the bradykinin-induced relaxation only in HgCl2-treated rats. Vascular O2(-) production was greater in mercury-treated when compared to control rats. Protein expressions of endothelial NO synthase, copper/zinc (Cu/Zn), Manganese (Mn) and extracellular-superoxide dismutases were similar in cerebral arteries from both groups. Results suggest that Hg treatment increases cerebrovascular reactivity by reducing endothelial negative modulation and NO bioavailability; this effect seems to be dependent on increased reactive oxygen species and prostanoids generation. These findings show, for the first time, that brain vasculature are also affected by chronic mercury exposure and offer further evidence that even at small concentration, HgCl2 is hazardous and might be an environmental risk factor accounting for cerebral vasospasm development.</style></abstract><notes><style face="normal" font="default" size="100%">Wiggers, Giulia Alessandra&#xD;Furieri, Lorena Barros&#xD;Briones, Ana Maria&#xD;Avendano, Maria Soledad&#xD;Pecanha, Franck Maciel&#xD;Vassallo, Dalton Valentim&#xD;Salaices, Mercedes&#xD;Alonso, Maria Jesus&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;Neurotoxicology. 2016 Mar;53:282-9. doi: 10.1016/j.neuro.2016.02.010. Epub 2016 Mar 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0161813X16300201/1-s2.0-S0161813X16300201-main.pdf?_tid=c4208830-d7d4-11e6-979b-00000aab0f27&amp;acdnat=1484122130_64d18b30fba5e09e684164f11706bb2f</style></url></related-urls><pdf-urls><url>internal-pdf://3052979089/Wiggers-2016-Cerebrovascular endo.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuro.2016.02.010</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>133</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">133</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wu, X.</style></author><author><style face="normal" font="default" size="100%">Li, L.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Wu, J.</style></author><author><style face="normal" font="default" size="100%">Zhou, Y.</style></author><author><style face="normal" font="default" size="100%">Zhou, Y.</style></author><author><style face="normal" font="default" size="100%">Zhao, Y.</style></author><author><style face="normal" font="default" size="100%">Zhao, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathophysiology, Chongqing Medical University, Chongqing, Peoples Republic of China; Institute of Neuroscience, Chongqing Medical University, Chongqing, Peoples Republic of China.&#xD;Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing, Peoples Republic of China.&#xD;Department of Pathology, Chongqing Medical University, Chongqing, Peoples Republic of China; Institute of Neuroscience, Chongqing Medical University, Chongqing, Peoples Republic of China.&#xD;Department of Pathophysiology, Chongqing Medical University, Chongqing, Peoples Republic of China; Institute of Neuroscience, Chongqing Medical University, Chongqing, Peoples Republic of China. Electronic address: zjbingsheng@sina.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inhibition of thioredoxin-1 with siRNA exacerbates apoptosis by activating the ASK1-JNK/p38 pathway in brain of a stroke model rats</style></title><secondary-title><style face="normal" font="default" size="100%">Brain Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">20-31</style></pages><volume><style face="normal" font="default" size="100%">1599</style></volume><edition><style face="normal" font="default" size="100%">2014/12/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Caspase 3/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cytochromes c/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery</style></keyword><keyword><style face="normal" font="default" size="100%">MAP Kinase Kinase 4/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">MAP Kinase Kinase Kinase 5/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">MAP Kinase Signaling System/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Thioredoxins/ antagonists &amp; inhibitors/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">p38 Mitogen-Activated Protein Kinases/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 02</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-6240 (Electronic)&#xD;0006-8993 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25541364</style></accession-num><abstract><style face="normal" font="default" size="100%">Apoptosis is critical for the development of cerebral ischemia/reperfusion injury. Thioredoxin-1(Trx-1) protein has been reported to have anti-apoptotic effects in a variety of cell types, and it has been implicated in brain injury after middle cerebral artery occlusion (MCAO). Thus, we studied the effects of Trx1 silencing after MCAO in rats and examined whether inhibition of endogenous Trx1 could increase tissue levels of apoptosis. Male Sprague-Dawley rats (N=170) were subjected to 1h of middle cerebral arterial occlusion followed by 24h of reperfusion. Trx1 siRNAs were injected into rat brains 24h prior to MCAO. Then, 24h after MCAO, brains were collected from euthanized rats for investigation. Treatment with Trx1 siRNA significantly increased mortality, behavioral deficits, and cerebral infarction volume and exacerbated neuronal cell apoptotic death after MCAO injury. Western blot revealed increased expression of apoptotic proteins such as P-ASK1, P-JNK, P-p38, cleaved caspase-3 and increased the level of cytochrome c in the cytosolic fraction in the Trx1 siRNA-treated group. Co-immunoprecipitation assay suggested an interaction between Trx1 and ASK1 in normal rat brains and Trx1 siRNA dissociated ASK1-Trx1 binding complex. Our data suggest that Trx1 siRNA increases apoptotic stress-induced ASK1 activation and this represents further evidence that Trx1 is an endogenous anti-apoptotic molecule that diminishes focal cerebral ischemia/reperfusion injury. Its mechanism of action is likely related to attenuation of the ASK1-JNK/p38 signaling pathway.</style></abstract><notes><style face="normal" font="default" size="100%">Wu, Xiaoying&#xD;Li, Lingyu&#xD;Zhang, Luyu&#xD;Wu, Jingxian&#xD;Zhou, Yunchuan&#xD;Zhou, Yang&#xD;Zhao, Yong&#xD;Zhao, Jing&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;Brain Res. 2015 Mar 2;1599:20-31. doi: 10.1016/j.brainres.2014.12.033. Epub 2014 Dec 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0006899314017405/1-s2.0-S0006899314017405-main.pdf?_tid=c70d8b6a-d7d4-11e6-8bfb-00000aacb35e&amp;acdnat=1484122135_b873091325a2c70d79813c6758c214f3</style></url></related-urls><pdf-urls><url>internal-pdf://1275258928/Wu-2015-Inhibition of thiore.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.brainres.2014.12.033</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>380</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">380</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xavier, A. R.</style></author><author><style face="normal" font="default" size="100%">Tiwari, A.</style></author><author><style face="normal" font="default" size="100%">Kansara, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Wayne State University, Detroit, MI, USA. axavier@med.wayne.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">Angioplasty and stenting for mechanical thrombectomy in acute ischemic stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Neurology</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurology</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurology</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">S142-7</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">13 Suppl 1</style></number><edition><style face="normal" font="default" size="100%">2012/10/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Angioplasty/instrumentation/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/pathology/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mechanical Thrombolysis/instrumentation/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Stents</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/pathology/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 25</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1526-632X (Electronic)&#xD;0028-3878 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23008389</style></accession-num><abstract><style face="normal" font="default" size="100%">A large number of patients presenting with acute ischemic stroke have large artery intracranial occlusions, and timely recanalization of these occlusions often leads to improved neurologic outcome. Starting with the widespread use of IV tissue plasminogen activator, a wide variety of pharmacologic and mechanical methods have been introduced to improve vessel recanalization and clinical outcome of patients with acute ischemic stroke, which include endovascular therapies such as intra-arterial thrombolytics and mechanical thrombectomy devices. One of the potential therapies is angioplasty and stenting, and this has been evaluated in multiple case reports and small series published by various centers regarding its use in this setting. In this article, we review the current literature on stenting with and without angioplasty, used alone or as a part of multimodal therapy for recanalization for acute cerebrovascular occlusions.</style></abstract><notes><style face="normal" font="default" size="100%">Xavier, Andrew R&#xD;Tiwari, Ambooj&#xD;Kansara, Amit&#xD;Review&#xD;United States&#xD;Neurology. 2012 Sep 25;79(13 Suppl 1):S142-7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.neurology.org/content/79/13_Supplement_1/S142.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0251255137/Xavier-2012-Angioplasty and sten.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1212/WNL.0b013e3182695896</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>458</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">458</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xu, X.</style></author><author><style face="normal" font="default" size="100%">Zhu, Y.</style></author><author><style face="normal" font="default" size="100%">Chuai, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Gastroenterology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Changes in serum ghrelin and small intestinal motility in rats with ischemic stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Anat Rec (Hoboken)</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Anatomical record (Hoboken, N.J. : 2007)</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Anat Rec (Hoboken)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Anatomical record (Hoboken, N.J. : 2007)</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Anat Rec (Hoboken)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Anatomical record (Hoboken, N.J. : 2007)</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">307-12</style></pages><volume><style face="normal" font="default" size="100%">295</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2011/12/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arterial Occlusive Diseases/blood/complications/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ blood/etiology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Enterocytes/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Gastrointestinal Motility/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Ghrelin/ blood</style></keyword><keyword><style face="normal" font="default" size="100%">Intestinal Mucosa/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Intestine, Small/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Cerebral Artery/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ blood/etiology/physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1932-8494 (Electronic)&#xD;1932-8486 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22190447</style></accession-num><abstract><style face="normal" font="default" size="100%">Ischemic stroke occurs as a result of an obstruction within a blood vessel supplying blood to the brain. Gastrointestinal mucosal damage not only induces local and systemic inflammatory reactions but may also result in multiple organ dysfunction syndrome. We studied whether the changes in serum ghrelin and small intestinal motility occur in cerebral ischemia. The focal cerebral ischemia rat models were produced by the middle cerebral artery occlusion (MCAO) method. The MCAO group was further equally divided into five subgroups at 3, 6, 12, 24, and 48 hr, and the sham operated rats were used as controls. Serum ghrelin level was analyzed using enzyme-linked immunosorbent assay, and small intestinal motility was measured by methylene blue staining. The ileum tissue was examined by light and electron microscopy. The neurologic scores were 0 for all the rats in the control group and 2-3 for those in the MCAO group, suggesting that rat models were established successfully. The serum ghrelin level was higher in the MCAO group when compared with the control group (P &lt; 0.05). However, the impelling force in MCAO rats was significantly lower than that of the control group (P &lt; 0.05), reaching the lowest level at 24 hr. Damage to the intestinal mucosa, including villus intestinalis, vacuolar degeneration of organelles, widened cell-cell junctions, and apoptotic cells could be found under the light and electron microscopy. Our results showed that higher level of serum ghrelin decreased gastrointestinal motility and damage to the intestinal mucosa existed in rats with MCAO.</style></abstract><notes><style face="normal" font="default" size="100%">Xu, Xinping&#xD;Zhu, Yuqun&#xD;Chuai, Jiaran&#xD;United States&#xD;Anat Rec (Hoboken). 2012 Feb;295(2):307-12. doi: 10.1002/ar.21490. Epub 2011 Dec 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1002/ar.21490/asset/21490_ftp.pdf?v=1&amp;t=ixsnwdkt&amp;s=a72c06c5b00919125bd57a39658c68fb1d5688da</style></url></related-urls><pdf-urls><url>internal-pdf://4222354660/Xu-2012-Changes in serum ghr.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/ar.21490</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>300</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">300</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yabuki, Y.</style></author><author><style face="normal" font="default" size="100%">Fukunaga, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Oral administration of glutathione improves memory deficits following transient brain ischemia by reducing brain oxidative stress</style></title><secondary-title><style face="normal" font="default" size="100%">Neuroscience</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">394-407</style></pages><volume><style face="normal" font="default" size="100%">250</style></volume><edition><style face="normal" font="default" size="100%">2013/07/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Avoidance Learning/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Blotting, Western</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Chemistry/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">CA1 Region, Hippocampal/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Death/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">DNA Fragmentation</style></keyword><keyword><style face="normal" font="default" size="100%">Glutathione/administration &amp; dosage/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Glutathione Disulfide/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Immunohistochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">In Situ Nick-End Labeling</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Attack, Transient/complications/pathology/ psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Maze Learning</style></keyword><keyword><style face="normal" font="default" size="100%">Memory Disorders/ drug therapy/etiology/ psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative Stress/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Psychomotor Performance/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Recognition (Psychology)/drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 10</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1873-7544 (Electronic)&#xD;0306-4522 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23872392</style></accession-num><abstract><style face="normal" font="default" size="100%">Oxidative stress aggravates brain injury following ischemia. The glutathione (GSH) system plays a pivotal role in combating oxidative stress in various cell types. To determine whether oral GSH administration elicits anti-oxidative effects, we assessed its potential neuroprotective effects in transient bilateral common carotid artery occlusion (BCCAO) mice. In naive mice, acute oral administration of GSH significantly increased GSH levels by 1h in the cortex and hippocampus. Eleven days after BCCAO, untreated mice showed significantly decreased GSH levels and an inverse elevation of glutathione-disulfide (GSSG) levels in both the cortex and hippocampus. Oral administration of GSH (100 and 500 mg/kg p.o.) for 10 consecutive days after ischemia restored reduced GSH levels and inhibited GSSG elevation. Notably, post-administration of GSH (100 and 500 mg/kg p.o.) significantly prevented neuronal cell death in the hippocampal CA1 region in BCCAO mice, an effect closely correlated with decreased levels of oxidative markers such as 4-hydroxy-2-nonenal (4-HNE), 8-hydroxy-2-deoxyguanosine (8-OHdG) and nitrotyrosine in that region. Finally, GSH administration for 10 days improved memory deficits observed in BCCAO mice. Taken together, our findings indicate that the anti-oxidative effect of oral GSH administration ameliorates post-ischemia neuronal cell death and, in turn, may improve memory.</style></abstract><notes><style face="normal" font="default" size="100%">Yabuki, Y&#xD;Fukunaga, K&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Neuroscience. 2013 Oct 10;250:394-407. doi: 10.1016/j.neuroscience.2013.07.017. Epub 2013 Jul 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0306452213005927/1-s2.0-S0306452213005927-main.pdf?_tid=cfac3776-d7d4-11e6-8695-00000aab0f26&amp;acdnat=1484122149_cf9062d5dfc9d2a540630e917015da39</style></url></related-urls><pdf-urls><url>internal-pdf://2004423634/Yabuki-2013-Oral administration.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuroscience.2013.07.017</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>33</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">33</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yakushiji, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Neurology, Department of Internal Medicine, Saga University Faculty of Medicine, Saga, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cerebral Microbleeds: Detection, Associations and Clinical Implications</style></title><secondary-title><style face="normal" font="default" size="100%">Front Neurol Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Frontiers of neurology and neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Front Neurol Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Frontiers of neurology and neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Front Neurol Neurosci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Frontiers of neurology and neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">78-92</style></pages><volume><style face="normal" font="default" size="100%">37</style></volume><edition><style face="normal" font="default" size="100%">2015/11/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Amyloid Angiopathy/complications/diagnosis/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage/complications/diagnosis/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Executive Function/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/complications/diagnosis/ therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1662-2804 (Electronic)&#xD;0300-5186 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26587900</style></accession-num><abstract><style face="normal" font="default" size="100%">Vigorous investigations for cerebral microbleeds (CMBs) have been made since the late 1990s. CMBs on paramagnetic-sensitive magnetic resonance sequences correspond pathologically to clusters of hemosiderin-laden macrophages and have emerged as an important new imaging marker of cerebral small vessel disease, including intracerebral hemorrhage (ICH). The prevalence of CMBs varies according to the specific disease settings (stroke subtypes and dementing disorders) and is highest (60%) in ICH patients. The associations of CMBs with aging, hypertension and apolipoprotein E genotype are consistent with the two major underlying pathogeneses of CMBs: hypertensive arteriopathy and cerebral amyloid angiopathy (CAA). The distributional patterns of CMBs might help us to understand the predominant small vessel disease pathogenesis in the brain; the strictly lobar type of CMBs often reflects the presence of advanced CAA, while the other types of CMBs, such as &apos;deep or infratentorial CMBs&apos;, including the mixed type, are strongly associated with hypertension. CMBs might be associated with cognitive function (especially executive function), gait performance, and cerebrovascular events (spontaneous, antithrombotic drug-related or post-thrombolysis ICH). In the field of CAA, an understanding of CAA-related CMBs might help to guide decision making with regard to new therapeutic approaches, including the use of monoclonal antibodies against vascular amyloid. These concepts of CMBs might allow us to advance research on ICH as well as for dementia.</style></abstract><notes><style face="normal" font="default" size="100%">Yakushiji, Yusuke&#xD;Review&#xD;Switzerland&#xD;Front Neurol Neurosci. 2015;37:78-92. doi: 10.1159/000437115. Epub 2015 Nov 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.karger.com/Article/Abstract/437115</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1159/000437115</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>229</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">229</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yamazaki, Y.</style></author><author><style face="normal" font="default" size="100%">Harada, S.</style></author><author><style face="normal" font="default" size="100%">Tokuyama, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Kobe Gakuin University, Japan.&#xD;Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Kobe Gakuin University, Japan. Electronic address: stoku@pharm.kobegakuin.ac.jp.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sodium-glucose transporter type 3-mediated neuroprotective effect of acetylcholine suppresses the development of cerebral ischemic neuronal damage</style></title><secondary-title><style face="normal" font="default" size="100%">Neuroscience</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">134-42</style></pages><volume><style face="normal" font="default" size="100%">269</style></volume><edition><style face="normal" font="default" size="100%">2014/04/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Acetylcholine/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Animals, Outbred Strains</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/drug effects/pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Glucose/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia</style></keyword><keyword><style face="normal" font="default" size="100%">Cholinesterase Inhibitors/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Corpus Striatum/drug effects/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Knockdown Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Hippocampus/drug effects/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Hypothalamus/drug effects/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Indans/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/drug therapy/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects/pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Piperidines/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium-Glucose Transport Proteins/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium-Glucose Transporter 1/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Stress, Physiological/drug effects/physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 06</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1873-7544 (Electronic)&#xD;0306-4522 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24699226</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebral ischemia can be exacerbated by post-ischemic hyperglycemia, which may involve the cerebral sodium-glucose transporter (SGLT). However, the contribution of each SGLT isoform in cerebral ischemia is still unclear. SGLT-1, -3, -4, and -6 have been reported to be expressed in various brain regions. Among these isoforms, only SGLT-3 does not transport glucose, but depolarizes the plasma membrane when glucose is bound, suggesting that SGLT-3 is a glucose sensor. Therefore, in this study, we investigated the involvement of cerebral SGLT-3 in the development of ischemia. The mouse model of focal ischemia was generated by middle cerebral artery occlusion (MCAO). Neuronal damage was assessed by histological and behavioral analyses. Fasting blood glucose levels on day 1 after MCAO were not affected in SGLT-3 siRNA-mediated knockdown of SGLT-3. The development of infarct volume and behavioral abnormalities on day 1 after MCAO were exacerbated in SGLT-3 knockdown mice (control group: n=7, 94.2 +/- 21.8 mm(3), 2 (1.6-2.4), SGLT-3 knockdown group: n=6, 1414.8 +/- 492.4 mm(3), 6 (5.8-6.3), P&lt;0.05). Moreover, SGLT-3 expression levels were significantly decreased in the striatum (65.0 +/- 8.1%, P&lt;0.05) on day 1, and in the hippocampus (67.6 +/- 7.2%, P&lt;0.05) and hypothalamus (47.5 +/- 5.1%, P&lt;0.01) on day 3 after MCAO (n=12-13). These effects were significantly inhibited by donepezil (DPZ) treatment (SGLT-3 knockdown group: n=6, 1419.0 +/- 181.5 mm(3), 3.6 (3.4-3.7), SGLT-3 knockdown and 3mg/kg DPZ-treated group: n=5, 611.3 +/- 205.3 mm(3), 1.5 (1.4-1.8), P&lt;0.05). Immunofluorescence revealed that SGLT-3 and choline acetyltransferase were co-localized in the cortex. Our results indicated that cerebral SGLT-3 suppressed neuronal damage by the activation of cholinergic neurons, which are neuroprotective. In contrast, other cerebral SGLT isoforms may be involved in the development of ischemia.</style></abstract><notes><style face="normal" font="default" size="100%">Yamazaki, Y&#xD;Harada, S&#xD;Tokuyama, S&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Neuroscience. 2014 Jun 6;269:134-42. doi: 10.1016/j.neuroscience.2014.03.046. Epub 2014 Apr 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0306452214002668/1-s2.0-S0306452214002668-main.pdf?_tid=d3972cba-d7d4-11e6-a0bc-00000aab0f26&amp;acdnat=1484122156_535e73bc34d7dbf38382b76bbd6224d0</style></url></related-urls><pdf-urls><url>internal-pdf://1893149902/Yamazaki-2014-Sodium-glucose trans.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuroscience.2014.03.046</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>97</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">97</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, C.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author><author><style face="normal" font="default" size="100%">Li, H.</style></author><author><style face="normal" font="default" size="100%">Zhai, F.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Bian, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Radiology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Aquaporin-4 knockdown ameliorates hypoxic-ischemic cerebral edema in newborn piglets</style></title><secondary-title><style face="normal" font="default" size="100%">IUBMB Life</style></secondary-title><alt-title><style face="normal" font="default" size="100%">IUBMB life</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">IUBMB Life</style></full-title><abbr-1><style face="normal" font="default" size="100%">IUBMB life</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">IUBMB Life</style></full-title><abbr-1><style face="normal" font="default" size="100%">IUBMB life</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">182-90</style></pages><volume><style face="normal" font="default" size="100%">67</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2015/04/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Animals, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Aquaporin 4/ genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Behavior, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/ genetics/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Knockdown Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia-Ischemia, Brain/genetics/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">RNA Interference</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering</style></keyword><keyword><style face="normal" font="default" size="100%">Sus scrofa</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1521-6551 (Electronic)&#xD;1521-6543 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25857369</style></accession-num><abstract><style face="normal" font="default" size="100%">Emerging evidence indicates that the water channel protein aquaporin 4 (AQP4) plays an essential role in water homeostasis and is implicated in the pathogenesis of brain edema. This study aimed to understand the physiological role of AQP4 in hypoxia-ischemia-mediated cytotoxic brain edema. We specifically knocked down AQP4 expression by intracerebral injection of a plasmid containing AQP4 siRNA into a neonatal piglet model. The success of the hypoxia-ischemia-induced piglet model was confirmed by conventional magnetic resonance imaging and diffusion-weighted imaging. AQP4 knockdown led to reduced brain edema accompanied by a higher apparent diffusion coefficient value, compared to the control group injected with a plasmid containing scrambled siRNA. Real-time polymerase chain reaction and immunohistochemical analysis confirmed that AQP4 siRNA significantly reduced AQP4 mRNA and protein expression. Finally, neurological function analysis revealed that AQP4 knockdown significantly improved neurobehavioral manifestation of the piglets after exposure to hypoxia-ischemia. Taken together, these results indicate that AQP4 plays an important role in mediating brain edema in hypoxic-ischemic encephalopathy. Therefore, AQP4 could be a therapeutic target to ameliorate early-stage brain edema.</style></abstract><notes><style face="normal" font="default" size="100%">Yang, Chao&#xD;Liu, Zhengjuan&#xD;Li, Hongjie&#xD;Zhai, Fangbing&#xD;Liu, Jing&#xD;Bian, Jie&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;IUBMB Life. 2015 Mar;67(3):182-90. doi: 10.1002/iub.1356. Epub 2015 Apr 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1002/iub.1356/asset/iub1356.pdf?v=1&amp;t=ixsnwlfg&amp;s=3e78722a046c7b67e2ade7bc9109284066d8b64b</style></url></related-urls><pdf-urls><url>internal-pdf://0841889313/Yang-2015-Aquaporin-4 knockdow.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/iub.1356</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>64</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">64</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, F.</style></author><author><style face="normal" font="default" size="100%">Zhou, L.</style></author><author><style face="normal" font="default" size="100%">Wang, D.</style></author><author><style face="normal" font="default" size="100%">Wang, Z.</style></author><author><style face="normal" font="default" size="100%">Huang, Q. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathophysiology and High Altitude Pathology, College of High Altitude Military Medicine, Third Military Medical University, 30 Gaotanyan, Shapingba, Chongqing 400038, China; Key Laboratory of High Altitude Medicine (Third Military Medical University), Ministry of Education, China; Key Laboratory of High Altitude Medicine, PLA, China.&#xD;Department of Pharmacology, Xinqiao Hospital &amp; The Second Affiliated Hospital, The Third Military Medical University, Chongqing, China.&#xD;Department of Neurosurgery and Key Laboratory of Neurotrauma, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.&#xD;Department of Pathophysiology and High Altitude Pathology, College of High Altitude Military Medicine, Third Military Medical University, 30 Gaotanyan, Shapingba, Chongqing 400038, China; Key Laboratory of High Altitude Medicine (Third Military Medical University), Ministry of Education, China; Key Laboratory of High Altitude Medicine, PLA, China. Electronic address: huangqingyuan@tmmu.edu.cn.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Minocycline ameliorates hypoxia-induced blood-brain barrier damage by inhibition of HIF-1alpha through SIRT-3/PHD-2 degradation pathway</style></title><secondary-title><style face="normal" font="default" size="100%">Neuroscience</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">250-9</style></pages><volume><style face="normal" font="default" size="100%">304</style></volume><edition><style face="normal" font="default" size="100%">2015/07/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/drug effects/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Hypoxia/ drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelial Cells/drug effects/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Knockdown Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia, Brain/ drug therapy/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia-Inducible Factor 1, alpha Subunit/ antagonists &amp; inhibitors/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia-Inducible Factor-Proline Dioxygenases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Minocycline/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Procollagen-Proline Dioxygenase/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Sirtuin 3/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Sirtuins/genetics/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 24</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1873-7544 (Electronic)&#xD;0306-4522 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26211444</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Minocycline, a second-generation tetracycline alleviates neuro-inflammation and protects the blood-brain barrier (BBB) in ischemia stroke. However, the effect of minocycline in hypoxia-induced BBB damage is unclear. Here, we have investigated the effect of minocycline under hypoxia and explored its possible underlying mechanisms. METHODS: The effect of minocycline was examined in vitro in Human Brain Microvascular Endothelial Cells (HBMECs) using Trans Epithelial Electric Resistance (TEER). Protein and mRNA expression of Hypoxia-Inducible Factors-1alpha (HIF-1alpha), matrix metalloproteinases (MMP-2 and MMP-9) and tight junction proteins (TJs) were detected by using Western blot and quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The translocation and transcription of HIF-1alpha were detected by using immunocytochemistry and luciferase reporter assay. In vivo, to adult male Sprague Dawley (SD) rats under hypobaric hypoxia were administered minocycline for 1h and BBB permeability was tested by using Evans Blue and Transmission Electron Microscopy (TEM). Also, reduction of NAD-dependent deacetylase sirtuin-3 (SIRT-3)/proline hydroxylase-2 (PHD-2) signaling pathway was evaluated. RESULTS: Minocycline increased TEER in HBMECs after hypoxia (P&lt;0.05), and reduced the extravasation of Evans Blue (P&lt;0.05) and colloidal gold nanoparticles in rats. Minocycline administration significantly reduced HIF-1alpha expression, protein and mRNA expression of MMP-2, MMP-9 and Vascular Endothelial Growth Factor (VEGF) (P&lt;0.05), and increased TJs (ZO-1, claudin-5 and occluding) (P&lt;0.05) in HBMECs after hypoxia. Furthermore, minocycline reversed the hypoxia-induced reduction of PHD-2 (P&lt;0.05) and SIRT-3 (P&lt;0.05). Effects of minocycline were abolished by siRNA-mediated knockdown of SIRT-3 in the brain. CONCLUSIONS: Minocycline inhibits HIF-1alpha-mediated cellular responses and protects BBB integrity through SIRT-3/PHD-2 pathway, proving to be a potential drug for the prevention and treatment of hypoxic brain injuries.</style></abstract><notes><style face="normal" font="default" size="100%">Yang, F&#xD;Zhou, L&#xD;Wang, D&#xD;Wang, Z&#xD;Huang, Q-Y&#xD;United States&#xD;Neuroscience. 2015 Sep 24;304:250-9. doi: 10.1016/j.neuroscience.2015.07.051. Epub 2015 Jul 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S030645221500665X/1-s2.0-S030645221500665X-main.pdf?_tid=da057db8-d7d4-11e6-b657-00000aab0f02&amp;acdnat=1484122167_86403ce059ecfa11a40e737db13ab4fd</style></url></related-urls><pdf-urls><url>internal-pdf://3076282386/Yang-2015-Minocycline ameliora.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuroscience.2015.07.051</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>363</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">363</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, J.</style></author><author><style face="normal" font="default" size="100%">Ahn, H. N.</style></author><author><style face="normal" font="default" size="100%">Chang, M.</style></author><author><style face="normal" font="default" size="100%">Narasimhan, P.</style></author><author><style face="normal" font="default" size="100%">Chan, P. H.</style></author><author><style face="normal" font="default" size="100%">Song, Y. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacology, College of Pharmacy, Sookmyung Women&apos;s University, Seoul, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Complement component 3 inhibition by an antioxidant is neuroprotective after cerebral ischemia and reperfusion in mice</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurochem</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neurochemistry</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurochem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurochemistry</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurochem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurochemistry</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">523-35</style></pages><volume><style face="normal" font="default" size="100%">124</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2012/12/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/drug effects/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/blood/complications/ drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Survival/drug effects/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/cytology</style></keyword><keyword><style face="normal" font="default" size="100%">Complement C3/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclic N-Oxides/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclooxygenase 2/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Down-Regulation/drug effects/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose/deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia</style></keyword><keyword><style face="normal" font="default" size="100%">L-Lactate Dehydrogenase/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Nervous System Diseases/etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroglia/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/ drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative Stress/drug effects/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Reactive Oxygen Species/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Superoxide Dismutase/deficiency/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Superoxide Dismutase-1</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation/drug effects/ physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1471-4159 (Electronic)&#xD;0022-3042 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23199288</style></accession-num><abstract><style face="normal" font="default" size="100%">Oxidative stress after stroke is associated with the inflammatory system activation in the brain. The complement cascade, especially the degradation products of complement component 3, is a key inflammatory mediator of cerebral ischemia. We have shown that pro-inflammatory complement component 3 is increased by oxidative stress after ischemic stroke in mice using DNA array. In this study, we investigated whether up-regulation of complement component 3 is directly related to oxidative stress after transient focal cerebral ischemia in mice and oxygen-glucose deprivation in brain cells. Persistent up-regulation of complement component 3 expression was reduced in copper/zinc-superoxide dismutase transgenic mice, and manganese-superoxide dismutase knock-out mice showed highly increased complement component 3 levels after transient focal cerebral ischemia. Antioxidant N-tert-butyl-alpha-phenylnitrone treatment suppressed complement component 3 expression after transient focal cerebral ischemia. Accumulation of complement component 3 in neurons and microglia was decreased by N-tert-butyl-alpha-phenylnitrone, which reduced infarct volume and impaired neurological deficiency after cerebral ischemia and reperfusion in mice. Small interfering RNA specific for complement component 3 transfection showed a significant increase in brain cells viability after oxygen-glucose deprivation. Our study suggests that the neuroprotective effect of antioxidants through complement component 3 suppression is a new strategy for potential therapeutic approaches in stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Yang, Jiwon&#xD;Ahn, Hye-Na&#xD;Chang, Minsun&#xD;Narasimhan, Purnima&#xD;Chan, Pak H&#xD;Song, Yun Seon&#xD;P01 NS014543/NS/NINDS NIH HHS/United States&#xD;R01 NS025372/NS/NINDS NIH HHS/United States&#xD;R01 NS038653/NS/NINDS NIH HHS/United States&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Neurochem. 2013 Feb;124(4):523-35. doi: 10.1111/jnc.12111. Epub 2012 Dec 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/jnc.12111/asset/jnc12111.pdf?v=1&amp;t=ixsnwtqz&amp;s=785c1c8fa8cfed847b5ea37fd09ba53d4e841d35</style></url></related-urls><pdf-urls><url>internal-pdf://3023266149/Yang-2013-Complement component.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3557607</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms425437</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/jnc.12111</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>172</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">172</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, L.</style></author><author><style face="normal" font="default" size="100%">Kan, E. M.</style></author><author><style face="normal" font="default" size="100%">Lu, J.</style></author><author><style face="normal" font="default" size="100%">Wu, C.</style></author><author><style face="normal" font="default" size="100%">Ling, E. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore. antlea@nus.edu.sg.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Expression of 2&apos;,3&apos;-cyclic nucleotide 3&apos;-phosphodiesterase (CNPase) and its roles in activated microglia in vivo and in vitro</style></title><secondary-title><style face="normal" font="default" size="100%">J Neuroinflammation</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neuroinflammation</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neuroinflammation</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroinflammation</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neuroinflammation</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neuroinflammation</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">148</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><edition><style face="normal" font="default" size="100%">2014/08/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">2&apos;,3&apos;-Cyclic-Nucleotide Phosphodiesterases/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Animals, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/etiology/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Cycle/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation, Enzymologic/drug effects/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Lipopolysaccharides/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Microglia/drug effects/ enzymology</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide Synthase Type II/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/genetics/metabolism/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 23</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1742-2094 (Electronic)&#xD;1742-2094 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25148928</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: We reported previously that amoeboid microglial cells in the postnatal rat brain expressed 2&apos;,3&apos;-cyclic nucleotide 3&apos;-phosphodiesterase (CNPase) both in vivo and in vitro; however, the functional role of CNPase in microglia has remained uncertain. This study extended the investigation to determine CNPase expression in activated microglia derived from cell culture and animal models of brain injury with the objective to clarify its putative functions. METHODS: Three-day-old Wistar rats were given an intraperitoneal injection of lipopolysaccharide to induce microglial activation, and the rats were killed at different time points. Along with this, primary cultured microglial cells were subjected to lipopolysaccharide treatment, and expression of CNPase was analyzed by real-time reverse transcription PCR and immunofluorescence. Additionally, siRNA transfection was employed to downregulate CNPase in BV-2 cells. Following this, inducible nitric oxide synthase, IL-1beta and TNF-alpha were determined at mRNA and protein levels. Reactive oxygen species and nitric oxide were also assessed by flow cytometry and colorimetric assay, respectively. In parallel to this, CNPase expression in activated microglia was also investigated in adult rats subjected to fluid percussion injury as well as middle cerebral artery occlusion. RESULTS: In vivo, CNPase immunofluorescence in activated microglia was markedly enhanced after lipopolysaccharide treatment. A similar feature was observed in the rat brain after fluid percussion injury and middle cerebral artery occlusion. In vitro, CNPase protein and mRNA expression was increased in primary microglia with lipopolysaccharide stimulation. Remarkably, inducible nitric oxide synthase, IL-1beta, TNF-alpha, reactive oxygen species and nitric oxide were significantly upregulated in activated BV-2 cells with CNPase knockdown. siRNA knockdown of CNPase increased microglia migration; on the other hand, microglial cells appeared to be arrested at G1 phase. CONCLUSIONS: The present results have provided the first morphological and molecular evidence that CNPase expression is increased in activated microglia. CNPase knockdown resulted in increased expression of various inflammatory mediators. It is concluded that CNPase may play an important role as a putative anti-inflammatory gene both in normal and injured brain.</style></abstract><notes><style face="normal" font="default" size="100%">Yang, Lijuan&#xD;Kan, Enci Mary&#xD;Lu, Jia&#xD;Wu, Chunyun&#xD;Ling, Eng-Ang&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Neuroinflammation. 2014 Aug 23;11:148. doi: 10.1186/s12974-014-0148-9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/234/art%253A10.1186%252Fs12974-014-0148-9.pdf?originUrl=http%3A%2F%2Fjneuroinflammation.biomedcentral.com%2Farticle%2F10.1186%2Fs12974-014-0148-9&amp;token2=exp=1484122294~acl=%2Fstatic%2Fpdf%2F234%2Fart%25253A10.1186%25252Fs12974-014-0148-9.pdf*~hmac=8fd1421c0ec97f085c6521d86f672d4493d52d74d50fac5a5a357aa1bf445410</style></url></related-urls><pdf-urls><url>internal-pdf://0516389504/Yang-2014-Expression of 2&apos;,3&apos;-.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4244045</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12974-014-0148-9</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>237</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">237</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, W.</style></author><author><style face="normal" font="default" size="100%">Sheng, H.</style></author><author><style face="normal" font="default" size="100%">Thompson, J. W.</style></author><author><style face="normal" font="default" size="100%">Zhao, S.</style></author><author><style face="normal" font="default" size="100%">Wang, L.</style></author><author><style face="normal" font="default" size="100%">Miao, P.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Moseley, M. A.</style></author><author><style face="normal" font="default" size="100%">Paschen, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From the Department of Anesthesiology (W.Y., H.S., L.W., P.M., X.L., W.P.), Proteomics Core Facility (J.W.T., M.A.M.), and Department of Neurobiology (S.Z.), Duke University Medical Center, Durham, NC; and Department of Neurosurgery, The Fifth Central Hospital of Tianjin, Tianjin, China (X.L.).</style></auth-address><titles><title><style face="normal" font="default" size="100%">Small ubiquitin-like modifier 3-modified proteome regulated by brain ischemia in novel small ubiquitin-like modifier transgenic mice: putative protective proteins/pathways</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1115-22</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2014/02/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/genetics/metabolism/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Attack, Transient/genetics/metabolism/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Mass Spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Proteome/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">RNA Processing, Post-Transcriptional</style></keyword><keyword><style face="normal" font="default" size="100%">SUMO-1 Protein/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Small Ubiquitin-Related Modifier Proteins/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/genetics/metabolism/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Ubiquitins/ genetics/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24569813</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: Small ubiquitin-like modifier (SUMO) conjugation is a post-translational modification associated with many human diseases. Characterization of the SUMO-modified proteome is pivotal to define the mechanistic link between SUMO conjugation and such diseases. This is particularly evident for SUMO2/3 conjugation, which is massively activated after brain ischemia/stroke, and is believed to be a protective response. The purpose of this study was to perform a comprehensive analysis of the SUMO3-modified proteome regulated by brain ischemia using a novel SUMO transgenic mouse. METHODS: To enable SUMO proteomics analysis in vivo, we generated transgenic mice conditionally expressing tagged SUMO1-3 paralogues. Transgenic mice were subjected to 10 minutes forebrain ischemia and 1 hour of reperfusion. SUMO3-conjugated proteins were enriched by anti-FLAG affinity purification and analyzed by liquid chromatography-tandem mass spectrometry. RESULTS: Characterization of SUMO transgenic mice demonstrated that all 3 tagged SUMO paralogues were functionally active, and expression of exogenous SUMOs did not modify the endogenous SUMOylation machinery. Proteomics analysis identified 112 putative SUMO3 substrates of which 91 candidates were more abundant in the ischemia group than the sham group. Data analysis revealed processes/pathways with putative neuroprotective functions, including glucocorticoid receptor signaling, RNA processing, and SUMOylation-dependent ubiquitin conjugation. CONCLUSIONS: The identified proteins/pathways modulated by SUMOylation could be the key to understand the mechanisms linking SUMOylation to neuroprotection, and thus provide new promising targets for therapeutic interventions. The new transgenic mouse will be an invaluable platform for analyzing the SUMO-modified proteome in models of human disorders and thereby help to mechanistically link SUMOylation to the pathological processes.</style></abstract><notes><style face="normal" font="default" size="100%">Yang, Wei&#xD;Sheng, Huaxin&#xD;Thompson, J Will&#xD;Zhao, Shengli&#xD;Wang, Liangli&#xD;Miao, Pei&#xD;Liu, Xiaozhi&#xD;Moseley, M Arthur&#xD;Paschen, Wulf&#xD;R01 HL095552/HL/NHLBI NIH HHS/United States&#xD;R01 NS081299/NS/NINDS NIH HHS/United States&#xD;HL095552/HL/NHLBI NIH HHS/United States&#xD;NS081299/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Stroke. 2014 Apr;45(4):1115-22. doi: 10.1161/STROKEAHA.113.004315. Epub 2014 Feb 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/45/4/1115.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0872890680/Yang-2014-Small ubiquitin-like.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3966925</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms561672</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.113.004315</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>478</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">478</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, Y.</style></author><author><style face="normal" font="default" size="100%">Rosenberg, G. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, University of New Mexico, Albuquerque, NM 87107, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Blood-brain barrier breakdown in acute and chronic cerebrovascular disease</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">3323-8</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2011/09/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Acute Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/ metabolism/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Capillary Permeability/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Disorders/ metabolism/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">21940972</style></accession-num><abstract><style face="normal" font="default" size="100%">Disruptions of the blood-brain barrier (BBB) and edema formation both play key roles in the development of neurological dysfunction in acute and chronic cerebral ischemia. Animal studies have revealed the molecular cascades that are initiated with hypoxia/ischemia in the cells forming the neurovascular unit and that contribute to cell death. Matrix metalloproteinases cause reversible degradation of tight junction proteins early after the onset of ischemia, and a delayed secondary opening during a neuroinflammatory response occurring from 24 to 72 hours after. Cyclooxygenases are important in the delayed opening as the neuroinflammatory response progresses. An early opening of the BBB within the 3-hour therapeutic window for tissue-type plasminogen activator can allow it to enter the brain and increase the risk of hemorrhage. Chronic hypoxic hypoperfusion opens the BBB, which contributes to the cognitive changes seen with lacunar strokes and white matter injury in subcortical ischemic vascular disease. This review will describe the molecular and cellular events associated with BBB disruption and potential therapies directed toward restoring the integrity of the neurovascular unit.</style></abstract><notes><style face="normal" font="default" size="100%">Yang, Yi&#xD;Rosenberg, Gary A&#xD;R21NS066418/NS/NINDS NIH HHS/United States&#xD;R01 NS052305/NS/NINDS NIH HHS/United States&#xD;R01 NS045847/NS/NINDS NIH HHS/United States&#xD;R01 NS021169/NS/NINDS NIH HHS/United States&#xD;R21 NS066418/NS/NINDS NIH HHS/United States&#xD;R21 NS066418-01/NS/NINDS NIH HHS/United States&#xD;R01 NS052305-01/NS/NINDS NIH HHS/United States&#xD;R01 NS021169-11/NS/NINDS NIH HHS/United States&#xD;R01NS045847/NS/NINDS NIH HHS/United States&#xD;R01 NS045847-01/NS/NINDS NIH HHS/United States&#xD;R01NS052305/NS/NINDS NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;United States&#xD;Stroke. 2011 Nov;42(11):3323-8. doi: 10.1161/STROKEAHA.110.608257. Epub 2011 Sep 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/42/11/3323.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3846987088/Yang-2011-Blood-brain barrier.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3584169</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms325716</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.110.608257</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>83</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">83</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Fan, C.</style></author><author><style face="normal" font="default" size="100%">Jiang, S.</style></author><author><style face="normal" font="default" size="100%">Zhao, L.</style></author><author><style face="normal" font="default" size="100%">Di, S.</style></author><author><style face="normal" font="default" size="100%">Xin, Z.</style></author><author><style face="normal" font="default" size="100%">Wang, B.</style></author><author><style face="normal" font="default" size="100%">Wu, G.</style></author><author><style face="normal" font="default" size="100%">Li, X.</style></author><author><style face="normal" font="default" size="100%">Li, Z.</style></author><author><style face="normal" font="default" size="100%">Gao, X.</style></author><author><style face="normal" font="default" size="100%">Dong, Y.</style></author><author><style face="normal" font="default" size="100%">Qu, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Xijing Hospital, The Fourth Military Medical University, 127 Changle West Road, Xi&apos;an, 710032, China.&#xD;Department of Biomedical Engineering, The Fourth Military Medical University, 169 Changle West Road, Xi&apos;an, 710032, China.&#xD;Department of Air Logistics, The 463rd Hospital of PLA, 46 Xiaoheyan Road, Shenyang, 110042, China.&#xD;Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University, 1 Xinsi Road, Xi&apos;an, 710038, China.&#xD;Department of Neurosurgery, General Hospital of Shenyang Military Area Command, 83 Wenhua Road, Shenyang, 110016, China.&#xD;Department of Neurosurgery, General Hospital of Shenyang Military Area Command, 83 Wenhua Road, Shenyang, 110016, China. yushudong111@126.com.&#xD;Department of Neurosurgery, Xijing Hospital, The Fourth Military Medical University, 127 Changle West Road, Xi&apos;an, 710032, China. yanqu1974@126.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">HO-1 Signaling Activation by Pterostilbene Treatment Attenuates Mitochondrial Oxidative Damage Induced by Cerebral Ischemia Reperfusion Injury</style></title><secondary-title><style face="normal" font="default" size="100%">Mol Neurobiol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Molecular neurobiology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Mol Neurobiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Molecular neurobiology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Mol Neurobiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Molecular neurobiology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">2339-53</style></pages><volume><style face="normal" font="default" size="100%">53</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2015/05/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/drug effects/enzymology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/complications/drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/complications/ drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Line</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Survival/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Glutathione Transferase/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Heme Oxygenase-1/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Ions</style></keyword><keyword><style face="normal" font="default" size="100%">L-Lactate Dehydrogenase/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mitochondria/drug effects/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">NAD(P)H Dehydrogenase (Quinone)/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative Stress/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Protoporphyrins/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/complications/ drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Stilbenes/pharmacology/ therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-1182 (Electronic)&#xD;0893-7648 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25983033</style></accession-num><abstract><style face="normal" font="default" size="100%">Ischemia reperfusion (IR) injury (IRI) is harmful to the cerebral system and causes mitochondrial oxidative stress. The antioxidant response element (ARE)-mediated antioxidant pathway plays an important role in maintaining the redox status of the brain. Heme oxygenase-1 (HO-1), combined with potent AREs in the promoter of HO-1, is a highly effective therapeutic target for protection against cerebral IRI. Pterostilbene (PTE), a natural dimethylated analog of resveratrol from blueberries, is a strong natural antioxidant. PTE has been shown to be beneficial for some nervous system diseases and may regulate HO-1 signaling. This study was designed to investigate the protective effects of PTE on cerebral IRI and to elucidate potential mechanisms underlying those effects. Mouse brains and cultured HT22 neuron cells were subjected to IRI. Prior to this procedure, the brains or cells were exposed to PTE in the absence or presence of the HO-1 inhibitor ZnPP or HO-1 small interfering RNA (siRNA). PTE conferred a cerebral protective effect, as shown by increased neurological scores, viable neurons and decreased brain edema as well as a decreased ion content and apoptotic ratio in vivo. PTE also increased the cell viability and decreased the lactate dehydrogenase (LDH) leakage and apoptotic ratio in vitro. ZnPP and HO-1 siRNA both blocked PTE-mediated cerebral protection by inhibiting HO-1 signaling and further inhibited two HO-1 signaling-related antioxidant molecules: NAD(P)H: quinone oxidoreductase 1 (NQO1) and glutathione S-transferases (GSTs), which are induced by PTE. PTE also promoted a well-preserved mitochondrial membrane potential (MMP), mitochondria complex I activity, and mitochondria complex IV activity, increased the mitochondrial cytochrome c level, and decreased the cytosolic cytochrome c level. However, this PTE-elevated mitochondrial function was reversed by ZnPP or HO-1 siRNA treatment. In summary, our results demonstrate that PTE treatment attenuates cerebral IRI by reducing IR-induced mitochondrial oxidative damage through the activation of HO-1 signaling.</style></abstract><notes><style face="normal" font="default" size="100%">Yang, Yang&#xD;Wang, Jiayi&#xD;Li, Yue&#xD;Fan, Chongxi&#xD;Jiang, Shuai&#xD;Zhao, Lei&#xD;Di, Shouyin&#xD;Xin, Zhenlong&#xD;Wang, Bodong&#xD;Wu, Guiling&#xD;Li, Xia&#xD;Li, Zhiqing&#xD;Gao, Xu&#xD;Dong, Yushu&#xD;Qu, Yan&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Mol Neurobiol. 2016 May;53(4):2339-53. doi: 10.1007/s12035-015-9194-2. Epub 2015 May 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/191/art%253A10.1007%252Fs12035-015-9194-2.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12035-015-9194-2&amp;token2=exp=1484123202~acl=%2Fstatic%2Fpdf%2F191%2Fart%25253A10.1007%25252Fs12035-015-9194-2.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs12035-015-9194-2*~hmac=f3833479cb72138accc6e7a8074f378bccaa3f0440c873564aebd5446f86a7db</style></url></related-urls><pdf-urls><url>internal-pdf://2345047688/Yang-2016-HO-1 Signaling Activ.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12035-015-9194-2</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>144</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">144</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, Y. Q.</style></author><author><style face="normal" font="default" size="100%">Li, H.</style></author><author><style face="normal" font="default" size="100%">Zhang, X.</style></author><author><style face="normal" font="default" size="100%">Wang, C. X.</style></author><author><style face="normal" font="default" size="100%">Sun, Q.</style></author><author><style face="normal" font="default" size="100%">Li, S.</style></author><author><style face="normal" font="default" size="100%">Li, W.</style></author><author><style face="normal" font="default" size="100%">Li, W.</style></author><author><style face="normal" font="default" size="100%">Ding, K.</style></author><author><style face="normal" font="default" size="100%">Liu, M.</style></author><author><style face="normal" font="default" size="100%">Yu, Z.</style></author><author><style face="normal" font="default" size="100%">Hang, C. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Jinling Hospital, School of Medicine, Nanjing University, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu Province, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Expression and cell distribution of SENP3 in the cerebral cortex after experimental subarachnoid hemorrhage in rats: a pilot study</style></title><secondary-title><style face="normal" font="default" size="100%">Cell Mol Neurobiol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Cellular and molecular neurobiology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cell Mol Neurobiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Cellular and molecular neurobiology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Cell Mol Neurobiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Cellular and molecular neurobiology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">407-16</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2014/11/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/ chemistry/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Endopeptidases/ analysis/ biosynthesis</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Pilot Projects</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Subarachnoid Hemorrhage/ metabolism/pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1573-6830 (Electronic)&#xD;0272-4340 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25423917</style></accession-num><abstract><style face="normal" font="default" size="100%">Subarachnoid hemorrhage (SAH) is one of the life-threatening diseases with high morbidity and mortality rates. Small ubiquitin-like modifier (SUMO)-specific proteases 3 (SENP3), a member of the SUMO-specific protease family, was identified as an isopeptidase that deconjugates SUMOylation (The covalent modification by SUMO) of modified protein substrates. It is reported that SUMO-2/3 conjugation, a member of SUMOylation, presented neuroprotection. The study aimed to evaluate the expression of SENP3 and to explore its role potential role in SAH. A total of 95 Sprague-Dawley rats were randomly divided into sham group and SAH groups at 6, 12, 24, 48 h, day 3, day 5, and day 7. SAH groups suffered experimental SAH by injection with 0.3 ml nonheparinized autoblood into the prechiasmatic cistern. SENP3 expression is surveyed by western blot analysis, real-time polymerase chain reaction, immunohistochemistry, and immunofluorescence. The levels of cleavage caspase-3 were determined by western blot and immunohistochemistry. SENP3 protein expression was significantly up-regulated after SAH which peaked at 24 h; however, the mRNA expression of SENP3 remained unchanged. Meanwhile, the level of cleaved caspase-3 was also increased after SAH. There is a highly positive correlation between cleavage caspase-3 and SENP3 in protein level. Immunofluorescent results showed that the expression of SENP3 was increased in neurons, rather than astrocytes nor microglia. Our findings indicated a possible role of SENP3 in the pathogenesis of early brain injury mediated by apoptosis following SAH.</style></abstract><notes><style face="normal" font="default" size="100%">Yang, Yi-qing&#xD;Li, Hua&#xD;Zhang, Xiangsheng&#xD;Wang, Chun-xi&#xD;Sun, Qing&#xD;Li, Song&#xD;Li, Weide&#xD;Li, Wei&#xD;Ding, Ke&#xD;Liu, Ming&#xD;Yu, Zhuang&#xD;Hang, Chun-hua&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Cell Mol Neurobiol. 2015 Apr;35(3):407-16. doi: 10.1007/s10571-014-0136-8. Epub 2014 Nov 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/38/art%253A10.1007%252Fs10571-014-0136-8.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs10571-014-0136-8&amp;token2=exp=1484123208~acl=%2Fstatic%2Fpdf%2F38%2Fart%25253A10.1007%25252Fs10571-014-0136-8.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs10571-014-0136-8*~hmac=6860dc2478c7e701680cb551853a49720319ac22f13c3b2f0e538667f20a9093</style></url></related-urls><pdf-urls><url>internal-pdf://3475942364/Yang-2015-Expression and cell.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s10571-014-0136-8</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>71</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">71</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, Y. Q.</style></author><author><style face="normal" font="default" size="100%">Li, H.</style></author><author><style face="normal" font="default" size="100%">Zhang, X. S.</style></author><author><style face="normal" font="default" size="100%">Li, W.</style></author><author><style face="normal" font="default" size="100%">Huang, L. T.</style></author><author><style face="normal" font="default" size="100%">Yu, Z.</style></author><author><style face="normal" font="default" size="100%">Jiang, T. W.</style></author><author><style face="normal" font="default" size="100%">Chen, Q.</style></author><author><style face="normal" font="default" size="100%">Hang, C. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu Province, China.&#xD;Department of Neurosurgery, Jinling Hospital, School of Medicine, Southern Medical University, Guangzhou, China.&#xD;Department of Neurosurgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu Province, China. Electronic address: hang_neurosurgery@163.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inhibition of SENP3 by lentivirus induces suppression of apoptosis in experimental subarachnoid hemorrhage in rats</style></title><secondary-title><style face="normal" font="default" size="100%">Brain Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">270-8</style></pages><volume><style face="normal" font="default" size="100%">1622</style></volume><edition><style face="normal" font="default" size="100%">2015/07/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Caspase 3/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Endopeptidases/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Vectors</style></keyword><keyword><style face="normal" font="default" size="100%">Glutathione/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lentivirus/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Malondialdehyde/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative Stress/genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Subarachnoid Hemorrhage/pathology/ physiopathology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Superoxide Dismutase/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 05</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-6240 (Electronic)&#xD;0006-8993 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26151898</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Subarachnoid hemorrhage (SAH) is one of the life-threatening diseases with high morbidity and mortality rates. SUMO-specific proteases 3 (SENP3), a member of the small ubiquitin-like modifier specific protease family, was identified as an isopeptidase that deconjugates SUMOylation (The covalent modification by SUMO) of modified protein substrates. It is reported that SUMO-2/3 conjugation, a member of SUMOylation, presented neuroprotection. The study aimed to evaluate the expression of SENP3 and to explore its potential role in SAH. MATERIALS AND METHODS: A total of 108 Sprague Dawley (SD) rats were randomly divided into 2 parts experiment and 9 subgroups (part 1:Sham group, SAH group, SAH+NAC group, SAH+vehicle group; part 2: Sham group, SAH group, SAH+lv-SENP3 group, SAH+lv-null group, SAH+NS group). 7 days before SAH, lentivirus was administrated into rats left lateral ventricle to down-regulate SENP3. Experimental SAH was imitated by injection with 0.3ml nonheparinized autoblood into the prechiasmatic cistern. MDA levels, SOD activities, and GSH contents were detected to evaluate oxidative stress level. SENP3 and cleaved caspase 3 were detected by western blot, apoptosis was observed by TUNEL staining. RESULTS: High oxidative stress level following SAH induced rising of SENP3. And inhibition of SENP3 by lentivirus induces suppression of apoptosis in experimental subarachnoid hemorrhage in rats. CONCLUSION: When SENP3 accumulated by high oxidative stress, caspase 3 activated subsequently. And it leads to more severe apoptosis than physiological.</style></abstract><notes><style face="normal" font="default" size="100%">Yang, Yi-Qing&#xD;Li, Hua&#xD;Zhang, Xiang-Sheng&#xD;Li, Wei&#xD;Huang, Li-Tian&#xD;Yu, Zhuang&#xD;Jiang, Tian-Wei&#xD;Chen, Qiang&#xD;Hang, Chun-Hua&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;Brain Res. 2015 Oct 5;1622:270-8. doi: 10.1016/j.brainres.2015.06.032. Epub 2015 Jul 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S000689931500503X/1-s2.0-S000689931500503X-main.pdf?_tid=e72b6fa2-d7d4-11e6-918b-00000aab0f27&amp;acdnat=1484122189_94d5a42524475f0700cfe800eb188651</style></url></related-urls><pdf-urls><url>internal-pdf://1055438080/Yang-2015-Inhibition of SENP3.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.brainres.2015.06.032</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>255</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">255</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yannopoulos, F. S.</style></author><author><style face="normal" font="default" size="100%">Arvola, O.</style></author><author><style face="normal" font="default" size="100%">Haapanen, H.</style></author><author><style face="normal" font="default" size="100%">Herajarvi, J.</style></author><author><style face="normal" font="default" size="100%">Miinalainen, I.</style></author><author><style face="normal" font="default" size="100%">Jensen, H.</style></author><author><style face="normal" font="default" size="100%">Kiviluoma, K.</style></author><author><style face="normal" font="default" size="100%">Juvonen, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Surgery, Oulu University Hospital, Oulu, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Leg ischaemia before circulatory arrest alters brain leucocyte count and respiratory chain redox state</style></title><secondary-title><style face="normal" font="default" size="100%">Interact Cardiovasc Thorac Surg</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Interactive cardiovascular and thoracic surgery</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Interact Cardiovasc Thorac Surg</style></full-title><abbr-1><style face="normal" font="default" size="100%">Interactive cardiovascular and thoracic surgery</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Interact Cardiovasc Thorac Surg</style></full-title><abbr-1><style face="normal" font="default" size="100%">Interactive cardiovascular and thoracic surgery</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">272-7</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2013/12/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ blood supply/metabolism/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/etiology/metabolism/pathology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Adhesion</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Electron Transport</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Arrest, Induced</style></keyword><keyword><style face="normal" font="default" size="100%">Hypothermia</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Preconditioning/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte Count</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte Rolling</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Lower Extremity/ blood supply</style></keyword><keyword><style face="normal" font="default" size="100%">Microcirculation</style></keyword><keyword><style face="normal" font="default" size="100%">Microscopy, Electron, Transmission</style></keyword><keyword><style face="normal" font="default" size="100%">Mitochondria/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidation-Reduction</style></keyword><keyword><style face="normal" font="default" size="100%">Regional Blood Flow</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/etiology/metabolism/pathology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Swine</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1569-9285 (Electronic)&#xD;1569-9285 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24343749</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVES: Remote ischaemic preconditioning and its neuroprotective abilities are currently under investigation and the method has shown significant effects in several small and large animal studies. In our previous studies, leucocyte filtration during cardiopulmonary bypass reduced cerebrocortical adherent leucocyte count and mitigated cerebral damage after hypothermic circulatory arrest (HCA) in piglets. This study aimed to obtain and assess direct visual data of leucocyte behaviour in cerebral vessels after hypothermic circulatory arrest following remote ischaemic preconditioning. METHODS: Twelve native stock piglets were randomized into a remote ischaemic preconditioning group (n = 6) and a control group (n = 6). The intervention group underwent hind-leg ischaemia, whereas the control group received a sham-treatment before a 60-min period of hypothermic circulatory arrest. An intravital microscope was used to obtain measurements from the cerebrocortical vessel in vivo. It included three sets of filters: a violet filter to visualize microvascular perfusion and vessel diameter, a green filter for visualization of rhodamine-labelled leucocytes and an ultraviolet filter for reduced nicotinamide adenine dinucleotide (NADH) analysis. The final magnification on the microscope was 400. After the experiment, cerebral and cerebellar biopsies were collected and analysed with transmission electron microscope by a blinded analyst. RESULTS: In the transmission electron microscope analysis, the entire intervention group had normal, unaffected rough endoplasmic reticulum&apos;s in their cerebellar tissue, whereas the control group had a mean score of 1.06 (standard deviation 0.41) (P = 0.026). The measured amount of adherent leucocytes was lower in the remote ischaemic preconditioning group. The difference was statistically significant at 5, 15 and 45 min after circulatory arrest. Statistically significant differences were seen also in the recovery phase at 90 and 120 min after reperfusion. Nicotinamide adenine dinucleotide autofluorescence had statistically significant differences at 10 min after cooling and at 120 and 180 min after hypothermic circulatory arrest. CONCLUSIONS: Remote ischaemic preconditioning seems to provide better mitochondrial respiratory chain function as indicated by the higher NADH content. It simultaneously provides a reduction of adherent leucocytes in cerebral vessels after hypothermic circulatory arrest. Additionally, it might provide some degree of cellular organ preservation as implied by the electron microscopy results.</style></abstract><notes><style face="normal" font="default" size="100%">Yannopoulos, Fredrik S&#xD;Arvola, Oiva&#xD;Haapanen, Henri&#xD;Herajarvi, Johanna&#xD;Miinalainen, Ilkka&#xD;Jensen, Hanna&#xD;Kiviluoma, Kai&#xD;Juvonen, Tatu&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Interact Cardiovasc Thorac Surg. 2014 Mar;18(3):272-7. doi: 10.1093/icvts/ivt415. Epub 2013 Dec 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://icvts.oxfordjournals.org/content/18/3/272.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://4287814999/Yannopoulos-2014-Leg ischaemia before.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3930203</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/icvts/ivt415</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>135</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">135</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yemisci, M.</style></author><author><style face="normal" font="default" size="100%">Caban, S.</style></author><author><style face="normal" font="default" size="100%">Gursoy-Ozdemir, Y.</style></author><author><style face="normal" font="default" size="100%">Lule, S.</style></author><author><style face="normal" font="default" size="100%">Novoa-Carballal, R.</style></author><author><style face="normal" font="default" size="100%">Riguera, R.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Megia, E.</style></author><author><style face="normal" font="default" size="100%">Andrieux, K.</style></author><author><style face="normal" font="default" size="100%">Couvreur, P.</style></author><author><style face="normal" font="default" size="100%">Capan, Y.</style></author><author><style face="normal" font="default" size="100%">Dalkara, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Faculty of Medicine, Institute of Neurological Sciences and Psychiatry, Hacettepe University, Ankara, Turkey.&#xD;Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.&#xD;Department of Organic Chemistry and Center for Research in Biological Chemistry and Molecular Materials (CIQUS), University of Santiago de Compostela, Santiago de Compostela, Spain.&#xD;Institut Galien Paris-Sud UMR CNRS 8612, Faculty of Pharmacy, University of Paris-Sud XI, Chatenay-Malabry, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Systemically administered brain-targeted nanoparticles transport peptides across the blood-brain barrier and provide neuroprotection</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">469-75</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2014/12/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier</style></keyword><keyword><style face="normal" font="default" size="100%">Fibroblast Growth Factor 2/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Nanoconjugates/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Oligopeptides/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ pathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25492116</style></accession-num><abstract><style face="normal" font="default" size="100%">Although growth factors and anti-apoptotic peptides have been shown to be neuroprotective in stroke models, translation of these experimental findings to clinic is hampered by limited penetration of peptides to the brain. Here, we show that a large peptide like the basic fibroblast growth factor (bFGF) and a small peptide inhibitor of caspase-3 (z-DEVD-FMK) can effectively be transported to the brain after systemic administration by incorporating these peptides to brain-targeted nanoparticles (NPs). Chitosan NPs were loaded with peptides and then functionalized by conjugating with antibodies directed against the transferrin receptor-1 on brain endothelia to induce receptor-mediated transcytosis across the blood-brain barrier (BBB). Pre-ischemic systemic administration of bFGF- or z-DEVD-FMK-loaded NPs significantly decreased the infarct volume after 2-hour middle cerebral artery occlusion and 22-hour reperfusion in mice. Co-administration of bFGF- or z-DEVD-FMK-loaded NPs reduced the infarct volume further and provided a 3-hour therapeutic window. bFGF-loaded NPs were histologically detected in the brain parenchyma and also restored ischemia-induced Akt dephosphorylation. The neuroprotection was not observed when receptor-mediated transcytosis was inhibited with imatinib or when bFGF-loaded NPs were not conjugated with the targeting antibody, which enables them to cross the BBB. Nanoparticles targeted to brain are promising drug carriers to transport large as well as small BBB-impermeable therapeutics for neuroprotection against stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Yemisci, Muge&#xD;Caban, Secil&#xD;Gursoy-Ozdemir, Yasemin&#xD;Lule, Sevda&#xD;Novoa-Carballal, Ramon&#xD;Riguera, Ricardo&#xD;Fernandez-Megia, Eduardo&#xD;Andrieux, Karine&#xD;Couvreur, Partick&#xD;Capan, Yilmaz&#xD;Dalkara, Turgay&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Cereb Blood Flow Metab. 2015 Mar;35(3):469-75. doi: 10.1038/jcbfm.2014.220. Epub 2014 Dec 10.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4348388</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2014.220</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>17</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">17</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yen, T. L.</style></author><author><style face="normal" font="default" size="100%">Chen, R. J.</style></author><author><style face="normal" font="default" size="100%">Jayakumar, T.</style></author><author><style face="normal" font="default" size="100%">Lu, W. J.</style></author><author><style face="normal" font="default" size="100%">Hsieh, C. Y.</style></author><author><style face="normal" font="default" size="100%">Hsu, M. J.</style></author><author><style face="normal" font="default" size="100%">Yang, C. H.</style></author><author><style face="normal" font="default" size="100%">Chang, C. C.</style></author><author><style face="normal" font="default" size="100%">Lin, Y. K.</style></author><author><style face="normal" font="default" size="100%">Lin, K. H.</style></author><author><style face="normal" font="default" size="100%">Sheu, J. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan; Department of Pharmacology, College of Medicine, Taipei Medical University, Taipei, Taiwan.&#xD;School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Division of General Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei, Taiwan; Department of Medical Research, Taipei Medical University Hospital, Taipei, Taiwan.&#xD;Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan; Department of Pharmacology, College of Medicine, Taipei Medical University, Taipei, Taiwan; Division of General Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei, Taiwan; Department of Medical Research, Taipei Medical University Hospital, Taipei, Taiwan.&#xD;Department of Pharmacology, College of Medicine, Taipei Medical University, Taipei, Taiwan.&#xD;Department of Pharmacology, College of Medicine, Taipei Medical University, Taipei, Taiwan; Department of Cardiology, Cathay General Hospital, Taipei, Taiwan.&#xD;Biostatistics Center, Taipei Medical University, Taipei, Taiwan.&#xD;Department of Pharmacology, College of Medicine, Taipei Medical University, Taipei, Taiwan; Central Laboratory, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan. Electronic address: d102092002@tmu.edu.tw.&#xD;Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan; Department of Pharmacology, College of Medicine, Taipei Medical University, Taipei, Taiwan. Electronic address: sheujr@tmu.edu.tw.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Andrographolide stimulates p38 mitogen-activated protein kinase-nuclear factor erythroid-2-related factor 2-heme oxygenase 1 signaling in primary cerebral endothelial cells for definite protection against ischemic stroke in rats</style></title><secondary-title><style face="normal" font="default" size="100%">Transl Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Translational research : the journal of laboratory and clinical medicine</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Transl Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Translational research : the journal of laboratory and clinical medicine</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Transl Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Translational research : the journal of laboratory and clinical medicine</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">57-72</style></pages><volume><style face="normal" font="default" size="100%">170</style></volume><edition><style face="normal" font="default" size="100%">2016/01/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/drug therapy/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/drug therapy/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/drug therapy/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Diterpenes/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelial Cells/drug effects/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelium, Vascular/cytology/drug effects/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Heme Oxygenase-1/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Membrane Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">NF-E2-Related Factor 2/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ metabolism/pathology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">p38 Mitogen-Activated Protein Kinases/drug effects/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1878-1810 (Electronic)&#xD;1878-1810 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26746802</style></accession-num><abstract><style face="normal" font="default" size="100%">Stroke pathogenesis involves complex oxidative stress-related pathways. The nuclear factor erythroid-2-related factor 2 (Nrf2) and heme oxygenase 1 (HO-1) pathways have been considered molecular targets in pharmacologic intervention for ischemic diseases. Andrographolide, a labdane diterpene, has received increasing attention in recent years because of its various pharmacologic activities. We determined that andrographolide modulates the mitogen-activated protein kinase (MAPK)-Nrf2-HO-1 signaling cascade in primary cerebral endothelial cells (CECs) to provide positive protection against middle cerebral artery occlusion (MCAO)-induced ischemic stroke in rats. In the present study, andrographolide (10 muM) increased HO-1 protein and messenger RNA expressions, Nrf2 phosphorylation, and nuclear translocation in CECs, and these activities were disrupted by a p38 MAPK inhibitor, SB203580, but not by the extracellular signal-regulated kinase inhibitor PD98059 or c-Jun amino-terminal kinase inhibitor SP600125. Similar results were observed in confocal microscopy analysis. Moreover, andrographolide-induced Nrf2 and HO-1 protein expressions were significantly inhibited by Nrf2 small interfering RNA. Moreover, HO-1 knockdown attenuated the protective effect of andrographolide against oxygen-glucose deprivation-induced CEC death. Andrographolide (0.1 mg/kg) significantly suppressed free radical formation, blood-brain barrier disruption, and brain infarction in MCAO-insulted rats, and these effects were reversed by the HO-1 inhibitor zinc protoporphyrin IX. The mechanism is attributable to HO-1 activation, as directly evidenced by andrographolide-induced pronounced HO-1 expression in brain tissues, which was highly localized in the cerebral capillary. In conclusion, andrographolide increased Nrf2-HO-1 expression through p38 MAPK regulation, confirming that it provides protection against MCAO-induced brain injury. These findings provide strong evidence that andrographolide could be a therapeutic agent for treating ischemic stroke or neurodegenerative diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Yen, Ting-Lin&#xD;Chen, Ray-Jade&#xD;Jayakumar, Thanasekaran&#xD;Lu, Wan-Jung&#xD;Hsieh, Cheng-Ying&#xD;Hsu, Ming-Jen&#xD;Yang, Chih-Hao&#xD;Chang, Chao-Chien&#xD;Lin, Yen-Kuang&#xD;Lin, Kuan-Hung&#xD;Sheu, Joen-Rong&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Transl Res. 2016 Apr;170:57-72. doi: 10.1016/j.trsl.2015.12.002. Epub 2015 Dec 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S1931524415004259/1-s2.0-S1931524415004259-main.pdf?_tid=f3eaf1ae-d7d4-11e6-b940-00000aab0f6c&amp;acdnat=1484122210_3a450b1473399034b99df162a3423a6e</style></url></related-urls><pdf-urls><url>internal-pdf://3852009554/Yen-2016-Andrographolide stim.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.trsl.2015.12.002</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>461</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">461</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yeung, M.</style></author><author><style face="normal" font="default" size="100%">Bhalla, A.</style></author><author><style face="normal" font="default" size="100%">Birns, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Ageing &amp; Health, St Thomas&apos; Hospital, London, UK. mhpyeung@hotmail.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recreational drug misuse and stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Drug Abuse Rev</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Current drug abuse reviews</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Drug Abuse Rev</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current drug abuse reviews</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Curr Drug Abuse Rev</style></full-title><abbr-1><style face="normal" font="default" size="100%">Current drug abuse reviews</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">286-91</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2011/12/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/epidemiology/ etiology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hemorrhages/epidemiology/etiology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/epidemiology/ etiology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Substance-Related Disorders/ complications/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1874-4745 (Electronic)&#xD;1874-4737 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22150621</style></accession-num><abstract><style face="normal" font="default" size="100%">Stroke is the third commonest cause of death and single largest cause of adult disability worldwide. Whilst the majority of strokes in older individuals are due to large or small vessel arterial disease or cardiac disease in association with classical vascular risk factors, strokes occurring in younger individuals may have atypical etiologies. Recreational substance misuse is on the increase worldwide, particularly in young adults in developed countries with commonly used substances including cocaine, amphetamines, heroin and other opiates, marijuana and gammahydroxybutyrate (GHB). Adverse vascular sequelae of inappropriate use of these substances is well recognized but the link between acute stroke and substance misuse is often underestimated. Both ischemic and hemorrhagic strokes may be caused by recreational substance misuse and this paper reviews the available evidence and discusses the potential pathophysiological links.</style></abstract><notes><style face="normal" font="default" size="100%">Yeung, Michael&#xD;Bhalla, Ajay&#xD;Birns, Jonathan&#xD;Review&#xD;United Arab Emirates&#xD;Curr Drug Abuse Rev. 2011 Dec;4(4):286-91.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>20</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">20</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yip, H. K.</style></author><author><style face="normal" font="default" size="100%">Yuen, C. M.</style></author><author><style face="normal" font="default" size="100%">Chen, K. H.</style></author><author><style face="normal" font="default" size="100%">Chai, H. T.</style></author><author><style face="normal" font="default" size="100%">Chung, S. Y.</style></author><author><style face="normal" font="default" size="100%">Tong, M. S.</style></author><author><style face="normal" font="default" size="100%">Chen, S. Y.</style></author><author><style face="normal" font="default" size="100%">Kao, G. S.</style></author><author><style face="normal" font="default" size="100%">Chen, C. H.</style></author><author><style face="normal" font="default" size="100%">Chen, Y. L.</style></author><author><style face="normal" font="default" size="100%">Huang, T. H.</style></author><author><style face="normal" font="default" size="100%">Sun, C. K.</style></author><author><style face="normal" font="default" size="100%">Lee, M. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan; Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan; Center for Shockwave Medicine and Tissue Engineering, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan; Department of Medical Research, China Medical University Hospital,, China Medical University, Taichung 40402, Taiwan.&#xD;Division of Trauma, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan.&#xD;Department of Anesthesiology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan.&#xD;Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan.&#xD;Division of General Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan.&#xD;Department of Emergency Medicine, Department of Medical Research, E-DA Hospital, I-Shou University, Kaohsiung 82445, Taiwan.&#xD;Department of Orthopedics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan. Electronic address: mellee@cgmh.org.tw.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tissue plasminogen activator deficiency preserves neurological function and protects against murine acute ischemic stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Cardiol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">International journal of cardiology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Int J Cardiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">International journal of cardiology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Int J Cardiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">International journal of cardiology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">133-41</style></pages><volume><style face="normal" font="default" size="100%">205</style></volume><edition><style face="normal" font="default" size="100%">2016/01/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/complications/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Nervous System Diseases/etiology/ metabolism/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/complications/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Tissue Plasminogen Activator/ deficiency</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1874-1754 (Electronic)&#xD;0167-5273 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26736088</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: We tested the hypothesis that tissue plasminogen activator (tPA) deficiency protected against acute ischemic stroke (AIS)-induced brain injury. METHODS AND RESULTS: Wild-type mice (n=54) were categorized into group 1 (sham control, n=18) and group 3 [AIS by permanent ligation of left common carotid artery (CCA) and cramping right CCA for 1h and then reperfusion followed by hypoxia (11% of oxygen supply for 2h), n=36]. Similarly, tPA knockout (tPA(-/-)) mice (n=54) were randomized into group 2 (sham control, n=18) and group 4 (AIS, n=36). By day 28 after AIS procedure, mortality rate was higher in group 3 (77.8%) than in group 4 (38.9%) and lowest in groups 1 (0%) and 2 (0%) (p&lt;0.001). By days 3 and 28, MRI demonstrated a pattern of changes in brain-infarct volume identical to that of mortality among four groups (p&lt;0.001). By day 28, protein expressions of inflammatory (MMP-9, TNF-alpha, NF-kappaB, iNOS, PAI-1, RANTES), oxidative (NOX-1, NOX-2, oxidized protein), apoptotic (cleaved caspase-3 &amp; PARP, Bax), and fibrotic (Smad3, TGF-beta) biomarkers and cellular expressions of inflammation (CD11, F4/80, GFAP), DNA-damage (gamma-H2AX) and brain-edema (AQP4) markers exhibited an identical pattern compared to that of mortality (all p&lt;0.001), whereas protein expressions of endothelial (eNOS, CD31), anti-fibrotic (Smad1/5, BMP-2) biomarkers, and number of small vessels displayed an opposite pattern (all p&lt;0.001) among four groups. Expressions of protein and cellular angiogenesis markers (VEGF, SDF-1alpha, CXCR4) were progressively increased from groups 1 and 2 to group 4 (all p&lt;0.0001). CONCLUSION: tPA deficiency protected the brain from AIS injury.</style></abstract><notes><style face="normal" font="default" size="100%">Yip, Hon-Kan&#xD;Yuen, Chun-Man&#xD;Chen, Kuan-Hung&#xD;Chai, Han-Tan&#xD;Chung, Sheng-Ying&#xD;Tong, Meng-Shen&#xD;Chen, Sheng-Yi&#xD;Kao, Gour-Shenq&#xD;Chen, Chih-Hung&#xD;Chen, Yi-Ling&#xD;Huang, Tien-Hung&#xD;Sun, Cheuk-Kwan&#xD;Lee, Mel S&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;Int J Cardiol. 2016 Feb 15;205:133-41. doi: 10.1016/j.ijcard.2015.11.168. Epub 2015 Nov 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S016752731530975X/1-s2.0-S016752731530975X-main.pdf?_tid=f9438968-d7d4-11e6-b069-00000aab0f6b&amp;acdnat=1484122219_ad27371717a69ad1f59acf9ff0c4717b</style></url></related-urls><pdf-urls><url>internal-pdf://1041900271/Yip-2016-Tissue plasminogen a.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ijcard.2015.11.168</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>126</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">126</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yu, S.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Lei, S.</style></author><author><style face="normal" font="default" size="100%">Chen, X.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Zhou, Y.</style></author><author><style face="normal" font="default" size="100%">Zhou, Y.</style></author><author><style face="normal" font="default" size="100%">Wu, J.</style></author><author><style face="normal" font="default" size="100%">Zhao, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathology, Chongqing Medical University, 400016 Chongqing, China; Institute of Neuroscience, Chongqing Medical University, 400016 Chongqing, China; Key Laboratory of Neurobiology, Chongqing Medical University, 400016 Chongqing, China.&#xD;Department of Respiratory Medicine, Jiangjin Center Hospital, 402260, Chongqing, China.&#xD;Department of Pathology, Chongqing Medical University, 400016 Chongqing, China; Institute of Neuroscience, Chongqing Medical University, 400016 Chongqing, China; Key Laboratory of Neurobiology, Chongqing Medical University, 400016 Chongqing, China. Electronic address: zhaoyong668@cqmu.edu.cn.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sulfiredoxin-1 protects primary cultured astrocytes from ischemia-induced damage</style></title><secondary-title><style face="normal" font="default" size="100%">Neurochem Int</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurochemistry international</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurochem Int</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurochemistry international</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurochem Int</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurochemistry international</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">19-27</style></pages><volume><style face="normal" font="default" size="100%">82</style></volume><edition><style face="normal" font="default" size="100%">2015/01/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/drug effects/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/metabolism/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Hypoxia/genetics/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Chemokines/biosynthesis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclooxygenase 2/biosynthesis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/biosynthesis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Knockdown Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrogen Peroxide/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">In Vitro Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Tissue Proteins/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide Synthase Type II/biosynthesis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidoreductases Acting on Sulfur Group Donors/antagonists &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">inhibitors/genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">RNA Interference</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Toll-Like Receptor 4/biosynthesis/genetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-9754 (Electronic)&#xD;0197-0186 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25620665</style></accession-num><abstract><style face="normal" font="default" size="100%">Astrocytes appear to be important regulators of the inflammatory events that occur in stroke. Sulfiredoxin-1 (Srxn1), an endogenous antioxidant protein, exhibits neuroprotective effects. Although the mechanism by which Srxn1 negatively regulates oxidative and apoptotic pathways has been extensively characterized, the impact of Srxn1 on inflammation has not been well studied. In this study, we used oxygen-glucose deprivation followed by recovery (OGD/R) and hydrogen peroxide (H2O2) to mimic stress from cerebral ischemic damage on primary cultured astrocytes. We found that knockdown of Srxn1 by two shRNAs resulted in decreased cell viability of astrocytes. Decreased level of Srxn1 also correlated with excessive levels of proinflammatory cytokines and chemokines such as TNF-alpha, MPO, IL-1beta, and IL-6. In addition, Srxn1 appeared to influence the strength of TLR4 signaling pathway; the expression of COX-2, IL-6, and NOS2 were strongly induced by OGD/R and H2O2 in astrocyte cultures with Srxn1-shRNAs. Our results suggested that loss of Srxn1 expression in astrocytes may cause excessive activation of inflammatory responses which contribute to OGD/R- and H2O2-induced cell death. Restoring Srxn1 function by gene therapy and/or pharmacology emerges as a promising strategy for the treatment of stroke and other chronic neurodegenerative diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Yu, Shanshan&#xD;Wang, Xiaoyan&#xD;Lei, Shipeng&#xD;Chen, Xi&#xD;Liu, Yuanling&#xD;Zhou, Yunchuan&#xD;Zhou, Yang&#xD;Wu, Jingxian&#xD;Zhao, Yong&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Neurochem Int. 2015 Mar;82:19-27. doi: 10.1016/j.neuint.2015.01.005. Epub 2015 Jan 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0197018615000170/1-s2.0-S0197018615000170-main.pdf?_tid=fc92ed7a-d7d4-11e6-918b-00000aab0f27&amp;acdnat=1484122225_f9e4581646c56250415bc7872460e130</style></url></related-urls><pdf-urls><url>internal-pdf://3831314764/Yu-2015-Sulfiredoxin-1 prote.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuint.2015.01.005</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>34</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">34</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yuan, F.</style></author><author><style face="normal" font="default" size="100%">Xu, Z. M.</style></author><author><style face="normal" font="default" size="100%">Lu, L. Y.</style></author><author><style face="normal" font="default" size="100%">Nie, H.</style></author><author><style face="normal" font="default" size="100%">Ding, J.</style></author><author><style face="normal" font="default" size="100%">Ying, W. H.</style></author><author><style face="normal" font="default" size="100%">Tian, H. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Shanghai Jiao Tong University Affiliated Sixth People&apos;s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.&#xD;Department of Radiology, Shanghai Jiao Tong University Affiliated Sixth People&apos;s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.&#xD;Neuroscience and Neuroengineering Research Center, Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">SIRT2 inhibition exacerbates neuroinflammation and blood-brain barrier disruption in experimental traumatic brain injury by enhancing NF-kappaB p65 acetylation and activation</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurochem</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of neurochemistry</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurochem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurochemistry</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurochem</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of neurochemistry</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">581-93</style></pages><volume><style face="normal" font="default" size="100%">136</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2015/11/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Acetylation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/ complications/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Encephalitis/ chemically induced</style></keyword><keyword><style face="normal" font="default" size="100%">Glial Fibrillary Acidic Protein/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Matrix Metalloproteinase 8/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Sirtuin 2/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Transcription Factor RelA/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Zonula Occludens-1 Protein/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1471-4159 (Electronic)&#xD;0022-3042 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26546505</style></accession-num><abstract><style face="normal" font="default" size="100%">Sirtuin 2 (SIRT2) is a member of the sirtuin family of NAD(+) -dependent protein deacetylases. In recent years, SIRT2 inhibition has emerged as a promising treatment for neurodegenerative diseases. However, to date, there is no evidence of a specific role for SIRT2 in traumatic brain injury (TBI). We investigated the effects of SIRT2 inhibition on experimental TBI using the controlled cortical impact (CCI) injury model. Adult male mice underwent CCI or sham surgery. A selective brain-permeable SIRT2 inhibitor, AK-7, was administrated 30 min before injury. The volume of the brain edema lesion and the water content of the brain were significantly increased in mice treated with AK-7 (20 mg/kg), compared with the vehicle group, following TBI (p &lt; 0.05 at 1 day and p &lt; 0.05 at 3 days, respectively). Concomitantly, AK-7 administration greatly worsened neurobehavioral deficits on days 3 and 7 after CCI. Furthermore, blood-brain barrier disruption and matrix metalloproteinases (MMP)-9 activity increased following SIRT2 inhibition. AK-7 treatment increased TBI-induced microglial activation both in vivo and in vitro, accompanied by a large increase in the expression and release of inflammatory cytokines. Mechanistically, SIRT2 inhibition increased both K310 acetylation and nuclear translocation of NF-kappaB p65, leading to enhanced NF-kappaB activation and up-regulation of its target genes, including aquaporin 4 (AQP4), MMP-9, and pro-inflammatory cytokines. Together, these data demonstrate that SIRT2 inhibition exacerbates TBI by increasing NF-kappaB p65 acetylation and activation. Our findings provide additional evidence of an anti-inflammatory effect of SIRT2. SIRT2 is a member of the sirtuin family of NAD+-dependent protein deacetylases. Our study suggests that the SIRT2 inhibitor AK-7 exacerbates traumatic brain injury (TBI) via a potential mechanism involving increased acetylation and nuclear translocation of NF-kappaB p65, resulting in up-regulation of NF-kappaB target genes, including aquaporin 4 (AQP4), matrix metalloproteinase 9 (MMP-9), and pro-inflammatory cytokines. Our findings provide additional evidence of an anti-inflammatory effect of SIRT2.</style></abstract><notes><style face="normal" font="default" size="100%">Yuan, Fang&#xD;Xu, Zhi-Ming&#xD;Lu, Li-Yan&#xD;Nie, Hui&#xD;Ding, Jun&#xD;Ying, Wei-Hai&#xD;Tian, Heng-Li&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Neurochem. 2016 Feb;136(3):581-93. doi: 10.1111/jnc.13423. Epub 2015 Dec 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/jnc.13423/asset/jnc13423.pdf?v=1&amp;t=ixsny3bw&amp;s=b8ad850b15aa6590714be9ef7ac14a374fa1440f</style></url></related-urls><pdf-urls><url>internal-pdf://0197617392/Yuan-2016-SIRT2 inhibition exa.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/jnc.13423</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>317</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">317</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zaucker, A.</style></author><author><style face="normal" font="default" size="100%">Mercurio, S.</style></author><author><style face="normal" font="default" size="100%">Sternheim, N.</style></author><author><style face="normal" font="default" size="100%">Talbot, W. S.</style></author><author><style face="normal" font="default" size="100%">Marlow, F. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">notch3 is essential for oligodendrocyte development and vascular integrity in zebrafish</style></title><secondary-title><style face="normal" font="default" size="100%">Dis Model Mech</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Disease models &amp; mechanisms</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Dis Model Mech</style></full-title><abbr-1><style face="normal" font="default" size="100%">Disease models &amp; mechanisms</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Dis Model Mech</style></full-title><abbr-1><style face="normal" font="default" size="100%">Disease models &amp; mechanisms</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1246-59</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2013/05/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Vessels/growth &amp; development/ metabolism/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Body Patterning/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Hemorrhage/metabolism/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Heterozygote</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Larva/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Myelin Basic Protein/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">Oligodendroglia/cytology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Notch3</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Notch/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Telencephalon/blood supply/metabolism/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilation</style></keyword><keyword><style face="normal" font="default" size="100%">Zebrafish/embryology/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Zebrafish Proteins/genetics/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1754-8411 (Electronic)&#xD;1754-8403 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23720232</style></accession-num><abstract><style face="normal" font="default" size="100%">Mutations in the human NOTCH3 gene cause CADASIL syndrome (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy). CADASIL is an inherited small vessel disease characterized by diverse clinical manifestations including vasculopathy, neurodegeneration and dementia. Here we report two mutations in the zebrafish notch3 gene, one identified in a previous screen for mutations with reduced expression of myelin basic protein (mbp) and another caused by a retroviral insertion. Reduced mbp expression in notch3 mutant embryos is associated with fewer oligodendrocyte precursor cells (OPCs). Despite an early neurogenic phenotype, mbp expression recovered at later developmental stages and some notch3 homozygous mutants survived to adulthood. These mutants, as well as adult zebrafish carrying both mutant alleles together, displayed a striking stress-associated accumulation of blood in the head and fins. Histological analysis of mutant vessels revealed vasculopathy, including: an enlargement (dilation) of vessels in the telencephalon and fin, disorganization of the normal stereotyped arrangement of vessels in the fin, and an apparent loss of arterial morphological structure. Expression of hey1, a well-known transcriptional target of Notch signaling, was greatly reduced in notch3 mutant fins, suggesting that Notch3 acts via a canonical Notch signaling pathway to promote normal vessel structure. Ultrastructural analysis confirmed the presence of dilated vessels in notch3 mutant fins and revealed that the vessel walls of presumed arteries showed signs of deterioration. Gaps in the arterial wall and the presence of blood cells outside of vessels in mutants indicated that compromised vessel structure led to hemorrhage. In notch3 heterozygotes, we found elevated expression of both notch3 itself and target genes, indicating that specific alterations in gene expression due to partial loss of Notch3 function might contribute to the abnormalities observed in heterozygous larvae and adults. Our analysis of zebrafish notch3 mutants indicates that Notch3 regulates OPC development and mbp gene expression in larvae, and maintains vascular integrity in adults.</style></abstract><notes><style face="normal" font="default" size="100%">Zaucker, Andreas&#xD;Mercurio, Sara&#xD;Sternheim, Nitzan&#xD;Talbot, William S&#xD;Marlow, Florence L&#xD;R01GM089979/GM/NIGMS NIH HHS/United States&#xD;GFP03011/PHS HHS/United States&#xD;R01 NS050223/NS/NINDS NIH HHS/United States&#xD;Howard Hughes Medical Institute/United States&#xD;R01 GM089979/GM/NIGMS NIH HHS/United States&#xD;GFP03011/Telethon/Italy&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Dis Model Mech. 2013 Sep;6(5):1246-59. doi: 10.1242/dmm.012005. Epub 2013 May 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://dmm.biologists.org/content/dmm/6/5/1246.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3957642369/Zaucker-2013-notch3 is essential.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3759344</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1242/dmm.012005</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>10</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">10</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, H.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Guan, S.</style></author><author><style face="normal" font="default" size="100%">Qu, D.</style></author><author><style face="normal" font="default" size="100%">Wang, L.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Li, X.</style></author><author><style face="normal" font="default" size="100%">Zhou, S.</style></author><author><style face="normal" font="default" size="100%">Zhou, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, N.</style></author><author><style face="normal" font="default" size="100%">Meng, J.</style></author><author><style face="normal" font="default" size="100%">Ma, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacology, School of Pharmacy, the Fourth Military Medical University, Xi&apos;an, China.&#xD;School of Nurse, the Fourth Military Medical University, Xi&apos;an, China.&#xD;Department of Health Statistics, Faculty of Preventative Medicine, the Fourth Military Medical University, Xi&apos;an, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An Orally Active Allosteric GLP-1 Receptor Agonist Is Neuroprotective in Cellular and Rodent Models of Stroke</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PloS one</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e0148827</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2016/02/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Allosteric Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Glucose</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/blood supply/drug effects/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Survival/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Evaluation, Preclinical</style></keyword><keyword><style face="normal" font="default" size="100%">Glucagon-Like Peptide-1 Receptor/ agonists</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/blood/ drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Inhibitory Concentration 50</style></keyword><keyword><style face="normal" font="default" size="100%">Insulin/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Peptides/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Cell Culture</style></keyword><keyword><style face="normal" font="default" size="100%">Quinoxalines/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfones/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Venoms/pharmacology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203 (Electronic)&#xD;1932-6203 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26863436</style></accession-num><abstract><style face="normal" font="default" size="100%">Diabetes is a major risk factor for the development of stroke. Glucagon-like peptide-1 receptor (GLP-1R) agonists have been in clinical use for the treatment of diabetes and also been reported to be neuroprotective in ischemic stroke. The quinoxaline 6,7-dichloro-2-methylsulfonyl-3-N-tert- butylaminoquinoxaline (DMB) is an agonist and allosteric modulator of the GLP-1R with the potential to increase the affinity of GLP-1 for its receptor. The aim of this study was to evaluate the neuroprotective effects of DMB on transient focal cerebral ischemia. In cultured cortical neurons, DMB activated the GLP-1R, leading to increased intracellular cAMP levels with an EC50 value about 100 fold that of exendin-4. Pretreatment of neurons with DMB protected against necrotic and apoptotic cell death was induced by oxygen-glucose deprivation (OGD). The neuroprotective effects of DMB were blocked by GLP-1R knockdown with shRNA but not by GLP-1R antagonism. In C57BL/6 mice, DMB was orally administered 30 min prior to middle cerebral artery occlusion (MCAO) surgery. DMB markedly reduced the cerebral infarct size and neurological deficits caused by MCAO and reperfusion. The neuroprotective effects were mediated by activation of the GLP-1R through the cAMP-PKA-CREB signaling pathway. DMB exhibited anti-apoptotic effects by modulating Bcl-2 family members. These results provide evidence that DMB, a small molecular GLP-1R agonist, attenuates transient focal cerebral ischemia injury and inhibits neuronal apoptosis induced by MCAO. Taken together, these data suggest that DMB is a potential neuroprotective agent against cerebral ischemia.</style></abstract><notes><style face="normal" font="default" size="100%">Zhang, Huinan&#xD;Liu, Yunhan&#xD;Guan, Shaoyu&#xD;Qu, Di&#xD;Wang, Ling&#xD;Wang, Xinshang&#xD;Li, Xubo&#xD;Zhou, Shimeng&#xD;Zhou, Ying&#xD;Wang, Ning&#xD;Meng, Jingru&#xD;Ma, Xue&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;PLoS One. 2016 Feb 10;11(2):e0148827. doi: 10.1371/journal.pone.0148827. eCollection 2016.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0148827&amp;type=printable</style></url></related-urls><pdf-urls><url>internal-pdf://1548585825/Zhang-2016-An Orally Active All.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4749391</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0148827</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>121</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">121</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, H.</style></author><author><style face="normal" font="default" size="100%">Meng, J.</style></author><author><style face="normal" font="default" size="100%">Li, X.</style></author><author><style face="normal" font="default" size="100%">Zhou, S.</style></author><author><style face="normal" font="default" size="100%">Qu, D.</style></author><author><style face="normal" font="default" size="100%">Wang, N.</style></author><author><style face="normal" font="default" size="100%">Jia, M.</style></author><author><style face="normal" font="default" size="100%">Ma, X.</style></author><author><style face="normal" font="default" size="100%">Luo, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacology, School of Pharmacy, The Fourth Military Medical University, Xi&apos;an, China.&#xD;Department of Pharmacology, School of Pharmacy, The Fourth Military Medical University, Xi&apos;an, China. Electronic address: xxluo3@fmmu.edu.cn.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pro-GLP-1, a Pro-drug of GLP-1, is neuroprotective in cerebral ischemia</style></title><secondary-title><style face="normal" font="default" size="100%">Eur J Pharm Sci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur J Pharm Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Eur J Pharm Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">82-91</style></pages><volume><style face="normal" font="default" size="100%">70</style></volume><edition><style face="normal" font="default" size="100%">2015/02/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Glucagon-Like Peptide 1/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Infusions, Intraventricular</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Prodrugs/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/administration &amp; dosage</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 05</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1879-0720 (Electronic)&#xD;0928-0987 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25640912</style></accession-num><abstract><style face="normal" font="default" size="100%">Pro-Glucagon-like peptide-1 (Pro-GLP-1), a long-lasting GLP-1 receptor (GLP-1R) agonist, was developed using a polymeric pro-drug strategy and its neuroprotective effects on ischemic stroke were investigated in C57BL/6 mice. Pro-GLP-1 was injected into the intraperitoneal cavity of C57BL/6 mice once a day for 7days before middle cerebral artery occlusion (MCAO) surgery. The neurological deficit score and TTC staining were determined 24h after ischemia. The results demonstrated that Pro-GLP-1 was slowly degraded in the plasma and brain of the mice, and GLP-1 could be detected even 12h after administration. Pro-GLP-1 was significantly neuroprotective in C57BL/6 mice subjected to MCAO. In cultured cortical neurons, treatment with Pro-GLP-1 attenuated apoptosis induced by oxygen-glucose deprivation (OGD). The neuroprotective effects of Pro-GLP-1 were blocked by a selective GLP-1 receptor antagonist and knockdown of GLP-1 receptor with shRNA. However, Pro-GLP-1 had no effect on blood glucose and insulin levels which indicated that neuroprotection was mediated by the activation of GLP-1 receptor in the brain. Pro-GLP-1 repaired the balance of pro- and anti-apoptotic proteins and decreased the expression of caspase-3. The anti-apoptotic effect was mediated by the cAMP/PKA and PI3K/Akt pathway. Our research provides evidence that pre-treatment of MCAO mice with Pro-GLP-1 exerts a neuroprotective effect mediated by a blockade of apoptosis and that Pro-GLP-1 might be a potential neuroprotective agent candidate against ischemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Zhang, Huinan&#xD;Meng, Jingru&#xD;Li, Xubo&#xD;Zhou, Shimeng&#xD;Qu, Di&#xD;Wang, Ning&#xD;Jia, Min&#xD;Ma, Xue&#xD;Luo, Xiaoxing&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;Eur J Pharm Sci. 2015 Apr 5;70:82-91. doi: 10.1016/j.ejps.2015.01.010. Epub 2015 Jan 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0928098715000287/1-s2.0-S0928098715000287-main.pdf?_tid=075130b4-d7d5-11e6-baec-00000aacb361&amp;acdnat=1484122243_b2b41891c06c6b8a658dd5b367949c3c</style></url></related-urls><pdf-urls><url>internal-pdf://2681110571/Zhang-2015-Pro-GLP-1, a Pro-dru.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ejps.2015.01.010</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>45</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">45</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, H.</style></author><author><style face="normal" font="default" size="100%">Song, F.</style></author><author><style face="normal" font="default" size="100%">Xu, C.</style></author><author><style face="normal" font="default" size="100%">Liu, H.</style></author><author><style face="normal" font="default" size="100%">Wang, Z.</style></author><author><style face="normal" font="default" size="100%">Li, J.</style></author><author><style face="normal" font="default" size="100%">Wu, S.</style></author><author><style face="normal" font="default" size="100%">YehuaShen,</style></author><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Zhu, Y.</style></author><author><style face="normal" font="default" size="100%">Du, R.</style></author><author><style face="normal" font="default" size="100%">Tian, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Nuclear Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China; Zhejiang University Medical PET Center, Zhejiang University, Hangzhou, China; Institute of Nuclear Medicine and Molecular Imaging, Zhejiang University, Hangzhou, China; Key Laboratory of Medical Molecular Imaging of Zhejiang Province, Hangzhou, China; and Collaborative Innovation Center for Brain Science, Fudan University, Shanghai, China.&#xD;Department of Nuclear Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China; Zhejiang University Medical PET Center, Zhejiang University, Hangzhou, China; Institute of Nuclear Medicine and Molecular Imaging, Zhejiang University, Hangzhou, China; Key Laboratory of Medical Molecular Imaging of Zhejiang Province, Hangzhou, China; and Collaborative Innovation Center for Brain Science, Fudan University, Shanghai, China meitian@zju.edu.cn.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Spatiotemporal PET Imaging of Dynamic Metabolic Changes After Therapeutic Approaches of Induced Pluripotent Stem Cells, Neuronal Stem Cells, and a Chinese Patent Medicine in Stroke</style></title><secondary-title><style face="normal" font="default" size="100%">J Nucl Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Nucl Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Nucl Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1774-9</style></pages><volume><style face="normal" font="default" size="100%">56</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2015/09/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Asian Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default" size="100%">Autoradiography</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Disorders/drug therapy/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">China</style></keyword><keyword><style face="normal" font="default" size="100%">Combined Modality Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Drugs, Chinese Herbal/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorodeoxyglucose F18/pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Induced Pluripotent Stem Cells/ diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/drug therapy/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Neural Stem Cells/ diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Positron-Emission Tomography/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Psychomotor Performance</style></keyword><keyword><style face="normal" font="default" size="100%">Radiopharmaceuticals/pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/drug therapy/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Stem Cell Transplantation/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ diagnostic imaging/drug therapy/ therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1535-5667 (Electronic)&#xD;0161-5505 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26359258</style></accession-num><abstract><style face="normal" font="default" size="100%">This study aimed to use spatiotemporal PET imaging to investigate the dynamic metabolic changes after a combined therapeutic approach of induced pluripotent stem cells (iPSCs), neuronal stem cells (NSCs), and Chinese patent medicine in a rat model of cerebral ischemia-reperfusion injury. METHODS: Cerebral ischemia was established by the middle cerebral artery occlusion approach. Thirty-six male rats were randomly assigned to 1 of the 6 groups: control phosphate-buffered saline (PBS), Chinese patent medicine (Qing-kai-ling [QKL]), induced pluripotent stem cells (iPSCs), combination of iPSCs and QKL, neuronal stem cells (NSCs), and combination of NSCs and QKL. Serial (18)F-FDG small-animal PET imaging and neurofunctional tests were performed weekly. Autoradiographic imaging and immunohistochemical and immunofluorescent analyses were performed at 4 wk after stem cell transplantation. RESULTS: Compared with the PBS control group, significantly higher (18)F-FDG accumulations in the ipsilateral cerebral infarction were observed in 5 treatment groups from weeks 1-4. Interestingly, the most intensive (18)F-FDG accumulation was found in the NSCs + QKL group at week 1 but in the iPSCs + QKL group at week 4. The neurofunctional scores in the 5 treatment groups were significantly higher than that of the PBS group from week 3 to 4. In addition, there was a significant correlation between the PET imaging findings and neurofunctional recovery (P &lt; 0.05) or glucose transporter-1 expression (P &lt; 0.01). Immunohistochemical and immunofluorescence studies found that transplanted iPSCs survived and migrated to the ischemic region and expressed protein markers for cells of interest. CONCLUSION: Spatiotemporal PET imaging with (18)F-FDG demonstrated dynamic metabolic and functional recovery after iPSCs or NSCs combined with QKL in a rat model of cerebral ischemia-reperfusion injury. iPSCs or NSCs combined with Chinese medicine QKL seemed to be a better therapeutic approach than these stem cells used individually.</style></abstract><notes><style face="normal" font="default" size="100%">Zhang, Hong&#xD;Song, Fahuan&#xD;Xu, Caiyun&#xD;Liu, Hao&#xD;Wang, Zefeng&#xD;Li, Jinhui&#xD;Wu, Shuang&#xD;YehuaShen&#xD;Chen, Yao&#xD;Zhu, Yunqi&#xD;Du, Ruili&#xD;Tian, Mei&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Nucl Med. 2015 Nov;56(11):1774-9. doi: 10.2967/jnumed.115.163170. Epub 2015 Sep 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://jnm.snmjournals.org/content/56/11/1774.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3818363409/Zhang-2015-Spatiotemporal PET I.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2967/jnumed.115.163170</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>400</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">400</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, J.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Zhu, P.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Lv, M.</style></author><author><style face="normal" font="default" size="100%">Feng, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, PR China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">siRNA-mediated silence of protease-activated receptor-1 minimizes ischemic injury of cerebral cortex through HSP70 and MAP2</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurol Sci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of the neurological sciences</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurol Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of the neurological sciences</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Neurol Sci</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of the neurological sciences</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">6-11</style></pages><volume><style face="normal" font="default" size="100%">320</style></volume><number><style face="normal" font="default" size="100%">1-2</style></number><edition><style face="normal" font="default" size="100%">2012/07/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/ drug effects/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Vectors/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">HSP70 Heat-Shock Proteins/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Injections, Intraventricular</style></keyword><keyword><style face="normal" font="default" size="100%">Lentivirus/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Microtubule-Associated Proteins/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">RNA Interference/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/administration &amp; dosage/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, PAR-1/ antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation/drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1878-5883 (Electronic)&#xD;0022-510X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22831762</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebral ischemic stroke is a prevalent disease in senior individuals. The anticoagulation and thrombolysis to recover blood supply as well as the diminution of neural excitotoxicity to protect brain cells have not shown to fully improve stroke patients. The comprehensive mechanisms and medication specificity remain to be addressed. The silence of specific mRNAs by RNA interference provides revenues for such goals. We examined whether the silence of protease-activated receptor-1 (PAR-1) by siRNA protects brain tissues from ischemic injury. In three groups of Wistar rats, their lateral ventricles received the injections of lentiviral vectors carrying siRNA for PAR1, small RNA in mismatching PAR1 or saline. A week after the injections, these rats were treated by one side of middle cerebral artery occlusion (MCAO). The scores of neurological deficits, the volume of ischemic infarction and the expressions of PAR-1, HSP-70 and MAP-2 were measured in 24h of MCAO. Our results show that the silence of PAR-1 significantly reduces neurological deficits and infarction volume, as well as elevates HSP-70 and MAP-2 expressions. Thus, the knock-down of PAR1 minimizes the ischemic impairments of cerebral cortex via HSP70 and MAP-2 pathways.</style></abstract><notes><style face="normal" font="default" size="100%">Zhang, Jun&#xD;Wang, Ying&#xD;Zhu, Ping&#xD;Wang, Xudong&#xD;Lv, Manhua&#xD;Feng, Honglin&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;J Neurol Sci. 2012 Sep 15;320(1-2):6-11. doi: 10.1016/j.jns.2012.05.040. Epub 2012 Jul 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0022510X12002687/1-s2.0-S0022510X12002687-main.pdf?_tid=153df0ae-d7d5-11e6-a984-00000aacb362&amp;acdnat=1484122266_1cd7af5f691c7c37e43be55b2809833d</style></url></related-urls><pdf-urls><url>internal-pdf://0804970923/Zhang-2012-siRNA-mediated silen.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jns.2012.05.040</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>329</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">329</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Tang, Y.</style></author><author><style face="normal" font="default" size="100%">Jiao, Z.</style></author><author><style face="normal" font="default" size="100%">Xie, C.</style></author><author><style face="normal" font="default" size="100%">Zhang, H.</style></author><author><style face="normal" font="default" size="100%">Gu, P.</style></author><author><style face="normal" font="default" size="100%">Wei, X.</style></author><author><style face="normal" font="default" size="100%">Yang, G. Y.</style></author><author><style face="normal" font="default" size="100%">Gu, H.</style></author><author><style face="normal" font="default" size="100%">Zhang, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Biomedical Engineering &amp; Med-X Research Institute, Shanghai Jiao Tong University, Shanghai 200030, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">High MRI performance fluorescent mesoporous silica-coated magnetic nanoparticles for tracking neural progenitor cells in an ischemic mouse model</style></title><secondary-title><style face="normal" font="default" size="100%">Nanoscale</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Nanoscale</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nanoscale</style></full-title><abbr-1><style face="normal" font="default" size="100%">Nanoscale</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Nanoscale</style></full-title><abbr-1><style face="normal" font="default" size="100%">Nanoscale</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">4506-16</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2013/04/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allografts</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ diagnostic imaging/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ diagnostic imaging/metabolism/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Line, Transformed</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Movement</style></keyword><keyword><style face="normal" font="default" size="100%">Coated Materials, Biocompatible/chemistry/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorescence</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetite Nanoparticles/ chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Neural Stem Cells/metabolism/ transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Radiography</style></keyword><keyword><style face="normal" font="default" size="100%">Silicon Dioxide/chemistry/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Stem Cell Transplantation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">May 21</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2040-3372 (Electronic)&#xD;2040-3364 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23591936</style></accession-num><abstract><style face="normal" font="default" size="100%">Multifunctional probes with high MRI sensitivity and high efficiency for cell labeling are desirable for MR cell imaging. Herein, we have fabricated fluorescent mesoporous silica-coated superparamagnetic iron oxide nanoparticles (fmSiO4@SPIONs) for neural progenitor cell (C17.2) MR imaging. FmSiO4@SPIONs were discrete and uniform in size, and had a clear core-shell structure. The magnetic core size was about 10 nm and the fluorescent mesoporous silica coating layer was around 20 nm. Compared with fluorescent dense silica-coated SPIONs (fdSiO4@SPIONs) with a similar size, fmSiO4@SPIONs demonstrated higher MR sensitivity and cell labeling efficiency. When implanted into the right hemisphere of stroke mice, contralateral to the ischemic territory, a small amount of labeled cells were able to be tracked migrating to the lesion sites using a clinical MRI scanner (3 T). More impressively, even when administered intravenously, the labeled cells could also be monitored homing to the ischemic area. MRI observations were corroborated by histological studies of the brain tissues. Our study demonstrated that fmSiO4@SPIONs are highly effective for cell imaging and hold great promise for MRI cell tracking in future.</style></abstract><notes><style face="normal" font="default" size="100%">Zhang, Lu&#xD;Wang, Yao&#xD;Tang, Yaohui&#xD;Jiao, Zheng&#xD;Xie, Chengying&#xD;Zhang, Haijiao&#xD;Gu, Ping&#xD;Wei, Xunbin&#xD;Yang, Guo-Yuan&#xD;Gu, Hongchen&#xD;Zhang, Chunfu&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Nanoscale. 2013 May 21;5(10):4506-16. doi: 10.1039/c3nr00119a.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://pubs.rsc.org/en/content/articlepdf/2013/nr/c3nr00119a</style></url></related-urls><pdf-urls><url>internal-pdf://3858164244/Zhang-2013-High MRI performance.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1039/c3nr00119a</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>66</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">66</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, Q.</style></author><author><style face="normal" font="default" size="100%">Lan, Y.</style></author><author><style face="normal" font="default" size="100%">He, X. F.</style></author><author><style face="normal" font="default" size="100%">Luo, C. M.</style></author><author><style face="normal" font="default" size="100%">Wang, Q. M.</style></author><author><style face="normal" font="default" size="100%">Liang, F. Y.</style></author><author><style face="normal" font="default" size="100%">Xu, G. Q.</style></author><author><style face="normal" font="default" size="100%">Pei, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Rehabilitation Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.&#xD;Department of Rehabilitation Medicine, Guangzhou First Peoples Hospital, Guangzhou Medical University, Guangzhou, China.&#xD;Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.&#xD;Key Laboratory on Assisted Circulation, Ministry of Health, Department of Cardiovascular Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.&#xD;Department of Rehabilitation Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Electronic address: guangchingx@163.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allopurinol protects against ischemic insults in a mouse model of cortical microinfarction</style></title><secondary-title><style face="normal" font="default" size="100%">Brain Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">361-7</style></pages><volume><style face="normal" font="default" size="100%">1622</style></volume><edition><style face="normal" font="default" size="100%">2015/07/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allopurinol/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arterioles</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/drug effects/pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ drug effects/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Proliferation/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/ drug therapy/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme Inhibitors/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorescent Antibody Technique</style></keyword><keyword><style face="normal" font="default" size="100%">Lasers</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Microglia/drug effects/pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects/pathology/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Xanthine Oxidase/antagonists &amp; inhibitors/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 05</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-6240 (Electronic)&#xD;0006-8993 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26187758</style></accession-num><abstract><style face="normal" font="default" size="100%">Microinfarcts are common in patients with cognitive decline and dementia. Allopurinol (ALLO), a xanthine oxidase (XO) enzyme inhibitor, has been found to reduce proinflammatory molecules and oxidative stress in the vasculature. We here examined the effect of pre-treatment with allopurinol on the cortical microinfarction. C57BL/6J mice were subjected to a permanent single penetrating arteriole occlusion induced by two-photon laser irradiation. Infarction volume, the activation of glial cells and nitrosative stress in the ischemic brain was assessed using immunohistochemistry. Pre-treatment with ALLO achieved 42% reduction of infarct volume and significantly reduced microglia infiltration, astrocyte proliferation and nitrosative stress in the ischemic brain. These data indicate that ALLO protects against microinfarcts possibly through inhibition of nitrosative stress and attenuation of microglia infiltration as well as astrocytes reactivation.</style></abstract><notes><style face="normal" font="default" size="100%">Zhang, Qun&#xD;Lan, Yue&#xD;He, Xiao-Fei&#xD;Luo, Chuan-Ming&#xD;Wang, Qin-Mei&#xD;Liang, Feng-Yin&#xD;Xu, Guang-Qing&#xD;Pei, Zhong&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;Brain Res. 2015 Oct 5;1622:361-7. doi: 10.1016/j.brainres.2015.07.010. Epub 2015 Jul 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0006899315005363/1-s2.0-S0006899315005363-main.pdf?_tid=10b83184-d7d5-11e6-8695-00000aab0f26&amp;acdnat=1484122259_c73d0d1ddcf9add87f14fb2632f0c35b</style></url></related-urls><pdf-urls><url>internal-pdf://1437450061/Zhang-2015-Allopurinol protects.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.brainres.2015.07.010</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>59</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">59</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, R.</style></author><author><style face="normal" font="default" size="100%">Tang, S.</style></author><author><style face="normal" font="default" size="100%">Huang, W.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Li, G.</style></author><author><style face="normal" font="default" size="100%">Chi, H.</style></author><author><style face="normal" font="default" size="100%">Zhu, M.</style></author><author><style face="normal" font="default" size="100%">Tang, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Qianfoshan Hospital, Shandong University, 16766 Jingshi Road, Jinan 250014, Shandong, PR China.&#xD;Department of Neurology, Shandong Provincial Hospital, Shandong University, 324 Jing Wu Wei Qi Road, Jinan 250021, Shandong, PR China.&#xD;Department of Neurology, Qianfoshan Hospital, Shandong University, 16766 Jingshi Road, Jinan 250014, Shandong, PR China. Electronic address: tjiyou@yahoo.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Protection of the brain following cerebral ischemia through the attenuation of PARP-1-induced neurovascular unit damage in rats</style></title><secondary-title><style face="normal" font="default" size="100%">Brain Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">9-18</style></pages><volume><style face="normal" font="default" size="100%">1624</style></volume><edition><style face="normal" font="default" size="100%">2015/07/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Animals, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/pathology/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation/genetics/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Hippocampus/cytology</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ complications</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Microscopy, Electron, Transmission</style></keyword><keyword><style face="normal" font="default" size="100%">Myelin Sheath/pathology/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Nervous System Diseases/ etiology/pathology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroglia/pathology/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/pathology/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Poly (ADP-Ribose) Polymerase-1</style></keyword><keyword><style face="normal" font="default" size="100%">Poly(ADP-ribose) Polymerases/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/genetics/metabolism/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Synapses/pathology/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Transfection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 22</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-6240 (Electronic)&#xD;0006-8993 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26220474</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebral ischemia is a major health crisis throughout the world, and the currently available thrombolytic therapy is unsatisfactory. Cell death following cerebral ischemia is mediated by a complex pathophysiological interaction of various mechanisms. During an ischemic insult, not only neurons but all of the components of the neurovascular unit, such as glia, endothelia, pericytes and basal membranes, are destroyed. Previous studies have shown that excessive stimulation of poly (ADP-ribose) polymerase (PARP-1) is crucial for cerebral injury after ischemic insult, which is an important cause of cell death in all cell types within the neurovascular unit. To investigate whether PARP-1 plays an important role in protecting the neurovascular unit following cerebral ischemia, we evaluated neurobehavioral deficits, PARP-1 activity, blood brain barrier (BBB) disruption and neurovascular unit deficits using Western blot analysis, TTC staining and electron microscopy in an MCAO rat model. The results revealed that PARP-1 enzymatic activity was dramatically increased after ischemia. Inhibition of PARP-1 significantly reduced the extent of both cerebral infarction and edema, improved neurological scores, and attenuated the damage to the neurovascular unit in cerebral ischemia. Collectively, these findings demonstrate that the down-regulation of PARP-1 activity contributes to reducing post-ischemic brain damage via protection of the neurovascular unit.</style></abstract><notes><style face="normal" font="default" size="100%">Zhang, Ruixue&#xD;Tang, Shi&#xD;Huang, Weiwei&#xD;Liu, Xiaomin&#xD;Li, Guohua&#xD;Chi, Heng&#xD;Zhu, Meijia&#xD;Tang, Jiyou&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;Brain Res. 2015 Oct 22;1624:9-18. doi: 10.1016/j.brainres.2015.07.023. Epub 2015 Jul 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0006899315005521/1-s2.0-S0006899315005521-main.pdf?_tid=19bd7b7c-d7d5-11e6-80ee-00000aacb362&amp;acdnat=1484122274_5fc06031b3ea1dbb7ff6ee63e4a40839</style></url></related-urls><pdf-urls><url>internal-pdf://3479436411/Zhang-2015-Protection of the br.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.brainres.2015.07.023</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>171</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">171</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, X.</style></author><author><style face="normal" font="default" size="100%">Lee, S. J.</style></author><author><style face="normal" font="default" size="100%">Young, K. Z.</style></author><author><style face="normal" font="default" size="100%">Josephson, D. A.</style></author><author><style face="normal" font="default" size="100%">Geschwind, M. D.</style></author><author><style face="normal" font="default" size="100%">Wang, M. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departments of Neurology, University of Michigan, Ann Arbor, MI 48109-5622, USA.&#xD;Josephson-Wallack-Munshower Neurology, Indianapolis, IN 46260, USA; Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46260, USA.&#xD;Department of Neurology, Memory and Aging Center, University of California, San Francisco, CA 94143, USA.&#xD;Departments of Neurology, University of Michigan, Ann Arbor, MI 48109-5622, USA; Molecular and Integrative Physiology, University of Michigan, 7725 Med Sci II 5622, 1137 Catherine Street, Ann Arbor, MI 48109-5622, USA; VA Ann Arbor Healthcare System, Ann Arbor, MI 48105, USA. Electronic address: micwang@umich.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Latent NOTCH3 epitopes unmasked in CADASIL and regulated by protein redox state</style></title><secondary-title><style face="normal" font="default" size="100%">Brain Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Brain research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">230-6</style></pages><volume><style face="normal" font="default" size="100%">1583</style></volume><edition><style face="normal" font="default" size="100%">2014/08/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arteries/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/blood supply/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">CADASIL/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Epitopes/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">HEK293 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunohistochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidation-Reduction</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Notch3</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Notch/chemistry/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Transfection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 02</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-6240 (Electronic)&#xD;0006-8993 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25150590</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy CADASIL is caused by more than a hundred NOTCH3 mutations. Virtually all encoded mutant proteins contain an odd number of cysteines. As such, structural changes in NOTCH3 may be the primary molecular abnormality in CADASIL. Thus, we sought evidence for structurally altered NOTCH3 protein in CADASIL tissue. Four antibodies were raised in rabbits against two non-overlapping N-terminal NOTCH3 sequences. These reagents were used in immunohistochemical experiments to detect epitopes in post-mortem CADASIL brains (n=8), control brains, and cells overexpressing NOTCH3. To determine the biochemical nature of NOTCH3 epitopes, we used these antibodies to probe pure NOTCH3-Fc fusion proteins treated with acid, urea, guanidinium, ionic detergents, acrylamide, and thiol- and phosphorus-based reductants. All antibodies avidly stained arteries in 8 of 8 CADASIL brain samples. The most prominent staining was in degenerating media of leptomeningeal arteries and sclerotic penetrating vessels. Normal appearing vessels from control brains were not reactive. Antibodies did not react with cultured cells overexpressing NOTCH3 or with purified NOTCH3-Fc protein. Furthermore, treatment of pure protein with acid, chaotropic denaturants, alkylators, and detergents failed to unmask N-terminal NOTCH3 epitopes. Antibodies, however, recognized novel N-terminal epitopes in purified NOTCH3-Fc protein treated with three different reductants (DTT, beta-mercaptoethanol, and TCEP). We conclude that CADASIL arteries feature latent N-terminal NOTCH3 epitopes, suggesting the first evidence in vivo of NOTCH3 structural alterations.</style></abstract><notes><style face="normal" font="default" size="100%">Zhang, Xiaojie&#xD;Lee, Soo Jung&#xD;Young, Kelly Z&#xD;Josephson, David A&#xD;Geschwind, Michael D&#xD;Wang, Michael M&#xD;P50-AG08671/AG/NIA NIH HHS/United States&#xD;P50 AG008671/AG/NIA NIH HHS/United States&#xD;I01 BX000375/BX/BLRD VA/United States&#xD;N01-HD-9-0011/HD/NICHD NIH HHS/United States&#xD;HHSN275200900011C/HD/NICHD NIH HHS/United States&#xD;NS062816/NS/NINDS NIH HHS/United States&#xD;R01 NS062816/NS/NINDS NIH HHS/United States&#xD;K02 NS054724/NS/NINDS NIH HHS/United States&#xD;NS054724/NS/NINDS NIH HHS/United States&#xD;275200900011C/PHS HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;Brain Res. 2014 Oct 2;1583:230-6. doi: 10.1016/j.brainres.2014.08.018. Epub 2014 Aug 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0006899314010828/1-s2.0-S0006899314010828-main.pdf?_tid=26eaf25c-d7d5-11e6-a41a-00000aacb360&amp;acdnat=1484122296_06e6cdfe7504ca3fd26151dc2760d3c7</style></url></related-urls><pdf-urls><url>internal-pdf://1042959439/Zhang-2014-Latent NOTCH3 epitop.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4206828</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms624448</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.brainres.2014.08.018</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>401</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">401</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Chen, J.</style></author><author><style face="normal" font="default" size="100%">Li, F.</style></author><author><style face="normal" font="default" size="100%">Li, D.</style></author><author><style face="normal" font="default" size="100%">Xiong, Q.</style></author><author><style face="normal" font="default" size="100%">Lin, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, D.</style></author><author><style face="normal" font="default" size="100%">Wang, X. F.</style></author><author><style face="normal" font="default" size="100%">Yang, P.</style></author><author><style face="normal" font="default" size="100%">Rui, Y. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A pentapeptide monocyte locomotion inhibitory factor protects brain ischemia injury by targeting the eEF1A1/endothelial nitric oxide synthase pathway</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">2764-73</style></pages><volume><style face="normal" font="default" size="100%">43</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2012/07/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/physiopathology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ complications/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelium, Vascular/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">In Vitro Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/complications/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide Synthase Type III/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Oligopeptides/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Peptide Elongation Factor 1/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22829547</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: Ischemic stroke is a major cause of death worldwide but lacks viable treatment or treatment targets. Monocyte locomotion inhibitory factor (MLIF) is a small heat-stable pentapeptide produced by Entamoeba histolytica in axenic culture, which is supposed to protect the brain from ischemic injury; the mechanism, however, remains unknown. In this study, we further investigated the mechanism underlying the protective role of MLIF in brain ischemia. METHODS: A middle cerebral artery occlusion model in rats was used for detecting the effect of MLIF in the brain ischemia in vivo. To identify targets of MLIF in brain endothelial cells, we performed immunoprecipitation of biotin-conjugated MLIF and mass spectrometry. RESULTS: MLIF can protect the brain from ischemic injury in vivo, yielding decreased ischemic volume, prolonged survival, and improved neurological outcome. In vitro studies showed that MLIF displayed protective effects through inhibition of expression of pathological inflammatory adhesion molecules and enhancing endothelial nitric oxide synthase expression and nitric oxide release in the cerebrovascular endothelium. The target screening experiments demonstrated binding of MLIF to the ribosomal protein translation elongation factor eEF1A1. MLIF enhanced endothelial nitric oxide synthase expression through stabilization of endothelial nitric oxide synthase mRNA, and eEF1A1 was shown to be necessary for this enhanced expression. Knockdown of eEF1A1 or inhibition of endothelial nitric oxide synthase attenuated MLIF-mediated inhibition of adhesion molecule expression. CONCLUSIONS: In this study, we identified a new potential pharmacologically targetable mechanism underlying MLIF&apos;s protective effects in brain ischemia through the eEF1A1/endothelial nitric oxide synthase pathway.</style></abstract><notes><style face="normal" font="default" size="100%">Zhang, Yuefan&#xD;Chen, Jun&#xD;Li, Fan&#xD;Li, Dong&#xD;Xiong, Qinhui&#xD;Lin, Yang&#xD;Zhang, Dazhi&#xD;Wang, Xiao-Fan&#xD;Yang, Pengyuan&#xD;Rui, Yao-Cheng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Stroke. 2012 Oct;43(10):2764-73. Epub 2012 Jul 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/43/10/2764.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3129744084/Zhang-2012-A pentapeptide monoc.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.112.657908</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>371</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">371</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Stevenson, G. D.</style></author><author><style face="normal" font="default" size="100%">Barber, C.</style></author><author><style face="normal" font="default" size="100%">Furenlid, L. R.</style></author><author><style face="normal" font="default" size="100%">Barrett, H. H.</style></author><author><style face="normal" font="default" size="100%">Woolfenden, J. M.</style></author><author><style face="normal" font="default" size="100%">Zhao, M.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Imaging, The University of Arizona, Tucson, AZ 85724-5067, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Imaging of rat cerebral ischemia-reperfusion injury using(99m)Tc-labeled duramycin</style></title><secondary-title><style face="normal" font="default" size="100%">Nucl Med Biol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Nuclear medicine and biology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nucl Med Biol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Nuclear medicine and biology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Nucl Med Biol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Nuclear medicine and biology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">80-8</style></pages><volume><style face="normal" font="default" size="100%">40</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2012/11/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteriocins</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/diagnostic imaging/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ complications</style></keyword><keyword><style face="normal" font="default" size="100%">Isotope Labeling</style></keyword><keyword><style face="normal" font="default" size="100%">Kinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Organotechnetium Compounds</style></keyword><keyword><style face="normal" font="default" size="100%">Peptides</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/ complications/ diagnostic imaging/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Tomography, Emission-Computed, Single-Photon/ methods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-9614 (Electronic)&#xD;0969-8051 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23123139</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVES: Prompt identification of necrosis and apoptosis in the infarct core and penumbra region is critical in acute stroke for delineating the underlying ischemic/reperfusion molecular pathologic events and defining therapeutic alternatives. The objective of this study was to investigate the capability of (99m)Tc-labeled duramycin in detecting ischemia-reperfusion injury in rat brain after middle cerebral artery (MCA) occlusion. METHODS: Ischemic cerebral injury was induced in ten rats by vascular insertion of a nylon suture in the left MCA for 3 hr followed by 21-24hr reperfusion. After i.v. injection of (99m)Tc-duramycin (1.0-3.5 mCi), dynamic cerebral images were acquired for 1 hr in six rats using a small-animal SPECT imager. Four other rats were imaged at 2 hr post-injection. Ex vivo images were obtained by autoradiography after sacrifice. Histologic analyses were performed to assess cerebral infarction and apoptosis. RESULTS: SPECT images showed that (99m)Tc-duramycin uptake in the left cerebral hemisphere was significantly higher than that in the right at 1 and 2 hr post-injection. The level of radioactive uptake in the ischemic brain varied based on ischemic severity. The average ratio of left cerebral hot-spot uptake to right hemisphere radioactivity, as determined by computerized ROI analysis, was 4.92+/-0.79. Fractional washout at 1 hr was 38.2+/-4.5% of peak activity for left cerebral hot-spot areas and 80.9+/-2.0% for remote control areas (P&lt;0.001). Based on triphenyltetrazolium chloride staining and autoradiograph image data, the hotspot uptake may be associated primarily with the ischemic penumbra, in which high apoptotic activity was observed by cleaved caspase-3 immunocytochemical staining. CONCLUSIONS: (99m)Tc-duramycin SPECT imaging may be useful for detecting and quantifying ongoing apoptotic neuronal cell loss induced by ischemia-reperfusion injury.</style></abstract><notes><style face="normal" font="default" size="100%">Zhang, Yuqing&#xD;Stevenson, Gail D&#xD;Barber, Christy&#xD;Furenlid, Lars R&#xD;Barrett, Harrison H&#xD;Woolfenden, James M&#xD;Zhao, Ming&#xD;Liu, Zhonglin&#xD;5P41-EB002035/EB/NIBIB NIH HHS/United States&#xD;P30 CA023074/CA/NCI NIH HHS/United States&#xD;CA023074/CA/NCI NIH HHS/United States&#xD;5R01-HL102085/HL/NHLBI NIH HHS/United States&#xD;R01 HL102085/HL/NHLBI NIH HHS/United States&#xD;P41 EB002035/EB/NIBIB NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;United States&#xD;Nucl Med Biol. 2013 Jan;40(1):80-8. doi: 10.1016/j.nucmedbio.2012.09.004. Epub 2012 Nov 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0969805112002491/1-s2.0-S0969805112002491-main.pdf?_tid=1ddc1f7e-d7d5-11e6-88aa-00000aacb35e&amp;acdnat=1484122281_99b7f123f65d354b1aa278aef5d5bd8e</style></url></related-urls><pdf-urls><url>internal-pdf://3201242066/Zhang-2013-Imaging of rat cereb.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3632380</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms419683</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.nucmedbio.2012.09.004</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>295</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">295</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhao, H.</style></author><author><style face="normal" font="default" size="100%">Chen, H.</style></author><author><style face="normal" font="default" size="100%">Li, H.</style></author><author><style face="normal" font="default" size="100%">Li, D.</style></author><author><style face="normal" font="default" size="100%">Wang, S.</style></author><author><style face="normal" font="default" size="100%">Han, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Cardiology, Cardiovascular Center, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Remodeling of small intramyocardial coronary arteries distal to total occlusions after myocardial infarction in pigs</style></title><secondary-title><style face="normal" font="default" size="100%">Coron Artery Dis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Coronary artery disease</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Coron Artery Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Coronary artery disease</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Coron Artery Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Coronary artery disease</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">493-500</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2013/08/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Coronary Angiography</style></keyword><keyword><style face="normal" font="default" size="100%">Coronary Occlusion/complications/diagnostic</style></keyword><keyword><style face="normal" font="default" size="100%">imaging/metabolism/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Coronary Vessels/diagnostic imaging/metabolism/ pathology/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Fibrillar Collagens/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Fibrosis</style></keyword><keyword><style face="normal" font="default" size="100%">Microscopy, Electron, Transmission</style></keyword><keyword><style face="normal" font="default" size="100%">Microvessels/diagnostic imaging/metabolism/ pathology/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle, Smooth, Vascular/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Infarction/diagnostic</style></keyword><keyword><style face="normal" font="default" size="100%">imaging/etiology/metabolism/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Stunning/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke Volume</style></keyword><keyword><style face="normal" font="default" size="100%">Swine</style></keyword><keyword><style face="normal" font="default" size="100%">Swine, Miniature</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Troponin I/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Ultrasonography</style></keyword><keyword><style face="normal" font="default" size="100%">Ventricular Function, Left</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1473-5830 (Electronic)&#xD;0954-6928 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23900045</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: The present study was designed to investigate whether microvascular remodeling could occur in hibernating myocardium and infarction regions distal to a total occluded coronary artery after acute myocardial infarction. MATERIALS AND METHODS: Copper stents were implanted in the left descending coronary arteries of 64 pigs to induce anterior wall myocardial infarction. The pigs were assigned randomly to group A (n=8; killed at 1 week), group B (n=8; killed at 2 weeks), group C (n=16; killed at 4 weeks), group D (n=16; killed at 3 months), and group E (n=16; killed at 6 months). The control group included six pigs that were subjected to the same procedures but without implantation of copper stents. The wall area (WA) and lumen area (LA) of small intramyocardial coronary arteries (SIMCA) distal to occlusions were measured and the ratios of WA/LA and LA/total vessel area (%L) were calculated. The composition of the arterial wall was determined by Masson&apos;s trichrome stain, transmission electron microscope. RESULTS: A significant increase in WA/LA and decrease %L in SIMCA were observed in group B (P&lt;0.05), group C (P&lt;0.01), group D (P&lt;0.01), and group E (P&lt;0.01) compared with the control. There was increased area of collagen fiber in the thickened arterial wall in group C (P&lt;0.05), group D (P&lt;0.01), and group E (P&lt;0.01) compared with the control group, group A, and group B. A significantly increased ratio of the synthetic phenotype vascular smooth muscle cells were found in group B (P&lt;0.05), group C (P&lt;0.01), group D (P&lt;0.01), and group E (P&lt;0.01) compared with the control group. CONCLUSION: Several weeks after occlusion of epicardial coronary, the SIMCAs distal to occlusion developed remodeling, with an increase in wall thickness and a decrease in lumen size. These structural changes may restrict blood flow to ischemic or hibernating myocardium after revascularization.</style></abstract><notes><style face="normal" font="default" size="100%">Zhao, Huiqiang&#xD;Chen, Hui&#xD;Li, Hongwei&#xD;Li, Dongbao&#xD;Wang, Shouli&#xD;Han, Yaling&#xD;England&#xD;Coron Artery Dis. 2013 Sep;24(6):493-500. doi: 10.1097/MCA.0b013e328363244b.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/MCA.0b013e328363244b</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>191</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">191</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhao, H.</style></author><author><style face="normal" font="default" size="100%">Wang, R.</style></author><author><style face="normal" font="default" size="100%">Tao, Z.</style></author><author><style face="normal" font="default" size="100%">Gao, L.</style></author><author><style face="normal" font="default" size="100%">Yan, F.</style></author><author><style face="normal" font="default" size="100%">Gao, Z.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Ji, X.</style></author><author><style face="normal" font="default" size="100%">Luo, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From the Cerebrovascular Diseases Research Institute (H.Z., R.W., Z.T., F.Y., Z.G., X.L., X.J., Y.L.) and Department of Neurology (L.G.), Xuanwu Hospital of Capital Medical University, Beijing, China; Cerebralvascular Diseases Research Laboratory, Beijing Geriatric Medical Research Center, Beijing, China (H.Z., R.W., Z.T., F.Y., Z.G., X.L., X.J., Y.L.); and Key Laboratory of Neurodegenerative Diseases of Ministry of Education and Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, Beijing, China (H.Z., R.W., Z.T., F.Y., Z.G., X.L., X.J., Y.L.).&#xD;From the Cerebrovascular Diseases Research Institute (H.Z., R.W., Z.T., F.Y., Z.G., X.L., X.J., Y.L.) and Department of Neurology (L.G.), Xuanwu Hospital of Capital Medical University, Beijing, China; Cerebralvascular Diseases Research Laboratory, Beijing Geriatric Medical Research Center, Beijing, China (H.Z., R.W., Z.T., F.Y., Z.G., X.L., X.J., Y.L.); and Key Laboratory of Neurodegenerative Diseases of Ministry of Education and Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, Beijing, China (H.Z., R.W., Z.T., F.Y., Z.G., X.L., X.J., Y.L.). yumin111@ccmu.edu.cn jixm@ccmu.edu.cn.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Ischemic postconditioning relieves cerebral ischemia and reperfusion injury through activating T-LAK cell-originated protein kinase/protein kinase B pathway in rats</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title><abbr-1><style face="normal" font="default" size="100%">Stroke</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">2417-24</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2014/07/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Postconditioning</style></keyword><keyword><style face="normal" font="default" size="100%">Lipid Peroxidation/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Malondialdehyde/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mitogen-Activated Protein Kinase Kinases/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphorylation</style></keyword><keyword><style face="normal" font="default" size="100%">Proto-Oncogene Proteins c-akt/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Reactive Oxygen Species/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/metabolism/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Superoxides/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-4628 (Electronic)&#xD;0039-2499 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25013016</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: Ischemic postconditioning (IPostC) protects against ischemic brain injury. To date, no study has examined the role of T-LAK-cell-originated protein kinase (TOPK) in IPostC-afforded neuroprotection. We explored the molecular mechanism related with TOPK in antioxidant effect of IPostC against ischemia/reperfusion. METHODS: Focal ischemia was induced in rats by transient middle cerebral artery occlusion. Reactive oxygen species production in the peri-infarct cortex was detected using dihydroethidium. Malondialdehyde, as a marker of lipid peroxidation, and 3-nitrotyrosine, as a marker of protein oxidation, were detected by ELISA. The expression or location of antioxidant proteins and signal molecules TOPK, phosphatase, and tensin homolog, and Akt was analyzed by Western blotting and immunofluorescence. RESULTS: Our results revealed that IPostC relieved transient middle cerebral artery occlusion-induced oxidative damage by reducing reactive oxygen species, malondialdehyde, and 3-nitrotyrosine accumulation in the peri-infarct cortex and raised levels of antioxidants perioxiredoxin-1, peroxiredoxin-2, and thioredoxin-1. In addition, IPostC increased p-AKT and p-TOPK levels, which colocalized in neural cells. In vitro TOPK knockdown by small interfering RNA decreased the levels of antioxidants peroxiredoxin-1, thioredoxin, and manganese superoxide dismutase activity in PC12 cells. In vivo intracerebroventricular injection of TOPK small interfering RNA reversed IPostC-induced neuroprotection by increasing infarct volume and nitric oxide content and reducing manganese superoxide dismutase activity. Moreover, IPostC-evoked Akt activation was blocked by TOPK small interfering RNA in vivo, but the decreased phosphorylated phosphatase and tensin homolog level in ischemia/reperfusion was not influenced by IPostC or by TOPK small interfering RNA treatment. CONCLUSIONS: Our results suggest that the antioxidative effects of TOPK/Akt might contribute to the neuroprotection of IPostC treatment against transient middle cerebral artery occlusion.</style></abstract><notes><style face="normal" font="default" size="100%">Zhao, Haiping&#xD;Wang, Rongliang&#xD;Tao, Zhen&#xD;Gao, Li&#xD;Yan, Feng&#xD;Gao, Zhi&#xD;Liu, Xiangrong&#xD;Ji, Xunming&#xD;Luo, Yumin&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Stroke. 2014 Aug;45(8):2417-24. doi: 10.1161/STROKEAHA.114.006135. Epub 2014 Jul 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://stroke.ahajournals.org/content/strokeaha/45/8/2417.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://4274082438/Zhao-2014-Ischemic postconditi.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1161/strokeaha.114.006135</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>183</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">183</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhao, H.</style></author><author><style face="normal" font="default" size="100%">Wang, R.</style></author><author><style face="normal" font="default" size="100%">Tao, Z.</style></author><author><style face="normal" font="default" size="100%">Yan, F.</style></author><author><style face="normal" font="default" size="100%">Gao, L.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Wang, N.</style></author><author><style face="normal" font="default" size="100%">Min, L.</style></author><author><style face="normal" font="default" size="100%">Jia, Y.</style></author><author><style face="normal" font="default" size="100%">Zhao, Y.</style></author><author><style face="normal" font="default" size="100%">Ji, X.</style></author><author><style face="normal" font="default" size="100%">Luo, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Cerebrovascular Diseases Research Institute and Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China; Beijing Geriatric Medical Research Center, Beijing, China; Key Laboratory of Neurodegenerative Diseases of Ministry of Education and Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Activation of T-LAK-cell-originated protein kinase-mediated antioxidation protects against focal cerebral ischemia-reperfusion injury</style></title><secondary-title><style face="normal" font="default" size="100%">FEBS J</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The FEBS journal</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">FEBS J</style></full-title><abbr-1><style face="normal" font="default" size="100%">The FEBS journal</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">FEBS J</style></full-title><abbr-1><style face="normal" font="default" size="100%">The FEBS journal</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">4411-20</style></pages><volume><style face="normal" font="default" size="100%">281</style></volume><number><style face="normal" font="default" size="100%">19</style></number><edition><style face="normal" font="default" size="100%">2014/07/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme Activation</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ enzymology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mitogen-Activated Protein Kinase Kinases/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/enzymology</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidation-Reduction</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative Stress</style></keyword><keyword><style face="normal" font="default" size="100%">PC12 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphorylation</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Processing, Post-Translational</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/ enzymology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1742-4658 (Electronic)&#xD;1742-464X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25065601</style></accession-num><abstract><style face="normal" font="default" size="100%">T-LAK-cell-originated protein kinase (TOPK), a MAPKK-like kinase, is crucial for neural progenitor cell proliferation; however, the function of TOPK and the molecular mechanism underlying cerebral ischemia-reperfusion injury remains unknown. Therefore, we investigated the role of TOPK in experimental stroke. Sprague-Dawley rats underwent transient middle cerebral artery occlusion (tMCAO) and reperfusion, and TOPK small interfering RNA (siRNA) was delivered by intracerebroventricular injection at the beginning of MCAO. After TOPK overexpression and H2O2 stimulation in PC12 neuronal cells, antioxidative proteins, apoptosis-related proteins and signal pathways were detected by western blot analysis, the levels of the peroxidation products (malondialdehyde and 3-nitrotyrosine) were measured with ELISA. Phosphorylation of TOPK was increased in rat cortical neurons following tMCAO. TOPK overexpression in PC12 cells augmented levels of antioxidative proteins (peroxiredoxin 1 and 2, heme oxygenase 1 and manganese superoxide dismutase), as well as total superoxide dismutase activity, along with inhibition of malondialdehyde and 3-nitrotyrosine upon H2O2 stimulation. TOPK overexpression increased cell viability and reduced expression of caspase 3 and caspase 12 in PC12 cells in response to H2O2 . The p-ERK level was increased by TOPK overexpression, and antioxidative protection afforded by TOPK was abolished by blocking the extracellular signal-regulated kinase pathway in PC12 cells. TOPK siRNA increased the infarct volume and reduced total superoxide dismutase activity in the cortex in vivo after MCAO. These data reveal that activating TOPK confers neuroprotection against focal cerebral ischemia-reperfusion injury by antioxidative function, in part through activation of the extracellular signal-regulated kinase pathway.</style></abstract><notes><style face="normal" font="default" size="100%">Zhao, Haiping&#xD;Wang, Rongliang&#xD;Tao, Zhen&#xD;Yan, Feng&#xD;Gao, Li&#xD;Liu, Xiangrong&#xD;Wang, Ningqun&#xD;Min, Lianqiu&#xD;Jia, Yujie&#xD;Zhao, Yongmei&#xD;Ji, Xunming&#xD;Luo, Yumin&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;FEBS J. 2014 Oct;281(19):4411-20. doi: 10.1111/febs.12948. Epub 2014 Aug 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/febs.12948/asset/febs12948.pdf?v=1&amp;t=ixsnzg8w&amp;s=558c18343c9f1ff2f43481178dfe7273c51e291e</style></url></related-urls><pdf-urls><url>internal-pdf://0724252910/Zhao-2014-Activation of T-LAK-.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/febs.12948</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>424</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">424</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhao, J. X.</style></author><author><style face="normal" font="default" size="100%">Tian, Y. X.</style></author><author><style face="normal" font="default" size="100%">Xiao, H. L.</style></author><author><style face="normal" font="default" size="100%">Hu, M. X.</style></author><author><style face="normal" font="default" size="100%">Chen, W. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Third Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100029, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of electroacupuncture on hippocampal and cortical apoptosis in a mouse model of cerebral ischemia-reperfusion injury</style></title><secondary-title><style face="normal" font="default" size="100%">J Tradit Chin Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Tradit Chin Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Tradit Chin Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">349-55</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2012/04/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ complications/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/ cytology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Electroacupuncture</style></keyword><keyword><style face="normal" font="default" size="100%">Hippocampus/ cytology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Reperfusion Injury/etiology/physiopathology/ therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0255-2922 (Print)&#xD;0255-2922 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22462244</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To observe the effects of electroacupuncture on hippocampal and cortical apoptosis in a mouse model of cerebral ischemia-reperfusion injury. METHODS: Mouse models established by repeated cerebral ischemia-reperfusion, followed by electroacupuncture at Shenshu, Geshu, and Baihui points. The control group mice were intragastrically administered Hydergine. On day 1 and 7 post-treatment, hippocampal and cortical apoptosis was detected by terminal-deoxynucleotidyl transferase mediated dUTP nick-end labeling (TUNEL), and apoptosis images in the hippocampal CA1 zone and cortical area were analyzed. RESULTS: In the model group, apoptotic cells were detected one day after treatment and some cellular fibers were disarrayed. By day 7 post-treatment, there was an increase in the number of apoptotic cells in the hippocampal CA1 region. In addition, there were apoptotic cells in the cortical area, the cortical layers were thinner with localized neuronal loss and sieve-like lymphocyte infiltration, as well as glial cell proliferation and visible infarct lesions. However, in the Hydergine and electroacupuncture groups, there was a small number of apoptotic cells. At 7 days post-treatment in the model group, field number, numerical density on area, and surface density were increased. However, in the Hydergine and electroacupuncture groups these parameters were decreased (P &lt; 0.01), with a significant difference between the two treatment groups (P &lt; 0.01). CONCLUSION: Electroacupuncture treatment inhibited apoptosis and provided neuroprotection.</style></abstract><notes><style face="normal" font="default" size="100%">Zhao, Jian-Xin&#xD;Tian, Yuan-Xiang&#xD;Xiao, Hong-Ling&#xD;Hu, Man-Xiang&#xD;Chen, Wei-Ran&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;China&#xD;J Tradit Chin Med. 2011 Dec;31(4):349-55.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>102</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">102</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhao, L.</style></author><author><style face="normal" font="default" size="100%">Nowak, T. S., Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Preconditioning cortical lesions reduce the incidence of peri-infarct depolarizations during focal ischemia in the Spontaneously Hypertensive Rat: interaction with prior anesthesia and the impact of hyperglycemia</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1181-90</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2015/03/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anesthesia</style></keyword><keyword><style face="normal" font="default" size="100%">Anesthetics, Inhalation/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Anesthetics, Intravenous/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebellar Cortex/blood supply/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Infarction/ complications/etiology/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Chloralose/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Cortical Spreading Depression</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Freezing</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperglycemia/ complications</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Preconditioning</style></keyword><keyword><style face="normal" font="default" size="100%">Isoflurane/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Inbred SHR</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25757750</style></accession-num><abstract><style face="normal" font="default" size="100%">The relationship between peri-infarct depolarizations (PIDs) and infarction was investigated in a model of preconditioning by cortical freeze lesions (cryogenic lesions, CL) in the Spontaneously Hypertensive Rat. Small (&lt; 5 mm(3)) lesions produced 24 hours before permanent focal ischemia were protective, without impacting baseline cerebral blood flow (CBF) and metabolism. Prior CL reduced infarct volume, associated with improved penumbral CBF as previously showed for ischemic preconditioning. The brief initial procedure avoided sham effects on infarct volume after subsequent occlusion under brief anesthesia. However, under prolonged isoflurane anesthesia for perfusion monitoring both sham and CL rats showed reduced PID incidence relative to naive animals. This anesthesia effect could be eliminated by using alpha-chloralose during perfusion imaging. As an additional methodological concern, blood glucose was frequently elevated at the time of the second surgery, reflecting buprenorphine-induced pica and other undefined mechanisms. Even modest hyperglycemia (&gt;10 mmol/L) reduced PID incidence. In normoglycemic animals CL preconditioning reduced PID number by 50%, demonstrating associated effects on PID incidence, penumbral perfusion, and infarct progression. Hyperglycemia suppressed PIDs without affecting the relationship between CBF and infarction. This suggests that the primary effect of preconditioning is to improve penumbral perfusion, which in turn impacts PID incidence and infarct size.</style></abstract><notes><style face="normal" font="default" size="100%">Zhao, Liang&#xD;Nowak, Thaddeus S Jr&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Cereb Blood Flow Metab. 2015 Jul;35(7):1181-90. doi: 10.1038/jcbfm.2015.37. Epub 2015 Mar 11.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4640273</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/jcbfm.2015.37</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>226</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">226</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhao, Y. X.</style></author><author><style face="normal" font="default" size="100%">Cui, M.</style></author><author><style face="normal" font="default" size="100%">Chen, S. F.</style></author><author><style face="normal" font="default" size="100%">Dong, Q.</style></author><author><style face="normal" font="default" size="100%">Liu, X. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, The 10th People&apos;s Hospital, Tongji University, Shanghai, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Amelioration of ischemic mitochondrial injury and Bax-dependent outer membrane permeabilization by Mdivi-1</style></title><secondary-title><style face="normal" font="default" size="100%">CNS Neurosci Ther</style></secondary-title><alt-title><style face="normal" font="default" size="100%">CNS neuroscience &amp; therapeutics</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">CNS Neurosci Ther</style></full-title><abbr-1><style face="normal" font="default" size="100%">CNS neuroscience &amp; therapeutics</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">CNS Neurosci Ther</style></full-title><abbr-1><style face="normal" font="default" size="100%">CNS neuroscience &amp; therapeutics</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">528-38</style></pages><volume><style face="normal" font="default" size="100%">20</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2014/04/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/drug effects/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema/drug therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Capillary Permeability/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Hypoxia/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Line, Tumor</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose/deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/complications/ drug</style></keyword><keyword><style face="normal" font="default" size="100%">therapy/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Membrane Potential, Mitochondrial/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mitochondria/ drug effects/metabolism/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroblastoma/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Quinazolinones/pharmacology/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">bcl-2-Associated X Protein/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1755-5949 (Electronic)&#xD;1755-5930 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24712408</style></accession-num><abstract><style face="normal" font="default" size="100%">AIMS: Disturbance of the balance between mitochondrial fission and fusion has been implicated in cerebral ischemia and several neurodegenerative diseases, whereas the underlying mechanisms remain poorly understood. In the present study, we attempted to investigate the role of dynamin-related protein 1 (Drp1), a key mitochondrial fission protein, in the pathogenesis of cerebral ischemia. METHODS: Using Drp1 siRNA or Mdivi-1, a small molecule inhibitor of Drp1, we examined the effect of Drp1 knockdown or inhibition on oxygen-glucose deprivation (OGD)-induced mitochondrial dysfunction and death of SH-SY-5Y cells. Cell death and viability were evaluated with LDH and MTT assays, respectively, and mitochondrial morphology, mitochondrial membrane potential (Deltapsim), and ATP production were assessed using epifluorescence microscopy, flow cytometry, and HPLC, respectively. Moreover, to examine the effect of Drp1 inhibition on ischemic brain injury, middle cerebral artery occlusion (MCAO) mice were injected (i.p.) with Mdivi1, and blood-brain barrier permeability, brain water content, and cell apoptosis were assessed. RESULTS: Knockdown or inhibition of Drp1 by Mdivi-1 significantly attenuated OGD-induced cell death in SH-SY-5Y cells, associated with reduced morphological change of mitochondria and attenuated Bax insertion,oligomerization. Moreover, treatment of the MCAO mice with Mdivi-1 remarkably reduced the infarct volume and neurological deficits in a dose-dependent manner, associated with marked reduction of mitochondrial fragmentation and BAX expression. CONCLUSIONS: Down-regulation or inhibition of Drp1 may reduce cerebral ischemic damage through maintaining normal mitochondrial morphology and function, and decreasing Bax insertion and oligomerization in mitochondria.</style></abstract><notes><style face="normal" font="default" size="100%">Zhao, Yan-Xin&#xD;Cui, Mei&#xD;Chen, Shu-Fen&#xD;Dong, Qiang&#xD;Liu, Xue-Yuan&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;CNS Neurosci Ther. 2014 Jun;20(6):528-38. doi: 10.1111/cns.12266. Epub 2014 Apr 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/cns.12266/asset/cns12266.pdf?v=1&amp;t=ixsnzlrf&amp;s=6dc235c5d484810b7f94a6fd3121be7661266015</style></url></related-urls><pdf-urls><url>internal-pdf://2797234918/Zhao-2014-Amelioration of isch.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/cns.12266</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>253</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">253</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zheng, R.</style></author><author><style face="normal" font="default" size="100%">Qin, L.</style></author><author><style face="normal" font="default" size="100%">Li, S.</style></author><author><style face="normal" font="default" size="100%">Xu, K.</style></author><author><style face="normal" font="default" size="100%">Geng, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departments of Radiology, First Affiliated Hospital of China Medical University, 155 Nanjing N St, Shenyang, 110001, Liaoning Province, People&apos;s Republic of China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">CT perfusion-derived mean transit time of cortical brain has a negative correlation with the plasma level of Nitric Oxide after subarachnoid hemorrhage</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Neurochir (Wien)</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Acta neurochirurgica</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Neurochir (Wien)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Acta neurochirurgica</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Acta Neurochir (Wien)</style></full-title><abbr-1><style face="normal" font="default" size="100%">Acta neurochirurgica</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">527-33</style></pages><volume><style face="normal" font="default" size="100%">156</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2013/12/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Angiography</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Volume</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/blood supply</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Mapping</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Hemodynamics</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Microcirculation</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide/ blood</style></keyword><keyword><style face="normal" font="default" size="100%">Perfusion</style></keyword><keyword><style face="normal" font="default" size="100%">Rabbits</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Subarachnoid Hemorrhage/ blood/ diagnostic imaging/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Tomography, X-Ray Computed</style></keyword><keyword><style face="normal" font="default" size="100%">Vasospasm, Intracranial/physiopathology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0942-0940 (Electronic)&#xD;0001-6268 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24366481</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Vasospasm of both large and small parenchymal arteries may contribute to the occurrence of delayed ischemic neurological deficits, and nitric oxide(NO) is an important mediators in the development of cerebral vasospasm after subarachnoid hemorrhage (SAH). We used a rabbit two-hemorrhage model to investigate changes in plasma NO after SAH, and the relationship between NO and brain microcirculation. METHODS: SAH was induced in rabbits and a control group was sham operated. There were 32 rabbits in each group that survived the second operation, and they were randomly assigned to four groups of eight rabbits each for follow-up assessments on Days 1, 4, 7, or 14, respectively. Cerebral blood flow (CBF), cerebral blood volume (CBV), and mean transit time (MTT) were calculated at six regions of interest (ROIs): symmetrical areas of the frontal, parietal-occipital, and temporal lobes. Before the contrast CT scan, blood was drawn from the central artery of the ear for measurement of plasma NO. RESULTS: In the control group, there was no difference in CBV, CBF, and MTT in the six ROIs, and plasma NO was unchanged. Compared to controls, in the SAH group, CBV decreased slightly in the six ROIs (P &gt; 0.05), frontal lobe CBF decreased, MTT increased (P &lt; 0.05, for both), and NO plasma levels were significantly lower (P &lt; 0.01). CONCLUSIONS: There was a significant correlation between the increase in MTT and the decrease in plasma NO (P &lt; 0.05), We hypothesized that normalization of NO might have a positive influence on brain microcirculation following SAH.</style></abstract><notes><style face="normal" font="default" size="100%">Zheng, Ruibin&#xD;Qin, Lei&#xD;Li, Songbai&#xD;Xu, Ke&#xD;Geng, Haiyang&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Austria&#xD;Acta Neurochir (Wien). 2014 Mar;156(3):527-33. doi: 10.1007/s00701-013-1968-6. Epub 2013 Dec 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/590/art%253A10.1007%252Fs00701-013-1968-6.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00701-013-1968-6&amp;token2=exp=1484123322~acl=%2Fstatic%2Fpdf%2F590%2Fart%25253A10.1007%25252Fs00701-013-1968-6.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs00701-013-1968-6*~hmac=89b4da52943003b88e4a6f4639edce954b39f17ad6c5e24d9191a2f5f4c6e64f</style></url></related-urls><pdf-urls><url>internal-pdf://3739313374/Zheng-2014-CT perfusion-derived.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00701-013-1968-6</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>204</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">204</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zheng, S.</style></author><author><style face="normal" font="default" size="100%">Bai, Y. Y.</style></author><author><style face="normal" font="default" size="100%">Changyi, Y.</style></author><author><style face="normal" font="default" size="100%">Gao, X.</style></author><author><style face="normal" font="default" size="100%">Zhang, W.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Zhou, L.</style></author><author><style face="normal" font="default" size="100%">Ju, S.</style></author><author><style face="normal" font="default" size="100%">Li, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Key Laboratory of Smart Drug Delivery Ministry of Education, School of Pharmacy Fudan University, Shanghai, 201203, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Multimodal nanoprobes evaluating physiological pore size of brain vasculatures in ischemic stroke models</style></title><secondary-title><style face="normal" font="default" size="100%">Adv Healthc Mater</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Advanced healthcare materials</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Adv Healthc Mater</style></full-title><abbr-1><style face="normal" font="default" size="100%">Advanced healthcare materials</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Adv Healthc Mater</style></full-title><abbr-1><style face="normal" font="default" size="100%">Advanced healthcare materials</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1909-18</style></pages><volume><style face="normal" font="default" size="100%">3</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2014/06/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/ drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ blood supply/ drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Fibrinolytic Agents/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Nude</style></keyword><keyword><style face="normal" font="default" size="100%">Multimodal Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Nanoparticles/ administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Particle Size</style></keyword><keyword><style face="normal" font="default" size="100%">Permeability</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ drug therapy/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Tissue Plasminogen Activator/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2192-2659 (Electronic)&#xD;2192-2640 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">24898608</style></accession-num><abstract><style face="normal" font="default" size="100%">Ischemic stroke accounts for 80% strokes and originates from a reduction of cerebral blood flow (CBF) after vascular occlusion. For treatment, the first action is to restore CBF by thrombolytic agent recombinant tissue-type plasminogen activator (rt-PA). Although rt-PA benefits clinical outcome, its application is limited by short therapeutic time window and risk of brain hemorrhage. Different to thrombolytic agents, neuroprotectants reduce neurological injuries by blocking ischemic cascade events such as excitotoxicity and oxidative stress. Nano-neuroprotectants demonstrate higher therapeutic effect than small molecular analogues due to their prolonged circulation lifetime and disrupted blood-brain barrier (BBB) in ischemic region. Even enhanced BBB permeability in ischemic territories is verified, the pore size of ischemic vasculatures determining how large and how efficient the therapeutics can pass is barely studied. In this work, nanoprobes (NPs) with different diameters are developed. In vivo multimodal imaging indicates that NP uptakes in ischemic region depended on their diameters and the pore size upper limit of ischemic vasculatures is determined as 10-11 nm. Additionally, penumbra defined as salvageable ischemic tissues performed a higher BBB permeability than infarct core. This work provides a guideline for developing nano-neuroprotectants by taking advantage of the locally enhanced BBB permeability in ischemic brain tissues.</style></abstract><notes><style face="normal" font="default" size="100%">Zheng, Shuyan&#xD;Bai, Ying-Ying&#xD;Changyi, Yinzhi&#xD;Gao, Xihui&#xD;Zhang, Wenqing&#xD;Wang, Yuancheng&#xD;Zhou, Lu&#xD;Ju, Shenghong&#xD;Li, Cong&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Germany&#xD;Adv Healthc Mater. 2014 Nov;3(11):1909-18. doi: 10.1002/adhm.201400159. Epub 2014 Jun 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1002/adhm.201400159/asset/adhm201400159.pdf?v=1&amp;t=ixsnzubl&amp;s=2a2a8007e31b2edeb56588e6bdc439ffc955e159</style></url></related-urls><pdf-urls><url>internal-pdf://2047915436/Zheng-2014-Multimodal nanoprobe.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/adhm.201400159</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>37</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">37</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zheng, W. X.</style></author><author><style face="normal" font="default" size="100%">Cao, X. L.</style></author><author><style face="normal" font="default" size="100%">Wang, F.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Ying, T. Z.</style></author><author><style face="normal" font="default" size="100%">Xiao, W.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Xing, H.</style></author><author><style face="normal" font="default" size="100%">Dong, W.</style></author><author><style face="normal" font="default" size="100%">Xu, S. Q.</style></author><author><style face="normal" font="default" size="100%">Min, Z. L.</style></author><author><style face="normal" font="default" size="100%">Wu, F. J.</style></author><author><style face="normal" font="default" size="100%">Hu, X. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacy, Yangtze River Shipping General Hospital, Wuhan, 430010 Hubei Province, China.&#xD;Department of Pharmacy, College of Medicine, Wuhan University of Science and Technology, Wuhan, 430065 Hubei Province, China; Drug research base of cardiovascular and cerebral vascular, Wuhan University of Science and Technology, China.&#xD;Department of Pharmacy, College of Medicine, Wuhan University of Science and Technology, Wuhan, 430065 Hubei Province, China.&#xD;Department of Pharmacy, Yangtze River Shipping General Hospital, Wuhan, 430010 Hubei Province, China. Electronic address: wu_fangjian@163.com.&#xD;Department of Pharmacy, College of Medicine, Wuhan University of Science and Technology, Wuhan, 430065 Hubei Province, China; Drug research base of cardiovascular and cerebral vascular, Wuhan University of Science and Technology, China. Electronic address: huxiaming@163.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Baicalin inhibiting cerebral ischemia/hypoxia-induced neuronal apoptosis via MRTF-A-mediated transactivity</style></title><secondary-title><style face="normal" font="default" size="100%">Eur J Pharmacol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">European journal of pharmacology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur J Pharmacol</style></full-title><abbr-1><style face="normal" font="default" size="100%">European journal of pharmacology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Eur J Pharmacol</style></full-title><abbr-1><style face="normal" font="default" size="100%">European journal of pharmacology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">201-10</style></pages><volume><style face="normal" font="default" size="100%">767</style></volume><edition><style face="normal" font="default" size="100%">2015/10/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Cortex/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Chromones/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Flavonoids/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia-Ischemia, Brain/metabolism/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">MAP Kinase Signaling System/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Morpholines/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Myeloid Cell Leukemia Sequence 1 Protein/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphatidylinositol 3-Kinases/antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Cell Culture</style></keyword><keyword><style face="normal" font="default" size="100%">Proto-Oncogene Proteins c-bcl-2/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Transcription Factors/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Transcriptional Activation/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation/drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1879-0712 (Electronic)&#xD;0014-2999 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26485504</style></accession-num><abstract><style face="normal" font="default" size="100%">Baicalin has been shown to provide the neuroprotective effect by alleviating cerebral ischemia injury. However, little&apos;s known about the underlying mechanism. Here, a cerebral artery occlusion (MACO)/reperfusion rat model and rat primary cortical neuron culture exposed to hydrogen peroxide (H2O2) were established to evaluate the effect of baicalin on ischemia-induced neuronal apoptosis. We found baicalin can significantly less neurological deficit and reduced infarct volume in vivo. And it efficiently inhibited neuronal apoptosis in vivo and vitro, which was especially characterized by the enhancing of transcription and expression of myeloid cell leukemia-1 (MCL-1) and B-cell lymphoma-2 (BCL-2) in a dose-dependent manner. Furthermore, Baicalin markedly increased myocardin-related transcription factor-A (MRTF-A) level either in ischemic hemisphere or in primary cortical neuron cultures, whiles the anti-apoptosis effect of baicalin was significantly inhibited by transfected with the small interfering RNA of MRTF-A (MRTF-A siRNA) in primary cortical neuron cultures. The luciferase assays also indicated baicalin enhanced the transactivity of MCL-1 and BCL-2 promoter by activating the key CArG box (CC [A/T] 6GG) element, which was reduced by MRTF-A siRNA, suggesting MRTF-A may participate the anti-apoptosis effect of baicalin, and MRTF-A was involved in the transcriptional activity of MCL-1 and BCL-2 that was induced by baicalin. LY294002 (phosphatidylinositol-3 kinase (PI3K) inhibitor) and PD98059 (extracellular signal regulates kinase-1/2 (ERK1/2) inhibitor) obviously reduced baicalin-induced MRTF-A expression and transactivity and expression of MCL-1 and BCL-2, which further abolished the anti-apoptotic effect of baicalin on neuronal apoptosis. Taken together, our data provided the evidence demonstrating the neuroprotective effect of baicalin partially due to MRTF-A-mediated transactivity and expression of MCL-1 and BCL-2 by triggering the CArG box, which might be controlled by the activation of PI3K and ERK1/2.</style></abstract><notes><style face="normal" font="default" size="100%">Zheng, Wen-xia&#xD;Cao, Xiao-lu&#xD;Wang, Feng&#xD;Wang, Jun&#xD;Ying, Ting-zi&#xD;Xiao, Wan&#xD;Zhang, Ying&#xD;Xing, Hong&#xD;Dong, Wei&#xD;Xu, Shi-qiang&#xD;Min, Zhen-li&#xD;Wu, Fang-jian&#xD;Hu, Xia-min&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;Eur J Pharmacol. 2015 Nov 15;767:201-10. doi: 10.1016/j.ejphar.2015.10.027. Epub 2015 Oct 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0014299915303071/1-s2.0-S0014299915303071-main.pdf?_tid=2de49a22-d7d5-11e6-be8a-00000aacb361&amp;acdnat=1484122308_6c35575524496e053f6f0b831b4e71d3</style></url></related-urls><pdf-urls><url>internal-pdf://4251023080/Zheng-2015-Baicalin inhibiting.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ejphar.2015.10.027</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>435</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">435</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zheng, X. R.</style></author><author><style face="normal" font="default" size="100%">Zhang, S. S.</style></author><author><style face="normal" font="default" size="100%">Yin, F.</style></author><author><style face="normal" font="default" size="100%">Tang, J. L.</style></author><author><style face="normal" font="default" size="100%">Yang, Y. J.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Zhong, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Xiangya Hospital, Central South University, Xiangya Road, Changsha City, Hunan Province, 410008, PR China. zxr 168@126.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">Neuroprotection of VEGF-expression neural stem cells in neonatal cerebral palsy rats</style></title><secondary-title><style face="normal" font="default" size="100%">Behav Brain Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Behavioural brain research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Behav Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Behavioural brain research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Behav Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Behavioural brain research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">108-15</style></pages><volume><style face="normal" font="default" size="100%">230</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2012/02/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Animals, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Artery Diseases/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Palsy/etiology/metabolism/pathology/ prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Vectors/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia/complications</style></keyword><keyword><style face="normal" font="default" size="100%">In Situ Nick-End Labeling</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mental Disorders/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Microvessels/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Neovascularization, Pathologic/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Stem Cell Transplantation/ methods</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Transfection</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Endothelial Growth Factor A/genetics/ metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 21</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-7549 (Electronic)&#xD;0166-4328 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22342488</style></accession-num><abstract><style face="normal" font="default" size="100%">Cerebral palsy (CP) is a very common neural system development disorder that can cause physical disability in human. Here, we studied the neuroprotective effect of vascular endothelial growth factor (VEGF)-transfected neural stem cells (NSCs) in newborn rats with cerebral palsy (CP). Seven-day-old Sprague-Dawley rats were randomly divided into four groups: sham operation (control group), PBS transplantation (PBS group), VEGF+NSCs transplantation (transgene NSCs group) and NSCs transplantation groups (NSCs group). PBS, Transgene NSCs and NSCs groups respectively received stereotactic injections of PBS, lentiviral vector (pGC-FU-VEGF) infected NSCs or a NSCs suspension in the left sensory-motor cortex 3 days after CP model was established. The NSCs activity, their impacts on neural cell growth and apoptosis, brain development and animal behaviors were examined on the animals up to age 35-days. As expected, unilateral carotid artery occlusion plus hypoxia (cerebral palsy model) resulted in severe neural developmental disorders, including slowed growth, increased in cortical neuron apoptosis, decreased cerebral cortex micro-vessel density and retarded behavior developments. Transplantation of NSCs not only resulted in increases in VEGF protein expression in rat brains, but also largely prevented the behavioral defects and brain tissue pathology that resulted from cerebral palsy procedure, with animals received VEGF transfected NSCs always being marginally better than these received un-transfected cells. In conclusion, NSCs transplantation can partially prevent/slow down the brain damages that are associated with CP in the newborn rats, suggesting a new possible strategy for CP treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Zheng, Xiang-Rong&#xD;Zhang, Shan-Shan&#xD;Yin, Fei&#xD;Tang, Jie-Lu&#xD;Yang, Yu-Jia&#xD;Wang, Xia&#xD;Zhong, Le&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;Behav Brain Res. 2012 Apr 21;230(1):108-15. doi: 10.1016/j.bbr.2012.01.026. Epub 2012 Feb 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0166432812000472/1-s2.0-S0166432812000472-main.pdf?_tid=3517cf6c-d7d5-11e6-b83e-00000aacb35f&amp;acdnat=1484122320_4b786c1a0b1c2224d6d39ae023377005</style></url></related-urls><pdf-urls><url>internal-pdf://2054007257/Zheng-2012-Neuroprotection of V.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.bbr.2012.01.026</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>122</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">122</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zheng, Y.</style></author><author><style face="normal" font="default" size="100%">Zhong, D.</style></author><author><style face="normal" font="default" size="100%">Chen, H.</style></author><author><style face="normal" font="default" size="100%">Ma, S.</style></author><author><style face="normal" font="default" size="100%">Sun, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, M.</style></author><author><style face="normal" font="default" size="100%">Liu, Q.</style></author><author><style face="normal" font="default" size="100%">Li, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, The First Affiliated Hospital, Harbin Medical University, 23 You Zheng Street, Harbin 150001, Heilong Jiang Province, PR China.&#xD;Department of Neurology, The First Affiliated Hospital, Harbin Medical University, 23 You Zheng Street, Harbin 150001, Heilong Jiang Province, PR China. Electronic address: hydlgz1962@163.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pivotal role of cerebral interleukin-23 during immunologic injury in delayed cerebral ischemia in mice</style></title><secondary-title><style face="normal" font="default" size="100%">Neuroscience</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuroscience</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuroscience</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">321-31</style></pages><volume><style face="normal" font="default" size="100%">290</style></volume><edition><style face="normal" font="default" size="100%">2015/02/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/ metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Forkhead Transcription Factors/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Knockdown Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery</style></keyword><keyword><style face="normal" font="default" size="100%">Interferon-gamma/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-17/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-23 Subunit p19/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 02</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1873-7544 (Electronic)&#xD;0306-4522 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25637493</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Interleukin-23 (IL-23) is required for T helper 17 (Th17) cell responses and IL-17 production in ischemic stroke. We previously showed that the IL-23/IL-17 axis aggravates immune injury after cerebral infarction in mice. However, IL-23 might activate other cytokines and transcription factor forkhead box P3 (Foxp3) production in cerebral ischemia. We aimed to determine whether IL-23p19 knockdown prevents cerebral ischemic injury by reducing ischemic-induced inflammation. METHODS: Ischemic stroke models were established by permanent middle cerebral arterial occlusion (pMCAO) in male C57BL/6 mice. In vivo gene knockdown was achieved by intravenous delivery of lentiviral vectors (LVs) encoding IL-23p19 short hairpin RNA (LV-IL-23p19 shRNA). Enzyme-linked immunoassay (ELISA) and quantitative real-time polymerase chain reaction (qRT-PCR) confirmed inhibitory efficiency. Behavioral deficits were evaluated by adhesive-removal somatic-sensory test. Brain infarct volume was measured at day 5 after pMCAO by 2,3,5-triphenyltetrazolium chloride (TTC) staining. Expression of IL-17, IL-4, interferon (IFN)-gamma and Foxp3 in ischemic brain tissues were detected by qRT-PCR and Western blotting, respectively. Additionally, immunohistochemical staining located cytokines in ischemic brain tissues. RESULTS: RNA interference knockdown of IL-23p19 resulted in improved neurological function and reduced infarct volume. IL-23p19 knockdown suppressed IL-17 gene and protein expression. Moreover, IL-23p19 deficiency enhanced IFN-gamma and Foxp3 expressions in delayed cerebral ischemic mice, and did not impact IL-4 expression. Immunohistochemical staining showed that IL-17, IL-4, IFN-gamma and Foxp3-positive cells were located around ischemic lesions of the ipsilateral hemisphere. CONCLUSIONS: IL-23p19 knockdown prevents delayed cerebral ischemic injury by dampening the ischemia-induced inflammation, and is a promising approach for clinically managing ischemic stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Zheng, Y&#xD;Zhong, D&#xD;Chen, H&#xD;Ma, S&#xD;Sun, Y&#xD;Wang, M&#xD;Liu, Q&#xD;Li, G&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Neuroscience. 2015 Apr 2;290:321-31. doi: 10.1016/j.neuroscience.2015.01.041. Epub 2015 Jan 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0306452215000962/1-s2.0-S0306452215000962-main.pdf?_tid=30e3a1e6-d7d5-11e6-bb4d-00000aacb35e&amp;acdnat=1484122313_b7a56afca6f801304ade105246e535a8</style></url></related-urls><pdf-urls><url>internal-pdf://0108169910/Zheng-2015-Pivotal role of cere.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuroscience.2015.01.041</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>342</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">342</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhong, M.</style></author><author><style face="normal" font="default" size="100%">Alonso, C. E.</style></author><author><style face="normal" font="default" size="100%">Taegtmeyer, H.</style></author><author><style face="normal" font="default" size="100%">Kundu, B. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Physics, University of Virginia, Charlottesville, VA 22908, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Quantitative PET imaging detects early metabolic remodeling in a mouse model of pressure-overload left ventricular hypertrophy in vivo</style></title><secondary-title><style face="normal" font="default" size="100%">J Nucl Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Nucl Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Nucl Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">609-15</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2013/02/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertrophy, Left Ventricular/ diagnostic imaging/ metabolism/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Biological</style></keyword><keyword><style face="normal" font="default" size="100%">Positron-Emission Tomography</style></keyword><keyword><style face="normal" font="default" size="100%">Pressure/ adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory-Gated Imaging Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke Volume</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Ventricular Remodeling</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1535-5667 (Electronic)&#xD;0161-5505 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23426760</style></accession-num><abstract><style face="normal" font="default" size="100%">We proposed that metabolic remodeling in the form of increased uptake of the myocardial glucose analog (18)F-FDG precedes and triggers the onset of severe contractile dysfunction in pressure-overload left ventricular hypertrophy in vivo. To test this hypothesis, we used a mouse model of transverse aortic constriction (TAC) together with PET and assessed serial changes in cardiac metabolism and function over 7 d. METHODS: Scans of 16 C57BL/6 male mice were obtained using a small-animal PET device under sevoflurane anesthesia. A 10-min transmission scan was followed by a 60-min dynamic (18)F-FDG PET scan with cardiac and respiratory gating. Blood glucose levels were measured before and after the emission scan. TAC and sham surgeries were performed after baseline imaging. Osmotic mini pumps containing either propranolol (5 mg/kg/d) or vehicle alone were implanted subcutaneously at the end of surgery. Subsequent scans were taken at days 1 and 7 after surgery. A compartment model, in which the blood input function with spillover and partial-volume corrections and the metabolic rate constants in a 3-compartment model are simultaneously estimated, was used to determine the net myocardial (18)F-FDG influx constant, Ki. The rate of myocardial glucose utilization, rMGU, was also computed. Estimations of the ejection fractions were based on the high-resolution gated PET images. RESULTS: Mice undergoing TAC surgery exhibited an increase in the Ki (580%) and glucose utilization the day after surgery, indicating early adaptive response. On day 7, the ejection fraction had decreased by 24%, indicating a maladaptive response. Average Ki increases were not linearly associated with increases in rMGU. Ki exceeded rMGU by 29% in the TAC mice. TAC mice treated with propranolol attenuated the rate of (18)F-FDG uptake, diminished mismatch between Ki and rMGU (9%), and rescued cardiac function. CONCLUSION: Metabolic maladaptation precedes the onset of severe contractile dysfunction. Both are prevented by treatment with propranolol. The early detection of metabolic remodeling may offer a metabolic target for modulation of hypertrophy.</style></abstract><notes><style face="normal" font="default" size="100%">Zhong, Min&#xD;Alonso, Clayton E&#xD;Taegtmeyer, Heinrich&#xD;Kundu, Bijoy K&#xD;R01 HL061483/HL/NHLBI NIH HHS/United States&#xD;R21 HL102627/HL/NHLBI NIH HHS/United States&#xD;United States&#xD;J Nucl Med. 2013 Apr;54(4):609-15. doi: 10.2967/jnumed.112.108092. Epub 2013 Feb 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://jnm.snmjournals.org/content/54/4/609.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3468664031/Zhong-2013-Quantitative PET ima.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3727159</style></custom2><custom6><style face="normal" font="default" size="100%">Nihms493261</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.2967/jnumed.112.108092</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>334</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">334</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhou, J.</style></author><author><style face="normal" font="default" size="100%">Zhuang, J.</style></author><author><style face="normal" font="default" size="100%">Li, J.</style></author><author><style face="normal" font="default" size="100%">Ooi, E.</style></author><author><style face="normal" font="default" size="100%">Bloom, J.</style></author><author><style face="normal" font="default" size="100%">Poon, C.</style></author><author><style face="normal" font="default" size="100%">Lax, D.</style></author><author><style face="normal" font="default" size="100%">Rosenbaum, D. M.</style></author><author><style face="normal" font="default" size="100%">Barone, F. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, State University of New York Downstate Medical Center, Brooklyn, New York, United States of America. jin.zhou@downstate.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">Long-term post-stroke changes include myelin loss, specific deficits in sensory and motor behaviors and complex cognitive impairment detected using active place avoidance</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PloS one</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e57503</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2013/03/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Avoidance Learning</style></keyword><keyword><style face="normal" font="default" size="100%">Behavior, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Body Weight</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Infarction/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition Disorders/diagnosis/ etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Demyelinating Diseases/diagnosis/ etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Electroretinography</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Motor Activity</style></keyword><keyword><style face="normal" font="default" size="100%">Neurologic Examination</style></keyword><keyword><style face="normal" font="default" size="100%">Prosencephalon/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Psychomotor Performance</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Retina/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ complications/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203 (Electronic)&#xD;1932-6203 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">23505432</style></accession-num><abstract><style face="normal" font="default" size="100%">Persistent neurobehavioral deficits and brain changes need validation for brain restoration. Two hours middle cerebral artery occlusion (tMCAO) or sham surgery was performed in male Sprague-Dawley rats. Neurobehavioral and cognitive deficits were measured over 10 weeks included: (1) sensory, motor, beam balance, reflex/abnormal responses, hindlimb placement, forepaw foot fault and cylinder placement tests, and (2) complex active place avoidance learning (APA) and simple passive avoidance retention (PA). Electroretinogram (ERG), hemispheric loss (infarction), hippocampus CA1 neuronal loss and myelin (Luxol Fast Blue) staining in several fiber tracts were also measured. In comparison to Sham surgery, tMCAO surgery produced significant deficits in all behavioral tests except reflex/abnormal responses. Acute, short lived deficits following tMCAO were observed for forelimb foot fault and forelimb cylinder placement. Persistent, sustained deficits for the whole 10 weeks were exhibited for motor (p&lt;0.001), sensory (p&lt;0.001), beam balance performance (p&lt;0.01) and hindlimb placement behavior (p&lt;0.01). tMCAO produced much greater and prolonged cognitive deficits in APA learning (maximum on last trial of 604+/-83% change, p&lt;0.05) but only a small, comparative effect on PA retention. Hemispheric loss/atrophy was measured 10 weeks after tMCAO and cross-validated by two methods (e.g., almost identical % ischemic hemispheric loss of 33.4+/-3.5% for H&amp;E and of 34.2+/-3.5% for TTC staining). No visual dysfunction by ERG and no hippocampus neuronal loss were detected after tMCAO. Fiber tract damage measured by Luxol Fast Blue myelin staining intensity was significant (p&lt;0.01) in the external capsule and striatum but not in corpus callosum and anterior commissure. In summary, persistent neurobehavioral deficits were validated as important endpoints for stroke restorative research in the future. Fiber myelin loss appears to contribute to these long term behavioral dysfunctions and can be important for cognitive behavioral control necessary for complex APA learning.</style></abstract><notes><style face="normal" font="default" size="100%">Zhou, Jin&#xD;Zhuang, Jian&#xD;Li, Jie&#xD;Ooi, Evelyn&#xD;Bloom, Jonathan&#xD;Poon, Carrie&#xD;Lax, Daniel&#xD;Rosenbaum, Daniel M&#xD;Barone, Frank C&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;PLoS One. 2013;8(3):e57503. doi: 10.1371/journal.pone.0057503. Epub 2013 Mar 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0057503&amp;type=printable</style></url></related-urls><pdf-urls><url>internal-pdf://3400879355/Zhou-2013-Long-term post-strok.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3591420</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0057503</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>50</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">50</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhou, L. Y.</style></author><author><style face="normal" font="default" size="100%">Wright, T. E.</style></author><author><style face="normal" font="default" size="100%">Clarkson, A. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Anatomy, Brain Health Research Center and Brain Research new Zealand, University of Otago, P.O. Box 913, Dunedin 9054, New Zealand.&#xD;Department of Anatomy, Brain Health Research Center and Brain Research new Zealand, University of Otago, P.O. Box 913, Dunedin 9054, New Zealand; Centre for Translational Physiology, University of Otago Wellington, New Zealand; Faculty of Pharmacy, The University of Sydney, Sydney, Australia. Electronic address: andrew.clarkson@otago.ac.nz.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prefrontal cortex stroke induces delayed impairment in spatial memory</style></title><secondary-title><style face="normal" font="default" size="100%">Behav Brain Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Behavioural brain research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Behav Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Behavioural brain research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Behav Brain Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Behavioural brain research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">373-8</style></pages><volume><style face="normal" font="default" size="100%">296</style></volume><edition><style face="normal" font="default" size="100%">2015/08/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Behavior, Animal/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/complications/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mediodorsal Thalamic Nucleus/ pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Memory Disorders/ etiology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Prefrontal Cortex/ pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Spatial Memory/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke/ complications/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 01</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1872-7549 (Electronic)&#xD;0166-4328 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26306825</style></accession-num><abstract><style face="normal" font="default" size="100%">Stroke is the leading cause of long-term disability. Little is known about the effects of stroke on cognitive deficits. The subtle nature of cognition and its respective domains in areas such as working memory and attention can make this difficult to diagnose and treat. We aimed to establish a model of focal ischemia that targets the prefrontal cortex (PFC) and induce memory impairments. Stroke and sham mice were assessed at one and four-weeks post-stroke on various tests: open-field task to assess activity; grid-walk and cylinder task to assess motor impairments; elevated plus maze to assess anxiety; novel-object and object-location recognition tasks to assess memory impairment. Stroke mice in the open-field showed a small increase in activity with no effects on gross motor tasks or anxiety levels (P &gt;/= 0.05) at one and four-weeks post-stroke. Assessment of stroke mice on the novel object task showed no differences at either one or four-weeks compared to sham mice (P &gt;/= 0.05). However, assessment of stroke mice on the object-location recognition task revealed a significant (P &gt;/= 0.05) impairment in spatial memory by four-weeks compared to controls. Further, we show that stroke results in a small decrease in volume of the medial dorsal nucleus of the thalamus (P &gt;/= 0.05). This is the first evidence that demonstrates stroke to the PFC results in delayed onset impairment in spatial memory, similar to findings in human epidemiological data. We suggest that this model may be a useful tool in assessing potential rehabilitative/cognitive therapies after stroke.</style></abstract><notes><style face="normal" font="default" size="100%">Zhou, Lisa Y Y&#xD;Wright, Tim E&#xD;Clarkson, Andrew N&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;Behav Brain Res. 2016 Jan 1;296:373-8. doi: 10.1016/j.bbr.2015.08.022. Epub 2015 Aug 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0166432815301558/1-s2.0-S0166432815301558-main.pdf?_tid=3baebe3a-d7d5-11e6-bb6e-00000aab0f27&amp;acdnat=1484122331_e0c9e2a9d693b4a9f5deb71762d81335</style></url></related-urls><pdf-urls><url>internal-pdf://2471285031/Zhou-2016-Prefrontal cortex st.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.bbr.2015.08.022</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>48</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">48</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhou, Y.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Yang, S. X.</style></author><author><style face="normal" font="default" size="100%">Wang, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Emergency Department, Peking University Ninth School of Clinical Medicine, Beijing, China.&#xD;Emergency Department, The 302 Hospital of PLA, Beijing, China.&#xD;Department of Cardiology, Peking University Ninth School of Clinical Medicine, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">N-ethylmaleimide-sensitive factor siRNA improves cardiac function following myocardial infarction in rats</style></title><secondary-title><style face="normal" font="default" size="100%">Genet Mol Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Genetics and molecular research : GMR</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Genet Mol Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Genetics and molecular research : GMR</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Genet Mol Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Genetics and molecular research : GMR</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">9478-85</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2015/09/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adenoviridae/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Electrocardiography</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Vectors/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Infarction/diagnosis/ genetics/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">N-Ethylmaleimide-Sensitive Proteins/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/ genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke Volume</style></keyword><keyword><style face="normal" font="default" size="100%">Ventricular Function, Left</style></keyword><keyword><style face="normal" font="default" size="100%">Ventricular Remodeling</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 14</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1676-5680 (Electronic)&#xD;1676-5680 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">26345881</style></accession-num><abstract><style face="normal" font="default" size="100%">This study examined the effects of N-ethylmaleimide-sensitive factor (NSF) small interfering RNA (siRNA) on cardiac function following myocardial infarction (MI) in rats. Thirty-six adult Sprague Dawley rats were randomly divided into three equivalent groups. An acute MI model was established by ligating the anterior descending branch of the left coronary artery and confirmed by electrocardiogram. Recombinant NSF-siRNA adenovirus (experimental), negative adenovirus (control), and normal saline were injected near the infarcted area of the left ventricle in each respective group. The left ventricular ejection fraction (LVEF) was measured with a noninvasive ultrasonic cardiogram. Left ventricular end-diastolic pressure (LVEDP) and the maximum rate of rise in left ventricular pressure (+dp/dt max) were measured using the BL-420 Biological Functional Experimental System. Hearts were sectioned and stained with 2,3,5,-triphenyl tetrazolium chloride (TTC) to observe the MI area. Two weeks after surgery, LVEF in the experimental group (46.0 +/- 7.5%) was higher than control (34.0 +/- 6.0%) and saline (37.5 +/- 4.5%) group LVEFs (P &lt; 0.05), whereas LVEDP was the lowest in the experimental group (18.51 +/- 6.87 vs 29.47 +/- 9.94 and 26.58 +/- 8.97 mmHg, respectively) (P &lt; 0.05). The +dp/dt max was also higher in the experimental group (9.74 +/- 1.16 vs 4.33 +/- 1.19 and 5.24 +/- 1.53 mmHg/s x 10(3), respectively) (P &lt; 0.05); however, the MI area did not differ significantly between groups. Local injection of an adenovirus-mediated NSF-siRNA expression vector near infarcted areas improved cardiac function two weeks after MI, but had no impact on the MI area.</style></abstract><notes><style face="normal" font="default" size="100%">Zhou, Y&#xD;Liu, Y&#xD;Yang, S X&#xD;Wang, Z&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Brazil&#xD;Genet Mol Res. 2015 Aug 14;14(3):9478-85. doi: 10.4238/2015.August.14.11.</style></notes><urls><pdf-urls><url>internal-pdf://0664586165/Zhou-2015-N-ethylmaleimide-sen.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.4238/2015.August.14.11</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>112</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">112</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhou, Z.</style></author><author><style face="normal" font="default" size="100%">Wei, X.</style></author><author><style face="normal" font="default" size="100%">Xiang, J.</style></author><author><style face="normal" font="default" size="100%">Gao, J.</style></author><author><style face="normal" font="default" size="100%">Wang, L.</style></author><author><style face="normal" font="default" size="100%">You, J.</style></author><author><style face="normal" font="default" size="100%">Cai, Y.</style></author><author><style face="normal" font="default" size="100%">Cai, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Second Affiliated Hospital, Guangzhou University of Chinese Medicine and Guangdong Provincial Academy of Chinese Medical Sciences, Guangdong Provincial Hospital of Chinese Medicine, No. 111 Dade Road, Guangzhou 510120, China.&#xD;Department of Chinese Integrative Medicine, Huashan Hospital, Fudan University, No.12 Mid. Wulumuqi Road, Shanghai 200040, China.&#xD;Laboratory for Neurological Research of the Institute of Chinese Integrative Medicine, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai 200032, China.&#xD;Department of Chinese Integrative Medicine, Guangzhou First People&apos;s Hospital, Guangzhou Medical University, No. 1 Panfu Road, Guangzhou 510180, China.&#xD;Department of Neurology, Second Affiliated Hospital, Guangzhou University of Chinese Medicine and Guangdong Provincial Academy of Chinese Medical Sciences, Guangdong Provincial Hospital of Chinese Medicine, No. 111 Dade Road, Guangzhou 510120, China. Electronic address: caiyefeng@126.com.&#xD;Laboratory for Neurological Research of the Institute of Chinese Integrative Medicine, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai 200032, China. Electronic address: caidingfang@163.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Protection of erythropoietin against ischemic neurovascular unit injuries through the effects of connexin43</style></title><secondary-title><style face="normal" font="default" size="100%">Biochem Biophys Res Commun</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Biochemical and biophysical research communications</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Biochem Biophys Res Commun</style></full-title><abbr-1><style face="normal" font="default" size="100%">Biochemical and biophysical research communications</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Biochem Biophys Res Commun</style></full-title><abbr-1><style face="normal" font="default" size="100%">Biochemical and biophysical research communications</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">656-62</style></pages><volume><style face="normal" font="default" size="100%">458</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2015/02/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Communication/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Connexin 43/analysis/ genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Erythropoietin/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Gap Junctions/drug effects/genetics/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression</style></keyword><keyword><style face="normal" font="default" size="100%">Glutamic Acid/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery/ drug therapy/genetics/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/drug effects/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroprotective Agents/ therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">RNA Interference</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 13</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1090-2104 (Electronic)&#xD;0006-291X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25684187</style></accession-num><abstract><style face="normal" font="default" size="100%">Erythropoietin (EPO) has protective effects on many neurological diseases, including cerebral ischemia. Here, we aimed to test EPO&apos;s effects on ischemic neurovascular unit (NVU) injuries and examine whether the effects were dependent on connexin43 (Cx43) mediated gap junctional intercellular communication (GJIC). We detected the expression of Cx43 and phosphorylation of Cx43 (p-Cx43) at 1 d, 3 d, and 7 d after middle cerebral artery occlusion (MCAO). Meanwhile, we examined the effects of EPO on NVU injuries including neuronal survival, astrocyte activation and regeneration of endothelial cells as well as whether the effects were Cx43 dependent by using multiple inhibitors. We found EPO highly increased p-Cx43, but not total Cx43 at all chosen times. Importantly, EPO led to neurological and blood-brain barrier functions improvement by associating with promotion of angiogenesis as well as reduction of neuronal death, astrocyte activation and neurotoxic substances levels. Moreover, these effects were significantly weakened by the inhibitors blocking GJIC, Cx43 communicative function, phosphorylation and expression, only Cx43 redistribution inhibitor excluded. Our data suggest the protective effects of EPO on NUV injuries are highly associated with the increase of p-Cx43, which improves GJIC to reduce neurotoxic substances.</style></abstract><notes><style face="normal" font="default" size="100%">Zhou, Ziyi&#xD;Wei, Xiaobai&#xD;Xiang, Jun&#xD;Gao, Junpeng&#xD;Wang, Lixin&#xD;You, Jinsong&#xD;Cai, Yefeng&#xD;Cai, Dingfang&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Biochem Biophys Res Commun. 2015 Mar 13;458(3):656-62. doi: 10.1016/j.bbrc.2015.02.020. Epub 2015 Feb 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0006291X15002363/1-s2.0-S0006291X15002363-main.pdf?_tid=3e4e44bc-d7d5-11e6-baec-00000aacb361&amp;acdnat=1484122335_cc187a0e5ed4d3e3a430994e73c2138a</style></url></related-urls><pdf-urls><url>internal-pdf://2194727526/Zhou-2015-Protection of erythr.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.bbrc.2015.02.020</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>445</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">445</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhu, L.</style></author><author><style face="normal" font="default" size="100%">Hoffmann, A.</style></author><author><style face="normal" font="default" size="100%">Wintermark, M.</style></author><author><style face="normal" font="default" size="100%">Pan, X.</style></author><author><style face="normal" font="default" size="100%">Tu, R.</style></author><author><style face="normal" font="default" size="100%">Rapp, J. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Vascular Surgery Service, San Francisco Department of Veterans Affairs Medical Center, San Francisco, California 94121, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Do microemboli reach the brain penetrating arteries?</style></title><secondary-title><style face="normal" font="default" size="100%">J Surg Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The Journal of surgical research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Surg Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of surgical research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Surg Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">The Journal of surgical research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">679-83</style></pages><volume><style face="normal" font="default" size="100%">176</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2012/01/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Infarction/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Arteries/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorescence</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Embolism/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Microspheres</style></keyword><keyword><style face="normal" font="default" size="100%">Pulmonary Embolism/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1095-8673 (Electronic)&#xD;0022-4804 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22261594</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: As they are &quot;end arteries,&quot; microembolic obstruction of brain penetrating arteries would be expected to create ischemia. Yet the mammalian brain appears to have an impressive tolerance to experimental microembolization with ischemia occurring only after the injection of large numbers of particulates. Potential explanations could be that the majority of these particulates marginate along the pial vasculature or escape the cerebral circulation via arteriovenous (AV) fistulae. METHODS: To test these theories, we first established the level of injury created by the injection of 20, 45, and 90 mum fluorescent microspheres in Sprague-Dawley rats. Brains were examined by immunohistochemistry for injury and for infarction. We then injected 1000 size 20 mum, 500 size 45 mum, and 150 size 90 mum and harvested the brains and lungs for assays of fluorescence. The location of microemboli within the brain was established by determining the percent of 20 and 45 mum fluorescent microspheres entering the superficial versus deeper layers of the brain. The location of larger microemboli was established by 2T-MRI after injection of 60-100 mum microthrombi labeled with supraparamagnetic iron oxide (SPIO) particles. RESULTS: With 20 mum microspheres there were no areas of injury or infarction after injection of 500 and rare areas of injury and no infarctions after injection of 1000 microspheres. With either 250 or 500 size 45 mum microspheres there were a few (&lt;/= 6) small areas of injury per animal with &lt;/= 2 areas of infarction. After injection, 93%-96% of injected microspheres remained in the brain. Approximately 40% of either fluorescent or SPIO labeled microthrombi were found on the brain surface. CONCLUSIONS: As in humans, the rat brain has an impressive tolerance to microemboli, although this clearly varies with emboli size and number. Wash out of particulates through AV connections is not a major factor in brain tolerance in this model. Approximately 40% of microemboli remain in the larger pial vasculature where the more extensive collateralization may limit their effects on distal perfusion. However, the remaining 60% enter penetrating arteries but few create ischemia.</style></abstract><notes><style face="normal" font="default" size="100%">Zhu, Lei&#xD;Hoffmann, Angelika&#xD;Wintermark, Max&#xD;Pan, Xianmang&#xD;Tu, Richard&#xD;Rapp, Joseph H&#xD;United States&#xD;J Surg Res. 2012 Aug;176(2):679-83. doi: 10.1016/j.jss.2011.09.059. Epub 2011 Oct 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0022480411008195/1-s2.0-S0022480411008195-main.pdf?_tid=4d223ade-d7d5-11e6-8ddb-00000aab0f6b&amp;acdnat=1484122360_d4e967814f011115e5e9cfeeeaade599</style></url></related-urls><pdf-urls><url>internal-pdf://2308195677/Zhu-2012-Do microemboli reach.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jss.2011.09.059</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>421</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">421</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhuang, P.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Cui, G.</style></author><author><style face="normal" font="default" size="100%">Bian, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, M.</style></author><author><style face="normal" font="default" size="100%">Zhang, J.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Yang, X.</style></author><author><style face="normal" font="default" size="100%">Isaiah, A. O.</style></author><author><style face="normal" font="default" size="100%">Lin, Y.</style></author><author><style face="normal" font="default" size="100%">Jiang, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Tianjin State Key Laboratory of Modern Chinese Medicine, Chinese Materia Medica College, Tianjin University of Traditional Chinese Medicine, Tianjin, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Direct stimulation of adult neural stem/progenitor cells in vitro and neurogenesis in vivo by salvianolic acid B</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PloS one</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title><abbr-1><style face="normal" font="default" size="100%">PloS one</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e35636</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2012/05/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult Stem Cells/cytology/ drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Benzofurans/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Bromodeoxyuridine/analysis/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Proliferation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Drugs, Chinese Herbal/ pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Learning/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">MAP Kinase Signaling System/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Memory/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Neural Stem Cells/cytology/ drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenesis/ drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphatidylinositol 3-Kinases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphorylation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Proto-Oncogene Proteins c-akt/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Notch/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203 (Electronic)&#xD;1932-6203 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">22545124</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Small molecules have been shown to modulate the neurogenesis processes. In search for new therapeutic drugs, the herbs used in traditional medicines for neurogenesis are promising candidates. METHODOLOGY AND PRINCIPAL FINDINGS: We selected a total of 45 natural compounds from Traditional Chinese herbal medicines which are extensively used in China to treat stroke clinically, and tested their proliferation-inducing activities on neural stem/progenitor cells (NSPCs). The screening results showed that salvianolic acid B (Sal B) displayed marked effects on the induction of proliferation of NSPCs. We further demonstrated that Sal B promoted NSPCs proliferation in dose- and time-dependent manners. To explore the molecular mechanism, PI3K/Akt, MEK/ERK and Notch signaling pathways were investigated. Cell proliferation assay demonstrated that Ly294002 (PI3K/Akt inhibitor), but neither U0126 (ERK inhibitor) nor DAPT (Notch inhibitor) inhibited the Sal B-induced proliferation of cells. Western Blotting results showed that stimulation of NSPCs with Sal B enhanced the phosphorylation of Akt, and Ly294002 abolished this effect, confirming the role of Akt in Sal B mediated proliferation of NSPCs. Rats exposed to transient cerebral ischemia were treated for 4 weeks with Sal B from the 7th day after stroke. BrdU incorporation assay results showed that exposure Sal B could maintain the proliferation of NSPCs after cerebral ischemia. Morris water maze test showed that delayed post-ischemic treatment with Sal B improved cognitive impairment after stroke in rats. SIGNIFICANCE: Sal B could maintain the NSPCs self-renew and promote proliferation, which was mediated by PI3K/Akt signal pathway. And delayed post-ischemic treatment with Sal B improved cognitive impairment after stroke in rats. These findings suggested that Sal B may act as a potential drug in treatment of brain injury or neurodegenerative diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Zhuang, Pengwei&#xD;Zhang, Yanjun&#xD;Cui, Guangzhi&#xD;Bian, Yuhong&#xD;Zhang, Mixia&#xD;Zhang, Jinbao&#xD;Liu, Yang&#xD;Yang, Xinpeng&#xD;Isaiah, Adejobi Oluwaniyi&#xD;Lin, Yingxue&#xD;Jiang, Yongbo&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;PLoS One. 2012;7(4):e35636. doi: 10.1371/journal.pone.0035636. Epub 2012 Apr 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0035636&amp;type=printable</style></url></related-urls><pdf-urls><url>internal-pdf://0595466917/Zhuang-2012-Direct stimulation o.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3335811</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0035636</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="lacunar3.enl" path="S:\TRIALDEV\CAMARADES\Private\Malcolm\lacunar3.enl">lacunar3.enl</database><source-app name="EndNote" version="17.7">EndNote</source-app><rec-number>189</rec-number><foreign-keys><key app="EN" db-id="wxpeawadzvt2siezrf2v0za45e2z5992dds5">189</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zuo, W.</style></author><author><style face="normal" font="default" size="100%">Zhang, S.</style></author><author><style face="normal" font="default" size="100%">Xia, C. Y.</style></author><author><style face="normal" font="default" size="100%">Guo, X. F.</style></author><author><style face="normal" font="default" size="100%">He, W. B.</style></author><author><style face="normal" font="default" size="100%">Chen, N. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Department of Pharmacology, Institute of Materia Medica, and Neuroscience Center, Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.&#xD;Shanxi University of Traditional Chinese Medicine, Taiyuan 030024, China.&#xD;State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Department of Pharmacology, Institute of Materia Medica, and Neuroscience Center, Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. Electronic address: chennh@imm.ac.cn.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mitochondria autophagy is induced after hypoxic/ischemic stress in a Drp1 dependent manner: the role of inhibition of Drp1 in ischemic brain damage</style></title><secondary-title><style face="normal" font="default" size="100%">Neuropharmacology</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neuropharmacology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuropharmacology</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuropharmacology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Neuropharmacology</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neuropharmacology</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">103-15</style></pages><volume><style face="normal" font="default" size="100%">86</style></volume><edition><style face="normal" font="default" size="100%">2014/07/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Autophagy/drug effects/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/drug effects/pathology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia/drug therapy/pathology/ physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Caspase 3/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Hypoxia/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Survival/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Dynamins/antagonists &amp; inhibitors/genetics/ metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose/deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mitochondria/drug effects/pathology/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Mitochondrial Degradation/drug effects/ physiology</style></keyword><keyword><style face="normal" font="default" size="100%">PC12 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">Reactive Oxygen Species/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1873-7064 (Electronic)&#xD;0028-3908 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">25018043</style></accession-num><abstract><style face="normal" font="default" size="100%">Mitochondria dysfunction is implicated in diverse conditions, including metabolic and neurodegenerative disorders. Mitochondrial dynamics has attracted increasing attention as to its relationship with mitochondria autophagy, also known as mitophagy, which is critical for degradation of dysfunctional mitochondria maintaining mitochondrial homeostasis. Mitochondrial fi ssion and its role in clearance of injured mitochondria in acute ischemic injury, however, have not been elucidated yet. Here we showed that hypoxic/ischemic conditions led to fragmentation of mitochondria and induction of mitophagy in permanent middle cerebral artery occlusion (pMCAO) rats and oxygen-glucose deprivation (OGD) PC12 cells. Inhibition of Drp1 by pharmacologic inhibitor or siRNA resulted in accumulation of damaged mitochondria mainly through selectively blocking mitophagy without affecting mitochondrial biogenesis and non-selective autophagy. Drp1 inhibitors increased the infarct volume and aggravated the neurological de fi cits in a rat model of pMCAO. We demonstrated that the devastating role of disturbed mitochondrial fission by inhibiting Drp1 contributed to the damaged mitochondria-mediated injury such as ROS generation, cyt-c release and activation of caspase-3. Taken together, we proved that under hypoxic/ischemic stress a Drp1-dependent mitophagy was triggered which was involved in the removal of damaged mitochondria and cellular survival at the early stage of hypoxic/ischemic injury. Thus, Drp1 related pathway involved in selective removal of dysfunctional mitochondria is proposed as an efficient target for treatment of cerebral ischemia.</style></abstract><notes><style face="normal" font="default" size="100%">Zuo, Wei&#xD;Zhang, Shuai&#xD;Xia, Cong-Yuan&#xD;Guo, Xiao-Feng&#xD;He, Wen-Bin&#xD;Chen, Nai-Hong&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Neuropharmacology. 2014 Nov;86:103-15. doi: 10.1016/j.neuropharm.2014.07.002. Epub 2014 Jul 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0028390814002512/1-s2.0-S0028390814002512-main.pdf?_tid=45568972-d7d5-11e6-9f37-00000aab0f02&amp;acdnat=1484122347_5dad39c1613b7dafbec02868406b8aa8</style></url></related-urls><pdf-urls><url>internal-pdf://3093303510/Zuo-2014-Mitochondria autopha.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.neuropharm.2014.07.002</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record></records></xml>